Although None None O
the None None O
total None None O
potential None None O
nitrogen None None O
load None None O
in None None O
Shanghai None None O
has None None O
decreased None None O
in None None O
the None None O
2000s None None O
and None None O
water None None O
pollution None None O
problems None None O
seem None None O
to None None O
have None None O
improved None None O
, None None O
the None None O
problem None None O
has None None O
shifted None None O
and None None O
expanded None None O
to None None O
affect None None O
a None None O
wider None None O
area None None O
through None None O
the None None O
food/product None None O
chain None None O
and None None O
water/air None None O
movement None None I-FUNC
. None None O

We None None O
defined None None O
250 None None O
peptides None None I-TRANS
commonly None None O
activated None None O
in None None O
both None None O
BCP-ALL None None O
and None None O
T-ALL None None O
representing None None O
major None None O
signal None None O
transduction None None O
pathways None None O
including None None O
MAPK None None O
, None None O
PI3K/Akt None None O
, None None O
and None None O
regulators None None O
of None None O
the None None O
cell None None O
cycle/p53 None None O
pathway None None O
. None None O

Among None None O
these None None O
, None None O
ten None None O
peptides None None I-TRANS
were None None O
more None None O
highly None None O
phosphorylated None None O
in None None O
BCP-ALL None None O
while None None O
17 None None O
peptides None None I-TRANS
showed None None O
increased None None O
phosphorylation None None O
in None None O
T-ALL None None O
. None None O

Cationic None None O
antimicrobial None None O
peptides None None I-TRANS
are None None O
considered None None O
promising None None O
candidates None None O
to None None O
complement None None O
currently None None O
used None None O
antibiotics None None O
, None None O
which None None O
are None None O
less None None O
effective None None O
against None None O
increasingly None None O
resistant None None O
pathogens None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
focused None None O
on None None O
the None None O
role None None O
of None None O
electrostatic None None O
interactions None None O
and None None O
amphiphilicity None None O
on None None O
the None None O
membrane None None O
interactions None None O
since None None O
the None None O
large None None O
majority None None O
of None None O
natural None None O
antimicrobial None None O
peptides None None I-TRANS
are None None O
cationic None None O
. None None O

The None None O
latter None None O
is None None O
a None None O
synthetic None None O
peptide None None O
composed None None O
of None None O
ten None None O
leucines None None I-TRANS
and None None O
four None None O
phenylalanines None None I-TRANS
, None None O
which None None O
are None None O
modified None None O
by None None O
the None None O
addition None None O
of None None O
the None None O
crown None None O
ether None None O
. None None O

Fluorescence None None O
vesicle None None O
leakage None None O
assays None None O
indicate None None O
, None None O
however None None O
, None None O
differences None None O
between None None O
the None None O
ability None None O
of None None O
cationic None None O
and None None O
anionic None None O
peptides None None I-TRANS
to None None O
induce None None O
calcein None None O
release None None O
in None None O
zwitterionic None None O
and None None O
anionic None None O
lipid None None O
vesicles None None O
, None None O
suggesting None None O
an None None O
importance None None O
of None None O
electrostatic None None O
interactions None None O
and None None O
repulsions None None O
. None None O

This None None O
study None None O
therefore None None O
indicates None None O
that None None O
the None None O
membrane None None O
interactions None None O
of None None O
model None None O
14-mer None None O
peptides None None I-TRANS
are None None O
mainly None None O
governed None None O
by None None O
their None None O
secondary None None O
structure None None O
, None None O
which None None O
depends None None O
on None None O
the None None O
position None None O
of None None O
substitution None None O
, None None O
and None None O
not None None O
the None None O
charge None None O
of None None O
the None None O
residues None None O
. None None O

© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
To None None O
improve None None O
the None None O
knowledge None None O
and None None O
skills None None O
of None None O
diabetic None None O
patients None None O
on None None O
insulin None None I-PROTEIN
injections None None O
using None None O
mobile None None O
phone None None O
short None None O
message None None O
services None None O
and None None O
to None None O
evaluate None None O
the None None O
association None None O
of None None O
this None None O
intervention None None O
with None None O
metabolic None None O
outcomes None None O
. None None O

Subsequently None None O
, None None O
12 None None O
short None None O
messages None None O
related None None O
to None None O
insulin None None I-PROTEIN
administration None None O
were None None O
sent None None O
to None None O
patients None None O
twice None None O
a None None O
week None None O
for None None O
six None None O
months None None O
. None None O

Following None None O
the None None O
text None None O
message None None O
reminders None None O
, None None O
the None None O
patients None None O
' None None O
level None None O
of None None O
knowledge None None O
and None None O
skills None None O
regarding None None O
the None None O
insulin None None I-PROTEIN
injection None None O
technique None None O
improved None None O
at None None O
month None None O
3 None None O
and None None O
6 None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0·05 None None O
) None None O
. None None O

The None None O
number None None O
of None None O
insulin None None I-PROTEIN
injection None None O
sites None None O
and None None O
the None None O
frequency None None O
of None None O
rotation None None O
of None None O
skin None None O
sites None None O
for None None O
insulin None None I-PROTEIN
injections None None O
also None None O
increased None None O
. None None O

Considering None None O
that None None O
female None None O
sex None None O
hormones None None I-PROTEIN
may None None O
play None None O
a None None O
preventative None None O
role None None O
in None None O
both None None O
cardiovascular None None O
and None None O
renal None None O
diseases None None O
, None None O
the None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
effects None None O
of None None O
female None None O
sex None None O
hormones None None I-PROTEIN
on None None O
hypercholesterolemia-induced None None O
renal None None O
dysfunction None None O
. None None O

Taken None None O
together None None O
these None None O
data None None O
indicate None None O
that None None O
female None None O
sex None None O
hormones None None I-PROTEIN
may None None O
delay None None O
hypercholesterolemia-induced None None O
renal None None O
dysfunction None None O
and None None O
emphasizes None None O
the None None O
importance None None O
of None None O
plasma None None O
cholesterol None None O
control None None O
in None None O
post-menopausal None None O
women None None O
. None None O

NF-AT3 None None O
, None None O
NF-AT4 None None O
, None None O
and None None O
collagen None None I-PROTEIN
I None None O
and None None O
III None None O
mRNA None None O
and None None O
protein None None O
expression None None O
in None None O
atria None None O
were None None O
measured None None O
. None None O

In None None O
patients None None O
with None None O
AF None None O
, None None O
the None None O
expression None None O
levels None None O
of None None O
nuclear None None O
NF-AT3 None None O
and None None O
NF-AT4 None None O
correlated None None O
with None None O
those None None O
of None None O
collagens None None I-PROTEIN
I None None O
and None None O
III None None O
in None None O
the None None O
atria None None O
and None None O
with None None O
PICP None None O
and None None O
TGF-β1 None None O
in None None O
blood None None O
. None None O

Adenosine None None I-TRANS
monophosphate-activated None None O
protein None None O
kinase None None O
( None None O
AMPK None None O
) None None O
is None None O
a None None O
cellular None None O
energy None None O
sensor None None O
, None None O
which None None O
once None None O
activated None None O
, None None O
plays None None O
a None None O
role None None O
in None None O
several None None O
processes None None O
within None None O
the None None O
cell None None O
to None None O
restore None None O
energy None None O
homeostasis None None O
. None None O

The None None O
modulatory None None O
effects None None O
of None None O
bile None None O
acids None None O
have None None O
been None None O
shown None None O
to None None O
affect None None O
the None None O
expression None None O
of None None O
genes None None O
responsible None None O
for None None O
lipid None None O
metabolism None None O
as None None O
well None None O
as None None O
membrane None None O
transporters None None I-PROTEIN
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
identified None None O
soluble None None O
carrier None None O
protein None None O
family None None O
22 None None O
member None None O
4 None None O
( None None O
Slc22a4 None None O
) None None O
, None None O
encoding None None I-FUNC
organic None None O
cation None None O
transporter None None O
novel None None O
type-1 None None O
( None None O
Octn1 None None O
) None None O
, None None O
as None None O
a None None O
PPARα-regulated None None O
gene None None O
and None None O
its None None O
intestinal None None O
expression None None O
exhibited None None O
circadian None None O
oscillations None None O
in None None O
a None None O
bile None None O
acid-dependent None None O
manner None None O
. None None O

These None None O
results None None O
suggest None None O
a None None O
molecular None None O
clock-independent None None O
mechanism None None O
by None None O
which None None O
bile None None O
acid-regulated None None O
PPARα None None O
activity None None O
governs None None O
the None None O
circadian None None O
expression None None O
of None None O
intestinal None None O
organic None None O
cation None None O
transporters None None I-PROTEIN
. None None O

To None None O
investigate None None O
the None None O
adaptive None None O
functions None None O
of None None O
attention None None I-FUNC
, None None O
we None None O
used None None O
a None None O
genetic None None O
algorithm None None O
to None None O
evolve None None O
simple None None O
connectionist None None O
networks None None O
that None None O
had None None O
to None None O
make None None O
categorization None None O
decisions None None O
in None None O
a None None O
variety None None O
of None None O
environmental None None O
structures None None O
. None None O

Instead None None O
, None None O
being None None O
able None None O
to None None O
shift None None O
attention None None I-FUNC
provides None None O
adaptive None None O
benefit None None O
by None None O
allowing None None O
faster None None O
learning None None I-FUNC
with None None O
fewer None None O
errors None None O
in None None O
a None None O
range None None O
of None None O
ecologically None None O
plausible None None O
environments None None O
. None None O

Also None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
and None None O
catalase None None I-PROTEIN
levels None None O
were None None O
increased None None O
21 None None O
, None None O
30 None None O
and None None O
60 None None O
days None None O
post None None O
treatment None None O
of None None O
MSCs None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
prospectively None None O
examine None None O
the None None O
relationships None None O
between None None O
maternal None None O
DSM-IV-TR None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
, None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
, None None O
and None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
with None None O
arterial None None O
hypertension None None O
and None None O
blood None None O
pressure None None O
during None None O
pregnancy None None O
. None None O

DSM-IV-TR None None O
anxiety None None O
and None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
prior None None O
to None None O
pregnancy None None O
, None None O
lifetime None None O
anxiety/depression None None O
liability None None O
, None None O
and None None O
BMI None None O
during None None O
early None None O
pregnancy None None O
were None None O
assessed None None O
with None None O
the None None O
Composite None None O
International None None O
Diagnostic None None O
Interview None None O
for None None O
Women None None O
( None None O
CIDI-V None None O
) None None O
. None None O

Nearly None None O
20 None None O
% None None O
of None None O
mothers None None O
will None None O
experience None None O
an None None O
episode None None O
of None None O
major None None O
or None None O
minor None None O
depression None None I-DISEASE
within None None O
the None None O
first None None O
3 None None O
months None None O
postpartum None None O
, None None O
making None None O
it None None O
the None None O
most None None O
common None None O
complication None None O
of None None O
childbearing None None O
. None None O

A None None O
new None None O
inhibition None None O
assays None None O
using None None O
Luminex None None O
technology None None O
was None None O
performed None None O
to None None O
identify None None O
peptides None None I-TRANS
able None None O
to None None O
inhibit None None O
the None None O
binding None None O
of None None O
anti-A2 None None O
Abs None None O
to None None O
A2 None None O
domain None None O
. None None O

The None None O
three-dimensional None None O
representation None None O
of None None O
these None None O
two None None O
peptides None None I-TRANS
on None None O
the None None O
A2 None None O
domain None None O
revealed None None O
that None None O
they None None O
are None None O
localized None None O
on None None O
a None None O
limited None None O
region None None O
of None None O
A2 None None O
. None None O

Although None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor-tyrosine None None O
kinase None None O
inhibitors None None O
( None None O
EGFR-TKIs None None O
) None None O
have None None O
become None None O
key None None O
therapeutic None None O
agents None None O
for None None O
non-small None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
patients None None O
with None None O
EGFR None None O
mutation None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
efficacy None None O
of None None O
EGFR-TKIs None None O
according None None O
to None None O
different None None O
treatment None None O
timings None None O
. None None O

Carbonic None None I-PROTEIN
anhydrase None None I-PROTEIN
IX None None I-REGION
( None None O
CAIX None None O
) None None O
is None None O
a None None O
hypoxia-inducible None None O
enzyme None None O
with None None O
extracellular None None O
catalytic None None O
domain None None O
that None None O
is None None O
overexpressed None None O
in None None O
a None None O
variety None None O
of None None O
cancers None None O
including None None O
breast None None O
cancer None None O
and None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
maintaining None None O
favourable None None O
intracellular None None O
pH None None O
and None None O
reducing None None O
extracellular None None O
pH None None O
. None None O

These None None O
priority None None O
areas None None O
were None None O
: None None O
1 None None O
) None None O
gender None None O
differences None None O
in None None O
the None None O
pharmacological None None O
and None None O
nonpharmacological None None O
interventions None None O
for None None O
pain None None O
, None None O
including None None O
differences None None O
in None None O
opioid None None O
tolerance None None O
, None None O
side None None O
effects None None O
, None None O
or None None O
misuse None None O
; None None O
2 None None O
) None None O
gender None None O
differences None None O
in None None O
pain None None O
severity None None O
perceptions None None I-FUNC
, None None O
clinically None None O
meaningful None None O
differences None None O
in None None O
acute None None O
pain None None O
, None None O
and None None O
pain None None O
treatment None None O
preferences None None O
; None None O
3 None None O
) None None O
gender None None O
differences None None O
in None None O
pain None None O
outcomes None None O
of None None O
ED None None O
patients None None O
across None None O
the None None O
life None None O
span None None O
; None None O
4 None None O
) None None O
gender None None O
differences None None O
in None None O
the None None O
relationship None None O
between None None O
acute None None O
pain None None O
and None None O
acute None None O
psychological None None O
responses None None O
; None None O
5 None None O
) None None O
the None None O
influence None None O
of None None O
physician-patient None None O
gender None None O
differences None None O
and None None O
characteristics None None O
on None None O
the None None O
assessment None None O
and None None O
treatment None None O
of None None O
pain None None O
; None None O
6 None None O
) None None O
gender None None O
differences None None O
in None None O
the None None O
influence None None O
of None None O
acute None None O
stress None None O
and None None O
chronic None None O
stress None None O
on None None O
acute None None O
pain None None O
responses None None O
; None None O
7 None None O
) None None O
gender None None O
differences None None O
in None None O
biological None None O
mechanisms None None O
and None None O
molecular None None O
pathways None None O
mediating None None O
acute None None O
pain None None O
in None None O
ED None None O
populations None None O
; None None O
and None None O
8 None None O
) None None O
gender None None O
differences None None O
in None None O
biological None None O
mechanisms None None O
and None None O
molecular None None O
pathways None None O
mediating None None O
chronic None None O
pain None None O
development None None O
after None None O
trauma None None O
, None None O
stress None None O
, None None O
or None None O
acute None None O
illness None None O
exposure None None O
. None None O

Comparison None None O
to None None O
homologous None None O
MDD None None O
structures None None O
show None None O
that None None O
both None None O
enzymes None None I-PROTEIN
employ None None O
analogous None None O
Arg None None O
or None None O
Lys None None O
residues None None O
to None None O
catalyze None None O
phosphate None None O
transfer None None O
. None None O

An None None O
elegant None None O
and None None O
efficient None None O
solution None None O
is None None O
to None None O
extend None None O
the None None O
textual None None O
and None None O
numerical None None O
information None None O
with None None O
an None None O
additional None None O
visual None None O
layer None None O
, None None O
referred None None O
to None None O
as None None O
sparklines None None O
, None None O
making None None O
it None None O
intuitive None None O
to None None O
draw None None O
inferences None None I-FUNC
about None None O
the None None O
properties None None O
of None None O
the None None O
underlying None None O
data None None O
. None None O

Significant None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
( None None O
sCBVD None None O
) None None O
was None None O
defined None None O
as None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
50 None None O
% None None O
diameter None None O
reduction None None O
in None None O
internal None None O
carotid None None O
arteries None None O
( None None O
ICA None None O
) None None O
or None None O
any None None O
degree None None O
of None None O
occlusion None None O
in None None O
vertebrobasilar None None O
system None None O
. None None O

The None None O
educational None None O
needs None None O
assessment None None O
tool None None O
has None None O
been None None O
translated None None O
into None None O
nine None None O
languages None None I-FUNC
and None None O
measurement None None O
properties None None O
have None None O
been None None O
established None None O
, None None O
however None None O
, None None O
its None None O
usability None None O
in None None O
clinical None None O
practice None None O
has None None O
not None None O
been None None O
studied None None O
. None None O

Increasing None None O
β-cell None None O
function None None O
across None None O
predefined None None O
C-peptide None None O
groups None None O
was None None O
associated None None O
with None None O
reduced None None O
insulin None None I-PROTEIN
dose None None O
, None None O
HbA1c None None O
, None None O
mean None None O
glucose None None O
( None None O
low None None O
[ None None O
& None None O
lt None None O
; None None O
200 None None O
pmol/L None None O
] None None O
10.7 None None O
vs. None None O
excellent None None O
[ None None O
& None None O
gt None None O
; None None O
1,000 None None O
pmol/L None None O
] None None O
7.5 None None O
mmol/L None None O
) None None O
, None None O
and None None O
glucose None None O
SD None None O
( None None O
low None None O
, None None O
4.4 None None O
vs. None None O
excellent None None O
, None None O
1.4 None None O
mmol/L None None O
) None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
systematically None None O
investigate None None O
the None None O
formation None None O
and None None O
metabolism None None O
of None None O
this None None O
pair None None O
of None None O
epimers None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
and None None O
to None None O
elucidate None None O
the None None O
isoforms None None O
of None None O
cytochrome None None O
P450 None None O
enzymes None None I-PROTEIN
responsible None None O
for None None O
the None None O
stereoselective None None O
metabolism None None O
of None None O
both None None O
epimers None None O
. None None O

Immunohistochemistry None None O
was None None O
performed None None O
to None None O
detect None None O
the None None O
expression None None O
of None None O
DcR3 None None O
, None None O
caspase-3 None None O
, None None O
Bcl-2 None None O
, None None O
VEGF None None O
, None None O
Ki-67 None None O
, None None O
PCNA None None O
and None None O
P53 None None I-PROTEIN
in None None O
166 None None O
BUC None None O
and None None O
56 None None O
normal None None O
bladder None None O
tissues None None O
. None None O

Furthermore None None O
, None None O
DcR3 None None O
expression None None O
was None None O
negatively None None O
correlated None None O
with None None O
caspase-3 None None O
and None None O
positively None None O
associated None None O
with None None O
Bcl-2 None None O
, None None O
VEGF None None O
, None None O
Ki-67 None None O
labeling None None O
index None None O
( None None O
LI None None O
) None None O
, None None O
PCNA None None O
LI None None O
and None None O
P53 None None I-PROTEIN
( None None O
all None None O
p None None O
& None None O
lt None None O
; None None O
0.0001 None None O
) None None O
, None None O
respectively None None O
. None None O

In None None O
this None None O
study None None O
eugenol None None O
( None None O
EU None None O
) None None O
loaded None None O
nanoemulsions None None O
( None None O
NEs None None I-TRANS
) None None O
emulsified None None O
with None None O
modified None None O
starch None None O
were None None O
prepared None None O
and None None O
their None None O
apoptotic None None O
potential None None O
against None None O
liver None None O
and None None O
colon None None O
cancer None None O
cells None None O
was None None O
examined None None O
in None None O
comparison None None O
with None None O
bulk None None O
EU None None O
. None None O

It None None O
was None None O
observed None None O
that None None O
EU None None O
and None None O
EU None None O
: None None O
CA None None O
NE None None I-TRANS
induced None None O
apoptosis None None O
in None None O
both None None O
cell None None O
lines None None O
via None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
generation None None O
. None None O

This None None O
is None None O
the None None O
first None None O
report None None O
on None None O
the None None O
antiproliferative None None O
mechanisms None None O
of None None O
EU None None O
loaded None None O
NE None None I-TRANS
. None None O

P53 None None I-PROTEIN
, None None O
the None None O
most None None O
commonly None None O
mutated None None O
tumor None None O
suppressor None None O
gene None None O
in None None O
all None None O
types None None O
of None None O
human None None O
cancer None None O
, None None O
is None None O
involved None None O
in None None O
cell None None O
cycle None None O
arrest None None O
and None None O
control None None O
of None None O
apoptosis None None O
. None None O

There None None O
are None None O
divergent None None O
reports None None O
but None None O
many None None O
studies None None O
suggest None None O
p53 None None I-PROTEIN
pro/pro None None O
SNP None None O
may None None O
be None None O
associated None None O
with None None O
susceptibility None None O
to None None O
developing None None O
various None None O
cancers None None O
in None None O
different None None O
regions None None O
of None None O
the None None O
world None None O
. None None O

A None None O
total None None O
of None None O
921 None None O
biopsies None None O
were None None O
collected None None O
and None None O
tested None None O
for None None O
prevalence None None O
of None None O
H. None None O
pylori None None O
by None None O
rapid None None O
urease None None I-PROTEIN
test None None O
( None None O
RUT None None O
) None None O
, None None O
imprint None None O
cytology None None O
and None None O
histology None None O
. None None O

Analysis None None O
of None None O
p53 None None I-PROTEIN
gene None None O
polymorphism None None O
at None None O
codon None None O
72 None None O
was None None O
accomplished None None O
by None None O
PCR None None O
using None None O
restriction None None O
enzyme None None O
BstU1 None None O
. None None O

The None None O
analysis None None O
of None None O
p53 None None I-PROTEIN
72 None None O
SNP None None O
revealed None None O
that None None O
p53 None None I-PROTEIN
( None None O
Arg/Arg None None O
) None None O
, None None O
( None None O
Pro None None O
/Arg None None O
) None None O
variant None None O
are None None O
higher None None O
( None None O
40.59 None None O
% None None O
and None None O
33.66 None None O
% None None O
) None None O
as None None O
compared None None O
to None None O
p53 None None I-PROTEIN
pro/pro None None O
variant None None O
( None None O
25.74 None None O
% None None O
) None None O
in None None O
the None None O
healthy None None O
population None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
study None None O
were None None O
to None None O
assess None None O
whether None None O
Indonesian None None O
women None None O
with None None O
breast None None O
cancer None None O
havea None None O
higher None None O
external None None O
health None None O
locus None None O
of None None O
control None None O
( None None O
HLC None None O
) None None O
than None None O
healthy None None O
women None None O
, None None O
and None None O
to None None O
explore None None O
the None None O
association None None O
between None None O
HLC None None O
and None None O
symptoms None None O
of None None O
anxiety None None O
and None None O
depression None None I-DISEASE
. None None O

CYP2E1 None None I-PROTEIN
and None None O
NAT2 None None O
polymorphisms None None O
were None None O
detected None None O
by None None O
PCR-RFLP None None O
in None None O
930 None None O
lung None None O
cancer None None O
patients None None O
and None None O
1000 None None O
controls None None O
. None None O

( None None O
2 None None O
) None None O
Lung None None O
cancer None None O
risk None None O
was None None O
higher None None O
in None None O
individuals None None O
with None None O
c1 None None O
, None None O
D None None O
allele None None O
of None None O
CYP2E1 None None I-PROTEIN
RsaI/PstI None None O
, None None O
DraI None None O
polymorphisms None None O
and None None O
slow None None O
acetylation None None O
of None None O
NAT2 None None O
( None None O
c1 None None O
compared None None O
with None None O
c2 None None O
, None None O
OR=1.382 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
1.178- None None O
1.587 None None O
, None None O
p=0.003 None None O
; None None O
D None None O
compared None None O
with None None O
C None None O
, None None O
OR=1.241 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
1.053-1.419 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
; None None O
slow None None O
acetylation None None O
compared None None O
with None None O
rapid None None O
acetylation None None O
, None None O
OR=1.359 None None O
, None None O
95 None None O
% None None O
CI:1.042-1.768 None None O
, None None O
p=0.056 None None O
) None None O
( None None O
3 None None O
) None None O
Compared None None O
with None None O
c2/c2 None None O
and None None O
rapid None None O
acetylation None None O
, None None O
c1/c1 None None O
together None None O
with None None O
slow None None O
acetylation None None O
synergetically None None O
increased None None O
risk None None O
of None None O
lung None None O
cancer None None O
2.83 None None O
fold None None O
. None None O

CYP2E1 None None I-PROTEIN
c1/c1 None None O
or None None O
DD None None O
genotype None None O
and None None O
NAT2 None None O
slow None None O
acetylation None None O
have None None O
strong None None O
synergistic None None O
action None None O
in None None O
increasing None None O
lung None None O
cancer None None O
risk None None O
. None None O

The None None O
Wilms None None O
' None None O
tumor None None O
gene None None O
( None None O
WT1 None None O
) None None O
and None None O
the None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
gene None None O
are None None O
highly None None O
expressed None None O
in None None O
patients None None O
with None None O
various None None O
cancers None None O
. None None O

Previous None None O
studies None None O
concerning None None O
the None None O
association None None O
between None None O
the None None O
5,10-methylenetetrahydrofolate None None O
reductase None None I-PROTEIN
( None None O
MTHFR None None O
) None None O
C677T None None O
gene None None O
polymorphism None None O
with None None O
lung None None O
cancer None None O
in None None O
Asian None None O
populations None None O
have None None O
provided None None O
inconclusive None None O
findings None None O
. None None O

Insulin None None I-PROTEIN
growth None None O
factor None None O
binding None None O
protein-5 None None O
( None None O
IGFBP-5 None None O
) None None O
can None None O
show None None O
different None None O
effects None None O
on None None O
apoptosis None None O
, None None O
cell None None O
motility None None O
and None None O
survival None None O
in None None O
breast None None O
cancer None None O
. None None O

ApN None None O
acts None None O
via None None O
two None None O
receptors None None I-PROTEIN
, None None O
namely None None O
adiponectin None None O
receptor-1 None None O
( None None O
Adipo-R1 None None O
) None None O
and None None O
adiponectin None None O
receptor-2 None None O
( None None O
Adipo-R2 None None O
) None None O
. None None O

The None None O
changes None None O
of None None O
intestinal None None O
flora None None O
, None None O
secretory None None O
immunoglobin None None O
A None None O
( None None O
SIgA None None O
) None None O
, None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
ALB None None O
) None None O
, None None O
prealbumin None None O
( None None O
PALB None None O
) None None O
, None None O
IgA None None O
and None None O
IgG None None O
at None None O
different None None O
time None None O
points None None O
in None None O
both None None O
groups None None O
were None None O
observed None None O
. None None O

Structural None None O
maintenance None None O
of None None O
chromosomes None None O
4 None None O
( None None O
SMC-4 None None O
) None None O
is None None O
a None None O
chromosomal None None O
ATPase None None I-PROTEIN
which None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
regulate None None O
chromosome None None O
assembly None None O
and None None O
segregation None None O
. None None O

The None None O
contents None None O
of None None O
plasma None None O
endothelin None None O
( None None O
ET None None O
) None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
and None None O
calcitonin None None I-TRANS
gene-related None None O
peptide None None O
( None None O
CGRP None None O
) None None O
were None None O
detected None None O
with None None O
enzyme None None O
linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
. None None O

Cathepsin None None O
B None None O
is None None O
a None None O
lysosomal None None O
cysteine None None I-TRANS
protease None None O
which None None O
is None None O
regulated None None O
by None None O
cysteine None None I-TRANS
proteinase None None O
inhibitors None None O
such None None O
as None None O
cystatin None None O
C. None None O
Elevation None None O
of None None O
cathepsin None None O
B None None O
levels None None O
in None None O
biological None None O
fluid None None O
has None None O
been None None O
observed None None O
in None None O
patients None None O
with None None O
inflammatory None None O
diseases None None O
and None None O
many None None O
cancers None None O
. None None O

Special None None O
attention None None I-FUNC
was None None O
given None None O
to None None O
the None None O
relationship None None O
between None None O
consumption None None O
of None None O
high None None O
fat None None O
meat None None O
, None None O
milk None None O
, None None O
yogurt None None O
and None None O
cheese None None O
as None None O
well None None O
use None None O
of None None O
frying None None O
oils None None O
for None None O
frying None None O
foods None None O
, None None O
use None None O
of None None O
olive/liquid None None O
oils None None O
for None None O
cooking None None O
, None None O
removing None None O
fat None None O
from None None O
meat None None O
and None None O
poultry None None O
, None None O
removing None None O
chicken None None O
skin None None O
and None None O
not None None O
use None None O
of None None O
mayonnaise None None O
as None None O
salad None None O
dressing None None O
and None None O
the None None O
risk None None O
of None None O
breast None None O
cancer None None O
. None None O

Adenylate None None I-PROTEIN
cyclase None None I-PROTEIN
translocation None None O
assays None None O
revealed None None O
13 None None O
proteins None None O
were None None O
secreted None None O
in None None O
a None None O
Dot/Icm-dependent None None O
fashion None None O
by None None O
C. None None O
burnetii None None O
during None None O
infection None None O
of None None O
human None None O
THP-1 None None O
macrophages None None O
. None None O

The None None O
suppressor None None O
of None None O
TCR None None O
signaling None None O
1 None None O
( None None O
Sts-1 None None O
) None None O
and None None O
Sts-2 None None O
are None None O
two None None O
homologous None None O
phosphatases None None I-PROTEIN
that None None O
negatively None None O
regulate None None O
signaling None None O
pathways None None O
in None None O
a None None O
number None None O
of None None O
hematopoietic None None O
cell None None O
lineages None None O
, None None O
including None None O
T None None O
lymphocytes None None O
, None None O
mast None None O
cells None None O
, None None O
and None None O
platelets None None O
. None None O

Instead None None O
, None None O
the None None O
absence None None O
of None None O
the None None O
Sts None None O
phosphatases None None I-PROTEIN
leads None None O
to None None O
the None None O
rapid None None O
induction None None O
of None None O
a None None O
unique None None O
immunological None None O
environment None None O
within None None O
the None None O
kidney None None O
, None None O
as None None O
indicated None None O
by None None O
the None None O
early None None O
induction None None O
of None None O
a None None O
proinflammatory None None O
cytokine None None O
( None None O
CXL10 None None O
) None None O
. None None O

Mutation None None O
of None None O
the None None O
genes None None O
encoding None None I-FUNC
the None None O
cytolysin None None O
ShlA None None O
and None None O
its None None O
transporter None None O
ShlB None None O
resulted None None O
in None None O
attenuated None None O
S. None None O
marcescens None None O
strains None None O
that None None O
failed None None O
to None None O
cause None None O
profound None None O
weight None None O
loss None None O
, None None O
extended None None O
illness None None O
, None None O
hemorrhage None None O
, None None O
and None None O
prolonged None None O
lung None None O
pathology None None O
in None None O
mice None None O
. None None O

Amyloids None None O
are None None O
proteins None None O
with None None O
cross-β-sheet None None O
structure None None O
that None None O
contribute None None O
to None None O
pathology None None O
and None None O
inflammation None None O
in None None O
complex None None O
human None None O
diseases None None O
, None None O
including None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
type None None O
II None None O
diabetes None None O
, None None O
and None None O
secondary None None O
amyloidosis None None O
. None None O

Interestingly None None O
, None None O
activation None None O
of None None O
the None None O
NLRP3 None None O
inflammasome None None O
by None None O
curli None None O
fibers None None O
or None None O
by None None O
amyloid None None O
β None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
does None None O
not None None O
cause None None O
cell None None O
death None None O
in None None O
macrophages None None O
. None None O

Though None None O
numerous None None O
studies None None O
apply None None O
unique None None O
clinical None None O
trial None None O
designs None None O
and None None O
considerations None None O
to None None O
assess None None O
patient None None O
health None None O
outcomes None None O
in None None O
rare None None O
diseases None None O
, None None O
less None None O
attention None None I-FUNC
has None None O
been None None O
paid None None O
to None None O
innovative None None O
methods None None O
for None None O
studying None None O
rare None None O
diseases None None O
using None None O
observational None None O
data None None O
. None None O

To None None O
critically None None O
review None None O
the None None O
learning None None I-FUNC
curve None None O
, None None O
safety None None O
issues None None O
and None None O
outcome None None O
of None None O
a None None O
single None None O
surgeon None None O
while None None O
starting None None O
up None None O
minimally None None O
invasive None None O
mitral None None O
valve None None O
surgery None None O
( None None O
MIMVS None None O
) None None O
. None None O

The None None O
learning None None I-FUNC
curve None None O
was None None O
assessed None None O
using None None O
a None None O
logarithmic None None O
curve-fit None None O
regression None None O
analysis None None O
of None None O
the None None O
cardiopulmonary None None O
bypass None None O
parameters None None O
and None None O
defined None None O
as None None O
the None None O
end None None O
of None None O
the None None O
steepest None None O
part None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
reduction None None O
in None None O
aortic None None O
cross-clamp None None O
time None None O
before None None O
and None None O
after None None O
the None None O
end None None O
of None None O
the None None O
learning None None I-FUNC
curve None None O
[ None None O
Patients None None O
1-30 None None O
: None None O
120.77 None None O
( None None O
±28.28 None None O
) None None O
; None None O
Patients None None O
31-138 None None O
: None None O
97.57 None None O
( None None O
±5.66 None None O
) None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.0001 None None O
] None None O
. None None O

However None None O
, None None O
minimally None None O
invasive None None O
mitral None None O
valve None None O
surgery None None O
with None None O
the None None O
endoclamp None None O
system None None O
is None None O
safe None None O
even None None O
during None None O
the None None O
learning None None I-FUNC
curve None None O
. None None O

A None None O
longer None None O
aortic None None O
cross-clamp None None O
time None None O
during None None O
the None None O
learning None None I-FUNC
curve None None O
did None None O
not None None O
result None None O
in None None O
longer None None O
ICU None None O
and None None O
hospital None None O
stay None None O
. None None O

We None None O
emphasize None None O
that None None O
this None None O
identifies None None O
the None None O
importance None None O
of None None O
appropriate None None O
patient None None O
selection None None O
, None None O
further None None O
investigation None None O
of None None O
risk None None O
factors None None O
and None None O
particular None None O
attention None None I-FUNC
to None None O
these None None O
risk None None O
factors None None O
during None None O
regular None None O
follow-up None None O
visits None None O
to None None O
improve None None O
PDM None None O
in None None O
this None None O
high-risk None None O
patient None None O
population None None O
. None None O

The None None O
TT None None O
carriers None None O
of None None O
polymorphism None None O
rs1937845 None None O
had None None O
a None None O
significantly None None O
increased None None O
homeostatic None None O
model None None O
assessment-B None None O
% None None O
( None None O
HOMA-B None None O
% None None O
) None None O
( None None O
P=0.045 None None O
) None None O
and None None O
that None None O
might None None O
be None None O
associated None None O
with None None O
the None None O
high None None O
risk None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

B. None None O
parapertussis None None O
contains None None O
a None None O
putative None None O
pagP None None O
homolog None None O
( None None O
encoding None None I-FUNC
B. None None O
parapertussis None None O
PagP None None O
[ None None O
PagPBPa None None O
] None None O
) None None O
, None None O
but None None O
its None None O
role None None O
in None None O
the None None O
biosynthesis None None O
of None None O
lipid None None O
A None None O
, None None O
the None None O
membrane None None O
anchor None None O
of None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
, None None O
has None None O
not None None O
been None None O
investigated None None O
. None None O

Additional None None O
virulence None None O
factor None None O
expression None None O
occurs None None O
with None None O
loss None None O
of None None O
resBC None None O
, None None O
encoding None None I-FUNC
cytochrome None None O
c None None O
maturation None None O
proteins None None O
, None None O
independently None None O
of None None O
the None None O
presence None None O
of None None O
the None None O
c-type None None O
cytochrome None None O
genes None None O
. None None O

Study None None O
3 None None O
evidenced None None O
a None None O
longitudinal None None O
mediation None None O
effect None None O
of None None O
goal None None O
ambivalence None None O
on None None O
1-year None None O
post-entry None None O
increases None None O
in None None O
life None None O
and None None O
study None None O
satisfaction None None O
, None None O
which None None O
were None None O
explained None None O
through None None O
perceptions None None I-FUNC
of None None O
goal None None O
progress None None O
at None None O
the None None O
end None None O
of None None O
the None None O
freshman None None O
year None None O
. None None O

The None None O
5-year None None O
survivors None None O
had None None O
a None None O
significantly None None O
increased None None O
hazard None None O
ratio None None O
( None None O
HR None None O
) None None O
for None None O
endocrine None None O
diseases None None O
( None None O
HR None None O
, None None O
14.7 None None O
) None None O
, None None O
psychiatric None None O
disorders None None O
( None None O
HR None None O
, None None O
1.8 None None O
) None None O
, None None O
cognitive None None O
and None None O
developmental None None O
disorders None None O
( None None O
HR None None O
, None None O
16.6 None None O
) None None O
, None None O
neurological None None O
diseases None None O
( None None O
HR None None O
, None None O
9.8 None None O
) None None O
, None None O
disorders None None O
of None None O
vision None None I-FUNC
and None None O
hearing None None O
( None None O
HR None None O
, None None O
10.5 None None O
) None None O
, None None O
and None None O
diseases None None O
of None None O
the None None O
circulatory None None O
system None None O
( None None O
HR None None O
, None None O
2.7 None None O
) None None O
compared None None O
with None None O
the None None O
sibling None None O
cohort None None O
. None None O

Five-year None None O
survivors None None O
GGCTs None None O
also None None O
experienced None None O
a None None O
nearly None None O
59-fold None None O
increase None None O
in None None O
risk None None O
of None None O
death None None O
from None None O
stroke None None I-DISEASE
( None None O
SMR None None O
, None None O
58.93 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
18.72-142.10 None None O
) None None O
. None None O

Although None None O
CNS None None O
germinomas None None O
have None None O
favorable None None O
cure None None O
rates None None O
, None None O
late None None O
recurrences None None O
, None None O
subsequent None None O
malignancies None None O
, None None O
and None None O
stroke None None I-DISEASE
significantly None None O
affect None None O
long-term None None O
survival None None O
. None None O

Stroke None None I-DISEASE
is None None O
a None None O
common None None O
and None None O
devastating None None O
embolic None None O
manifestation None None O
of None None O
infective None None O
endocarditis None None O
. None None O

This None None O
case None None O
demonstrates None None O
avoidance None None O
of None None O
a None None O
large None None O
stroke None None I-DISEASE
due None None O
to None None O
a None None O
subocclusive None None O
thrombus None None O
and None None O
anticipated None None O
intraoperative None None O
hypotension None None O
with None None O
preoperative None None O
mechanical None None O
thrombectomy None None O
. None None O

The None None O
region None None O
of None None O
CAD None None O
where None None O
Rheb None None O
binds None None O
is None None O
located None None O
at None None O
the None None O
C-terminal None None O
region None None O
of None None O
the None None O
carbamoyl-phosphate None None O
synthetase None None O
domain None None O
and None None O
not None None O
in None None O
the None None O
dihydroorotase None None O
and None None O
aspartate None None I-TRANS
transcarbamoylase None None O
domains None None O
. None None O

© None None O
2015 None None O
by None None O
The None None O
American None None O
Society None None O
for None None O
Biochemistry None None O
and None None O
Molecular None None O
Biology None None O
, None None O
Inc. None None O
Bacteriochlorophyll None None O
a None None O
biosynthesis None None O
requires None None O
the None None O
stereo- None None O
and None None O
regiospecific None None O
two None None O
electron None None O
reduction None None O
of None None O
the None None O
C7-C8 None None O
double None None O
bond None None O
of None None O
chlorophyllide None None O
a None None O
by None None O
the None None O
nitrogenase-like None None O
multisubunit None None O
metalloenzyme None None O
, None None O
chlorophyllide None None O
a None None O
oxidoreductase None None I-PROTEIN
( None None O
COR None None O
) None None O
. None None O

In None None O
subsequent None None O
mutagenesis None None O
experiments None None O
a None None O
DPOR-like None None O
aspartate None None I-TRANS
ligation None None O
pattern None None O
was None None O
implemented None None O
for None None O
the None None O
catalytic None None O
[ None None O
4Fe-4S None None O
] None None O
cluster None None O
of None None O
COR None None O
. None None O

A None None O
tentative None None O
substrate None None O
binding None None O
mode None None O
was None None O
concluded None None O
in None None O
analogy None None I-FUNC
to None None O
the None None O
related None None O
DPOR None None O
system None None O
. None None O

© None None O
2015 None None O
by None None O
The None None O
American None None O
Society None None O
for None None O
Biochemistry None None O
and None None O
Molecular None None O
Biology None None O
, None None O
Inc. None None O
ADAMTS13 None None O
is None None O
a None None O
plasma None None O
metalloproteinase None None O
that None None O
cleaves None None O
large None None O
multimeric None None O
forms None None O
of None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VWF None None O
) None None O
to None None O
smaller None None O
, None None O
less None None O
adhesive None None O
forms None None O
. None None O

Treatment None None O
with None None O
25 None None O
nm None None O
myeloperoxidase None None I-PROTEIN
plus None None O
50 None None O
μm None None O
H2O2 None None O
reduced None None O
ADAMTS13 None None O
activity None None O
by None None O
& None None O
gt None None O
; None None O
85 None None O
% None None O
. None None O

ADAMTS13 None None O
treated None None O
with None None O
either None None O
neutrophil None None O
elastase None None I-PROTEIN
or None None O
plasmin None None I-PROTEIN
was None None O
inhibited None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
especially None None O
in None None O
the None None O
presence None None O
of None None O
plasma None None O
. None None O

Moreover None None O
, None None O
GALNT10 None None O
was None None O
found None None O
to None None O
intensify None None O
O-glycosylation None None O
following None None O
signal None None O
activation None None O
of None None O
the None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
. None None O

A None None O
diagnosis None None O
of None None O
idiopathic None None O
recurrent None None O
arterial None None O
thrombosis None None I-DISEASE
was None None O
established None None O
and None None O
the None None O
patient None None O
was None None O
discharged None None O
home None None O
on None None O
aspirin None None O
and None None O
warfarin None None O
. None None O

Physical None None O
examination None None O
revealed None None O
an None None O
injected None None O
sclera None None O
and None None O
limited None None O
vertical None None O
movement None None I-FUNC
of None None O
the None None O
left None None O
eye None None O
. None None O

Performing None None O
upward None None O
gaze None None O
extra None None O
ocular None None O
movements None None I-FUNC
exacerbated None None O
the None None O
patient None None O
's None None O
bradycardia None None O
and None None O
confirmed None None O
the None None O
presence None None O
of None None O
the None None O
oculocardiac None None O
reflex None None O
. None None O

A None None O
shy None None O
, None None O
immature None None O
and None None O
timid None None O
individual None None O
, None None O
she None None O
began None None O
to None None O
have None None O
recurring None None O
, None None O
progressive None None O
episodes None None O
characterised None None O
by None None O
insomnia None None O
, None None O
paranoia None None O
, None None O
distorted None None O
thinking None None O
and None None O
mood None None I-FUNC
instability None None O
with None None O
a None None O
mix None None O
of None None O
depressive None None O
and None None O
manic-like None None O
symptoms None None O
. None None O

Although None None O
antibiotic None None O
therapy None None O
was None None O
initiated None None O
, None None O
she None None O
further None None O
showed None None O
multiple None None O
complications None None O
including None None O
Janeway None None O
lesions None None O
and None None O
cerebral None None I-DISEASE
infarctions None None I-DISEASE
, None None O
suggestive None None O
of None None O
septic None None O
systemic None None O
embolism None None I-DISEASE
. None None O

A None None O
chest None None O
CT None None O
scan None None O
ruled None None O
out None None O
a None None O
potential None None O
pulmonary None None O
embolism None None I-DISEASE
. None None O

2014 None None O
BMJ None None O
Publishing None None O
Group None None O
Ltd. None None O
A None None O
33-year-old None None O
Vietnamese None None O
man None None O
with None None O
a None None O
history None None O
of None None O
superior None None O
sagittal None None O
sinus None None O
thrombosis None None I-DISEASE
secondary None None O
to None None O
tuberculous None None O
meningitis None None O
presented None None O
with None None O
severe None None O
recurrent None None O
trigeminal None None O
neuralgia None None O
. None None O

She None None O
presented None None O
with None None O
profound None None O
disturbance None None O
of None None O
consciousness None None I-FUNC
and None None O
toxic None None O
levels None None O
of None None O
both None None O
drugs None None O
, None None O
raised None None O
in None None O
the None None O
first None None O
hours None None O
after None None O
the None None O
ingestion None None O
. None None O

Tumor-related None None O
antigens None None O
can None None O
be None None O
presented None None O
as None None O
peptides None None I-TRANS
forming None None O
complexes None None O
with None None O
major None None O
histocompatibility None None O
complex None None O
( None None O
MHC None None O
) None None O
molecules None None O
that None None O
interact None None O
with None None O
T-cell None None O
receptors None None I-PROTEIN
, None None O
thus None None O
generating None None O
an None None O
immunologic None None O
anti-tumor None None O
response None None O
. None None O

Cancers None None O
lacking None None O
expression None None O
of None None O
all None None O
three None None O
of None None O
these None None O
receptors None None I-PROTEIN
( None None O
triple-negative None None O
breast None None O
cancer None None O
; None None O
TNBC None None O
) None None O
is None None O
of None None O
particular None None O
interest None None O
for None None O
molecular None None O
research None None O
because None None O
these None None O
tumors None None O
currently None None O
have None None O
no None None O
effective None None O
targets None None O
for None None O
therapy None None O
. None None O

Dorsal None None I-NEURON
root None None O
ganglion None None O
( None None O
DRG None None O
) None None O
sensory None None I-NEURON
neurons None None I-NEURON
were None None O
also None None O
activated None None O
by None None O
the None None O
incubated None None O
EGCG None None O
through None None O
TRPV1 None None O
and None None O
TRPA1 None None O
channels None None O
. None None O

Accumulation None None O
of None None O
type None None O
I None None O
collagen None None I-PROTEIN
fibrils None None O
in None None O
tumors None None O
is None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
metastasis None None O
. None None O

We None None O
previously None None O
found None None O
that None None O
collagen None None I-PROTEIN
I None None O
fibrils None None O
induced None None O
the None None O
formation None None O
of None None O
peculiar None None O
linear None None O
invadosomes None None O
in None None O
an None None O
unexpected None None O
integrin-independent None None O
manner None None O
. None None O

Unexpectedly None None O
, None None O
DDR1 None None O
kinase None None O
activity None None O
is None None O
not None None O
required None None O
for None None O
invadosome None None O
formation None None O
or None None O
activity None None O
, None None O
nor None None O
is None None O
Src None None O
tyrosine None None I-TRANS
kinase None None O
. None None O

Model None None O
1 None None O
identified None None O
6 None None O
biomarkers None None O
strongly None None O
associated None None O
with None None O
death/MI None None O
: None None O
intercellular None None O
adhesion None None O
molecule-1 None None O
, None None O
matrix None None I-PROTEIN
metalloproteinase-3 None None O
, None None O
N-terminal None None O
pro-B-type None None O
natriuretic None None I-TRANS
peptide None None I-TRANS
, None None O
interleukin-6 None None O
, None None O
soluble None None O
CD40 None None O
ligand None None O
, None None O
and None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
binding None None O
protein-2 None None O
. None None O

Model None None O
3 None None O
identified None None O
a None None O
set None None O
of None None O
6 None None O
biomarkers None None O
( None None O
intercellular None None O
adhesion None None O
molecule-1 None None O
, None None O
matrix None None I-PROTEIN
metalloproteinase-3 None None O
, None None O
N-terminal None None O
pro-B-type None None O
natriuretic None None I-TRANS
peptide None None I-TRANS
, None None O
interleukin-6 None None O
, None None O
soluble None None O
CD40 None None O
ligand None None O
, None None O
and None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
binding None None O
protein-2 None None O
) None None O
and None None O
5 None None O
clinical None None O
variables None None O
( None None O
age None None O
, None None O
red-cell None None O
distribution None None O
width None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
hemoglobin None None O
, None None O
and None None O
New None None O
York None None O
Heart None None O
Association None None O
class None None O
) None None O
strongly None None O
associated None None O
with None None O
death/MI None None O
. None None O

A None None O
muscle None None O
acetylcholine None None I-TRANS
receptor None None I-PROTEIN
( None None O
AChR None None O
) None None O
has None None O
two None None O
neurotransmitter None None I-TRANS
binding None None O
sites None None O
located None None O
in None None O
the None None O
extracellular None None O
domain None None O
, None None O
at None None O
αδ None None O
and None None O
either None None O
αε None None O
( None None O
adult None None O
) None None O
or None None O
αγ None None O
( None None O
fetal None None O
) None None O
subunit None None O
interfaces None None O
. None None O

We None None O
speculate None None O
that None None O
the None None O
different None None O
sensitivities None None O
of None None O
the None None O
fetal None None O
αγ None None O
site None None O
versus None None O
the None None O
adult None None O
αε None None O
and None None O
αδ None None O
sites None None O
to None None O
choline None None O
and None None O
ACh None None I-TRANS
are None None O
important None None O
for None None O
the None None O
proper None None O
maturation None None O
and None None O
function None None O
of None None O
the None None O
neuromuscular None None O
synapse None None O
. None None O

Single None None O
nucleotide None None O
polymorphisms None None O
within None None O
the None None O
aminopeptidase None None O
endoplasmic None None O
reticulum None None O
aminopeptidase None None O
1 None None O
( None None O
ERAP1 None None O
) None None O
, None None O
which None None O
is None None O
essential None None O
for None None O
trimming None None O
peptides None None I-TRANS
before None None O
they None None O
are None None O
presented None None O
to None None O
T None None O
cells None None O
by None None O
major None None O
histocompatibility None None O
complex None None O
( None None O
MHC None None O
) None None O
class None None O
I None None O
molecules None None O
, None None O
have None None O
been None None O
linked None None O
with None None O
disease None None O
. None None O

Certain None None O
HCMV None None O
GCV None None O
resistance None None O
( None None O
GCV None None O
( None None O
r None None O
) None None O
) None None O
mutations None None O
, None None O
including None None O
ones None None O
associated None None O
with None None O
treatment None None O
failures None None O
, None None O
result None None O
in None None O
substitutions None None O
in None None O
the None None O
3'-5 None None O
' None None O
exonuclease None None I-PROTEIN
( None None O
Exo None None O
) None None O
domain None None O
of None None O
the None None O
catalytic None None O
subunit None None O
of None None O
the None None O
viral None None O
DNA None None O
polymerase None None O
( None None O
Pol None None O
) None None O
. None None O

Molecular None None O
modeling None None O
of None None O
collagen None None I-PROTEIN
binding None None O
to None None O
the None None O
dimer None None O
indicates None None O
the None None O
participation None None O
of None None O
nonactive None None O
site None None O
amino None None O
acid None None O
residues None None O
, None None O
Q21 None None O
and None None O
Q92 None None O
, None None O
in None None O
collagen None None I-PROTEIN
unfolding None None O
. None None O

Using None None O
scanning None None O
electron None None O
microscopy None None O
, None None O
we None None O
demonstrate None None O
the None None O
specific None None O
binding None None O
of None None O
cathepsin None None O
K None None O
at None None O
the None None O
edge None None O
of None None O
the None None O
fibrillar None None O
gap None None O
region None None O
of None None O
collagen None None I-PROTEIN
fibers None None O
, None None O
which None None O
suggest None None O
initial None None O
cleavage None None O
events None None O
at None None O
the None None O
N- None None O
and None None O
C-terminal None None O
ends None None O
of None None O
tropocollagen None None O
molecules None None O
. None None O

We None None O
propose None None O
that None None O
one None None O
cathepsin None None O
K None None O
molecule None None O
binds None None O
to None None O
collagen-bound None None O
glycosaminoglycans None None O
at None None O
the None None O
gap None None O
region None None O
and None None O
recruits None None O
a None None O
second None None O
protease None None O
molecule None None O
that None None O
provides None None O
an None None O
unfolding None None O
and None None O
cleavage None None O
mechanism None None O
for None None O
triple None None O
helical None None O
collagen None None I-PROTEIN
. None None O

Together None None O
, None None O
these None None O
data None None O
support None None O
the None None O
emerging None None O
paradigm None None O
shift None None O
that None None O
pore-forming None None O
toxins None None O
, None None O
including None None O
CDCs None None O
, None None O
have None None O
cellular None None O
receptors None None I-PROTEIN
other None None O
than None None O
cholesterol None None O
that None None O
define None None O
target None None O
cell None None O
tropism None None O
. None None O

Specifically None None O
, None None O
this None None O
network None None O
, None None O
while None None O
derived None None O
solely None None O
from None None O
healthy None None O
subjects None None O
, None None O
spatially None None O
recapitulates None None O
the None None O
pattern None None O
of None None O
brain None None O
abnormalities None None O
observed None None O
in None None O
both None None O
schizophrenia None None I-DISEASE
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Tamoxifen None None O
is None None O
effective None None O
for None None O
treating None None O
estrogen None None I-PROTEIN
receptor-alpha None None O
( None None O
ER None None O
) None None O
positive None None O
breast None None O
cancers None None O
. None None O

Cytoskeletal None None O
actin None None I-PROTEIN
assemblies None None O
transmit None None O
mechanical None None O
stresses None None O
that None None O
molecular None None O
sensors None None O
transduce None None O
into None None O
biochemical None None O
signals None None O
to None None O
trigger None None O
cytoskeletal None None O
remodeling None None O
and None None O
other None None O
downstream None None O
events None None O
. None None O

The None None O
disassembly None None O
rate None None O
was None None O
accelerated None None O
more None None O
than None None O
twofold None None O
above None None O
the None None O
resting None None O
value None None O
, None None O
but None None O
only None None O
when None None O
contraction None None O
increased None None O
the None None O
actin None None I-PROTEIN
density None None O
to None None O
a None None O
threshold None None O
value None None O
following None None O
a None None O
time None None O
delay None None O
. None None O

The None None O
model None None O
showed None None O
that None None O
this None None O
feedback None None O
mechanism None None O
, None None O
together None None O
with None None O
rapid None None O
stress None None O
transmission None None O
along None None O
the None None O
actin None None I-PROTEIN
bundle None None O
, None None O
spatiotemporally None None O
synchronizes None None O
actin None None I-PROTEIN
disassembly None None O
and None None O
fiber None None O
contraction None None O
. None None O

The None None O
VB None None O
, None None O
seen None None O
in None None O
a None None O
mirror None None O
, None None O
spoke None None O
with None None O
corresponding None None O
lip None None O
movements None None I-FUNC
, None None O
and None None O
for None None O
half None None O
of None None O
the None None O
participants None None O
this None None O
was None None O
accompanied None None O
by None None O
synchronous None None O
vibrotactile None None O
stimulation None None O
on None None O
the None None O
thyroid None None O
cartilage None None O
( None None O
Von None None O
) None None O
but None None O
this None None O
was None None O
not None None O
so None None O
for None None O
the None None O
other None None O
half None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
human None None O
FOXP2 None None I-PROTEIN
gene None None O
undergoes None None O
RMAE None None O
. None None O

Together None None O
these None None O
data None None O
suggest None None O
the None None O
intriguing None None O
possibility None None O
that None None O
RMAE None None O
impacts None None O
the None None O
haploinsufficiency None None O
phenotypes None None O
observed None None O
for None None O
FOXP2 None None I-PROTEIN
mutations None None O
. None None O

To None None O
understand None None O
this None None O
process None None O
better None None O
, None None O
we None None O
created None None O
a None None O
genetically None None O
encoded None None O
optical None None O
probe None None O
, None None O
named None None O
actin-cpstFRET-actin None None O
( None None O
AcpA None None O
) None None O
, None None O
to None None O
report None None O
forces None None O
in None None O
actin None None I-PROTEIN
in None None O
living None None O
cells None None O
in None None O
real None None O
time None None O
. None None O

We None None O
reprogrammed None None O
HEK-293 None None O
cells None None O
into None None O
stem-like None None O
cells None None O
using None None O
no None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
but None None O
simply None None O
by None None O
softening None None O
the None None O
substrate None None O
. None None O

Replating None None O
the None None O
stem-like None None O
cells None None O
on None None O
glass None None O
led None None O
to None None O
redifferentiation None None O
and None None O
reduced None None O
force None None O
in None None O
actin None None I-PROTEIN
. None None O

The None None O
labeled None None O
actin None None I-PROTEIN
expressed None None O
efficiently None None O
in None None O
HEK None None O
, None None O
MDCK None None O
, None None O
3T3 None None O
, None None O
and None None O
bovine None None O
aortic None None O
endothelial None None O
cells None None O
and None None O
in None None O
multiple None None O
stable None None O
cell None None O
lines None None O
created None None O
from None None O
those None None O
cells None None O
. None None O

The None None O
labeled None None O
actin None None I-PROTEIN
distribution None None O
was None None O
similar None None O
to None None O
that None None O
observed None None O
with None None O
GFP-tagged None None O
actin None None I-PROTEIN
. None None O

Actinin None None O
force None None O
was None None O
not None None O
always None None O
correlated None None O
with None None O
actin None None I-PROTEIN
force None None O
, None None O
emphasizing None None O
the None None O
need None None O
for None None O
addressing None None O
protein None None O
specificity None None O
when None None O
discussing None None O
forces None None O
. None None O

This None None O
new None None O
probe None None O
permits None None O
measuring None None O
actin None None I-PROTEIN
forces None None O
in None None O
a None None O
wide None None O
range None None O
of None None O
experiments None None O
on None None O
preparations None None O
ranging None None O
from None None O
isolated None None O
proteins None None O
to None None O
transgenic None None O
animals None None O
. None None O

In None None O
exponentially None None O
growing None None O
yeast None None O
, None None O
the None None O
heme None None O
enzyme None None O
, None None O
cytochrome None None I-PROTEIN
c None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
Ccp1 None None O
) None None O
is None None O
targeted None None O
to None None O
the None None O
mitochondrial None None O
intermembrane None None O
space None None O
. None None O

Learning None None I-FUNC
, None None O
defined None None O
as None None O
an None None O
increase None None O
in None None O
the None None O
prediction None None O
accuracy None None O
, None None O
occurred None None O
at None None O
the None None O
level None None O
of None None O
neuronal None None O
ensembles None None O
, None None O
particularly None None O
for None None O
difficult None None O
predictions None None O
. None None O

These None None O
findings None None O
show None None O
that None None O
BMIs None None O
for None None O
eye None None O
movements None None I-FUNC
are None None O
promising None None O
aids None None O
for None None O
assisting None None O
paralyzed None None O
patients None None O
. None None O

NLRC4-induced None None O
changes None None O
in None None O
actin None None I-PROTEIN
polymerization None None O
are None None O
physically None None O
manifested None None O
as None None O
increased None None O
cellular None None O
stiffness None None O
, None None O
and None None O
leads None None O
to None None O
reduced None None O
bacterial None None O
uptake None None O
, None None O
production None None O
of None None O
antimicrobial None None O
molecules None None O
, None None O
and None None O
arrested None None O
cellular None None O
migration None None O
. None None O

We None None O
show None None O
, None None O
therefore None None O
, None None O
a None None O
functional None None O
link None None O
between None None O
innate None None O
immunity None None O
and None None O
actin None None I-PROTEIN
turnover None None O
in None None O
macrophages None None O
that None None O
underpins None None O
a None None O
key None None O
host None None O
defense None None O
mechanism None None O
for None None O
the None None O
control None None O
of None None O
salmonellosis None None O
. None None O

Functional None None O
MRI None None O
( None None O
fMRI None None O
) None None O
studies None None O
have None None O
identified None None O
several None None O
resting-state None None O
networks None None O
, None None O
including None None O
the None None O
default None None O
mode None None O
network None None O
( None None O
DMN None None O
) None None O
, None None O
which None None O
contains None None O
a None None O
set None None O
of None None O
cortical None None O
regions None None O
that None None O
interact None None O
with None None O
a None None O
hippocampus None None I-REGION
( None None O
HC None None O
) None None O
subsystem None None O
. None None O

However None None O
, None None O
the None None O
exact None None O
form None None O
of None None O
DMN-HC None None O
alterations None None O
in None None O
aging None None O
and None None O
concomitant None None O
memory None None I-FUNC
deficits None None O
is None None O
largely None None O
unknown None None O
. None None O

Elevated None None O
HC None None O
connectivity None None O
at None None O
rest None None O
, None None O
which None None O
was None None O
partly None None O
accounted None None O
for None None O
by None None O
age-related None None O
decline None None O
in None None O
white None None I-REGION
matter None None I-REGION
integrity None None O
of None None O
the None None O
fornix None None I-REGION
, None None O
was None None O
associated None None O
with None None O
lower None None O
cross-sectional None None O
episodic None None I-FUNC
memory None None I-FUNC
performance None None O
and None None O
declining None None O
longitudinal None None O
memory None None I-FUNC
performance None None O
over None None O
20 None None O
y. None None O
Additionally None None O
, None None O
elevated None None O
HC None None O
connectivity None None O
at None None O
rest None None O
was None None O
associated None None O
with None None O
reduced None None O
HC None None O
neural None None O
recruitment None None O
and None None O
HC-cortical None None O
connectivity None None O
during None None O
active None None O
memory None None I-FUNC
encoding None None I-FUNC
, None None O
which None None O
suggests None None O
that None None O
strong None None O
HC None None O
connectivity None None O
restricts None None O
the None None O
degree None None O
to None None O
which None None O
the None None O
HC None None O
interacts None None O
with None None O
other None None O
brain None None O
regions None None O
during None None O
active None None O
memory None None I-FUNC
processing None None O
revealed None None O
by None None O
task None None O
fMRI None None O
. None None O

Learning None None I-FUNC
to None None O
read None None O
requires None None O
the None None O
acquisition None None O
of None None O
an None None O
efficient None None O
visual None None O
procedure None None O
for None None O
quickly None None O
recognizing None None O
fine None None O
print None None O
. None None O

Thus None None O
, None None O
learning None None I-FUNC
to None None O
read None None O
affects None None O
the None None O
magnitude None None O
, None None O
precision None None O
, None None O
and None None O
invariance None None O
of None None O
early None None O
visual None None O
processing None None O
. None None O

GABA-A None None O
receptors None None I-PROTEIN
mediating None None O
synaptic None None O
or None None O
extrasynaptic None None O
transmission None None O
are None None O
molecularly None None O
and None None O
functionally None None O
distinct None None O
, None None O
and None None O
glial None None O
cells None None O
are None None O
known None None O
to None None O
express None None O
a None None O
plethora None None O
of None None O
GABA-A None None O
subunits None None O
. None None O

Electrophysiological None None O
studies None None O
in None None O
vitro None None O
revealed None None O
that None None O
astrocytes None None O
express None None O
functional None None O
receptors None None I-PROTEIN
with None None O
an None None O
EC50 None None O
of None None O
52.2 None None O
± None None O
11.8 None None O
μM None None O
for None None O
GABA None None I-TRANS
. None None O

Clusters None None O
of None None O
GABA-A None None O
receptors None None I-PROTEIN
were None None O
distributed None None O
in None None O
the None None O
perinuclear None None O
space None None O
and None None O
along None None O
the None None O
processes None None O
of None None O
GFAP None None O
( None None O
+ None None O
) None None O
cells None None O
. None None O

The None None O
clusters None None O
were None None O
relatively None None O
immobile None None O
, None None O
with None None O
mean None None O
displacement None None O
of None None O
9.4 None None O
± None None O
0.9 None None O
μm None None O
and None None O
a None None O
net None None O
distance None None O
traveled None None O
of None None O
1-2 None None O
μm None None O
, None None O
owing None None O
mainly None None O
to None None O
directional None None O
movement None None I-FUNC
or None None O
simple None None O
diffusion None None O
. None None O

Essential None None I-DISEASE
tremor None None I-DISEASE
is None None O
one None None O
of None None O
the None None O
most None None O
frequent None None O
movement None None I-FUNC
disorders None None O
of None None O
humans None None O
and None None O
can None None O
be None None O
associated None None O
with None None O
substantial None None O
disability None None O
. None None O

In None None O
a None None O
six-generation None None O
consanguineous None None O
Turkish None None O
kindred None None O
with None None O
both None None O
essential None None I-DISEASE
tremor None None I-DISEASE
and None None O
Parkinson None None I-DISEASE
disease None None O
, None None O
we None None O
carried None None O
out None None O
whole None None O
exome None None O
sequencing None None O
and None None O
pedigree None None O
analysis None None O
, None None O
identifying None None O
HTRA2 None None O
p.G399S None None O
as None None O
the None None O
allele None None O
likely None None O
responsible None None O
for None None O
both None None O
conditions None None O
. None None O

Loss None None O
of None None O
function None None O
of None None O
HtrA2 None None O
was None None O
previously None None O
shown None None O
to None None O
lead None None O
to None None O
parkinsonian None None O
features None None O
in None None O
motor None None I-NEURON
neuron None None I-NEURON
degeneration None None O
( None None O
mnd2 None None O
) None None O
mice None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
in None None O
some None None O
families None None O
, None None O
HTRA2 None None O
p.G399S None None O
is None None O
responsible None None O
for None None O
hereditary None None O
essential None None I-DISEASE
tremor None None I-DISEASE
and None None O
that None None O
homozygotes None None O
for None None O
this None None O
allele None None O
develop None None O
Parkinson None None I-DISEASE
disease None None O
. None None O

Its None None O
localization None None O
is None None O
mediated None None O
by None None O
the None None O
Knk1 None None O
N None None O
terminus None None O
and None None O
is None None O
enhanced None None O
upon None None O
ATP None None O
binding None None O
to None None O
the None None O
C-terminal None None O
ATPase None None I-PROTEIN
domain None None O
. None None O

The None None O
theory None None O
identifies None None O
three None None O
classes None None O
of None None O
resources None None O
that None None O
are None None O
required None None O
for None None O
sensing None None O
: None None O
receptors None None I-PROTEIN
and None None O
their None None O
integration None None O
time None None O
, None None O
readout None None O
molecules None None O
, None None O
and None None O
energy None None O
( None None O
fuel None None O
turnover None None O
) None None O
. None None O

Using None None O
X-ray None None O
crystallography None None O
, None None O
we None None O
show None None O
, None None O
in None None O
contrast None None O
, None None O
that None None O
a None None O
sluggish None None O
variant None None O
of None None O
Bacillus None None O
subtilis None None O
CM None None O
, None None O
in None None O
which None None O
a None None O
cationic None None O
active-site None None O
arginine None None I-TRANS
was None None O
replaced None None O
by None None O
a None None O
neutral None None O
citrulline None None O
, None None O
is None None O
a None None O
poor None None O
catalyst None None O
even None None O
though None None O
it None None O
effectively None None O
preorganizes None None O
chorismate None None O
for None None O
the None None O
reaction None None O
. None None O

Instead None None O
, None None O
as None None O
with None None O
other None None O
enzymes None None I-PROTEIN
, None None O
electrostatic None None O
stabilization None None O
of None None O
the None None O
CM None None O
transition None None O
state None None O
appears None None O
to None None O
be None None O
crucial None None O
for None None O
achieving None None O
high None None O
reaction None None O
rates None None O
. None None O

Many None None O
hPS None None O
cell None None O
differentiation None None O
protocols None None O
use None None O
Matrigel None None O
, None None O
a None None O
complex None None O
and None None O
undefined None None O
substrate None None O
that None None O
engages None None O
multiple None None O
adhesion None None O
and None None O
signaling None None O
receptors None None I-PROTEIN
. None None O

For None None O
ectoderm None None O
and None None O
motor None None I-NEURON
neuron None None I-NEURON
differentiation None None O
, None None O
peptide-modified None None O
surfaces None None O
that None None O
can None None O
engage None None O
both None None O
glycosaminoglycans None None O
and None None O
integrins None None I-PROTEIN
are None None O
effective None None O
. None None O

This None None O
difference None None O
in None None O
OS None None O
seemed None None O
confined None None O
to None None O
patients None None O
with None None O
hormone None None O
receptor-negative/human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
( None None O
HER2 None None O
) None None O
-negative None None O
tumors None None O
( None None O
P None None O
= None None O
.067 None None O
) None None O
, None None O
with None None O
no None None O
differences None None O
seen None None O
with None None O
hormone None None O
receptor-positive/HER2-negative None None O
( None None O
P None None O
= None None O
.90 None None O
) None None O
or None None O
HER2-positive None None O
tumors None None O
( None None O
P None None O
= None None O
.40 None None O
) None None O
. None None O

Cytothripsis None None O
of None None O
DOCK8-deficient None None O
cells None None O
prevents None None O
the None None O
generation None None O
of None None O
long-lived None None O
skin-resident None None O
memory None None I-FUNC
CD8 None None O
T None None O
cells None None O
, None None O
which None None O
in None None O
turn None None O
impairs None None O
control None None O
of None None O
herpesvirus None None O
skin None None O
infections None None O
. None None O

Age-related None None O
aggregation None None O
of None None O
amyloid-β None None O
( None None O
Aβ None None O
) None None O
is None None O
an None None O
upstream None None O
pathological None None O
event None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
pathogenesis None None O
, None None O
and None None O
it None None O
disrupts None None O
the None None O
sleep-wake None None O
cycle None None O
. None None O

Orexins None None O
( None None O
hypocretins None None O
) None None O
initiate None None O
and None None O
maintain None None O
wakefulness None None O
, None None O
and None None O
loss None None O
of None None O
orexin-producing None None O
neurons None None O
causes None None O
narcolepsy None None I-DISEASE
. None None O

Amyloid None None O
precursor None None O
protein None None O
( None None O
APP None None I-TRANS
) None None O
/Presenilin None None O
1 None None O
( None None O
PS1 None None O
) None None O
transgenic None None O
mice None None O
, None None O
in None None O
which None None O
the None None O
orexin None None O
gene None None O
is None None O
knocked None None O
out None None O
, None None O
showed None None O
a None None O
marked None None O
decrease None None O
in None None O
the None None O
amount None None O
of None None O
Aβ None None O
pathology None None O
in None None O
the None None O
brain None None O
with None None O
an None None O
increase None None O
in None None O
sleep None None O
time None None O
. None None O

We None None O
assessed None None O
the None None O
ability None None O
of None None O
mouse None None O
CMV None None O
( None None O
MCMV None None O
) None None O
-induced None None O
memory None None I-FUNC
Ly49H None None O
( None None O
+ None None O
) None None O
NK None None O
cells None None O
to None None O
respond None None O
to None None O
challenges None None O
with None None O
influenza None None O
, None None O
an None None O
acute None None O
viral None None O
infection None None O
localized None None O
to None None O
the None None O
lung None None O
, None None O
and None None O
Listeria None None O
monocytogenes None None O
, None None O
a None None O
systemic None None O
bacterial None None O
infection None None O
. None None O

Memory None None I-FUNC
NK None None O
cells None None O
also None None O
showed None None O
impaired None None O
activation None None O
compared None None O
with None None O
naive None None O
cells None None O
when None None O
challenged None None O
with None None O
a None None O
mutant None None O
MCMV None None O
lacking None None O
m157 None None O
, None None O
highlighting None None O
their None None O
antigen-specific None None O
response None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
signals None None O
through None None O
β2-adrenergic None None O
receptors None None I-PROTEIN
( None None O
β2ARs None None O
) None None O
expressed None None O
on None None O
lymphocytes None None O
are None None O
involved None None O
in None None O
the None None O
control None None O
of None None O
lymphocyte None None O
dynamics None None O
by None None O
altering None None O
the None None O
responsiveness None None O
of None None O
chemoattractant None None O
receptors None None I-PROTEIN
. None None O

Physiological None None O
inputs None None O
from None None O
adrenergic None None O
nerves None None O
contributed None None O
to None None O
retention None None I-FUNC
of None None O
lymphocytes None None O
within None None O
LNs None None O
and None None O
homeostasis None None O
of None None O
their None None O
distribution None None O
among None None O
lymphoid None None O
tissues None None O
. None None O

These None None O
cells None None O
constitutively None None O
or None None O
inducibly None None O
express None None O
a None None O
number None None O
of None None O
receptors None None I-PROTEIN
of None None O
the None None O
TNFR None None O
and None None O
TLR None None O
families None None O
, None None O
whose None None O
signals None None O
are None None O
transduced None None O
by None None O
TNFR-associated None None O
factor None None O
( None None O
TRAF None None O
) None None O
molecules None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
both None None O
excess None None O
overall None None O
and None None O
cardiovascular None None O
mortality None None O
in None None O
schizophrenia None None I-DISEASE
is None None O
attributable None None O
to None None O
other None None O
factors None None O
than None None O
antipsychotic None None O
treatment None None O
when None None O
used None None O
in None None O
adequate None None O
dosages None None O
. None None O

Hospice None None O
volunteers None None O
are None None O
involved None None O
because None None O
they None None O
seek None None O
to None None O
help None None O
others None None O
, None None O
seek None None O
new None None O
learning None None I-FUNC
experiences None None O
, None None O
seek None None O
social None None O
contacts None None O
, None None O
or None None O
seek None None O
personal None None O
growth None None O
. None None O

We None None O
introduce None None O
a None None O
ranking None None O
approach None None O
for None None O
emotion None None I-FUNC
recognition None None O
which None None O
naturally None None O
incorporates None None O
information None None O
about None None O
the None None O
general None None O
expressivity None None O
of None None O
speakers None None O
. None None O

We None None O
train None None O
ranking None None O
SVMs None None O
for None None O
individual None None O
emotions None None I-FUNC
, None None O
treating None None O
the None None O
data None None O
from None None O
each None None O
speaker None None O
as None None O
a None None O
separate None None O
query None None O
, None None O
and None None O
combine None None O
the None None O
predictions None None O
from None None O
all None None O
rankers None None O
to None None O
perform None None O
multi-class None None O
prediction None None O
. None None O

We None None O
compare None None O
the None None O
performance None None O
of None None O
the None None O
rankers None None O
and None None O
their None None O
combination None None O
to None None O
standard None None O
SVM None None O
classification None None O
approaches None None O
on None None O
two None None O
publicly None None O
available None None O
datasets None None O
of None None O
acted None None O
emotional None None O
speech None None I-FUNC
, None None O
Berlin None None O
and None None O
LDC None None O
, None None O
as None None O
well None None O
as None None O
on None None O
spontaneous None None O
emotional None None O
data None None O
from None None O
the None None O
FAU None None O
Aibo None None O
dataset None None O
. None None O

In None None O
addition None None O
, None None O
uracil None None O
, None None O
hypoxanthine None None O
, None None O
uridine None None O
, None None O
inosine None None O
, None None O
guanosine None None O
, None None O
and None None O
adenosine None None I-TRANS
were None None O
chosen None None O
to None None O
be None None O
used None None O
for None None O
simultaneous None None O
HPLC None None O
quantification None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
TNC None None O
( None None O
such None None O
as None None O
particularly None None O
highly None None O
contained None None O
adenosine None None I-TRANS
and None None O
uracil None None O
) None None O
in None None O
HLR None None O
has None None O
a None None O
certain None None O
correlation None None O
with None None O
the None None O
activity None None O
of None None O
splenocyte-proliferating None None O
, None None O
and None None O
it None None O
may None None O
be None None O
used None None O
as None None O
a None None O
quality None None O
control None None O
for None None O
HLR None None O
. None None O

Astragalus None None O
and None None O
Panax None None O
notoginseng None None O
are None None O
traditional None None O
Chinese None None O
Medicines None None O
used None None O
for None None O
the None None O
treatments None None O
of None None O
ischemic None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
, None None O
being None None O
often None None O
combined None None O
together None None O
in None None O
China None None O
and None None O
achieving None None O
a None None O
good None None O
effect None None O
. None None O

With None None O
optimized None None O
conditions None None O
, None None O
a None None O
total None None O
of None None O
34 None None O
peaks None None O
were None None O
obtained None None O
from None None O
FC None None O
, None None O
23 None None O
of None None O
which None None O
were None None O
tentatively None None O
characterized None None O
by None None O
comparing None None O
the None None O
retention None None I-FUNC
time None None O
and None None O
mass None None O
spectrometry None None O
data None None O
and None None O
retrieving None None O
the None None O
reference None None O
literatures None None O
. None None O

Standard None None O
cytochrome None None I-PROTEIN
C None None I-PROTEIN
oxidase None None I-PROTEIN
subunit None None O
I None None O
( None None O
COI None None O
) None None O
gene None None O
fragments None None O
were None None O
sequenced None None O
for None None O
DNA None None O
barcoding None None O
of None None O
39 None None O
samples None None O
from None None O
9 None None O
snake None None O
species None None O
, None None O
including None None O
Bungarus None None O
multicinctus None None O
, None None O
the None None O
officially None None O
recognized None None O
origin None None O
animal None None O
by None None O
Chinese None None O
Pharmacopoeia None None O
, None None O
and None None O
other None None O
8 None None O
adulterate None None O
species None None O
. None None O

Chaihu-Shugan-San None None O
( None None O
CHSGS None None O
) None None O
is None None O
a None None O
well-known None None O
Chinese None None O
traditional None None O
prescription None None O
used None None O
for None None O
depression None None I-DISEASE
. None None O

A None None O
total None None O
of None None O
33 None None O
unmedicated None None O
patients None None O
with None None O
major None None O
depression None None I-DISEASE
and None None O
12 None None O
healthy None None O
comparison None None O
subjects None None O
underwent None None O
single None None O
photon None None O
emission None None O
computed None None O
tomography None None O
( None None O
SPECT None None O
) None None O
imaging None None O
. None None O

The None None O
semiquantitative None None O
values None None O
of None None O
bilateral None None O
frontal None None O
and None None O
left None None I-REGION
temporal None None I-REGION
lobes None None I-REGION
both None None O
in None None O
CHSGS None None O
group None None O
and None None O
fluoxetine None None O
group None None O
were None None O
lower None None O
than None None O
that None None O
in None None O
healthy None None O
group None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

However None None O
, None None O
few None None O
researches None None O
have None None O
been None None O
concerned None None O
with None None O
its None None O
effect None None O
on None None O
ameliorating None None O
memory None None I-FUNC
and None None O
learning None None I-FUNC
performance None None O
. None None O

Body None None O
weight None None O
, None None O
body None None O
length None None O
, None None O
testis None None O
weight None None O
, None None O
T None None O
, None None O
E2 None None O
and None None O
luteinizing None None O
hormone None None O
( None None O
LH None None O
) None None O
in None None O
serum None None O
, None None O
gonadotropin None None O
releasing None None O
hormone None None O
( None None O
GnRH None None O
) None None O
in None None O
hypothalamus None None I-REGION
, None None O
follicle None None O
stimulating None None O
hormone None None O
( None None O
FSH None None O
) None None O
and None None O
LH None None O
in None None O
pituitary None None I-REGION
gland None None I-REGION
were None None O
determined None None O
by None None O
ELISA None None O
. None None O

Soy None None O
isoflavones None None O
could None None O
significantly None None O
decrease None None O
body None None O
weight None None O
, None None O
body None None O
length None None O
, None None O
testicular None None O
organ None None O
coefficient None None O
T None None O
in None None O
serum None None O
, None None O
GnRH None None O
in None None O
hypothalamus None None I-REGION
, None None O
FSH None None O
and None None O
LH None None O
in None None O
pituitary None None I-REGION
gland None None I-REGION
. None None O

The None None O
endogenous None None O
antioxidant None None O
enzymes None None I-PROTEIN
including None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GSH-px None None O
) None None O
and None None O
intercellular None None O
glutathione None None O
( None None O
GSH None None O
) None None O
levels None None O
were None None O
determined None None O
using None None O
commercial None None O
assay None None O
kits None None O
according None None O
to None None O
the None None O
manufacturer None None O
's None None O
instructions None None O
. None None O

LFME None None O
also None None O
decreased None None O
the None None O
total None None O
intercellular None None O
levels None None O
of None None O
ROS None None O
, None None O
reduced None None O
lipid None None O
peroxidation None None O
and None None O
increased None None O
the None None O
GSH None None O
levels None None O
as None None O
well None None O
as None None O
the None None O
activities None None O
of None None O
endogenous None None O
antioxidant None None O
enzymes None None I-PROTEIN
to None None O
protect None None O
LLC-PK1 None None O
cells None None O
against None None O
AAPH-induced None None O
oxidative None None O
damage None None O
. None None O

3T3-L1 None None O
pre-adipocytes None None O
were None None O
grown None None O
in None None O
Dulbecco None None O
's None None O
Modified None None O
Eagle None None O
's None None O
Medium None None O
( None None O
DMEM None None O
) None None O
containing None None O
10 None None O
% None None O
calf None None O
serum None None O
; None None O
fully None None O
confluent None None O
cells None None O
were None None O
differentiated None None O
with None None O
insulin None None I-PROTEIN
, None None O
dexamethasone None None O
, None None O
and None None O
3-isobutylmethylxanthine None None O
in None None O
the None None O
presence None None O
and None None O
absence None None O
of None None O
LMP-09-1 None None O
and None None O
-2 None None O
( None None O
100 None None O
μg/mL None None O
) None None O
for None None O
10 None None O
days None None O
. None None O

We None None O
propose None None O
that None None O
the None None O
emergence None None O
of None None O
these None None O
symptoms None None O
may None None O
be None None O
a None None O
complication None None O
of None None O
treatment None None O
with None None O
this None None O
drug None None O
in None None O
susceptible None None O
individuals None None O
, None None O
of None None O
which None None O
the None None O
clinicians None None O
should None None O
be None None O
aware None None O
, None None O
mainly None None O
in None None O
those None None O
diagnosed None None O
with None None O
schizophrenia None None I-DISEASE
and None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
. None None O

Substance None None I-DISEASE
abuse None None I-DISEASE
was None None O
a None None O
common None None O
component None None O
of None None O
the None None O
relationships None None O
and None None O
very None None O
few None None O
involved None None O
consistent None None O
condom None None O
use None None O
. None None O

These None None O
narratives None None O
indicate None None O
that None None O
although None None O
many None None O
leave None None O
, None None O
many None None O
other None None O
women None None O
remain None None O
in None None O
relationships None None O
after None None O
learning None None I-FUNC
of None None O
a None None O
male None None O
partners None None O
' None None O
high-risk None None O
activity None None O
. None None O

MDR1 None None O
, None None O
CYP3A4 None None I-PROTEIN
, None None O
and None None O
CYP3A5 None None O
were None None O
genotyped None None O
. None None O

Also None None O
in None None O
an None None O
ischemic None None O
stroke None None I-DISEASE
setting None None O
, None None O
an None None O
important None None O
mediator None None O
of None None O
this None None O
inflammatory None None O
reaction None None O
is None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
-α None None O
, None None O
which None None O
seems None None O
to None None O
be None None O
involved None None O
in None None O
every None None O
phase None None O
of None None O
stroke-related None None O
neuronal None None O
damage None None O
such None None O
as None None O
inflammatory None None O
and None None O
prothrombotic None None O
events None None O
. None None O

Endogenous None None O
inhibitors None None O
of None None O
TNF None None O
include None None O
prostaglandins None None O
, None None O
cyclic None None O
adenosine None None I-TRANS
monophosphate None None O
, None None O
and None None O
glucocorticoids None None O
. None None O

Glucocorticoids None None O
are None None O
a None None O
class None None O
of None None O
steroid None None I-PROTEIN
hormones None None I-PROTEIN
that None None O
bind None None O
to None None O
and None None O
activate None None O
the None None O
glucocorticoid None None O
receptor None None I-PROTEIN
( None None O
GR None None O
) None None O
, None None O
which None None O
then None None O
positively None None O
or None None O
negatively None None O
regulates None None O
transcription None None O
of None None O
many None None O
genes None None O
that None None O
govern None None O
multiple None None O
important None None O
physiological None None O
pathways None None O
such None None O
as None None O
inflammation None None O
and None None O
metabolism None None O
of None None O
glucose None None O
, None None O
fat None None O
and None None O
bone None None O
. None None O

Molecular None None O
chaperones None None O
and None None O
cochaperones None None O
are None None O
typically None None O
known None None O
to None None O
provide None None O
the None None O
correct None None O
conformation None None O
for None None O
ligand None None O
binding None None O
by None None O
the None None O
steroid None None O
receptors None None I-PROTEIN
. None None O

This None None O
study None None O
assessed None None O
parents None None O
' None None O
perceptions None None I-FUNC
of None None O
the None None O
ability None None O
of None None O
their None None O
son None None O
or None None O
daughter None None O
with None None O
fragile None None O
X None None O
syndrome None None O
( None None O
FXS None None O
) None None O
, None None O
an None None O
inherited None None O
form None None O
of None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
to None None O
participate None None O
in None None O
the None None O
consent None None O
process None None O
for None None O
clinical None None O
trials None None O
. None None O

The None None O
DSM None None O
scale None None O
showed None None O
that None None O
children None None O
with None None O
SCD None None O
scored None None O
significantly None None O
higher None None O
in None None O
pervasive None None I-DISEASE
developmental None None I-DISEASE
disorder None None I-DISEASE
compared None None O
to None None O
the None None O
control None None O
group None None O
( None None O
60.9 None None O
vs. None None O
53.9 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
respectively None None O
. None None O

A None None O
double-blind None None O
, None None O
prospective None None O
, None None O
randomized None None O
, None None O
controlled None None O
study None None O
in None None O
patients None None O
American None None O
Society None None O
of None None O
Anesthesiologists None None O
I-III None None O
randomized None None O
into None None O
two None None O
groups None None O
: None None O
GA None None O
plus None None O
IIB None None O
group None None O
, None None O
induction None None O
of None None O
anesthesia None None O
with None None O
propofol None None O
, None None O
maintenance None None O
with None None O
sevoflurane None None O
, None None O
airway None None O
management None None O
with None None O
laryngeal None None O
mask None None O
allowing None None O
spontaneous None None O
ventilation None None O
and None None O
ultrasound-guided None None O
IIB None None O
; None None O
SA None None O
group None None O
, None None O
patients None None O
who None None O
underwent None None O
spinal None None O
block None None O
with None None O
2 None None O
% None None O
mepivacaine None None O
. None None O

First None None O
, None None O
the None None O
patient None None O
had None None O
warm None None O
sensation None None I-FUNC
and None None O
cutaneous None None O
anesthesia None None O
, None None O
but None None O
due None None O
to None None O
deep None None O
tissue None None O
pain None None O
, None None O
general None None O
anesthesia None None O
was None None O
induced None None O
by None None O
thiopental None None O
and None None O
atracurium None None O
. None None O

Neuroprotection None None O
and None None O
neuroregeneration None None O
are None None O
two None None O
of None None O
the None None O
most None None O
promising None None O
disease-modifying None None O
therapies None None O
for None None O
the None None O
incurable None None O
and None None O
widespread None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
used None None O
immunohistochemistry None None O
and None None O
western None None O
blot None None O
methods None None O
to None None O
weekly None None O
detect None None O
the None None O
biological None None O
behaviors None None O
of None None O
nerve None None O
cells None None O
in None None O
the None None O
hippocampal None None O
dentate None None I-REGION
gyrus None None I-REGION
of None None O
adult None None O
mice None None O
that None None O
received None None O
intraperitoneal None None O
administration None None O
of None None O
scopolamine None None O
for None None O
4 None None O
weeks None None O
. None None O

After None None O
scopolamine None None O
treatment None None O
for None None O
4 None None O
weeks None None O
, None None O
nearly None None O
all None None O
of None None O
the None None O
5-bromo-2'-deoxyuridine None None O
( None None O
BrdU None None O
) None None O
-labeled None None O
newly None None O
generated None None O
cells None None O
were None None O
located None None O
in None None O
the None None O
subgranular None None O
zone None None O
of None None O
the None None O
dentate None None I-REGION
gyrus None None I-REGION
, None None O
but None None O
they None None O
did None None O
not None None O
migrate None None O
into None None O
the None None O
granule None None O
cell None None O
layer None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
long-term None None O
administration None None O
of None None O
scopolamine None None O
interferes None None O
with None None O
the None None O
proliferation None None O
, None None O
differentiation None None O
and None None O
migration None None O
of None None O
nerve None None O
cells None None O
in None None O
the None None O
adult None None O
mouse None None O
hippocampal None None O
dentate None None I-REGION
gyrus None None I-REGION
, None None O
but None None O
it None None O
does None None O
not None None O
induce None None O
cell None None O
death None None O
. None None O

Treatment None None O
with None None O
bone None None O
marrow None None O
mesenchymal None None O
stem None None O
cells None None O
significantly None None O
increased None None O
the None None O
number None None O
of None None O
neuronal None None O
cells None None O
in None None O
hippocampal None None O
CA1 None None I-REGION
region None None O
. None None O

Neural None None O
stem None None O
cell None None O
transplantation None None O
is None None O
a None None O
useful None None O
treatment None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
, None None O
but None None O
apoptosis None None O
often None None O
occurs None None O
in None None O
the None None O
hypoxic-ischemic None None O
environment None None O
of None None O
the None None O
brain None None O
after None None O
cell None None O
transplantation None None O
. None None O

In None None O
the None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
model None None O
of None None O
ischemic None None O
injury None None O
, None None O
inflammation None None O
primarily None None O
occurs None None O
in None None O
the None None O
infarct None None O
and None None O
peripheral None None O
zones None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
pathological None None O
changes None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
. None None O

Inflammatory None None O
cytokines None None O
and None None O
microglia None None O
play None None O
a None None O
role None None O
in None None O
damage None None O
and None None O
repair None None O
after None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
. None None O

These None None O
findings None None O
indicate None None O
that None None O
intercellular None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecule-1 None None O
may None None O
be None None O
involved None None O
in None None O
blood-brain None None O
barrier None None O
injury None None O
, None None O
microglial None None O
activation None None O
, None None O
and None None O
neuronal None None O
apoptosis None None O
. None None O

Transplantation None None O
of None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor-transfected None None O
neural None None O
stem None None O
cells None None O
may None None O
be None None O
neuroprotective None None O
in None None O
rats None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
. None None O

The None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
model None None O
was None None O
established None None O
by None None O
ligating None None O
the None None O
left None None O
common None None O
carotid None None O
artery None None O
followed None None O
by None None O
exposure None None O
to None None O
hypoxia None None O
. None None O

Results None None O
revealed None None O
that None None O
the None None O
number None None O
of None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor-positive None None O
cells None None O
in None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
rats None None O
transplanted None None O
with None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor-transfected None None O
neural None None O
stem None None O
cells None None O
was None None O
increased None None O
, None None O
the None None O
time None None O
for None None O
finding None None O
water None None O
and None None O
the None None O
finding None None O
repetitions None None O
were None None O
reduced None None O
, None None O
the None None O
holding None None O
time None None O
was None None O
prolonged None None O
, None None O
and None None O
the None None O
degree None None O
of None None O
cell None None O
degeneration None None O
or None None O
necrosis None None O
was None None O
reduced None None O
. None None O

In None None O
this None None O
study None None O
, None None O
embryonic None None O
neural None None O
stem None None O
cells None None O
obtained None None O
from None None O
human None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
1 None None O
mutant None None O
( None None O
SOD1 None None O
( None None O
G93A None None O
) None None O
) None None O
and None None O
wild-type None None O
( None None O
SOD1 None None O
( None None O
WT None None O
) None None O
) None None O
mouse None None O
models None None O
were None None O
exposed None None O
to None None O
H2O2 None None O
. None None O

Moreover None None O
, None None O
we None None O
evaluated None None O
the None None O
expression None None O
of None None O
the None None O
adenosine None None I-TRANS
monophosphate-activated None None O
protein None None O
kinase None None O
( None None O
AMPK None None O
) None None O
α-subunit None None O
, None None O
paired None None O
box None None O
3 None None O
( None None O
Pax3 None None O
) None None O
protein None None O
, None None O
and None None O
p53 None None I-PROTEIN
in None None O
western None None O
blot None None O
analyses None None O
. None None O

p53 None None I-PROTEIN
protein None None O
levels None None O
were None None O
also None None O
correlated None None O
with None None O
AMPKα None None O
phosphorylation None None O
levels None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
embryonic None None O
neural None None O
stem None None O
cells None None O
from None None O
SOD1 None None O
( None None O
G93A None None O
) None None O
mice None None O
are None None O
more None None O
susceptible None None O
to None None O
apoptosis None None O
in None None O
the None None O
presence None None O
of None None O
oxidative None None O
stress None None O
compared None None O
with None None O
those None None O
from None None O
wild-type None None O
controls None None O
, None None O
and None None O
the None None O
effects None None O
are None None O
mainly None None O
mediated None None O
by None None O
Pax3 None None O
and None None O
p53 None None I-PROTEIN
in None None O
the None None O
AMPKα None None O
pathway None None O
. None None O

The None None O
succinate None None O
dehydrogenase None None I-PROTEIN
activity None None O
in None None O
the None None O
protoscolex None None O
in None None O
bone None None O
parasitized None None O
with None None O
Echinococcus None None O
granulosus None None O
was None None O
lower None None O
in None None O
the None None O
left None None O
femur None None O
than None None O
in None None O
the None None O
right None None O
femur None None O
. None None O

Expression None None O
of None None O
neuronal None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
did None None O
not None None O
change None None O
in None None O
brachial None None O
plexus None None O
root None None O
avulsion None None O
rats None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
a None None O
decrease None None O
in None None O
neuronal None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
expression None None O
in None None O
the None None O
penis None None O
may None None O
play None None O
a None None O
role None None O
in None None O
erectile None None O
dysfunction None None O
caused None None O
by None None O
the None None O
combination None None O
of None None O
brachial None None O
plexus None None O
root None None O
avulsion None None O
and None None O
spinal None None O
cord None None O
injury None None O
. None None O

A None None O
computer-based None None O
online None None O
search None None O
of None None O
Medline None None O
( None None O
1989-2013 None None O
) None None O
, None None O
Embase None None O
( None None O
1989-2013 None None O
) None None O
, None None O
Cochrane None None O
library None None O
( None None O
1989-2013 None None O
) None None O
, None None O
Chinese None None O
Biomedical None None O
Literature None None O
Database None None O
( None None O
1989-2013 None None O
) None None O
, None None O
China None None O
National None None O
Knowledge None None O
Infrastructure None None O
( None None O
1989-2013 None None O
) None None O
, None None O
VIP None None I-TRANS
( None None O
1989-2013 None None O
) None None O
, None None O
Wanfang None None O
databases None None O
( None None O
1989-2013 None None O
) None None O
and None None O
Chinese None None O
Clinical None None O
Trial None None O
Register None None O
was None None O
conducted None None O
to None None O
collect None None O
randomized None None O
controlled None None O
trial None None O
data None None O
regarding None None O
olfactory None None O
ensheathing None None O
cell None None O
transplantation None None O
for None None O
the None None O
treatment None None O
of None None O
complete None None O
spinal None None O
cord None None O
transection None None O
in None None O
rats None None O
. None None O

We None None O
have None None O
found None None O
that None None O
, None None O
there None None O
were None None O
significant None None O
differences None None O
between None None O
the None None O
two None None O
groups None None O
in None None O
volumes None None O
of None None O
left None None O
fusiform None None O
( None None O
P None None O
= None None O
0.039 None None O
) None None O
, None None O
left None None O
pars None None O
triangularis None None O
( None None O
P None None O
= None None O
0.003 None None O
) None None O
and None None O
left None None I-REGION
superior None None I-REGION
temporal None None I-REGION
gyrus None None I-REGION
( None None O
P None None O
= None None O
0.009 None None O
) None None O
, None None O
after None None O
controlling None None O
for None None O
intracranial None None O
volumes None None O
. None None O

The None None O
English None None O
version None None O
of None None O
the None None O
DHI None None O
is None None O
translated None None O
to None None O
Persian None None O
language None None I-FUNC
based None None O
on None None O
international None None O
quality None None O
of None None O
life None None O
assessment None None O
protocol None None O
. None None O

Oropharyngeal None None O
dysphagia None None O
following None None O
stroke None None I-DISEASE
enhances None None O
the None None O
risk None None O
of None None O
dehydration None None O
, None None O
malnutrition None None O
, None None O
aspiration None None O
pneumonia None None O
, None None O
persistent None None O
disablement None None O
, None None O
and None None O
even None None O
death None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
systematically None None O
introduce None None O
the None None O
published None None O
swallowing None None O
screening None None O
methods None None O
in None None O
patients None None O
with None None O
stroke None None I-DISEASE
and None None O
their None None O
appropriateness None None O
for None None O
detecting None None O
swallowing None None O
disorders None None O
following None None O
stroke None None I-DISEASE
with None None O
an None None O
emphasis None None O
on None None O
the None None O
methodological None None O
quality None None O
of None None O
their None None O
research None None O
studies None None O
. None None O

We None None O
ultimately None None O
found None None O
four None None O
simple None None O
, None None O
valid None None O
, None None O
reliable None None O
, None None O
sensitive None None O
, None None O
and None None O
specific None None O
tests None None O
for None None O
screening None None O
swallowing None None O
disorders None None O
in None None O
the None None O
almost None None O
all None None O
acute None None O
alert None None O
stroke None None I-DISEASE
patients None None O
. None None O

Predawn None None O
water None None O
loading None None O
and None None O
dehydration None None O
in None None O
the None None O
evening None None O
are None None O
shown None None O
to None None O
increase None None O
and None None O
decrease None None O
IOP None None I-TRANS
and None None O
tear None None O
secretion None None O
, None None O
respectively None None O
. None None O

Despite None None O
substantial None None O
research None None O
on None None O
the None None O
comorbidity None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
including None None O
posttraumatic None None O
stress None None O
disorder None None O
( None None O
PTSD None None O
) None None O
and None None O
chronic None None O
pain None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
mechanisms None None O
underlying None None O
these None None O
conditions None None O
that None None O
might None None O
be None None O
potentially None None O
similar None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
preliminary None None O
study None None O
was None None O
to None None O
examine None None O
evoked None None O
pain None None O
sensitivity None None O
in None None O
PTSD None None O
compared None None O
to None None O
other None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
and None None O
in None None O
control None None O
participants None None O
. None None O

These None None O
findings None None O
are None None O
similar None None O
to None None O
some None None O
of None None O
the None None O
prior None None O
research None None O
and None None O
suggest None None O
that None None O
individuals None None O
with None None O
PTSD None None O
may None None O
exhibit None None O
lower None None O
cold None None O
pain None None O
sensitivity None None O
compared None None O
to None None O
those None None O
with None None O
other None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

This None None O
study None None O
examined None None O
the None None O
moderator None None O
effect None None O
of None None O
social None None O
support None None O
on None None O
the None None O
relationship None None O
between None None O
stress None None O
and None None O
depression None None I-DISEASE
of None None O
university None None O
students None None O
. None None O

Hierarchical None None O
regression None None O
analysis None None O
showed None None O
that None None O
social None None O
support None None O
moderated None None O
the None None O
association None None O
between None None O
stress None None O
and None None O
depression None None I-DISEASE
. None None O

However None None O
, None None O
the None None O
impact None None O
of None None O
stress None None O
on None None O
depression None None I-DISEASE
was None None O
much None None O
smaller None None O
in None None O
the None None O
high None None O
social None None O
support None None O
group None None O
compared None None O
with None None O
that None None O
in None None O
the None None O
low None None O
social None None O
support None None O
group None None O
. None None O

The None None O
surgical None None O
manipulation None None O
of None None O
this None None O
metastasis None None O
had None None O
caused None None O
an None None O
acute None None O
circulatory None None O
deficiency None None O
due None None O
to None None O
massive None None O
serotonin None None I-TRANS
release None None O
. None None O

Hyperglycemia None None O
is None None O
an None None O
important None None O
diagnostic None None O
differential None None O
and None None O
has None None O
been None None O
reported None None O
to None None O
cause None None O
focal None None O
neurological None None O
deficits None None O
masquerading None None O
as None None O
stroke None None I-DISEASE
. None None O

A None None O
67 None None O
year-old None None O
right-handed None None O
woman None None O
with None None O
presented None None O
with None None O
lethargy None None O
, None None O
global None None O
aphasia None None I-DISEASE
, None None O
left None None O
eye None None O
deviation None None O
and None None O
right None None O
hemiparesis None None O
. None None O

The None None O
patient None None O
was None None O
admitted None None O
and None None O
treated None None O
with None None O
medical None None O
resuscitation None None O
including None None O
IV None None O
fluids None None O
and None None O
an None None O
insulin None None I-PROTEIN
drip None None O
. None None O

Moyamoya None None I-DISEASE
disease None None I-DISEASE
is None None O
highly None None O
prevalent None None O
among None None O
patients None None O
with None None O
syndromes None None O
that None None O
have None None O
unique None None O
cephalometric None None O
characteristics None None O
such None None O
as None None O
Down None None O
syndrome None None O
. None None O

Patients None None O
[ None None O
aged None None O
16-82 None None O
years None None O
] None None O
with None None O
angiographically None None O
confirmed None None O
Moyamoya None None I-DISEASE
disease None None I-DISEASE
who None None O
underwent None None O
cranial None None O
CT None None O
scan None None O
were None None O
analyzed None None O
. None None O

A None None O
total None None O
of None None O
13 None None O
cases None None O
of None None O
Moyamoya None None I-DISEASE
disease None None I-DISEASE
and None None O
39 None None O
controls None None O
were None None O
analyzed None None O
. None None O

There None None O
was None None O
a None None O
significantly None None O
greater None None O
bi-parietal None None O
diameter None None O
in None None O
Moyamoya None None I-DISEASE
disease None None I-DISEASE
patients None None O
compared None None O
with None None O
controls None None O
( None None O
141.5±3.7 None None O
mm None None O
versus None None O
136.9±5.4 None None O
mm None None O
, None None O
p=0.007 None None O
) None None O
. None None O

Further None None O
study None None O
of None None O
the None None O
unique None None O
cephalometric None None O
characteristics None None O
among None None O
Moyamoya None None I-DISEASE
disease None None I-DISEASE
patients None None O
may None None O
provide None None O
additional None None O
insight None None O
into None None O
disease None None O
occurrence None None O
in None None O
white None None O
and None None O
African None None O
American None None O
populations None None O
. None None O

Cerebral None None O
edema None None O
is None None O
a None None O
serious None None O
side None None O
effect None None O
of None None O
malignant None None O
stroke None None I-DISEASE
. None None O

Our None None O
study None None O
indicates None None O
that None None O
glibenclamide None None O
may None None O
decrease None None O
cerebral None None O
edema None None O
by None None O
blocking None None O
SUR1 None None O
receptors None None I-PROTEIN
in None None O
ischemic None None O
stroke None None I-DISEASE
and None None O
non-ischemic None None O
etiologies None None O
. None None O

Approximately None None O
25 None None O
% None None O
of None None O
patients None None O
with None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
( None None O
MCA None None O
) None None O
occlusion None None O
will None None O
have None None O
a None None O
concomitant None None O
ICA None None O
occlusion None None O
and None None O
50 None None O
% None None O
of None None O
patients None None O
with None None O
an None None O
ICA None None O
occlusion None None O
will None None O
have None None O
a None None O
proximal None None O
MCA None None O
occlusion None None O
. None None O

We None None O
report None None O
our None None O
experience None None O
on None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
with None None O
TIM None None O
occlusion None None O
treated None None O
with None None O
extracranial None None O
ICA None None O
angioplasty/stenting None None O
and None None O
intracranial None None O
thrombectomy None None O
and/or None None O
standard None None O
intravenous None None O
thrombolysis None None O
. None None O

We None None O
also None None O
evaluated None None O
the None None O
rate None None O
of None None O
successful None None O
recanalization None None O
based None None O
on None None O
thrombolysis None None O
in None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
( None None O
TICI None None O
) None None O
score None None O
of None None O
2b None None O
or None None O
3 None None O
. None None O

These None None O
findings None None O
, None None O
and None None O
other None None O
literature None None O
, None None O
provide None None O
a None None O
guide None None O
as None None O
to None None O
how None None O
the None None O
further None None O
development None None O
of None None O
ICT None None O
based None None O
guidelines None None O
may None None O
be None None O
implemented None None O
to None None O
improve None None O
health None None O
care None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

However None None O
, None None O
the None None O
RSN None None O
was None None O
initially None None O
an None None O
order None None O
of None None O
magnitude None None O
larger None None O
than None None O
the None None O
SN None None O
, None None O
which None None O
is None None O
undesirable None None O
since None None O
to None None O
be None None O
useful None None O
, None None O
a None None O
semantic None None I-FUNC
network None None I-FUNC
should None None O
be None None O
compact None None O
. None None O

New None None O
tools None None O
are None None O
being None None O
developed None None O
for None None O
the None None O
purposes None None O
of None None O
providing None None O
information None None O
to None None O
patients None None O
and None None O
the None None O
public None None O
which None None O
has None None O
enhanced None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
health None None O
matters None None O
and None None O
an None None O
avenue None None O
for None None O
clinicians None None O
and None None O
consumers None None O
to None None O
exchange None None O
health None None O
information None None O
for None None O
personal None None O
and None None O
public None None O
use None None O
. None None O

Pragmatics None None O
is None None O
defined None None O
as None None O
appropriate None None O
use None None O
of None None O
language None None I-FUNC
either None None O
to None None O
comprehend None None O
ideas None None O
or None None O
to None None O
interact None None O
in None None O
social None None O
situations None None O
effectively None None O
. None None O

Due None None O
to None None O
the None None O
widespread None None O
influence None None O
of None None O
language None None I-FUNC
in None None O
communication None None O
, None None O
studying None None O
pragmatic None None O
profiles None None O
, None None O
by None None O
developing None None O
appropriate None None O
tools None None O
, None None O
is None None O
of None None O
importance None None O
. None None O

We None None O
aimed None None O
to None None O
ascertain None None O
the None None O
proportion None None O
of None None O
stroke None None I-DISEASE
mimics None None O
amongst None None O
suspected None None O
TIA None None O
patients None None O
. None None O

Consecutive None None O
TIA None None O
patients None None O
were None None O
identified None None O
in None None O
a None None O
stroke None None I-DISEASE
center None None O
. None None O

The None None O
presence None None O
of None None O
hypertension None None O
, None None O
aphasia None None I-DISEASE
, None None O
duration None None O
of None None O
symptoms None None O
, None None O
and None None O
increased None None O
age None None O
was None None O
the None None O
strongest None None O
predictor None None O
of None None O
a None None O
true None None O
TIA None None O
. None None O

It None None O
seems None None O
that None None O
many None None O
signs None None O
and None None O
symptoms None None O
have None None O
low None None O
diagnostic None None O
usefulness None None O
for None None O
discrimination None None O
of None None O
true None None O
TIA None None O
from None None O
non-cerebrovascular None None O
events None None O
and None None O
predictive None None O
usefulness None None O
of None None O
any None None O
sign None None O
or None None O
symptom None None O
should None None O
be None None O
interpreted None None O
by None None O
a None None O
stroke None None I-DISEASE
neurologist None None O
. None None O

For None None O
this None None O
reason None None O
, None None O
110 None None O
brain None None O
magnetic None None O
resonance None None O
imaging None None O
confirmed None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
and None None O
110 None None O
patients None None O
age None None O
and None None O
sex None None O
matched None None O
controls None None O
went None None O
through None None O
liver None None O
ultrasound None None O
to None None O
detect None None O
NAFLD None None O
and None None O
common None None O
carotid None None O
ultrasound None None O
to None None O
measure None None O
IMT None None O
. None None O

NAFLD None None O
was None None O
found None None O
in None None O
47 None None O
( None None O
42.7 None None O
% None None O
) None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
and None None O
25 None None O
( None None O
22.7 None None O
% None None O
) None None O
of None None O
controls None None O
. None None O

However None None O
, None None O
after None None O
adjusting None None O
for None None O
other None None O
confounding None None O
risk None None O
factors None None O
( None None O
waist None None O
circumference None None O
, None None O
hypertension None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
low-density None None O
lipoprotein None None O
, None None O
triglyceride None None O
, None None O
alanine None None I-TRANS
aminotransferase None None O
, None None O
aspartate None None I-TRANS
aminotransferase None None O
, None None O
creatine None None O
, None None O
body None None O
mass None None O
index None None O
, None None O
cigarette None None O
smoking None None O
, None None O
and None None O
ischemic None None O
heart None None O
disease None None O
) None None O
, None None O
the None None O
OR None None O
decrease None None O
to None None O
1.68 None None O
( None None O
95 None None O
% None None O
CI None None O
: None None O
0.42-6.76 None None O
) None None O
that None None O
was None None O
not None None O
statistically None None O
significant None None O
( None None O
P None None O
= None None O
0.460 None None O
) None None O
. None None O

Although None None O
the None None O
risk None None O
of None None O
occurrence None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
is None None O
higher None None O
in None None O
NAFLD None None O
patients None None O
, None None O
but None None O
NAFLD None None O
is None None O
not None None O
associated None None O
independently None None O
with None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

The None None O
significant None None O
change None None O
value None None O
on None None O
the None None O
before-after None None O
BICAMS None None O
points None None O
were None None O
considered None None O
to None None O
be None None O
8 None None O
, None None O
13 None None O
, None None O
and None None O
7 None None O
points None None O
for None None O
the None None O
symbol None None O
digit None None O
modality None None O
test None None O
( None None O
SDMT None None O
) None None O
, None None O
the None None O
California None None O
verbal None None O
learning None None I-FUNC
test None None O
( None None O
CVLT None None O
) None None O
, None None O
and None None O
the None None O
brief None None O
visual-spatial None None O
memory None None I-FUNC
test None None O
revised None None O
( None None O
BVMT-R None None O
) None None O
, None None O
respectively None None O
. None None O

Migraine None None I-DISEASE
is None None O
a None None O
chronic None None O
neurological None None O
disorder None None O
, None None O
characterized None None O
by None None O
recurrent None None O
moderate None None O
to None None O
severe None None O
headaches None None O
. None None O

Studies None None O
suggest None None O
that None None O
genes None None O
involved None None O
in None None O
the None None O
production None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
may None None O
act None None O
as None None O
genetic None None O
factors None None O
for None None O
migraine None None I-DISEASE
. None None O

One None None O
class None None O
of None None O
medications None None O
used None None O
as None None O
first-line None None O
treatment None None O
in None None O
migraine None None I-DISEASE
prophylaxis None None O
is None None O
tricyclic None None O
antidepressants None None O
( None None O
TCAs None None O
) None None O
. None None O

A None None O
total None None O
of None None O
80 None None O
migraine None None I-DISEASE
patients None None O
were None None O
invited None None O
to None None O
participate None None O
in None None O
the None None O
study None None O
. None None O

At None None O
the None None O
end None None O
of None None O
3 None None O
( None None O
rd None None O
) None None O
month None None O
of None None O
the None None O
treatment None None O
patients None None O
again None None O
recorded None None O
the None None O
migraine None None I-DISEASE
characteristics None None O
for None None O
1 None None O
month None None O
and None None O
blood None None O
sampling None None O
was None None O
performed None None O
in None None O
order None None O
to None None O
determine None None O
the None None O
level None None O
of None None O
plasma None None O
NO None None O
. None None O

Mean None None O
frequency None None O
of None None O
migraine None None I-DISEASE
attacks None None O
after None None O
use None None O
of None None O
TCAs None None O
was None None O
significantly None None O
decreased None None O
in None None O
all None None O
genotypes None None O
of None None O
NOS3 None None O
Glu298Asp None None O
polymorphism None None O
particularly None None O
in None None O
TT None None O
genotype None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Non-ketotic None None O
hyperglycemia None None O
( None None O
NKHG None None O
) None None O
may None None O
increase None None O
the None None O
probability None None O
of None None O
seizures None None O
and None None O
movement None None I-FUNC
disorders None None O
. None None O

Twelve None None O
patients None None O
developed None None O
motor None None O
seizures None None O
and None None O
two None None O
others None None O
movement None None I-FUNC
disorders None None O
. None None O

All None None O
patients None None O
responded None None O
well None None O
to None None O
insulin None None I-PROTEIN
therapy None None O
and None None O
four None None O
of None None O
them None None O
needed None None O
anti-epileptic None None O
drugs None None O
. None None O

Blood None None O
glucose None None O
must None None O
be None None O
audited None None O
whenever None None O
patients None None O
with None None O
seizures None None O
or None None O
movement None None I-FUNC
disorders None None O
are None None O
encountered None None O
, None None O
as None None O
the None None O
condition None None O
may None None O
quickly None None O
resolve None None O
when None None O
NKHG None None O
is None None O
controlled None None O
. None None O

Furthermore None None O
, None None O
results None None O
show None None O
that None None O
using None None O
both None None O
physical None None O
( None None O
EF None None O
) None None O
and None None O
chemical None None O
( None None O
TGFβ3 None None O
) None None O
inducers None None O
simultaneously None None O
, None None O
has None None O
best None None O
outcomes None None O
in None None O
chondrogenesis None None O
, None None O
and None None O
expression None None O
of None None O
SOX None None O
( None None O
9 None None O
) None None O
and None None O
type None None O
II None None O
collagen None None I-PROTEIN
genes None None O
. None None O

The None None O
present None None O
study None None O
examined None None O
the None None O
modulation None None O
of None None O
S1P None None O
and None None O
ApoM None None O
levels None None O
in None None O
the None None O
plasma None None O
, None None O
liver None None O
and None None O
kidneys None None O
in None None O
streptozotocin-induced None None O
diabetes None None O
( None None O
STZ None None O
) None None O
mice None None O
, None None O
and None None O
the None None O
effects None None O
of None None O
insulin None None I-PROTEIN
on None None O
the None None O
S1P None None O
and None None O
ApoM None None O
levels None None O
in None None O
the None None O
plasma None None O
and None None O
liver None None O
in None None O
STZ None None O
mice None None O
and None None O
normal None None O
mice None None O
. None None O

The None None O
hepatic None None O
S1P None None O
and None None O
ApoM None None O
contents None None O
were None None O
reduced None None O
by None None O
insulin None None I-PROTEIN
treatment None None O
, None None O
whereas None None O
high-dose None None O
insulin None None I-PROTEIN
decreased None None O
the None None O
plasma None None O
S1P None None O
and None None O
ApoM None None O
levels None None O
. None None O

Treatment None None O
with None None O
insulin None None I-PROTEIN
and None None O
incubation None None O
under None None O
a None None O
low None None O
glucose None None O
level None None O
decreased None None O
the None None O
ApoM None None O
levels None None O
in None None O
HepG2 None None O
cells None None O
. None None O

Type None None O
1 None None O
diabetes None None O
mellitus None None O
is None None O
a None None O
serious None None O
disorder None None O
characterized None None O
by None None O
destruction None None O
of None None O
pancreatic None None O
β-cells None None O
, None None O
culminating None None O
in None None O
absolute None None O
insulin None None I-PROTEIN
deficiency None None O
. None None O

In None None O
addition None None O
to None None O
the None None O
importance None None O
of None None O
decreased None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
insulin None None I-PROTEIN
sensitivity None None O
, None None O
age None None O
was None None O
the None None O
strong None None O
factor None None O
to None None O
elevate None None O
2-h None None O
PG None None O
levels None None O
in None None O
the None None O
2-h None None O
PG-side None None O
group None None O
and None None O
triglyceride None None O
was None None O
the None None O
strong None None O
factor None None O
to None None O
elevate None None O
FPG None None O
levels None None O
in None None O
the None None O
FPG-side None None O
group None None O
in None None O
the None None O
early None None O
stage None None O
of None None O
development None None O
of None None O
type None None O
2 None None O
diabetes None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
identified None None O
six None None O
patient None None O
individual None None O
and None None O
environmental None None O
characteristics None None O
, None None O
namely None None O
, None None O
age None None O
, None None O
sex None None O
, None None O
physical None None O
activity None None O
, None None O
psychological None None O
distress None None O
, None None O
social None None O
support None None O
and None None O
adequacy None None O
of None None O
income None None O
, None None O
that None None O
significantly None None O
influence None None O
HRQOL None None O
directly None None O
or None None O
by None None O
way None None O
of None None O
physical None None O
functional None None O
status None None O
and None None O
general None None O
health None None O
perception None None I-FUNC
. None None O

DPN None None O
was None None O
diagnosed None None O
by None None O
the None None O
combination None None O
of None None O
more None None O
than None None O
one None None O
abnormal None None O
result None None O
of None None O
10-g None None O
monofilament None None O
, None None O
pinprick None None O
sensations None None I-FUNC
and None None O
ankle None None O
reflexes None None O
, None None O
and None None O
categorized None None O
according None None O
to None None O
the None None O
severity None None O
level None None O
using None None O
vibration None None O
perception None None I-FUNC
threshold None None O
. None None O

To None None O
compare None None O
carotid None None O
and None None O
lower None None O
limb None None O
atherosclerotic None None O
lesions None None O
, None None O
and None None O
examine None None O
if None None O
carotid None None O
atherosclerotic None None O
lesions None None O
are None None O
in None None O
line None None O
with None None O
lower None None O
limb None None O
atherosclerotic None None O
lesions None None O
, None None O
and None None O
can None None O
reflect None None O
generalized None None O
atherosclerosis None None I-DISEASE
in None None O
inpatients None None O
with None None O
type None None O
2 None None O
diabetes None None O
. None None O

Extracranial-intracranial None None O
arterial None None O
bypass None None O
surgery None None O
is None None O
rarely None None O
performed None None O
for None None O
recurrent None None O
or None None O
progressing None None O
stroke None None I-DISEASE
due None None O
to None None O
vertebrobasilar None None O
artery None None O
steno-occlusive None None O
disease None None O
. None None O

Preoperative None None O
7.0-T None None O
MR None None O
imaging None None O
visualized None None O
the None None O
marginal None None O
tentorial None None O
artery None None O
as None None O
an None None O
unusual None None O
collateral None None O
pathway None None O
in None None O
a None None O
patient None None O
with None None O
symptomatic None None O
bilateral None None O
vertebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
undergoing None None O
arterial None None O
bypass None None O
surgery None None O
. None None O

A None None O
53-year-old None None O
male None None O
presented None None O
with None None O
sudden None None O
onset None None O
of None None O
right None None O
hemiparesis None None O
and None None O
aphasia None None I-DISEASE
. None None O

Hydrocephalus None None I-DISEASE
was None None O
diagnosed None None O
by None None O
computed None None O
tomography None None O
and None None O
the None None O
obstruction None None O
of None None O
the None None O
peritoneal None None O
catheter None None O
was None None O
revealed None None O
by None None O
shuntgraphy None None O
. None None O

Cavernous None None O
malformations None None O
arising None None O
in None None O
a None None O
single None None O
optic None None I-REGION
nerves None None I-REGION
paring None None O
the None None O
chiasm None None O
( None None O
intracranial None None O
prechiasmatic None None O
optic None None I-REGION
nerve None None I-REGION
) None None O
and None None O
expanding None None O
into None None O
the None None O
optic None None O
canal None None O
are None None O
extremely None None O
rare None None O
lesions None None O
. None None O

We None None O
present None None O
the None None O
first None None O
case None None O
to None None O
be None None O
published None None O
, None None O
of None None O
an None None O
intracranial None None O
optic None None I-REGION
nerve None None I-REGION
cavernous None None O
malformation None None O
with None None O
a None None O
contiguous None None O
canalicular None None O
component None None O
that None None O
was None None O
totally None None O
and None None O
successfully None None O
removed None None O
through None None O
a None None O
microsurgical None None O
pterional None None O
approach None None O
with None None O
excellent None None O
clinical None None O
outcome None None O
. None None O

We None None O
previously None None O
reported None None O
a None None O
case None None O
of None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
complicated None None O
by None None O
myocardial None None O
infarction None None O
. None None O

The None None O
case None None O
of None None O
a None None O
ruptured None None O
fusiform None None O
aneurysm None None O
accompanied None None O
by None None O
dissection None None O
at None None O
the None None O
M2 None None O
portion None None O
of None None O
the None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
( None None O
MCA None None O
) None None O
is None None O
reported None None O
, None None O
along None None O
with None None O
pathological None None O
findings None None O
. None None O

In None None O
an None None O
exploratory None None O
manner None None O
we None None O
examined None None O
change None None O
in None None O
parent None None O
distress None None O
and None None O
child None None O
physical None None O
function None None O
and None None O
depression None None I-DISEASE
from None None O
pre- None None O
to None None O
post-treatment None None O
. None None O

As None None O
the None None O
overall None None O
smoking None None O
prevalence None None O
grows None None O
, None None O
female None None O
smoking None None O
is None None O
growing None None O
at None None O
a None None O
faster None None O
rate None None O
than None None O
smoking None None O
among None None O
males None None O
, None None O
which None None O
is None None O
an None None O
emerging None None O
concern None None O
for None None O
tobacco None None O
control None None O
in None None O
India None None O
and None None O
requires None None O
the None None O
attention None None I-FUNC
of None None O
policymakers None None O
. None None O

Based None None O
on None None O
VFG None None O
findings None None O
, None None O
seven None None O
patients None None O
( None None O
4/9 None None O
oropharynx None None O
and None None O
3/11 None None O
laryngopharynx None None O
) None None O
were None None O
grouped None None O
as None None O
aspirators None None O
( None None O
A None None O
) None None O
and None None O
remaining None None O
13 None None O
as None None O
non-aspirators None None O
( None None O
NA None None I-TRANS
) None None O
. None None O

In None None O
group None None O
A None None O
, None None O
deaths None None O
attributable None None O
to None None O
aspiration None None O
were None None O
seen None None O
in None None O
3/7 None None O
patients None None O
, None None O
while None None O
none None None O
occurred None None O
in None None O
the None None O
NA None None I-TRANS
group None None O
( None None O
Fisher None None O
's None None O
exact None None O
P None None O
= None None O
0.03 None None O
) None None O
. None None O

VFG None None O
helps None None O
identify None None O
patients None None O
who None None O
aspirate None None O
and None None O
are None None O
at None None O
risk None None O
of None None O
premature None None O
death None None O
due None None O
to None None O
its None None O
complications None None O
, None None O
alerting None None O
caregivers None None O
to None None O
direct None None O
attention None None I-FUNC
appropriately None None O
. None None O

There None None O
were None None O
no None None O
restrictions None None O
with None None O
regard None None O
to None None O
publication None None O
language None None I-FUNC
. None None O

With None None O
model None None O
peptides None None I-TRANS
as None None O
the None None O
sample None None O
, None None O
the None None O
labeling None None O
efficiency None None O
and None None O
the None None O
stability None None O
of None None O
the None None O
peptide None None O
derivatives None None O
were None None O
investigated None None O
. None None O

For None None O
example None None O
, None None O
the None None O
identification None None O
efficiency None None O
of None None O
the None None O
thiol-containing None None O
peptides None None I-TRANS
of None None O
α-transferrin None None O
increased None None O
more None None O
than None None O
42 None None O
% None None O
upon None None O
combination None None O
with None None O
the None None O
IMP None None O
or None None O
IPP None None O
derivatives None None O
. None None O

Dopamine None None I-TRANS
( None None O
DA None None O
) None None O
has None None O
attracted None None O
extensive None None O
interest None None O
due None None O
to None None O
not None None O
only None None O
its None None O
important None None O
roles None None O
in None None O
physiological None None O
and None None O
pathological None None O
processes None None O
, None None O
but None None O
also None None O
its None None O
prospective None None O
applications None None O
in None None O
chemistry None None O
and None None O
materials None None O
science None None O
. None None O

Heat None None O
illness None None O
spans None None O
a None None O
broad None None O
spectrum None None O
of None None O
disease None None O
, None None O
with None None O
outcomes None None O
ranging None None O
from None None O
benign None None O
rash None None O
to None None O
fatal None None O
heat None None O
stroke None None I-DISEASE
. None None O

Dopaminergic None None I-NEURON
neurons None None I-NEURON
in None None O
Drosophila None None O
play None None O
critical None None O
roles None None O
in None None O
diverse None None O
brain None None O
functions None None O
such None None O
as None None O
motor None None I-FUNC
control None None I-FUNC
, None None O
arousal None None O
, None None O
learning None None I-FUNC
, None None O
and None None O
memory None None I-FUNC
. None None O

Dopamine None None I-TRANS
mediates None None O
its None None O
functions None None O
through None None O
interaction None None O
with None None O
its None None O
receptors None None I-PROTEIN
. None None O

Currently None None O
, None None O
no None None O
study None None O
has None None O
attempted None None O
to None None O
characterize None None O
the None None O
role None None O
of None None O
DD2R None None O
in None None O
Drosophila None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

The None None O
function None None O
of None None O
postsynaptic None None O
DD2R None None O
expressed None None O
in None None O
mushroom None None O
body None None O
( None None O
MB None None O
) None None O
was None None O
also None None O
studied None None O
as None None O
MB None None O
is None None O
the None None O
center None None O
for None None O
Drosophila None None O
learning None None I-FUNC
, None None O
with None None O
a None None O
function None None O
analogous None None O
to None None O
that None None O
of None None O
the None None O
mammalian None None O
hippocampus None None I-REGION
. None None O

Similarly None None O
, None None O
postsynaptic None None O
DD2R None None O
in None None O
MB None None O
neurons None None O
appears None None O
to None None O
be None None O
involved None None O
in None None O
both None None O
appetitive None None O
and None None O
aversive None None O
learning None None I-FUNC
. None None O

Similar None None O
effect None None O
on None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
homeostasis None None O
was None None O
recently None None O
reported None None O
for None None O
spiroindolones None None O
, None None O
which None None O
are None None O
antimalarials None None O
of None None O
a None None O
chemical None None O
class None None O
quite None None O
distinct None None O
from None None O
pyrazoleamides None None O
. None None O

These None None O
studies None None O
show None None O
that None None O
the None None O
extraction None None O
of None None O
Th None None O
( None None O
IV None None O
) None None O
is None None O
significantly None None O
suppressed None None O
compared None None O
to None None O
that None None O
of None None O
U None None O
( None None O
VI None None I-REGION
) None None O
with None None O
increased None None O
branching None None O
at None None O
the None None O
Cα None None O
atom None None O
adjacent None None O
to None None O
the None None O
carbonyl None None O
group None None O
. None None O

Other None None O
features None None O
included None None O
a None None O
reduced None None O
level None None O
of None None O
consciousness None None I-FUNC
( None None O
32 None None O
% None None O
) None None O
, None None O
dilated None None O
pupils None None O
( None None O
24 None None O
% None None O
) None None O
, None None O
hallucinations None None O
( None None O
20 None None O
% None None O
) None None O
, None None O
diaphoresis None None O
( None None O
12 None None O
% None None O
) None None O
, None None O
seizures None None O
( None None O
8 None None O
% None None O
) None None O
, None None O
and None None O
hyperthermia None None O
( None None O
6 None None O
% None None O
) None None O
. None None O

Cataract None None O
is None None O
the None None O
leading None None O
cause None None O
of None None O
impaired None None O
vision None None I-FUNC
and None None O
vision None None I-FUNC
loss None None O
in None None O
dogs None None O
. None None O

This None None O
article None None O
aims None None O
to None None O
aid None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
cataract None None O
therapy None None O
on None None O
the None None O
basis None None O
of None None O
diagnostic None None O
guidance None None O
and None None O
to None None O
facilitate None None O
the None None O
selection None None O
of None None O
an None None O
appropriate None None O
point None None O
of None None O
time None None O
for None None O
surgery None None O
. None None O

Aβ42 None None O
peptides None None I-TRANS
associate None None O
into None None O
soluble None None O
oligomers None None O
and None None O
protofibrils None None O
in None None O
the None None O
process None None O
of None None O
forming None None O
the None None O
amyloid None None O
fibrils None None O
associated None None O
with None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Two None None O
patients None None O
sustained None None O
contusions None None O
; None None O
two None None O
nerve None None O
injuries None None O
; None None O
one None None O
dorsal None None I-NEURON
skin None None O
loss None None O
; None None O
one None None O
nail None None O
complex None None O
injury None None O
; None None O
two None None O
extensor None None O
tendon None None O
injury None None O
; None None O
three None None O
distal None None O
phalangeal None None O
fracture None None O
; None None O
one None None O
interphalangeal None None O
fracture-dislocation None None O
; None None O
two None None O
complete None None O
or None None O
partial None None O
amputations None None O
. None None O

The None None O
physiological None None O
response None None O
was None None O
assessed None None O
based None None O
on None None O
heart None None O
rate None None O
measurements None None O
( None None O
HR None None O
, None None O
bpm None None O
) None None O
at None None O
a None None O
sampling None None O
rate None None O
of None None O
1 None None O
Hz None None O
during None None O
several None None O
basic None None O
aquatic None None O
motor None None O
skills None None O
: None None O
1 None None O
) None None O
individual None None O
displacement None None O
in None None O
ventral None None I-NEURON
position None None O
( None None O
HR None None O
@ None None O
InD None None O
) None None O
; None None O
2 None None O
) None None O
Individual None None O
displacement None None O
in None None O
vertical None None O
position None None O
( None None O
HR None None O
@ None None O
VD None None O
) None None O
; None None O
3 None None O
) None None O
immersion None None O
( None None O
HR None None O
@ None None O
Im None None O
) None None O
; None None O
4 None None O
) None None O
voluntary None None O
underwater None None O
displacement None None O
( None None O
HR None None O
@ None None O
UnD None None O
) None None O
; None None O
5 None None O
) None None O
jump None None O
from None None O
the None None O
deck None None O
( None None O
HR None None O
@ None None O
JD None None O
) None None O
; None None O
6 None None O
) None None O
jump None None O
from None None O
the None None O
swimming None None O
mat None None O
( None None O
HR None None O
@ None None O
JM None None O
) None None O
; None None O
7 None None O
) None None O
from None None O
a None None O
swimming None None O
slider None None O
( None None O
HR None None O
@ None None O
Sli None None O
) None None O
. None None O

The None None O
associated None None O
physicochemical None None O
insight None None O
is None None O
contributing None None O
to None None O
our None None O
mechanistic None None O
understanding None None O
of None None O
oral None None O
processing None None O
and None None O
textural None None O
perception None None I-FUNC
of None None O
food None None O
systems None None O
and None None O
to None None O
the None None O
development None None O
of None None O
colloid-based None None O
strategies None None O
to None None O
control None None O
delivery None None O
of None None O
nutrients None None O
during None None O
food None None O
digestion None None O
within None None O
the None None O
human None None O
gastrointestinal None None O
tract None None O
. None None O

First None None O
, None None O
central None None O
infusion None None O
of None None O
specific None None O
agonists None None O
for None None O
the None None O
receptors None None I-PROTEIN
of None None O
SP None None O
( None None O
neurokinin None None O
receptor None None I-PROTEIN
1 None None O
, None None O
NK1R None None O
) None None O
, None None O
NKA None None O
( None None O
NK2R None None O
) None None O
and None None O
NKB None None O
( None None O
NK3R None None O
) None None O
each None None O
induced None None O
gonadotropin None None O
release None None O
in None None O
adult None None O
male None None O
and None None O
ovariectomized None None O
, None None O
estradiol-replaced None None O
female None None O
mice None None O
, None None O
which None None O
was None None O
absent None None O
in None None O
Kiss1r None None O
( None None O
-/- None None O
) None None O
mice None None O
, None None O
indicating None None O
a None None O
kisspeptin-dependent None None O
action None None O
. None None O

Second None None O
, None None O
Tac1 None None O
( None None O
encoding None None I-FUNC
SP None None O
and None None O
NKA None None O
) None None O
expression None None O
in None None O
the None None O
ARC None None O
and None None O
ventromedial None None O
nucleus None None O
was None None O
inhibited None None O
by None None O
circulating None None O
estradiol None None O
but None None O
did None None O
not None None O
colocalize None None O
with None None O
Kiss1 None None O
mRNA None None O
. None None O

The None None O
expression None None O
of None None O
canonical None None O
histones None None I-PROTEIN
is None None O
normally None None O
coupled None None O
to None None O
DNA None None O
synthesis None None O
during None None O
the None None O
S None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
the None None O
thyroid None None O
hormone None None O
can None None O
increase None None O
the None None O
levels None None O
of None None O
canonical None None O
histones None None I-PROTEIN
independent None None O
of None None O
DNA None None O
replication None None O
. None None O

These None None O
results None None O
point None None O
out None None O
the None None O
importance None None O
of None None O
the None None O
thyroid None None O
hormones None None I-PROTEIN
on None None O
the None None O
posttranscriptional None None O
regulation None None O
of None None O
histone None None O
biosynthesis None None O
in None None O
a None None O
cell None None O
cycle-independent None None O
manner None None O
and None None O
also None None O
suggest None None O
the None None O
potential None None O
regulation None None O
of None None O
eukaryotic None None O
translation None None O
by None None O
the None None O
modulation None None O
of None None O
the None None O
initiation None None O
factor None None O
EIF4G2 None None O
, None None O
which None None O
also None None O
operates None None O
in None None O
the None None O
translation None None O
of None None O
canonical None None O
mRNAs None None O
. None None O

After None None O
open-label None None O
treatment None None O
with None None O
an None None O
SSRI None None O
for None None O
8 None None O
weeks None None O
, None None O
subjects None None O
with None None O
a None None O
Hamilton None None O
Depression None None I-DISEASE
Scale None None O
17 None None O
score None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
16 None None O
were None None O
entered None None O
into None None O
a None None O
double-blind None None O
phase None None O
and None None O
randomized None None O
to None None O
CP-601,927 None None O
2 None None O
mg None None O
twice None None O
daily None None O
or None None O
placebo None None O
for None None O
6 None None O
weeks None None O
. None None O

CP-601,927 None None O
was None None O
equivalent None None O
to None None O
placebo None None O
as None None O
an None None O
augmenting None None O
agent None None O
of None None O
antidepressants None None O
in None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
patients None None O
with None None O
insufficient None None O
response None None O
to None None O
SSRIs None None O
. None None O

The None None O
regulation None None O
networks None None O
between None None O
the None None O
p53 None None I-PROTEIN
tumor None None O
suppressor None None O
and None None O
these None None O
RNAs None None O
in None None O
nasopharyngeal None None O
carcinoma None None O
remains None None O
unclear None None O
. None None O

Further None None O
studies None None O
indicated None None O
that None None O
LOC401317 None None O
is None None O
directly None None O
regulated None None O
by None None O
p53 None None I-PROTEIN
and None None O
that None None O
ectopic None None O
expression None None O
of None None O
LOC401317 None None O
inhibits None None O
HNE2 None None O
cell None None O
proliferation None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
by None None O
inducing None None O
cell None None O
cycle None None O
arrest None None O
and None None O
apoptosis None None O
. None None O

Collectively None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
LOC401317 None None O
is None None O
directly None None O
regulated None None O
by None None O
p53 None None I-PROTEIN
and None None O
exerts None None O
antitumor None None O
effects None None O
in None None O
HNE2 None None O
nasopharyngeal None None O
carcinoma None None O
cells None None O
. None None O

Knowledge None None O
of None None O
the None None O
detailed None None O
mechanism None None O
by None None O
which None None O
proteins None None O
such None None O
as None None O
human None None O
αB- None None O
crystallin None None O
and None None O
human None None O
lysozyme None None I-PROTEIN
inhibit None None O
amyloid None None O
beta None None O
( None None O
Aβ None None O
) None None O
peptide None None O
aggregation None None O
is None None O
crucial None None O
for None None O
designing None None O
treatment None None O
for None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Simulations None None O
reveal None None O
that None None O
both None None O
inhibitor None None O
proteins None None O
compete None None O
with None None O
inter-peptide None None O
interaction None None O
by None None O
binding None None O
to None None O
the None None O
peptides None None I-TRANS
during None None O
the None None O
early None None O
stage None None O
of None None O
aggregation None None O
, None None O
which None None O
is None None O
consistent None None O
with None None O
their None None O
inhibitory None None O
action None None O
reported None None O
in None None O
experiments None None O
. None None O

In None None O
contrast None None O
, None None O
a None None O
high None None O
local None None O
density None None O
of None None O
arginines None None I-TRANS
from None None O
lysozyme None None I-PROTEIN
allows None None O
strong None None O
binding None None O
with None None O
Aβ None None O
peptide None None O
monomers None None O
, None None O
resulting None None O
in None None O
stable None None O
complexes None None O
. None None O

Seven None None O
days None None O
after None None O
RTX None None O
administration None None O
, None None O
PUs None None O
were None None O
induced None None O
by None None O
applying None None O
two None None O
magnetic None None O
plates None None O
on None None O
the None None O
dorsal None None I-NEURON
skin None None O
. None None O

A None None O
new None None O
melatonin None None I-TRANS
1 None None O
and None None O
melatonin None None I-TRANS
2 None None O
agonist None None O
tasimelteon None None O
improves None None O
sleep None None O
in None None O
these None None O
patients None None O
, None None O
resetting None None O
their None None O
circadian None None O
sleep-wake None None O
clocks None None O
. None None O

In None None O
the None None O
selected None None O
mutant None None O
mice—activating None None O
transcription None None O
factor None None O
4 None None O
( None None O
ATF4 None None O
) None None O
or None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
9 None None O
( None None O
MMP9 None None O
) None None O
knock-outs—toughness None None O
is None None O
reduced None None O
but None None O
differences None None O
in None None O
bone None None O
strength None None O
do None None O
not None None O
exist None None O
between None None O
knock-out None None O
and None None O
corresponding None None O
wild-type None None O
controls None None O
. None None O

Overall None None O
, None None O
increasing None None O
polarization None None O
information None None O
by None None O
collecting None None O
spectra None None O
from None None O
two None None O
bone None None O
orientations None None O
improves None None O
the None None O
ability None None O
of None None O
multivariate None None O
RS None None O
to None None O
explain None None O
variance None None O
in None None O
bone None None O
toughness None None O
, None None O
likely None None O
due None None O
to None None O
polarization None None O
sensitivity None None O
to None None O
organizational None None O
changes None None O
in None None O
both None None O
mineral None None O
and None None O
collagen None None I-PROTEIN
. None None O

In None None O
fact None None O
, None None O
the None None O
four None None O
oligosaccharides None None O
are None None O
presented None None O
in None None O
close None None O
proximity None None O
on None None O
the None None O
same None None O
side None None O
of None None O
the None None O
dimer None None O
surface None None O
, None None O
which None None O
increases None None O
avidity None None O
for None None O
cellular None None O
receptors None None I-PROTEIN
, None None O
e.g None None O
. None None O

We None None O
recently None None O
synthesised None None O
two None None O
new None None O
compounds None None O
( None None O
ISA27 None None O
and None None O
SM13 None None O
) None None O
, None None O
which None None O
block None None O
p53-MDM2 None None O
interaction None None O
and None None O
induce None None O
apoptosis None None O
in None None O
p53 None None I-PROTEIN
wild-type None None O
( None None O
WT None None O
) None None O
tumour None None O
cells None None O
. None None O

In None None O
vitro None None O
we None None O
evaluated None None O
the None None O
effectiveness None None O
of None None O
our None None O
compounds None None O
in None None O
cancer None None O
cell None None O
lines None None O
carrying None None O
WT None None O
, None None O
mutated None None O
and None None O
null None None O
p53 None None I-PROTEIN
gene None None O
. None None O

Both None None O
ISA27 None None O
and None None O
SM13 None None O
reduced None None O
cell None None O
proliferation None None O
and None None O
induced None None O
apoptosis None None O
in None None O
vitro None None O
in None None O
cells None None O
carrying None None O
either None None O
p53 None None I-PROTEIN
WT None None O
or None None O
mutated None None O
gene None None O
, None None O
suggesting None None O
that None None O
its None None O
effect None None O
is None None O
independent None None O
from None None O
p53 None None I-PROTEIN
transcriptional None None O
activity None None O
. None None O

Our None None O
study None None O
proposes None None O
SM13 None None O
as None None O
anticancer None None O
compound None None O
to None None O
use None None O
for None None O
the None None O
treatment None None O
of None None O
p53-dependent None None O
tumours None None O
, None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
p53 None None I-PROTEIN
transcriptional None None O
activity None None O
. None None O

PARVB None None O
is None None O
known None None O
to None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
actin None None I-PROTEIN
reorganization None None O
and None None O
focal None None O
adhesions None None O
. None None O

Dual-luciferase None None O
reporter None None O
assay None None O
and None None O
real-time None None O
PCR None None O
analysis None None O
are None None O
used None None O
to None None O
examine None None O
the None None O
regulation None None O
of None None O
p53 None None I-PROTEIN
. None None O

miR-1228 None None O
downregulated None None O
p53 None None I-PROTEIN
expression None None O
by None None O
binding None None O
to None None O
its None None O
3'UTR None None O
. None None O

An None None O
inverse None None O
correlation None None O
existed None None O
between None None O
miR-1228 None None O
and None None O
p53 None None I-PROTEIN
expression None None O
in None None O
hepatoma None None O
tissues None None O
compared None None O
with None None O
the None None O
adjacent None None O
tissues None None O
and None None O
three None None O
hepatoma None None O
cell None None O
lines None None O
. None None O

miR-1228 None None O
functions None None O
as None None O
an None None O
oncogene None None O
by None None O
promoting None None O
cell None None O
cycle None None O
progression None None O
and None None O
cell None None O
mobility None None O
and None None O
negatively None None O
regulates None None O
the None None O
expression None None O
of None None O
p53 None None I-PROTEIN
. None None O

We None None O
propose None None O
a None None O
molecular None None O
( None None O
epi None None I-TRANS
) None None O
genetic None None O
mechanism None None O
by None None O
which None None O
increased None None O
EMT-like None None O
cell None None O
shape None None O
transformation None None O
and None None O
integration None None O
into None None O
mesothelial None None O
monolayers None None O
of None None O
PDAC None None O
cells None None O
can None None O
be None None O
observed None None O
. None None O

Only None None O
SYMRK None None O
but None None O
not None None O
NFR None None O
overexpression None None O
triggered None None O
the None None O
expression None None O
of None None O
AM-related None None O
genes None None O
, None None O
indicating None None O
that None None O
the None None O
receptors None None I-PROTEIN
play None None O
a None None O
key None None O
role None None O
in None None O
the None None O
decision None None O
between None None O
AM- None None O
or None None O
root None None O
nodule None None O
symbiosis-development None None O
. None None O

Congenital None None O
amusia None None I-DISEASE
is None None O
defined None None O
by None None O
marked None None O
deficits None None O
in None None O
pitch None None O
perception None None I-FUNC
and None None O
production None None O
. None None O

The None None O
current None None O
study None None O
used None None O
structural None None O
T1-weighted None None O
magnetic None None O
resonance None None O
imaging None None O
and None None O
diffusion None None O
tensor None None O
imaging None None O
to None None O
examine None None O
neural None None O
correlates None None O
of None None O
amusia None None I-DISEASE
in None None O
17 None None O
individuals None None O
with None None O
WS None None O
( None None O
4 None None O
of None None O
whom None None O
met None None O
criteria None None O
for None None O
amusia None None I-DISEASE
) None None O
. None None O

The None None O
relationship None None O
between None None O
amusia None None I-DISEASE
and None None O
FA None None O
in None None O
the None None O
inferior None None O
component None None O
of None None O
the None None O
SLF None None O
was None None O
particularly None None O
robust None None O
, None None O
withstanding None None O
corrections None None O
for None None O
cognitive None None O
functioning None None O
, None None O
auditory None None O
sensitivities None None O
, None None O
or None None O
musical None None O
training None None O
. None None O

Clinical None None O
symptoms None None O
and None None O
examination None None O
findings None None O
at None None O
relapses None None O
of None None O
30 None None O
NMO None None I-TRANS
patients None None O
were None None O
retrospectively None None O
reviewed None None O
. None None O

These None None O
results None None O
indicate None None O
MEPs None None O
and None None O
SSEPs None None O
of None None O
the None None O
lower None None O
limbs None None O
are None None O
good None None O
indicators None None O
for None None O
the None None O
disability None None O
status None None O
at None None O
relapses None None O
of None None O
NMO None None I-TRANS
. None None O

Synthetic None None O
DmSP None None O
shows None None O
the None None O
potential None None O
to None None O
inhibit None None O
forskolin None None O
( None None O
FSK None None O
) None None O
or None None O
adipokinetic None None O
hormone None None O
( None None O
AKH None None O
) None None O
-induced None None O
cAMP-response None None O
element None None O
( None None O
CRE None None O
) None None O
-driven None None O
luciferase None None I-PROTEIN
( None None O
Luc None None O
) None None O
activity None None O
in None None O
a None None O
manner None None O
comparable None None O
with None None O
synthetic None None O
BmPTSP1 None None O
. None None O

Coexpression None None O
and None None O
protein-protein None None O
interaction None None O
network None None O
analyses None None O
revealed None None O
a None None O
dynamic None None O
range None None O
in None None O
the None None O
expression None None O
levels None None O
of None None O
genes None None O
encoding None None I-FUNC
regulatory None None O
proteins None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
a None None O
bacterial None None O
lysozyme None None I-PROTEIN
family None None O
integrated None None O
independently None None O
in None None O
all None None O
domains None None O
of None None O
life None None O
across None None O
diverse None None O
environments None None O
, None None O
generating None None O
the None None O
only None None O
glycosyl None None O
hydrolase None None I-PROTEIN
25 None None O
muramidases None None O
in None None O
plants None None O
and None None O
archaea None None O
. None None O

Moreover None None O
, None None O
recombinant None None O
lysozyme None None I-PROTEIN
exhibits None None O
broad-spectrum None None O
antibacterial None None O
action None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
. None None O

Rhythmic None None O
movements None None I-FUNC
of None None O
the None None O
proboscis None None O
may None None O
help None None O
to None None O
increase None None O
convection None None O
. None None O

Neuronal None None O
firing None None O
, None None O
synaptic None None O
transmission None None O
, None None O
and None None O
its None None O
plasticity None None O
form None None O
the None None O
building None None O
blocks None None O
for None None O
processing None None O
and None None O
storage None None I-FUNC
of None None O
information None None O
in None None O
the None None O
brain None None O
. None None O

To None None O
test None None O
this None None O
, None None O
we None None O
recorded None None O
from None None O
connected None None O
pairs None None O
of None None O
pyramidal None None O
neurons None None O
in None None O
acute None None O
brain None None O
slices None None O
of None None O
adult None None O
human None None O
and None None O
mouse None None O
temporal None None I-REGION
cortex None None I-REGION
and None None O
probed None None O
the None None O
dynamical None None O
properties None None O
of None None O
use-dependent None None O
plasticity None None O
. None None O

We None None O
sought None None O
to None None O
characterise None None O
human None None O
mesenchymal-stem None None O
cell None None O
( None None O
hMSC None None O
) None None O
behaviour None None O
in None None O
response None None O
to None None O
two None None O
different None None O
mechanisms None None O
of None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
; None None O
( None None O
i None None O
) None None O
FGF2-heparan None None O
sulphate None None O
proteoglycan None None O
( None None O
HSPG None None O
) None None O
-mediated None None O
adhesion None None O
vs. None None O
( None None O
ii None None O
) None None O
fibronectin None None I-PROTEIN
( None None O
FN None None O
) None None O
-integrin-mediated None None O
adhesion None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
whether None None O
the None None O
messenger None None O
RNA None None O
( None None O
mRNA None None O
) None None O
expression None None O
of None None O
glucocorticoid None None O
inducible None None O
genes None None O
is None None O
associated None None O
with None None O
changes None None O
in None None O
the None None O
cornu None None O
ammonis None None O
( None None O
CA None None O
) None None O
and None None O
dentate None None I-REGION
gyrus None None I-REGION
subfields None None O
. None None O

Patients None None O
with None None O
MDD None None O
had None None O
significantly None None O
smaller None None O
volumes None None O
of None None O
CA1 None None I-REGION
, None None O
CA2/3 None None O
, None None O
CA4/DG None None O
, None None O
and None None O
subiculum None None I-REGION
compared None None O
to None None O
healthy None None O
controls None None O
. None None O

DNA None None O
was None None O
obtained None None O
from None None O
buccal None None O
cell None None O
or None None O
saliva None None O
samples None None O
and None None O
genotyped None None O
for None None O
polymorphisms None None O
of None None O
the None None O
following None None O
genes None None O
: None None O
serotonin None None I-TRANS
transporter None None O
linked None None O
polymorphic None None O
region None None O
( None None O
5-HTTLPR None None O
) None None O
, None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
, None None O
norepinephrine None None I-TRANS
transporter None None O
, None None O
and None None O
corticotropin None None I-TRANS
releasing None None O
hormone None None O
receptor None None I-PROTEIN
1 None None O
. None None O

Maltreatment None None O
consistently None None O
was None None O
associated None None O
with None None O
higher None None O
Children None None O
's None None O
Depression None None I-DISEASE
Inventory None None O
and None None O
Teacher None None O
Report None None O
Form None None O
symptoms None None O
. None None O

The None None O
findings None None O
illustrate None None O
the None None O
variable None None O
influence None None O
of None None O
specific None None O
genotypes None None O
in None None O
G None None O
× None None O
E None None O
interactions None None O
based None None O
on None None O
variation None None O
in None None O
maltreatment None None O
experiences None None O
and None None O
the None None O
importance None None O
of None None O
a None None O
multigenic None None O
approach None None O
for None None O
understanding None None O
influences None None O
on None None O
depression None None I-DISEASE
and None None O
internalizing None None O
symptoms None None O
among None None O
African None None O
American None None O
children None None O
. None None O

The None None O
current None None O
study None None O
tested None None O
a None None O
gene-environment-environment None None O
interaction None None O
( None None O
G None None O
× None None O
E None None O
× None None O
E None None O
; None None O
specifically None None O
, None None O
gene-EA-proximal None None O
stress None None O
interaction None None O
) None None O
model None None O
of None None O
depression None None I-DISEASE
in None None O
a None None O
20-year None None O
longitudinal None None O
study None None O
. None None O

EA None None O
predicted None None O
stronger None None O
associations None None O
between None None O
recent None None O
chronic None None O
stress None None O
and None None O
depression None None I-DISEASE
, None None O
and None None O
the None None O
effect None None O
was None None O
moderated None None O
by None None O
genes None None O
. None None O

Childhood None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
may None None O
arise None None O
from None None O
genetic None None O
and None None O
environmental None None O
risks None None O
, None None O
which None None O
act None None O
to None None O
bias None None O
the None None O
ways None None O
in None None O
which None None O
children None None O
process None None O
emotional None None O
information None None O
. None None O

Past None None O
research None None O
suggests None None O
that None None O
many None None O
cognitive None None O
biases None None O
only None None O
reflect None None O
genetic None None O
risks None None O
for None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
from None None O
adolescence None None O
. None None O

The None None O
absence None None O
of None None O
positive None None O
self/other None None O
perceptions None None I-FUNC
shared None None O
genetic None None O
influences None None O
with None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
within None None O
and None None O
across None None O
time None None O
. None None O

Maltreated None None O
children None None O
had None None O
higher None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
and None None O
posttraumatic None None O
stress None None O
disorder None None O
symptoms None None O
and None None O
marginally None None O
higher None None O
internalizing None None O
symptoms None None O
on None None O
the None None O
Child None None O
Behavior None None O
Checklist None None O
. None None O

The None None O
majority None None O
of None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
studies None None O
have None None O
examined None None O
mean None None O
group None None O
differences None None O
in None None O
amygdala None None I-REGION
activation None None O
or None None O
connectivity None None O
in None None O
children None None O
and None None O
adolescents None None O
with None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
relative None None O
to None None O
controls None None O
, None None O
but None None O
emerging None None O
evidence None None O
suggests None None O
that None None O
abnormalities None None O
in None None O
amygdala None None I-REGION
function None None O
are None None O
dependent None None O
on None None O
the None None O
timing None None O
of None None O
the None None O
task None None O
and None None O
may None None O
vary None None O
across None None O
the None None O
course None None O
of None None O
a None None O
scanning None None O
session None None O
. None None O

In None None O
addition None None O
, None None O
controls None None O
evidenced None None O
greater None None O
context-modulated None None O
prefrontal None None I-REGION
cortex-amygdala None None O
connectivity None None O
during None None O
the None None O
beginning None None O
of None None O
scanning None None O
relative None None O
to None None O
patients None None O
. None None O

Implications None None O
are None None O
discussed None None O
regarding None None O
how None None O
this None None O
pattern None None O
of None None O
neural None None O
activation None None O
may None None O
relate None None O
to None None O
altered None None O
early-occurring None None O
or None None O
anticipatory None None O
emotion-regulation None None O
strategies None None O
and None None O
maladaptive None None O
later-occurring None None O
strategies None None O
in None None O
children None None O
and None None O
adolescents None None O
with None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

A None None O
majority None None O
of None None O
these None None O
regions None None O
are None None O
associated None None O
with None None O
emotion None None I-FUNC
reactivity None None O
and/or None None O
regulation None None O
. None None O

A None None O
first None None O
step None None O
toward None None O
understanding None None O
this None None O
is None None O
to None None O
characterize None None O
the None None O
relationships None None O
between None None O
variation None None O
in None None O
brain None None O
structure/function None None O
and None None O
individual None None O
differences None None O
in None None O
depression None None I-DISEASE
severity None None O
and None None O
related None None O
processes None None O
, None None O
particularly None None O
emotion None None I-FUNC
regulation None None O
. None None O

Specifically None None O
, None None O
we None None O
found None None O
that None None O
smaller None None O
hippocampus None None I-REGION
volumes None None O
and None None O
greater None None O
responses None None O
to None None O
sad None None O
faces None None O
in None None O
emotion None None I-FUNC
reactivity None None O
regions None None O
predict None None O
increased None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
the None None O
time None None O
of None None O
scan None None O
, None None O
whereas None None O
larger None None O
amygdala None None I-REGION
volumes None None O
, None None O
smaller None None O
insula None None I-REGION
volumes None None O
, None None O
and None None O
greater None None O
responses None None O
in None None O
emotion None None I-FUNC
reactivity None None O
regions None None O
predict None None O
decreased None None O
emotion None None I-FUNC
regulation None None O
skills None None O
. None None O

Understanding None None O
brain-behavior None None O
relationships None None O
in None None O
psychiatrically None None O
healthy None None O
samples None None O
, None None O
especially None None O
early None None O
in None None O
development None None O
, None None O
will None None O
help None None O
inform None None O
normative None None O
developmental None None O
trajectories None None O
and None None O
neural None None O
alterations None None O
in None None O
depression None None I-DISEASE
and None None O
other None None O
affective None None O
pathology None None O
. None None O

Amygdala None None I-REGION
activation None None O
in None None O
response None None O
to None None O
emotional None None O
stimuli None None O
was None None O
positively None None O
associated None None O
with None None O
cortisol None None O
responses None None O
. None None O

Using None None O
respiratory None None O
sinus None None O
arrhythmia None None O
( None None O
RSA None None O
) None None O
as None None O
an None None O
index None None O
of None None O
parasympathetic None None O
nervous None None O
system None None O
function None None O
, None None O
we None None O
examined None None O
this None None O
question None None O
in None None O
two None None O
studies None None O
: None None O
one None None O
involving None None O
mothers None None O
with None None O
and None None O
without None None O
depression None None I-DISEASE
histories None None O
and None None O
their None None O
offspring None None O
( None None O
at None None O
high None None O
and None None O
low None None O
risk None None O
for None None O
depression None None I-DISEASE
, None None O
respectively None None O
) None None O
, None None O
and None None O
a None None O
further None None O
study None None O
of None None O
adolescent None None O
sibling None None O
pairs None None O
concordant None None O
and None None O
discordant None None O
for None None O
major None None O
depression None None I-DISEASE
. None None O

Thus None None O
, None None O
the None None O
results None None O
support None None O
atypical None None O
RSA None None O
patterns None None O
as None None O
an None None O
endophenotype None None O
for None None O
depression None None I-DISEASE
. None None O

In None None O
171 None None O
youths None None O
( None None O
84 None None O
female None None O
, None None O
M None None O
= None None O
13.69 None None O
years None None O
, None None O
SD None None O
= None None O
1.84 None None O
) None None O
, None None O
we None None O
measured None None O
changes None None O
of None None O
respiratory None None O
sinus None None O
arrhythmia None None O
( None None O
RSA None None O
) None None O
in None None O
response None None O
to None None O
sadness- None None O
and None None O
fear-inducing None None O
film None None O
clips None None O
and None None O
maternal None None O
supportive None None O
and None None O
punitive None None O
responses None None O
to None None O
youths None None O
' None None O
internalizing None None O
emotions None None I-FUNC
. None None O

Maternal None None O
supportive None None O
emotion None None I-FUNC
socialization None None O
predicted None None O
fewer None None O
, None None O
and None None O
punitive None None O
socialization None None O
predicted None None O
more None None O
, None None O
mother-reported None None O
internalizing None None O
problems None None O
at None None O
Time None None O
2 None None O
only None None O
for None None O
youths None None O
who None None O
showed None None O
RSA None None O
suppression None None O
to None None O
fear-inducing None None O
films None None O
. None None O

In None None O
addition None None O
, None None O
less None None O
supportive None None O
emotion None None I-FUNC
socialization None None O
predicted None None O
more None None O
youth-reported None None O
depression None None I-DISEASE
symptoms None None I-DISEASE
at None None O
Time None None O
2 None None O
only None None O
for None None O
girls None None O
who None None O
showed None None O
more None None O
RSA None None O
suppression None None O
to None None O
sadness None None O
. None None O

We None None O
investigated None None O
whether None None O
the None None O
stress None None O
of None None O
having None None O
a None None O
mother None None O
with None None O
recurrent None None O
depression None None I-DISEASE
is None None O
associated None None O
with None None O
dysfunction None None O
in None None O
adolescents None None O
in None None O
the None None O
HPA None None O
axis None None O
and None None O
whether None None O
the None None O
tendency None None O
to None None O
use None None O
involuntary None None O
coping None None O
strategies None None O
in None None O
dealing None None O
with None None O
this None None O
stress None None O
is None None O
associated None None O
with None None O
exacerbation None None O
of None None O
dysfunction None None O
in None None O
this None None O
system None None O
. None None O

Finally None None O
, None None O
in None None O
contrast None None O
to None None O
low-risk None None O
girls None None O
, None None O
girls None None O
at None None O
familial None None O
risk None None O
for None None O
depression None None I-DISEASE
who None None O
more None None O
frequently None None O
used None None O
involuntary None None O
versus None None O
voluntary None None O
coping None None O
exhibited None None O
the None None O
greatest None None O
elevations None None O
in None None O
diurnal None None O
cortisol None None O
. None None O

The None None O
participants None None O
in None None O
Study None None O
1 None None O
included None None O
240 None None O
adolescents None None O
who None None O
differed None None O
with None None O
regard None None O
to None None O
their None None O
mothers None None O
' None None O
history None None O
of None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
. None None O

Consistent None None O
with None None O
the None None O
depression None None I-DISEASE
autonomy None None O
model None None O
, None None O
higher None None O
numbers None None O
of None None O
prior None None O
major None None O
depressive None None O
episodes None None O
( None None O
MDEs None None O
) None None O
were None None O
associated None None O
with None None O
weaker None None O
stress None None O
generation None None O
effects None None O
, None None O
such None None O
that None None O
higher None None O
levels None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
predicted None None O
increases None None O
in None None O
levels None None O
of None None O
dependent None None O
stressors None None O
for None None O
adolescents None None O
with None None O
two None None O
or None None O
more None None O
prior None None O
MDEs None None O
, None None O
but None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
were None None O
not None None O
significantly None None O
related None None O
to None None O
dependent None None O
stress None None O
levels None None O
for None None O
youth None None O
with None None O
three None None O
or None None O
more None None O
prior None None O
MDEs None None O
. None None O

Stress None None O
generation None None O
effects None None O
were None None O
moderated None None O
by None None O
cortisol None None O
responses None None O
to None None O
a None None O
laboratory None None O
psychosocial None None O
stressor None None O
, None None O
such None None O
that None None O
individuals None None O
with None None O
higher None None O
cortisol None None O
responses None None O
exhibited None None O
a None None O
pattern None None O
consistent None None O
with None None O
the None None O
depression None None I-DISEASE
autonomy None None O
model None None O
, None None O
whereas None None O
individuals None None O
with None None O
lower None None O
cortisol None None O
responses None None O
showed None None O
a None None O
pattern None None O
more None None O
consistent None None O
with None None O
the None None O
depression None None I-DISEASE
sensitization None None O
model None None O
. None None O

The None None O
complex None None O
, None None O
multifactorial None None O
relation None None O
between None None O
stress None None O
and None None O
depression None None I-DISEASE
is None None O
discussed None None O
. None None O

A None None O
sample None None O
of None None O
167 None None O
youth None None O
( None None O
M None None O
age None None O
= None None O
12.41 None None O
years None None O
, None None O
SD None None O
= None None O
1.19 None None O
) None None O
and None None O
their None None O
caregivers None None O
completed None None O
measures None None O
of None None O
puberty None None O
and None None O
semistructured None None O
interviews None None O
of None None O
interpersonal None None O
stress None None O
and None None O
youth None None O
depression None None I-DISEASE
. None None O

Early None None O
maturation None None O
predicted None None O
stable None None O
high None None O
trajectories None None O
of None None O
depression None None I-DISEASE
in None None O
girls None None O
; None None O
although None None O
early None None O
maturing None None O
boys None None O
showed None None O
low None None O
initial None None O
levels None None O
of None None O
depression None None I-DISEASE
, None None O
they None None O
did None None O
not None None O
differ None None O
from None None O
girls None None O
by None None O
the None None O
final None None O
wave None None O
of None None O
the None None O
study None None O
. None None O

These None None O
findings None None O
provide None None O
novel None None O
insight None None O
into None None O
multilevel None None O
processes None None O
accounting None None O
for None None O
sex None None O
differences None None O
in None None O
depression None None I-DISEASE
across None None O
the None None O
adolescent None None O
transition None None O
. None None O

For None None O
example None None O
, None None O
parental None None O
depression None None I-DISEASE
and None None O
cognitive None None O
vulnerability None None O
are None None O
known None None O
markers None None O
of None None O
depression None None I-DISEASE
risk None None O
, None None O
but None None O
no None None O
study None None O
has None None O
examined None None O
their None None O
interactive None None O
effects None None O
on None None O
children None None O
's None None O
cortisol None None O
reactivity None None O
, None None O
a None None O
likely None None O
mediator None None O
of None None O
early None None O
depression None None I-DISEASE
risk None None O
. None None O

Children None None O
were None None O
assessed None None O
for None None O
cognitive None None O
vulnerability None None O
using None None O
self-reports None None O
( None None O
Study None None O
1 None None O
; None None O
n None None O
= None None O
244 None None O
) None None O
and None None O
tasks None None O
tapping None None O
memory None None I-FUNC
and None None O
attentional None None O
bias None None O
( None None O
Study None None O
2 None None O
; None None O
n None None O
= None None O
205 None None O
) None None O
, None None O
and None None O
their None None O
parents None None O
were None None O
assessed None None O
for None None O
depression None None I-DISEASE
history None None O
using None None O
structured None None O
clinical None None O
interviews None None O
. None None O

Cross-sectionally None None O
and None None O
longitudinally None None O
, None None O
parental None None O
depression None None I-DISEASE
history None None O
and None None O
child None None O
cognitive None None O
vulnerability None None O
interacted None None O
to None None O
predict None None O
children None None O
's None None O
cortisol None None O
reactivity None None O
; None None O
associations None None O
between None None O
parent None None O
depression None None I-DISEASE
and None None O
elevated None None O
child None None O
cortisol None None O
activity None None O
were None None O
found None None O
when None None O
children None None O
also None None O
showed None None O
elevated None None O
depressotypic None None O
attributions None None O
as None None O
well None None O
as None None O
attentional None None O
and None None O
memory None None I-FUNC
biases None None O
. None None O

Past None None O
research None None O
has None None O
identified None None O
maternal None None O
depression None None I-DISEASE
and None None O
family None None O
of None None O
origin None None O
maltreatment None None O
as None None O
precursors None None O
to None None O
adolescent None None O
depression None None I-DISEASE
and None None O
antisocial None None O
behavior None None O
. None None O

Using None None O
a None None O
multilevel None None O
approach None None O
that None None O
pools None None O
the None None O
unique None None O
attributes None None O
of None None O
two None None O
geographically None None O
diverse None None O
, None None O
yet None None O
complementary None None O
, None None O
longitudinal None None O
research None None O
designs None None O
, None None O
the None None O
present None None O
study None None O
examined None None O
the None None O
role None None O
of None None O
maternal None None O
caregiver None None O
involvement None None O
as None None O
a None None O
factor None None O
that None None O
promotes None None O
resilience-based None None O
trajectories None None O
related None None O
to None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
antisocial None None O
behaviors None None O
among None None O
adolescent None None O
girls None None O
. None None O

The None None O
second None None O
sample None None O
comprises None None O
a None None O
group None None O
of None None O
UK-based None None O
adolescent None None O
girls None None O
at None None O
high None None O
familial None None O
risk None None O
for None None O
depression None None I-DISEASE
( None None O
n None None O
= None None O
145 None None O
; None None O
mean None None O
age None None O
= None None O
11.70 None None O
years None None O
) None None O
, None None O
with None None O
all None None O
girls None None O
having None None O
biological None None O
mothers None None O
who None None O
experienced None None O
recurrent None None O
depression None None I-DISEASE
. None None O

Results None None O
suggest None None O
increasing None None O
levels None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
for None None O
girls None None O
at None None O
familial None None O
risk None None O
for None None O
depression None None I-DISEASE
but None None O
decreasing None None O
levels None None O
of None None O
depression None None I-DISEASE
for None None O
girls None None O
in None None O
foster None None O
care None None O
. None None O

Premorbid None None O
risk None None O
for None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
and None None O
predictors None None O
of None None O
an None None O
earlier None None O
onset None None O
and None None O
recurrent None None O
course None None O
were None None O
examined None None O
in None None O
two None None O
studies None None O
in None None O
a None None O
large None None O
, None None O
community-based None None O
sample None None O
of None None O
parents None None O
and None None O
offspring None None O
, None None O
prospectively None None O
assessed None None O
from None None O
late None None O
childhood None None O
into None None O
adulthood None None O
. None None O

This None None O
article None None O
outlines None None O
a None None O
novel None None O
theoretical None None O
model None None O
that None None O
specifies None None O
three None None O
hypotheses None None O
about None None O
comorbid None None O
anxious None None O
and None None O
aggressive None None O
children None None O
: None None O
( None None O
a None None O
) None None O
unpredictable None None O
parenting None None O
induces None None O
anxiety None None O
in None None O
children None None O
that None None O
in None None O
turn None None O
triggers None None O
aggressive None None O
behavior None None O
; None None O
( None None O
b None None O
) None None O
prolonged None None O
periods None None O
of None None O
anxiety None None O
deplete None None O
children None None O
's None None O
capacity None None O
to None None O
inhibit None None O
impulses None None O
and None None O
trigger None None O
bouts None None O
of None None O
aggression None None O
, None None O
and None None O
aggression None None O
in None None O
turn None None O
functions None None O
to None None O
regulate None None O
levels None None O
of None None O
anxiety None None O
; None None O
and None None O
( None None O
c None None O
) None None O
minor None None O
daily None None O
stressors None None O
give None None O
rise None None O
to None None O
anxiety None None O
while None None O
cognitive None None O
perseveration None None O
maintains None None O
anxious None None O
moods None None I-FUNC
, None None O
increasingly None None O
disposing None None O
children None None O
to None None O
aggress None None O
. None None O

Anxious None None O
mothers None None O
' None None O
parenting None None O
, None None O
particularly None None O
transfer None None O
of None None O
threat None None O
information None None O
, None None O
has None None O
been None None O
considered None None O
important None None O
in None None O
their None None O
children None None O
's None None O
risk None None O
for None None O
social None None O
anxiety None None I-DISEASE
disorder None None I-DISEASE
( None None O
SAnxD None None O
) None None O
, None None O
and None None O
maternal None None O
narratives None None O
concerning None None O
potential None None O
social None None O
threat None None O
could None None O
elucidate None None O
this None None O
contribution None None O
. None None O

We None None O
capitalized None None O
on None None O
the None None O
experimental None None O
leverage None None O
provided None None O
by None None O
a None None O
routine None None O
vaccination None None O
to None None O
examine None None O
the None None O
link None None O
between None None O
mood None None I-FUNC
symptoms None None O
and None None O
the None None O
immune None None O
response None None O
to None None O
a None None O
vaccine None None O
challenge None None O
in None None O
early None None O
adolescence None None O
. None None O

Analyses None None O
indicated None None O
that None None O
children None None O
's None None O
internalizing None None O
mood None None I-FUNC
symptoms None None O
were None None O
associated None None O
with None None O
elevated None None O
and None None O
persistently None None O
higher None None O
antibody None None O
responses None None O
, None None O
with None None O
evidence None None O
extending None None O
to None None O
two None None O
of None None O
the None None O
four None None O
serogroups None None O
. None None O

This None None O
has None None O
been None None O
associated None None O
with None None O
a None None O
high None None O
risk None None O
of None None O
thrombosis None None I-DISEASE
. None None O

However None None O
, None None O
this None None O
important None None O
interpersonal None None O
skill None None O
set None None O
may None None O
also None None O
confer None None O
risk None None O
for None None O
depression None None I-DISEASE
and None None O
anxiety None None O
when None None O
present None None O
at None None O
extreme None None O
levels None None O
and None None O
in None None O
combination None None O
with None None O
certain None None O
individual None None O
characteristics None None O
or None None O
within None None O
particular None None O
contexts None None O
. None None O

We None None O
propose None None O
a None None O
model None None O
in None None O
which None None O
typical None None O
development None None O
of None None O
affective None None O
and None None O
cognitive None None I-FUNC
empathy None None I-FUNC
can None None O
be None None O
influenced None None O
by None None O
complex None None O
interplay None None O
among None None O
intraindividual None None O
and None None O
interindividual None None O
moderators None None O
that None None O
increase None None O
risk None None O
for None None O
empathic None None O
personal None None O
distress None None O
and None None O
excessive None None O
interpersonal None None O
guilt None None O
. None None O

In None None O
DPCs None None O
with None None O
Oct4A None None O
overexpression None None O
, None None O
Oct4A None None O
, None None O
Oct4B1 None None O
, None None O
Sox2 None None O
, None None O
Nanog None None O
, None None O
Klf4 None None O
, None None O
c-Myc None None I-PROTEIN
, None None O
and None None O
Utf1 None None O
were None None O
significantly None None O
upregulated None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
and None None O
the None None O
cell None None O
proliferation None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
odontogenic None None O
and None None O
adipogenic None None O
differentiation None None O
were None None O
significantly None None O
enhanced None None O
. None None O

T2DM None None O
rats None None O
showed None None O
worse None None O
renal None None O
morphology None None O
and None None O
impaired None None O
renal None None O
function None None O
compared None None O
with None None O
control None None O
rats None None O
, None None O
including None None O
elevated None None O
levels None None O
of None None O
serum None None O
creatinine None None O
( None None O
CREA None None O
) None None O
, None None O
blood None None O
urea None None O
nitrogen None None O
( None None O
BUN None None O
) None None O
and None None O
urine None None O
albumin None None O
excretion None None O
( None None O
UACR None None O
) None None O
, None None O
as None None O
well None None O
as None None O
increased None None O
levels None None O
of None None O
C3a None None O
, None None O
C3aR None None O
, None None O
IL-6 None None O
, None None O
p-IKBα None None O
, None None O
collagen None None I-PROTEIN
I None None O
, None None O
TGF-β None None O
and None None O
p-Smad3 None None O
in None None O
the None None O
kidney None None O
of None None O
T2DM None None O
rats None None O
and None None O
C3a-treated None None O
HRGECs None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
analysis None None O
was None None O
to None None O
investigate None None O
total None None O
healthcare None None O
costs None None O
, None None O
HbA1c None None O
, None None O
and None None O
weight None None O
changes None None O
over None None O
a None None O
36-month None None O
period None None O
in None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
initiated None None O
on None None O
NPH None None O
or None None O
long-acting None None O
insulin None None I-PROTEIN
analogs None None O
. None None O

Annualized None None O
healthcare None None O
costs None None O
and None None O
clinical None None O
outcomes None None O
in None None O
years None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
3 None None O
following None None O
insulin None None I-PROTEIN
initiation None None O
were None None O
quantified None None O
and None None O
compared None None O
with None None O
baseline None None O
, None None O
using None None O
ANOVA None None O
and None None O
linear None None O
regression None None O
models None None O
. None None O

However None None O
, None None O
increases None None O
by None None O
year None None O
3 None None O
were None None O
not None None O
significantly None None O
different None None O
between None None O
the None None O
insulins None None I-PROTEIN
. None None O

Following None None O
insulin None None I-PROTEIN
initiation None None O
, None None O
the None None O
difference None None O
in None None O
healthcare None None O
costs None None O
of None None O
long-acting None None O
analogs None None O
compared None None O
to None None O
NPH None None O
insulin None None I-PROTEIN
was None None O
transient None None O
. None None O

Electrophysiological None None O
recordings None None O
of None None O
the None None O
auditory None None O
event-related None None O
potential None None O
( None None O
ERP None None O
) None None O
, None None O
including None None O
the None None O
onset None None O
ERP None None O
response None None O
and None None O
the None None O
ACC None None O
, None None O
were None None O
completed None None O
in None None O
all None None O
subjects None None O
and None None O
open-set None None O
speech None None I-FUNC
perception None None I-FUNC
was None None O
evaluated None None O
for None None O
a None None O
subgroup None None O
of None None O
16 None None O
subjects None None O
. None None O

The None None O
aided None None O
open-set None None O
speech None None I-FUNC
perception None None I-FUNC
ability None None O
was None None O
assessed None None O
using None None O
the None None O
Phonetically None None O
Balanced None None O
Kindergarten None None O
( None None O
PBK None None O
) None None O
word None None O
lists None None O
presented None None O
at None None O
60 None None O
dB None None O
SPL None None O
using None None O
recorded None None O
testing None None O
material None None O
in None None O
a None None O
sound None None O
booth None None O
. None None O

We None None O
studied None None O
372 None None O
FDR-T2DM None None O
subjects None None O
( None None O
ages,18-65 None None O
) None None O
and None None O
determined None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
, None None O
fasting None None O
plasma None None O
glucose None None O
( None None O
FPG None None O
) None None O
, None None O
oral None None O
glucose None None O
tolerance None None O
test None None O
( None None O
OGTT None None O
) None None O
, None None O
insulin None None I-PROTEIN
, None None O
and None None O
TGs None None O
levels None None O
. None None O

The None None O
samples None None O
were None None O
ultracentrifuged None None O
and None None O
fractionated None None O
, None None O
and None None O
all None None O
fractions None None O
were None None O
hydrolyzed None None O
( None None O
trypsin None None I-PROTEIN
) None None O
and None None O
injected None None O
into None None O
an None None O
LTQ-VELOS None None O
ORBITRAP None None O
. None None O

The None None O
data None None O
showed None None O
a None None O
reduced None None O
presence None None O
of None None O
complement None None O
C3 None None O
, None None O
ceruloplasmin None None I-PROTEIN
, None None O
alpha None None O
( None None O
1 None None O
) None None O
-acid None None O
glycoprotein None None O
and None None O
alpha None None O
( None None O
2 None None O
) None None O
-acid None None O
glycoprotein None None O
in None None O
the None None O
hepatitis-infected None None O
patients None None O
. None None O

A None None O
13-year-old None None O
Caucasian None None O
female None None O
presented None None O
with None None O
bilateral None None O
vision None None I-FUNC
loss None None O
accompanied None None O
by None None O
mental None None O
status None None O
changes None None O
and None None O
flu None None O
symptoms None None O
. None None O

The None None O
poor None None O
vision None None I-FUNC
is None None O
not None None O
entirely None None O
accounted None None O
for None None O
by None None O
the None None O
macular None None O
disease None None O
. None None O

High-throughput None None O
sequencing None None O
of None None O
small None None O
RNA None None O
( None None O
sRNA None None O
) None None O
populations None None O
of None None O
two None None O
infected None None O
Pinot None None O
gris None None O
accessions None None O
confirmed None None O
the None None O
existence None None O
of None None O
nearly None None O
overlapping None None O
viromes None None O
in None None O
vines None None O
with None None O
or None None O
without None None O
symptoms None None O
but None None O
phylogenetic None None O
analyses None None O
of None None O
the None None O
genomes None None O
of None None O
seven None None O
GPGV None None O
isolates None None O
from None None O
Italy None None O
and None None O
the None None O
Czech None None I-TRANS
and None None O
Slovak None None O
Republics None None O
clearly None None O
differentiated None None O
those None None O
infecting None None O
symptomatic None None O
vines None None O
. None None O

Maximum None None O
likelihood None None O
and None None O
Bayesian None None O
phylogenetic None None O
analysis None None O
of None None O
two None None O
GPGV None None O
genomic None None O
regions None None O
, None None O
encompassing None None O
part None None O
of None None O
the None None O
movement None None I-FUNC
protein None None O
( None None O
MP None None O
) None None O
and None None O
coat None None O
protein None None O
gene None None O
sequences None None O
and None None O
the None None O
RNA-dependent None None O
RNA None None O
polymerase None None O
domain None None O
of None None O
the None None O
replicase None None O
gene None None O
, None None O
showed None None O
that None None O
isolates None None O
from None None O
symptomatic None None O
vines None None O
form None None O
a None None O
lineage None None O
distinct None None O
from None None O
that None None O
of None None O
symptomless None None O
vines None None O
. None None O

Insulin None None I-PROTEIN
resistance None None O
was None None O
defined None None O
as None None O
homeostasis None None O
model None None O
assessment None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
HOMA-IR None None O
) None None O
4th None None O
quartile None None O
( None None O
≥2.70 None None O
) None None O
. None None O

Inhibitor None None O
of None None O
apoptosis None None O
( None None O
IAP None None O
) None None O
proteins None None O
use None None O
their None None O
ubiquitin None None O
E3 None None O
ligase None None I-PROTEIN
activity None None O
to None None O
promote None None O
cancer None None O
cell None None O
survival None None O
by None None O
mediating None None O
proliferative None None O
signalling None None O
and None None O
blocking None None O
cell None None O
death None None O
in None None O
response None None O
to None None O
diverse None None O
stimuli None None O
. None None O

Our None None O
analyses None None O
identified None None O
hundreds None None O
of None None O
proteins None None O
with None None O
elevated None None O
levels None None O
of None None O
ubiquitin-remnant None None O
[ None None O
K-GG None None O
( None None O
Lys-Gly-Gly None None O
) None None O
] None None O
peptides None None I-TRANS
upon None None O
activation None None O
of None None O
cell None None O
death None None O
by None None O
the None None O
IAP None None O
antagonist None None O
BV6 None None O
. None None O

Growing None None O
evidence None None O
suggests None None O
that None None O
histone None None I-PROTEIN
methyltransferases None None I-PROTEIN
( None None O
HMTs None None O
, None None O
also None None O
known None None O
as None None O
protein None None O
methyltransferases None None O
( None None O
PMTs None None O
) None None O
) None None O
play None None O
an None None O
important None None O
role None None O
in None None O
diverse None None O
biological None None O
processes None None O
and None None O
human None None O
diseases None None O
by None None O
regulating None None O
gene None None O
expression None None O
and None None O
the None None O
chromatin None None O
state None None O
. None None O

Advances None None O
in None None O
microscopy None None O
techniques None None O
applied None None O
to None None O
living None None O
cells None None O
have None None O
dramatically None None O
transformed None None O
our None None O
view None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
as None None O
a None None O
framework None None O
for None None O
cellular None None O
processes None None O
. None None O

However None None O
, None None O
new None None O
imaging None None O
techniques None None O
have None None O
revealed None None O
remarkably None None O
dynamic None None O
features None None O
of None None O
individual None None O
actin None None I-PROTEIN
filaments None None O
and None None O
the None None O
mechanisms None None O
that None None O
underpin None None O
their None None O
construction None None O
and None None O
turnover None None O
. None None O

We None None O
focus None None O
on None None O
the None None O
quantitative None None O
properties None None O
of None None O
the None None O
turnover None None O
of None None O
individual None None O
actin None None I-PROTEIN
filaments None None O
, None None O
highlight None None O
actin-binding None None O
proteins None None O
that None None O
participate None None O
in None None O
actin None None I-PROTEIN
dynamics None None O
, None None O
and None None O
summarize None None O
the None None O
current None None O
genetic None None O
evidence None None O
that None None O
has None None O
been None None O
used None None O
to None None O
dissect None None O
specific None None O
aspects None None O
of None None O
the None None O
stochastic None None O
dynamics None None O
model None None O
. None None O

The None None O
lack None None O
of None None O
a None None O
late None None O
myristoyl None None O
transferase None None I-PROTEIN
, None None O
encoded None None O
by None None O
MsbB None None O
leads None None O
to None None O
attenuated None None O
TLR4 None None O
stimulation None None O
. None None O

Nod1 None None O
and None None O
Nod2 None None O
are None None O
cytosolic None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
recognizing None None O
bacterial None None O
peptidoglycan None None O
. None None O

To None None O
elucidate None None O
why None None O
S. None None O
Typhimurium None None O
ΔmsbB None None O
, None None O
but None None O
not None None O
wild-type None None O
S. None None O
Typhimurium None None O
, None None O
induced None None O
an None None O
exacerbated None None O
inflammatory None None O
response None None O
in None None O
Nod2-/- None None O
mice None None O
, None None O
we None None O
used None None O
HEK293 None None O
cells None None O
which None None O
were None None O
transiently None None O
transfected None None O
with None None O
pathogen None None O
recognition None None O
receptors None None I-PROTEIN
. None None O

Matrix None None I-PROTEIN
metalloproteinase-11 None None O
( None None O
MMP-11 None None O
) None None O
is None None O
reported None None O
to None None O
be None None O
overexpressed None None O
in None None O
several None None O
cancers None None O
and None None O
may None None O
contribute None None O
to None None O
tumorigenesis None None O
. None None O

Much None None O
less None None O
is None None O
known None None O
about None None O
reverse None None O
transcriptases None None O
( None None O
RTs None None O
) None None O
in None None O
prokaryotes None None O
than None None O
in None None O
eukaryotes None None O
, None None O
with None None O
most None None O
prokaryotic None None O
enzymes None None I-PROTEIN
still None None O
uncharacterized None None O
. None None O

Multiple None None O
reaction None None O
monitoring None None O
( None None O
MRM None None O
) None None O
mass None None O
spectroscopy None None O
was None None O
used None None O
to None None O
assess None None O
changes None None O
in None None O
relative None None O
phosphorylation None None O
on None None O
18 None None O
of None None O
23 None None O
serine None None I-TRANS
and None None O
threonine None None I-TRANS
residues None None O
and None None O
sumoylation None None O
on None None O
one None None O
of None None O
two None None O
lysine None None I-TRANS
resides None None O
in None None O
BCL11B None None O
. None None O

There None None O
are None None O
yet None None O
no None None O
successful None None O
precedents None None O
of None None O
FGNs None None O
on None None O
sparsely None None O
studied None None O
non-model None None O
organisms None None O
, None None O
such None None O
as None None O
soybean None None O
( None None O
Glycine None None I-TRANS
max None None O
) None None O
, None None O
due None None O
to None None O
the None None O
absence None None O
of None None O
sufficient None None O
heterogeneous None None O
interaction None None O
data None None O
. None None O

Additionally None None O
, None None O
a None None O
web None None O
tool None None O
for None None O
information None None I-FUNC
retrieval None None I-FUNC
and None None O
analysis None None O
of None None O
SoyFGNs None None O
can None None O
be None None O
accessed None None O
at None None O
SoyFN None None O
: None None O
http None None O
: None None O
//nclab.hit.edu.cn/SoyFN None None O
. None None O

Here None None O
we None None O
describe None None O
a None None O
new None None O
SSO None None O
non-base None None O
modifier None None O
( None None O
a None None O
naphthyl-azo None None O
group None None O
, None None O
`` None None O
ZEN™ None None O
'' None None O
) None None O
to None None O
direct None None O
exon None None O
exclusion None None O
in None None O
mutant None None O
dystrophin None None I-PROTEIN
pre-mRNA None None O
to None None O
generate None None O
functional None None O
dystrophin None None I-PROTEIN
protein None None O
. None None O

In None None O
cultured None None O
H2K None None O
cells None None O
, None None O
a None None O
ZEN-modified None None O
2'OMe None None O
phosphorothioate None None O
( None None O
PS None None O
) None None O
oligonucleotide None None O
delivered None None O
by None None O
lipid None None O
transfection None None O
greatly None None O
enhanced None None O
dystrophin None None I-PROTEIN
exon None None O
skipping None None O
over None None O
the None None O
same None None O
2'OMePS None None O
SSO None None O
lacking None None O
ZEN None None O
. None None O

Products None None O
were None None O
also None None O
stored None None O
for None None O
21 None None O
days None None O
at None None O
+4°C None None O
and None None O
monitored None None O
for None None O
cell None None O
quality None None O
throughout None None O
storage None None I-FUNC
. None None O

Thrombin None None I-PROTEIN
generation None None O
was None None O
assessed None None O
according None None O
to None None O
a None None O
calibrated None None O
automated None None O
thrombogram None None O
. None None O

Soluble None None O
fibrin None None O
levels None None O
( None None O
a None None O
marker None None O
of None None O
thrombin None None I-PROTEIN
generation None None O
in None None O
the None None O
systemic None None O
circulation None None O
) None None O
were None None O
50-fold None None O
greater None None O
in None None O
the None None O
trauma None None O
groups None None O
than None None O
in None None O
the None None O
control None None O
group None None O
. None None O

Endogenous None None O
thrombin None None I-PROTEIN
potential None None O
and None None O
factor None None O
II None None O
ratio None None O
were None None O
significantly None None O
negatively None None O
correlated None None O
with None None O
antithrombin None None O
levels None None O
, None None O
suggesting None None O
insufficient None None O
control None None O
of None None O
thrombin None None I-PROTEIN
generation None None O
by None None O
antithrombin None None O
. None None O

The None None O
systemic None None O
thrombin None None I-PROTEIN
generation None None O
accelerated None None O
by None None O
insufficient None None O
antithrombin None None O
control None None O
leads None None O
to None None O
the None None O
consumption None None O
of None None O
platelets None None O
and None None O
coagulation None None I-PROTEIN
factors None None I-PROTEIN
associated None None O
with None None O
hyperfibrin None None O
( None None O
ogen None None O
) None None O
olysis None None O
. None None O

To None None O
determine None None O
if None None O
Src None None O
induced None None O
phosphorylation None None O
of None None O
β-catenin None None O
Tyr-654 None None O
, None None O
Western None None O
blot None None O
analysis None None O
was None None O
also None None O
performed None None O
on None None O
nuclear None None O
proteins None None O
from None None O
C6 None None O
cells None None O
treated None None O
with None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
PP2 None None O
using None None O
then None None O
p- None None O
β-catenin None None O
antibody None None O
. None None O

An None None O
extensive None None O
search None None O
of None None O
the None None O
PubMed None None O
, None None O
EMBASE None None O
, None None O
and None None O
Cochrane None None O
was None None O
conducted None None O
using None None O
varying None None O
combinations None None O
of None None O
the None None O
search None None O
terms None None O
, None None O
`` None None O
hemicraniectomy None None O
, None None O
'' None None O
`` None None O
decompressive None None O
craniectomy None None O
, None None O
'' None None O
`` None None O
malignant None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
territory None None O
infarction None None O
, None None O
'' None None O
`` None None O
massive None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
territory None None O
infarction None None O
, None None O
'' None None O
`` None None O
massive None None O
ischemic None None O
stroke None None I-DISEASE
, None None O
'' None None O
`` None None O
decompressive None None O
surgery None None O
, None None O
'' None None O
and None None O
`` None None O
neurosurgery None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
. None None O
'' None None O

Carotid None None O
artery None None O
revascularization None None O
is None None O
an None None O
effective None None O
means None None O
of None None O
stroke None None I-DISEASE
prevention None None O
in None None O
selected None None O
patients None None O
with None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
. None None O

We None None O
report None None O
that None None O
Nrxn2α None None O
KO None None O
mice None None O
displayed None None O
deficits None None O
in None None O
sociability None None O
and None None O
social None None O
memory None None I-FUNC
when None None O
exposed None None O
to None None O
novel None None O
conspecifics None None O
. None None O

However None None O
, None None O
Nrxn2α None None O
KO None None O
mice None None O
did None None O
not None None O
exhibit None None O
any None None O
obvious None None O
changes None None O
in None None O
prepulse None None O
inhibition None None O
or None None O
in None None O
passive None None O
avoidance None None O
learning None None I-FUNC
. None None O

Quantification None None O
of None None O
protein None None O
expression None None O
revealed None None O
that None None O
Munc18-1 None None O
, None None O
encoded None None O
by None None O
Stxbp1 None None O
, None None O
was None None O
significantly None None O
decreased None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
Nrxn2α None None O
KO None None O
mice None None O
, None None O
which None None O
is None None O
suggestive None None O
of None None O
deficiencies None None O
in None None O
presynaptic None None O
vesicular None None O
release None None O
. None None O

Stress-induced None None O
alterations None None O
in None None O
neuronal None None O
plasticity None None O
and None None O
in None None O
hippocampal None None O
functions None None O
have None None O
been None None O
suggested None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
development None None O
of None None O
mood None None I-DISEASE
disorders None None I-DISEASE
. None None O

One None None O
of None None O
the None None O
possible None None O
scenarios None None O
suggests None None O
that None None O
the None None O
code None None O
evolved None None O
in None None O
response None None O
to None None O
direct None None O
interactions None None O
between None None O
peptides None None I-TRANS
and None None O
RNA None None O
oligonucleotides None None O
in None None O
the None None O
primordial None None O
environment None None O
. None None O

Based None None O
on None None O
these None None O
studies None None O
, None None O
we None None O
provide None None O
a None None O
proof None None O
of None None O
concept None None O
that None None O
targeting None None O
CDC25 None None O
phosphatases None None I-PROTEIN
by None None O
inhibiting None None O
their None None O
protein-protein None None O
interactions None None O
with None None O
CDK2/Cyclin None None O
A None None O
substrate None None O
represents None None O
a None None O
novel None None O
, None None O
viable None None O
opportunity None None O
to None None O
target None None O
this None None O
important None None O
class None None O
of None None O
enzymes None None I-PROTEIN
. None None O

Animals None None O
injected None None O
with None None O
human None None O
fibroblasts None None O
, None None O
prostate None None O
cancer None None O
cells None None O
, None None O
or None None O
collagen None None I-PROTEIN
served None None O
as None None O
control None None O
animals None None O
( None None O
four None None O
in None None O
each None None O
group None None O
) None None O
. None None O

We None None O
recommend None None O
a None None O
move None None O
away None None O
from None None O
prognosis None None O
based None None O
criteria None None O
for None None O
palliative None None O
care None None O
towards None None O
a None None O
patient None None O
centred None None O
approach None None O
, None None O
with None None O
assessment None None O
of None None O
and None None O
attention None None I-FUNC
to None None O
palliative None None O
needs None None O
including None None O
advance None None O
care None None O
planning None None O
throughout None None O
the None None O
disease None None O
trajectory None None O
. None None O

In None None O
MODY None None O
patients None None O
, None None O
this None None O
mutation None None O
is None None O
heterozygous None None O
, None None O
and None None O
both None None O
mutant None None O
and None None O
wild-type None None O
( None None O
WT None None O
) None None O
human None None O
insulin None None I-PROTEIN
are None None O
produced None None O
simultaneously None None O
. None None O

In None None O
vitro None None O
and None None O
in None None O
vivo None None O
tests None None O
showed None None O
that None None O
its None None O
binding None None O
affinity None None O
and None None O
biological None None O
activity None None O
are None None O
reduced None None O
( None None O
both None None O
approximately None None O
20 None None O
% None None O
that None None O
of None None O
human None None O
insulin None None I-PROTEIN
) None None O
. None None O

However None None O
, None None O
it None None O
remains None None O
controversial None None O
whether None None O
treatment None None O
with None None O
CPAP None None O
or None None O
MAD None None O
also None None O
improves None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

CPAP None None O
treatment None None O
resulted None None O
in None None O
significantly None None O
greater None None O
improvement None None O
in None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
the None None O
two None None O
trials None None O
with None None O
a None None O
higher None None O
burden None None O
of None None O
depression None None I-DISEASE
at None None O
baseline None None O
( None None O
meta-regression None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Studies None None O
were None None O
limited None None O
by None None O
the None None O
use None None O
of None None O
depressive None None I-DISEASE
symptom None None I-DISEASE
scales None None O
that None None O
have None None O
not None None O
been None None O
validated None None O
specifically None None O
in None None O
people None None O
with None None O
OSA None None O
. None None O

The None None O
efficacy None None O
of None None O
CPAP None None O
and None None O
MADs None None O
compared None None O
to None None O
standard None None O
therapies None None O
for None None O
depression None None I-DISEASE
is None None O
unknown None None O
. None None O

The None None O
human None None O
homologue None None O
Staufen1 None None O
forms None None O
RNA-containing None None O
complexes None None O
that None None O
include None None O
proteins None None O
involved None None O
in None None O
translation None None O
and None None O
motor None None O
proteins None None O
to None None O
allow None None O
their None None O
movement None None I-FUNC
within None None O
the None None O
cell None None O
, None None O
but None None O
the None None O
mechanism None None O
underlying None None O
translation None None O
repression None None O
in None None O
these None None O
complexes None None O
is None None O
poorly None None O
understood None None O
. None None O

Significantly None None O
lower None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
levels None None O
of None None O
plasma None None I-PROTEIN
proteins None None I-PROTEIN
, None None O
globular None None O
volume None None O
, None None O
hemoglobin None None O
concentration None None O
, None None O
packed None None O
cell None None O
volume None None O
, None None O
total None None O
erythrocytes None None O
, None None O
mean None None O
corpuscular None None O
volume None None O
and None None O
mean None None O
corpuscular None None O
hemoglobin None None O
concentration None None O
were None None O
found None None O
in None None O
infected None None O
chickens None None O
compared None None O
with None None O
non-infected None None O
control None None O
chickens None None O
. None None O

The None None O
objective None None O
of None None O
the None None O
study None None O
was None None O
to None None O
audit None None O
contemporary None None O
data None None O
on None None O
radiation None None O
exposure None None O
during None None O
percutaneous None None O
nephrolithotomy None None O
( None None O
PCNL None None O
) None None O
, None None O
in None None O
comparison None None O
with None None O
published None None O
series None None O
, None None O
and None None O
demonstrate None None O
that None None O
relatively None None O
low None None O
levels None None O
are None None O
achievable None None O
with None None O
clinical None None O
vigilance None None O
and None None O
attention None None I-FUNC
to None None O
technique None None O
Methods None None O
: None None O
A None None O
retrospective None None O
analysis None None O
was None None O
performed None None O
of None None O
all None None O
PCNLs None None O
undertaken None None O
between None None O
July None None O
2005 None None O
and None None O
December None None O
2011 None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
culture None None O
media None None O
enriched None None O
in None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
produced None None O
by None None O
these None None O
hMSCs None None O
in None None O
expansion None None O
( None None O
Conditioned None None O
medium None None O
-- None None O
CM None None O
) None None O
can None None O
be None None O
an None None O
alternative None None O
to None None O
hMSCs None None O
application None None O
. None None O

The None None O
nocturnal None None O
IOP None None I-TRANS
was None None O
measured None None O
in None None O
the None None O
supine None None O
position None None O
, None None O
right None None O
LDP None None O
, None None O
and None None O
left None None O
LDP None None O
, None None O
with None None O
randomized None None O
sequences None None O
, None None O
under None None O
dim None None O
light None None O
( None None O
& None None O
lt None None O
; None None O
10 None None O
lux None None O
) None None O
at None None O
11:30 None None O
pm None None O
, None None O
1:30 None None O
am None None O
, None None O
3:30 None None O
am None None O
, None None O
and None None O
5:30 None None O
am None None O
. None None O

The None None O
24-hour None None O
habitual None None O
IOP None None I-TRANS
patterns None None O
were None None O
obtained None None O
according None None O
to None None O
the None None O
nocturnal None None O
position None None O
( None None O
supine None None O
, None None O
right None None O
LDP None None O
and None None O
left None None O
LDP None None O
) None None O
for None None O
either None None O
eye None None O
. None None O

Over None None O
a None None O
24-hour None None O
period None None O
, None None O
the None None O
effect None None O
of None None O
LDP None None O
on None None O
habitual None None O
IOP None None I-TRANS
pattern None None O
was None None O
not None None O
statistically None None O
significant None None O
, None None O
although None None O
the None None O
mean None None O
nocturnal None None O
IOP None None I-TRANS
and None None O
the None None O
diurnal-nocturnal None None O
IOP None None I-TRANS
change None None O
for None None O
the None None O
right None None O
and None None O
the None None O
left None None O
eye None None O
in None None O
the None None O
LDP None None O
pattern None None O
was None None O
slightly None None O
higher None None O
than None None O
that None None O
in None None O
the None None O
sitting-supine None None O
pattern None None O
. None None O

Over None None O
a None None O
24-hour None None O
period None None O
, None None O
the None None O
effect None None O
of None None O
LDP None None O
on None None O
habitual None None O
IOP None None I-TRANS
pattern None None O
was None None O
not None None O
statistically None None O
significant None None O
in None None O
healthy None None O
subjects None None O
. None None O

Vulnerability None None O
for None None O
5-HT None None I-TRANS
disturbances None None O
is None None O
considered None None O
to None None O
be None None O
genetically None None O
determined None None O
, None None O
including None None O
a None None O
short None None O
( None None O
S None None O
) None None O
allele None None O
polymorphism None None O
in None None O
the None None O
serotonin None None I-TRANS
transporter None None O
gene None None O
( None None O
5-HTTLPR None None O
) None None O
that None None O
is None None O
associated None None O
with None None O
lower None None O
serotonin None None I-TRANS
function None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
current None None O
study None None O
was None None O
to None None O
investigate None None O
whether None None O
a None None O
sugar-containing None None O
preload None None O
may None None O
reduce None None O
appetite None None O
and None None O
energy None None O
intake None None O
after None None O
exposure None None O
to None None O
stress None None O
to None None O
induce None None O
negative None None O
mood None None I-FUNC
, None None O
depending None None O
on None None O
genetic None None O
5-HT None None I-TRANS
vulnerability None None O
. None None O

Although None None O
alternative None None O
explanations None None O
are None None O
possible None None O
, None None O
it None None O
is None None O
suggested None None O
that None None O
S/S None None O
participants None None O
may None None O
have None None O
enhanced None None O
brain None None O
( None None O
hypothalamic None None O
) None None O
5-HT None None I-TRANS
responsiveness None None O
to None None O
food None None O
that None None O
makes None None O
them None None O
more None None O
susceptible None None O
to None None O
the None None O
beneficial None None O
satiation None None O
effects None None O
of None None O
a None None O
sucrose-preload None None O
as None None O
well None None O
as None None O
to None None O
the None None O
negative None None O
effects None None O
of None None O
mild None None O
mental None None O
stress None None O
on None None O
weight None None O
gain None None O
. None None O

Localisation None None O
and None None O
type None None O
of None None O
injury None None O
reflect None None O
the None None O
characteristic None None O
movement None None I-FUNC
elements None None O
in None None O
dance None None O
sport None None O
. None None O

Full-day None None O
preschool None None O
participants None None O
had None None O
higher None None O
scores None None O
than None None O
part-day None None O
peers None None O
on None None O
socioemotional None None O
development None None O
( None None O
58.6 None None O
vs None None O
54.5 None None O
; None None O
difference None None O
, None None O
4.1 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
0.5-7.6 None None O
; None None O
P None None O
= None None O
.03 None None O
) None None O
, None None O
language None None I-FUNC
( None None O
39.9 None None O
vs None None O
37.3 None None O
; None None O
difference None None O
, None None O
2.6 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
0.6-4.6 None None O
; None None O
P None None O
= None None O
.01 None None O
) None None O
, None None O
math None None O
( None None O
40.0 None None O
vs None None O
36.4 None None O
; None None O
difference None None O
, None None O
3.6 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
0.5-6.7 None None O
; None None O
P None None O
= None None O
.02 None None O
) None None O
, None None O
physical None None O
health None None O
( None None O
35.5 None None O
vs None None O
33.6 None None O
; None None O
difference None None O
, None None O
1.9 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
0.5-3.2 None None O
; None None O
P None None O
= None None O
.006 None None O
) None None O
, None None O
and None None O
the None None O
total None None O
score None None O
( None None O
298.1 None None O
vs None None O
278.2 None None O
; None None O
difference None None O
, None None O
19.9 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.2-38.4 None None O
; None None O
P None None O
= None None O
.04 None None O
) None None O
. None None O

Mapping None None O
approaches None None O
offer None None O
great None None O
potential None None O
for None None O
community-based None None O
participatory None None O
researchers None None O
interested None None O
in None None O
displaying None None O
youth None None O
perceptions None None I-FUNC
and None None O
advocating None None O
for None None O
change None None O
. None None O

Maps None None O
reflecting None None O
youth None None O
perceptions None None I-FUNC
aid None None O
policy None None O
makers None None O
in None None O
making None None O
place-based None None O
improvements None None O
for None None O
youth None None O
neighborhood None None O
environments None None O
. None None O

In None None O
response None None O
to None None O
a None None O
lack None None O
of None None O
information None None O
related None None O
to None None O
girls None None O
' None None O
health None None O
in None None O
a None None O
low-income None None O
community None None O
, None None O
an None None O
initiative None None O
was None None O
developed None None O
to None None O
create None None O
a None None O
community-wide None None O
vision None None I-FUNC
for None None O
girls None None O
' None None O
health None None O
. None None O

To None None O
evaluate None None O
bilateral None None O
EAS None None O
efficacy None None O
of None None O
sound None None I-FUNC
localization None None I-FUNC
detection None None O
and None None O
speech None None I-FUNC
perception None None I-FUNC
in None None O
noise None None O
in None None O
two None None O
cases None None O
of None None O
high-frequency None None O
hearing None None O
loss None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
sound None None I-FUNC
localization None None I-FUNC
ability None None O
of None None O
both None None O
cases None None O
with None None O
bilateral None None O
EAS None None O
improved None None O
remarkably None None O
. None None O

Insulin None None I-PROTEIN
resistance None None O
and None None O
the None None O
metabolic None None O
components None None O
were None None O
assessed None None O
. None None O

Adiponectin None None O
was None None O
negatively None None O
correlated None None O
with None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
, None None O
and None None O
total None None O
testosterone None None O
, None None O
triglyceride None None O
, None None O
and None None O
low-density None None O
lipoprotein None None O
( None None O
LDL None None O
) None None O
levels None None O
; None None O
conversely None None O
, None None O
leptin None None O
reversed None None O
the None None O
aforementioned None None O
reaction None None O
and None None O
was None None O
negatively None None O
correlated None None O
with None None O
adiponectin None None O
levels None None O
. None None O

Venlafaxine None None O
( None None O
VLX None None O
) None None O
, None None O
a None None O
serotonine-noradrenaline None None O
reuptake None None O
inhibitor None None O
, None None O
is None None O
one None None O
of None None O
the None None O
most None None O
commonly None None O
used None None O
antidepressant None None O
drugs None None O
in None None O
clinical None None O
practice None None O
for None None O
the None None O
treatment None None O
of None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
. None None O

Furthermore None None O
, None None O
recent None None O
papers None None O
show None None O
that None None O
antidepressants None None O
, None None O
including None None O
also None None O
VLX None None O
, None None O
enhance None None O
the None None O
motor None None O
recovery None None O
after None None O
stroke None None I-DISEASE
even None None O
in None None O
non None None O
depressed None None O
persons None None O
. None None O

Additionally None None O
, None None O
VLX None None O
administration None None O
also None None O
modulated None None O
genes None None O
related None None O
to None None O
insulin None None I-PROTEIN
signaling None None O
pathway None None O
( None None O
Negr1 None None O
, None None O
Ppp3r1 None None O
, None None O
Slc2a4 None None O
and None None O
Enpp1 None None O
) None None O
, None None O
a None None O
mechanism None None O
that None None O
has None None O
recently None None O
been None None O
linked None None O
to None None O
neuroprotection None None O
, None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

These None None O
results None None O
are None None O
consonant None None O
with None None O
the None None O
synaptic None None O
( None None O
network None None O
) None None O
hypothesis None None O
of None None O
depression None None I-DISEASE
and None None O
antidepressant-induced None None O
motor None None O
recovery None None O
after None None O
stroke None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
describe None None O
the None None O
baseline None None O
clinical None None O
features None None O
and None None O
long-term None None O
outcomes None None O
of None None O
patients None None O
with None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
( None None O
MMD None None O
) None None O
based None None O
on None None O
a None None O
25-year None None O
period None None O
at None None O
a None None O
single None None O
center None None O
in None None O
China None None O
. None None O

This None None O
retrospective None None O
cohort None None O
study None None O
included None None O
both None None O
pediatric None None O
and None None O
adult None None O
patients None None O
with None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
who None None O
had None None O
undergone None None O
140 None None O
consecutive None None O
direct None None O
bypass None None O
procedures None None O
at None None O
Kyoto None None O
University None None O
Hospital None None O
. None None O

Univariate None None O
analysis None None O
revealed None None O
that None None O
unstable None None O
disease None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
underlying None None O
disease None None O
( None None O
p=0.028 None None O
) None None O
, None None O
and None None O
recent None None O
stroke None None I-DISEASE
( None None O
p=0.012 None None O
) None None O
were None None O
factors None None O
associated None None O
with None None O
DWI-detected None None O
lesions None None O
. None None O

Unstable None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
, None None O
more None None O
prevalent None None O
in None None O
younger None None O
patients None None O
and None None O
those None None O
with None None O
underlying None None O
disease None None O
, None None O
is None None O
a None None O
possible None None O
risk None None O
factor None None O
for None None O
perioperative None None O
ischemic None None O
complications None None O
. None None O

These None None O
theories None None O
have None None O
predominated None None O
for None None O
more None None O
than None None O
a None None O
century None None O
, None None O
but None None O
advances None None O
in None None O
neuroimaging None None O
and None None O
stimulation None None O
mapping None None O
have None None O
provided None None O
a None None O
more None None O
detailed None None O
description None None O
of None None O
the None None O
functional None None O
neuroanatomy None None O
of None None O
language None None I-FUNC
. None None O

Recent None None O
models None None O
emphasize None None O
processing None None O
in None None O
`` None None O
dorsal None None I-NEURON
'' None None O
and None None O
`` None None O
ventral None None I-NEURON
'' None None O
pathways None None O
, None None O
mediating None None O
phonological None None O
and None None O
semantic None None O
processing None None O
, None None O
respectively None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
semantic None None O
information None None O
is None None O
carried None None O
in None None O
a None None O
ventral None None I-NEURON
pathway None None O
that None None O
runs None None O
from None None O
the None None O
temporal None None I-REGION
pole None None I-REGION
to None None O
the None None O
basal None None O
occipitotemporal None None O
cortex None None O
, None None O
with None None O
anterior None None O
connections None None O
. None None O

NAD None None I-TRANS
plays None None O
essential None None O
redox None None O
and None None O
non-redox None None O
roles None None O
in None None O
cell None None O
biology None None O
. None None O

Here None None O
we None None O
focused None None O
on None None O
the None None O
indispensable None None O
enzymes None None I-PROTEIN
gating None None O
these None None O
two None None O
routes None None O
, None None O
i.e None None O
. None None O

First None None O
, None None O
we None None O
measured None None O
the None None O
in None None O
vitro None None O
activity None None O
of None None O
the None None O
enzymes None None I-PROTEIN
, None None O
and None None O
the None None O
levels None None O
of None None O
all None None O
their None None O
substrates None None O
and None None O
products None None O
in None None O
a None None O
number None None O
of None None O
tissues None None O
from None None O
the None None O
C57BL/6 None None O
mouse None None O
. None None O

In None None O
all None None O
tissues None None O
, None None O
the None None O
amidated None None O
NAD None None I-TRANS
route None None O
was None None O
predominant None None O
, None None O
displaying None None O
highest None None O
rates None None O
in None None O
liver None None O
and None None O
kidney None None O
, None None O
and None None O
lowest None None O
in None None O
blood None None O
. None None O

Such None None O
results None None O
provide None None O
the None None O
first None None O
comprehensive None None O
picture None None O
of None None O
the None None O
balance None None O
of None None O
the None None O
two None None O
alternative None None O
NAD None None I-TRANS
biosynthetic None None O
routes None None O
in None None O
different None None O
mammalian None None O
tissues None None O
under None None O
physiological None None O
conditions None None O
. None None O

BBR None None O
treatment None None O
also None None O
inhibits None None O
AMPK None None O
activity None None O
in None None O
the None None O
hypothalamus None None I-REGION
, None None O
but None None O
genetic None None O
activation None None O
of None None O
AMPK None None O
in None None O
the None None O
ventromedial None None O
nucleus None None O
of None None O
the None None O
hypothalamus None None I-REGION
does None None O
not None None O
prevent None None O
BBR-induced None None O
weight None None O
loss None None O
and None None O
activation None None O
of None None O
the None None O
thermogenic None None O
programme None None O
. None None O

Studies None None O
in None None O
vision None None I-FUNC
show None None O
that None None O
attention None None I-FUNC
enhances None None O
the None None O
firing None None O
rates None None O
of None None O
cells None None O
when None None O
it None None O
is None None O
directed None None O
towards None None O
their None None O
preferred None None O
stimulus None None O
feature None None O
. None None O

Moreover None None O
, None None O
whether None None O
feature-based None None O
attention None None I-FUNC
modulates None None O
the None None O
correlated None None O
activity None None O
of None None O
a None None O
population None None O
is None None O
unclear None None O
. None None O

Here None None O
, None None O
we None None O
investigate None None O
( None None O
1 None None O
) None None O
whether None None O
feature-based None None O
attention None None I-FUNC
biases None None O
the None None O
correlated None None O
activity None None O
between None None O
neurons None None O
when None None O
attention None None I-FUNC
is None None O
directed None None O
towards None None O
their None None O
common None None O
preferred None None O
feature None None O
, None None O
( None None O
2 None None O
) None None O
the None None O
interplay None None O
between None None O
spike-synchrony None None O
and None None O
rsc None None O
during None None O
feature None None O
selection None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
whether None None O
feature None None O
attention None None I-FUNC
effects None None O
are None None O
common None None O
across None None O
the None None O
visual None None O
and None None O
tactile None None O
systems None None O
. None None O

We None None O
found None None O
that None None O
both None None O
firing None None O
rate None None O
and None None O
spike-synchrony None None O
between None None O
neurons None None O
with None None O
similar None None O
feature None None O
selectivity None None O
were None None O
enhanced None None O
when None None O
attention None None I-FUNC
was None None O
directed None None O
towards None None O
their None None O
preferred None None O
feature None None O
. None None O

Further None None O
, None None O
we None None O
observed None None O
increased None None O
r None None O
( None None O
sc None None O
) None None O
when None None O
attention None None I-FUNC
was None None O
directed None None O
towards None None O
the None None O
visual None None O
modality None None O
( None None O
i.e. None None O
, None None O
away None None O
from None None O
touch None None O
) None None O
. None None O

Furthermore None None O
, None None O
NO None None O
produced None None O
during None None O
exposure None None O
to None None O
high None None O
temperature None None O
also None None O
increased None None O
intracellular None None O
copper None None O
content None None O
, None None O
the None None O
activity None None O
of None None O
Cu None None O
, None None O
Zn-superoxide None None O
dismutase None None I-PROTEIN
Sod1 None None O
, None None O
and None None O
cell None None O
viability None None O
after None None O
exposure None None O
to None None O
high-temperature None None O
in None None O
a None None O
manner None None O
dependent None None O
on None None O
Mac1 None None O
. None None O

Using None None O
specific None None O
nucleases None None I-PROTEIN
, None None O
T1 None None O
, None None O
V1 None None O
and None None O
S1 None None O
as None None O
well None None O
as None None O
NMR None None O
, None None O
UV/Vis None None O
and None None O
CD None None O
spectroscopies None None O
, None None O
we None None O
found None None O
that None None O
miR-21 None None O
, None None O
miR-93 None None O
and None None O
miR-296 None None O
can None None O
adopt None None O
hairpin None None O
and/or None None O
homoduplex None None O
structures None None O
. None None O

During None None O
development None None O
, None None O
cell None None O
fate None None O
specification None None O
and None None O
tissue None None O
development None None O
are None None O
orchestrated None None O
by None None O
the None None O
sequential None None O
presentation None None O
of None None O
soluble None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
( None None O
GF None None O
) None None O
and None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
molecules None None O
. None None O

Between None None O
baseline None None O
and None None O
week None None O
12 None None O
, None None O
depression None None I-DISEASE
symptoms None None I-DISEASE
decreased None None O
and None None O
physical None None O
activity None None O
level None None O
increased None None O
only None None O
for None None O
the None None O
outdoor None None O
group None None O
( None None O
P None None O
≤ None None O
0.01 None None O
and None None O
P None None O
≤ None None O
0.05 None None O
, None None O
respectively None None O
) None None O
. None None O

Treatment None None O
of None None O
menopausal None None O
symptoms None None O
by None None O
compounds None None O
with None None O
tissue-selective None None O
estrogen None None O
agonist/antagonist None None O
effects None None O
, None None O
often None None O
called None None O
selective None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
modulators None None O
, None None O
has None None O
been None None O
researched None None O
as None None O
an None None O
alternative None None O
to None None O
the None None O
use None None O
of None None O
estrogen None None O
therapy None None O
. None None O

This None None O
literature None None O
review None None O
investigates None None O
whether None None O
preclinical None None O
data None None O
predicted None None O
the None None O
clinical None None O
effects None None O
of None None O
ospemifene None None O
on None None O
female None None O
reproductive None None O
and None None O
urinary None None O
tract None None O
tissues None None O
and None None O
compares None None O
these None None O
findings None None O
with None None O
the None None O
specific None None O
vaginal None None O
effects None None O
of None None O
other None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
agonists/antagonists None None O
( None None O
tamoxifen None None O
, None None O
raloxifene None None O
, None None O
and None None O
bazedoxifene None None O
) None None O
in None None O
preclinical None None O
and None None O
clinical None None O
studies None None O
. None None O

The None None O
response None None O
of None None O
endometrial None None O
and None None O
vaginal None None O
tissues None None O
to None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
agonists/antagonists None None O
can None None O
be None None O
differentiated None None O
using None None O
transvaginal None None O
ultrasound None None O
, None None O
endometrial None None O
histopathology None None O
, None None O
cytologic None None O
examination None None O
of None None O
vaginal None None O
smears None None O
, None None O
assessment None None O
of None None O
physical None None O
changes None None O
in None None O
the None None O
vagina None None O
, None None O
and None None O
relief None None O
of None None O
symptoms None None O
associated None None O
with None None O
vulvar None None O
and None None O
vaginal None None O
atrophy None None O
( None None O
such None None O
as None None O
dyspareunia None None O
) None None O
. None None O

Therapy None None O
with None None O
autologous None None O
T None None O
cells None None O
that None None O
have None None O
been None None O
gene-engineered None None O
to None None O
express None None O
chimeric None None O
antigen None None O
receptors None None I-PROTEIN
( None None O
CAR None None O
) None None O
or None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptors None None I-PROTEIN
( None None O
TCR None None O
) None None O
provides None None O
a None None O
feasible None None O
and None None O
broadly None None O
applicable None None O
treatment None None O
for None None O
cancer None None O
patients None None O
. None None O

For None None O
their None None O
impact None None O
on None None O
gene-modified None None O
T None None O
cell None None O
phenotype None None O
and None None O
function None None O
, None None O
we None None O
have None None O
tested None None O
various None None O
anti-CD3/CD28 None None O
mAb-based None None O
T None None O
cell None None O
activation None None O
and None None O
expansion None None O
conditions None None O
as None None O
well None None O
as None None O
several None None O
cytokines None None O
prior None None O
to None None O
and/or None None O
after None None O
gene None None O
transfer None None O
using None None O
two None None O
different None None O
receptors None None I-PROTEIN
: None None O
CAIX None None O
CAR None None O
and None None O
MAGE-C2 None None O
( None None O
ALK None None O
) None None O
/HLA-A2 None None O
TCR None None O
. None None O

A None None O
53-year None None O
old None None O
woman None None O
suspicious None None O
for None None O
having None None O
pulmonary None None O
embolism None None I-DISEASE
on None None O
enhanced None None O
chest None None O
CT None None O
was None None O
proven None None O
to None None O
have None None O
metabolically None None O
active None None O
tumor None None O
in None None O
her None None O
pulmonary None None O
arteries None None O
on None None O
F-FDG None None O
PET/CT None None O
. None None O

Nipah None None O
virus None None O
emerged None None O
a None None O
few None None O
years None None O
later None None O
, None None O
causing None None O
respiratory None None O
infections None None O
and None None O
encephalitis None None I-DISEASE
in None None O
Southeast None None O
Asia None None O
, None None O
with None None O
case None None O
fatality None None O
rates None None O
ranging None None O
from None None O
40 None None O
% None None O
to None None O
more None None O
than None None O
90 None None O
% None None O
. None None O

The None None O
insect None None O
olfactory None None O
receptor None None I-PROTEIN
gene None None O
family None None O
is None None O
absent None None O
from None None O
S. None None O
maritima None None O
, None None O
and None None O
olfaction None None I-FUNC
in None None O
air None None O
is None None O
likely None None O
effected None None O
by None None O
expansion None None O
of None None O
other None None O
receptor None None I-PROTEIN
gene None None O
families None None O
. None None O

Trypan None None O
blue None None O
exclusion None None O
, None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
and None None O
DNA None None O
content None None O
were None None O
measured None None O
in None None O
LiverBead None None O
cultures None None O
. None None O

Cultures None None O
from None None O
cryopreserved None None O
cells None None O
were None None O
more None None O
susceptible None None O
to None None O
the None None O
toxicants None None O
tested None None O
, None None O
and None None O
contained None None O
less None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
and None None O
DNA None None O
than None None O
the None None O
conventional None None O
cultures None None O
. None None O

At None None O
6 None None O
hours None None O
, None None O
striatum None None I-REGION
showed None None O
a None None O
massive None None O
increase None None O
in None None O
interleukin None None O
( None None O
IL None None O
) None None O
-1α None None O
and None None O
tumor None None O
necrosis None None O
factor-alpha None None O
( None None O
TNF-α None None O
) None None O
( None None O
& None None O
gt None None O
; None None O
100-fold None None O
higher None None O
than None None O
in None None O
hippocampus None None I-REGION
) None None O
, None None O
which None None O
was None None O
attenuated None None O
by None None O
deeper None None O
hypothermia None None O
in None None O
the None None O
IC None None O
versus None None O
RT None None O
group None None O
. None None O

In None None O
hippocampus None None I-REGION
, None None O
IL-12 None None O
colocalized None None O
with None None O
hippocampal None None O
hilar None None O
neurons None None O
, None None O
the None None O
only None None O
region None None O
where None None O
neuronal None None O
degeneration None None O
was None None O
observed None None O
at None None O
24 None None O
hours None None O
at None None O
both None None O
IC None None O
and None None O
RT None None O
groups None None O
. None None O

When None None O
using None None O
alternate None None O
flight None None O
teams None None O
, None None O
particular None None O
attention None None I-FUNC
should None None O
focus None None O
on None None O
resuscitation None None O
and None None O
maintenance None None O
of None None O
euthermia None None O
with None None O
large None None O
burn None None O
patients None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
objective None None O
and None None O
subjective None None O
quantification None None O
of None None O
habitual None None O
physical None None O
activity None None O
( None None O
HPA None None O
) None None O
and None None O
sedentary None None O
time None None O
in None None O
ambulatory None None O
and None None O
nonambulatory None None O
adults None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
CP None None O
) None None O
. None None O

Nonambulatory None None O
adults None None O
( None None O
GMFCS None None O
levels None None O
IV-V None None O
) None None O
differed None None O
from None None O
ambulatory None None O
adults None None O
( None None O
GMFCS None None O
levels None None O
I-III None None O
) None None O
for None None O
recorded None None O
activity None None O
counts None None O
( None None O
hip None None O
and None None O
wrist None None O
sites None None O
) None None O
, None None O
minutes None None O
of None None O
MVPA None None O
with None None O
each None None O
cut-point None None O
value None None O
, None None O
and None None O
breaks None None O
from None None O
sedentary None None O
time None None O
( None None O
all None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Localized None None O
hypersensitivity None None O
reaction None None O
, None None O
delayed None None O
arterial None None O
healing None None O
, None None O
and None None O
neoatherosclerosis None None O
inside None None O
the None None O
stent None None O
have None None O
been None None O
suggested None None O
as None None O
the None None O
underlying None None O
pathologic None None O
mechanisms None None O
of None None O
very None None O
late None None O
stent None None O
thrombosis None None I-DISEASE
( None None O
VLST None None O
) None None O
of None None O
drug-eluting None None O
stent None None O
( None None O
DES None None O
) None None O
. None None O

From None None O
April None None O
2004 None None O
to None None O
September None None O
2012 None None O
, None None O
48 None None O
patients None None O
with None None O
stent None None O
thrombosis None None I-DISEASE
( None None O
ST None None O
) None None O
of None None O
DES None None O
underwent None None O
thrombus None None O
aspiration None None O
with None None O
retrieved None None O
material None None O
sufficient None None O
for None None O
the None None O
histopathologic None None O
analysis None None O
; None None O
early None None O
ST None None O
( None None O
EST None None O
, None None O
within None None O
30 None None O
days None None O
) None None O
: None None O
N None None O
= None None O
17 None None O
, None None O
late None None O
ST None None O
( None None O
LST None None O
, None None O
between None None O
31 None None O
and None None O
365 None None O
days None None O
) None None O
: None None O
N None None O
= None None O
7 None None O
, None None O
and None None O
very None None O
late None None O
ST None None O
( None None O
VLST None None O
, None None O
& None None O
gt None None O
; None None O
1 None None O
year None None O
) None None O
: None None O
N None None O
= None None O
24 None None O
. None None O

Here None None O
, None None O
we None None O
found None None O
that None None O
the None None O
cot None None O
mutant None None O
showed None None O
a None None O
seizure None None O
phenotype None None O
including None None O
contraction None None O
of None None O
the None None O
body None None O
, None None O
rolling None None O
, None None O
vomiting None None O
gut None None O
juice None None O
and None None O
a None None O
momentary None None O
cessation None None O
of None None O
movement None None I-FUNC
, None None O
and None None O
the None None O
heartbeat None None O
rhythm None None O
of None None O
the None None O
dorsal None None I-NEURON
vessel None None O
significantly None None O
increases None None O
after None None O
hyperthermia None None O
. None None O

Unique None None O
DEGs None None O
of None None O
interest None None O
were None None O
mainly None None O
involved None None O
in None None O
the None None O
ubiquitin None None O
system None None O
, None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptor None None I-PROTEIN
genes None None O
, None None O
cardiac None None O
excitation-contraction None None O
coupling None None O
or None None O
the None None O
Notch None None O
signaling None None O
pathway None None O
. None None O

This None None O
work None None O
is None None O
intended None None O
to None None O
establish None None O
a None None O
standardized None None O
qRT-PCR None None O
protocol None None O
in None None O
pea None None I-TRANS
aphid None None O
and None None O
serves None None O
as None None O
a None None O
starting None None O
point None None O
for None None O
the None None O
genomics None None O
and None None O
functional None None O
genomics None None O
research None None O
in None None O
this None None O
emerging None None O
insect None None O
model None None O
. None None O

In None None O
addition None None O
, None None O
several None None O
well-established None None O
methods None None O
that None None O
do None None O
not None None O
directly None None O
fall None None O
into None None O
machine None None O
learning None None I-FUNC
theory None None O
are None None O
also None None O
reviewed None None O
, None None O
including None None O
neural None None O
networks None None O
, None None O
PAM None None O
( None None O
pattern None None O
analysis None None O
for None None O
microarrays None None O
) None None O
, None None O
SAM None None O
( None None O
significance None None O
analysis None None O
for None None O
microarrays None None O
) None None O
, None None O
GSEA None None O
( None None O
gene None None O
set None None O
enrichment None None O
analysis None None O
) None None O
, None None O
and None None O
k-means None None O
clustering None None O
. None None O

Novel None None O
magnesium None None O
and None None O
zinc None None I-TRANS
phthalocyaninates None None O
, None None O
bearing None None O
four None None O
lateral None None O
electron-rich None None O
15-crown-5-oxanthrene None None O
fragments None None O
, None None O
were None None O
synthesized None None O
starting None None O
from None None O
benzo-15-crown-5 None None O
. None None O

Because None None O
of None None O
the None None O
wafer-scale None None O
manufacturability None None O
, None None O
single-digit-nanometer None None O
control None None O
of None None O
the None None O
gap None None O
size None None O
via None None O
ALD None None O
, None None O
and None None O
long-term None None O
storage None None I-FUNC
enabled None None O
by None None O
template None None O
stripping None None O
, None None O
our None None O
buried None None O
plasmonic None None O
nanocavity None None O
substrates None None O
will None None O
benefit None None O
broad None None O
applications None None O
in None None O
sensing None None O
and None None O
spectroscopy None None O
. None None O

The None None O
highest None None O
electrical None None O
performance None None O
levels None None O
for None None O
the None None O
application None None O
to None None O
the None None O
high-voltage None None O
charge None None O
storage None None I-FUNC
capacitors None None O
in None None O
flat None None O
panel None None O
displays None None O
were None None O
achieved None None O
with None None O
the None None O
4.7-9.7 None None O
% None None O
Al-doped None None O
AHO None None O
films None None O
and None None O
the None None O
2.6 None None O
% None None O
Al-doped None None O
AZO None None O
films None None O
. None None O

In None None O
this None None O
study None None O
we None None O
demonstrate None None O
that None None O
DNA None None O
isolated None None O
from None None O
the None None O
cerebellum None None I-REGION
of None None O
BTBR None None O
T+tf/J None None O
mice None None O
, None None O
a None None O
relevant None None O
mouse None None O
model None None O
of None None O
autism None None O
, None None O
and None None O
from None None O
human None None O
post-mortem None None O
cerebellum None None I-REGION
of None None O
individuals None None O
with None None O
autism None None O
, None None O
are None None O
both None None O
characterized None None O
by None None O
an None None O
increased None None O
levels None None O
of None None O
8-oxo-7-hydrodeoxyguanosine None None O
( None None O
8-oxodG None None O
) None None O
, None None O
5-methylcytosine None None O
( None None O
5mC None None O
) None None O
, None None O
and None None O
5-hydroxymethylcytosine None None O
( None None O
5hmC None None O
) None None O
. None None O

The None None O
retention None None I-FUNC
times None None O
of None None O
the None None O
xenon None None O
in None None O
the None None O
column None None O
are None None O
61.2 None None O
, None None O
42.2 None None O
and None None O
23.5 None None O
at None None O
the None None O
flow None None O
rate None None O
of None None O
1200 None None O
, None None O
1600 None None O
and None None O
2000 None None O
mL None None O
min None None O
( None None O
-1 None None O
) None None O
, None None O
respectively None None O
, None None O
but None None O
the None None O
breakthrough None None O
times None None O
are None None O
51.4 None None O
, None None O
38.6 None None O
and None None O
35.1 None None O
min None None O
. None None O

In None None O
mammals None None O
, None None O
the None None O
relative None None O
activity None None O
of None None O
the None None O
biosynthetic None None O
enzyme None None O
N-acyl None None O
phosphatidylethanolamine-specific None None O
phospholipase-D None None O
and None None O
the None None O
hydrolytic None None I-PROTEIN
enzyme None None I-PROTEIN
fatty None None O
acid None None O
amide None None O
hydrolase None None I-PROTEIN
determine None None O
N-acylethanolamine None None O
levels None None O
. None None O

We None None O
also None None O
find None None O
that None None O
over-expression None None O
of None None O
either None None O
nape-1 None None O
or None None O
nape-2 None None O
significantly None None O
enhances None None O
recovery None None O
from None None O
the None None O
dauer None None O
larval None None O
stage None None O
in None None O
the None None O
insulin None None I-PROTEIN
signaling None None O
mutant None None O
daf-2 None None O
( None None O
e1368 None None O
) None None O
, None None O
but None None O
only None None O
nape-1 None None O
over-expression None None O
reduces None None O
daf-2 None None O
adult None None O
lifespan None None O
, None None O
consistent None None O
with None None O
increased None None O
levels None None O
of None None O
the None None O
N-acylethanolamine None None O
eicosapentaenoyl None None O
ethanolamine None None O
. None None O

Wnt/β-catenin None None O
signalling None None O
is None None O
an None None O
important None None O
pathway None None O
that None None O
regulates None None O
multiple None None O
biological None None O
processes None None O
, None None O
including None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
determination None None O
of None None O
cell None None O
fate None None O
during None None O
animal None None O
development None None O
; None None O
in None None O
the None None O
adult None None O
nervous None None O
system None None O
it None None O
regulates None None O
the None None O
structure None None O
and None None O
function None None O
of None None O
synapses None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
that None None O
histamine None None I-TRANS
modulates None None O
pancreatic None None O
adenocarcinoma None None O
PANC-1 None None O
cell None None O
proliferation None None O
. None None O

Immediately None None O
after None None O
γ None None O
irradiation None None O
, None None O
intracellular None None O
hydrogen None None O
peroxide None None O
was None None O
markedly None None O
decreased None None O
together None None O
with None None O
a None None O
rapid None None O
increase None None O
in None None O
catalase None None I-PROTEIN
activity None None O
. None None O

In None None O
both None None O
control None None O
and None None O
histamine-treated None None O
irradiated None None O
cells None None O
, None None O
the None None O
rise None None O
in None None O
catalase None None I-PROTEIN
activity None None O
lowered None None O
reactive None None O
oxygen None None O
species None None O
levels None None O
and None None O
only None None O
a None None O
small None None O
increase None None O
in None None O
phosphorylated None None O
GSK-3β None None O
was None None O
detected None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
upon None None O
irradiation None None O
, None None O
early None None O
catalase None None I-PROTEIN
activation None None O
may None None O
be None None O
responsible None None O
for None None O
keeping None None O
GSK-3β None None O
active None None O
conceding None None O
cells None None O
a None None O
survival None None O
advantage None None O
toward None None O
cytotoxic None None O
effects None None O
of None None O
ionizing None None O
radiation None None O
. None None O

Cardiac None None O
enzymes None None I-PROTEIN
began None None O
to None None O
trend None None O
up None None O
along None None O
with None None O
worsening None None O
of None None O
her None None O
renal None None O
function None None O
tests None None O
and None None O
hepatic None None O
enzymes None None I-PROTEIN
. None None O

Utp8p None None O
is None None O
an None None O
essential None None O
nucleolar None None O
protein None None O
that None None O
channels None None O
aminoacyl-tRNAs None None O
from None None O
aminoacyl-tRNA None None O
synthetases None None O
in None None O
the None None O
nucleolus None None O
to None None O
the None None O
nuclear None None O
tRNA None None O
export None None O
receptors None None I-PROTEIN
located None None O
in None None O
the None None O
nucleoplasm None None O
and None None O
nuclear None None O
pore None None O
complex None None O
in None None O
Saccharomyces None None O
cerevisiae None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
paper None None O
was None None O
to None None O
compare None None O
the None None O
efficacy None None O
of None None O
in None None O
vitro None None O
calycosin None None O
and None None O
irbesartan None None O
for None None O
the None None O
treatment None None O
of None None O
angiotensin None None O
II None None O
( None None O
AngII None None O
) None None O
-induced None None O
renin None None I-PROTEIN
angiotensin None None O
system None None O
( None None O
RAS None None O
) None None O
disorder None None O
in None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVECs None None O
) None None O
. None None O

Demographic None None O
and None None O
continuous None None O
noninvasive None None O
vital None None O
sign None None O
wave None None O
form None None O
data None None O
were None None O
collected None None O
, None None O
including None None O
PPG None None O
, None None O
heart None None O
rate None None O
, None None O
systolic None None O
blood None None O
pressure None None O
, None None O
cardiac None None O
output None None O
, None None O
and None None O
stroke None None I-DISEASE
volume None None O
. None None O

Among None None O
61 None None O
individuals None None O
who None None O
underwent None None O
adenosine None None I-TRANS
CMR None None O
stress None None O
testing None None O
before None None O
cardiac None None O
catheterization None None O
, None None O
we None None O
assessed None None O
the None None O
severity None None O
of None None O
coronary None None O
artery None None O
stenoses None None O
, None None O
mortality None None O
, None None O
the None None O
presence None None O
of None None O
stress None None O
and None None O
rest None None O
perfusion None None O
defects None None O
, None None O
as None None O
well None None O
as None None O
the None None O
presence None None O
of None None O
late None None O
gadolinium None None O
enhancement None None O
( None None O
LGE None None O
) None None O
. None None O

Toll-like None None O
receptors None None I-PROTEIN
( None None O
TLRs None None O
) None None O
are None None O
damage-associated None None O
molecular None None O
patterns None None O
receptors None None I-PROTEIN
, None None O
which None None O
are None None O
essential None None O
in None None O
the None None O
activation None None O
of None None O
the None None O
inflammasome None None O
cascade None None O
, None None O
required None None O
for None None O
the None None O
initiation None None O
of None None O
inflammation None None O
. None None O

The None None O
SF-12 None None O
Health None None O
Survey None None O
, None None O
the None None O
State-Trait None None O
Anxiety None None O
Inventory None None O
Y-1 None None O
and None None O
Y-2 None None O
, None None O
the None None O
12-Item None None O
General None None O
Health None None O
Questionnaire None None O
, None None O
as None None O
well None None O
as None None O
the None None O
Beck None None O
Depression None None I-DISEASE
Inventory-II None None O
were None None O
used None None O
to None None O
evaluate None None O
the None None O
QoL None None O
once None None O
a None None O
year None None O
. None None O

New None None O
insomnia None None O
therapies None None O
will None None O
most None None O
likely None None O
move None None O
away None None O
from None None O
GABAAR None None O
receptors None None I-PROTEIN
' None None O
modulation None None O
to None None O
more None None O
subtle None None O
neurological None None O
pathways None None O
that None None O
regulate None None O
the None None O
sleep-wake None None O
cycle None None O
. None None O

Age None None O
, None None O
sex None None O
, None None O
25OHD None None O
sampling None None O
seasonality None None O
, None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
and None None O
creatinine None None O
levels None None O
, None None O
and None None O
fluid None None O
load None None O
did None None O
not None None O
vary None None O
among None None O
the None None O
3 None None O
groups None None O
. None None O

This None None O
study None None O
used None None O
metabolomic None None O
profiling None None O
to None None O
identify None None O
analytes None None O
associated None None O
with None None O
insulin None None I-PROTEIN
sensitivity None None O
( None None O
SI None None O
) None None O
and None None O
conversion None None O
to None None O
type None None O
2 None None O
diabetes None None O
( None None O
T2D None None O
) None None O
. None None O

glucose None None O
tolerance None None O
test None None O
to None None O
measure None None O
SI None None O
and None None O
acute None None O
insulin None None I-PROTEIN
response None None O
. None None O

Logistic None None O
regression None None O
analysis None None O
from None None O
72 None None O
high None None O
and None None O
75 None None O
low None None O
SI None None O
subjects None None O
revealed None None O
significantly None None O
decreased None None O
glycine None None I-TRANS
and None None O
increased None None O
valine None None I-TRANS
, None None O
leucine None None I-TRANS
, None None O
phenylalanine None None I-TRANS
, None None O
and None None O
combined None None O
glutamine None None I-TRANS
and None None O
glutamate None None I-TRANS
( None None O
P None None O
= None None O
.0079-7.7 None None O
× None None O
10 None None O
( None None O
-6 None None O
) None None O
) None None O
in None None O
insulin-resistant None None O
subjects None None O
. None None O

Comparing None None O
amino None None O
acid None None O
profiles None None O
between None None O
subjects None None O
that None None O
converted None None O
to None None O
T2D None None O
( None None O
76 None None O
converters None None O
; None None O
70 None None O
nonconverters None None O
) None None O
yielded None None O
a None None O
similar None None O
pattern None None O
of None None O
associations None None O
: None None O
decreased None None O
glycine None None I-TRANS
and None None O
increased None None O
valine None None I-TRANS
, None None O
leucine None None I-TRANS
, None None O
and None None O
combined None None O
glutamine None None I-TRANS
and None None O
glutamate None None I-TRANS
( None None O
P None None O
= None None O
.016-.00010 None None O
) None None O
. None None O

A None None O
distinct None None O
pattern None None O
of None None O
differences None None O
in None None O
amino None None I-TRANS
acids None None I-TRANS
were None None O
observed None None O
when None None O
comparing None None O
subjects None None O
with None None O
high None None O
and None None O
low None None O
levels None None O
of None None O
SI None None O
. None None O

These None None O
results None None O
demonstrate None None O
a None None O
consistent None None O
metabolic None None O
signature None None O
associated None None O
with None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
conversion None None O
to None None O
T2D None None O
, None None O
providing None None O
potential None None O
insight None None O
into None None O
underlying None None O
mechanisms None None O
of None None O
disease None None O
pathogenesis None None O
. None None O

This None None O
cross-sectional None None O
study None None O
analyzed None None O
DTI None None O
metrics None None O
( None None O
primary None None O
[ None None O
λ None None O
( None None O
1 None None O
) None None O
] None None O
, None None O
secondary None None O
[ None None O
λ None None O
( None None O
2 None None O
) None None O
] None None O
, None None O
and None None O
tertiary None None O
[ None None O
λ None None O
( None None O
3 None None O
) None None O
] None None O
eigenvalues None None O
; None None O
fractional None None O
anisotropy None None O
; None None O
and None None O
mean None None O
diffusivity None None O
) None None O
in None None O
the None None O
hypothalamus None None I-REGION
of None None O
24 None None O
consecutive None None O
middle-age None None O
obese None None O
subjects None None O
( None None O
13 None None O
women None None O
; None None O
49.8 None None O
± None None O
8.1 None None O
y None None O
; None None O
body None None O
mass None None O
index None None O
[ None None O
BMI None None O
] None None O
, None None O
43.9 None None O
± None None O
0.92 None None O
kg/m None None O
( None None O
2 None None O
) None None O
) None None O
and None None O
20 None None O
healthy None None O
volunteers None None O
( None None O
10 None None O
women None None O
; None None O
48.8 None None O
± None None O
9.5 None None O
y None None O
; None None O
BMI None None O
, None None O
24.3 None None O
± None None O
0.79 None None O
kg/m None None O
( None None O
2 None None O
) None None O
) None None O
. None None O

λ None None O
( None None O
1 None None O
) None None O
values None None O
in None None O
the None None O
hypothalamus None None I-REGION
were None None O
significantly None None O
lower None None O
in None None O
obese None None O
subjects None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.0001 None None O
) None None O
. None None O

Intestinal None None O
glucose None None O
absorption None None O
is None None O
mediated None None O
by None None O
sodium-dependent None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
1 None None O
( None None O
SGLT-1 None None O
) None None O
and None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
2 None None O
( None None O
GLUT2 None None O
) None None O
, None None O
which None None O
are None None O
linked None None O
to None None O
sweet None None O
taste None None O
receptor None None I-PROTEIN
( None None O
STR None None O
) None None O
signaling None None O
and None None O
incretin None None O
responses None None O
. None None O

Expression None None O
of None None O
SGLT-1 None None O
( None None O
P None None O
= None None O
.035 None None O
) None None O
, None None O
but None None O
not None None O
GLUT2 None None O
or None None O
T1R2 None None O
, None None O
was None None O
higher None None O
in None None O
the None None O
obese None None O
, None None O
and None None O
related None None O
to None None O
peak None None O
plasma None None O
3-OMG None None O
( None None O
r None None O
= None None O
0.60 None None O
, None None O
P None None O
= None None O
.01 None None O
) None None O
, None None O
GIP None None O
( None None O
r None None O
= None None O
0.67 None None O
, None None O
P None None O
= None None O
.003 None None O
) None None O
, None None O
and None None O
insulin None None I-PROTEIN
( None None O
r None None O
= None None O
0.58 None None O
, None None O
P None None O
= None None O
.02 None None O
) None None O
. None None O

As None None O
an None None O
adrenal-associated None None O
endocrinopathy None None O
was None None O
excluded None None O
and None None O
a None None O
complete None None O
fur None None O
recovery None None O
was None None O
observed None None O
after None None O
removal None None O
of None None O
the None None O
cryptorchid None None O
testicle None None O
the None None O
alopecia None None O
was None None O
eventually None None O
due None None O
to None None O
hormones None None I-PROTEIN
produced None None O
by None None O
the None None O
hyperplastic None None O
interstitial None None O
( None None O
Leydig None None O
) None None O
cells None None O
. None None O

When None None O
applied None None O
in None None O
lithium None None O
( None None O
Li None None O
) None None O
and None None O
sodium None None O
( None None O
Na None None I-TRANS
) None None O
ion None None O
batteries None None O
, None None O
these None None O
MoS2 None None O
nanostructures None None O
exhibit None None O
distinguished None None O
intercalation None None O
thermodynamics None None O
and None None O
cycling None None O
performances None None O
. None None O

An None None O
association None None O
of None None O
obesity None None O
with None None O
cancer None None O
is None None O
biologically None None O
plausible None None O
because None None O
adipose None None O
tissue None None O
is None None O
biologically None None O
active None None O
, None None O
secreting None None O
estrogens None None I-PROTEIN
, None None O
adipokines None None O
, None None O
and None None O
cytokines None None O
. None None O

Emphasis None None O
is None None O
placed None None O
on None None O
valuation None None O
of None None O
conservation None None O
biological None None O
control None None O
, None None O
which None None O
has None None O
received None None O
little None None O
attention None None I-FUNC
. None None O

In None None O
these None None O
past None None O
2 None None O
years None None O
, None None O
two None None O
compounds None None O
( None None O
the None None O
anticonvulsant/anxiolytic None None O
pregabalin None None O
and None None O
the None None O
atypical None None O
antipsychotic None None O
quetiapine None None O
) None None O
were None None O
on None None O
Phase None None O
III/IV None None O
clinical None None O
trials None None O
for None None O
schizophrenia None None I-DISEASE
, None None O
with None None O
comorbid None None O
anxiety None None O
as None None O
a None None O
primary None None O
outcome None None O
measure None None O
. None None O

Anxiety None None O
( None None O
as None None O
a None None O
symptom None None O
) None None O
was None None O
a None None O
secondary None None O
outcome None None O
measure None None O
in None None O
trials None None O
for None None O
schizophrenia None None I-DISEASE
involving None None O
seven None None O
other None None O
compounds None None O
( None None O
lurasidone None None O
, None None O
amisulpride None None O
, None None O
bitopertin None None O
, None None O
oxytocin None None I-TRANS
, None None O
famotidine None None O
, None None O
cannabidiol None None O
and None None O
the None None O
L-theanine None None O
and None None O
pregnenolone None None O
combination None None O
) None None O
. None None O

CAG None None O
repeat None None O
expansions None None O
in None None O
humans None None O
trigger None None O
neurological None None O
diseases None None O
that None None O
include None None O
myotonic None None O
dystrophy None None O
, None None O
Huntington None None I-DISEASE
disease None None O
, None None O
and None None O
several None None O
spinocerebellar None None O
ataxias None None O
. None None O

The None None O
active None None O
site None None O
cysteine None None I-TRANS
of None None O
Ubc13 None None O
, None None O
and None None O
E2 None None O
enzymes None None I-PROTEIN
in None None O
general None None O
, None None O
is None None O
buttressed None None O
by None None O
a None None O
flexible None None O
loop None None O
. None None O

Coupled None None O
to None None O
liquid None None O
chromatography None None O
( None None O
LC None None O
) None None O
, None None O
this None None O
LC-ECD None None O
workflow None None O
provides None None O
good None None O
sequence None None O
coverage None None O
for None None O
both None None O
trypsin None None I-PROTEIN
and None None O
Lys None None O
C None None O
digests None None O
of None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
, None None O
providing None None O
ECD None None O
spectra None None O
for None None O
doubly None None O
charged None None O
precursor None None O
ions None None O
with None None O
very None None O
good None None O
efficiency None None O
. None None O

The None None O
protocol None None O
allowed None None O
sensitive None None O
and None None O
selective None None O
precursor None None O
ion None None O
scans None None O
to None None O
detect None None O
the None None O
modified None None O
peptides None None I-TRANS
in None None O
complex None None O
sample None None O
mixtures None None O
. None None O

The None None O
same None None O
strategy None None O
revealed None None O
21 None None O
CML None None O
sites None None O
in None None O
17 None None O
different None None O
proteins None None O
, None None O
including None None O
modified None None O
lysine None None I-TRANS
residues None None O
88 None None O
and None None O
396 None None O
of None None O
human None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
, None None O
in None None O
a None None O
pooled None None O
plasma None None O
sample None None O
that None None O
was None None O
obtained None None O
from None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
. None None O

In None None O
the None None O
case None None O
of None None O
the None None O
SeCobA None None O
ACAT None None O
, None None O
crystallographic None None O
and None None O
kinetic None None O
studies None None O
have None None O
revealed None None O
that None None O
the None None O
phenylalanine None None I-TRANS
91 None None O
( None None O
F91 None None O
) None None O
and None None O
tryptophan None None I-TRANS
93 None None O
( None None O
W93 None None O
) None None O
residues None None O
are None None O
critical None None O
for None None O
in None None O
vivo None None O
activity None None O
, None None O
presumably None None O
by None None O
blocking None None O
access None None O
to None None O
the None None O
lower None None O
axial None None O
ligand None None O
site None None O
of None None O
the None None O
Co None None O
( None None O
II None None O
) None None O
rrinoid None None O
substrate None None O
. None None O

We None None O
determined None None O
that None None O
the None None O
Pol None None O
I None None O
subunits None None O
, None None O
A190 None None O
, None None O
A43 None None O
and None None O
A34.5 None None O
, None None O
can None None O
accept None None O
a None None O
β-phosphate None None O
moiety None None O
from None None O
inositol None None O
pyrophosphates None None O
to None None O
undergo None None O
serine None None I-TRANS
pyrophosphorylation None None O
. None None O

We None None O
investigated None None O
the None None O
mechanism None None O
underlying None None O
the None None O
undesirable None None O
radioactivity None None O
after None None O
subcutaneous None None O
injection None None O
of None None O
( None None O
99m None None O
) None None O
Tc-labeled None None O
mannosylated None None O
dextran None None O
( None None O
( None None O
99m None None O
) None None O
Tc None None O
( None None O
CO None None O
) None None O
3-DCM20 None None O
) None None O
, None None O
a None None O
SLN None None O
mapping None None O
agent None None O
targeting None None O
mannose None None O
receptors None None I-PROTEIN
on None None O
macrophages None None O
and None None O
dendritic None None O
cells None None O
, None None O
in None None O
a None None O
mouse None None O
model None None O
. None None O

Biodistribution None None O
studies None None O
were None None O
also None None O
conducted None None O
after None None O
subcutaneous None None O
injection None None O
of None None O
[ None None O
( None None O
125 None None O
) None None O
I None None O
] None None O
radioiodinated None None O
mannosyl-neoglycoalbumin None None O
( None None O
( None None O
125 None None O
) None None O
I-NMA None None O
) None None O
from None None O
the None None O
rear None None O
footpad None None O
. None None O

We None None O
address None None O
this None None O
problem None None O
by None None O
extending None None O
the None None O
generating None None O
function None None O
approach None None O
to None None O
rigorously None None O
compute None None O
the None None O
joint None None O
spectral None None O
probability None None O
of None None O
multiple None None O
spectra None None O
being None None O
matched None None O
to None None O
peptides None None I-TRANS
with None None O
overlapping None None O
sequences None None O
, None None O
thus None None O
enabling None None O
the None None O
confident None None O
assignment None None O
of None None O
higher None None O
significance None None O
to None None O
overlapping None None O
peptide-spectrum None None O
matches None None O
( None None O
PSMs None None O
) None None O
. None None O

After None None O
benchmarking None None O
this None None O
approach None None O
on None None O
a None None O
typical None None O
lysate None None O
MS/MS None None O
dataset None None O
, None None O
we None None O
show None None O
that None None O
the None None O
proposed None None O
intersecting None None O
spectral None None O
probabilities None None O
for None None O
spectra None None O
from None None O
overlapping None None O
peptides None None I-TRANS
improve None None O
peptide None None O
identification None None O
by None None O
30-62 None None O
% None None O
. None None O

Enhanced None None O
depth None None O
imaging None None O
of None None O
the None None O
optic None None I-REGION
nerve None None I-REGION
of None None O
a None None O
patient None None O
with None None O
a None None O
serous None None O
detachment None None O
and None None O
profound None None O
cupping None None O
of None None O
the None None O
optic None None I-REGION
nerve None None I-REGION
secondary None None O
to None None O
angle-closure None None O
glaucoma None None O
revealed None None O
a None None O
large None None O
dehiscence None None O
of None None O
the None None O
lamina None None O
cribrosa None None O
. None None O

The None None O
most None None O
temporal None None O
of None None O
these None None O
could None None O
be None None O
seen None None O
to None None O
extend None None O
through None None O
the None None O
optic None None I-REGION
nerve None None I-REGION
and None None O
up None None O
into None None O
the None None O
macula None None O
. None None O

This None None O
report None None O
describes None None O
a None None O
patient None None O
with None None O
MPGN None None O
type None None O
2 None None O
who None None O
developed None None O
progressive None None O
loss None None O
of None None O
vision None None I-FUNC
secondary None None O
to None None O
CNV None None O
. None None O

Although None None O
studies None None O
have None None O
applied None None O
machine None None O
learning None None I-FUNC
methods None None O
for None None O
the None None O
computer-aided None None O
diagnosis None None O
of None None O
AD None None O
, None None O
a None None O
bottleneck None None O
in None None O
the None None O
diagnostic None None O
performance None None O
was None None O
shown None None O
in None None O
previous None None O
methods None None O
, None None O
due None None O
to None None O
the None None O
lacking None None O
of None None O
efficient None None O
strategies None None O
for None None O
representing None None O
neuroimaging None None O
biomarkers None None O
. None None O

We None None O
investigated None None O
early None None O
signs None None O
of None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease-related None None O
impairment None None O
in None None O
mediolateral None None O
postural None None O
control None None O
. None None O

As None None O
expected None None O
, None None O
the None None O
patients None None O
exhibited None None O
significantly None None O
greater None None O
angular None None O
movements None None I-FUNC
of None None O
the None None O
lower None None O
back None None O
and None None O
significantly None None O
lower None None O
angular None None O
movements None None I-FUNC
of None None O
the None None O
head None None O
( None None O
relative None None O
to None None O
controls None None O
) None None O
when None None O
performing None None O
gaze None None O
shifts None None O
. None None O

Relative None None O
to None None O
controls None None O
, None None O
the None None O
patients None None O
performed None None O
`` None None O
en None None O
block None None O
'' None None O
body None None O
movements None None I-FUNC
. None None O

It None None O
comprises None None O
an None None O
analog None None O
front None None O
end None None O
, None None O
a None None O
12-bit None None O
ADC None None O
, None None O
a None None O
robust None None O
Instantaneous None None O
Heart None None O
Rate None None O
( None None O
IHR None None O
) None None O
monitor None None O
, None None O
a None None O
32-bit None None O
Cortex-M0 None None O
core None None O
, None None O
and None None O
64 None None O
Kbyte None None O
Ferroelectric None None O
Random None None O
Access None None O
Memory None None I-FUNC
( None None O
FeRAM None None O
) None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
two None None O
twin None None O
extreme None None O
learning None None I-FUNC
machine None None O
( None None O
TELM None None O
) None None O
models None None O
for None None O
constructing None None O
PIs None None O
are None None O
proposed None None O
. None None O

Then None None O
, None None O
we None None O
propose None None O
an None None O
asymmetric None None O
Bayesian None None O
extreme None None O
learning None None I-FUNC
machine None None O
( None None O
AB-ELM None None O
) None None O
method None None O
based None None O
on None None O
the None None O
Bayesian None None O
framework None None O
with None None O
the None None O
asymmetric None None O
Gaussian None None O
distribution None None O
( None None O
AB-ELM None None O
) None None O
, None None O
in None None O
which None None O
the None None O
weights None None O
of None None O
its None None O
likelihood None None O
function None None O
are None None O
determined None None O
as None None O
the None None O
same None None O
method None None O
in None None O
RALS-ELM None None O
, None None O
and None None O
the None None O
type None None O
II None None O
maximum None None O
likelihood None None O
algorithm None None O
is None None O
derived None None O
to None None O
learn None None O
the None None O
parameters None None O
of None None O
AB-ELM None None O
. None None O

Via None None O
the None None O
learning None None I-FUNC
process None None O
, None None O
users None None O
can None None O
construct None None O
a None None O
linear None None O
or None None O
nonlinear None None O
model None None O
between None None O
the None None O
alpha None None O
mattes None None O
and None None O
the None None O
image None None O
colors None None O
using None None O
a None None O
training None None O
set None None O
to None None O
estimate None None O
the None None O
alpha None None O
matte None None O
of None None O
an None None O
unknown None None O
pixel None None O
without None None O
any None None O
assumption None None O
about None None O
the None None O
characteristics None None O
of None None O
the None None O
testing None None O
image None None O
. None None O

When None None O
facing None None O
multitask-learning None None O
problems None None O
, None None O
it None None O
is None None O
desirable None None O
that None None O
the None None O
learning None None I-FUNC
method None None O
could None None O
find None None O
the None None O
correct None None O
input-output None None O
features None None O
and None None O
share None None O
the None None O
commonality None None O
among None None O
multiple None None O
domains None None O
and None None O
also None None O
scale-up None None O
for None None O
large None None O
multitask None None O
datasets None None O
. None None O

The None None O
basic None None O
idea None None O
of None None O
MTC-LR None None O
is None None O
to None None O
use None None O
all None None O
individual None None O
LR None None O
based None None O
classifiers None None O
, None None O
each None None O
one None None O
appropriate None None O
for None None O
each None None O
task None None O
domain None None O
, None None O
but None None O
in None None O
contrast None None O
to None None O
other None None O
support None None O
vector None None O
machine None None O
( None None O
SVM None None O
) None None O
-based None None O
proposals None None O
, None None O
learning None None I-FUNC
all None None O
the None None O
parameter None None O
vectors None None O
of None None O
all None None O
individual None None O
classifiers None None O
by None None O
using None None O
the None None O
conjugate None None O
gradient None None O
method None None O
, None None O
in None None O
a None None O
global None None O
way None None O
and None None O
without None None O
the None None O
use None None O
of None None O
kernel None None O
trick None None O
, None None O
and None None O
being None None O
easily None None O
extended None None O
into None None O
its None None O
scaled None None O
version None None O
. None None O

This None None O
paper None None O
develops None None O
a None None O
semi-supervised None None O
learning None None I-FUNC
mechanism None None O
to None None O
reduce None None O
the None None O
above None None O
two None None O
limitations None None O
. None None O

Finally None None O
, None None O
we None None O
link None None O
the None None O
multitask None None O
model None None O
and None None O
SFSMR None None O
, None None O
and None None O
propose None None O
the None None O
semi-supervised None None O
learning None None I-FUNC
method None None O
to None None O
reduce None None O
the None None O
two None None O
limitations None None O
. None None O

To None None O
evaluate None None O
the None None O
framework None None O
, None None O
we None None O
have None None O
developed None None O
a None None O
method None None O
for None None O
simultaneously None None O
learning None None I-FUNC
multiple None None O
3-D None None O
object None None O
models None None O
directly None None O
from None None O
the None None O
cluttered None None O
indoor None None O
environment None None O
and None None O
tested None None O
it None None O
using None None O
several None None O
everyday None None O
scenes None None O
. None None O

X-linked None None O
adrenoleukodystrophy None None I-DISEASE
( None None O
X-ALD None None O
) None None O
( None None O
OMIM None None O
: None None O
300100 None None O
) None None O
is None None O
a None None O
recessive None None O
neurodegenerative None None O
disorder None None O
caused None None O
by None None O
defects None None O
in None None O
the None None O
ABCD1 None None O
gene None None O
on None None O
chromosome None None O
Xq28 None None O
. None None O

Hydrogen-oxidizing None None O
membranes None None O
also None None O
catalyzed None None O
H₂-ubiquinone None None O
oxidoreductase None None I-PROTEIN
activity None None O
, None None O
and None None O
the None None O
site None None O
of None None O
ubiquinone None None O
reduction None None O
was None None O
localized None None O
to None None O
the None None O
He-quinone None None O
oxidoreductase None None I-PROTEIN
complex None None O
based None None O
on None None O
comparative None None O
antimycin None None O
A None None O
and None None O
HQNO None None O
titrations None None O
of None None O
both None None O
H₂-ubiquinone-1 None None O
oxidoreductase None None I-PROTEIN
and None None O
ubiquinol-1 None None O
oxidase None None O
activities None None O
. None None O

This None None O
is None None O
, None None O
to None None O
our None None O
knowledge None None O
, None None O
the None None O
first None None O
report None None O
of None None O
antimycin None None O
A None None O
inhibition None None O
of None None O
a None None O
hydrogenase None None O
complex None None O
, None None O
and None None O
also None None O
of None None O
a None None O
quinone None None O
reducing None None O
site None None O
of None None O
a None None O
primary None None O
dehydrogenase None None I-PROTEIN
. None None O

Tau None None O
was None None O
also None None O
compared None None O
between None None O
patients None None O
with None None O
progesterone None None O
receptor None None I-PROTEIN
( None None O
PgR None None O
) None None O
positive None None O
and None None O
negative None None O
and None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
positive None None O
and None None O
negative None None O
breast None None O
cancer None None O
, None None O
respectively None None O
. None None O

The None None O
tumor None None O
cells None None O
were None None O
strongly None None O
positive None None O
for None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
π None None O
, None None O
and None None O
positive None None O
for None None O
cal- None None O
retinin None None O
, None None O
vimentin None None O
, None None O
c-Kit None None O
, None None O
CD99 None None O
, None None O
and None None O
CD56 None None O
; None None O
neuron-specific None None O
enolase None None O
was None None O
also None None O
partially None None O
expressed None None O
. None None O

Analysis None None O
of None None O
the None None O
fragments None None O
of None None O
the None None O
pmoA None None O
gene None None O
encoding None None I-FUNC
particulate None None O
methane None None O
monooxygenase None None O
revealed None None O
predominance None None O
of None None O
the None None O
genus None None O
Methylocystis None None O
( None None O
92 None None O
% None None O
of None None O
the None None O
clones None None O
) None None O
in None None O
the None None O
studied None None O
sample None None O
of None None O
acidic None None O
peat None None O
, None None O
while None None O
the None None O
proportion None None O
of None None O
the None None O
pmoA None None O
sequences None None O
of None None O
type None None O
I None None O
methanotrophs None None O
was None None O
insignificant None None O
( None None O
8 None None O
% None None O
) None None O
. None None O

Their None None O
structural None None O
features None None O
included None None O
the None None O
presence None None O
of None None O
electron-transparent None None O
zones None None O
, None None O
presumably None None O
inclusions None None O
containing None None O
storage None None I-FUNC
compounds None None O
, None None O
and None None O
microenvironment None None O
( None None O
capsules None None O
or None None O
external None None O
sheaths None None O
) None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
analyzed None None O
available None None O
literature None None O
about None None O
S. None None O
marcescens None None O
efflux None None O
systems None None O
and None None O
carried None None O
out None None O
the None None O
comparative None None O
analysis None None O
of None None O
the None None O
genes None None O
encoding None None I-FUNC
the None None O
RND None None O
type None None O
systems None None O
in None None O
different None None O
Serratia None None O
species None None O
and None None O
in None None O
other None None O
enterobacteria None None O
. None None O

Elevated None None O
levels None None O
of None None O
Cu None None O
and None None O
Zn None None O
( None None O
which None None O
impair None None O
the None None O
activity None None O
of None None O
the None None O
respiratory None None O
chain None None O
enzymes None None I-PROTEIN
) None None O
and None None O
of None None O
Mn None None O
, None None O
which None None O
is None None O
known None None O
as None None O
a None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
cofactor None None O
, None None O
confirmed None None O
development None None O
of None None O
the None None O
oxidative None None O
stress None None O
in None None O
bacteria None None O
. None None O

B7b None None O
, None None O
B106a None None O
, None None O
G12a None None O
, None None O
P2kr None None O
, None None O
P2 None None O
( None None O
51 None None O
) None None O
, None None O
and None None O
P2m None None O
) None None O
, None None O
as None None O
well None None O
as None None O
in None None O
an None None O
active None None O
biphenyl None None O
degrader None None O
Rhodococcus None None O
ruber None None O
P25 None None O
indicated None None O
the None None O
absence None None O
of None None O
the None None O
genes None None O
encoding None None I-FUNC
the None None O
proteins None None O
of None None O
the None None O
biphenyl/toluene None None O
dioxygenase None None O
subfamily None None O
and None None O
participation None None O
of None None O
the None None O
enzymes None None I-PROTEIN
other None None O
than None None O
this None None O
protein None None O
family None None O
in None None O
biphenyl/CB None None O
degradation None None O
. None None O

Primers None None O
designed None None O
to None None O
amplify None None O
the None None O
genes None None O
of None None O
ATP None None O
citrate None None O
lyase None None I-PROTEIN
( None None O
aclB None None O
) None None O
and None None O
citrate None None O
synthase None None O
( None None O
gltA None None O
) None None O
revealed None None O
the None None O
respective None None O
genes None None O
in None None O
the None None O
genomes None None O
of None None O
all None None O
of None None O
the None None O
newly None None O
studied None None O
GSB None None O
strains None None O
. None None O

This None None O
component None None O
has None None O
shown None None O
chemopreventive None None O
and None None O
therapeutic None None O
activity None None O
against None None O
a None None O
wide None None O
variety None None O
of None None O
experimental None None O
tumors None None O
, None None O
but None None O
D-limonene None None O
is None None O
unstable None None O
and None None O
lose None None O
its None None O
lemon-like None None O
flavor None None O
under None None O
normal None None O
storage None None I-FUNC
condition None None O
, None None O
and None None O
it None None O
is None None O
almost None None O
insoluble None None O
in None None O
water None None O
. None None O

Together None None O
with None None O
active None None O
inorganic None None O
carbon None None O
uptake None None O
transporters None None I-PROTEIN
, None None O
carboxysomes None None O
accumulate None None O
HCO3 None None O
( None None O
- None None O
) None None O
in None None O
the None None O
cytoplasm None None O
, None None O
leading None None O
to None None O
high None None O
efficiency None None O
of None None O
carbon None None O
fixation None None O
. None None O

In None None O
fact None None O
, None None O
the None None O
genes None None O
encoding None None I-FUNC
either None None O
vacant None None O
carboxysome None None O
shell None None O
or None None O
only None None O
interior None None O
components None None O
have None None O
been None None O
characterized None None O
. None None O

Due None None O
to None None O
their None None O
potential None None O
application None None O
as None None O
novel None None O
antibiotics None None O
, None None O
antimicrobial None None O
peptides None None I-TRANS
are None None O
attracting None None O
much None None O
attention None None I-FUNC
. None None O

Natural None None O
resources None None O
of None None O
antimicrobial None None O
peptides None None I-TRANS
are None None O
limited None None O
and None None O
hard None None O
to None None O
purify None None O
, None None O
chemical None None O
synthesis None None O
is None None O
of None None O
high-cost None None O
and None None O
unstable None None O
, None None O
so None None O
recombinant None None O
expression None None O
of None None O
antimicrobial None None O
peptides None None I-TRANS
is None None O
a None None O
cost-effective None None O
way None None O
. None None O

Combined None None O
with None None O
our None None O
research None None O
, None None O
the None None O
present None None O
article None None O
reviews None None O
the None None O
progress None None O
of None None O
fusion None None O
vector None None O
, None None O
cleavage None None O
methods None None O
and None None O
optimization None None O
options None None O
for None None O
antimicrobial None None O
peptides None None I-TRANS
production None None O
with None None O
fusion None None O
protein None None O
in None None O
Escherichia None None O
coli None None O
. None None O

Expression None None O
of None None O
three None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
MYB None None O
, None None O
bHLH None None O
and None None O
WD40 None None O
) None None O
in None None O
red None None O
line None None O
was None None O
significantly None None O
higher None None O
than None None O
that None None O
in None None O
white None None O
line None None O
, None None O
especially None None O
the None None O
expression None None O
of None None O
MYB None None O
( None None O
19.70 None None O
times None None O
higher None None O
compared None None O
to None None O
white None None O
line None None O
) None None O
. None None O

he None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
obtain None None O
a None None O
cell-penetrating None None O
cytoglobin None None O
( None None O
Cygb None None O
) None None O
, None None O
which None None O
combines None None O
the None None O
transmembrane None None O
function None None O
of None None O
cell-penetrating None None O
peptides None None I-TRANS
TAT None None O
with None None O
the None None O
anti-aging None None O
and None None O
anti-fibrotic None None O
role None None O
of None None O
cytoglobin None None O
. None None O

We None None O
proposed None None O
that None None O
the None None O
solvent None None O
accessible None None O
charged None None O
area None None O
of None None O
the None None O
enzymes None None I-PROTEIN
could None None O
interact None None O
with None None O
the None None O
ELPs None None O
, None None O
the None None O
sterical None None O
hindrance None None O
of None None O
the None None O
enzymes None None I-PROTEIN
prevent None None O
the None None O
aggregation None None O
of None None O
the None None O
ELPs None None O
. None None O

SDS-PAGE None None O
and None None O
Western None None O
blotting None None O
analysis None None O
confirmed None None O
the None None O
detection None None O
of None None O
a None None O
68 None None O
kDa None None O
protein None None O
by None None O
the None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
( None None O
GST None None O
) None None O
monoclonal None None O
antibody None None O
. None None O

Specific None None O
attention None None I-FUNC
to None None O
respiratory None None O
management None None O
, None None O
temperature None None O
regulation None None O
, None None O
and None None O
vascular None None O
access None None O
, None None O
undertaken None None O
via None None O
a None None O
standardized None None O
approach None None O
may None None O
have None None O
immeasurable None None O
long-term None None O
benefits None None O
, None None O
and None None O
make None None O
the None None O
difference None None O
between None None O
life None None O
and None None O
death None None O
. None None O

Infestation None None O
, None None O
moldy None None O
and None None O
other None None O
phenomenon None None O
in None None O
the None None O
processing None None O
and None None O
storage None None I-FUNC
of None None O
Chinese None None O
herbal None None O
medicines None None O
is None None O
a None None O
problem None None O
that None None O
faced None None O
in None None O
the None None O
production None None O
of None None O
Chinese None None O
traditional None None O
medicine None None O
. None None O

It None None O
is None None O
now None None O
well None None O
established None None O
that None None O
inflammation None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
development None None O
of None None O
numerous None None O
chronic None None O
metabolic None None O
diseases None None O
including None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
IR None None O
) None None O
and None None O
type None None O
2 None None O
diabetes None None O
( None None O
T2DM None None O
) None None O
. None None O

Thus None None O
, None None O
our None None O
objective None None O
was None None O
to None None O
investigate None None O
effects None None O
of None None O
Rut None None O
on None None O
inflammatory None None O
cytokines None None O
interleukiri None None O
( None None O
IL None None O
) None None O
-1 None None O
, None None O
IL-6 None None O
and None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
-α None None O
in None None O
insulin None None I-PROTEIN
resistant None None O
primary None None O
skeletal None None O
muscle None None O
cells None None O
( None None O
IR-PSMC None None O
) None None O
. None None O

IR-PSMC None None O
cells None None O
were None None O
induced None None O
by None None O
palmitic None None O
acid None None O
( None None O
PA None None O
) None None O
, None None O
the None None O
glucose None None O
concentration None None O
was None None O
measured None None O
by None None O
glucose None None I-PROTEIN
oxidase None None I-PROTEIN
and None None O
peroxidase None None O
( None None O
GOD-POD None None O
) None None O
method None None O
. None None O

Our None None O
results None None O
demonstrated None None O
that None None O
the None None O
Rut None None O
promoted None None O
glucose None None O
consumption None None O
and None None O
improved None None O
insulin None None I-PROTEIN
resistance None None O
possibly None None O
through None None O
suppression None None O
of None None O
inflammatory None None O
cytokines None None O
in None None O
the None None O
IR-PSMC None None O
cells None None O
. None None O

Ser- None None O
um None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
8-iso None None O
prostaglandin None None O
F2α None None O
( None None O
8-iso-PGF2α None None O
) None None O
and None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
were None None O
detected None None O
by None None O
ELISA None None O
. None None O

The None None O
expression None None O
quantity None None O
of None None O
c-myc None None I-PROTEIN
and None None O
hTERT None None O
mRNA None None O
were None None O
determined None None O
by None None O
semi-quantitative None None O
RT-PCR None None O
The None None O
effect None None O
of None None O
DMC None None O
on None None O
expression None None O
levels None None O
of None None O
cmyc None None O
and None None O
hTERT None None O
protein None None O
were None None O
measured None None O
by None None O
western None None O
blot None None O
. None None O

DMC None None O
can None None O
induce None None O
SMMC-7721 None None O
cell None None O
apoptosis None None O
and None None O
the None None O
apoptosis None None O
mechanism None None O
may None None O
be None None O
related None None O
to None None O
the None None O
decreased None None O
mRNA None None O
and None None O
protein None None O
expression None None O
of None None O
c-myc None None I-PROTEIN
and None None O
hTERT None None O
. None None O

NOD-like None None O
receptors None None I-PROTEIN
( None None O
NLRs None None O
) None None O
are None None O
a None None O
family None None O
of None None O
cytoplasmic None None O
pattern-recognition None None O
receptors None None I-PROTEIN
that None None O
have None None O
critical None None O
roles None None O
in None None O
innate None None O
immunity None None O
. None None O

Mean None None O
untreated None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
( None None O
14.0 None None O
± None None O
1.3 None None O
vs. None None O
16.0 None None O
± None None O
l.4 None None O
mmHg None None O
; None None O
p None None O
= None None O
0.0102 None None O
) None None O
was None None O
significantly None None O
lower None None O
in None None O
patients None None O
with None None O
an None None O
IPFS None None O
than None None O
in None None O
patients None None O
with None None O
an None None O
INS None None O
. None None O

Initial None None O
visual None None O
field None None O
pattern None None O
of None None O
NTG None None O
is None None O
influenced None None O
by None None O
untreated None None O
IOP None None I-TRANS
level None None O
. None None O

Part None None O
A None None O
, None None O
assessed None None O
patients None None O
' None None O
perception None None I-FUNC
of None None O
their None None O
current None None O
level None None O
of None None O
function None None O
and None None O
pain None None O
, None None O
and None None O
Part None None O
B None None O
, None None O
assessed None None O
patients None None O
' None None O
desired None None O
outcomes None None O
of None None O
the None None O
surgery None None O
. None None O

A None None O
discrepancy None None O
score None None O
between None None O
patients None None O
' None None O
expectations None None O
and None None O
desired None None O
outcome None None O
( None None O
Part None None O
B None None O
) None None O
and None None O
their None None O
perception None None I-FUNC
of None None O
current None None O
function None None O
( None None O
Part None None O
A None None O
) None None O
was None None O
also None None O
calculated None None O
. None None O

The None None O
discrepancy None None O
score None None O
in None None O
each None None O
subscale None None O
and None None O
the None None O
overall None None O
score None None O
showed None None O
relatively None None O
large None None O
discrepancy None None O
between None None O
patients None None O
' None None O
expectations None None O
and None None O
their None None O
perception None None I-FUNC
of None None O
current None None O
function None None O
; None None O
with None None O
higher None None O
discrepancy None None O
score None None O
reported None None O
for None None O
pain None None O
and None None O
walking None None O
. None None O

Recently None None O
, None None O
forms None None O
of None None O
quinolone None None O
toxicity None None O
such None None O
as None None O
peripheral None None O
neuropathy None None O
, None None O
retinal None None O
detachment None None O
or None None O
QTc-prolongation None None O
have None None O
attracted None None O
attention None None I-FUNC
. None None O

He None None O
also None None O
lacked None None O
congenital None None O
heart None None O
defects None None O
, None None O
characteristic None None O
facial None None O
features None None O
, None None O
or None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
frequently None None O
observed None None O
in None None O
those None None O
with None None O
CFCS None None O
caused None None O
by None None O
MAP2K1 None None O
or None None O
MAP2K2 None None O
mutations None None O
. None None O

Discriminability None None O
draws None None O
on None None O
memory None None I-FUNC
processes None None O
while None None O
criterion None None O
setting None None O
( None None O
i.e. None None O
, None None O
the None None O
application None None O
of None None O
a None None O
threshold None None O
resulting None None O
in None None O
a None None O
yes/no None None O
response None None O
) None None O
is None None O
regarded None None O
as None None O
a None None O
process None None O
of None None O
cognitive None None O
control None None O
. None None O

We None None O
applied None None O
voxel-based None None O
and None None O
region None None O
of None None O
interest-based None None O
lesion-symptom None None O
mapping None None O
to None None O
83 None None O
patients None None O
in None None O
the None None O
acute None None O
phase None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
to None None O
determine None None O
the None None O
anatomical None None O
correlates None None O
of None None O
discriminability None None O
and None None O
criterion None None O
setting None None O
in None None O
verbal None None O
recognition None None O
memory None None I-FUNC
. None None O

Lesions None None O
in None None O
the None None O
right None None I-REGION
inferior None None I-REGION
frontal None None I-REGION
gyrus None None I-REGION
were None None O
associated None None O
with None None O
liberal None None O
response None None O
bias None None O
. None None O

As None None O
homeostatic None None O
regulators None None O
of None None O
brain None None O
function None None O
, None None O
some None None O
hormones None None I-PROTEIN
exert None None O
neuroprotective None None O
actions None None O
. None None O

By None None O
contrast None None O
, None None O
malaria None None O
was None None O
associated None None O
with None None O
increased None None O
identification None None O
of None None O
viral None None O
and None None O
bacterial None None O
NA None None I-TRANS
and None None O
with None None O
impaired None None O
consciousness None None I-FUNC
, None None O
multiple None None O
convulsions None None O
and None None O
age None None O
. None None O

Amongst None None O
children None None O
with None None O
HHV None None O
infection None None O
, None None O
those None None O
with None None O
HHV-6 None None O
and None None O
-7 None None O
were None None O
younger None None O
, None None O
were None None O
more None None O
likely None None O
have None None O
impaired None None O
consciousness None None I-FUNC
and None None O
had None None O
a None None O
higher None None O
proportion None None O
of None None O
adverse None None O
outcomes None None O
than None None O
children None None O
with None None O
CMV None None O
. None None O

Two None None O
host None None O
proteins None None O
that None None O
had None None O
not None None O
previously None None O
been None None O
reported None None O
to None None O
interact None None O
with None None O
T. None None O
gondii None None O
MIC2 None None O
were None None O
identified None None O
: None None O
they None None O
are None None O
LAMTOR1 None None O
( None None O
late None None O
endosomal/lysosomal None None O
adaptor None None O
, None None O
MAPK None None O
and None None O
mTOR None None O
activator None None O
1 None None O
) None None O
and None None O
RNaseH2B None None O
( None None O
ribonuclease None None I-PROTEIN
H2 None None O
subunit None None O
B None None O
) None None O
. None None O

Spike None None O
parallel None None O
processing None None O
, None None O
memory None None I-FUNC
, None None O
and None None O
plasticity None None O
functions None None O
of None None O
the None None O
module None None O
are None None O
demonstrated None None O
. None None O

Fabry None None O
disease None None O
( None None O
FD None None O
) None None O
is None None O
a None None O
multisystemic None None O
disorder None None O
with None None O
typical None None O
neurological None None O
manifestations None None O
such None None O
as None None O
stroke None None I-DISEASE
and None None O
small None None O
fiber None None O
neuropathy None None O
( None None O
SFN None None O
) None None O
, None None O
caused None None O
by None None O
mutations None None O
of None None O
the None None O
alpha-galactosidase None None O
A None None O
( None None O
GLA None None O
) None None O
gene None None O
. None None O

Patients None None O
were None None O
retrospectively None None O
analyzed None None O
for None None O
stroke None None I-DISEASE
, None None O
transient None None O
ischemic None None O
attack None None O
( None None O
TIA None None O
) None None O
, None None O
white None None I-REGION
matter None None I-REGION
lesions None None O
( None None O
WML None None O
) None None O
and None None O
SFN None None O
with None None O
neuropathic None None O
pain None None O
. None None O

Symptomatic None None O
-10T None None O
allele None None O
carriers None None O
suffered None None O
from None None O
stroke None None I-DISEASE
, None None O
TIA None None O
, None None O
WML None None O
, None None O
and None None O
SFN None None O
with None None O
neuropathic None None O
pain None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
body None None O
condition None None O
affects None None O
the None None O
initial None None O
quality None None O
of None None O
oocytes None None O
, None None O
but None None O
does None None O
not None None O
affect None None O
embryo None None O
cleavage None None O
, None None O
blastocyst None None O
rate None None O
and None None O
actin None None I-PROTEIN
quality None None O
. None None O

Elevations None None O
in None None O
FGF23 None None O
may None None O
also None None O
suggest None None O
the None None O
presence None None O
of None None O
compensatory None None O
response None None O
to None None O
phosphate None None O
retention None None I-FUNC
, None None O
underscoring None None O
the None None O
potential None None O
of None None O
FGF23 None None O
as None None O
a None None O
new None None O
biomarker None None O
of None None O
phosphate None None O
balance None None O
. None None O

Identification None None O
, None None O
functional None None O
characterization None None O
and None None O
analysis None None O
of None None O
knockout None None O
mice None None O
of None None O
Pi None None O
transporters None None I-PROTEIN
contributed None None O
to None None O
clarify None None O
the None None O
role None None O
of None None O
each None None O
transporter None None O
in None None O
Pi None None O
homeostasis None None O
. None None O

Parathyroid None None O
monitors None None O
the None None O
calcium None None O
concentration None None O
in None None O
blood None None O
by None None O
signals None None O
from None None O
calcium-sensing None None O
receptors None None I-PROTEIN
, None None O
adjusts None None O
secretion None None O
of None None O
parathyroid None None O
hormone None None O
to None None O
keep None None O
constant None None O
calcium None None O
concentration None None O
in None None O
the None None O
body None None O
. None None O

In None None O
the None None O
past None None O
, None None O
empirical None None O
data None None O
regarding None None O
larval None None O
dispersal None None O
and None None O
movement None None I-FUNC
patterns None None O
of None None O
adults None None O
and None None O
juveniles None None O
of None None O
many None None O
tropical None None O
marine None None O
species None None O
have None None O
been None None O
unavailable None None O
or None None O
inaccessible None None O
to None None O
practitioners None None O
responsible None None O
for None None O
marine None None O
reserve None None O
design None None O
. None None O

Our None None O
review None None O
of None None O
movement None None I-FUNC
patterns None None O
of None None O
34 None None O
families None None O
( None None O
210 None None O
species None None O
) None None O
of None None O
coral None None O
reef None None O
fishes None None O
demonstrates None None O
that None None O
movement None None I-FUNC
patterns None None O
( None None O
home None None O
ranges None None O
, None None O
ontogenetic None None O
shifts None None O
and None None O
spawning None None O
migrations None None O
) None None O
vary None None O
among None None O
and None None O
within None None O
species None None O
, None None O
and None None O
are None None O
influenced None None O
by None None O
a None None O
range None None O
of None None O
factors None None O
( None None O
e.g None None O
. None None O

Patient-oriented None None O
composite None None O
endpoint None None O
( None None O
POCE None None O
, None None O
including None None O
all None None O
death None None O
, None None O
all None None O
myocardial None None O
infarction None None O
( None None O
MI None None O
) None None O
and None None O
all None None O
revascularisations None None O
) None None O
, None None O
major None None O
adverse None None O
cardiac None None O
events None None O
( None None O
MACE None None O
, None None O
including None None O
cardiac None None O
death None None O
, None None O
MI None None O
and None None O
clinically None None O
indicated None None O
target None None O
vessel None None O
revascularisation None None O
) None None O
and None None O
stent None None O
thrombosis None None I-DISEASE
were None None O
assessed None None O
at None None O
5-year None None O
follow-up None None O
. None None O

In None None O
patients None None O
with None None O
ST-elevation None None O
MI None None O
( None None O
STEMI None None O
) None None O
, None None O
coronary None None O
intervention None None O
with None None O
BES None None O
significantly None None O
reduced None None O
POCE None None O
( None None O
24.4 None None O
% None None O
vs None None O
39.3 None None O
% None None O
; None None O
RR None None O
0.55 None None O
, None None O
95 None None O
% None None O
CI None None O
0.36 None None O
to None None O
0.85 None None O
, None None O
p=0.006 None None O
) None None O
, None None O
MACE None None O
( None None O
12.6 None None O
% None None O
vs None None O
25.0 None None O
% None None O
; None None O
RR None None O
0.47 None None O
, None None O
95 None None O
% None None O
CI None None O
0.26 None None O
to None None O
0.83 None None O
, None None O
p=0.008 None None O
) None None O
and None None O
cardiac None None O
death None None O
( None None O
3.0 None None O
% None None O
vs None None O
11.4 None None O
% None None O
; None None O
RR None None O
0.25 None None O
, None None O
95 None None O
% None None O
CI None None O
0.08 None None O
to None None O
0.75 None None O
, None None O
p=0.007 None None O
) None None O
, None None O
along None None O
with None None O
a None None O
trend None None O
towards None None O
reduction None None O
in None None O
definite None None O
stent None None O
thrombosis None None I-DISEASE
( None None O
3.7 None None O
% None None O
vs None None O
8.6 None None O
% None None O
; None None O
RR None None O
0.41 None None O
, None None O
95 None None O
% None None O
CI None None O
0.15 None None O
to None None O
1.18 None None O
, None None O
p=0.088 None None O
) None None O
, None None O
compared None None O
with None None O
SES None None O
. None None O

This None None O
work None None O
offers None None O
a None None O
facile None None O
, None None O
cost-effective None None O
, None None O
and None None O
green None None O
strategy None None O
to None None O
rationally None None O
design None None O
and None None O
synthesize None None O
functional None None O
nanomaterials None None O
for None None O
future None None O
applications None None O
in None None O
catalysis None None O
, None None O
magnetism None None O
, None None O
gas None None O
storage None None I-FUNC
or None None O
separation None None O
, None None O
and None None O
sensing None None O
technology None None O
. None None O

To None None O
test None None O
the None None O
potential None None O
chemotherapeutic None None O
importance None None O
of None None O
disrupting None None O
ergosterol None None O
biosynthesis None None O
using None None O
pairs None None O
of None None O
mechanism-based None None O
inhibitors None None O
that None None O
block None None O
two None None O
enzymes None None I-PROTEIN
in None None O
the None None O
post-squalene None None O
segment None None O
, None None O
parasites None None O
were None None O
treated None None O
with None None O
AZA None None O
and None None O
itraconazole None None O
at None None O
1 None None O
μM None None O
each None None O
( None None O
ED50 None None O
values None None O
) None None O
resulting None None O
in None None O
parasite None None O
death None None O
. None None O

Acidity None None O
enhances None None O
the None None O
proteolytic None None O
, None None O
lipolytic None None O
, None None O
and None None O
oxidative None None O
modifications None None O
of None None O
LDL None None O
and None None O
other None None O
apoB-containing None None O
lipoproteins None None O
, None None O
and None None O
strongly None None O
increases None None O
their None None O
affinity None None O
for None None O
proteoglycans None None O
, None None O
and None None O
may None None O
thus None None O
have None None O
major None None O
effects None None O
on None None O
their None None O
retention None None I-FUNC
and None None O
the None None O
ensuing None None O
cellular None None O
responses None None O
in None None O
the None None O
arterial None None O
intima None None O
. None None O

The None None O
results None None O
demonstrated None None O
how None None O
CETP None None O
can None None O
penetrate None None O
the None None O
HDL None None O
particle None None O
surface None None O
, None None O
with None None O
the None None O
formation None None O
of None None O
an None None O
opening None None O
in None None O
the None None O
N None None O
barrel None None I-REGION
domain None None O
end None None O
of None None O
CETP None None O
, None None O
put None None O
in None None O
evidence None None O
the None None O
major None None O
anchoring None None O
role None None O
of None None O
a None None O
tryptophan-rich None None O
region None None O
of None None O
this None None O
domain None None O
, None None O
and None None O
unveiled None None O
the None None O
presence None None O
of None None O
a None None O
phenylalanine None None I-TRANS
barrier None None O
controlling None None O
further None None O
access None None O
of None None O
HDL-derived None None O
lipids None None O
to None None O
the None None O
tunnel None None O
of None None O
CETP None None O
. None None O

Juvenile None None O
cataracts None None O
, None None O
progressive None None O
neurologic None None O
dysfunction None None O
, None None O
and None None O
mild None None O
pulmonary None None O
insufficiency None None O
are None None O
unique None None O
symptoms None None O
that None None O
distinguish None None O
CTX None None O
from None None O
other None None O
lipid None None O
storage None None I-FUNC
disorders None None O
including None None O
familial None None O
dysbetalipoproteinemia None None O
, None None O
homozygous None None O
familial None None O
hypercholesterolemia None None O
, None None O
and None None O
sitosterolemia None None O
, None None O
all None None O
of None None O
which None None O
might None None O
also None None O
present None None O
with None None O
xanthomas None None O
and None None O
cardiovascular None None O
diseases None None O
. None None O

This None None O
area None None O
is None None O
characterized None None O
by None None O
symptoms None None O
of None None O
anxiety None None O
and/or None None O
depression None None I-DISEASE
, None None O
self-withdrawal None None O
, None None O
somatic None None O
complaints None None O
and None None O
dissociation None None O
. None None O

Special None None O
attention None None I-FUNC
to None None O
this None None O
cardiac None None O
rhythm None None O
disorder None None O
is None None O
required None None O
because None None O
of None None O
its None None O
pathologic None None O
implications None None O
. None None O

Except None None O
for None None O
the None None O
depression None None I-DISEASE
of None None O
matrix None None I-PROTEIN
metalloproteinase-2 None None O
and None None O
matrix None None I-PROTEIN
metalloproteinase-9 None None O
expressions None None O
, None None O
cHAb18 None None O
antibody None None O
suppressed None None O
cell None None O
motility None None O
by None None O
rearrangement None None O
of None None O
actin None None I-PROTEIN
cytoskeleton None None O
, None None O
which None None O
was None None O
probably None None O
induced None None O
by None None O
decreasing None None O
the None None O
phosphorylation None None O
of None None O
focal None None O
adhesion None None O
kinase None None O
, None None O
phosphatidylinositide-3 None None O
kinase None None O
( None None O
PI3K None None O
) None None O
, None None O
Akt None None O
, None None O
and None None O
Girdin None None O
in None None O
the None None O
integrin None None I-PROTEIN
signaling None None O
pathway None None O
. None None O

Subsequently None None O
, None None O
seasonings None None O
( None None O
3:1 None None O
) None None O
were None None O
prepared None None O
containing None None O
0 None None O
% None None O
, None None O
50 None None O
% None None O
and None None O
25 None None O
% None None O
less None None O
NaCl None None O
using None None O
a None None O
mixture None None O
of None None O
salts None None O
consisting None None O
of None None O
KCl None None O
and None None O
monosodium None None O
glutamate None None I-TRANS
; None None O
a None None O
seasoning None None O
with None None O
a None None O
0 None None O
% None None O
NaCl None None O
reduction None None O
was None None O
established None None O
as None None O
a None None O
control None None O
. None None O

Therefore None None O
, None None O
a None None O
mixture None None O
of None None O
NaCl None None O
, None None O
KCl None None O
and None None O
monosodium None None O
glutamate None None I-TRANS
is None None O
a None None O
viable None None O
alternative None None O
to None None O
develop None None O
a None None O
garlic None None O
and None None O
salt None None O
spice None None O
with None None O
reduced None None O
sodium None None O
intake None None O
. None None O

Protein None None O
tau None None O
plays None None O
a None None O
pivotal None None O
role None None O
in None None O
the None None O
pathophysiology None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
where None None O
its None None O
hyperphos-phorylation None None O
promotes None None O
aggregation None None O
and None None O
microtubule None None O
destabilization None None O
. None None O

Dysregulation None None O
of None None O
the None None O
splicing None None O
process None None O
of None None O
tau None None O
exon None None O
10 None None O
is None None O
sufficient None None O
to None None O
cause None None O
tauopathy None None O
and None None O
has None None O
shown None None O
to None None O
be None None O
influenced None None O
by None None O
beta-amyloid None None O
peptides None None I-TRANS
, None None O
but None None O
splicing None None O
of None None O
other None None O
exons None None O
is None None O
less None None O
studied None None O
. None None O

Here None None O
, None None O
we None None O
present None None O
a None None O
case None None O
of None None O
inadvertent None None O
stent None None O
detachment None None O
during None None O
stroke None None I-DISEASE
treatment None None O
for None None O
a None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
M1 None None O
occlusion None None O
resulting None None O
in None None O
progressive None None O
thrombosis None None I-DISEASE
. None None O

Immediately None None O
after None None O
the None None O
injection None None O
of None None O
100 None None O
µg None None O
histamine None None I-TRANS
on None None O
both None None O
arms None None O
, None None O
subjects None None O
received None None O
topical None None O
treatment None None O
and None None O
pruritus None None O
was None None O
subsequently None None O
assessed None None O
with None None O
visual None None O
analogue None None O
scale None None O
( None None O
VASpruritus None None O
) None None O
and None None O
Eppendorfer None None O
questionnaire None None O
. None None O

Ninety-three None None O
probands None None O
with None None O
DSM-IV None None O
PG None None O
, None None O
91 None None O
controls None None O
, None None O
and None None O
their None None O
395 None None O
first-degree None None O
relatives None None O
were None None O
evaluated None None O
for None None O
the None None O
presence None None O
of None None O
personality None None I-DISEASE
disorder None None I-DISEASE
with None None O
the None None O
Structured None None O
Interview None None O
for None None O
DSM-IV None None O
Personality None None O
. None None O

PG None None O
probands None None O
had None None O
a None None O
significantly None None O
higher None None O
prevalence None None O
of None None O
personality None None I-DISEASE
disorders None None I-DISEASE
than None None O
controls None None O
( None None O
41 None None O
vs. None None O
7 None None O
% None None O
, None None O
OR None None O
= None None O
9.0 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
along None None O
with None None O
higher None None O
levels None None O
of None None O
impulsiveness None None O
and None None O
novelty None None O
seeking None None O
. None None O

PG None None O
relatives None None O
had None None O
a None None O
significantly None None O
higher None None O
prevalence None None O
of None None O
personality None None I-DISEASE
disorder None None I-DISEASE
than None None O
relatives None None O
of None None O
controls None None O
( None None O
24 None None O
vs. None None O
9 None None O
% None None O
, None None O
OR None None O
= None None O
3.2 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
higher None None O
levels None None O
of None None O
impulsiveness None None O
. None None O

Personality None None I-DISEASE
disorders None None I-DISEASE
, None None O
impulsiveness None None O
, None None O
and None None O
novelty None None O
seeking None None O
are None None O
common None None O
in None None O
people None None O
with None None O
PG None None O
and None None O
their None None O
first-degree None None O
relatives None None O
. None None O

Risk None None O
for None None O
PG None None O
in None None O
relatives None None O
is None None O
associated None None O
with None None O
the None None O
presence None None O
of None None O
personality None None I-DISEASE
disorder None None I-DISEASE
and None None O
trait None None O
impulsiveness None None O
. None None O

This None None O
article None None O
focuses None None O
on None None O
the None None O
psychological None None O
implications None None O
of None None O
living None None O
with None None O
rheumatoid None None O
arthritis None None O
, None None O
including None None O
reaction None None O
to None None O
diagnosis None None O
, None None O
anxiety None None O
and None None O
depression None None I-DISEASE
, None None O
body None None O
image None None O
, None None O
sexuality None None O
, None None O
self-esteem None None O
and None None O
social None None O
role None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
CT None None O
group None None O
, None None O
total None None O
cholesterol None None O
, None None O
alanine None None I-TRANS
aminotransferase None None O
, None None O
systolic None None O
and None None O
diastolic None None O
BP None None O
did None None O
not None None O
change None None O
significantly None None O
in None None O
the None None O
LC None None O
group None None O
after None None O
prolonged None None O
fasting None None O
. None None O

Secondary None None O
endpoints None None O
included None None O
changes None None O
in None None O
scores None None O
for None None O
TSQM None None O
Effectiveness None None O
, None None O
Side None None O
Effects None None O
and None None O
Convenience None None O
subscales None None O
, None None O
Beck None None O
Depression None None I-DISEASE
Inventory-II None None O
( None None O
BDI-II None None O
) None None O
, None None O
Fatigue None None O
Severity None None O
Scale None None O
( None None O
FSS None None O
) None None O
, None None O
Patient-Reported None None O
Outcome None None O
Indices None None O
for None None O
Multiple None None O
Sclerosis None None O
( None None O
PRIMUS None None O
) None None O
Activities None None O
, None None O
36-item None None O
Short-Form None None O
Health None None O
Survey None None O
( None None O
SF-36 None None O
) None None O
Mental None None O
Component None None O
Summary None None O
( None None O
MCS None None O
) None None O
and None None O
Physical None None O
Component None None O
Summary None None O
( None None O
PCS None None O
) None None O
and None None O
mean None None O
investigator-reported None None O
Clinical None None O
Global None None O
Impressions None None O
of None None O
Improvement None None O
( None None O
CGI-I None None O
) None None O
. None None O

The None None O
mRNA None None O
and None None O
protein None None O
levels None None O
of None None O
HDAC4 None None O
, None None O
Runx2 None None O
, None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
( None None O
MMP None None O
) None None O
-13 None None O
, None None O
Indian None None O
hedgehog None None O
( None None O
Ihh None None O
) None None O
and None None O
type None None O
X None None O
collagen None None I-PROTEIN
were None None O
detected None None O
by None None O
performing None None O
real-time None None O
PCR None None O
( None None O
RT-PCR None None O
) None None O
, None None O
western None None O
blotting None None O
and None None O
immunohistochemistry None None O
on None None O
specimens None None O
from None None O
human None None O
OA None None O
and None None O
normal None None O
cartilage None None O
. None None O

Runx2 None None O
and None None O
MMP-13 None None O
promoter None None O
activities None None O
were None None O
measured None None O
by None None O
dual None None O
luciferase None None I-PROTEIN
assays None None O
. None None O

Decreased None None O
HDAC4 None None O
was None None O
associated None None O
with None None O
increased None None O
Runx2 None None O
and None None O
other None None O
OA-related None None O
genes None None O
in None None O
human None None O
OA None None O
cartilage None None O
, None None O
specifically None None O
: None None O
MMP-13 None None O
, None None O
Ihh None None O
and None None O
type None None O
X None None O
collagen None None I-PROTEIN
. None None O

Here None None O
we None None O
utilize None None O
this None None O
directionality None None O
information None None O
by None None O
measuring None None O
encoding None None I-FUNC
activity None None O
within None None O
HC/EC None None O
subregions None None O
with None None O
7 None None O
T None None O
high None None O
resolution None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
. None None O

This None None O
suggests None None O
that None None O
while None None O
novelty None None O
processing None None O
is None None O
strongly None None O
related None None O
to None None O
HC-EC None None O
input None None O
pathways None None O
, None None O
the None None O
memory None None I-FUNC
fate None None O
of None None O
a None None O
novel None None O
stimulus None None O
depends None None O
more None None O
on None None O
HC-EC None None O
output None None O
. None None O

To None None O
date None None O
, None None O
studies None None O
have None None O
predominantly None None O
focused None None O
on None None O
terrestrial None None O
taxa None None O
, None None O
and None None O
coral None None O
reef None None O
fishes None None O
in None None O
particular None None O
have None None O
received None None O
little None None O
attention None None I-FUNC
. None None O

Academic-related None None O
measures None None O
included None None O
a None None O
standardised None None O
reading None None O
test None None O
( None None O
the None None O
Neale None None O
Analysis None None O
of None None O
Reading None None O
Ability None None O
) None None O
, None None O
visual None None I-FUNC
information None None I-FUNC
processing None None I-FUNC
tests None None O
( None None O
Coding None None O
and None None O
Symbol None None O
Search None None O
subtests None None O
from None None O
the None None O
Wechsler None None O
Intelligence None None O
Scale None None O
for None None O
Children None None O
) None None O
and None None O
a None None O
reading-related None None O
eye None None O
movement None None I-FUNC
test None None O
( None None O
the None None O
Developmental None None O
Eye None None O
Movement None None I-FUNC
test None None O
) None None O
. None None O

Reading None None O
, None None O
visual None None I-FUNC
information None None I-FUNC
processing None None I-FUNC
and None None O
reading-related None None O
eye None None O
movement None None I-FUNC
performance None None O
were None None O
all None None O
significantly None None O
impaired None None O
by None None O
both None None O
simulated None None O
bilateral None None O
astigmatism None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
sustained None None O
near None None O
work None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
however None None O
, None None O
there None None O
was None None O
no None None O
significant None None O
interaction None None O
between None None O
these None None O
factors None None O
( None None O
p None None O
& None None O
gt None None O
; None None O
0.05 None None O
) None None O
. None None O

Bioinformatics None None O
analysis None None O
showed None None O
that None None O
miR-148a None None O
may None None O
form None None O
a None None O
negative None None O
feedback None None O
loop None None O
with None None O
its None None O
targets None None O
DNMT1 None None O
and None None O
DNMT3B None None O
and None None O
the None None O
expression None None O
of None None O
the None None O
miR-195/497 None None O
cluster None None O
may None None O
be None None O
affected None None O
not None None O
only None None O
by None None O
their None None O
hypermethylated None None O
promoter None None O
region None None O
but None None O
also None None O
by None None O
their None None O
hypermethylated None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
NEUROG2 None None O
and None None O
DDIT3 None None O
. None None O

This None None O
study None None O
provides None None O
data None None O
regarding None None O
the None None O
lateral None None O
distribution None None O
of None None O
sunitinib None None O
, None None O
an None None O
oral None None O
antiangiogenic None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
using None None O
an None None O
in None None O
vitro None None O
animal None None O
model None None O
as None None O
well None None O
as None None O
an None None O
in None None O
vitro None None O
experimental None None O
model None None O
that None None O
involved None None O
deposition None None O
of None None O
a None None O
solution None None O
of None None O
sunitinib None None O
onto None None O
tissue None None O
sections None None O
. None None O

We None None O
correlated None None O
quantitative None None O
relaxometry None None O
and None None O
DTI None None O
with None None O
histological None None O
features None None O
of None None O
neuronal None None O
density None None O
and None None O
morphology None None O
in None None O
55 None None O
regions None None O
of None None O
the None None O
temporal None None I-REGION
lobe None None I-REGION
neocortex None None I-REGION
, None None O
selected None None O
from None None O
13 None None O
patients None None O
who None None O
underwent None None O
epilepsy None None O
surgery None None O
. None None O

Even None None O
with None None O
these None None O
promising None None O
results None None O
, None None O
clinical None None O
delivery None None O
of None None O
cell None None O
therapy None None O
is None None O
hampered None None O
by None None O
manufacturing None None O
hurdles None None O
, None None O
including None None O
cell None None O
sourcing None None O
, None None O
large-scale None None O
device None None O
manufacture None None O
, None None O
storage None None I-FUNC
and None None O
delivery None None O
. None None O

Other None None O
barriers None None O
reported None None O
by None None O
patients None None O
were None None O
disinterest None None O
in None None O
managing None None O
their None None O
own None None O
disease None None O
( None None O
28.5 None None O
% None None O
, None None O
216/758 None None O
) None None O
and None None O
feelings None None I-FUNC
of None None O
inadequacy None None O
with None None O
the None None O
use None None O
of None None O
computers None None O
and None None O
Internet None None O
( None None O
11.6 None None O
% None None O
, None None O
88/758 None None O
) None None O
. None None O

This None None O
tool None None O
is None None O
currently None None O
available None None O
in None None O
French None None O
language None None I-FUNC
only None None O
. None None O

The None None O
DMRS-C None None O
has None None O
been None None O
translated None None O
into None None O
Italian None None O
and None None O
back-translated None None O
into None None O
French None None O
in None None O
order None None O
to None None O
verify None None O
the None None O
correspondence None None O
with None None O
the None None O
original None None O
language None None I-FUNC
. None None O

This None None O
demonstrated None None O
that None None O
the None None O
paclitaxel None None O
metabolism None None O
was None None O
mainly None None O
catalysed None None O
by None None O
CYP3A4 None None I-PROTEIN
in None None O
HL60 None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
50 None None O
μmol/L None None O
of None None O
losartan None None O
inhibits None None O
both None None O
CYP2C8 None None O
and None None O
CYP3A4 None None I-PROTEIN
in None None O
HLMs None None O
. None None O

The None None O
CYP2C8*3 None None O
allele None None O
carriers None None O
are None None O
likely None None O
susceptible None None O
to None None O
the None None O
interactions None None O
of None None O
losartan None None O
and None None O
CYP3A4 None None I-PROTEIN
inhibitors None None O
to None None O
paclitaxel None None O
metabolism None None O
. None None O

Larvae None None O
of None None O
some None None O
species None None O
of None None O
mosquitoes None None O
have None None O
been None None O
shown None None O
to None None O
respond None None O
to None None O
water-borne None None O
kairomones None None O
from None None O
predators None None O
by None None O
reducing None None O
bottom-feeding None None O
and None None O
replacing None None O
it None None O
with None None O
surface None None O
filter-feeding None None O
, None None O
which None None O
uses None None O
less None None O
movement None None I-FUNC
and None None O
is None None O
thus None None O
less None None O
likely None None O
to None None O
attract None None O
a None None O
predator None None O
. None None O

Thermophilic None None O
fungi None None O
are None None O
potential None None O
sources None None O
of None None O
thermostable None None O
enzymes None None I-PROTEIN
and None None O
other None None O
value None None O
added None None O
products None None O
. None None O

The None None O
crude None None O
enzymes None None I-PROTEIN
hydrolyzed None None O
phosphoric None None O
acid-swollen None None O
wheat None None O
straw None None O
, None None O
avicel None None O
and None None O
untreated None None O
xylan None None O
up None None O
to None None O
74 None None O
, None None O
71 None None O
and None None O
90 None None O
% None None O
, None None O
respectively None None O
. None None O

Organophosphate None None O
hydrolase None None I-PROTEIN
( None None O
opdA None None O
gene None None O
) None None O
involved None None O
in None None O
the None None O
initial None None O
biodegradation None None O
of None None O
monocrotophos None None O
in None None O
KPA-1 None None O
was None None O
quantitatively None None O
expressed None None O
, None None O
which None None O
was None None O
a None None O
constitutively None None O
expressed None None O
cytosolic None None O
enzyme None None O
. None None O

To None None O
verify None None O
the None None O
effects None None O
of None None O
different None None O
catecholamines None None I-TRANS
on None None O
volemic None None O
expansion None None O
and None None O
on None None O
the None None O
autonomic None None O
nervous None None O
system None None O
in None None O
rabbits None None O
that None None O
were None None O
subjected None None O
to None None O
hemorrhage None None O
. None None O

Replacement None None O
with None None O
SS None None O
and None None O
an None None O
α- None None O
or None None O
β-agonist None None O
did None None O
not None None O
produce None None O
differences None None O
in None None O
the None None O
intravascular None None O
retention None None I-FUNC
compared None None O
to None None O
replacement None None O
with None None O
SS None None O
alone None None O
. None None O

No None None O
difference None None O
in None None O
vascular None None O
retention None None I-FUNC
when None None O
α- None None O
or None None O
β- None None O
agonists None None O
were None None O
added None None O
to None None O
SS None None O
during None None O
post-hemorrhagic None None O
recovery None None O
. None None O

Seminars None None O
or None None O
lectures None None O
are None None O
students None None O
' None None O
preferred None None O
methods None None O
of None None O
learning None None I-FUNC
( None None O
Guck None None O
and None None O
Kavan None None O
in None None O
Med None None O
Teach None None O
28 None None O
( None None O
8 None None O
) None None O
:702-707 None None O
, None None O
2006 None None O
) None None O
. None None O

Suppression None None O
of None None O
the None None O
PsCRN63-induced None None O
PCD None None O
by None None O
PsCRN115 None None O
is None None O
compromised None None O
when None None O
catalases None None I-PROTEIN
are None None O
silenced None None O
in None None O
N. None None O
benthamiana None None O
. None None O

Thus None None O
, None None O
PsCRN63/115 None None O
manipulates None None O
plant None None O
PCD None None O
through None None O
interfering None None O
with None None O
catalases None None I-PROTEIN
and None None O
perturbing None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
homeostasis None None O
. None None O

Taken None None O
together None None O
, None None O
we None None O
suggest None None O
that None None O
P. None None O
sojae None None O
secretes None None O
these None None O
two None None O
effectors None None O
to None None O
regulate None None O
plant None None O
PCD None None O
and None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
homeostasis None None O
through None None O
direct None None O
interaction None None O
with None None O
catalases None None I-PROTEIN
and None None O
, None None O
therefore None None O
, None None O
overcome None None O
host None None O
immune None None O
responses None None O
. None None O

This None None O
notion None None O
was None None O
further None None O
supported None None O
by None None O
the None None O
inhibitory None None O
effect None None O
of None None O
RFA None None O
expression None None O
on None None O
the None None O
cell-to-cell None None O
movement None None I-FUNC
of None None O
Bean None None O
dwarf None None O
mosaic None None O
virus None None O
, None None O
a None None O
single-stranded None None O
DNA None None O
virus None None O
. None None O

Baseline None None O
measures None None O
included None None O
socio-demographic None None O
data None None O
, None None O
preferred None None O
brand None None O
of None None O
cigarettes None None O
, None None O
number None None O
of None None O
years None None O
smoking None None O
, None None O
use None None O
of None None O
alcohol None None O
and/or None None O
tranquilizers None None O
, None None O
past None None O
attempts None None O
to None None O
quit None None O
, None None O
Fargerström None None O
Test None None O
for None None O
Nicotine None None I-DISEASE
Dependence None None I-DISEASE
, None None O
Smoking None None O
Processes None None O
of None None O
Change None None O
Scale None None O
, None None O
and None None O
Coping None None O
with None None O
Withdrawal None None O
Symptoms None None O
Interview None None O
. None None O

The None None O
overexpression None None O
of None None O
a None None O
miR-124 None None O
mimic None None O
suppressed None None O
the None None O
osteogenic None None O
marker None None O
gene None None O
expression None None O
levels None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
and None None O
matrix None None O
mineralization None None O
, None None O
which None None O
were None None O
all None None O
significantly None None O
increased None None O
by None None O
the None None O
overexpression None None O
of None None O
a None None O
miR-124 None None O
inhibitor None None O
. None None O

This None None O
report None None O
describes None None O
a None None O
Brazilian None None O
boy None None O
with None None O
syndromic None None O
craniosynostosis None None O
who None None O
also None None O
presented None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
microcephaly None None O
, None None O
frontal None None O
bossing None None O
, None None O
bitemporal None None O
narrowing None None O
, None None O
short None None O
neck None None O
, None None O
syndactyly None None O
, None None O
and None None O
cardiac None None O
defects None None O
. None None O

Cortactin None None O
knockdown None None O
or None None O
inhibition None None O
of None None O
the None None O
nuclear None None O
export None None O
of None None O
cortactin None None O
induced None None O
actin None None I-PROTEIN
cytoskeleton None None O
derangement None None O
and None None O
dissociation None None O
of None None O
cortactin None None O
from None None O
F-actin None None O
, None None O
suggesting None None O
the None None O
necessity None None O
of None None O
cytoplasmic None None O
cortactin None None O
for None None O
maintenance None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
. None None O

Psoriasis None None O
has None None O
been None None O
associated None None O
with None None O
numerous None None O
psychological None None O
disorders None None O
such None None O
as None None O
low None None O
self-esteem None None O
, None None O
depression None None I-DISEASE
, None None O
anxiety None None O
, None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
or None None O
suicidal None None O
ideation None None O
. None None O

We None None O
performed None None O
a None None O
systematic None None O
review None None O
of None None O
the None None O
available None None O
studies None None O
on None None O
psoriasis None None O
and None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
. None None O

It None None O
is None None O
an None None O
escape None None O
from None None O
intolerable None None O
suffering None None O
; None None O
and None None O
this None None O
construct None None O
views None None O
suicide None None O
not None None O
as None None O
a None None O
movement None None I-FUNC
toward None None O
death None None O
but None None O
a None None O
remedy None None O
to None None O
escape None None O
from None None O
intolerable None None O
emotion None None I-FUNC
, None None O
unendurable None None O
, None None O
or None None O
unacceptable None None O
anguish None None O
. None None O

The None None O
scientific None None O
literature None None O
focused None None O
on None None O
factors None None O
involved None None O
in None None O
the None None O
onset None None O
of None None O
borderline None None I-DISEASE
personality None None I-DISEASE
disorder None None I-DISEASE
( None None O
BPD None None O
) None None O
has None None O
given None None O
a None None O
central None None O
role None None O
to None None O
the None None O
families None None O
of None None O
these None None O
patients None None O
. None None O

PubMed None None O
and None None O
PsycINFO None None O
have None None O
been None None O
used None None O
for None None O
review None None O
with None None O
the None None O
following None None O
keywords None None O
: None None O
`` None None O
borderline None None I-DISEASE
personality None None I-DISEASE
disorder None None I-DISEASE
'' None None O
, None None O
`` None None O
family None None O
'' None None O
, None None O
`` None None O
psychopathology None None O
'' None None O
, None None O
`` None None O
burden None None O
'' None None O
, None None O
`` None None O
psychoeducation None None O
'' None None O
, None None O
`` None None O
caregiver None None O
'' None None O
, None None O
`` None None O
caretaker None None O
'' None None O
. None None O

Research None None O
shows None None O
that None None O
the None None O
family None None O
burden None None O
of None None O
BPD None None O
patients None None O
is None None O
comparable None None O
with None None O
that None None O
of None None O
families None None O
of None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
. None None O

A None None O
PubMed None None O
, None None O
PsychInfo None None O
, None None O
Google None None O
Scolar None None O
search None None O
was None None O
done None None O
using None None O
the None None O
key None None O
words None None O
`` None None O
resistant None None O
depression None None I-DISEASE
'' None None O
, None None O
`` None None O
STAR*D None None O
'' None None O
, None None O
`` None None O
bipolar None None O
depression None None I-DISEASE
'' None None O
, None None O
`` None None O
staging None None O
'' None None O
. None None O

Treatment-resistant None None O
depression None None I-DISEASE
is None None O
one None None O
of None None O
the None None O
most None None O
important None None O
problem None None O
in None None O
public None None O
health None None O
. None None O

Finally None None O
, None None O
it None None O
is None None O
shown None None O
that None None O
they None None O
are None None O
real None None O
psychosomatic None None O
therapies None None O
that None None O
are None None O
able None None O
to None None O
produce None None O
somatic None None O
peripheral None None O
changes None None O
( None None O
neuroendocrine None None O
, None None O
neurovegetative None None O
and None None O
muscular None None O
systems None None O
) None None O
generated None None O
by None None O
the None None O
mind None None O
and None None O
secondary None None O
to None None O
the None None O
involvement None None O
of None None O
central None None O
neurotransmitter None None I-TRANS
circuits None None O
. None None O

About None None O
the None None O
diagnosis None None O
, None None O
schizophrenic None None O
spectrum None None O
disorders None None O
prevail None None O
, None None O
there None None O
is None None O
history None None O
of None None O
substance None None I-DISEASE
abuse None None I-DISEASE
in None None O
35 None None O
% None None O
of None None O
cases None None O
, None None O
history None None O
of None None O
previous None None O
admission None None O
to None None O
psychiatric None None O
facilities None None O
in None None O
87 None None O
% None None O
of None None O
these None None O
subjects None None O
. None None O

Serotonin None None I-TRANS
and None None O
dopamine None None I-TRANS
seemed None None O
to None None O
be None None O
strongly None None O
involved None None O
: None None O
both None None O
showed None None O
higher None None O
concentration None None O
in None None O
females None None O
; None None O
serotonin None None I-TRANS
seemed None None O
to None None O
be None None O
more None None O
associated None None O
with None None O
anxiety None None O
and None None O
depression None None I-DISEASE
disorders None None I-DISEASE
, None None O
to None None O
have None None O
a None None O
better None None O
response None None O
to None None O
SSRI None None O
treatment None None O
among None None O
women None None O
, None None O
and None None O
also None None O
is None None O
associated None None O
with None None O
a None None O
different None None O
repertoire None None O
of None None O
behavior None None O
. None None O

Furthermore None None O
, None None O
we None None O
provide None None O
a None None O
review None None O
of None None O
the None None O
literature None None O
on None None O
noradrenaline None None I-TRANS
, None None O
glutamate None None I-TRANS
and None None O
GABA None None I-TRANS
. None None O

Our None None O
data None None O
underlined None None O
most None None O
of None None O
all None None O
a None None O
prevalence None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
in None None O
the None None O
31.4 None None O
% None None O
of None None O
our None None O
patients None None O
with None None O
TD None None O
, None None O
of None None O
depression None None I-DISEASE
in None None O
the None None O
27.44 None None O
% None None O
, None None O
and None None O
of None None O
somatization None None O
symptoms None None O
in None None O
the None None O
22.54 None None O
% None None O
. None None O

This None None O
study None None O
suggests None None O
the None None O
important None None O
prevalence None None O
of None None O
non-OCD None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
in None None O
TD None None O
patients None None O
and None None O
shows None None O
they None None O
have None None O
a None None O
central None None O
role None None O
in None None O
their None None O
psychopathological None None O
profile None None O
. None None O

This None None O
indicated None None O
that None None O
tet None None O
A None None O
gene None None O
could None None O
accumulate None None O
in None None O
activated None None O
sludge None None O
with None None O
slower None None O
and None None O
continuous None None O
influent None None O
, None None O
while None None O
the None None O
accumulation None None O
of None None O
tet None None O
B None None O
gene None None O
could None None O
be None None O
attributed None None O
to None None O
shorter None None O
hydraulic None None O
retention None None I-FUNC
time None None O
. None None O

Further None None O
experiments None None O
confirmed None None O
that None None O
miRNA-149 None None O
directly None None O
targeted None None O
AKT1 None None O
in None None O
HCC None None O
by None None O
a None None O
miRNA None None O
luciferase None None I-PROTEIN
reporter None None O
approach None None O
. None None O

Although None None O
insulin None None I-PROTEIN
is None None O
the None None O
dominant None None O
treatment None None O
, None None O
the None None O
use None None O
of None None O
anti-hyperglycemic None None O
agents None None O
such None None O
as None None O
glyburide None None O
and None None O
metformin None None O
in None None O
treating None None O
GDM None None O
has None None O
gained None None O
popularity None None O
and None None O
consideration None None O
should None None O
be None None O
made None None O
using None None O
these None None O
agents None None O
as None None O
first-line None None O
pharmacological None None O
treatment None None O
. None None O

Further None None O
studies None None O
are None None O
needed None None O
regarding None None O
long-acting None None O
insulin None None I-PROTEIN
and None None O
other None None O
anti-hyperglycemic None None O
agents None None O
such None None O
as None None O
thiazolidinediones None None O
, None None O
as None None O
well None None O
as None None O
identifying None None O
treatment None None O
options None None O
more None None O
specific None None O
to None None O
an None None O
individual None None O
based None None O
on None None O
risk None None O
factors None None O
and None None O
other None None O
variables None None O
predicting None None O
treatment None None O
outcomes None None O
in None None O
GDM None None O
. None None O

Premature None None I-DISEASE
ejaculation None None I-DISEASE
( None None O
PE None None O
) None None O
is None None O
the None None O
most None None O
common None None O
male None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
. None None O

Similarly None None O
, None None O
tertiary None None O
structural None None O
changes None None O
were None None O
monitored None None O
by None None O
tryptophan None None I-TRANS
fluorescence None None O
. None None O

Compared None None O
with None None O
negative None None O
control None None O
, None None O
cell None None O
proliferation None None O
and None None O
p53 None None I-PROTEIN
and None None O
Bcl-2 None None O
expression None None O
significantly None None O
decreased None None O
after None None O
microRNA-449a None None O
mimic None None O
transfection None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Three None None O
patients None None O
had None None O
a None None O
glucose None None O
level None None O
& None None O
lt None None O
; None None O
3.9 None None O
mmol/L None None O
, None None O
which None None O
was None None O
corrected None None O
after None None O
adjusting None None O
the None None O
dose None None O
of None None O
insulin None None I-PROTEIN
infusion None None O
. None None O

Moreover None None O
, None None O
our None None O
results None None O
demonstrated None None O
that None None O
PRMT5 None None O
overexpression None None O
stimulated None None O
GEF None None O
proliferation None None O
and None None O
down-regulated None None O
p53 None None I-PROTEIN
, None None O
p21 None None O
( None None O
a None None O
target None None O
gene None None O
of None None O
p53 None None I-PROTEIN
) None None O
and None None O
the None None O
apoptotic None None O
marker None None O
caspase None None O
3 None None O
, None None O
to None None O
enhance None None O
somatic None None O
cell None None O
reprogramming None None O
. None None O

We None None O
studied None None O
the None None O
effects None None O
of None None O
microinjections None None O
of None None O
neuroactive None None O
peptides None None I-TRANS
markedly None None O
found None None O
in None None O
the None None O
MePD None None O
, None None O
namely None None O
oxytocin None None I-TRANS
( None None O
OT None None O
, None None O
10 None None O
ng None None O
and None None O
25 None None O
pg None None O
; None None O
n=6/group None None O
) None None O
, None None O
somatostatin None None I-TRANS
( None None O
SST None None O
, None None O
1 None None O
and None None O
0.05 None None O
μM None None O
; None None O
n=8 None None O
and None None O
5 None None O
, None None O
respectively None None O
) None None O
, None None O
and None None O
angiotensin None None O
II None None O
( None None O
Ang None None O
II None None O
, None None O
50 None None O
pmol None None O
and None None O
50 None None O
fmol None None O
; None None O
n=7/group None None O
) None None O
, None None O
on None None O
basal None None O
cardiovascular None None O
activity None None O
and None None O
on None None O
baroreflex- None None O
and None None O
chemoreflex-mediated None None O
responses None None O
in None None O
awake None None O
adult None None O
male None None O
rats None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
effect None None O
of None None O
tamoxifen None None O
on None None O
the None None O
plasma None None O
concentration None None O
of None None O
NT-pro-B-type None None O
natriuretic None None I-TRANS
peptide None None I-TRANS
( None None O
NT-proBNP None None O
) None None O
in None None O
women None None O
undergoing None None O
chemotherapy None None O
for None None O
breast None None O
cancer None None O
and None None O
to None None O
correlate None None O
changes None None O
in None None O
NT-proBNP None None O
with None None O
the None None O
left None None O
ventricular None None O
ejection None None O
fraction None None O
( None None O
LVEF None None O
) None None O
. None None O

Calcium None None O
storage None None I-FUNC
, None None O
release None None O
, None None O
and None None O
reuptake None None O
are None None O
essential None None O
for None None O
normal None None O
physiological None None O
function None None O
of None None O
muscle None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
is None None O
a None None O
neurodegenerative None None O
disease None None O
that None None O
inhibits None None O
cognitive None None O
functions None None O
and None None O
has None None O
no None None O
cure None None O
. None None O

Speech None None I-FUNC
and None None O
song None None O
are None None O
universal None None O
forms None None O
of None None O
vocalization None None O
that None None O
may None None O
share None None O
aspects None None O
of None None O
emotional None None O
expression None None O
. None None O

In None None O
three None None O
experiments None None O
, None None O
we None None O
compared None None O
moving None None O
facial None None O
expressions None None O
in None None O
speech None None I-FUNC
and None None O
song None None O
. None None O

Vocalists None None O
exhibited None None O
emotion-dependent None None O
movements None None I-FUNC
of None None O
the None None O
eyebrows None None O
and None None O
lip None None O
corners None None O
that None None O
transcended None None O
speech-song None None O
differences None None O
. None None O

Vocalists None None O
' None None O
emotional None None O
movements None None I-FUNC
extended None None O
beyond None None O
vocal None None O
sound None None O
to None None O
include None None O
large None None O
sustained None None O
expressions None None O
, None None O
suggesting None None O
a None None O
communicative None None O
function None None O
. None None O

Emotional None None O
intentions None None O
were None None O
identified None None O
accurately None None O
for None None O
movements None None I-FUNC
during None None O
and None None O
after None None O
vocalization None None O
, None None O
suggesting None None O
that None None O
these None None O
movements None None I-FUNC
support None None O
the None None O
acoustic None None O
message None None O
. None None O

Emotion None None I-FUNC
judgements None None O
for None None O
voice-only None None O
singing None None O
were None None O
poorly None None O
identified None None O
, None None O
yet None None O
were None None O
accurate None None O
for None None O
all None None O
other None None O
conditions None None O
, None None O
confirming None None O
that None None O
facial None None O
expressions None None O
conveyed None None O
emotion None None I-FUNC
more None None O
accurately None None O
than None None O
the None None O
voice None None O
in None None O
song None None O
, None None O
yet None None O
were None None O
equivalent None None O
in None None O
speech None None I-FUNC
. None None O

Several None None O
genetic None None O
variations None None O
associated None None O
with None None O
nicotine None None I-DISEASE
dependence None None I-DISEASE
and None None O
lung None None O
cancer None None O
exist None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
cardiac None None O
effects None None O
of None None O
a None None O
novel None None O
positive None None O
inotropic None None O
peptide None None O
isolated None None O
from None None O
the None None O
toxin None None O
of None None O
the None None O
Black None None O
Judean None None O
scorpion None None O
that None None O
activates None None O
neuronal None None O
tetrodotoxin-sensitive None None O
sodium None None I-PROTEIN
channels None None I-PROTEIN
. None None O

BjIP None None O
did None None O
not None None O
alter None None O
the None None O
function None None O
of None None O
Nav1.5 None None O
, None None O
but None None O
selectively None None O
activated None None O
the None None O
brain-type None None O
sodium None None I-PROTEIN
channels None None I-PROTEIN
Nav1.6 None None O
or None None O
Nav1.3 None None O
in None None O
cellular None None O
electrophysiological None None O
recordings None None O
obtained None None O
from None None O
rodent None None O
thalamic None None O
slices None None O
. None None O

Our None None O
pilot None None O
experiments None None O
suggest None None O
that None None O
selective None None O
activation None None O
of None None O
tetrodotoxin-sensitive None None O
neuronal None None O
sodium None None I-PROTEIN
channels None None I-PROTEIN
can None None O
safely None None O
increase None None O
cardiac None None O
contractility None None O
. None None O

Elevated None None O
glucose None None O
oxidation None None O
was None None O
mediated None None O
by None None O
a None None O
reduction None None O
in None None O
pyruvate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
kinase None None O
4 None None O
expression None None O
, None None O
enabling None None O
pyruvate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
to None None O
compete None None O
against None None O
anaplerotic None None O
enzymes None None I-PROTEIN
for None None O
pyruvate None None O
carboxylation None None O
. None None O

Examine None None O
the None None O
efficacy None None O
of None None O
a None None O
personalized None None O
, None None O
modular None None O
cognitive-behavioral None None O
therapy None None O
( None None O
CBT None None O
) None None O
protocol None None O
among None None O
early None None O
adolescents None None O
with None None O
high-functioning None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorders None None I-DISEASE
( None None O
ASDs None None O
) None None O
and None None O
co-occurring None None O
anxiety None None O
relative None None O
to None None O
treatment None None O
as None None O
usual None None O
( None None O
TAU None None O
) None None O
. None None O

The None None O
current None None O
study None None O
sought None None O
to None None O
replicate None None O
and None None O
build None None O
on None None O
their None None O
earlier None None O
work None None O
by None None O
examining None None O
the None None O
impact None None O
of None None O
additional None None O
maternal None None O
risk None None O
factors None None O
, None None O
identified None None O
in None None O
previous None None O
research None None O
with None None O
non-American None None O
Indian None None O
populations None None O
, None None O
on None None O
the None None O
development None None O
of None None O
American None None O
Indian None None O
toddlers None None O
: None None O
maternal None None O
depression None None I-DISEASE
, None None O
negative None None O
social None None O
influences None None O
, None None O
and None None O
mother None None O
's None None O
feelings None None I-FUNC
of None None O
isolation None None O
. None None O

Mothers None None O
with None None O
borderline None None I-DISEASE
personality None None I-DISEASE
disorder None None I-DISEASE
( None None O
BPD None None O
) None None O
have None None O
disturbed None None O
relationships None None O
with None None O
their None None O
infants None None O
, None None O
possibly None None O
associated None None O
with None None O
poor None None O
nonverbal None None O
cue None None O
perception None None I-FUNC
. None None O

This None None O
study None None O
extends None None O
previous None None O
research None None O
by None None O
examining None None O
how None None O
mothers None None O
with None None O
BPD None None O
perceive None None O
known None None O
( None None O
own None None O
) None None O
and None None O
unknown None None O
( None None O
control None None O
) None None O
infant None None O
stimuli None None O
depicting None None O
happy None None O
, None None O
sad None None O
, None None O
and None None O
neutral None None O
emotions None None I-FUNC
. None None O

All None None O
participants None None O
completed None None O
clinical None None O
and None None O
parenting None None O
questionnaires None None O
and None None O
an None None O
infant None None O
emotion None None I-FUNC
recognition None None O
task None None O
. None None O

Higher None None O
levels None None O
of None None O
anxiety None None O
symptoms None None O
in None None O
the None None O
first None None O
trimester None None O
predicted None None O
less None None O
positive None None O
change None None O
in None None O
parenting None None O
self-efficacy None None O
over None None O
the None None O
course None None O
of None None O
pregnancy None None O
, None None O
but None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
did None None O
not None None O
when None None O
anxiety None None O
levels None None O
were None None O
taken None None O
into None None O
account None None O
. None None O

The None None O
effects None None O
of None None O
skin-to-skin None None O
contact None None O
( None None O
SSC None None O
) None None O
on None None O
the None None O
maintenance None None O
of None None O
mothers None None O
' None None O
decision None None O
to None None O
breastfeed None None O
, None None O
the None None O
effects None None O
of None None O
breastfeeding None None O
and None None O
SSC None None O
on None None O
mother-infant None None O
interactions None None O
, None None O
and None None O
whether None None O
maternal None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
mediate None None O
these None None O
effects None None O
were None None O
investigated None None O
over None None O
infants None None O
' None None O
first None None O
3 None None O
months None None O
. None None O

Results None None O
are None None O
discussed None None O
in None None O
terms None None O
of None None O
attention None None I-FUNC
, None None O
potential None None O
physiological None None O
mechanisms None None O
, None None O
and None None O
implications None None O
for None None O
later None None O
problem None None I-FUNC
solving None None I-FUNC
. None None O

Health None None O
personnel None None O
's None None O
own None None O
movement None None I-FUNC
between None None O
these None None O
phenomena None None O
may None None O
represent None None O
a None None O
resource None None O
because None None O
it None None O
can None None O
help None None O
women None None O
to None None O
handle None None O
sexual None None O
and None None O
intimacy None None O
challenges None None O
following None None O
gynecological None None O
cancer None None O
. None None O

The None None O
epithelial-to-mesenchymal None None O
transition None None O
( None None O
EMT None None O
) None None O
process None None O
results None None O
in None None O
a None None O
loss None None O
of None None O
cell-cell None None O
adhesion None None I-PROTEIN
, None None O
increased None None O
cell None None O
mobility None None O
, None None O
and None None O
is None None O
crucial None None O
for None None O
enabling None None O
the None None O
metastasis None None O
of None None O
cancer None None O
cells None None O
. None None O

Here None None O
, None None O
we None None O
propose None None O
a None None O
mechanism None None O
by None None O
which None None O
the None None O
enzyme None None O
sirtuin1 None None O
( None None O
SIRT1 None None O
) None None O
regulates None None O
the None None O
EMT None None O
process None None O
in None None O
oral None None O
cancer None None O
by None None O
deacetylating None None O
Smad4 None None O
and None None O
repressing None None O
the None None O
effect None None O
of None None O
TGF-β None None O
signaling None None O
on None None O
matrix None None I-PROTEIN
metalloproteinase-7 None None O
( None None O
MMP7 None None O
) None None O
. None None O

In None None O
conclusion None None O
, None None O
creatine None None O
and None None O
PCr None None O
minimize None None O
oxidative None None O
stress None None O
in None None O
striatum None None I-REGION
to None None O
afford None None O
neuroprotection None None O
of None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
. None None O

We None None O
systematically None None O
reviewed None None O
476 None None O
empirical None None O
papers None None O
published None None O
between None None O
2005 None None O
and None None O
2012 None None O
( None None O
inclusive None None O
) None None O
that None None O
used None None O
otoliths None None O
to None None O
examine None None O
fish None None O
ELH None None O
phases None None O
, None None O
which None None O
has None None O
been None None O
an None None O
area None None O
of None None O
increasing None None O
attention None None I-FUNC
over None None O
this None None O
period None None O
. None None O

A None None O
likely None None O
explanation None None O
is None None O
that None None O
thrombin None None I-PROTEIN
, None None O
a None None O
strong None None O
inductor None None O
of None None O
apoptotic None None O
cell None None O
death None None O
and None None O
blood-brain None None O
barrier None None O
disruption None None O
, None None O
is None None O
produced None None O
to None None O
a None None O
lesser None None O
extent None None O
in None None O
OAC-ICH None None O
. None None O

Furthermore None None O
there None None O
were None None O
no None None O
significant None None O
changes None None O
in None None O
percentage None None O
body None None O
fat None None O
, None None O
lipid None None O
profile None None O
, None None O
or None None O
fasting None None O
insulin None None I-PROTEIN
between None None O
the None None O
intervention None None O
and None None O
control None None O
schools None None O
. None None O

Fragile None None O
X None None O
syndrome None None O
( None None O
FXS None None O
) None None O
is None None O
associated None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
and None None O
behavioral None None O
dysfunction None None O
, None None O
including None None O
anxiety None None O
, None None O
ADHD None None O
symptoms None None O
, None None O
and None None O
autistic None None O
features None None O
. None None O

Generally None None O
, None None O
oxidative None None O
stress None None O
represents None None O
cell None None O
toxicity None None O
; None None O
however None None O
, None None O
we None None O
recently None None O
found None None O
that None None O
oxidative None None O
stress None None O
promotes None None O
the None None O
expression None None O
of None None O
growth None None O
factor None None O
progranulin None None O
( None None O
PGRN None None O
) None None O
in None None O
HT22 None None O
murine None None O
hippocampus None None I-REGION
cells None None O
, None None O
thereby None None O
protecting None None O
the None None O
HT22 None None O
cells None None O
. None None O

Increasing None None O
age None None O
confers None None O
a None None O
higher None None O
risk None None O
of None None O
stroke None None I-DISEASE
and None None O
bleeding None None O
when None None O
antithrombotic None None O
therapy None None O
is None None O
used None None O
. None None O

We None None O
identified None None O
elderly None None O
( None None O
age None None O
, None None O
& None None O
gt None None O
; None None O
75 None None O
years None None O
) None None O
patients None None O
with None None O
AF None None O
, None None O
assessed None None O
their None None O
risk None None O
factors None None O
, None None O
and None None O
followed None None O
up None None O
for None None O
stroke None None I-DISEASE
, None None O
thromboembolism None None O
, None None O
death None None O
, None None O
or None None O
major None None O
bleeding None None O
. None None O

In None None O
elderly None None O
patients None None O
, None None O
age None None O
and None None O
previous None None O
stroke None None I-DISEASE
emerged None None O
as None None O
the None None O
main None None O
predictors None None O
of None None O
stroke None None I-DISEASE
and None None O
thromboembolism None None O
. None None O

Elderly None None O
patients None None O
with None None O
AF None None O
have None None O
a None None O
higher None None O
risk None None O
of None None O
stroke None None I-DISEASE
and None None O
bleeding None None O
, None None O
but None None O
the None None O
benefits None None O
of None None O
VKA None None O
therapy None None O
for None None O
stroke/thromboembolism None None O
or None None O
mortality None None O
were None None O
present None None O
regardless None None O
of None None O
increasing None None O
age None None O
. None None O

A None None O
protective None None O
pattern None None O
was None None O
observed None None O
, None None O
with None None O
U-shaped None None O
temperature None None O
dependence None None O
in None None O
delayed None None O
cell None None O
death None None O
in None None O
periventricular None None O
white None None I-REGION
matter None None I-REGION
, None None O
caudate None None I-REGION
nucleus None None I-REGION
, None None O
putamen None None I-REGION
, None None O
hippocampus None None I-REGION
, None None O
and None None O
thalamus None None I-REGION
. None None O

© None None O
2014 None None O
American None None O
Heart None None O
Association None None O
, None None O
Inc. None None O
We None None O
aimed None None O
to None None O
assess None None O
the None None O
interaction None None O
between None None O
intravenous None None O
thrombolysis None None O
( None None O
IVT None None O
) None None O
and None None O
arterial None None O
occlusion None None O
on None None O
acute None None O
cervicocerebral None None O
computed None None O
tomographic None None O
angiography None None O
on None None O
the None None O
outcome None None O
of None None O
patients None None O
with None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Despite None None O
the None None O
absence None None O
of None None O
definitive None None O
data None None O
from None None O
randomized None None O
clinical None None O
trials None None O
on None None O
the None None O
comparative None None O
effectiveness None None O
of None None O
carotid None None O
artery None None O
stenting None None O
( None None O
CAS None None O
) None None O
versus None None O
carotid None None O
endarterectomy None None O
( None None O
CEA None None O
) None None O
for None None O
asymptomatic None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
, None None O
the None None O
use None None O
of None None O
CAS None None O
has None None O
been None None O
expanding None None O
and None None O
seems None None O
to None None O
be None None O
displacing None None O
the None None O
use None None O
of None None O
CEA None None O
in None None O
some None None O
parts None None O
of None None O
the None None O
United None None O
States None None O
. None None O

In-hospital None None O
death None None O
and None None O
postoperative None None O
stroke None None I-DISEASE
after None None O
CAS None None O
and None None O
after None None O
CEA None None O
were None None O
compared None None O
using None None O
multivariable None None O
logistic None None O
regression None None O
, None None O
propensity None None O
score None None O
matching None None O
, None None O
and None None O
a None None O
grouped-treatment None None O
approach None None O
using None None O
multilevel None None O
mixed-effects None None O
models None None O
to None None O
adjust None None O
for None None O
baseline None None O
characteristics None None O
of None None O
patients None None O
selected None None O
for None None O
these None None O
procedures None None O
. None None O

Postoperative None None O
stroke None None I-DISEASE
or None None O
in-hospital None None O
death None None O
was None None O
more None None O
frequent None None O
after None None O
CAS None None O
( None None O
4.0 None None O
% None None O
versus None None O
1.5 None None O
% None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
and None None O
patients None None O
with None None O
CAS None None O
were None None O
more None None O
likely None None O
to None None O
have None None O
these None None O
adverse None None O
outcomes None None O
even None None O
after None None O
adjusting None None O
for None None O
baseline None None O
characteristics None None O
using None None O
multivariable None None O
analysis None None O
( None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
, None None O
2.5 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
, None None O
2.1-3.1 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
propensity None None O
score None None O
matching None None O
( None None O
OR None None O
, None None O
2.5 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.9-3.4 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

For None None O
asymptomatic None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
, None None O
CAS None None O
is None None O
associated None None O
with None None O
a None None O
substantially None None O
higher None None O
risk None None O
of None None O
postoperative None None O
stroke None None I-DISEASE
or None None O
in-hospital None None O
death None None O
than None None O
CEA None None O
even None None O
after None None O
adjustment None None O
for None None O
baseline None None O
differences None None O
in None None O
hospital None None O
and None None O
patient None None O
characteristics None None O
. None None O

Chronic None None O
kidney None None O
disease None None O
may None None O
increase None None O
the None None O
risk None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
or None None O
systemic None None O
embolism None None I-DISEASE
in None None O
patients None None O
with None None O
nonvalular None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
. None None O

Impaired None None O
renal None None O
function None None O
is None None O
an None None O
independent None None O
predictor None None O
of None None O
stroke None None I-DISEASE
or None None O
systemic None None O
embolism None None I-DISEASE
in None None O
patients None None O
with None None O
nonvalvular None None O
AF None None O
. None None O

© None None O
2014 None None O
American None None O
Heart None None O
Association None None O
, None None O
Inc. None None O
Migraine None None I-DISEASE
with None None O
aura None None O
is None None O
an None None O
established None None O
stroke None None I-DISEASE
risk None None O
factor None None O
, None None O
and None None O
excitatory None None O
mechanisms None None O
such None None O
as None None O
spreading None None O
depression None None I-DISEASE
( None None O
SD None None O
) None None O
are None None O
implicated None None O
in None None O
the None None O
pathogenesis None None O
of None None O
both None None O
migraine None None I-DISEASE
and None None O
stroke None None I-DISEASE
. None None O

We None None O
measured None None O
the None None O
cortical None None O
susceptibility None None O
to None None O
SD None None O
and None None O
ischemic None None O
depolarizations None None O
, None None O
and None None O
determined None None O
tissue None None O
and None None O
neurological None None O
outcomes None None O
after None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
in None None O
wild-type None None O
and None None O
familial None None I-DISEASE
hemiplegic None None I-DISEASE
migraine None None I-DISEASE
type None None O
1 None None O
knock-in None None O
mice None None O
treated None None O
with None None O
vehicle None None O
, None None O
topiramate None None O
or None None O
lamotrigine None None O
daily None None O
for None None O
7 None None O
weeks None None O
or None None O
as None None O
a None None O
single None None O
dose None None O
shortly None None O
before None None O
testing None None O
. None None O

These None None O
data None None O
underscore None None O
the None None O
importance None None O
of None None O
hyperexcitability None None O
as None None O
a None None O
mechanism None None O
for None None O
increased None None O
stroke None None I-DISEASE
risk None None O
in None None O
migraineurs None None O
, None None O
and None None O
suggest None None O
that None None O
migraine None None I-DISEASE
prophylaxis None None O
may None None O
not None None O
only None None O
prevent None None O
migraine None None I-DISEASE
attacks None None O
but None None O
also None None O
protect None None O
migraineurs None None O
against None None O
ischemic None None O
injury None None O
. None None O

Lacunes None None O
, None None O
white None None I-REGION
matter None None I-REGION
hyperintensity None None O
, None None O
and None None O
cerebral None None O
microbleed None None O
( None None O
CMB None None O
) None None O
were None None O
assessed None None O
using None None O
MR None None O
images None None O
. None None O

Also None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
deficiency None None O
( None None O
≤25 None None O
nmol/L None None O
) None None O
was None None O
associated None None O
with None None O
lacunes None None O
( None None O
regression None None O
coefficient None None O
, None None O
0.5 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
0.04-0.95 None None O
) None None O
, None None O
severe None None O
white None None I-REGION
matter None None I-REGION
hyperintensity None None O
( None None O
odds None None O
ratio None None O
, None None O
2.74 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.31-6.45 None None O
) None None O
, None None O
and None None O
deep None None O
CMB None None O
( None None O
odds None None O
ratio None None O
, None None O
1.68 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.03-2.78 None None O
) None None O
. None None O

25 None None O
( None None O
OH None None O
) None None O
D None None O
is None None O
inversely None None O
associated None None O
with None None O
lacunes None None O
, None None O
white None None I-REGION
matter None None I-REGION
hyperintensity None None O
, None None O
and None None O
deep None None O
CMB None None O
. None None O

However None None O
, None None O
the None None O
relationship None None O
of None None O
initial None None O
BT None None O
to None None O
stroke None None I-DISEASE
severity None None O
and None None O
degree None None O
of None None O
benefit None None O
from None None O
thrombolytic None None O
therapy None None O
has None None O
been None None O
delineated None None O
incompletely None None O
. None None O

In None None O
patients None None O
with None None O
hyperacute None None O
stroke None None I-DISEASE
, None None O
higher None None O
presenting None None O
temperatures None None O
are None None O
associated None None O
with None None O
less None None O
severe None None O
neurological None None O
deficits None None O
and None None O
reduced None None O
final None None O
infarct None None O
volumes None None O
. None None O

The None None O
statin None None O
class None None O
of None None O
cholesterol-lowering None None O
drugs None None O
have None None O
been None None O
observed None None O
to None None O
have None None O
anti-inflammatory None None O
and None None O
protective None None O
effects None None O
in None None O
both None None O
neurodegenerative None None O
diseases None None O
and None None O
ischemic None None O
stroke None None I-DISEASE
, None None O
and None None O
are None None O
suggested None None O
to None None O
act None None O
by None None O
attenuating None None O
microglial None None O
activity None None O
. None None O

On None None O
logistic None None O
regression None None O
analysis None None O
, None None O
the None None O
significant None None O
independent None None O
predictors None None O
of None None O
medication None None O
non-adherence None None O
were None None O
lower None None O
educational None None O
level None None O
( None None O
OR None None O
5.6 None None O
, None None O
95 None None O
% None None O
CI None None O
2.1-7.3 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
very None None O
low None None O
and None None O
low None None O
socioeconomic None None O
status None None O
( None None O
OR None None O
2.6 None None O
, None None O
95 None None O
% None None O
CI None None O
1.6-4.3 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.04 None None O
) None None O
, None None O
rural None None O
residency None None O
( None None O
OR None None O
3.4 None None O
, None None O
95 None None O
% None None O
CI None None O
1.4-5 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
more None None O
number None None O
of None None O
medications None None O
( None None O
OR None None O
3.2 None None O
, None None O
95 None None O
% None None O
CI None None O
2.3-6.9 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
and None None O
higher None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
OR None None O
3.7 None None O
, None None O
95 None None O
% None None O
CI None None O
1.4-10.2 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Appropriate None None O
adherence None None O
enhancing None None O
intervention None None O
strategies None None O
targeted None None O
at None None O
reducing None None O
pill None None O
load None None O
, None None O
minimizing None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
and None None O
ensuring None None O
an None None O
uninterrupted None None O
access None None O
to None None O
free None None O
services None None O
regimen None None O
for None None O
patients None None O
with None None O
low None None O
socioeconomic None None O
status None None O
is None None O
strongly None None O
recommended None None O
. None None O

Eating None None O
behaviors None None O
( None None O
cognitive None None O
restraint None None O
, None None O
uncontrolled None None O
eating None None O
, None None O
and None None O
emotional None None O
eating None None O
) None None O
, None None O
food None None O
group None None O
choices None None O
( None None O
sweets None None O
, None None O
salty None None O
snacks None None O
, None None O
and None None O
fruits None None O
) None None O
, None None O
and None None O
mental None None O
health None None O
indices None None O
( None None O
depression None None I-DISEASE
, None None O
anxiety None None O
, None None O
and None None O
stress None None O
) None None O
were None None O
recorded None None O
by None None O
questionnaire None None O
and None None O
related None None O
to None None O
measured None None O
occurrence None None O
of None None O
OB-BMI None None O
and None None O
OB-WC None None O
. None None O

In None None O
the None None O
fully None None O
adjusted None None O
model None None O
, None None O
cognitive None None O
restraint None None O
, None None O
consumption None None O
of None None O
sweets None None O
, None None O
anxiety None None O
, None None O
and None None O
lack None None O
of None None O
depression None None I-DISEASE
were None None O
associated None None O
with None None O
OB-WC None None O
. None None O

The None None O
whitish None None O
nodule None None O
corresponded None None O
to None None O
the None None O
sarcomatoid None None O
component None None O
, None None O
and None None O
the None None O
spindled None None O
and None None O
pleomorphic None None O
tumor None None O
cells None None O
showed None None O
diffuse None None O
positivity None None O
of None None O
p53 None None I-PROTEIN
on None None O
immunohistochemistry None None O
. None None O

Unfortunately None None O
, None None O
modern None None O
society None None O
has None None O
modified None None O
this None None O
life-governing None None O
cycle None None O
by None None O
stressing None None O
maximum None None O
production None None O
and None None O
by None None O
giving None None O
insufficient None None O
attention None None I-FUNC
to None None O
the None None O
ecological None None O
balance None None O
and None None O
homeostasis None None O
of None None O
the None None O
human None None O
metabolism None None O
. None None O

In None None O
terms None None O
of None None O
the None None O
melatonin None None I-TRANS
levels None None O
, None None O
the None None O
groups None None O
differed None None O
at None None O
two None None O
different None None O
times None None O
of None None O
day None None O
: None None O
08:00 None None O
am None None O
( None None O
t None None O
= None None O
2.593 None None O
, None None O
p None None O
= None None O
0.018 None None O
) None None O
and None None O
10:00 None None O
pm None None O
( None None O
t None None O
= None None O
-2.939 None None O
, None None O
p None None O
= None None O
0.009 None None O
) None None O
. None None O

Higher None None O
cortisol None None O
levels None None O
were None None O
positively None None O
correlated None None O
with None None O
minor None None O
psychiatric None None O
disorders None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
MA None None O
) None None O
at None None O
10:00 None None O
pm None None O
. None None O

Our None None O
study None None O
demonstrated None None O
that None None O
not None None O
only None None O
may None None O
light None None O
pollution None None O
affect None None O
human None None O
physiology None None O
but None None O
also None None O
lack None None O
of None None O
exposure None None O
to None None O
natural None None O
light None None O
is None None O
related None None O
to None None O
high None None O
levels None None O
of None None O
cortisol None None O
and None None O
lower None None O
levels None None O
of None None O
melatonin None None I-TRANS
at None None O
night None None O
, None None O
and None None O
these None None O
, None None O
in None None O
turn None None O
, None None O
are None None O
related None None O
to None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
poor None None O
quality None None O
of None None O
sleep None None O
. None None O

It None None O
is None None O
caused None None O
in None None O
the None None O
majority None None O
of None None O
cases None None O
by None None O
either None None O
unilateral None None O
aldosterone None None O
overproduction None None O
due None None O
to None None O
an None None O
aldosterone-producing None None O
adenoma None None O
( None None O
APA None None O
) None None O
or None None O
by None None O
bilateral None None O
adrenal None None I-TRANS
hyperplasia None None O
. None None O

Recurrent None None O
somatic None None O
mutations None None O
in None None O
genes None None O
coding None None O
for None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
( None None O
KCNJ5 None None O
and None None O
CACNA1D None None O
) None None O
and None None O
ATPases None None I-PROTEIN
( None None O
ATP1A1 None None O
and None None O
ATP2B3 None None O
) None None O
regulating None None O
intracellular None None O
ionic None None O
homeostasis None None O
and None None O
cell None None O
membrane None None O
potential None None O
have None None O
been None None O
identified None None O
in None None O
APA None None O
. None None O

Acupuncture None None O
stimulates None None O
points None None O
on None None O
the None None O
body None None O
, None None O
influencing None None O
the None None O
perception None None I-FUNC
of None None O
myofascial None None O
pain None None O
or None None O
altering None None O
physiologic None None O
functions None None O
. None None O

Since None None O
the None None O
introduction None None O
of None None O
computed None None O
tomography None None O
pulmonary None None O
angiography None None O
, None None O
isolated None None O
subsegmental None None O
pulmonary None None O
embolism None None I-DISEASE
has None None O
become None None O
a None None O
commonly None None O
recognized None None O
clinical None None O
problem None None O
, None None O
but None None O
its None None O
clinical None None O
relevance None None O
remains None None O
unclear None None O
. None None O

In None None O
all None None O
species None None O
, None None O
rods None None O
follow None None O
a None None O
pronounced None None O
dorsoventral None None O
gradient None None O
with None None O
highest None None O
densities None None O
in None None O
the None None O
ventral None None I-NEURON
retina None None O
. None None O

chlorpyrifos None None O
, None None O
aldicarb None None O
, None None O
benzo-e-pyrene None None O
and None None O
anti-CD3 None None O
, None None O
affected None None O
genes None None O
in None None O
cholesterol None None O
metabolism None None O
and None None O
transport None None O
, None None O
protein None None O
metabolism None None O
and None None O
transcription None None I-PROTEIN
regulation None None I-PROTEIN
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
use None None O
methods None None O
based None None O
on None None O
item None None O
response None None O
theory None None O
( None None O
IRT None None O
) None None O
to None None O
examine None None O
, None None O
after None None O
equating None None O
for None None O
depression None None I-DISEASE
severity None None O
, None None O
differences None None O
in None None O
the None None O
likelihood None None O
of None None O
reporting None None O
DSM-IV None None O
symptoms None None O
of None None O
major None None O
depressive None None O
episode None None O
( None None O
MDE None None O
) None None O
in None None O
women None None O
of None None O
childbearing None None O
age None None O
( None None O
i.e. None None O
, None None O
aged None None O
18-50 None None O
) None None O
during None None O
pregnancy None None O
, None None O
the None None O
postpartum None None O
period None None O
and None None O
outside None None O
the None None O
peripartum None None O
period None None O
. None None O

This None None O
study None None O
suggests None None O
that None None O
the None None O
clinical None None O
presentation None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
women None None O
of None None O
childbearing None None O
age None None O
does None None O
not None None O
differ None None O
during None None O
pregnancy None None O
, None None O
the None None O
postpartum None None O
period None None O
and None None O
outside None None O
the None None O
peripartum None None O
period None None O
. None None O

Hepatic None None O
protein None None O
levels None None O
of None None O
CYP2E1 None None I-PROTEIN
, None None O
ADH None None O
, None None O
and None None O
ALDH2 None None O
were None None O
unaffected None None O
by None None O
treatment None None O
with None None O
TCE None None O
. None None O

When None None O
measured None None O
0.5 None None O
hr None None O
after None None O
injection None None O
of None None O
bilirubin None None O
, None None O
levels None None O
of None None O
the None None O
amino None None O
acid None None O
neurotransmitters None None I-TRANS
glutamate None None I-TRANS
( None None O
Glu None None O
) None None O
, None None O
glutamine None None I-TRANS
( None None O
Gln None None O
) None None O
, None None O
and None None O
γ-aminobutyric None None O
acid None None O
( None None O
GABA None None I-TRANS
) None None O
in None None O
hippocampus None None I-REGION
and None None O
occipital None None I-REGION
cortex None None I-REGION
significantly None None O
decreased None None O
, None None O
by None None O
contrast None None O
, None None O
levels None None O
of None None O
aspartate None None I-TRANS
( None None O
Asp None None O
) None None O
considerably None None O
increased None None O
. None None O

In None None O
BE None None O
24 None None O
hr None None O
rats None None O
, None None O
all None None O
of None None O
the None None O
metabolic None None O
changes None None O
observed None None O
returned None None O
to None None O
normal None None O
in None None O
the None None O
hippocampus None None I-REGION
and None None O
occipital None None I-REGION
cortex None None I-REGION
; None None O
however None None O
, None None O
levels None None O
of None None O
Glu None None O
, None None O
Gln None None O
, None None O
GABA None None I-TRANS
, None None O
and None None O
glycine None None I-TRANS
significantly None None O
increased None None O
in None None O
the None None O
cerebellum None None I-REGION
. None None O

Early None None O
adverse None None O
caregiving None None O
experiences None None O
have None None O
been None None O
associated None None O
with None None O
structural None None O
alterations None None O
in None None O
the None None O
amygdala None None I-REGION
and None None O
hippocampus None None I-REGION
, None None O
which None None O
parallel None None O
findings None None O
of None None O
cortical None None O
regions None None O
altered None None O
in None None O
adults None None O
with None None O
behavior None None O
problems None None O
related None None O
to None None O
emotion None None I-FUNC
regulation None None O
. None None O

Offspring None None O
brain None None O
structure None None O
, None None O
aggression None None O
, None None O
and None None O
depression None None I-DISEASE
were None None O
assessed None None O
at None None O
age None None O
20 None None O
( None None O
n None None O
= None None O
170 None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
stable None None O
and None None O
very None None O
elevated None None O
trajectories None None O
of None None O
maternal None None O
depression None None I-DISEASE
during None None O
childhood None None O
predicted None None O
depression None None I-DISEASE
in None None O
adult None None O
offspring None None O
. None None O

Offspring None None O
amygdala None None I-REGION
: None None O
hippocampal None None O
volume None None O
ratio None None O
mediated None None O
the None None O
relationship None None O
found None None O
between None None O
trajectories None None O
of None None O
moderately None None O
elevated None None O
maternal None None O
depression None None I-DISEASE
during None None O
childhood None None O
and None None O
aggression None None O
in None None O
adult None None O
offspring None None O
. None None O

In None None O
order None None O
to None None O
elucidate None None O
the None None O
possible None None O
roles None None O
of None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factors None None I-PROTEIN
I None None O
and None None O
II None None O
( None None O
IGF-I None None O
and None None O
IGF-II None None O
) None None O
in None None O
the None None O
embryonic None None O
development None None O
of None None O
Platichthys None None O
stellatus None None O
, None None O
their None None O
cDNAs None None O
were None None O
isolated None None O
and None None O
their None None O
spatial None None O
expression None None O
pattern None None O
in None None O
adult None None O
organs None None O
and None None O
temporal None None O
expression None None O
pattern None None O
throughout None None O
embryonic None None O
development None None O
were None None O
examined None None O
by None None O
quantitative None None O
real-time None None O
PCR None None O
assay None None O
. None None O

The None None O
copper None None O
sequestering None None O
ability None None O
of None None O
melatonin None None I-TRANS
and None None O
its None None O
metabolites None None O
cyclic None None O
3-hydroxymelatonin None None O
( None None O
3OHM None None O
) None None O
, None None O
N None None O
( None None O
1 None None O
) None None O
-acetyl-N None None O
( None None O
2 None None O
) None None O
-formyl-5-methoxykynuramine None None O
( None None O
AFMK None None O
) None None O
, None None O
and None None O
N None None O
( None None O
1 None None O
) None None O
-acetyl-5-methoxykynuramine None None O
( None None O
AMK None None O
) None None O
was None None O
investigated None None O
within None None O
the None None O
frame None None O
of None None O
the None None O
Density None None O
Functional None None O
Theory None None O
. None None O

In None None O
the None None O
same None None O
way None None O
, None None O
melatonin None None I-TRANS
, None None O
AFMK None None O
, None None O
and None None O
3OHM None None O
also None None O
prevented None None O
the None None O
first None None O
step None None O
of None None O
the None None O
Haber-Weiss None None O
reaction None None O
, None None O
consequently None None O
turning None None O
off None None O
the None None O
˙OH None None O
production None None O
via None None O
the None None O
Fenton None None O
reaction None None O
. None None O

3OHM None None O
was None None O
identified None None O
as None None O
the None None O
most None None O
efficient None None O
of None None O
the None None O
studied None None O
compounds None None O
for None None O
that None None O
purpose None None O
, None None O
supporting None None O
the None None O
important None None O
role None None O
of None None O
this None None O
metabolite None None O
in None None O
the None None O
beneficial None None O
effects None None O
of None None O
melatonin None None I-TRANS
against None None O
oxidative None None O
stress None None O
. None None O

The None None O
species None None O
was None None O
produced None None O
in None None O
the None None O
gas None None O
phase None None O
by None None O
reaction None None O
of None None O
zinc None None I-TRANS
vapor None None O
with None None O
iodomethane None None O
in None None O
the None None O
presence None None O
of None None O
a None None O
dc None None O
discharge None None O
. None None O

Experimental None None O
observations None None O
suggest None None O
that None None O
IZnCH3 None None O
is None None O
synthesized None None O
in None None O
the None None O
gas None None O
phase None None O
by None None O
direct None None O
insertion None None O
of None None O
activated None None O
atomic None None O
zinc None None I-TRANS
into None None O
the None None O
carbon-iodine None None O
bond None None O
of None None O
iodomethane None None O
. None None O

Others None None O
reported None None O
a None None O
lack None None O
of None None O
time None None O
or None None O
privacy None None O
, None None O
forgetting None None O
, None None O
or None None O
feeling None None I-FUNC
tired None None O
. None None O

Influencing None None O
factors None None O
were None None O
negative None None O
emotions None None I-FUNC
regarding None None O
dilator None None O
use None None O
or None None O
its None None O
hard None None O
plastic None None O
design None None O
, None None O
( None None O
being None None O
anxious None None O
for None None O
) None None O
pain None None O
or None None O
blood None None O
loss None None O
, None None O
and None None O
an None None O
association None None O
with None None O
EBRT/BT None None O
. None None O

Among None None O
these None None O
10 None None O
compounds None None O
, None None O
farobin None None O
A None None O
( None None O
4 None None O
) None None O
and None None O
isoorientin None None O
( None None O
7 None None O
) None None O
showed None None O
significant None None O
antioxidant None None O
activity None None O
evaluated None None O
by None None O
1,1-diphenyl-2-picrylhydrazyl None None O
, None None O
2,2'-azinobis None None O
( None None O
3-ethylbenzothiazoline-6-sulfonic None None O
acid None None O
) None None O
, None None O
superoxide None None O
anion None None O
and None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
radical-scavenging None None O
assays None None O
. None None O

Transcranial None None O
direct None None O
current None None O
stimulation None None O
( None None O
tDCS None None O
) None None O
of None None O
the None None O
primary None None I-REGION
motor None None I-REGION
cortex None None I-REGION
has None None O
been None None O
shown None None O
to None None O
modulate None None O
pain None None O
and None None O
trigeminal None None O
nociceptive None None O
processing None None O
. None None O

Using None None O
primary None None O
hippocampal None None O
neuronal None None O
cultures None None O
as None None O
a None None O
model None None O
system None None O
, None None O
we None None O
report None None O
that None None O
Frizzled4 None None O
( None None O
Fzd4 None None O
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
Fzd None None O
family None None O
of None None O
Wnt None None O
receptors None None I-PROTEIN
, None None O
specifically None None O
signals None None O
downstream None None O
of None None O
Wnt5a None None O
to None None O
promote None None O
dendrite None None O
branching None None O
and None None O
growth None None O
. None None O

Understanding None None O
the None None O
roles None None O
of None None O
these None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
in None None O
zebrafish None None O
( None None O
Danio None None O
rerio None None O
) None None O
is None None O
important None None O
to None None O
the None None O
use None None O
of None None O
this None None O
non-mammalian None None O
model None None O
in None None O
toxicological None None O
, None None O
pharmacological None None O
, None None O
and None None O
carcinogenesis None None O
research None None O
. None None O

The None None O
short None None O
form None None O
36 None None O
( None None O
SF-36 None None O
) None None O
questionnaire None None O
was None None O
also None None O
completed None None O
in None None O
order None None O
to None None O
seek None None O
a None None O
relationship None None O
between None None O
the None None O
patients None None O
perception None None I-FUNC
of None None O
quality None None O
of None None O
life None None O
and None None O
the None None O
different None None O
aspects None None O
of None None O
the None None O
smell None None O
sense None None O
. None None O

However None None O
the None None O
correlation None None O
between None None O
depression None None I-DISEASE
, None None O
defined None None O
by None None O
the None None O
BDI-II None None O
score None None O
, None None O
and None None O
the None None O
sense None None O
of None None O
smell None None O
differed None None O
between None None O
patients None None O
with None None O
FM None None O
and None None O
patients None None O
with None None O
SSc None None O
. None None O

We None None O
address None None O
the None None O
problem None None O
of None None O
estimating None None O
the None None O
unknown None None O
parameters None None O
of None None O
a None None O
model None None O
of None None O
tracer None None O
kinetics None None O
from None None O
sequences None None O
of None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
scan None None O
data None None O
using None None O
a None None O
statistical None None O
sequential None None O
algorithm None None O
for None None O
the None None O
inference None None I-FUNC
of None None O
magnitudes None None O
of None None O
dynamic None None O
parameters None None O
. None None O

Moreover None None O
, None None O
we None None O
derived None None O
5 None None O
peptides None None I-TRANS
from None None O
the None None O
sequence None None O
of None None O
PB1 None None O
that None None O
form None None O
the None None O
TBC None None O
channel None None O
and None None O
4 None None O
of None None O
them None None O
can None None O
inhibit None None O
the None None O
viral None None O
RNA None None O
polymerase None None O
activity None None O
. None None O

Outcomes None None O
were None None O
changes None None O
in None None O
serum None None O
25-hydroxyvitamin None None O
D None None O
( None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
) None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
glutathione None None O
( None None O
GSH None None O
) None None O
, None None O
total None None O
antioxidant None None O
capacity None None O
( None None O
TAC None None O
) None None O
and None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
. None None O

Only None None O
a None None O
few None None O
distantly None None O
related None None O
mammals None None O
and None None O
birds None None O
have None None O
the None None O
trait None None O
of None None O
complex None None O
vocal None None O
learning None None I-FUNC
, None None O
which None None O
is None None O
the None None O
ability None None O
to None None O
imitate None None O
novel None None O
sounds None None O
. None None O

As None None O
a None None O
result None None O
, None None O
it None None O
has None None O
been None None O
hypothesized None None O
that None None O
there None None O
could None None O
exist None None O
convergent None None O
changes None None O
in None None O
genes None None O
involved None None O
in None None O
neural None None O
connectivity None None O
of None None O
vocal None None O
learning None None I-FUNC
circuits None None O
. None None O

[ None None O
2014 None None O
] None None O
Science None None O
346 None None O
: None None O
1256846 None None O
) None None O
, None None O
here None None O
we None None O
show None None O
that None None O
the None None O
forebrain None None I-REGION
part None None O
of None None O
this None None O
circuit None None O
that None None O
makes None None O
a None None O
relatively None None O
rare None None O
direct None None O
connection None None O
to None None O
brainstem None None I-REGION
vocal None None O
motor None None I-NEURON
neurons None None I-NEURON
in None None O
independent None None O
lineages None None O
of None None O
vocal None None O
learning None None I-FUNC
birds None None O
( None None O
songbird None None O
, None None O
parrot None None O
, None None O
and None None O
hummingbird None None O
) None None O
has None None O
specialized None None O
regulation None None O
of None None O
axon None None O
guidance None None O
genes None None O
from None None O
the None None O
SLIT-ROBO None None O
molecular None None O
pathway None None O
. None None O

Enzymatic None None O
alteration None None O
of None None O
aminoglycosides None None O
( None None O
AMEs None None O
) None None O
by None None O
aminoglycoside- None None O
modifying None None O
enzymes None None I-PROTEIN
is None None O
the None None O
main None None O
mechanism None None O
of None None O
resistance None None O
to None None O
these None None O
antibiotics None None O
in None None O
E. None None O
coli None None O
. None None O

mRNA None None O
expression None None O
in None None O
the None None O
dentate None None I-REGION
gyrus None None I-REGION
examined None None O
at None None O
200 None None O
ppm None None O
decreased None None O
with None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
Bdnf None None O
) None None O
and None None O
very None None O
low None None O
density None None O
lipoprotein None None O
receptor None None I-PROTEIN
. None None O

Thus None None O
, None None O
maternal None None O
IDPN None None O
exposure None None O
may None None O
reversibly None None O
affect None None O
late-stage None None O
differentiation None None O
of None None O
granule None None O
cell None None O
lineages None None O
involving None None O
neuronal None None O
plasticity None None O
as None None O
evident None None O
by None None O
immediate-early None None O
gene None None O
responses None None O
to None None O
cause None None O
BDNF None None O
downregulation None None O
resulting None None O
in None None O
a None None O
reduction None None O
in None None O
parvalbumin None None O
( None None O
+ None None O
) None None O
or None None O
reelin None None O
( None None O
+ None None O
) None None O
interneurons None None I-NEURON
and None None O
suppression None None O
of None None O
axonal None None O
plasticity None None O
in None None O
the None None O
mossy None None O
cells None None O
and None None O
CA3 None None I-REGION
pyramidal None None O
neurons None None O
. None None O

A None None O
twofold None None O
elevation None None O
in None None O
Hg None None O
was None None O
associated None None O
with None None O
higher None None O
protein None None O
and None None O
reduced None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
. None None O

We None None O
performed None None O
an None None O
integrated None None O
safety None None O
analysis None None O
of None None O
15 None None O
clinical None None O
trials None None O
in None None O
adults None None O
with None None O
attention None None I-DISEASE
deficit None None I-DISEASE
hyperactivity None None I-DISEASE
disorder None None I-DISEASE
. None None O

The None None O
primary None None O
goal None None O
of None None O
this None None O
report None None O
was None None O
to None None O
compare None None O
and None None O
contrast None None O
the None None O
prevalence None None O
of None None O
self-reported None None O
measures None None O
of None None O
impulsivity None None O
, None None O
depression None None I-DISEASE
, None None O
lifetime None None O
stress None None O
and None None O
sensation-seeking None None O
in None None O
healthy None None O
controls None None O
versus None None O
individuals None None O
with None None O
cocaine None None O
or None None O
methamphetamine None None O
use None None O
disorders None None O
. None None O

All None None O
participants None None O
were None None O
administered None None O
behavioral None None O
questionnaires None None O
including None None O
the None None O
Barrett None None O
Impulsiveness None None O
Scale None None O
( None None O
assessing None None O
impulsivity None None O
) None None O
, None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
II None None O
( None None O
assessing None None O
depression None None I-DISEASE
) None None O
, None None O
Life None None O
Stressor None None O
Checklist-Revised None None O
( None None O
assessing None None O
lifetime None None O
stress None None O
) None None O
and None None O
the None None O
Impulsive None None O
Sensation None None I-FUNC
Seeking None None O
Scale None None O
( None None O
assessing None None O
sensation-seeking None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
when None None O
compared None None O
to None None O
healthy None None O
controls None None O
, None None O
individuals None None O
with None None O
cocaine None None O
use None None O
disorders None None O
had None None O
significantly None None O
higher None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
II None None O
scores None None O
, None None O
while None None O
individuals None None O
with None None O
methamphetamine None None O
use None None O
disorders None None O
had None None O
significantly None None O
higher None None O
Life None None O
Stressor None None O
Checklist-Revised None None O
scores None None O
. None None O

The None None O
fruit None None O
fly None None O
Drosophila None None O
melanogaster None None O
has None None O
several None None O
different None None O
ommatidium None None O
types None None O
that None None O
can None None O
be None None O
localised None None O
to None None O
specific None None O
retinal None None O
regions None None O
, None None O
such None None O
as None None O
the None None O
dorsal None None I-NEURON
rim None None O
area None None O
( None None O
DRA None None O
) None None O
, None None O
or None None O
distributed None None O
stochastically None None O
in None None O
a None None O
mosaic None None O
across None None O
the None None O
retina None None O
, None None O
like None None O
the None None O
'pale None None O
' None None O
and None None O
'yellow None None O
' None None O
types None None O
. None None O

This None None O
suggests None None O
that None None O
evolutionary None None O
changes None None O
in None None O
the None None O
underlying None None O
regulatory None None O
mechanisms None None O
can None None O
alter None None O
the None None O
distribution None None O
of None None O
ommatidium None None O
types None None O
to None None O
promote None None O
or None None O
restrict None None O
their None None O
expression None None O
in None None O
specific None None O
regions None None O
of None None O
the None None O
eye None None O
within None None O
and None None O
between None None O
species None None O
, None None O
and None None O
that None None O
this None None O
could None None O
cause None None O
differences None None O
in None None O
vision None None I-FUNC
among None None O
these None None O
flies None None O
. None None O

Based None None O
on None None O
the None None O
24-week None None O
, None None O
prospective None None O
, None None O
non-interventional None None O
, None None O
observational None None O
study None None O
, None None O
A1chieve® None None O
, None None O
we None None O
investigated None None O
how None None O
health-related None None O
quality None None O
of None None O
life None None O
( None None O
HRQoL None None O
) None None O
changed None None O
, None None O
and None None O
the None None O
predictors None None O
of None None O
such None None O
changes None None O
, None None O
in None None O
Chinese None None O
people None None O
with None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
( None None O
T2DM None None O
) None None O
after None None O
starting None None O
with None None O
, None None O
or None None O
switching None None O
to None None O
, None None O
biphasic None None O
insulin None None I-PROTEIN
aspart None None O
30 None None O
( None None O
BIAsp None None O
30 None None O
) None None O
. None None O

In None None O
addition None None O
to None None O
its None None O
lifelong None None O
impact None None O
on None None O
affected None None O
individuals None None O
, None None O
families None None O
and None None O
society None None O
as None None O
a None None O
whole None None O
, None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
is None None O
associated None None O
with None None O
the None None O
highest None None O
healthcare None None O
costs None None O
of None None O
any None None O
disease None None O
. None None O

A None None O
2.5-year None None O
study None None O
in None None O
a None None O
tertiary None None O
setting None None O
treatable None None O
inborn None None O
errors None None O
of None None O
metabolism None None O
were None None O
identified None None O
as None None O
cause None None O
of None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
in None None O
more None None O
than None None O
5 None None O
% None None O
of None None O
the None None O
children None None O
studied None None O
. None None O

These None None O
results None None O
should None None O
motivate None None O
clinicians None None O
to None None O
aim None None O
diagnostic None None O
assessment None None O
of None None O
an None None O
individual None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
at None None O
treatable None None O
inborn None None O
errors None None O
of None None O
metabolism None None O
. None None O

The None None O
implementation None None O
of None None O
far-reaching None None O
changes None None O
in None None O
acute None None O
stroke None None I-DISEASE
care None None O
in None None O
the None None O
Netherlands None None O
would None None O
be None None O
dangerous None None O
, None None O
and None None O
would None None O
not None None O
lead None None O
to None None O
better None None O
and None None O
cheaper None None O
, None None O
but None None O
to None None O
worse None None O
and None None O
more None None O
expensive None None O
care None None O
. None None O

This None None O
picture None None O
is None None O
stereotypically None None O
associated None None O
with None None O
migraine None None I-DISEASE
provoked None None O
by None None O
minor None None O
head None None O
injury None None O
. None None O

Trauma None None O
triggered None None O
migraine None None I-DISEASE
is None None O
seen None None O
more None None O
frequently None None O
in None None O
children None None O
, None None O
adolescents None None O
and None None O
young None None O
adults None None O
. None None O

`` None None O
Self-awareness None None I-FUNC
and None None O
understanding None None O
'' None None O
was None None O
the None None O
most None None O
commonly None None O
reported None None O
primary None None O
and None None O
contributing None None O
reason None None O
for None None O
being None None O
in None None O
psychotherapy None None O
. None None O

Neither None None O
uses None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
to None None O
achieve None None O
reduction None None O
of None None O
the None None O
aromatic None None O
ring None None O
. None None O

Melatonin None None I-TRANS
, None None O
a None None O
lipophilic None None O
compound None None O
synthesized None None O
and None None O
released None None O
from None None O
the None None O
pineal None None I-REGION
gland None None O
, None None O
effectively None None O
acts None None O
against None None O
ultraviolet None None O
radiation None None O
( None None O
UVR None None O
) None None O
, None None O
one None None O
of None None O
the None None O
main None None O
inducers None None O
of None None O
epidermal None None O
damage None None O
, None None O
skin None None O
cancer None None O
, None None O
inflammation None None O
, None None O
and None None O
DNA None None O
photo None None O
damage None None O
. None None O

Here None None O
, None None O
using None None O
human None None O
full-thickness None None O
skin None None O
and None None O
normal None None O
human None None O
epidermal None None O
keratinocytes None None O
( None None O
NHEK None None O
) None None O
, None None O
we None None O
investigated None None O
the None None O
interaction None None O
of None None O
melatonin None None I-TRANS
and None None O
Hsp70 None None O
toward None None O
UVR-induced None None O
inflammatory None None O
and None None O
apoptotic None None O
responses None None O
. None None O

Parallel None None O
investigation None None O
using None None O
melatonin None None I-TRANS
( None None O
10 None None O
( None None O
-3 None None O
) None None O
m None None O
) None None O
significantly None None O
inverted None None O
these None None O
responses None None O
regardless None None O
depletion None None O
of None None O
Hsp70 None None O
RNA None None O
suggesting None None O
a None None O
compensatory None None O
action None None O
of None None O
this None None O
compound None None O
in None None O
the None None O
defense None None O
mechanisms None None O
. None None O

Furthermore None None O
, None None O
attention None None I-FUNC
to None None O
preventive None None O
care None None O
and None None O
comorbid None None O
medical None None O
conditions None None O
is None None O
critical None None O
. None None O

Purines None None O
are None None O
imported None None O
from None None O
the None None O
host None None O
erythrocyte None None O
by None None O
equilibrative None None O
nucleoside None None O
transporters None None I-PROTEIN
( None None O
ENTs None None O
) None None O
. None None O

Hexathiophenalenylium None None O
( None None O
HTPLY None None O
) None None O
has None None O
gained None None O
increasing None None O
attention None None I-FUNC
for None None O
its None None O
interesting None None O
and None None O
potentially None None O
useful None None O
optical None None O
properties None None O
as None None O
a None None O
result None None O
of None None O
the None None O
enhancement None None O
in None None O
spin None None O
delocalization None None O
and None None O
charge-transfer None None O
of None None O
phenalenyl None None O
radicals None None O
, None None O
occasioned None None O
by None None O
the None None O
attachment None None O
of None None O
successive None None O
three None None O
disulfide None None O
linkages None None O
. None None O

Conformationally None None O
irregular None None O
peptides None None I-TRANS
therefore None None O
offer None None O
a None None O
great None None O
opportunity None None O
to None None O
explore None None O
the None None O
differences None None O
between None None O
these None None O
codes None None O
. None None O

In None None O
this None None O
work None None O
, None None O
we None None O
have None None O
carried None None O
out None None O
Molecular None None O
Dynamics None None O
simulations None None O
of None None O
( None None O
relatively None None O
) None None O
disordered None None O
peptides None None I-TRANS
, None None O
specifically None None O
gp41659-671 None None O
( None None O
ELLELDKWASLWN None None O
) None None O
, None None O
the None None O
homopeptide None None O
polyasparagine None None O
( None None O
N18 None None O
) None None O
, None None O
and None None O
polyasparagine None None O
dimers None None O
. None None O

A None None O
total None None O
of None None O
2596 None None O
unrelated None None O
subjects None None O
from None None O
the None None O
Study None None O
of None None O
Addiction None None O
: None None O
Genetics None None O
and None None O
Environment None None O
provided None None O
information None None O
on None None O
alcohol None None O
, None None O
tobacco None None O
, None None O
cocaine None None O
, None None O
cannabis None None O
and None None O
other None None O
illicit None None O
substance None None I-DISEASE
dependence None None I-DISEASE
. None None O

To None None O
explore None None O
aspects None None O
that None None O
hamper None None O
or None None O
facilitate None None O
tutorial None None O
problem None None O
based None None O
learning None None I-FUNC
from None None O
the None None O
perspective None None O
of None None O
tutors None None O
. None None O

We None None O
report None None O
a None None O
57-year-old None None O
woman None None O
who None None O
presented None None O
with None None O
low None None O
back None None O
pain None None O
, None None O
fever None None O
and None None O
impairment None None O
of None None O
consciousness None None I-FUNC
. None None O

The None None O
deduced None None O
product None None O
of None None O
rapY None None O
, None None O
rapR None None O
, None None O
and None None O
rapS None None O
showed None None O
high None None O
sequence None None O
similarity None None O
to None None O
the None None O
TetR None None O
family None None O
transcription None None O
regulators None None O
, None None O
response None None O
regulators None None O
and None None O
histidine None None I-TRANS
kinases None None I-PROTEIN
of None None O
two-component None None O
systems None None O
, None None O
respectively None None O
. None None O

Both None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
B None None O
( None None O
VEGF-B None None O
) None None O
and None None O
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
9 None None O
( None None O
MMP9 None None O
) None None O
play None None O
essential None None O
roles None None O
in None None O
neovascularization None None O
of None None O
NSCLC None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
reviewed None None O
the None None O
current None None O
status None None O
of None None O
active None None O
targeting None None O
strategies None None O
for None None O
nanoparticulate None None O
systems None None O
based None None O
on None None O
various None None O
receptors None None I-PROTEIN
such None None O
as None None O
asialoglycoprotein None None O
receptor None None I-PROTEIN
, None None O
transferrin None None O
receptor None None I-PROTEIN
, None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
, None None O
folate None None O
receptor None None I-PROTEIN
, None None O
integrin None None I-PROTEIN
, None None O
and None None O
CD44 None None O
, None None O
which None None O
are None None O
abundantly None None O
expressed None None O
on None None O
the None None O
surfaces None None O
of None None O
hepatocytes None None O
or None None O
liver None None O
cancer None None O
cells None None O
. None None O

Moreover None None O
, None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
overexpression None None O
was None None O
not None None O
correlated None None O
with None None O
SPRR1A None None O
expression None None O
, None None O
whereas None None O
Ki67 None None O
was None None O
associated None None O
with None None O
SPRR1A None None O
expression None None O
( None None O
P None None O
= None None O
0.155 None None O
and None None O
0.028 None None O
, None None O
respectively None None O
) None None O
. None None O

We None None O
conducted None None O
a None None O
cross-sectional None None O
study None None O
of None None O
US None None O
individuals None None O
aged None None O
≥40 None None O
years None None O
for None None O
whom None None O
information None None O
on None None O
statin None None O
use None None O
, None None O
serum None None O
25-hydroxy None None O
vitamin None None O
D None None O
( None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
) None None O
, None None O
and None None O
self-reported None None O
severe None None O
headache None None O
or None None O
migraine None None I-DISEASE
had None None O
been None None O
collected None None O
. None None O

Among None None O
5938 None None O
participants None None O
, None None O
multivariable-adjusted None None O
logistic None None O
regression None None O
showed None None O
that None None O
statin None None O
use None None O
was None None O
significantly None None O
associated None None O
with None None O
a None None O
lower None None O
prevalence None None O
of None None O
severe None None O
headache None None O
or None None O
migraine None None I-DISEASE
( None None O
OR None None O
0.67 None None O
; None None O
95 None None O
% None None O
CI None None O
0.46 None None O
, None None O
0.98 None None O
, None None O
p None None O
= None None O
0.04 None None O
) None None O
. None None O

Among None None O
participants None None O
who None None O
had None None O
serum None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
& None None O
gt None None O
; None None O
57 None None O
nmol/l None None O
, None None O
statin None None O
use None None O
was None None O
associated None None O
with None None O
a None None O
multivariable-adjusted None None O
odds None None O
ratio None None O
of None None O
0.48 None None O
( None None O
95 None None O
% None None O
CI None None O
0.32 None None O
, None None O
0.71 None None O
, None None O
p None None O
= None None O
0.001 None None O
) None None O
for None None O
having None None O
severe None None O
headache None None O
or None None O
migraine None None I-DISEASE
. None None O

Statin None None O
use None None O
in None None O
those None None O
with None None O
higher None None O
serum None None O
vitamin None None O
D None None O
levels None None O
is None None O
significantly None None O
associated None None O
with None None O
lower None None O
odds None None O
of None None O
having None None O
severe None None O
headache None None O
or None None O
migraine None None I-DISEASE
. None None O

Clinical None None O
characteristics None None O
were None None O
systematically None None O
and None None O
prospectively None None O
collected None None O
from None None O
patients None None O
with None None O
1.2.1 None None O
MTA None None O
, None None O
1.2.4 None None O
familial None None I-DISEASE
hemiplegic None None I-DISEASE
migraine None None I-DISEASE
( None None O
FHM None None O
) None None O
, None None O
1.2.5 None None O
sporadic None None O
hemiplegic None None O
migraine None None I-DISEASE
( None None O
SHM None None O
) None None O
and None None O
1.2.6 None None O
basilar-type None None O
migraine None None I-DISEASE
according None None O
to None None O
ICHD-2 None None O
in None None O
a None None O
cross-sectional None None O
study None None O
design None None O
. None None O

The None None O
criteria None None O
for None None O
1.2.2 None None O
migraine None None I-DISEASE
with None None O
brainstem None None I-REGION
aura None None O
should None None O
be None None O
more None None O
restrictive None None O
. None None O

Migraine None None I-DISEASE
headache None None O
is None None O
one None None O
of None None O
the None None O
most None None O
common None None O
primary None None O
headache None None O
disorders None None O
and None None O
is None None O
three None None O
times None None O
more None None O
prevalent None None O
in None None O
women None None O
than None None O
in None None O
men None None O
, None None O
especially None None O
during None None O
the None None O
reproductive None None O
ages None None O
. None None O

The None None O
present None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
gender None None O
on None None O
the None None O
headache None None O
manifestations None None O
in None None O
migraine None None I-DISEASE
patients None None O
. None None O

The None None O
relationship None None O
between None None O
headache None None O
characteristics None None O
and None None O
gender None None O
was None None O
evaluated None None O
in None None O
migraine None None I-DISEASE
with None None O
aura None None O
( None None O
MwA None None O
) None None O
and None None O
migraine None None I-DISEASE
without None None I-DISEASE
aura None None I-DISEASE
( None None O
MwoA None None O
) None None O
. None None O

Women None None O
with None None O
migraine None None I-DISEASE
were None None O
prone None None O
to None None O
significantly None None O
longer None None O
duration None None O
and None None O
intensity None None O
of None None O
headache None None O
attacks None None O
. None None O

Gender None None O
has None None O
an None None O
influence None None O
on None None O
the None None O
characteristics None None O
of None None O
the None None O
headache None None O
as None None O
well None None O
as None None O
on None None O
the None None O
associated None None O
symptoms None None O
in None None O
migraine None None I-DISEASE
patients None None O
, None None O
and None None O
this None None O
impact None None O
varies None None O
across None None O
the None None O
age None None O
groups None None O
, None None O
particularly None None O
in None None O
women None None O
. None None O

Several None None O
potential None None O
dietary None None O
trigger None None O
factors None None O
for None None O
migraine None None I-DISEASE
have None None O
been None None O
proposed None None O
. None None O

A None None O
total None None O
of None None O
25,755 None None O
women None None O
reported None None O
no None None O
history None None O
of None None O
migraine None None I-DISEASE
or None None O
headache None None O
, None None O
5573 None None O
reported None None O
non-migraine None None O
headache None None O
and None None O
7042 None None O
reported None None O
any None None O
migraine None None I-DISEASE
. None None O

Intake None None O
of None None O
most None None O
suggested None None O
migraine None None I-DISEASE
dietary None None O
triggers None None O
differs None None O
by None None O
migraine None None I-DISEASE
aura None None O
status None None O
and None None O
attack None None O
frequency None None O
, None None O
a None None O
pattern None None O
not None None O
found None None O
for None None O
non-migraine None None O
headache None None O
. None None O

We None None O
estimated None None O
the None None O
SNP-based None None O
heritability None None O
of None None O
levels None None O
of None None O
three None None O
liver None None O
enzymes None None I-PROTEIN
( None None O
gamma-glutamyl None None O
transferase None None I-PROTEIN
( None None O
GGT None None O
) None None O
; None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
; None None O
and None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
) None None O
using None None O
genome-wide None None O
SNP None None O
data None None O
in None None O
a None None O
sample None None O
of None None O
5421 None None O
unrelated None None O
Dutch None None O
individuals None None O
. None None O

DE None None O
estimates None None O
in None None O
the None None O
same None None O
sample None None O
varied None None O
as None None O
a None None O
function None None O
of None None O
pruning None None O
and None None O
were None None O
around None None O
23 None None O
% None None O
for None None O
all None None O
liver None None O
enzymes None None I-PROTEIN
. None None O

This None None O
cost-effectiveness None None O
study None None O
comparing None None O
two None None O
available None None O
HPV None None O
vaccines None None O
in None None O
Chile None None O
was None None O
performed None None O
to None None O
support None None O
decision None None I-FUNC
making None None I-FUNC
on None None O
the None None O
implementation None None O
of None None O
universal None None O
HPV None None O
vaccination None None O
. None None O

In None None O
patients None None O
with None None O
obstructive None None O
sleep None None O
apnea None None O
, None None O
airway None None O
obstruction None None O
during None None O
sleep None None O
produces None None O
hypercapnia None None O
, None None O
which None None O
in None None O
turn None None O
activates None None O
respiratory None None O
muscles None None O
that None None O
pump None None O
air None None O
into None None O
the None None O
lungs None None O
( None None O
e.g. None None O
, None None O
the None None O
diaphragm None None I-REGION
) None None O
and None None O
that None None O
dilate None None O
and None None O
stabilize None None O
the None None O
upper None None O
airway None None O
( None None O
e.g. None None O
, None None O
the None None O
genioglossus None None O
) None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
, None None O
we None None O
combined None None O
c-Fos None None O
immunohistochemistry None None O
with None None O
in None None O
situ None None O
hybridization None None O
for None None O
vGluT2 None None O
or None None O
GAD67 None None O
or None None O
with None None O
retrograde None None O
tracing None None O
from None None O
the None None O
ventrolateral None None O
medullary None None O
region None None O
that None None O
contains None None O
phrenic None None O
premotor None None O
neurons None None O
, None None O
the None None O
phrenic None None O
motor None None O
nucleus None None O
in None None O
the None None O
C3-C5 None None O
spinal None None O
ventral None None I-NEURON
horn None None O
, None None O
or None None O
the None None O
hypoglossal None None O
motor None None O
nucleus None None O
. None None O

Female None None O
stroke None None I-DISEASE
victims None None O
have None None O
a None None O
higher None None O
survival None None O
rate None None O
and None None O
experience None None O
a None None O
greater None None O
loss None None O
of None None O
quality None None O
of None None O
life None None O
than None None O
do None None O
male None None O
stroke None None I-DISEASE
victims None None O
. None None O

Participants None None O
included None None O
women None None O
stroke None None I-DISEASE
survivors None None O
, None None O
aged None None O
45-65 None None O
years None None O
, None None O
who None None O
were None None O
patients None None O
at None None O
a None None O
medical None None O
center None None O
in None None O
Taiwan None None O
. None None O

Overall None None O
, None None O
women None None O
's None None O
physical None None O
functioning None None O
( None None O
PF None None O
; None None O
stroke None None I-DISEASE
severity None None O
) None None O
, None None O
cognitive None None O
appraisal None None O
of None None O
coping None None O
, None None O
and None None O
caregiver None None O
's None None O
psychosocial None None O
functioning None None O
were None None O
the None None O
predictors None None O
, None None O
explaining None None O
43.3 None None O
% None None O
of None None O
the None None O
variance None None O
in None None O
women None None O
's None None O
health-related None None O
quality None None O
of None None O
life None None O
. None None O

In None None O
addition None None O
to None None O
assisting None None O
women None None O
in None None O
their None None O
PF None None O
rehabilitation None None O
, None None O
rehabilitation None None O
nurses None None O
also None None O
should None None O
help None None O
to None None O
develop None None O
survivors None None O
' None None O
self-care None None O
confidence None None O
as None None O
a None None O
means None None O
to None None O
avoid None None O
the None None O
recurrence None None O
of None None O
stroke None None I-DISEASE
. None None O

To None None O
do None None O
this None None O
we None None O
generated None None O
DNA None None O
sequence None None O
data None None O
from None None O
three None None O
endosymbiont None None O
loci None None O
( None None O
rspB None None O
, None None O
GroEL None None I-PROTEIN
, None None O
and None None O
16S None None O
) None None O
and None None O
analyzed None None O
each None None O
locus None None O
independently None None O
using None None O
statistical None None O
parsimony None None O
network None None O
analyses None None O
and None None O
as None None O
a None None O
concatenated None None O
dataset None None O
using None None O
Bayesian None None O
phylogenetic None None O
reconstructions None None O
. None None O

Ectopic None None O
expression None None O
of None None O
miR-125b None None O
reduced None None O
HOTTIP-coupled None None O
luciferase None None I-PROTEIN
activity None None O
and None None O
suppressed None None O
the None None O
endogenous None None O
level None None O
of None None O
HOTTIP None None O
. None None O

This None None O
prospective None None O
, None None O
observational None None O
, None None O
1-year None None O
study None None O
focused None None O
on None None O
73 None None O
adolescents None None O
with None None O
type None None O
1 None None O
diabetes None None O
, None None O
using None None O
multiple None None O
daily None None O
injections None None O
or None None O
continuous None None O
subcutaneous None None O
insulin None None I-PROTEIN
infusion None None O
. None None O

Published None None O
by None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Substance None None I-TRANS
P None None I-TRANS
( None None O
SP None None O
) None None O
and None None O
its None None O
natural None None O
analogue None None O
hemokinin-1 None None O
( None None O
HK1 None None O
) None None O
are None None O
produced None None O
by None None O
lymphocytes None None O
and None None O
macrophages None None O
, None None O
and None None O
at None None O
times None None O
B None None O
cells None None O
. None None O

Cadherins None None I-PROTEIN
are None None O
calcium-dependent None None O
cell-to-cell None None O
adhesion None None I-PROTEIN
glycoproteins None None O
playing None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
formation None None O
and None None O
maintenance None None O
of None None O
normal None None O
tissue None None O
architecture None None O
. None None O

The None None O
two None None O
cadherins None None I-PROTEIN
were None None O
found None None O
to None None O
be None None O
co-expressed None None O
in None None O
carcinomas None None O
with None None O
aberrant None None O
P-cadherin None None O
expression None None O
and None None O
preserved None None O
E-cadherin None None O
. None None O

To None None O
survey None None O
veterinary None None O
practitioners None None O
in None None O
Australia None None O
on None None O
how None None O
they None None O
administer None None O
pentosan None None O
polysulfate None None O
( None None O
PPS None None O
) None None O
to None None O
horses None None O
and None None O
their None None O
perceptions None None I-FUNC
of None None O
the None None O
efficacy None None O
of None None O
PPS None None O
for None None O
: None None O
the None None O
prevention None None O
and None None O
treatment None None O
of None None O
osteoarthritis None None O
( None None O
OA None None O
) None None O
, None None O
the None None O
treatment None None O
of None None O
OA None None O
when None None O
PPS None None O
is None None O
combined None None O
with None None O
other None None O
drugs None None O
, None None O
and None None O
the None None O
efficacy None None O
of None None O
PPS None None O
compared None None O
with None None O
other None None O
disease-modifying None None O
osteoarthritic None None O
drugs None None O
. None None O

Histologically None None O
, None None O
intracytoplasmic None None O
accumulation None None O
of None None O
pigment None None O
granules None None O
was None None O
detected None None O
in None None O
the None None O
neurons None None O
, None None O
most None None O
prominently None None O
in None None O
the None None O
thalamus None None I-REGION
, None None O
brainstem None None I-REGION
and None None O
ventral None None I-NEURON
horns None None O
of None None O
the None None O
spinal None None O
cord None None O
. None None O

Overall None None O
perceptions None None I-FUNC
of None None O
cancer None None O
immunotherapy None None O
among None None O
HCPs None None O
were None None O
largely None None O
positive None None O
( None None O
60 None None O
% None None O
) None None O
and None None O
rarely None None O
negative None None O
( None None O
3 None None O
% None None O
) None None O
. None None O

The None None O
rBCG None None O
strain None None O
significantly None None O
enhanced None None O
phagocytic None None O
activity None None O
, None None O
production None None O
of None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
-α None None O
, None None O
interleukin None None O
( None None O
IL None None O
) None None O
-1β None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
and None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
as None None O
compared None None O
with None None O
parental None None O
BCG None None O
strain None None O
, None None O
and None None O
these None None O
activities None None O
increased None None O
in None None O
the None None O
presence None None O
of None None O
LPS None None O
and None None O
LPS+IFN-γ None None O
. None None O

Previously None None O
, None None O
we None None O
reported None None O
on None None O
the None None O
expression None None O
and None None O
purification None None O
of None None O
a None None O
highly None None O
promising None None O
hookworm None None O
vaccine None None O
candidate None None O
, None None O
Na-GST-1 None None O
, None None O
an None None O
N. None None O
americanus None None O
glutathione None None I-PROTEIN
s-transferase None None I-PROTEIN
expressed None None O
in None None O
Pichia None None O
pastoris None None O
( None None O
yeast None None O
) None None O
, None None O
which None None O
led None None O
to None None O
production None None O
of None None O
1.5 None None O
g None None O
of None None O
95 None None O
% None None O
pure None None O
recombinant None None O
protein None None O
at None None O
a None None O
20L None None O
scale None None O
. None None O

Acute None None O
disseminated None None O
encephalomyelitis None None O
( None None O
ADEM None None O
) None None O
is None None O
an None None O
inflammatory None None O
, None None O
usually None None O
monophasic None None O
, None None O
immune None None O
mediate None None O
, None None O
demyelinating None None O
disease None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
which None None O
involves None None O
the None None O
white None None I-REGION
matter None None I-REGION
. None None O

The None None O
magnetic None None O
resonance None None O
imaging None None O
of None None O
the None None O
brain None None O
showed None None O
multiple None None O
and None None O
symmetrical None None O
white None None I-REGION
matter None None I-REGION
lesions None None O
in None None O
both None None O
cerebellar None None O
and None None O
cerebral None None O
hemispheres None None O
, None None O
suggesting None None O
demyelinating None None O
disease None None O
with None None O
inflammatory None None O
activity None None O
, None None O
compatible None None O
with None None O
ADEM None None O
. None None O

Racial/ethnic None None O
minorities None None O
are None None O
underrepresented None None O
in None None O
actual None None O
HIV None None O
vaccine None None O
trials None None O
in None None O
North None None O
America None None O
, None None O
and None None O
willingness None None O
to None None O
participate None None O
( None None O
WTP None None O
) None None O
and None None O
retention None None I-FUNC
in None None O
an None None O
HIV None None O
vaccine None None O
trial None None O
may None None O
differ None None O
from None None O
that None None O
in None None O
Whites None None O
. None None O

Strategies None None O
to None None O
increase None None O
WTP None None O
and None None O
enhanced None None O
retention None None I-FUNC
( None None O
ER None None O
) None None O
strategies None None O
may None None O
help None None O
in None None O
recruiting None None O
and None None O
retaining None None O
minority None None O
participants None None O
in None None O
actual None None O
HIV None None O
vaccine None None O
trials None None O
and None None O
other None None O
trials None None O
of None None O
biomedical None None O
prevention None None O
. None None O

Priming None None O
with None None O
DNA None None O
also None None O
caused None None O
more None None O
activated None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
to None None O
become None None O
TFH None None O
cells None None O
and None None O
more None None O
GC None None O
B None None O
cells None None O
to None None O
become None None O
memory None None I-FUNC
cells None None O
. None None O

In None None O
the None None O
investigation None None O
reported None None O
here None None O
an None None O
Aβ None None O
1-42 None None O
peptide None None O
vaccine None None O
was None None O
administered None None O
to None None O
16-month None None O
old None None O
APP+PS1 None None O
transgenic None None O
( None None O
Tg None None O
) None None O
mice None None O
in None None O
which None None O
Aβ None None O
deposition None None O
, None None O
cognitive None None O
memory None None I-FUNC
deficits None None O
as None None O
well None None O
as None None O
levels None None O
of None None O
several None None O
pro-inflammatory None None O
cytokines None None O
were None None O
measured None None O
in None None O
response None None O
to None None O
the None None O
vaccination None None O
regimen None None O
. None None O

Following None None O
immunization None None O
mice None None O
were None None O
challenged None None O
orally None None O
with None None O
murine None None O
RV None None O
strain None None O
EDIMwt None None O
( None None O
SG None None O
non-I-non-II None None O
, None None O
G3P10 None None O
[ None None O
16 None None O
] None None O
) None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
L-glutaminase None None O
, None None O
a None None O
marine None None O
bacterial None None O
enzyme None None O
with None None O
a None None O
molecular None None O
weight None None O
of None None O
37 None None O
kDa None None O
, None None O
inhibits None None O
cancer None None O
cell None None O
proliferation None None O
in None None O
vitro None None O
through None None O
glutamine None None I-TRANS
deprivation None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
Beclin-1 None None O
, None None O
light None None O
chain None None O
( None None O
LC None None O
) None None O
3B None None O
, None None O
and None None O
p62 None None O
expression None None O
in None None O
6-hydroxydopamine None None O
( None None O
6-OHDA None None O
) None None O
-induced None None O
parkinsonian None None O
rats None None O
after None None O
β-asarone None None O
and None None O
levodopa None None O
( None None O
l-dopa None None I-TRANS
) None None O
co-administration None None O
. None None O

The None None O
mesencephalon None None I-REGION
was None None O
also None None O
observed None None O
by None None O
transmission None None O
electron None None O
microscope None None O
. None None O

Beclin-1 None None O
and None None O
LC3B None None O
expression None None O
in None None O
the None None O
β-asarone None None O
and None None O
co-administered None None O
groups None None O
were None None O
less None None O
than None None O
in None None O
the None None O
madopar None None O
or None None O
l-dopa None None I-TRANS
groups None None O
, None None O
whereas None None O
p62 None None O
expression None None O
in None None O
the None None O
β-asarone None None O
and None None O
co-administered None None O
groups None None O
was None None O
higher None None O
than None None O
in None None O
the None None O
madopar None None O
or None None O
l-dopa None None I-TRANS
groups None None O
. None None O

The None None O
sweet None None O
, None None O
salty None None O
, None None O
and None None O
umami None None O
taste None None O
modalities None None O
convey None None O
the None None O
carbohydrate None None O
, None None O
electrolyte None None O
, None None O
and None None O
glutamate None None I-TRANS
content None None O
of None None O
food None None O
, None None O
indicating None None O
its None None O
desirability None None O
and None None O
stimulating None None O
appetitive None None O
responses None None O
. None None O

In None None O
recent None None O
years None None O
, None None O
the None None O
receptors None None I-PROTEIN
mediating None None O
sweet None None O
, None None O
bitter None None O
, None None O
and None None O
umami None None O
tastes None None O
have None None O
been None None O
identified None None O
as None None O
members None None O
of None None O
the None None O
T1R None None O
and None None O
T2R None None O
G-protein-coupled None None I-PROTEIN
receptor None None I-PROTEIN
families None None O
; None None O
however None None O
, None None O
the None None O
molecular None None O
mechanisms None None O
underlying None None O
sour None None O
taste None None O
detection None None O
have None None O
yet None None O
to None None O
be None None O
clearly None None O
elucidated None None O
. None None O

We None None O
conducted None None O
a None None O
phase None None O
I None None O
study None None O
to None None O
evaluate None None O
the None None O
safety None None O
and None None O
immunogenicity None None O
of None None O
subcutaneous None None O
vaccinations None None O
with None None O
synthetic None None O
peptides None None I-TRANS
for None None O
glioma-associated None None O
antigen None None O
( None None O
GAA None None O
) None None O
epitopes None None O
in None None O
HLA-A2 None None O
( None None O
+ None None O
) None None O
adults None None O
with None None O
high-risk None None O
LGGs None None O
in None None O
the None None O
following None None O
three None None O
cohorts None None O
: None None O
( None None O
i None None O
) None None O
patients None None O
without None None O
prior None None O
progression None None O
, None None O
chemotherapy None None O
, None None O
or None None O
radiotherapy None None O
( None None O
RT None None O
) None None O
; None None O
( None None O
ii None None O
) None None O
patients None None O
without None None O
prior None None O
progression None None O
or None None O
chemotherapy None None O
but None None O
with None None O
prior None None O
RT None None O
; None None O
and None None O
( None None O
iii None None O
) None None O
recurrent None None O
patients None None O
. None None O

Synthetic None None O
peptides None None I-TRANS
were None None O
emulsified None None O
in None None O
Montanide-ISA-51 None None O
and None None O
given None None O
every None None O
3 None None O
weeks None None O
for None None O
eight None None O
courses None None O
with None None O
intramuscular None None O
injections None None O
of None None O
poly-ICLC None None O
, None None O
followed None None O
by None None O
q12 None None O
week None None O
booster None None O
vaccines None None O
. None None O

No None None O
regimen-limiting None None O
toxicity None None O
was None None O
encountered None None O
except None None O
for None None O
one None None O
case None None O
with None None O
grade None None O
3 None None O
fever None None O
, None None O
fatigue None None O
, None None O
and None None O
mood None None I-FUNC
disturbance None None O
( None None O
cohort None None O
1 None None O
) None None O
. None None O

Standard None None O
HD None None O
IL2 None None O
was None None O
administered None None O
to None None O
prospectively None None O
evaluate None None O
whether None None O
the None None O
ORR None None O
of None None O
patients None None O
with None None O
mRCC None None O
with None None O
`` None None O
good None None O
'' None None O
predictive None None O
pathologic None None O
features None None O
based None None O
on None None O
an None None O
`` None None O
integrated None None O
selection None None O
'' None None O
model None None O
[ None None O
ISM None None O
( None None O
e.g. None None O
, None None O
clear-cell None None O
histology None None O
subclassification None None O
and None None O
carbonic None None I-PROTEIN
anhydrase-9 None None O
( None None O
CA-9 None None O
) None None O
IHC None None O
staining None None O
] None None O
was None None O
significantly None None O
higher None None O
than None None O
the None None O
ORR None None O
of None None O
a None None O
historical None None O
, None None O
unselected None None O
population None None O
. None None O

Safety None None O
was None None O
assessed None None O
using None None O
Common None None O
Terminology None None O
Criteria None None O
for None None O
Adverse None None O
Events None None O
version None None O
3.0 None None O
, None None O
echocardiography/Doppler None None O
imaging None None O
, None None O
serum None None O
troponin None None O
I None None O
, None None O
and None None O
brain None None O
natriuretic None None O
peptide None None O
( None None O
BNP None None I-TRANS
) None None O
levels None None O
. None None O

We None None O
hypothesized None None O
that None None O
a None None O
clinical None None O
strategy None None O
involving None None O
the None None O
iterative None None O
adoptive None None O
transfer None None O
of None None O
selected None None O
autologous None None O
antigen-specific None None O
T-cell None None O
clones None None O
could None None O
help None None O
systematically None None O
define None None O
immunologic None None O
targets None None O
associated None None O
with None None O
successful None None O
cancer None None O
therapy None None O
, None None O
without None None O
the None None O
interpretative None None O
ambiguity None None I-FUNC
of None None O
transferring None None O
polyclonal None None O
populations None None O
. None None O

The None None O
sense None None O
of None None O
body-ownership None None O
involves None None O
the None None O
integration None None O
of None None O
vision None None I-FUNC
and None None O
somatosensation None None I-FUNC
. None None O

This None None O
associative None None O
learning None None I-FUNC
has None None O
a None None O
cellular None None O
correlate None None O
, None None O
as None None O
there None None O
are None None O
more None None O
cFos+ None None O
neurons None None O
in None None O
the None None O
hippocampal None None O
dentate None None I-REGION
gyrus None None I-REGION
( None None O
DG None None O
) None None O
after None None O
psychostimulant None None O
conditioned None None O
place None None O
preference None None O
( None None O
CPP None None O
) None None O
versus None None O
saline None None O
controls None None O
. None None O

The None None O
introduction None None O
of None None O
small-molecule None None O
tyrosine None None I-TRANS
kinase None None O
VEGFR2 None None O
( None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
) None None O
inhibitors None None O
has None None O
added None None O
another None None O
dimension None None O
in None None O
the None None O
treatment None None O
of None None O
several None None O
oncology None None O
indications None None O
as None None O
they None None O
offer None None O
a None None O
unique None None O
mechanism None None O
. None None O

The None None O
human None None O
RECQ None None O
DNA None None O
helicase None None I-PROTEIN
family None None O
is None None O
involved None None O
in None None O
genomic None None O
stability None None O
. None None O

These None None O
results None None O
provide None None O
important None None O
information None None O
on None None O
the None None O
assembly None None O
of None None O
the None None O
Vif-CUL5-E3 None None O
ubiquitin None None O
ligase None None I-PROTEIN
. None None O

To None None O
better None None O
understand None None O
West None None O
Nile None None O
encephalitis None None I-DISEASE
epidemiology None None O
and None None O
improve None None O
risk None None O
assessment None None O
, None None O
local None None O
distinction None None O
between None None O
these None None O
forms None None O
is None None O
essential None None O
. None None O

Physical None None O
exercise None None O
may None None O
attenuate None None O
the None None O
effects None None O
of None None O
cancer None None O
cachexia None None O
via None None O
several None None O
mechanisms None None O
, None None O
including None None O
the None None O
modulation None None O
of None None O
muscle None None O
metabolism None None O
, None None O
insulin None None I-PROTEIN
sensitivity None None O
and None None O
levels None None O
of None None O
inflammation None None O
. None None O

We None None O
imposed None None O
no None None O
language None None I-FUNC
restriction None None O
. None None O

Liver None None O
enzyme None None O
abnormality None None O
was None None O
defined None None O
as None None O
a None None O
10-fold None None O
or None None O
greater None None O
increase None None O
in None None O
aspartate None None I-TRANS
aminotransferase None None O
and None None O
alanine None None I-TRANS
aminotransferase None None O
. None None O

Elevated None None O
liver None None O
enzymes None None I-PROTEIN
are None None O
a None None O
major None None O
concern None None O
and None None O
should None None O
be None None O
well None None O
investigated None None O
in None None O
SLE None None O
patients None None O
. None None O

Grain None None O
aphid None None O
( None None O
Sitobion None None O
avenae None None O
F None None O
) None None O
and None None O
pea None None I-TRANS
aphid None None O
( None None O
Acyrthosiphon None None O
pisum None None O
) None None O
are None None O
two None None O
agriculturally None None O
important None None O
pest None None O
species None None O
, None None O
which None None O
cause None None O
significant None None O
yield None None O
losses None None O
to None None O
crop None None O
plants None None O
each None None O
year None None O
by None None O
inflicting None None O
damage None None O
both None None O
through None None O
the None None O
direct None None O
effects None None O
of None None O
feeding None None O
and None None O
by None None O
vectoring None None O
debilitating None None O
plant None None O
viruses None None O
. None None O

While None None O
the None None O
host None None O
ranges None None O
of None None O
grain None None O
aphid None None O
is None None O
restricted None None O
to None None O
cereal None None O
crops None None O
and None None O
in None None O
particular None None O
wheat None None O
, None None O
that None None O
of None None O
pea None None I-TRANS
aphid None None O
is None None O
wider None None O
, None None O
mainly None None O
colonizing None None O
leguminous None None O
plant None None O
species None None O
. None None O

Based None None O
on None None O
a None None O
set None None O
of None None O
transcriptome None None O
data None None O
of None None O
grain None None O
aphid None None O
generated None None O
by None None O
using None None O
Roche None None O
454 None None O
GS-FLX None None O
pyrosequencing None None O
, None None O
comparative None None O
analysis None None O
between None None O
this None None O
set None None O
of None None O
transcriptome None None O
data None None O
of None None O
grain None None O
aphid None None O
and None None O
mRNA None None O
sequences None None O
of None None O
pea None None I-TRANS
aphid None None O
available None None O
in None None O
the None None O
public None None O
databases None None O
was None None O
performed None None O
. None None O

Moreover None None O
, None None O
the None None O
demonstration None None O
of None None O
divergent None None O
transcriptome None None O
sequences None None O
between None None O
grain None None O
aphid None None O
and None None O
pea None None I-TRANS
aphid None None O
pave None None O
the None None O
way None None O
for None None O
the None None O
investigation None None O
of None None O
the None None O
molecular None None O
mechanisms None None O
underpinning None None O
the None None O
biological None None O
variations None None O
of None None O
these None None O
two None None O
agriculturally None None O
important None None O
aphid None None O
species None None O
. None None O

Western None None O
blot None None O
data None None O
proved None None O
that None None O
the None None O
expression None None O
of None None O
E-cadherin None None O
and None None O
keratin None None I-PROTEIN
was None None O
elevated None None O
, None None O
whereas None None O
the None None O
expression None None O
of None None O
N-cadherin None None O
and None None O
Vimentin None None O
was None None O
decreased None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
compared None None O
with None None O
the None None O
untreated None None O
cells None None O
, None None O
the None None O
expression None None O
of None None O
p-AKT None None O
, None None O
p-ERK None None O
and None None O
ZEB1 None None O
was None None O
also None None O
obviously None None O
elevated None None O
. None None O

© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Cellular None None O
events None None O
are None None O
regulated None None O
by None None O
the None None O
interaction None None O
between None None O
integrin None None I-PROTEIN
receptors None None I-PROTEIN
in None None O
the None None O
cell None None O
membrane None None O
and None None O
the None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
. None None O

A None None O
depression None None I-DISEASE
in None None O
the None None O
populations None None O
of None None O
Neisseria None None O
weaveri None None O
, None None O
Ruminobacter None None O
amylophilus None None O
and None None O
other None None O
unclassified None None O
bacteria None None O
related None None O
to None None O
members None None O
of None None O
the None None O
Lachnospiraceae None None O
and None None O
Pasteurellaceae None None O
families None None O
was None None O
detected None None O
, None None O
suggesting None None O
that None None O
these None None O
microbial None None O
groups None None O
may None None O
be None None O
involved None None O
in None None O
rumen None None O
biohydrogenation None None O
. None None O

Consistent None None O
with None None O
associations None None O
found None None O
among None None O
general None None O
population None None O
samples None None O
, None None O
among None None O
our None None O
sample None None O
of None None O
1934 None None O
participants None None O
, None None O
we None None O
found None None O
that None None O
indicators None None O
of None None O
psychosocial None None O
adversity None None O
were None None O
associated None None O
with None None O
CMD None None O
( None None O
common None None O
mental None None O
disorder None None O
- None None O
major None None O
depression None None I-DISEASE
, None None O
generalised None None O
anxiety None None O
and None None O
panic None None I-DISEASE
disorder None None I-DISEASE
) None None O
among None None O
people None None O
coming None None O
for None None O
testing None None O
for None None O
HIV None None O
. None None O

Understanding None None O
associations None None O
between None None O
these None None O
background None None O
characteristics None None O
and None None O
psychological None None O
morbidity None None O
may None None O
help None None O
inform None None O
the None None O
design None None O
of None None O
appropriate None None O
early None None O
interventions None None O
for None None O
depression None None I-DISEASE
among None None O
people None None O
newly None None O
diagnosed None None O
HIV/AIDS None None O
. None None O

Luciferase None None I-PROTEIN
reporter None None O
assays None None O
in None None O
cultured None None O
S2 None None O
cells None None O
revealed None None O
that None None O
one None None O
of None None O
two None None O
DREs None None O
identified None None O
in None None O
the None None O
hpo None None O
gene None None O
promoter None None O
region None None O
was None None O
responsible None None O
for None None O
promoter None None O
activity None None O
in None None O
S2 None None O
cells None None O
. None None O

We None None O
aim None None O
to None None O
demonstrate None None O
the None None O
role None None O
of None None O
Alk None None O
receptors None None I-PROTEIN
in None None O
the None None O
response None None O
of None None O
hydrogel None None O
expansion None None O
. None None O

Our None None O
findings None None O
indicate None None O
that None None O
these None None O
two None None O
receptors None None I-PROTEIN
are None None O
important None None O
mediators None None O
in None None O
the None None O
response None None O
of None None O
chondrocytes None None O
to None None O
changes None None O
in None None O
the None None O
mechanical None None O
environment None None O
, None None O
making None None O
them None None O
suitable None None O
targets None None O
for None None O
modulating None None O
chondrogenesis None None O
. None None O

However None None O
, None None O
those None None O
efforts None None O
focused None None O
mainly None None O
on None None O
HCV None None O
genotypes None None O
1 None None O
and None None O
2 None None O
as None None O
vaccine None None O
targets None None O
and None None O
barely None None O
enough None None O
attention None None I-FUNC
was None None O
given None None O
to None None O
genotype None None O
4 None None O
, None None O
the None None O
variant None None O
most None None O
prevalent None None O
in None None O
the None None O
Middle None None O
East None None O
and None None O
central None None O
Africa None None O
. None None O

Earlier None None O
studies None None O
have None None O
shown None None O
that None None O
osthole None None O
, None None O
a None None O
main None None O
active None None O
constituent None None O
isolated None None O
from None None O
Cnidium None None O
monnieri None None O
( None None O
L. None None O
) None None O
Cusson None None O
, None None O
could None None O
be None None O
considered None None O
as None None O
an None None O
attractive None None O
therapeutic None None O
agent None None O
in None None O
the None None O
treatment None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Behavioral None None O
test None None O
was None None O
performed None None O
at None None O
4 None None O
days None None O
after None None O
ischemia None None O
, None None O
followed None None O
by None None O
assessment None None O
of None None O
neuronal None None O
loss None None O
in None None O
hippocampal None None O
CA1 None None I-REGION
region None None O
. None None O

Further None None O
studies None None O
showed None None O
that None None O
osthole None None O
attenuated None None O
the None None O
permeation None None O
of None None O
BBB None None O
, None None O
which None None O
may None None O
contribute None None O
to None None O
antioxidative None None O
effect None None O
by None None O
increasing None None O
the None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
activity None None O
and None None O
decreasing None None O
the None None O
malondialdehyde None None O
level None None O
in None None O
model None None O
mice None None O
. None None O

Patients None None O
with None None O
a None None O
baseline None None O
HbA1c None None O
of None None O
& None None O
lt None None O
; None None O
8.0 None None O
% None None O
receiving None None O
alogliptin None None O
were None None O
also None None O
more None None O
likely None None O
to None None O
achieve None None O
HbA1c None None O
≤7.0 None None O
% None None O
without None None O
hypoglycemia None None I-DISEASE
or None None O
weight None None O
gain None None O
than None None O
those None None O
receiving None None O
glipizide None None O
( None None O
29 None None O
% None None O
vs None None O
13 None None O
% None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.03 None None O
) None None O
. None None O

Robust None None O
evidence None None O
exists None None O
that None None O
positive None None O
psychology None None O
interventions None None O
are None None O
effective None None O
in None None O
enhancing None None O
well-being None None O
and None None O
ameliorating None None O
depression None None I-DISEASE
. None None O

A None None O
sample None None O
of None None O
165 None None O
women None None O
completed None None O
measures None None O
for None None O
happiness None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
before None None O
and None None O
about None None O
3.5 None None O
years None None O
after None None O
completion None None O
of None None O
a None None O
positive None None O
intervention None None O
( None None O
random None None O
assignment None None O
to None None O
one None None O
out None None O
of None None O
nine None None O
interventions None None O
, None None O
which None None O
were None None O
aggregated None None O
for None None O
the None None O
analyses None None O
) None None O
. None None O

Three None None O
out None None O
of None None O
four None None O
person None None O
× None None O
intervention None None O
fit None None O
indicators None None O
were None None O
positively None None O
related None None O
to None None O
happiness None None O
or None None O
negatively None None O
related None None O
to None None O
depression None None I-DISEASE
when None None O
controlled None None O
for None None O
the None None O
pretest None None O
scores None None O
. None None O

Most None None O
tested None None O
indicators None None O
of None None O
a None None O
person None None O
× None None O
intervention None None O
fit None None O
are None None O
robust None None O
predictors None None O
of None None O
happiness None None O
and None None O
depressive None None I-DISEASE
symptoms-even None None O
after None None O
3.5 None None O
years None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
used None None O
FTIR None None O
analysis None None O
of None None O
a None None O
series None None O
of None None O
biochemically None None O
characterized None None O
collagen None None I-PROTEIN
peptides None None I-TRANS
, None None O
as None None O
well None None O
as None None O
skin None None O
, None None O
dentin None None O
, None None O
and None None O
predentin None None O
, None None O
to None None O
examine None None O
the None None O
potential None None O
reasons None None O
underlying None None O
discrepancies None None O
between None None O
two None None O
different None None O
analytical None None O
methodologies None None O
specifically None None O
related None None O
to None None O
spectral None None O
processing None None O
. None None O

The None None O
extent None None O
to None None O
which None None O
crowding None None O
impairs None None O
our None None O
perception None None I-FUNC
is None None O
generally None None O
governed None None O
by None None O
the None None O
degree None None O
of None None O
similarity None None O
between None None O
a None None O
target None None O
stimulus None None O
and None None O
its None None O
surrounding None None O
flankers None None O
. None None O

This None None O
gene None None O
is None None O
frequently None None O
involved None None O
in None None O
1q44 None None O
deletion None None O
syndrome None None O
in None None O
patients None None O
with None None O
microcephaly None None O
, None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
and None None O
dysmorphic None None O
features None None O
. None None O

This None None O
is None None O
also None None O
the None None O
first None None O
report None None O
to None None O
suggest None None O
that None None O
( None None O
1 None None O
) None None O
AKT3 None None O
deletion None None O
is None None O
associated None None O
with None None O
microcephaly None None O
and None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
with None None O
incomplete None None O
penetrance None None O
; None None O
( None None O
2 None None O
) None None O
a None None O
pure None None O
AKT3 None None O
deletion None None O
is None None O
likely None None O
to None None O
be None None O
inherited None None O
in None None O
contrast None None O
to None None O
the None None O
larger None None O
1q44 None None O
deletions None None O
, None None O
which None None O
are None None O
mostly None None O
de None None O
novo None None O
and None None O
( None None O
3 None None O
) None None O
there None None O
seems None None O
to None None O
be None None O
no None None O
consistent None None O
or None None O
characteristic None None O
dysmorphism None None O
associated None None O
with None None O
pure None None O
AKT3 None None O
deletion None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
NOG None None O
mice None None O
expressing None None O
a None None O
thymidine None None O
kinase None None O
transgene None None O
( None None O
TK-NOG None None O
) None None O
with None None O
humanized None None O
livers None None O
have None None O
a None None O
humanized None None O
profile None None O
of None None O
biliary None None O
excretion None None O
of None None O
a None None O
test None None O
( None None O
cefmetazole None None O
) None None O
drug None None O
, None None O
which None None O
was None None O
shown None None O
by None None O
an None None O
in None None O
situ None None O
perfusion None None O
study None None O
to None None O
result None None O
from None None O
interspecies None None O
differences None None O
in None None O
the None None O
rate None None O
of None None O
biliary None None O
transport None None O
and None None O
in None None O
liver None None O
retention None None I-FUNC
of None None O
this None None O
drug None None O
. None None O

Moreover None None O
, None None O
this None None O
was None None O
associated None None O
with None None O
significant None None O
increases None None O
in None None O
the None None O
expression None None O
of None None O
the None None O
mRNAs None None O
encoding None None I-FUNC
the None None O
thermogenic None None O
genes None None O
( None None O
i.e. None None O
, None None O
markers None None O
of None None O
brown None None O
and None None O
beige None None O
adipose None None O
) None None O
Pparα None None O
, None None O
Errα None None O
, None None O
Dio2 None None O
, None None O
Acot11/Bfit None None O
, None None O
Cpt1β None None O
, None None O
and None None O
Cidea None None O
in None None O
the None None O
subcutaneous None None O
adipose None None O
in None None O
the None None O
sg/sg None None O
relative None None O
to None None O
WT None None O
mice None None O
. None None O

Cell None None O
cycle None None O
analysis None None O
, None None O
colony None None O
forming None None O
ability None None O
( None None O
CFU-F None None O
) None None O
, None None O
differentiation None None O
ability None None O
, None None O
and None None O
expression None None O
of None None O
osteogenic-specific None None O
runt-related None None O
transcription None None O
factor None None O
2 None None O
( None None O
RUNX2 None None O
) None None O
, None None O
adipogenic None None O
peroxisome None None O
proliferator-activated None None O
receptor None None I-PROTEIN
gamma None None O
( None None O
PPARγ None None O
) None None O
, None None O
oxidative None None O
stress-specific None None O
dismutase-1 None None O
( None None O
SOD1 None None O
) None None O
and None None O
Glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPX1 None None O
) None None O
were None None O
analyzed None None O
. None None O

Here None None O
, None None O
we None None O
propose None None O
a None None O
novel None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
-mediated None None O
metabolic None None O
coupling None None O
between None None O
O-ASCs None None O
and None None O
gynecologic None None O
cancer None None O
cells None None O
in None None O
which None None O
O-ASCs None None O
support None None O
NO None None O
homeostasis None None O
in None None O
malignant None None O
cells None None O
. None None O

Through None None O
arginine None None I-TRANS
depletion None None O
in None None O
the None None O
media None None O
using None None O
l-arginase None None O
and None None O
NOS None None I-TRANS
inhibition None None O
in None None O
cancer None None O
cells None None O
using None None O
N None None O
( None None O
G None None O
) None None O
-nitro-l-arginine None None O
methyl None None O
ester None None O
( None None O
l-NAME None None O
) None None O
, None None O
we None None O
demonstrate None None O
that None None O
patient-derived None None O
O-ASCs None None O
increase None None O
NO None None O
levels None None O
in None None O
ovarian None None O
and None None O
endometrial None None O
cancer None None O
cells None None O
and None None O
promote None None O
proliferation None None O
in None None O
these None None O
cells None None O
. None None O

A None None O
combined None None O
approach None None O
of None None O
targeting None None O
secreted None None O
arginine None None I-TRANS
through None None O
l-arginase None None O
, None None O
along None None O
with None None O
targeting None None O
microenvironment-secreted None None O
factors None None O
using None None O
l-NAME None None O
, None None O
may None None O
be None None O
a None None O
viable None None O
therapeutic None None O
approach None None O
for None None O
targeting None None O
ovarian None None O
and None None O
endometrial None None O
cancers None None O
. None None O

The None None O
questionnaire None None O
collected None None O
data None None O
on None None O
the None None O
general None None O
organization None None O
of None None O
the None None O
pharmacy None None O
, None None O
management None None O
of None None O
outpatients None None O
with None None O
cancer None None O
and None None O
thrombosis None None I-DISEASE
, None None O
and None None O
the None None O
level None None O
of None None O
knowledge None None O
regarding None None O
recommendations None None O
on None None O
the None None O
management None None O
of None None O
thrombosis None None I-DISEASE
in None None O
patients None None O
with None None O
cancer None None O
. None None O

[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
LY341495 None None O
binding None None O
density None None O
was None None O
statistically None None O
significantly None None O
increased None None O
( None None O
P None None O
= None None O
0.046 None None O
) None None O
in None None O
the None None O
perigenual None None O
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
( None None O
pACC None None O
) None None O
of None None O
type None None O
2 None None O
alcoholics None None O
when None None O
compared None None O
with None None O
controls None None O
. None None O

Further None None O
studies None None O
evaluating None None O
the None None O
effectiveness None None O
of None None O
different None None O
strategies None None O
for None None O
expanding None None O
health None None O
insurance None None O
coverage None None O
in None None O
vulnerable None None O
population None None O
are None None O
needed None None O
in None None O
different None None O
settings None None O
, None None O
with None None O
careful None None O
attention None None I-FUNC
given None None O
to None None O
study None None O
design None None O
. None None O

We None None O
only None None O
included None None O
studies None None O
on None None O
taste None None O
disorders None None O
in None None O
this None None O
review None None O
that None None O
were None None O
either None None O
idiopathic None None O
, None None O
or None None O
resulting None None O
from None None O
zinc None None I-TRANS
deficiency None None O
or None None O
chronic None None O
renal None None O
failure.Of None None O
these None None O
, None None O
eight None None O
trials None None O
with None None O
529 None None O
people None None O
compared None None O
zinc None None I-TRANS
supplements None None O
to None None O
placebo None None O
for None None O
patients None None O
with None None O
taste None None O
disorders None None O
. None None O

Out None None O
of None None O
these None None O
eight None None O
, None None O
two None None O
trials None None O
assessed None None O
the None None O
patient None None O
reported None None O
outcome None None O
for None None O
improvement None None O
in None None O
taste None None O
acuity None None O
using None None O
zinc None None I-TRANS
supplements None None O
( None None O
RR None None O
1.45 None None O
, None None O
95 None None O
% None None O
CI None None O
1.0 None None O
to None None O
2.1 None None O
; None None O
very None None O
low None None O
quality None None O
evidence None None O
) None None O
. None None O

Only None None O
one None None O
trial None None O
tested None None O
taste None None O
discrimination None None O
using None None O
acupuncture None None O
( None None O
effect None None O
size None None O
2.80 None None O
, None None O
95 None None O
% None None O
CI None None O
-1.18 None None O
to None None O
6.78 None None O
; None None O
low None None O
quality None None O
evidence None None O
) None None O
.Out None None O
of None None O
the None None O
eight None None O
trials None None O
using None None O
zinc None None I-TRANS
supplementation None None O
, None None O
four None None O
reported None None O
adverse None None O
events None None O
like None None O
eczema None None O
, None None O
nausea None None O
, None None O
abdominal None None O
pain None None O
, None None O
diarrhoea None None O
, None None O
constipation None None O
, None None O
decrease None None O
in None None O
blood None None O
iron None None O
, None None O
increase None None O
in None None O
blood None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
, None None O
and None None O
minor None None O
increase None None O
in None None O
blood None None O
triglycerides None None O
. None None O

We None None O
found None None O
very None None O
low None None O
quality None None O
evidence None None O
that None None O
was None None O
insufficient None None O
to None None O
conclude None None O
on None None O
the None None O
role None None O
of None None O
zinc None None I-TRANS
supplements None None O
to None None O
improve None None O
taste None None O
perception None None I-FUNC
by None None O
patients None None O
, None None O
however None None O
we None None O
found None None O
moderate None None O
quality None None O
evidence None None O
that None None O
zinc None None I-TRANS
supplements None None O
improve None None O
overall None None O
taste None None O
improvement None None O
in None None O
patients None None O
with None None O
zinc None None I-TRANS
deficiency/idiopathic None None O
taste None None O
disorders None None O
. None None O

We None None O
did None None O
not None None O
find None None O
any None None O
evidence None None O
to None None O
conclude None None O
the None None O
role None None O
of None None O
zinc None None I-TRANS
supplements None None O
for None None O
improving None None O
taste None None O
discrimination None None O
, None None O
or None None O
any None None O
evidence None None O
addressing None None O
health-related None None O
quality None None O
of None None O
life None None O
due None None O
to None None O
taste None None O
disorders.We None None O
found None None O
low None None O
quality None None O
evidence None None O
that None None O
is None None O
not None None O
sufficient None None O
to None None O
conclude None None O
on None None O
the None None O
role None None O
of None None O
acupuncture None None O
for None None O
improving None None O
taste None None O
discrimination None None O
in None None O
cases None None O
of None None O
idiopathic None None O
dysgeusia None None O
( None None O
distortion None None O
of None None O
taste None None O
) None None O
and None None O
hypogeusia None None O
( None None O
reduced None None O
ability None None O
to None None O
taste None None O
) None None O
. None None O

Leaders None None O
@ None None O
Play None None O
is None None O
a None None O
park None None O
after-school None None O
program None None O
for None None O
urban None None O
middle None None O
school None None O
youth None None O
designed None None O
to None None O
leverage None None O
recreational None None O
activities None None O
for None None O
social None None O
emotional None None O
learning None None I-FUNC
. None None O

Transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
TFs None None O
) None None O
are None None O
also None None O
often None None O
duplicated None None O
. None None O

Nine None None O
hundred None None O
and None None O
fifty None None O
individuals None None O
with None None O
bleeding None None O
episodes None None O
or None None O
abnormal None None O
coagulation None None O
test None None O
results None None O
were None None O
investigated None None O
with None None O
first-level None None O
tests None None O
( None None O
blood None None O
count None None O
, None None O
prothrombin None None O
time None None O
, None None O
activated None None O
partial None None O
thromboplastin None None O
time None None O
, None None O
blood None None O
clotting None None O
factor None None I-PROTEIN
VIII None None I-PROTEIN
, None None O
VWF None None O
ristocetin None None O
cofactor None None O
activity None None O
[ None None O
VWF None None O
: None None O
RCo None None O
] None None O
, None None O
and None None O
VWF None None O
antigen None None O
) None None O
, None None O
and None None O
93 None None O
( None None O
62 None None O
females None None O
and None None O
31 None None O
males None None O
; None None O
median None None O
age None None O
, None None O
28 None None O
years None None O
; None None O
interquartile None None O
range None None O
15-44 None None O
) None None O
had None None O
borderline None None O
VWF None None O
: None None O
RCo None None O
levels None None O
. None None O

Disruption None None O
in None None O
the None None O
neural None None O
network None None O
has None None O
been None None O
observed None None O
in None None O
the None None O
clinical None None O
studies None None O
on None None O
dementia None None I-DISEASE
. None None O

Earlier None None O
analysis None None O
on None None O
P. None None O
falciparum None None O
protein-phosphatome None None O
revealed None None O
presence None None O
of None None O
34 None None O
phosphatases None None I-PROTEIN
in None None O
Plasmodium None None O
genome None None O
. None None O

Plasmodium None None O
database None None O
( None None O
PlasmoDB None None O
9.2 None None O
) None None O
search None None O
, None None O
combined None None O
with None None O
PFAM None None O
and None None O
CDD None None O
searches None None O
, None None O
revealed None None O
67 None None O
candidate None None O
phosphatases None None I-PROTEIN
in None None O
P. None None O
falciparum None None O
. None None O

These None None O
Plasmodium None None O
phosphatase None None I-PROTEIN
proteins None None O
were None None O
classified None None O
into None None O
13 None None O
super None None O
families None None O
based None None O
on None None O
NCBI None None O
CDD None None O
search None None O
. None None O

Fourteen None None O
phosphatases None None I-PROTEIN
are None None O
common None None O
in None None O
schizont None None O
, None None O
ring None None O
and None None O
trophozoite None None O
stages None None O
, None None O
four None None O
phosphatases None None I-PROTEIN
are None None O
restricted None None O
to None None O
gametocytes None None O
, None None O
whereas None None O
another None None O
three None None O
restricted None None O
to None None O
schizont None None O
stage None None O
. None None O

The None None O
GO None None O
assignments None None O
and None None O
predicted None None O
interaction None None O
partners None None O
of None None O
the None None O
parasite None None O
phosphatases None None I-PROTEIN
indicate None None O
its None None O
important None None O
role None None O
in None None O
diverse None None O
cellular None None O
processes None None O
. None None O

Intriguingly None None O
, None None O
amongst None None O
these None None O
phosphatases None None I-PROTEIN
, None None O
we None None O
could None None O
identify None None O
six None None O
Plasmodium None None O
specific None None O
phosphatases None None I-PROTEIN
and None None O
33 None None O
putative None None O
phosphatases None None I-PROTEIN
that None None O
do None None O
not None None O
have None None O
human None None O
orthologs None None O
, None None O
thereby None None O
suggesting None None O
that None None O
these None None O
phosphatases None None I-PROTEIN
have None None O
the None None O
potential None None O
to None None O
be None None O
explored None None O
as None None O
novel None None O
antimalarial None None O
drug None None O
targets None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
effect None None O
of None None O
zoledronic None None O
acid None None O
on None None O
the None None O
early None None O
radiation-induced None None O
degradation None None O
of None None O
bone None None O
collagen None None I-PROTEIN
fibrils None None O
by None None O
monitoring None None O
the None None O
urinary None None O
excretion None None O
of None None O
hydroxylysylpyridinoline None None O
and None None O
lysylpyridinoline None None O
under None None O
radiotherapy None None O
. None None O

The None None O
results None None O
indicate None None O
the None None O
ability None None O
of None None O
zoledronate None None O
to None None O
prevent None None O
the None None O
early None None O
radiation-induced None None O
bone None None O
collagen None None I-PROTEIN
degradation None None O
suggesting None None O
that None None O
the None None O
radiation-induced None None O
bone None None O
loss None None O
is None None O
mainly None None O
caused None None O
by None None O
osteoclastic None None O
bone None None O
resorption None None O
rather None None O
than None None O
by None None O
a None None O
direct None None O
radiation-induced None None O
damage None None O
. None None O

The None None O
study None None O
included None None O
695 None None O
male None None O
adolescents None None O
from None None O
11 None None O
to None None O
16 None None O
years None None O
of None None O
age None None O
who None None O
filled None None O
out None None O
self-report None None O
questionnaires None None O
based None None O
on None None O
the None None O
European None None O
Smoking None None O
Framework None None O
Approach None None O
questionnaire None None O
, None None O
which None None O
uses None None O
the None None O
I-Change None None O
model None None O
to None None O
assess None None O
attitude None None O
, None None O
social None None O
influence None None O
and None None O
the None None O
self-efficacy None None O
of None None O
the None None O
participants None None O
. None None O

Connectivity None None O
between None None O
the None None O
amygdala None None I-REGION
and None None O
cortical None None O
regions None None O
is None None O
thought None None O
to None None O
be None None O
important None None O
for None None O
emotion None None I-FUNC
regulation None None O
, None None O
a None None O
function None None O
that None None O
is None None O
compromised None None O
in None None O
SAD None None O
. None None O

Here None None O
we None None O
investigate None None O
changes None None O
in None None O
cortical-amygdala None None O
coupling None None O
in None None O
SAD None None O
during None None O
the None None O
anticipation None None O
of None None O
giving None None O
a None None O
public None None O
speech None None I-FUNC
. None None O

During None None O
the None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
session None None O
, None None O
participants None None O
underwent None None O
three None None O
'resting-state None None O
' None None O
fMRI None None O
scans None None O
: None None O
one None None O
before None None O
, None None O
one None None O
during None None O
, None None O
and None None O
one None None O
after None None O
the None None O
anticipation None None O
of None None O
giving None None O
a None None O
public None None O
speech None None I-FUNC
. None None O

Compared None None O
to None None O
controls None None O
, None None O
SAD None None O
participants None None O
showed None None O
reduced None None O
functional None None O
integration None None O
between None None O
cortical None None O
emotion None None I-FUNC
regulation None None O
regions None None O
and None None O
the None None O
amygdala None None I-REGION
during None None O
the None None O
public None None O
speech None None I-FUNC
anticipation None None O
. None None O

Repeat-derived None None O
and None None O
gene-derived None None O
piRNAs None None O
, None None O
which None None O
possibly None None O
participate None None O
in None None O
the None None O
regulation None None O
of None None O
the None None O
corresponding None None O
elements None None O
, None None O
have None None O
been None None O
given None None O
particular None None O
attention None None I-FUNC
. None None O

The None None O
connectivity None None O
information None None O
of None None O
the None None O
modified None None O
amino None None I-TRANS
acids None None I-TRANS
is None None O
necessary None None O
for None None O
correct None None O
representation None None O
of None None O
these None None O
biologically None None O
interesting None None O
molecules None None O
. None None O

In None None O
the None None O
post-submission None None O
experiment None None O
, None None O
we None None O
obtained None None O
22.1 None None O
% None None O
and None None O
35.7 None None O
% None None O
F1 None None O
performance None None O
by None None O
incorporating None None O
bigram None None O
features None None O
in None None O
RDE None None O
learning None None I-FUNC
. None None O

The None None O
Bonebridge None None O
significantly None None O
improved None None O
speech None None I-FUNC
recognition None None I-FUNC
in None None O
noisy None None O
environments None None O
and None None O
sound None None I-FUNC
localization None None I-FUNC
. None None O

Compounds None None O
inhibiting None None O
septum None None I-REGION
formation None None O
boosted None None O
the None None O
antifungal None None O
activity None None O
of None None O
caspofungin None None O
. None None O

Oxidative None None O
stress None None O
is None None O
also None None O
important None None O
in None None O
migraine None None I-DISEASE
pathophysiology None None O
. None None O

The None None O
current None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
glyceryl None None O
trinitrate None None O
( None None O
GTN None None O
) None None O
-sourced None None O
exogen None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
in None None O
particular None None O
, None None O
and None None O
also None None O
riboflavin None None O
and/or None None O
vitamin None None O
E None None O
on None None O
involved None None O
in None None O
the None None O
headache None None O
model None None O
induced None None O
via None None O
GTN-sourced None None O
exogen None None O
NO None None O
on None None O
oxidative None None O
stress None None O
, None None O
total None None O
brain None None O
calcium None None O
levels None None O
, None None O
and None None O
microsomal None None O
membrane None None O
Ca None None O
( None None O
2+ None None O
) None None O
-ATPase None None O
levels None None O
. None None O

GTN None None O
resulted None None O
in None None O
a None None O
significant None None O
increase None None O
in None None O
brain None None O
cortex None None O
and None None O
microsomal None None O
lipid None None O
peroxidation None None O
levels None None O
although None None O
brain None None O
calcium None None O
, None None O
vitamin None None O
A None None O
, None None O
vitamin None None O
C None None O
, None None O
and None None O
vitamin None None O
E None None O
, None None O
and None None O
brain None None O
microsomal-reduced None None O
glutathione None None O
( None None O
GSH None None O
) None None O
, None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GSH-Px None None O
) None None O
, None None O
and None None O
plasma-membrane None None O
Ca None None O
( None None O
2+ None None O
) None None O
-ATPase None None O
values None None O
decreased None None O
through None None O
GTN None None O
. None None O

The None None O
definitions None None O
have None None O
to None None O
be None None O
adapted None None O
to None None O
different None None O
languages None None I-FUNC
and None None O
cultures None None O
to None None O
provide None None O
comparable None None O
frequency None None O
estimates None None O
. None None O

Our None None O
study None None O
shows None None O
that None None O
protection None None O
afforded None None O
by None None O
artesunate None None O
was None None O
brought None None O
about None None O
by None None O
decreasing None None O
the None None O
levels None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
influx None None O
of None None O
neutrophils None None O
, None None O
maintenance None None O
of None None O
oxidative None None O
homeostasis None None O
, None None O
inhibition None None O
of None None O
COX-2 None None O
expression None None O
, None None O
and None None O
apoptosis None None O
. None None O

Understanding None None O
and None None O
controlling None None O
the None None O
sulfur None None O
reduction None None O
species None None O
( None None O
Li2Sx None None O
, None None O
1 None None O
≤ None None O
x None None O
≤ None None O
8 None None O
) None None O
under None None O
realistic None None O
battery None None O
conditions None None O
are None None O
essential None None O
for None None O
the None None O
development None None O
of None None O
advanced None None O
practical None None O
Li-S None None O
cells None None I-NEURON
that None None O
can None None O
reach None None O
their None None O
full None None O
theoretical None None O
capacity None None O
. None None O

This None None O
may None None O
be None None O
the None None O
reason None None O
for None None O
the None None O
capacity None None O
fade None None O
in None None O
Li-S None None O
cells None None I-NEURON
( None None O
as None None O
also None None O
suggested None None O
by None None O
EIS None None O
experiment None None O
in None None O
Supporting None None O
Information None None O
) None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
efficacy None None O
and None None O
safety None None O
of None None O
lercanidipine None None O
and None None O
amlodipine None None O
in None None O
the None None O
treatment None None O
of None None O
hypertensive None None O
patients None None O
with None None O
acute None None O
cerebral None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Lercanidipine None None O
is None None O
as None None O
effective None None O
as None None O
amlodipine None None O
in None None O
the None None O
reduction None None O
and None None O
stabilization None None O
of None None O
BP None None O
in None None O
hypertensive None None O
patients None None O
after None None O
a None None O
stroke None None I-DISEASE
, None None O
and None None O
presents None None O
some None None O
advantages None None O
in None None O
terms None None O
of None None O
safety None None O
. None None O

Theoretical None None O
models None None O
of None None O
perception None None I-FUNC
assume None None O
that None None O
confidence None None O
is None None O
related None None O
to None None O
the None None O
quality None None O
or None None O
strength None None O
of None None O
sensory None None O
processing None None O
. None None O

© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
Several None None O
epidemiological None None O
studies None None O
have None None O
found None None O
a None None O
lower None None O
incidence None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
in None None O
highly None None O
educated None None O
populations None None O
, None None O
but None None O
the None None O
protective None None O
mechanism None None O
of None None O
education None None O
against None None O
the None None O
disease None None O
is None None O
still None None O
unclear None None O
. None None O

At None None O
the None None O
same None None O
time None None O
, None None O
they None None O
have None None O
a None None O
greater None None O
reserve None None O
capacity None None O
, None None O
and None None O
greater None None O
pathological None None O
changes None None O
are None None O
required None None O
for None None O
dementia None None I-DISEASE
to None None O
manifest None None O
. None None O

Moreover None None O
, None None O
CYP2D6 None None I-PROTEIN
and None None O
2E1 None None O
are None None O
also None None O
more None None O
important None None O
CYP None None O
isoforms None None O
for None None O
the None None O
metabolism None None O
of None None O
BLA None None O
. None None O

Electroconvulsive None None O
therapy None None O
( None None O
ECT None None O
) None None O
is None None O
an None None O
effective None None O
and None None O
safe None None O
treatment None None O
method None None O
for None None O
a None None O
variety None None O
of None None O
psychiatric None None O
disorders None None O
, None None O
including None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
ECT None None O
performed None None O
on None None O
a None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
patient None None O
with None None O
an None None O
open None None O
wound None None O
after None None O
craniectomy None None O
. None None O

Ischemic None None O
stroke None None I-DISEASE
not None None O
only None None O
impairs None None O
neuronal None None O
function None None O
but None None O
also None None O
affects None None O
the None None O
cerebral None None O
vasculature None None O
as None None O
indicated None None O
by None None O
loss None None O
of None None O
blood-brain None None O
barrier None None O
( None None O
BBB None None O
) None None O
integrity None None O
. None None O

To None None O
investigate None None O
the None None O
mechanisms None None O
underlying None None O
ischemia-/reperfusion-related None None O
BBB None None O
opening None None O
, None None O
we None None O
applied None None O
multiple None None O
immunofluorescence None None O
labeling None None O
and None None O
electron None None O
microscopy None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
thromboembolic None None O
stroke None None I-DISEASE
as None None O
well None None O
as None None O
mouse None None O
models None None O
of None None O
permanent None None O
and None None O
transient None None O
focal None None O
cerebral None None O
ischemia None None O
. None None O

Treatment None None O
with None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
( None None O
tPA None None O
) None None O
beyond None None O
the None None O
therapeutic None None O
time None None O
window None None O
( None None O
& None None O
gt None None O
; None None O
4.5 None None O
hours None None O
post None None O
stroke None None I-DISEASE
) None None O
may None None O
produce None None O
hemorrhagic None None O
transformation None None O
( None None O
HT None None O
) None None O
. None None O

Male None None O
Sprague-Dawley None None O
rats None None O
underwent None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
( None None O
MCAo None None O
) None None O
and None None O
given None None O
vehicle None None O
, None None O
tPA None None O
( None None O
10 None None O
mg/kg None None O
) None None O
, None None O
or None None O
tPA None None O
and None None O
granulocyte None None O
colony-stimulating None None O
factor None None O
( None None O
G-CSF None None O
, None None O
300 None None O
μg/kg None None O
) None None O
, None None O
at None None O
6 None None O
hours None None O
after None None O
MCAo None None O
. None None O

Immunohistochemistry None None O
also None None O
showed None None O
2- None None O
and None None O
2.8-fold None None O
increase None None O
in None None O
von-Willebrand None None O
expression None None O
, None None O
3.2- None None O
and None None O
2.2-fold None None O
increased None None O
CD34+ None None O
expression None None O
, None None O
and None None O
4- None None O
and None None O
13-fold None None O
upregulation None None O
of None None O
VEGFR-2 None None O
expression None None O
in None None O
the None None O
ischemic None None O
cortex None None O
and None None O
striatum None None I-REGION
, None None O
respectively None None O
, None None O
in None None O
G-CSF+tPA-treated None None O
stroke None None I-DISEASE
rats None None O
relative None None O
to None None O
tPA-treated None None O
subjects None None O
. None None O

The None None O
use None None O
of None None O
G-CSF None None O
to None None O
protect None None O
the None None O
vasculature None None O
may None None O
improve None None O
the None None O
clinical None None O
outcome None None O
of None None O
tPA None None O
even None None O
outside None None O
the None None O
currently None None O
indicated None None O
therapeutic None None O
window None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

In None None O
addition None None O
to None None O
being None None O
exchanged None None O
as None None O
a None None O
fuel None None O
by None None O
the None None O
monocarboxylate None None O
transporters None None I-PROTEIN
( None None O
MCTs None None O
) None None O
between None None O
cells None None O
and None None O
tissues None None O
with None None O
different None None O
glycolytic None None O
and None None O
oxidative None None O
rates None None O
, None None O
lactate None None O
may None None O
be None None O
a None None O
'volume None None O
transmitter None None O
' None None O
of None None O
brain None None O
signals None None O
. None None O

Mere None None O
disagreement None None O
is None None O
not None None O
evidence None None O
of None None O
ambiguity None None I-FUNC
. None None O

No None None O
difference None None O
in None None O
outcome None None O
was None None O
found None None O
between None None O
studies None None O
that None None O
excluded None None O
patients None None O
with None None O
a None None O
high None None O
level None None O
of None None O
positive None None O
or None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
compared None None O
to None None O
those None None O
that None None O
did None None O
not None None O
. None None O

The None None O
PM None None O
decreased None None O
the None None O
concentrations None None O
of None None O
neutrophils None None O
( None None O
2.9 None None O
, None None O
3.2 None None O
, None None O
and None None O
2.8 None None O
10 None None O
( None None O
9 None None O
) None None O
/L None None O
) None None O
and None None O
acute None None I-PROTEIN
phase None None I-PROTEIN
proteins None None I-PROTEIN
: None None O
SAA None None O
( None None O
37.1 None None O
, None None O
28.6 None None O
and None None O
20.1 None None O
μg/mL None None O
) None None O
, None None O
LBP None None O
( None None O
4.1 None None O
, None None O
3.8 None None O
, None None O
and None None O
2.9 None None O
μg/mL None None O
) None None O
, None None O
and None None O
Hp None None O
( None None O
675 None None O
, None None O
695 None None O
and None None O
601 None None O
μg/mL None None O
) None None O
. None None O

This None None O
article None None O
explores None None O
optimal None None O
levels None None O
of None None O
these None None O
parenting None None O
behaviors None None O
in None None O
preventing None None O
adolescent None None O
psychopathology None None O
in None None O
impoverished None None O
, None None O
urban None None O
high-crime None None O
areas None None O
while None None O
accounting None None O
for None None O
child None None O
perceptions None None I-FUNC
of None None O
neighborhood None None O
danger None None O
. None None O

Parental None None O
monitoring None None O
and None None O
warmth None None O
, None None O
child None None O
perception None None I-FUNC
of None None O
neighborhood None None O
danger None None O
, None None O
and None None O
child None None O
internalizing None None O
and None None O
externalizing None None O
behaviors None None O
were None None O
measured None None O
using None None O
questionnaires None None O
. None None O

In None None O
addition None None O
, None None O
adolescents None None O
' None None O
perceptions None None I-FUNC
of None None O
neighborhood None None O
danger None None O
emerged None None O
as None None O
equally None None O
strong None None O
as None None O
monitoring None None O
and None None O
warmth None None O
in None None O
predicting None None O
symptoms None None O
. None None O

It None None O
also None None O
highlights None None O
how None None O
context None None O
affects None None O
mental None None O
health None None O
, None None O
specifically None None O
how None None O
perceptions None None I-FUNC
of None None O
danger None None O
negatively None None O
influence None None O
adolescents None None O
' None None O
psychopathology None None O
, None None O
emphasizing None None O
the None None O
importance None None O
of None None O
initiatives None None O
to None None O
reduce None None O
violence None None O
in None None O
communities None None O
. None None O

Prolidase None None O
is None None O
a None None O
specific None None O
imidodipeptidase None None O
that None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
breakdown None None O
of None None O
collagen None None I-PROTEIN
. None None O

The None None O
combined None None O
application None None O
of None None O
IVB None None O
and None None O
triamcinolone None None O
may None None O
improve None None O
vision None None I-FUNC
and None None O
decrease None None O
CMT None None O
in None None O
severe None None O
DDME None None O
cases None None O
refractory None None O
to None None O
previous None None O
monotherapies None None O
. None None O

The None None O
protein None None O
( None None O
82 None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
was None None O
successfully None None O
synthesised None None O
by None None O
using None None O
Boc None None O
solid-phase None None O
peptide None None O
synthesis None None O
and None None O
native None None O
chemical None None O
ligation None None O
. None None O

Pallister-Killian None None O
syndrome None None O
( None None O
PKS None None O
) None None O
is None None O
characterized None None O
by None None O
craniofacial None None O
dysmorphism None None O
, None None O
pigmentary None None O
skin None None O
anomalies None None O
, None None O
congenital None None O
heart None None O
defects None None O
, None None O
congenital None None O
diaphragmatic None None O
hernia None None O
, None None O
hypotonia None None O
, None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
and None None O
epilepsy None None O
. None None O

The None None O
questionnaire None None O
included None None O
questions None None O
on None None O
demographics None None O
, None None O
work None None O
history None None O
, None None O
perceived None None O
stress None None O
, None None O
work None None O
productivity None None O
, None None O
depression None None I-DISEASE
and None None O
mania None None O
screeners None None O
, None None O
tobacco None None O
use None None O
, None None O
dietary None None O
information None None O
, None None O
vacation None None O
habits None None O
, None None O
and None None O
technology None None O
use None None O
. None None O

A None None O
possible None None O
reason None None O
for None None O
the None None O
elevated None None O
hepatic None None O
uptake None None O
of None None O
( None None O
99m None None O
) None None O
Tc-ZIGF1R:4551-GGGC None None O
is None None O
a None None O
high None None O
lipophilicity None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
the None None O
binding None None O
site None None O
of None None O
ZIGF1R:4551 None None O
, None None O
which None None O
is None None O
not None None O
compensated None None O
in None None O
( None None O
99m None None O
) None None O
Tc-ZIGF1R:4551-GGGC None None O
. None None O

The None None O
present None None O
study None None O
was None None O
undertaken None None O
to None None O
determine None None O
the None None O
in None None O
vivo None None O
effects None None O
of None None O
EH None None O
on None None O
hepatic None None O
CYP2B None None O
, None None O
CYP2C None None O
, None None O
CYP2D None None O
, None None O
and None None O
CYP3A None None O
enzymes None None I-PROTEIN
that None None O
are None None O
primarily None None O
involved None None O
in None None O
drug None None O
metabolism None None O
. None None O

qRT-PCR None None O
analyses None None O
also None None O
showed None None O
that None None O
mRNA None None O
levels None None O
of None None O
these None None O
enzymes None None I-PROTEIN
were None None O
significantly None None O
inhibited None None O
with None None O
bothEHWE None None O
and None None O
EA None None O
treatments None None O
. None None O

The None None O
objective None None O
was None None O
to None None O
examine None None O
the None None O
effectiveness None None O
of None None O
a None None O
3-week None None O
balance None None O
training None None O
program None None O
using None None O
the None None O
Nintendo None None O
Wii None None O
Fit None None O
gaming None None O
system None None O
( None None O
Nintendo None None O
Wii None None O
Sports None None O
, None None O
Nintendo None None O
, None None O
Redmond None None O
, None None O
WA None None O
) None None O
on None None O
lower None None O
limb None None O
corticomotor None None O
excitability None None O
and None None O
other None None O
clinical None None O
measures None None O
in None None O
chronic None None O
stroke None None I-DISEASE
survivors None None O
. None None O

We None None O
report None None O
here None None O
on None None O
an None None O
8-year-old None None O
girl None None O
and None None O
her None None O
mother None None O
, None None O
both None None O
displaying None None O
similar None None O
facial None None O
dysmorphism None None O
, None None O
speech None None I-FUNC
delay None None O
, None None O
and None None O
mild None None O
to None None O
moderate None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
. None None O

Our None None O
findings None None O
suggest None None O
that None None O
TBL1XR1 None None O
haploinsufficiency None None O
can None None O
cause None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
with None None O
a None None O
recognizable None None O
dysmorphism None None O
, None None O
without None None O
necessarily None None O
causing None None O
autistic None None O
behavior None None O
. None None O

Depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
obesity None None O
are None None O
positively None None O
related None None O
; None None O
as None None O
body None None O
weight None None O
increases None None O
, None None O
individuals None None O
are None None O
more None None O
likely None None O
to None None O
display None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

Exercise None None O
attenuates None None O
the None None O
relationship None None O
between None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
obesity None None O
. None None O

Using None None O
three None None O
multilevel None None O
models None None O
, None None O
we None None O
tested None None O
the None None O
moderation None None O
of None None O
health None None O
behaviours None None O
on None None O
the None None O
BMI-depressive None None O
symptoms None None I-DISEASE
relationship None None O
. None None O

Smokers None None O
reported None None O
more None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
whereas None None O
vigorous None None O
exercisers None None O
reported None None O
fewer None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Night-eating None None O
syndrome None None O
( None None O
NES None None I-TRANS
) None None O
can None None O
be None None O
a None None O
feature None None O
of None None O
severe None None O
obesity None None O
. None None O

Night None None O
eaters None None O
with None None O
severe None None O
obesity None None O
are None None O
more None None O
likely None None O
to None None O
be None None O
low None None O
in None None O
mood None None I-FUNC
and None None O
unemployed None None O
compared None None O
with None None O
non-night None None O
eaters None None O
. None None O

Research None None O
interest None None O
in None None O
night-eating None None O
syndrome None None O
( None None O
NES None None I-TRANS
) None None O
has None None O
grown None None O
in None None O
recent None None O
years None None O
in None None O
line None None O
with None None O
increased None None O
rates None None O
of None None O
obesity None None O
. None None O

Eighty-one None None O
individuals None None O
( None None O
mean None None O
[ None None O
standard None None O
deviation None None O
] None None O
age None None O
44.6 None None O
[ None None O
11.6 None None O
] None None O
years None None O
, None None O
[ None None O
body None None O
mass None None O
index None None O
] None None O
50.0 None None O
[ None None O
10.7 None None O
] None None O
kg None None O
m None None O
( None None O
-2 None None O
) None None O
; None None O
43 None None O
% None None O
men None None O
) None None O
from None None O
a None None O
hospital-based None None O
UK None None O
obesity None None O
clinic None None O
were None None O
interviewed None None O
for None None O
NES None None I-TRANS
based None None O
on None None O
2003 None None O
criteria None None O
. None None O

NEB None None O
individuals None None O
had None None O
lower None None O
mood None None I-FUNC
( None None O
P None None O
= None None O
0.01 None None O
) None None O
and None None O
were None None O
less None None O
likely None None O
to None None O
be None None O
employed None None O
( None None O
P None None O
= None None O
0.03 None None O
) None None O
. None None O

Thematic None None O
analysis None None O
of None None O
patient None None O
perceptions None None I-FUNC
of None None O
NEB None None O
highlighted None None O
the None None O
potential None None O
heterogeneity None None O
of None None O
NEB None None O
development None None O
: None None O
NEB None None O
developed None None O
in None None O
childhood None None O
, None None O
adolescence None None O
and None None O
adulthood None None O
. None None O

Severely None None O
obese None None O
night None None O
eaters None None O
are None None O
characterized None None O
by None None O
low None None O
mood None None I-FUNC
and None None O
lack None None O
of None None O
employment None None O
. None None O

The None None O
combination None None O
of None None O
obesity None None O
and None None O
depression None None I-DISEASE
exacerbates None None O
costs None None O
. None None O

Persons None None O
were None None O
categorized None None O
by None None O
one None None O
or None None O
more None None O
comorbid None None O
diagnoses None None O
for None None O
diabetes None None O
mellitus None None O
, None None O
hypertension None None O
, None None O
depression None None I-DISEASE
or None None O
congestive None None O
heart None None O
failure None None O
. None None O

The None None O
most None None O
expensive None None O
condition None None O
was None None O
obesity None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
hypertension None None O
and None None O
depression None None I-DISEASE
at None None O
$ None None O
15,733 None None O
. None None O

Literature None None O
review None None O
and None None O
applying None None O
the None None O
learning None None I-FUNC
from None None O
a None None O
European None None O
research None None O
readiness None None O
assessment None None O
tool None None O
, None None O
the None None O
TRANSFoRm None None O
International None None O
Research None None O
Readiness None None O
instrument None None O
( None None O
TIRRE None None O
) None None O
, None None O
to None None O
the None None O
context None None O
of None None O
the None None O
English None None O
NHS None None O
in None None O
order None None O
to None None O
develop None None O
a None None O
model None None O
to None None O
assess None None O
a None None O
practice None None O
's None None O
research None None O
readiness None None O
. None None O

Microglia None None O
are None None O
observed None None O
in None None O
the None None O
early None None O
developing None None O
forebrain None None I-REGION
and None None O
contribute None None O
to None None O
the None None O
regulation None None O
of None None O
neurogenesis None None O
through None None O
still None None O
unravelled None None O
mechanisms None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
cell None None O
death None None O
in None None O
the None None O
developing None None O
forebrain None None I-REGION
triggers None None O
microglial None None O
proliferation None None O
and None None O
that None None O
this None None O
is None None O
mediated None None O
by None None O
the None None O
release None None O
of None None O
macrophage None None O
migration None None O
inhibitory None None O
factor None None O
( None None O
MIF None None O
) None None O
. None None O

To None None O
implement None None O
a None None O
multidirectional None None O
motion None None O
encoding None None I-FUNC
scheme None None O
for None None O
magnetic None None O
resonance None None O
elastography None None O
( None None O
MRE None None O
) None None O
of None None O
the None None O
human None None O
brain None None O
with None None O
reduced None None O
acquisition None None O
time None None O
, None None O
and None None O
investigate None None O
its None None O
performance None None O
relative None None O
to None None O
a None None O
conventional None None O
MRE None None O
scheme None None O
. None None O

The None None O
use None None O
of None None O
SLIM None None O
provides None None O
very None None O
similar None None O
quantitative None None O
property None None O
estimates None None O
compared None None O
with None None O
the None None O
conventional None None O
MRE None None O
encoding None None I-FUNC
scheme None None O
. None None O

This None None O
effect None None O
was None None O
measured None None O
by None None O
quenching None None O
of None None O
tryptophan None None I-TRANS
fluorescence None None O
of None None O
the None None O
enzyme None None O
, None None O
when None None O
it None None O
was None None O
incubated None None O
with None None O
each None None O
liquid None None O
salt None None O
. None None O

The None None O
effect None None O
of None None O
various None None O
concentrations None None O
of None None O
ammonium None None O
nitrate None None O
( None None O
5-60 None None O
mM None None O
) None None O
, None None O
an None None O
economical None None O
nitrogen None None O
source None None O
, None None O
on None None O
the None None O
growth None None O
, None None O
nitrate-ammonium None None O
uptake None None O
rates None None O
, None None O
production None None O
of None None O
some None None O
pigments None None O
and None None O
metabolites None None O
, None None O
and None None O
some None None O
nitrogen None None O
assimilation None None O
enzymes None None I-PROTEIN
such None None O
as None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
NR None None O
) None None O
, None None O
nitrite None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
NiR None None O
) None None O
, None None O
glutamine None None I-TRANS
synthetase None None I-PROTEIN
( None None O
GS None None O
) None None O
, None None O
and None None O
glutamate None None I-TRANS
synthase None None O
( None None O
GOGAT None None O
) None None O
in None None O
Spirulina None None O
platensis None None O
( None None O
Gamont None None O
) None None O
Geitler None None O
was None None O
investigated None None O
. None None O

This None None O
process None None O
could None None O
be None None O
utilized None None O
to None None O
bring None None O
about None None O
a None None O
highly None None O
stereoselective None None O
ligation-type None None O
coupling None None O
of None None O
protected None None O
serines None None I-TRANS
( None None O
at None None O
stoichiometric None None O
loadings None None O
) None None O
with None None O
racemic None None O
azlactones None None O
derived None None O
from None None O
both None None O
natural None None O
and None None O
abiotic None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

Following None None O
mutagenic None None O
PCR None None O
and None None O
gene None None O
replacement None None O
, None None O
we None None O
characterized None None O
thermosensitive None None O
mutations None None O
in None None O
sarA None None O
( None None O
SAR1 None None O
) None None O
encoding None None I-FUNC
a None None O
key None None O
regulator None None O
of None None O
endoplasmic None None O
reticulum None None O
( None None O
ER None None O
) None None O
exit None None O
. None None O

Nuclear None None O
factor None None O
( None None O
erythroid-derived None None O
2 None None O
) None None O
-like None None O
2 None None O
( None None O
Nrf2 None None O
) None None O
is None None O
the None None O
master None None O
regulator None None O
of None None O
oxidative None None O
stress None None O
, None None O
and None None O
melatonin None None I-TRANS
is None None O
an None None O
endogenous None None O
hormone None None O
with None None O
antioxidative None None O
properties None None O
that None None O
reduces None None O
its None None O
levels None None O
with None None O
ageing None None O
. None None O

Compound None None O
ITH12674 None None O
is None None O
a None None O
hybrid None None O
of None None O
melatonin None None I-TRANS
and None None O
sulforaphane None None O
designed None None O
to None None O
exert None None O
a None None O
dual None None O
drug-prodrug None None O
mechanism None None O
of None None O
action None None O
. None None O

In None None O
the None None O
structure None None O
of None None O
protein None None O
L None None O
, None None O
each None None O
amino None None O
acid None None O
residue None None O
( None None O
except None None O
for None None O
alanines None None I-TRANS
and None None O
glycines None None I-TRANS
) None None O
was None None O
replaced None None O
sequentially None None O
by None None O
alanine None None I-TRANS
. None None O

We None None O
review None None O
the None None O
xanthine None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
XO None None O
) None None O
family None None O
of None None O
pyranopterin None None O
molybdenum None None O
enzymes None None I-PROTEIN
with None None O
a None None O
specific None None O
emphasis None None O
on None None O
electronic None None O
structure None None O
contributions None None O
to None None O
reactivity None None O
. None None O

The None None O
ethylene None None O
biosynthetic None None O
and None None O
perception None None I-FUNC
gene None None O
expressions None None O
were None None O
studied None None O
immediately None None O
after None None O
treatment None None O
until None None O
24 None None O
h None None O
and None None O
all None None O
genes None None O
were None None O
repressed None None O
, None None O
while None None O
ethylene None None O
production None None O
was None None O
strongly None None O
induced None None O
after None None O
4 None None O
days None None O
. None None O

Array None None O
comparative None None O
genomic None None O
hybridization None None O
( None None O
array None None O
CGH None None O
) None None O
has None None O
proven None None O
its None None O
utility None None O
in None None O
uncovering None None O
cryptic None None O
rearrangements None None O
in None None O
patients None None O
with None None O
X-linked None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
. None None O

identified None None O
inherited None None O
and None None O
de None None O
novo None None O
recurrent None None O
Xp11.23p11.22 None None O
microduplications None None O
in None None O
two None None O
males None None O
and None None O
six None None O
females None None O
from None None O
a None None O
wide None None O
cohort None None O
of None None O
patients None None O
presenting None None O
with None None O
syndromic None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
. None None O

Patients None None O
shared None None O
several None None O
common None None O
major None None O
characteristics None None O
including None None O
moderate None None O
to None None O
severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
early None None O
onset None None O
of None None O
puberty None None O
, None None O
language None None I-FUNC
impairment None None O
, None None O
and None None O
age None None O
related None None O
epileptic None None O
syndromes None None O
such None None O
as None None O
West None None I-DISEASE
syndrome None None I-DISEASE
and None None O
focal None None I-DISEASE
epilepsy None None I-DISEASE
with None None O
activation None None O
during None None O
sleep None None O
evolving None None O
in None None O
some None None O
patients None None O
to None None O
continuous None None O
spikes-and-waves None None O
during None None O
slow None None O
sleep None None O
. None None O

Xp11.23p11.22 None None O
microduplication None None O
is None None O
a None None O
recently-recognized None None O
syndrome None None O
associated None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
epilepsy None None O
, None None O
and None None O
early None None O
onset None None O
of None None O
puberty None None O
in None None O
females None None O
. None None O

Enriched None None O
glycopeptides None None O
were None None O
deglycosylated None None O
with None None O
peptide-N-glycosidase None None O
F None None O
in None None O
heavy-oxygen None None O
water None None O
, None None O
and None None O
in None None O
the None None O
process None None O
of None None O
glycan None None O
removal None None O
, None None O
asparagine None None I-TRANS
was None None O
converted None None O
to None None O
aspartic None None I-TRANS
acid None None I-TRANS
and None None O
tagged None None O
with None None O
18O None None O
for None None O
MS None None O
analysis None None O
. None None O

Acute None None O
cerebellar None None I-DISEASE
ataxia None None I-DISEASE
( None None O
ACA None None O
) None None O
is None None O
a None None O
relatively None None O
common None None O
neurological None None O
disease None None O
in None None O
children None None O
. None None O

We None None O
performed None None O
a None None O
Bayesian None None O
reanalysis None None O
of None None O
the None None O
data None None O
underlying None None O
a None None O
reimbursement None None O
advice None None O
by None None O
the None None O
Dutch None None O
National None None O
Health None None O
Insurance None None O
Board None None O
( None None O
CVZ None None O
) None None O
regarding None None O
the None None O
anti-diabetic None None O
drug None None O
exenatide None None O
( None None O
an None None O
alternative None None O
to None None O
insulin None None I-PROTEIN
) None None O
. None None O

Impairment None None O
in None None O
learning None None I-FUNC
from None None O
punishment None None O
( None None O
`` None None O
punishment None None O
insensitivity None None O
'' None None O
) None None O
is None None O
an None None O
established None None O
feature None None O
of None None O
severe None None O
antisocial None None O
behavior None None O
in None None O
adults None None O
and None None O
youth None None O
but None None O
it None None O
has None None O
not None None O
been None None O
well None None O
studied None None O
as None None O
a None None O
developmental None None O
phenomenon None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
ion None None O
channel None None O
probes None None O
( None None O
ICPs None None O
) None None O
, None None O
which None None O
consist None None O
of None None O
multiple None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
reconstituted None None O
into None None O
lipid None None O
bilayers None None O
suspended None None O
across None None O
the None None O
opening None None O
of None None O
perflourinated None None O
glass None None O
micropipets None None O
. None None O

dhBBR None None O
and None None O
Di-MeBBR None None O
, None None O
but None None O
not None None O
BBR None None O
, None None O
reduced None None O
atherosclerotic None None O
plaque None None O
size None None O
and None None O
improved None None O
plaque None None O
stability None None O
indicated None None O
by None None O
increased None None O
α-smooth None None O
muscle None None O
actin None None I-PROTEIN
and None None O
collagen None None I-PROTEIN
content None None O
, None None O
and None None O
thicker None None O
fibrous None None O
caps None None O
. None None O

Here None None O
we None None O
demonstrate None None O
a None None O
strategy None None O
to None None O
construct None None O
size-controlled None None O
NPCs None None O
using None None O
the None None O
DNA-binding None None O
zinc None None I-TRANS
finger None None O
( None None O
ZnF None None O
) None None O
protein None None O
. None None O

These None None O
models None None O
have None None O
been None None O
recently None None O
questioned None None O
by None None O
findings None None O
that None None O
prove None None O
that None None O
the None None O
kind None None O
of None None O
influence None None O
on None None O
movement None None I-FUNC
of None None O
the None None O
same None None O
attentional None None O
cue-with None None O
a None None O
supposedly None None O
similar None None O
neuronal None None O
codification-depends None None O
on None None O
their None None O
contextual None None O
significance None None O
. None None O

Antimicrobial None None O
peptides None None I-TRANS
, None None O
as None None O
a None None O
new None None O
class None None O
of None None O
antibiotics None None O
, None None O
have None None O
generated None None O
tremendous None None O
interest None None O
as None None O
potential None None O
alternatives None None O
to None None O
classical None None O
antibiotics None None O
. None None O

This None None O
paper None None O
reports None None O
a None None O
simple None None O
and None None O
low-cost None None O
chromatography-free None None O
platform None None O
technology None None O
for None None O
producing None None O
antimicrobial None None O
peptides None None I-TRANS
in None None O
Escherichia None None O
coli None None O
( None None O
E. None None O
coli None None O
) None None O
. None None O

Shortening None None O
of None None O
the None None O
spacer None None O
( None None O
1,3-propanediyl None None O
to None None O
methylene None None O
) None None O
between None None O
the None None O
N-heterocyclic None None O
carbene None None O
ligand None None O
and None None O
the None None O
cysteine None None I-TRANS
site None None O
545 None None O
increased None None O
the None None O
ROMP None None O
activity None None O
toward None None O
a None None O
water-soluble None None O
7-oxanorbornene None None O
derivative None None O
. None None O

We None None O
tested None None O
the None None O
hypothesis None None O
that None None O
these None None O
nutritional None None O
modifications None None O
differentially None None O
improve None None O
whole-body None None O
insulin None None I-PROTEIN
sensitivity None None O
( None None O
primary None None O
outcome None None O
) None None O
and None None O
secretion None None O
. None None O

Insulin None None I-PROTEIN
sensitivity None None O
and None None O
secretion None None O
were None None O
assessed None None O
by None None O
hyperinsulinaemic-euglycaemic None None O
clamp None None O
and None None O
intravenous None None O
glucose None None O
tolerance None None O
tests None None O
with None None O
isotope None None O
dilution None None O
. None None O

Whole-body None None O
insulin None None I-PROTEIN
sensitivity None None O
increased None None O
in None None O
both None None O
groups None None O
( None None O
mean None None O
[ None None O
95 None None O
% None None O
CI None None O
] None None O
) None None O
( None None O
H-RISK None None O
vs None None O
L-RISK None None O
: None None O
0.8 None None O
[ None None O
0.2 None None O
, None None O
1.4 None None O
] None None O
vs None None O
1.0 None None O
[ None None O
0.4 None None O
, None None O
1.7 None None O
] None None O
mg None None O
kg None None O
( None None O
-1 None None O
) None None O
min None None O
( None None O
-1 None None O
) None None O
, None None O
p None None O
= None None O
0.59 None None O
) None None O
, None None O
while None None O
body None None O
weight None None O
decreased None None O
( None None O
-4.8 None None O
% None None O
[ None None O
-6.1 None None O
% None None O
, None None O
-3.5 None None O
% None None O
] None None O
vs None None O
-4.6 None None O
% None None O
[ None None O
-6.0 None None O
% None None O
, None None O
-3.3 None None O
% None None O
] None None O
, None None O
respectively None None O
) None None O
. None None O

Activated None None O
clotting None None O
time None None O
( None None O
ACT None None O
) None None O
has None None O
been None None O
successfully None None O
applied None None O
during None None O
percutaneous None None O
coronary None None O
intervention None None O
( None None O
PCI None None O
) None None O
to None None O
monitor None None O
the None None O
extent None None O
of None None O
thrombin None None I-PROTEIN
inhibition None None O
and None None O
anti-coagulation None None O
from None None O
unfractionated None None O
heparin None None O
( None None O
UFH None None O
) None None O
aiming None None O
to None None O
reduce None None O
the None None O
incidence None None O
of None None O
thrombotic None None O
adverse None None O
events None None O
and None None O
hemorrhagic None None O
complications None None O
. None None O

Emergency None None O
department None None O
treatment None None O
translated None None O
to None None O
successful None None O
retention None None I-FUNC
of None None O
teeth None None O
in None None O
58 None None O
% None None O
of None None O
the None None O
cases None None O
with None None O
documented None None O
follow None None O
up None None O
. None None O

We None None O
report None None O
that None None O
Salmonella None None O
limits None None O
exposure None None O
to None None O
oxidative None None O
damage None None O
elicited None None O
by None None O
D-amino None None O
acid None None O
oxidase None None O
( None None O
DAO None None O
) None None O
in None None O
neutrophils None None O
by None None O
expressing None None O
an None None O
ABC None None O
importer None None O
specific None None O
for None None O
D-alanine None None O
, None None O
a None None O
DAO None None O
substrate None None O
found None None O
in None None O
peptidoglycan None None O
stem None None O
peptides None None I-TRANS
. None None O

While None None O
ICE None None O
propagates None None O
horizontally None None O
from None None O
ICE-positive None None O
to None None O
ICE-negative None None O
cells None None O
, None None O
chromosomal None None O
transfers None None O
( None None O
CTs None None O
) None None O
occurred None None O
in None None O
the None None O
opposite None None O
direction None None O
, None None O
from None None O
ICE-negative None None O
to None None O
ICE-positive None None O
cells None None O
, None None O
independently None None O
of None None O
ICE None None O
movement None None I-FUNC
. None None O

Here None None O
, None None O
we None None O
examined None None O
the None None O
potential None None O
role None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
initiating None None O
intracellular None None O
replication None None O
. None None O

Pretreatment None None O
of None None O
E. None None O
chaffeensis None None O
with None None O
a None None O
proline None None I-TRANS
transporter None None O
inhibitor None None O
( None None O
protamine None None O
) None None O
, None None O
a None None O
glutamine None None I-TRANS
transporter None None O
inhibitor None None O
( None None O
histidine None None I-TRANS
) None None O
, None None O
or None None O
proline None None I-TRANS
analogs None None O
inhibited None None O
E. None None O
chaffeensis None None O
infection None None O
, None None O
whereas None None O
pretreatment None None O
with None None O
proline None None I-TRANS
or None None O
glutamine None None I-TRANS
enhanced None None O
infection None None O
and None None O
upregulated None None O
putA None None O
and None None O
glnA None None O
faster None None O
than None None O
no None None O
treatment None None O
or None None O
glutamate None None I-TRANS
pretreatment None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
proline None None I-TRANS
and None None O
glutamine None None I-TRANS
uptake None None O
regulates None None O
putA None None O
and None None O
glnA None None O
expression None None O
through None None O
NtrY/NtrX None None O
and None None O
facilitates None None O
degradation None None O
of None None O
CtrA None None O
to None None O
initiate None None O
a None None O
new None None O
cycle None None O
of None None O
E. None None O
chaffeensis None None O
growth None None O
. None None O

FtsA None None O
is None None O
a None None O
protein None None O
needed None None O
in None None O
many None None O
bacteria None None O
to None None O
construct None None O
a None None O
septum None None I-REGION
that None None O
divides None None O
one None None O
fully None None O
grown None None O
cell None None O
, None None O
producing None None O
two None None O
daughters None None O
. None None O

To None None O
date None None O
, None None O
little None None O
attention None None I-FUNC
has None None O
been None None O
paid None None O
to None None O
how None None O
fairness None None O
considerations None None O
affect None None O
scientific None None O
material None None O
sharing None None O
, None None O
and None None O
no None None O
empirical None None O
research None None O
has None None O
been None None O
carried None None O
out None None O
to None None O
determine None None O
the None None O
role None None O
that None None O
fairness None None O
plays None None O
in None None O
collaborative None None O
studies None None O
. None None O

© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
Alpha-1 None None O
antitrypsin None None O
( None None O
AAT None None O
) None None O
is None None O
the None None O
most None None O
abundant None None O
circulating None None O
antiprotease None None O
and None None O
is None None O
a None None O
member None None O
of None None O
the None None O
serine None None I-TRANS
protease None None I-PROTEIN
inhibitor None None O
( None None O
SERPIN None None O
) None None O
superfamily None None O
. None None O

We None None O
report None None O
the None None O
case None None O
of None None O
a None None O
patient None None O
, None None O
on None None O
long-term None None O
bisoprolol None None O
, None None O
who None None O
developed None None O
acute None None O
epigastric None None O
pain None None O
and None None O
dyspnoea None None O
shortly None None O
after None None O
receiving None None O
ECT None None O
for None None O
treatment-refractory None None O
depression None None I-DISEASE
. None None O

Based None None O
on None None O
the None None O
enhanced None None O
permeability None None O
and None None O
retention None None I-FUNC
( None None O
EPR None None O
) None None O
effect None None O
, None None O
the None None O
mechanism None None O
for None None O
more None None O
efficient None None O
universal None None O
tumor None None O
delivery None None O
using None None O
macromolecular None None O
drugs None None O
to None None O
cover None None O
wider None None O
tumor None None O
types None None O
than None None O
single None None O
molecular None None O
target None None O
is None None O
discussed None None O
. None None O

The None None O
criteria None None O
for None None O
such None None O
macromolecular None None O
drugs None None O
or None None O
nanomedicines None None O
for None None O
effective None None O
accumulation None None O
at None None O
tumor None None O
sites None None O
is None None O
commented None None O
on None None O
as None None O
well None None O
as None None O
the None None O
importance None None O
of None None O
long None None O
plasma None None O
retention None None I-FUNC
time None None O
of None None O
such None None O
drugs None None O
and None None O
a None None O
need None None O
to None None O
release None None O
active None None O
principles None None O
from None None O
nanoparticles None None O
at None None O
target None None O
sites None None O
. None None O

To None None O
test None None O
the None None O
hypothesis None None O
that None None O
the None None O
hypoxia None None O
marker None None O
carbonic None None I-PROTEIN
anhydrase None None I-PROTEIN
IX None None I-REGION
( None None O
CAIX None None O
) None None O
, None None O
and None None O
the None None O
cholangiocytic/progenitor None None O
markers None None O
cytokeratin None None O
( None None O
CK None None O
) None None O
19 None None O
and None None O
epithelial None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecule None None O
( None None O
EpCAM None None O
) None None O
, None None O
may None None O
be None None O
expressed None None O
in None None O
areas None None O
of None None O
hypoxia None None O
in None None O
hepatocellular None None O
carcinoma None None O
( None None O
HCC None None O
) None None O
after None None O
transarterial None None O
chemoembolization None None O
( None None O
TACE None None O
) None None O
. None None O

© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
Two None None O
flexible None None O
Tröger None None O
's None None O
base None None O
ditopic None None O
receptors None None I-PROTEIN
C4TB None None O
and None None O
C5TB None None O
incorporating None None O
monoaza None None O
crown None None O
ether None None O
were None None O
designed None None O
and None None O
synthesized None None O
for None None O
bisammonium None None O
ion None None O
complexation None None O
. None None O

Bisammonium None None O
chloride None None O
( None None O
A1 None None O
) None None O
with None None O
a None None O
shorter None None O
alkyl None None O
chain None None O
spacer None None O
showed None None O
the None None O
highest None None O
affinity None None O
for None None O
the None None O
receptors None None I-PROTEIN
. None None O

This None None O
prompted None None O
us None None O
to None None O
investigate None None O
the None None O
adjuvant None None O
effect None None O
of None None O
CT None None O
in None None O
wild-type None None O
, None None O
IL-12p40-/- None None O
, None None O
Batf3-/- None None O
, None None O
and None None O
IL-17A-/- None None O
mice None None O
and None None O
in None None O
mice None None O
that None None O
selectively None None O
lack None None O
the None None O
Gsα None None O
target None None O
protein None None O
for None None O
CT None None O
adenosine None None I-TRANS
diphosphate None None O
( None None O
ADP None None O
) None None O
-ribosylation None None O
in None None O
DCs None None O
. None None O

We None None O
have None None O
established None None O
an None None O
experimental None None O
approach None None O
in None None O
which None None O
mice None None O
tolerized None None O
to None None O
ovalbumin None None O
( None None O
OVA None None O
) None None O
were None None O
sensitized None None O
to None None O
the None None O
Leishmania None None O
homolog None None O
of None None O
receptors None None I-PROTEIN
for None None O
activated None None O
c None None O
kinase None None O
( None None O
LACK None None O
) None None O
antigen None None O
, None None O
and None None O
subsequently None None O
challenged None None O
with None None O
aerosols None None O
of None None O
LACK None None O
alone None None O
or None None O
LACK None None O
and None None O
OVA None None O
together None None O
. None None O

Diffuse None None O
hyperpigmentation None None O
was None None O
reported None None O
and None None O
generally None None O
resulted None None O
from None None O
overproduction None None O
of None None O
melanocyte-stimulating None None O
hormone None None O
or None None O
adrenocorticotropic None None I-TRANS
hormone None None I-TRANS
. None None O

Here None None O
the None None O
authors None None O
analyzed None None O
movement None None I-FUNC
patterns None None O
of None None O
highly None None O
talented None None O
baseball None None O
batters None None O
facing None None O
randomly None None O
presented None None O
fastballs None None O
and None None O
change-ups None None O
( None None O
a None None O
slower None None O
type None None O
of None None O
pitch None None O
) None None O
. None None O

More None None O
specifically None None O
, None None O
the None None O
movement None None I-FUNC
initiation None None O
pattern None None O
was None None O
not None None O
adjusted None None O
to None None O
the None None O
slower None None O
speeds None None O
of None None O
change-ups None None O
, None None O
resulting None None O
in None None O
a None None O
miss None None O
. None None O

Psychometric None None O
tests None None O
specific None None O
for None None O
assessing None None O
the None None O
presence None None O
of None None O
post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
( None None O
PTSD None None O
) None None O
are None None O
commonly None None O
employed None None O
by None None O
forensic None None O
mental None None O
health None None O
evaluators None None O
. None None O

Molecular None None O
modelling None None O
of None None O
CXCR3 None None O
, None None O
followed None None O
by None None O
virtual None None O
ligand None None O
docking None None O
, None None O
highlighted None None O
several None None O
CXCR3 None None O
residues None None O
likely None None O
to None None O
contact None None O
either None None O
antagonist None None O
, None None O
notably None None O
a None None O
conserved None None O
aspartate None None I-TRANS
in None None O
helix None None O
2 None None O
( None None O
Asp-112 None None O
( None None O
2:63 None None O
) None None O
) None None O
, None None O
which None None O
was None None O
postulated None None O
to None None O
interact None None O
with None None O
the None None O
quaternary None None O
nitrogen None None O
of None None O
TAK-779 None None O
. None None O

© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Niemann-Pick None None O
disease None None O
type None None O
C None None O
( None None O
NPC None None O
) None None O
is None None O
an None None O
atypical None None O
lysosomal None None O
storage None None I-FUNC
disease None None O
resulting None None O
from None None O
mutations None None O
in None None O
one None None O
of None None O
two None None O
genes None None O
, None None O
either None None O
NPC1 None None O
or None None O
NPC2 None None O
. None None O

At None None O
12 None None O
weeks None None O
, None None O
the None None O
effect None None O
of None None O
BM-MSCs None None O
on None None O
hepatic None None O
fibrosis None None O
was None None O
analyzed None None O
histomorphologically None None O
using None None O
the None None O
Laennec None None O
fibrosis None None O
scoring None None O
system None None O
, None None O
and None None O
the None None O
collagen None None I-PROTEIN
proportionate None None O
area None None O
was None None O
quantified None None O
. None None O

In None None O
this None None O
work None None O
, None None O
rovibrational None None O
energies None None O
and None None O
spectroscopic None None O
constants None None O
for None None O
the None None O
water None None O
-Ng None None O
complexes None None O
( None None O
Ng None None O
= None None O
He None None O
, None None O
Ne None None I-TRANS
, None None O
Ar None None O
, None None O
Kr None None O
and None None O
Xe None None O
) None None O
were None None O
calculated None None O
through None None O
two None None O
different None None O
approaches None None O
( None None O
by None None O
solving None None O
the None None O
Nuclear None None O
Schrödinger None None O
equation None None O
and None None O
by None None O
applying None None O
the None None O
Dunham None None O
's None None O
method None None O
) None None O
and None None O
using None None O
two None None O
different None None O
potential None None O
energy None None O
curves None None O
( None None O
PEC None None O
) None None O
. None None O

Glucocorticoid None None O
replacement None None O
is None None O
essential None None O
in None None O
patients None None O
with None None O
primary None None O
and None None O
secondary None None O
adrenal None None I-TRANS
insufficiency None None O
, None None O
but None None O
many None None O
patients None None O
remain None None O
on None None O
higher None None O
than None None O
recommended None None O
dose None None O
regimens None None O
. None None O

We None None O
present None None O
the None None O
identification None None O
of None None O
a None None O
novel None None O
point None None O
mutation None None O
in None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
( None None O
FGFR2 None None O
) None None O
, None None O
c.812G None None O
& None None O
gt None None O
; None None O
T None None O
, None None O
p. None None O
( None None O
Gly271Val None None O
) None None O
or None None O
c.1851G None None O
& None None O
gt None None O
; None None O
C None None O
, None None O
p. None None O
( None None O
Leu617Phe None None O
) None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
study None None O
were None None O
to None None O
examine None None O
the None None O
responsiveness None None O
of None None O
EQ-5D-5L None None O
in None None O
patients None None O
with None None O
stroke None None I-DISEASE
and None None O
to None None O
compare None None O
it None None O
with None None O
responsiveness None None O
of None None O
EQ-5D-3L None None O
and None None O
visual None None O
analogue None None O
scale None None O
( None None O
EQ None None O
VAS None None O
) None None O
. None None O

A None None O
total None None O
of None None O
112 None None O
patients None None O
( None None O
52 None None O
% None None O
females None None O
; None None O
mean None None O
age None None O
70.6 None None O
years None None O
; None None O
93 None None O
% None None O
ischemic None None O
stroke None None I-DISEASE
) None None O
completed None None O
all None None O
the None None O
instruments None None O
at None None O
both None None O
occasions None None O
. None None O

As None None O
far None None O
as None None O
EQ-5D-5L None None O
index None None O
is None None O
scored None None O
according None None O
to None None O
crosswalk None None O
approach None None O
, None None O
the None None O
EQ-5D-3L None None O
index None None O
appears None None O
to None None O
be None None O
more None None O
responsive None None O
in None None O
stroke None None I-DISEASE
population None None O
. None None O

A None None O
serologic None None O
hallmark None None O
of None None O
autoimmune None None O
hepatitis None None O
( None None O
AIH None None O
) None None O
type None None O
1 None None O
are None None O
anti-smooth None None O
muscle None None O
autoantibodies None None O
( None None O
ASMA None None O
) None None O
with None None O
specificity None None O
for None None O
filamentous None None O
actin None None I-PROTEIN
( None None O
F-actin None None O
; None None O
AAA None None O
( None None O
anti-actin None None O
antibodies None None O
) None None O
) None None O
, None None O
traditionally None None O
detected None None O
by None None O
indirect None None O
immunofluorescence None None O
( None None O
IFT None None O
) None None O
using None None O
rat None None O
liver None None O
, None None O
kidney None None O
, None None O
and None None O
stomach None None O
tissue None None O
sections None None O
as None None O
substrates None None O
. None None O

In None None O
both None None O
groups None None O
, None None O
later None None O
test None None O
discriminations None None O
were None None O
learned None None O
more None None O
readily None None O
if None None O
the None None O
discriminative None None O
cues None None O
had None None O
been None None O
predictive None None O
in None None O
the None None O
previous None None O
learning None None I-FUNC
stage None None O
than None None O
if None None O
they None None O
had None None O
been None None O
nonpredictive None None O
. None None O

The None None O
data None None O
are None None O
discussed None None O
with None None O
respect None None O
to None None O
attentional None None O
models None None O
of None None O
associative None None O
learning None None I-FUNC
. None None O

The None None O
serum None None O
insulin None None I-PROTEIN
glargine None None O
concentration None None O
( None None O
INS None None O
) None None O
and None None O
glucose None None O
infusion None None O
rate None None O
( None None O
GIR None None O
) None None O
developed None None O
more None None O
gradually None None O
into None None O
more None None O
constant None None O
and None None O
prolonged None None O
profiles None None O
with None None O
Gla-300 None None O
than None None O
with None None O
Gla-100 None None O
. None None O

To None None O
develop None None O
and None None O
characterize None None O
a None None O
feline None None O
model None None O
of None None O
retinal None None O
degeneration None None O
induced None None O
by None None O
intravitreal None None O
injection None None O
of None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
( None None O
ATP None None O
) None None O
. None None O

Copyright None None O
2014 None None O
The None None O
Association None None O
for None None O
Research None None O
in None None O
Vision None None I-FUNC
and None None O
Ophthalmology None None O
, None None O
Inc. None None O
To None None O
assess None None O
the None None O
capacity None None O
of None None O
internal None None O
retinal None None O
layer None None O
thickness None None O
measurements None None O
made None None O
at None None O
the None None O
macula None None O
using None None O
new None None O
spectral-domain None None O
optical None None O
coherence None None O
tomography None None O
( None None O
OCT None None O
) None None O
software None None O
to None None O
distinguish None None O
between None None O
healthy None None O
subjects None None O
and None None O
those None None O
with None None O
suspected None None O
glaucoma None None O
. None None O

Copyright None None O
2015 None None O
The None None O
Association None None O
for None None O
Research None None O
in None None O
Vision None None I-FUNC
and None None O
Ophthalmology None None O
, None None O
Inc None None O
. None None O

Copyright None None O
2015 None None O
The None None O
Association None None O
for None None O
Research None None O
in None None O
Vision None None I-FUNC
and None None O
Ophthalmology None None O
, None None O
Inc. None None O
Anterior None None O
corneal None None O
curvature None None O
shows None None O
significant None None O
heritability None None O
. None None O

The None None O
width None None O
and None None O
angle None None O
of None None O
collagen None None I-PROTEIN
lamellae None None O
in None None O
the None None O
keratoconic None None O
cornea None None O
were None None O
significantly None None O
larger None None O
and None None O
smaller None None O
, None None O
respectively None None O
, None None O
relative None None O
to None None O
those None None O
in None None O
the None None O
normal None None O
cornea None None O
. None None O

These None None O
properties None None O
of None None O
collagen None None I-PROTEIN
lamellae None None O
are None None O
altered None None O
in None None O
keratoconus None None O
and None None O
are None None O
likely None None O
related None None O
to None None O
abnormalities None None O
of None None O
corneal None None O
shape None None O
. None None O

We None None O
evaluated None None O
the None None O
prognostic None None O
significance None None O
of None None O
prolonged None None O
P None None O
wave None None O
duration None None O
among None None O
middle-aged None None O
Finnish None None O
type None None O
2 None None O
diabetes None None O
patients None None O
with None None O
and None None O
without None None O
prevalent None None O
non-major None None O
macrovascular None None O
disease None None O
( None None O
PNMMVD None None O
) None None O
with None None O
respect None None O
to None None O
total None None O
and None None O
stroke None None I-DISEASE
mortality None None O
. None None O

Those None None O
who None None O
had None None O
prolonged None None O
P None None O
wave None None O
duration None None O
had None None O
2.45 None None O
( None None O
95 None None O
% None None O
confidence None None O
interval None None O
: None None O
1.11-5.37 None None O
) None None O
increased None None O
stroke None None I-DISEASE
mortality None None O
among None None O
PNMMVD None None O
patients None None O
. None None O

As None None O
an None None O
easily None None O
measurable None None O
factor None None O
P None None O
wave None None O
duration None None O
merits None None O
further None None O
studies None None O
with None None O
higher None None O
number None None O
of None None O
patients None None O
to None None O
evaluate None None O
its None None O
importance None None O
in None None O
the None None O
estimation None None O
of None None O
stroke None None I-DISEASE
risk None None O
in None None O
type None None O
2 None None O
diabetic None None O
patients None None O
with None None O
PNMMVD None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
performance None None O
of None None O
conditioned None None O
approach None None O
behavior None None O
, None None O
but None None O
not None None O
conditioned None None O
orientation None None O
, None None O
was None None O
attenuated None None O
by None None O
pretreatment None None O
with None None O
the None None O
dopamine None None I-TRANS
receptor None None I-PROTEIN
antagonist None None O
, None None O
flupenthixol None None O
, None None O
into None None O
the None None O
core None None O
of None None O
the None None O
nucleus None None I-REGION
accumbens None None I-REGION
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
demonstrate None None O
that None None O
, None None O
similar None None O
to None None O
food None None O
and None None O
cocaine None None O
cues None None O
: None None O
( None None O
1 None None O
) None None O
a None None O
discrete None None O
opioid None None O
cue None None O
attains None None O
greater None None O
incentive None None O
motivational None None O
value None None O
in None None O
STs None None O
than None None O
GTs None None O
; None None O
( None None O
2 None None O
) None None O
the None None O
attribution None None O
of None None O
incentive None None O
motivational None None O
properties None None O
to None None O
an None None O
opioid None None O
cue None None O
is None None O
dopamine None None I-TRANS
dependent None None O
; None None O
and None None O
( None None O
3 None None O
) None None O
an None None O
opioid None None O
cue None None O
engages None None O
the None None O
so-called None None O
'motive None None O
circuit None None O
' None None O
only None None O
if None None O
it None None O
is None None O
imbued None None O
with None None O
incentive None None O
salience None None O
. None None O

The None None O
mutation None None O
, None None O
absent None None O
in None None O
controls None None O
, None None O
results None None O
in None None O
a None None O
change None None O
of None None O
a None None O
highly None None O
conserved None None O
glutamic None None I-TRANS
acid None None I-TRANS
to None None O
alanine None None I-TRANS
. None None O

These None None O
proteins None None O
are None None O
drug None None O
targets None None O
in None None O
the None None O
treatment None None O
of None None O
depression None None I-DISEASE
, None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
obsessive None None O
disorders None None O
, None None O
and None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

The None None O
cheminformatic None None O
targets None None O
identifications None None O
were None None O
in None None O
agreement None None O
with None None O
four None None O
3D-QSAR None None O
( None None O
H3R/D1R/D2R/5-HT2aR None None O
) None None O
models None None O
and None None O
by None None O
in None None O
vitro None None O
assays None None O
for None None O
serotonin None None I-TRANS
5-HT1a None None O
and None None O
5-HT2a None None O
receptor None None I-PROTEIN
binding None None O
of None None O
the None None O
most None None O
promising None None O
ligand None None O
( None None O
71/MBA-VEG8 None None O
) None None O
. None None O

Gene None None O
therapy None None O
has None None O
received None None O
much None None O
attention None None I-FUNC
in None None O
the None None O
field None None O
of None None O
drug None None O
delivery None None O
. None None O

Transcription None None I-PROTEIN
factors None None I-PROTEIN
of None None O
the None None O
cAMP None None O
response None None O
element-binding None None O
protein None None O
( None None O
Creb None None O
) None None O
/cAMP None None O
response None None O
element None None O
modulator None None O
( None None O
Crem None None O
) None None O
family None None O
were None None O
linked None None O
to None None O
the None None O
switch None None O
from None None O
a None None O
contractile None None O
to None None O
a None None O
proliferating None None O
phenotype None None O
in None None O
vascular None None O
smooth None None O
muscle None None O
cells None None O
( None None O
VSMCs None None O
) None None O
. None None O

CRE-mediated None None O
transcriptional None None O
activity None None O
was None None O
enhanced None None O
in None None O
primary None None O
Crem None None O
( None None O
-/- None None O
) None None O
VSMCs None None O
under None None O
nonstimulated None None O
conditions None None O
and None None O
under None None O
stimulation None None O
with None None O
Forskolin None None O
and None None O
platelet-derived None None O
growth None None O
factor None None O
( None None O
Pdgf None None O
) None None O
whereas None None O
stimulation None None O
with None None O
nitric None None I-TRANS
oxide None None I-TRANS
or None None O
cGMP None None O
showed None None O
no None None O
effect None None O
. None None O

A None None O
secondary None None O
purpose None None O
was None None O
to None None O
examine None None O
the None None O
validity None None O
of None None O
skin None None O
conductance None None O
level None None O
in None None O
measuring None None O
perception None None I-FUNC
of None None O
pressure None None O
. None None O

The None None O
validity None None O
of None None O
skin None None O
conductance None None O
readings None None O
as None None O
an None None O
index None None O
of None None O
pressure None None O
perception None None I-FUNC
was None None O
called None None O
into None None O
question None None O
. None None O

The None None O
recently None None O
emerged None None O
carbohydrate None None O
esterase None None O
( None None O
CE None None O
) None None O
15 None None O
family None None O
of None None O
glucuronoyl None None O
esterases None None O
( None None O
GEs None None O
) None None O
has None None O
been None None O
proposed None None O
to None None O
degrade None None O
ester None None O
LCC None None O
bonds None None O
between None None O
glucuronic None None O
acids None None O
in None None O
xylans None None O
and None None O
lignin None None O
alcohols None None O
thereby None None O
potentially None None O
improving None None O
delignification None None O
of None None O
lignocellulosic None None O
biomass None None O
when None None O
applied None None O
in None None O
conjunction None None O
with None None O
other None None O
cellulases None None O
, None None O
hemicellulases None None O
and None None O
oxidoreductases None None I-PROTEIN
. None None O

Our None None O
results None None O
show None None O
that None None O
( None None O
i None None O
) None None O
ribosomes None None O
in None None O
persisters None None O
exist None None O
largely None None O
as None None O
inactive None None O
ribosomal None None O
subunits None None O
, None None O
( None None O
ii None None O
) None None O
rRNAs None None O
and None None O
tRNAs None None O
are None None O
mostly None None O
degraded None None O
and None None O
( None None O
iii None None O
) None None O
a None None O
small None None O
fraction None None O
of None None O
the None None O
ribosomes None None O
remain None None O
mostly None None O
intact None None O
, None None O
except None None O
for None None O
reduced None None O
amounts None None O
of None None O
seven None None O
ribosomal None None I-PROTEIN
proteins None None I-PROTEIN
. None None O

The None None O
creation None None O
of None None O
biobanks None None O
depends None None O
upon None None O
people None None O
's None None O
willingness None None O
to None None O
donate None None O
their None None O
samples None None O
for None None O
research None None O
purposes None None O
and None None O
to None None O
agree None None O
to None None O
sample None None O
storage None None I-FUNC
. None None O

People None None O
in None None O
favour None None O
of None None O
providing None None O
biological None None O
samples None None O
for None None O
a None None O
biobank None None O
expressed None None O
a None None O
more None None O
positive None None O
view None None O
on None None O
biomedical None None O
research None None O
than None None O
did None None O
people None None O
who None None O
were None None O
not None None O
in None None O
favour None None O
; None None O
attitude None None O
towards None None O
genetic None None O
research None None O
in None None O
dementia None None I-DISEASE
was None None O
the None None O
strongest None None O
predictor None None O
of None None O
participation None None O
. None None O

Measurement None None O
of None None O
both None None O
absolute None None O
and None None O
virtual None None O
volumes None None O
indicated None None O
that None None O
aneurysm None None O
resection None None O
, None None O
including None None O
the None None O
original None None O
site None None O
of None None O
rupture None None O
, None None O
was None None O
surgically None None O
feasible None None O
without None None O
reducing None None O
postoperative None None O
stroke None None I-DISEASE
volume None None O
. None None O

The None None O
proband None None O
was None None O
presented None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
and None None O
multiple None None O
congenital None None O
anomalies None None O
including None None O
cleft None None O
palate None None O
, None None O
low-set None None O
ears None None O
, None None O
everted None None O
upper None None O
lip None None O
, None None O
diaphragmatic None None O
hernia None None O
, None None O
and None None O
arthrogryposis None None O
. None None O

Accordingly None None O
, None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
hypertelorism None None O
, None None O
cupped None None O
ears None None O
, None None O
everted None None O
upper None None O
lip None None O
, None None O
and None None O
limb None None O
anomalies None None O
were None None O
presenting None None O
clinical None None O
features None None O
of None None O
the None None O
16p13 None None O
duplication None None O
syndrome None None O
while None None O
deep None None O
set None None O
eyes None None O
were None None O
perhaps None None O
related None None O
to None None O
the None None O
1p None None O
terminal None None O
deletion None None O
. None None O

Transcranial None None O
sonography None None O
showed None None O
substantia None None I-REGION
nigra None None I-REGION
hyperechogenicity None None O
as None None O
a None None O
typical None None O
echo None None O
feature None None O
in None None O
idiopathic None None O
Parkinson None None I-DISEASE
disease None None O
and None None O
lenticular None None O
nucleus None None O
hyperechogenicity None None O
as None None O
a None None O
characteristic None None O
finding None None O
in None None O
atypical None None O
parkinsonian None None O
syndromes None None O
. None None O

Transcranial None None O
sonography None None O
also None None O
revealed None None O
basal None None I-REGION
ganglia None None I-REGION
hyperechoic None None O
changes None None O
in None None O
movement None None I-FUNC
disorders None None O
with None None O
trace None None O
metal None None O
accumulation None None O
such None None O
as None None O
Wilson None None O
disease None None O
, None None O
some None None O
entities None None O
of None None O
neurodegeneration None None O
with None None O
brain None None O
iron None None O
accumulation None None O
, None None O
as None None O
well None None O
as None None O
several None None O
forms None None O
of None None O
spinocerebellar None None O
ataxia None None O
. None None O

Cutoff None None O
values None None O
for None None O
the None None O
substantia None None I-REGION
nigra None None I-REGION
echogenic None None O
area None None O
, None None O
defining None None O
substantia None None I-REGION
nigra None None I-REGION
hyperechogenicity None None O
, None None O
vary None None O
among None None O
ultrasound None None O
systems None None O
from None None O
different None None O
manufacturers None None O
. None None O

Three None None O
hundred None None O
participants None None O
( None None O
controls None None O
, None None O
n None None O
= None None O
138 None None O
; None None O
patients None None O
with None None O
PD None None O
, None None O
n None None O
= None None O
105 None None O
; None None O
and None None O
patients None None O
with None None O
essential None None I-DISEASE
tremor None None I-DISEASE
, None None O
n None None O
= None None O
57 None None O
) None None O
underwent None None O
transcranial None None O
sonography None None O
following None None O
a None None O
standardized None None O
protocol None None O
. None None O

The None None O
substantia None None I-REGION
nigra None None I-REGION
echogenic None None O
area None None O
( None None O
larger None None O
of None None O
bilateral None None O
measurements None None O
) None None O
was None None O
larger None None O
in None None O
patients None None O
with None None O
PD None None O
( None None O
mean None None O
± None None O
SD None None O
, None None O
0.24 None None O
± None None O
0.05 None None O
cm None None O
( None None O
2 None None O
) None None O
) None None O
than None None O
controls None None O
( None None O
0.14 None None O
± None None O
0.05 None None O
cm None None O
( None None O
2 None None O
) None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
patients None None O
with None None O
essential None None I-DISEASE
tremor None None I-DISEASE
( None None O
0.14 None None O
± None None O
0.04 None None O
cm None None O
( None None O
2 None None O
) None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Age None None O
did None None O
not None None O
correlate None None O
with None None O
substantia None None I-REGION
nigra None None I-REGION
echogenicity None None O
in None None O
any None None O
group None None O
. None None O

On None None O
multivariate None None O
analysis None None O
, None None O
only None None O
substantia None None I-REGION
nigra None None I-REGION
hyperechogenicity None None O
was None None O
associated None None O
with None None O
the None None O
diagnosis None None O
of None None O
PD None None O
. None None O

Motor None None O
symptoms None None O
were None None O
measured None None O
by None None O
the None None O
Unified None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Rating None None O
Scale None None O
III None None O
. None None O

The None None O
median None None O
nerve None None O
cross-sectional None None O
area None None O
was None None O
associated None None O
with None None O
the None None O
severity None None O
of None None O
the None None O
tremor None None O
but None None O
not None None O
with None None O
the None None O
Unified None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Rating None None O
Scale None None O
motor None None O
score None None O
. None None O

To None None O
explore None None O
the None None O
application None None O
of None None O
instantaneous None None O
wave None None O
intensity None None O
for None None O
early None None O
diagnosis None None O
of None None O
systemic None None O
lupus None None O
erythematosus None None O
( None None O
SLE None None O
) None None O
-induced None None O
atherosclerosis None None I-DISEASE
, None None O
we None None O
observed None None O
carotid None None O
elasticity None None O
by None None O
instantaneous None None O
wave None None O
intensity None None O
in None None O
premenopausal None None O
women None None O
with None None O
SLE None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
explore None None O
the None None O
potential None None O
role None None O
of None None O
transcranial None None O
color None None O
Doppler None None O
sonography None None O
in None None O
assessing None None O
intracranial None None O
pressure None None O
by None None O
observing None None O
the None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
blood None None O
flow None None O
parameters None None O
in None None O
patients None None O
with None None O
increased None None O
intracranial None None O
pressure None None O
of None None O
varying None None O
etiology None None O
. None None O

Middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
Doppler None None O
flow None None O
spectra None None O
changed None None O
regularly None None O
as None None O
intracranial None None O
pressure None None O
increased None None O
. None None O

To None None O
characterize None None O
the None None O
variability None None O
in None None O
exposure None None O
and None None O
metabolic None None O
effect None None O
of None None O
insulin None None I-PROTEIN
glargine None None O
300 None None O
U/ml None None O
( None None O
Gla-300 None None O
) None None O
at None None O
steady None None O
state None None O
in None None O
people None None O
with None None O
type None None O
1 None None O
diabetes None None O
( None None O
T1DM None None O
) None None O
. None None O

Day-to-day None None O
reproducibility None None O
of None None O
exposure None None O
was None None O
high None None O
: None None O
the None None O
between-day None None O
within-subject None None O
coefficients None None O
of None None O
variation None None O
for None None O
total None None O
systemic None None O
exposure None None O
( None None O
area None None O
under None None O
the None None O
serum None None O
insulin None None I-PROTEIN
glargine None None O
concentration None None O
time None None O
curve None None O
from None None O
time None None O
0 None None O
to None None O
24 None None O
h None None O
after None None O
dosing None None O
) None None O
and None None O
maximum None None O
insulin None None I-PROTEIN
concentration None None O
were None None O
17.4 None None O
% None None O
[ None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
15-21 None None O
] None None O
and None None O
33.4 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
28-41 None None O
) None None O
, None None O
respectively None None O
. None None O

Gla-300 None None O
provides None None O
predictable None None O
, None None O
evenly None None O
distributed None None O
24-h None None O
coverage None None O
as None None O
a None None O
result None None O
of None None O
low None None O
fluctuation None None O
and None None O
high None None O
reproducibility None None O
in None None O
insulin None None I-PROTEIN
exposure None None O
, None None O
and None None O
appears None None O
suitable None None O
for None None O
effective None None O
basal None None O
insulin None None I-PROTEIN
use None None O
. None None O

The None None O
retention None None I-FUNC
resulted None None O
in None None O
higher None None O
ER None None O
stress None None O
levels None None O
that None None O
were None None O
accompanied None None O
by None None O
increased None None O
ROS None None O
production None None O
, None None O
Ca None None O
( None None O
2+ None None O
) None None O
leakage None None O
, None None O
ER-containing None None O
autophagosomes None None O
, None None O
shortened None None O
cortical None None O
ER None None O
length None None O
and None None O
compromised None None O
induction None None O
of None None O
the None None O
unfolded None None O
protein None None O
response None None O
( None None O
UPR None None O
) None None O
. None None O

High-temperature None None O
cultivation None None O
of None None O
an None None O
rhIL-10 None None O
expression None None O
strain None None O
leads None None O
to None None O
prolonged None None O
retention None None I-FUNC
of None None O
immature None None O
G3-pro-rhIL10 None None O
in None None O
ER None None O
, None None O
causing None None O
higher None None O
ER None None O
stress None None O
levels None None O
and None None O
thus None None O
greater None None O
yeast None None O
cell None None O
death None None O
rates None None O
and None None O
lower None None O
production None None O
of None None O
rhIL-10 None None O
. None None O

Then None None O
, None None O
we None None O
construct None None O
for None None O
the None None O
first None None O
time None None O
a None None O
1-error-correcting None None O
code None None O
of None None O
4 None None O
physical None None O
qudits None None O
capable None None O
of None None O
encoding None None I-FUNC
1 None None O
qubit None None O
of None None O
information None None O
, None None O
which None None O
is None None O
impossible None None O
in None None O
standard None None O
quantum None None O
error None None O
correction None None O
, None None O
demonstrating None None O
that None None O
our None None O
protocol None None O
can None None O
also None None O
improve None None O
the None None O
encoding None None I-FUNC
rate None None O
in None None O
some None None O
sense None None O
. None None O

Regional None None O
analysis None None O
of None None O
sulcal None None O
depth None None O
and None None O
cortical None None O
shape None None O
showed None None O
the None None O
greatest None None O
impact None None O
of None None O
preterm None None O
birth None None O
on None None O
the None None O
insula None None I-REGION
, None None O
superior None None I-REGION
temporal None None I-REGION
sulcus None None I-REGION
, None None O
and None None O
ventral None None I-NEURON
portions None None O
of None None O
the None None O
pre- None None O
and None None O
postcentral None None O
sulci None None O
in None None O
both None None O
hemispheres None None O
. None None O

Indeed None None O
, None None O
at None None O
least None None O
four None None O
families None None O
of None None O
nitrate None None O
transporters None None I-PROTEIN
operating None None O
at None None O
both None None O
high None None O
and/or None None O
low None None O
external None None O
nitrate None None O
concentrations None None O
, None None O
and None None O
which None None O
are None None O
located None None O
in None None O
series None None O
and/or None None O
parallel None None O
in None None O
the None None O
different None None O
cellular None None O
layers None None O
of None None O
the None None O
mature None None O
root None None O
, None None O
are None None O
involved None None O
in None None O
nitrate None None O
uptake None None O
. None None O

The None None O
more None None O
opportunities None None O
a None None O
participant None None O
has None None O
to None None O
share None None O
thoughts None None O
and None None O
feelings None None I-FUNC
about None None O
the None None O
research None None O
study None None O
with None None O
investigators None None O
will None None O
likely None None O
result None None O
in None None O
a None None O
positive None None O
overall None None O
experience None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
calcium None None O
cations None None O
induce None None O
the None None O
formation None None O
of None None O
a None None O
more None None O
homogeneous None None O
network None None O
of None None O
pectin None None O
than None None O
zinc None None I-TRANS
cations None None O
do None None O
. None None O

This None None O
different None None O
binding None None O
behavior None None O
seems None None O
to None None O
arise None None O
from None None O
the None None O
stronger None None O
interaction None None O
of None None O
water None None O
molecules None None O
with None None O
zinc None None I-TRANS
than None None O
with None None O
calcium None None O
. None None O

Immunologic None None O
abnormalities None None O
have None None O
been None None O
found None None O
in None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
but None None O
pentraxin None None O
3 None None O
, None None O
a None None O
marker None None O
of None None O
innate None None O
immunity None None O
, None None O
has None None O
not None None O
been None None O
studied None None O
in None None O
this None None O
population None None O
. None None O

The None None O
sample None None O
consisted None None O
of None None O
831 None None O
individuals None None O
: None None O
256 None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
309 None None O
with None None O
schizophrenia None None I-DISEASE
, None None O
and None None O
266 None None O
without None None O
a None None O
psychiatric None None O
disorder None None O
. None None O

The None None O
individuals None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
also None None O
had None None O
significantly None None O
increased None None O
odds None None O
of None None O
having None None O
low None None O
levels None None O
of None None O
pentraxin None None O
3 None None O
relative None None O
to None None O
both None None O
the None None O
10th None None O
and None None O
25th None None O
percentile None None O
level None None O
of None None O
the None None O
controls None None O
and None None O
significantly None None O
decreased None None O
odds None None O
of None None O
having None None O
a None None O
level None None O
greater None None O
than None None O
the None None O
75th None None O
and None None O
the None None O
90th None None O
percentile None None O
level None None O
of None None O
the None None O
controls None None O
, None None O
adjusting None None O
for None None O
the None None O
same None None O
covariates None None O
. None None O

An None None O
increased None None O
understanding None None O
of None None O
the None None O
role None None O
of None None O
innate None None O
immunity None None O
in None None O
the None None O
etiopathogenesis None None O
of None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
might None None O
lead None None O
to None None O
new None None O
modalities None None O
for None None O
the None None O
diagnosis None None O
and None None O
treatment None None O
of None None O
this None None O
disorder None None O
. None None O

The None None O
ATPase None None I-PROTEIN
activity None None O
and None None O
C-terminal None None O
zinc None None I-TRANS
finger None None O
motif None None O
of None None O
yejH None None O
play None None O
an None None O
important None None O
role None None O
in None None O
its None None O
repair None None O
function None None O
, None None O
as None None O
targeted None None O
mutant None None O
alleles None None O
of None None O
yejH None None O
did None None O
not None None O
rescue None None O
sensitivity None None O
. None None O

PubMed None None O
, None None O
the None None O
Cochrane None None O
Central None None O
Register None None O
of None None O
Controlled None None O
Trials None None O
, None None O
the None None O
Web None None O
of None None O
Science None None O
, None None O
Google None None O
Scholar None None O
, None None O
and None None O
a None None O
clinical None None O
trial None None O
registry None None O
from None None O
inception None None O
to None None O
October None None O
2014 None None O
were None None O
searched None None O
without None None O
language None None I-FUNC
restrictions None None O
. None None O

The None None O
impedance None None O
spectra None None O
of None None O
the None None O
samples None None O
displayed None None O
semicircular None None O
arcs None None O
in None None O
the None None O
complex None None O
plane None None O
plot None None O
at None None O
all None None O
temperatures None None O
, None None O
with None None O
their None None O
centres None None O
lying None None O
below None None O
the None None O
real None None O
axis None None O
at None None O
a None None O
particular None None O
angle None None O
of None None O
depression None None I-DISEASE
indicating None None O
the None None O
distribution None None O
of None None O
relaxation None None O
times None None O
. None None O

This None None O
qualitative None None O
study None None O
used None None O
semi-structured None None O
interviews None None O
with None None O
people None None O
with None None O
dementia None None I-DISEASE
and None None O
their None None O
carers None None O
. None None O

Social None None O
inclusiveness None None O
and None None O
improvements None None O
in None None O
relationships None None O
, None None O
memory None None I-FUNC
and None None O
mood None None I-FUNC
were None None O
found None None O
to None None O
be None None O
especially None None O
important None None O
to None None O
participants None None O
. None None O

To None None O
test None None O
our None None O
hypothesis None None O
that None None O
initiating None None O
therapy None None O
with None None O
a None None O
combination None None O
of None None O
agents None None O
known None None O
to None None O
improve None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
insulin None None I-PROTEIN
sensitivity None None O
in None None O
subjects None None O
with None None O
new-onset None None O
diabetes None None O
would None None O
produce None None O
greater None None O
, None None O
more None None O
durable None None O
reduction None None O
in None None O
glycated None None O
haemoglobin None None O
( None None O
HbA1c None None O
) None None O
levels None None O
, None None O
while None None O
avoiding None None O
hypoglycaemia None None O
and None None O
weight None None O
gain None None O
, None None O
compared None None O
with None None O
sequential None None O
addition None None O
of None None O
agents None None O
that None None O
lower None None O
plasma None None O
glucose None None O
but None None O
do None None O
not None None O
correct None None O
established None None O
pathophysiological None None O
abnormalities None None O
. None None O

Selenite None None O
reducing None None O
heterotrophic None None O
non-halophilic None None O
aerobic None None O
bacteria None None O
revived None None O
from None None O
3.5 None None O
months None None O
freeze None None O
storage None None I-FUNC
could None None O
successfully None None O
reduce None None O
toxic None None O
tellurite None None O
to None None O
non None None O
toxic None None O
elemental None None O
form None None O
and None None O
produced None None O
extracellular None None O
nanospheres None None O
during None None O
detoxification None None O
. None None O

Inborn None None O
errors None None O
of None None O
metabolism None None O
( None None O
IEM None None O
) None None O
form None None O
an None None O
important None None O
cause None None O
of None None O
movement None None I-FUNC
disorders None None O
in None None O
children None None O
. None None O

We None None O
therefore None None O
conducted None None O
a None None O
case None None O
study None None O
on None None O
the None None O
HRQOL None None O
and None None O
development None None O
of None None O
adaptive None None O
functioning None None O
in None None O
children None None O
with None None O
an None None O
IEM None None O
and None None O
a None None O
movement None None I-FUNC
disorder None None O
. None None O

Six None None O
types None None O
of None None O
movement None None I-FUNC
disorders None None O
were None None O
recognised None None O
by None None O
the None None O
expert None None O
panel None None O
, None None O
most None None O
frequently None None O
dystonia None None O
( None None O
16/24 None None O
) None None O
, None None O
myoclonus None None O
( None None O
7/24 None None O
) None None O
and None None O
ataxia None None O
( None None O
6/24 None None O
) None None O
. None None O

malignancy None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
rheumatic None None O
disease None None O
, None None O
psychiatric None None O
disorders None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
tended None None O
to None None O
diminish None None O
with None None O
the None None O
severity None None O
of None None O
the None None O
movement None None I-FUNC
disorder None None O
. None None O

We None None O
plead None None O
for None None O
a None None O
greater None None O
awareness None None O
of None None O
movement None None I-FUNC
disorders None None O
and None None O
that None None O
specialists None None O
should None None O
be None None O
asked None None O
to None None O
diagnose None None O
and None None O
treat None None O
these None None O
wherever None None O
possible None None O
. None None O

Consistent None None O
with None None O
this None None O
protection None None O
, None None O
immunization None None O
also None None O
appeared None None O
to None None O
lead None None O
to None None O
a None None O
tolerogenic None None O
response None None O
with None None O
an None None O
increase None None O
in None None O
myeloid None None O
derived None None O
suppressor None None O
cells None None O
, None None O
M2 None None O
macrophages None None O
, None None O
and None None O
FoxP3 None None I-PROTEIN
( None None O
+ None None O
) None None O
T-cells None None O
. None None O

However None None O
, None None O
potential None None O
off-target None None O
effects None None O
of None None O
the None None O
Cas9 None None O
nuclease None None I-PROTEIN
represent None None O
a None None O
major None None O
safety None None O
concern None None O
for None None O
any None None O
therapeutic None None O
application None None O
. None None O

In None None O
the None None O
realm None None O
of None None O
social None None O
effectiveness None None O
constructs None None O
, None None O
political None None O
skill None None O
has None None O
seen None None O
increased None None O
attention None None I-FUNC
as None None O
a None None O
predictor None None O
of None None O
work None None O
performance None None O
and None None O
attitudes None None O
. None None O

We None None O
show None None O
here None None O
that None None O
depletion None None O
of None None O
potassium None None O
from None None O
the None None O
medium None None O
or None None O
alteration None None O
of None None O
diverse None None O
regulatory None None O
pathways None None O
controlling None None O
potassium None None O
uptake None None O
, None None O
such None None O
as None None O
the None None O
Trk None None O
potassium None None O
transporters None None I-PROTEIN
or None None O
the None None O
Pma1 None None O
H None None O
( None None O
+ None None O
) None None O
-ATPase None None O
, None None O
triggers None None O
a None None O
response None None O
that None None O
mimics None None O
that None None O
of None None O
phosphate None None O
( None None O
Pi None None O
) None None O
deprivation None None O
, None None O
exemplified None None O
by None None O
accumulation None None O
of None None O
the None None O
high-affinity None None O
Pi None None O
transporter None None O
Pho84 None None O
. None None O

Using None None O
the None None O
freshwater None None O
crab None None O
Sinopotamon None None O
henanense None None O
as None None O
an None None O
example None None O
, None None O
we None None O
explored None None O
the None None O
effects None None O
of None None O
Cd None None O
on None None O
submicroscopic None None O
structures None None O
in None None O
hepatopancreatic None None O
cells None None O
through None None O
transmission None None O
electron None None O
microscopy None None O
( None None O
TEM None None O
) None None O
and None None O
energy-related None None O
parameters None None O
such None None O
as None None O
adenosine None None I-TRANS
triphosphate/adenosine None None O
diphosphate None None O
( None None O
ATP/ADP None None O
) None None O
ratios None None O
, None None O
reduced/oxidized None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
( None None O
NADH/NAD None None O
( None None O
+ None None O
) None None O
) None None O
ratios None None O
, None None O
and None None O
the None None O
mitochondrial None None O
membrane None None O
potential None None O
( None None O
Δψm None None O
) None None O
. None None O

Experimental None None O
10 None None O
day None None O
exposure None None O
increased None None O
NADH None None O
and None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
and None None O
provided None None O
a None None O
higher None None O
NADH/NAD None None O
( None None O
+ None None O
) None None O
ratio None None O
and None None O
Δψm None None O
in None None O
hepatopancreatic None None O
cells None None O
. None None O

Anatomical None None O
relationships None None O
with None None O
the None None O
surrounding None None O
cranial None None I-REGION
nerves None None I-REGION
and None None O
blood None None O
vessels None None O
are None None O
described None None O
, None None O
with None None O
emphasis None None O
on None None O
their None None O
clinical None None O
correlation None None O
during None None O
surgery None None O
in None None O
this None None O
region None None O
. None None O

During None None O
the None None O
dissection None None O
, None None O
we None None O
noted None None O
the None None O
relationships None None O
of None None O
the None None O
V1 None None O
nerve None None O
with None None O
the None None O
other None None O
trigeminal None None O
branches None None O
, None None O
as None None O
well None None O
as None None O
with None None O
the None None O
oculomotor None None O
and None None O
trochlear None None I-REGION
nerves None None I-REGION
, None None O
the None None O
paraclival None None O
and None None O
cavernous None None O
portions None None O
of None None O
the None None O
internal None None O
carotid None None O
artery None None O
, None None O
and None None O
the None None O
superior None None O
orbital None None O
fissure None None O
( None None O
SOF None None O
) None None O
. None None O

The None None O
V1 None None O
nerve None None O
joins None None O
the None None O
oculomotor None None O
and None None O
trochlear None None I-REGION
nerves None None I-REGION
to None None O
exit None None O
the None None O
cavernous None None O
sinus None None O
and None None O
enter None None O
the None None O
orbit None None O
through None None O
the None None O
SOF None None O
. None None O

The None None O
V1 None None O
nerve None None O
borders None None O
two None None O
key None None O
triangles None None O
in None None O
the None None O
lateral None None O
wall None None O
of None None O
the None None O
cavernous None None O
sinus None None O
, None None O
and None None O
the None None O
Parkinson None None I-DISEASE
's None None O
and None None O
anteromedial None None O
triangles None None O
. None None O

This None None O
potential None None O
space None None O
can None None O
serve None None O
as None None O
an None None O
adequate None None O
window None None O
to None None O
access None None O
the None None O
temporal None None I-REGION
lobe None None I-REGION
. None None O

NA None None I-TRANS
. None None O

The None None O
sample None None O
consisted None None O
of None None O
45 None None O
patients None None O
with None None O
panic None None I-DISEASE
disorder None None I-DISEASE
and/or None None O
agoraphobia None None I-DISEASE
and None None O
Diagnostic None None O
and None None O
Statistical None None O
Manual None None O
of None None O
Mental None None O
Disorders None None O
, None None O
fourth None None O
edition None None O
, None None O
Cluster None None O
C None None O
personality None None O
traits None None O
who None None O
participated None None O
in None None O
an None None O
11-week None None O
inpatient None None O
programme None None O
consisting None None O
of None None O
two None None O
phases None None O
; None None O
the None None O
first None None O
was None None O
a None None O
5-week None None O
panic/agoraphobia-focused None None O
cognitive None None O
therapy None None O
, None None O
whereas None None O
the None None O
second None None O
phase None None O
was None None O
a None None O
personality-focused None None O
schema None None O
therapy None None O
. None None O

The None None O
diagnosis None None O
of None None O
POI None None O
was None None O
made None None O
on None None O
pubertal None None O
delay None None O
or None None O
primary None None O
amenorrhea None None O
in None None O
these None None O
five None None O
patients None None O
, None None O
whilst None None O
the None None O
others None None O
presented None None O
with None None O
clitoral None None O
hypertrophy None None O
at None None O
birth None None O
or None None O
short None None O
stature None None O
and None None O
pubertal None None O
delay None None O
in None None O
two None None O
cases None None O
with None None O
NR5A1 None None O
mutation None None O
or None None O
with None None O
short None None O
stature None None O
and None None O
learning None None I-FUNC
difficulties None None O
in None None O
one None None O
case None None O
with None None O
mitochondrial None None O
disease None None O
. None None O

Histopathologic None None O
lesions None None O
included None None O
chronic None None O
multifocal None None O
lymphoplasmacytic None None O
encephalitis None None I-DISEASE
( None None O
nonsuppurative None None O
) None None O
with None None O
extensive None None O
perivascular None None O
cuffing None None O
in None None O
some None None O
cases None None O
, None None O
formation None None O
of None None O
glial None None O
nodules None None O
mainly None None O
in None None O
the None None O
mesencephalon None None I-REGION
, None None O
thalamus None None I-REGION
, None None O
hippocampus None None I-REGION
, None None O
pons None None I-REGION
and None None O
medulla None None I-REGION
oblongata None None I-REGION
in None None O
the None None O
brain None None O
of None None O
aborted None None O
fetuses None None O
, None None O
and None None O
neuronal None None O
degeneration None None O
, None None O
necrosis None None O
and None None O
central None None O
chromatolysis None None O
mainly None None O
in None None O
the None None O
cortex None None O
and None None O
subcortical None None O
of None None O
the None None O
brain None None O
and None None O
brain None None O
stem None None O
regions None None O
of None None O
them None None O
. None None O

Briefly None None O
, None None O
histopathologic None None O
findings None None O
in None None O
the None None O
brain None None O
and None None O
spinal None None O
cord None None O
included None None O
hyperemia None None O
, None None O
hemorrhage None None O
, None None O
non-suppurative None None O
encephalitis None None I-DISEASE
, None None O
mononuclear None None O
perivascular None None O
cuffing None None O
, None None O
multifocal None None O
gliosis None None O
, None None O
cavitation None None O
, None None O
central None None O
chromatolysis None None O
, None None O
neuronal None None O
degeneration None None O
and None None O
necrosis None None O
, None None O
perineuronal None None O
and None None O
perivascular None None O
edema None None O
in None None O
the None None O
all None None O
regions None None O
of None None O
the None None O
brain None None O
and None None O
acute None None O
neuronal None None O
necrosis None None O
in None None O
the None None O
gray None None O
matter None None O
of None None O
ventral None None I-NEURON
horn None None O
of None None O
the None None O
spinal None None O
cord None None O
were None None O
also None None O
seen None None O
. None None O

Specifically None None O
, None None O
it None None O
was None None O
discovered None None O
that None None O
4 None None O
nm None None O
Au None None O
nanoparticles None None O
deposited None None O
on None None O
zinc None None I-TRANS
oxide None None O
catalyze None None O
the None None O
transformation None None O
of None None O
the None None O
oxide None None O
into None None O
the None None O
sulfide None None O
in None None O
the None None O
presence None None O
of None None O
an None None O
organosulfur None None O
species None None O
. None None O

Electron None None O
transfer None None O
from None None O
oxygen None None O
vacancies None None O
to None None O
Au None None O
nanoparticles None None O
is None None O
proposed None None O
to None None O
generate None None O
acidic None None O
sites None None O
on None None O
the None None O
surface None None O
of None None O
the None None O
zinc None None I-TRANS
oxide None None O
, None None O
resulting None None O
in None None O
the None None O
enhanced None None O
reactivity None None O
of None None O
the None None O
oxide None None O
. None None O

Nonapeptide None None O
hormones None None I-PROTEIN
of None None O
the None None O
vasopressin/oxytocin None None O
family None None O
regulate None None O
social None None O
behaviours None None O
. None None O

Genome None None O
duplications None None O
, None None O
however None None O
, None None O
expand None None O
the None None O
diversity None None O
of None None O
nonapeptide None None O
receptors None None I-PROTEIN
in None None O
actinopterygian None None O
fishes None None O
, None None O
and None None O
two None None O
distinct None None O
V1a-type None None O
receptors None None I-PROTEIN
( None None O
v1a1 None None O
and None None O
v1a2 None None O
) None None O
for None None O
vasotocin None None O
, None None O
as None None O
well None None O
as None None O
at None None O
least None None O
two None None O
V2-type None None O
receptors None None I-PROTEIN
( None None O
v2a None None O
and None None O
v2b None None O
) None None O
, None None O
have None None O
been None None O
identified None None O
in None None O
these None None O
taxa None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
link None None O
hypothalamic None None O
proVT None None O
expression None None O
to None None O
aggression None None O
and None None O
implicate None None O
forebrain None None I-REGION
expression None None O
of None None O
the None None O
V1a-type None None O
receptor None None I-PROTEIN
v1a2 None None O
as None None O
potentially None None O
mediating None None O
the None None O
effects None None O
of None None O
vasotocin None None O
on None None O
behaviour None None O
in None None O
male None None O
fish None None O
. None None O

Depending None None O
on None None O
differences None None O
in None None O
topographical None None O
anatomy None None O
, None None O
the None None O
sinus None None O
septum None None I-REGION
separated None None O
the None None O
coronary None None O
sinus None None O
opening None None O
from None None O
either None None O
the None None O
right None None O
or None None O
the None None O
left None None O
atrium None None O
. None None O

Rather None None O
than None None O
the None None O
counter-side None None O
position None None O
of None None O
the None None O
right None None O
valve None None O
being None None O
at None None O
the None None O
IVC None None O
terminal None None O
, None None O
the None None O
left None None O
sinus None None O
valve None None O
protruded None None O
leftward None None O
, None None O
forming None None O
an None None O
incomplete None None O
interatrial None None O
septum None None I-REGION
. None None O

Additionally None None O
, None None O
as None None O
a None None O
secondary None None O
outcome None None O
measure None None O
, None None O
changes None None O
in None None O
the None None O
Sino-Nasal None None O
Outcome None None O
Test-20 None None O
score None None O
, None None O
olfaction None None I-FUNC
, None None O
saccharin None None O
transit None None O
time None None O
, None None O
nasal None None O
endoscopy None None O
score None None O
, None None O
and None None O
self-rating None None O
of None None O
nasal None None O
health None None O
using None None O
a None None O
visual None None O
analogue None None O
scale None None O
were None None O
evaluated None None O
. None None O

I None None O
outline None None O
why None None O
an None None O
eliminativist None None O
position None None O
should None None O
be None None O
taken None None O
with None None O
regard None None O
to None None O
this None None O
concept None None O
in None None O
light None None O
of None None O
these None None O
concerns None None O
but None None O
mitigate None None O
some None None O
of None None O
the None None O
severity None None O
of None None O
this None None O
position None None O
by None None O
arguing None None O
that None None O
we None None O
can None None O
still None None O
make None None O
sense None None O
of None None O
retaining None None O
our None None O
widespread None None O
use None None O
of None None O
the None None O
term None None O
by None None O
viewing None None O
it None None O
as None None O
nothing None None O
more None None O
than None None O
a None None O
useful None None O
pragmatic None None O
linguistic None None O
device None None O
that None None O
acts None None O
as None None O
a None None O
marker None None O
to None None O
draw None None O
attention None None I-FUNC
to None None O
certain None None O
kinds None None O
of None None O
issue None None O
. None None O

© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Congenital None None O
neuromuscular None None O
disorders None None O
, None None O
such None None O
as None None O
Duchenne None None O
muscular None None O
dystrophy None None O
( None None O
DMD None None O
) None None O
, None None O
spinal None None O
muscular None None O
atrophy None None O
( None None O
SMA None None O
) None None O
, None None O
and None None O
Pompe None None O
disease None None O
( None None O
acid None None O
maltase None None I-PROTEIN
deficiency None None O
[ None None O
AMD None None O
] None None O
) None None O
, None None O
are None None O
candidates None None O
for None None O
universal None None O
newborn None None O
screening None None O
( None None O
NBS None None O
) None None O
. None None O

Recent None None O
neuroanatomical None None O
work None None O
has None None O
identified None None O
pathways None None O
for None None O
communication None None O
across None None O
striatal None None O
subdivisions None None O
, None None O
suggesting None None O
that None None O
the None None O
striatum None None I-REGION
provides None None O
a None None O
platform None None O
for None None O
integration None None O
of None None O
information None None O
across None None O
parallel None None O
corticostriatal None None O
circuits None None O
. None None O

Utilizing None None O
resting-state None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
, None None O
we None None O
analyzed None None O
functional None None O
connectivity None None O
in None None O
39 None None O
patients None None O
with None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
both None None O
`` None None O
on None None O
'' None None O
and None None O
`` None None O
off None None O
'' None None O
their None None O
regular None None O
dopaminergic None None O
medications None None O
, None None O
along None None O
with None None O
40 None None O
age-matched None None O
healthy None None O
controls None None O
. None None O

The None None O
administration None None O
of None None O
dopaminergic None None O
medication None None O
significantly None None O
improved None None O
connectivity None None O
across None None O
striatal None None O
subdivisions None None O
in None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
implicating None None O
dopaminergic None None O
deficits None None O
in None None O
the None None O
pathogenesis None None O
of None None O
impaired None None O
striatal None None O
interconnectivity None None O
. None None O

Specifically None None O
, None None O
we None None O
found None None O
that None None O
although None None O
the None None O
strength None None O
of None None O
striatal None None O
interconnectivity None None O
was None None O
positively None None O
correlated None None O
with None None O
both None None O
( None None O
i None None O
) None None O
the None None O
strength None None O
of None None O
internal None None O
thalamic None None O
connectivity None None O
, None None O
and None None O
( None None O
ii None None O
) None None O
the None None O
strength None None O
of None None O
internal None None O
SM None None O
connectivity None None O
, None None O
in None None O
both None None O
healthy None None O
controls None None O
and None None O
the None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
`` None None O
on None None O
'' None None O
state None None O
, None None O
these None None O
relationships None None O
were None None O
absent None None O
in None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
when None None O
in None None O
the None None O
`` None None O
off None None O
'' None None O
state None None O
. None None O

Luciferase None None I-PROTEIN
reporter None None O
assays None None O
and None None O
Western None None O
blots None None O
were None None O
used None None O
to None None O
validate None None O
HNF-3β None None O
as None None O
a None None O
direct None None O
target None None O
gene None None O
of None None O
miR-141 None None O
. None None O

Only None None O
ATV None None O
at None None O
10 None None O
mg/kg/day None None O
decreased None None O
reduced None None O
glutathione None None O
( None None O
GSH None None O
) None None O
levels None None O
and None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
activity None None O
, None None O
increased None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
levels None None O
, None None O
and None None O
elicited None None O
histopathological None None O
changes None None O
in None None O
the None None O
liver None None O
. None None O

Production None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
prostaglandin None None O
E2 None None O
( None None O
PGE2 None None O
) None None O
, None None O
messenger None None O
RNA None None O
( None None O
mRNA None None O
) None None O
and None None O
protein None None O
expressions None None O
of None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
, None None O
cyclooxygenase-2 None None O
( None None O
COX-2 None None O
) None None O
, None None O
interleukin None None O
6 None None O
( None None O
IL-6 None None O
) None None O
, None None O
and None None O
granulocyte None None O
macrophage None None O
colony-stimulating None None O
factor None None O
( None None O
GM-CSF None None O
) None None O
, None None O
phosphorylation None None O
of None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
; None None O
extracellular None None O
signal-regulated None None O
kinase None None O
( None None O
ERK None None O
) None None O
, None None O
c-Jun None None O
N-terminal None None O
kinase None None O
( None None O
JNK None None O
) None None O
, None None O
p38 None None O
) None None O
, None None O
and None None O
the None None O
activation None None O
of None None O
nuclear None None O
factor None None O
κ-light None None O
chain None None O
enhancer None None O
of None None O
activated None None O
B None None O
cells None None O
( None None O
NFκB None None O
) None None O
with None None O
OxyR None None O
were None None O
assayed None None O
in None None O
LPS-stimulated None None O
RAW264.7 None None O
cells None None O
. None None O

The None None O
gene None None O
expression None None O
profiles None None O
from None None O
drug-treated None None O
cells None None O
revealed None None O
changes None None O
in None None O
the None None O
integrin None None I-PROTEIN
signaling None None O
pathway None None O
, None None O
suggesting None None O
that None None O
cardiac None None O
arrhythmias None None O
induced None None O
by None None O
antihistamine None None O
treatment None None O
may None None O
be None None O
mediated None None O
by None None O
changes None None O
in None None O
integrin-mediated None None O
signaling None None O
. None None O

The None None O
30-day None None O
stroke None None I-DISEASE
rate None None O
was None None O
2.8 None None O
% None None O
and None None O
the None None O
mean None None O
transvalvular None None O
gradient None None O
was None None O
12.4 None None O
± None None O
5.8 None None O
mmHg None None O
. None None O

The None None O
former None None O
had None None O
higher None None O
flexural None None O
rigidity None None O
and None None O
suture None None O
retention None None I-FUNC
strength None None O
compared None None O
to None None O
the None None O
latter None None O
, None None O
but None None O
both None None O
of None None O
them None None O
had None None O
the None None O
essential None None O
flexural None None O
rigidity None None O
and None None O
suture None None O
retention None None I-FUNC
strength None None O
required None None O
for None None O
skin None None O
grafts None None O
. None None O

Copyright None None O
2014 None None O
The None None O
Association None None O
for None None O
Research None None O
in None None O
Vision None None I-FUNC
and None None O
Ophthalmology None None O
, None None O
Inc. None None O
We None None O
report None None O
the None None O
discovery None None O
of None None O
a None None O
new None None O
allotrope None None O
of None None O
iron None None O
by None None O
first None None O
principles None None O
calculations None None O
. None None O

Signals None None O
flow None None O
through None None O
Mst/Lats None None O
kinases None None I-PROTEIN
, None None O
which None None O
phosphorylate None None O
and None None O
promote None None O
cytoplasmic None None O
localization None None O
of None None O
the None None O
transcriptional None None O
regulators None None O
Yap None None O
and None None O
Taz None None O
to None None O
inhibit None None O
transcription None None O
. None None O

In None None O
vivo None None O
studies None None O
utilizing None None O
acetylation-mimic None None O
and None None O
acetylation-defective None None O
K217 None None O
mutants None None O
and None None O
gene None None O
expression None None O
profiling None None O
revealed None None O
that None None O
FXR None None O
acetylation None None O
increased None None O
proinflammatory None None O
gene None None O
expression None None O
, None None O
macrophage None None O
infiltration None None O
, None None O
and None None O
liver None None O
cytokine None None O
and None None O
triglyceride None None O
levels None None O
, None None O
impaired None None O
insulin None None I-PROTEIN
signaling None None O
, None None O
and None None O
increased None None O
glucose None None O
intolerance None None O
. None None O

Low-contrast None None O
vision None None I-FUNC
is None None O
thought None None O
to None None O
be None None O
reduced None None O
in None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
. None None O

Low-contrast None None O
letter None None O
acuity None None O
testing None None O
has None None O
been None None O
successful None None O
in None None O
assessing None None O
low-contrast None None O
vision None None I-FUNC
in None None O
multiple None None O
sclerosis None None O
. None None O

PD None None O
patients None None O
had None None O
significantly None None O
lower None None O
scores None None O
( None None O
indicating None None O
worse None None O
vision None None I-FUNC
) None None O
for None None O
2.5 None None O
% None None O
low None None O
contrast None None O
at None None O
both None None O
distances None None O
and None None O
for None None O
high None None O
contrast None None O
at None None O
2 None None O
m None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.003 None None O
) None None O
compared None None O
to None None O
controls None None O
. None None O

Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
patients None None O
have None None O
reduced None None O
low None None O
and None None O
high None None O
contrast None None O
acuity None None O
compared None None O
to None None O
controls None None O
. None None O

Continued None None O
and None None O
frequent None None O
use None None O
of None None O
the None None O
affected None None O
arm None None O
can None None O
result None None O
in None None O
increased None None O
function None None O
after None None O
stroke None None I-DISEASE
. None None O

Kinect None None O
games None None O
were None None O
created None None O
with None None O
special None None O
consideration None None O
for None None O
the None None O
stroke None None I-DISEASE
population None None O
and None None O
retraining None None O
normal None None O
movement None None I-FUNC
kinematics None None O
. None None O

Strategic None None O
vibration None None O
of None None O
musculotendinous None None O
regions None None O
of None None O
a None None O
limb None None O
elicits None None O
illusionary None None O
sensations None None I-FUNC
of None None O
movement None None I-FUNC
. None None O

Movement None None I-FUNC
illusions None None O
were None None O
induced None None O
in None None O
12 None None O
participants None None O
' None None O
biceps None None O
and None None O
triceps None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
gain None None O
knowledge None None O
about None None O
participants None None O
' None None O
experience None None O
and None None O
perceptions None None I-FUNC
of None None O
a None None O
workplace None None O
intervention None None O
involving None None O
the None None O
introduction None None O
of None None O
SSDs None None O
. None None O

There None None O
was None None O
no None None O
perception None None I-FUNC
of None None O
decreased None None O
productivity None None O
or None None O
reduced None None O
workplace None None O
privacy None None O
among None None O
participants None None O
. None None O

Due None None O
to None None O
their None None O
intersectional None None O
identities None None O
as None None O
immigrants/refugees None None O
and None None O
HIV None None O
positive None None O
individuals None None O
, None None O
participants None None O
face None None O
compounded None None O
barriers None None O
to None None O
employment None None O
: None None O
Language None None I-FUNC
difficulties None None O
, None None O
lack None None O
of None None O
migrant None None O
status None None O
and None None O
Canadian None None O
work None None O
experience None None O
, None None O
anti-immigrant None None O
sentiments None None O
in None None O
the None None O
labor None None O
market None None O
, None None O
ageism None None O
, None None O
HIV None None O
related None None O
stigma None None O
and None None O
side None None O
effects None None O
of None None O
medications None None O
among None None O
other None None O
barriers None None O
related None None O
with None None O
an None None O
HIV None None O
positive None None O
condition None None O
. None None O

A None None O
42 None None O
years None None O
female None None O
patient None None O
came None None O
to None None O
clinical None None O
observation None None O
for None None O
a None None O
voluminous None None O
thoraco-abdominal None None O
mass None None O
located None None O
in None None O
right None None O
side None None O
, None None O
infiltrating None None O
the None None O
diaphragm None None I-REGION
. None None O

Identification None None O
and None None O
classification None None O
of None None O
common None None O
gait None None O
deviation None None O
patterns None None O
in None None O
children None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
facilitates None None O
communication None None O
between None None O
healthcare None None O
providers None None O
, None None O
provides None None O
insight None None O
into None None O
the None None O
natural None None O
history None None O
of None None O
functional None None O
ambulation None None O
, None None O
guides None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
and None None O
clarifies None None O
outcomes None None O
assessment None None O
. None None O

In None None O
a None None O
parallel None None O
process None None O
, None None O
governed None None O
by None None O
a None None O
similar None None O
set None None O
of None None O
signaling None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
endothelial-to-mesenchymal None None O
transitions None None O
( None None O
EndoMT None None O
) None None O
contribute None None O
to None None O
heart None None O
valve None None O
formation None None O
and None None O
the None None O
generation None None O
of None None O
cancer-associated None None O
fibroblasts None None O
. None None O

In None None O
contrast None None O
, None None O
arrestin-3 None None O
interaction None None O
with None None O
a None None O
β2-adrenoceptor None None O
fused None None O
to None None O
the None None O
carboxyl-terminal None None O
tail None None O
of None None O
the None None O
vasopressin None None I-TRANS
type None None O
2 None None O
receptor None None I-PROTEIN
was None None O
nearly None None O
irreversible None None O
. None None O

Thus None None O
, None None O
we None None O
show None None O
how None None O
the None None O
interaction None None O
between None None O
arrestins None None O
and None None O
receptors None None I-PROTEIN
can None None O
be None None O
increased None None O
with None None O
minimal None None O
receptor None None I-PROTEIN
modification None None O
and None None O
that None None O
relatively None None O
modest None None O
increases None None O
in None None O
receptor-arrestin None None O
affinity None None O
are None None O
sufficient None None O
to None None O
alter None None O
arrestin None None O
trafficking None None O
. None None O

The None None O
loss None None O
of None None O
Synpo None None O
protein None None O
after None None O
Stattic None None O
or None None O
cycloheximide None None O
treatment None None O
did None None O
not None None O
occur None None O
when None None O
podocytes None None O
were None None O
simultaneously None None O
exposed None None O
to None None O
1- None None O
[ None None O
N- None None O
[ None None O
( None None O
l-3-trans-carboxyoxirane-2-carbonyl None None O
) None None O
-l-leucyl None None O
] None None O
amino None None O
] None None O
-4-guanidinobutane None None O
( None None O
E-64 None None O
) None None O
, None None O
an None None O
inhibitor None None O
of None None O
thiol None None O
proteases None None O
such None None O
as None None O
cathepsin None None O
L. None None O
Treatment None None O
with None None O
interleukin-6 None None O
( None None O
IL-6 None None O
) None None O
increased None None O
tyrosine None None I-TRANS
phosphorylation None None O
of None None O
STAT3 None None O
and None None O
evoked None None O
a None None O
parallel None None O
increase None None O
in None None O
Synpo None None O
levels None None O
in None None O
podocytes None None O
. None None O

Inhibition None None O
of None None O
STAT3 None None O
by None None O
Stattic None None O
caused None None O
marked None None O
changes None None O
in None None O
the None None O
distribution None None O
of None None O
podocyte None None O
actin None None I-PROTEIN
filaments None None O
, None None O
and None None O
caused None None O
a None None O
nearly None None O
complete None None O
suppression None None O
of None None O
the None None O
migration None None O
of None None O
these None None O
cells None None O
in None None O
wound None None O
assays None None O
, None None O
consistent None None O
with None None O
the None None O
loss None None O
of None None O
Synpo None None O
. None None O

Using None None O
a None None O
heterologous None None O
GABA None None I-TRANS
( None None O
B None None O
) None None O
R None None O
expression None None O
system None None O
, None None O
electrophysiology None None O
, None None O
and None None O
mutagenesis None None O
, None None O
we None None O
showed None None O
α-conotoxin None None O
Vc1.1 None None O
modulates None None O
Cav2.2 None None O
via None None O
a None None O
different None None O
pathway None None O
from None None O
that None None O
of None None O
the None None O
GABA None None I-TRANS
( None None O
B None None O
) None None O
R None None O
agonists None None O
GABA None None I-TRANS
and None None O
baclofen None None O
. None None O

We None None O
then None None O
systematically None None O
truncated None None O
the None None O
GABA None None I-TRANS
( None None O
B None None O
) None None O
( None None O
1a None None O
) None None O
C None None O
terminus None None O
and None None O
discovered None None O
that None None O
removing None None O
the None None O
proximal None None O
carboxyl None None O
terminus None None O
of None None O
the None None O
GABA None None I-TRANS
( None None O
B None None O
) None None O
( None None O
1a None None O
) None None O
subunit None None O
significantly None None O
reduced None None O
Vc1.1 None None O
inhibition None None O
of None None O
Cav2.2 None None O
currents None None O
. None None O

These None None O
findings None None O
provide None None O
important None None O
insights None None O
into None None O
how None None O
GABA None None I-TRANS
( None None O
B None None O
) None None O
Rs None None O
mediate None None O
Cav2.2 None None O
channel None None O
inhibition None None O
and None None O
alter None None O
nociceptive None None O
transmission None None O
. None None O

Deep None None O
vein None None O
thrombosis None None I-DISEASE
related None None O
to None None O
immobilization None None O
is None None O
a None None O
common None None O
and None None O
extensively None None O
studied None None O
disorder None None O
, None None O
particularly None None O
in None None O
hospitalized None None O
patients None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
experiences None None O
of None None O
parents None None O
having None None O
a None None O
child None None O
with None None O
Autism None None I-DISEASE
Spectrum None None I-DISEASE
Disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
and None None O
what None None O
kind None None O
of None None O
support None None O
parents None None O
would None None O
like None None O
to None None O
receive None None O
in None None O
primary None None O
care None None O
. None None O

Managing None None O
patients None None O
coinfected None None O
with None None O
HIV/TB None None O
is None None O
complex None None O
, None None O
and None None O
, None None O
therefore None None O
, None None O
TDM None None O
of None None O
drug None None O
concentrations None None O
can None None O
help None None O
guide None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Bovine None None O
β-arrestin None None O
2 None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
SUMOylated None None O
on None None O
the None None O
lysine None None I-TRANS
400 None None O
residue None None O
, None None O
which None None O
links None None O
it None None O
to None None O
the None None O
endocytosis None None O
of None None O
the None None O
β2-adrenergic None None O
receptor None None I-PROTEIN
. None None O

However None None O
, None None O
in None None O
contrast None None O
to None None O
high None None O
resolution None None O
structural None None O
understanding None None O
of None None O
agonist None None O
action None None O
in None None O
the None None O
receptors None None I-PROTEIN
, None None O
comparatively None None O
little None None O
is None None O
known None None O
about None None O
the None None O
molecular None None O
basis None None O
of None None O
antagonist None None O
binding None None O
. None None O

There None None O
was None None O
little None None O
or None None O
no None None O
effect None None O
on None None O
sensitivity None None O
to None None O
suramin None None O
and None None O
pyridoxal-phosphate-6-azophenyl-2,4-disulfonate None None O
in None None O
chimeric None None O
P2X1/4 None None O
receptors None None I-PROTEIN
, None None O
indicating None None O
that None None O
a None None O
significant None None O
number None None O
of None None O
residues None None O
required None None O
for None None O
binding None None O
of None None O
these None None O
antagonists None None O
are None None O
present None None O
in None None O
the None None O
P2X4 None None O
receptor None None I-PROTEIN
. None None O

Point None None O
mutants None None O
identified None None O
the None None O
importance None None O
of None None O
four None None O
positively None None O
charged None None O
residues None None O
at None None O
the None None O
base None None O
of None None O
the None None O
cysteine-rich None None O
head None None O
and None None O
two None None O
variant None None O
residues None None O
in None None O
the None None O
dorsal None None I-NEURON
fin None None O
for None None O
high None None O
affinity None None O
NF449 None None O
binding None None O
. None None O

The None None O
four None None O
best None None O
potential None None O
NF449-binding None None O
poses None None O
were None None O
then None None O
discriminated None None O
by None None O
correspondence None None O
with None None O
the None None O
mutagenesis None None O
data None None O
and None None O
an None None O
additional None None O
mutant None None O
to None None O
validate None None O
the None None O
binding None None O
of None None O
one None None O
lobe None None O
of None None O
NF449 None None O
within None None O
the None None O
core None None O
conserved None None O
ATP-binding None None O
pocket None None O
and None None O
the None None O
other None None O
lobes None None O
coordinated None None O
by None None O
positive None None O
charge None None O
on None None O
the None None O
cysteine-rich None None O
head None None O
region None None O
and None None O
residues None None O
in None None O
the None None O
adjacent None None O
dorsal None None I-NEURON
fin None None O
. None None O

We None None O
confirmed None None O
that None None O
PI None None O
( None None O
4,5 None None O
) None None O
P2 None None O
behaves None None O
as None None O
a None None O
channel None None O
agonist None None O
and None None O
found None None O
that None None O
Arg-575 None None O
, None None O
Arg-579 None None O
, None None O
and None None O
Lys-694 None None O
mutations None None O
to None None O
alanine None None I-TRANS
reduce None None O
PI None None O
( None None O
4,5 None None O
) None None O
P2 None None O
binding None None O
affinity None None O
. None None O

Here None None O
we None None O
define None None O
the None None O
minimal None None O
linear None None O
sequence None None O
for None None O
inhibitor None None O
activity None None O
( None None O
determined None None O
as None None O
TM4 None None O
( None None O
88-100 None None O
) None None O
, None None O
and None None O
then None None O
`` None None O
staple None None O
'' None None O
this None None O
sequence None None O
via None None O
Grubbs None None O
metathesis None None O
to None None O
produce None None O
peptides None None I-TRANS
typified None None O
by None None O
acetyl-A- None None O
( None None O
Sar None None O
) None None O
3- None None O
( None None O
88 None None O
) None None O
VVGLXLIZXGVVV None None O
( None None O
100 None None O
) None None O
-KKK-NH2 None None O
( None None O
X None None O
= None None O
2- None None O
( None None O
4'-pentenyl None None O
) None None O
alanine None None I-TRANS
at None None O
positions None None O
92 None None O
and None None O
96 None None O
; None None O
Z None None O
= None None O
Val None None O
, None None O
Gly None None I-TRANS
, None None O
or None None O
Asn None None O
at None None O
position None None O
95 None None O
) None None O
) None None O
. None None O

Knockdown None None O
of None None O
MCM7 None None O
or None None O
SF3B3 None None O
significantly None None O
increased None None O
unspliced None None O
RNA None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
, None None O
platelet-derived None None O
growth None None O
factor None None O
receptor None None I-PROTEIN
, None None O
and None None O
c-Met None None O
. None None O

© None None O
2015 None None O
by None None O
The None None O
American None None O
Society None None O
for None None O
Biochemistry None None O
and None None O
Molecular None None O
Biology None None O
, None None O
Inc. None None O
Aromatase None None I-PROTEIN
( None None O
CYP19A1 None None O
) None None O
, None None O
the None None O
enzyme None None O
that None None O
converts None None O
androgens None None I-PROTEIN
to None None O
estrogens None None I-PROTEIN
, None None O
is None None O
of None None O
significant None None O
mechanistic None None O
and None None O
therapeutic None None O
interest None None O
. None None O

Aromatase None None I-PROTEIN
binding None None O
to None None O
anastrozole None None O
is None None O
pH-independent None None O
, None None O
consistent None None O
with None None O
the None None O
hypothesis None None O
that None None O
this None None O
ligand None None O
exploits None None O
a None None O
distinct None None O
set None None O
of None None O
interactions None None O
in None None O
the None None O
active None None O
site None None O
. None None O

The None None O
polyubiquitin None None O
chain None None O
must None None O
be None None O
assembled None None O
rapidly None None O
in None None O
cells None None O
, None None O
because None None O
a None None O
chain None None O
of None None O
at None None O
least None None O
four None None O
ubiquitins None None O
is None None O
required None None O
to None None O
signal None None O
for None None O
degradation None None O
, None None O
and None None O
chain-editing None None O
enzymes None None I-PROTEIN
in None None O
the None None O
cell None None O
may None None O
cleave None None O
premature None None O
polyubiquitin None None O
chains None None O
before None None O
achieving None None O
this None None O
critical None None O
length None None O
. None None O

While None None O
the None None O
majority None None O
of None None O
cases None None O
are None None O
attributed None None O
to None None O
pituitary None None O
or None None O
ectopic None None O
corticotropin None None I-TRANS
( None None O
ACTH None None O
) None None O
overproduction None None O
, None None O
primary None None O
cortisol-producing None None O
adrenal None None I-TRANS
cortical None None O
lesions None None O
are None None O
increasingly None None O
recognised None None O
in None None O
the None None O
pathophysiology None None O
of None None O
Cushing None None O
's None None O
syndrome None None O
. None None O

Recently None None O
, None None O
important None None O
mechanisms None None O
underlying None None O
the None None O
pathogenesis None None O
of None None O
adrenal None None I-TRANS
hypercortisolism None None O
have None None O
been None None O
elucidated None None O
with None None O
the None None O
discovery None None O
of None None O
mutations None None O
in None None O
cyclic None None O
AMP None None O
signalling None None O
( None None O
PRKACA None None O
, None None O
PRKAR1A None None O
, None None O
GNAS None None O
, None None O
PDE11A None None O
, None None O
PDE8B None None O
) None None O
, None None O
armadillo None None O
repeat None None O
containing None None O
5 None None O
gene None None O
( None None O
ARMC5 None None O
) None None O
a None None O
putative None None O
tumour None None O
suppressor None None O
gene None None O
, None None O
aberrant None None O
G-protein-coupled None None I-PROTEIN
receptors None None I-PROTEIN
, None None O
and None None O
intra-adrenal None None O
secretion None None O
of None None O
ACTH None None O
. None None O

Pathological None None O
correlates None None O
in None None O
the None None O
adrenal None None I-TRANS
glands None None O
include None None O
hyperplasia None None O
, None None O
adenoma None None O
and None None O
carcinoma None None O
. None None O

DNA None None O
methylation None None O
in None None O
Arabidopsis None None O
thaliana None None O
is None None O
maintained None None O
by None None O
at None None O
least None None O
four None None O
different None None O
enzymes None None I-PROTEIN
: None None O
DNA None None O
methyltransferase1 None None O
( None None O
MET1 None None O
) None None O
, None None O
chromomethylase3 None None O
( None None O
CMT3 None None O
) None None O
, None None O
domains None None O
rearranged None None O
methyltransferase2 None None O
( None None O
DRM2 None None O
) None None O
, None None O
and None None O
chromomethylase2 None None O
( None None O
CMT2 None None O
) None None O
. None None O

We None None O
used None None O
integrated None None O
X-ray- None None O
and None None O
terahertz- None None O
based None None O
time-resolved None None O
spectroscopic None None O
tools None None O
to None None O
study None None O
protein-water None None O
dynamics None None O
during None None O
proteolysis None None O
of None None O
collagen-like None None O
substrates None None O
by None None O
a None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
. None None O

The None None O
activated None None O
FPS None None O
expression None None O
enables None None O
the None None O
PS None None O
reaction None None O
between None None O
1-MT None None O
and None None O
flavipin None None O
( None None O
fungal None None O
aldehyde None None O
) None None O
to None None O
form None None O
`` None None O
unnatural None None O
'' None None O
natural None None O
products None None O
with None None O
unprecedented None None O
skeletons None None O
, None None O
of None None O
which None None O
chaetoglines None None O
B None None O
and None None O
F None None O
are None None O
potently None None O
antibacterial None None O
with None None O
the None None O
latter None None O
inhibiting None None O
acetylcholinesterase None None I-PROTEIN
. None None O

In None None O
addition None None O
, None None O
they None None O
have None None O
been None None O
classified None None O
as None None O
a None None O
new None None O
group None None O
of None None O
plant None None O
hormones None None I-PROTEIN
essential None None O
for None None O
shoot None None O
branching None None O
inhibition None None O
. None None O

First None None O
, None None O
we None None O
developed None None O
and None None O
validated None None O
a None None O
mitochondrial None None O
DNA None None O
assay None None O
based None None O
on None None O
species-specific None None O
amplification None None O
of None None O
the None None O
cytochrome None None I-PROTEIN
c None None I-PROTEIN
oxidase None None I-PROTEIN
subunit None None O
1 None None O
( None None O
COI None None O
) None None O
. None None O

Indeed None None O
, None None O
an None None O
increased None None O
risk None None O
of None None O
acute None None O
graft-versus-host None None O
disease None None O
was None None O
observed None None O
in None None O
association None None O
with None None O
single None None O
nucleotide None None O
polymorphisms None None O
located None None O
in None None O
5-aminoimidazole-4-carboxamide None None O
ribonucleotide None None O
formyltransferase/inosine None None O
monophosphate None None O
cyclohydrolase None None O
( None None O
hazard None None O
ratio=3.04 None None O
; None None O
P=0.002 None None O
) None None O
, None None O
nuclear None None O
factor None None O
of None None O
activated None None O
T None None O
cells None None O
( None None O
cytoplasmic None None O
1 None None O
) None None O
( None None O
hazard None None O
ratio=2.69 None None O
; None None O
P=0.004 None None O
) None None O
, None None O
adenosine None None I-TRANS
triphosphate-binding None None O
cassette None None O
sub-family None None O
C2 None None O
( None None O
hazard None None O
ratio=3.53 None None O
; None None O
P=0.0018 None None O
) None None O
and None None O
adenosine None None I-TRANS
triphosphate-binding None None O
cassette None None O
sub-family None None O
C1 None None O
( None None O
hazard None None O
ratio=3.67 None None O
; None None O
P=0.0005 None None O
) None None O
. None None O

Patients None None O
with None None O
a None None O
high None None O
density None None O
of None None O
CD3 None None O
and None None O
FoxP3 None None I-PROTEIN
by None None O
both None None O
methods None None O
had None None O
a None None O
better None None O
outcome None None O
. None None O

Following None None O
the None None O
use None None O
of None None O
two None None O
methods None None O
of None None O
semi-automated None None O
analysis None None O
we None None O
suggest None None O
that None None O
CD3 None None O
and None None O
FoxP3 None None I-PROTEIN
play None None O
a None None O
role None None O
in None None O
predicting None None O
response None None O
to None None O
chemoimmunotherapy None None O
in None None O
diffuse None None O
large None None O
B-cell None None O
lymphoma None None O
. None None O

Interactive None None O
neurorehabilitation None None O
( None None O
INR None None O
) None None O
systems None None O
provide None None O
therapy None None O
that None None O
can None None O
evaluate None None O
and None None O
deliver None None O
feedback None None O
on None None O
a None None O
patient None None O
's None None O
movement None None I-FUNC
computationally None None O
. None None O

This None None O
article None None O
presents None None O
key None None O
interactive None None O
computing None None O
, None None O
motor None None O
learning None None I-FUNC
, None None O
and None None O
media None None O
arts None None O
concepts None None O
utilized None None O
by None None O
an None None O
interdisciplinary None None O
group None None O
to None None O
develop None None O
adaptive None None O
, None None O
mixed None None O
reality None None O
INR None None O
systems None None O
for None None O
upper None None O
extremity None None O
therapy None None O
of None None O
patients None None O
with None None O
stroke None None I-DISEASE
. None None O

Vaccine-induced None None O
memory None None I-FUNC
B None None O
cell None None O
counts None None O
were None None O
significantly None None O
increased None None O
, None None O
and None None O
the None None O
response None None O
persisted None None O
for None None O
one None None O
year None None O
. None None O

There None None O
was None None O
a None None O
clinically None None O
important None None O
drop None None O
in None None O
manually None None O
set None None O
cuff None None O
pressure None None O
during None None O
simulated None None O
mechanical None None O
ventilation None None O
in None None O
a None None O
stationary None None O
model None None O
and None None O
an None None O
even None None O
larger None None O
drop None None O
with None None O
movement None None I-FUNC
, None None O
but None None O
this None None O
was None None O
significantly None None O
reduced None None O
by None None O
the None None O
IntelliCuff None None O
in None None O
both None None O
scenarios None None O
. None None O

The None None O
Hazard None None O
Perception None None I-FUNC
Test None None O
( None None O
HPT None None O
) None None O
is None None O
a None None O
computer-based None None O
component None None O
of None None O
the None None O
UK None None O
examination None None O
for None None O
learner None None O
drivers None None O
. None None O

Thirty None None O
UK None None O
drivers None None O
with None None O
healthy None None O
vision None None I-FUNC
completed None None O
three None None O
versions None None O
of None None O
the None None O
HPT None None O
in None None O
a None None O
random None None O
order None None O
. None None O

Through None None O
the None None O
lens None None O
of None None O
the None None O
socioecological None None O
model None None O
, None None O
we None None O
highlight None None O
reported None None O
barriers None None O
and None None O
facilitators None None O
to None None O
recruitment None None O
and None None O
retention None None I-FUNC
of None None O
pregnant None None O
women None None O
in None None O
studies None None O
that None None O
sought None None O
their None None O
participation None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
diagnostic None None O
utility None None O
of None None O
lung-specific None None O
X None None O
protein None None O
( None None O
LUNX None None O
) None None O
mRNA None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
mRNA None None O
in None None O
differentiating None None O
pleural None None O
effusion None None O
of None None O
different None None O
origin None None O
. None None O

Levels None None O
of None None O
LUNX None None O
mRNA None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
mRNA None None O
in None None O
pleural None None O
fluid None None O
were None None O
detected None None O
by None None O
real-time None None O
quantitative None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

For None None O
the None None O
diagnosis None None O
of None None O
malignant None None O
pleural None None O
effusion None None O
caused None None O
by None None O
lung None None O
cancer None None O
, None None O
LUNX None None O
mRNA None None O
exhibited None None O
higher None None O
sensitivity None None O
( None None O
80 None None O
% None None O
) None None O
, None None O
when None None O
compared None None O
with None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
mRNA None None O
( None None O
65 None None O
% None None O
) None None O
, None None O
carcinoembryonic None None O
antigen None None O
( None None O
67 None None O
% None None O
) None None O
and None None O
Cyfra21-1 None None O
( None None O
61 None None O
% None None O
) None None O
, None None O
with None None O
the None None O
same None None O
specificity None None O
( None None O
95 None None O
% None None O
) None None O
. None None O

The None None O
combined None None O
use None None O
of None None O
LUNX None None O
mRNA None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
mRNA None None O
and None None O
cytology None None O
raised None None O
the None None O
sensitivity None None O
to None None O
89 None None O
% None None O
, None None O
with None None O
95 None None O
% None None O
specificity None None O
. None None O

The None None O
detection None None O
of None None O
LUNX None None O
mRNA None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
mRNA None None O
in None None O
pleural None None O
fluid None None O
may None None O
be None None O
a None None O
complementary None None O
tool None None O
for None None O
the None None O
diagnosis None None O
of None None O
malignant None None O
pleural None None O
effusion None None O
. None None O

In None None O
the None None O
United None None O
States None None O
half None None O
of None None O
the None None O
15 None None O
million None None O
informal None None O
caregivers None None O
of None None O
persons None None O
with None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
or None None O
a None None O
related None None O
dementia None None I-DISEASE
( None None O
PWDs None None O
) None None O
do None None O
not None None O
live None None O
with None None O
the None None O
PWD None None O
. None None O

Variables None None O
of None None O
interest None None O
were None None O
caregiving None None O
experience None None O
( None None O
hours None None O
caregiving None None O
, None None O
problematic None None O
behaviors None None O
of None None O
the None None O
PWD None None O
, None None O
caregivers None None O
' None None O
perception None None I-FUNC
of None None O
dementia None None I-DISEASE
severity None None O
) None None O
, None None O
sleep None None O
quality None None O
, None None O
and None None O
health None None O
( None None O
perceived None None O
health None None O
, None None O
stress None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
) None None O
. None None O

Multiple None None O
regression None None O
models None None O
were None None O
constructed None None O
, None None O
controlling None None O
for None None O
age None None O
, None None O
gender None None O
, None None O
behavior None None O
index None None O
, None None O
and None None O
dementia None None I-DISEASE
severity None None O
to None None O
examine None None O
the None None O
variance None None O
explained None None O
by None None O
living None None O
arrangements None None O
on None None O
sleep None None O
quality None None O
and None None O
health None None O
. None None O

Findings None None O
indicate None None O
that None None O
the None None O
Alzheimer None None I-DISEASE
's None None O
Association None None O
Web None None O
site None None O
is None None O
effective None None O
at None None O
producing None None O
higher None None O
scores None None O
for None None O
AD None None O
knowledge None None O
relative None None O
to None None O
no None None O
Web None None O
site None None O
at None None O
all None None O
and None None O
that None None O
it None None O
is None None O
especially None None O
helpful None None O
for None None O
health None None O
care None None O
workers None None O
compared None None O
to None None O
those None None O
who None None O
are None None O
not None None O
health None None O
care None None O
workers None None O
. None None O

Millions None None O
face None None O
the None None O
challenges None None O
of None None O
caregiving None None O
for None None O
a None None O
loved None None O
one None None O
with None None O
dementia None None I-DISEASE
. None None O

PSGL-1 None None O
ligation None None O
induced None None O
dissociation None None O
of None None O
the None None O
raft-associated None None O
protein None None O
β-adducin None None O
from None None O
lipid None None O
rafts None None O
and None None O
actin None None I-PROTEIN
, None None O
as None None O
well None None O
as None None O
phosphorylation None None O
of None None O
β-adducin None None O
, None None O
indicating None None O
a None None O
transient None None O
uncoupling None None O
of None None O
lipid None None O
rafts None None O
from None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
. None None O

Individuals None None O
at None None O
ultra-high None None O
risk None None O
( None None O
UHR None None O
) None None O
for None None O
psychosis None None O
, None None O
the None None O
'putative None None O
' None None O
prodrome None None O
of None None O
schizophrenia None None I-DISEASE
, None None O
generally None None O
show None None O
levels None None O
of None None O
impairments None None O
intermediate None None O
between None None O
schizophrenia None None I-DISEASE
patients None None O
and None None O
healthy None None O
controls None None O
. None None O

Attention/working None None O
memory None None I-FUNC
and None None O
verbal None None O
memory None None I-FUNC
were None None O
significantly None None O
different None None O
from None None O
both None None O
the None None O
FES None None O
and None None O
HC None None O
groups None None O
. None None O

In None None O
the None None O
Cox None None O
regression None None O
model None None O
, None None O
spatial None None I-FUNC
memory None None I-FUNC
significantly None None O
predicted None None O
the None None O
transition None None O
to None None O
overt None None O
psychosis None None O
in None None O
the None None O
UHR None None O
group None None O
. None None O

Our None None O
findings None None O
generally None None O
support None None O
the None None O
neurodevelopmental None None O
model None None O
of None None O
schizophrenia None None I-DISEASE
and None None O
suggest None None O
that None None O
there None None O
could None None O
be None None O
different None None O
developmental None None O
trajectories None None O
between None None O
converters None None O
and None None O
non-converters None None O
. None None O

This None None O
study None None O
aims None None O
to None None O
quantify None None O
the None None O
potential None None O
economic None None O
impact None None O
of None None O
five-yearly None None O
screening None None O
for None None O
sub-syndromal None None O
depression None None I-DISEASE
in None None O
general None None O
practice None None O
among None None O
Australians None None O
aged None None O
45-64 None None O
years None None O
, None None O
followed None None O
by None None O
a None None O
group-based None None O
psychological None None O
intervention None None O
to None None O
prevent None None O
progression None None O
to None None O
depression None None I-DISEASE
. None None O

Group None None O
therapy None None O
is None None O
estimated None None O
to None None O
prevent None None O
around None None O
5,200 None None O
prevalent None None O
cases None None O
of None None O
depression None None I-DISEASE
( None None O
2.2 None None O
% None None O
) None None O
and None None O
add None None O
about None None O
520 None None O
people None None O
to None None O
the None None O
labour None None O
force None None O
. None None O

Group-based None None O
psychological None None O
intervention None None O
to None None O
prevent None None O
depression None None I-DISEASE
could None None O
result None None O
in None None O
considerable None None O
economic None None O
benefits None None O
in None None O
addition None None O
to None None O
its None None O
clinical None None O
effects None None O
. None None O

Cytohesins None None O
are None None O
small None None O
guanine None None O
nucleotide None None O
exchange None None O
factors None None O
that None None O
stimulate None None O
ADP None None O
ribosylation None None O
factors None None O
, None None O
Ras-like None None O
GTPases None None O
, None None O
which None None O
control None None O
various None None O
cellular None None O
regulatory None None O
networks None None O
ranging None None O
from None None O
vesicle None None O
trafficking None None O
to None None O
integrin None None I-PROTEIN
activation None None O
. None None O

Recent None None O
developments None None O
in None None O
the None None O
study None None O
of None None O
cognitive None None O
emotion None None I-FUNC
regulation None None O
illustrate None None O
how None None O
functional None None O
imaging None None O
is None None O
extending None None O
behavioral None None O
analyses None None O
. None None O

In None None O
this None None O
article None None O
, None None O
we None None O
review None None O
imaging None None O
studies None None O
of None None O
one None None O
type None None O
of None None O
cognitive None None O
emotion None None I-FUNC
regulation None None O
, None None O
namely None None O
reappraisal None None O
. None None O

Hemodynamic None None O
variables None None O
like None None O
heart None None O
rate None None O
( None None O
HR None None O
) None None O
and None None O
mean None None O
arterial None None O
pressure None None O
( None None O
MAP None None O
) None None O
, None None O
oxygen None None O
saturation None None O
, None None O
electrocardiogram None None O
changes None None O
, None None O
sedation None None O
score None None O
( None None O
modified None None O
Observer None None O
assessment None None O
of None None O
alertness/sedation None None O
score None None O
) None None O
, None None O
intubation None None O
score None None O
( None None O
vocal None None O
cord None None O
movement None None I-FUNC
and None None O
coughing None None O
) None None O
, None None O
grimace None None O
score None None O
, None None O
time None None O
taken None None O
for None None O
intubation None None O
, None None O
amount None None O
of None None O
lignocaine None None O
used None None O
were None None O
noted None None O
during None None O
the None None O
course None None O
of None None O
study None None O
. None None O

In None None O
addition None None O
, None None O
mean None None O
rise None None O
in None None O
systolic None None O
, None None O
diastolic None None O
and None None O
mean None None O
arterial None None O
pressure None None O
was None None O
also None None O
significantly None None O
lower None None O
in None None O
Group None None O
B None None O
as None None O
compared None None O
with None None O
Group None None O
A. None None O
Adrenaline None None I-TRANS
in None None O
a None None O
concentration None None O
of None None O
1:400,000 None None O
added None None O
to None None O
2 None None O
% None None O
lignocaine None None O
for None None O
nasal None None O
mucosa None None O
infiltration None None O
produces None None O
less None None O
hemodynamic None None O
response None None O
as None None O
compared None None O
with None None O
adrenaline None None I-TRANS
1:200,000 None None O
added None None O
to None None O
2 None None O
% None None O
lignocaine None None O
while None None O
at None None O
the None None O
same None None O
time None None O
providing None None O
similar None None O
operating None None O
conditions None None O
. None None O

Mucopolysaccharidosis None None O
( None None O
lysosomal None None O
storage None None I-FUNC
diseases None None O
) None None O
are None None O
a None None O
group None None O
of None None O
inherited None None O
disorders None None O
caused None None O
by None None O
deficiency None None O
of None None O
specific None None O
lysosomal None None O
enzyme None None O
required None None O
for None None O
a None None O
normal None None O
degradation None None O
of None None O
glycosaminoglycons None None O
( None None O
GAGs None None O
) None None O
. None None O

Bonfils None None O
rigid None None O
fiberscope None None O
is None None O
one None None O
of None None O
the None None O
airway None None O
assist None None O
devices None None O
widely None None O
used None None O
for None None O
endotracheal None None O
intubation None None O
in None None O
the None None O
individuals None None O
with None None O
cervical None None O
instability None None O
warranting None None O
limited None None O
neck None None O
movements None None I-FUNC
. None None O

Beta-lactamase None None I-PROTEIN
producing None None O
organisms None None O
are None None O
not None None O
only None None O
more None None O
virulent None None O
they None None O
also None None O
cause None None O
surrounding None None O
bacteria None None O
to None None O
become None None O
resistant None None O
. None None O

Hence None None O
, None None O
the None None O
delay None None O
in None None O
seeking None None O
medical None None O
attention None None I-FUNC
could None None O
lead None None O
to None None O
the None None O
increased None None O
rate None None O
of None None O
mortality None None O
. None None O

This None None O
paper None None O
reviews None None O
the None None O
following None None O
topics None None O
: None None O
the None None O
effect None None O
of None None O
dead None None O
regions None None O
on None None O
the None None O
audiogram None None O
; None None O
methods None None O
for None None O
the None None O
detection None None O
and None None O
delineation None None O
of None None O
dead None None O
regions None None O
based None None O
on None None O
psychophysical None None O
tuning None None O
curves None None O
( None None O
PTCs None None O
) None None O
and None None O
on None None O
the None None O
measurement None None O
of None None O
thresholds None None O
for None None O
pure None None O
tones None None O
in None None O
`` None None O
threshold None None O
equalizing None None O
noise None None O
'' None None O
( None None O
TEN None None O
) None None O
; None None O
effects None None O
of None None O
dead None None O
regions None None O
on None None O
speech None None I-FUNC
perception None None I-FUNC
; None None O
effects None None O
of None None O
dead None None O
regions None None O
on None None O
the None None O
perception None None I-FUNC
of None None O
tones None None O
; None None O
implications None None O
of None None O
dead None None O
regions None None O
for None None O
fitting None None O
hearing None None O
aids None None O
. None None O

However None None O
, None None O
the None None O
determination None None O
of None None O
PTCs None None O
is None None O
probably None None O
too None None O
time-consuming None None O
to None None O
be None None O
used None None O
for None None O
routine None None O
diagnosis None None O
of None None O
dead None None O
regions None None O
in None None O
clinical None None O
practice None None O
; None None O
( None None O
4 None None O
) None None O
The None None O
measurement None None O
of None None O
detection None None O
thresholds None None O
for None None O
pure None None O
tones None None O
in None None O
TEN None None O
provides None None O
a None None O
simple None None O
method None None O
for None None O
clinical None None O
diagnosis None None O
of None None O
dead None None O
regions None None O
; None None O
( None None O
5 None None O
) None None O
Pure None None O
tones None None O
with None None O
frequencies None None O
falling None None O
in None None O
a None None O
dead None None O
region None None O
do None None O
not None None O
evoke None None O
clear None None O
pitch None None O
sensations None None I-FUNC
( None None O
pitch None None O
matching None None O
is None None O
highly None None O
variable None None O
) None None O
and None None O
the None None O
perceived None None O
pitch None None O
is None None O
sometimes None None O
, None None O
but None None O
not None None O
always None None O
, None None O
different None None O
from None None O
`` None None O
normal None None O
'' None None O
. None None O

We None None O
now None None O
have None None O
digital None None O
hearing None None O
aids None None O
, None None O
which None None O
provide None None O
us None None O
the None None O
opportunity None None O
to None None O
conduct None None O
real-ear None None O
measures None None O
of None None O
the None None O
effects None None O
of None None O
digital None None O
noise None None O
reduction None None O
, None None O
speech None None I-FUNC
enhancement None None O
, None None O
adaptive None None O
feedback None None O
, None None O
expansion None None O
, None None O
and None None O
all None None O
the None None O
other None None O
features None None O
. None None O

During None None O
the None None O
first None None O
half None None O
of None None O
the None None O
20th None None O
century None None O
, None None O
communications None None O
engineers None None O
at None None O
Bell None None O
Telephone None None O
Laboratories None None O
developed None None O
the None None O
articulation None None O
model None None O
for None None O
predicting None None O
speech None None I-FUNC
intelligibility None None O
transmitted None None O
through None None O
different None None O
telecommunication None None O
devices None None O
under None None O
varying None None O
electroacoustic None None O
conditions None None O
. None None O

What None None O
effect None None O
will None None O
compression None None O
have None None O
on None None O
speech None None I-FUNC
quality None None O
? None None O

This None None O
article None None O
reviews None None O
the None None O
effects None None O
of None None O
compression None None O
on None None O
the None None O
speech None None I-FUNC
signal None None O
and None None O
the None None O
implications None None O
for None None O
speech None None I-FUNC
intelligibility None None O
, None None O
quality None None O
, None None O
and None None O
design None None O
of None None O
clinical None None O
procedures None None O
. None None O

The None None O
vaccine None None O
was None None O
progressively None None O
introduced None None O
into None None O
the None None O
Expanded None None O
Program None None O
of None None O
Immunization None None O
( None None O
EPI None None I-TRANS
) None None O
of None None O
The None None O
Gambia None None O
over None None O
four None None O
years None None O
in None None O
a None None O
phased None None O
manner None None O
, None None O
called None None O
the None None O
`` None None O
stepped-wedge None None O
'' None None O
design None None O
. None None O

However None None O
, None None O
this None None O
design None None O
also None None O
allowed None None O
the None None O
study None None O
to None None O
have None None O
an None None O
unvaccinated None None O
control None None O
group None None O
which None None O
consisted None None O
of None None O
the None None O
newborns None None O
of None None O
the None None O
areas None None O
where None None O
HBV None None O
vaccine None None O
has None None O
not None None O
yet None None O
been None None O
incorporated None None O
in None None O
the None None O
EPI None None I-TRANS
. None None O

An None None O
increase None None O
in None None O
narcolepsy None None I-DISEASE
diagnoses None None O
was None None O
not None None O
observed None None O
in None None O
other None None O
countries None None O
, None None O
where None None O
vaccination None None O
coverage None None O
was None None O
low None None O
in None None O
the None None O
affected None None O
age None None O
group None None O
, None None O
or None None O
did None None O
not None None O
follow None None O
influenza None None O
. None None O

Most None None O
notably None None O
, None None O
treatment None None O
of None None O
SF1126 None None O
blocked None None O
integrin-dependent None None O
migration None None O
in None None O
transwell None None O
and None None O
scratch None None O
assays None None O
and None None O
caused None None O
a None None O
significant None None O
change None None O
in None None O
the None None O
organization None None O
and None None O
distribution None None O
of None None O
cortical None None O
actin None None I-PROTEIN
on None None O
vitronectin None None O
in None None O
the None None O
glioma None None O
cells None None O
. None None O

Global None None O
gene None None O
expression None None O
profiling None None O
, None None O
pathway None None O
analysis None None O
, None None O
and None None O
experimental None None O
validation None None O
indicate None None O
that None None O
multiple None None O
mechanisms None None O
could None None O
mediate None None O
the None None O
tumor-promoting None None O
effect None None O
of None None O
Klf5 None None O
deletion None None O
, None None O
including None None O
the None None O
up-regulation None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
and None None O
its None None O
downstream None None O
signaling None None O
molecules None None O
AKT None None O
and None None O
ERK None None O
and None None O
the None None O
inactivation None None O
of None None O
the None None O
p15 None None O
cell None None O
cycle None None O
inhibitor None None O
. None None O

Transcription None None I-PROTEIN
factors None None I-PROTEIN
bind None None O
to None None O
response None None O
elements None None O
on None None O
the None None O
promoter None None O
regions None None O
of None None O
genes None None O
to None None O
regulate None None O
transcriptional None None O
activity None None O
. None None O

Developing None None O
a None None O
purification None None O
technique None None O
specific None None O
for None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
is None None O
crucial None None O
to None None O
the None None O
understanding None None O
of None None O
gene None None O
regulation None None O
. None None O

Low None None O
nuclear None None O
ATM None None O
protein None None O
level None None O
was None None O
significantly None None O
associated None None O
with None None O
aggressive None None O
breast None None O
cancer None None O
including None None O
larger None None O
tumors None None O
, None None O
higher None None O
tumor None None O
grade None None O
, None None O
higher None None O
mitotic None None O
index None None O
, None None O
pleomorphism None None O
, None None O
tumor None None O
type None None O
, None None O
lymphovascular None None O
invasion None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
- None None O
, None None O
PR None None O
- None None O
, None None O
AR None None O
- None None O
, None None O
triple-negative None None O
, None None O
and None None O
basal-like None None O
phenotypes None None O
( None None O
Ps None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
. None None O

That None None O
alternative None None O
should None None O
always None None O
be None None O
considered None None O
before None None O
settling None None O
on None None O
a None None O
diagnosis None None O
of None None O
pulmonary None None O
embolism None None I-DISEASE
. None None O

Treatment None None O
included None None O
extraction None None O
of None None O
the None None O
dual-coil None None O
lead None None O
and None None O
placement None None O
of None None O
a None None O
new None None O
single-coil None None O
right None None O
ventricular None None O
lead None None O
at None None O
the None None O
mid None None O
septum None None I-REGION
. None None O

The None None O
results None None O
indicated None None O
that None None O
seven None None O
protein None None O
spots None None O
, None None O
ubiquitin-conjugating None None O
enzyme None None O
E2 None None O
( None None O
E2 None None O
) None None O
, None None O
glutathione None None O
synthetases None None O
( None None O
GS None None O
) None None O
, None None O
triosephosphate None None O
isomerase None None I-PROTEIN
( None None O
TSP None None O
) None None O
, None None O
T-complex None None O
protein None None O
1 None None O
subunit None None O
zeta None None O
( None None O
TCPZ None None O
) None None O
, None None O
lamin-B1 None None O
, None None O
heterogeneous None None O
nuclear None None O
ribonucleoprotein None None O
F None None O
( None None O
hnRNP None None O
F None None O
) None None O
, None None O
and None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
[ None None O
Cu-Zn None None O
] None None O
( None None O
Cu None None O
, None None O
Zn-SOD None None O
) None None O
were None None O
significantly None None O
different None None O
among None None O
all None None O
the None None O
groups None None O
. None None O

It None None O
is None None O
an None None O
analogue None None O
of None None O
melatonin None None I-TRANS
and None None O
features None None O
a None None O
unique None None O
pharmacodynamic None None O
profile None None O
with None None O
agonism None None O
on None None O
both None None O
types None None O
of None None O
melatonergic None None O
receptors None None I-PROTEIN
( None None O
MT1/MT2 None None O
) None None O
and None None O
antagonism None None O
at None None O
serotonergic None None O
5-HT2C None None O
receptors None None I-PROTEIN
. None None O

In None None O
excitable None None O
tissue None None O
, None None O
to None None O
which None None O
the None None O
brain None None O
and None None O
the None None O
retina None None O
belong None None O
, None None O
propagating None None O
excitation None None O
waves None None O
can None None O
be None None O
expected None None O
, None None O
and None None O
the None None O
spreading None None O
depression None None I-DISEASE
is None None O
such None None O
a None None O
phenomenon None None O
. None None O

Later None None O
, None None O
Martins-Ferreira None None O
established None None O
it None None O
in None None O
the None None O
chicken None None O
retina None None O
( None None O
retinal None None O
spreading None None O
depression None None I-DISEASE
or None None O
RSD None None O
) None None O
. None None O

Gastrin-releasing None None O
peptide None None O
( None None O
GRP None None I-TRANS
) None None O
is None None O
a None None O
mammalian None None O
neuropeptide None None O
that None None O
acts None None O
through None None O
the None None O
G None None O
protein-coupled None None O
receptor None None I-PROTEIN
, None None O
GRP None None I-TRANS
receptor None None I-PROTEIN
( None None O
GRPR None None O
) None None O
. None None O

Additionally None None O
, None None O
we None None O
have None None O
recently None None O
reported None None O
that None None O
the None None O
GRP None None I-TRANS
system None None O
within None None O
the None None O
lumbosacral None None O
spinal None None O
cord None None O
not None None O
only None None O
controls None None O
erection None None O
but None None O
also None None O
triggers None None O
ejaculation None None O
in None None O
male None None O
rats None None O
. None None O

Interestingly None None O
, None None O
these None None O
two None None O
distinct None None O
functions None None O
in None None O
the None None O
same None None O
spinal None None O
region None None O
are None None O
both None None O
regulated None None O
by None None O
the None None O
neuropeptide None None O
, None None O
GRP None None I-TRANS
. None None O

In None None O
the None None O
last None None O
decades None None O
, None None O
an None None O
important None None O
role None None O
of None None O
glutamate None None I-TRANS
in None None O
mood None None I-FUNC
modulation None None O
has None None O
been None None O
hypothesized None None O
and None None O
ketamine None None O
, None None O
a None None O
non None None O
noncompetitive None None O
antagonist None None O
of None None O
the None None O
N-methyl-D-aspartate None None O
( None None O
NMDA None None O
) None None O
receptors None None I-PROTEIN
, None None O
has None None O
been None None O
demonstrated None None O
to None None O
be None None O
effective None None O
in None None O
both None None O
MDD None None O
and None None O
TRD None None O
. None None O

Most None None O
studies None None O
demonstrated None None O
that None None O
the None None O
NMDA None None O
antagonist None None O
ketamine None None O
has None None O
rapid None None O
antidepressant None None O
effects None None O
in None None O
TRD None None O
patients None None O
, None None O
confirming None None O
the None None O
active None None O
role None None O
of None None O
glutamate None None I-TRANS
in None None O
the None None O
pathophysiology None None O
of None None O
this None None O
complex None None O
condition None None O
. None None O

Despite None None O
the None None O
many None None O
preclinical None None O
and None None O
clinical None None O
studies None None O
that None None O
have None None O
addressed None None O
this None None O
brain None None O
disorder None None O
, None None O
the None None O
pathophysiology None None O
of None None O
depression None None I-DISEASE
is None None O
not None None O
well None None O
understood None None O
and None None O
the None None O
available None None O
antidepressant None None O
drugs None None O
are None None O
therapeutically None None O
inadequate None None O
in None None O
many None None O
patients None None O
. None None O

There None None O
are None None O
many None None O
indications None None O
that None None O
the None None O
eCB/endovanilloid None None O
system None None O
is None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
depression None None I-DISEASE
, None None O
including None None O
the None None O
localization None None O
of None None O
receptors None None I-PROTEIN
, None None O
modulation None None O
of None None O
monoaminergic None None O
transmission None None O
, None None O
inhibition None None O
of None None O
the None None O
stress None None O
axis None None O
and None None O
promotion None None O
of None None O
neuroplasticity None None O
in None None O
the None None O
brain None None O
. None None O

In None None O
this None None O
article None None O
, None None O
we None None O
review None None O
the None None O
current None None O
knowledge None None O
of None None O
the None None O
role None None O
of None None O
the None None O
eCB/endovanilloid None None O
system None None O
in None None O
depression None None I-DISEASE
, None None O
as None None O
well None None O
as None None O
the None None O
effects None None O
of None None O
its None None O
ligands None None O
, None None O
models None None O
of None None O
depression None None I-DISEASE
and None None O
antidepressant None None O
drugs None None O
in None None O
preclinical None None O
and None None O
clinical None None O
settings None None O
. None None O

We None None O
found None None O
that None None O
the None None O
fly None None O
surface None None O
glia None None O
show None None O
high None None O
expression None None O
of None None O
many None None O
ATP-binding None None O
cassette None None O
( None None O
ABC None None O
) None None O
and None None O
solute None None O
carrier None None O
( None None O
SLC None None O
) None None O
transporters None None I-PROTEIN
, None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecules None None O
, None None O
metabolic None None O
enzymes None None I-PROTEIN
, None None O
signaling None None O
molecules None None O
, None None O
and None None O
components None None O
of None None O
xenobiotic None None O
metabolism None None O
pathways None None O
. None None O

Clinical None None O
data None None O
continue None None O
to None None O
reveal None None O
that None None O
the None None O
incidence None None O
of None None O
perinatal None None O
stroke None None I-DISEASE
is None None O
high None None O
, None None O
similar None None O
to None None O
that None None O
in None None O
the None None O
elderly None None O
. None None O

We None None O
also None None O
discuss None None O
a None None O
possible None None O
role None None O
of None None O
the None None O
neonatal None None O
blood-CSF None None O
barrier None None O
in None None O
modulating None None O
inflammation None None O
and None None O
the None None O
long-term None None O
effects None None O
of None None O
early None None O
neurovascular None None O
integrity None None O
after None None O
neonatal None None O
stroke None None I-DISEASE
on None None O
angiogenesis None None O
and None None O
neurogenesis None None O
. None None O

Indeed None None O
, None None O
emerging None None O
evidence None None O
from None None O
both None None O
human None None O
and None None O
animal None None O
studies None None O
demonstrates None None O
that None None O
early-onset None None O
marijuana None None O
use None None O
has None None O
long-lasting None None O
consequences None None O
on None None O
cognition None None O
; None None O
moreover None None O
, None None O
in None None O
humans None None O
, None None O
this None None O
use None None O
is None None O
associated None None O
with None None O
a None None O
two-fold None None O
increase None None O
in None None O
the None None O
risk None None O
of None None O
developing None None O
a None None O
psychotic None None I-DISEASE
disorder None None I-DISEASE
. None None O

The None None O
choroid None None I-REGION
plexus None None I-REGION
, None None O
an None None O
epithelial-based None None O
structure None None O
localized None None O
in None None O
the None None O
brain None None O
ventricle None None O
, None None O
is None None O
the None None O
major None None O
component None None O
of None None O
the None None O
blood-cerebrospinal None None O
fluid None None O
barrier None None O
. None None O

Abnormal None None O
choroid None None I-REGION
plexus None None I-REGION
function None None O
is None None O
associated None None O
with None None O
neurodegenerative None None O
diseases None None O
, None None O
tumor None None O
formation None None O
in None None O
the None None O
choroid None None I-REGION
plexus None None I-REGION
epithelium None None O
, None None O
and None None O
hydrocephaly None None O
. None None O

We None None O
generated None None O
an None None O
enhancer None None O
trap None None O
line None None O
, None None O
Et None None O
( None None O
cp None None O
: None None O
EGFP None None O
) None None O
( None None O
sj2 None None O
) None None O
, None None O
that None None O
expresses None None O
enhanced None None O
green None None O
fluorescent None None O
protein None None O
( None None O
EGFP None None O
) None None O
in None None O
the None None O
choroid None None I-REGION
plexus None None I-REGION
epithelium None None O
. None None O

Thus None None O
, None None O
we None None O
have None None O
established None None O
zebrafish None None O
as None None O
a None None O
functionally None None O
relevant None None O
model None None O
to None None O
study None None O
choroid None None I-REGION
plexus None None I-REGION
development None None O
. None None O

Using None None O
Et None None O
( None None O
cp None None O
: None None O
EGFP None None O
) None None O
( None None O
sj2 None None O
) None None O
, None None O
we None None O
isolated None None O
10 None None O
recessive None None O
mutant None None O
lines None None O
with None None O
choroid None None I-REGION
plexus None None I-REGION
abnormalities None None O
, None None O
which None None O
were None None O
grouped None None O
into None None O
five None None O
classes None None O
based None None O
on None None O
GFP None None O
intensity None None O
, None None O
epithelial None None O
localization None None O
, None None O
and None None O
overall None None O
choroid None None I-REGION
plexus None None I-REGION
morphology None None O
. None None O

The None None O
mutants None None O
generated None None O
in None None O
this None None O
study None None O
can None None O
be None None O
used None None O
to None None O
elucidate None None O
specific None None O
genes None None O
and None None O
signaling None None O
pathways None None O
essential None None O
for None None O
choroid None None I-REGION
plexus None None I-REGION
development None None O
, None None O
function None None O
, None None O
and/or None None O
maintenance None None O
and None None O
will None None O
provide None None O
important None None O
insights None None O
into None None O
how None None O
these None None O
genetic None None O
mutations None None O
contribute None None O
to None None O
disease None None O
. None None O

The None None O
neurons None None O
of None None O
the None None O
dorsal None None I-NEURON
root None None O
ganglia None None O
( None None O
DRG None None O
) None None O
are None None O
an None None O
important None None O
model None None O
for None None O
studies None None O
of None None O
neuronal None None O
injury None None O
, None None O
regeneration None None O
and None None O
pain None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
a None None O
negative None None O
feedback None None O
of None None O
NO None None O
signaling None None O
on None None O
synaptic None None O
secretion None None O
of None None O
neurotrophins None None O
operates None None O
only None None O
at None None O
high None None O
intracellular None None O
levels None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
that None None O
are None None O
under None None O
physiological None None O
conditions None None O
not None None O
reached None None O
by None None O
depolarization None None O
or None None O
BDNF None None O
signaling None None O
. None None O

In None None O
several None None O
neurodegenerative None None O
diseases None None O
, None None O
including None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
, None None O
there None None O
are None None O
disruptions None None O
of None None O
the None None O
blood-brain None None O
barrier None None O
. None None O

Knowledge None None O
of None None O
pro- None None O
and None None O
anti-inflammatory None None O
signals None None O
after None None O
nervous None None O
system None None O
injury None None O
is None None O
extensive None None O
, None None O
most None None O
of None None O
them None None O
being None None O
proteins None None O
acting None None O
through None None O
well-known None None O
receptors None None I-PROTEIN
and None None O
intracellular None None O
cascades None None O
. None None O

The None None O
activation None None O
of None None O
NMDA None None O
receptors None None I-PROTEIN
plays None None O
a None None O
key None None O
role None None O
in None None O
brain None None O
development None None O
, None None O
synaptic None None O
plasticity None None O
, None None O
and None None O
memory None None I-FUNC
formation None None O
, None None O
and None None O
is None None O
a None None O
major None None O
contributor None None O
to None None O
many None None O
neuropsychiatric None None O
disorders None None O
. None None O

Using None None O
an None None O
approach None None O
combining None None O
molecular None None O
biology None None O
, None None O
microscopy None None O
, None None O
and None None O
electrophysiology None None O
in None None O
mammalian None None O
cell None None O
lines None None O
and None None O
cultured None None O
cerebellar None None O
granule None None O
cells None None O
, None None O
we None None O
found None None O
that None None O
the None None O
surface None None O
delivery None None O
of None None O
GluN2C-containing None None O
receptors None None I-PROTEIN
is None None O
reduced None None O
compared None None O
to None None O
GluN2A- None None O
and None None O
GluN2B-containing None None O
receptors None None I-PROTEIN
. None None O

We None None O
demonstrate None None O
that None None O
multiple None None O
injections None None O
can None None O
be None None O
performed None None O
through None None O
the None None O
silicone None None O
port None None O
by None None O
repetitively None None O
bolus None None O
loading None None O
calcium None None O
sensitive None None O
dye None None O
into None None O
mouse None None O
barrel None None I-REGION
cortex None None I-REGION
and None None O
recording None None O
spontaneous None None O
cellular None None O
activity None None O
over None None O
a None None O
period None None O
of None None O
weeks None None O
. None None O

The None None O
development None None O
of None None O
more None None O
accurate None None O
and None None O
efficient None None O
methods None None O
to None None O
quantify None None O
changes None None O
in None None O
subcellular None None O
microanatomy None None O
has None None O
already None None O
proven None None O
key None None O
to None None O
understanding None None O
the None None O
pathogenesis None None O
of None None O
Parkinson None None I-DISEASE
's None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
diseases None None I-DISEASE
, None None O
as None None O
well None None O
as None None O
glaucoma None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
N-methyl-D-aspartate None None O
, None None O
all None None O
applied None None O
TAs None None O
supported None None O
expression None None O
of None None O
a None None O
locomotor-like None None O
activity None None O
( None None O
LLA None None O
) None None O
that None None O
was None None O
indistinguishable None None O
from None None O
that None None O
ordinarily None None O
observed None None O
with None None O
serotonin None None I-TRANS
, None None O
suggesting None None O
that None None O
the None None O
TAs None None O
act None None O
on None None O
common None None O
central None None O
pattern None None O
generating None None O
neurons None None O
. None None O

TA None None O
actions None None O
on None None O
locomotor None None O
circuits None None O
did None None O
not None None O
require None None O
interaction None None O
with None None O
descending None None O
monoaminergic None None O
projections None None O
since None None O
evoked None None O
LLA None None O
was None None O
maintained None None O
following None None O
block None None O
of None None O
all None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
-dependent None None O
monoamine None None O
transporters None None I-PROTEIN
or None None O
the None None O
vesicular None None O
monoamine None None O
transporter None None O
. None None O

Requirement None None O
for None None O
intracellular None None O
transport None None O
is None None O
consistent None None O
with None None O
the None None O
TAs None None O
having None None O
much None None O
slower None None O
LLA None None O
onset None None O
than None None O
serotonin None None I-TRANS
and None None O
for None None O
activation None None O
of None None O
intracellular None None O
TAARs None None O
. None None O

Based None None O
on None None O
the None None O
notion None None O
that None None O
the None None O
brain None None O
is None None O
equipped None None O
with None None O
a None None O
hierarchical None None O
organization None None O
, None None O
which None None O
embodies None None O
environmental None None O
contingencies None None O
across None None O
many None None O
time None None O
scales None None O
, None None O
this None None O
paper None None O
suggests None None O
that None None O
the None None O
medial None None O
temporal None None I-REGION
lobe None None I-REGION
( None None O
MTL None None O
) None None O
-located None None O
deep None None O
in None None O
the None None O
hierarchy-serves None None O
as None None O
a None None O
bridge None None O
connecting None None O
supra- None None O
to None None O
infra-MTL None None O
levels None None O
. None None O

In None None O
the None None O
event None None O
that None None O
these None None O
`` None None O
bridge None None O
'' None None O
predictions None None O
are None None O
inaccurate None None O
, None None O
this None None O
architecture None None O
enables None None O
the None None O
rapid None None O
encoding None None I-FUNC
of None None O
novel None None O
contingencies None None O
. None None O

Dopamine None None I-TRANS
reduced None None O
synaptic None None O
efficacy None None O
at None None O
a None None O
key None None O
central None None O
synapse None None O
between None None O
campaniform None None O
sensilla None None O
( None None O
CS None None O
) None None O
and None None O
a None None O
fast None None O
extensor None None O
tibiae None None O
motor None None I-NEURON
neuron None None I-NEURON
that None None O
is None None O
involved None None O
in None None O
limb None None O
movement None None I-FUNC
. None None O

Further None None O
, None None O
injection None None O
of None None O
a None None O
dopamine None None I-TRANS
antagonist None None O
, None None O
fluphenazine None None O
, None None O
into None None O
isolated None None O
locusts None None O
induced None None O
gregarious-like None None O
behavior None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
sympathetic None None O
activity None None O
was None None O
associated None None O
with None None O
exploration None None O
in None None O
decision-making None None O
indexed None None O
by None None O
entropy None None O
, None None O
which None None O
is None None O
a None None O
concept None None O
in None None O
information None None O
theory None None O
and None None O
indexes None None O
randomness None None O
of None None O
choices None None O
or None None O
the None None O
degree None None O
of None None O
deviation None None O
from None None O
sticking None None O
to None None O
recent None None O
experiences None None O
of None None O
gains None None O
and None None O
losses None None O
, None None O
and None None O
that None None O
activation None None O
of None None O
the None None O
anterior None None O
insula None None I-REGION
mediated None None O
this None None O
association None None O
. None None O

In None None O
the None None O
contingent-reward None None O
condition None None O
, None None O
norepinephrine None None I-TRANS
as None None O
an None None O
index None None O
of None None O
sympathetic None None O
activity None None O
was None None O
positively None None O
correlated None None O
with None None O
entropy None None O
indicating None None O
exploration None None O
in None None O
decision-making None None O
. None None O

We None None O
found None None O
a None None O
decreased None None O
neural None None O
activation None None O
in None None O
the None None O
ventral None None I-REGION
striatum None None I-REGION
during None None O
the None None O
anticipation None None O
of None None O
both None None O
small None None O
and None None O
large None None O
monetary None None O
rewards None None O
. None None O

Numerous None None O
studies None None O
show None None O
that None None O
sleep None None O
deprivation None None O
( None None O
SD None None O
) None None O
impacts None None O
negatively None None O
on None None O
cognitive None None O
processes None None O
, None None O
including None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
animals None None O
were None None O
first None None O
trained None None O
in None None O
contextual None None O
and None None O
tone None None O
fear None None O
conditioning None None O
( None None O
TFC None None O
) None None O
tasks None None O
and None None O
then None None O
submitted None None O
to None None O
SD None None O
with None None O
the None None O
purpose None None O
to None None O
evaluate None None O
the None None O
effect None None O
of None None O
this None None O
manipulation None None O
on None None O
different None None O
stages None None O
of None None O
the None None O
learning None None I-FUNC
process None None O
, None None O
e.g. None None O
, None None O
in None None O
the None None O
uptake None None O
of None None O
( None None O
new None None O
) None None O
information None None O
during None None O
learning None None I-FUNC
, None None O
its None None O
encoding None None I-FUNC
and None None O
stabilization None None O
, None None O
and None None O
the None None O
recall None None O
of None None O
stored None None O
memories None None O
. None None O

Overall None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
SD None None O
interferes None None O
with None None O
acquisition None None O
, None None O
recall None None O
and None None O
extinction None None O
, None None O
but None None O
not None None O
necessarily None None O
with None None O
consolidation None None O
of None None O
emotional None None O
memory None None I-FUNC
. None None O

Application None None O
of None None O
LP None None O
12 None None O
to None None O
primary None None O
cerebral None None O
cortical None None O
cultures None None O
, None None O
SH-SY5Y None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
the None None O
retinal None None O
ganglion None None I-NEURON
cell None None I-NEURON
line None None O
, None None O
RGC-5 None None O
, None None O
increased None None O
both None None O
the None None O
expression None None O
of None None O
full None None O
length None None O
TrkB None None O
as None None O
well None None O
as None None O
its None None O
basal None None O
phosphorylation None None O
state None None O
at None None O
tyrosine None None I-TRANS
816 None None O
. None None O

Although None None O
TrkB None None O
receptor None None I-PROTEIN
expression None None O
is None None O
regulated None None O
by None None O
cyclic None None O
AMP None None O
and None None O
Gαs-coupled None None O
GPCRs None None O
in None None O
several None None O
systems None None O
, None None O
we None None O
demonstrate None None O
that None None O
, None None O
depending None None O
on None None O
the None None O
model None None O
system None None O
, None None O
pathways None None O
downstream None None O
of None None O
both None None O
Gαs None None O
and None None O
Gα12 None None O
are None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
TrkB None None O
expression None None O
by None None O
5-HT7 None None O
receptors None None I-PROTEIN
. None None O

Here None None O
we None None O
examined None None O
: None None O
( None None O
1 None None O
) None None O
differences None None O
between None None O
22q11DS None None O
participants None None O
and None None O
typically None None O
developing None None O
controls None None O
in None None O
diffusion None None O
tensor None None O
imaging None None O
( None None O
DTI None None O
) None None O
measures None None O
within None None O
white None None I-REGION
matter None None I-REGION
tracts None None O
; None None O
( None None O
2 None None O
) None None O
whether None None O
there None None O
is None None O
an None None O
altered None None O
age-related None None O
trajectory None None O
of None None O
white None None I-REGION
matter None None I-REGION
pathways None None O
in None None O
22q11DS None None O
; None None O
and None None O
( None None O
3 None None O
) None None O
relationships None None O
between None None O
DTI None None O
measures None None O
, None None O
social None None I-FUNC
cognition None None I-FUNC
task None None O
performance None None O
, None None O
and None None O
positive None None O
symptoms None None O
of None None O
psychosis None None O
in None None O
22q11DS None None O
and None None O
typically None None O
developing None None O
controls None None O
. None None O

Additionally None None O
, None None O
22q11DS None None O
participants None None O
failed None None O
to None None O
show None None O
typical None None O
age-associated None None O
changes None None O
in None None O
FA None None O
and None None O
RD None None O
in None None O
the None None O
left None None I-REGION
inferior None None I-REGION
longitudinal None None I-REGION
fasciculus None None I-REGION
. None None O

Developmental None None O
dyslexia None None I-DISEASE
has None None O
been None None O
the None None O
focus None None O
of None None O
much None None O
functional None None O
anatomical None None O
research None None O
. None None O

Additional None None O
deficits None None O
of None None O
motor None None O
and None None O
attentional None None O
systems None None O
relevant None None O
for None None O
reading None None O
may None None O
be None None O
associated None None O
with None None O
altered None None O
functionality None None O
of None None O
dorsal None None I-NEURON
left None None O
fronto-parietal None None O
cortex None None I-REGION
. None None O

Activity None None O
in None None O
the None None O
right-lateralized None None O
ventral None None I-NEURON
temporal None None O
area None None O
( None None O
inclusive None None O
of None None O
the None None O
FG None None O
) None None O
peaked None None O
at None None O
~160 None None O
ms None None O
and None None O
was None None O
largest None None O
to None None O
inverted None None O
faces None None O
. None None O

This None None O
observation None None O
is None None O
consistent None None O
with None None O
the None None O
dual None None O
route None None O
model None None O
and None None O
spared None None O
processing None None O
of None None O
inverted None None O
faces None None O
in None None O
prosopagnosia None None I-DISEASE
. None None O

Relative None None O
to None None O
non-experienced None None O
drivers None None O
, None None O
professional None None O
drivers None None O
showed None None O
a None None O
more None None O
consistent None None O
recruitment None None O
of None None O
motor None None I-FUNC
control None None I-FUNC
and None None O
spatial None None O
navigation None None O
devoted None None O
areas None None O
, None None O
including None None O
premotor/motor None None O
cortex None None O
, None None O
striatum None None I-REGION
, None None O
anterior None None O
, None None O
and None None O
posterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
and None None O
retrosplenial None None O
cortex None None O
, None None O
precuneus None None I-REGION
, None None O
middle None None O
temporal None None I-REGION
cortex None None I-REGION
, None None O
and None None O
parahippocampus None None O
. None None O

Furthermore None None O
, None None O
the None None O
retrosplenial None None O
cortex None None O
, None None O
which None None O
has None None O
been None None O
previously None None O
associated None None O
with None None O
the None None O
storage None None I-FUNC
of None None O
observer-independent None None O
spatial None None O
maps None None O
, None None O
revealed None None O
a None None O
specific None None O
correlation None None O
with None None O
the None None O
individual None None O
driver None None O
's None None O
success None None O
in None None O
official None None O
competitions None None O
. None None O

Working None None I-FUNC
memory None None I-FUNC
is None None O
the None None O
structure None None O
devoted None None O
to None None O
the None None O
maintenance None None O
of None None O
information None None O
at None None O
short None None O
term None None O
during None None O
concurrent None None O
processing None None O
activities None None O
. None None O

Besides None None O
this None None O
domain-specific None None O
mechanism None None O
, None None O
an None None O
executive None None O
loop None None O
allows None None O
the None None O
reconstruction None None O
of None None O
memory None None I-FUNC
traces None None O
through None None O
an None None O
attention-based None None O
mechanism None None O
of None None O
refreshing None None O
. None None O

We None None O
used None None O
easily None None O
distinguishable None None O
stimuli None None O
of None None O
faces None None O
and None None O
houses None None O
constituted None None O
from None None O
straight None None O
lines None None O
, None None O
with None None O
the None None O
aim None None O
of None None O
learning None None I-FUNC
whether None None O
they None None O
activate None None O
V1 None None O
on None None O
the None None O
one None None O
hand None None O
, None None O
and None None O
the None None O
specialized None None O
areas None None O
that None None O
are None None O
critical None None O
for None None O
the None None O
processing None None O
of None None O
faces None None O
and None None O
houses None None O
on None None O
the None None O
other None None O
, None None O
with None None O
similar None None O
latencies None None O
. None None O

This None None O
paper None None O
describes None None O
two None None O
experiments None None O
, None None O
one None None O
dealing None None O
with None None O
period None None O
locking None None O
to None None O
different None None O
metrical None None O
levels None None O
in None None O
full-body None None O
movement None None I-FUNC
and None None O
its None None O
relationships None None O
to None None O
beat- None None O
and None None O
rhythm-related None None O
musical None None O
characteristics None None O
, None None O
and None None O
the None None O
other None None O
dealing None None O
with None None O
phase None None O
locking None None O
in None None O
the None None O
more None None O
constrained None None O
condition None None O
of None None O
sideways None None O
swaying None None O
motions None None O
. None None O

Experiment None None O
2 None None O
was None None O
assumed None None O
to None None O
yield None None O
a None None O
common None None O
phase None None O
relationship None None O
between None None O
participants None None O
' None None O
swaying None None O
movements None None I-FUNC
and None None O
the None None O
musical None None O
beat None None O
. None None O

At None None O
faster None None O
tempi None None O
higher None None O
metrical None None O
levels None None O
became None None O
more None None O
apparent None None O
in None None O
participants None None O
' None None O
movement None None I-FUNC
. None None O

However None None O
, None None O
the None None O
relationship None None O
between None None O
movement None None I-FUNC
phase None None O
and None None O
beat None None O
locations None None O
was None None O
not None None O
consistent None None O
between None None O
participants None None O
, None None O
as None None O
the None None O
beat None None O
locations None None O
occurred None None O
at None None O
different None None O
phase None None O
angles None None O
of None None O
their None None O
movements None None I-FUNC
. None None O

Adults None None O
address None None O
infants None None O
with None None O
a None None O
special None None O
speech None None I-FUNC
register None None O
known None None O
as None None O
infant-directed None None O
speech None None I-FUNC
( None None O
IDS None None O
) None None O
, None None O
which None None O
conveys None None O
both None None O
linguistic None None O
and None None O
emotional None None O
information None None O
through None None O
its None None O
characteristic None None O
lexicon None None O
and None None O
exaggerated None None O
prosody None None O
( None None O
e.g. None None O
, None None O
higher None None O
pitched None None O
, None None O
slower None None O
, None None O
and None None O
hyperarticulated None None O
) None None O
. None None O

Here None None O
, None None O
using None None O
an None None O
auditory None None O
observation None None O
method None None O
and None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
of None None O
four None None O
different None None O
groups None None O
of None None O
females None None O
, None None O
we None None O
revealed None None O
the None None O
experience-dependent None None O
influence None None O
of None None O
the None None O
emotional None None O
component None None O
on None None O
linguistic None None O
processing None None O
in None None O
the None None O
right None None I-REGION
caudate None None I-REGION
nucleus None None I-REGION
when None None O
mothers None None O
process None None O
IDS None None O
: None None O
( None None O
1 None None O
) None None O
non-mothers None None O
, None None O
who None None O
do None None O
not None None O
use None None O
IDS None None O
regularly None None O
, None None O
showed None None O
no None None O
significant None None O
difference None None O
between None None O
IDS None None O
and None None O
adult-directed None None O
speech None None I-FUNC
( None None O
ADS None None O
) None None O
; None None O
( None None O
2 None None O
) None None O
mothers None None O
with None None O
preverbal None None O
infants None None O
, None None O
who None None O
primarily None None O
use None None O
the None None O
emotional None None O
component None None O
of None None O
IDS None None O
, None None O
showed None None O
the None None O
main None None O
effect None None O
of None None O
the None None O
emotional None None O
component None None O
of None None O
IDS None None O
; None None O
( None None O
3 None None O
) None None O
mothers None None O
with None None O
toddlers None None O
at None None O
the None None O
two-word None None O
stage None None O
, None None O
who None None O
use None None O
both None None O
linguistic None None O
and None None O
emotional None None O
components None None O
of None None O
IDS None None O
, None None O
showed None None O
an None None O
interaction None None O
between None None O
the None None O
linguistic None None O
and None None O
emotional None None O
components None None O
of None None O
IDS None None O
; None None O
and None None O
( None None O
4 None None O
) None None O
mothers None None O
with None None O
school-age None None O
children None None O
, None None O
who None None O
use None None O
ADS None None O
rather None None O
than None None O
IDS None None O
toward None None O
their None None O
children None None O
, None None O
showed None None O
a None None O
tendency None None O
toward None None O
the None None O
main None None O
effect None None O
of None None O
ADS None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
the None None O
right None None I-REGION
caudate None None I-REGION
nucleus None None I-REGION
processes None None O
experience-and None None O
task-dependent None None O
interactions None None O
between None None O
language None None I-FUNC
and None None O
emotion None None I-FUNC
in None None O
mothers None None O
' None None O
IDS None None O
. None None O

To None None O
estimate None None O
the None None O
contributions None None O
of None None O
feedforward None None O
vs. None None O
feedback None None O
control None None O
systems None None O
in None None O
speech None None I-FUNC
articulation None None O
, None None O
we None None O
analyzed None None O
the None None O
correspondence None None O
between None None O
initial None None O
and None None O
final None None O
kinematics None None O
in None None O
unperturbed None None O
tongue None None O
and None None O
jaw None None O
movements None None I-FUNC
for None None O
consonant-vowel None None O
( None None O
CV None None O
) None None O
and None None O
vowel-consonant None None O
( None None O
VC None None O
) None None O
syllables None None O
. None None O

Five None None O
adult None None O
speakers None None O
produced None None O
CV None None O
and None None O
VC None None O
syllables None None O
with None None O
high None None O
, None None O
mid None None O
, None None O
or None None O
low None None O
vowels None None O
while None None O
movements None None I-FUNC
of None None O
the None None O
tongue None None O
and None None O
jaw None None O
were None None O
tracked None None O
electromagnetically None None O
. None None O

Taken None None O
together None None O
, None None O
results None None O
suggest None None O
that None None O
jaw None None O
and None None O
tongue None None O
movements None None I-FUNC
for None None O
these None None O
CV None None O
and None None O
VC None None O
syllables None None O
are None None O
mostly None None O
under None None O
feedforward None None O
control None None O
but None None O
with None None O
feedback-based None None O
contributions None None O
. None None O

Additionally None None O
, None None O
the None None O
functional None None O
connectivity None None O
of None None O
these None None O
brain None None O
regions None None O
with None None O
other None None O
areas None None O
involved None None O
in None None O
gaze None None O
processing None None O
and None None O
spatial None None O
attention None None I-FUNC
was None None O
investigated None None O
. None None O

Sixty-two None None O
soccer None None O
players None None O
performed None None O
a None None O
newly None None O
designed None None O
peripheral None None O
vision None None I-FUNC
task None None O
in None None O
which None None O
the None None O
visual None None O
stimuli None None O
were None None O
dynamic None None O
, None None O
while None None O
their None None O
EEG None None O
signals None None O
were None None O
recorded None None O
from None None O
Cz None None O
, None None O
O1 None None O
, None None O
and None None O
O2 None None O
locations None None O
. None None O

We None None O
present None None O
a None None O
high-capacity None None O
model None None O
for None None O
one-shot None None O
association None None O
learning None None I-FUNC
( None None O
hetero-associative None None O
memory None None I-FUNC
) None None O
in None None O
sparse None None O
networks None None O
. None None O

The None None O
dynamic None None O
interaction None None O
of None None O
limb None None O
segments None None O
during None None O
movements None None I-FUNC
that None None O
involve None None O
multiple None None O
joints None None O
creates None None O
torques None None O
in None None O
one None None O
joint None None O
due None None O
to None None O
motion None None O
about None None O
another None None O
. None None O

The None None O
alternative None None O
, None None O
based None None O
on None None O
the None None O
equilibrium-point None None O
hypothesis None None O
, None None O
claims None None O
that None None O
descending None None O
signals None None O
can None None O
be None None O
simple None None O
and None None O
related None None O
to None None O
the None None O
desired None None O
movement None None I-FUNC
kinematics None None O
only None None O
, None None O
while None None O
spinal None None O
feedback None None O
mechanisms None None O
are None None O
responsible None None O
for None None O
the None None O
appropriate None None O
creation None None O
and None None O
coordination None None O
of None None O
dynamic None None O
muscle None None O
forces None None O
. None None O

Even None None O
though None None O
the None None O
model None None O
makes None None O
various None None O
simplifications None None O
and None None O
abstractions None None O
compared None None O
to None None O
the None None O
complexities None None O
involved None None O
in None None O
the None None O
control None None O
of None None O
human None None O
arm None None O
movements None None I-FUNC
, None None O
the None None O
finding None None O
lends None None O
plausibility None None O
to None None O
the None None O
hypothesis None None O
that None None O
some None None O
multijoint None None O
movements None None I-FUNC
can None None O
in None None O
principle None None O
be None None O
controlled None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
internal None None O
models None None O
of None None O
intersegmental None None O
dynamics None None O
or None None O
learned None None O
compensatory None None O
motor None None O
signals None None O
. None None O

In None None O
fact None None O
, None None O
the None None O
claustrum None None I-REGION
is None None O
such None None O
an None None O
enigma None None O
that None None O
the None None O
only None None O
things None None O
known None None O
for None None O
certain None None O
about None None O
it None None O
are None None O
its None None O
histology None None O
, None None O
and None None O
that None None O
it None None O
is None None O
extraordinarily None None O
well None None O
connected None None O
. None None O

By None None O
providing None None O
an None None O
explanation None None O
of None None O
the None None O
neuroimaging None None O
and None None O
histology None None O
methods None None O
have None None O
been None None O
undertaken None None O
to None None O
study None None O
the None None O
claustrum None None I-REGION
thus None None O
far-and None None O
the None None O
conclusions None None O
these None None O
studies None None O
have None None O
drawn-we None None O
illustrate None None O
this None None O
example None None O
of None None O
how None None O
the None None O
shift None None O
from None None O
micro-connectomics None None O
to None None O
macro-connectomics None None O
advances None None O
the None None O
field None None O
of None None O
neuroscience None None O
and None None O
improves None None O
our None None O
capacity None None O
to None None O
understand None None O
the None None O
brain None None O
. None None O

In None None O
various None None O
independent None None O
studies None None O
to None None O
date None None O
, None None O
cerebral None None O
cortical None None O
thickness None None O
and None None O
white None None I-REGION
matter None None I-REGION
hyperintensity None None O
( None None O
WMH None None O
) None None O
volume None None O
have None None O
been None None O
associated None None O
with None None O
episodic None None I-FUNC
memory None None I-FUNC
, None None O
depression None None I-DISEASE
, None None O
and None None O
mild None None O
cognitive None None O
impairment None None O
( None None O
MCI None None O
) None None O
. None None O

The None None O
participants None None O
were None None O
186 None None O
individuals None None O
with None None O
MCI None None O
( None None O
clinical None None O
dementia None None I-DISEASE
rating None None O
[ None None O
CDR None None O
] None None O
of None None O
0.5 None None O
) None None O
and None None O
136 None None O
healthy None None O
elderly None None O
controls None None O
( None None O
HCs None None O
; None None O
CDR None None O
of None None O
0 None None O
) None None O
drawn None None O
from None None O
two None None O
community-based None None O
cohort None None O
studies None None O
in None None O
northern None None O
Japan None None O
. None None O

We None None O
also None None O
assessed None None O
the None None O
associations None None O
of None None O
these None None O
indices None None O
with None None O
memory None None I-FUNC
performance None None O
and None None O
depressive None None O
state None None O
in None None O
participants None None O
with None None O
MCI None None O
. None None O

In None None O
MCI None None O
participants None None O
, None None O
poor None None O
episodic None None I-FUNC
memory None None I-FUNC
was None None O
associated None None O
with None None O
thinner None None O
cortices None None O
in None None O
the None None O
left None None O
entorhinal None None O
region None None O
and None None O
increased None None O
WMH None None O
volume None None O
in None None O
the None None O
posterior None None O
periventricular None None O
regions None None O
. None None O

An None None O
increasing None None O
body None None O
of None None O
evidence None None O
is None None O
emerging None None O
, None None O
which None None O
demonstrates None None O
that None None O
memory None None I-FUNC
and None None O
vision None None I-FUNC
impairment None None O
are None None O
closely None None O
, None None O
significantly None None O
, None None O
and None None O
positively None None O
linked None None O
and None None O
that None None O
statins None None O
and None None O
aspirin None None O
may None None O
lessen None None O
the None None O
risk None None O
of None None O
developing None None O
age-related None None O
visual None None O
and None None O
neurological None None O
problems None None O
. None None O

Thus None None O
, None None O
the None None O
intent None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
reliably None None O
establish None None O
whether None None O
a None None O
relationship None None O
exist None None O
between None None O
various None None O
types None None O
of None None O
dementia None None I-DISEASE
and None None O
age-related None None O
vision None None I-FUNC
disorders None None O
, None None O
and None None O
to None None O
establish None None O
whether None None O
statins None None O
and None None O
aspirin None None O
may None None O
or None None O
may None None O
not None None O
have None None O
beneficial None None O
effects None None O
on None None O
these None None O
two None None O
types None None O
of None None O
disorders None None O
. None None O

Mini None None O
mental None None O
state None None O
examination None None O
scores None None O
were None None O
significantly None None O
lower None None O
in None None O
patients None None O
with None None O
vision None None I-FUNC
disorders None None O
compared None None O
to None None O
subjects None None O
without None None O
vision None None I-FUNC
disorders None None O
. None None O

When None None O
we None None O
considered None None O
the None None O
associations None None O
between None None O
different None None O
types None None O
of None None O
dementia None None I-DISEASE
and None None O
vision None None I-FUNC
disorders None None O
and None None O
the None None O
use None None O
of None None O
statins None None O
and None None O
aspirin None None O
, None None O
we None None O
found None None O
a None None O
significant None None O
positive None None O
association None None O
between None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
statins None None O
on None None O
their None None O
own None None O
or None None O
in None None O
combination None None O
with None None O
aspirin None None O
, None None O
indicating None None O
that None None O
these None None O
two None None O
drugs None None O
do None None O
not None None O
appear None None O
to None None O
reduce None None O
the None None O
risk None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
or None None O
improve None None O
its None None O
clinical None None O
evolution None None O
and None None O
may None None O
, None None O
on None None O
the None None O
contrary None None O
, None None O
favor None None O
its None None O
development None None O
. None None O

Overall None None O
, None None O
these None None O
results None None O
confirm None None O
the None None O
general None None O
impression None None O
so None None O
far None None O
; None None O
namely None None O
, None None O
that None None O
macular None None O
degeneration None None O
may None None O
contribute None None O
to None None O
cognitive None None I-DISEASE
disorders None None I-DISEASE
( None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
in None None O
particular None None O
) None None O
. None None O

Inflammation None None O
is None None O
observed None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
subject None None O
brains None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
if None None O
aged None None O
monkeys None None O
exhibiting None None O
spatial None None I-FUNC
memory None None I-FUNC
impairment None None O
and None None O
levels None None O
of None None O
biomarkers None None O
indicative None None O
of None None O
AD None None O
, None None O
had None None O
brain None None O
lesions None None O
similar None None O
to None None O
human None None O
patients None None O
suffering None None O
from None None O
senile None None O
dementia None None I-DISEASE
. None None O

Six None None O
aged None None O
monkeys None None O
were None None O
selected None None O
based None None O
on None None O
their None None O
spatial None None I-FUNC
memory None None I-FUNC
performance None None O
and None None O
profile None None O
of None None O
biomarkers None None O
of None None O
AD None None O
, None None O
divided None None O
equally None None O
to None None O
affected None None O
aged None None O
subject None None O
- None None O
with None None O
Memory-affected None None O
and None None O
low None None O
amyloid None None O
level None None O
, None None O
and None None O
aged None None O
with None None O
higher None None O
performance None None O
in None None O
memory None None I-FUNC
and None None O
amyloid None None O
, None None O
as None None O
the None None O
age-matched None None O
subjects None None O
. None None O

OPMD None None O
is None None O
caused None None O
by None None O
an None None O
expansion None None O
mutation None None O
in None None O
the None None O
gene None None O
encoding None None I-FUNC
for None None O
poly-adenylate None None O
RNA None None O
binding None None O
protein1 None None O
( None None O
PABPN1 None None O
) None None O
. None None O

Importantly None None O
, None None O
EET-mediated None None O
effects None None O
were None None O
significantly None None O
reduced None None O
by None None O
pharmacological None None O
inhibition None None O
of None None O
peroxisome None None O
proliferator-activated None None O
receptors None None I-PROTEIN
γ None None O
( None None O
PPARγ None None O
) None None O
suggesting None None O
that None None O
PPARγ None None O
signaling None None O
was None None O
required None None O
for None None O
EETs None None O
exerted None None O
protective None None O
effects None None O
. None None O

Tenofovir None None O
is None None O
predominantly None None O
eliminated None None O
via None None O
the None None O
proximal None None O
tubules None None O
of None None O
the None None O
kidney None None O
, None None O
therefore None None O
drug None None O
transporters None None I-PROTEIN
expressed None None O
in None None O
renal None None O
proximal None None O
tubule None None O
cells None None O
are None None O
believed None None O
to None None O
influence None None O
tenofovir None None O
plasma None None O
concentration None None O
and None None O
toxicity None None O
in None None O
the None None O
kidney None None O
. None None O

The None None O
use None None O
of None None O
creatinine None None O
and None None O
novel None None O
biomarkers None None O
for None None O
kidney None None O
damage None None O
, None None O
and None None O
the None None O
role None None O
that None None O
drug None None O
transporters None None I-PROTEIN
play None None O
in None None O
biomarker None None O
disposition None None O
, None None O
are None None O
discussed None None O
. None None O

Our None None O
simulations None None O
were None None O
based None None O
on None None O
the None None O
recommended None None O
anticoagulant None None O
dosing None None O
regimen None None O
for None None O
stroke None None I-DISEASE
prevention None None O
in None None O
patients None None O
with None None O
atrial None None O
fibrillation None None O
. None None O

Insulin None None I-PROTEIN
, None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor-1 None None O
( None None O
IGF-1 None None O
) None None O
, None None O
and None None O
certain None None O
hormones None None I-PROTEIN
play None None O
an None None O
important None None O
role None None O
in None None O
promoting None None O
neoplasia None None O
in None None O
diabetics None None O
. None None O

Other None None O
potential None None O
anti-tumorigenic None None O
effects None None O
of None None O
metformin None None O
include None None O
the None None O
ability None None O
to None None O
downregulate None None O
specificity None None O
protein None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
and None None O
associated None None O
genes None None O
, None None O
alter None None O
microRNAs None None O
, None None O
decrease None None O
cancer None None O
stem None None O
cell None None O
proliferation None None O
, None None O
and None None O
reduce None None O
DNA None None O
damage None None O
and None None O
inflammation None None O
. None None O

When None None O
examined None None O
for None None O
long-term None None O
crystal None None O
growth None None O
, None None O
polyproline None None O
repeat None None O
peptides None None I-TRANS
of None None O
increasing None None O
length None None O
promoted None None O
the None None O
growth None None O
of None None O
shorter None None O
calcium None None O
carbonate None None O
crystals None None O
with None None O
broader None None O
basis None None O
, None None O
contrary None None O
to None None O
the None None O
positive None None O
correlation None None O
between None None O
polyproline None None O
repeat None None O
element None None O
length None None O
and None None O
apatite None None O
mineralization None None O
published None None O
earlier None None O
. None None O

Languages None None I-FUNC
are None None O
composed None None O
of None None O
a None None O
conventionalized None None O
system None None O
of None None O
parts None None O
which None None O
allow None None O
speakers None None O
and None None O
signers None None O
to None None O
generate None None O
an None None O
infinite None None O
number None None O
of None None O
form-meaning None None O
mappings None None O
through None None O
phonological None None O
and None None O
morphological None None O
combinations None None O
. None None O

This None None O
is None None O
interesting None None O
, None None O
because None None O
signed None None O
languages None None I-FUNC
are None None O
perceived None None O
and None None O
articulated None None O
in None None O
very None None O
different None None O
ways None None O
to None None O
their None None O
spoken None None O
counterparts None None O
with None None O
many None None O
signs None None O
displaying None None O
surface None None O
resemblances None None O
to None None O
gestures None None O
. None None O

Yet None None O
in None None O
one None None O
sense None None O
both None None O
groups None None O
are None None O
faced None None O
with None None O
a None None O
similar None None O
problem None None O
: None None O
`` None None O
how None None O
do None None O
I None None O
make None None O
a None None O
language None None I-FUNC
with None None O
combinatorial None None O
structure None None O
'' None None O
? None None O

Combinatorial None None O
structure None None O
is None None O
the None None O
outcome None None O
of None None O
phonological None None O
simplifications None None O
and None None O
productivity None None O
in None None O
using None None O
verb None None O
morphology None None O
by None None O
children None None O
in None None O
sign None None O
and None None O
speech None None I-FUNC
. None None O

Yet None None O
, None None O
congruent None None O
with None None O
the None None O
more None None O
pragmatic None None O
views None None O
of None None O
linguistic None None O
behavior None None O
, None None O
in None None O
which None None O
language None None I-FUNC
is None None O
treated None None O
as None None O
social None None O
coordination None None O
, None None O
understanding None None O
each None None O
other None None O
is None None O
not None None O
the None None O
purpose None None O
( None None O
or None None O
not None None O
the None None O
sole None None O
purpose None None O
) None None O
of None None O
linguistic None None O
interactions None None O
. None None O

These None None O
two None None O
factors None None O
mediated None None O
the None None O
symptoms None None O
of None None O
GIA None None O
if None None O
other None None O
risk None None O
factors None None O
were None None O
present None None O
such None None O
as None None O
depression None None I-DISEASE
, None None O
social None None O
anxiety None None O
, None None O
low None None O
self-esteem None None O
, None None O
low None None O
self-efficacy None None O
, None None O
and None None O
high None None O
stress None None O
vulnerability None None O
to None None O
name None None O
a None None O
few None None O
areas None None O
that None None O
were None None O
measured None None O
in None None O
the None None O
study None None O
. None None O

Besides None None O
stimuli None None O
characteristics None None O
, None None O
individual None None O
characteristics None None O
such None None O
as None None O
the None None O
presence None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
could None None O
also None None O
influence None None O
the None None O
broadening None None O
effects None None O
as None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
have None None O
previously None None O
been None None O
related None None O
to None None O
a None None O
more None None O
narrow None None O
attentional None None O
scope None None O
. None None O

Results None None O
showed None None O
no None None O
direct None None O
relation None None O
between None None O
positive None None O
mood None None I-FUNC
and None None O
attentional None None O
breadth None None O
, None None O
regardless None None O
of None None O
the None None O
emotional None None O
valence None None O
of None None O
the None None O
stimuli None None O
. None None O

The None None O
current None None O
findings None None O
suggest None None O
that None None O
both None None O
stimuli None None O
characteristics None None O
, None None O
individual None None O
characteristics None None O
and None None O
their None None O
interplay None None O
should None None O
be None None O
taken None None O
into None None O
account None None O
when None None O
investigating None None O
the None None O
broadening None None O
effects None None O
of None None O
positive None None O
emotions None None I-FUNC
. None None O

The None None O
updated None None O
reward None None O
prediction None None O
error None None O
( None None O
RPE None None O
) None None O
-a None None O
discrepancy None None O
between None None O
the None None O
predicted None None O
and None None O
actual None None O
rewards-is None None O
thought None None O
to None None O
be None None O
encoded None None O
by None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
. None None O

Accordingly None None O
, None None O
the None None O
measurement None None O
of None None O
RPE None None O
provides None None O
a None None O
potential None None O
behavioral None None O
index None None O
for None None O
the None None O
evaluation None None O
of None None O
brain None None O
dopamine None None I-TRANS
activity None None O
and None None O
psychotic None None O
symptoms None None O
. None None O

Forty-five None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
[ None None O
26 None None O
high-psychosis None None O
and None None O
19 None None O
low-psychosis None None O
, None None O
based None None O
on None None O
their None None O
p1 None None O
and None None O
p3 None None O
scores None None O
in None None O
the None None O
positive-symptom None None O
subscales None None O
of None None O
the None None O
Positive None None O
and None None O
Negative None None O
Syndrome None None O
Scale None None O
( None None O
PANSS None None O
) None None O
] None None O
and None None O
24 None None O
controls None None O
were None None O
tested None None O
in None None O
a None None O
feedback-based None None O
dynamic None None O
reward None None O
task None None O
for None None O
their None None O
RPE-related None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Trial-by-trial None None O
data None None O
were None None O
further None None O
fit None None O
with None None O
a None None O
reinforcement None None I-FUNC
learning None None I-FUNC
model None None O
using None None O
the None None O
Bayesian None None O
estimation None None O
approach None None O
. None None O

Our None None O
method None None O
provides None None O
an None None O
alternative None None O
for None None O
investigating None None O
reward-related None None O
learning None None I-FUNC
and None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
basic None None O
and None None O
clinical None None O
settings None None O
. None None O

To None None O
measure None None O
spatial None None O
working None None I-FUNC
memory None None I-FUNC
, None None O
the None None O
Corsi None None O
blocks None None O
task None None O
, None None O
which None None O
separates None None O
the None None O
memory None None I-FUNC
into None None O
two None None O
types None None O
, None None O
forward None None O
and None None O
backward None None O
, None None O
is None None O
often None None O
used None None O
. None None O

However None None O
, None None O
the None None O
effects None None O
of None None O
physical None None O
activity None None O
on None None O
multiple None None O
aspects None None O
of None None O
selective None None I-FUNC
attention None None I-FUNC
and None None O
whether None None O
these None None O
effects None None O
are None None O
mediated None None O
by None None O
aerobic None None O
capacity None None O
, None None O
remains None None O
unclear None None O
. None None O

Language None None I-FUNC
has None None O
an None None O
intrinsically None None O
evaluative None None O
and None None O
communicative None None O
function None None O
. None None O

This None None O
indicates None None O
that None None O
more None None O
visual None None I-FUNC
attention None None I-FUNC
is None None O
allocated None None O
to None None O
the None None O
presented None None O
adjectives None None O
when None None O
putatively None None O
interacting None None O
with None None O
a None None O
human None None O
. None None O

Larger None None O
LPP None None O
amplitudes None None O
are None None O
related None None O
to None None O
stimulus None None O
elaboration None None O
and None None O
memory None None I-FUNC
consolidation None None O
. None None O

Our None None O
results None None O
specify None None O
differential None None O
effects None None O
of None None O
even None None O
implied None None O
communicative None None O
partners None None O
on None None O
emotional None None O
language None None I-FUNC
processing None None O
. None None O

Visual-vestibular None None O
conflicts None None O
have None None O
been None None O
traditionally None None O
used None None O
to None None O
explain None None O
both None None O
perceptions None None I-FUNC
of None None O
self-motion None None O
and None None O
experiences None None O
of None None O
motion None None O
sickness None None O
. None None O

Vestibular None None O
migraine None None I-DISEASE
( None None O
VM None None O
) None None O
, None None O
a None None O
common None None O
cause None None O
of None None O
vestibular None None O
symptoms None None O
within None None O
the None None O
general None None O
population None None O
, None None O
is None None O
a None None O
disabling None None O
and None None O
poorly None None O
understood None None O
form None None O
of None None O
dizziness None None O
. None None O

Based None None O
on None None O
these None None O
preliminary None None O
perceptual None None O
and None None O
eye None None O
movement None None I-FUNC
results None None O
obtained None None O
with None None O
three None None O
different None None O
motion None None O
paradigms None None O
, None None O
we None None O
present None None O
a None None O
hypothesis None None O
that None None O
the None None O
integration None None O
of None None O
canal None None O
and None None O
otolith None None O
signals None None O
by None None O
the None None O
brain None None O
is None None O
abnormal None None O
in None None O
VM None None O
and None None O
that None None O
this None None O
abnormality None None O
could None None O
be None None O
cerebellar None None O
in None None O
origin None None O
. None None O

Prolactin-releasing None None O
peptide None None O
( None None O
PrRP None None O
) None None O
is None None O
one None None O
of None None O
the None None O
RF-amide None None O
peptides None None I-TRANS
and None None O
was None None O
originally None None O
identified None None O
in None None O
the None None O
bovine None None O
hypothalamus None None I-REGION
as None None O
a None None O
stimulator None None O
of None None O
prolactin None None O
( None None O
PRL None None O
) None None O
release None None O
. None None O

Analogous None None O
inhibition None None O
of None None O
the None None O
renal None None O
Na None None I-TRANS
, None None O
K-ATPase None None O
may None None O
be None None O
partly None None O
responsible None None O
for None None O
the None None O
increased None None O
sodium None None O
excretion None None O
. None None O

classical None None O
( None None O
M1 None None O
) None None O
, None None O
producing None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
NO None None O
, None None O
and None None O
M2 None None O
, None None O
in None None O
which None None O
arginase None None I-PROTEIN
activity None None O
is None None O
primarily None None O
expressed None None O
. None None O

M2 None None O
macrophages None None O
, None None O
expressing None None O
high None None O
level None None O
of None None O
mitochondrial None None O
arginase None None I-PROTEIN
, None None O
have None None O
been None None O
implicated None None O
in None None O
promoting None None O
cell None None O
division None None O
and None None O
deposition None None O
of None None O
collagen None None I-PROTEIN
during None None O
ontogeny None None O
and None None O
wound None None O
repair None None O
. None None O

In None None O
worms None None O
, None None O
the None None O
induction None None O
of None None O
collagen None None I-PROTEIN
gene None None O
is None None O
coupled None None O
with None None O
induction None None O
of None None O
immune None None O
response None None O
genes None None O
, None None O
both None None O
depending None None O
on None None O
the None None O
same None None O
TGF-β-like None None O
pathway None None O
. None None O

While None None O
professional None None O
and None None O
non-professional None None O
phagocytes None None O
utilize None None O
a None None O
wide None None O
array None None O
of None None O
surface None None O
receptors None None I-PROTEIN
to None None O
recognize None None O
apoptotic None None O
cells None None O
, None None O
the None None O
recognition None None O
of None None O
phosphatidylserine None None O
( None None O
PS None None O
) None None O
on None None O
apoptotic None None O
cells None None O
by None None O
PS None None O
receptors None None I-PROTEIN
on None None O
phagocytes None None O
is None None O
the None None O
emblematic None None O
signal None None O
for None None O
efferocytosis None None O
in None None O
metazoans None None O
. None None O

Eosinophils None None O
possess None None O
a None None O
range None None O
of None None O
immunomodulatory None None O
factors None None O
that None None O
are None None O
released None None O
upon None None O
cell None None O
activation None None O
, None None O
including None None O
over None None O
35 None None O
cytokines None None O
, None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
, None None O
and None None O
chemokines None None O
. None None O

These None None O
intracellular None None I-PROTEIN
receptors None None I-PROTEIN
regulate None None O
the None None O
release None None O
of None None O
granules None None O
and None None O
vesicles None None O
containing None None O
a None None O
range None None O
of None None O
secreted None None O
proteins None None O
, None None O
among None None O
which None None O
are None None O
cytokines None None O
and None None O
chemokines None None O
. None None O

Skin None None O
epidermal None None O
γδ None None O
T None None O
cells None None O
recognize None None O
antigen None None O
expressed None None O
by None None O
damaged None None O
or None None O
stressed None None O
keratinocytes None None O
and None None O
play None None O
an None None O
indispensable None None O
role None None O
in None None O
tissue None None O
homeostasis None None O
and None None O
repair None None O
through None None O
secretion None None O
of None None O
distinct None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Both None None O
subsets None None O
can None None O
be None None O
activated None None O
by None None O
stress-induced None None O
molecules None None O
( None None O
MIC-A None None O
, None None O
MIC-B None None O
, None None O
ULBPs None None O
) None None O
to None None O
produce None None O
pro-inflammatory None None O
cytokines None None O
and None None O
lytic None None O
enzymes None None I-PROTEIN
and None None O
destroy None None O
bacteria None None O
or None None O
damaged None None O
cells None None O
. None None O

Overall None None O
these None None O
two None None O
groups None None O
of None None O
genes None None O
are None None O
distinct None None O
in None None O
the None None O
functional None None O
categories None None O
of None None O
the None None O
proteins None None O
they None None O
encode None None O
, None None O
their None None O
promoter None None O
cis-elements None None O
and None None O
their None None O
regulation None None O
by None None O
DGK None None O
or None None O
phospholipase None None I-PROTEIN
D. None None O
SA-regulated None None O
genes None None O
dependent None None O
on None None O
phosphoinositides None None O
are None None O
typical None None O
SA None None O
response None None O
genes None None O
while None None O
those None None O
with None None O
an None None O
SA None None O
response None None O
that None None O
is None None O
possibly None None O
dependent None None O
on None None O
PI-PLC None None O
products None None O
are None None O
less None None O
SA-specific None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
possible None None O
role None None O
of None None O
MYBs None None O
in None None O
the None None O
regulation None None O
of None None O
essential None None O
S None None O
assimilation None None O
enzymes None None I-PROTEIN
, None None O
in None None O
the None None O
regulation None None O
of None None O
GSL None None O
biosynthesis None None O
upon None None O
accelerated None None O
termination None None O
of None None O
life None None O
cycles None None O
, None None O
in None None O
the None None O
mobilization None None O
of None None O
auxin None None O
and None None O
lateral None None O
root None None O
formation None None O
at None None O
S None None O
deficiency None None O
is None None O
discussed None None O
. None None O

The None None O
role None None O
of None None O
varied None None O
sodium None None O
( None None O
Na None None I-TRANS
) None None O
supply None None O
in None None O
K None None O
nutrition None None O
of None None O
wheat None None O
( None None O
Triticum None None O
aestivum None None O
L. None None O
) None None O
is None None O
not None None O
well None None O
understood None None O
especially None None O
among None None O
cultivars None None O
differing None None O
in None None O
K None None O
efficiency None None O
. None None O

By None None O
contrast None None O
, None None O
low None None O
to None None O
moderate None None O
soil None None O
Na None None I-TRANS
levels None None O
( None None O
25 None None O
, None None O
50 None None O
mg None None O
Na/kg None None O
) None None O
stimulated None None O
root None None O
dry None None O
weight None None O
at None None O
low None None O
K None None O
supply None None O
, None None O
particularly None None O
in None None O
K-efficient None None O
cultivars None None O
compared None None O
with None None O
K-inefficient None None O
cultivars None None O
. None None O

However None None O
, None None O
low None None O
to None None O
moderate None None O
Na None None I-TRANS
supply None None O
increased None None O
shoot None None O
K None None O
concentration None None O
and None None O
content None None O
in None None O
all None None O
four None None O
wheat None None O
cultivars None None O
, None None O
and None None O
it None None O
increased None None O
leaf None None O
photosynthesis None None O
and None None O
stomatal None None O
conductance None None O
to None None O
measured None None O
values None None O
similar None None O
to None None O
those None None O
under None None O
adequate None None O
K None None O
and None None O
nil None None O
Na None None I-TRANS
conditions None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
utilized None None O
RNAi None None O
technology None None O
to None None O
suppress None None O
the None None O
expression None None O
of None None O
the None None O
β-conglycinin None None O
, None None O
the None None O
abundant None None O
7S None None O
seed None None O
storage None None I-FUNC
proteins None None O
of None None O
soybean None None O
. None None O

We None None O
also None None O
discuss None None O
how None None O
the None None O
LRRK2 None None O
, None None O
α-syn None None O
, None None O
and None None O
tau None None O
phosphatases None None I-PROTEIN
may None None O
point None None O
to None None O
separate None None O
or None None O
cross-talking None None O
pathological None None O
pathways None None O
in None None O
PD None None O
. None None O

It None None O
is None None O
assumed None None O
that None None O
tumor None None O
necrosis None None O
factor-α None None O
, None None O
which None None O
is None None O
a None None O
key None None O
factor None None O
in None None O
Alzheimer None None I-DISEASE
, None None O
has None None O
a None None O
relation None None O
with None None O
periodontal None None O
complications None None O
in None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
disease None None O
. None None O

This None None O
case-control None None O
study None None O
was None None O
performed None None O
on None None O
80 None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
disease None None O
seeking None None O
medical None None O
care None None O
at None None O
Nour None None O
Hospital None None O
, None None O
Isfahan None None O
, None None O
Iran None None O
. None None O

Independent None None O
t-test None None O
showed None None O
that None None O
the None None O
mean None None O
of None None O
tumor None None O
necrosis None None O
factor-α None None O
in None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
and None None O
periodontitis None None O
was None None O
approximately None None O
three None None O
folds None None O
higher None None O
than None None O
the None None O
patients None None O
only None None O
with None None O
Alzheimer None None I-DISEASE
, None None O
and None None O
this None None O
difference None None O
was None None O
statistically None None O
significant None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Tumor None None O
necrosis None None O
factor-α None None O
level None None O
in None None O
serum None None O
may None None O
act None None O
as None None O
a None None O
diagnostic None None O
marker None None O
of None None O
periodontal None None O
disease None None O
in None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
disease None None O
. None None O

Fifteen None None O
disc-shaped None None O
samples None None O
( None None O
6 None None O
mm None None O
in None None O
diameter None None O
and None None O
2 None None O
mm None None O
in None None O
thickness None None O
) None None O
from None None O
three None None O
GIs None None O
( None None O
Fuji None None O
II None None O
, None None O
Fuji None None O
IX None None I-REGION
, None None O
Chem None None O
Flex None None O
) None None O
were None None O
made None None O
and None None O
suspended None None O
in None None O
a None None O
polypropylene None None O
recipient None None O
containing None None O
10 None None O
mL None None O
distilled None None O
water None None O
and None None O
stored None None O
at None None O
37°C None None O
. None None O

Highly None None O
viscous None None O
conventional None None O
GIs None None O
( None None O
Fuji None None O
IX None None I-REGION
and None None O
Chem None None O
Flex None None O
) None None O
released None None O
higher None None O
quantity None None O
of None None O
fluoride None None O
. None None O

Keratoameloblastoma None None O
is None None O
a None None O
rare None None O
histologic None None O
sub None None O
type None None O
, None None O
characterized None None O
by None None O
extensive None None O
keratin None None I-PROTEIN
formation None None O
within None None O
ameloblastic None None O
epithelium None None O
, None None O
with None None O
only None None O
a None None O
handful None None O
number None None O
of None None O
cases None None O
described None None O
in None None O
the None None O
literature None None O
. None None O

Histamine None None I-TRANS
and None None O
its None None O
receptors None None I-PROTEIN
were None None O
first None None O
described None None O
as None None O
part None None O
of None None O
immune None None O
and None None O
gastrointestinal None None O
systems None None O
, None None O
but None None O
their None None O
presence None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
and None None O
importance None None O
in None None O
behavior None None O
are None None O
gaining None None O
more None None O
attention None None I-FUNC
. None None O

Histamine None None I-TRANS
receptors None None I-PROTEIN
( None None O
H1R None None O
, None None O
H2R None None O
, None None O
H3R None None O
, None None O
and None None O
H4R None None O
) None None O
belong None None O
to None None O
the None None O
rhodopsin-like None None O
family None None O
of None None O
G None None O
protein-coupled None None O
receptors None None I-PROTEIN
, None None O
present None None O
constitutive None None O
activity None None O
, None None O
and None None O
are None None O
subjected None None O
to None None O
inverse None None O
agonist None None O
action None None O
. None None O

Data None None O
obtained None None O
from None None O
preclinical None None O
studies None None O
point None None O
antagonists None None O
of None None O
histamine None None I-TRANS
receptors None None I-PROTEIN
as None None O
promising None None O
alternatives None None O
to None None O
treat None None O
brain None None O
disorders None None O
. None None O

This None None O
review None None O
summarizes None None O
the None None O
role None None O
of None None O
histaminergic None None O
system None None O
in None None O
brain None None O
disorders None None O
, None None O
as None None O
well None None O
as None None O
the None None O
effects None None O
of None None O
different None None O
histamine None None I-TRANS
antagonists None None O
on None None O
animal None None O
models None None O
and None None O
humans None None O
. None None O

We None None O
believe None None O
the None None O
entropy-reducing None None O
constraint None None O
imparted None None O
to None None O
polymer None None O
associated None None O
water None None O
plays None None O
a None None O
negative None None O
role None None O
by None None O
increasing None None O
the None None O
probability None None O
of None None O
detrimental None None O
interactions None None O
such None None O
as None None O
junction None None O
zone None None O
formation None None O
and None None O
the None None O
non-productive None None O
binding None None O
of None None O
enzymes None None I-PROTEIN
. None None O

Structural None None O
brain None None O
malformations None None O
are None None O
consistently None None O
observed None None O
, None None O
including None None O
agenesis None None O
of None None O
the None None O
corpus None None I-REGION
callosum None None I-REGION
, None None O
hydrocephalus None None I-DISEASE
, None None O
periventricular None None O
nodular None None O
heterotopia None None O
, None None O
polymicrogyria None None O
, None None O
and None None O
cerebellar None None O
malformations None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
further None None O
explore None None O
the None None O
role None None O
of None None O
ankle None None O
DF None None O
ROM None None O
as None None O
measured None None O
with None None O
the None None O
knee None None O
bent None None O
and None None O
that None None O
of None None O
lower None None O
extremity None None O
movement None None I-FUNC
pattern None None O
as None None O
risk None None O
factors None None O
for None None O
mid-portion None None O
AT None None O
. None None O

Ankle None None O
DF None None O
ROM None None O
as None None O
measured None None O
with None None O
the None None O
knee None None O
bent None None O
in None None O
weight-bearing None None O
( None None O
WB None None O
) None None O
and None None O
non-weight-bearing None None O
( None None O
NWB None None O
) None None O
, None None O
as None None O
well None None O
as None None O
lower None None O
extremity None None O
quality None None O
of None None O
movement None None I-FUNC
during None None O
a None None O
lateral None None O
step None None O
down None None O
( None None O
LSD None None O
) None None O
test None None O
were None None O
measured None None O
at None None O
baseline None None O
. None None O

The None None O
quality None None O
of None None O
lower None None O
extremity None None O
movement None None I-FUNC
did None None O
not None None O
differ None None O
between None None O
injured None None O
and None None O
uninjured None None O
participants None None O
( None None O
p None None O
= None None O
0.361 None None O
) None None O
. None None O

The None None O
article None None O
by None None O
Song None None O
and None None O
colleagues None None O
presents None None O
findings None None O
from None None O
the None None O
Canadian None None O
Study None None O
of None None O
Health None None O
and None None O
Aging None None O
showing None None O
that None None O
the None None O
accumulation None None O
of None None O
health None None O
deficits None None O
, None None O
defined None None O
dichotomously None None O
and None None O
unqualified None None O
by None None O
severity None None O
or None None O
domain None None O
, None None O
predicted None None O
late-life None None O
dementia None None I-DISEASE
independent None None O
of None None O
chronological None None O
age None None O
. None None O

Importantly None None O
, None None O
this None None O
article None None O
broadens None None O
the None None O
perspective None None O
of None None O
research None None O
into None None O
measuring None None O
risk None None O
of None None O
dementia None None I-DISEASE
from None None O
focusing None None O
on None None O
specific None None O
neuropathological None None O
markers None None O
of None None O
dementia None None I-DISEASE
subtypes None None O
, None None O
to None None O
mechanisms None None O
underlying None None O
more None None O
general None None O
bodily None None O
vitality None None O
and None None O
health None None O
, None None O
as None None O
well None None O
as None None O
dysfunctions None None O
in None None O
repair None None O
. None None O

Such None None O
reverse None None O
inferences None None I-FUNC
, None None O
however None None O
, None None O
requires None None O
a None None O
set None None O
of None None O
meta-analysis None None O
, None None O
one None None O
for None None O
each None None O
possible None None O
cognitive None None O
domain None None O
. None None O

Commonly None None O
used None None O
methods None None O
for None None O
neuroimaging None None O
meta-analysis None None O
are None None O
not None None O
model None None O
based None None O
, None None O
do None None O
not None None O
provide None None O
interpretable None None O
parameter None None O
estimates None None O
, None None O
and None None O
only None None O
produce None None O
null None None O
hypothesis None None O
inferences None None I-FUNC
; None None O
further None None O
, None None O
they None None O
are None None O
generally None None O
designed None None O
for None None O
a None None O
single None None O
group None None O
of None None O
studies None None O
and None None O
can None None O
not None None O
produce None None O
reverse None None O
inferences None None I-FUNC
. None None O

We None None O
illustrate None None O
our None None O
model None None O
on None None O
simulation None None O
studies None None O
and None None O
a None None O
meta None None O
analysis None None O
of None None O
five None None O
emotions None None I-FUNC
from None None O
219 None None O
studies None None O
and None None O
check None None O
model None None O
fit None None O
by None None O
a None None O
posterior None None O
predictive None None O
assessment None None O
. None None O

Delayed None None O
leukoencephalopathy None None O
is None None O
an None None O
uncommon None None O
complication None None O
of None None O
hypoxic-ischemic None None O
events None None O
of None None O
different None None O
etiologies None None O
, None None O
including None None O
carbon None None I-TRANS
monoxide None None I-TRANS
intoxication None None O
. None None O

There None None O
was None None O
a None None O
history None None O
of None None O
accidental None None O
carbon None None I-TRANS
monoxide None None I-TRANS
intoxication None None O
one None None O
month None None O
before None None O
, None None O
presenting None None O
with None None O
loss None None O
of None None O
consciousness None None I-FUNC
and None None O
short None None O
hospitalization None None O
, None None O
followed None None O
by None None O
a None None O
complete None None O
clinical None None O
recovery None None O
. None None O

Vessel None None O
wall None None O
magnetic None None O
resonance None None O
imaging None None O
at None None O
ultra-high None None O
field None None O
( None None O
7 None None O
Tesla None None O
) None None O
can None None O
be None None O
used None None O
to None None O
visualize None None O
vascular None None O
lesions None None O
noninvasively None None O
and None None O
holds None None O
potential None None O
for None None O
improving None None O
stroke-risk None None O
assessment None None O
in None None O
patients None None O
with None None O
ischemic None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
. None None O

A None None O
51-year-old None None O
male None None O
with None None O
history None None O
of None None O
resected None None O
renal None None O
cell None None O
carcinoma None None O
and None None O
prior None None O
pulmonary None None O
embolism None None I-DISEASE
presented None None O
with None None O
tachypnea None None O
, None None O
tachycardia None None O
and None None O
progressive None None O
dyspnea None None O
on None None O
exertion None None O
. None None O

Transthoracic None None O
echocardiogram None None O
showed None None O
severe None None O
pulmonary None None O
hypertension None None O
with None None O
severe None None O
cor-pulmonale None None O
and None None O
presence None None O
of None None O
a None None O
large None None O
worm-like None None O
thrombus None None O
extending None None O
across None None O
the None None O
foramen None None O
ovale None None O
, None None O
entering None None O
both None None O
ventricles None None I-REGION
through None None O
the None None O
mitral None None O
and None None O
tricuspid None None O
valves None None O
. None None O

We None None O
report None None O
an None None O
interesting None None O
case None None O
of None None O
a None None O
19 None None O
year None None O
old None None O
female None None O
with None None O
findings None None O
on None None O
MRI None None O
suggestive None None O
of None None O
viral None None I-DISEASE
encephalitis None None I-DISEASE
. None None O

Anti-NMDA None None O
encephalitis None None I-DISEASE
is None None O
a None None O
highly None None O
lethal None None O
but None None O
treatable None None O
form None None O
of None None O
autoimmune None None O
encephalitis None None I-DISEASE
that None None O
has None None O
recently None None O
been None None O
characterized None None O
. None None O

Although None None O
rare None None O
, None None O
this None None O
diagnosis None None O
should None None O
be None None O
considered None None O
in None None O
young None None O
females None None O
for None None O
whom None None O
a None None O
rapid None None O
onset None None O
of None None O
encephalitis None None I-DISEASE
can None None O
not None None O
be None None O
explained None None O
by None None O
more None None O
common None None O
causes None None O
. None None O

Post-translational None None O
modifications None None O
of None None O
histones None None I-PROTEIN
dynamically None None O
influence None None O
gene None None O
expression None None O
independent None None O
of None None O
alterations None None O
to None None O
the None None O
DNA None None O
sequence None None O
. None None O

Different None None O
methods None None O
for None None O
their None None O
identification None None O
and None None O
isolation None None O
through None None O
stemness None None O
markers None None O
using None None O
various None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
methods None None O
such None None O
as None None O
flow None None O
cytometry None None O
, None None O
thyrosphere None None O
formation None None O
assay None None O
, None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
activity None None O
and None None O
ATP-binding None None O
cassette None None O
sub-family None None O
G None None O
member None None O
2 None None O
efflux-pump None None O
mediated None None O
Hoechst None None O
33342 None None O
dye None None O
exclusion None None O
have None None O
been None None O
discussed None None O
. None None O

Furthermore None None O
, None None O
based None None O
on None None O
their None None O
critical None None O
assessment None None O
of None None O
the None None O
present None None O
academic None None O
literature None None O
the None None O
authors None None O
of None None O
this None None O
review None None O
share None None O
their None None O
vision None None I-FUNC
about None None O
the None None O
future None None O
of None None O
stem None None O
cell None None O
applications None None O
in None None O
the None None O
treatment None None O
of None None O
knee None None O
osteoarthritis None None O
. None None O

Recent None None O
work None None O
has None None O
also None None O
demonstrated None None O
that None None O
pseudouridylation None None O
can None None O
be None None O
induced None None O
at None None O
novel None None O
positions None None O
under None None O
stress None None O
conditions None None O
, None None O
suggesting None None O
a None None O
regulatory None None O
role None None O
for None None O
Ψ. None None O
Brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
attracts None None O
increasing None None O
attention None None I-FUNC
from None None O
both None None O
research None None O
and None None O
clinical None None O
fields None None O
because None None O
of None None O
its None None O
important None None O
functions None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

We None None O
also None None O
introduce None None O
implications None None O
of None None O
BDNF None None O
in None None O
several None None O
brain-related None None O
diseases None None O
including None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
Huntington None None I-DISEASE
's None None O
disease None None O
, None None O
depression None None I-DISEASE
and None None O
schizophrenia None None I-DISEASE
. None None O

The None None O
P2X None None O
receptor None None I-PROTEIN
are None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
( None None O
ATP None None O
) None None O
gated None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
expressed None None O
by None None O
several None None O
cells None None O
including None None O
neurons None None O
, None None O
cancer None None O
and None None O
immune None None O
cells None None O
. None None O

Indeed None None O
, None None O
tumor None None O
microenvironment None None O
is None None O
rich None None O
in None None O
extracellular None None O
ATP None None O
, None None O
which None None O
has None None O
a None None O
role None None O
in None None O
both None None O
tumor None None O
development None None O
and None None O
pain None None O
sensation None None I-FUNC
. None None O

This None None O
review None None O
summarizes None None O
recent None None O
findings None None O
linking None None O
P2X None None O
receptors None None I-PROTEIN
and None None O
ATP None None O
to None None O
cancer None None O
growth None None O
, None None O
progression None None O
and None None O
related None None O
pain None None O
. None None O

Therapeutic None None O
implications None None O
of None None O
the None None O
administration None None O
of None None O
different None None O
P2X None None O
receptor None None I-PROTEIN
blockers None None O
to None None O
alleviate None None O
cancer-associated None None O
pain None None O
sensations None None I-FUNC
contemporarily None None O
reducing None None O
tumor None None O
progression None None O
are None None O
also None None O
discussed None None O
. None None O

At None None O
high None None O
concentrations None None O
, None None O
Ag None None O
NP None None O
determine None None O
loss None None O
of None None O
membrane None None O
integrity None None O
as None None O
demonstrated None None O
by None None O
the None None O
increased None None O
activity None None O
of None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
in None None O
the None None O
culture None None O
medium None None O
. None None O

Women None None O
treated None None O
with None None O
the None None O
selective None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
modulator None None O
tamoxifen None None O
for None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
positive None None O
breast None None O
cancer None None O
experience None None O
a None None O
50 None None O
% None None O
reduction None None O
in None None O
risk None None O
of None None O
contralateral None None O
breast None None O
cancer None None O
and None None O
overall None None O
reduction None None O
of None None O
similar None None O
magnitude None None O
has None None O
been None None O
identified None None O
among None None O
high-risk None None O
women None None O
receiving None None O
the None None O
drug None None O
for None None O
prevention None None O
. None None O

Measurement None None O
of None None O
lipid None None O
peroxidation None None O
and None None O
glutathione None None O
transferase None None I-PROTEIN
activity None None O
was None None O
also None None O
performed None None O
. None None O

Understanding None None O
the None None O
psychological None None O
factors None None O
associated None None O
with None None O
different None None O
eating None None I-DISEASE
disorders None None I-DISEASE
is None None O
important None None O
for None None O
assessment None None O
, None None O
diagnosis None None O
, None None O
and None None O
treatment None None O
. None None O

Because None None O
we None None O
were None None O
interested None None O
in None None O
both None None O
whether None None O
the None None O
PAI None None O
could None None O
be None None O
used None None O
to None None O
differentiate None None O
eating None None I-DISEASE
disorder None None I-DISEASE
subtypes None None O
from None None O
each None None O
other None None O
, None None O
as None None O
well None None O
as None None O
from None None O
other None None O
disorders None None O
, None None O
we None None O
also None None O
included None None O
a None None O
group None None O
of None None O
patients None None O
with None None O
major None None O
depression None None I-DISEASE
. None None O

Only None None O
two None None O
PAI None None O
scales None None O
( None None O
Anxiety None None O
and None None O
Depression None None I-DISEASE
) None None O
, None None O
however None None O
, None None O
exceeded None None O
a None None O
T-score None None O
of None None O
70 None None O
for None None O
the None None O
patients None None O
with None None O
anorexia None None I-DISEASE
nervosa None None I-DISEASE
, None None O
no None None O
scales None None O
exceeded None None O
a None None O
T-score None None O
of None None O
70 None None O
for None None O
the None None O
patients None None O
with None None O
bulimia None None I-DISEASE
nervosa None None I-DISEASE
or None None O
EDNOS None None O
, None None O
and None None O
only None None O
two None None O
exceeded None None O
a None None O
T-score None None O
of None None O
70 None None O
for None None O
the None None O
patients None None O
with None None O
depression None None I-DISEASE
( None None O
Depression None None I-DISEASE
and None None O
Suicide None None O
) None None O
. None None O

The None None O
PAI None None O
helps None None O
to None None O
understand None None O
the None None O
psychological None None O
factors None None O
associated None None O
with None None O
eating None None I-DISEASE
disorders None None I-DISEASE
and None None O
can None None O
be None None O
used None None O
to None None O
assist None None O
with None None O
assessment None None O
. None None O

Seventy-seven None None O
adults None None O
with None None O
varying None None O
experience None None O
of None None O
eating None None I-DISEASE
disorders None None I-DISEASE
took None None O
part None None O
in None None O
this None None O
Q None None O
methodological None None O
study None None O
. None None O

Mentoring None None O
programs None None O
have None None O
been None None O
useful None None O
with None None O
other None None O
psychiatric None None O
disorders None None O
such None None O
as None None O
addictions None None O
, None None O
and None None O
may None None O
be None None O
useful None None O
for None None O
individuals None None O
recovering None None O
from None None O
an None None O
eating None None I-DISEASE
disorder None None I-DISEASE
. None None O

The None None O
study None None O
included None None O
mentors None None O
( None None O
i.e. None None O
, None None O
individuals None None O
who None None O
have None None O
recovered None None O
from None None O
an None None O
eating None None I-DISEASE
disorder None None I-DISEASE
for None None O
an None None O
extended None None O
period None None O
of None None O
time None None O
) None None O
, None None O
and None None O
mentees None None O
( None None O
i.e. None None O
, None None O
individuals None None O
who None None O
were None None O
in None None O
the None None O
process None None O
of None None O
recovering None None O
from None None O
an None None O
eating None None I-DISEASE
disorder None None I-DISEASE
and None None O
wanting None None O
additional None None O
support None None O
aside None None O
from None None O
their None None O
treatment None None O
team None None O
) None None O
. None None O

Participants None None O
completed None None O
questions None None O
assessing None None O
eating None None I-DISEASE
disorder None None I-DISEASE
symptoms None None O
, None None O
quality None None O
of None None O
life None None O
, None None O
motivation None None O
towards None None O
recovery None None O
, None None O
and None None O
treatment None None O
compliance None None O
. None None O

The None None O
findings None None O
in None None O
this None None O
study None None O
suggest None None O
that None None O
mentor None None O
programs None None O
warrant None None O
further None None O
investigation None None O
as None None O
ancillary None None O
support None None O
services None None O
for None None O
individuals None None O
recovering None None O
from None None O
an None None O
eating None None I-DISEASE
disorder None None I-DISEASE
. None None O

Only None None O
subjects None None O
who None None O
had None None O
previously None None O
heard None None O
about None None O
radon None None O
were None None O
asked None None O
to None None O
answer None None O
knowledge-based None None O
and None None O
risk None None O
perception None None I-FUNC
questions None None O
and None None O
report None None O
source None None O
of None None O
knowledge None None O
, None None O
willingness None None O
to None None O
test None None O
and None None O
willingness None None O
to None None O
pay None None O
for None None O
radon None None O
test None None O
kits None None O
. None None O

A None None O
2-year-old None None O
boy None None O
with None None O
hypoplastic None None O
left None None O
heart None None O
syndrome None None O
that None None O
required None None O
multiple None None O
cardiovascular None None O
surgeries None None O
and None None O
a None None O
heterozygous None None O
prothrombin None None O
G20210A None None O
mutation None None O
with None None O
resulting None None O
thrombophilia None None O
maintained None None O
on None None O
warfarin None None O
presented None None O
with None None O
acute None None O
right None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
( None None O
MCA None None O
) None None O
infarction None None O
manifesting None None O
as None None O
a None None O
left None None O
hemiplegia None None O
. None None O

The None None O
cerebral None None O
arteries None None O
may None None O
be None None O
uniquely None None O
susceptible None None O
to None None O
the None None O
atherosclerotic None None O
effects None None O
of None None O
smoking None None O
, None None O
such None None O
that None None O
it None None O
has None None O
a None None O
different None None O
risk None None O
profile None None O
for None None O
stroke None None I-DISEASE
compared None None O
with None None O
other None None O
atherosclerosis None None I-DISEASE
risk None None O
factors None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
design None None O
will None None O
be None None O
to None None O
evaluate None None O
the None None O
association None None O
between None None O
smoking None None O
and None None O
severe None None O
IC None None O
stenosis None None O
, None None O
adjusting None None O
for None None O
other None None O
atherosclerosis None None I-DISEASE
risk None None O
factors None None O
, None None O
particularly None None O
age None None O
distribution None None O
. None None O

Participants None None O
are None None O
patients None None O
( None None O
n=1714 None None O
) None None O
with None None O
severe None None O
atherosclerotic None None O
stenosis None None O
undergoing None None O
cerebral None None O
catheter None None O
angiography None None O
because None None O
of None None O
stroke None None I-DISEASE
or None None O
transient None None O
ischaemic None None O
attack None None O
. None None O

The None None O
atherosclerotic None None O
or None None O
stroke None None I-DISEASE
risk None None O
factors None None O
for None None O
analysis None None O
include None None O
age None None O
, None None O
gender None None O
, None None O
smoking None None O
history None None O
, None None O
number None None O
of None None O
lesions None None O
( None None O
single None None O
versus None None O
multiple None None O
) None None O
, None None O
cardiac None None O
disease None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
hypertension None None O
, None None O
family None None O
history None None O
, None None O
dyslipidemia None None O
, None None O
history None None O
of None None O
previous None None O
stroke None None I-DISEASE
, None None O
alcohol None None O
intake None None O
, None None O
metabolic None None O
syndrome None None O
and None None O
body None None O
mass None None O
index None None O
. None None O

A None None O
40-year-old None None O
woman None None O
presented None None O
with None None O
acute None None O
stroke None None I-DISEASE
due None None O
to None None O
left None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
. None None O

Therefore None None O
, None None O
we None None O
can None None O
consider None None O
intra-arterial None None O
mechanical None None O
thrombectomy None None O
as None None O
a None None O
first-line None None O
treatment None None O
option None None O
in None None O
patients None None O
with None None O
acute None None O
stroke None None I-DISEASE
resulting None None O
from None None O
infective None None O
endocarditis None None O
. None None O

This None None O
may None None O
result None None O
in None None O
restrictions None None O
of None None O
movement None None I-FUNC
and None None O
pain None None O
. None None O

The None None O
OCT None None O
indicator None None O
of None None O
degradation None None O
depends None None O
on None None O
the None None O
dimension None None O
of None None O
areas None None O
of None None O
the None None O
media None None O
layer None None O
where None None O
backscattered None None O
reflectivity None None O
becomes None None O
smaller None None O
due None None O
to None None O
a None None O
disorder None None O
on None None O
the None None O
morphology None None O
of None None O
elastin None None I-PROTEIN
, None None O
collagen None None I-PROTEIN
and None None O
smooth None None O
muscle None None O
cells None None O
( None None O
SMCs None None O
) None None O
. None None O

Placental None None O
vascular None None O
pathology None None O
and None None O
increased None None O
thrombin None None I-PROTEIN
generation None None O
were None None O
reported None None O
in None None O
all None None O
of None None O
these None None O
obstetrical None None O
syndromes None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
will None None O
assess None None O
the None None O
changes None None O
in None None O
the None None O
hemostatic None None O
system None None O
during None None O
normal None None O
and None None O
complicated None None O
pregnancy None None O
in None None O
maternal None None O
blood None None O
, None None O
maternal-fetal None None O
interface None None O
and None None O
amniotic None None O
fluid None None O
, None None O
and None None O
describe None None O
the None None O
contribution None None O
of None None O
thrombosis None None I-DISEASE
and None None O
vascular None None O
pathology None None O
to None None O
the None None O
development None None O
of None None O
the None None O
great None None O
obstetrical None None O
syndromes None None O
. None None O

Rosettes None None O
were None None O
immunopositive None None O
for None None O
the None None O
Sox1 None None O
, None None O
Sox2 None None O
, None None O
Pax6 None None O
and None None O
Pax7 None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
govern None None O
neural None None O
development None None O
in None None O
the None None O
earliest None None O
stage None None O
of None None O
development None None O
and None None O
for None None O
the None None O
Isl1/2 None None O
and None None O
Otx2 None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
are None None O
expressed None None O
in None None O
the None None O
dorsal None None I-NEURON
and None None O
ventral None None I-NEURON
domains None None O
, None None O
respectively None None O
, None None O
of None None O
the None None O
neural None None O
tube None None O
in None None O
vivo None None O
. None None O

Artificially None None O
created None None O
facial None None I-REGION
nerve None None I-REGION
defects None None O
were None None O
reconstructed None None O
with None None O
a None None O
nerve None None O
graft None None O
, None None O
which None None O
was None None O
end-to-end None None O
sutured None None O
from None None O
proximal None None O
facial None None I-REGION
nerve None None I-REGION
stump None None O
to None None O
the None None O
mandibular None None O
branch None None O
( None None O
nonsupercharge None None O
group None None O
) None None O
, None None O
or None None O
with None None O
the None None O
graft None None O
of None None O
which None None O
other None None O
end None None O
was None None O
end-to-side None None O
sutured None None O
to None None O
the None None O
hypoglossal None None I-REGION
nerve None None I-REGION
( None None O
supercharge None None O
group None None O
) None None O
. None None O

Retrograde None None O
labeling None None O
showed None None O
that None None O
the None None O
mimetic None None O
muscles None None O
were None None O
double-innervated None None O
by None None O
facial None None O
and None None O
hypoglossal None None I-REGION
nerve None None I-REGION
nuclei None None O
in None None O
the None None O
supercharge None None O
group None None O
. None None O

Additionally None None O
, None None O
axonal None None O
supercharge None None O
from None None O
the None None O
hypoglossal None None I-REGION
nerve None None I-REGION
significantly None None O
improved None None O
outcomes None None O
. None None O

The None None O
safety None None O
and None None O
efficacy None None O
of None None O
using None None O
a None None O
components None None O
separation None None O
technique None None O
to None None O
treat None None O
large None None O
ventral None None I-NEURON
hernias None None O
in None None O
pediatric None None O
patients None None O
in None None O
this None None O
setting None None O
remains None None O
understudied None None O
. None None O

Abdominal None None O
trauma None None O
with None None O
a None None O
large None None O
ventral None None I-NEURON
hernia None None O
requiring None None O
components None None O
separation None None O
is None None O
extremely None None O
rare None None O
. None None O

These None None O
cells None None O
contain None None O
cytoplasmic None None O
angiogenic None None O
factors None None O
, None None O
including None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
, None None O
basic None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
, None None O
and None None O
hepatocyte None None O
growth None None O
factor None None O
. None None O

The None None O
series None None O
comprised None None O
6 None None O
male None None O
patients None None O
( None None O
mean None None O
age None None O
, None None O
46 None None O
years None None O
) None None O
who None None O
presented None None O
with None None O
upper None None O
extremity None None O
ischemia None None O
related None None O
to None None O
hypothenar None None O
hammer None None O
syndrome None None O
( None None O
n None None O
= None None O
2 None None O
) None None O
, None None O
embolism None None I-DISEASE
with None None O
patent None None O
foramen None None O
ovale None None O
( None None O
n None None O
= None None O
2 None None O
) None None O
, None None O
atherosclerosis None None I-DISEASE
( None None O
n None None O
= None None O
1 None None O
) None None O
, None None O
and None None O
avulsion None None O
amputation None None O
of None None O
the None None O
thumb None None O
( None None O
n None None O
= None None O
1 None None O
) None None O
; None None O
the None None O
patient None None O
with None None O
the None None O
avulsion None None O
amputation None None O
was None None O
diagnosed None None O
with None None O
thromboangiitis None None O
obliterans None None O
at None None O
the None None O
time None None O
of None None O
replantation None None O
. None None O

In None None O
addition None None O
, None None O
pin None None O
loosening None None O
in None None O
22.5 None None O
% None None O
required None None O
pin None None O
replacement None None O
or None None O
led None None O
to None None O
reduced None None O
retention None None I-FUNC
period None None O
. None None O

The None None O
scar None None O
often None None O
heals None None O
slowly None None O
and None None O
widens None None O
over None None O
time None None O
, None None O
perpetuated None None O
by None None O
the None None O
effects None None O
of None None O
gravity None None O
, None None O
body None None O
movements None None I-FUNC
, None None O
and None None O
the None None O
thin None None O
nature None None O
of None None O
the None None O
superficial None None O
fascial None None O
system None None O
( None None O
SFS None None O
) None None O
of None None O
the None None O
arm None None O
. None None O

As None None O
experience None None O
with None None O
vascularized None None O
lymph None None O
node None None O
( None None O
VLN None None I-NEURON
) None None O
transfer None None O
has None None O
grown None None O
, None None O
new None None O
VLN None None I-NEURON
sources None None O
have None None O
become None None O
apparent None None O
. None None O

Yet None None O
, None None O
no None None O
study None None O
has None None O
evaluated None None O
preoperative None None O
imaging None None O
evaluation None None O
between None None O
donor None None O
sites None None O
in None None O
patients None None O
undergoing None None O
VLN None None I-NEURON
transfer None None O
. None None O

A None None O
review None None O
of None None O
a None None O
prospective None None O
database None None O
was None None O
performed None None O
for None None O
patients None None O
who None None O
had None None O
undergone None None O
preoperative None None O
planning None None O
for None None O
VLN None None I-NEURON
transfer None None O
with None None O
duplex None None O
ultrasonography None None O
to None None O
provide None None O
objective None None O
donor-site None None O
characteristics None None O
. None None O

Rat None None O
tail None None O
models None None O
of None None O
lymphedema None None O
were None None O
assigned None None O
to None None O
groups None None O
that None None O
received None None O
either None None O
daily None None O
topical None None O
basic None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
bFGF None None O
) None None O
or None None O
saline None None O
( None None O
control None None O
) None None O
groups None None O
. None None O

The None None O
mRNA None None O
levels None None O
of None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
-C None None O
and None None O
VEGF-D None None O
and None None O
the None None O
protein None None O
levels None None O
of None None O
VEGF-C None None O
were None None O
evaluated None None O
at None None O
postoperative None None O
days None None O
( None None O
PODs None None O
) None None O
7 None None O
, None None O
14 None None O
, None None O
and None None O
28 None None O
. None None O

As None None O
nipple-sparing None None O
mastectomy None None O
with None None O
implant-based None None O
reconstruction None None O
has None None O
increased None None O
, None None O
attention None None I-FUNC
must None None O
be None None O
paid None None O
to None None O
the None None O
viability None None O
of None None O
the None None O
nipple-areolar None None O
complex None None O
. None None O

Fifteen None None O
English None None O
language None None I-FUNC
articles None None O
were None None O
included None None O
. None None O

Fat None None O
grafts None None O
must None None O
obtain None None O
oxygen None None O
via None None O
diffusion None None O
until None None O
neovascularization None None O
occurs None None O
, None None O
so None None O
oxygen None None O
delivery None None O
may None None O
be None None O
the None None O
overarching None None O
variable None None O
in None None O
graft None None O
retention None None I-FUNC
. None None O

Ten None None O
genes None None O
encoding None None I-FUNC
novel None None O
cellulases None None O
with None None O
putative None None O
signal None None O
peptides None None I-TRANS
at None None O
the None None O
N-terminus None None O
, None None O
termed None None O
pre-LC-CelA-J None None O
, None None O
were None None O
isolated None None O
from None None O
a None None O
fosmid None None O
library None None O
of None None O
a None None O
leaf-branch None None O
compost None None O
metagenome None None O
by None None O
functional None None O
screening None None O
using None None O
agar None None O
plates None None O
containing None None O
carboxymethyl None None O
cellulose None None O
and None None O
trypan None None O
blue None None O
. None None O

FABPs None None O
are None None O
known None None O
to None None O
be None None O
carrier None None O
proteins None None O
for None None O
transporting None None O
fatty None None O
acids None None O
and None None O
other None None O
lipophilic None None O
substances None None O
from None None O
the None None O
cytoplasm None None O
to None None O
the None None O
nucleus None None O
, None None O
where None None O
these None None O
lipids None None O
are None None O
released None None O
to None None O
a None None O
group None None O
of None None O
nuclear None None O
receptors None None I-PROTEIN
such None None O
as None None O
peroxisome None None O
proliferator-activated None None O
receptors None None I-PROTEIN
( None None O
PPARs None None O
) None None O
. None None O

The None None O
results None None O
also None None O
showed None None O
that None None O
inhibition None None O
or None None O
down-regulation None None O
of None None O
ornithine None None I-PROTEIN
decarboxylase None None I-PROTEIN
( None None O
ODC None None O
) None None O
inhibited None None O
TRPM7 None None O
expression None None O
, None None O
a None None O
process None None O
that None None O
was None None O
reversed None None O
by None None O
spermidine None None O
. None None O

Multilocus None None O
molecular None None O
analyses None None O
are None None O
essential None None O
for None None O
the None None O
determination None None O
of None None O
G. None None O
duodenalis None None O
assemblages None None O
and None None O
subsequent None None O
inferences None None I-FUNC
on None None O
transmission None None O
routes None None O
to None None O
endangered None None O
marine None None O
mammal None None O
populations None None O
. None None O

The None None O
optimum None None O
number None None O
of None None O
the None None O
rules None None O
for None None O
all None None O
trials None None O
was None None O
4 None None O
± None None O
1 None None O
, None None O
that None None O
might None None O
be None None O
related None None O
to None None O
motor None None I-FUNC
control None None I-FUNC
strategies None None O
and None None O
the None None O
% None None O
variance None None O
accounted None None O
for None None O
criterion None None O
was None None O
96.40 None None O
± None None O
3.38 None None O
which None None O
in None None O
fact None None O
showed None None O
considerable None None O
improvement None None O
compared None None O
with None None O
the None None O
previous None None O
methods None None O
. None None O

A None None O
cochlear None None O
implant None None O
is None None O
an None None O
implanted None None O
electronic None None O
device None None O
used None None O
to None None O
provide None None O
a None None O
sensation None None I-FUNC
of None None O
hearing None None O
to None None O
a None None O
person None None O
who None None O
is None None O
hard None None O
of None None O
hearing None None O
. None None O

This None None O
paper None None O
presents None None O
an None None O
undecimated None None O
wavelet-based None None O
speech None None I-FUNC
coding None None O
strategy None None O
for None None O
cochlear None None O
implants None None O
, None None O
which None None O
gives None None O
a None None O
novel None None O
speech None None I-FUNC
processing None None O
strategy None None O
. None None O

The None None O
speech None None I-FUNC
data None None O
used None None O
for None None O
the None None O
current None None O
study None None O
consists None None O
of None None O
30 None None O
consonants None None O
, None None O
sampled None None O
at None None O
16 None None O
kbps None None O
. None None O

Undecimated None None O
wavelet None None O
had None None O
better None None O
segmental None None O
SNR None None O
in None None O
about None None O
96 None None O
% None None O
of None None O
the None None O
input None None O
speech None None I-FUNC
data None None O
. None None O

Thus None None O
, None None O
the None None O
information None None O
loss None None O
is None None O
minimal None None O
and None None O
that None None O
is None None O
why None None O
the None None O
UWPT None None O
performance None None O
was None None O
better None None O
than None None O
that None None O
of None None O
traditional None None O
filter-bank None None O
strategies None None O
in None None O
speech None None I-FUNC
recognition None None I-FUNC
tests None None O
. None None O

Shape None None O
and None None O
movement None None I-FUNC
features None None O
of None None O
sperms None None O
are None None O
important None None O
parameters None None O
for None None O
infertility None None O
study None None O
and None None O
treatment None None O
. None None O

This None None O
article None None O
also None None O
includes None None O
the None None O
stability None None O
and None None O
storage None None I-FUNC
issues None None O
with None None O
reference None None O
to None None O
photolysis None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
investigation None None O
was None None O
to None None O
enhance None None O
the None None O
hepatoprotective None None O
activity None None O
of None None O
silymarin None None O
by None None O
incorporating None None O
it None None O
in None None O
chitosan None None O
( None None O
Ch None None O
) None None O
nanoparticles None None O
( None None O
NPs None None O
) None None O
for None None O
passive None None O
targeted None None O
delivery None None O
, None None O
thereby None None O
prolonging None None O
its None None O
retention None None I-FUNC
time None None O
. None None O

Optimized None None O
formulation None None O
was None None O
characterized None None O
for None None O
various None None O
in-vitro None None O
attributes None None O
, None None O
including None None O
particles None None O
size None None O
, None None O
zeta None None O
potential None None O
, None None O
shape None None O
and None None O
morphology None None O
, None None O
in-vitro None None O
release None None O
profile None None O
, None None O
corneal None None O
permeation None None O
, None None O
corneal None None O
retention None None I-FUNC
, None None O
ocular None None O
tolerance None None O
test None None O
as None None O
well None None O
as None None O
antimicrobial None None O
activity None None O
. None None O

Mox None None O
loaded None None O
CS-DS None None O
NPs None None O
exhibited None None O
a None None O
significantly None None O
higher None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
approximately None None O
1.8-fold None None O
transcorneal None None O
permeation None None O
as None None O
well None None O
as None None O
significantly None None O
higher None None O
corneal None None O
retention None None I-FUNC
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
around None None O
4-5-fold None None O
when None None O
compared None None O
to None None O
free None None O
solution None None O
. None None O

Zinc None None I-TRANS
oxide None None O
suspension None None O
was None None O
prepared None None O
by None None O
varying None None O
the None None O
concentration None None O
of None None O
C. None None O
fistula None None O
pulp None None O
polymer None None O
and None None O
compared None None O
with None None O
suspension None None O
made None None O
by None None O
use None None O
of None None O
tragacanth None None O
, None None O
sodium None None O
carboxymethyl None None O
cellulose None None O
and None None O
bentonite None None O
. None None O

The None None O
tumor None None O
suppressor None None O
, None None O
phosphatase None None I-PROTEIN
and None None O
tensin None None O
homolog None None O
on None None O
chromosome None None O
10 None None O
( None None O
PTEN None None O
) None None O
, None None O
is None None O
a None None O
dual-specificity None None O
phosphatase None None I-PROTEIN
, None None O
which None None O
has None None O
protein None None O
phosphatase None None I-PROTEIN
activity None None O
and None None O
lipid None None O
phosphatase None None I-PROTEIN
activity None None O
that None None O
antagonizes None None O
PI3K None None O
activity None None O
. None None O

We None None O
identified None None O
seven None None O
preoperative None None O
clinical None None O
variables None None O
( None None O
age None None O
, None None O
duration None None O
of None None O
diabetes None None O
, None None O
body None None O
mass None None O
index None None O
, None None O
micro None None O
and None None O
macrovascular None None O
complications None None O
, None None O
use None None O
of None None O
insulin None None I-PROTEIN
and None None O
stimulated None None O
C-peptide None None O
) None None O
based None None O
on None None O
our None None O
previous None None O
reports None None O
to None None O
be None None O
included None None O
in None None O
the None None O
diabetes None None O
remission None None O
score None None O
( None None O
DRS None None O
) None None O
. None None O

TH None None O
expressions None None O
in None None O
the None None O
substantia None None I-REGION
nigra None None I-REGION
and None None O
striatum None None I-REGION
were None None O
evaluated None None O
by None None O
immunohistochemistry None None O
. None None O

TH None None O
expressions None None O
in None None O
the None None O
substantia None None I-REGION
nigra None None I-REGION
and None None O
striatum None None I-REGION
were None None O
decreased None None O
in None None O
the None None O
rats None None O
of None None O
ADHD None None O
model None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
is None None O
a None None O
most None None O
common None None O
age-related None None O
neurodegenerative None None O
disease None None O
. None None O

The None None O
cerebellum None None I-REGION
is None None O
closely None None O
associated None None O
with None None O
integration None None O
of None None O
movement None None I-FUNC
, None None O
including None None O
motor None None O
coordination None None O
, None None O
control None None O
, None None O
and None None O
equilibrium None None O
. None None O

The None None O
present None None O
study None None O
demonstrated None None O
that None None O
treadmill None None O
exercises None None O
alleviated None None O
dysfunction None None O
of None None O
motor None None O
coordination None None O
and None None O
balance None None O
by None None O
reduction None None O
of None None O
Purkinje None None I-NEURON
cell None None I-NEURON
loss None None O
through None None O
suppressing None None O
reactive None None O
astrocytes None None O
in None None O
the None None O
cerebellum None None I-REGION
of None None O
AD None None O
rats None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
research None None O
is None None O
to None None O
verify None None O
the None None O
effects None None O
of None None O
horseback None None O
riding None None O
participation None None O
on None None O
the None None O
muscle None None O
tone None None O
of None None O
pelvic None None O
limbs None None O
and None None O
articular None None O
range None None O
of None None O
motion None None O
for None None O
children None None O
with None None O
spastic None None I-DISEASE
cerebral None None I-DISEASE
palsy None None I-DISEASE
. None None O

The None None O
results None None O
are None None O
as None None O
follows None None O
: None None O
First None None O
, None None O
the None None O
participation None None O
in None None O
the None None O
therapeutic None None O
horseback None None O
riding None None O
program None None O
showed None None O
a None None O
statistically None None O
significant None None O
difference None None O
in None None O
the None None O
muscle None None O
tone None None O
for None None O
the None None O
knee None None O
of None None O
children None None O
with None None O
spastic None None I-DISEASE
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Third None None O
, None None O
the None None O
participation None None O
in None None O
the None None O
therapeutic None None O
horseback None None O
riding None None O
program None None O
showed None None O
a None None O
statistically None None O
significant None None O
difference None None O
in None None O
the None None O
hip-joint None None O
motion None None O
range None None O
for None None O
the None None O
knee None None O
of None None O
children None None O
with None None O
spastic None None I-DISEASE
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

The None None O
club None None O
speeds None None O
were None None O
measured None None O
using None None O
the None None O
Golfzon None None O
Vision None None I-FUNC
machine None None O
and None None O
the None None O
handicap None None O
points None None O
were None None O
measured None None O
using None None O
a None None O
simple None None O
questionnaire None None O
. None None O

Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
is None None O
a None None O
chronically None None O
developing None None O
neurodegenerative None None O
disease None None O
showing None None O
typical None None O
motor None None O
symptoms None None O
of None None O
the None None O
following None None O
triad None None O
: None None O
resting None None O
tremor None None O
, None None O
freezing None None O
of None None O
gait None None O
, None None O
and None None O
bradykinesia-hypokinesia None None O
. None None O

Subjects None None O
consisted None None O
of None None O
29 None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
patients None None O
who None None O
were None None O
non-demented None None O
individuals None None O
. None None O

To None None O
this None None O
end None None O
, None None O
this None None O
study None None O
investigated None None O
how None None O
exercise None None O
affects None None O
frailty None None O
, None None O
depression None None I-DISEASE
, None None O
and None None O
cognitive None None O
functions None None O
in None None O
older None None O
adults None None O
. None None O

Results None None O
revealed None None O
that None None O
participants None None O
' None None O
frailty None None O
and None None O
depression None None I-DISEASE
varied None None O
according None None O
to None None O
exercise None None O
participation None None O
time None None O
and None None O
frequency None None O
. None None O

It None None O
was None None O
designed None None O
as None None O
a None None O
program None None O
of None None O
17 None None O
sessions None None O
including None None O
3 None None O
interviews None None O
and None None O
diagnostic None None O
checks None None O
( None None O
psychological None None O
skill None None O
questionnaire None None O
: None None O
PSQ None None O
, None None O
profiles None None O
of None None O
mood None None I-FUNC
states None None O
: None None O
POMS None None O
) None None O
and None None O
14 None None O
sessions None None O
of None None O
PST None None O
( None None O
goal None None O
setting None None O
, None None O
anxiety None None O
reduction None None O
, None None O
concentration None None O
, None None O
confidence None None O
) None None O
. None None O

Meanwhile None None O
negative None None O
emotions None None I-FUNC
, None None O
such None None O
as None None O
tension None None O
, None None O
depression None None I-DISEASE
, None None O
and None None O
fatigue None None O
were None None O
decreased None None O
. None None O

Muscle None None O
activity None None O
onset None None O
of None None O
the None None O
internal None None O
oblique None None O
( None None O
IO None None O
) None None O
and None None O
external None None O
oblique None None O
( None None O
EO None None O
) None None O
muscles None None O
was None None O
measured None None O
by None None O
electromyography None None O
( None None O
EMG None None O
) None None O
activity None None O
with None None O
a None None O
rapid None None O
arm None None O
movement None None I-FUNC
and None None O
during None None O
the None None O
performance None None O
of None None O
a None None O
walking None None O
task None None O
. None None O

Preplate None None O
splitting None None O
involves None None O
the None None O
establishment None None O
of None None O
prospective None None O
cortical None None O
layer None None O
6 None None O
( None None O
L6 None None O
) None None O
neurons None None O
within None None O
a None None O
plexus None None O
of None None O
pioneer None None I-NEURON
neurons None None I-NEURON
called None None O
the None None O
preplate None None O
. None None O

Disruptions None None O
of None None O
this None None O
early None None O
developmental None None O
event None None O
by None None O
toxin None None O
exposure None None O
or None None O
mutation None None O
are None None O
associated None None O
with None None O
neurological None None O
disease None None O
including None None O
severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
. None None O

Low None None O
or None None O
unskilled None None O
industrial None None O
and None None O
construction None None O
workers None None O
are None None O
less None None O
frequently None None O
affected None None O
by None None O
higher None None O
degrees None None O
of None None O
WLC None None O
but None None O
are None None O
then None None O
at None None O
no None None O
lower None None O
risk None None O
of None None O
suffering None None O
poor None None O
self-rated None None O
health None None O
or None None O
severe None None O
backaches None None O
and None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
than None None O
university None None O
graduates None None O
working None None O
in None None O
the None None O
service None None O
sector None None O
with None None O
comparable None None O
exposure None None O
to None None O
WLC None None O
. None None O

With None None O
the None None O
actual None None O
growth None None O
of None None O
the None None O
natural None None O
gas None None O
industry None None O
in None None O
the None None O
US None None O
as None None O
well None None O
as None None O
the None None O
potential None None O
and None None O
availability None None O
of None None O
this None None O
non-renewable None None O
carbon None None O
source None None O
worldwide None None O
, None None O
reforming None None O
of None None O
methane None None O
gas None None O
is None None O
getting None None O
increasing None None O
attention None None I-FUNC
. None None O

Attention None None I-FUNC
will None None O
as None None O
well None None O
be None None O
given None None O
to None None O
other None None O
emerging None None O
techniques None None O
that None None O
may None None O
allow None None O
countering None None O
at None None O
one None None O
point None None O
the None None O
high None None O
thermodynamic None None O
penalties None None O
that None None O
accompanies None None O
conversion None None O
of None None O
methane None None O
using None None O
carbon None None O
dioxide None None O
. None None O

) None None O
, None None O
participants None None O
completed None None O
the None None O
Perceived None None O
Stress None None O
Scale None None O
, None None O
Stressful None None O
Life None None O
Events None None O
checklist None None O
, None None O
CES-D None None O
( None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
) None None O
, None None O
and None None O
Life None None O
Orientation None None O
Test None None O
( None None O
optimism None None O
) None None O
. None None O

The None None O
app None None I-TRANS
was None None O
used None None O
by None None O
18 None None O
blind None None O
participants None None O
to None None O
find None None O
visual None None O
targets None None O
beyond None None O
arm None None O
's None None O
reach None None O
and None None O
approach None None O
them None None O
to None None O
within None None O
30 None None O
cm None None O
. None None O

These None None O
results None None O
have None None O
important None None O
implications None None O
for None None O
the None None O
design None None O
of None None O
object None None I-FUNC
recognition None None I-FUNC
systems None None O
for None None O
blind None None O
users None None O
. None None O

Blood None None O
samples None None O
were None None O
taken None None O
before None None O
the None None O
first None None O
match None None O
and None None O
after None None O
the None None O
third None None O
match None None O
for None None O
serum None None O
creatine None None O
kinase None None O
( None None O
CK None None O
) None None O
and None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
analysis None None O
. None None O

Resistance None None O
exercise None None O
may None None O
offer None None O
additional None None O
benefits None None O
regarding None None O
the None None O
ability None None O
to None None O
fall None None O
asleep None None O
and None None O
stay None None O
asleep None None O
to None None O
populations None None O
with None None O
osteoporosis None None O
, None None O
sarcopenia None None O
, None None O
anxiety None None O
, None None O
or None None O
depression None None I-DISEASE
. None None O

The None None O
conversion None None O
of None None O
cellular None None O
prion None None O
protein None None O
( None None O
PrP None None O
( None None O
C None None O
) None None O
) None None O
to None None O
its None None O
infectious None None O
protease None None O
resistant None None O
counterpart None None O
( None None O
PrP None None O
( None None O
Res None None O
) None None O
) None None O
is None None O
the None None O
essential None None O
feature None None O
of None None O
prion None None I-DISEASE
diseases None None I-DISEASE
. None None O

Beta-amyloid None None O
( None None O
Aβ None None O
) None None O
synaptotoxicity None None O
and None None O
cognitive None None O
dysfunction None None O
in None None O
mouse None None O
models None None O
of None None O
Alzheimer None None I-DISEASE
disease None None O
are None None O
mediated None None O
by None None O
a None None O
PrP None None O
( None None O
C None None O
) None None O
-dependent None None O
pathway None None O
. None None O

The None None O
NOX None None O
signaling None None O
pathway None None O
may None None O
also None None O
be None None O
integrated None None O
with None None O
those None None O
of None None O
other None None O
transmembrane None None I-PROTEIN
receptors None None I-PROTEIN
clustered None None O
in None None O
PrP None None O
( None None O
C None None O
) None None O
-enriched None None O
membrane None None O
domains None None O
. None None O

PrP None None O
( None None O
C None None O
) None None O
overexpression None None O
alone None None O
activates None None O
NOX None None O
and None None O
generates None None O
a None None O
local None None O
increase None None O
in None None O
ROS None None O
that None None O
initiates None None O
cofilin None None O
activation None None O
and None None O
formation None None O
of None None O
cofilin-saturated None None O
actin None None I-PROTEIN
bundles None None O
( None None O
rods None None O
) None None O
. None None O

A None None O
descriptive None None O
qualitative None None O
design None None O
was None None O
chosen None None O
to None None O
elicit None None O
practice None None O
nurses None None O
' None None O
perceptions None None I-FUNC
. None None O

Peach None None O
purée None None O
was None None O
exposed None None O
to None None O
different None None O
pH None None O
( None None O
2.5 None None O
, None None O
3.0 None None O
, None None O
3.5 None None O
, None None O
4.0 None None O
, None None O
and None None O
4.5 None None O
) None None O
conditions None None O
, None None O
and None None O
its None None O
phytochemical None None O
alteration None None O
was None None O
estimated None None O
after None None O
fruit None None O
pasteurization None None O
and None None O
over None None O
a None None O
90 None None O
day None None O
storage None None I-FUNC
period None None O
at None None O
both None None O
4 None None O
and None None O
23 None None O
°C None None O
. None None O

Neochlorogenic None None O
acid None None O
( None None O
34 None None O
and None None O
27 None None O
% None None O
) None None O
and None None O
chlorogenic None None O
acid None None O
( None None O
34 None None O
and None None O
37 None None O
% None None O
) None None O
presented None None O
lower None None O
retention None None I-FUNC
at None None O
the None None O
higher None None O
pH None None O
( None None O
4.5 None None O
) None None O
for None None O
both None None O
storage None None I-FUNC
temperatures None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
showed None None O
that None None O
MDM2 None None O
inhibitor None None O
Nutlin-3 None None O
upregulated None None O
p53 None None I-PROTEIN
protein None None O
and None None O
downregulated None None O
FoxM1 None None O
expression None None O
in None None O
several None None O
cancer None None O
cell None None O
lines None None O
with None None O
wild None None O
type None None O
TP53 None None O
but None None O
not None None O
in None None O
cell None None O
lines None None O
with None None O
mutant None None O
TP53 None None O
. None None O

Knockdown None None O
of None None O
p53 None None I-PROTEIN
using None None O
shRNAs None None O
abrogated None None O
the None None O
FoxM1 None None O
downregulation None None O
by None None O
Nutlin-3 None None O
, None None O
indicating None None O
a None None O
p53-dependent None None O
mechanism None None O
. None None O

We None None O
constructed None None O
a None None O
truncated None None O
version None None O
of None None O
human None None O
RNASET2 None None O
, None None O
starting None None O
at None None O
E50 None None O
( None None O
trT2-50 None None O
) None None O
and None None O
devoid None None O
of None None O
ribonuclease None None I-PROTEIN
activity None None O
. None None O

trT2-50 None None O
binds None None O
to None None O
cell None None O
surface None None O
actin None None I-PROTEIN
and None None O
formed None None O
a None None O
complex None None O
with None None O
actin None None I-PROTEIN
in None None O
vitro None None O
. None None O

The None None O
exchange None None O
activity None None O
is None None O
under None None O
the None None O
unique None None O
regulation None None O
by None None O
phosphorylation None None O
of None None O
tyrosine None None I-TRANS
residues None None O
hidden None None O
by None None O
intra-molecular None None O
interactions None None O
. None None O

To None None O
avoid None None O
lymphoma None None O
development None None O
, None None O
we None None O
crossed None None O
p53 None None I-PROTEIN
knockout None None O
mice None None O
( None None O
BALB-p53 None None O
mice None None O
) None None O
with None None O
alymphocytic None None O
BALB/c None None O
Rag2-/- None None O
; None None O
Il2rg-/- None None O
( None None O
RGKO None None O
) None None O
mice None None O
. None None O

Tumor None None O
spectrum None None O
changes None None O
occurred None None O
also None None O
in None None O
p53 None None I-PROTEIN
heterozygotes None None O
, None None O
in None None O
which None None O
lymphomas None None O
are None None O
relatively None None O
rare None None O
( None None O
~20 None None O
% None None O
) None None O
. None None O

Genetic None None O
prevention None None O
of None None O
lymphoma None None O
in None None O
p53 None None I-PROTEIN
knockout None None O
mice None None O
led None None O
to None None O
new None None O
models None None O
of None None O
sarcoma None None O
development None None O
, None None O
available None None O
for None None O
studies None None O
on None None O
hemangiosarcoma None None O
and None None O
osteosarcoma None None O
onset None None O
and None None O
metastatization None None O
. None None O

Subsequent None None O
investigations None None O
revealed None None O
that None None O
Cx32 None None O
directly None None O
enhanced None None O
the None None O
acetylation None None O
and None None O
transcriptional None None O
activity None None O
of None None O
p53 None None I-PROTEIN
, None None O
thus None None O
upregulating None None O
the None None O
expression None None O
of None None O
the None None O
tumor None None O
metastasis None None O
suppressor None None O
protein None None O
KAI1/CD82 None None O
, None None O
which None None O
is None None O
a None None O
p53 None None I-PROTEIN
target None None O
gene None None O
. None None O

Although None None O
it None None O
is None None O
well-known None None O
that None None O
integrins None None I-PROTEIN
mediate None None O
adhesion None None O
of None None O
malignant None None O
cells None None O
to None None O
bone None None O
extracellular None None O
matrix None None O
, None None O
their None None O
role None None O
during None None O
bone None None O
colonization None None O
remains None None O
unclear None None O
. None None O

In None None O
vitro None None O
, None None O
bone-metastatic None None O
breast None None O
cancer None None O
cells None None O
with None None O
suppressed None None O
integrin None None I-PROTEIN
β1 None None O
expression None None O
showed None None O
reduced None None O
attachment None None O
, None None O
spreading None None O
, None None O
and None None O
migration None None O
within None None O
human None None O
bone None None O
matrix None None O
compared None None O
to None None O
control None None O
cells None None O
. None None O

Tumor None None O
cells None None O
invaded None None O
bone None None O
marrow None None O
spaces None None O
in None None O
the None None O
humanized None None O
bone None None O
and None None O
formed None None O
osteolytic None None O
lesions None None O
; None None O
osteoclastic None None O
bone None None O
resorption None None O
was None None O
, None None O
however None None O
, None None O
not None None O
reduced None None O
by None None O
β1 None None O
integrin None None I-PROTEIN
knockdown None None O
. None None O

Evidence None None O
is None None O
considered None None O
suggesting None None O
that None None O
the None None O
neurobiological None None O
condition None None O
for None None O
the None None O
pathogenesis None None O
of None None O
compulsive None None O
checking None None O
is None None O
two-fold None None O
: None None O
activation None None O
of None None O
dopamine None None I-TRANS
D2/D3 None None O
receptors None None I-PROTEIN
without None None O
concurrent None None O
stimulation None None O
of None None O
D1-like None None O
receptors None None I-PROTEIN
and None None O
long-term None None O
plastic None None O
changes None None O
related None None O
to None None O
quinpirole-induced None None O
sensitization None None O
. None None O

These None None O
modifications None None O
are None None O
mediated None None O
by None None O
β2-subunit-containing None None O
( None None O
β2* None None O
) None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptors None None I-PROTEIN
in None None O
the None None O
hippocampus None None I-REGION
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
modulation None None O
of None None O
hippocampal None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
using None None O
ABT-089 None None O
may None None O
be None None O
an None None O
effective None None O
component None None O
of None None O
novel None None O
therapeutic None None O
strategies None None O
for None None O
nicotine None None O
addiction None None O
. None None O

Inhaled None None O
nitric None None I-TRANS
oxide None None I-TRANS
has None None O
been None None O
shown None None O
to None None O
improve None None O
short None None O
term None None O
outcomes None None O
only None None O
. None None O

It None None O
has None None O
been None None O
reported None None O
that None None O
the None None O
inclusion None None O
of None None O
pyruvate None None O
and None None O
various None None O
hormones None None I-PROTEIN
in None None O
the None None O
culture None None O
medium None None O
improves None None O
the None None O
maintenance None None O
of None None O
various None None O
hepatic None None O
functions None None O
, None None O
including None None O
that None None O
of None None O
CYP2C11 None None O
mRNA None None O
expression None None O
. None None O

The None None O
storage None None I-FUNC
medium None None O
is None None O
one None None O
of None None O
the None None O
important None None O
factors None None O
that None None O
will None None O
help None None O
the None None O
dentist None None O
in None None O
rendering None None O
successful None None O
treatment None None O
for None None O
the None None O
avulsed None None O
tooth None None O
. None None O

This None None O
review None None O
paper None None O
focuses None None O
on None None O
the None None O
various None None O
storage None None I-FUNC
media None None O
, None None O
with None None O
special None None O
reference None None O
to None None O
coconut None None O
water None None O
. None None O

Seventy-nine None None O
participants None None O
underwent None None O
an None None O
oral None None O
examination None None O
and None None O
completed None None O
a None None O
Depression None None I-DISEASE
Anxiety None None O
Stress None None O
Scale-21 None None O
questionnaire None None O
. None None O

Insulin None None I-PROTEIN
secretion None None O
( None None O
GSIS None None O
) None None O
, None None O
glucose None None O
oxidation None None O
, None None O
protein None None O
expression None None O
, None None O
and None None O
superoxide None None O
content None None O
were None None O
analyzed None None O
. None None O

Moreover None None O
, None None O
FO None None O
reduced None None O
the None None O
expression None None O
of None None O
NAD None None I-TRANS
( None None O
P None None O
) None None O
H None None O
oxidase None None O
subunits None None O
and None None O
increased None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
without None None O
altering None None O
β-cell None None O
function None None O
. None None O

This None None O
article None None O
reports None None O
on None None O
changes None None O
in None None O
electric None None O
double None None O
layer None None O
charge None None O
storage None None I-FUNC
capacity None None O
as None None O
a None None O
function None None O
of None None O
surface None None O
chemistry None None O
and None None O
graphitic None None O
structure None None O
of None None O
porous None None O
carbon None None O
electrodes None None O
. None None O

We None None O
therefore None None O
corroborate None None O
the None None O
theory None None O
that None None O
surface None None O
groups None None O
and None None O
defects None None O
in None None O
the None None O
graphitic None None O
structure None None O
act None None O
as None None O
dopants None None O
that None None O
allow None None O
facile None None O
movement None None I-FUNC
of None None O
ions None None O
into None None O
pores None None O
, None None O
improve None None O
screening None None O
in None None O
the None None O
superionic None None O
state None None O
, None None O
and None None O
affect None None O
the None None O
quantum None None O
capacitance None None O
contribution None None O
from None None O
the None None O
carbon None None O
structure None None O
. None None O

In None None O
two None None O
experiments None None O
, None None O
we None None O
focused None None O
on None None O
gestures None None O
produced None None O
without None None O
accompanying None None O
speech None None I-FUNC
, None None O
i.e. None None O
, None None O
co-thought None None O
gestures None None O
( None None O
e.g. None None O
, None None O
an None None O
index None None O
finger None None O
traces None None O
the None None O
spatial None None O
sequence None None O
of None None O
a None None O
route None None O
in None None O
the None None O
air None None O
) None None O
. None None O

Tyrosinase None None I-PROTEIN
is None None O
the None None O
key None None O
enzyme None None O
involved None None O
in None None O
the None None O
human None None O
pigmentation None None O
process None None O
, None None O
as None None O
well None None O
as None None O
the None None O
undesired None None O
browning None None O
of None None O
fruits None None O
and None None O
vegetables None None O
. None None O

The None None O
multi-step None None O
protocol None None O
employed None None O
for None None O
the None None O
identification None None O
of None None O
novel None None O
tyrosinase None None I-PROTEIN
inhibitors None None O
incorporated None None O
the None None O
Shape None None O
Signatures None None O
computational None None O
algorithm None None O
for None None O
rapid None None O
screening None None O
of None None O
chemical None None O
libraries None None O
. None None O

This None None O
change None None O
in None None O
morphology None None O
occurred None None O
simultaneously None None O
with None None O
increased None None O
production None None O
of None None O
the None None O
key None None O
extracellular None None O
matrix None None O
protein None None O
, None None O
fibronectin None None I-PROTEIN
and None None O
increased None None O
expression None None O
of None None O
the None None O
fibronectin-binding None None O
integrin None None I-PROTEIN
, None None O
ITGA5 None None O
. None None O

Currently None None O
, None None O
it None None O
is None None O
not None None O
well None None O
understood None None O
, None None O
however None None O
, None None O
which None None O
specific None None O
movement None None I-FUNC
skills None None O
are None None O
required None None O
for None None O
successful None None O
stone None None O
knapping None None O
and None None O
accordingly None None O
it None None O
is None None O
unknown None None O
how None None O
these None None O
skills None None O
emerged None None O
during None None O
early None None O
hominin None None O
evolution None None O
. None None O

The None None O
present None None O
study None None O
addresses None None O
these None None O
questions None None O
by None None O
investigating None None O
striking None None O
movement None None I-FUNC
patterns None None O
and None None O
striking None None O
variability None None O
in None None O
18 None None O
modern None None O
stone None None O
knappers None None O
( None None O
nine None None O
experienced None None O
and None None O
nine None None O
novices None None O
) None None O
. None None O

Participants None None O
showed None None O
large None None O
inter-individual None None O
movement None None I-FUNC
variability None None O
of None None O
the None None O
elementary None None O
knapping None None O
action None None O
irrespective None None O
of None None O
knapping None None O
experience None None O
and None None O
knapping None None O
performance None None O
. None None O

The None None O
cost-effectiveness None None O
analyses None None O
are None None O
based None None O
on None None O
the None None O
Acupuncture None None O
, None None O
Counselling None None O
or None None O
Usual None None O
care None None O
for None None O
Depression None None I-DISEASE
( None None O
ACUDep None None O
) None None O
trial None None O
results None None O
. None None O

Furthermore None None O
, None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
spurious None None O
effects None None O
are None None O
not None None O
eliminated None None O
by None None O
stationary None None O
processes None None O
when None None O
these None None O
possess None None O
strong None None O
long None None O
memory None None I-FUNC
. None None O

To None None O
evaluate None None O
age-related None None O
ART None None O
retention None None I-FUNC
challenges None None O
, None None O
data None None O
from None None O
retrospective None None O
cohort None None O
studies None None O
conducted None None O
in None None O
seven None None O
African None None O
countries None None O
among None None O
16,421 None None O
patients None None O
, None None O
aged None None O
≥15 None None O
years None None O
at None None O
enrollment None None O
, None None O
who None None O
initiated None None O
ART None None O
during None None O
2004-2012 None None O
were None None O
analyzed None None O
. None None O

The None None O
key None None O
components None None O
for None None O
a None None O
successful None None O
rural None None O
placement None None O
program None None O
were None None O
described None None O
by None None O
the None None O
surveyed None None O
students None None O
as None None O
social None None O
awareness None None O
, None None O
recognising None None O
job None None O
opportunities None None O
and None None O
interprofessional None None O
learning None None I-FUNC
. None None O

Organic None None O
field-effect None None O
transistor None None O
( None None O
OFET None None O
) None None O
memories None None O
have None None O
rapidly None None O
evolved None None O
from None None O
low-cost None None O
and None None O
flexible None None O
electronics None None O
with None None O
relatively None None O
low-memory None None O
capacities None None O
to None None O
memory None None I-FUNC
devices None None O
that None None O
require None None O
high-capacity None None O
memory None None I-FUNC
such None None O
as None None O
smart None None O
memory None None I-FUNC
cards None None O
or None None O
solid-state None None O
hard None None O
drives None None O
. None None O

We None None O
demonstrated None None O
that None None O
the None None O
memory None None I-FUNC
performances None None O
of None None O
devices None None O
could None None O
be None None O
significantly None None O
enhanced None None O
by None None O
controlling None None O
the None None O
adsorption None None O
isotherm None None O
behavior None None O
, None None O
multilayer None None O
stacking None None O
structure None None O
and None None O
hydrophobicity None None O
of None None O
the None None O
metal None None O
NPs None None O
. None None O

PAD/TOA-Au None None O
( None None O
NP None None O
) None None O
) None None O
1 None None O
) None None O
with None None O
a None None O
number None None O
density None None O
of None None O
1.82 None None O
× None None O
10 None None O
( None None O
12 None None O
) None None O
cm None None O
( None None O
-2 None None O
) None None O
, None None O
the None None O
memory None None I-FUNC
window None None O
of None None O
the None None O
OFET None None O
memory None None I-FUNC
device None None O
was None None O
measured None None O
to None None O
be None None O
approximately None None O
97 None None O
V. None None O
The None None O
multilayer None None O
stacked None None O
OFET None None O
memory None None I-FUNC
devices None None O
prepared None None O
with None None O
four None None O
Au None None O
( None None O
NP None None O
) None None O
layers None None O
exhibited None None O
excellent None None O
programmable None None O
memory None None I-FUNC
properties None None O
( None None O
i.e None None O
. None None O

This None None O
study None None O
explored None None O
the None None O
feasibility None None O
of None None O
measuring None None O
electrically None None O
evoked None None O
cortical None None O
auditory None None O
event-related None None O
potentials None None O
( None None O
eERPs None None O
) None None O
in None None O
children None None O
with None None O
auditory None None O
brainstem None None I-REGION
implants None None O
( None None O
ABIs None None O
) None None O
. None None O

The None None O
onset None None O
eERP None None O
was None None O
recorded None None O
in None None O
four None None O
subjects None None O
who None None O
demonstrated None None O
auditory None None I-FUNC
perception None None I-FUNC
. None None O

No None None O
eERPs None None O
were None None O
observed None None O
in None None O
one None None O
subject None None O
who None None O
received None None O
no None None O
auditory None None O
sensation None None I-FUNC
from None None O
ABI None None O
stimulation None None O
. None None O

Specific None None O
common None None O
psychiatric None None O
diagnoses None None O
NOS None None I-TRANS
compared None None O
with None None O
full-criteria None None O
psychiatric None None O
diagnoses None None O
. None None O

Among None None O
all None None O
visits None None O
for None None O
mood None None I-DISEASE
disorders None None I-DISEASE
, None None O
NOS None None I-TRANS
visits None None O
grew None None O
proportionally None None O
1.5-fold None None O
from None None O
45.3 None None O
% None None O
in None None O
the None None O
1999-2002 None None O
period None None O
to None None O
68.8 None None O
% None None O
in None None O
the None None O
2007-2010 None None O
period None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
anxiety None None I-DISEASE
disorder None None I-DISEASE
NOS None None I-TRANS
increased None None O
from None None O
44.6 None None O
% None None O
in None None O
the None None O
1999-2002 None None O
period None None O
to None None O
58.1 None None O
% None None O
in None None O
the None None O
2007-2010 None None O
period None None O
. None None O

The None None O
expansion None None O
of None None O
subthreshold None None O
( None None O
NOS None None I-TRANS
) None None O
DSM-IV None None O
diagnoses None None O
of None None O
mood None None I-DISEASE
disorder None None I-DISEASE
, None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
and None None O
anxiety None None I-DISEASE
disorder None None I-DISEASE
in None None O
youth None None O
that None None O
has None None O
occurred None None O
since None None O
1999 None None O
in None None O
all None None O
likelihood None None O
will None None O
continue None None O
in None None O
the None None O
DSM-5 None None O
era None None O
unless None None O
administrative None None O
efforts None None O
are None None O
made None None O
to None None O
alter None None O
this None None O
practice None None O
. None None O

Kidney None None O
type None None O
glutaminase None None O
( None None O
GLS1 None None O
) None None O
, None None O
which None None O
is None None O
responsible None None O
for None None O
the None None O
conversion None None O
of None None O
glutamine None None I-TRANS
to None None O
glutamate None None I-TRANS
, None None O
produces None None O
ammonia None None O
as None None O
part None None O
of None None O
its None None O
catalytic None None O
activities None None O
and None None O
has None None O
been None None O
shown None None O
to None None O
modulate None None O
cellular None None O
acidity None None O
. None None O

She None None O
presented None None O
electrocardiogram None None O
changes None None O
( None None O
sinus None None O
tachycardia None None O
and None None O
flattening None None O
T-waves None None O
) None None O
but None None O
normal None None O
cardiac None None O
enzymes None None I-PROTEIN
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
the None None O
RIBI None None O
mice None None O
model None None O
was None None O
established None None O
and None None O
the None None O
changes None None O
in None None O
the None None O
expression None None O
of None None O
tumor None None O
necrosis None None O
factor None None O
alpha None None O
( None None O
TNF-α None None O
) None None O
and None None O
interleukin-1beta None None O
( None None O
IL-1β None None O
) None None O
mRNA None None O
, None None O
and None None O
the None None O
related None None O
signal None None O
pathways None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
this None None O
model None None O
were None None O
investigated None None O
. None None O

The None None O
changes None None O
of None None O
microglial None None O
activation None None O
and None None O
neurogensis None None O
in None None O
the None None O
hippocampus None None I-REGION
were None None O
analyzed None None O
by None None O
immunofluorescence None None O
and None None O
immunohistochemistry None None O
. None None O

Polyvalent None None O
interactions None None O
, None None O
where None None O
multiple None None O
ligands None None O
and None None O
receptors None None I-PROTEIN
interact None None O
simultaneously None None O
, None None O
are None None O
ubiquitous None None O
in None None O
nature None None O
. None None O

One None None O
protein None None O
was None None O
found None None O
to None None O
be None None O
decreased None None O
; None None O
malate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
. None None O

Decreased None None O
malate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
indicated None None O
enhanced None None O
ROS None None O
scavenging None None O
within None None O
the None None O
mitochondria None None O
. None None O

Abstract None None O
Purpose None None O
: None None O
To None None O
investigate None None O
whether None None O
high None None O
power None None O
microwave None None O
could None None O
cause None None O
continuous None None O
disorders None None O
to None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
in None None O
Wistar None None O
rats None None O
and None None O
to None None O
explore None None O
the None None O
underlying None None O
mechanisms None None O
. None None O

The None None O
spatial None None I-FUNC
memory None None I-FUNC
ability None None O
, None None O
the None None O
structure None None O
of None None O
the None None O
hippocampus None None I-REGION
, None None O
contents None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
neurotransmitters None None I-TRANS
in None None O
hippocampus None None I-REGION
and None None O
the None None O
expression None None O
of None None O
N-methyl-D-aspartic None None O
acid None None I-TRANS
receptors None None I-PROTEIN
( None None O
NMDAR None None O
) None None O
subunit None None O
1 None None O
, None None O
2A None None O
and None None O
2B None None O
( None None O
NR1 None None O
, None None O
NR2A None None O
and None None O
NR2B None None O
) None None O
were None None O
detected None None O
at None None O
1 None None O
, None None O
3 None None O
, None None O
6 None None O
, None None O
9 None None O
, None None O
12 None None O
and None None O
18 None None O
months None None O
after None None O
microwave None None O
exposure None None O
. None None O

The None None O
level None None O
of None None O
amino None None O
acid None None O
neurotransmitters None None I-TRANS
also None None O
decreased None None O
after None None O
microwave None None O
radiation None None O
. None None O

Besides None None O
, None None O
the None None O
hippocampus None None I-REGION
showed None None O
varying None None O
degrees None None O
of None None O
degeneration None None O
of None None O
neurons None None O
, None None O
increased None None O
postsynaptic None None O
density None None O
and None None O
blurred None None O
synaptic None None O
clefts None None O
in None None O
the None None O
exposure None None O
group None None O
. None None O

This None None O
study None None O
indicated None None O
that None None O
the None None O
content None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
neurotransmitters None None I-TRANS
, None None O
the None None O
expression None None O
of None None O
NMDAR None None O
subunits None None O
and None None O
the None None O
variation None None O
of None None O
hippocampal None None O
structure None None O
might None None O
contribute None None O
to None None O
the None None O
long-term None None O
cognitive None None O
impairment None None O
after None None O
microwave None None O
exposure None None O
. None None O

Using None None O
fleet None None O
fractions None None O
from None None O
previous None None O
data None None O
sets None None O
, None None O
we None None O
estimated None None O
age-adjusted None None O
mean None None O
emissions None None O
increases None None O
for None None O
the None None O
2013 None None O
fleet None None O
to None None O
be None None O
17-29 None None O
% None None O
higher None None O
for None None O
carbon None None I-TRANS
monoxide None None I-TRANS
, None None O
9-14 None None O
% None None O
higher None None O
for None None O
hydrocarbons None None O
, None None O
27-30 None None O
% None None O
higher None None O
for None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
and None None O
7-16 None None O
% None None O
higher None None O
for None None O
ammonia None None O
emissions None None O
than None None O
if None None O
historical None None O
fleet None None O
turnover None None O
rates None None O
had None None O
prevailed None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
we None None O
manipulate None None O
, None None O
in None None O
a None None O
single None None O
task None None O
, None None O
both None None O
reactive None None O
and None None O
proactive None None O
inhibition None None O
mechanisms None None O
, None None O
and None None O
we None None O
investigate None None O
the None None O
within-subjects None None O
effect None None O
of None None O
increasing None None O
, None None O
by None None O
means None None O
of None None O
anodal None None O
transcranial None None O
direct None None O
current None None O
stimulation None None O
( None None O
tDCS None None O
) None None O
, None None O
the None None O
involvement None None O
of None None O
the None None O
right None None O
inferior None None O
frontal None None I-REGION
cortex None None I-REGION
( None None O
rIFC None None O
) None None O
. None None O

In None None O
the None None O
present None None O
paper None None O
, None None O
the None None O
effects None None O
of None None O
glutamatergic None None O
receptor None None I-PROTEIN
antagonists None None O
, None None O
including None None O
amantadine None None O
, None None O
memantine None None O
, None None O
LY None None O
367583 None None O
, None None O
and None None O
MPEP None None O
, None None O
on None None O
glutamate None None I-TRANS
transport None None O
, None None O
the None None O
expression None None O
of None None O
mRNA None None O
of None None O
glutamate None None I-TRANS
transporters None None I-PROTEIN
( None None O
EAATs None None O
) None None O
, None None O
the None None O
kinetic None None O
parameters None None O
of None None O
ligand None None O
binding None None O
to None None O
N-methyl-D-aspartate None None O
( None None O
NMDA None None O
) None None O
receptors None None I-PROTEIN
, None None O
and None None O
the None None O
morphology None None O
of None None O
nerve None None O
endings None None O
in None None O
EAE None None O
rat None None O
brains None None O
were None None O
investigated None None O
. None None O

Excess None None O
glutamate None None I-TRANS
is None None O
taken None None O
up None None O
from None None O
the None None O
synaptic None None O
space None None O
and None None O
metabolized None None O
by None None O
astrocytes None None O
. None None O

Our None None O
investigations None None O
showed None None O
changes None None O
in None None O
the None None O
expression None None O
of None None O
EAAT None None O
mRNA None None O
, None None O
glutamate None None I-TRANS
transport None None O
( None None O
uptake None None O
and None None O
release None None O
) None None O
by None None O
synaptosomal None None O
and None None O
glial None None O
plasmalemmal None None O
vesicle None None O
fractions None None O
, None None O
and None None O
ligand None None O
binding None None O
to None None O
NMDA None None O
receptors None None I-PROTEIN
; None None O
these None None O
effects None None O
were None None O
partially None None O
reversed None None O
after None None O
the None None O
treatment None None O
of None None O
EAE None None O
rats None None O
with None None O
the None None O
NMDA None None O
antagonists None None O
amantadine None None O
and None None O
memantine None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
disturbances None None O
in None None O
these None None O
mechanisms None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
processes None None O
associated None None O
with None None O
glutamate None None I-TRANS
excitotoxicity None None O
and None None O
the None None O
progressive None None O
brain None None O
damage None None O
in None None O
EAE None None O
. None None O

RT-qPCR None None O
profiling None None O
was None None O
used None None O
to None None O
reveal None None O
possible None None O
differences None None O
in None None O
the None None O
expression None None O
of None None O
ion None None I-PROTEIN
channels/transporters None None O
that None None O
participate None None O
in None None O
maintaining None None O
ionic/neurotransmitter None None O
homeostasis None None O
. None None O

These None None O
ribbons None None O
are None None O
interspaced None None O
by None None O
organic None None O
countercations None None O
in None None O
1 None None O
and None None O
2 None None O
, None None O
while None None O
in None None O
4 None None O
they None None O
are None None O
linked None None O
by None None O
highly None None O
unusual None None O
[ None None O
Na None None I-TRANS
( None None O
DABCO None None O
) None None O
2 None None O
] None None O
( None None O
+ None None O
) None None O
units None None O
into None None O
a None None O
three-dimensional None None O
framework None None O
. None None O

Statin None None O
treatment None None O
, None None O
despite None None O
the None None O
presence None None O
of None None O
dyslipidaemia None None O
, None None O
deserves None None O
special None None O
attention None None I-FUNC
because None None O
it None None O
has None None O
been None None O
proven None None O
, None None O
mainly None None O
in None None O
small None None O
studies None None O
or None None O
post None None O
hoc None None O
analyses None None O
of None None O
trials None None O
, None None O
that None None O
it None None O
offers None None O
a None None O
substantial None None O
improvement None None O
in None None O
quality None None O
of None None O
life None None O
and None None O
a None None O
reduction None None O
in None None O
mortality None None O
rates None None O
. None None O

Responses None None O
were None None O
examined None None O
by None None O
faculty None None O
members None None O
`` None None O
just None None O
in None None O
time None None O
'' None None O
to None None O
tailor None None O
session None None O
content None None O
to None None O
residents None None O
' None None O
learning None None I-FUNC
needs None None O
. None None O

Participants None None O
completed None None O
surveys None None O
assessing None None O
their None None O
perceptions None None I-FUNC
of None None O
JiTT/PI None None O
. None None O

Responses None None O
to None None O
topic None None O
session None None O
MCQs None None O
repeated None None O
in None None O
review None None O
sessions None None O
were None None O
evaluated None None O
to None None O
study None None O
retention None None I-FUNC
. None None O

At None None O
least None None O
90 None None O
% None None O
of None None O
faculty None None O
survey None None O
respondents None None O
reported None None O
positive None None O
perceptions None None I-FUNC
of None None O
aspects None None O
of None None O
the None None O
JiTT/PI None None O
strategy None None O
. None None O

JiTT/PI None None O
represents None None O
an None None O
effective None None O
approach None None O
for None None O
meaningful None None O
and None None O
active None None O
learning None None I-FUNC
in None None O
core None None O
curriculum None None O
sessions None None O
. None None O

Dialogues None None O
allow None None O
for None None O
the None None O
inclusion None None O
of None None O
affective None None O
and None None O
experiential None None O
dimensions None None O
in None None O
addition None None O
to None None O
intellectual/cognitive None None O
domains None None O
in None None O
learning None None I-FUNC
, None None O
and None None O
for None None O
an None None O
emphasis None None O
on None None O
discovering None None O
new None None O
perspectives None None O
, None None O
insights None None O
, None None O
and None None O
questions None None O
instead None None O
of None None O
limiting None None O
participants None None O
solely None None O
to None None O
an None None O
instrumental None None O
search None None O
for None None O
solutions None None O
. None None O

It None None O
had None None O
the None None O
following None None O
five None None O
goals None None O
: None None O
( None None O
1 None None O
) None None O
enhance None None O
bedside None None O
clinical None None O
skills None None O
, None None O
( None None O
2 None None O
) None None O
promote None None O
a None None O
culture None None O
of None None O
patient None None O
safety None None O
, None None O
( None None O
3 None None O
) None None O
emphasize None None O
diagnostic None None O
reasoning None None I-FUNC
, None None O
( None None O
4 None None O
) None None O
engage None None O
patients None None O
, None None O
and None None O
( None None O
5 None None O
) None None O
provide None None O
learners None None O
with None None O
an None None O
expanded None None O
perspective None None O
on None None O
patients None None O
' None None O
experiences None None O
of None None O
care None None O
. None None O

Almost None None O
all None None O
of None None O
the None None O
participants None None O
expressed None None O
agreement None None O
in None None O
considering None None O
rivaroxaban None None O
a None None O
new None None O
cornerstone None None O
of None None O
stroke None None I-DISEASE
prevention None None O
and None None O
treatment None None O
of None None O
VTE None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
study None None O
were None None O
to None None O
investigate None None O
the None None O
hypometabolic None None O
regions None None O
of None None O
FDG None None O
PET None None O
compared None None O
with None None O
the None None O
nigrostriatal None None O
dopamine None None I-TRANS
pathway None None O
abnormalities None None O
in None None O
TRODAT-1 None None O
scan None None O
in None None O
patients None None O
with None None O
dementia None None I-DISEASE
with None None I-DISEASE
Lewy None None I-DISEASE
bodies None None I-DISEASE
( None None O
DLBs None None O
) None None O
at None None O
mild None None O
and None None O
dementia None None I-DISEASE
stages None None O
as None None O
well None None O
as None None O
to None None O
validate None None O
the None None O
correlation None None O
among None None O
networks None None O
being None None O
constructed None None O
with None None O
clinical None None O
data None None O
. None None O

Neuroimaging None None O
survey None None O
was None None O
applied None None O
using None None O
information None None O
derived None None O
from None None O
FDG None None O
PET None None O
by None None O
performing None None O
voxel-based None None O
analysis None None O
and None None O
a None None O
semiquantitative None None O
Tc-TRODAT-1 None None O
scan None None O
to None None O
correlate None None O
these None None O
results None None O
with None None O
the None None O
cognitive None None O
and None None O
Unified None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Rating None None O
Scale None None O
. None None O

Although None None O
at None None O
the None None O
dementia None None I-DISEASE
stage None None O
, None None O
more None None O
extensive None None O
cortical None None O
hypometabolism None None O
involving None None O
occipital None None O
region None None O
were None None O
found None None O
. None None O

Dopamine None None I-TRANS
transporter None None O
levels None None O
may None None O
serve None None O
as None None O
early None None O
diagnostic None None O
tool None None O
and None None O
FDG None None O
PET None None O
as None None O
staging None None O
indicator None None O
for None None O
DLB None None O
pathology None None O
. None None O

Developmental None None O
dyslexia None None I-DISEASE
( None None O
DD None None O
) None None O
is None None O
a None None O
complex None None O
heritable None None O
condition None None O
associated None None O
with None None O
impairments None None O
in None None O
multiple None None O
neurocognitive None None O
domains None None O
. None None O

Recently None None O
, None None O
a None None O
candidate None None O
gene None None O
for None None O
human None None O
cognitive None None O
processes None None O
, None None O
that None None O
is None None O
, None None O
GRIN2B None None O
, None None O
has None None O
been None None O
found None None O
to None None O
be None None O
associated None None O
significantly None None O
with None None O
working None None I-FUNC
memory None None I-FUNC
in None None O
a None None O
German None None O
DD None None O
sample None None O
. None None O

Lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
extracellular None None O
concentration None None O
rapidly None None O
increased None None O
within None None O
a None None O
few None None O
hours None None O
of None None O
exposure None None O
of None None O
the None None O
monolayer None None O
to None None O
S. None None O
marcescens None None O
. None None O

Impaired None None O
cognition None None O
was None None O
significantly None None O
associated None None O
with None None O
lower None None O
FA None None O
in None None O
the None None O
callosal None None O
genu None None O
, None None O
thalamus None None I-REGION
, None None O
right None None O
posterior None None O
cingulum None None O
, None None O
and None None O
fornix None None I-REGION
crus None None O
( None None O
seven None None O
studies None None O
; None None O
largest None None O
cluster None None O
, None None O
980 None None O
voxels None None O
; None None O
z None None O
= None None O
2.5 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Heavy None None O
menstrual None None O
bleeding None None O
without None None O
an None None O
organic None None O
lesion None None O
is None None O
mainly None None O
due None None O
to None None O
an None None O
imbalance None None O
of None None O
the None None O
various None None O
hormones None None I-PROTEIN
which None None O
have None None O
a None None O
regulatory None None O
effect None None O
on None None O
the None None O
menstrual None None O
cycle None None O
. None None O

Antinutrients None None O
( None None O
trypsin None None I-PROTEIN
inhibitors None None O
, None None O
phytic None None O
acid None None O
, None None O
glucosinolates None None O
, None None O
and None None O
condensed None None O
tannins None None O
) None None O
were None None O
mostly None None O
located None None O
in None None O
the None None O
cotyledon None None O
fractions None None O
. None None O

Adhesion None None O
rates None None O
were None None O
assessed None None O
by None None O
crystal None None O
violet None None O
retention None None I-FUNC
technique None None O
. None None O

Recently None None O
, None None O
micelles None None O
, None None O
which None None O
are None None O
self-assembled None None O
by None None O
amphiphilic None None O
copolymers None None O
, None None O
have None None O
attracted None None O
tremendous None None O
attention None None I-FUNC
as None None O
promising None None O
drug None None O
delivery None None O
systems None None O
for None None O
cancer None None O
treatment None None O
. None None O

The None None O
ion None None O
is None None O
coordinated None None O
by None None O
three None None O
acidic None None O
sidechains None None O
, None None O
a None None O
water None None O
molecule None None O
, None None O
a None None O
serine None None I-TRANS
and None None O
a None None O
main-chain None None O
carbonyl None None O
in None None O
the None None O
unwound None None O
stretch None None O
of None None O
trans-membrane None None O
helix None None O
5 None None O
at None None O
the None None O
deepest None None O
point None None O
of None None O
a None None O
negatively None None O
charged None None O
cytoplasmic None None O
funnel None None O
. None None O

( None None O
22 None None O
) None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
uptake None None O
measurements None None O
indicate None None O
non-cooperative None None O
transport None None O
with None None O
an None None O
activity None None O
maximum None None O
at None None O
pH None None O
7.5 None None O
. None None O

Whilst None None O
effective None None O
antiretroviral None None O
therapy None None O
is None None O
protective None None O
against None None O
the None None O
more None None O
severe None None O
forms None None O
of None None O
HIV-associated None None O
brain None None I-DISEASE
disease None None I-DISEASE
, None None O
there None None O
remains None None O
a None None O
large None None O
burden None None O
of None None O
clinically None None O
symptomatic None None O
cognitive None None O
impairment None None O
in None None O
the None None O
modern None None O
era None None O
. None None O

The None None O
study None None O
included None None O
19,968 None None O
patients None None O
, None None O
of None None O
whom None None O
9.1 None None O
, None None O
68.3 None None O
, None None O
9.1 None None O
, None None O
5.8 None None O
, None None O
3.5 None None O
, None None O
and None None O
4.3 None None O
% None None O
were None None O
in None None O
weight None None O
groups None None O
I-VI None None O
, None None O
respectively None None O
. None None O

Further None None O
specific None None O
symptoms None None O
indicating None None O
OCD None None O
were None None O
`` None None O
enhanced None None O
feeling None None I-FUNC
of None None O
responsibility None None O
, None None O
'' None None O
`` None None O
exact None None O
attention None None I-FUNC
concerning None None O
details None None O
, None None O
'' None None O
`` None None O
being None None O
eager None None O
for None None O
order None None O
and None None O
cleanness None None O
, None None O
'' None None O
`` None None O
difficulties None None O
with None None O
decisions None None O
, None None O
'' None None O
and None None O
`` None None O
repetitive None None O
controlling None None O
, None None O
'' None None O
but None None O
were None None O
less None None O
remembered None None O
. None None O

This None None O
substantiates None None O
the None None O
view None None O
that None None O
OCD-similar None None O
to None None O
other None None O
psychiatric None None O
disorders None None O
such None None O
as None None O
schizophrenia None None I-DISEASE
and None None O
bipolar None None I-DISEASE
disorder-seems None None O
to None None O
be None None O
characterized None None O
by None None O
a None None O
psychopathologically None None O
less None None O
specific None None O
prodrome None None O
with None None O
rather None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
relationship None None O
between None None O
the None None O
functional None None O
connectivity None None O
of None None O
the None None O
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
( None None O
ACC None None O
) None None O
and None None O
the None None O
recovery None None O
process None None O
of None None O
BP None None O
. None None O

Early None None O
life None None O
stress None None O
is None None O
a None None O
risk None None O
factor None None O
for None None O
developing None None O
functional None None O
pain None None I-DISEASE
disorders None None I-DISEASE
. None None O

Functional None None O
connectivity None None O
density None None O
( None None O
FCD None None O
) None None O
is None None O
a None None O
newly None None O
developed None None O
data-driven None None O
method None None O
to None None O
measure None None O
the None None O
number None None O
of None None O
functional None None O
connections None None O
of None None O
each None None O
voxel None None O
, None None O
possibly None None O
providing None None O
new None None O
insight None None O
into None None O
the None None O
neural None None O
correlates None None O
of None None O
fluid None None O
reasoning None None I-FUNC
. None None O

Our None None O
findings None None O
confirmed None None O
the None None O
association None None O
between None None O
fluid None None O
reasoning None None I-FUNC
and None None O
functional None None O
connectivity None None O
of None None O
multiple None None O
cognitive-related None None O
brain None None O
regions None None O
. None None O

The None None O
sex None None O
dichotomy None None O
of None None O
this None None O
association None None O
indicates None None O
that None None O
the None None O
fluid None None O
reasoning None None I-FUNC
capacity None None O
of None None O
men None None O
and None None O
women None None O
may None None O
have None None O
different None None O
neural None None O
substrates None None O
. None None O

The None None O
prefrontal None None I-REGION
cortex None None I-REGION
is None None O
particularly None None O
vulnerable None None O
to None None O
injury None None O
in None None O
late None None O
prematurity None None O
because None None O
of None None O
its None None O
protracted None None O
development None None O
and None None O
extensive None None O
cortical None None O
connections None None O
. None None O

Late None None O
preterm None None O
children None None O
showed None None O
increased None None O
functional None None O
connectivity None None O
within None None O
regions None None O
of None None O
the None None O
default None None O
mode None None O
, None None O
salience None None O
, None None O
and None None O
central-executive None None O
networks None None O
from None None O
both None None O
right None None O
and None None O
left None None I-REGION
frontal None None I-REGION
cortex None None I-REGION
seeds None None O
. None None O

Probabilistic None None O
tractography None None O
showed None None O
a None None O
pattern None None O
of None None O
decreased None None O
streamlines None None O
in None None O
frontal None None O
white None None I-REGION
matter None None I-REGION
pathways None None O
and None None O
the None None O
corpus None None I-REGION
callosum None None I-REGION
, None None O
but None None O
also None None O
increased None None O
streamlines None None O
in None None O
the None None O
left None None O
orbitofrontal None None O
white None None I-REGION
matter None None I-REGION
and None None O
the None None O
right None None O
frontal None None O
white None None I-REGION
matter None None I-REGION
when None None O
seeded None None O
from None None O
the None None O
right None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
study None None O
was None None O
to None None O
assess None None O
the None None O
relationship None None O
between None None O
procalcitonin None None O
( None None O
PCT None None O
) None None O
serum None None O
levels None None O
and None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
AIS None None O
) None None O
in None None O
a None None O
Chinese None None O
sample None None O
. None None O

PCT None None O
levels None None O
and None None O
National None None O
Institutes None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
scores None None O
were None None O
evaluated None None O
at None None O
the None None O
time None None O
of None None O
admission None None O
. None None O

A None None O
replication-defective None None O
recombinant None None O
chimpanzee None None O
adenovirus None None O
type None None O
3-vectored None None O
ebolavirus None None O
vaccine None None O
( None None O
cAd3-EBO None None O
) None None O
, None None O
encoding None None I-FUNC
the None None O
glycoprotein None None O
from None None O
Zaire None None O
and None None O
Sudan None None O
species None None O
that None None O
offers None None O
protection None None O
in None None O
the None None O
nonhuman None None O
primate None None O
model None None O
, None None O
was None None O
rapidly None None O
advanced None None O
into None None O
phase None None O
1 None None O
clinical None None O
evaluation None None O
. None None O

We None None O
construct None None O
brain None None O
representation None None O
maps None None O
that None None O
replicate None None O
many None None O
results None None O
from None None O
a None None O
wide None None O
range None None O
of None None O
classical None None O
studies None None O
that None None O
focus None None O
each None None O
on None None O
one None None O
aspect None None O
of None None O
language None None I-FUNC
processing None None O
and None None O
offer None None O
new None None O
insights None None O
on None None O
which None None O
type None None O
of None None O
information None None O
is None None O
processed None None O
by None None O
different None None O
areas None None O
involved None None O
in None None O
language None None I-FUNC
processing None None O
. None None O

Cardiac None None O
toxicity None None O
was None None O
evaluated None None O
by None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
and None None O
creatine None None O
kinase None None O
in None None O
the None None O
serum None None O
, None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
level None None O
in None None O
plasma None None O
and None None O
cardiac None None O
tissue None None O
, None None O
and None None O
antioxidant None None O
enzyme None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
in None None O
cardiac None None O
tissue None None O
. None None O

However None None O
, None None O
this None None O
inference None None I-FUNC
of None None O
derivation None None O
and None None O
directionality None None O
assumes None None O
an None None O
ancestral None None O
state None None O
of None None O
olfaction None None I-FUNC
, None None O
usually None None O
by None None O
comparison None None O
to None None O
a None None O
group None None O
of None None O
extant None None O
non-primate None None O
mammals None None O
. None None O

Here None None O
I None None O
present None None O
a None None O
phylogenetic None None O
model None None O
of None None O
continuous None None O
trait None None O
evolution None None O
that None None O
reconstructs None None O
olfactory None None I-REGION
bulb None None I-REGION
volumes None None O
for None None O
ancestral None None O
nodes None None O
of None None O
primates None None O
and None None O
mammal None None O
outgroups None None O
. None None O

Neither None None O
the None None O
Atg8-associated None None O
puncta None None O
nor None None O
the None None O
Atg8 None None O
expression None None O
level None None O
was None None O
significantly None None O
altered None None O
by None None O
treatment None None O
of None None O
parasites None None O
with None None O
routinely None None O
used None None O
autophagy None None O
inhibitors None None O
( None None O
cysteine None None I-TRANS
( None None O
E64 None None O
) None None O
and None None O
aspartic None None O
( None None O
pepstatin None None O
) None None O
protease None None O
inhibitors None None O
, None None O
the None None O
kinase None None O
inhibitor None None O
3-methyladenine None None O
, None None O
and None None O
the None None O
lysosomotropic None None O
agent None None O
chloroquine None None O
) None None O
, None None O
indicating None None O
an None None O
atypical None None O
feature None None O
of None None O
autophagy None None O
. None None O

Here None None O
, None None O
we None None O
constructed None None O
fifteen None None O
TEVp None None O
( None None O
5M None None O
) None None O
variants None None O
with None None O
one None None O
or None None O
more None None O
of None None O
six None None O
rare None None O
arginine None None I-TRANS
codons None None O
in None None O
the None None O
coding None None O
sequence None None O
replaced None None O
with None None O
abundant None None O
E. None None O
coli None None O
arginine None None I-TRANS
codons None None O
. None None O

To None None O
determine None None O
the None None O
origin None None O
of None None O
these None None O
apomorphic None None O
genomic None None O
traits None None O
, None None O
we None None O
combined None None O
aquaporin None None O
sequencing None None O
from None None O
jawless None None O
and None None O
jawed None None O
vertebrates None None O
with None None O
broad None None O
taxon None None O
assembly None None O
of None None O
& None None O
gt None None O
; None None O
2,000 None None O
transcripts None None O
amongst None None O
131 None None O
deuterostome None None O
genomes None None O
and None None O
developed None None O
a None None O
model None None O
based None None O
upon None None O
Bayesian None None O
inference None None I-FUNC
that None None O
traces None None O
their None None O
convergent None None O
roots None None O
to None None O
stem None None O
subfamilies None None O
in None None O
basal None None O
Metazoa None None O
and None None O
Prokaryota None None O
. None None O

Targeted None None O
release None None O
of None None O
cortisol None None O
is None None O
triggered None None O
by None None O
cleavage None None O
of None None O
CBG None None O
's None None O
reactive None None O
centre None None O
loop None None O
by None None O
elastase None None I-PROTEIN
, None None O
a None None O
protease None None O
released None None O
by None None O
neutrophils None None O
in None None O
inflamed None None O
tissues None None O
. None None O

Cysteine None None I-TRANS
proteinases None None O
are None None O
involved None None O
in None None O
many None None O
aspects None None O
of None None O
physiological None None O
regulation None None O
. None None O

In None None O
this None None O
work None None O
, None None O
we None None O
present None None O
a None None O
fluorometric None None O
and None None O
computational None None O
study None None O
of None None O
the None None O
binding None None O
of None None O
one None None O
representative None None O
plant None None O
cysteine None None I-TRANS
proteinase None None O
, None None O
chymopapain None None O
, None None O
to None None O
one None None O
of None None O
the None None O
most None None O
studied None None O
inhibitors None None O
of None None O
these None None O
proteinases None None O
: None None O
chicken None None O
cystatin None None O
. None None O

During None None O
pregnancy None None O
, None None O
5-HT None None I-TRANS
increases None None O
β-cell None None O
proliferation None None O
and None None O
glucose-stimulated None None O
insulin None None I-PROTEIN
secretion None None O
( None None O
GSIS None None O
) None None O
through None None O
the None None O
Gαq-coupled None None O
5-HT2b None None O
receptor None None I-PROTEIN
( None None O
Htr2b None None O
) None None O
and None None O
the None None O
5-HT3 None None O
receptor None None I-PROTEIN
( None None O
Htr3 None None O
) None None O
, None None O
a None None O
ligand-gated None None O
cation None None O
channel None None O
, None None O
respectively None None O
. None None O

Here None None O
, None None O
we None None O
characterized None None O
the None None O
metabolic None None O
phenotypes None None O
of None None O
β-cell-specific None None O
Htr2b None None O
( None None O
-/- None None O
) None None O
( None None O
Htr2b None None O
βKO None None O
) None None O
, None None O
Htr3a None None O
( None None O
-/- None None O
) None None O
( None None O
Htr3a None None O
knock-out None None O
[ None None O
KO None None O
] None None O
) None None O
, None None O
and None None O
β-cell-specific None None O
tryptophan None None I-TRANS
hydroxylase None None O
1 None None O
( None None O
Tph1 None None O
) None None O
( None None O
-/- None None O
) None None O
( None None O
Tph1 None None O
βKO None None O
) None None O
mice None None O
on None None O
a None None O
high-fat None None O
diet None None O
( None None O
HFD None None O
) None None O
. None None O

GSIS None None O
was None None O
impaired None None O
in None None O
islets None None O
isolated None None O
from None None O
HFD-fed None None O
Htr3a None None O
KO None None O
and None None O
Tph1 None None O
βKO None None O
mice None None O
, None None O
and None None O
5-HT None None I-TRANS
treatment None None O
improved None None O
insulin None None I-PROTEIN
secretion None None O
from None None O
Tph1 None None O
βKO None None O
islets None None O
but None None O
not None None O
from None None O
Htr3a None None O
KO None None O
islets None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
demonstrate None None O
that None None O
basal None None O
5-HT None None I-TRANS
levels None None O
in None None O
β-cells None None O
play None None O
a None None O
role None None O
in None None O
GSIS None None O
through None None O
Htr3 None None O
, None None O
which None None O
becomes None None O
more None None O
evident None None O
in None None O
a None None O
diet-induced None None O
insulin-resistant None None O
state None None O
. None None O

It None None O
is None None O
an None None O
area None None O
of None None O
patient None None O
care None None O
that None None O
has None None O
received None None O
little None None O
attention None None I-FUNC
compared None None O
with None None O
other None None O
types None None O
of None None O
parenteral None None O
therapies None None O
. None None O

Findings None None O
indicated None None O
that None None O
this None None O
joint None None O
learning None None I-FUNC
activity None None O
was None None O
viewed None None O
positively None None O
by None None O
all None None O
students None None O
and None None O
has None None O
enabled None None O
them None None O
to None None O
learn None None O
with None None O
and None None O
from None None O
each None None O
other None None O
, None None O
potentially None None O
impacting None None O
on None None O
their None None O
future None None O
practice None None O
. None None O

Under None None O
these None None O
conditions None None O
, None None O
TORC2 None None O
, None None O
through None None O
its None None O
downstream None None O
target None None O
kinase None None O
Ypk1 None None O
, None None O
inhibits None None O
the None None O
Ca None None O
( None None O
2+ None None O
) None None O
- None None O
and None None O
Cmd1/calmodulin-dependent None None O
phosphatase None None I-PROTEIN
, None None O
calcineurin None None O
, None None O
to None None O
enable None None O
the None None O
activation None None O
of None None O
the None None O
amino None None O
acid-sensing None None O
EIF2S1/eIF2α None None O
kinase None None O
, None None O
Gcn2 None None O
, None None O
and None None O
promote None None O
autophagy None None O
. None None O

There None None O
are None None O
no None None O
reported None None O
cases None None O
of None None O
prion None None I-DISEASE
disease None None I-DISEASE
transmission None None O
arising None None O
from None None O
dental None None O
procedures None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
the None None O
presence None None O
of None None O
receptors None None I-PROTEIN
of None None O
advanced None None O
glycation None None O
end-products None None O
in None None O
patients None None O
with None None O
chronic None None O
periodontitis None None O
, None None O
with None None O
and None None O
without None None O
type None None O
2 None None O
diabetes None None O
. None None O

On None None O
immunohistochemical None None O
analysis None None O
, None None O
positive None None O
staining None None O
for None None O
receptors None None I-PROTEIN
of None None O
advanced None None O
glycation None None O
end-products None None O
was None None O
seen None None O
in None None O
the None None O
endothelium None None O
and None None O
the None None O
basal None None O
and None None O
spinous None None O
layers None None O
of None None O
the None None O
inflamed None None O
gingival None None O
epithelium None None O
in None None O
both None None O
type None None O
2 None None O
diabetes None None O
and None None O
non-diabetes None None O
tissue None None O
, None None O
with None None O
a None None O
statistically-significant None None O
difference None None O
between None None O
both None None O
groups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0 None None O
.05 None None O
) None None O
. None None O

Receptors None None I-PROTEIN
of None None O
advanced None None O
glycation None None O
end-product None None O
increase None None O
in None None O
type None None O
2 None None O
diabetes None None O
gingival None None O
tissue None None O
might None None O
indicate None None O
possible None None O
involvement None None O
of None None O
this None None O
receptor None None I-PROTEIN
in None None O
periodontal None None O
destruction None None O
in None None O
individuals None None O
with None None O
type None None O
2 None None O
diabetes None None O
. None None O

The None None O
isolated None None O
hypoglossal None None I-REGION
nerve None None I-REGION
palsy None None O
could None None O
have None None O
been None None O
due None None O
to None None O
the None None O
infected None None O
impacted None None O
tooth None None O
. None None O

Collectively None None O
, None None O
the None None O
evidence None None O
suggests None None O
that None None O
the None None O
Report None None O
Card None None O
has None None O
been None None O
successful None None O
at None None O
powering None None O
the None None O
movement None None I-FUNC
to None None O
get None None O
kids None None O
moving None None O
, None None O
and None None O
in None None O
achieving None None O
demonstrable None None O
success None None O
on None None O
immediate None None O
and None None O
intermediate None None O
outcomes None None O
, None None O
although None None O
the None None O
long-term None None O
goal None None O
of None None O
improving None None O
the None None O
PA None None O
of None None O
Canadian None None O
children None None O
and None None O
youth None None O
remains None None O
to None None O
be None None O
realized None None O
. None None O

Brain None None O
injuries None None O
promote None None O
upregulation None None O
of None None O
so-called None None O
proinflammatory None None O
prostaglandins None None O
, None None O
notably None None O
prostaglandin None None O
E2 None None O
( None None O
PGE2 None None O
) None None O
, None None O
leading None None O
to None None O
overactivation None None O
of None None O
a None None O
class None None O
of None None O
its None None O
cognate None None O
G-protein-coupled None None I-PROTEIN
receptors None None I-PROTEIN
, None None O
including None None O
EP1 None None O
, None None O
which None None O
is None None O
considered None None O
a None None O
promising None None O
target None None O
for None None O
treatment None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

We None None O
asked None None O
whether None None O
dual None None O
inhibition None None O
of None None O
BCR-ABL None None O
and None None O
Aurora None None O
kinases None None I-PROTEIN
A-C None None O
could None None O
overcome None None O
resistance None None O
mediated None None O
by None None O
ABL None None O
kinase None None O
mutations None None O
. None None O

We None None O
present None None O
a None None O
method None None O
for None None O
giant None None O
lipid None None O
vesicle None None O
shape None None O
analysis None None O
that None None O
combines None None O
manually None None O
guided None None O
large-scale None None O
video None None O
microscopy None None O
and None None O
computer None None O
vision None None I-FUNC
algorithms None None O
to None None O
enable None None O
analyzing None None O
vesicle None None O
populations None None O
. None None O

Two None None O
different None None O
ball None None O
tracking None None O
methods None None O
are None None O
used None None O
that None None O
detect None None O
ball None None O
candidates None None O
from None None O
movement None None I-FUNC
difference None None O
images None None O
using None None O
a None None O
background None None O
subtraction None None O
algorithm None None O
. None None O

In None None O
making None None O
landing None None O
decisions None None O
, None None O
High None None O
Expertise None None O
pilots None None O
showed None None O
lower None None O
activation None None O
in None None O
the None None O
bilateral None None O
caudate None None I-REGION
nucleus None None I-REGION
( None None O
0.97 None None O
± None None O
0.80 None None O
) None None O
compared None None O
to None None O
Moderate None None O
Expertise None None O
pilots None None O
( None None O
1.91 None None O
± None None O
1.16 None None O
) None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
. None None O

The None None O
high None None O
expression None None O
of None None O
PACAP None None O
( None None O
pituitary None None O
adenylate None None I-PROTEIN
cyclase-activating None None O
polypeptide None None O
) None None O
-preferring None None O
receptor None None I-PROTEIN
PAC1 None None O
is None None O
associated None None O
with None None O
nerve None None O
injury None None O
and None None O
tumors None None O
. None None O

PAC1-CHO None None O
had None None O
significantly None None O
higher None None O
β-catenin None None O
, None None O
cyclin None None O
D1 None None O
and None None O
c-myc None None I-PROTEIN
levels None None O
corresponding None None O
to None None O
the None None O
Wnt/β-catenin None None O
signal None None O
than None None O
did None None O
M-PAC1-CHO None None O
. None None O

Coronary None None O
stenotic None None O
lesions None None O
were None None O
considered None None O
to None None O
be None None O
the None None O
incidence None None O
of None None O
coronary None None O
atherosclerosis None None I-DISEASE
. None None O

Moreover None None O
, None None O
fibrinogen None None O
level None None O
was None None O
also None None O
independently None None O
related None None O
to None None O
the None None O
presence None None O
of None None O
coronary None None O
atherosclerosis None None I-DISEASE
( None None O
fibrinogen None None O
tertile None None O
2 None None O
: None None O
OR None None O
= None None O
1.192 None None O
, None None O
95 None None O
% None None O
CI None None O
0.889-1.598 None None O
, None None O
p None None O
= None None O
0.241 None None O
; None None O
tertile None None O
3 None None O
: None None O
OR None None O
= None None O
2.003 None None O
, None None O
95 None None O
% None None O
CI None None O
1.383-2.903 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
high None None O
GS None None O
( None None O
fibrinogen None None O
tertile None None O
2 None None O
: None None O
OR None None O
= None None O
1.079 None None O
, None None O
95 None None O
% None None O
CI None None O
0.833-1.397 None None O
, None None O
p None None O
= None None O
0.565 None None O
; None None O
tertile None None O
3 None None O
: None None O
OR None None O
= None None O
1.524 None None O
, None None O
95 None None O
% None None O
CI None None O
1.155-2.011 None None O
, None None O
p None None O
= None None O
0.003 None None O
) None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
. None None O

Higher None None O
fibrinogen None None O
level None None O
is None None O
independently None None O
linked None None O
with None None O
the None None O
presence None None O
and None None O
severity None None O
of None None O
new-onset None None O
coronary None None O
atherosclerosis None None I-DISEASE
in None None O
Han None None O
Chinese None None O
population None None O
. None None O

Among None None O
which None None O
, None None O
four None None O
sterol-resistant None None O
mutants None None O
either None None O
contain None None O
a None None O
truncated None None O
NH2-terminal None None O
domain None None O
of None None O
sterol None None O
regulatory None None O
element-binding None None O
protein None None O
( None None O
SREBP None None O
) None None O
-2 None None O
terminating None None O
at None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
aa None None O
) None None O
400 None None O
, None None O
or None None O
harbor None None O
an None None O
overexpressed None None O
SREBP None None O
cleavage-activating None None O
protein None None O
( None None O
SCAP None None O
) None None O
. None None O

Embryonic None None O
cortical None None O
neurons None None O
challenged None None O
with None None O
glutamate None None I-TRANS
resulted None None O
in None None O
attenuated None None O
FGF2 None None O
levels None None O
and None None O
cell None None O
death None None O
, None None O
but None None O
CPE-ΔN None None O
transduced None None O
neurons None None O
treated None None O
in None None O
the None None O
same None None O
manner None None O
showed None None O
increased None None O
FGF2 None None O
expression None None O
and None None O
normal None None O
viability None None O
. None None O

This None None O
will None None O
be None None O
useful None None O
in None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
when None None O
evaluating None None O
cardiopulmonary None None O
health None None O
in None None O
similar None None O
populations None None O
. None None O

nePTM None None O
mapping None None O
showed None None O
carboxyethylation None None O
of None None O
lysine None None I-TRANS
( None None O
CEL None None O
) None None O
and None None O
the None None O
N-terminus None None O
without None None O
preferential None None O
modification None None O
sites None None O
. None None O

Fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
14 None None O
( None None O
FGF14 None None O
) None None O
is None None O
a None None O
member None None O
of None None O
the None None O
intracellular None None O
FGF None None O
( None None O
iFGFs None None O
) None None O
family None None O
and None None O
a None None O
functionally None None O
relevant None None O
component None None O
of None None O
the None None O
neuronal None None O
voltage-gated None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
( None None O
Nav None None O
) None None O
channel None None O
complex None None O
. None None O

The None None O
first None None O
two None None O
sessions None None O
of None None O
twelve None None O
for None None O
the None None O
response None None O
variables None None O
were None None O
discarded None None O
to None None O
avoid None None O
early None None O
effects None None O
of None None O
learning None None I-FUNC
thereby None None O
providing None None O
10 None None O
sessions None None O
spread None None O
across None None O
each None None O
participant None None O
's None None O
complete None None O
menstrual None None O
cycle None None O
. None None O

There None None O
is None None O
emerging None None O
evidence None None O
that None None O
the None None O
long-accepted None None O
hypothesis None None O
of None None O
diverticulosis None None O
as None None O
a None None O
consequence None None O
of None None O
fiber None None O
deficiency None None O
may None None O
be None None O
more None None O
complex None None O
than None None O
commonly None None O
thought None None O
, None None O
with None None O
recent None None O
evidence None None O
suggesting None None O
that None None O
high-fiber None None O
diet None None O
and None None O
frequent None None O
bowel None None O
movements None None I-FUNC
are None None O
associated None None O
with None None O
a None None O
greater None None O
and None None O
not None None O
lower None None O
prevalence None None O
of None None O
diverticular None None O
disease None None O
. None None O

Three None None O
dimensional None None O
( None None O
3D None None O
) None None O
nanostructures None None O
with None None O
extremely None None O
large None None O
porosity None None O
possess None None O
a None None O
great None None O
promise None None O
for None None O
the None None O
development None None O
of None None O
high-performance None None O
energy None None O
harvesting None None O
and None None O
storage None None I-FUNC
devices None None O
. None None O

The None None O
C677T None None O
mutation None None O
in None None O
5,10-methylenetetrahydrofolate None None O
reductase None None I-PROTEIN
( None None O
MTHFR None None O
) None None O
was None None O
found None None O
in None None O
29 None None O
of None None O
the None None O
38 None None O
patients None None O
tested None None O
. None None O

During None None O
the None None O
60 None None O
years None None O
, None None O
the None None O
diseases None None O
associated None None O
with None None O
highest None None O
diagnostic None None O
inaccuracy None None O
rates None None O
were None None O
circulatory None None O
diseases None None O
( None None O
76.97 None None O
% None None O
) None None O
, None None O
cancer None None O
( None None O
60.99 None None O
% None None O
) None None O
, None None O
and None None O
brain None None I-DISEASE
diseases None None I-DISEASE
( None None O
54.48 None None O
% None None O
) None None O
. None None O

In None None O
the None None O
autopsied None None O
disease None None O
spectrum None None O
over None None O
the None None O
60 None None O
years None None O
, None None O
the None None O
most None None O
common None None O
diseases None None O
were None None O
respiratory None None O
( None None O
1349 None None O
, None None O
32.58 None None O
% None None O
) None None O
, None None O
circulatory None None O
( None None O
495 None None O
, None None O
11.96 None None O
% None None O
) None None O
, None None O
and None None O
brain None None I-DISEASE
diseases None None I-DISEASE
( None None O
424 None None O
, None None O
10.24 None None O
% None None O
) None None O
. None None O

We None None O
present None None O
a None None O
toolbox None None O
for None None O
the None None O
study None None O
of None None O
molecular None None O
interactions None None O
occurring None None O
between None None O
NGF None None O
and None None O
its None None O
receptors None None I-PROTEIN
. None None O

These None None O
tags None None O
are None None O
shortened None None O
versions None None O
of None None O
the None None O
acyl None None O
and None None O
peptidyl None None O
carrier None None O
proteins None None O
; None None O
they None None O
are None None O
here None None O
covalently None None O
conjugated None None O
to None None O
the None None O
biotin-substituted None None O
arm None None O
of None None O
a None None O
coenzyme None None O
A None None O
( None None O
coA None None O
) None None O
substrate None None O
by None None O
phosphopantetheinyl None None O
transferase None None I-PROTEIN
enzymes None None I-PROTEIN
( None None O
PPTases None None O
) None None O
. None None O

Crucially None None O
, None None O
the None None O
two None None O
tags None None O
are None None O
labeled None None O
selectively None None O
by None None O
two None None O
different None None O
PPTases None None O
: None None O
this None None O
is None None O
exploited None None O
to None None O
reach None None O
orthogonal None None O
fluorolabeling None None O
of None None O
the None None O
two None None O
receptors None None I-PROTEIN
co-expressed None None O
at None None O
low None None O
density None None O
in None None O
living None None O
cells None None O
. None None O

By None None O
scanning None None O
forward None None O
and None None O
reverse None None O
( None None O
trace None None O
and None None O
retrace None None O
) None None O
over None None O
the None None O
same None None O
region None None O
of None None O
a None None O
SWNT None None O
, None None O
it None None O
is None None O
also None None O
possible None None O
to None None O
assess None None O
any None None O
blocking None None O
of None None O
EC None None O
activity None None O
by None None O
serotonin None None I-TRANS
oxidation None None O
reaction None None O
products None None O
. None None O

At None None O
higher None None O
serotonin None None I-TRANS
concentration None None O
( None None O
2 None None O
mM None None O
) None None O
, None None O
oligomer None None O
formation None None O
from None None O
oxidation None None O
products None None O
is None None O
much None None O
more None None O
significant None None O
and None None O
major None None O
blocking None None O
of None None O
the None None O
EC None None O
process None None O
is None None O
observed None None O
from None None O
line None None O
profiles None None O
recorded None None O
as None None O
the None None O
SECCM None None O
meniscus None None O
moves None None O
over None None O
an None None O
SWNT None None O
. None None O

We None None O
selected None None O
randomized None None O
or None None O
quasi-randomized None None O
studies None None O
involving None None O
participants None None O
with None None O
the None None O
diagnosis None None O
of None None O
TOS None None O
of None None O
any None None O
type None None O
( None None O
neurogenic None None O
, None None O
vascular None None O
, None None O
and None None O
'disputed None None O
' None None O
) None None O
, None None O
without None None O
limitations None None O
as None None O
to None None O
language None None I-FUNC
of None None O
publication.We None None O
accepted None None O
studies None None O
that None None O
examined None None O
any None None O
intervention None None O
aimed None None O
at None None O
treating None None O
TOS.The None None O
primary None None O
outcome None None O
measure None None O
was None None O
change None None O
in None None O
pain None None O
rating None None O
, None None O
measured None None O
on None None O
a None None O
validated None None O
visual None None O
analog None None O
or None None O
similar None None O
scale None None O
at None None O
least None None O
six None None O
months None None O
after None None O
the None None O
intervention.The None None O
secondary None None O
outcomes None None O
were None None O
change None None O
in None None O
muscle None None O
strength None None O
, None None O
disability None None O
, None None O
experiences None None O
of None None O
paresthesias None None O
( None None O
numbness None None O
and None None O
tingling None None O
sensations None None I-FUNC
) None None O
, None None O
and None None O
adverse None None O
effects None None O
of None None O
the None None O
interventions None None O
. None None O

Four None None O
interface None None O
residues None None O
were None None O
mutated None None O
to None None O
alanine None None I-TRANS
, None None O
and None None O
interaction None None O
studies None None O
were None None O
employed None None O
to None None O
decode None None O
the None None O
key None None O
role None None O
of None None O
these None None O
residues None None O
in None None O
the None None O
peptide None None O
molecular None None O
recognition None None O
. None None O

To None None O
evaluate None None O
the None None O
association None None O
between None None O
myelomeningocele None None O
( None None O
MM None None O
) None None O
and None None O
c.A1298C None None O
and None None O
c.C677T None None O
polymorphisms None None O
within None None O
the None None O
coding None None O
gene None None O
for None None O
5,10-methylenetetrahydrofolate None None O
reductase None None I-PROTEIN
( None None O
MTHFR None None O
) None None O
in None None O
the None None O
Chilean None None O
population None None O
. None None O

Pulmonary None None O
alveolar None None O
microlithiasis None None O
is None None O
an None None O
extremely None None O
rare None None O
disease None None O
characterized None None O
by None None O
intra-alveolar None None O
accumulation None None O
of None None O
calcified None None O
spherical None None O
particles None None O
( None None O
called None None O
microliths None None O
) None None O
, None None O
due None None O
to None None O
a None None O
mutation None None O
of None None O
the None None O
gene None None O
encoding None None I-FUNC
a None None O
membrane None None O
transport None None O
protein None None O
of None None O
the None None O
alveolar None None O
surface None None O
. None None O

Noninvasive None None O
brain None None O
stimulation None None O
, None None O
including None None O
repetitive None None O
transcranial None None O
magnetic None None O
stimulation None None O
( None None O
rTMS None None O
) None None O
and None None O
transcranial None None O
direct None None O
current None None O
stimulation None None O
( None None O
tDCS None None O
) None None O
, None None O
have None None O
gained None None O
popularity None None O
in None None O
the None None O
stroke None None I-DISEASE
rehabilitation None None O
literature None None O
. None None O

We None None O
examined None None O
the None None O
aftereffects None None O
of None None O
a None None O
single None None O
session None None O
of None None O
high-frequency None None O
rTMS None None O
( None None O
5 None None O
Hz None None O
) None None O
and None None O
anodal None None O
tDCS None None O
on None None O
corticospinal None None O
excitability None None O
in None None O
the None None O
same None None O
sample None None O
of None None O
participants None None O
with None None O
chronic None None O
stroke None None I-DISEASE
. None None O

Atherosclerosis None None I-DISEASE
is None None O
a None None O
systemic None None O
inflammatory None None O
disease None None O
able None None O
to None None O
deeply None None O
worsen None None O
the None None O
outcome None None O
of None None O
patients None None O
because None None O
of None None O
its None None O
serious None None O
clinical None None O
consequences None None O
. None None O

inflammatory None None O
diseases None None O
of None None O
the None None O
liver None None O
mainly None None O
due None None O
to None None O
viral None None O
infections None None O
) None None O
and None None O
nonalcoholic None None O
fatty None None O
liver None None O
disease None None O
could None None O
be None None O
aligned None None O
to None None O
inflammatory None None O
bowel None None O
disease None None O
in None None O
such None None O
an None None O
induction None None O
of None None O
atherosclerosis None None I-DISEASE
disease.Many None None O
studies None None O
tried None None O
to None None O
point None None O
out None None O
the None None O
relationship None None O
between None None O
bowel None None O
and None None O
liver None None O
inflammatory None None O
diseases None None O
and None None O
early None None O
vascular None None O
changes None None O
, None None O
considered None None O
the None None O
first None None O
step None None O
for None None O
atherosclerosis None None I-DISEASE
development.The None None O
aim None None O
of None None O
such None None O
a None None O
narrative None None O
review None None O
is None None O
to None None O
explain None None O
the None None O
relationship None None O
between None None O
inflammatory None None O
bowel None None O
disease None None O
, None None O
hepatitis None None O
and None None O
nonalcoholic None None O
fatty None None O
liver None None O
disease None None O
and None None O
their None None O
role None None O
in None None O
increasing None None O
cardiovascular None None O
risk None None O
profile None None O
due None None O
to None None O
early None None O
impairment None None O
in None None O
vascular None None O
function None None O
and None None O
morphology None None O
. None None O

Efficacy None None O
of None None O
different None None O
mAb None None O
versions None None O
of None None O
GNbAC1 None None O
were None None O
assessed None None O
in None None O
MSRV-Env None None O
induced None None O
experimental None None O
allergic None None O
encephalitis None None I-DISEASE
( None None O
EAE None None O
) None None O
, None None O
an None None O
animal None None O
model None None O
of None None O
MS. None None O
Because None None O
the None None O
target None None O
MSRV-Env None None O
is None None O
not None None O
expressed None None O
in None None O
animals None None O
, None None O
no None None O
relevant None None O
animal None None O
model None None O
exists None None O
for None None O
a None None O
proper None None O
in None None O
vivo None None O
toxicological None None O
program None None O
. None None O

Recent None None O
publications None None O
suggested None None O
solutions None None O
to None None O
alarm-related None None O
hazards None None O
associated None None O
with None None O
usage None None O
errors None None O
based None None O
on None None O
assumptions None None O
on None None O
the None None O
causal None None O
relations None None O
between None None O
, None None O
for None None O
example None None O
, None None O
alarm None None O
management None None O
and None None O
human None None O
perception None None I-FUNC
, None None O
cognition None None O
, None None O
and None None O
responding None None O
. None None O

Because None None O
the None None O
patient None None O
was None None O
adrenalectomized None None O
, None None O
extra None None O
adrenal None None I-TRANS
androgen None None O
production None None O
was None None O
suspected None None O
. None None O

Abdominal None None O
MRI None None O
was None None O
obtained None None O
to None None O
evaluate None None O
for None None O
residual None None O
adrenal None None I-TRANS
tissue None None O
. None None O

Although None None O
rare None None O
, None None O
we None None O
propose None None O
that None None O
the None None O
ovaries None None O
were None None O
the None None O
origin None None O
of None None O
androgen None None O
production None None O
and None None O
not None None O
residual None None O
adrenal None None I-TRANS
tissue None None O
. None None O

In None None O
particular None None O
, None None O
attention None None I-FUNC
is None None O
devoted None None O
to None None O
the None None O
identification None None O
of None None O
the None None O
appropriate None None O
scale None None O
and None None O
level None None O
of None None O
accuracy None None O
in None None O
the None None O
reconstruction None None O
of None None O
metabolic None None O
networks None None O
, None None O
and None None O
to None None O
the None None O
inference None None I-FUNC
of None None O
model None None O
structure None None O
and None None O
parameters None None O
, None None O
especially None None O
when None None O
dealing None None O
with None None O
a None None O
shortage None None O
of None None O
experimental None None O
measurements None None O
. None None O

Here None None O
, None None O
we None None O
use None None O
light None None O
level None None O
and None None O
depth None None O
data None None O
to None None O
generate None None O
a None None O
phytoplankton None None O
index None None O
that None None O
matches None None O
daily None None O
seal None None O
movements None None I-FUNC
. None None O

TDLR None None O
data None None O
were None None O
used None None O
to None None O
calculate None None O
integrated None None O
light None None O
attenuation None None O
of None None O
the None None O
top None None O
250 None None O
m None None O
of None None O
the None None O
water None None O
column None None O
( None None O
LA None None O
( None None O
250 None None O
) None None O
) None None O
, None None O
which None None O
provided None None O
an None None O
index None None O
of None None O
phytoplankton None None O
density None None O
at None None O
the None None O
daily None None O
scale None None O
that None None O
was None None O
concurrent None None O
with None None O
the None None O
movement None None I-FUNC
and None None O
behaviour None None O
of None None O
seals None None O
throughout None None O
their None None O
entire None None O
foraging None None O
trip None None O
. None None O

No None None O
reports None None O
, None None O
however None None O
, None None O
have None None O
described None None O
an None None O
association None None O
between None None O
the None None O
multiple None None O
electrode None None O
platelet None None O
aggregometry None None O
( None None O
MEA None None O
; None None O
Dynabyte None None O
, None None O
Munich None None O
, None None O
Germany None None O
) None None O
adenosine None None I-TRANS
diphosphate None None O
( None None O
ADP None None O
) None None O
assay None None O
results None None O
and None None O
hematocrit None None O
. None None O

Anemic None None O
patients None None O
( None None O
n None None O
= None None O
152 None None O
, None None O
32.9 None None O
% None None O
) None None O
demonstrated None None O
a None None O
significantly None None O
higher None None O
rate None None O
of None None O
cardiac None None O
death None None O
, None None O
myocardial None None O
infarction None None O
, None None O
and None None O
stroke None None I-DISEASE
( None None O
5.3 None None O
% None None O
vs. None None O
2.3 None None O
% None None O
, None None O
p None None O
= None None O
0.046 None None O
) None None O
during None None O
the None None O
follow-up None None O
( None None O
median None None O
: None None O
18.8 None None O
months None None O
) None None O
. None None O

Specifically None None O
, None None O
oestradiol None None O
, None None O
when None None O
combined None None O
with None None O
IGF-1 None None O
, None None O
insulin None None I-PROTEIN
and None None O
FSH None None O
, None None O
stimulated None None O
HAS2 None None O
mRNA None None O
expression None None O
. None None O

In None None O
conclusion None None O
, None None O
we None None O
suggest None None O
that None None O
the None None O
hormones None None I-PROTEIN
studied None None O
differentially None None O
regulate None None O
HAS2 None None O
, None None O
HAS3 None None O
and None None O
CD44 None None O
in None None O
ovine None None O
granulosa None None O
cells None None O
in None None O
vitro None None O
. None None O

We None None O
evaluated None None O
a None None O
novel None None O
visual None None O
representation None None O
for None None O
current None None O
and None None O
near-term None None O
prosthetic None None O
vision None None I-FUNC
. None None O

Eight None None O
participants None None O
with None None O
normal None None O
vision None None I-FUNC
used None None O
simulated None None O
prosthetic None None O
vision None None I-FUNC
with None None O
20 None None O
phosphenes None None O
and None None O
eight None None O
perceivable None None O
brightness None None O
levels None None O
to None None O
traverse None None O
a None None O
course None None O
with None None O
randomly None None O
placed None None O
small None None O
and None None O
low-contrast None None O
obstacles None None O
on None None O
the None None O
ground None None O
. None None O

Neutrophil None None O
extravasation None None O
from None None O
the None None O
blood None None O
into None None O
tissues None None O
is None None O
initiated None None O
by None None O
tethering None None O
and None None O
rolling None None O
of None None O
neutrophils None None O
on None None O
endothelial None None O
cells None None O
, None None O
followed None None O
by None None O
neutrophil None None O
integrin None None I-PROTEIN
activation None None O
and None None O
shear None None O
resistant None None O
arrest None None O
, None None O
crawling None None O
, None None O
diapedesis None None O
and None None O
breaching None None O
the None None O
endothelial None None O
basement None None O
membrane None None O
harbouring None None O
pericytes None None O
. None None O

Mutations None None O
in None None O
the None None O
gene None None O
for None None O
neutrophil None None O
elastase None None I-PROTEIN
, None None O
ELANE None None O
, None None O
cause None None O
cyclic None None O
neutropenia None None O
( None None O
CyN None None O
) None None O
and None None O
severe None None O
congenital None None O
neutropenia None None O
( None None O
SCN None None O
) None None O
. None None O

Adolescents None None O
with None None O
gender None None O
dysphoria None None O
( None None O
GD None None O
) None None O
treated None None O
with None None O
gonadotropin-releasing None None O
hormone None None O
analog None None O
( None None O
GnRHa None None O
) None None O
therapy None None O
are None None O
temporarily None None O
sex-steroid None None O
deprived None None O
until None None O
the None None O
addition None None O
of None None O
cross-sex None None O
hormones None None I-PROTEIN
( None None O
CSH None None O
) None None O
. None None O

Young None None O
adults None None O
diagnosed None None O
with None None O
gender None None I-DISEASE
identity None None I-DISEASE
disorder None None I-DISEASE
of None None O
adolescence None None O
( None None O
DSM None None O
IV-TR None None O
) None None O
who None None O
started None None O
SR None None O
in None None O
puberty None None O
and None None O
had None None O
undergone None None O
gonadectomy None None O
between None None O
June None None O
1998 None None O
and None None O
August None None O
2012 None None O
were None None O
included None None O
. None None O

However None None O
, None None O
there None None O
is None None O
evidence None None O
of None None O
this None None O
sequence None None O
being None None O
effective None None O
in None None O
replacing None None O
certain None None O
neuronal None None O
populations None None O
in None None O
brain None None I-DISEASE
disease None None I-DISEASE
. None None O

The None None O
ErbB None None O
protein None None O
tyrosine None None I-TRANS
kinases None None I-PROTEIN
are None None O
among None None O
the None None O
most None None O
important None None O
cell None None O
signaling None None O
families None None O
and None None O
mutation-induced None None O
modulation None None O
of None None O
their None None O
activity None None O
is None None O
associated None None O
with None None O
diverse None None O
functions None None O
in None None O
biological None None O
networks None None O
and None None O
human None None O
disease None None O
. None None O

Some None None O
6 None None O
network None None O
clusters None None O
were None None O
found None None O
, None None O
including None None O
`` None None O
Depression None None I-DISEASE
'' None None O
, None None O
`` None None O
Mania None None O
'' None None O
, None None O
`` None None O
Anxiety None None O
'' None None O
, None None O
`` None None O
Psychosis None None O
'' None None O
, None None O
`` None None O
Retardation None None O
'' None None O
, None None O
and None None O
`` None None O
Behavioral None None O
Disorganization None None O
'' None None O
. None None O

Although None None O
hydrogen None None O
peroxide None None O
and None None O
menadione None None O
reduced None None O
cell None None O
viability None None O
, None None O
the None None O
toxicity None None O
was None None O
prevented None None O
by None None O
desferrioxamine None None O
or None None O
catalase None None I-PROTEIN
but None None O
not None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
suggesting None None O
the None None O
involvement None None O
of None None O
hydrogen None None O
peroxide None None O
in None None O
both None None O
cases None None O
. None None O

We None None O
conducted None None O
a None None O
study None None O
to None None O
ascertain None None O
the None None O
association None None O
of None None O
natural None None O
killer None None O
cell None None O
killer None None O
immunoglobulin-like None None O
receptors None None I-PROTEIN
and None None O
human None None O
leukocyte None None O
antigen None None O
( None None O
HLA None None O
) None None O
genotype None None O
with None None O
risk None None O
of None None O
CMV None None O
disease None None O
. None None O

The None None O
present None None O
work None None O
retrospectively None None O
evaluated None None O
single-center None None O
prevalence None None O
of None None O
CPM/EPM None None O
and None None O
associated None None O
risk None None O
factors None None O
: None None O
cause None None O
of None None O
liver None None O
disease None None O
, None None O
hepatic None None O
encephalopathy None None O
, None None O
preoperative None None O
, None None O
intraoperative None None O
, None None O
and None None O
perioperative None None O
blood None None O
components None None O
use None None O
, None None O
serum None None O
levels None None O
, None None O
and None None O
variation None None O
of None None O
Na None None I-TRANS
, None None O
Cl None None O
, None None O
and None None O
K None None O
and None None O
immunosuppression None None O
were None None O
compared None None O
between None None O
CPM/EPM None None O
patients None None O
and None None O
control None None O
group None None O
of None None O
transplanted None None O
patients None None O
without None None O
neurologic None None O
complications None None O
. None None O

Maximum None None O
peak None None O
of None None O
intraoperative None None O
or None None O
perioperative None None O
serum None None O
Na None None I-TRANS
was None None O
significantly None None O
higher None None O
in None None O
patients None None O
compared None None O
to None None O
controls None None O
( None None O
151.5 None None O
± None None O
3.3 None None O
vs. None None O
140.8 None None O
± None None O
6.2 None None O
mEq/L None None O
, None None O
P None None O
≤ None None O
0.001 None None O
) None None O
, None None O
but None None O
no None None O
difference None None O
in None None O
preoperative None None O
serum None None O
Na None None I-TRANS
was None None O
detected None None O
. None None O

Electrochemical None None O
sensing None None O
of None None O
glutamate None None I-TRANS
has None None O
been None None O
developed None None O
recently None None O
mainly None None O
using None None O
platinum None None O
, None None O
carbon None None O
fibre None None O
and None None O
carbon None None O
nanotube None None O
electrodes None None O
. None None O

The None None O
sensors None None O
incorporate None None O
platinum None None O
nanoparticles None None O
to None None O
catalyse None None O
the None None O
electrooxidation None None O
of None None O
hydrogen None None O
peroxide None None O
, None None O
glutamate None None I-TRANS
oxidase None None O
to None None O
oxidise None None O
glutamate None None I-TRANS
, None None O
and None None O
a None None O
layer None None O
of None None O
poly-phenylenediamine None None O
to None None O
impart None None O
selectivity None None O
. None None O

Major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
is None None O
a None None O
debilitating None None O
disease None None O
affecting None None O
a None None O
wide None None O
cross None None O
section None None O
of None None O
people None None O
around None None O
the None None O
world None None O
. None None O

Dopamine None None I-TRANS
has None None O
been None None O
shown None None O
to None None O
play None None O
a None None O
significant None None O
role None None O
in None None O
depression None None I-DISEASE
including None None O
production None None O
of None None O
anhedonia None None O
which None None O
has None None O
been None None O
one None None O
of None None O
the None None O
untreated None None O
symptoms None None O
in None None O
MDD None None O
. None None O

This None None O
has None None O
led None None O
to None None O
the None None O
development None None O
of None None O
triple None None O
reuptake None None O
inhibitor None None O
D-473 None None O
which None None O
is None None O
a None None O
novel None None O
pyran None None O
based None None O
molecule None None O
and None None O
interacts None None O
with None None O
all None None O
three None None O
monoamine None None O
transporters None None I-PROTEIN
. None None O

Microdialysis None None O
experiment None None O
demonstrated None None O
that None None O
systemic None None O
administration None None O
of None None O
D-473 None None O
elevated None None O
extracellular None None O
level None None O
of None None O
the None None O
three None None O
monoamines None None I-TRANS
DA None None O
, None None O
5-HT None None I-TRANS
, None None O
and None None O
NE None None I-TRANS
efficaciously None None O
in None None O
the None None O
dorsal None None I-NEURON
lateral None None O
striatum None None I-REGION
( None None O
DLS None None O
) None None O
and None None O
the None None O
medial None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
mPFC None None O
) None None O
area None None O
, None None O
indicating None None O
in None None O
vivo None None O
blockade None None O
of None None O
all None None O
three None None O
monoamine None None O
transporters None None I-PROTEIN
by None None O
D-473 None None O
. None None O

Burning None None O
sensation None None I-FUNC
was None None O
the None None O
most None None O
common None None O
symptom None None O
( None None O
72.9 None None O
% None None O
) None None O
, None None O
followed None None O
by None None O
pain None None O
( None None O
26.5 None None O
% None None O
) None None O
, None None O
roughness None None O
( None None O
6.4 None None O
% None None O
) None None O
, None None O
and None None O
then None None O
no None None O
other None None O
symptoms None None O
( None None O
7.9 None None O
% None None O
) None None O
. None None O

Positive None None O
immunohistological None None O
staining None None O
with None None O
CD-34 None None O
presented None None O
a None None O
large None None O
number None None O
of None None O
blood None None O
vessels None None O
of None None O
different None None O
sizes None None O
located None None O
between None None O
collagen None None I-PROTEIN
fibers None None O
and None None O
adipocytes None None O
. None None O

To None None O
identify None None O
the None None O
molecule None None O
that None None O
triggered None None O
this None None O
innate None None O
immunity None None O
, None None O
we None None O
fractionated None None O
and None None O
purified None None O
candidates None None O
extracted None None O
from None None O
Corynebacterium None None O
glutamicum None None O
, None None O
a None None O
bacterium None None O
used None None O
in None None O
the None None O
production None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
by None None O
fermentation None None O
. None None O

Other None None O
human None None O
CYP None None O
isoforms None None O
including None None O
CYP2A6 None None O
, None None O
CYP2C9 None None O
, None None O
CYP2D6 None None I-PROTEIN
, None None O
CYP2E1 None None I-PROTEIN
and None None O
CYP3A4 None None I-PROTEIN
showed None None O
minimal None None O
or None None O
no None None O
effect None None O
on None None O
MH None None O
metabolism None None O
. None None O

Their None None O
stimulation None None O
by None None O
specific None None O
testosterone None None O
albumin None None O
conjugates None None O
( None None O
TAC None None O
) None None O
activate None None O
rapidly None None O
non-genomic None None O
FAK/PI3K/Rac1/Cdc42 None None O
signaling None None O
, None None O
trigger None None O
actin None None I-PROTEIN
reorganization None None O
and None None O
inhibit None None O
cell None None O
motility None None O
. None None O

Blocking None None O
actin None None I-PROTEIN
restructuring None None O
with None None O
cytochalasin None None O
B None None O
abrogated None None O
the None None O
TAC- None None O
and None None O
EMD638683-induced None None O
pro-apoptotic None None O
responses None None O
. None None O

Our None None O
results None None O
demonstrate None None O
that None None O
mAR None None O
activation None None O
triggers None None O
pro-apoptotic None None O
responses None None O
in None None O
breast None None O
tumor None None O
cells None None O
, None None O
an None None O
effect None None O
significantly None None O
enhanced None None O
by None None O
SGK1 None None O
inhibition None None O
, None None O
involving None None O
actin None None I-PROTEIN
reorganization None None O
and None None O
paralleled None None O
by None None O
down-regulation None None O
of None None O
FAK/Akt None None O
signaling None None O
. None None O

Although None None O
characterized None None O
as None None O
type None None O
VI None None I-REGION
( None None O
non-immune None None O
rapidly None None O
progressive None None O
sensorineural None None O
hearing None None O
loss None None O
) None None O
within None None O
the None None O
Harris None None O
autoimmune None None O
inner None None O
ear None None O
disease None None O
classification None None O
system None None O
, None None O
the None None O
mechanism None None O
of None None O
paraneoplastic None None O
cochleovestibulopathy None None O
is None None O
not None None O
well None None O
understood None None O
. None None O

We None None O
hereby None None O
proposed None None O
a None None O
strategy None None O
to None None O
maximize None None O
biological None None O
information None None I-FUNC
retrieval None None I-FUNC
from None None O
a None None O
limited None None O
TTNA None None O
specimen None None O
in None None O
patients None None O
with None None O
peripheral None None O
lung None None O
cancer None None O
. None None O

Molecular None None O
bases None None O
of None None O
peptide None None O
recognition None None O
by None None O
Dug1p None None O
and None None O
other None None O
M20 None None O
family None None O
peptidases None None I-PROTEIN
remain None None O
unclear None None O
in None None O
the None None O
absence None None O
of None None O
structural None None O
information None None O
about None None O
enzyme-peptide None None O
complexes None None O
. None None O

In None None O
summary None None O
, None None O
results None None O
reveal None None O
that None None O
peptides None None I-TRANS
are None None O
recognized None None O
primarily None None O
through None None O
their None None O
amino None None O
and None None O
carboxyl None None O
termini None None O
, None None O
but None None O
hydrolysis None None O
depends None None O
on None None O
the None None O
properties None None O
of None None O
peptide None None O
substrates None None O
, None None O
dictated None None O
by None None O
their None None O
respective None None O
sequences None None O
. None None O

Postlarvae None None O
fed None None O
with None None O
each None None O
diet None None O
were None None O
exposed None None O
to None None O
different None None O
concentrations None None O
of None None O
nitrite None None O
( None None O
NO None None O
( None None O
2 None None O
) None None O
Na None None I-TRANS
) None None O
( None None O
0-200 None None O
mg None None O
L None None O
( None None O
-1 None None O
) None None O
) None None O
. None None O

Such None None O
efforts None None O
are None None O
motivated None None O
by None None O
a None None O
fundamental None None O
interest None None O
in None None O
understanding None None O
the None None O
role None None O
of None None O
nanosizing None None O
on None None O
metal None None O
hydride None None O
formation None None O
processes None None O
in None None O
the None None O
quest None None O
to None None O
develop None None O
efficient None None O
solid-state None None O
hydrogen None None O
storage None None I-FUNC
materials None None O
with None None O
fast None None O
response None None O
times None None O
, None None O
reasonable None None O
thermodynamics None None O
, None None O
and None None O
acceptable None None O
long-term None None O
stability None None O
. None None O

Although None None O
lymphocyte-like None None O
cells None None O
secreting None None O
somatically-recombining None None O
receptors None None I-PROTEIN
have None None O
been None None O
identified None None O
in None None O
the None None O
jawless None None O
fishes None None O
( None None O
hagfish None None O
and None None O
lamprey None None O
) None None O
, None None O
the None None O
cartilaginous None None O
fishes None None O
( None None O
sharks None None O
, None None O
skates None None O
, None None O
rays None None O
and None None O
chimaera None None O
) None None O
are None None O
the None None O
most None None O
phylogenetically None None O
distant None None O
group None None O
relative None None O
to None None O
mammals None None O
in None None O
which None None O
bona None None O
fide None None O
immunoglobulins None None O
( None None O
Igs None None O
) None None O
have None None O
been None None O
found None None O
. None None O

Interestingly None None O
, None None O
peripherally None None O
administered None None O
R1c None None O
mAb None None O
accumulated None None O
in None None O
the None None O
median None None I-REGION
eminence None None I-REGION
, None None O
adjacent None None O
arcuate None None O
nucleus None None O
and None None O
in None None O
the None None O
circumventricular None None I-REGION
organs None None I-REGION
where None None O
it None None O
activated None None O
the None None O
early None None O
response None None O
gene None None O
c-Fos None None O
. None None O

Traumatic None None O
brain None None O
injury None None O
was None None O
defined None None O
as None None O
loss None None O
of None None O
consciousness None None I-FUNC
for None None O
at None None O
least None None O
5 None None O
minutes None None O
or None None O
a None None O
minimum None None O
1-night None None O
hospital None None O
stay None None O
due None None O
to None None O
symptoms None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
detect None None O
the None None O
C-deletion None None O
mutation None None O
of None None O
the None None O
p53 None None I-PROTEIN
gene None None O
at None None O
exon None None O
4 None None O
of None None O
codon None None O
63 None None O
in None None O
the None None O
saliva None None O
of None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
in None None O
central None None O
India None None O
. None None O

The None None O
C-deletion None None O
mutation None None O
of None None O
the None None O
p53 None None I-PROTEIN
gene None None O
at None None O
exon None None O
4 None None O
of None None O
codon None None O
63 None None O
was None None O
detected None None O
in None None O
the None None O
saliva None None O
samples None None O
by None None O
using None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

The None None O
results None None O
indicated None None O
that None None O
C-deletion None None O
mutation None None O
at None None O
exon None None O
4 None None O
of None None O
codon None None O
63 None None O
of None None O
the None None O
p53 None None I-PROTEIN
gene None None O
in None None O
the None None O
saliva None None O
might None None O
be None None O
a None None O
plausible None None O
molecular None None O
marker None None O
for None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
patients None None O
with None None O
a None None O
habit None None O
of None None O
betel None None O
nut None None O
and None None O
tobacco None None O
lime None None O
quid None None O
chewing None None O
. None None O

Hardness None None O
was None None O
measured None None O
, None None O
and None None O
samples None None O
were None None O
stored None None O
in None None O
absolute None None O
ethanol None None O
for None None O
24 None None O
h. None None O
A None None O
second None None O
hardness None None O
measurement None None O
was None None O
executed None None O
after None None O
storage None None I-FUNC
to None None O
assess None None O
plasticization None None O
by None None O
the None None O
percentage None None O
of None None O
hardness None None O
decrease None None O
. None None O

The None None O
current None None O
report None None O
describes None None O
the None None O
conversion None None O
of None None O
a None None O
laboratory-based None None O
test None None O
for None None O
phenylalanine None None I-TRANS
detection None None O
to None None O
a None None O
simple None None O
paper-based None None O
test None None O
appropriate None None O
for None None O
use None None O
in None None O
low-resource None None O
settings None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
demonstrate None None O
that None None O
rapid None None O
and None None O
reliable None None O
protein None None O
digestion None None O
can None None O
be None None O
performed None None O
on None None O
a None None O
single None None O
thin None None O
tissue None None O
section None None O
while None None O
preserving None None O
the None None O
relationship None None O
between None None O
the None None O
molecular None None O
information None None O
obtained None None O
and None None O
the None None O
tissue None None O
architecture None None O
, None None O
and None None O
the None None O
resulting None None O
peptides None None I-TRANS
can None None O
be None None O
extracted None None O
in None None O
sufficient None None O
abundance None None O
to None None O
permit None None O
analysis None None O
using None None O
LC-MS/MS None None O
. None None O

Cabozantinib None None O
S-malate None None O
is None None O
a None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
, None None O
c-MET None None O
, None None O
and None None O
RET None None O
multitargeted None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
that None None O
has None None O
antiangiogenic None None O
and None None O
antitumorigenic None None O
properties None None O
with None None O
potential None None O
efficacy None None O
for None None O
the None None O
treatment None None O
of None None O
several None None O
cancers None None O
. None None O

Early None None O
detection None None O
and None None O
prompt None None O
treatment None None O
may None None O
increase None None O
patients None None O
' None None O
adherence None None O
to None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
therapy None None O
. None None O

Existing None None O
tumor None None O
growth None None O
models None None O
based None None O
on None None O
fluid None None O
analogy None None I-FUNC
for None None O
the None None O
cells None None O
do None None O
not None None O
generally None None O
include None None O
the None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
, None None O
or None None O
if None None O
present None None O
, None None O
take None None O
it None None O
as None None O
rigid None None O
. None None O

2-AG None None O
acted None None O
by None None O
binding None None O
to None None O
CB1 None None O
and None None O
CB2 None None O
receptors None None I-PROTEIN
, None None O
because None None O
specific None None O
antagonists None None O
reverted None None O
its None None O
effect None None O
. None None O

Given None None O
the None None O
importance None None O
of None None O
2-AG None None O
for None None O
driving None None O
megakaryopoiesis None None O
and None None O
thrombopoiesis None None O
, None None O
not None None O
surprisingly None None O
we None None O
found None None O
that None None O
its None None O
hydrolytic None None I-PROTEIN
enzymes None None I-PROTEIN
were None None O
tightly None None O
controlled None None O
by None None O
classical None None O
inducers None None O
of None None O
megakaryocyte None None O
differentiation None None O
. None None O

Accumulating None None O
evidence None None O
supports None None O
a None None O
role None None O
for None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
as None None O
a None None O
possible None None O
modulator None None O
of None None O
ketamine None None O
's None None O
side None None O
effects None None O
. None None O

Ketamine None None O
interfered None None O
with None None O
complex None None O
I None None O
function None None O
, None None O
revealing None None O
increased None None O
oxygen None None O
consumption None None O
in None None O
state None None O
4 None None O
, None None O
impaired None None O
oxidative None None O
phosphorylation None None O
efficiency None None O
of None None O
glutamate-malate None None O
substrate None None O
, None None O
and None None O
decreased None None O
NADH-ubiquinone None None O
oxidoreductase None None I-PROTEIN
activity None None O
. None None O

Ketamine None None O
administration None None O
increased None None O
hydrogen None None O
peroxide None None O
generation None None O
and None None O
triggered None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
activity None None O
. None None O

Acute None None O
ketamine None None O
administration None None O
impaired None None O
the None None O
function None None O
of None None O
mitochondrial None None O
complex None None O
I None None O
leading None None O
to None None O
increased None None O
mtNOS None None O
activity None None O
, None None O
increased None None O
generation None None O
of None None O
hydrogen None None O
peroxide None None O
and None None O
NO None None O
, None None O
resulting None None O
in None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
triggering None None O
, None None O
and None None O
improved None None O
antioxidant None None O
activity None None O
. None None O

Antidepressants None None O
are None None O
often None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
neuropathic None None O
pain None None O
, None None O
and None None O
their None None O
analgesic None None O
effects None None O
rely None None O
on None None O
increased None None O
noradrenaline None None I-TRANS
and None None O
serotonin None None I-TRANS
levels None None O
in None None O
the None None O
spinal None None O
cord None None O
. None None O

We None None O
hypothesized None None O
that None None O
bupropion None None O
inhibits None None O
neuropathic None None O
pain None None O
by None None O
increasing None None O
noradrenaline None None I-TRANS
and None None O
dopamine None None I-TRANS
in None None O
the None None O
spinal None None O
cord None None O
. None None O

In None None O
vivo None None O
microdialysis None None O
was None None O
performed None None O
in None None O
the None None O
dorsal None None I-NEURON
horn None None O
of None None O
the None None O
lumbar None None O
spinal None None O
cord None None O
to None None O
measure None None O
noradrenaline None None I-TRANS
and None None O
dopamine None None I-TRANS
concentrations None None O
after None None O
intrathecal None None O
injection None None O
of None None O
bupropion None None O
. None None O

Microdialysis None None O
revealed None None O
that None None O
noradrenaline None None I-TRANS
and None None O
dopamine None None I-TRANS
concentrations None None O
in None None O
the None None O
spinal None None O
dorsal None None I-NEURON
horn None None O
were None None O
increased None None O
after None None O
intrathecal None None O
injection None None O
of None None O
bupropion None None O
( None None O
30 None None O
μg None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
and None None O
P None None O
= None None O
0.001 None None O
, None None O
respectively None None O
) None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
plasticity None None O
of None None O
descending None None O
inhibitory None None O
pathways None None O
such None None O
as None None O
the None None O
noradrenaline None None I-TRANS
and None None O
dopamine None None I-TRANS
systems None None O
contributes None None O
to None None O
the None None O
maintenance None None O
of None None O
neuropathic None None O
pain None None O
and None None O
that None None O
spinal None None O
cord None None O
noradrenaline None None I-TRANS
and None None O
dopamine None None I-TRANS
both None None O
play None None O
an None None O
inhibitory None None O
role None None O
in None None O
neuropathic None None O
pain None None O
. None None O

These None None O
negative None None O
feelings None None I-FUNC
then None None O
changed None None O
into None None O
a None None O
positive None None O
desire None None O
for None None O
lifestyle None None O
changes None None O
caused None None O
by None None O
a None None O
fear None None O
of None None O
cardiovascular None None O
disease None None O
which None None O
in None None O
turn None None O
changed None None O
the None None O
attitude None None O
towards None None O
drugs None None O
into None None O
seeing None None O
them None None O
as None None O
a None None O
rescue None None O
remedy None None O
and None None O
something None None O
normal None None O
and None None O
this None None O
then None None O
evoked None None O
health None None O
care None None O
trust None None O
. None None O

It None None O
is None None O
still None None O
debatable None None O
whether None None O
anemia None None O
predicts None None O
stroke None None I-DISEASE
outcome None None O
. None None O

All None None O
2439 None None O
patients None None O
of None None O
the None None O
Acute None None O
Stroke None None I-DISEASE
Registry None None O
and None None O
Analysis None None O
of None None O
Lausanne None None O
( None None O
ASTRAL None None O
) None None O
between None None O
January None None O
2003 None None O
and None None O
June None None O
2011 None None O
were None None O
selected None None O
. None None O

Anemia None None O
was None None O
associated None None O
with None None O
more None None O
severe None None O
stroke None None I-DISEASE
manifestations None None O
, None None O
lower None None O
systolic None None O
and None None O
diastolic None None O
blood None None O
pressure None None O
measurements None None O
, None None O
worse None None O
estimated None None O
glomerular None None O
filtration None None O
rate None None O
and None None O
elevated None None O
C-reactive None None O
protein None None O
concentrations None None O
upon None None O
admission None None O
and None None O
with None None O
increased None None O
modified None None O
Rankin None None O
scores None None O
during None None O
the None None O
follow-up None None O
. None None O

Hemoglobin None None O
levels None None O
were None None O
inversely None None O
associated None None O
with None None O
recurrent None None O
stroke None None I-DISEASE
and None None O
mortality None None O
throughout None None O
the None None O
12-month None None O
follow-up None None O
. None None O

The None None O
results None None O
can None None O
improve None None O
our None None O
understandings None None O
of None None O
the None None O
storage None None I-FUNC
efficiency None None O
by None None O
the None None O
effects None None O
of None None O
pore-scale None None O
displacement None None O
phenomena None None O
. None None O

The None None O
chemical None None O
and None None O
physical None None O
properties None None O
of None None O
PEUs None None O
can None None O
be None None O
controlled None None O
using None None O
different None None O
diols None None O
and None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
making None None O
the None None O
polymers None None O
candidates None None O
for None None O
the None None O
development None None O
of None None O
biological None None O
glues None None O
for None None O
use None None O
in None None O
clinical None None O
applications None None O
. None None O

© None None O
2010 None None O
Blackwell None None O
Publishing None None O
Asia None None O
Pty None None O
Ltd. None None O
To None None O
assess None None O
and None None O
compare None None O
the None None O
efficacy None None O
of None None O
single None None O
buccal None None O
and None None O
palatal None None O
infiltration None None O
of None None O
lidocaine None None O
, None None O
mepivacaine None None O
, None None O
or None None O
articaine None None O
with None None O
1:100 None None O
000 None None O
epinephrine None None I-TRANS
by None None O
maxillary None None O
anesthetic None None O
injection None None O
. None None O

The None None O
patients None None O
were None None O
randomly None None O
allocated None None O
into None None O
one None None O
of None None O
three None None O
groups None None O
, None None O
according None None O
to None None O
the None None O
local None None O
anesthetic None None O
agent None None O
used None None O
: None None O
2 None None O
% None None O
lidocaine None None O
, None None O
2 None None O
% None None O
mepivacaine None None O
, None None O
or None None O
4 None None O
% None None O
articaine None None O
, None None O
all None None O
with None None O
1:100 None None O
000 None None O
epinephrine None None I-TRANS
, None None O
and None None O
were None None O
blinded None None O
to None None O
the None None O
anesthetic None None O
used None None O
. None None O

Matrix None None I-PROTEIN
metalloproteinase-8 None None O
and None None O
-9 None None O
levels None None O
secreted None None O
by None None O
whole None None O
blood None None O
also None None O
increased None None O
following None None O
stimulation None None O
. None None O

This None None O
study None None O
suggests None None O
that None None O
Porphyromonas None None O
gingivalis None None O
can None None O
provoke None None O
an None None O
inflammatory None None O
response None None O
and None None O
promote None None O
the None None O
progression None None O
of None None O
periodontitis None None O
by None None O
inducing None None O
the None None O
secretion None None O
of None None O
high None None O
levels None None O
of None None O
cytokines None None O
and None None O
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
by None None O
a None None O
mixed None None O
leukocyte None None O
population None None O
. None None O

Acquired None None O
deficiency None None O
of None None O
protein None None I-PROTEIN
C None None I-PROTEIN
levels None None O
was None None O
detected None None O
. None None O

Acquired None None O
protein None None I-PROTEIN
C None None I-PROTEIN
deficiency None None O
possibly None None O
precipitated None None O
acute None None O
retinal None None O
vein None None O
occlusion None None O
during None None O
laser None None O
therapy None None O
in None None O
this None None O
infant None None O
. None None O

In None None O
2012 None None O
to None None O
2013 None None O
, None None O
2,750 None None O
low-income None None O
school None None O
children None None O
ages None None O
3 None None O
to None None O
5 None None O
years None None O
were None None O
screened None None O
using None None O
the None None O
Plusoptix None None O
Vision None None I-FUNC
screener None None O
( None None O
Atlanta None None O
, None None O
GA None None O
) None None O
. None None O

These None None O
antiplasmodials None None O
comprised None None O
alkaloids None None O
, None None O
angucyclinones None None O
, None None O
anthraquinones None None O
, None None O
azaanthraquinone None None O
, None None O
azaphilones None None O
, None None O
ben- None None O
zoquinones None None O
, None None O
bioxanthracenes None None O
, None None O
carbazomycins None None O
, None None O
chalcones None None O
, None None O
chromone None None O
, None None O
clerodane None None O
, None None O
coumarins None None O
, None None O
cyclomarin None None O
, None None O
cyclopeptides None None O
, None None O
cytochalasins None None O
, None None O
depsidones None None O
, None None O
depudecin None None O
, None None O
flavaglines None None O
, None None O
flavonoids None None O
, None None O
furans None None O
, None None O
isoflavonoid None None O
limonoids None None O
, None None O
macrolides None None O
, None None O
nucleoside None None O
, None None O
oxepin None None O
, None None O
peptides None None I-TRANS
, None None O
phloroglucinol None None O
, None None O
polylactone None None O
, None None O
polypropionate None None O
, None None O
preussomerins None None O
, None None O
prodigiosin None None O
, None None O
pterocarpans None None O
, None None O
pyrenocines None None O
, None None O
pyridones None None O
, None None O
pyrrolidines None None O
, None None O
quassinoids None None O
, None None O
quinone None None O
, None None O
stilbenes None None O
, None None O
styryl None None O
lactones None None O
, None None O
terpenoids None None O
, None None O
tetramic None None O
acids None None O
, None None O
tetronic None None O
acids None None O
, None None O
tri- None None O
norcadalenes None None O
, None None O
tropolones None None O
, None None O
xanthones None None O
, None None O
and None None O
a None None O
variety None None O
of None None O
miscellaneous None None O
molecules None None O
( None None O
a None None O
total None None O
of None None O
293 None None O
compounds None None O
) None None O
. None None O

Many None None O
of None None O
the None None O
recorded None None O
species None None O
were None None O
medically None None O
im- None None O
portant None None O
as None None O
potential None None O
vectors None None O
of None None O
dengue None None O
fever None None O
, None None O
chikungunya None None O
, None None O
Japanese None None O
encephalitis None None I-DISEASE
, None None O
malaria None None O
and None None O
filariasis None None O
. None None O

Feeling None None I-FUNC
healthy None None O
and None None O
having None None O
financial None None O
problems None None O
were None None O
the None None O
most None None O
common None None O
reasons None None O
for None None O
TB None None O
treatment None None O
non-adherence None None O
. None None O

This None None O
study None None O
identified None None O
, None None O
using None None O
PCR None None O
blaoxA None None O
, None None O
,23 None None O
encoding None None I-FUNC
carbapenamase None None O
OXA-23 None None O
in None None O
42 None None O
carbapenem-resistant None None O
Acinetobacter None None O
baumannii None None O
( None None O
CRAB None None O
) None None O
clinical None None O
iso- None None O
lates None None O
and None None O
blaOXA-40-like None None O
encoding None None I-FUNC
carbapenamase None None O
OXA-40-like None None O
in None None O
one None None O
isolate None None O
( None None O
the None None O
first None None O
such None None O
Thai None None O
sample None None O
) None None O
obtained None None O
from None None O
patients None None O
admitted None None O
to None None O
Hua None None O
Hin None None O
Hospital None None O
, None None O
Thailand None None O
during None None O
November None None O
2011-September None None O
2012 None None O
. None None O

The None None O
prevalaence None None O
of None None O
anemia None None O
, None None O
iron None None O
deficiency None None O
, None None O
thalassemia None None O
and None None O
glucose-6-phosphate None None O
dehydrogenase None None I-PROTEIN
( None None O
G-6-PD None None O
) None None O
deficiency None None O
were None None O
examined None None O
among None None O
265 None None O
hill-tribe None None O
school None None O
children None None O
, None None O
8-14 None None O
years None None O
of None None O
age None None O
, None None O
from None None O
Omkoi None None O
District None None O
, None None O
Chiang None None O
Mai None None O
Province None None O
, None None O
Thailand None None O
. None None O

Analysis None None O
of None None O
population None None O
genotype None None O
frequency None None O
and None None O
alleles None None O
of None None O
genes None None O
CYP1A1 None None O
* None None O
2A None None O
, None None O
CYP1A1 None None O
* None None O
2C None None O
, None None O
CYP2E1 None None I-PROTEIN
* None None O
6 None None O
, None None O
mEPOX None None O
Tyr113His None None O
, None None O
and None None O
mEPOXHis139Arg None None O
was None None O
conducted None None O
in None None O
the None None O
group None None O
of None None O
Mayak None None O
workers None None O
( None None O
289 None None O
individuals None None O
) None None O
. None None O

Two None None O
variants None None O
of None None O
pair None None O
allelic None None O
combinations None None O
of None None O
genes None None O
( None None O
genotypes None None O
ww None None O
CYP1A1 None None O
* None None O
2A/genotype None None O
wp None None O
mEPOX None None O
Tyr113His None None O
, None None O
and None None O
genotype None None O
ww None None O
CYP2E1 None None I-PROTEIN
* None None O
6/genotype None None O
wp None None O
mEPOX None None O
Tyr113His None None O
) None None O
were None None O
revealed None None O
, None None O
which None None O
carriers None None O
had None None O
a None None O
statistically None None O
significant None None O
increase None None O
in None None O
the None None O
odds None None O
ratio None None O
of None None O
lung None None O
can- None None O
cer None None O
. None None O

It None None O
was None None O
shown None None O
that None None O
the None None O
use None None O
of None None O
collagen None None I-PROTEIN
as None None O
a None None O
carrier None None O
for None None O
immobilization None None O
of None None O
glucoamylase None None O
reduces None None O
the None None O
constant None None O
photoinactivation None None O
of None None O
the None None O
enzyme None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
work None None O
was None None O
the None None O
analysis None None O
of None None O
the None None O
changes None None O
in None None O
a None None O
number None None O
of None None O
labile None None O
synaptopodin-positi- None None O
ve None None O
dendritic None None O
spines None None O
in None None O
parietal None None I-REGION
cortex None None I-REGION
and None None O
the None None O
CA1 None None I-REGION
field None None I-REGION
of None None O
the None None O
hippocampus None None I-REGION
, None None O
which None None O
characterize None None O
plasticity None None O
of None None O
intracellular None None O
interaction None None O
, None None O
and None None O
of None None O
the None None O
memorization None None O
after None None O
short-term None None O
repeated None None O
immobili- None None O
zation None None O
stress None None O
( None None O
daily None None O
for None None O
5 None None O
minutes None None O
, None None O
10 None None O
days None None O
) None None O
, None None O
both None None O
in None None O
control None None O
rats None None O
and None None O
in None None O
rats None None O
subjected None None O
to None None O
prenatal None None O
hypoxia None None O
( None None O
E14 None None O
, None None O
7 None None O
% None None O
of None None O
O2 None None O
, None None O
3 None None O
hours None None O
) None None O
. None None O

At None None O
the None None O
rats None None O
subjected None None O
to None None O
a None None O
prenatal None None O
hypoxia None None O
, None None O
regardless None None O
of None None O
that None None O
, None None O
they None None O
were None None O
ex- None None O
posed None None O
to None None O
an None None O
immobilized None None O
stress None None O
at None None O
an None None O
adult None None O
stage None None O
or None None O
not None None O
, None None O
was None None O
noted None None O
both None None O
violation None None O
of None None O
short-term None None O
and None None O
long-term None None I-FUNC
memory None None I-FUNC
, None None O
and None None O
decrease None None O
in None None O
number None None O
labile None None O
spines None None O
in None None O
the None None O
CA1 None None I-REGION
field None None I-REGION
of None None O
the None None O
hippocampus None None I-REGION
( None None O
for None None O
22.9 None None O
± None None O
10.5 None None O
% None None O
) None None O
and None None O
parietal None None I-REGION
cortex None None I-REGION
( None None O
for None None O
28.1 None None O
± None None O
9.3 None None O
% None None O
) None None O
. None None O

In None None O
experiments None None O
at None None O
78 None None O
adult None None O
white None None O
outbred None None O
male None None O
rats None None O
were None None O
demonstrated None None O
that None None O
experimental None None O
hypothyroidism None None O
( None None O
injection None None O
of None None O
25 None None O
mg/kg None None O
merkazolil None None O
within None None O
20 None None O
days None None O
) None None O
stimulates None None O
, None None O
while None None O
small None None O
doses None None O
of None None O
L-thyroxine None None O
( None None O
1.5-3.0 None None O
μg/kg None None O
within None None O
28 None None O
days None None O
) None None O
limit None None O
the None None O
intensification None None O
of None None O
lipid None None O
peroxidation None None O
in None None O
the None None O
myocardium None None O
under None None O
short None None O
exposure None None O
to None None O
stressors None None O
of None None O
a None None O
different None None O
nature None None O
: None None O
physical None None O
( None None O
t None None O
4-5 None None O
°C None None O
within None None O
30 None None O
minutes None None O
) None None O
, None None O
chemical None None O
( None None O
injection None None O
of None None O
25 None None O
% None None O
ethanol None None O
at None None O
a None None O
dose None None O
of None None O
3.5 None None O
g/kg None None O
body None None O
weight None None O
) None None O
, None None O
and None None O
emotional None None O
( None None O
free None None O
swimming None None O
of None None O
rats None None O
in None None O
the None None O
cage None None O
within None None O
30 None None O
minutes None None O
) None None O
by None None O
influence None None O
on None None O
the None None O
activity None None O
of None None O
enzymatic None None O
( None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
catalase None None I-PROTEIN
) None None O
and None None O
non-enzymatic None None O
( None None O
reduced None None O
glutathione None None O
) None None O
components None None O
of None None O
the None None O
antioxidant None None O
system None None O
. None None O

Intraperitoneal None None O
melatonin None None I-TRANS
injections None None O
in None None O
the None None O
doses None None O
0.2 None None O
or None None O
1 None None O
mg/kg None None O
during None None O
7 None None O
days None None O
cause None None O
the None None O
decrease None None O
of None None O
the None None O
content None None O
of None None O
lipid None None O
peroxidation None None O
metabolites None None O
in None None O
both None None O
blood None None O
plasma None None O
and None None O
liver None None O
tissue None None O
in None None O
animals None None O
after None None O
prolonged None None O
stress None None O
, None None O
as None None O
well None None O
as None None O
leads None None O
to None None O
the None None O
increase None None O
superoxiddismutase None None O
activity None None O
in None None O
both None None O
blood None None O
plasma None None O
and None None O
liver None None O
tissue None None O
in None None O
comparison None None O
with None None O
the None None O
control None None O
group None None O
. None None O

The None None O
results None None O
of None None O
investigation None None O
confir- None None O
med None None O
the None None O
literature None None O
data None None O
about None None O
the None None O
antioxidant None None O
effects None None O
of None None O
melatonin None None I-TRANS
and None None O
opened None None O
the None None O
perspectives None None O
of None None O
its None None O
using None None O
for None None O
the None None O
prevention None None O
of None None O
stress-induced None None O
organ None None O
injury None None O
. None None O

Introduction None None O
of None None O
merkazolil None None O
( None None O
25 None None O
mg/kg None None O
, None None O
20 None None O
da- None None O
ys None None O
) None None O
causes None None O
a None None O
fall None None O
of None None O
level None None O
of None None O
iodine-containing None None O
thyroid None None O
hormones None None I-PROTEIN
( None None O
ITH None None O
) None None O
in None None O
the None None O
blood None None O
and None None O
causes None None O
a None None O
significant None None O
reduction None None O
of None None O
all None None O
types None None O
of None None O
MA None None O
and None None O
change None None O
of None None O
the None None O
structure None None O
of None None O
behavior None None O
in None None O
the None None O
alarm-stage None None O
, None None O
practically None None O
eliminating None None O
its None None O
normalization None None O
in None None O
stage None None O
of None None O
resistance None None O
and None None O
provokes None None O
its None None O
greatest None None O
violation None None O
in None None O
a None None O
stage None None O
of None None O
exhaustion None None O
of None None O
stress None None O
reaction None None O
. None None O

Such None None O
changes None None O
are None None O
due None None O
, None None O
apparently None None O
, None None O
with None None O
the None None O
initial None None O
depression None None I-DISEASE
ofmelatonin None None O
secretion None None O
under None None O
the None None O
influence None None O
of None None O
the None None O
electromagnetic None None O
shielding None None O
, None None O
which None None O
leads None None O
to None None O
the None None O
development None None O
ofhyperalgesia None None O
. None None O

Persistent None None O
inflammation None None O
through None None O
its None None O
complex None None O
mechanisms None None O
results None None O
in None None O
many None None O
systemic None None O
and None None O
extraarticular None None O
RA None None O
manifestations None None O
of None None O
almost None None O
all None None O
organ None None O
systems None None O
, None None O
resulting None None O
in None None O
severe None None O
complications None None O
and None None O
comorbidities None None O
such None None O
as None None O
rheumatoid None None O
lung None None O
, None None O
carditis None None O
, None None O
vasculitis None None O
, None None O
cahexia None None O
, None None O
anemia None None O
, None None O
accelerated None None O
atherosclerosis None None I-DISEASE
, None None O
myocardial None None O
and None None O
cerebrovascular None None O
vascular None None O
disease None None O
, None None O
lymphoma None None O
, None None O
osteoporosis None None O
, None None O
depression None None I-DISEASE
etc None None O
. None None O

Disorder None None O
of None None O
bone None None O
turnover None None O
plays None None O
key None None O
role None None O
in None None O
the None None O
pathophysiology None None O
of None None O
osteoporosis None None O
and None None O
presents None None O
a None None O
complex None None O
process None None O
which None None O
involves None None O
bone None None O
cells None None O
, None None O
cytokines None None O
and None None O
their None None O
receptors None None I-PROTEIN
. None None O

Semi-structured None None O
interviews None None O
were None None O
conducted None None O
with None None O
study None None O
participants None None O
by None None O
a None None O
single None None O
interviewer None None O
, None None O
focusing None None O
on None None O
three None None O
key None None O
topics None None O
: None None O
their None None O
individual None None O
opinions None None O
regarding None None O
important None None O
learning None None I-FUNC
outcomes None None O
( None None O
LOs None None O
) None None O
for None None O
a None None O
modern None None O
model None None O
GUM None None O
curriculum None None O
, None None O
their None None O
preferred None None O
teaching None None O
methods None None O
and None None O
the None None O
total None None O
recommended None None O
teaching None None O
time None None O
required None None O
. None None O

Respondents None None O
were None None O
keen None None O
for None None O
a None None O
mixture None None O
of None None O
teaching None None O
methods None None O
, None None O
but None None O
generally None None O
agreed None None O
that None None O
clinic None None O
attendance None None O
and None None O
experiential None None O
learning None None I-FUNC
were None None O
beneficial None None O
. None None O

In None None O
this None None O
study None None O
, None None O
heterologous None None O
expression None None O
of None None O
the None None O
biosynthetic None None O
genes None None O
encoding None None I-FUNC
type None None O
I None None O
polyketide None None O
synthases None None O
( None None O
PKS None None O
) None None O
involved None None O
in None None O
biosynthesis None None O
of None None O
fostriecin None None O
, None None O
a None None O
unique None None O
phosphate None None O
monoester None None O
polyketide None None O
antibiotic None None O
, None None O
was None None O
attempted None None O
. None None O

[ None None O
6 None None O
] None None O
2011 None None O
NA None None I-TRANS
NA None None I-TRANS
36 None None O
NA None None I-TRANS
Robot None None O
MRND None None O
27.7 None None O
280.91 None None O
1 None None O
3 None None O
NA None None I-TRANS
Kang None None O
et None None O
al None None O
. None None O

technique None None O
, None None O
LNY None None O
lymph None None O
node None None O
yield None None O
, None None O
PHS None None O
postoperative None None O
hospital None None O
stay None None O
, None None O
VAT None None O
video-assisted None None O
thyroidectomy None None O
, None None O
SLND None None O
selective None None O
lateral None None O
neck None None O
dissection None None O
, None None O
MRND None None O
modified None None O
radical None None O
neck None None O
dissection None None O
, None None O
AP None None O
axillary None None O
approach None None O
, None None O
NA None None I-TRANS
not None None O
available None None O
According None None O
to None None O
the None None O
present None None O
SET None None O
data None None O
, None None O
level None None O
II None None O
dissection None None O
by None None O
SET None None O
was None None O
a None None O
feasible None None O
and None None O
safe None None O
procedure None None O
. None None O

Measures None None O
of None None O
workload None None O
( None None O
the None None O
surgery None None O
task None None O
load None None O
index None None O
) None None O
, None None O
mental None None O
effort None None O
( None None O
subjective None None O
: None None O
rating None None O
scale None None O
for None None O
mental None None O
effort None None O
and None None O
objective None None O
: None None O
standard None None O
deviation None None O
of None None O
beat-to-beat None None O
intervals None None O
) None None O
, None None O
gaze None None O
control None None O
( None None O
using None None O
a None None O
mobile None None O
eye None None O
movement None None I-FUNC
recorder None None O
) None None O
, None None O
and None None O
task None None O
performance None None O
( None None O
completion None None O
time None None O
and None None O
number None None O
of None None O
errors None None O
) None None O
were None None O
recorded None None O
. None None O

Testing None None O
stimulates None None O
learning None None I-FUNC
, None None O
improves None None O
long-term None None O
retention None None I-FUNC
, None None O
and None None O
promotes None None O
technical None None O
performance None None O
. None None O

Using None None O
the None None O
extracellular None None O
recording None None O
technique None None O
, None None O
we None None O
investigated None None O
the None None O
changes None None O
of None None O
spontaneous None None O
and None None O
stimulation-evoked None None O
activities None None O
within None None O
and None None O
between None None O
the None None O
ventral None None I-REGION
posteromedial None None I-REGION
nucleus None None I-REGION
( None None O
VPM None None O
) None None O
and None None O
primary None None I-REGION
somatosensory None None I-REGION
cortex None None I-REGION
barrel None None I-REGION
field None None O
( None None O
S1BF None None O
) None None O
of None None O
the None None O
rat None None O
in None None O
vivo None None O
during None None O
propofol None None O
anesthesia None None O
. None None O

The None None O
impact None None O
of None None O
pulmonary None None O
embolism None None I-DISEASE
on None None O
right None None O
ventricular None None O
( None None O
RV None None O
) None None O
performance None None O
can None None O
be None None O
evaluated None None O
by None None O
echocardiography None None O
, None None O
however None None O
, None None O
the None None O
relationship None None O
between None None O
pulmonary None None O
vascular None None O
involvement None None O
and None None O
RV None None O
burden None None O
is None None O
controversial None None O
. None None O

However None None O
, None None O
due None None O
to None None O
ethical None None O
and None None O
methodological None None O
limitations None None O
, None None O
few None None O
studies None None O
have None None O
examined None None O
these None None O
learning None None I-FUNC
processes None None O
across None None O
development None None O
, None None O
particularly None None O
among None None O
anxious None None O
individuals None None O
. None None O

Immunohistochemistry None None O
and None None O
high None None O
resolution None None O
melting None None O
were None None O
used None None O
to None None O
determine None None O
p53 None None I-PROTEIN
protein None None O
expression None None O
and None None O
TP53 None None O
mutation None None O
status None None O
respectively None None O
in None None O
normal None None O
gastric None None O
mucosa None None O
, None None O
IM None None O
without None None O
concurrent None None O
GC None None O
( None None O
IM-GC None None O
) None None O
, None None O
IM None None O
with None None O
concurrent None None O
GC None None O
( None None O
IM+GC None None O
) None None O
and None None O
GC None None O
. None None O

We None None O
investigated None None O
the None None O
effect None None O
of None None O
a None None O
combination None None O
of None None O
vaginal None None O
ultra-low-dose None None O
estriol None None O
with None None O
lactobacilli None None O
on None None O
the None None O
sexual None None O
functioning None None O
domain None None O
of None None O
quality None None O
of None None O
life None None O
during None None O
the None None O
treatment None None O
of None None O
breast None None O
cancer None None O
survivors None None O
on None None O
an None None O
aromatase None None I-PROTEIN
inhibitor None None O
with None None O
vaginal None None O
atrophy None None O
. None None O

Atrophy None None O
symptoms None None O
were None None O
assessed None None O
by None None O
scoring None None O
with None None O
an None None O
11-point None None O
estimation None None O
scale None None O
( None None O
0 None None O
= None None O
not None None O
at None None O
all None None O
, None None O
10 None None O
= None None O
worst None None O
imaginable None None O
feeling None None I-FUNC
) None None O
. None None O

Local None None O
vaginal None None O
therapy None None O
with None None O
Gynoflor None None O
( None None O
® None None O
) None None O
in None None O
breast None None O
cancer None None O
survivors None None O
on None None O
aromatase None None I-PROTEIN
inhibitors None None O
reporting None None O
atrophic None None O
vaginitis None None O
could None None O
be None None O
considered None None O
as None None O
a None None O
useful None None O
treatment None None O
for None None O
the None None O
quality None None O
of None None O
sexual None None O
life None None O
. None None O

Chondrocytes None None O
maintained None None O
typical None None O
round None None O
morphology None None O
throughout None None O
the None None O
course None None O
of None None O
this None None O
investigation None None O
, None None O
indicating None None O
preservation None None O
of None None O
their None None O
phenotype None None O
with None None O
sufficient None None O
production None None O
of None None O
extracellular None None O
matrix None None O
and None None O
expression None None O
of None None O
typical None None O
chondrogenic None None O
markers None None O
Collagen None None I-PROTEIN
type None None O
2 None None O
and None None O
aggrecan None None O
. None None O

Glucose None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
GOx None None O
) None None O
was None None O
used None None O
as None None O
a None None O
model None None O
enzyme None None O
and None None O
was None None O
immobilized None None O
onto None None O
the None None O
gold None None O
surface None None O
forming None None O
a None None O
self None None O
assembled None None O
monolayer None None O
via None None O
FcSH None None O
and None None O
cysteamine None None O
. None None O

The None None O
cytocompatibility None None O
, None None O
in None None O
vivo None None O
biodegradation None None O
and None None O
wound None None O
healing None None O
of None None O
keratin None None I-PROTEIN
biomaterials None None O
were None None O
investigated None None O
. None None O

A None None O
faster None None O
keratin None None I-PROTEIN
biodegradation None None O
was None None O
observed None None O
in None None O
repairing None None O
full-thickness None None O
skin None None O
defects None None O
. None None O

These None None O
preliminary None None O
results None None O
suggest None None O
that None None O
human None None O
hair None None O
keratin None None I-PROTEIN
scaffolds None None O
are None None O
promising None None O
dermal None None O
substitutes None None O
for None None O
skin None None O
regeneration None None O
. None None O

The None None O
cell None None O
culture None None O
experiments None None O
revealed None None O
that None None O
the None None O
difference None None O
of None None O
morphology None None O
and None None O
components None None O
of None None O
calcium None None O
phosphate None None O
apatite None None O
did None None O
not None None O
show None None O
much None None O
influence None None O
on None None O
the None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
, None None O
proliferation None None O
and None None O
activity None None O
. None None O

We None None O
observed None None O
that None None O
Fe3O4-TiO2 None None O
composite None None O
nanofibers None None O
could None None O
support None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
growth None None O
. None None O

The None None O
results None None O
indicated None None O
that None None O
HLC/nHA None None O
porous None None O
scaffolds None None O
were None None O
capable None None O
of None None O
encouraging None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
, None None O
homogeneous None None O
distribution None None O
and None None O
abundant None None O
GAG None None O
synthesis None None O
, None None O
and None None O
maintaining None None O
natural None None O
chondrocyte None None O
morphology None None O
compared None None O
to None None O
RAB None None O
scaffolds None None O
. None None O

Thus None None O
, None None O
an None None O
innovative None None O
and None None O
relatively None None O
simple None None O
processing None None O
method None None O
was None None O
developed None None O
to None None O
extract None None O
and None None O
purify None None O
type None None O
I None None O
collagen None None I-PROTEIN
from None None O
bovine None None O
tissue None None O
with None None O
potential None None O
applications None None O
as None None O
a None None O
biomaterial None None O
for None None O
regenerative None None O
tissue None None O
engineering None None O
. None None O

The None None O
NH2 None None I-TRANS
group None None O
served None None O
as None None O
anchor None None O
binding None None O
site None None O
for None None O
immobilization None None O
of None None O
functional None None O
groups None None O
on None None O
the None None O
hydrogel None None O
film None None O
via None None O
direct None None O
epoxy None None O
ring None None O
opening None None O
reaction None None O
. None None O

The None None O
effect None None O
of None None O
modified None None O
hydrogel None None O
films None None O
, None None O
including None None O
NH2 None None I-TRANS
, None None O
( None None O
using None None O
different None None O
aliphatic None None O
CH2 None None O
chain None None O
lengths None None O
) None None O
CH3 None None O
, None None O
SO3H None None O
, None None O
aromatic None None O
groups None None O
with None None O
substituted None None O
OH None None O
and None None O
COOH None None O
groups None None O
, None None O
and None None O
amino None None I-TRANS
acids None None I-TRANS
were None None O
also None None O
investigated None None O
on None None O
the None None O
adhesion None None O
, None None O
morphology None None O
and None None O
survival None None O
of None None O
rat None None O
mesenchymal None None O
stem None None O
cells None None O
( None None O
MSCs None None O
) None None O
. None None O

These None None O
anisotropic None None O
properties None None O
can None None O
be None None O
attributed None None O
to None None O
the None None O
differences None None O
in None None O
collagen None None I-PROTEIN
fibers None None O
alignment None None O
and None None O
different None None O
microstructural None None O
architecture None None O
in None None O
three None None O
different None None O
anatomical None None O
bone None None O
directions None None O
. None None O

The None None O
proposed None None O
options None None O
for None None O
problem None None I-FUNC
solving None None I-FUNC
in None None O
PGMT None None O
at None None O
anthroposophic None None O
hospitals None None O
emerge None None O
from None None O
concrete None None O
problem None None O
perceptions None None I-FUNC
of None None O
the None None O
trainers None None O
and None None O
trainees None None O
. None None O

Ultrasonic None None O
treatments None None O
may None None O
also None None O
be None None O
used None None O
to None None O
extend None None O
the None None O
shelf None None O
life None None O
of None None O
egg None None O
during None None O
storage None None I-FUNC
period None None O
in None None O
ambient None None O
temperature None None O
. None None O

The None None O
study None None O
showed None None O
that None None O
ultrasound None None O
treatment None None O
could None None O
be None None O
an None None O
alternative None None O
and None None O
effective None None O
technique None None O
for None None O
maintaining None None O
the None None O
internal None None O
qualities None None O
of None None O
fresh None None O
eggs None None O
during None None O
long-term None None O
storage None None I-FUNC
while None None O
Fourier None None O
transform None None O
near None None O
infrared None None O
spectroscopy None None O
could None None O
be None None O
used None None O
as None None O
a None None O
new None None O
tool None None O
for None None O
the None None O
assessment None None O
of None None O
freshness None None O
. None None O

Hierarchical None None O
clustering None None O
analysis None None O
indicated None None O
that None None O
the None None O
DEPs None None O
involved None None O
in None None O
starch None None O
biosynthesis None None O
, None None O
storage None None I-FUNC
proteins None None O
, None None O
and None None O
defense/stress-related None None O
proteins None None O
significantly None None O
accumulated None None O
at None None O
the None None O
late None None O
grain None None O
development None None O
stages None None O
, None None O
while None None O
those None None O
related None None O
to None None O
protein None None O
synthesis/assembly/degradation None None O
and None None O
photosynthesis None None O
showed None None O
an None None O
opposite None None O
expression None None O
model None None O
during None None O
grain None None O
development None None O
. None None O

In None None O
this None None O
case-control None None O
study None None O
, None None O
116 None None O
patients None None O
with None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
AIS None None O
) None None O
or None None O
transitory None None O
ischemic None None O
attack None None O
( None None O
TIA None None O
) None None O
, None None O
117 None None O
patients None None O
with None None O
CCD None None O
, None None O
and None None O
104 None None O
healthy None None O
volunteers None None O
( None None O
HVs None None O
) None None O
were None None O
enrolled None None O
between None None O
2010 None None O
and None None O
2013 None None O
at None None O
our None None O
University None None O
hospital None None O
. None None O

In None None O
contrast None None O
, None None O
no None None O
statistical None None O
significant None None O
influence None None O
was None None O
found None None O
for None None O
treatment None None O
modality None None O
( None None O
thrombolysis None None O
or None None O
not None None O
) None None O
, None None O
pre-treatment None None O
with None None O
platelet None None O
inhibitors None None O
, None None O
and None None O
severity None None O
of None None O
stroke None None I-DISEASE
. None None O

FXI None None O
and None None O
FXII None None O
levels None None O
might None None O
be None None O
no None None O
valid None None O
biomarker None None O
for None None O
predicting None None O
stroke None None I-DISEASE
risk None None O
. None None O

Focus None None O
is None None O
given None None O
on None None O
data None None O
concerning None None O
the None None O
therapeutic None None O
somatostatin None None I-TRANS
analogue None None O
radiopeptides None None O
( None None O
111 None None O
) None None O
In- None None O
[ None None O
DTPA None None O
( None None O
0 None None O
) None None O
, None None O
D-Phe None None O
( None None O
1 None None O
) None None O
] None None O
-octreotide None None O
( None None O
( None None O
111 None None O
) None None O
In-DTPA-octreotide None None O
) None None O
, None None O
( None None O
90 None None O
) None None O
Y- None None O
[ None None O
DOTA None None O
( None None O
0 None None O
) None None O
, None None O
Tyr None None O
( None None O
3 None None O
) None None O
] None None O
-octreotide None None O
( None None O
( None None O
90 None None O
) None None O
Y-DOTATOC None None O
) None None O
and None None O
( None None O
177 None None O
) None None O
Lu- None None O
[ None None O
DOTA None None O
( None None O
0 None None O
) None None O
, None None O
Tyr None None O
( None None O
3 None None O
) None None O
, None None O
Thr None None O
( None None O
8 None None O
) None None O
] None None O
-octreotide None None O
( None None O
( None None O
177 None None O
) None None O
Lu-DOTATATE None None O
) None None O
. None None O

The None None O
social None None O
meaning None None O
of None None O
HIV None None O
infection None None O
and None None O
perceptions None None I-FUNC
of None None O
an None None O
HIV None None O
cure None None O
reflected None None O
patients None None O
' None None O
relationships None None O
with None None O
society None None O
, None None O
health None None O
systems None None O
, None None O
and None None O
physicians None None O
. None None O

Observational None None O
items None None O
found None None O
to None None O
be None None O
different None None O
between None None O
children None None O
with None None O
SB None None O
and None None O
their None None O
peers None None O
were None None O
best None None O
predicted None None O
by None None O
social None None O
language None None I-FUNC
and None None O
attention None None I-FUNC
abilities None None O
. None None O

Although None None O
the None None O
electrostatic None None O
interaction None None O
provided None None O
by None None O
arginines None None I-TRANS
is None None O
crucial None None O
in None None O
the None None O
recognition None None O
between None None O
PRM None None O
and None None O
SH3 None None O
domain None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
attaching None None O
multiple None None O
arginines None None I-TRANS
to None None O
the None None O
SWCNT None None O
has None None O
a None None O
detrimental None None O
effect None None O
on None None O
the None None O
binding None None O
affinity None None O
. None None O

We None None O
present None None O
a None None O
case None None O
of None None O
a None None O
3-month-old None None O
male None None O
with None None O
a None None O
history None None O
of None None O
a None None O
ventriculoperitoneal None None O
shunt None None O
for None None O
posthemorrhagic None None O
hydrocephalus None None I-DISEASE
after None None O
premature None None O
birth None None O
who None None O
presented None None O
to None None O
the None None O
emergency None None O
department None None O
with None None O
irritability None None O
and None None O
decreased None None O
oral None None O
intake None None O
. None None O

Microvasculature None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
stroke None None I-DISEASE
pathophysiology None None O
both None None O
during None None O
initial None None O
damage None None O
and None None O
extended None None O
neural None None O
repair None None O
. None None O

However None None O
, None None O
dynamic None None O
changes None None O
of None None O
microvessels None None O
after None None O
stroke None None I-DISEASE
still None None O
remain None None O
unclear None None O
, None None O
and None None O
MRI None None O
follow-up None None O
could None None O
be None None O
interesting None None O
as None None O
an None None O
in None None O
vivo None None O
biomarker None None O
of None None O
these None None O
. None None O

3 None None O
successive None None O
stages None None O
were None None O
observed None None O
: None None O
1 None None O
) None None O
'Acute None None O
stage None None O
' None None O
from None None O
day None None O
1 None None O
to None None O
day None None O
3 None None O
post-stroke None None O
( None None O
D1-D3 None None O
) None None O
characterized None None O
by None None O
high None None O
levels None None O
of None None O
angiopoietin-2 None None O
( None None O
Ang2 None None O
) None None O
, None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor-2 None None O
( None None O
VEGFR-2 None None O
) None None O
and None None O
endothelial None None O
NO None None O
synthase None None O
( None None O
eNOS None None O
) None None O
that None None O
may None None O
be None None O
associated None None O
with None None O
deleterious None None O
vascular None None O
permeability None None O
and None None O
vasodilation None None O
; None None O
2 None None O
) None None O
'Transition None None O
stage None None O
' None None O
( None None O
D3-D7 None None O
) None None O
that None None O
involves None None O
transforming None None O
the None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
β1 None None O
( None None O
TGFβ1 None None O
) None None O
, None None O
Ang1 None None O
, None None O
and None None O
tyrosine None None I-TRANS
kinase None None O
with None None O
immunoglobulin-like None None O
and None None O
endothelial None None O
growth None None O
factor-like None None O
domains None None O
1 None None O
( None None O
Tie1 None None O
) None None O
, None None O
stromal-derived None None O
factor-1 None None O
( None None O
SDF-1 None None O
) None None O
, None None O
chemokine None None O
receptor None None I-PROTEIN
type None None O
4 None None O
( None None O
CXCR-4 None None O
) None None O
; None None O
and None None O
3 None None O
) None None O
'Subacute None None O
stage None None O
' None None O
( None None O
D7-D25 None None O
) None None O
with None None O
high None None O
levels None None O
of None None O
Ang1 None None O
, None None O
Ang2 None None O
, None None O
VEGF None None O
, None None O
VEGFR-1 None None O
and None None O
TGFβ1 None None O
leading None None O
to None None O
favorable None None O
stabilization None None O
and None None O
maturation None None O
of None None O
microvessels None None O
. None None O

Microvasculature None None O
MRI None None O
can None None O
provide None None O
imaging None None O
of None None O
different None None O
states None None O
of None None O
functional None None O
( None None O
perfused None None O
) None None O
microvessels None None O
after None None O
stroke None None I-DISEASE
. None None O

In None None O
the None None O
intervention None None O
group None None O
three None None O
different None None O
actions None None O
on None None O
frailty None None O
dimensions None None O
: None None O
rehabilitative None None O
therapy None None O
plus None None O
intake None None O
of None None O
hyperproteic None None O
nutritional None None O
shakes None None O
, None None O
memory None None I-FUNC
workshop None None O
, None None O
and None None O
medication None None O
review None None O
are None None O
applied None None O
to None None O
sets None None O
of None None O
16 None None O
patients None None O
. None None O

Penicillinase-producing None None O
N. None None O
gonorrhoeae None None O
( None None O
PPNG None None O
) None None O
and None None O
tetracycline-resistant None None O
N. None None O
gonorrhoeae None None O
( None None O
TRNG None None O
) None None O
were None None O
examined None None O
and None None O
typed None None O
for None None O
β-lactamase None None O
and None None O
tetM None None O
encoding None None I-FUNC
plasmids None None O
respectively None None O
. None None O

A None None O
56-year-old None None O
Moroccan None None O
man None None O
known None None O
to None None O
have None None O
untreated None None O
paranoid None None I-DISEASE
schizophrenia None None I-DISEASE
and None None O
a None None O
history None None O
of None None O
several None None O
previous None None O
suicide None None O
attempts None None O
was None None O
presented None None O
to None None O
the None None O
emergency None None O
unit None None O
of None None O
our None None O
hospital None None O
after None None O
self-stabbing None None O
with None None O
a None None O
15 None None O
cm None None O
sewing None None O
needle None None O
. None None O

Tissue None None O
viability None None O
was None None O
evaluated None None O
by None None O
LDH None None O
( None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
) None None O
in None None O
culture None None O
supernatants None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
the None None O
expression None None O
status None None O
of None None O
hormone None None O
receptors None None I-PROTEIN
and None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
( None None O
HER2 None None O
) None None O
in None None O
breast None None O
cancer None None O
may None None O
change None None O
during None None O
disease None None O
progression None None O
. None None O

The None None O
luciferase None None I-PROTEIN
reporter None None O
assay None None O
was None None O
used None None O
to None None O
assess None None O
ZEB2 None None O
as None None O
a None None O
target None None O
of None None O
miR-205 None None O
. None None O

To None None O
identify None None O
effective None None O
dissemination None None O
strategies None None O
regarding None None O
a None None O
family None None O
peer-education None None O
program None None O
, None None O
the None None O
Omotenashi-Family None None O
Experiences None None O
Learning None None I-FUNC
Program None None O
, None None O
on None None O
mental None None O
disorders None None O
, None None O
we None None O
evaluated None None O
factors None None O
related None None O
to None None O
the None None O
program None None O
adoption None None O
by None None O
family None None O
groups None None O
. None None O

Pepsin None None I-PROTEIN
( None None O
Pep None None O
) None None O
accelerated None None O
the None None O
electron None None O
transferring None None O
rate None None O
of None None O
excited None None O
3-aminophathlate None None O
and None None O
enhanced None None O
luminol-dissolved None None O
oxygen None None O
chemiluminescence None None O
( None None O
CL None None O
) None None O
intensity None None O
, None None O
and None None O
the None None O
flow None None O
injection None None O
( None None O
FI None None O
) None None O
luminol-Pep None None O
CL None None O
system None None O
was None None O
first None None O
developed None None O
. None None O

Fluorescence None None O
spectroscopy None None O
in None None O
combination None None O
with None None O
circular None None O
dichroism None None O
( None None O
CD None None O
) None None O
and None None O
ultraviolet-visible None None O
( None None O
UV-vis None None O
) None None O
absorption None None O
spectroscopy None None O
were None None O
employed None None O
to None None O
investigate None None O
the None None O
binding None None O
of None None O
a None None O
new None None O
platinum None None O
( None None O
II None None O
) None None O
complex None None O
containing None None O
an None None O
antiepileptic None None O
drug None None O
`` None None O
Levetiracetam None None O
'' None None O
to None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
under None None O
the None None O
physiological None None O
conditions None None O
. None None O

Aminoacyl-tRNA None None O
synthetases None None O
( None None O
aaRSs None None O
) None None O
constitute None None O
a None None O
family None None O
of None None O
ubiquitously None None O
expressed None None O
essential None None O
enzymes None None I-PROTEIN
that None None O
ligate None None O
amino None None I-TRANS
acids None None I-TRANS
to None None O
their None None O
cognate None None O
tRNAs None None O
for None None O
protein None None O
synthesis None None O
. None None O

Depression None None I-DISEASE
is None None O
a None None O
distressing None None O
emotion None None I-FUNC
that None None O
occurs None None O
during None None O
various None None O
times None None O
of None None O
the None None O
cancer None None O
trajectory None None O
. None None O

The None None O
Oncology None None O
Nursing None None O
Society None None O
's None None O
Putting None None O
Evidence None None O
Into None None O
Practice None None O
depression None None I-DISEASE
project None None O
team None None O
reviewed None None O
current None None O
literature None None O
to None None O
identify None None O
evidence-based None None O
interventions None None O
to None None O
reduce None None O
depression None None I-DISEASE
in None None O
people None None O
with None None O
cancer None None O
. None None O

Interventions None None O
that None None O
are None None O
recommended None None O
for None None O
practice None None O
or None None O
likely None None O
to None None O
be None None O
effective None None O
in None None O
improving None None O
fatigue None None O
outcomes None None O
include None None O
exercise None None O
; None None O
screening None None O
for None None O
treatable None None O
risk None None O
factors None None O
; None None O
management None None O
of None None O
concurrent None None O
symptoms None None O
; None None O
yoga None None O
; None None O
structured None None O
rehabilitation None None O
; None None O
Wisconsin None None O
ginseng None None O
; None None O
cognitive-behavioral None None O
therapies None None O
for None None O
insomnia None None O
, None None O
pain None None O
, None None O
and None None O
depression None None I-DISEASE
; None None O
mindfulness-based None None O
stress None None O
reduction None None O
; None None O
and None None O
psychoeducational None None O
interventions None None O
such None None O
as None None O
anticipatory None None O
guidance None None O
, None None O
psychosocial None None O
support None None O
, None None O
and None None O
energy None None O
conservation None None O
and None None O
activity None None O
management None None O
. None None O

AAV2-Hsp70 None None O
expression None None O
in None None O
the None None O
retina None None O
was None None O
primarily None None O
observed None None O
in None None O
the None None O
ganglion None None I-NEURON
cell None None I-NEURON
layer None None O
. None None O

The None None O
amylin None None I-TRANS
peptide None None O
in None None O
a None None O
dioleoylphosphatidylcholine None None O
( None None O
DOPC None None O
) None None O
bilayer None None O
is None None O
studied None None O
using None None O
united None None O
atom None None O
molecular None None O
dynamics None None O
( None None O
MD None None O
) None None O
simulations None None O
. None None O

The None None O
secondary None None O
structure None None O
of None None O
amylin None None I-TRANS
peptide None None O
shows None None O
that None None O
the None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
two None None O
terminals None None O
are None None O
structureless None None O
and None None O
two None None O
α-helical None None O
segments None None O
in None None O
the None None O
peptide None None O
are None None O
connected None None O
through None None O
an None None O
unstructured None None O
link None None O
. None None O

Free None None O
energy None None O
calculations None None O
of None None O
the None None O
Ile26 None None O
→ None None O
Pro None None O
mutation None None O
in None None O
the None None O
amylin None None I-TRANS
peptide None None O
are None None O
performed None None O
in None None O
the None None O
bilayer None None O
and None None O
in None None O
aqueous None None O
solution None None O
using None None O
molecular None None O
dynamics None None O
simulations None None O
and None None O
a None None O
thermodynamic None None O
cycle None None O
. None None O

In None None O
patients None None O
affected None None O
by None None O
chronic None None O
arthritis None None O
, None None O
TNF-α None None O
is None None O
considered None None O
as None None O
one None None O
of None None O
the None None O
factors None None O
responsible None None O
for None None O
favouring None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
dyslipidemia None None O
, None None O
which None None O
are None None O
important None None O
features None None O
of None None O
the None None O
metabolic None None O
syndrome None None O
. None None O

In None None O
response None None O
to None None O
CXCL12 None None O
stimulation None None O
, None None O
Rac1 None None O
, None None O
a None None O
GTPase None None O
, None None O
along None None O
with None None O
its None None O
effectors None None O
, None None O
regulates None None O
actin None None I-PROTEIN
polymerization None None O
to None None O
form None None O
lamellipodia None None O
, None None O
which None None O
is None None O
a None None O
critical None None O
event None None O
for None None O
cell None None O
migration None None O
. None None O

The None None O
influence None None O
of None None O
individual None None O
surfactants None None O
towards None None O
the None None O
morphology None None O
of None None O
the None None O
emulsion None None O
electrospun None None O
poly None None O
( None None O
ɛ-caprolactone None None O
) None None O
/bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
PCL/BSA None None O
) None None O
nanofibers None None O
were None None O
investigated None None O
by None None O
using None None O
( None None O
i None None O
) None None O
non-ionic None None O
surfactant None None O
sorbitane None None O
monooleate None None O
( None None O
Span80 None None O
) None None O
; None None O
( None None O
ii None None O
) None None O
anionic None None O
sodium None None O
dodecyl None None O
sulfate None None O
( None None O
SDS None None O
) None None O
; None None O
and None None O
( None None O
iii None None O
) None None O
cationic None None O
benzyltriethylammonium None None O
chloride None None O
, None None O
and None None O
poly None None O
( None None O
ethylene None None O
oxide None None O
) None None O
-poly None None O
( None None O
propylene None None O
oxide None None O
) None None O
-poly None None O
( None None O
ethylene None None O
oxide None None O
) None None O
triblock None None O
copolymer None None O
Pluronic None None O
F108 None None O
of None None O
different None None O
concentrations None None O
. None None O

The None None O
main None None O
reasons None None O
for None None O
failure None None O
were None None O
urinary None None O
retention None None I-FUNC
, None None O
postoperative None None O
haemorrhage None None O
and None None O
unsatisfactory None None O
pain None None O
control None None O
. None None O

Urinary None None O
retention None None I-FUNC
is None None O
a None None O
common None None O
issue None None O
that None None O
can None None O
be None None O
responsible None None O
for None None O
failure None None O
; None None O
it None None O
requires None None O
a None None O
preventive None None O
strategy None None O
including None None O
short None None O
duration None None O
spinal None None O
anaesthesia None None O
. None None O

Adjusted None None O
logistic None None O
regression None None O
model None None O
showed None None O
that None None O
male None None O
gender None None O
, None None O
middle None None O
age None None O
( None None O
45-64 None None O
years None None O
) None None O
, None None O
hypertension None None O
, None None O
and None None O
previous None None O
history None None O
of None None O
stroke None None I-DISEASE
were None None O
the None None O
independent None None O
predictors None None O
for None None O
the None None O
occurrence None None O
of None None O
intracerebral None None O
hemorrhage None None O
among None None O
chronic None None O
dialysis None None O
patients None None O
. None None O

Adjusted None None O
Cox None None O
regression None None O
analyses None None O
demonstrated None None O
that None None O
the None None O
factors None None O
independently None None O
associated None None O
with None None O
mortality None None O
after None None O
intracerebral None None O
hemorrhage None None O
among None None O
dialysis None None O
patients None None O
included None None O
diabetes None None O
mellitus None None O
, None None O
malignancy None None O
and None None O
a None None O
history None None O
of None None O
prior None None O
stroke None None I-DISEASE
. None None O

Attention None None I-FUNC
must None None O
focus None None O
on None None O
providing None None O
optimal None None O
medical None None O
care None None O
after None None O
hemorrhagic None None O
stroke None None I-DISEASE
for None None O
these None None O
target None None O
groups None None O
to None None O
reduce None None O
mortality None None O
. None None O

Comparative None None O
proteomics None None O
based None None O
on None None O
two-dimensional None None O
differential None None O
in-gel None None O
electrophoresis None None O
( None None O
2D-DIGE None None O
) None None O
was None None O
employed None None O
to None None O
quantitatively None None O
analyze None None O
plasma None None I-PROTEIN
proteins None None I-PROTEIN
of None None O
healthy None None O
Uyghur None None O
women None None O
and None None O
with None None O
early None None O
stage None None O
cervical None None O
carcinoma None None O
. None None O

Bioinformatic None None O
analysis None None O
within None None O
the None None O
framework None None O
of None None O
Ingenuity None None O
Pathway None None O
Analysis None None O
( None None O
IPA None None O
( None None O
@ None None O
) None None O
) None None O
showed None None O
that None None O
10 None None O
plasma None None I-PROTEIN
proteins None None I-PROTEIN
as None None O
candidate None None O
biomarker None None O
were None None O
screened None None O
, None None O
mainly None None O
including None None O
lipid None None O
metabolism-related None None O
proteins None None O
( None None O
APOA4 None None O
, None None O
APOA1 None None O
, None None O
APOE None None O
) None None O
, None None O
complement None None O
( None None O
EPPK1 None None O
, None None O
CFHR1 None None O
) None None O
, None None O
metabolic None None O
enzymes None None I-PROTEIN
( None None O
CP None None O
, None None O
F2 None None O
, None None O
MASP2 None None O
) None None O
, None None O
glycoprotein None None O
( None None O
CLU None None O
) None None O
, None None O
and None None O
immune None None O
function-related None None O
proteins None None O
( None None O
IGK None None O
@ None None O
) None None O
. None None O

Among None None O
596 None None O
patients None None O
, None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
was None None O
found None None O
only None None O
in None None O
87 None None O
patients None None O
. None None O

As None None O
a None None O
result None None O
, None None O
multifunctional None None O
BSA None None O
scaffolds None None O
with None None O
controlled None None O
porosity None None O
containing None None O
PLGA None None O
, None None O
PMSQ None None O
and None None O
collagen None None I-PROTEIN
particles/fibres None None O
were None None O
obtained None None O
. None None O

In None None O
cell None None O
biological None None O
assays None None O
, None None O
the None None O
actin None None I-PROTEIN
cross-linking None None O
domain None None O
( None None O
ACD None None O
) None None O
and None None O
Rho-inactivation None None O
domain None None O
( None None O
RID None None O
) None None O
are None None O
found None None O
to None None O
cross-link None None O
actin None None I-PROTEIN
and None None O
inactivate None None O
RhoA None None O
, None None O
respectively None None O
, None None O
when None None O
other None None O
effector None None O
domains None None O
are None None O
absent None None O
, None None O
with None None O
toxin None None O
autoprocessing None None O
required None None O
for None None O
high None None O
efficiency None None O
. None None O

The None None O
sufficiency None None O
of None None O
ACD None None O
but None None O
strong None None O
selection None None O
for None None O
retention None None I-FUNC
of None None O
RID None None O
and None None O
ABH None None O
suggests None None O
these None None O
two None None O
domains None None O
may None None O
primarily None None O
function None None O
by None None O
modulating None None O
cell None None O
signaling None None O
. None None O

Carers None None O
of None None O
people None None O
with None None O
dementia None None I-DISEASE
were None None O
recruited None None O
through None None O
a None None O
variety None None O
of None None O
rural None None O
community None None O
services None None O
and None None O
invited None None O
to None None O
complete None None O
a None None O
survey None None O
related None None O
to None None O
the None None O
utilisation None None O
of None None O
community None None O
services None None O
. None None O

Rural None None O
carers None None O
of None None O
care None None O
recipients None None O
with None None O
behavioural None None O
and None None O
psychological None None O
symptoms None None O
of None None O
dementia None None I-DISEASE
underutilise None None O
community None None O
services None None O
. None None O

Glucagon None None I-TRANS
like None None O
peptide-1 None None O
( None None O
GLP-1 None None O
) None None O
, None None O
an None None O
incretin None None O
hormone None None O
, None None O
regulates None None O
glucose None None O
metabolism None None O
by None None O
inducing None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
suppressing None None O
glucagon None None I-TRANS
secretion None None O
. None None O

Once None None O
the None None O
requirement None None O
of None None O
deformity None None O
correction None None O
has None None O
been None None O
established None None O
with None None O
specific None None O
attention None None I-FUNC
to None None O
the None None O
pelvic None None O
incidence None None O
and None None O
amount None None O
of None None O
lordosis None None O
required None None O
two None None O
basic None None O
choices None None O
can None None O
be None None O
made None None O
. None None O

Attention None None I-FUNC
to None None O
anterior None None O
column None None O
reconstruction None None O
and None None O
solid None None O
posterior None None O
instrumentation None None O
( None None O
iliac None None O
screws None None O
, None None O
four None None O
rods None None O
) None None O
should None None O
be None None O
given None None O
to None None O
all None None O
these None None O
revisions None None O
to None None O
have None None O
a None None O
long-lasting None None O
result None None O
. None None O

Thematic None None O
analysis None None O
was None None O
conducted None None O
to None None O
identify None None O
the None None O
main None None O
themes None None O
relating None None O
to None None O
participants None None O
' None None O
perceptions None None I-FUNC
of None None O
the None None O
CORAL None None O
decision None None O
aid None None O
. None None O

Conclusions None None O
Data None None O
from None None O
our None None O
13 None None O
participants None None O
suggest None None O
that None None O
the None None O
CORAL None None O
decision None None O
aid None None O
acts None None O
on None None O
several None None O
dimensions None None O
of None None O
decisional None None O
conflict None None O
: None None O
clarifying None None O
the None None O
pros None None O
and None None O
cons None None O
of None None O
different None None O
choices None None O
; None None O
increasing None None O
knowledge None None O
; None None O
structuring None None O
the None None O
decision None None I-FUNC
making None None I-FUNC
process None None O
; None None O
and None None O
clarifying None None O
needs None None O
and None None O
values None None O
. None None O

Inhibition None None O
of None None O
NO None None O
synthase None None O
, None None O
CO None None O
synthase None None O
, None None O
soluble None None O
guanylate None None I-PROTEIN
cyclase None None I-PROTEIN
( None None O
sGC None None O
) None None O
, None None O
and None None O
protein None None O
kinase None None O
G None None O
( None None O
PKG None None O
) None None O
all None None O
attenuated None None O
the None None O
enhanced None None O
relaxation None None O
in None None O
Tg None None O
, None None O
demonstrating None None O
the None None O
importance None None O
of None None O
NCX1 None None O
in None None O
NO/sGC/PKG None None O
signaling None None O
. None None O

Unlike None None O
NOR-1 None None O
, None None O
pituitary None None O
adenylate None None I-PROTEIN
cyclase-activating None None O
peptide None None O
and None None O
vasoactive None None I-TRANS
intestinal None None I-TRANS
peptide None None I-TRANS
induced None None O
a None None O
similar None None O
relaxation None None O
in None None O
Tg None None O
compared None None O
with None None O
that None None O
in None None O
WT None None O
. None None O

The None None O
evolution None None O
of None None O
the None None O
Na-ion None None O
displacements None None O
of None None O
Na3 None None O
[ None None O
Ti2P2O10F None None O
] None None O
was None None O
investigated None None O
with None None O
high-temperature None None O
neutron None None O
diffraction None None O
( None None O
HTND None None O
) None None O
from None None O
room None None O
temperature None None O
to None None O
600°C None None O
; None None O
difference None None O
Fourier None None O
maps None None O
were None None O
utilized None None O
to None None O
estimate None None O
the None None O
Na None None I-TRANS
nuclear-density None None O
distribution None None O
. None None O

In None None O
order None None O
to None None O
know None None O
the None None O
function None None O
of None None O
pyruvate None None I-PROTEIN
carboxylase None None I-PROTEIN
( None None O
PYC None None O
) None None O
in None None O
lipid None None O
biosynthesis None None O
, None None O
the None None O
PYC None None O
gene None None O
cloned None None O
from None None O
Pichia None None O
guilliermondii None None O
Pcla22 None None O
was None None O
overexpressed None None O
in None None O
the None None O
oleaginous None None O
yeast None None O
. None None O

In None None O
in None None O
vitro None None O
studies None None O
, None None O
Ang None None O
II None None O
decreased None None O
the None None O
cellular None None O
concentration None None O
of None None O
NO None None O
, None None O
which None None O
was None None O
accompanied None None O
by None None O
a None None O
reduction None None O
in None None O
phosphorylated None None O
endothelial None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
eNOS None None O
) None None O
and None None O
an None None O
increase None None O
in None None O
ROS None None O
production None None O
. None None O

By None None O
luciferase None None I-PROTEIN
reporter None None O
and None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
, None None O
the None None O
core None None O
promoter None None O
region None None O
to None None O
regulate None None O
the None None O
ZAG None None O
gene None None O
expression None None O
was None None O
found None None O
to None None O
exist None None O
between None None O
-110 None None O
and None None O
-101 None None O
. None None O

The None None O
rats None None O
given None None O
ATZ None None O
alone None None O
also None None O
had None None O
significantly None None O
decreased None None O
3β-hydroxtsteroid None None O
dehydrogenase None None I-PROTEIN
( None None O
HSD None None O
) None None O
and None None O
17β-HSD None None O
activities None None O
than None None O
the None None O
control None None O
rats None None O
. None None O

In None None O
this None None O
study None None O
, None None O
kidney None None O
cancer None None O
cells None None O
namely None None O
human None None O
embryonic None None O
kidney None None O
293-containing None None O
SV40 None None O
large None None O
T-antigen None None O
( None None O
HEK293T None None O
) None None O
and None None O
786-0 None None O
were None None O
incubated None None O
with None None O
various None None O
concentrations None None O
of None None O
nickel None None O
chloride None None O
for None None O
24 None None O
h None None O
before None None O
analysing None None O
the None None O
expression None None O
of None None O
three None None O
histone None None O
H3K27 None None O
methylation-modifying None None O
enzymes None None I-PROTEIN
and None None O
H3K27me3 None None O
using None None O
quantitative None None O
real-time None None O
polymerase None None O
chain None None O
reaction None None O
, None None O
Western None None O
blot None None O
and None None O
immunofluorescence None None O
analyses None None O
. None None O

Histidine None None I-TRANS
and None None O
n-acetylcysteine None None O
were None None O
i.p None None O
. None None O

Combination None None O
treatment None None O
with None None O
histidine None None I-TRANS
and None None O
n-acetylcysteine None None O
showed None None O
better None None O
responses None None O
when None None O
compared None None O
with None None O
them None None O
used None None O
alone None None O
. None None O

Reduction None None O
of None None O
free None None O
radical-induced None None O
toxic None None O
effects None None O
may None None O
have None None O
a None None O
role None None O
in None None O
neuroprotective None None O
properties None None O
of None None O
histidine None None I-TRANS
and None None O
n-acetylcysteine None None O
. None None O

Evaluation None None O
of None None O
five None None O
trypsin None None I-PROTEIN
genes None None O
revealed None None O
99 None None O
% None None O
reduced None None O
transcription None None O
of None None O
one None None O
trypsin None None I-PROTEIN
gene None None O
( None None O
HaTryR None None O
) None None O
was None None O
associated None None O
with None None O
resistance None None O
. None None O

Because None None O
trypsin None None I-PROTEIN
activation None None O
of None None O
protoxin None None O
is None None O
a None None O
critical None None O
step None None O
in None None O
toxicity None None O
, None None O
transgenic None None O
plants None None O
with None None O
activated None None O
toxins None None O
rather None None O
than None None O
protoxins None None O
might None None O
increase None None O
the None None O
durability None None O
of None None O
Bt None None O
crops None None O
. None None O

These None None O
apps None None I-TRANS
are None None O
targeted None None O
to None None O
the None None O
oncology None None O
healthcare None None O
provider None None O
as None None O
well None None O
as None None O
the None None O
patient None None O
. None None O

Maximum None None O
retention None None I-FUNC
is None None O
largely None None O
based None None O
on None None O
patient None None O
preference None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
is None None O
to None None O
illustrate None None O
some None None O
of None None O
the None None O
challenges None None O
and None None O
perceptions None None I-FUNC
of None None O
people None None O
diagnosed None None O
with None None O
SCD None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
is None None O
to None None O
assess None None O
patients None None O
with None None O
DCIS None None O
and None None O
EIBC None None O
and None None O
their None None O
perceived None None O
risk None None O
of None None O
recurrence None None O
and None None O
perceived None None O
risk None None O
of None None O
dying None None O
, None None O
and None None O
evaluate None None O
their None None O
outlook None None O
for None None O
the None None O
future None None O
, None None O
the None None O
degree None None O
of None None O
social None None O
support None None O
from None None O
spouses None None O
and None None O
significant None None O
others None None O
of None None O
patients None None O
who None None O
have None None O
been None None O
diagnosed None None O
with None None O
DCIS None None O
and None None O
EIBC None None O
, None None O
and None None O
the None None O
relationship None None O
to None None O
the None None O
patient None None O
's None None O
perceived None None O
risk None None O
perception None None I-FUNC
of None None O
recurrence None None O
and None None O
dying None None O
from None None O
the None None O
diseases None None O
. None None O

As None None O
a None None O
nontraditional None None O
form None None O
of None None O
exercise None None O
, None None O
Nia None None O
integrates None None O
body None None O
, None None O
mind None None O
, None None O
and None None O
spirit None None O
as None None O
well None None O
as None None O
the None None O
five None None O
sensations None None I-FUNC
of None None O
flexibility None None O
, None None O
agility None None O
, None None O
mobility None None O
, None None O
strength None None O
, None None O
and None None O
stability None None O
. None None O

The None None O
current None None O
standard None None O
of None None O
care None None O
for None None O
treating None None O
metastatic None None O
renal None None O
cell None None O
carcinoma None None O
is None None O
sequential None None O
therapy None None O
with None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor-targeted None None O
agents None None O
( None None O
i.e. None None O
, None None O
axitinib None None O
, None None O
bevacizumab None None O
, None None O
pazopanib None None O
, None None O
sorafenib None None O
, None None O
and None None O
sunitinib None None O
) None None O
and None None O
mammalian None None O
target None None O
of None None O
rapamycin None None O
inhibitors None None O
( None None O
i.e. None None O
, None None O
everolimus None None O
and None None O
temsirolimus None None O
) None None O
. None None O

The None None O
author None None O
extracted None None O
eight None None O
categories None None O
pertaining None None O
to None None O
nurse None None O
consultation None None O
techniques None None O
for None None O
the None None O
SDM None None O
process None None O
: None None O
sharing None None O
feelings None None I-FUNC
, None None O
helping None None O
to None None O
identify None None O
the None None O
focus None None O
of None None O
the None None O
consultations None None O
, None None O
helping None None O
to None None O
devise None None O
a None None O
personalized None None O
recovery None None O
plan None None O
, None None O
providing None None O
information None None O
in None None O
accordance None None O
with None None O
the None None O
patient None None O
's None None O
responses None None O
, None None O
supporting None None O
the None None O
patient None None O
to None None O
understand None None O
the None None O
information None None O
provided None None O
, None None O
ensuring None None O
continued None None O
treatment None None O
and None None O
care None None O
, None None O
strengthening None None O
the None None O
patient None None O
support None None O
system None None O
, None None O
and None None O
exploring None None O
possibilities None None O
on None None O
the None None O
basis None None O
of None None O
patient None None O
needs None None O
. None None O

This None None O
article None None O
explores None None O
barriers None None O
to None None O
informed None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
health None None O
care None None O
, None None O
and None None O
it None None O
proposes None None O
palliative None None O
care None None O
as None None O
one None None O
means None None O
of None None O
responding None None O
to None None O
the None None O
challenge None None O
of None None O
a None None O
widespread None None O
lack None None O
of None None O
autonomy None None O
in None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

To None None O
gain None None O
benefit None None O
from None None O
asparaginase None None O
, None None O
asparagine None None I-TRANS
depletion None None O
must None None O
be None None O
ensured None None O
by None None O
giving None None O
intensive None None O
therapy None None O
and None None O
completing None None O
the None None O
full None None O
course None None O
of None None O
treatment None None O
. None None O

In None None O
addition None None O
, None None O
networking None None O
within None None O
faith None None O
communities None None O
, None None O
connecting None None O
with None None O
complementary None None O
activities None None O
scheduled None None O
in None None O
those None None O
communities None None O
, None None O
and None None O
offering None None O
refreshments None None O
and None None O
gift None None O
items None None O
that None None O
support None None O
educational None None O
efforts None None O
were None None O
identified None None O
as None None O
effective None None O
ways None None O
of None None O
maximizing None None O
outcomes None None O
and None None O
reinforcing None None O
learning None None I-FUNC
. None None O

Although None None O
the None None O
past None None O
two None None O
decades None None O
have None None O
witnessed None None O
a None None O
significant None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
studies None None O
investigating None None O
effects None None O
of None None O
estrogenic None None O
chemicals None None O
on None None O
amphibians None None O
, None None O
to None None O
date None None O
little None None O
is None None O
known None None O
about None None O
specific None None O
molecular None None O
interactions None None O
of None None O
estrogens None None I-PROTEIN
with None None O
the None None O
hypothalamus-pituitary-gonadal-hepatic None None O
axis None None O
in None None O
developing None None O
amphibians None None O
. None None O

Specifically None None O
, None None O
expression None None O
of None None O
androgen None None O
receptor None None I-PROTEIN
, None None O
farnesyl None None O
diphosphate None None O
synthase None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
, None None O
and None None O
vitellogenin None None O
A2 None None O
was None None O
significantly None None O
greater None None O
( None None O
& None None O
gt None None O
; None None O
2-fold None None O
) None None O
than None None O
in None None O
controls None None O
while None None O
expression None None O
of None None O
farnesoid None None O
x-activated None None O
receptors None None I-PROTEIN
α None None O
and None None O
β None None O
was None None O
significantly None None O
less None None O
( None None O
& None None O
gt None None O
; None None O
2-fold None None O
reduction None None O
) None None O
than None None O
in None None O
controls None None O
. None None O

Lead None None O
, None None O
nickel None None O
, None None O
chromium None None O
, None None O
copper None None O
and None None O
zinc None None I-TRANS
concentrations None None O
were None None O
determined None None O
in None None O
the None None O
test None None O
mixtures None None O
. None None O

© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
Serotonin None None I-TRANS
stimulation None None O
of None None O
the None None O
5HT4 None None O
receptor None None I-PROTEIN
might None None O
be None None O
responsible None None O
for None None O
an None None O
increased None None O
risk None None O
of None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
. None None O

Using None None O
the None None O
UK None None O
Clinical None None O
Practice None None O
Research None None O
Datalink None None O
, None None O
a None None O
nested None None O
case-control None None O
analysis None None O
was None None O
conducted None None O
within None None O
a None None O
cohort None None O
of None None O
new None None O
AD None None O
users None None O
having None None O
a None None O
diagnosis None None O
of None None O
depression None None I-DISEASE
and/or None None O
anxiety None None O
. None None O

Race-ethnic None None O
differences None None O
in None None O
initial None None O
stroke None None I-DISEASE
severity None None O
may None None O
be None None O
one None None O
important None None O
determinant None None O
of None None O
differences None None O
in None None O
the None None O
outcome None None O
after None None O
stroke None None I-DISEASE
. None None O

Additionally None None O
, None None O
we None None O
investigated None None O
whether None None O
age None None O
modifies None None O
the None None O
relationship None None O
between None None O
ethnicity None None O
and None None O
initial None None O
stroke None None I-DISEASE
severity None None O
as None None O
this None None O
may None None O
be None None O
an None None O
important None None O
determinant None None O
of None None O
racial None None O
differences None None O
in None None O
the None None O
outcome None None O
after None None O
stroke None None I-DISEASE
. None None O

National None None O
Institutes None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
( None None O
NIHSS None None O
) None None O
was None None O
determined None None O
from None None O
the None None O
medical None None O
record None None O
or None None O
abstracted None None O
from None None O
the None None O
chart None None O
. None None O

However None None O
, None None O
in None None O
the None None O
older None None O
age None None O
category None None O
( None None O
75+ None None O
) None None O
, None None O
there None None O
was None None O
a None None O
reversal None None O
of None None O
this None None O
pattern None None O
; None None O
MAs None None O
had None None O
more None None O
severe None None O
strokes None None I-DISEASE
than None None O
NHWs None None O
by None None O
about None None O
2 None None O
points None None O
, None None O
though None None O
not None None O
reaching None None O
statistical None None O
significance None None O
. None None O

However None None O
, None None O
several None None O
potentially None None O
important None None O
ethnic None None O
differences None None O
among None None O
individuals None None O
with None None O
the None None O
most None None O
severe None None O
strokes None None I-DISEASE
were None None O
seen None None O
in None None O
younger None None O
and None None O
older None None O
stroke None None I-DISEASE
patients None None O
that None None O
were None None O
not None None O
explained None None O
by None None O
traditional None None O
risk None None O
factors None None O
. None None O

Functional None None O
analysis None None O
of None None O
the None None O
miRNA None None O
and None None O
a None None O
luciferase None None I-PROTEIN
reporter None None O
assay None None O
were None None O
performed None None O
to None None O
demonstrate None None O
that None None O
the None None O
predicted None None O
miRNA None None O
suppressed None None O
ANXA2 None None O
expression None None O
by None None O
directly None None O
targeting None None O
the None None O
predicted None None O
3´-UTR None None O
site None None O
of None None O
the None None O
ANXA2 None None O
mRNA None None O
. None None O

Higher None None O
values None None O
of None None O
creatinine None None O
, None None O
lactate None None O
, None None O
anion None None O
gap None None O
, None None O
alanine None None I-TRANS
transaminase None None I-PROTEIN
( None None O
ALT None None O
) None None O
, None None O
and None None O
APPLE None None O
fast None None O
score None None O
were None None O
significantly None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
death None None O
in None None O
SIRS None None O
dogs None None O
, None None O
while None None O
higher None None O
values None None O
of None None O
total None None O
protein None None O
, None None O
albumin None None O
, None None O
ATA None None O
, None None O
and None None O
BE None None O
were None None O
associated None None O
with None None O
a None None O
significantly None None O
reduced None None O
risk None None O
of None None O
mortality None None O
. None None O

The None None O
determination None None O
of None None O
the None None O
APPLE None None O
fast None None O
score None None O
in None None O
clinical None None O
setting None None O
, None None O
as None None O
well None None O
as None None O
the None None O
measurement None None O
of None None O
APP None None I-TRANS
, None None O
ATA None None O
, None None O
lactate None None O
, None None O
BE None None O
, None None O
anion None None O
gap None None O
, None None O
ALT None None O
, None None O
urinary None None O
proteins None None O
, None None O
and None None O
electrolytes None None O
may None None O
be None None O
beneficial None None O
for None None O
a None None O
better None None O
assessment None None O
of None None O
dogs None None O
with None None O
SIRS None None O
. None None O

Blood None None O
samples None None O
from None None O
healthy None None O
female None None O
cattle None None O
were None None O
collected None None O
at None None O
days None None O
1 None None O
and None None O
7 None None O
post None None O
natum None None O
( None None O
p. None None O
n. None None O
) None None O
and None None O
during None None O
the None None O
1st None None O
, None None O
3rd None None O
, None None O
6th None None O
, None None O
9th None None O
, None None O
12th None None O
and None None O
18th None None O
month None None O
p. None None O
n. None None O
The None None O
antioxidant None None O
parameters None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPX None None O
) None None O
and None None O
Trolox None None O
equivalent None None O
antioxidative None None O
capacity None None O
( None None O
TEAC None None O
) None None O
, None None O
haematocrit None None O
( None None O
Hct None None O
) None None O
and None None O
the None None O
metabolic None None O
parameters None None O
total None None O
protein None None O
, None None O
albumin None None O
, None None O
bilirubin None None O
, None None O
calcium None None O
, None None O
inorganic None None O
phosphate None None O
, None None O
iron None None O
, None None O
urea None None O
, None None O
cholesterol None None O
, None None O
β-hydroxybutyrate None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
, None None O
aspartate None None I-TRANS
transaminase None None I-PROTEIN
, None None O
glutamate None None I-TRANS
dehydrogenase None None I-PROTEIN
, None None O
creatine None None O
kinase None None O
and None None O
haptoglobin None None O
were None None O
determined None None O
. None None O

Despite None None O
an None None O
increase None None O
in None None O
the None None O
relative None None O
brain None None O
weight None None O
in None None O
the None None O
PR None None O
group None None O
, None None O
there None None O
was None None O
no None None O
difference None None O
in None None O
blood None None O
flow None None O
to None None O
the None None O
brain None None O
between None None O
the None None O
groups None None O
, None None O
although None None O
PR None None O
fetuses None None O
had None None O
higher None None O
blood None None O
flow None None O
to None None O
the None None O
temporal None None I-REGION
lobe None None I-REGION
. None None O

In None None O
contrast None None O
to None None O
the None None O
response None None O
to None None O
acute None None O
hypoxemia None None O
, None None O
these None None O
data None None O
show None None O
that None None O
there None None O
is None None O
a None None O
redistribution None None O
of None None O
blood None None O
flow None None O
to None None O
the None None O
adrenals None None I-TRANS
and None None O
temporal None None I-REGION
lobe None None I-REGION
, None None O
but None None O
not None None O
the None None O
heart None None O
or None None O
whole None None O
brain None None O
, None None O
in None None O
chronically None None O
hypoxemic None None O
PR None None O
fetuses None None O
in None None O
late None None O
gestation None None O
. None None O

Within None None O
the None None O
embryonic None None O
kidney None None O
, None None O
several None None O
putative None None O
progenitors None None O
marked None None O
by None None O
the None None O
expression None None O
of None None O
either None None O
the None None O
winged-forkhead None None O
transcription None None O
factor None None O
1 None None O
( None None O
Foxd1+ None None O
progenitor None None O
) None None O
, None None O
the None None O
aspartyl-protease None None O
renin None None I-PROTEIN
( None None O
Ren+ None None O
progenitor None None O
) None None O
, None None O
and/or None None O
hemangioblasts None None O
( None None O
Scl+ None None O
progenitor None None O
) None None O
are None None O
likely None None O
to None None O
differentiate None None O
and None None O
endow None None O
most None None O
of None None O
the None None O
cells None None O
of None None O
the None None O
renal None None O
arterial None None O
tree None None O
. None None O

Results None None O
suggest None None O
that None None O
farmers None None O
more None None O
likely None None O
to None None O
show None None O
willingness None None O
to None None O
spend None None O
money/time None None O
or None None O
vaccinate None None O
to None None O
control None None O
Escherichia None None O
coli None None O
O157 None None O
are None None O
those None None O
: None None O
who None None O
think None None O
farmers None None O
are None None O
most None None O
responsible None None O
for None None O
control None None O
; None None O
whose None None O
income None None O
depends None None O
more None None O
on None None O
opening None None O
farms None None O
to None None O
the None None O
public None None O
; None None O
with None None O
stronger None None O
disease None None O
control None None O
attitudes None None O
; None None O
affected None None O
by None None O
outbreaks None None O
; None None O
with None None O
better None None O
knowledge None None O
and None None O
more None None O
informed None None O
; None None O
with None None O
stronger None None O
perceptions None None I-FUNC
of None None O
biosecurity None None O
measures None None O
' None None O
practicality None None O
; None None O
using None None O
a None None O
health None None O
plan None None O
; None None O
who None None O
think None None O
farmers None None O
are None None O
the None None O
main None None O
beneficiaries None None O
of None None O
control None None O
; None None O
and None None O
whose None None O
farms None None O
are None None O
dairy None None O
rather None None O
than None None O
beef None None O
. None None O

The None None O
isocyanide None None O
derivatives None None O
are None None O
the None None O
least None None O
stable None None O
complexes None None O
, None None O
and None None O
the None None O
S-bound None None O
methionine None None I-TRANS
oxide None None O
derivative None None O
is None None O
the None None O
more None None O
stable None None O
one None None O
. None None O

X-ray None None O
diffraction None None O
of None None O
crystals None None O
of None None O
the None None O
model None None O
protein None None O
Hen None None O
Egg None None O
White None None O
Lysozyme None None I-PROTEIN
soaked None None O
with None None O
6b None None O
( None None O
4UWN None None O
) None None O
and None None O
8 None None O
( None None O
4UWN None None O
) None None O
shows None None O
the None None O
addition None None O
of None None O
Ru None None O
( None None O
II None None O
) None None O
( None None O
CO None None O
) None None O
( None None O
H2O None None O
) None None O
4 None None O
at None None O
the None None O
His15 None None O
binding None None O
site None None O
. None None O

A None None O
common None None O
method None None O
of None None O
managing None None O
challenging None None O
behaviour None None O
associated None None O
with None None O
dementia None None I-DISEASE
is None None O
long-stay None None O
special None None O
care None None O
units None None O
, None None O
though None None O
models None None O
are None None O
very None None O
diverse None None O
. None None O

Transitional None None O
Behavioural None None O
Assessment None None O
and None None O
Intervention None None O
Service None None O
Units None None O
, None None O
incorporating None None O
an None None O
integrated None None O
outreach None None O
team None None O
, None None O
were None None O
to None None O
provide None None O
multi-disciplinary None None O
assessments None None O
, None None O
develop None None O
individualised None None O
bio-psychosocial None None O
management None None O
plans None None O
for None None O
, None None O
and None None O
appropriately None None O
discharge None None O
people None None O
with None None O
significant None None O
levels None None O
of None None O
Behavioural None None O
and None None O
Psychological None None O
Symptoms None None O
in None None O
Dementia None None I-DISEASE
. None None O

Transitional None None O
Behaviour None None O
Assessment None None O
and None None O
Intervention None None O
Service None None O
units None None O
were None None O
admitting None None O
patients None None O
with None None O
dementia None None I-DISEASE
and None None O
a None None O
variety None None O
of None None O
significant None None O
challenging None None O
behaviours None None O
. None None O

This None None O
study None None O
investigates None None O
the None None O
impact None None O
of None None O
a None None O
weekly None None O
group None None O
providing None None O
sport None None O
and None None O
physical None None O
activities None None O
for None None O
men None None O
with None None O
early None None O
onset None None O
dementia None None I-DISEASE
established None None O
by None None O
Notts None None O
County None None O
Football None None O
in None None O
the None None O
Community None None O
( None None O
NCFC None None O
) None None O
. None None O

Men None None O
with None None O
dementia None None I-DISEASE
( None None O
n None None O
= None None O
5 None None O
) None None O
attending None None O
the None None O
sessions None None O
, None None O
their None None O
carers None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
, None None O
NCFC None None O
coaching None None O
staff None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
and None None O
people None None O
organizing/facilitating None None O
the None None O
sessions None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
were None None O
interviewed None None O
. None None O

The None None O
NCFC None None O
sessions None None O
provided None None O
a None None O
safe None None O
low-cost None None O
intervention None None O
with None None O
positive None None O
effects None None O
upon None None O
quality None None O
of None None O
life None None O
for None None O
both None None O
people None None O
with None None O
early None None O
onset None None O
dementia None None I-DISEASE
, None None O
their None None O
carers None None O
and None None O
the None None O
staff None None O
involved None None O
. None None O

By None None O
combining None None O
sequence None None O
optimization None None O
of None None O
existing None None O
repeats None None O
and None None O
de None None O
novo None None O
design None None O
of None None O
capping None None O
structures None None O
, None None O
we None None O
designed None None O
leucine-rich None None O
repeats None None O
( None None O
LRRs None None O
) None None O
from None None O
the None None O
ribonuclease None None I-PROTEIN
inhibitor None None O
( None None O
RI None None O
) None None O
family None None O
that None None O
assemble None None O
into None None O
structures None None O
with None None O
a None None O
predefined None None O
geometry None None O
. None None O

The None None O
present None None O
findings None None O
demonstrate None None O
reliability-dependent None None O
contributions None None O
of None None O
visual None None O
orientation None None O
cues None None O
at None None O
the None None O
level None None O
of None None O
the None None O
CIP None None O
, None None O
thus None None O
revealing None None O
a None None O
neural None None O
correlate None None O
of None None O
this None None O
property None None O
of None None O
human None None O
visual None None I-FUNC
perception None None I-FUNC
. None None O

Dorsal None None I-NEURON
is None None O
activated None None O
on None None O
wounding None None O
, None None O
and None None O
Dif None None O
and None None O
Dorsal None None I-NEURON
are None None O
required None None O
for None None O
the None None O
sustained None None O
down-regulation None None O
of None None O
E-cadherin None None O
, None None O
an None None O
obligatory None None O
component None None O
of None None O
the None None O
adherens None None O
junctions None None O
( None None O
AJs None None O
) None None O
, None None O
at None None O
the None None O
wound None None O
edge None None O
. None None O

In None None O
the None None O
absence None None O
of None None O
Toll None None O
or None None O
Dif None None O
and None None O
dorsal None None I-NEURON
( None None O
dl None None O
) None None O
, None None O
both None None O
E-cadherin None None O
down-regulation None None O
and None None O
actin-cable None None O
formation None None O
fail None None O
, None None O
thus None None O
resulting None None O
in None None O
open None None O
epidermal None None O
gaps None None O
. None None O

One None None O
of None None O
these None None O
, None None O
the None None O
incretin None None O
glucagon-like None None O
peptide None None O
1 None None O
( None None O
GLP-1 None None O
) None None O
, None None O
like None None O
insulin None None I-PROTEIN
, None None O
needs None None O
subcutaneous None None O
administration None None O
causing None None O
inconvenience None None O
to None None O
patients None None O
. None None O

To None None O
improve None None O
patient None None O
convenience None None O
inhaled None None O
insulin None None I-PROTEIN
( None None O
Exubera None None O
( None None O
® None None O
) None None O
) None None O
was None None O
developed None None O
and None None O
approved None None O
but None None O
failed None None O
market None None O
acceptance None None O
some None None O
years None None O
ago None None O
. None None O

Working None None I-FUNC
memory None None I-FUNC
contributes None None O
to None None O
accurate None None O
stepping None None O
over None None O
obstacles None None O
during None None O
locomotion None None O
, None None O
and None None O
AD-induced None None O
deficits None None O
of None None O
this None None O
memory None None I-FUNC
function None None O
may None None O
lead None None O
to None None O
an None None O
increased None None O
risk None None O
of None None O
contact None None O
with None None O
obstacles None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
memory-based None None O
movements None None I-FUNC
in None None O
stepping None None O
over None None O
an None None O
obstacle None None O
were None None O
impaired None None O
in None None O
these None None O
mice None None O
. None None O

Additionally None None O
, None None O
although None None O
only None None O
approximately None None O
75 None None O
% None None O
of None None O
WT None None O
mice None None O
developed None None O
clinical None None O
disease None None O
, None None O
lesions None None O
were None None O
observed None None O
in None None O
100 None None O
% None None O
of None None O
the None None O
mice None None O
, None None O
principally None None O
in None None O
the None None O
cerebellum None None I-REGION
, None None O
mid-brain None None O
and None None O
cerebral None None O
hemispheres None None O
, None None O
and None None O
lesion None None O
load None None O
increased None None O
with None None O
increasing None None O
pro-inflammatory None None O
cytokine None None O
production None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
search None None O
for None None O
somatic None None O
mutations None None O
in None None O
the None None O
tyrosine None None I-TRANS
kinome None None O
of None None O
serous None None O
and None None O
clear None None O
cell None None O
ECs None None O
, None None O
because None None O
mutated None None O
kinases None None I-PROTEIN
can None None O
point None None O
to None None O
potential None None O
therapeutic None None O
targets None None O
. None None O

Overall None None O
, None None O
we None None O
identified None None O
somatic None None O
mutations None None O
in None None O
TNK2 None None O
( None None O
tyrosine None None I-TRANS
kinase None None O
non-receptor None None I-PROTEIN
, None None O
2 None None O
) None None O
and None None O
DDR1 None None O
( None None O
discoidin None None O
domain None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
1 None None O
) None None O
in None None O
5.3 None None O
% None None O
( None None O
6 None None O
of None None O
112 None None O
) None None O
and None None O
2.7 None None O
% None None O
( None None O
3 None None O
of None None O
112 None None O
) None None O
of None None O
ECs None None O
. None None O

Our None None O
findings None None O
indicate None None O
that None None O
high-frequency None None O
somatic None None O
mutations None None O
in None None O
the None None O
catalytic None None O
domains None None O
of None None O
the None None O
tyrosine None None I-TRANS
kinome None None O
are None None O
rare None None O
in None None O
clear None None O
cell None None O
ECs None None O
. None None O

The None None O
relative None None O
nature None None O
of None None O
shared None None O
resilience None None O
is None None O
discussed None None O
, None None O
bearing None None O
in None None O
mind None None O
that None None O
resilience None None O
can None None O
be None None O
manifested None None O
as None None O
emotions None None I-FUNC
, None None O
behaviors None None O
, None None O
and None None O
conceptions None None O
. None None O

Huperzine None None O
A None None O
( None None O
HupA None None O
) None None O
, None None O
a None None O
naturally None None O
occurring None None O
alkaloid None None O
in None None O
the None None O
plant None None O
family None None O
Huperziaceae None None O
, None None O
has None None O
drawn None None O
great None None O
interest None None O
for None None O
its None None O
potential None None O
application None None O
in None None O
Alzheimer None None I-DISEASE
disease None None O
therapy None None O
. None None O

A None None O
recent None None O
surgery None None O
may None None O
be None None O
one None None O
of None None O
the None None O
trigger None None O
factors None None O
precipitating None None O
stroke None None I-DISEASE
and None None O
transient None None O
ischemic None None O
attack None None O
( None None O
TIA None None O
) None None O
. None None O

We None None O
tested None None O
the None None O
hypothesis None None O
that None None O
preceding None None O
non-neurosurgical None None O
, None None O
non-cardiothoracic None None O
, None None O
and None None O
non-carotid None None O
surgery None None O
and None None O
other None None O
interventions None None O
temporarily None None O
increase None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
and None None O
transient None None O
ischemic None None O
attack None None O
( None None O
TIA None None O
) None None O
and None None O
investigated None None O
the None None O
risk None None O
related None None O
to None None O
different None None O
time None None O
periods None None O
between None None O
interventions None None O
and None None O
stroke/TIA None None O
. None None O

The None None O
risk None None O
factor None None O
profiles None None O
of None None O
patients None None O
with None None O
and None None O
without None None O
prior None None O
intervention None None O
were None None O
compared None None O
and None None O
rate None None O
ratios None None O
( None None O
RR None None O
) None None O
were None None O
calculated None None O
for None None O
different None None O
time None None O
periods None None O
with None None O
91-365 None None O
days None None O
before None None O
stroke None None I-DISEASE
and None None O
TIA None None O
serving None None O
as None None O
reference None None O
period None None O
. None None O

Interventions None None O
within None None O
30 None None O
days None None O
before None None O
stroke/TIA None None O
, None None O
were None None O
associated None None O
with None None O
total None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
RR None None O
6.11 None None O
; None None O
95 None None O
% None None O
CI None None O
3.32-11.2 None None O
) None None O
, None None O
first-ever None None O
in None None O
a None None O
lifetime None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
RR None None O
5.62 None None O
; None None O
95 None None O
% None None O
CI None None O
2.83-11.1 None None O
) None None O
and None None O
recurrent None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
RR None None O
7.50 None None O
; None None O
95 None None O
% None None O
CI None None O
2.88-19.6 None None O
) None None O
. None None O

AF None None O
may None None O
be None None O
among None None O
the None None O
mechanisms None None O
linking None None O
interventions None None O
and None None O
stroke None None I-DISEASE
besides None None O
induction None None O
of None None O
a None None O
procoagulant None None O
state None None O
and None None O
interruption None None O
of None None O
medication None None O
. None None O

Continuity None None O
among None None O
peers None None O
during None None O
clinical None None O
clerkships None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
this None None O
different None None O
mode None None O
of None None O
learning None None I-FUNC
. None None O

We None None O
invited None None O
students None None O
in None None O
clerkship None None O
program None None O
models None None O
with None None O
continuity None None O
( None None O
CMCs None None O
) None None O
and None None O
in None None O
traditional None None O
block None None O
clerkships None None O
( None None O
BCs None None O
) None None O
to None None O
complete None None O
a None None O
survey None None O
about None None O
peer None None O
relationships None None O
with None None O
open-ended None None O
questions None None O
based None None O
on None None O
a None None O
workplace None None O
learning None None I-FUNC
framework None None O
, None None O
including None None O
themes None None O
of None None O
workplace-based None None O
relationships None None O
, None None O
the None None O
nature None None O
of None None O
work None None O
practices None None O
, None None O
and None None O
selection None None O
of None None O
tasks None None O
and None None O
activities None None O
. None None O

Students None None O
achieve None None O
many None None O
aspects None None O
of None None O
workplace None None O
learning None None I-FUNC
in None None O
clerkships None None O
through None None O
formal None None O
or None None O
informal None None O
workplace-based None None O
peer None None O
groups None None O
. None None O

Medical None None O
schools None None O
can None None O
support None None O
effective None None O
workplace None None O
learning None None I-FUNC
for None None O
medical None None O
students None None O
by None None O
incorporating None None O
continuity None None O
with None None O
peers None None O
in None None O
the None None O
main None None O
clinical None None O
clerkship None None O
year None None O
. None None O

This None None O
study None None O
examines None None O
the None None O
psychological None None O
and None None O
social None None O
barriers None None O
to None None O
institutional None None O
delivery None None O
, None None O
namely None None O
women None None O
's None None O
decision-making None None O
autonomy None None O
and None None O
their None None O
perceptions None None I-FUNC
about None None O
social None None O
support None None O
for None None O
institutional None None O
delivery None None O
in None None O
their None None O
community None None O
. None None O

To None None O
determine None None O
the None None O
relationship None None O
between None None O
institutional None None O
delivery None None O
and None None O
the None None O
two None None O
key None None O
social None None O
barriers-women None None O
's None None O
decision-making None None O
autonomy None None O
and None None O
community None None O
perceptions None None I-FUNC
of None None O
institutional None None O
delivery-we None None O
used None None O
multi-level None None O
logistic None None O
regression None None O
models None None O
, None None O
including None None O
cross-level None None O
interactions None None O
between None None O
community-level None None O
attitudes None None O
and None None O
individual-level None None O
autonomy None None O
. None None O

Corticosterone None None O
( None None O
CORT None None O
) None None O
is None None O
a None None O
glucocorticoid None None O
produced None None O
by None None O
adrenal None None I-TRANS
glands None None O
under None None O
the None None O
control None None O
of None None O
the None None O
hypothalamic-pituitary-adrenal None None O
axis None None O
. None None O

In None None O
the None None O
dorsal None None I-NEURON
spinal None None O
cord None None O
, None None O
GABAergic None None O
transmission None None O
modulates None None O
integration None None O
of None None O
nociceptive None None O
information None None O
. None None O

Factor None None I-PROTEIN
VII None None I-PROTEIN
( None None O
FVII None None O
) None None O
activating None None O
protease None None O
( None None O
FSAP None None O
) None None O
is None None O
a None None O
circulating None None O
protease None None O
with None None O
a None None O
putative None None O
function None None O
in None None O
blood None None O
coagulation None None O
and None None O
fibrinolysis None None O
. None None O

FeCl3-induced None None O
arterial None None O
thrombosis None None I-DISEASE
in None None O
carotid None None O
and None None O
mesenteric None None O
artery None None O
revealed None None O
that None None O
the None None O
occlusion None None O
time None None O
was None None O
significantly None None O
increased None None O
in None None O
FSAP-/- None None O
mice None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
and None None O
that None None O
some None None O
FSAP-/- None None O
mice None None O
did None None O
not None None O
occlude None None O
at None None O
all None None O
. None None O

In None None O
vertebrates None None O
, None None O
Otp None None O
is None None O
necessary None None O
for None None O
the None None O
proper None None O
development None None O
of None None O
different None None O
regions None None O
of None None O
the None None O
brain None None O
and None None O
is None None O
required None None O
in None None O
the None None O
diencephalon None None I-REGION
to None None O
specify None None O
several None None O
hypothalamic None None O
cell None None O
types None None O
, None None O
including None None O
the None None O
cells None None O
that None None O
control None None O
the None None O
stress None None O
response None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
identification None None O
of None None O
an None None O
evolutionarily None None O
conserved None None O
vertebrate None None O
enhancer None None O
module None None O
with None None O
activity None None O
in None None O
a None None O
restricted None None O
area None None O
of None None O
the None None O
forebrain None None I-REGION
, None None O
which None None O
includes None None O
the None None O
region None None O
of None None O
the None None O
hypothalamus None None I-REGION
that None None O
controls None None O
the None None O
stress None None O
response None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
relationship None None O
between None None O
the None None O
NPY None None I-TRANS
gene None None O
rs16147 None None O
polymorphism None None O
and None None O
the None None O
presence None None O
of None None O
CAD None None O
in None None O
an None None O
Iranian None None O
population None None O
. None None O

Previous None None O
autoradiography None None O
studies None None O
illustrated None None O
that None None O
several None None O
areas None None O
of None None O
the None None O
avian None None O
brain None None O
can None None O
bind None None O
the None None O
pineal None None I-REGION
hormone None None O
melatonin None None I-TRANS
. None None O

Further None None O
, None None O
the None None O
area-specific None None O
expression None None O
patterns None None O
suggest None None O
that None None O
the None None O
regulatory None None O
role None None O
of None None O
melatonin None None I-TRANS
differs None None O
among None None O
different None None O
brain None None O
areas None None O
. None None O

The None None O
middle None None O
meningeal None None O
artery None None O
( None None O
MMA None None O
) None None O
is None None O
known None None O
to None None O
function None None O
as None None O
one None None O
of None None O
the None None O
important None None O
collateral None None O
routes None None O
in None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
. None None O

This None None O
prospective None None O
study None None O
aimed None None O
to None None O
study None None O
the None None O
surgical None None O
anatomy None None O
of None None O
the None None O
MMA None None O
and None None O
to None None O
establish None None O
the None None O
technique None None O
to None None O
preserve None None O
it None None O
during None None O
bypass None None O
surgery None None O
for None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
. None None O

Two None None O
multilinear None None O
radioligand None None O
quantification None None O
techniques None None O
were None None O
used None None O
to None None O
estimate None None O
binding None None O
potential None None O
: None None O
MA1 None None O
, None None O
using None None O
arterial None None O
input None None O
function None None O
data None None O
, None None O
and None None O
the None None O
second None None O
version None None O
of None None O
the None None O
multilinear None None O
reference None None O
tissue None None O
model None None O
analysis None None O
( None None O
MRTM2 None None O
) None None O
, None None O
using None None O
the None None O
cerebellum None None I-REGION
as None None O
the None None O
reference None None O
region None None O
. None None O

Face-space None None O
as None None O
a None None O
theoretical None None O
framework None None O
for None None O
understanding None None O
the None None O
effect None None O
of None None O
ethnicity None None O
and None None O
the None None O
development None None O
of None None O
face None None I-FUNC
recognition None None I-FUNC
is None None O
evaluated None None O
. None None O

While None None O
being None None O
in None None O
principle None None O
a None None O
simple None None O
concept None None O
, None None O
face-space None None O
has None None O
shaped None None O
, None None O
and None None O
continues None None O
to None None O
shape None None O
, None None O
our None None O
understanding None None O
of None None O
face None None O
perception None None I-FUNC
. None None O

We None None O
report None None O
duplications None None O
of None None O
maternally None None O
derived None None O
chromosome None None O
11p15 None None O
involving None None O
CDKN1C None None O
encoding None None I-FUNC
a None None O
negative None None O
regulator None None O
for None None O
cell None None O
proliferation None None O
in None None O
three None None O
Japanese None None O
patients None None O
( None None O
cases None None O
1 None None O
and None None O
2 None None O
from None None O
family None None O
A None None O
and None None O
case None None O
3 None None O
from None None O
family None None O
B None None O
) None None O
with None None O
Silver-Russell None None O
syndrome None None O
( None None O
SRS None None O
) None None O
phenotype None None O
lacking None None O
hemihypotrophy None None O
. None None O

The None None O
concentration None None O
of None None O
reduced None None O
glutathione None None O
may None None O
be None None O
decreased None None O
by None None O
oxidative None None O
stress None None O
and None None O
by None None O
decreased None None O
in None None O
situ None None O
glutathione None None I-PROTEIN
reductase None None I-PROTEIN
activity None None O
in None None O
diabetes None None O
mellitus None None O
. None None O

In None None O
this None None O
work None None O
, None None O
the None None O
supporting None None O
data None None O
about None None O
the None None O
association None None O
between None None O
the None None O
-262T None None O
& None None O
gt None None O
; None None O
C None None O
polymorphism None None O
of None None O
the None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
gene None None O
and None None O
DN None None O
were None None O
shown None None O
. None None O

The None None O
role None None O
of None None O
these None None O
factors None None O
in None None O
the None None O
development None None O
of None None O
diabetic None None O
complications None None O
and None None O
the None None O
prospective None None O
prevention None None O
of None None O
DN None None O
by None None O
supplementation None None O
in None None O
formulations None None O
of None None O
transglycating None None O
imidazole-containing None None O
peptide-based None None O
antioxidants None None O
( None None O
non-hydrolyzed None None O
carnosine None None O
, None None O
carcinine None None O
, None None O
n-acetylcarcinine None None O
) None None O
scavenging None None O
ROS None None O
in None None O
the None None O
glycation None None O
reaction None None O
, None None O
modifying None None O
the None None O
activity None None O
of None None O
enzymic None None O
and None None O
non-enzymic None None O
antioxidant None None O
defenses None None O
that None None O
participate None None O
in None None O
metabolic None None O
processes None None O
with None None O
ability None None O
of None None O
controlling None None O
at None None O
transcriptional None None O
levels None None O
the None None O
differential None None O
expression None None O
of None None O
several None None O
genes None None O
encoding None None I-FUNC
antioxidant None None O
enzymes None None I-PROTEIN
inherent None None O
to None None O
DN None None O
in None None O
Type None None O
I None None O
Diabetic None None O
patients None None O
, None None O
now None None O
deserve None None O
investigation None None O
. None None O

Inclusion None None O
criteria None None O
for None None O
studies None None O
were None None O
electronically None None O
accessible None None O
English None None O
language None None I-FUNC
literature None None O
with None None O
Bobath None None O
and/or None None O
Neurodevelopmental None None O
Therapy None None O
as None None O
the None None O
subject None None O
heading None None O
in None None O
the None None O
title/keyword/abstract/intervention None None O
comparison None None O
with None None O
respect None None O
to None None O
adult None None O
neurological None None O
conditions None None O
. None None O

This None None O
is None None O
probably None None O
just None None O
the None None O
tip None None O
of None None O
the None None O
iceberg None None O
, None None O
since None None O
more None None O
recent None None O
epidemiological None None O
studies None None O
have None None O
also None None O
shown None None O
significant None None O
positive None None O
associations None None O
between None None O
the None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
ALDH2 None None O
( None None O
rs671 None None O
) None None O
*2 None None O
allele None None O
( None None O
encoding None None I-FUNC
inactive None None O
enzyme None None O
causing None None O
high None None O
acetaldehyde None None O
elevations None None O
) None None O
and None None O
gastric None None O
, None None O
colorectal None None O
, None None O
lung None None O
, None None O
and None None O
hepatocellular None None O
cancers None None O
. None None O

The None None O
mechanisms None None O
by None None O
which None None O
chronic None None O
alcohol None None O
consumption None None O
enhances None None O
carcinogenesis None None O
include None None O
acetaldehyde None None O
( None None O
AA None None O
) None None O
generated None None O
by None None O
alcohol None None I-PROTEIN
dehydrogenase None None I-PROTEIN
and None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
generated None None O
predominantly None None O
by None None O
cytochrome None None O
P450 None None O
2E1 None None O
( None None O
CYP2E1 None None I-PROTEIN
) None None O
, None None O
but None None O
also None None O
by None None O
other None None O
factors None None O
during None None O
inflammation None None O
. None None O

Synergistic None None O
toxicity None None O
occurs None None O
between None None O
CYP2E1 None None I-PROTEIN
and None None O
the None None O
JNK1 None None O
but None None O
not None None O
the None None O
JNK2 None None O
isoform None None O
as None None O
JNK1 None None O
knockout None None O
mice None None O
are None None O
completely None None O
protected None None O
against None None O
CYP2E1 None None I-PROTEIN
plus None None O
TNFα None None O
toxicity None None O
, None None O
elevated None None O
oxidative None None O
stress None None O
, None None O
and None None O
mitochondrial None None O
dysfunction None None O
. None None O

The None None O
tumor None None O
suppressor None None O
phosphatase None None I-PROTEIN
and None None O
tensin None None O
homolog None None O
deleted None None O
on None None O
chromosome None None O
10 None None O
( None None O
PTEN None None O
) None None O
is None None O
a None None O
phosphatidylinositol None None O
( None None O
PtdIns None None O
) None None O
phosphatase None None I-PROTEIN
that None None O
regulates None None O
Akt None None O
activation None None O
via None None O
PtdIns None None O
3 None None O
kinase None None O
. None None O

While None None O
the None None O
majority None None O
of None None O
research None None O
on None None O
PTEN None None O
concerns None None O
obesity None None O
and None None O
NASH None None O
, None None O
PTEN None None O
clearly None None O
has None None O
a None None O
role None None O
in None None O
hepatic None None O
insulin None None I-PROTEIN
sensitivity None None O
and None None O
in None None O
the None None O
development None None O
of None None O
steatosis None None O
during None None O
chronic None None O
alcoholism None None O
. None None O

Analysis None None O
of None None O
EtOH-treated None None O
livers None None O
from None None O
a None None O
previously None None O
published None None O
rat None None O
model None None O
of None None O
chronic None None O
liver None None O
disease None None O
revealed None None O
increases None None O
in None None O
hepatocyte None None O
proliferation None None O
accompanied None None O
by None None O
a None None O
hepatic None None O
depletion None None O
of None None O
retinol None None O
and None None O
retinoic None None O
acid None None O
stores None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
nuclear None None O
accumulation None None O
of None None O
β-catenin None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
increased None None O
cytosolic None None O
expression None None O
p-GSK3β None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
significant None None O
upregulation None None O
of None None O
soluble None None O
Wnts None None O
, None None O
Wnt2 None None O
, None None O
and None None O
Wnt7a None None O
, None None O
and None None O
increased None None O
expression None None O
of None None O
several None None O
β-catenin None None O
targets None None O
involved None None O
in None None O
tumor None None O
promotion None None O
and None None O
progression None None O
, None None O
cyclin None None O
D1 None None O
, None None O
c-myc None None I-PROTEIN
, None None O
WISP1 None None O
, None None O
and None None O
MMP7 None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
acetaldehyde-producing None None O
strain None None O
Streptococcus None None O
gordonii None None O
V2016 None None O
was None None O
analyzed None None O
for None None O
adh None None O
genes None None O
and None None O
activities None None O
of None None O
alcohol None None O
and None None O
aldehyde None None O
dehydrogenases None None I-PROTEIN
. None None O

S. None None O
gordonii None None O
V2016 None None O
did None None O
not None None O
show None None O
a None None O
detectable None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
. None None O

Genetic None None O
polymorphisms None None O
of None None O
alcohol None None I-PROTEIN
dehydrogenase-1B None None O
( None None O
ADH1B None None O
) None None O
and None None O
aldehyde None None O
dehydrogenase-2 None None O
( None None O
ALDH2 None None O
) None None O
modulate None None O
exposure None None O
levels None None O
to None None O
ethanol/acetaldehyde None None O
. None None O

Additionally None None O
, None None O
it None None O
is None None O
appreciated None None O
that None None O
other None None O
major None None O
health None None O
issues None None O
are None None O
associated None None O
with None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
, None None O
including None None O
colorectal None None O
cancer None None O
( None None O
CRC None None O
) None None O
and None None O
its None None O
metastatic None None O
growth None None O
to None None O
the None None O
liver None None O
. None None O

RA None None O
is None None O
synthesized None None O
from None None O
retinaldehyde None None O
by None None O
the None None O
retinaldehyde None None O
dehydrogenases None None I-PROTEIN
, None None O
specifically None None O
ALDH1A1 None None O
, None None O
ALDH1A2 None None O
, None None O
ALDH1A3 None None O
, None None O
and None None O
ALDH8A1 None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
study None None O
were None None O
to None None O
investigate None None O
Sirt1 None None O
expression None None O
in None None O
mouse None None O
models None None O
of None None O
HCC None None O
and None None O
chronic None None O
EtOH-feeding None None O
, None None O
and None None O
in None None O
human None None O
HCC None None O
cells None None O
expressing None None O
alcohol None None O
metabolizing None None O
enzymes None None I-PROTEIN
. None None O

The None None O
primary None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
ethanol None None O
metabolism None None O
include None None O
alcohol None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
ADH None None O
) None None O
, None None O
cytochrome None None O
P450 None None O
isoform None None O
2E1 None None O
, None None O
( None None O
CYP2E1 None None I-PROTEIN
) None None O
, None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
, None None O
and None None O
aldehyde None None O
dehydrogenases None None I-PROTEIN
( None None O
ALDH None None O
) None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
provide None None O
a None None O
brief None None O
discussion None None O
on None None O
several None None O
animal None None O
models None None O
with None None O
genetic None None O
defects None None O
in None None O
alcohol-metabolizing None None O
enzymes None None I-PROTEIN
and None None O
GSH-synthesizing None None O
enzymes None None I-PROTEIN
and None None O
their None None O
relevance None None O
to None None O
alcohol None None O
research None None O
. None None O

First None None O
, None None O
we None None O
reviewed None None O
and None None O
analyzed None None O
relevant None None O
scientific None None O
articles None None O
and None None O
software None None O
apps None None I-TRANS
to None None O
determine None None O
the None None O
current None None O
state None None O
of None None O
knowledge None None O
flow None None O
within None None O
health None None O
care None None O
. None None O

2014 None None O
BMJ None None O
Publishing None None O
Group None None O
Ltd. None None O
Foix-Chavany-Marie None None O
syndrome None None O
( None None O
FCMS None None O
) None None O
also None None O
known None None O
as None None O
bilateral None None O
anterior None None O
opercular None None O
syndrome None None O
is None None O
a None None O
form None None O
of None None O
suprabulbar None None O
palsy None None O
defined None None O
by None None O
the None None O
presence None None O
of None None O
bilateral None None O
voluntary None None O
facial None None O
, None None O
pharyngeal None None O
, None None O
lingual None None O
and None None O
masticatory None None O
paralysis None None O
with None None O
automatic-voluntary None None O
movement None None I-FUNC
dissociation None None O
. None None O

Salt None None O
stress None None O
significantly None None O
reduced None None O
relative None None O
water None None O
content None None O
, None None O
leaf None None O
surface None None O
area None None O
, None None O
ribulose None None O
bisphosphate None None O
carboxylase None None O
expression None None O
, None None O
and None None O
chlorophyll None None O
content None None O
but None None O
increased None None O
the None None O
content None None O
of None None O
osmo-regulator None None O
protein None None O
, None None O
carbohydrates None None O
and None None O
proline None None I-TRANS
. None None O

While None None O
it None None O
elevated None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
content None None O
compared None None O
to None None O
control None None O
, None None O
Ca None None O
content None None O
and None None O
K None None O
( None None O
+ None None O
) None None O
/Na None None O
( None None O
+ None None O
) None None O
ratio None None O
were None None O
reduced None None O
. None None O

Similarly None None O
, None None O
LA None None O
prevented None None O
excessive None None O
accumulation None None O
of None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
and None None O
promoted None None O
K None None O
( None None O
+ None None O
) None None O
/Na None None O
( None None O
+ None None O
) None None O
ratio None None O
and None None O
Ca None None O
content None None O
. None None O

Stressors None None O
and/or None None O
disruption None None O
of None None O
glucocorticoid None None O
dynamics None None O
also None None O
target None None O
genes None None O
such None None O
as None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
and None None O
tyrosine None None I-TRANS
hydroxylase None None O
( None None O
TH None None O
) None None O
that None None O
are None None O
important None None O
for None None O
neuronal None None O
function None None O
and None None O
behavior None None O
. None None O

Inferences None None I-FUNC
can None None O
be None None O
based None None O
on None None O
individual None None O
response None None O
patterns None None O
or None None O
sets None None O
of None None O
response None None O
patterns None None O
such None None O
as None None O
sum None None O
scores None None O
. None None O

However None None O
, None None O
the None None O
role None None O
of None None O
the None None O
angiotensin None None O
type-2 None None O
receptor None None I-PROTEIN
( None None O
AT2R None None O
) None None O
in None None O
the None None O
neural None None O
control None None O
of None None O
these None None O
processes None None O
has None None O
received None None O
far None None O
less None None O
attention None None I-FUNC
, None None O
largely None None O
because None None O
of None None O
limited None None O
ability None None O
to None None O
effectively None None O
localize None None O
these None None O
receptors None None I-PROTEIN
at None None O
a None None O
cellular None None O
level None None O
in None None O
the None None O
brain None None O
. None None O

No None None O
co-localization None None O
was None None O
observed None None O
with None None O
tyrosine None None I-TRANS
hydroxylase None None O
in None None O
the None None O
NTS None None O
. None None O

However None None O
, None None O
the None None O
current None None O
closed-form None None O
equations None None O
for None None O
this None None O
method None None O
limit None None O
the None None O
ease None None O
, None None O
flexibility None None O
, None None O
and None None O
inferences None None I-FUNC
that None None O
researchers None None O
have None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
ketamine None None O
on None None O
proliferation None None O
of None None O
NSCs None None O
from None None O
neonatal None None O
rat None None O
hippocampus None None I-REGION
. None None O

The None None O
activation None None O
of None None O
protein None None O
kinase None None O
C-α None None O
( None None O
PKCα None None O
) None None O
and None None O
the None None O
phosphorylation None None O
of None None O
extracellular None None O
signal-regulated None None O
kinases None None I-PROTEIN
1/2 None None O
( None None O
ERK1/2 None None O
) None None O
were None None O
measured None None O
by None None O
western None None O
blot None None O
analysis None None O
. None None O

Cognition None None O
was None None O
assessed None None O
with None None O
a None None O
neuropsychological None None O
battery None None O
, None None O
providing None None O
summary None None O
scores None None O
for None None O
memory None None I-FUNC
, None None O
language None None I-FUNC
, None None O
executive None None O
, None None O
and None None O
visuospatial None None O
abilities None None O
. None None O

Future None None O
work None None O
should None None O
examine None None O
how None None O
cerebral None None O
amyloid None None O
angiopathy None None O
interacts None None O
with None None O
neurodegenerative None None O
processes None None O
, None None O
such None None O
as None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
is None None O
associated None None O
with None None O
very None None O
high None None O
recurrence None None O
rates None None O
, None None O
and None None O
specific None None O
vulnerability None None O
factors None None O
that None None O
increase None None O
the None None O
risk None None O
for None None O
repeated None None O
episodes None None O
should None None O
be None None O
identified None None O
. None None O

Inhibition None None O
and None None O
shifting None None O
data None None O
derived None None O
from None None O
neutral None None O
and None None O
emotional None None O
computerized None None O
tasks None None O
, None None O
and None None O
questionnaire None None O
data None None O
on None None O
emotion None None I-FUNC
regulation None None O
and None None O
trait None None O
rumination None None O
, None None O
were None None O
obtained None None O
from None None O
previously None None O
depressed None None O
( None None O
n None None O
= None None O
109 None None O
) None None O
and None None O
never-depressed None None O
women None None O
( None None O
n None None O
= None None O
64 None None O
) None None O
and None None O
analyzed None None O
in None None O
independent None None O
samples None None O
t-tests None None O
. None None O

The None None O
associations None None O
of None None O
executive None None O
functions None None O
to None None O
emotion None None I-FUNC
regulation None None O
and None None O
rumination None None O
were None None O
investigated None None O
in None None O
a None None O
series None None O
of None None O
linear None None O
regression None None O
analyses None None O
. None None O

Executive None None O
function None None O
was None None O
unrelated None None O
to None None O
rumination None None O
and None None O
emotion None None I-FUNC
regulation None None O
in None None O
this None None O
sample None None O
. None None O

Trait None None O
rumination None None O
and None None O
expressive None None O
suppression None None O
are None None O
known None None O
to None None O
increase None None O
depression None None I-DISEASE
risk None None O
, None None O
but None None O
were None None O
unrelated None None O
to None None O
executive None None O
functions None None O
in None None O
this None None O
population None None O
. None None O

Concentrations None None O
of None None O
cadmium None None O
( None None O
Cd None None O
) None None O
, None None O
copper None None O
( None None O
Cu None None O
) None None O
, None None O
mercury None None O
( None None O
Hg None None O
) None None O
, None None O
and None None O
zinc None None I-TRANS
( None None O
Zn None None O
) None None O
were None None O
determined None None O
by None None O
atomic None None O
absorption None None O
spectrophotometry None None O
in None None O
the None None O
muscle None None O
tissues None None O
( None None O
arms None None O
and None None O
mantle None None O
) None None O
of None None O
3 None None O
commercial None None O
cephalopods None None O
( None None O
Loligo None None O
vulgaris None None O
, None None O
Octopus None None O
vulgaris None None O
, None None O
and None None O
Sepia None None O
officinalis None None O
) None None O
caught None None O
in None None O
3 None None O
different None None O
Tunisian None None O
coastal None None O
regions None None O
. None None O

The None None O
assay None None O
was None None O
tested None None O
on None None O
the None None O
protein None None O
kinases None None I-PROTEIN
PIM-1 None None O
and None None O
Src None None O
and None None O
validated None None O
through None None O
a None None O
direct None None O
comparison None None O
with None None O
the None None O
classical None None O
radiometric None None O
assay None None O
using None None O
the None None O
[ None None O
γ- None None O
( None None O
32 None None O
) None None O
P None None O
] None None O
-labeled None None O
ATP None None O
. None None O

To None None O
improve None None O
the None None O
prevention None None O
and None None O
management None None O
of None None O
depression None None I-DISEASE
among None None O
nurses None None O
in None None O
mainland None None O
China None None O
, None None O
we None None O
investigated None None O
the None None O
association None None O
between None None O
working None None O
conditions None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
using None None O
a None None O
cross-sectional None None O
study None None O
with None None O
a None None O
sample None None O
of None None O
3474 None None O
nurses None None O
with None None O
more None None O
than None None O
1 None None O
year None None O
of None None O
work None None O
experience None None O
in None None O
public None None O
hospitals None None O
in None None O
Shenzhen None None O
in None None O
southern None None O
China None None O
. None None O

Multivariable None None O
linear None None O
mixed None None O
models None None O
were None None O
used None None O
to None None O
identify None None O
work-related None None O
risk None None O
factors None None O
for None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
scores None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
interventions None None O
to None None O
minimize None None O
workload None None O
and None None O
improve None None O
nurse-patient None None O
relationships None None O
are None None O
essential None None O
to None None O
combat None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
among None None O
nurses None None O
. None None O

Many None None O
studies None None O
show None None O
that None None O
spatial None None I-FUNC
reasoning None None I-FUNC
with None None O
information None None O
that None None O
describe None None O
relations None None O
between None None O
two None None O
or None None O
more None None O
objects None None O
relies None None O
on None None O
the None None O
construction None None O
and None None O
inspection None None O
of None None O
mental None None O
models None None O
. None None O

The None None O
results None None O
support None None O
the None None O
second None None O
assumption None None O
and None None O
offer None None O
a None None O
new None None O
view None None O
on None None O
the None None O
continuity None None O
effect None None O
and None None O
the None None O
fundamental None None O
principles None None O
of None None O
model None None O
construction None None O
and None None O
variation None None O
in None None O
human None None O
spatial None None I-FUNC
reasoning None None I-FUNC
. None None O

Participants None None O
who None None O
shared None None O
results None None O
with None None O
their None None O
family None None O
were None None O
more None None O
likely None None O
to None None O
be None None O
female None None O
and None None O
to None None O
have None None O
a None None O
personal None None O
history None None O
of None None O
cancer None None O
, None None O
and None None O
had None None O
greater None None O
self-efficacy None None O
for None None O
health None None O
management None None O
, None None O
perceived None None O
less None None O
ambiguity None None I-FUNC
in None None O
cancer None None O
prevention None None O
recommendations None None O
, None None O
and None None O
lower None None O
cancer None None O
prevention None None O
fatalism None None O
. None None O

We None None O
determined None None O
luciferase None None I-PROTEIN
gene None None O
reporter None None O
activity None None O
in None None O
the None None O
two None None O
above-mentioned None None O
SNPs None None O
and None None O
studied None None O
genotype None None O
distributions None None O
among None None O
centenarians None None O
( None None O
n None None O
= None None O
175 None None O
, None None O
144 None None O
women None None O
) None None O
and None None O
healthy None None O
controls None None O
( None None O
n None None O
= None None O
347 None None O
, None None O
142 None None O
women None None O
) None None O
from None None O
Spain None None O
. None None O

The None None O
rs726344 None None O
SNP None None O
had None None O
functional None None O
significance None None O
, None None O
as None None O
shown None None O
by None None O
differences None None O
in None None O
luciferase None None I-PROTEIN
activity None None O
between None None O
the None None O
constructs None None O
of None None O
this None None O
SNP None None O
( None None O
all None None O
P None None O
≤ None None O
0.05 None None O
) None None O
, None None O
with None None O
the None None O
variant None None O
A-allele None None O
having None None O
higher None None O
luciferase None None I-PROTEIN
activity None None O
compared None None O
with None None O
the None None O
G-allele None None O
( None None O
P None None O
= None None O
0.04 None None O
) None None O
. None None O

Fortunately None None O
, None None O
a None None O
large None None O
number None None O
of None None O
remedies None None O
for None None O
the None None O
latter None None O
problem None None O
have None None O
been None None O
discovered None None O
over None None O
the None None O
past None None O
30+ None None O
years None None O
, None None O
and None None O
the None None O
former None None O
problem None None O
can None None O
in None None O
most None None O
cases None None O
be None None O
eliminated None None O
or None None O
adequately None None O
controlled None None O
by None None O
careful None None O
attention None None I-FUNC
to None None O
technique None None O
. None None O

In None None O
this None None O
chapter None None O
we None None O
describe None None O
the None None O
entire None None O
cryopreservation None None O
process None None O
for None None O
stallion None None O
and None None O
bull None None O
sperm None None O
including None None O
dilution None None O
of None None O
sperm None None O
in None None O
primary None None O
and None None O
freezing None None O
extender None None O
, None None O
cooling None None O
and None None O
packaging None None O
in None None O
straws None None O
, None None O
freezing None None O
in None None O
liquid None None O
nitrogen None None O
vapor None None O
, None None O
cryogenic None None O
storage None None I-FUNC
, None None O
and None None O
thawing None None O
. None None O

In None None O
this None None O
chapter None None O
, None None O
we None None O
describe None None O
specific None None O
protocols None None O
for None None O
clinical None None O
processing None None O
, None None O
cryopreservation None None O
, None None O
and None None O
storage None None I-FUNC
of None None O
UCB None None O
used None None O
by None None O
the None None O
Canadian None None O
Blood None None O
Services None None O
National None None O
Public None None O
Umbilical None None O
Cord None None O
Blood None None O
Bank None None O
. None None O

In None None O
contrast None None O
, None None O
ice-free None None O
cryopreservation None None O
using None None O
VS83 None None O
, None None O
Protocols None None O
2 None None O
and None None O
3 None None O
, None None O
has None None O
several None None O
advantages None None O
over None None O
conventional None None O
cryopreservation None None O
methods None None O
and None None O
VS55 None None O
preservation None None O
, None None O
including None None O
long-term None None O
preservation None None O
capability None None O
at None None O
-80 None None O
°C None None O
; None None O
better None None O
matrix None None O
preservation None None O
than None None O
freezing None None O
with None None O
retention None None I-FUNC
of None None O
material None None O
properties None None O
; None None O
very None None O
low None None O
cell None None O
viability None None O
, None None O
reducing None None O
the None None O
risks None None O
of None None O
an None None O
immune None None O
reaction None None O
in None None O
vivo None None O
; None None O
reduced None None O
risks None None O
of None None O
microbial None None O
contamination None None O
associated None None O
with None None O
use None None O
of None None O
liquid None None O
nitrogen None None O
; None None O
improved None None O
in None None O
vivo None None O
functions None None O
; None None O
no None None O
significant None None O
recipient None None O
allogeneic None None O
immune None None O
response None None O
; None None O
simplified None None O
manufacturing None None O
process None None O
; None None O
increased None None O
operator None None O
safety None None O
because None None O
liquid None None O
nitrogen None None O
is None None O
not None None O
used None None O
; None None O
and None None O
reduced None None O
manufacturing None None O
costs None None O
. None None O

This None None O
chapter None None O
is None None O
pertinent None None O
to None None O
other None None O
biopreservation None None O
sectors None None O
because None None O
how None None O
methods None None O
are None None O
written None None O
, None None O
interpreted None None O
, None None O
and None None O
implemented None None O
can None None O
affect None None O
the None None O
quality None None O
of None None O
storage None None I-FUNC
outcomes None None O
. None None O

As None None O
part None None O
of None None O
the None None O
development None None O
of None None O
new None None O
eHealth None None O
technologies None None O
to None None O
support None None O
patients None None O
with None None O
CCDD None None O
in None None O
primary None None O
care None None O
settings None None O
, None None O
we None None O
sought None None O
to None None O
determine None None O
the None None O
perceived None None O
needs None None O
of None None O
these None None O
patients None None O
with None None O
respect None None O
to None None O
( None None O
1 None None O
) None None O
the None None O
kinds None None O
of None None O
health None None O
and None None O
health None None O
service None None O
issues None None O
that None None O
are None None O
important None None O
to None None O
them None None O
, None None O
( None None O
2 None None O
) None None O
the None None O
information None None O
that None None O
should None None O
be None None O
collected None None O
and None None O
how None None O
it None None O
could None None O
be None None O
collected None None O
in None None O
order None None O
to None None O
help None None O
meet None None O
their None None O
needs None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
their None None O
views None None O
on None None O
the None None O
challenges/barriers None None O
to None None O
using None None O
eHealth None None O
mobile None None O
apps None None I-TRANS
to None None O
collect None None O
the None None O
information None None O
. None None O

Real-time None None O
PCR None None O
( None None O
qPCR None None O
) None None O
, None None O
western None None O
blot None None O
, None None O
and None None O
luciferase None None I-PROTEIN
assays None None O
were None None O
used None None O
to None None O
examine None None O
the None None O
molecules None None O
' None None O
expression None None O
and None None O
biological None None O
activity None None O
in None None O
canonical None None O
and None None O
noncanonical None None O
Wnt None None O
signaling None None O
pathways None None O
. None None O

Pretreatment None None O
with None None O
Shinzami None None O
extract None None O
decreased None None O
the None None O
aspirate None None O
aminotransferase None None O
and None None O
alanine None None I-TRANS
aminotransferase None None O
serum None None O
levels None None O
in None None O
our None None O
hepatic None None O
I/R None None O
rat None None O
model None None O
. None None O

The None None O
total None None O
anthocyanins None None O
extracted None None O
from None None O
Shinzami None None O
, None None O
however None None O
, None None O
only None None O
increased None None O
the None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
activity None None O
level None None O
in None None O
the None None O
hepatic None None O
I/R None None O
rats None None O
. None None O

This None None O
should None None O
preserve None None O
collagen None None I-PROTEIN
from None None O
hydrolysis None None O
upon None None O
aging None None O
of None None O
the None None O
hybrid None None O
layer None None O
. None None O

The None None O
fabricated None None O
construct None None O
did None None O
not None None O
present None None O
a None None O
release None None O
neither None None O
of None None O
collagen None None I-PROTEIN
neither None None O
of None None O
genipin None None O
over None None O
its None None O
toxic None None O
level None None O
in None None O
the None None O
surrounding None None O
aqueous None None O
environment None None O
. None None O

Additionally None None O
, None None O
the None None O
available None None O
area None None O
for None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
, None None O
which None None O
is None None O
related None None O
to None None O
fiber None None O
and None None O
pore None None O
size None None O
, None None O
was None None O
a None None O
crucial None None O
factor None None O
for None None O
the None None O
viability None None O
of None None O
L929 None None O
cells None None O
. None None O

The None None O
Mg-3Zn None None O
substrate None None O
is None None O
first None None O
immersed None None O
into None None O
0.02 None None O
mol None None O
L None None O
( None None O
-1 None None O
) None None O
nicotinic None None O
acid None None O
( None None O
NA None None I-TRANS
) None None O
solution None None O
, None None O
named None None O
as None None O
vitamin None None O
B3 None None O
, None None O
to None None O
obtain None None O
a None None O
pretreatment None None O
film None None O
, None None O
and None None O
then None None O
the None None O
electrodeposition None None O
of None None O
calcium None None O
phosphate None None O
coating None None O
with None None O
ultrasonic None None O
agitation None None O
is None None O
carried None None O
out None None O
on None None O
the None None O
NA None None I-TRANS
pretreatment None None O
film None None O
to None None O
obtain None None O
a None None O
NA/calcium None None O
phosphate None None O
composite None None O
coating None None O
. None None O

Subunit None None O
composition None None O
of None None O
C. None None O
saira None None O
collagen None None I-PROTEIN
( None None O
2α1+α2 None None O
) None None O
was None None O
similar None None O
to None None O
that None None O
of None None O
red None None O
sea None None O
bream None None O
( None None O
Pagrus None None O
major None None O
) None None O
and None None O
porcine None None O
collagen None None I-PROTEIN
. None None O

The None None O
temperature None None O
of None None O
denaturation None None O
( None None O
24-25 None None O
°C None None O
) None None O
of None None O
C. None None O
saira None None O
collagen None None I-PROTEIN
was None None O
slightly None None O
lower None None O
than None None O
that None None O
of None None O
P. None None O
major None None O
collagen None None I-PROTEIN
( None None O
26-27 None None O
°C None None O
) None None O
. None None O

Circular None None O
dichroism None None O
spectra None None O
and None None O
Fourier-transformed None None O
infrared None None O
spectra None None O
showed None None O
that None None O
heat None None O
denaturation None None O
caused None None O
unfolding None None O
of None None O
the None None O
triple None None O
helices None None O
in None None O
all None None O
three None None O
collagens None None I-PROTEIN
. None None O

This None None O
paper None None O
presents None None O
the None None O
crosslinked None None O
collagen None None I-PROTEIN
( None None O
Col None None O
) None None O
-gelatin None None O
( None None O
Gel None None O
) None None O
-hyaluronic None None O
acid None None O
( None None O
HA None None O
) None None O
films None None O
developed None None O
by None None O
making None None O
use None None O
of None None O
1-ethyl-3- None None O
( None None O
3-dimethyl None None O
aminopropyl None None O
) None None O
carbodiimide None None O
( None None O
EDC None None O
) None None O
and None None O
N-hydroxysuccinimide None None O
( None None O
NHS None None O
) None None O
as None None O
the None None O
crosslinker None None O
. None None O

The None None O
diffusion None None O
properties None None O
of None None O
the None None O
CGH631 None None O
film None None O
to None None O
NaCl None None O
and None None O
tryptophan None None I-TRANS
are None None O
also None None O
satisfactory None None O
and None None O
the None None O
measured None None O
data None None O
are None None O
2.43×10 None None O
( None None O
-6 None None O
) None None O
cm None None O
( None None O
2 None None O
) None None O
/s None None O
and None None O
7.97×10 None None O
( None None O
-7 None None O
) None None O
cm None None O
( None None O
2 None None O
) None None O
/s None None O
, None None O
respectively None None O
. None None O

In None None O
vitro None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
tests None None O
confirmed None None O
the None None O
osteoblast None None O
attachment None None O
and None None O
growth None None O
on None None O
the None None O
HApTiR None None O
's None None O
surface None None O
. None None O

And None None O
then None None O
, None None O
in None None O
order None None O
to None None O
avoid None None O
the None None O
influence None None O
from None None O
the None None O
other None None O
factors None None O
such None None O
as None None O
hypoxia None None O
which None None O
emerge None None O
in None None O
vivo None None O
study None None O
and None None O
affect None None O
the None None O
secretion None None O
of None None O
VEGF None None O
and None None O
bFGF None None O
from None None O
host None None O
cells None None O
, None None O
human None None O
osteoblast-like None None O
cells None None O
( None None O
MG63 None None O
) None None O
were None None O
seeded None None O
to None None O
SCPP None None O
, None None O
CPP None None O
and None None O
HA None None O
scaffolds None None O
in None None O
vitro None None O
to None None O
determine None None O
the None None O
ability None None O
of None None O
these None None O
scaffolds None None O
to None None O
stimulate None None O
the None None O
secretion None None O
of None None O
angiogenic None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
( None None O
VEGF None None O
and None None O
bFGF None None O
) None None O
from None None O
MG63 None None O
and None None O
further None None O
explore None None O
the None None O
reason None None O
for None None O
the None None O
better None None O
osteogenic None None O
properties None None O
of None None O
SCPP None None O
scaffolds None None O
. None None O

We None None O
have None None O
developed None None O
self-assembled None None O
chitosan/insulin None None O
nanoparticles None None O
for None None O
successful None None O
oral None None O
insulin None None I-PROTEIN
delivery None None O
. None None O

An None None O
average None None O
insulin None None I-PROTEIN
encapsulation None None O
within None None O
the None None O
nanoparticles None None O
was None None O
~85 None None O
% None None O
. None None O

The None None O
electrochemical None None O
behaviors None None O
of None None O
dopamine None None I-TRANS
( None None O
DA None None O
) None None O
and None None O
epinephrine None None I-TRANS
( None None O
EP None None O
) None None O
at None None O
the None None O
electrode None None O
were None None O
investigated None None O
by None None O
cyclic None None O
voltammetry None None O
( None None O
CV None None O
) None None O
. None None O

In None None O
the None None O
in None None O
vitro None None O
study None None O
using None None O
luciferase None None I-PROTEIN
gene None None O
, None None O
the None None O
DLp-Ap None None O
layers None None O
showed None None O
1-2 None None O
orders None None O
of None None O
magnitudes None None O
higher None None O
gene None None O
transfer None None O
efficiency None None O
to None None O
MSCs None None O
than None None O
the None None O
D-Ap None None O
layer None None O
. None None O

The None None O
maximum None None O
lysozyme None None I-PROTEIN
adsorption None None O
capacity None None O
of None None O
the None None O
PHEMATrp None None O
nanoparticles None None O
was None None O
found None None O
to None None O
be None None O
326.9 None None O
mg/g None None O
polymer None None O
at None None O
pH None None O
7.0 None None O
. None None O

In None None O
terms None None O
of None None O
protein None None O
desorption None None O
, None None O
it None None O
was None None O
observed None None O
that None None O
adsorbed None None O
lysozyme None None I-PROTEIN
was None None O
readily None None O
desorbed None None O
in None None O
medium None None O
containing None None O
1.0 None None O
M None None O
NaCl None None O
. None None O

We None None O
used None None O
electrochemical None None O
impedance None None O
spectroscopy None None O
( None None O
EIS None None O
) None None O
and None None O
attenuated None None O
total None None O
reflectance None None O
Fourier None None O
transform None None O
infrared None None O
( None None O
ATR-FTIR None None O
) None None O
spectroscopy None None O
to None None O
evaluate None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
as None None O
model None None O
protein None None O
, None None O
adsorbed None None O
to None None O
these None None O
biomaterial None None O
surfaces None None O
. None None O

The None None O
cyclability None None O
experiments None None O
are None None O
carried None None O
out None None O
in None None O
a None None O
static None None O
cell None None O
; None None O
the None None O
results None None O
showed None None O
that None None O
these None None O
materials None None O
exhibit None None O
stable None None O
capacity None None O
retention None None I-FUNC
and None None O
predictable None None O
discharge None None O
potentials None None O
, None None O
which None None O
agree None None O
with None None O
the None None O
potential None None O
values None None O
from None None O
the None None O
cyclic None None O
voltammograms None None O
. None None O

Menkes None None O
disease None None O
( None None O
MD None None O
; None None O
OMIM None None O
309400 None None O
) None None O
is None None O
an None None O
X-linked None None O
, None None O
neurodegenerative None None O
disorder None None O
resulting None None O
from None None O
deficient None None O
activity None None O
of None None O
copper-dependent None None O
enzymes None None I-PROTEIN
and None None O
caused None None O
by None None O
alterations None None O
in None None O
the None None O
APT7A None None O
gene None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
identify None None O
prevalences None None O
of None None O
self-reported None None O
skin None None O
disease None None O
and None None O
skin-related None None O
concerns None None O
in None None O
elderly None None O
African-Americans None None O
, None None O
and None None O
to None None O
assess None None O
participants None None O
' None None O
perceptions None None I-FUNC
of None None O
skin None None O
disease None None O
and None None O
awareness None None O
of None None O
skin None None O
cancer None None O
. None None O

Metformin None None O
( None None O
the None None O
best None None O
known None None O
clinical None None O
activator None None O
of None None O
AMPK None None O
) None None O
suppressed None None O
TM- None None O
or None None O
TG-induced None None O
ER None None O
stress None None O
, None None O
as None None O
shown None None O
by None None O
the None None O
inhibition None None O
of None None O
TM- None None O
or None None O
TG-induced None None O
upregulation None None O
of None None O
glucose-related None None O
protein None None O
( None None O
GRP None None I-TRANS
) None None O
78 None None O
and None None O
phosphorylated None None O
eukaryotic None None O
initiation None None O
factor-2α None None O
through None None O
induction None None O
of None None O
heme None None O
oxygenase-1 None None O
. None None O

Additionally None None O
, None None O
oxidative None None O
stress None None O
was None None O
significantly None None O
increased None None O
in None None O
OZ None None O
rats None None O
, None None O
as None None O
evidenced None None O
by None None O
increased None None O
renal None None O
NADPH None None O
oxidase None None O
activity None None O
and None None O
urine None None O
lipid None None O
peroxidation None None O
products None None O
( None None O
thiobarbituric None None O
acid-reactive None None O
substances None None O
) None None O
, None None O
and None None O
OZ None None O
rats None None O
also None None O
had None None O
suppressed None None O
renal None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
activity None None O
. None None O

We None None O
retrieved None None O
data None None O
from None None O
all None None O
patients None None O
with None None O
posterior None None O
fossa None None O
parenchymal None None O
lesions None None O
in None None O
the None None O
International None None O
Study None None O
on None None O
Cerebral None None O
Vein None None O
and None None O
Dural None None O
Sinus None None O
Thrombosis None None I-DISEASE
( None None O
ISCVT None None O
) None None O
cohort None None O
related None None O
to None None O
clinical None None O
features None None O
, None None O
therapy None None O
and None None O
outcome None None O
. None None O

In None None O
order None None O
to None None O
investigate None None O
the None None O
influence None None O
of None None O
platelet None None O
( None None O
pP-selectin None None O
) None None O
and None None O
soluble None None O
P-selectin None None O
( None None O
sP-selectin None None O
) None None O
, None None O
and None None O
of None None O
variations None None O
in None None O
the None None O
genes None None O
encoding None None I-FUNC
for None None O
P-selectin None None O
( None None O
SELP None None O
) None None O
and None None O
PSGL-1 None None O
( None None O
SELPLG None None O
) None None O
on None None O
LPA None None O
formation None None O
, None None O
we None None O
assessed None None O
monocyte None None O
( None None O
MPA None None O
) None None O
- None None O
and None None O
neutrophil-platelet None None O
aggregates None None O
( None None O
NPA None None O
) None None O
as None None O
well None None O
as None None O
pP-selectin None None O
by None None O
flow None None O
cytometry None None O
in None None O
263 None None O
patients None None O
undergoing None None O
angioplasty None None O
and None None O
stenting None None O
. None None O

Other None None O
predictive None None O
variables None None O
taken None None O
into None None O
account None None O
in None None O
the None None O
analyses None None O
are None None O
presence None None O
of None None O
comorbid None None O
psychopathology None None O
and None None O
personality None None I-DISEASE
disorder None None I-DISEASE
, None None O
subtype None None O
of None None O
the None None O
offender None None O
, None None O
and None None O
dynamics None None O
of None None O
the None None O
domestic None None O
violence None None O
. None None O

A None None O
specific None None O
, None None O
miniaturized None None O
filter None None O
was None None O
developed None None O
and None None O
tested None None O
for None None O
leukocyte None None O
and None None O
plasma None None O
virus None None O
retention None None I-FUNC
, None None O
WB None None O
sample None None O
dilution None None O
, None None O
and None None O
filtration None None O
parameters None None O
in None None O
HIV-1-spiked None None O
WB None None O
samples None None O
. None None O

Transgenic None None O
mice None None O
with None None O
postnatal None None O
dominant-negative None None O
ActRIB None None O
expression None None O
causing None None O
disruption None None O
of None None O
activin None None O
signaling None None O
in None None O
vivo None None O
were None None O
used None None O
for None None O
assessing None None O
cochlear None None O
morphology None None O
and None None O
hearing None None O
ability None None O
through None None O
the None None O
auditory None None O
brainstem None None I-REGION
response None None O
( None None O
ABR None None O
) None None O
threshold None None O
. None None O

One None None O
of None None O
the None None O
peptides None None I-TRANS
was None None O
also None None O
labeled None None O
with None None O
the None None O
paramagnetic None None O
probe None None O
MTSL None None O
. None None O

1D-NMR None None O
confirmed None None O
that None None O
the None None O
peptides None None I-TRANS
K None None O
and None None O
E None None O
form None None O
a None None O
heterodimeric None None O
coiled None None O
coil None None O
with None None O
a None None O
parallel None None O
orientation None None O
. None None O

Thus None None O
, None None O
paramagnetic None None O
nitroxide None None O
and None None O
aromatic None None O
fluorophore None None O
labeling None None O
of None None O
peptides None None I-TRANS
yields None None O
valuable None None O
information None None O
regarding None None O
the None None O
quaternary None None O
structure None None O
from None None O
1D-NMR None None O
and None None O
steady-state None None O
fluorescence None None O
measurements None None O
. None None O

Moreover None None O
, None None O
GSH None None O
reacts None None O
with None None O
the None None O
reactive None None O
endogenous None None O
carbonyls None None O
methylglyoxal None None O
and None None O
formaldehyde None None O
to None None O
intermediates None None O
which None None O
are None None O
substrates None None O
of None None O
detoxifying None None O
enzymes None None I-PROTEIN
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
CXC195 None None O
on None None O
the None None O
phosphorylation None None O
of None None O
endothelial None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
eNOS None None O
) None None O
in None None O
response None None O
to None None O
cerebral None None O
I/R None None O
and None None O
to None None O
determine None None O
whether None None O
phosphatidylinositol-3-kinase None None O
( None None O
PI3K None None O
) None None O
/Akt None None O
signaling None None O
pathway None None O
might None None O
be None None O
involved None None O
. None None O

CXC195 None None O
increased None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
production None None O
and None None O
the None None O
phosphorylation None None O
but None None O
not None None O
the None None O
protein None None O
level None None O
of None None O
eNOS None None O
in None None O
HAECs None None O
subjected None None O
to None None O
1 None None O
h None None O
OGD None None O
followed None None O
by None None O
reperfusion None None O
. None None O

Men None None O
in None None O
our None None O
sample None None O
expressed None None O
strong None None O
feelings None None I-FUNC
of None None O
interdependence None None O
and None None O
trust None None O
towards None None O
their None None O
co-workers None None O
which None None O
we None None O
defined None None O
as None None O
'social None None O
solidarity None None O
' None None O
. None None O

Recorded None None O
red None None O
blood None None O
cell None None O
width None None O
and None None O
amylase None None I-PROTEIN
values None None O
of None None O
104 None None O
patients None None O
diagnosed None None O
with None None O
acute None None O
pancreatitis None None O
were None None O
statistically None None O
compared None None O
according None None O
to None None O
the None None O
time None None O
of None None O
sample None None O
collection None None O
. None None O

Values None None O
of None None O
red None None O
blood None None O
cell None None O
width None None O
and None None O
amylase None None I-PROTEIN
were None None O
found None None O
to None None O
be None None O
significantly None None O
higher None None O
in None None O
samples None None O
collected None None O
during None None O
hospital None None O
admission None None O
in None None O
comparison None None O
to None None O
those None None O
obtained None None O
from None None O
patients None None O
after None None O
fully None None O
recovering None None O
from None None O
acute None None O
pancreatitis None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Stroke None None I-DISEASE
is None None O
an None None O
abrupt None None O
onset None None O
of None None O
both None None O
focal None None O
and None None O
global None None O
neurological None None O
deficits None None O
secondary None None O
to None None O
a None None O
vascular None None O
event None None O
lasting None None O
more None None O
than None None O
24 None None O
h None None O
and None None O
with None None O
a None None O
vascular None None O
background None None O
as None None O
its None None O
only None None O
cause None None O
. None None O

The None None O
history None None O
of None None O
acute None None O
brain None None O
ischemia None None O
is None None O
burdened None None O
with None None O
neurological None None O
complications None None O
such None None O
as None None O
motor None None O
impairment None None O
, None None O
speech None None I-FUNC
impairment None None O
and None None O
intellectual None None O
delay None None O
. None None O

Stroke None None I-DISEASE
is None None O
a None None O
heterogeneous None None O
disorder None None O
; None None O
its None None O
risk None None O
factors None None O
in None None O
adults None None O
are None None O
well None None O
known None None O
, None None O
however None None O
, None None O
in None None O
pediatrics None None O
, None None O
in None None O
more None None O
than None None O
20 None None O
% None None O
cases None None O
, None None O
the None None O
cause None None O
of None None O
stroke None None I-DISEASE
is None None O
impossible None None O
to None None O
determine None None O
. None None O

We None None O
have None None O
reviewed None None O
the None None O
recent None None O
case-control None None O
studies None None O
conducted None None O
on None None O
pediatric None None O
patients None None O
regarding None None O
biochemical None None O
risk None None O
factors None None O
such None None O
as None None O
elevated None None O
levels None None O
of None None O
homocysteine None None O
, None None O
fibrinogen None None O
, None None O
protein None None I-PROTEIN
C None None I-PROTEIN
, None None O
protein None None I-PROTEIN
S None None I-PROTEIN
, None None O
antithrombin None None O
III None None O
, None None O
lipoprotein None None O
( None None O
a None None O
) None None O
, None None O
cholesterol None None O
and None None O
its None None O
fractions None None O
, None None O
and None None O
compared None None O
them None None O
with None None O
the None None O
results None None O
obtained None None O
from None None O
adult None None O
patients None None O
. None None O

Not None None O
only None None O
direct None None O
smears None None O
but None None O
also None None O
LBC None None O
slides None None O
represent None None O
an None None O
effective None None O
preparation None None O
and None None O
storage None None I-FUNC
medium None None O
for None None O
cytological None None O
material None None O
to None None O
be None None O
used None None O
for None None O
EGFR None None O
molecular None None O
testing None None O
. None None O

The None None O
TL None None O
intensity None None O
was None None O
1.17 None None O
times None None O
less None None O
than None None O
that None None O
of None None O
the None None O
standard None None O
CaSO4 None None O
: None None O
Dy None None O
thermoluminescence None None O
dosimetry None None O
( None None O
TLD None None O
) None None O
phosphor None None O
, None None O
the None None O
phosphor None None O
showed None None O
a None None O
linear None None O
dose-response None None O
curve None None O
for None None O
different None None O
γ-ray None None O
irradiation None None O
doses None None O
( None None O
0.002-1.25 None None O
Gy None None O
) None None O
and None None O
fading None None O
of None None O
5-7 None None O
% None None O
was None None O
observed None None O
for None None O
higher None None O
temperature None None O
peaks None None O
upon None None O
storage None None I-FUNC
. None None O

The None None O
Xist None None O
binding None None O
accumulates None None O
histones None None I-PROTEIN
H3 None None O
methylation None None O
and None None O
H4 None None O
hypoacetylation None None O
required None None O
for None None O
X None None O
inactivation None None O
that None None O
leads None None O
to None None O
proper None None O
dosage None None O
compensation None None O
of None None O
the None None O
X-linked None None O
genes None None O
. None None O

Attention None None I-FUNC
orienting None None O
is None None O
a None None O
cognitive None None O
process None None O
that None None O
facilitates None None O
the None None O
movement None None I-FUNC
of None None O
attention None None I-FUNC
focus None None O
from None None O
one None None O
location None None O
to None None O
another None None O
: None None O
this None None O
may None None O
be None None O
impaired None None O
in None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
functional None None O
connectivity None None O
of None None O
attention None None I-FUNC
orienting None None O
in None None O
these None None O
networks None None O
in None None O
ASD None None O
using None None O
the None None O
Posner None None O
Cueing None None O
Task None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
use None None O
the None None O
sulfinyl None None O
radical None None O
( None None O
-SO None None O
( None None O
• None None O
) None None O
) None None O
as None None O
a None None O
model None None O
to None None O
show None None O
that None None O
the None None O
dual None None O
properties None None O
of None None O
heteroatom-centered None None O
radicals None None O
, None None O
that None None O
is None None O
, None None O
their None None O
ability None None O
to None None O
function None None O
as None None O
a None None O
radical None None O
and None None O
a None None O
base None None O
, None None O
can None None O
coexist None None O
in None None O
peptides None None I-TRANS
and None None O
be None None O
differentiated None None O
by None None O
examining None None O
the None None O
loss None None O
of None None O
hydrosulfinyl None None O
radical None None O
( None None O
SOH None None O
) None None O
upon None None O
unimolecular None None O
dissociation None None O
of None None O
the None None O
peptide None None O
sulfinyl None None O
radical None None O
ions None None O
in None None O
the None None O
gas None None O
phase None None O
. None None O

The None None O
selectin None None I-PROTEIN
pathway None None O
recruiter None None O
, None None O
α-1,3-fucosyltransferase-VI None None O
enzyme None None O
, None None O
significantly None None O
increased None None O
Treg None None O
surface None None O
fucosylation None None O
( None None O
66 None None O
% None None O
vs None None O
8 None None O
% None None O
) None None O
. None None O

Inhibition None None O
of None None O
vasodilator-stimulated None None O
phosphoprotein None None O
phosphorylation None None O
and None None O
prostaglandin None None O
E1-induced None None O
increase None None O
in None None O
cyclic None None O
adenosine None None I-TRANS
monophosphate None None O
( None None O
cAMP None None O
) None None O
by None None O
ADP None None O
was None None O
impaired None None O
, None None O
whereas None None O
inhibition None None O
of None None O
cAMP None None O
increase None None O
by None None O
epinephrine None None I-TRANS
was None None O
normal None None O
. None None O

We None None O
attempted None None O
to None None O
identify None None O
blood None None O
fatty None None O
acids None None O
as None None O
biomarkers None None O
of None None O
dementia None None I-DISEASE
. None None O

The None None O
severity None None O
of None None O
dementia None None I-DISEASE
was None None O
evaluated None None O
with None None O
the None None O
Mini-Mental None None O
State None None O
Examination None None O
test None None O
. None None O

Tauopathies None None O
, None None O
such None None O
as None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
and None None O
Frontotemporal None None I-DISEASE
dementia None None I-DISEASE
with None None O
Parkinsonism None None O
linked None None O
to None None O
chromosome None None O
17 None None O
( None None O
FTDP-17 None None O
) None None O
, None None O
are None None O
characterized None None O
by None None O
tau None None O
accumulation None None O
. None None O

The None None O
recent None None O
finding None None O
of None None O
activity-dependent None None O
neuroprotective None None O
protein None None O
( None None O
ADNP None None O
) None None O
as None None O
a None None O
protein None None O
decreased None None O
in None None O
serum None None O
of None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
compared None None O
to None None O
controls None None O
, None None O
alongside None None O
with None None O
the None None O
discovery None None O
of None None O
ADNP None None O
mutations None None O
in None None O
autism None None O
and None None O
coupled None None O
with None None O
the None None O
original None None O
description None None O
of None None O
cancer None None O
mutations None None O
, None None O
ignited None None O
an None None O
interest None None O
for None None O
a None None O
comparative None None O
analysis None None O
of None None O
ADNP None None O
with None None O
other None None O
AD/autism/cancer-associated None None O
genes None None O
. None None O

Clinical None None O
diagnosis None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
relying None None O
on None None O
symptomatic None None O
features None None O
has None None O
a None None O
low None None O
specificity None None O
, None None O
emphasizing None None O
the None None O
importance None None O
of None None O
the None None O
pragmatic None None O
use None None O
of None None O
neurochemical None None O
biomarkers None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
is None None O
a None None O
neurodegenerative None None O
disorder None None O
with None None O
emerging None None O
evidence None None O
that None None O
it None None O
is None None O
associated None None O
with None None O
retinal None None O
ganglion None None I-NEURON
cell None None I-NEURON
loss None None O
; None None O
however None None O
, None None O
few None None O
data None None O
exist None None O
to None None O
establish None None O
this None None O
association None None O
. None None O

The None None O
earliest None None O
sites None None O
of None None O
brain None None O
atrophy None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
are None None O
in None None O
the None None O
medial None None O
temporal None None I-REGION
lobe None None I-REGION
, None None O
following None None O
widespread None None O
cerebral None None O
cortical None None O
amyloid None None O
deposition None None O
. None None O

Compared None None O
to None None O
amyloid-negative None None O
participants None None O
, None None O
amyloid-positive None None O
participants None None O
had None None O
significantly None None O
smaller None None O
hippocampal None None O
tail None None O
, None None O
presubiculum None None I-REGION
, None None O
subiculum None None I-REGION
, None None O
and None None O
total None None O
hippocampal None None O
gray None None O
matter None None O
volumes None None O
. None None O

The None None O
diagnosis None None O
of None None O
idiopathic None None O
normal None None I-DISEASE
pressure None None I-DISEASE
hydrocephalus None None I-DISEASE
( None None O
iNPH None None O
) None None O
is None None O
sometimes None None O
complicated None None O
by None None O
concomitant None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
pathology None None O
. None None O

Total None None O
tau None None O
( None None O
t-tau None None O
) None None O
, None None O
tau None None O
phosphorylated None None O
at None None O
threonine None None I-TRANS
181 None None O
( None None O
p-tau None None O
) None None O
, None None O
amyloid-β None None O
( None None O
Aβ None None O
) None None O
42 None None O
and None None O
40 None None O
, None None O
and None None O
leucine-rich None None O
α-2-glycoprotein None None O
( None None O
LRG None None O
) None None O
were None None O
measured None None O
in None None O
93 None None O
consecutive None None O
CSF None None O
samples None None O
consisting None None O
of None None O
55 None None O
iNPH None None O
( None None O
46 None None O
tap None None O
test None None O
responders None None O
) None None O
, None None O
20 None None O
AD None None O
, None None O
11 None None O
corticobasal None None O
syndrome None None O
, None None O
and None None O
7 None None O
spinocerebeller None None O
disease None None O
. None None O

The None None O
majority None None O
of None None O
KLF2 None None O
mutations None None O
were None None O
frameshift None None O
indels None None O
or None None O
nonsense None None O
changes None None O
, None None O
with None None O
missense None None O
mutations None None O
clustered None None O
in None None O
the None None O
C-terminal None None O
zinc None None I-TRANS
finger None None O
domains None None O
. None None O

Secondary None None O
outcomes None None O
include None None O
( None None O
i None None O
) None None O
ulcer-related None None O
outcomes None None O
: None None O
time None None O
to None None O
healing None None O
, None None O
change None None O
in None None O
ulcer None None O
area None None O
, None None O
minor None None O
and None None O
major None None O
amputation None None O
, None None O
secondary None None O
infection None None O
and None None O
( None None O
ii None None O
) None None O
patient-related None None O
outcomes None None O
: None None O
local None None O
pain None None O
, None None O
mood None None I-FUNC
and None None O
function None None O
( None None O
EQ-5D None None O
) None None O
, None None O
impact None None O
of None None O
the None None O
ulcer None None O
( None None O
Cardiff None None O
Wound None None O
Impact None None O
Schedule None None O
) None None O
and None None O
survival None None O
. None None O

This None None O
review None None O
and None None O
prospectus None None O
is None None O
the None None O
result None None O
of None None O
a None None O
collaborative None None O
effort None None O
between None None O
43 None None O
scientists None None O
from None None O
the None None O
fields None None O
of None None O
animal None None O
behaviour None None O
, None None O
ecology None None O
and None None O
evolution None None O
, None None O
signal None None O
processing None None O
, None None O
machine None None O
learning None None I-FUNC
, None None O
quantitative None None O
linguistics None None O
, None None O
and None None O
information None None O
theory None None O
, None None O
who None None O
gathered None None O
for None None O
a None None O
2013 None None O
workshop None None O
entitled None None O
, None None O
'Analysing None None O
vocal None None O
sequences None None O
in None None O
animals None None O
' None None O
. None None O

The None None O
exogenous None None O
DNA-binding None None I-PROTEIN
protein None None I-PROTEIN
fused None None O
with None None O
a None None O
tag None None O
( None None O
s None None O
) None None O
is None None O
expressed None None O
in None None O
the None None O
cell None None O
and None None O
the None None O
target None None O
genomic None None O
region None None O
is None None O
purified None None O
with None None O
antibody None None O
against None None O
the None None O
tag None None O
( None None O
s None None O
) None None O
. None None O

The None None O
iChIP None None O
system None None O
using None None O
r3xFNLDD-D None None O
can None None O
isolate None None O
specific None None O
genomic None None O
regions None None O
retaining None None O
molecular None None O
interactions None None O
without None None O
expression None None O
of None None O
the None None O
exogenous None None O
DNA-binding None None I-PROTEIN
protein None None I-PROTEIN
in None None O
the None None O
cell None None O
to None None O
be None None O
analyzed None None O
. None None O

Special None None O
attention None None I-FUNC
was None None O
given None None O
to None None O
additional None None O
medical None None O
examinations None None O
, None None O
reaction None None O
tests None None O
and None None O
alcohol None None O
consumption None None O
under None None O
real-life None None O
conditions None None O
. None None O

The None None O
screening None None O
accuracy None None O
of None None O
the None None O
parent None None O
and None None O
teacher-reported None None O
Social None None O
Responsiveness None None O
Scale None None O
( None None O
SRS None None O
) None None O
was None None O
compared None None O
with None None O
an None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
classification None None O
according None None O
to None None O
( None None O
1 None None O
) None None O
the None None O
Developmental None None O
, None None O
Dimensional None None O
, None None O
and None None O
Diagnostic None None O
Interview None None O
( None None O
3 None None O
Di None None O
) None None O
, None None O
( None None O
2 None None O
) None None O
the None None O
Autism None None O
Diagnostic None None O
Observation None None O
Schedule None None O
( None None O
ADOS None None O
) None None O
, None None O
( None None O
3 None None O
) None None O
both None None O
the None None O
3 None None O
Di None None O
and None None O
ADOS None None O
, None None O
in None None O
186 None None O
children None None O
referred None None O
to None None O
six None None O
mental None None O
health None None O
centers None None O
. None None O

The None None O
Healthcare None None O
Innovation None None O
Exchange None None O
( None None O
HELIX None None O
) None None O
Centre None None O
, None None O
at None None O
www.helixcentre.com None None O
, None None O
has None None O
released None None O
apps None None I-TRANS
on None None O
the None None O
iTunes None None O
( None None O
tinyurl.com/nzt2xd5 None None O
) None None O
and None None O
Google None None O
Play None None O
( None None O
tinyurl.com/n2safby None None O
) None None O
stores None None O
to None None O
provide None None O
end None None O
of None None O
life None None O
care None None O
guidance None None O
to None None O
nurses None None O
, None None O
doctors None None O
and None None O
carers None None O
working None None O
on None None O
the None None O
front None None O
line None None O
. None None O

The None None O
app None None I-TRANS
is None None O
based None None O
around None None O
the None None O
five None None O
LACDP None None O
priorities None None O
for None None O
care None None O
and None None O
includes None None O
a None None O
short None None O
training None None O
quiz None None O
. None None O

Users None None O
can None None O
view None None O
their None None O
registration None None O
status None None O
, None None O
update None None O
contact None None O
details None None O
, None None O
view None None O
and None None O
print None None O
a None None O
statement None None O
of None None O
entry None None O
, None None O
submit None None O
notification None None O
of None None O
practice None None O
, None None O
pay None None O
the None None O
annual None None O
retention None None I-FUNC
or None None O
renewal None None O
fees None None O
, None None O
set None None O
up None None O
a None None O
direct None None O
debit None None O
for None None O
annual None None O
fee None None O
payments None None O
, None None O
provide None None O
equality None None O
and None None O
diversity None None O
information None None O
, None None O
and None None O
give None None O
the None None O
geographical None None O
location None None O
of None None O
employment None None O
. None None O

Specifically None None O
, None None O
probable None None O
alcohol None None I-DISEASE
dependence None None I-DISEASE
and None None O
traditional None None O
circumcision None None O
were None None O
independent None None O
risk None None O
factors None None O
for None None O
engaging None None O
in None None O
unprotected None None O
sex None None O
among None None O
tavern-going None None O
men None None O
. None None O

To None None O
observe None None O
the None None O
clinical None None O
curative None None O
effect None None O
of None None O
Chinese None None O
medicine None None O
Bushen None None O
Huoxue None None O
Granule None None O
( None None O
补肾活血颗粒 None None O
, None None O
BHG None None O
) None None O
on None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
patients None None O
with None None O
depressive None None O
state None None O
. None None O

The None None O
contents None None O
of None None O
norepinephrine None None I-TRANS
( None None O
NE None None I-TRANS
) None None O
and None None O
5-serotonin None None O
( None None O
5-HT None None I-TRANS
) None None O
in None None O
the None None O
PD None None O
patients None None O
were None None O
obviously None None O
lower None None O
than None None O
normal None None O
value None None O
. None None O

The None None O
contents None None O
of None None O
NE None None I-TRANS
and None None O
5-HT None None I-TRANS
were None None O
all None None O
increased None None O
in None None O
the None None O
two None None O
groups None None O
after None None O
treatment None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
with None None O
significant None None O
differences None None O
between None None O
the None None O
two None None O
groups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

After None None O
treatment None None O
, None None O
the None None O
score None None O
of None None O
I-PSS None None O
was None None O
decreased None None O
from None None O
16.9±5.6 None None O
to None None O
12.5±4.6 None None O
in None None O
the None None O
treatment None None O
group None None O
, None None O
significantly None None O
lower None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
; None None O
the None None O
levels None None O
of None None O
Qmax None None O
and None None O
Qave None None O
were None None O
from None None O
10.9±3.5 None None O
to None None O
15.6±4.5 None None O
and None None O
5.4±2.1 None None O
to None None O
7.3±2.5 None None O
( None None O
mL/s None None O
) None None O
in None None O
the None None O
treatment None None O
group None None O
, None None O
significantly None None O
higher None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
; None None O
the None None O
levels None None O
of None None O
RUV None None O
and None None O
TPV None None O
were None None O
from None None O
70.8±28.2 None None O
to None None O
35.2±21.8 None None O
and None None O
37.2±16.9 None None O
to None None O
30.1±10.8 None None O
( None None O
mL None None O
) None None O
in None None O
the None None O
treatment None None O
group None None O
, None None O
significantly None None O
lower None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
( None None O
all None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
nucleosome-shifting None None O
action None None O
of None None O
remodeling None None O
enzymes None None I-PROTEIN
has None None O
been None None O
proposed None None O
as None None O
a None None O
mechanism None None O
to None None O
resolve None None O
such None None O
jams None None O
. None None O

At None None O
least None None O
8 None None O
of None None O
the None None O
16 None None O
genes None None O
found None None O
mutated None None O
in None None O
FA None None O
encode None None O
proteins None None O
that None None O
assemble None None O
into None None O
the None None O
FA None None O
core None None O
complex None None O
, None None O
a None None O
multisubunit None None O
monoubiquitin None None O
E3 None None O
ligase None None I-PROTEIN
. None None O

The None None O
ions None None O
investigated None None O
include None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
, None None O
K None None O
( None None O
+ None None O
) None None O
and None None O
Mg None None O
( None None O
2 None None O
+ None None O
) None None O
, None None O
with None None O
various None None O
concentrations None None O
of None None O
their None None O
chloride None None O
salts None None O
. None None O

RNA None None O
helicases None None I-PROTEIN
are None None O
essential None None O
for None None O
virtually None None O
all None None O
cellular None None O
processes None None O
, None None O
however None None O
, None None O
their None None O
regulation None None O
is None None O
poorly None None O
understood None None O
. None None O

Amongst None None O
these None None O
, None None O
Brr2p None None O
is None None O
unusual None None O
in None None O
having None None O
two None None O
helicase None None I-PROTEIN
modules None None O
, None None O
of None None O
which None None O
only None None O
the None None O
amino-terminal None None O
helicase None None I-PROTEIN
domain None None O
appears None None O
to None None O
be None None O
catalytically None None O
active None None O
. None None O

We None None O
therefore None None O
propose None None O
that None None O
the None None O
carboxy-terminal None None O
helicase None None I-PROTEIN
module None None O
of None None O
Brr2p None None O
acquired None None O
a None None O
regulatory None None O
function None None O
that None None O
allows None None O
Brr2p None None O
to None None O
modulate None None O
the None None O
ATPase None None I-PROTEIN
activity None None O
of None None O
Prp16p None None O
in None None O
the None None O
spliceosome None None O
by None None O
controlling None None O
access None None O
to None None O
its None None O
RNA None None O
substrate/cofactor None None O
. None None O

Results None None O
showed None None O
that None None O
LMW-HA None None O
increased None None O
the None None O
permeability None None O
of None None O
cancer None None O
LEC None None O
monolayers None None O
and None None O
induced None None O
disruption None None O
of None None O
Zonula None None O
Occludens-1 None None O
( None None O
ZO-1 None None O
) None None O
-mediated None None O
intercellular None None O
tight None None O
junction None None O
and None None O
actin None None I-PROTEIN
stress None None O
fiber None None O
formation None None O
. None None O

As None None O
reported None None O
, None None O
sphingosine None None O
1-phosphate None None O
( None None O
S1P None None O
) None None O
receptors None None I-PROTEIN
are None None O
involved None None O
in None None O
vascular None None O
integrity None None O
. None None O

PRRX1 None None O
overexpression None None O
resulted None None O
in None None O
the None None O
regulation None None O
of None None O
the None None O
EMT None None O
molecular None None O
markers None None O
N-cadherin None None O
, None None O
E-cadherin None None O
and None None O
vimentin None None O
as None None O
well None None O
as None None O
the None None O
levels None None O
of None None O
intranuclear None None O
β-catenin None None O
and None None O
the None None O
Wnt/β-catenin None None O
target None None O
c-Myc None None I-PROTEIN
. None None O

The None None O
role None None O
of None None O
bone None None O
marrow-derived None None O
mesenchymal None None O
stem None None O
cells None None O
( None None O
BMSCs None None O
) None None O
in None None O
the None None O
pathogenesis None None O
and None None O
therapy None None O
of None None O
osteoporosis None None O
has None None O
drawn None None O
increasing None None O
attention None None I-FUNC
in None None O
recent None None O
years None None O
. None None O

Magnetic None None O
resonance None None O
imaging None None O
helped None None O
identify None None O
a None None O
mass None None O
at None None O
the None None O
level None None O
of None None O
the None None O
main None None O
olfactory None None I-REGION
bulb None None I-REGION
that None None O
compressed None None O
and None None O
displaced None None O
adjacent None None O
tissues None None O
in None None O
the None None O
cribriform None None O
plate None None O
into None None O
the None None O
nasal None None O
cavity None None O
and None None O
nasopharynx None None O
. None None O

Microscopic None None O
lesions None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
showed None None O
rarefaction None None O
and None None O
cavitation None None O
in None None O
the None None O
white None None I-REGION
matter None None I-REGION
, None None O
as None None O
well None None O
as None None O
degeneration None None O
, None None O
necrosis None None O
, None None O
and None None O
loss None None O
of None None O
neurons None None O
in None None O
the None None O
gray None None O
matter None None O
. None None O

However None None O
, None None O
the None None O
loss None None O
of None None O
spinal None None O
ventral None None I-NEURON
motor None None I-NEURON
neurons None None I-NEURON
and None None O
their None None O
tracts None None O
, None None O
resulting None None O
in None None O
micromyelia None None O
, None None O
distinguishes None None O
SBV None None O
infection None None O
from None None O
other None None O
viral None None O
central None None O
nervous None None O
system None None O
lesions None None O
in None None O
newborn None None O
ruminants None None O
. None None O

Baseline None None O
hemoglobin None None O
, None None O
ferritin None None I-PROTEIN
, None None O
hepcidin None None O
, None None O
soluble None None O
transferrin None None O
receptor None None I-PROTEIN
( None None O
sTfR None None O
) None None O
, None None O
and None None O
transferrin None None O
were None None O
measured None None O
in None None O
45 None None O
patients None None O
with None None O
confirmed None None O
pulmonary None None O
tuberculosis None None O
( None None O
cases None None O
) None None O
, None None O
47 None None O
tuberculin None None O
skin None None O
test None None O
( None None O
TST None None O
) None None O
-positive None None O
controls None None O
, None None O
and None None O
39 None None O
TST-negative None None O
controls None None O
in None None O
The None None O
Gambia None None O
. None None O

TPH1 None None O
gene None None O
polymorphisms None None O
and None None O
S100A10 None None O
expression None None O
, None None O
which None None O
correlate None None O
with None None O
5-HT None None I-TRANS
signaling None None O
were None None O
associated None None O
with None None O
ramosetron None None O
effectiveness None None O
in None None O
IBS-D None None O
, None None O
and None None O
may None None O
possibly None None O
lead None None O
to None None O
prospective None None O
identification None None O
of None None O
the None None O
resistance None None O
to None None O
treatment None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
phylogenetic None None O
inference None None I-FUNC
, None None O
DNA-DNA None None O
relatedness None None O
, None None O
chemotaxonomic None None O
analysis None None O
and None None O
physiological None None O
data None None O
, None None O
the None None O
isolate None None O
represents None None O
a None None O
novel None None O
species None None O
of None None O
the None None O
genus None None O
Vitellibacter None None O
, None None O
for None None O
which None None O
the None None O
name None None O
Vitellibacter None None O
nionensis None None O
sp None None O
. None None O

Based None None O
on None None O
previous None None O
studies None None O
and None None O
knowledge None None O
on None None O
occupational None None O
injuries None None O
the None None O
transient None None O
risk None None O
factors None None O
we None None O
chose None None O
to None None O
examine None None O
were None None O
: None None O
time None None O
pressure None None O
, None None O
performing None None O
a None None O
task None None O
with None None O
a None None O
different None None O
method/using None None O
unaccustomed None None O
technique None None O
, None None O
change None None O
in None None O
working None None O
surroundings None None O
, None None O
using None None O
a None None O
phone None None O
, None None O
disagreement None None O
, None None O
feeling None None I-FUNC
ill None None O
, None None O
being None None O
distracted None None O
and None None O
using None None O
malfunctioning None None O
machinery/tools None None O
or None None O
work None None O
material None None O
. None None O

Platelet None None O
aggregation None None O
was None None O
monitored None None O
using None None O
turbidometric None None O
principle None None O
, None None O
AA None None O
metabolism None None O
through None None O
radioimmunoassay None None O
and None None O
antioxidant None None O
enzymes None None I-PROTEIN
by None None O
commercial None None O
kits None None O
using None None O
spectrophotometer None None O
. None None O

It None None O
also None None O
elevated None None O
the None None O
activities None None O
of None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPx None None O
) None None O
. None None O

The None None O
assay None None O
employs None None O
the None None O
etching None None O
of None None O
silver None None O
in None None O
the None None O
Ag/Au None None O
core-shell None None O
nanoprisms None None O
, None None O
accompanied None None O
by None None O
surface None None O
plasmon None None O
resonance None None O
( None None O
SPR None None O
) None None O
signal None None O
depression None None I-DISEASE
and None None O
shift None None O
. None None O

The None None O
thin None None O
gold None None O
layer None None O
not None None O
only None None O
guarantees None None O
the None None O
high None None O
stability None None O
of None None O
the None None O
plasmonic None None O
nanoprobes None None O
but None None O
also None None O
ensures None None O
the None None O
high None None O
selectivity None None O
toward None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
. None None O

Moreover None None O
, None None O
the None None O
SPR None None O
peak None None O
is None None O
located None None O
in None None O
the None None O
NIR None None O
region None None O
that None None O
makes None None O
these None None O
plasmonic None None O
nanoprobes None None O
more None None O
appealing None None O
for None None O
the None None O
detection None None O
of None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
in None None O
real-world None None O
samples None None O
and None None O
in None None O
in None None O
vivo None None O
applications None None O
. None None O

During None None O
the None None O
warfarin None None O
exposure None None O
period None None O
, None None O
the None None O
incidence None None O
of None None O
events None None O
per None None O
100 None None O
person-years None None O
was None None O
highest None None O
when None None O
patients None None O
had None None O
international None None O
normalized None None O
ratio None None O
& None None O
lt None None O
; None None O
2:13.66 None None O
for None None O
acute None None O
coronary None None O
syndrome None None O
; None None O
10.30 None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
; None None O
2.93 None None O
for None None O
transient None None O
ischemic None None O
attack None None O
; None None O
1.81 None None O
for None None O
systemic None None O
embolism None None I-DISEASE
; None None O
and None None O
4.55 None None O
for None None O
major None None O
bleeding None None O
. None None O

A None None O
30-year-old None None O
woman None None O
complained None None O
of None None O
slurring None None O
of None None O
speech None None I-FUNC
, None None O
right None None O
eye None None O
proptosis None None O
, None None O
recurrent None None O
vomiting None None O
, None None O
and None None O
loss None None O
of None None O
bladder None None O
and None None O
bowel None None O
control None None O
, None None O
followed None None O
by None None O
drowsiness None None O
lasting None None O
30-40 None None O
min None None O
, None None O
for None None O
the None None O
past None None O
6 None None O
months None None O
. None None O

Independently None None O
of None None O
the None None O
technique None None O
, None None O
a None None O
higher None None O
complication None None O
rate None None O
was None None O
observed None None O
with None None O
bifurcational None None O
aneurysms None None O
, None None O
particularly None None O
in None None O
the None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
( None None O
p=0.016 None None O
) None None O
. None None O

Recent None None O
work None None O
has None None O
confirmed None None O
that None None O
mutant None None O
peptides None None I-TRANS
can None None O
serve None None O
as None None O
T-cell None None O
epitopes None None O
. None None O

We None None O
sought None None O
to None None O
simplify None None O
the None None O
discovery None None O
of None None O
immunogenic None None O
mutant None None O
peptides None None I-TRANS
by None None O
characterizing None None O
their None None O
general None None O
properties None None O
. None None O

Mutations None None O
that None None O
were None None O
solvent-exposed None None O
and None None O
therefore None None O
accessible None None O
to None None O
T-cell None None O
antigen None None O
receptors None None I-PROTEIN
were None None O
predicted None None O
to None None O
be None None O
immunogenic None None O
. None None O

In None None O
mechanism None None O
studies None None O
, None None O
BRE None None O
selectively None None O
stimulated None None O
Wnt-driven None None O
luciferase None None I-PROTEIN
activities None None O
. None None O

To None None O
evaluate None None O
the None None O
role None None O
of None None O
plasma None None O
total None None O
homocysteine None None O
( None None O
tHcy None None O
) None None O
and None None O
homozygosity None None O
for None None O
the None None O
thermolabile None None O
variant None None O
of None None O
the None None O
methylenetetrahydrofolate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
MTHFR None None O
) None None O
C677T None None O
genotype None None O
in None None O
the None None O
risk None None O
of None None O
retinal None None O
vein None None O
occlusion None None O
( None None O
RVO None None O
) None None O
. None None O

The None None O
decreased None None O
prefrontal None None I-REGION
cortex None None I-REGION
connectivity None None O
correlated None None O
with None None O
cognitive None None O
parameters None None O
but None None O
not None None O
with None None O
clinical None None O
variables None None O
. None None O

Carnitine None None O
is None None O
a None None O
quaternary None None O
ammonium None None O
compound None None O
biosynthesized None None O
from None None O
phosphatidylcholine None None O
and None None O
the None None O
amino None None I-TRANS
acids None None I-TRANS
lysine None None I-TRANS
and None None O
methionine None None I-TRANS
( None None O
Fig None None O
. None None O

Thiobarbutiric None None O
Acid-Reactive None None O
Substances None None O
( None None O
TBARS None None O
) None None O
, None None O
glutathioneS-transferase None None O
( None None O
GST None None O
) None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
Catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
, None None O
and None None O
Paraoxonase None None O
1 None None O
( None None O
PON-1 None None O
) None None O
were None None O
investigated None None O
in None None O
blood None None O
samples None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
p53 None None I-PROTEIN
expression None None O
was None None O
also None None O
significantly None None O
increased None None O
between None None O
I/R None None O
, None None O
I/R-D None None O
and None None O
C None None O
groups None None O
At None None O
the None None O
same None None O
time None None O
, None None O
there None None O
were None None O
no None None O
significant None None O
differences None None O
between None None O
I/R-D None None O
and None None O
C None None O
groups None None O
( None None O
p None None O
= None None O
0.354 None None O
) None None O
. None None O

Beside None None O
the None None O
major None None O
action None None O
based None None O
on None None O
antagonism None None O
on None None O
adenosine None None I-TRANS
receptor None None I-PROTEIN
, None None O
it None None O
is None None O
involved None None O
in None None O
other None None O
neurotransmission None None O
pathways None None O
as None None O
well None None O
. None None O

The None None O
genotypes None None O
of None None O
129 None None O
acute None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
patients None None O
and None None O
100 None None O
healthy None None O
control None None O
subjects None None O
were None None O
determined None None O
by None None O
PCR None None O
and None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
( None None O
PAGE None None O
) None None O
. None None O

It None None O
also None None O
provides None None O
information None None O
about None None O
optic None None I-REGION
nerve None None I-REGION
head None None O
topography None None O
, None None O
peripapillary None None O
retinal None None O
nerve None None O
fiber None None O
layer None None O
thickness None None O
, None None O
and None None O
macular None None O
volume None None O
which None None O
correlates None None O
with None None O
axonal None None O
loss None None O
. None None O

Prosody None None O
is None None O
an None None O
important None None O
tool None None O
of None None O
human None None O
communication None None O
, None None O
carrying None None O
both None None O
affective None None O
and None None O
pragmatic None None O
messages None None O
in None None O
speech None None I-FUNC
. None None O

Individuals None None O
with None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorders None None I-DISEASE
( None None O
ASD None None O
) None None O
show None None O
deficiencies None None O
in None None O
affective None None O
prosody None None O
recognition None None O
. None None O

These None None O
included None None O
affective None None O
and None None O
pragmatic None None O
prosody None None O
recognition None None O
tasks None None O
, None None O
two None None O
psychoacoustic None None O
tasks None None O
( None None O
pitch None None O
direction None None O
recognition None None O
and None None O
pitch None None O
discrimination None None O
) None None O
, None None O
and None None O
a None None O
facial None None O
emotion None None I-FUNC
recognition None None O
task None None O
, None None O
representing None None O
nonvocal None None O
emotion None None I-FUNC
recognition None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
auditory None None O
perceptual None None O
abilities None None O
, None None O
alongside None None O
general None None O
emotion None None I-FUNC
recognition None None O
abilities None None O
, None None O
play None None O
a None None O
significant None None O
role None None O
in None None O
affective None None O
prosody None None O
recognition None None O
in None None O
ASD None None O
. None None O

The None None O
most None None O
frequently None None O
described None None O
ophthalmologic None None O
complications None None O
include None None O
diplopia None None O
( None None O
double None None O
vision None None I-FUNC
) None None O
, None None O
ptosis None None O
( None None O
drooping None None O
of None None O
upper None None O
eyelid None None O
) None None O
, None None O
and None None O
mydriasis None None O
( None None O
dilatation None None O
of None None O
pupil None None O
) None None O
. None None O

Reduced None None O
odds None None O
of None None O
having None None O
a None None O
recent None None O
HIV None None O
test None None O
was None None O
also None None O
significantly None None O
associated None None O
with None None O
being None None O
a None None O
migrant/new None None O
immigrant None None O
to None None O
Canada None None O
( None None O
AOR None None O
: None None O
0.33 None None O
, None None O
95 None None O
% None None O
CIs None None O
: None None O
0.19-0.56 None None O
) None None O
and None None O
having None None O
a None None O
language None None I-FUNC
barrier None None O
to None None O
health None None O
care None None O
access None None O
( None None O
AOR None None O
: None None O
0.26 None None O
, None None O
95 None None O
% None None O
CIs None None O
: None None O
0.09-0.73 None None O
) None None O
. None None O

To None None O
maximize None None O
the None None O
effectiveness None None O
of None None O
including None None O
HIV None None O
testing None None O
as None None O
part None None O
of None None O
comprehensive None None O
HIV None None O
prevention None None O
and None None O
care None None O
to None None O
SWs None None O
, None None O
increased None None O
mobile None None O
outreach None None O
and None None O
safer-environment None None O
interventions None None O
that None None O
facilitate None None O
access None None O
to None None O
voluntary None None O
, None None O
confidential None None O
and None None O
non-coercive None None O
HIV None None O
testing None None O
remain None None O
a None None O
critical None None O
priority None None O
, None None O
in None None O
addition None None O
to None None O
culturally None None O
safe None None O
services None None O
with None None O
language None None I-FUNC
support None None O
. None None O

To None None O
study None None O
the None None O
development None None O
of None None O
the None None O
bilateral None None O
benefit None None O
in None None O
children None None O
using None None O
bilateral None None O
cochlear None None O
implants None None O
by None None O
measurements None None O
of None None O
speech None None I-FUNC
recognition None None I-FUNC
and None None O
sound None None I-FUNC
localization None None I-FUNC
. None None O

For None None O
children None None O
with None None O
cochlear None None O
implants None None O
, None None O
bilateral None None O
and None None O
unilateral None None O
speech None None I-FUNC
recognition None None I-FUNC
in None None O
quiet None None O
was None None O
comparable None None O
whereas None None O
a None None O
bilateral None None O
benefit None None O
for None None O
speech None None I-FUNC
recognition None None I-FUNC
in None None O
noise None None O
and None None O
sound None None I-FUNC
localization None None I-FUNC
was None None O
found None None O
at None None O
all None None O
three None None O
test None None O
occasions None None O
. None None O

Early None None O
bilateral None None O
implantation None None O
facilitated None None O
sound None None I-FUNC
localization None None I-FUNC
. None None O

Taken None None O
together None None O
, None None O
the None None O
combination None None O
of None None O
orthogonal None None O
information None None O
sources None None O
led None None O
to None None O
investigation None None O
of None None O
a None None O
surprising None None O
predicted None None O
relationship None None O
between None None O
a None None O
transcription None None O
factor None None O
and None None O
an None None O
enzyme None None O
, None None O
specifically None None O
, None None O
PPARα None None O
and None None O
the None None O
cyclooxygenase None None O
enzymes None None I-PROTEIN
. None None O

During None None O
the None None O
preparation None None O
of None None O
this None None O
article None None O
other None None O
mutations None None O
were None None O
reported None None O
to None None O
cause None None O
frontotemporal None None I-DISEASE
dementia-amyotrophic None None O
lateral None None O
sclerosis None None O
syndrome None None O
, None None O
indicating None None O
that None None O
the None None O
CHCHD10 None None O
gene None None O
is None None O
largely None None O
important None None O
for None None O
the None None O
motor None None O
and None None O
cognitive None None O
neuronal None None O
systems None None O
. None None O

Use None None O
of None None O
the None None O
internet None None O
to None None O
meet None None O
sexual None None O
partners None None O
was None None O
associated None None O
with None None O
lower None None O
self-esteem None None O
but None None O
not None None O
with None None O
depression None None I-DISEASE
, None None O
anxiety None None O
, None None O
somatic None None O
distress None None O
or None None O
discrimination None None O
experiences None None O
. None None O

Long None None O
intergenic None None O
non-coding None None O
RNAs None None O
( None None O
lincRNAs None None O
) None None O
as None None O
a None None O
key None None O
group None None O
of None None O
non-coding None None O
RNAs None None O
have None None O
gained None None O
substantial None None O
attention None None I-FUNC
. None None O

In None None O
April None None O
2013 None None O
, None None O
new None None O
and None None O
progressive None None O
contrast None None O
enhancement None None O
, None None O
edema None None O
, None None O
( None None O
23 None None O
) None None O
Na None None I-TRANS
content None None O
, None None O
and None None O
increased None None O
uptake None None O
in None None O
the None None O
( None None O
18 None None O
) None None O
F-FET-PET None None O
were None None O
visible None None O
, None None O
indicating None None O
tumor None None O
recurrence None None O
. None None O

The None None O
clearly None None O
delineable None None O
zone None None O
of None None O
edema None None O
in None None O
both None None O
examinations None None O
exhibits None None O
a None None O
lower None None O
( None None O
23 None None O
) None None O
Na None None I-TRANS
content None None O
compared None None O
to None None O
areas None None O
with None None O
suspected None None O
proliferating None None O
tumor None None O
tissue None None O
. None None O

This None None O
article None None O
focuses None None O
on None None O
the None None O
bereavement None None O
experience None None O
of None None O
adult None None O
children None None O
's None None O
loss None None O
of None None O
a None None O
first None None O
parent None None O
during None None O
adulthood None None O
and None None O
examines None None O
the None None O
downward None None O
influence None None O
of None None O
emotional None None O
closeness None None O
with None None O
a None None O
surviving None None O
parent None None O
on None None O
adult None None O
children None None O
's None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
following None None O
loss None None O
. None None O

Multilevel None None O
lagged None None O
dependent None None O
variable None None O
models None None O
indicate None None O
that None None O
an None None O
emotionally None None O
close None None O
relationship None None O
with None None O
a None None O
surviving None None O
parent None None O
is None None O
related None None O
with None None O
fewer None None O
post-bereavement None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
when None None O
a None None O
mother None None O
survives None None O
a None None O
father None None O
, None None O
but None None O
not None None O
vice None None O
versa None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
whether None None O
alcohol None None O
and None None O
diet None None O
, None None O
assessed None None O
as None None O
both None None O
macronutrients None None O
and None None O
dietary None None O
patterns None None O
, None None O
increased None None O
the None None O
risk None None O
of None None O
development None None O
of None None O
rheumatoid None None O
arthritis None None O
( None None O
RA None None O
) None None O
through None None O
a None None O
nested None None O
case-control None None O
design None None O
in None None O
the None None O
Västerbotten None None O
Intervention None None O
Program None None O
( None None O
VIP None None I-TRANS
) None None O
cohort None None O
. None None O

Creatine None None O
is None None O
a None None O
nitrogenous None None O
organic None None O
acid None None O
known None None O
to None None O
function None None O
in None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
( None None O
ATP None None O
) None None O
metabolism None None O
. None None O

Consistently None None O
, None None O
a None None O
dramatic None None O
reduction None None O
in None None O
mRNA None None O
expression None None O
of None None O
adipogenic None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
peroxisome None None O
proliferator-activated None None O
receptor None None I-PROTEIN
γ None None O
( None None O
PPARγ None None O
) None None O
and None None O
CCAAT/enhancer-binding None None O
protein None None O
α None None O
( None None O
C/EBPα None None O
) None None O
, None None O
glucose None None I-PROTEIN
transporters None None I-PROTEIN
, None None O
1 None None O
and None None O
4 None None O
( None None O
Glut1 None None O
, None None O
Glut4 None None O
) None None O
, None None O
and None None O
adipocyte None None O
markers None None O
, None None O
aP2 None None O
and None None O
adipsin None None O
, None None O
was None None O
observed None None O
in None None O
the None None O
presence None None O
of None None O
creatine None None O
. None None O

A None None O
set None None O
of None None O
genes None None O
with None None O
higher None None O
basal None None O
expression None None O
in None None O
both None None O
H471 None None O
and None None O
P28 None None O
compared None None O
with None None O
HHZ None None O
were None None O
functionally None None O
enriched None None O
in None None O
oxidoreductase None None I-PROTEIN
and None None O
lyase None None I-PROTEIN
activities None None O
, None None O
implying None None O
their None None O
positive None None O
role None None O
in None None O
intrinsic None None O
DT None None O
. None None O

We None None O
investigated None None O
electrophysiological None None O
and None None O
behavioral None None O
changes None None O
in None None O
epileptic None None O
rats None None O
after None None O
lentivirally None None O
mediated None None O
NL1 None None O
knockdown None None O
in None None O
the None None O
hippocampus None None I-REGION
to None None O
determine None None O
whether None None O
NL1 None None O
suppression None None O
prevented None None O
seizures None None O
and None None O
, None None O
if None None O
so None None O
, None None O
to None None O
explore None None O
the None None O
probable None None O
underlying None None O
mechanisms None None O
. None None O

Whole-cell None None O
patch-clamp None None O
recordings None None O
of None None O
CA1 None None I-REGION
pyramidal None None O
neurons None None O
in None None O
hippocampal None None O
slices None None O
from None None O
NL1 None None O
knockdown None None O
epileptic None None O
rats None None O
revealed None None O
a None None O
decrease None None O
in None None O
spontaneous None None O
action None None O
potential None None O
frequency None None O
and None None O
a None None O
decrease None None O
in None None O
miniature None None O
excitatory None None O
postsynaptic None None O
current None None O
( None None O
mEPSC None None O
) None None O
frequency None None O
but None None O
not None None O
amplitude None None O
. None None O

Notably None None O
, None None O
NL1 None None O
knockdown None None O
reduced None None O
total None None O
NMDAR1 None None O
expression None None O
and None None O
the None None O
surface/total None None O
ratio None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
epileptic None None O
rats None None O
. None None O

Co-treatment None None O
of None None O
antioxidant None None O
melatonin None None I-TRANS
was None None O
also None None O
given None None O
to None None O
assess None None O
the None None O
role None None O
of None None O
oxidative None None O
stress None None O
in None None O
rotenone-induced None None O
apoptosis None None O
. None None O

Co-treatment None None O
of None None O
antioxidant None None O
melatonin None None I-TRANS
( None None O
1 None None O
mM None None O
) None None O
did None None O
not None None O
offer None None O
attenuation None None O
against None None O
rotenone-induced None None O
increased None None O
expression None None O
of None None O
caspase-9 None None O
, None None O
caspase-12 None None O
and None None O
caspase-3 None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
examine None None O
whether None None O
the None None O
neuroprotective None None O
effects None None O
of None None O
Mdivi-1 None None O
are None None O
attributable None None O
to None None O
extracellular None None O
ATP None None O
and None None O
adenosine None None I-TRANS
. None None O

The None None O
extracellular None None O
adenosine None None I-TRANS
was None None O
measured None None O
by None None O
in None None O
vivo None None O
microdialysis None None O
and None None O
high-pressure None None O
liquid None None O
chromatography None None O
( None None O
HPLC None None O
) None None O
in None None O
MCAO None None O
mouse None None O
model None None O
. None None O

Interestingly None None O
, None None O
pretreatment None None O
with None None O
Mdivi-1 None None O
resulted None None O
in None None O
marked None None O
increase None None O
of None None O
extracellular None None O
adenosine None None I-TRANS
and None None O
concomitant None None O
decrease None None O
in None None O
ATP None None O
. None None O

Figure None None O
Potential None None O
mechanisms None None O
by None None O
which None None O
Mdivi-1 None None O
mediates None None O
the None None O
neuroprotection None None O
on None None O
cerebral None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Paraquat None None O
( None None O
PQ None None O
) None None O
exposure None None O
causes None None O
degeneration None None O
of None None O
the None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
in None None O
an None None O
exposed None None O
organism None None O
while None None O
altered None None O
metabolism None None O
has None None O
a None None O
role None None O
in None None O
various None None O
neurodegenerative None None O
disorders None None O
. None None O

In None None O
addition None None O
, None None O
PQ None None O
attenuated None None O
brain None None O
dopamine None None I-TRANS
content None None O
in None None O
the None None O
exposed None None O
organism None None O
. None None O

While None None O
AtPHT1 None None O
; None None O
1 None None O
to None None O
AtPHT1 None None O
; None None O
4 None None O
are None None O
involved None None O
in None None O
Pi None None O
acquisition None None O
from None None O
the None None O
rhizosphere None None O
, None None O
the None None O
role None None O
of None None O
the None None O
remaining None None O
transporters None None I-PROTEIN
is None None O
less None None O
clear None None O
. None None O

Logical None None O
regression None None O
analysis None None O
showed None None O
that None None O
FSS≥5 None None O
at None None O
contact None None O
2 None None O
was None None O
associated None None O
with None None O
depression None None I-DISEASE
, None None O
arthralgia None None O
and None None O
long None None O
disease None None O
duration None None O
( None None O
all None None O
at None None O
contact None None O
1 None None O
) None None O
. None None O

Risk None None O
factors None None O
for None None O
transition None None O
to None None O
permanent None None O
disability None None O
were None None O
depression None None I-DISEASE
, None None O
arthralgia None None O
and None None O
disease None None O
duration None None O
. None None O

Given None None O
the None None O
discordant None None O
results None None O
of None None O
studies None None O
that None None O
have None None O
reported None None O
cases None None O
of None None O
RLS None None O
associated None None O
with None None O
brainstem None None I-REGION
stroke None None I-DISEASE
and None None O
the None None O
absence None None O
of None None O
RLS None None O
in None None O
large None None O
series None None O
describing None None O
the None None O
clinical None None O
spectrum None None O
of None None O
brainstem None None I-REGION
infarctions None None O
, None None O
we None None O
decided None None O
to None None O
assess None None O
RLS None None O
in None None O
all None None O
patients None None O
admitted None None O
for None None O
brainstem None None I-REGION
stroke None None I-DISEASE
. None None O

The None None O
different None None O
parameters None None O
analyzed None None O
were None None O
the None None O
topography None None O
of None None O
the None None O
ischemic None None O
lesions None None O
( None None O
magnetic None None O
resonance None None O
imaging None None O
) None None O
, None None O
the None None O
different None None O
symptoms None None O
( None None O
sensory None None O
, None None O
motor None None O
, None None O
cerebellar None None O
, None None O
cranial None None I-REGION
nerves None None I-REGION
and None None O
dysarthria None None O
) None None O
and None None O
the None None O
NIH None None O
stroke None None I-DISEASE
scale None None O
. None None O

Patients None None O
with None None O
stroke-induced None None O
sensory None None O
symptoms None None O
have None None O
a None None O
higher None None O
risk None None O
to None None O
develop None None O
brainstem None None I-REGION
stroke-related None None O
RLS None None O
as None None O
compared None None O
to None None O
patients None None O
without None None O
sensory None None O
symptoms None None O
. None None O

Clinicians None None O
should None None O
be None None O
aware None None O
of None None O
this None None O
association None None O
, None None O
especially None None O
as None None O
efficient None None O
treatments None None O
are None None O
available None None O
and None None O
allow None None O
improving None None O
the None None O
management None None O
of None None O
patients None None O
affected None None O
with None None O
stroke None None I-DISEASE
. None None O

Although None None O
there None None O
is None None O
convincing None None O
evidence None None O
that None None O
decompression None None O
craniectomy None None O
can None None O
significantly None None O
reduce None None O
mortality None None O
rate None None O
and None None O
improve None None O
neurological None None O
outcome None None O
in None None O
young None None O
patients None None O
( None None O
& None None O
lt None None O
; None None O
60 None None O
years None None O
) None None O
, None None O
many None None O
surgeons None None O
are None None O
still None None O
hesitant None None O
to None None O
recommend None None O
hemicraniectomy None None O
for None None O
stroke None None I-DISEASE
patients None None O
. None None O

Involvement None None O
of None None O
the None None O
dominant None None O
hemisphere None None O
results None None O
in None None O
aphasia None None I-DISEASE
that None None O
might None None O
partly None None O
recover None None O
in None None O
younger None None O
patients None None O
, None None O
although None None O
, None None O
considering None None O
the None None O
neuropsychological None None O
deficits None None O
caused None None O
by None None O
infarctions None None O
of None None O
the None None O
nondominant None None O
hemisphere None None O
, None None O
involvement None None O
of None None O
the None None O
dominant None None O
hemisphere None None O
does None None O
not None None O
pose None None O
as None None O
a None None O
contraindication None None O
for None None O
decompression None None O
craniectomy None None O
. None None O

Complications None None O
associated None None O
with None None O
decompression None None O
surgery None None O
( None None O
hemorrhages None None O
, None None O
infections None None O
, None None O
'sinking None None O
skin-flap None None O
syndrome None None O
' None None O
, None None O
cerebrospinal None None O
fluid None None O
leakages None None O
, None None O
hydrocephalus None None I-DISEASE
, None None O
seizures None None O
) None None O
, None None O
with None None O
the None None O
infarction None None O
itself None None O
, None None O
or None None O
with None None O
those None None O
that None None O
occur None None O
during None None O
the None None O
ICU None None O
course None None O
( None None O
cardiac None None O
and None None O
pulmonary None None O
complications None None O
) None None O
appear None None O
acceptable None None O
and None None O
are None None O
mostly None None O
treatable None None O
, None None O
especially None None O
considering None None O
the None None O
fatal None None O
course None None O
of None None O
conservative None None O
treatment None None O
. None None O

Hypophysiotropic None None O
gonadotropin-releasing None None O
hormone None None O
( None None O
GnRH None None O
) None None O
neurons None None O
in None None O
the None None O
hypothalamus None None I-REGION
orchestrate None None O
the None None O
activity None None O
of None None O
this None None O
axis None None O
and None None O
are None None O
regulated None None O
by None None O
hormonal None None O
feedback None None O
loops None None O
. None None O

Our None None O
goal None None O
was None None O
to None None O
determine None None O
whether None None O
the None None O
G None None O
protein-coupled None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
GPER None None O
) None None O
is None None O
co-expressed None None O
in None None O
adult None None O
primate None None O
GnRH None None O
neurons None None O
and None None O
whether None None O
this None None O
changes None None O
with None None O
aging None None O
and/or None None O
E2 None None O
treatment None None O
. None None O

To None None O
improve None None O
enfuvirtide None None O
's None None O
anti-HIV None None O
efficacy None None O
, None None O
drug-resistance None None O
profile None None O
, None None O
half-life None None O
and None None O
pharmaceutical None None O
properties None None O
, None None O
the None None O
best None None O
approaches None None O
include None None O
the None None O
addition None None O
of None None O
the None None O
pocket-binding None None O
domain None None O
( None None O
PBD None None O
) None None O
to None None O
the None None O
N-terminus None None O
of None None O
T20 None None O
and None None O
linking None None O
of None None O
the None None O
M-T None None O
hook None None O
to None None O
the None None O
N-terminus None None O
of None None O
PBD None None O
, None None O
as None None O
well None None O
as None None O
conjugation None None O
of None None O
cholesterol None None O
, None None O
serum None None I-PROTEIN
albumin-binding None None O
motif None None O
or None None O
gp120-binding None None O
fragment None None O
with None None O
a None None O
PBD-containing None None O
C-terminal None None O
heptad None None O
repeat-peptide None None O
. None None O

We None None O
used None None O
data None None O
from None None O
a None None O
community-representative None None O
study None None O
to None None O
determine None None O
whether None None O
there None None O
are None None O
age-related None None O
differences None None O
in None None O
simple None None O
cognitive None None O
and None None O
gait None None O
tests None None O
by None None O
the None None O
40s None None O
, None None O
and None None O
whether None None O
these None None O
differences None None O
were None None O
associated None None O
with None None O
covert None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
on None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
. None None O

Higher None None O
volume None None O
of None None O
supratentorial None None O
MRI None None O
white None None I-REGION
matter None None I-REGION
hyperintensity None None O
was None None O
associated None None O
with None None O
slower None None O
timed None None O
gait None None O
and None None O
worse None None O
performance None None O
on None None O
DSST None None O
, None None O
and None None O
lower None None O
volumes None None O
of None None O
the None None O
supratentorial None None O
cortex None None O
and None None O
white None None I-REGION
matter None None I-REGION
, None None O
and None None O
cerebellum None None I-REGION
. None None O

Ferroelectric None None O
organic None None O
field-effect None None O
transistors None None O
( None None O
Fe-OFETs None None O
) None None O
have None None O
been None None O
attractive None None O
for None None O
a None None O
variety None None O
of None None O
non-volatile None None O
memory None None I-FUNC
device None None O
applications None None O
. None None O

The None None O
major None None O
clinical None None O
manifestations None None O
are None None O
asymptomatic None None O
cerebral None None I-DISEASE
atherosclerosis None None I-DISEASE
, None None O
stroke None None I-DISEASE
, None None O
cerebral None None O
small None None O
vessel None None O
disease None None O
and None None O
acute None None O
cerebral None None O
vascular None None O
disease None None O
. None None O

This None None O
paper None None O
will None None O
focus None None O
on None None O
the None None O
diabetic None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
, None None O
including None None O
its None None O
latest None None O
research None None O
progress None None O
. None None O

In None None O
this None None O
present None None O
study None None O
, None None O
the None None O
effects None None O
of None None O
vitamin None None O
E None None O
( None None O
TRF None None O
and None None O
α-TCP None None O
) None None O
in None None O
protecting None None O
astrocytes None None O
against None None O
glutamate None None I-TRANS
injury None None O
were None None O
elucidated None None O
. None None O

However None None O
, None None O
glutamate None None I-TRANS
mediated None None O
cytotoxicity None None O
was None None O
diminished None None O
via None None O
pre None None O
and None None O
post None None O
supplementation None None O
of None None O
TRF None None O
and None None O
α-TCP None None O
. None None O

After None None O
amplification None None O
, None None O
we None None O
used None None O
restriction None None O
enzymes None None I-PROTEIN
( None None O
HphI None None O
and None None O
NcoI None None O
) None None O
to None None O
digest None None O
the None None O
amplified None None O
product None None O
. None None O

Third None None O
and None None O
fourth None None O
generation None None O
cephalosporins None None O
should None None O
not None None O
be None None O
used None None O
for None None O
empirical None None O
treatment None None O
because None None O
of None None O
the None None O
high None None O
prevalence None None O
of None None O
extended None None O
spectrum None None O
beta-lactamase None None I-PROTEIN
production None None O
among None None O
E.coli None None O
and None None O
Klebsiella None None O
isolates None None O
. None None O

Insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor-1 None None O
( None None O
IGF-1 None None O
) None None O
may None None O
make None None O
endothelial None None O
cells None None O
and None None O
smooth None None O
muscle None None O
cells None None O
more None None O
sensitive None None O
to None None O
the None None O
effects None None O
of None None O
growth None None O
hormone None None O
. None None O

In None None O
Hadean None None O
oceans None None O
, None None O
these None None O
inorganic None None O
barriers None None O
should None None O
have None None O
contained None None O
catalytic None None O
Fe None None O
( None None O
Ni None None O
) None None O
S None None O
minerals None None O
similar None None O
in None None O
structure None None O
to None None O
cofactors None None O
in None None O
modern None None O
metabolic None None O
enzymes None None I-PROTEIN
, None None O
suggesting None None O
a None None O
possible None None O
abiotic None None O
origin None None O
of None None O
chemiosmotic None None O
coupling None None O
. None None O

Two None None O
hundred None None O
ninety-seven None None O
of None None O
845 None None O
subjects None None O
in None None O
the None None O
Aging None None O
, None None O
Demographics None None O
, None None O
and None None O
Memory None None I-FUNC
Study None None O
( None None O
ADAMS None None O
) None None O
, None None O
a None None O
nationally None None O
representative None None O
community-based None None O
cohort None None O
study None None O
, None None O
met None None O
criteria None None O
for None None O
dementia None None I-DISEASE
after None None O
a None None O
detailed None None O
in-person None None O
study None None O
examination None None O
. None None O

Among None None O
subjects None None O
with None None O
dementia None None I-DISEASE
, None None O
we None None O
evaluated None None O
demographic None None O
, None None O
socioeconomic None None O
, None None O
and None None O
clinical None None O
factors None None O
associated None None O
with None None O
an None None O
informant-reported None None O
clinical None None O
cognitive None None O
evaluation None None O
using None None O
bivariate None None O
analyses None None O
and None None O
multivariable None None O
logistic None None O
regression None None O
. None None O

In None None O
a None None O
multivariable None None O
logistic None None O
regression None None O
model None None O
( None None O
n None None O
= None None O
297 None None O
) None None O
controlling None None O
for None None O
demographics None None O
, None None O
physical None None O
function None None O
measures None None O
, None None O
and None None O
dementia None None I-DISEASE
severity None None O
, None None O
marital None None O
status None None O
( None None O
odds None None O
ratio None None O
for None None O
currently None None O
married None None O
: None None O
2.63 None None O
[ None None O
95 None None O
% None None O
confidence None None O
interval None None O
: None None O
1.10-6.35 None None O
] None None O
) None None O
was None None O
the None None O
only None None O
significant None None O
independent None None O
predictor None None O
of None None O
receiving None None O
a None None O
clinical None None O
cognitive None None O
evaluation None None O
among None None O
subjects None None O
with None None O
study-confirmed None None O
dementia None None I-DISEASE
. None None O

The None None O
likelihood None None O
of None None O
receiving None None O
a None None O
clinical None None O
cognitive None None O
evaluation None None O
in None None O
elderly None None O
individuals None None O
with None None O
dementia None None I-DISEASE
associates None None O
with None None O
certain None None O
patient-specific None None O
factors None None O
, None None O
particularly None None O
severity None None O
of None None O
cognitive None None O
impairment None None O
and None None O
current None None O
marital None None O
status None None O
. None None O

Excessive None None O
localization None None O
of None None O
elastin None None I-PROTEIN
from None None O
septal None None O
tips None None O
to None None O
alveolar None None O
walls None None O
is None None O
a None None O
key None None O
feature None None O
of None None O
bronchopulmonary None None O
dysplasia None None O
( None None O
BPD None None O
) None None O
. None None O

To None None O
further None None O
investigate None None O
the None None O
mechanisms None None O
accounting None None O
for None None O
the None None O
abnormal None None O
accumulation None None O
of None None O
elastin None None I-PROTEIN
in None None O
the None None O
lungs None None O
of None None O
newborn None None O
mice None None O
with None None O
BPD None None O
, None None O
we None None O
evaluate None None O
elastin None None I-PROTEIN
distribution None None O
and None None O
its None None O
interaction None None O
with None None O
proteins None None O
involved None None O
in None None O
its None None O
aberrant None None O
localization None None O
, None None O
such None None O
as None None O
integrin None None I-PROTEIN
αv None None O
, None None O
fibulin-5 None None O
and None None O
transforming None None O
growth None None O
factor None None O
β1 None None O
( None None O
TGF-β1 None None O
) None None O
, None None O
in None None O
lungs None None O
of None None O
newborn None None O
mice None None O
exposed None None O
to None None O
60 None None O
% None None O
O2 None None O
for None None O
21 None None O
days None None O
. None None O

Dual None None O
staining None None O
image None None O
analysis None None O
of None None O
lung None None O
sections None None O
revealed None None O
that None None O
co-localization None None O
of None None O
integrin None None I-PROTEIN
αv None None O
and None None O
elastin None None I-PROTEIN
increased None None O
following None None O
O2 None None O
exposure None None O
with None None O
elastin None None I-PROTEIN
distributed None None O
throughout None None O
the None None O
walls None None O
of None None O
air None None O
spaces None None O
rather None None O
than None None O
at None None O
septal None None O
tips None None O
. None None O

Concurrently None None O
, None None O
increased None None O
fibulin-5 None None O
and None None O
TGF-β1 None None O
( None None O
which None None O
may None None O
regulate None None O
elastic None None O
fiber None None O
assembly None None O
) None None O
expression None None O
was None None O
detected None None O
, None None O
which None None O
may None None O
explain None None O
the None None O
altered None None O
lung None None O
elastin None None I-PROTEIN
deposition None None O
and None None O
defective None None O
septation None None O
that None None O
are None None O
observed None None O
during None None O
BPD None None O
. None None O

Laparoscopic None None O
colon None None O
resection None None O
surgery None None O
is None None O
now None None O
taught None None O
within None None O
surgical None None O
residency None None O
programs None None O
, None None O
and None None O
assessment None None O
tools None None O
are None None O
increasingly None None O
used None None O
to None None O
stimulate None None O
formative None None O
feedback None None O
and None None O
enhance None None O
learning None None I-FUNC
. None None O

Haematopoietic None None O
stem None None O
cells None None O
( None None O
HSCs None None O
) None None O
derive None None O
from None None O
haemogenic None None O
endothelial None None O
cells None None O
of None None O
the None None O
primitive None None O
dorsal None None I-NEURON
aorta None None O
( None None O
DA None None O
) None None O
during None None O
vertebrate None None O
embryogenesis None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
a None None O
novel None None O
requirement None None O
for None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
FGF None None O
) None None O
signalling None None O
in None None O
HSC None None O
emergence None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
examined None None O
the None None O
time-dependent None None O
changes None None O
of None None O
calbindin None None O
D-28k None None O
( None None O
CB None None O
) None None O
protein None None O
expression None None O
in None None O
the None None O
mouse None None O
hippocampus None None I-REGION
after None None O
a None None O
systemic None None O
administration None None O
of None None O
1 None None O
mg/kg None None O
LPS None None O
. None None O

At None None O
this None None O
point None None O
in None None O
time None None O
, None None O
CB None None O
protein None None O
level None None O
was None None O
also None None O
significantly None None O
increased None None O
in None None O
the None None O
mouse None None O
hippocampus None None I-REGION
. None None O

The None None O
abdominal None None O
drawing-in None None O
maneuver None None O
( None None O
ADIM None None O
) None None O
is None None O
used None None O
to None None O
prevent None None O
abnormal None None O
movements None None I-FUNC
of None None O
the None None O
lumbar None None O
spine None None O
and None None O
pelvis None None O
during None None O
therapeutic None None O
exercises None None O
. None None O

Recently None None O
, None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
focusing None None O
internal None None O
attention None None I-FUNC
to None None O
a None None O
specific None None O
item None None O
in None None O
memory None None I-FUNC
not None None O
only None None O
increases None None O
the None None O
accessibility None None O
of None None O
that None None O
specific None None O
item None None O
for None None O
retrieval None None O
, None None O
but None None O
also None None O
results None None O
in None None O
increased None None O
attentional None None O
guidance None None O
toward None None O
matching None None O
external None None O
stimuli None None O
by None None O
that None None O
item None None O
. None None O

Following None None O
a None None O
retro-cue None None O
that None None O
prioritized None None O
one None None O
of None None O
two None None O
memory None None I-FUNC
items None None O
, None None O
participants None None O
performed None None O
a None None O
visual None None O
search None None O
task None None O
. None None O

Consistent None None O
with None None O
earlier None None O
findings None None O
, None None O
we None None O
observed None None O
memory-related None None O
capture None None O
when None None O
the None None O
search None None O
display None None O
contained None None O
a None None O
distractor None None O
that None None O
was None None O
related None None O
to None None O
the None None O
cued None None O
item None None O
in None None O
memory None None I-FUNC
. None None O

In None None O
the None None O
USA None None O
, None None O
binge None None O
eating None None I-DISEASE
disorder None None I-DISEASE
( None None O
BED None None O
) None None O
is None None O
the None None O
most None None O
common None None O
eating None None I-DISEASE
disorder None None I-DISEASE
, None None O
with None None O
a None None O
lifetime None None O
prevalence None None O
of None None O
~3.5 None None O
% None None O
in None None O
adult None None O
women None None O
, None None O
2.0 None None O
% None None O
in None None O
adult None None O
men None None O
, None None O
and None None O
1.6 None None O
% None None O
in None None O
adolescents None None O
. None None O

BED None None O
is None None O
highly None None O
co-morbid None None O
with None None O
obesity None None O
and None None O
with None None O
depression None None I-DISEASE
and None None O
other None None O
psychiatric None None O
conditions None None O
, None None O
and None None O
it None None O
is None None O
associated None None O
with None None O
substantial None None O
role None None O
impairment None None O
. None None O

Animal None None O
and None None O
human None None O
studies None None O
implicate None None O
underlying None None O
dysregulation None None O
in None None O
dopamine None None I-TRANS
, None None O
opioid None None O
, None None O
acetylcholine None None I-TRANS
, None None O
and None None O
serotonin None None I-TRANS
neurocircuitry None None O
within None None O
brain None None O
reward None None O
regions None None O
in None None O
the None None O
pathogenesis None None O
and None None O
maintenance None None O
of None None O
BED None None O
. None None O

After None None O
homogenization None None O
of None None O
77 None None O
tissue None None O
samples None None O
, None None O
evaluation None None O
was None None O
made None None O
of None None O
thiobarbituric None None O
reactive None None O
substances None None O
( None None O
TBARS None None O
) None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
total None None O
antioxidant None None O
status None None O
( None None O
TAS None None O
) None None O
and None None O
the None None O
activity None None O
of None None O
the None None O
three None None O
main None None O
antioxidant None None O
enzymes None None I-PROTEIN
: None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
catalase None None I-PROTEIN
. None None O

Compared None None O
to None None O
the None None O
control None None O
group None None O
, None None O
in None None O
the None None O
primary None None O
pterygium None None O
group None None O
there None None O
was None None O
an None None O
increase None None O
in None None O
NO None None O
and None None O
TAS None None O
, None None O
and None None O
a None None O
tendency None None O
to None None O
a None None O
decrease None None O
of None None O
all None None O
antioxidant None None O
enzymes None None I-PROTEIN
, None None O
indicating None None O
an None None O
increase None None O
in None None O
non-enzymatic None None O
antioxidant None None O
activity None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
assessed None None O
the None None O
diagnostic None None O
utility None None O
of None None O
ZPP None None O
( None None O
measured None None O
in None None O
whole None None O
blood None None O
and None None O
erythrocytes None None O
) None None O
, None None O
alone None None O
or None None O
in None None O
combination None None O
with None None O
haemoglobin None None O
concentration None None O
, None None O
in None None O
detecting None None O
iron None None O
deficiency None None O
( None None O
plasma None None O
ferritin None None I-PROTEIN
concentration None None O
& None None O
lt None None O
; None None O
15 None None O
μg/L None None O
) None None O
. None None O

We None None O
used None None O
linear None None O
regression None None O
analysis None None O
to None None O
assess None None O
associations None None O
between None None O
ZPP None None O
and None None O
iron None None O
markers None None O
( None None O
including None None O
anaemia None None O
) None None O
, None None O
factors None None O
known None None O
or None None O
suspected None None O
to None None O
be None None O
associated None None O
with None None O
iron None None O
status None None O
, None None O
inflammation None None O
markers None None O
( None None O
plasma None None O
concentrations None None O
of None None O
C-reactive None None O
protein None None O
and None None O
α None None O
1-acid None None O
glycoprotein None None O
) None None O
, None None O
infections None None O
( None None O
Plasmodium None None O
infection None None O
, None None O
HIV None None O
infection None None O
) None None O
, None None O
and None None O
other None None O
disorders None None O
( None None O
α None None O
( None None O
+ None None O
) None None O
-thalassaemia None None O
, None None O
plasma None None O
concentrations None None O
of None None O
total None None O
bilirubin None None O
, None None O
and None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
) None None O
. None None O

Electrical None None O
activity None None O
, None None O
consisting None None O
of None None O
single None None O
and None None O
multiple None None O
pulses None None O
, None None O
was None None O
noticed None None O
in None None O
seven-day-old None None O
larvae None None O
that None None O
began None None O
to None None O
exhibit None None O
swimming None None O
movements None None I-FUNC
. None None O

Characteristic None None O
phosphorylation None None O
times None None O
for None None O
the None None O
receptors None None I-PROTEIN
were None None O
between None None O
13 None None O
and None None O
35 None None O
seconds None None O
, None None O
whereas None None O
for None None O
downstream None None O
kinases None None I-PROTEIN
between None None O
25 None None O
and None None O
200 None None O
seconds None None O
. None None O

Susceptibility None None O
to None None O
sepsis None None O
is None None O
identified None None O
to None None O
be None None O
mediated None None O
by None None O
innate None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
and None None O
responsive None None O
signaling None None O
pathways None None O
of None None O
the None None O
host None None O
. None None O

We None None O
searched None None O
for None None O
homologs None None O
of None None O
a None None O
set None None O
of None None O
proteins None None O
encoded None None O
in None None O
the None None O
structural None None O
module None None O
using None None O
a None None O
phage None None O
learning None None I-FUNC
database None None O
. None None O

We None None O
also None None O
conducted None None O
a None None O
flow None None O
cytometric None None O
analysis None None O
of None None O
systemic None None O
CD4 None None O
( None None O
+ None None O
) None None O
CD25 None None O
( None None O
+ None None O
) None None O
FOXP3 None None I-PROTEIN
( None None O
+ None None O
) None None O
T None None O
regulatory None None O
cells None None O
( None None O
Tregs None None O
) None None O
and None None O
histological None None O
analysis None None O
of None None O
melanoma None None O
tumors None None O
. None None O

LTB4 None None O
is None None O
a None None O
pro-inflammatory None None O
mediator None None O
associated None None O
with None None O
the None None O
etiology None None O
and None None O
progression None None O
of None None O
atherosclerosis None None I-DISEASE
. None None O

Our None None O
population None None O
with None None O
AF None None O
have None None O
similar None None O
risk None None O
of None None O
stroke None None I-DISEASE
and None None O
bleeding None None O
as None None O
in None None O
European None None O
registries None None O
. None None O

Although None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
ablation None None O
is None None O
considered None None O
a None None O
technically None None O
challenging None None O
procedure None None O
, None None O
studies None None O
on None None O
the None None O
learning None None I-FUNC
curve None None O
of None None O
different None None O
pulmonary None None O
vein None None O
isolation None None O
( None None O
PVI None None O
) None None O
techniques None None O
are None None O
limited None None O
. None None O

A None None O
learning None None I-FUNC
curve None None O
effect None None O
was None None O
demonstrated None None O
in None None O
fluoroscopy None None O
times None None O
and None None O
in None None O
the None None O
number None None O
of None None O
RF None None O
applications None None O
but None None O
not None None O
in None None O
the None None O
acute None None O
success None None O
and None None O
in None None O
the None None O
long-term None None O
arrhythmia-free None None O
survival None None O
with None None O
circular None None O
multipolar None None O
RF None None O
ablations None None O
. None None O

In None None O
atherosclerosis None None I-DISEASE
pathology None None O
, None None O
monocytes None None O
and None None O
macrophages None None O
play None None O
the None None O
most None None O
important None None O
role None None O
by None None O
accumulating None None O
redundant None None O
LDL None None O
particles None None O
in None None O
their None None O
oxidized None None O
form None None O
and None None O
producing None None O
proinflammatory None None O
cytokines None None O
. None None O

There None None O
are None None O
37 None None O
Centers None None O
for None None O
Tobacco None None O
Dependence None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
, None None O
which None None O
offer None None O
treatment None None O
including None None O
a None None O
psychobehavioral None None O
intervention None None O
and None None O
pharmacotherapy None None O
( None None O
varenicline None None O
, None None O
nicotine None None O
, None None O
bupropion None None O
) None None O
. None None O

These None None O
FA None None O
patterns None None O
are None None O
supposed None None O
to None None O
be None None O
connected None None O
with None None O
the None None O
progression None None O
and/or None None O
impaired None None O
biochemical None None O
measures None None O
of None None O
MS None None O
( None None O
lipolysis None None O
, None None O
oxidative None None O
stress None None O
, None None O
dysglycidemia None None O
, None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
) None None O
. None None O

Furthermore None None O
, None None O
we None None O
compared None None O
the None None O
parameters None None O
of None None O
lipid None None O
metabolism None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
between None None O
smokers None None O
and None None O
non-smokers None None O
. None None O

We None None O
measured None None O
lipid None None O
profile None None O
, None None O
parameters None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
fasting None None O
glycemia None None O
, None None O
insulin None None I-PROTEIN
, None None O
HOMA-IR None None O
, None None O
C-peptide None None O
, None None O
proinsulin None None O
) None None O
and None None O
calculated None None O
atherogenic None None O
indexes None None O
- None None O
atherogenic None None O
index None None O
of None None O
plasma None None O
( None None O
log None None O
( None None O
TAG/HDL-C None None O
) None None O
, None None O
AIP None None O
) None None O
, None None O
ApoB/ApoA1 None None O
index None None O
and None None O
nonHDL-C. None None O
AIP None None O
was None None O
found None None O
out None None O
to None None O
show None None O
stronger None None O
correlations None None O
with None None O
parameters None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
, None None O
correlation None None O
coefficients None None O
ranging None None O
between None None O
0.457 None None O
and None None O
0.243 None None O
) None None O
than None None O
other None None O
indexes None None O
( None None O
ApoB/ApoA1 None None O
or None None O
nonHDL None None O
cholesterol None None O
) None None O
. None None O

AIP None None O
can None None O
be None None O
used None None O
in None None O
daily None None O
praxis None None O
for None None O
predicting None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
patients None None O
with None None O
dyslipidemia None None O
, None None O
predominantly None None O
in None None O
non-smokers None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
assessed None None O
changes None None O
in None None O
selected None None O
risk None None O
factors None None O
of None None O
atherosclerosis None None I-DISEASE
. None None O

In None None O
summary None None O
, None None O
patients None None O
with None None O
thrombophilia None None O
and None None O
history None None O
of None None O
VTE None None O
showed None None O
no None None O
evidence None None O
of None None O
greater None None O
progression None None O
of None None O
atherosclerosis None None I-DISEASE
or None None O
increase None None O
in None None O
traditional None None O
risk None None O
factors None None O
of None None O
atherosclerosis None None I-DISEASE
than None None O
patients None None O
with None None O
thrombophilia None None O
without None None O
history None None O
of None None O
VTE None None O
. None None O

The None None O
abnormal None None O
proliferation None None O
of None None O
vascular None None O
smooth None None O
muscle None None O
cells None None O
( None None O
VSMC None None O
) None None O
is None None O
thought None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
pathogenesis None None O
of None None O
atherosclerosis None None I-DISEASE
. None None O

The None None O
addition None None O
of None None O
both None None O
renal None None O
preadipocyte- None None O
and None None O
epicardial None None O
adipocyte- None None O
CM None None O
resulted None None O
in None None O
the None None O
elevated None None O
production None None O
of None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
compared None None O
with None None O
the None None O
control None None O
HASoSMC None None O
CM None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Patients None None O
in None None O
group None None O
3 None None O
showed None None O
significantly None None O
less None None O
increase None None O
in None None O
the None None O
total None None O
IPSS None None O
and None None O
storage None None I-FUNC
symptom None None O
subscores None None O
than None None O
did None None O
those None None O
in None None O
the None None O
other None None O
groups None None O
. None None O

Eleven None None O
patients None None O
had None None O
urinary None None O
incontinence None None O
grade None None O
1-2 None None O
and None None O
three None None O
had None None O
grade None None O
3-4 None None O
, None None O
seven None None O
had None None O
pelvic None None O
pain None None O
, None None O
three None None O
had None None O
severe None None O
but None None O
transitory None None O
tissue None None O
sloughing None None O
, None None O
three None None O
developed None None O
a None None O
urethral None None O
stricture None None O
or None None O
had None None O
prolonged None None O
urinary None None O
retention None None I-FUNC
, None None O
and None None O
one None None O
developed None None O
a None None O
urinary None None O
fistula None None O
4.5 None None O
years None None O
after None None O
cryotherapy None None O
. None None O

Hip None None O
dislocation None None O
in None None O
children None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
CP None None O
) None None O
is None None O
a None None O
common None None O
and None None O
severe None None O
problem None None O
. None None O

Chitosan None None O
films None None O
with None None O
20 None None O
g None None O
kg None None O
( None None O
-1 None None O
) None None O
CEO None None O
were None None O
combined None None O
with None None O
high-pressure None None O
( None None O
HPP None None O
) None None O
processing None None O
as None None O
treatments None None O
for None None O
trout None None O
fillets None None O
, None None O
and None None O
changes None None O
in None None O
physicochemical None None O
parameters None None O
and None None O
microbial None None O
load None None O
were None None O
evaluated None None O
at None None O
4 None None O
°C None None O
over None None O
22 None None O
days None None O
of None None O
storage None None I-FUNC
. None None O

Copyright None None O
© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
, None None O
Ltd. None None O
Elevated None None O
lipoprotein-associated None None O
phospholipase None None O
A2 None None O
( None None O
Lp-PLA2 None None O
) None None O
levels None None O
are None None O
associated None None O
with None None O
both None None O
coronary None None O
artery None None O
and None None O
cerebrovascular None None I-DISEASE
diseases None None I-DISEASE
. None None O

Subsequently None None O
, None None O
we None None O
reported None None O
efficient None None O
self-formation None None O
of None None O
3-dimensional None None O
adenohypophysis None None I-REGION
tissues None None O
in None None O
aggregate None None O
cultures None None O
of None None O
mouse None None O
ES None None O
cells None None O
. None None O

A None None O
standard None None O
set None None O
of None None O
three None None O
APSY-NMR None None O
experiments None None O
has None None O
been None None O
used None None O
in None None O
daily None None O
practice None None O
to None None O
obtain None None O
polypeptide None None O
backbone None None O
NMR None None O
assignments None None O
in None None O
globular None None I-PROTEIN
proteins None None I-PROTEIN
with None None O
sizes None None O
up None None O
to None None O
about None None O
150 None None O
residues None None O
, None None O
which None None O
had None None O
been None None O
identified None None O
as None None O
targets None None O
for None None O
structure None None O
determination None None O
by None None O
the None None O
Joint None None O
Center None None O
for None None O
Structural None None O
Genomics None None O
( None None O
JCSG None None O
) None None O
under None None O
the None None O
auspices None None O
of None None O
the None None O
Protein None None O
Structure None None O
Initiative None None O
( None None O
PSI None None O
) None None O
. None None O

Such None None O
programmes None None O
should None None O
pay None None O
special None None O
attention None None I-FUNC
to None None O
females None None O
and None None O
younger None None O
children None None O
who None None O
are None None O
highly None None O
susceptible None None O
to None None O
the None None O
adverse None None O
conditions None None O
on None None O
the None None O
street None None O
. None None O

Its None None O
downstream None None O
effectors None None O
, None None O
carbon None None I-TRANS
monoxide None None I-TRANS
and None None O
biliverdin None None O
have None None O
also None None O
been None None O
shown None None O
to None None O
offer None None O
these None None O
beneficial None None O
effects None None O
. None None O

This None None O
supports None None O
the None None O
view None None O
of None None O
work-family None None O
conflict None None O
as None None O
a None None O
psychosocial None None O
risk None None O
factor None None O
for None None O
health None None O
outcomes None None O
spanning None None O
function None None O
, None None O
health None None O
perceptions None None I-FUNC
and None None O
well-being None None O
, None None O
and None None O
encompassing None None O
both None None O
oral None None O
health None None O
and None None O
general None None O
health None None O
. None None O

A None None O
high None None O
Vmes/Vmic None None O
ratio None None O
in None None O
porous None None O
carbons None None O
is None None O
favorable None None O
for None None O
enhancing None None O
the None None O
accessibility None None O
of None None O
Li None None O
ions None None O
to None None O
active None None O
sites None None O
provided None None O
by None None O
the None None O
micropores None None O
and None None O
for None None O
achieving None None O
good None None O
lithium None None O
storage None None I-FUNC
performance None None O
. None None O

Rate None None O
constants None None O
for None None O
indole None None O
itself None None O
, None None O
tryptophan None None I-TRANS
and None None O
indole-3 None None O
carboxylic None None O
acid None None O
are None None O
one None None O
order None None O
of None None O
magnitude None None O
lower None None O
. None None O

Null None None O
mutations None None O
in None None O
plant None None O
vegetative None None O
actins None None I-PROTEIN
produce None None O
dramatically None None O
altered None None O
cell None None O
, None None O
tissue None None O
, None None O
and None None O
organ None None O
morphologies None None O
. None None O

Considering None None O
that None None O
fungi None None O
have None None O
a None None O
phylogenetic None None O
origin None None O
closer None None O
to None None O
animals None None O
than None None O
plants None None O
, None None O
we None None O
were None None O
interested None None O
to None None O
explore None None O
whether None None O
the None None O
fungal None None O
actins None None I-PROTEIN
may None None O
have None None O
this None None O
same None None O
capacity None None O
to None None O
function None None O
in None None O
plants None None O
and None None O
support None None O
development None None O
. None None O

We None None O
found None None O
that None None O
expression None None O
of None None O
actin None None I-PROTEIN
from None None O
the None None O
earliest None None O
diverging None None O
ascomycete None None O
subphyla None None O
, None None O
the None None O
archiascomycete None None O
Schizosaccharomyces None None O
pombe None None O
, None None O
qualitatively None None O
and None None O
quantitatively None None O
suppressed None None O
the None None O
root None None O
cell None None O
polarity None None O
and None None O
root None None O
organ None None O
developmental None None O
defects None None O
of None None O
act8/act7 None None O
mutants None None O
and None None O
the None None O
root-hairless None None O
cell None None O
elongation None None O
phenotype None None O
of None None O
act2/act8 None None O
mutants None None O
. None None O

In None None O
contrast None None O
, None None O
actins None None I-PROTEIN
from None None O
the None None O
saccharomycetes None None O
Saccharomyces None None O
cerevisiae None None O
and None None O
Candida None None O
albicans None None O
were None None O
unable None None O
to None None O
support None None O
any None None O
aspect None None O
of None None O
plant None None O
development None None O
, None None O
and None None O
moreover None None O
induced None None O
severe None None O
dwarfism None None O
and None None O
sterility None None O
. None None O

The None None O
gustatory None None O
plasticity None None O
was None None O
also None None O
augmented None None O
when None None O
tph-1 None None O
mutants None None O
, None None O
with None None O
a None None O
defect None None O
in None None O
serotonin None None I-TRANS
biosynthesis None None O
, None None O
were None None O
maintained None None O
on None None O
a None None O
medium None None O
containing None None O
nicotine None None O
until None None O
the None None O
YA None None O
stage None None O
. None None O

However None None O
, None None O
augmentation None None O
of None None O
gustatory None None O
plasticity None None O
was None None O
observed None None O
when None None O
bas-1 None None O
and None None O
cat-2 None None O
mutants None None O
were None None O
maintained None None O
on None None O
a None None O
growth None None O
medium None None O
containing None None O
nicotine None None O
along None None O
with None None O
dopamine None None I-TRANS
, None None O
suggesting None None O
that None None O
dopamine None None I-TRANS
signaling None None O
is None None O
involved None None O
in None None O
the None None O
augmentation None None O
of None None O
gustatory None None O
plasticity None None O
due None None O
to None None O
chronic None None O
nicotine None None O
exposure None None O
. None None O

Cost-effectiveness None None O
shows None None O
that None None O
the None None O
dronedarone None None O
treatment None None O
option None None O
has None None O
the None None O
most None None O
advantageous None None O
relationship None None O
, None None O
where None None O
, None None O
for None None O
one None None O
year None None O
without None None O
a None None O
stroke None None I-DISEASE
, None None O
the None None O
total None None O
cost None None O
is None None O
€1,779.23 None None O
. None None O

Cross-sectional None None O
data None None O
on None None O
766 None None O
girls None None O
, None None O
aged None None O
15 None None O
years None None O
and None None O
under None None O
, None None O
with None None O
genetically None None O
confirmed None None O
Rett None None I-DISEASE
syndrome None None I-DISEASE
was None None O
obtained None None O
from None None O
the None None O
Australian None None O
Rett None None I-DISEASE
Syndrome None None I-DISEASE
Database None None O
( None None O
ARSD None None O
) None None O
( None None O
n None None O
= None None O
244 None None O
) None None O
and None None O
the None None O
International None None O
Rett None None I-DISEASE
Syndrome None None I-DISEASE
Phenotype None None O
Database None None O
( None None O
InterRett None None O
) None None O
( None None O
n None None O
= None None O
522 None None O
) None None O
. None None O

Girls None None O
with None None O
Rett None None I-DISEASE
syndrome None None I-DISEASE
vary None None O
in None None O
their None None O
use None None O
of None None O
speech None None I-FUNC
and None None O
language None None I-FUNC
, None None O
and None None O
in None None O
their None None O
experience None None O
of None None O
speech-language None None O
regression None None O
and None None O
these None None O
variations None None O
are None None O
partly None None O
explained None None O
by None None O
genotype None None O
. None None O

A None None O
forced None None O
HOXB7 None None O
expression None None O
was None None O
associated None None O
with None None O
an None None O
improved None None O
cell None None O
growth None None O
, None None O
a None None O
reduction None None O
of None None O
senescence None None O
, None None O
and None None O
an None None O
improved None None O
osteogenesis None None O
linked None None O
to None None O
a None None O
dramatic None None O
increase None None O
of None None O
autocrine None None O
basic None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
secretion None None O
. None None O

The None None O
biofilm None None O
matrix None None O
was None None O
highly None None O
sensitive None None O
to None None O
degradation None None O
by None None O
proteinase None None I-PROTEIN
K. None None O
Comparison None None O
of None None O
transcriptional None None O
profiles None None O
of None None O
biofilm None None O
and None None O
planktonic None None O
cells None None O
of None None O
the None None O
non-virulent None None O
H. None None O
parasuis None None O
F9 None None O
strain None None O
revealed None None O
a None None O
significant None None O
number None None O
of None None O
up-regulated None None O
membrane-related None None O
genes None None O
in None None O
biofilms None None O
, None None O
and None None O
genes None None O
previously None None O
identified None None O
in None None O
Actinobacillus None None O
pleuropneumoniae None None O
biofilms None None O
. None None O

Wood None None O
biophysical None None O
properties None None O
and None None O
the None None O
dynamics None None O
of None None O
water None None O
storage None None I-FUNC
discharge None None O
and None None O
refilling None None O
were None None O
studied None None O
in None None O
the None None O
trunk None None O
of None None O
canopy None None O
tree None None O
species None None O
with None None O
diverse None None O
life None None O
history None None O
and None None O
functional None None O
traits None None O
in None None O
subtropical None None O
forests None None O
of None None O
northeast None None O
Argentina None None O
. None None O

Simultaneous None None O
sap None None O
flow None None O
measurements None None O
on None None O
branches None None O
and None None O
at None None O
the None None O
base None None O
of None None O
the None None O
tree None None O
trunk None None O
, None None O
as None None O
well None None O
as None None O
diurnal None None O
variations None None O
in None None O
trunk None None O
contraction None None O
and None None O
expansion None None O
, None None O
were None None O
used None None O
as None None O
additional None None O
measures None None O
of None None O
stem None None O
water None None O
storage None None I-FUNC
use None None O
and None None O
refilling None None O
dynamics None None O
. None None O

The None None O
large None None O
sapwood None None O
capacitance None None O
in None None O
deciduous None None O
species None None O
may None None O
help None None O
to None None O
avoid None None O
catastrophic None None O
embolism None None I-DISEASE
in None None O
xylem None None O
conduits None None O
. None None O

For None None O
example None None O
, None None O
Cathepsin None None O
K None None O
has None None O
already None None O
been None None O
identified None None O
as None None O
a None None O
collagen None None I-PROTEIN
degradation None None O
protease None None O
produced None None O
by None None O
mature None None O
osteoclasts None None O
with None None O
high None None O
activity None None O
in None None O
the None None O
acidic None None O
osteoclast None None O
resorption None None O
pits None None O
. None None O

Family None None O
was None None O
more None None O
protective None None O
when None None O
the None None O
patients None None O
were None None O
elderly None None O
( None None O
p None None O
0.036 None None O
) None None O
, None None O
depressed None None O
( None None O
p None None O
0.054 None None O
) None None O
, None None O
had None None O
dementia None None I-DISEASE
( None None O
p None None O
0.03 None None O
) None None O
, None None O
had None None O
poor None None O
performance None None O
status None None O
( None None O
p None None O
0.03 None None O
) None None O
, None None O
or None None O
complied None None O
with None None O
frailty None None O
criteria None None O
( None None O
p None None O
0.014 None None O
) None None O
. None None O

This None None O
syndrome None None O
is None None O
defined None None O
by None None O
the None None O
occurrence None None O
of None None O
two None None O
or None None O
more None None O
risk None None O
factors None None O
including None None O
obesity None None O
, None None O
hypertension None None O
, None None O
dyslipidemia None None O
, None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

The None None O
health None None O
of None None O
Australian None None O
men None None O
has None None O
recently None None O
received None None O
greater None None O
attention None None I-FUNC
. None None O

The None None O
brain None None O
( None None O
particularly None None O
some None None O
hypothalamic None None O
structures None None O
located None None O
in None None O
the None None O
preoptic None None I-REGION
area None None I-REGION
) None None O
modulates None None O
efferent None None O
activities None None O
that None None O
cause None None O
changes None None O
in None None O
heat None None O
production None None O
( None None O
modulating None None O
brown None None O
adipose None None O
tissue None None O
activity None None O
and None None O
perfusion None None O
, None None O
for None None O
instance None None O
) None None O
and None None O
heat None None O
loss None None O
( None None O
modulating None None O
tail None None O
skin None None O
vasculature None None O
blood None None O
flow None None O
, None None O
for None None O
instance None None O
) None None O
. None None O

The None None O
human None None O
adrenal None None I-TRANS
produces None None O
more None None O
19 None None O
carbon None None O
( None None O
C19 None None O
) None None O
steroids None None O
, None None O
by None None O
mass None None O
, None None O
than None None O
either None None O
glucocorticoids None None O
or None None O
mineralocorticoids None None O
. None None O

This None None O
review None None O
will None None O
discuss None None O
the None None O
C19 None None O
steroids None None O
synthesized None None O
by None None O
the None None O
human None None O
adrenal None None I-TRANS
and None None O
the None None O
features None None O
within None None O
the None None O
adrenal None None I-TRANS
that None None O
allow None None O
production None None O
of None None O
these None None O
steroids None None O
. None None O

Most None None O
impairments None None O
of None None O
the None None O
lower None None O
urinary None None O
tract None None O
manifest None None O
in None None O
two None None O
interrelated None None O
complications None None O
: None None O
bladder None None O
storage None None I-FUNC
and None None O
emptying None None O
. None None O

Dysfunction None None O
of None None O
the None None O
hypothalamic-pituitary-adrenal None None O
( None None O
HPA None None O
) None None O
axis None None O
may None None O
contribute None None O
to None None O
aging-related None None O
diseases None None O
like None None O
depression None None I-DISEASE
, None None O
cognitive None None O
deficits None None O
, None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
in None None O
some None None O
older None None O
individuals None None O
. None None O

This None None O
article None None O
reviews None None O
the None None O
pathophysiology None None O
of None None O
HPA None None O
dysfunction None None O
with None None O
respect None None O
to None None O
increased None None O
basal None None O
adrenocorticotropic None None I-TRANS
hormone None None I-TRANS
( None None O
ACTH None None O
) None None O
and None None O
cortisol None None O
secretion None None O
, None None O
decreased None None O
glucocorticoid None None O
( None None O
GC None None O
) None None O
negative None None O
feedback None None O
at None None O
the None None O
level None None O
of None None O
the None None O
paraventricular None None O
nucleus None None O
( None None O
PVN None None O
) None None O
of None None O
the None None O
hypothalamus None None I-REGION
, None None O
hippocampus None None I-REGION
( None None O
HC None None O
) None None O
, None None O
and None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
PFC None None O
) None None O
, None None O
and None None O
flattening None None O
of None None O
diurnal None None O
pattern None None O
of None None O
cortisol None None O
release None None O
. None None O

Under None None O
normal None None O
conditions None None O
, None None O
the None None O
chemoreflexes None None O
contribute None None O
to None None O
PaCO2 None None O
stability None None O
by None None O
producing None None O
small None None O
corrective None None O
cardiorespiratory None None O
adjustments None None O
mediated None None O
by None None O
lower None None O
brainstem None None I-REGION
circuits None None O
. None None O

However None None O
, None None O
close None None O
attention None None I-FUNC
to None None O
how None None O
therapy None None O
is None None O
set None None O
up None None O
and None None O
used None None O
are None None O
key None None O
factors None None O
in None None O
achieving None None O
clinical None None O
benefits None None O
. None None O

The None None O
first None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
-coupled None None O
bicarbonate None None O
transporter None None O
( None None O
NCBT None None O
) None None O
was None None O
expression-cloned None None O
in None None O
the None None O
late None None O
1990s None None O
. None None O

In None None O
nonepithelial None None O
tissues None None O
, None None O
NCBTs None None O
contribute None None O
to None None O
intracellular None None O
pH None None O
regulation None None O
; None None O
and None None O
hence None None O
, None None O
they None None O
are None None O
crucial None None O
for None None O
diverse None None O
tissue None None O
functions None None O
including None None O
neuronal None None O
discharge None None O
, None None O
sensory None None I-NEURON
neuron None None I-NEURON
development None None O
, None None O
performance None None O
of None None O
the None None O
heart None None O
, None None O
and None None O
vascular None None O
tone None None O
regulation None None O
. None None O

Animal None None O
models None None O
have None None O
revealed None None O
pathophysiological None None O
roles None None O
of None None O
the None None O
transporters None None I-PROTEIN
in None None O
disease None None O
states None None O
including None None O
metabolic None None O
acidosis None None O
, None None O
hypertension None None O
, None None O
visual None None O
defects None None O
, None None O
and None None O
epileptic None None O
seizures None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
the None None O
current None None O
knowledge None None O
regarding None None O
the None None O
function None None O
, None None O
structure None None O
, None None O
and None None O
regulation None None O
of None None O
the None None O
mammalian None None O
cation-coupled None None O
HCO3 None None O
( None None O
- None None O
) None None O
transporters None None I-PROTEIN
of None None O
the None None O
SLC4-family None None O
. None None O

Other None None O
studies None None O
identified None None O
a None None O
seven None None O
transmembrane None None O
domain None None O
glycoprotein None None O
, None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
/taurocholate None None O
transporting None None O
protein None None O
( None None O
ntcp None None O
) None None O
as None None O
mediating None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
-dependent None None O
uptake None None O
of None None O
bile None None O
acids None None O
as None None O
well None None O
as None None O
other None None O
organic None None O
anions None None O
. None None O

Factors None None O
that None None O
regulate None None O
this None None O
motility None None O
are None None O
under None None O
study None None O
and None None O
may None None O
provide None None O
a None None O
unique None None O
mechanism None None O
that None None O
can None None O
alter None None O
the None None O
plasma None None O
membrane None None O
content None None O
of None None O
these None None O
transporters None None I-PROTEIN
and None None O
consequently None None O
their None None O
accessibility None None O
to None None O
circulating None None O
ligands None None O
. None None O

Human None None O
and None None O
veterinary None None O
clinical None None O
studies None None O
, None None O
experimental None None O
animal None None O
model None None O
studies None None O
, None None O
and None None O
reviews None None O
of None None O
the None None O
RBC None None O
storage None None I-FUNC
lesion None None O
with None None O
no None None O
date None None O
restrictions None None O
. None None O

Although None None O
4 None None O
randomized None None O
controlled None None O
trials None None O
of None None O
varying None None O
sizes None None O
failed None None O
to None None O
find None None O
an None None O
association None None O
between None None O
RBC None None O
storage None None I-FUNC
time None None O
and None None O
negative None None O
clinical None None O
outcomes None None O
, None None O
a None None O
recent None None O
meta-analysis None None O
and None None O
numerous None None O
observational None None O
clinical None None O
studies None None O
have None None O
demonstrated None None O
that None None O
transfusion None None O
of None None O
old None None O
versus None None O
fresh None None O
stored None None O
RBCs None None O
is None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
morbidity None None O
and None None O
mortality None None O
, None None O
particularly None None O
among None None O
trauma None None O
victims None None O
and None None O
cardiac None None O
surgery None None O
patients None None O
. None None O

Experimental None None O
animal None None O
models None None O
have None None O
contributed None None O
to None None O
the None None O
evidence None None O
supporting None None O
adverse None None O
consequences None None O
of None None O
the None None O
RBC None None O
storage None None I-FUNC
lesion None None O
. None None O

Most None None O
reports None None O
in None None O
the None None O
human None None O
and None None O
veterinary None None O
literature None None O
support None None O
the None None O
concept None None O
that None None O
there None None O
are None None O
deleterious None None O
effects None None O
of None None O
the None None O
RBC None None O
storage None None I-FUNC
lesion None None O
, None None O
but None None O
additional None None O
studies None None O
with None None O
improved None None O
experimental None None O
design None None O
are None None O
needed None None O
to None None O
identify None None O
compelling None None O
reasons None None O
to None None O
modify None None O
current None None O
blood None None O
banking None None O
and None None O
transfusion None None O
practices None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
identified None None O
a None None O
NiV-G None None O
stalk None None O
C-terminal None None O
region None None O
( None None O
amino None None I-TRANS
acids None None I-TRANS
159 None None O
to None None O
163 None None O
) None None O
that None None O
is None None O
important None None O
for None None O
multiple None None O
G None None O
functions None None O
, None None O
including None None O
G None None O
tetramerization None None O
, None None O
conformational None None O
integrity None None O
, None None O
G-F None None O
interactions None None O
, None None O
receptor-induced None None O
conformational None None O
changes None None O
in None None O
G None None O
, None None O
and None None O
F None None O
triggering None None O
. None None O

However None None O
, None None O
the None None O
adaptive None None O
immune None None O
system None None O
was None None O
required None None O
for None None O
protection None None O
since None None O
N1347A None None O
virus None None O
was None None O
able None None O
to None None O
cause None None O
lethal None None O
encephalitis None None I-DISEASE
in None None O
RAG1 None None O
( None None O
-/- None None O
) None None O
( None None O
recombination None None O
activation None None O
gene None None O
1 None None O
knockout None None O
) None None O
mice None None O
although None None O
disease None None O
onset None None O
was None None O
modestly None None O
delayed None None O
. None None O

For None None O
MHV None None O
, None None O
this None None O
domain None None O
has None None O
now None None O
been None None O
shown None None O
to None None O
promote None None O
multiple None None O
types None None O
of None None O
disease None None O
, None None O
including None None O
hepatitis None None O
and None None O
encephalitis None None I-DISEASE
. None None O

The None None O
ability None None O
of None None O
the None None O
kidney None None O
to None None O
perform None None O
these None None O
functions None None O
requires None None O
that None None O
various None None O
cell None None O
types None None O
throughout None None O
the None None O
nephron None None I-TRANS
respond None None O
to None None O
changes None None O
in None None O
acid-base None None O
chemistry None None O
by None None O
modulating None None O
specific None None O
ion None None O
transport None None O
and/or None None O
metabolic None None O
processes None None O
in None None O
a None None O
coordinated None None O
fashion None None O
such None None O
that None None O
the None None O
urine None None O
and None None O
renal None None O
vein None None O
chemistry None None O
is None None O
altered None None O
appropriately None None O
. None None O

Further None None O
manipulation None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
through None None O
conditional None None O
expression None None O
of None None O
dominant None None O
positive None None O
or None None O
negative None None O
mutants None None O
of None None O
Rac1 None None O
, None None O
PAK1 None None O
, None None O
and None None O
RhoG None None O
, None None O
to None None O
increase None None O
or None None O
decrease None None O
macropinocytosis None None O
, None None O
similarly None None O
correlated None None O
with None None O
an None None O
augmented None None O
or None None O
inhibited None None O
infection None None O
with None None O
A-MLV None None O
, None None O
respectively None None O
. None None O

We None None O
used None None O
drugs None None O
or None None O
the None None O
introduction None None O
of None None O
mutant None None O
proteins None None O
that None None O
affect None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
and None None O
cell None None O
surface None None O
dynamics None None O
to None None O
show None None O
that None None O
macropinocytosis None None O
and None None O
A-MLV None None O
infection None None O
are None None O
correlated None None O
, None None O
and None None O
we None None O
provide None None O
both None None O
light- None None O
and None None O
electron-microscopic None None O
evidence None None O
to None None O
show None None O
the None None O
localization None None O
of None None O
A-MLV None None O
in None None O
macropinosomes None None O
. None None O

The None None O
movement None None I-FUNC
of None None O
tagged None None O
protein None None O
was None None O
saltatory None None O
but None None O
overall None None O
traveled None None O
only None None O
in None None O
one None None O
direction None None O
. None None O

The None None O
intercellular None None O
connections None None O
have None None O
a None None O
core None None O
of None None O
filamentous None None O
actin None None I-PROTEIN
, None None O
which None None O
hints None None O
toward None None O
transport None None O
of None None O
virus None None O
particles None None O
through None None O
the None None O
use None None O
of None None O
a None None O
myosin None None O
motor None None O
. None None O

The None None O
formation None None O
of None None O
these None None O
connections None None O
requires None None O
actin None None I-PROTEIN
dynamics None None O
and None None O
is None None O
enhanced None None O
by None None O
viral None None O
infection None None O
and None None O
the None None O
absence None None O
of None None O
microtubules None None O
. None None O

For None None O
example None None O
, None None O
highly None None O
similar None None O
coronavirus None None O
S1-CTDs None None O
within None None O
the None None O
same None None O
genus None None O
can None None O
recognize None None O
different None None O
receptors None None I-PROTEIN
, None None O
whereas None None O
very None None O
different None None O
coronavirus None None O
S1-CTDs None None O
from None None O
different None None O
genera None None O
can None None O
recognize None None O
the None None O
same None None O
receptor None None I-PROTEIN
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
strongly None None O
suggest None None O
that None None O
the None None O
viral None None O
replication None None O
levels None None O
in None None O
APCs None None O
critically None None O
affect None None O
the None None O
induction None None O
of None None O
protective None None O
versus None None O
pathogenic None None O
Th None None O
cell None None O
types None None O
via None None O
the None None O
signaling None None O
of None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
for None None O
innate None None O
immune None None O
responses None None O
. None None O

These None None O
results None None O
are None None O
consistent None None O
with None None O
the None None O
notion None None O
that None None O
the None None O
effectiveness None None O
of None None O
the None None O
smallpox None None O
vaccine None None O
is None None O
related None None O
to None None O
its None None O
capacity None None O
to None None O
induce None None O
both None None O
B None None O
and None None O
T None None O
cell None None O
memory None None I-FUNC
. None None O

Inactivation None None O
of None None O
Tra2β None None O
causing None None O
a None None O
switch None None O
to None None O
the None None O
isoform None None O
of None None O
MYPT1 None None O
containing None None O
the None None O
COOH-terminal None None O
leucine None None I-TRANS
zipper None None O
motif None None O
( None None O
E24- None None O
) None None O
increased None None O
arterial None None O
sensitivity None None O
to None None O
cGMP-mediated None None O
relaxation None None O
. None None O

This None None O
longitudinal None None O
study None None O
compares None None O
developmental None None O
changes None None O
in None None O
psychosocial None None O
functioning None None O
during None None O
the None None O
transition None None O
into None None O
school None None O
of None None O
children None None O
with None None O
and None None O
without None None O
dyslexia None None I-DISEASE
. None None O

Children None None O
's None None O
psychosocial None None O
functioning None None O
( None None O
social None None O
skills None None O
, None None O
inattention None None O
and None None O
externalizing None None O
and None None O
internalizing None None O
problems None None O
) None None O
was None None O
evaluated None None O
by None None O
their None None O
parents None None O
at None None O
ages None None O
4 None None O
, None None O
6 None None O
and None None O
9 None None O
, None None O
and None None O
diagnosis None None O
for None None O
dyslexia None None I-DISEASE
was None None O
made None None O
at None None O
age None None O
8 None None O
( None None O
in None None O
grade None None O
2 None None O
) None None O
. None None O

Significant None None O
interactions None None O
of None None O
gender None None O
and None None O
diagnosis None None O
of None None O
dyslexia None None I-DISEASE
emerged None None O
for None None O
social None None O
skills None None O
and None None O
inattention None None O
. None None O

Boys None None O
with None None O
dyslexia None None I-DISEASE
were None None O
rated None None O
as None None O
showing None None O
a None None O
high None None O
level None None O
of None None O
inattention None None O
both None None O
prior None None O
to None None O
and None None O
after None None O
school None None O
entry None None O
, None None O
whereas None None O
, None None O
for None None O
girls None None O
with None None O
dyslexia None None I-DISEASE
, None None O
inattention None None O
ratings None None O
increased None None O
after None None O
school None None O
entry None None O
, None None O
eventually None None O
matching None None O
the None None O
boys None None O
' None None O
levels None None O
. None None O

We None None O
propose None None O
a None None O
minimal None None O
region None None O
shared None None O
among None None O
patients None None O
contributing None None O
to None None O
the None None O
etiology None None O
of None None O
the None None O
common None None O
clinical None None O
features None None O
observed None None O
suggesting None None O
as None None O
candidate None None O
, None None O
for None None O
the None None O
first None None O
time None None O
, None None O
the None None O
gene None None O
SETD1B None None O
which None None O
is None None O
a None None O
component None None O
of None None O
a None None O
histone None None I-PROTEIN
methyltransferase None None I-PROTEIN
complex None None O
. None None O

These None None O
conditions None None O
share None None O
the None None O
common None None O
feature None None O
of None None O
tissue-nonspecific None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
TNAP None None O
) None None O
upregulation None None O
in None None O
the None None O
vasculature None None O
. None None O

In None None O
our None None O
previous None None O
study None None O
, None None O
we None None O
have None None O
produced None None O
a None None O
neutralizing None None O
mAb None None O
of None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
3 None None O
( None None O
VEGFR-3 None None O
) None None O
, None None O
specifically None None O
BDD073 None None O
, None None O
which None None O
could None None O
inhibit None None O
angiogenesis None None O
in None None O
the None None O
CAM None None O
model None None O
. None None O

The None None O
aim None None O
was None None O
to None None O
evaluate None None O
the None None O
association None None O
of None None O
obesity None None O
and None None O
migraine None None I-DISEASE
in None None O
selected None None O
pediatric None None O
patients None None O
and None None O
compare None None O
the None None O
findings None None O
with None None O
the None None O
literature None None O
. None None O

Comparison None None O
of None None O
the None None O
3 None None O
subgroups None None O
of None None O
migraine None None I-DISEASE
patients None None O
of None None O
normal None None O
weight None None O
, None None O
overweight None None O
, None None O
and None None O
obese None None O
with None None O
the None None O
corresponding None None O
body None None O
mass None None O
index None None O
standard None None O
deviation None None O
score None None O
subgroups None None O
of None None O
patients None None O
with None None O
tension-type None None O
headache None None O
yielded None None O
no None None O
statistically None None O
significant None None O
differences None None O
in None None O
frequency None None O
of None None O
headache None None O
attacks None None O
per None None O
month None None O
, None None O
or None None O
duration None None O
of None None O
headache None None O
attacks None None O
in None None O
hours None None O
. None None O

Zip14 None None O
is None None O
upregulated None None O
during None None O
endotoxemia None None O
and None None O
leads None None O
to None None O
increased None None O
liver None None O
zinc None None I-TRANS
content None None O
and None None O
transient None None O
hypozinemia None None O
. None None O

Wild-type None None O
( None None O
WT None None O
) None None O
and None None O
Zip14 None None O
knockout None None O
( None None O
KO None None O
) None None O
mice None None O
were None None O
used None None O
to None None O
determine None None O
ZIP14-associated None None O
intestinal None None O
zinc None None I-TRANS
metabolism None None O
and None None O
effects None None O
on None None O
permeability None None O
. None None O

Studies None None O
utilizing None None O
( None None O
65 None None O
) None None O
Zn None None O
administered None None O
by None None O
subcutaneous None None O
injection None None O
revealed None None O
greater None None O
zinc None None I-TRANS
accumulation None None O
in None None O
the None None O
SI None None O
of None None O
Zip14 None None O
KO None None O
mice None None O
compared None None O
with None None O
WT None None O
mice None None O
. None None O

Quantification None None O
of None None O
endosomal None None O
zinc None None I-TRANS
concentration None None O
by None None O
FluoZin-3AM None None O
fluorescence None None O
demonstrated None None O
that None None O
zinc None None I-TRANS
is None None O
trapped None None O
in None None O
endosomes None None O
of None None O
Zip14 None None O
KO None None O
mice None None O
. None None O

Threonine None None I-TRANS
phosphorylation None None O
of None None O
the None None O
tight None None O
junction None None O
protein None None O
occludin None None O
, None None O
which None None O
is None None O
necessary None None O
for None None O
tight None None O
junction None None O
assembly None None O
, None None O
was None None O
reduced None None O
in None None O
KO None None O
mice None None O
. None None O

These None None O
data None None O
suggest None None O
involvement None None O
of None None O
ZIP14 None None O
in None None O
providing None None O
zinc None None I-TRANS
for None None O
a None None O
regulatory None None O
role None None O
needed None None O
for None None O
maintenance None None O
of None None O
the None None O
intestinal None None O
barrier None None O
. None None O

Down-regulation None None O
of None None O
miR-126 None None O
was None None O
found None None O
to None None O
inversely None None O
correlate None None O
with None None O
an None None O
increased None None O
microvessel None None O
density None None O
( None None O
MVD None None O
) None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
A None None O
( None None O
VEGF-A None None O
) None None O
expression None None O
in None None O
gastric None None O
cancer None None O
tissues None None O
. None None O

However None None O
, None None O
the None None O
mechanism None None O
of None None O
CD147 None None O
involved None None O
in None None O
mesenchymal None None O
movement None None I-FUNC
is None None O
still None None O
unclear None None O
. None None O

Evidence None None O
indicated None None O
that None None O
the None None O
mesenchymal-type None None O
cell None None O
movement None None I-FUNC
induced None None O
by None None O
CD147 None None O
was None None O
Src None None O
dependent None None O
, None None O
as None None O
observed None None O
by None None O
confocal None None O
microscopy None None O
and None None O
Rac1 None None O
activity None None O
assay None None O
. None None O

Next None None O
, None None O
we None None O
identified None None O
DOCK8 None None O
as None None O
a None None O
GEF None None O
for None None O
Rac1 None None O
, None None O
a None None O
key None None O
molecule None None O
driving None None O
mesenchymal-type None None O
movement None None I-FUNC
. None None O

This None None O
study None None O
provides None None O
a None None O
novel None None O
mechanism None None O
of None None O
CD147 None None O
regulating None None O
mesenchymal-type None None O
movement None None I-FUNC
in None None O
HCC None None O
cells None None O
. None None O

Other None None O
structurally-related None None O
peptides-galanin-like None None O
peptide None None O
and None None O
alarin-with None None O
diverse None None O
biologic None None O
actions None None O
in None None O
brain None None O
and None None O
other None None O
tissues None None O
have None None O
since None None O
been None None O
identified None None O
, None None O
although None None O
, None None O
unlike None None O
galanin None None I-TRANS
, None None O
their None None O
cognate None None O
receptors None None I-PROTEIN
are None None O
currently None None O
unknown None None O
. None None O

Galanin None None I-TRANS
has None None O
been None None O
shown None None O
to None None O
regulate None None O
its None None O
numerous None None O
physiologic None None O
and None None O
pathophysiological None None O
processes None None O
through None None O
interactions None None O
with None None O
three None None O
G None None O
protein-coupled None None O
receptors None None I-PROTEIN
, None None O
GAL1 None None O
, None None O
GAL2 None None O
, None None O
and None None O
GAL3 None None O
, None None O
and None None O
signaling None None O
via None None O
multiple None None O
transduction None None O
pathways None None O
, None None O
including None None O
inhibition None None O
of None None O
cAMP/PKA None None O
( None None O
GAL1 None None O
, None None O
GAL3 None None O
) None None O
and None None O
stimulation None None O
of None None O
phospholipase None None I-PROTEIN
C None None I-PROTEIN
( None None O
GAL2 None None O
) None None O
. None None O

Also None None O
, None None O
other None None O
approaches None None O
, None None O
including None None O
new None None O
transgenic None None O
mouse None None O
lines None None O
( None None O
such None None O
as None None O
a None None O
recently None None O
characterized None None O
GAL3 None None O
knockout None None O
mouse None None O
) None None O
represent None None O
, None None O
in None None O
combination None None O
with None None O
viral-based None None O
techniques None None O
, None None O
critical None None O
tools None None O
required None None O
to None None O
better None None O
evaluate None None O
galanin None None I-TRANS
system None None O
physiology None None O
. None None O

Within None None O
the None None O
oxidative None None O
enzymes None None I-PROTEIN
, None None O
we None None O
found None None O
two None None O
cellobiose None None O
dehydrogenases None None I-PROTEIN
that None None O
produce None None O
oxygen None None O
radicals None None O
utilized None None O
by None None O
eight None None O
lytic None None O
polysaccharide None None O
monooxygenases None None O
that None None O
oxidize None None O
glycosidic None None O
linkages None None O
, None None O
breaking None None O
crystalline None None O
cellulose None None O
chains None None O
and None None O
making None None O
them None None O
accessible None None O
to None None O
hydrolytic None None I-PROTEIN
enzymes None None I-PROTEIN
. None None O

A None None O
right None None O
frontoorbital None None O
craniotomy None None O
was None None O
performed None None O
, None None O
and None None O
a None None O
mucocele None None O
in None None O
the None None O
frontal None None O
sinus None None O
extending None None O
into None None O
the None None O
frontal None None I-REGION
lobe None None I-REGION
and None None O
orbit None None O
was None None O
totally None None O
removed None None O
. None None O

Cutaneous None None O
microvascular None None O
reactivity None None O
to None None O
acetylcholine None None I-TRANS
and None None O
sodium None None O
nitroprusside None None O
, None None O
delivered None None O
locally None None O
by None None O
iontophoresis None None O
, None None O
was None None O
measured None None O
by None None O
laser None None O
Doppler None None O
flowmetry None None O
. None None O

In None None O
conscious None None O
, None None O
unrestrained None None O
C57BL/6J None None O
mice None None O
, None None O
we None None O
investigated None None O
whether None None O
the None None O
24 None None O
h None None O
pattern None None O
of None None O
arterial None None O
blood None None O
pressure None None O
is None None O
determined None None O
by None None O
variation None None O
in None None O
cardiac None None O
output None None O
, None None O
systemic None None O
vascular None None O
resistance None None O
, None None O
or None None O
both None None O
and None None O
also None None O
whether None None O
variations None None O
in None None O
cardiac None None O
output None None O
are None None O
mediated None None O
by None None O
variations None None O
in None None O
heart None None O
rate None None O
and None None O
or None None O
stroke None None I-DISEASE
volume None None O
. None None O

This None None O
study None None O
compared None None O
the None None O
effects None None O
of None None O
a None None O
simple None None O
versus None None O
complex None None O
contraction None None O
pattern None None O
on None None O
the None None O
acquisition None None O
, None None O
retention None None I-FUNC
, None None O
and None None O
transfer None None O
of None None O
maximal None None O
isometric None None O
strength None None O
gains None None O
and None None O
reductions None None O
in None None O
force None None O
variability None None O
. None None O

For None None O
the None None O
retention None None I-FUNC
test None None O
, None None O
the None None O
groups None None O
performed None None O
their None None O
assigned None None O
contraction None None O
pattern None None O
followed None None O
by None None O
a None None O
transfer None None O
test None None O
that None None O
consisted None None O
of None None O
the None None O
other None None O
contraction None None O
pattern None None O
for None None O
a None None O
cross-over None None O
design None None O
. None None O

The None None O
control None None O
group None None O
underwent None None O
a None None O
decrease None None O
in None None O
variability None None O
of None None O
the None None O
torque- None None O
and None None O
sEMG-time None None O
curves None None O
from None None O
the None None O
first None None O
day None None O
of None None O
training None None O
to None None O
retention None None I-FUNC
, None None O
but None None O
participants None None O
returned None None O
to None None O
baseline None None O
levels None None O
during None None O
the None None O
transfer None None O
condition None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Sequence None None O
analysis None None O
showed None None O
1 None None O
amino None None O
acid None None O
deletion None None O
in None None O
HA1 None None O
and None None O
3 None None O
amino None None O
acid None None O
deletions None None O
in None None O
the None None O
NA None None I-TRANS
stalk None None O
region None None O
. None None O

strain None None O
P1-3 None None O
, None None O
harboring None None O
keratin None None I-PROTEIN
degrading None None O
activity None None O
, None None O
has None None O
recently None None O
been None None O
isolated None None O
from None None O
poultry None None O
waste None None O
. None None O

Plant None None O
cryptochrome None None O
( None None O
cry1 None None O
and None None O
cry2 None None O
) None None O
biological None None O
activity None None O
has None None O
been None None O
linked None None O
to None None O
flavin None None O
photoreduction None None O
via None None O
an None None O
electron None None O
transport None None O
chain None None O
comprising None None O
three None None O
evolutionarily None None O
conserved None None O
tryptophan None None I-TRANS
residues None None O
known None None O
as None None O
the None None O
Trp None None O
triad None None O
. None None O

Overall None None O
our None None O
results None None O
suggest None None O
that None None O
FMNL3 None None O
functions None None O
in None None O
assembly None None O
of None None O
actin-based None None O
protrusions None None O
that None None O
are None None O
specialized None None O
for None None O
cell-cell None None O
adhesion None None I-PROTEIN
. None None O

Misfolded None None O
proteins None None O
of None None O
the None None O
secretory None None O
pathway None None O
are None None O
extracted None None O
from None None O
the None None O
endoplasmic None None O
reticulum None None O
( None None O
ER None None O
) None None O
, None None O
polyubiquitylated None None O
by None None O
a None None O
protein None None O
complex None None O
termed None None O
the None None O
Hmg-CoA None None I-PROTEIN
reductase None None I-PROTEIN
degradation None None O
ligase None None I-PROTEIN
( None None O
HRD-ligase None None O
) None None O
, None None O
and None None O
degraded None None O
by None None O
cytosolic None None O
26S None None O
proteasomes None None O
. None None O

Peptide None None O
methionine None None I-TRANS
sulfoxide None None O
reductases None None O
are None None O
conserved None None O
enzymes None None I-PROTEIN
that None None O
reduce None None O
oxidized None None O
methionines None None I-TRANS
in None None O
protein None None O
( None None O
s None None O
) None None O
. None None O

By None None O
using None None O
Saccharomyces None None O
cerevisiae None None O
as None None O
a None None O
model None None O
, None None O
we None None O
show None None O
that None None O
of None None O
the None None O
two None None O
methionine None None I-TRANS
sulfoxide None None O
reductases None None O
( None None O
MXR1 None None O
, None None O
MXR2 None None O
) None None O
, None None O
deletion None None O
of None None O
mitochondrial None None O
MXR2 None None O
renders None None O
yeast None None O
cells None None O
more None None O
sensitive None None O
to None None O
oxidative None None O
stress None None O
than None None O
the None None O
cytosolic None None O
MXR1 None None O
. None None O

Schizosaccharomyces None None O
pombe None None O
cdc15 None None O
homology None None O
( None None O
PCH None None O
) None None O
family None None O
members None None O
participate None None O
in None None O
numerous None None O
biological None None O
processes None None O
, None None O
including None None O
cytokinesis None None O
, None None O
typically None None O
by None None O
bridging None None O
the None None O
plasma None None O
membrane None None O
via None None O
their None None O
F-BAR None None O
domains None None O
to None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
. None None O

We None None O
describe None None O
the None None O
interplay None None O
between None None O
three None None O
sensory None None O
protein None None O
kinases None None I-PROTEIN
in None None O
yeast None None O
: None None O
AMP-regulated None None O
kinase None None O
( None None O
AMPK None None O
, None None O
or None None O
SNF1 None None O
in None None O
yeast None None O
) None None O
, None None O
PAS None None O
kinase None None O
1 None None O
( None None O
Psk1 None None O
in None None O
yeast None None O
) None None O
, None None O
and None None O
the None None O
target None None O
of None None O
rapamycin None None O
complex None None O
1 None None O
( None None O
TORC1 None None O
) None None O
. None None O

Inhibitors None None O
of None None O
tyrosine None None I-TRANS
kinases None None I-PROTEIN
, None None O
actin None None I-PROTEIN
polymerization None None O
, None None O
and None None O
the None None O
phosphatidylinositol None None O
cascade None None O
prevent None None O
opsonized- None None O
and None None O
nonopsonized-particle None None O
uptake None None O
similarly None None O
. None None O

Despite None None O
the None None O
importance None None O
of None None O
superoxide None None I-PROTEIN
dismutases None None I-PROTEIN
( None None O
SODs None None O
) None None O
in None None O
the None None O
plant None None O
antioxidant None None O
defence None None O
system None None O
little None None O
is None None O
known None None O
about None None O
their None None O
regulation None None O
by None None O
post-translational None None O
modifications None None O
. None None O

S-nitrosoglutathione None None O
, None None O
which None None O
causes None None O
S-nitrosylation None None O
of None None O
cysteine None None I-TRANS
residues None None O
, None None O
did None None O
not None None O
influence None None O
SOD None None O
activities None None O
. None None O

In None None O
general None None O
, None None O
genes None None O
involved None None O
in None None O
leucine None None I-TRANS
biosynthesis None None O
were None None O
robustly None None O
associated None None O
with None None O
H3k4me2 None None O
and None None O
H3K4me3 None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
role None None O
of None None O
TaHsfA6f None None O
, None None O
a None None O
member None None O
of None None O
the None None O
A6 None None O
subclass None None O
of None None O
heat None None O
shock None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
in None None O
the None None O
regulation None None O
of None None O
heat None None O
stress None None O
protection None None O
genes None None O
in None None O
Triticum None None O
aestivum None None O
( None None O
bread None None O
wheat None None O
) None None O
, None None O
a None None O
poorly None None O
understood None None O
phenomenon None None O
in None None O
this None None O
crop None None O
species None None O
. None None O

Overexpression None None O
of None None O
TaHsfA6f None None O
in None None O
transgenic None None O
wheat None None O
using None None O
a None None O
drought-inducible None None O
promoter None None O
resulted None None O
in None None O
up-regulation None None O
of None None O
heat None None O
shock None None O
proteins None None O
( None None O
HSPs None None O
) None None O
and None None O
a None None O
number None None O
of None None O
other None None O
heat None None O
stress None None O
protection None None O
genes None None O
that None None O
included None None O
some None None O
previously None None O
unknown None None O
Hsf None None O
target None None O
genes None None O
such None None O
as None None O
Golgi None None O
anti-apoptotic None None O
protein None None O
( None None O
GAAP None None O
) None None O
and None None O
the None None O
large None None O
isoform None None O
of None None O
Rubisco None None I-PROTEIN
activase None None O
. None None O

Field None None O
pea None None I-TRANS
( None None O
Pisum None None O
sativum None None O
) None None O
was None None O
grown None None O
in None None O
a None None O
P-deficient None None O
vertisol None None O
, None None O
supplied None None O
with None None O
15 None None O
mg None None O
P None None O
kg None None O
( None None O
-1 None None O
) None None O
( None None O
deficient None None O
) None None O
or None None O
60 None None O
mg None None O
P None None O
kg None None O
( None None O
-1 None None O
) None None O
( None None O
adequate None None O
for None None O
crop None None O
growth None None O
) None None O
and None None O
exposed None None O
to None None O
ambient None None O
CO2 None None O
( None None O
aCO2 None None O
; None None O
380-400 None None O
ppm None None O
) None None O
or None None O
eCO2 None None O
( None None O
550-580 None None O
ppm None None O
) None None O
. None None O

The None None O
term None None O
visual-motor None None O
memory None None I-FUNC
( None None O
VMM None None O
) None None O
describes None None O
this None None O
psychological None None O
ability None None O
, None None O
which None None O
must None None O
have None None O
conveyed None None O
an None None O
evolutionary None None O
advantage None None O
and None None O
remains None None O
critically None None O
important None None O
to None None O
humans None None O
( None None O
e.g None None O
. None None O

Children None None O
drew None None O
novel None None O
shapes None None O
presented None None O
briefly None None O
on None None O
a None None O
tablet None None O
laptop None None O
screen None None O
, None None O
drawing None None O
their None None O
responses None None O
from None None O
memory None None I-FUNC
on None None O
the None None O
screen None None O
using None None O
a None None O
digitizer None None O
stylus None None O
. None None O

Moreover None None O
, None None O
a None None O
relationship None None O
between None None O
VMM None None O
and None None O
the None None O
nationally None None O
standardized None None O
reading None None O
test None None O
was None None O
mediated None None O
via None None O
writing None None O
ability None None O
, None None O
suggesting None None O
VMM None None O
's None None O
wider None None O
importance None None O
within None None O
language None None I-FUNC
development None None O
. None None O

Yet None None O
little None None O
attention None None I-FUNC
has None None O
been None None O
given None None O
to None None O
whether None None O
HPV None None O
could None None O
respond None None O
evolutionarily None None O
to None None O
the None None O
new None None O
selection None None O
pressures None None O
imposed None None O
on None None O
it None None O
by None None O
the None None O
novel None None O
immunity None None O
response None None O
created None None O
by None None O
the None None O
vaccine None None O
. None None O

However None None O
, None None O
the None None O
two None None O
phenomena None None O
were None None O
also None None O
dissociable None None O
at None None O
the None None O
neural None None O
level None None O
, None None O
with None None O
both None None O
mental None None I-FUNC
imagery None None I-FUNC
and None None O
visual None None O
misperceptions None None O
associated None None O
with None None O
specific None None O
abnormalities None None O
in None None O
attentional None None O
network None None O
connectivity None None O
. None None O

One None None O
way None None O
to None None O
test None None O
these None None O
theories None None O
is None None O
to None None O
focus None None O
on None None O
the None None O
visual None None O
system None None O
, None None O
which None None O
can None None O
be None None O
achieved None None O
by None None O
studying None None O
the None None O
opsin-based None None O
visual None None O
pigments None None O
that None None O
mediate None None O
vision None None I-FUNC
. None None O

Expression None None O
of None None O
the None None O
opsins None None I-PROTEIN
at None None O
the None None O
extremes None None O
of None None O
the None None O
light None None O
spectrum None None O
, None None O
Lws None None O
and None None O
Uvs None None O
, None None O
correlates None None O
with None None O
the None None O
inferred None None O
light None None O
environment None None O
occupied None None O
by None None O
the None None O
different None None O
species None None O
. None None O

This None None O
study None None O
was None None O
a None None O
preliminary None None O
examination None None O
of None None O
whether None None O
a None None O
sample None None O
with None None O
a None None O
greater None None O
proportion None None O
of None None O
older None None O
dementia None None I-DISEASE
caregivers None None O
exhibits None None O
similar None None O
daily None None O
sleep/affect None None O
associations None None O
. None None O

Characterization None None O
of None None O
the None None O
chromodomain None None O
helicase None None I-PROTEIN
DNA-binding None None O
enzyme None None O
CHD1 None None O
revealed None None O
DNA None None O
methylation None None O
in None None O
the None None O
promoter None None O
of None None O
the None None O
central None None O
clock None None O
gene None None O
frequency None None O
( None None O
frq None None O
) None None O
in None None O
Neurospora None None O
crassa None None O
. None None O

Histone None None O
H3 None None O
lysine None None I-TRANS
9 None None O
trimethylation None None O
( None None O
H3K9me3 None None O
) None None O
occurs None None O
at None None O
frq None None O
and None None O
is None None O
most None None O
prominent None None O
30 None None O
min None None O
after None None O
light-activated None None O
expression None None O
. None None O

The None None O
ITS None None O
amplified None None O
products None None O
were None None O
digested None None O
with None None O
nine None None O
restriction None None O
enzymes None None I-PROTEIN
, None None O
but None None O
only None None O
four None None O
( None None O
HaeIII None None O
, None None O
HpaII None None O
, None None O
TaqI None None O
and None None O
Sau96I None None O
) None None O
produced None None O
polymorphic/discriminative None None O
patterns None None O
. None None O

We None None O
used None None O
a None None O
recently None None O
described None None O
HBV-persistent None None O
mouse None None O
model None None O
based None None O
on None None O
a None None O
recombinant None None O
adenovirus-associated None None O
virus None None O
encoding None None I-FUNC
an None None O
over None None O
length None None O
genome None None O
of None None O
HBV None None O
that None None O
induces None None O
the None None O
chronic None None O
production None None O
of None None O
HBsAg None None O
, None None O
HBeAg None None O
and None None O
infectious None None O
HBV None None O
particles None None O
to None None O
assess None None O
the None None O
ability None None O
of None None O
TG1050 None None O
to None None O
induce None None O
functional None None O
T None None O
cells None None O
in None None O
face None None O
of None None O
a None None O
chronic None None O
status None None O
. None None O

In None None O
addition None None O
, None None O
control None None O
of None None O
circulating None None O
levels None None O
of None None O
HBV None None O
DNA None None O
and None None O
HBsAg None None O
was None None O
observed None None O
while None None O
alanine None None I-TRANS
aminotransferase None None O
levels None None O
remain None None O
in None None O
the None None O
normal None None O
range None None O
. None None O

TTP None None O
is None None O
an None None O
mRNA-destabilizing None None O
, None None O
RNA-binding None None O
protein None None O
that None None O
enhances None None O
the None None O
decay None None O
of None None O
mRNAs None None O
, None None O
including None None O
those None None O
encoding None None I-FUNC
proteins None None O
implicated None None O
in None None O
chronic None None O
respiratory None None O
diseases None None O
. None None O

These None None O
revertant None None O
iPSCs None None O
were None None O
then None None O
differentiated None None O
into None None O
naturally None None O
genetically None None O
corrected None None O
keratinocytes None None O
that None None O
expressed None None O
type None None O
XVII None None O
collagen None None I-PROTEIN
( None None O
Col17 None None O
) None None O
. None None O

Genetically None None O
repaired None None O
iPSCs None None O
could None None O
be None None O
differentiated None None O
into None None O
functional None None O
fibroblasts None None O
that None None O
reexpressed None None O
and None None O
secreted None None O
type None None O
VII None None O
collagen None None I-PROTEIN
. None None O

Moreover None None O
, None None O
iPSC-based None None O
cell None None O
therapy None None O
resulted None None O
in None None O
faithful None None O
and None None O
long-term None None O
restoration None None O
of None None O
type None None O
VII None None O
collagen None None I-PROTEIN
deposition None None O
at None None O
the None None O
epidermal-dermal None None O
junction None None O
of None None O
Col7a1 None None O
mutant None None O
mice None None O
. None None O

SMBL None None O
language None None I-FUNC
map None None O
is None None O
available None None O
in None None O
the None None O
Supplementary None None O
Data None None O
: None None O
core_map.xml None None O
, None None O
basic_map.xml None None O
. None None O

Obesity None None O
and None None O
stroke None None I-DISEASE
are None None O
multifactorial None None O
diseases None None O
in None None O
which None None O
genetic None None O
, None None O
epigenetic None None O
and None None O
lifestyle None None O
factors None None O
are None None O
involved None None O
. None None O

The None None O
second None None O
population None None O
included None None O
60 None None O
stroke None None I-DISEASE
patients None None O
and None None O
55 None None O
controls None None O
classified None None O
by None None O
adiposity None None O
. None None O

After None None O
validating None None O
these None None O
data None None O
by None None O
MassArray None None O
Epityper None None O
, None None O
the None None O
promoter None None O
region None None O
of None None O
peptidase None None O
M20 None None O
domain None None O
containing None None O
1 None None O
( None None O
PM20D1 None None O
) None None O
gene None None O
was None None O
significantly None None O
hypermethylated None None O
in None None O
stroke None None I-DISEASE
patients None None O
. None None O

In None None O
conclusion None None O
, None None O
obesity None None O
induced None None O
changes None None O
in None None O
the None None O
KCNQ1 None None O
methylation None None O
pattern None None O
which None None O
were None None O
also None None O
dependent None None O
on None None O
stroke None None I-DISEASE
. None None O

These None None O
DNA None None O
methylation None None O
patterns None None O
could None None O
be None None O
used None None O
as None None O
future None None O
potential None None O
stroke None None I-DISEASE
biomarkers None None O
. None None O

For None None O
example None None O
, None None O
the None None O
Toll None None O
pathway None None O
, None None O
which None None O
promotes None None O
activation None None O
of None None O
NF-κB None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
Dorsal/Dorsal-related None None O
immune None None O
factor None None O
( None None O
Dif None None O
) None None O
, None None O
was None None O
first None None O
identified None None O
in None None O
Drosophila None None O
. None None O

In None None O
this None None O
article None None O
, None None O
we None None O
demonstrate None None O
involvement None None O
of None None O
specific None None O
calcineurin None None O
isoforms None None O
, None None O
protein None None O
phosphatase None None I-PROTEIN
at None None O
14D None None O
( None None O
Pp2B-14D None None O
) None None O
/calcineurin None None O
A None None O
at None None O
14F None None O
( None None O
CanA-14F None None O
) None None O
, None None O
in None None O
Toll-mediated None None O
immune None None O
signaling None None O
. None None O

Tryptase None None O
and None None O
thrombin None None I-PROTEIN
are None None O
upregulated None None O
in None None O
wound None None O
healing None None O
and None None O
fibrotic None None O
lesions None None O
, None None O
and None None O
inhibition None None O
of None None O
these None None O
proteases None None O
attenuates None None O
fibrosis None None O
. None None O

Fibrocyte None None O
potentiation None None O
by None None O
thrombin None None I-PROTEIN
and None None O
tryptase None None O
is None None O
mediated None None O
by None None O
protease-activated None None O
receptors None None I-PROTEIN
1 None None O
and None None O
2 None None O
, None None O
respectively None None O
. None None O

In None None O
addition None None O
, None None O
RBCs None None O
and None None O
Hb None None O
increased None None O
several None None O
nucleotide-binding None None O
oligomerization None None O
domain-like None None O
receptors None None I-PROTEIN
' None None O
expression None None O
and None None O
induced None None O
IL-1β None None O
release None None O
. None None O

We None None O
obtained None None O
invasive None None O
breast None None O
ductal None None O
carcinoma None None O
cells None None O
of None None O
various None None O
subtypes None None O
by None None O
fine-needle None None O
aspiration None None O
( None None O
FNA None None O
) None None O
biopsies None None O
from None None O
patients None None O
and None None O
found None None O
that None None O
, None None O
in None None O
an None None O
in None None O
vitro None None O
transendothelial None None O
migration None None O
assay None None O
, None None O
cells None None O
that None None O
migrated None None O
through None None O
a None None O
layer None None O
of None None O
human None None O
endothelial None None O
cells None None O
were None None O
enriched None None O
for None None O
the None None O
transcript None None O
encoding None None I-FUNC
Mena None None O
( None None O
INV None None O
) None None O
, None None O
an None None O
invasive None None O
isoform None None O
of None None O
Mena None None O
. None None O

Mice None None O
expressing None None O
a None None O
form None None O
of None None O
Apoer2 None None O
lacking None None O
the None None O
OLS None None O
domain None None O
and None None O
containing None None O
an None None O
alternatively None None O
spliced None None O
cytoplasmic None None O
tail None None O
region None None O
that None None O
promotes None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
signaling None None O
showed None None O
enhanced None None O
hippocampal None None O
long-term None None I-FUNC
potentiation None None I-FUNC
( None None O
LTP None None O
) None None O
, None None O
a None None O
phenomenon None None O
associated None None O
with None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

Reducing None None O
the None None O
expression None None O
of None None O
the None None O
mutant None None O
Apoer2 None None O
allele None None O
so None None O
that None None O
the None None O
abundance None None O
of None None O
the None None O
protein None None O
was None None O
similar None None O
to None None O
that None None O
of None None O
Apoer2 None None O
in None None O
wild-type None None O
mice None None O
normalized None None O
spine None None O
density None None O
, None None O
hippocampal None None O
LTP None None O
, None None O
and None None O
cued None None O
fear None None O
learning None None I-FUNC
. None None O

To None None O
investigate None None O
the None None O
large None None O
number None None O
of None None O
phosphorylation None None O
events None None O
with None None O
unknown None None O
functions None None O
, None None O
we None None O
monitored None None O
the None None O
concentrations None None O
of None None O
several None None O
hundred None None O
intracellular None None O
metabolites None None O
in None None O
Saccharomyces None None O
cerevisiae None None O
yeast None None O
strains None None O
with None None O
deletions None None O
of None None O
118 None None O
kinases None None I-PROTEIN
or None None O
phosphatases None None I-PROTEIN
. None None O

For None None O
about None None O
half None None O
of None None O
the None None O
kinases None None I-PROTEIN
and None None O
phosphatases None None I-PROTEIN
encoded None None O
by None None O
the None None O
deleted None None O
genes None None O
, None None O
we None None O
inferred None None O
specific None None O
regulatory None None O
roles None None O
on None None O
the None None O
basis None None O
of None None O
knowledge None None O
about None None O
the None None O
affected None None O
metabolic None None O
pathways None None O
. None None O

Combining None None O
metabolomic None None O
data None None O
with None None O
published None None O
phosphoproteomic None None O
data None None O
in None None O
a None None O
stoichiometric None None O
model None None O
enabled None None O
us None None O
to None None O
predict None None O
functions None None O
for None None O
phosphorylation None None O
in None None O
the None None O
regulation None None O
of None None O
47 None None O
enzymes None None I-PROTEIN
. None None O

Students None None O
' None None O
favorable None None O
feedback None None O
indicated None None O
that None None O
the None None O
quality None None O
of None None O
learning None None I-FUNC
in None None O
the None None O
laboratories None None O
was None None O
enhanced None None O
by None None O
the None None O
addition None None O
of None None O
physiologic None None O
measurements None None O
. None None O

Clarithromycin None None O
is None None O
an None None O
inhibitor None None O
of None None O
CYP3A4 None None I-PROTEIN
, None None O
whereas None None O
azithromycin None None O
is None None O
not None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
inhaled None None O
nitric None None I-TRANS
oxide None None I-TRANS
significantly None None O
alters None None O
the None None O
distribution None None O
of None None O
blood None None O
flow None None O
in None None O
both None None O
hypoxic None None O
and None None O
normoxic None None O
healthy None None O
subjects None None O
, None None O
and None None O
suggests None None O
that None None O
some None None O
baseline None None O
HPV None None O
may None None O
indeed None None O
be None None O
present None None O
in None None O
the None None O
normoxic None None O
lung None None O
. None None O

Chronically None None O
elevated None None O
SAA None None O
was None None O
recently None None O
shown None None O
to None None O
increase None None O
atherosclerosis None None I-DISEASE
in None None O
mice None None O
. None None O

The None None O
recombination None None O
activating None None O
gene None None O
1-deficient None None O
( None None O
rag1 None None O
( None None O
-/- None None O
) None None O
) None None O
× None None O
apolipoprotein None None O
E-deficient None None O
( None None O
apoe None None O
( None None O
-/- None None O
) None None O
) None None O
and None None O
apoe None None O
( None None O
-/- None None O
) None None O
male None None O
mice None None O
were None None O
injected None None O
, None None O
multiple None None O
times None None O
or None None O
just None None O
once None None O
respectively None None O
, None None O
with None None O
an None None O
adenoviral None None O
vector None None O
encoding None None I-FUNC
human None None O
SAA1 None None O
( None None O
ad-SAA None None O
) None None O
; None None O
the None None O
injected None None O
mice None None O
and None None O
controls None None O
were None None O
maintained None None O
on None None O
chow None None O
for None None O
12-16 None None O
weeks None None O
. None None O

Strikingly None None O
, None None O
mice None None O
receiving None None O
only None None O
a None None O
single None None O
injection None None O
of None None O
ad-SAA None None O
, None None O
in None None O
which None None O
SAA None None O
was None None O
only None None O
briefly None None O
elevated None None O
, None None O
also None None O
had None None O
increased None None O
atherosclerosis None None I-DISEASE
compared None None O
with None None O
controls None None O
. None None O

We None None O
propose None None O
that None None O
SAA None None O
increases None None O
atherosclerosis None None I-DISEASE
development None None O
via None None O
induction None None O
of None None O
TGF-β None None O
, None None O
increased None None O
vascular None None O
biglycan None None O
content None None O
, None None O
and None None O
increased None None O
LDL None None O
retention None None I-FUNC
. None None O

Mutations None None O
in None None O
glucocerebrosidase None None O
( None None O
GCase None None O
) None None O
, None None O
the None None O
enzyme None None O
deficient None None O
in None None O
Gaucher None None O
disease None None O
, None None O
are None None O
a None None O
common None None O
genetic None None O
risk None None O
factor None None O
for None None O
the None None O
development None None O
of None None O
Parkinson None None I-DISEASE
disease None None O
and None None O
related None None O
disorders None None O
, None None O
implicating None None O
the None None O
role None None O
of None None O
this None None O
lysosomal None None O
hydrolase None None I-PROTEIN
in None None O
the None None O
disease None None O
etiology None None O
. None None O

The None None O
ubiquitin-like None None O
interferon None None O
( None None O
IFN None None O
) None None O
-stimulated None None O
gene None None O
15 None None O
( None None O
ISG15 None None O
) None None O
and None None O
its None None O
specific None None O
E1 None None O
, None None O
E2 None None O
, None None O
and None None O
E3 None None O
enzymes None None I-PROTEIN
are None None O
transcriptionally None None O
induced None None O
by None None O
type None None O
I None None O
IFNs None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
background None None O
visual None None O
motion None None O
, None None O
usually None None O
caused None None O
by None None O
body None None O
movement None None I-FUNC
, None None O
plays None None O
a None None O
significant None None O
role None None O
in None None O
such None None O
online None None O
corrections None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
measured None None O
MFR None None O
amplitudes None None O
during None None O
a None None O
task None None O
in None None O
which None None O
the None None O
participant None None O
performed None None O
a None None O
saccadic None None O
eye None None O
movement None None I-FUNC
that None None O
altered None None O
the None None O
gaze-reach None None O
coordination None None O
during None None O
reaching None None O
. None None O

Our None None O
findings None None O
suggest None None O
that None None O
the None None O
brain None None O
flexibly None None O
updates None None O
the None None O
visuomotor None None O
gain None None O
for None None O
an None None O
online None None O
controller None None O
even None None O
during None None O
reaching None None O
movements None None I-FUNC
based None None O
on None None O
continuous None None O
monitoring None None O
of None None O
the None None O
gaze-reach None None O
coordination None None O
. None None O

Acquiring None None O
the None None O
skill None None O
of None None O
speaking None None O
in None None O
another None None O
language None None I-FUNC
, None None O
or None None O
for None None O
that None None O
matter None None O
a None None O
child None None O
's None None O
learning None None I-FUNC
to None None O
talk None None O
, None None O
does None None O
not None None O
follow None None O
a None None O
single None None O
recipe None None O
. None None O

A None None O
major None None O
component None None O
of None None O
speech None None I-FUNC
learnability None None O
seems None None O
to None None O
be None None O
sensing None None O
precise None None O
feedback None None O
errors None None O
to None None O
correct None None O
subsequent None None O
utterances None None O
that None None O
help None None O
maintain None None O
speech None None I-FUNC
goals None None O
. None None O

Our None None O
findings None None O
rely None None O
on None None O
a None None O
novel None None O
use None None O
of None None O
information-rich None None O
formant None None O
trajectories None None O
in None None O
evaluating None None O
speech None None I-FUNC
motor None None O
learning None None I-FUNC
and None None O
argue None None O
for None None O
their None None O
relevance None None O
in None None O
auditory None None O
speech None None I-FUNC
goals None None O
of None None O
vowel None None O
sounds None None O
. None None O

To None None O
elucidate None None O
this None None O
matter None None O
, None None O
two None None O
groups None None O
of None None O
subjects None None O
learned None None O
to None None O
execute None None O
reaching None None O
arm None None O
movements None None I-FUNC
in None None O
environments None None O
with None None O
task-irrelevant None None O
visual None None O
cues None None O
. None None O

The None None O
results None None O
demonstrate None None O
that None None O
the None None O
two None None O
groups None None O
used None None O
different None None O
learning None None I-FUNC
strategies None None O
for None None O
the None None O
same None None O
visual None None O
environment None None O
and None None O
that None None O
the None None O
learning None None I-FUNC
strategy None None O
was None None O
influenced None None O
by None None O
prior None None O
learning None None I-FUNC
experience None None O
. None None O

Chemosensitive None None O
neurons None None O
in None None O
the None None O
retrotrapezoid None None I-REGION
nucleus None None I-REGION
( None None O
RTN None None O
) None None O
provide None None O
a None None O
CO2/H None None O
( None None O
+ None None O
) None None O
-dependent None None O
drive None None O
to None None O
breathe None None O
and None None O
function None None O
as None None O
an None None O
integration None None O
center None None O
for None None O
the None None O
respiratory None None O
network None None O
, None None O
including None None O
serotonergic None None O
raphe None None O
neurons None None O
. None None O

Hyperpolarization-activated None None O
cyclic-nucleotide-gated None None O
( None None O
HCN None None O
) None None O
channels None None O
are None None O
the None None O
molecular None None O
correlate None None O
of None None O
the None None O
hyperpolarization-activated None None O
inward None None O
current None None O
( None None O
Ih None None O
) None None O
and None None O
have None None O
a None None O
high None None O
propensity None None O
for None None O
modulation None None O
by None None O
serotonin None None I-TRANS
. None None O

These None None O
results None None O
suggest None None O
that None None O
HCN None None O
channels None None O
contribute None None O
to None None O
resting None None O
chemoreceptor None None I-PROTEIN
activity None None O
and None None O
that None None O
serotonin None None I-TRANS
activates None None O
RTN None None O
chemoreceptors None None O
and None None O
breathing None None O
in None None O
part None None O
by None None O
a None None O
5-HT7 None None O
receptor-dependent None None O
mechanism None None O
and None None O
downstream None None O
activation None None O
of None None O
Ih None None O
. None None O

Visual None None O
recognition None None O
takes None None O
a None None O
small None None O
fraction None None O
of None None O
a None None O
second None None O
and None None O
relies None None O
on None None O
the None None O
cascade None None O
of None None O
signals None None O
along None None O
the None None O
ventral None None I-NEURON
visual None None O
stream None None O
. None None O

This None None O
rapid None None O
progression None None O
of None None O
information None None O
suggests None None O
that None None O
fine None None O
temporal None None O
details None None O
of None None O
the None None O
neural None None O
response None None O
may None None O
be None None O
important None None O
to None None O
the None None O
brain None None O
's None None O
encoding None None I-FUNC
of None None O
visual None None O
signals None None O
. None None O

Visual None None O
responses None None O
along None None O
the None None O
ventral None None I-NEURON
stream None None O
were None None O
sensitive None None O
to None None O
timing None None O
differences None None O
as None None O
small None None O
as None None O
17 None None O
ms None None O
between None None O
parts None None O
. None None O

Clinical None None O
DBS None None O
electrodes None None O
were None None O
implanted None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
an None None O
epileptic None None O
NHP None None O
bilaterally None None O
, None None O
and None None O
baseline None None O
local None None O
field None None O
potential None None O
( None None O
LFP None None O
) None None O
recordings None None O
were None None O
collected None None O
for None None O
seizure None None O
characterization None None O
with None None O
the None None O
PC+S None None O
. None None O

Previous None None O
studies None None O
have None None O
demonstrated None None O
that None None O
the None None O
majority None None O
of None None O
caudal None None O
NTS None None O
neurons None None O
that None None O
project None None O
to None None O
the None None O
DMV None None O
respond None None O
robustly None None O
to None None O
nicotine None None O
and None None O
express None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptors None None I-PROTEIN
( None None O
nAChRs None None O
) None None O
. None None O

The None None O
present None None O
study None None O
used None None O
transgenic None None O
mice None None O
that None None O
express None None O
enhanced None None O
green None None O
fluorescent None None O
protein None None O
( None None O
EGFP None None O
) None None O
under None None O
a None None O
GAD67 None None O
promoter None None O
in None None O
a None None O
subset None None O
of None None O
GABAergic None None I-NEURON
neurons None None I-NEURON
, None None O
in None None O
vivo None None O
retrograde None None O
pseudorabies None None O
viral None None O
labeling None None O
to None None O
identify None None O
gastric-related None None O
vagal None None O
complex None None O
neurons None None O
, None None O
and None None O
patch-clamp None None O
electrophysiology None None O
in None None O
acute None None O
brain None None O
stem None None O
slices None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
gastric-related None None O
and None None O
GABAergic None None O
inhibitory None None O
synaptic None None O
input None None O
to None None O
the None None O
DMV None None O
from None None O
the None None O
caudal None None O
NTS None None O
is None None O
under None None O
a None None O
robust None None O
modulatory None None O
control None None O
by None None O
nAChRs None None O
. None None O

Our None None O
findings None None O
suggest None None O
that None None O
the None None O
increase None None O
in None None O
inspiratory None None O
burst None None O
duration None None O
is None None O
determined None None O
by None None O
a None None O
presynaptic None None O
mechanism None None O
involving None None O
desynchronization None None O
of None None O
glutamate None None I-TRANS
release None None O
within None None O
the None None O
network None None O
. None None O

This None None O
study None None O
sought None None O
to None None O
utilize None None O
complex None None O
tasks None None O
and None None O
compare None None O
separate None None O
motor None None O
paradigms None None O
to None None O
determine None None O
which None None O
one None None O
best None None O
facilitates None None O
long-term None None O
learning None None I-FUNC
. None None O

The None None O
changes None None O
seen None None O
following None None O
motor None None O
learning None None I-FUNC
were None None O
congruent None None O
with None None O
those None None O
associated None None O
with None None O
long-term None None O
learning None None I-FUNC
, None None O
which None None O
was None None O
also None None O
reflected None None O
by None None O
significant None None O
increases None None O
in None None O
accuracy None None O
during None None O
retention None None I-FUNC
. None None O

In None None O
the None None O
diabetic None None O
retina None None O
, None None O
cellular None None O
changes None None O
in None None O
the None None O
retinal None None O
pigment None None O
epithelium None None O
( None None O
RPE None None O
) None None O
and None None O
neurons None None O
occur None None O
before None None O
vision None None I-FUNC
loss None None O
or None None O
diabetic None None O
retinopathy None None O
can None None O
be None None O
identified None None O
clinically None None O
. None None O

Hilar None None O
ectopic None None O
dentate None None O
granule None None O
cells None None O
( None None O
DGCs None None O
) None None O
are None None O
a None None O
salient None None O
feature None None O
of None None O
aberrant None None O
plasticity None None O
in None None O
human None None O
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
( None None O
TLE None None O
) None None O
and None None O
most None None O
rodent None None O
models None None O
of None None O
the None None O
disease None None O
. None None O

Motor None None O
thalamus None None I-REGION
( None None O
Mthal None None O
) None None O
is None None O
a None None O
key None None O
node None None O
in None None O
the None None O
corticobasal None None O
ganglia None None O
( None None O
BG None None O
) None None O
loop None None O
that None None O
controls None None O
complex None None O
, None None O
cognitive None None O
aspects None None O
of None None O
movement None None I-FUNC
. None None O

We None None O
show None None O
for None None O
the None None O
first None None O
time None None O
that None None O
Mthal None None O
firing None None O
rate None None O
in None None O
control None None O
rats None None O
is None None O
modulated None None O
in None None O
a None None O
temporally None None O
precise None None O
pattern None None O
during None None O
reach-to-grasp None None O
movements None None I-FUNC
, None None O
with None None O
a None None O
peak None None O
at None None O
the None None O
time None None O
of None None O
the None None O
reach-end None None O
and None None O
troughs None None O
just None None O
before None None O
and None None O
after None None O
it None None O
. None None O

These None None O
data None None O
confirm None None O
that None None O
nigrostriatal None None O
dopamine None None I-TRANS
depletion None None O
is None None O
accompanied None None O
by None None O
profound None None O
and None None O
specific None None O
deficits None None O
in None None O
movement-related None None O
Mthal None None O
activity None None O
. None None O

We None None O
addressed None None O
this None None O
question None None O
by None None O
monitoring None None O
CA1 None None I-REGION
place None None O
cell None None O
activity None None O
, None None O
with None None O
tetrodes None None O
, None None O
in None None O
control None None O
and None None O
KO None None O
mice None None O
lacking None None O
the None None O
NMDA None None O
receptor None None I-PROTEIN
in None None O
this None None O
region None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
TMR None None O
during None None O
sleep None None O
can None None O
alter None None O
memory None None I-FUNC
representations None None O
and None None O
promote None None O
the None None O
emergence None None O
of None None O
explicit None None O
knowledge None None O
, None None O
supporting None None O
the None None O
notion None None O
that None None O
reactivation None None O
during None None O
sleep None None O
is None None O
a None None O
key None None O
mechanism None None O
in None None O
this None None O
process None None O
. None None O

Synaptic None None O
vesicles None None O
release None None O
both None None O
neurotransmitter None None I-TRANS
and None None O
protons None None O
during None None O
exocytosis None None O
, None None O
which None None O
may None None O
result None None O
in None None O
a None None O
transient None None O
acidification None None O
of None None O
the None None O
synaptic None None O
cleft None None O
that None None O
can None None O
block None None O
Ca None None O
( None None O
2+ None None O
) None None O
channels None None O
located None None O
close None None O
to None None O
the None None O
sites None None O
of None None O
exocytosis None None O
. None None O

Using None None O
perforated-patch None None O
electrophysiological None None O
techniques None None O
to None None O
maintain None None O
the None None O
intracellular None None O
milieu None None O
, None None O
we None None O
investigated None None O
how None None O
the None None O
activation None None O
of None None O
D1-type None None O
DA None None O
receptors None None I-PROTEIN
regulates None None O
spike None None O
timing-dependent None None O
plasticity None None O
( None None O
STDP None None O
) None None O
of None None O
the None None O
medial None None O
perforant None None O
path None None O
( None None O
mPP None None O
) None None O
synapse None None O
onto None None O
dentate None None O
granule None None O
cells None None O
. None None O

When None None O
D1-type None None O
receptors None None I-PROTEIN
were None None O
activated None None O
, None None O
however None None O
, None None O
the None None O
same None None O
mild None None O
STDP None None O
protocol None None O
induced None None O
tLTP None None O
over None None O
a None None O
much None None O
broader None None O
timing None None O
window None None O
: None None O
tLTP None None O
was None None O
induced None None O
when None None O
-30 None None O
ms None None O
≤ None None O
Δt None None O
≤ None None O
+30 None None O
ms None None O
. None None O

Results None None O
with None None O
null None None O
mice None None O
lacking None None O
the None None O
Kv4.2 None None O
potassium None None O
channel None None O
and None None O
with None None O
the None None O
potassium None None O
channel None None O
inhibitor None None O
, None None O
4-aminopyridine None None O
, None None O
suggested None None O
that None None O
D1-type None None O
receptors None None I-PROTEIN
enhanced None None O
tLTP None None O
induction None None O
by None None O
suppressing None None O
the None None O
transient None None O
IA-type None None O
K None None O
( None None O
+ None None O
) None None O
current None None O
. None None O

The None None O
DA None None O
D5 None None O
receptors None None I-PROTEIN
appeared None None O
particularly None None O
important None None O
in None None O
regulating None None O
plasticity None None O
of None None O
the None None O
mPP None None O
onto None None O
the None None O
dentate None None O
granule None None O
cells None None O
. None None O

Cortical None None O
interneurons None None I-NEURON
activate None None O
GABA-A None None O
receptors None None I-PROTEIN
to None None O
rapidly None None O
control None None O
electrical None None O
and None None O
biochemical None None O
signaling None None O
at None None O
pyramidal None None O
neurons None None O
. None None O

However None None O
, None None O
the None None O
ability None None O
of None None O
these None None O
interneurons None None I-NEURON
to None None O
inhibit None None O
Ca None None O
( None None O
2+ None None O
) None None O
signaling None None O
at None None O
spines None None O
and None None O
dendrites None None O
is None None O
largely None None O
unexplored None None O
. None None O

We None None O
first None None O
show None None O
that None None O
GABA-A None None O
receptors None None I-PROTEIN
strongly None None O
inhibit None None O
action None None O
potential None None O
( None None O
AP None None O
) None None O
-evoked None None O
Ca None None O
( None None O
2+ None None O
) None None O
signals None None O
at None None O
both None None O
spines None None O
and None None O
dendrites None None O
. None None O

We None None O
determine None None O
that None None O
these None None O
populations None None O
of None None O
interneurons None None I-NEURON
make None None O
unique None None O
contacts None None O
onto None None O
the None None O
apical None None O
and None None O
basal None None O
dendrites None None O
of None None O
L5 None None O
pyramidal None None O
neurons None None O
. None None O

These None None O
findings None None O
reveal None None O
how None None O
multiple None None O
interneurons None None I-NEURON
regulate None None O
local None None O
Ca None None O
( None None O
2+ None None O
) None None O
signaling None None O
in None None O
pyramidal None None O
neurons None None O
, None None O
with None None O
implications None None O
for None None O
cortical None None O
function None None O
and None None O
disease None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
not None None O
only None None O
do None None O
such None None O
oscillatory None None O
patterns None None O
exist None None O
within None None O
human None None O
temporal None None O
neocortex None None I-REGION
, None None O
but None None O
that None None O
the None None O
strength None None O
of None None O
one None None O
is None None O
related None None O
to None None O
the None None O
strength None None O
of None None O
the None None O
other None None O
. None None O

Specifically None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
interlaminar None None O
communication None None O
within None None O
human None None O
temporal None None O
neocortex None None I-REGION
and None None O
local None None O
laminar None None O
excitability None None O
are None None O
linked None None O
to None None O
one None None O
another None None O
through None None O
a None None O
dependence None None O
mediated None None O
by None None O
theta None None O
oscillations None None O
. None None O

Complete None None O
inactivation None None O
of None None O
presenilins None None O
in None None O
excitatory None None O
neurons None None O
of None None O
the None None O
adult None None O
mouse None None O
cerebral None None I-REGION
cortex None None I-REGION
results None None O
in None None O
progressive None None O
memory None None I-FUNC
impairment None None O
and None None O
age-dependent None None O
neurodegeneration None None O
, None None O
recapitulating None None O
key None None O
features None None O
of None None O
AD None None O
. None None O

We None None O
found None None O
that None None O
PS1 None None O
cKO None None O
; None None O
PS2 None None O
( None None O
+/- None None O
) None None O
mice None None O
at None None O
16 None None O
months None None O
exhibit None None O
marked None None O
neurodegeneration None None O
in None None O
the None None O
cerebral None None I-REGION
cortex None None I-REGION
with None None O
∼17 None None O
% None None O
reduction None None O
of None None O
cortical None None O
volume None None O
and None None O
neuron None None O
number None None O
, None None O
as None None O
well None None O
as None None O
astrogliosis None None O
and None None O
microgliosis None None O
compared None None O
with None None O
∼50 None None O
% None None O
reduction None None O
of None None O
cortical None None O
volume None None O
and None None O
neuron None None O
number None None O
in None None O
PS1 None None O
cKO None None O
; None None O
PS2 None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Together None None O
, None None O
our None None O
findings None None O
show None None O
that None None O
partial None None O
to None None O
complete None None O
loss None None O
of None None O
presenilin None None O
activity None None O
causes None None O
progressively None None O
more None None O
severe None None O
neurodegeneration None None O
in None None O
the None None O
mouse None None O
cerebral None None I-REGION
cortex None None I-REGION
during None None O
aging None None O
, None None O
suggesting None None O
that None None O
impaired None None O
presenilin None None O
function None None O
by None None O
PSEN None None O
mutations None None O
may None None O
lead None None O
to None None O
neurodegeneration None None O
and None None O
dementia None None I-DISEASE
in None None O
AD None None O
. None None O

To None None O
evaluate None None O
the None None O
accuracy None None O
and None None O
sensitivity None None O
of None None O
this None None O
approach None None O
, None None O
the None None O
topology None None O
of None None O
functional None None O
connections None None O
between None None O
somatomotor None None O
cortex None None O
( None None O
primary None None O
S1 None None O
and None None O
secondary None None O
S2 None None O
somatosensory None None O
, None None O
and None None O
primary None None I-REGION
motor None None I-REGION
cortex None None I-REGION
M1 None None O
) None None O
was None None O
estimated None None O
. None None O

In None None O
the None None O
context None None O
of None None O
TDP-43-induced None None O
proteinopathy None None O
, None None O
there None None O
is None None O
a None None O
significant None None O
reduction None None O
of None None O
futsch None None O
mRNA None None O
at None None O
the None None O
NMJ None None O
compared None None O
with None None O
motor None None I-NEURON
neuron None None I-NEURON
cell None None O
bodies None None O
where None None O
we None None O
find None None O
higher None None O
levels None None O
of None None O
transcript None None O
compared None None O
with None None O
controls None None O
. None None O

Furthermore None None O
, None None O
the None None O
localization None None O
of None None O
MAP1B None None O
, None None O
the None None O
mammalian None None O
homolog None None O
of None None O
Futsch None None O
, None None O
is None None O
altered None None O
in None None O
ALS None None O
spinal None None O
cords None None O
in None None O
a None None O
manner None None O
similar None None O
to None None O
our None None O
observations None None O
in None None O
Drosophila None None O
motor None None I-NEURON
neurons None None I-NEURON
. None None O

Hypoxia None None O
produced None None O
PARP1-dependent None None O
depletion None None O
of None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
( None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
) None None O
and None None O
inhibition None None O
of None None O
the None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
-dependent None None O
class None None O
III None None O
histone None None O
deactelyase None None O
( None None O
HDAC None None O
) None None O
sirtuin-1 None None O
( None None O
SIRT1 None None O
) None None O
. None None O

We None None O
tested None None O
the None None O
hypothesis None None O
that None None O
interactions None None O
between None None O
regions None None O
of None None O
dorsolateral None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
dlPFC None None O
) None None O
and None None O
ventromedial None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
vmPFC None None O
) None None O
implicated None None O
in None None O
self-control None None O
choices None None O
would None None O
also None None O
underlie None None O
the None None O
more None None O
general None None O
function None None O
of None None O
context-dependent None None O
valuation None None O
. None None O

Specifically None None O
, None None O
we None None O
use None None O
functional None None O
neuroimaging None None O
to None None O
measure None None O
neural None None O
responses None None O
to None None O
dynamic None None O
facial None None O
expressions None None O
with None None O
positive None None O
and None None O
negative None None O
valence None None O
and None None O
to None None O
short None None O
animations None None O
in None None O
which None None O
the None None O
valence None None O
of None None O
a None None O
character None None O
's None None O
emotion None None I-FUNC
could None None O
be None None O
identified None None O
only None None O
from None None O
the None None O
situation None None O
. None None O

In None None O
regions None None O
of None None O
medial None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
MPFC None None O
) None None O
, None None O
a None None O
classifier None None O
trained None None O
to None None O
discriminate None None O
emotional None None O
valence None None O
for None None O
one None None O
stimulus None None O
( None None O
e.g. None None O
, None None O
animated None None O
situations None None O
) None None O
could None None O
successfully None None O
discriminate None None O
valence None None O
for None None O
the None None O
remaining None None O
stimulus None None O
( None None O
e.g. None None O
, None None O
facial None None O
expressions None None O
) None None O
, None None O
indicating None None O
a None None O
representation None None O
of None None O
valence None None O
that None None O
abstracts None None O
away None None O
from None None O
perceptual None None O
features None None O
and None None O
generalizes None None O
across None None O
different None None O
forms None None O
of None None O
evidence None None O
. None None O

These None None O
data None None O
provide None None O
a None None O
step None None O
toward None None O
understanding None None O
how None None O
the None None O
brain None None O
transforms None None O
stimulus-bound None None O
inputs None None O
into None None O
abstract None None O
representations None None O
of None None O
emotion None None I-FUNC
. None None O

In None None O
cortical None None O
principal None None O
neurons None None O
, None None O
deletion None None O
of None None O
GluN2B None None O
results None None O
in None None O
an None None O
increase None None O
in None None O
functional None None O
AMPAR None None O
synapses None None O
, None None O
suggesting None None O
that None None O
GluN2B-containing None None O
NMDARs None None O
set None None O
a None None O
brake None None O
on None None O
glutamate None None I-TRANS
synapse None None O
maturation None None O
. None None O

To None None O
examine None None O
the None None O
function None None O
of None None O
GluN2B None None O
in None None O
interneurons None None I-NEURON
, None None O
we None None O
generated None None O
mutant None None O
mice None None O
with None None O
conditional None None O
deletion None None O
of None None O
GluN2B None None O
in None None O
interneurons None None I-NEURON
( None None O
GluN2B None None O
( None None O
ΔGAD67 None None O
) None None O
) None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
GluN2B-containing None None O
NMDARs None None O
keep None None O
the None None O
circuit None None O
activity None None O
under None None O
control None None O
by None None O
promoting None None O
the None None O
maturation None None O
of None None O
excitatory None None O
synapses None None O
in None None O
interneurons None None I-NEURON
. None None O

The None None O
extracellular None None O
signal-regulated None None O
kinases-1 None None O
and None None O
-2 None None O
( None None O
ERK1/2 None None O
) None None O
, None None O
downstream None None O
mediators None None O
of None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
) None None O
, None None O
have None None O
emerged None None O
as None None O
prominent None None O
regulators None None O
of None None O
myelin None None O
formation None None O
. None None O

Sensory None None I-NEURON
neuron None None I-NEURON
input None None O
to None None O
the None None O
olfactory None None I-REGION
bulb None None I-REGION
( None None O
OB None None O
) None None O
was None None O
activated None None O
precisely None None O
for None None O
different None None O
durations None None O
with None None O
blue None None O
light None None O
in None None O
mice None None O
expressing None None O
channelrhodopsin-2 None None O
in None None O
olfactory None None O
sensory None None I-NEURON
neurons None None I-NEURON
. None None O

Neurophysiological None None O
studies None None O
suggest None None O
that None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
PFC None None O
) None None O
and None None O
the None None O
inferior None None O
temporal None None I-REGION
cortex None None I-REGION
( None None O
ITC None None O
) None None O
are None None O
involved None None O
in None None O
visual None None O
shape None None O
categorization None None O
. None None O

GABAergic None None O
modulation None None O
of None None O
neuronal None None O
activity None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
physiological None None O
processes None None O
including None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
in None None O
both None None O
insects None None O
and None None O
mammals None None O
. None None O

In None None O
the None None O
whole None None O
population None None O
of None None O
honeybee None None O
KCs None None O
we None None O
find None None O
that None None O
pairing None None O
of None None O
acetylcholine None None I-TRANS
( None None O
ACh None None I-TRANS
) None None O
and None None O
γ-aminobutyric None None O
acid None None O
( None None O
GABA None None I-TRANS
) None None O
Comment None None O
: None None O
Please None None O
use None None O
the None None O
greek None None O
letter None None O
for None None O
gamma None None O
reduces None None O
the None None O
ACh-induced None None O
calcium None None O
influx None None O
, None None O
and None None O
depending None None O
on None None O
their None None O
temporal None None O
sequence None None O
, None None O
induces None None O
different None None O
forms None None O
of None None O
neuronal None None O
plasticity None None O
. None None O

In None None O
an None None O
exactly None None O
defined None None O
subset None None O
of None None O
Drosophila None None O
KCs None None O
implicated None None O
in None None O
learning None None I-FUNC
we None None O
find None None O
similar None None O
pairing-specific None None O
differences None None O
. None None O

Our None None O
findings None None O
provide None None O
evidence None None O
that None None O
insect None None O
KCs None None O
are None None O
capable None None O
of None None O
contributing None None O
to None None O
temporal None None O
processing None None O
of None None O
cholinergic None None O
and None None O
GABAergic None None O
inputs None None O
, None None O
which None None O
provides None None O
a None None O
neuronal None None O
mechanism None None O
of None None O
the None None O
differential None None O
temporal None None O
role None None O
of None None O
GABAergic None None O
inhibition None None O
during None None O
learning None None I-FUNC
. None None O

Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
, None None O
the None None O
second None None O
most None None O
prevalent None None O
neurodegenerative None None O
disorder None None O
, None None O
is None None O
characterized None None O
by None None O
the None None O
degeneration None None O
of None None O
dopamine None None I-TRANS
( None None O
DA None None O
) None None O
neurons None None O
and None None O
age-dependent None None O
formation None None O
of None None O
protein None None O
inclusions None None O
that None None O
contain None None O
the None None O
α-synuclein None None O
( None None O
α-syn None None O
) None None O
protein None None O
. None None O

HSPC117 None None O
has None None O
been None None O
characterized None None O
recently None None O
as None None O
an None None O
essential None None O
subunit None None O
of None None O
the None None O
human None None O
tRNA None None O
splicing None None O
ligase None None I-PROTEIN
complex None None O
. None None O

For None None O
example None None O
, None None O
in None None O
yeast None None O
, None None O
unconventional None None O
splicing None None O
of None None O
HAC1 None None O
, None None O
a None None O
transcription None None O
factor None None O
that None None O
controls None None O
the None None O
unfolded None None O
protein None None O
response None None O
( None None O
UPR None None O
) None None O
, None None O
is None None O
mediated None None O
by None None O
a None None O
tRNA None None O
ligase None None I-PROTEIN
. None None O

Moreover None None O
, None None O
using None None O
a None None O
RNA None None O
ligase-dead None None O
mutant None None O
, None None O
we None None O
determine None None O
that None None O
the None None O
ligase None None I-PROTEIN
activity None None O
of None None O
worm None None O
RTCB-1 None None O
is None None O
required None None O
for None None O
its None None O
neuroprotective None None O
role None None O
, None None O
which None None O
, None None O
in None None O
turn None None O
, None None O
is None None O
mediated None None O
through None None O
XBP-1 None None O
in None None O
the None None O
UPR None None O
pathway None None O
. None None O

The None None O
function None None O
of None None O
xCT None None O
, None None O
and None None O
extracellular None None O
glutamate None None I-TRANS
in None None O
general None None O
, None None O
remains None None O
unclear None None O
. None None O

We None None O
saw None None O
no None None O
evidence None None O
for None None O
changes None None O
in None None O
GABA None None I-TRANS
receptor None None I-PROTEIN
abundance None None O
or None None O
the None None O
overall None None O
number None None O
of None None O
glutamatergic None None O
synapses None None O
. None None O

We None None O
conclude None None O
that None None O
glutamate None None I-TRANS
secreted None None O
via None None O
xCT None None O
suppresses None None O
glutamatergic None None O
synapse None None O
strength None None O
by None None O
triggering None None O
removal None None O
of None None O
postsynaptic None None O
AMPA None None O
receptors None None I-PROTEIN
. None None O

Animals None None O
must None None O
distinguish None None O
behaviorally None None O
relevant None None O
patterns None None O
of None None O
sensory None None O
stimulation None None O
from None None O
those None None O
that None None O
are None None O
attributable None None O
to None None O
their None None O
own None None O
movements None None I-FUNC
. None None O

Here None None O
we None None O
use None None O
an None None O
advantageous None None O
model None None O
system None None O
-- None None O
the None None O
electrosensory None None O
lobe None None O
( None None O
ELL None None O
) None None O
of None None O
weakly None None O
electric None None O
mormyrid None None O
fish None None O
-- None None O
to None None O
directly None None O
examine None None O
how None None O
CD None None O
and None None O
proprioceptive None None O
feedback None None O
signals None None O
are None None O
transformed None None O
into None None O
negative None None O
images None None O
of None None O
the None None O
predictable None None O
electrosensory None None O
consequences None None O
of None None O
the None None O
fish None None O
's None None O
motor None None O
commands None None O
and/or None None O
movements None None I-FUNC
. None None O

Here None None O
we None None O
describe None None O
an None None O
essential None None O
molecular None None O
component None None O
underlying None None O
classical None None O
accommodation None None O
in None None O
juvenile None None O
mouse None None O
hippocampal None None O
CA1 None None I-REGION
pyramidal None None O
neurons None None O
. None None O

In None None O
peripheral None None O
nerves None None O
and None None O
cells None None O
from None None O
mice None None O
with None None O
PMP22 None None O
deletion None None O
, None None O
we None None O
assessed None None O
the None None O
organization None None O
of None None O
filamentous None None O
actin None None I-PROTEIN
( None None O
F-actin None None O
) None None O
, None None O
and None None O
actin-dependent None None O
cellular None None O
functions None None O
. None None O

Our None None O
findings None None O
support None None O
a None None O
novel None None O
role None None O
for None None O
PMP22 None None O
in None None O
the None None O
linkage None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
with None None O
the None None O
plasma None None O
membrane None None O
, None None O
likely None None O
through None None O
regulating None None O
the None None O
cholesterol None None O
content None None O
of None None O
lipid None None O
rafts None None O
. None None O

By None None O
a None None O
year None None O
after None None O
neonatal None None O
xenograft None None O
, None None O
the None None O
forebrain None None I-REGION
GPC None None O
populations None None O
of None None O
implanted None None O
mice None None O
were None None O
largely None None O
, None None O
and None None O
often None None O
entirely None None O
, None None O
of None None O
human None None O
origin None None O
. None None O

The None None O
International None None O
Atomic None None O
Energy None None O
Agency None None O
sponsored None None O
a None None O
large None None O
, None None O
multinational None None O
, None None O
prospective None None O
study None None O
to None None O
further None None O
define None None O
PET None None O
for None None O
risk None None O
stratification None None O
of None None O
diffuse None None O
large None None O
B-cell None None O
lymphoma None None O
and None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
international None None O
biological None None O
diversity None None O
or None None O
diversity None None O
of None None O
healthcare None None O
systems None None O
may None None O
influence None None O
the None None O
kinetics None None O
of None None O
treatment None None O
response None None O
as None None O
assessed None None O
by None None O
interim None None O
PET None None O
( None None O
I-PET None None O
) None None O
. None None O

Two-year None None O
EFS None None O
was None None O
90 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
85 None None O
% None None O
-93 None None O
% None None O
) None None O
for None None O
I-PET-negative None None O
and None None O
58 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
48 None None O
% None None O
-66 None None O
% None None O
) None None O
for None None O
I-PET-positive None None O
, None None O
with None None O
a None None O
hazard None None O
ratio None None O
of None None O
5.31 None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
3.29-8.56 None None O
) None None O
. None None O

On None None O
sequential None None O
monitoring None None O
, None None O
192 None None O
of None None O
312 None None O
( None None O
62 None None O
% None None O
) None None O
patients None None O
had None None O
complete None None O
response None None O
at None None O
both None None O
I-PET None None O
and None None O
end-of-chemotherapy None None O
PET None None O
, None None O
with None None O
an None None O
EFS None None O
of None None O
97 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
92 None None O
% None None O
-98 None None O
% None None O
) None None O
; None None O
110 None None O
of None None O
these None None O
with None None O
favorable None None O
clinical None None O
indicators None None O
had None None O
an None None O
EFS None None O
of None None O
98 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
92 None None O
% None None O
-100 None None O
% None None O
) None None O
. None None O

Heterogeneity None None O
analysis None None O
found None None O
no None None O
significant None None O
difference None None O
between None None O
countries None None O
for None None O
outcomes None None O
stratified None None O
by None None O
I-PET None None O
. None None O

This None None O
research None None O
examined None None O
an None None O
integration None None O
of None None O
cognitive None None O
and None None O
interpersonal None None O
theories None None O
of None None O
depression None None I-DISEASE
by None None O
investigating None None O
the None None O
prospective None None O
contribution None None O
of None None O
depressive None None O
rumination None None O
to None None O
perceptions None None I-FUNC
of None None O
social None None O
support None None O
, None None O
the None None O
generation None None O
of None None O
interpersonal None None O
stress None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

Further None None O
, None None O
depressive None None O
rumination None None O
and None None O
dependent None None O
interpersonal None None O
stress None None O
were None None O
examined None None O
as None None O
joint None None O
and None None O
unique None None O
predictors None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
over None None O
time None None O
. None None O

Results None None O
revealed None None O
that None None O
social None None O
support None None O
discontent None None O
accounted None None O
for None None O
the None None O
prospective None None O
association None None O
between None None O
depressive None None O
rumination None None O
and None None O
dependent None None O
interpersonal None None O
stress None None O
, None None O
and None None O
that None None O
both None None O
depressive None None O
rumination None None O
and None None O
dependent None None O
interpersonal None None O
stress None None O
contributed None None O
to None None O
elevations None None O
in None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
over None None O
time None None O
. None None O

The None None O
results None None O
confirm None None O
that None None O
the None None O
Persian None None O
version None None O
of None None O
this None None O
instrument None None O
is None None O
valid None None O
and None None O
reliable None None O
, None None O
similar None None O
to None None O
its None None O
English None None O
index None None O
and None None O
its None None O
subsequent None None O
translations None None O
in None None O
different None None O
languages None None I-FUNC
. None None O

Stroke None None I-DISEASE
is None None O
the None None O
third None None O
leading None None O
cause None None O
of None None O
invalidism None None O
and None None O
death None None O
in None None O
industrialized None None O
countries None None O
. None None O

Tissue None None O
swelling None None O
was None None O
calculated None None O
for None None O
the None None O
investigation None None O
of None None O
ischemic None None O
brain None None I-DISEASE
edema None None I-DISEASE
formation None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
characterize None None O
receptors None None I-PROTEIN
for None None O
Amylin None None I-TRANS
and None None O
Salmon None None O
Calcitonin None None I-TRANS
functionally None None O
in None None O
the None None O
spinal None None O
cord None None O
of None None O
rats None None O
. None None O

Amylin None None I-TRANS
( None None O
0.05 None None O
nmoles None None O
) None None O
or None None O
Salmon None None O
Calcitonin None None I-TRANS
( None None O
0.005 None None O
nmoles None None O
) None None O
was None None O
administered None None O
intrathecally None None O
( None None O
i.t None None O
. None None O
) None None O

Antagonists None None O
were None None O
injected None None O
intrathecally None None O
10 None None O
minutes None None O
before None None O
the None None O
administration None None O
of None None O
either None None O
of None None O
the None None O
peptides None None I-TRANS
. None None O

These None None O
effects None None O
were None None O
reversed None None O
upon None None O
co-administration None None O
of None None O
either None None O
of None None O
the None None O
Amylin None None I-TRANS
antagonists None None O
AC187 None None O
or None None O
rat None None O
amylin8-37 None None O
, None None O
but None None O
not None None O
rat None None O
α-CGRP8-37 None None O
( None None O
. None None O
) None None O

injection None None O
of None None O
saline None None O
, None None O
Amylin None None I-TRANS
and/or None None O
Salmon None None O
Calcitonin None None I-TRANS
. None None O

Effects None None O
of None None O
the None None O
two None None O
peptides None None I-TRANS
were None None O
possibly None None O
produced None None O
by None None O
undefined None None O
receptors None None I-PROTEIN
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
a None None O
42-year-old None None O
woman None None O
, None None O
presenting None None O
a None None O
palpable None None O
painful None None O
mass None None O
and None None O
burning None None O
sensation None None I-FUNC
on None None O
the None None O
left None None O
side None None O
of None None O
vulva None None O
during None None O
the None None O
preceding None None O
two None None O
months None None O
. None None O

To None None O
describe None None O
the None None O
types None None O
of None None O
talking None None O
tracheostomy None None O
tubes None None O
available None None O
, None None O
present None None O
four None None O
case None None O
studies None None O
of None None O
critically None None O
ill None None O
patients None None O
who None None O
used None None O
a None None O
specialized None None O
tracheostomy None None O
tube None None O
to None None O
improve None None O
speech None None I-FUNC
, None None O
discuss None None O
their None None O
advantages None None O
and None None O
disadvantages None None O
, None None O
propose None None O
patient None None O
selection None None O
criteria None None O
, None None O
and None None O
provide None None O
practical None None O
recommendations None None O
for None None O
medical None None O
care None None O
providers None None O
. None None O

Phonological None None O
dyslexia None None I-DISEASE
was None None O
associated None None O
with None None O
a None None O
pronounced None None O
phonological None None O
awareness None None O
deficit None None O
, None None O
but None None O
subgroups None None O
otherwise None None O
had None None O
similar None None O
cognitive None None O
profiles None None O
. None None O

A None None O
few None None O
important None None O
themes None None O
are None None O
generalized None None O
: None None O
1 None None O
) None None O
the None None O
functional None None O
and None None O
cognitive None None O
status None None O
is None None O
critical None None O
for None None O
older None None O
people None None O
with None None O
T2DM None None O
considering None None O
their None None O
life None None O
expectancy None None O
compared None None O
to None None O
younger None None O
counterparts None None O
; None None O
2 None None O
) None None O
both None None O
severe None None O
hypoglycemia None None I-DISEASE
and None None O
persistent None None O
hyperglycemia None None O
are None None O
deleterious None None O
to None None O
older None None O
adults None None O
with None None O
T2DM None None O
, None None O
and None None O
both None None O
conditions None None O
should None None O
be None None O
avoided None None O
when None None O
determining None None O
therapeutic None None O
goals None None O
; None None O
3 None None O
) None None O
recently None None O
developed None None O
guidelines None None O
emphasize None None O
the None None O
avoidance None None O
of None None O
hypoglycemic None None O
episodes None None O
in None None O
older None None O
people None None O
, None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
symptoms None None O
. None None O

To None None O
study None None O
the None None O
incidence None None O
of None None O
MCI None None O
and None None O
dementia None None I-DISEASE
and None None O
their None None O
relationship None None O
to None None O
OH None None O
and None None O
subclinical None None O
OH None None O
with None None O
orthostatic None None O
symptoms None None O
( None None O
orthostatic None None O
intolerance None None O
) None None O
. None None O

Among None None O
controls None None O
, None None O
the None None O
proportion None None O
of None None O
those None None O
with None None O
OH None None O
was None None O
16 None None O
% None None O
; None None O
those None None O
with None None O
MCI None None O
24 None None O
% None None O
; None None O
and None None O
those None None O
with None None O
dementia None None I-DISEASE
31 None None O
% None None O
( None None O
age-adjusted None None O
OR None None O
1.93 None None O
[ None None O
1.19-3.14 None None O
] None None O
) None None O
. None None O

The None None O
collagen None None I-PROTEIN
constructs None None O
were None None O
designed None None O
as None None O
potential None None O
biocompatible None None O
inserts None None O
into None None O
wounded None None O
human None None O
gingiva None None O
. None None O

The None None O
collagen None None I-PROTEIN
constructs None None O
containing None None O
biomolecules/nanoconstructs None None O
were None None O
incubated None None O
under None None O
physiological None None O
conditions None None O
( None None O
ie None None O
, None None O
37°C None None O
and None None O
5 None None O
% None None O
CO2 None None O
) None None O
for None None O
24 None None O
hours None None O
, None None O
and None None O
the None None O
release None None O
profile None None O
was None None O
tuned None None O
from None None O
20 None None O
% None None O
to None None O
70 None None O
% None None O
of None None O
initially None None O
loaded None None O
materials None None O
by None None O
varying None None O
the None None O
gelation None None O
conditions None None O
of None None O
the None None O
collagen None None I-PROTEIN
constructs None None O
. None None O

The None None O
collagen None None I-PROTEIN
hydrogel None None O
we None None O
fabricated None None O
may None None O
serve None None O
as None None O
an None None O
efficient None None O
platform None None O
for None None O
the None None O
controlled None None O
release None None O
of None None O
biomolecules None None O
and None None O
imaging None None O
agents None None O
in None None O
human None None O
gingiva None None O
to None None O
facilitate None None O
the None None O
regeneration None None O
of None None O
oral None None O
tissues None None O
. None None O

Importantly None None O
, None None O
since None None O
the None None O
efficient None None O
decoding None None O
of None None O
emotions None None I-FUNC
is None None O
a None None O
crucial None None O
ability None None O
for None None O
the None None O
development None None O
and None None O
maintenance None None O
of None None O
satisfactory None None O
interpersonal None None O
relationships None None O
, None None O
we None None O
suggest None None O
that None None O
disruption None None O
of None None O
this None None O
ability None None O
in None None O
alcohol-dependent None None O
individuals None None O
may None None O
have None None O
adverse None None O
consequences None None O
for None None O
their None None O
social None None O
integration None None O
. None None O

MMT None None O
patients None None O
with None None O
comorbid None None O
pain None None O
were None None O
shown None None O
to None None O
have None None O
elevated None None O
IFN-γ None None O
and None None O
higher None None O
rates None None O
of None None O
continued None None O
opioid None None I-DISEASE
abuse None None I-DISEASE
. None None O

Foix-Chavany-Marie None None O
syndrome None None O
is None None O
characterized None None O
by None None O
bilateral None None O
facio-glosso-pharyngo-masticatory None None O
paralysis None None O
of None None O
voluntary None None O
movement None None I-FUNC
due None None O
to None None O
bilateral None None O
anterior None None O
opercular None None O
lesions None None O
. None None O

Brain None None O
magnetic None None O
resonance None None O
imaging None None O
revealed None None O
an None None O
infarct-like None None O
lesion None None O
in None None O
the None None O
pons None None I-REGION
, None None O
although None None O
no None None O
paralysis None None O
was None None O
observed None None O
. None None O

Obese None None O
sheep None None O
were None None O
used None None O
to None None O
assess None None O
the None None O
effects None None O
of None None O
palmitoleic None None O
( None None O
C16:1 None None O
cis-9 None None O
) None None O
acid None None O
infusion None None O
on None None O
lipogenesis None None O
and None None O
circulating None None O
insulin None None I-PROTEIN
levels None None O
. None None O

Plasma None None O
insulin None None I-PROTEIN
levels None None O
were None None O
lower None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
( None None O
10 None None O
mg/kg None None O
BW/day None None O
C16:1 None None O
) None None O
than None None O
controls None None O
( None None O
0 None None O
mg/kg None None O
BW/day None None O
C16:1 None None O
) None None O
at None None O
14 None None O
days None None O
and None None O
28 None None O
days None None O
of None None O
infusion None None O
. None None O

However None None O
, None None O
mRNA None None O
expression None None O
of None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
type None None O
4 None None O
( None None O
GLUT4 None None O
) None None O
and None None O
carnitine None None O
palmitoyltransferase None None O
1b None None O
( None None O
CPT1B None None O
) None None O
differed None None O
between None None O
tissues None None O
. None None O

These None None O
results None None O
show None None O
that None None O
C16:1 None None O
infusion None None O
for None None O
28 None None O
days None None O
reduced None None O
weight None None O
gain None None O
, None None O
intramuscular None None O
adipocyte None None O
size None None O
and None None O
total None None O
lipid None None O
content None None O
, None None O
and None None O
circulating None None O
insulin None None I-PROTEIN
levels None None O
. None None O

Alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
levels None None O
were None None O
significantly None None O
elevated None None O
in None None O
patients None None O
with None None O
JD None None O
( None None O
P=0.0237 None None O
) None None O
. None None O

They None None O
suffer None None O
more None None O
often None None O
from None None O
insomnia None None O
, None None O
anxiety None None O
, None None O
and None None O
depression None None I-DISEASE
. None None O

The None None O
purpose None None O
of None None O
this None None O
article None None O
is None None O
to None None O
investigate None None O
the None None O
current None None O
state None None O
of None None O
the None None O
GCC None None O
medical None None O
device None None O
industry None None O
, None None O
with None None O
respect None None O
to None None O
market None None O
, None None O
regulation None None O
, None None O
and None None O
reimbursement None None O
, None None O
paying None None O
special None None O
attention None None I-FUNC
to None None O
the None None O
three None None O
largest None None O
medical None None O
device None None O
markets None None O
: None None O
Saudi None None O
Arabia None None O
, None None O
the None None O
United None None O
Arab None None O
Emirates None None O
, None None O
and None None O
Qatar None None O
. None None O

Use None None O
of None None O
assistive None None O
devices None None O
in None None O
caring None None O
for None None O
individuals None None O
with None None O
dementia None None I-DISEASE
has None None O
not None None O
been None None O
systematically None None O
examined None None O
, None None O
particularly None None O
as None None O
it None None O
concerns None None O
managing None None O
behavioral None None O
symptoms None None O
. None None O

Consequently None None O
, None None O
an None None O
aim None None O
of None None O
present None None O
study None None O
was None None O
to None None O
examine None None O
the None None O
influence None None O
of None None O
drinking None None O
buddies None None O
on None None O
alcohol None None O
outcomes None None O
and None None O
the None None O
extent None None O
to None None O
which None None O
the None None O
relationship None None O
may None None O
be None None O
dependent None None O
on None None O
one None None O
's None None O
normative None None O
perceptions None None I-FUNC
. None None O

Memory None None I-FUNC
consolidation None None O
is None None O
the None None O
process None None O
by None None O
which None None O
fragile None None O
short-term None None I-FUNC
memory None None I-FUNC
is None None O
converted None None O
into None None O
stable None None O
long-term None None I-FUNC
memory None None I-FUNC
. None None O

Interestingly None None O
, None None O
similar None None O
molecular None None O
mechanisms None None O
subserve None None O
both None None O
memory None None I-FUNC
and None None O
synaptic None None O
plasticity None None O
consolidation None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
describe None None O
the None None O
technical None None O
obstacles None None O
and None None O
possible None None O
new None None O
methods None None O
to None None O
determine None None O
neuronal None None O
proteostasis None None O
of None None O
synaptic None None O
function None None O
and None None O
better None None O
explain None None O
the None None O
process None None O
of None None O
memory None None I-FUNC
and None None O
synaptic None None O
plasticity None None O
consolidation None None O
. None None O

AMPAR None None O
trafficking None None O
involves None None O
the None None O
dynamic None None O
processes None None O
of None None O
exocytosis None None O
, None None O
endocytosis None None O
and None None O
endosomal None None O
recycling None None O
, None None O
all None None O
of None None O
which None None O
involve None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
. None None O

Actin None None I-PROTEIN
dynamics None None O
generate None None O
forces None None O
that None None O
manipulate None None O
membranes None None O
in None None O
the None None O
process None None O
of None None O
vesicle None None O
biogenesis None None O
, None None O
and None None O
also None None O
for None None O
propelling None None O
vesicles None None O
through None None O
the None None O
cytoplasm None None O
to None None O
reach None None O
their None None O
destination None None O
. None None O

Numerous None None O
studies None None O
have None None O
shown None None O
that None None O
actin None None I-PROTEIN
dynamics None None O
are None None O
critical None None O
for None None O
AMPAR None None O
localization None None O
and None None O
function None None O
. None None O

Such None None O
proteins None None O
either None None O
regulate None None O
actin None None I-PROTEIN
dynamics None None O
to None None O
modulate None None O
mechanical None None O
forces None None O
exerted None None O
on None None O
AMPAR-containing None None O
membranes None None O
, None None O
or None None O
associate None None O
with None None O
actin None None I-PROTEIN
filaments None None O
to None None O
target None None O
or None None O
transport None None O
AMPAR-containing None None O
vesicles None None O
to None None O
specific None None O
subcellular None None O
regions None None O
. None None O

Our None None O
findings None None O
suggest None None O
that None None O
the None None O
scaling None None O
rules None None O
found None None O
to None None O
be None None O
shared None None O
across None None O
modern None None O
afrotherians None None O
, None None O
glires None None O
, None None O
and None None O
artiodactyls None None O
applied None None O
to None None O
the None None O
common None None O
Eutherian None None O
ancestor None None O
, None None O
such None None O
as None None O
the None None O
relationship None None O
between None None O
the None None O
mass None None O
of None None O
the None None O
cerebral None None I-REGION
cortex None None I-REGION
as None None O
a None None O
whole None None O
and None None O
its None None O
number None None O
of None None O
neurons None None O
. None None O

If None None O
the None None O
neuronal None None O
scaling None None O
rules None None O
for None None O
artiodactyls None None O
extend None None O
to None None O
all None None O
cetartiodactyls None None O
, None None O
we None None O
predict None None O
that None None O
the None None O
large None None O
cerebral None None I-REGION
cortex None None I-REGION
of None None O
cetaceans None None O
will None None O
still None None O
have None None O
fewer None None O
neurons None None O
than None None O
the None None O
human None None O
cerebral None None I-REGION
cortex None None I-REGION
. None None O

Calcium-dependent None None O
release None None O
of None None O
gliotransmitters None None O
by None None O
astrocytes None None O
is None None O
reported None None O
to None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
synaptic None None O
transmission None None O
and None None O
be None None O
necessary None None O
for None None O
long-term None None I-FUNC
potentiation None None I-FUNC
( None None O
LTP None None O
) None None O
, None None O
long-term None None I-FUNC
depression None None I-DISEASE
( None None O
LTD None None O
) None None O
and None None O
other None None O
forms None None O
of None None O
synaptic None None O
modulation None None O
that None None O
are None None O
correlates None None O
of None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

Morris None None O
water None None O
maze None None O
testing None None O
, None None O
a None None O
behavioral None None O
correlate None None O
of None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
, None None O
was None None O
unaffected None None O
by None None O
lack None None O
of None None O
astrocyte None None O
IP3R2-mediated None None O
Ca None None O
( None None O
2+ None None O
) None None O
-signaling None None O
. None None O

Autism None None I-DISEASE
Spectrum None None I-DISEASE
Disorders None None I-DISEASE
( None None O
ASD None None O
) None None O
are None None O
complex None None O
neurodevelopmental None None O
disorders None None O
characterized None None O
by None None O
repetitive None None O
behavior None None O
and None None O
impaired None None O
social None None O
communication None None O
and None None O
interactions None None O
. None None O

We None None O
therefore None None O
sought None None O
to None None O
further None None O
examine None None O
anxiety None None O
and None None O
emotional None None O
learning None None I-FUNC
in None None O
an None None O
environmentally None None O
induced None None O
animal None None O
model None None O
of None None O
ASD None None O
that None None O
utilizes None None O
the None None O
administration None None O
of None None O
the None None O
known None None O
teratogen None None O
, None None O
valproic None None O
acid None None O
( None None O
VPA None None O
) None None O
during None None O
gestation None None O
. None None O

Our None None O
data None None O
indicate None None O
that None None O
animals None None O
exposed None None O
to None None O
VPA None None O
in None None O
utero None None O
exhibit None None O
enhanced None None O
anxiety None None O
in None None O
the None None O
open None None O
field None None O
test None None O
and None None O
normal None None O
object None None I-FUNC
recognition None None I-FUNC
memory None None I-FUNC
compared None None O
to None None O
control None None O
animals None None O
. None None O

In None None O
conclusion None None O
, None None O
considering None None O
that None None O
progeny None None O
from None None O
dams None None O
exposed None None O
to None None O
rather None None O
similar None None O
doses None None O
of None None O
VPA None None O
exhibit None None O
striking None None O
differences None None O
in None None O
emotional None None O
learning None None I-FUNC
, None None O
the None None O
VPA None None O
model None None O
may None None O
serve None None O
as None None O
a None None O
useful None None O
tool None None O
to None None O
explore None None O
the None None O
molecular None None O
and None None O
cellular None None O
mechanisms None None O
that None None O
contribute None None O
to None None O
not None None O
only None None O
ASD None None O
, None None O
but None None O
also None None O
emotional None None O
learning None None I-FUNC
. None None O

Of None None O
primary None None O
interest None None O
was None None O
the None None O
extent None None O
to None None O
which None None O
the None None O
various None None O
measures None None O
correlate None None O
with None None O
listeners None None O
' None None O
abilities None None O
to None None O
perceive None None O
speech None None I-FUNC
in None None O
noise None None O
. None None O

In None None O
addition None None O
, None None O
older None None O
adults None None O
showed None None O
some None None O
cognitive None None O
processing None None O
declines None None O
( None None O
working None None I-FUNC
memory None None I-FUNC
and None None O
processing None None O
speed None None O
) None None O
although None None O
no None None O
declines None None O
in None None O
auditory None None O
temporal None None O
processing None None O
. None None O

Despite None None O
declines None None O
in None None O
cognitive None None O
processing None None O
, None None O
normal-hearing None None O
older None None O
adults None None O
do None None O
not None None O
necessarily None None O
have None None O
problems None None O
understanding None None O
speech None None I-FUNC
in None None O
noise None None O
as None None O
SRTs None None O
in None None O
SS None None O
and None None O
AM None None O
noise None None O
did None None O
not None None O
differ None None O
significantly None None O
between None None O
the None None O
two None None O
groups None None O
. None None O

We None None O
test None None O
the None None O
hypothesis None None O
that None None O
age-related None None O
neurodegenerative None None O
eye None None O
disease None None O
can None None O
be None None O
detected None None O
by None None O
examining None None O
patterns None None O
of None None O
eye None None O
movement None None I-FUNC
recorded None None O
whilst None None O
a None None O
person None None O
naturally None None O
watches None None O
a None None O
movie None None O
. None None O

Eye None None O
movement None None I-FUNC
scanpaths None None O
were None None O
plotted None None O
using None None O
novel None None O
methods None None O
that None None O
first None None O
filtered None None O
the None None O
data None None O
and None None O
then None None O
generated None None O
saccade None None O
density None None O
maps None None O
. None None O

Huge None None O
data None None O
from None None O
scanpaths None None O
of None None O
eye None None O
movements None None I-FUNC
recorded None None O
whilst None None O
people None None O
freely None None O
watch None None O
TV None None O
type None None O
films None None O
can None None O
be None None O
processed None None O
into None None O
maps None None O
that None None O
contain None None O
a None None O
signature None None O
of None None O
vision None None I-FUNC
loss None None O
. None None O

H2S None None I-TRANS
is None None O
well-known None None O
to None None O
act None None O
on None None O
various None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
and None None O
receptors None None I-PROTEIN
. None None O

The None None O
goal None None O
of None None O
the None None O
present None None O
study None None O
is None None O
to None None O
investigate None None O
the None None O
modulatory None None O
effect None None O
of None None O
BK None None O
channel None None O
phosphorylation None None O
on None None O
the None None O
action None None O
of None None O
H2S None None I-TRANS
on None None O
the None None O
channel None None O
as None None O
well None None O
as None None O
to None None O
recalculate None None O
and None None O
determine None None O
the None None O
H2S None None I-TRANS
concentrations None None O
in None None O
aqueous None None O
sodium None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
( None None O
NaHS None None O
) None None O
solutions None None O
. None None O

H2S None None I-TRANS
was None None O
measured None None O
with None None O
an None None O
anion None None O
selective None None O
electrode None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
from None None O
a None None O
concentration None None O
of None None O
300 None None O
μM None None O
NaHS None None O
, None None O
only None None O
11-13 None None O
% None None O
, None None O
i.e. None None O
, None None O
34-41 None None O
μM None None O
is None None O
effective None None O
as None None O
H2S None None I-TRANS
in None None O
solution None None O
. None None O

BK None None O
channel None None O
open None None O
probability None None O
( None None O
Po None None O
) None None O
of None None O
all None None O
cells None None O
lines None None O
used None None O
was None None O
increased None None O
by None None O
H2S None None I-TRANS
in None None O
ATP-containing None None O
solutions None None O
. None None O

H2S None None I-TRANS
, None None O
high None None O
significantly None None O
increased None None O
Po None None O
of None None O
all None None O
PKG None None O
pretreated None None O
cells None None O
. None None O

H2S None None I-TRANS
increased None None O
open None None O
dwell None None O
times None None O
of None None O
GH3 None None O
cells None None O
in None None O
the None None O
absence None None O
of None None O
ATP None None O
significantly None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
phosphorylation None None O
by None None O
PKG None None O
primes None None O
the None None O
channels None None O
for None None O
H2S None None I-TRANS
activation None None O
and None None O
indicate None None O
that None None O
channel None None O
phosphorylation None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
response None None O
to None None O
H2S None None I-TRANS
. None None O

Previously None None O
, None None O
we None None O
showed None None O
that None None O
listening None None O
to None None O
metronomes None None O
and None None O
subjectively None None O
imagining None None O
the None None O
two None None O
different None None O
meters None None O
of None None O
march None None O
and None None O
waltz None None O
modulated None None O
the None None O
resulting None None O
auditory None None O
evoked None None O
responses None None O
in None None O
the None None O
temporal None None I-REGION
lobe None None I-REGION
and None None O
motor-related None None O
brain None None O
areas None None O
such None None O
as None None O
the None None O
motor None None O
cortex None None O
, None None O
basal None None I-REGION
ganglia None None I-REGION
, None None O
and None None O
cerebellum None None I-REGION
. None None O

Brain None None O
areas None None O
related None None O
to None None O
the None None O
metric None None O
transition None None O
were None None O
identified None None O
from None None O
source None None O
reconstruction None None O
of None None O
the None None O
MEG None None O
using None None O
a None None O
beamformer None None O
and None None O
included None None O
auditory None None O
cortices None None O
, None None O
sensorimotor None None O
and None None O
premotor None None O
cortices None None O
, None None O
cerebellum None None I-REGION
, None None O
inferior/middle None None O
frontal None None I-REGION
gyrus None None I-REGION
, None None O
parahippocampal None None I-REGION
gyrus None None I-REGION
, None None O
inferior None None I-REGION
parietal None None I-REGION
lobule None None I-REGION
, None None O
cingulate None None I-REGION
cortex None None I-REGION
, None None O
and None None O
precuneus None None I-REGION
. None None O

Alexithymia None None I-DISEASE
is None None O
a None None O
personality None None O
trait None None O
characterized None None O
by None None O
difficulties None None O
in None None O
identifying None None O
, None None O
describing None None O
, None None O
and None None O
communicating None None O
one None None O
's None None O
emotions None None I-FUNC
. None None O

The None None O
present None None O
study None None O
suggests None None O
the None None O
importance None None O
of None None O
a None None O
specific None None O
combination None None O
of None None O
alexithymic None None O
features None None O
, None None O
rather None None O
than None None O
total None None O
alexithymia None None I-DISEASE
scores None None O
, None None O
as None None O
a None None O
risk None None O
factor None None O
for None None O
psychological None None O
distress None None O
. None None O

In None None O
recent None None O
years None None O
, None None O
researchers None None O
in None None O
social None None I-FUNC
cognition None None I-FUNC
have None None O
found None None O
the None None O
`` None None O
perceptual None None O
crossing None None O
paradigm None None O
'' None None O
to None None O
be None None O
both None None O
a None None O
theoretical None None O
and None None O
practical None None O
advance None None O
toward None None O
meeting None None O
particular None None O
challenges None None O
. None None O

However None None O
, None None O
little None None O
attention None None I-FUNC
has None None O
been None None O
paid None None O
to None None O
another None None O
relevant None None O
factor None None O
: None None O
translation None None O
expertise None None O
( None None O
TI None None O
) None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
TI None None O
contributes None None O
to None None O
modulating None None O
inter-equivalent None None O
connections None None O
in None None O
bilingual None None O
memory None None I-FUNC
. None None O

MCMI-III None None O
evidenced None None O
axis None None O
II None None O
DSM-IV None None O
personality None None I-DISEASE
disorders None None I-DISEASE
[ None None O
4.1 None None O
% None None O
schizoid None None O
, None None O
depressive None None O
, None None O
sadistic None None O
, None None O
negativistic None None O
( None None O
passive-aggressive None None O
) None None O
, None None O
and None None O
masochistic None None O
, None None O
6.1 None None O
% None None O
avoiding None None O
, None None O
12.2 None None O
% None None O
dependent None None O
, None None O
20.4 None None O
% None None O
histrionic None None O
, None None O
16.3 None None O
% None None O
narcissistic None None O
, None None O
2.0 None None O
% None None O
obsessive-compulsive None None O
] None None O
, None None O
and None None O
axis None None O
I None None O
DSM-IV None None O
psychiatric None None O
disorders None None O
: None None O
10.2 None None O
% None None O
anxiety None None O
, None None O
2.0 None None O
% None None O
somatoform None None I-DISEASE
disorder None None I-DISEASE
and None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
16.3 None None O
% None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
. None None O

Rorschach None None O
test None None O
's None None O
results None None O
show None None O
53.1 None None O
% None None O
reduced None None O
coping None None O
abilities None None O
and None None O
social None None O
skills None None O
, None None O
55.1 None None O
% None None O
depression None None I-DISEASE
, None None O
30.6 None None O
% None None O
perceptual None None O
distortion None None O
and None None O
cognitive None None O
slippage None None O
, None None O
24.5 None None O
% None None O
constantly None None O
alert None None O
and None None O
worry None None O
, None None O
8.1 None None O
% None None O
at None None O
risk None None O
for None None O
suicide None None O
, None None O
and None None O
finally None None O
about None None O
50 None None O
% None None O
of None None O
our None None O
patients None None O
had None None O
chronic None None O
stress None None O
. None None O

Under None None O
salt None None O
stress None None O
( None None O
150 None None O
mM None None O
NaCl None None O
over None None O
7 None None O
days None None O
) None None O
roots None None O
of None None O
Rex None None O
variety None None O
accumulated None None O
50 None None O
times None None O
more None None O
compatible None None O
solutes None None O
such None None O
as None None O
proline None None I-TRANS
compared None None O
to None None O
Chichen-Itza None None O
. None None O

Fluorescence None None O
analysis None None O
suggested None None O
an None None O
efficient None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
compartmentalization None None O
in None None O
vacuole-like None None O
structures None None O
and None None O
in None None O
small None None O
intracellular None None O
compartments None None O
in None None O
roots None None O
of None None O
Rex None None O
variety None None O
. None None O

Sucrose None None O
transporters None None I-PROTEIN
( None None O
SUTs None None O
) None None O
are None None O
essential None None O
for None None O
the None None O
export None None O
and None None O
efficient None None O
movement None None I-FUNC
of None None O
sucrose None None O
from None None O
source None None O
leaves None None O
to None None O
sink None None O
organs None None O
in None None O
plants None None O
. None None O

To None None O
shed None None O
light None None O
on None None O
the None None O
underlying None None O
drivers None None O
of None None O
SUT None None O
evolution None None O
, None None O
Bayesian None None O
phylogenetic None None O
inference None None I-FUNC
was None None O
undertaken None None O
using None None O
41 None None O
sequenced None None O
plant None None O
genomes None None O
, None None O
including None None O
seven None None O
basal None None O
lineages None None O
at None None O
key None None O
evolutionary None None O
junctures None None O
. None None O

The None None O
concentration None None O
and None None O
composition None None O
of None None O
the None None O
gliadin None None O
and None None O
glutenin None None O
seed None None O
storage None None I-FUNC
proteins None None O
( None None O
SSPs None None O
) None None O
in None None O
wheat None None O
flour None None O
are None None O
the None None O
most None None O
important None None O
determinants None None O
of None None O
its None None O
end-use None None O
value None None O
. None None O

Many None None O
extracellular None None O
and None None O
intracellular None None O
signals None None O
promote None None O
the None None O
c-Abl None None O
tyrosine None None I-TRANS
kinase None None O
activity None None O
. None None O

These None None O
changes None None O
affect None None O
surface None None O
features None None O
of None None O
the None None O
c-Abl None None O
kinase None None O
and None None O
likely None None O
its None None O
capability None None O
to None None O
bind None None O
actin None None I-PROTEIN
and/or None None O
DNA None None O
. None None O

The None None O
collaboration None None O
generated None None O
an None None O
alternative None None O
emphasis None None O
on None None O
movement None None I-FUNC
, None None O
rather None None O
than None None O
behaviour None None O
, None None O
as None None O
the None None O
focus None None O
of None None O
managing None None O
spatialities None None O
. None None O

This None None O
attention None None I-FUNC
to None None O
movement None None I-FUNC
enables None None O
a None None O
versatile None None O
conceptualisation None None O
of None None O
social None None O
and None None O
emotional None None O
wellbeing None None O
that None None O
is None None O
still None None O
situated None None O
and None None O
relational None None O
but None None O
also None None O
expressive None None O
of None None O
habituation None None O
and None None O
improvisation None None O
. None None O

We None None O
investigated None None O
the None None O
contribution None None O
of None None O
dopamine None None I-TRANS
deficiency None None O
to None None O
cognition None None O
in None None O
Parkinson None None I-DISEASE
disease None None O
( None None O
PD None None O
) None None O
and None None O
dementia None None I-DISEASE
with None None I-DISEASE
Lewy None None I-DISEASE
bodies None None I-DISEASE
( None None O
DLB None None O
) None None O
with None None O
dopamine None None I-TRANS
transporter None None O
( None None O
DAT None None O
) None None O
imaging None None O
. None None O

We None None O
analyzed None None O
DAT None None O
concentration None None O
in None None O
putamen None None I-REGION
, None None O
caudate None None O
, None None O
anterior None None O
cingulate None None O
( None None O
AC None None O
) None None O
, None None O
orbitofrontal None None O
and None None O
prefrontal None None O
regions None None O
, None None O
using None None O
the None None O
Standardized None None O
Uptake None None O
Volume None None O
Ratio None None O
with None None O
partial None None O
volume None None O
correction None None O
, None None O
and None None O
we None None O
related None None O
DAT None None O
concentration None None O
and None None O
global None None O
cortical None None O
thickness None None O
to None None O
neuropsychological None None O
performance None None O
. None None O

Reduced None None O
caudate None None O
DAT None None O
concentration None None O
was None None O
associated None None O
with None None O
worse None None O
Clinical None None O
Dementia None None I-DISEASE
Rating None None O
Scale-sum None None O
of None None O
boxes None None O
( None None O
CDR-SB None None O
) None None O
scores None None O
and None None O
visuospatial None None O
skills None None O
in None None O
DLB None None O
but None None O
not None None O
in None None O
PD None None O
or None None O
HCS None None O
groups None None O
. None None O

Higher None None O
AC None None O
DAT None None O
concentration None None O
was None None O
associated None None O
with None None O
lower None None O
putamen None None I-REGION
DAT None None O
concentration None None O
in None None O
DLB None None O
and None None O
with None None O
higher None None O
putamen None None I-REGION
DAT None None O
concentration None None O
in None None O
PD None None O
. None None O

Caudate None None O
and None None O
AC None None O
dopamine None None I-TRANS
dysfunction None None O
contribute None None O
in None None O
opposing None None O
directions None None O
to None None O
cognitive None None O
impairment None None O
in None None O
DLB None None O
. None None O

As None None O
non-alcoholic None None O
fatty None None O
liver None None O
disease None None O
can None None O
progress None None O
to None None O
liver None None O
cirrhosis None None O
, None None O
its None None O
treatment None None O
is None None O
attracting None None O
greater None None O
attention None None I-FUNC
. None None O

We None None O
also None None O
discuss None None O
established None None O
drugs None None O
that None None O
are None None O
already None None O
being None None O
used None None O
to None None O
treat None None O
non-alcoholic None None O
fatty None None O
liver None None O
disease None None O
, None None O
in None None O
addition None None O
to None None O
newly None None O
discovered None None O
agents None None O
, None None O
with None None O
respect None None O
to None None O
their None None O
mechanisms None None O
of None None O
drug None None O
action None None O
, None None O
focusing None None O
mainly None None O
on None None O
hepatic None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Data None None O
indicating None None O
that None None O
pre-transplant None None O
abstinence None None O
is None None O
an None None O
associated None None O
predictive None None O
factor None None O
for None None O
alcoholic None None O
recidivism None None O
supports None None O
the None None O
reasoning None None I-FUNC
behind None None O
this None None O
. None None O

Although None None O
fatty None None O
acid None None O
oxidation None None O
disorders None None O
, None None O
lysosomal None None O
and None None O
glycogen None None O
storage None None I-FUNC
disorders None None O
and None None O
organic None None O
acidurias None None O
are None None O
well-known None None O
to None None O
be None None O
associated None None O
with None None O
cardiomyopathies None None O
, None None O
emerging None None O
reports None None O
suggest None None O
that None None O
mitochondrial None None O
dysfunction None None O
and None None O
congenital None None O
disorders None None O
of None None O
glycosylation None None O
may None None O
also None None O
account None None O
for None None O
a None None O
proportion None None O
of None None O
cardiomyopathies None None O
. None None O

Myocardial None None O
cells None None O
, None None O
fibroblasts None None O
and None None O
vascular None None O
endothelial/smooth None None O
muscle None None O
cells None None O
represent None None O
intracellular None None O
compartment None None O
and None None O
the None None O
main None None O
proteins None None O
in None None O
the None None O
interstitium None None O
are None None O
types None None O
I/III None None O
collagens None None I-PROTEIN
. None None O

Neurological None None O
deficits None None O
were None None O
assessed None None O
at None None O
24 None None O
and None None O
48 None None O
hr None None O
after None None O
stroke None None I-DISEASE
by None None O
using None None O
sticky None None O
tape None None O
test None None O
, None None O
hanging-wire None None O
test None None O
and None None O
Bederson None None O
's None None O
scoring None None O
system None None O
. None None O

The None None O
Oct4 None None O
5´UTR None None O
and None None O
3´UTR None None O
sequences None None O
were None None O
cloned None None O
into None None O
pGL3 None None O
luciferase None None I-PROTEIN
plasmid None None O
which None None O
led None None O
to None None O
the None None O
generation None None O
of None None O
pGL3 None None O
5´-UTR None None O
, None None O
pGL3 None None O
5´ None None O
& None None O
amp None None O
; None None O
3´-UTRs None None O
and None None O
pGL3 None None O
3´-UTR None None O
vectors None None O
. None None O

The None None O
assay None None O
of None None O
luciferase None None I-PROTEIN
expression None None O
exhibited None None O
a None None O
direct None None O
link None None O
between None None O
the None None O
presence None None O
of None None O
Oct4 None None O
3´- None None O
UTR None None O
and None None O
the None None O
decrease None None O
of None None O
luciferase None None I-PROTEIN
count None None O
in None None O
both None None O
cell None None O
lines None None O
; None None O
whereas None None O
5´UTR None None O
indicated None None O
diverse None None O
behaviors None None O
in None None O
two None None O
cells None None O
. None None O

Nine None None O
of None None O
the None None O
STPKs None None O
are None None O
receptor None None I-PROTEIN
type None None O
kinases None None I-PROTEIN
, None None O
with None None O
an None None O
extracytoplasmic None None O
sensor None None O
domain None None O
and None None O
an None None O
intracellular None None O
kinase None None O
domain None None O
, None None O
indicating None None O
that None None O
these None None O
kinases None None I-PROTEIN
transduce None None O
external None None O
signals None None O
. None None O

Ischemic None None O
stroke None None I-DISEASE
patients None None O
recruited None None O
for None None O
the None None O
MONITOR None None O
and None None O
VISION None None I-FUNC
studies None None O
were None None O
retrospectively None None O
screened None None O
and None None O
patients None None O
who None None O
had None None O
infarcts None None O
on None None O
diffusion-weighted None None O
imaging None None O
( None None O
DWI None None O
) None None O
at None None O
baseline None None O
and None None O
had None None O
at None None O
least None None O
two None None O
follow-up None None O
MR None None O
scans None None O
( None None O
n None None O
= None None O
56 None None O
) None None O
were None None O
included None None O
. None None O

Voxel-based None None O
morphometry None None O
from None None O
conventional None None O
T1-weighted None None O
images None None O
has None None O
proved None None O
effective None None O
to None None O
quantify None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
related None None O
brain None None O
atrophy None None O
and None None O
to None None O
enable None None O
fairly None None O
accurate None None O
automated None None O
classification None None O
of None None O
AD None None O
patients None None O
, None None O
mild None None O
cognitive None None O
impaired None None O
patients None None O
( None None O
MCI None None O
) None None O
and None None O
elderly None None O
controls None None O
. None None O

hippocampi None None O
, None None O
lobes None None O
, None None O
ventricles None None I-REGION
) None None O
as None None O
opposed None None O
to None None O
hundreds None None O
of None None O
thousands None None O
of None None O
voxel-wise None None O
gray None None O
matter None None O
concentrations None None O
. None None O

Results None None O
indicate None None O
that None None O
both None None O
algorithms None None O
achieve None None O
classification None None O
accuracy None None O
comparable None None O
to None None O
the None None O
conventional None None O
whole-brain None None O
voxel-based None None O
morphometry None None O
pipeline None None O
using None None O
SPM None None O
for None None O
AD None None O
vs None None O
elderly None None O
controls None None O
and None None O
MCI None None O
vs None None O
controls None None O
, None None O
and None None O
higher None None O
accuracy None None O
for None None O
classification None None O
of None None O
AD None None O
vs None None O
MCI None None O
and None None O
early None None O
vs None None O
late None None O
AD None None O
converters None None O
, None None O
thereby None None O
demonstrating None None O
the None None O
potential None None O
of None None O
volume-based None None O
morphometry None None O
to None None O
assist None None O
diagnosis None None O
of None None O
mild None None O
cognitive None None O
impairment None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

In None None O
both None None O
experiments None None O
, None None O
E+ None None O
reduced None None O
HR None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
and None None O
increased None None O
insulin None None I-PROTEIN
( None None O
P None None O
= None None O
0.07 None None O
) None None O
. None None O

This None None O
stone None None O
slab None None O
made None None O
possible None None O
the None None O
initial None None O
decipherment None None O
of None None O
Egyptian None None O
hieroglyphics None None O
because None None O
it None None O
allowed None None O
us None None O
to None None O
see None None O
this None None O
language None None I-FUNC
in None None O
a None None O
way None None O
that None None O
was None None O
previously None None O
impossible None None O
. None None O

Impaired None None O
glucose None None O
metabolism None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
have None None O
been None None O
linked None None O
to None None O
excess None None O
body None None O
fat None None O
composition None None O
. None None O

Good None None O
labeling None None O
efficiency None None O
and None None O
quantification None None O
accuracy None None O
were None None O
demonstrated None None O
with None None O
a None None O
mixture None None O
of None None O
12 None None O
metabolite None None O
standards None None O
including None None O
amino None None I-TRANS
acids None None I-TRANS
and None None O
small None None O
molecule None None O
neurotransmitters None None I-TRANS
. None None O

Nitric None None I-TRANS
oxide None None I-TRANS
was None None O
used None None O
in None None O
six None None O
infants None None O
before None None O
commencement None None O
of None None O
milrinone None None O
. None None O

Survival None None O
in None None O
patients None None O
with None None O
pleural None None O
infection None None O
was None None O
compared None None O
with None None O
788 None None O
patients None None O
with None None O
MPE None None O
( None None O
known None None O
as None None O
the None None O
LENT None None O
[ None None O
pleural None None O
fluid None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
, None None O
Eastern None None O
Cooperative None None O
Oncology None None O
Group None None O
performance None None O
status None None O
, None None O
serum None None O
neutrophil None None O
to None None O
lymphocyte None None O
ratio None None O
, None None O
and None None O
tumor None None O
type None None O
] None None O
cohort None None O
) None None O
and None None O
with None None O
national None None O
statistics None None O
. None None O

Despite None None O
implications None None O
for None None O
carcinogenesis None None O
and None None O
other None None O
chronic None None O
diseases None None O
, None None O
basic None None O
mechanisms None None O
of None None O
p53 None None I-PROTEIN
and None None O
its None None O
variants None None O
in None None O
suppressing None None O
Bcl-2 None None O
levels None None O
are None None O
poorly None None O
understood None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
p53 None None I-PROTEIN
decreases None None O
bcl-2 None None O
mRNA None None O
half-life None None O
by None None O
interacting None None O
with None None O
the None None O
5 None None O
' None None O
untranslated None None O
region None None O
( None None O
UTR None None O
) None None O
. None None O

Accordingly None None O
, None None O
more None None O
mucous None None O
cells None None O
are None None O
present None None O
in None None O
primary None None O
human None None O
airway None None O
cultures None None O
with None None O
p53 None None I-PROTEIN
( None None O
Arg None None O
) None None O
compared None None O
with None None O
p53 None None I-PROTEIN
( None None O
Pro None None O
) None None O
. None None O

On None None O
two None None O
genetic None None O
backgrounds None None O
, None None O
mice None None O
with None None O
targeted None None O
replacement None None O
of None None O
prolines None None I-TRANS
in None None O
p53 None None I-PROTEIN
PRD None None O
show None None O
enhanced None None O
expression None None O
of None None O
SPDEF None None O
and None None O
Bcl-2 None None O
and None None O
mucous None None O
cell None None O
metaplasia None None O
. None None O

Carotid None None O
arteriosclerosis None None O
and None None O
sleep None None O
apnea None None O
are None None O
considered None None O
as None None O
independent None None O
risk None None O
factors None None O
for None None O
stroke None None I-DISEASE
. None None O

Sleep None None O
apnea None None O
comprises None None O
two None None O
pathophysiologic None None O
conditions None None O
: None None O
OSA None None O
and None None O
central None None I-DISEASE
sleep None None I-DISEASE
apnea None None I-DISEASE
( None None O
CSA None None O
) None None O
. None None O

Ninety-six None None O
patients None None O
with None None O
asymptomatic None None O
extracranial None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
of None None O
≥ None None O
50 None None O
% None None O
underwent None None O
polysomnography None None O
to None None O
( None None O
1 None None O
) None None O
determine None None O
prevalence None None O
and None None O
severity None None O
of None None O
sleep None None O
apnea None None O
for None None O
different None None O
degrees None None O
of None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
and None None O
( None None O
2 None None O
) None None O
analyze None None O
associations None None O
between None None O
OSA None None O
and None None O
CSA None None O
, None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
severity None None O
, None None O
and None None O
other None None O
arteriosclerotic None None O
risk None None O
factors None None O
. None None O

Sleep None None O
apnea None None O
is None None O
highly None None O
prevalent None None O
in None None O
asymptomatic None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
. None None O

In None None O
comparison None None O
with None None O
individual None None O
Sn None None O
and None None O
Sb None None O
NCs None None O
and None None O
their None None O
mixtures None None O
, None None O
we None None O
show None None O
that None None O
through None None O
the None None O
creation None None O
of None None O
SnSb None None O
alloyed None None O
NCs None None O
the None None O
Li-ion None None O
storage None None I-FUNC
properties None None O
are None None O
enhanced None None O
due None None O
to None None O
combination None None O
of None None O
high None None O
cycling None None O
stability None None O
of None None O
Sb None None O
with None None O
higher None None O
specific None None O
Li-ion None None O
storage None None I-FUNC
capacity None None O
of None None O
Sn None None O
. None None O

Furthermore None None O
, None None O
Na-ion None None O
storage None None I-FUNC
capacities None None O
of None None O
& None None O
gt None None O
; None None O
350 None None O
mA None None O
h None None O
g None None O
( None None O
-1 None None O
) None None O
and None None O
& None None O
gt None None O
; None None O
200 None None O
mA None None O
h None None O
g None None O
( None None O
-1 None None O
) None None O
were None None O
obtained None None O
at None None O
1C None None O
and None None O
20C None None O
rates None None O
, None None O
respectively None None O
. None None O

As None None O
the None None O
epoch-differenced None None O
method None None O
can None None O
only None None O
derive None None O
temporal None None O
clock None None O
changes None None O
which None None O
have None None O
to None None O
be None None O
aligned None None O
to None None O
the None None O
absolute None None O
clocks None None O
but None None O
always None None O
in None None O
a None None O
rather None None O
complicated None None O
way None None O
, None None O
in None None O
this None None O
paper None None O
, None None O
an None None O
efficient None None O
method None None O
for None None O
high-rate None None O
clock None None O
estimation None None O
is None None O
proposed None None O
using None None O
the None None O
concept None None O
of None None O
`` None None O
carrier-range None None O
'' None None O
realized None None O
by None None O
means None None O
of None None O
PPP None None O
with None None O
integer None None O
ambiguity None None I-FUNC
resolution None None O
. None None O

To None None O
assess None None O
the None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
-lowering None None O
efficacy None None O
of None None O
SLT None None O
in None None O
eyes None None O
with None None O
primary None None O
angle None None O
closure None None O
( None None O
PAC None None O
) None None O
and None None O
PAC None None O
glaucoma None None O
( None None O
PACG None None O
) None None O
. None None O

The None None O
SLT None None O
was None None O
repeated None None O
if None None O
the None None O
IOP None None I-TRANS
reduction None None O
was None None O
less None None O
than None None O
20.0 None None O
% None None O
from None None O
baseline None None O
at None None O
the None None O
1- None None O
or None None O
3-month None None O
follow-up None None O
visit None None O
. None None O

At None None O
6 None None O
months None None O
, None None O
IOP None None I-TRANS
decreased None None O
by None None O
4.0 None None O
mm None None O
Hg None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
3.2-4.8 None None O
) None None O
in None None O
the None None O
SLT None None O
group None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
by None None O
4.2 None None O
mm None None O
Hg None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
3.5-4.9 None None O
) None None O
in None None O
the None None O
PGA None None O
group None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Complete None None O
success None None O
( None None O
IOP None None I-TRANS
≤21 None None O
mm None None O
Hg None None O
without None None O
medications None None O
) None None O
was None None O
achieved None None O
in None None O
60.0 None None O
% None None O
eyes None None O
of None None O
the None None O
SLT None None O
group None None O
, None None O
compared None None O
with None None O
84.0 None None O
% None None O
of None None O
eyes None None O
in None None O
the None None O
PGA None None O
group None None O
( None None O
P None None O
= None None O
.008 None None O
) None None O
. None None O

Among None None O
new None None O
possibilities None None O
for None None O
cancer None None O
chemoprevention None None O
, None None O
much None None O
attention None None I-FUNC
is None None O
paid None None O
to None None O
curcumin-A None None O
broad-spectrum None None O
anticancer None None O
polyphenolic None None O
derivative None None O
extracted None None O
from None None O
the None None O
rhizome None None O
of None None O
Curcuma None None O
longa None None O
L. None None O
According None None O
to None None O
ClinicalTrials.gov None None O
at None None O
present None None O
there None None O
are None None O
no None None O
running None None O
pilot None None O
studies None None O
, None None O
which None None O
could None None O
assess None None O
possible None None O
therapeutic None None O
benefits None None O
from None None O
curcumin None None O
supplementation None None O
to None None O
patients None None O
with None None O
primary None None O
epithelial None None O
ovarian None None O
cancer None None O
. None None O

Calreticulin None None O
is None None O
down-regulated None None O
in None None O
the None None O
cortical None None O
neurons None None O
of None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
and None None O
may None None O
be None None O
a None None O
potential None None O
biomarker None None O
for None None O
the None None O
diagnosis None None O
of None None O
AD None None O
. None None O

Compared None None O
to None None O
the None None O
5 None None O
' None None O
end None None O
flanking None None O
sequences None None O
, None None O
the None None O
3 None None O
' None None O
end None None O
flanking None None O
sequences None None O
of None None O
the None None O
tetrad None None O
contribute None None O
significantly None None O
less None None O
to None None O
the None None O
recognition None None O
of None None O
EPI None None I-TRANS
. None None O

The None None O
steady-state None None O
absorption None None O
, None None O
steady-state/time-resolved None None O
fluorescence None None O
, None None O
and None None O
NMR None None O
studies None None O
demonstrate None None O
that None None O
EPI None None I-TRANS
most None None O
likely None None O
interact None None O
with None None O
the None None O
5 None None O
' None None O
end None None O
flanking None None O
sequence None None O
substructure None None O
beyond None None O
the None None O
core None None O
[ None None O
Q None None O
] None None O
and None None O
the None None O
G-quadruplex None None O
tetrad None None O
in None None O
a None None O
much None None O
more None None O
specific None None O
manner None None O
than None None O
the None None O
other None None O
alkaloids None None O
. None None O

More None None O
importantly None None O
, None None O
EPI None None I-TRANS
, None None O
as None None O
the None None O
brightest None None O
FSA None None O
emitter None None O
among None None O
the None None O
alkaloids None None O
, None None O
can None None O
also None None O
serve None None O
as None None O
an None None O
efficient None None O
conformation None None O
probe None None O
for None None O
HTG None None O
DNA None None O
and None None O
discriminate None None O
the None None O
DNA None None O
G-quadruplex None None O
from None None O
the None None O
RNA None None O
counterpart None None O
. None None O

Our None None O
work None None O
suggests None None O
the None None O
potential None None O
use None None O
of None None O
EPI None None I-TRANS
as None None O
a None None O
bioimaging None None O
probe None None O
and None None O
a None None O
therapeutic None None O
DNA None None O
binder None None O
. None None O

Optimal None None O
removal None None O
of None None O
Cr None None O
( None None O
VI None None I-REGION
) None None O
was None None O
achieved None None O
using None None O
the None None O
QPVA/0.5PDADMAC/0.1TEOSm None None O
membrane None None O
at None None O
a None None O
pH None None O
value None None O
of None None O
2 None None O
. None None O

Adding None None O
potassium None None O
( None None O
K None None O
( None None O
+ None None O
) None None O
) None None O
or None None O
sodium None None O
( None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
) None None O
to None None O
solution None None O
can None None O
reduce None None O
R None None O
( None None O
Mg None None O
( None None O
2+ None None O
) None None O
) None None O
and None None O
SF None None O
. None None O

Some None None O
protein None None O
fragments None None O
had None None O
their None None O
sequences None None O
elucidated None None O
, None None O
presenting None None O
similarities None None O
to None None O
jacalin None None O
and None None O
Kunitz-type None None O
trypsin None None I-PROTEIN
inhibitors None None O
. None None O

The None None O
immobilised None None O
Kunitz-type None None O
trypsin None None I-PROTEIN
inhibitor None None O
presence None None O
in None None O
the None None O
latex None None O
film None None O
allow None None O
us None None O
to None None O
point None None O
out None None O
to None None O
applications None None O
related None None O
to None None O
this None None O
inhibition None None O
, None None O
as None None O
in None None O
active None None O
food None None O
packaging None None O
, None None O
since None None O
these None None O
peptidase None None O
inhibitors None None O
are None None O
able None None O
to None None O
inhibit None None O
pests None None O
and None None O
microorganism None None O
proliferation None None O
. None None O

Furthermore None None O
, None None O
the None None O
method None None O
was None None O
also None None O
compared None None O
with None None O
the None None O
common None None O
method None None O
Primer3 None None O
according None None O
to None None O
their None None O
method None None O
type None None O
, None None O
primers None None O
presentation None None O
, None None O
parameters None None O
setting None None O
, None None O
speed None None O
and None None O
memory None None I-FUNC
usage None None O
. None None O

These None None O
results None None O
might None None O
provide None None O
the None None O
basis None None O
of None None O
a None None O
simple None None O
diagnostic None None O
tool None None O
for None None O
detecting None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Varying None None O
from None None O
person None None O
to None None O
person None None O
, None None O
schizophrenia None None I-DISEASE
is None None O
a None None O
heterogeneous None None O
disease None None O
with None None O
symptoms None None O
of None None O
positive None None O
, None None O
negative None None O
, None None O
and None None O
cognitive None None O
deficits None None O
. None None O

Examination None None O
of None None O
the None None O
medial None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
revealed None None O
that None None O
a None None O
combination None None O
of None None O
PRX-07034 None None O
and None None O
prazosin None None O
reduced None None O
the None None O
dizocilpine-mediated None None O
increase None None O
of None None O
5-HT None None I-TRANS
. None None O

Subjective None None O
SRBD None None O
symptoms None None O
, None None O
Epworth None None O
sleepiness None None O
scale None None O
score None None O
, None None O
snoring None None O
severity None None O
( None None O
visual None None O
analog None None O
scale None None O
, None None O
rated None None O
0-10 None None O
by None None O
bed None None O
partner None None O
) None None O
, None None O
and None None O
objective None None O
full-night None None O
polysomnographic None None O
parameters None None O
( None None O
apnea-hypopnea None None O
index None None O
[ None None O
AHI None None O
] None None O
, None None O
AHI None None O
in None None O
rapid None None O
eye None None O
movement None None I-FUNC
[ None None O
REM None None O
] None None O
sleep None None O
, None None O
central None None I-DISEASE
sleep None None I-DISEASE
apnea None None I-DISEASE
index None None O
, None None O
percentage None None O
of None None O
light None None O
sleep None None O
, None None O
percentage None None O
of None None O
deep None None O
sleep None None O
, None None O
percentage None None O
of None None O
REM None None O
sleep None None O
, None None O
sleep None None O
efficiency None None O
, None None O
sleep None None O
latency None None O
, None None O
arousal None None O
index None None O
, None None O
mean None None O
oxygen None None O
saturation None None O
, None None O
lowest None None O
oxygen None None O
saturation None None O
, None None O
desaturation None None O
index None None O
, None None O
and None None O
snoring None None O
index None None O
) None None O
were None None O
collected None None O
before None None O
and None None O
at None None O
least None None O
6 None None O
months None None O
after None None O
treatment None None O
. None None O

We None None O
observe None None O
for None None O
most None None O
of None None O
the None None O
mutants None None O
the None None O
occurrence None None O
of None None O
an None None O
unstructured None None O
SOD1 None None O
species None None O
, None None O
unable None None O
to None None O
bind None None O
zinc None None I-TRANS
. None None O

Haematopoietic None None O
stem None None O
cells None None O
( None None O
HSCs None None O
) None None O
are None None O
produced None None O
during None None O
embryogenesis None None O
from None None O
the None None O
floor None None O
of None None O
the None None O
dorsal None None I-NEURON
aorta None None O
. None None O

Results None None O
showed None None O
that None None O
, None None O
compared None None O
to None None O
the None None O
other None None O
conditions None None O
, None None O
only None None O
IE None None O
causes None None O
general None None O
adaptive None None O
syndrome None None O
( None None O
GAS None None O
) None None O
, None None O
including None None O
adrenal None None I-TRANS
hypertrophy None None O
, None None O
thymic None None O
atrophy None None O
and None None O
hypercorticosteronemia None None O
. None None O

These None None O
findings None None O
support None None O
the None None O
hypothesis None None O
that None None O
6 None None O
weeks None None O
of None None O
continuous None None O
ME None None O
training None None O
leads None None O
to None None O
enhanced None None O
hippocampus-related None None O
memory None None I-FUNC
, None None O
which None None O
may None None O
have None None O
implications None None O
for None None O
both None None O
healthy None None O
adults None None O
and None None O
subjects None None O
with None None O
low None None O
physical None None O
capacity None None O
. None None O

EOP None None O
significantly None None O
decreased None None O
the None None O
production None None O
of None None O
NO None None O
, None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
, None None O
cyclooxygenase None None O
and None None O
other None None O
proinflammatory None None O
cytokines None None O
, None None O
such None None O
as None None O
interleukin None None O
( None None O
IL None None O
) None None O
-6 None None O
, None None O
IL-1β None None O
and None None O
tumor None None O
necrosis None None O
factor-α None None O
, None None O
in None None O
LPS-stimulated None None O
BV-2 None None O
microglia None None O
. None None O

The None None O
CLSM None None O
images None None O
, None None O
which None None O
we None None O
believe None None O
are None None O
the None None O
first None None O
to None None O
be None None O
published None None O
, None None O
corroborate None None O
that None None O
more None None O
BG None None O
aggregates None None O
were None None O
entrapped None None O
in None None O
the None None O
matrix None None O
when None None O
the None None O
enzymes None None I-PROTEIN
were None None O
cross-linked None None O
by None None O
glutaraldehyde None None O
as None None O
opposed None None O
to None None O
when None None O
they None None O
are None None O
not None None O
cross-linked None None O
. None None O

Learning None None I-FUNC
outcomes None None O
and None None O
entry None None O
and None None O
exit None None O
criteria None None O
were None None O
defined None None O
for None None O
all None None O
subjects None None O
. None None O

Based None None O
on None None O
this None None O
finding None None O
, None None O
it None None O
may None None O
be None None O
necessary None None O
to None None O
include None None O
ambiguity None None I-FUNC
in None None O
handedness None None O
as None None O
a None None O
part None None O
of None None O
pedicle None None O
screw None None O
insertion None None O
training None None O
for None None O
spinal None None O
surgeons None None O
. None None O

Indeed None None O
, None None O
recent None None O
advances None None O
have None None O
provided None None O
a None None O
better None None O
understanding None None O
of None None O
different None None O
aspects None None O
of None None O
this None None O
prototypical None None O
family None None O
of None None O
receptors None None I-PROTEIN
: None None O
1 None None O
) None None O
elucidation None None O
of None None O
LPHN None None O
ectodomain None None O
organization None None O
by None None O
crystallography None None O
has None None O
unveiled None None O
a None None O
new None None O
functional None None O
domain None None O
with None None O
great None None O
repercussion None None O
on None None O
all None None O
the None None O
other None None O
members None None O
of None None O
the None None O
aGPCR None None O
family None None O
, None None O
2 None None O
) None None O
proteomic None None O
approaches None None O
have None None O
opened None None O
the None None O
gate None None O
to None None O
unsuspected None None O
functional None None O
characteristics None None O
of None None O
LPHN None None O
cellular None None O
role None None O
, None None O
and None None O
3 None None O
) None None O
genetic None None O
approaches None None O
have None None O
provided None None O
hints None None O
into None None O
the None None O
physiological None None O
functions None None O
of None None O
LPHN None None O
in None None O
specific None None O
systems None None O
and None None O
organisms None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
will None None O
provide None None O
a None None O
historical None None O
perspective None None O
addressing None None O
experimental None None O
research None None O
on None None O
these None None O
receptors None None I-PROTEIN
while None None O
highlighting None None O
the None None O
new None None O
advances None None O
and None None O
discoveries None None O
concerning None None O
LPHN None None O
functions None None O
. None None O

Peptides None None I-TRANS
and None None O
peptide-cargo None None O
complexes None None O
have None None O
been None None O
used None None O
for None None O
drug None None O
delivery None None O
and None None O
gene None None O
therapy None None O
. None None O

CtBP1 None None O
and None None O
CtBP2 None None O
are None None O
closely None None O
related None None O
and None None O
act None None O
as None None O
transcriptional None None O
corepressors None None O
when None None O
activated None None O
by None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
binding None None O
to None None O
their None None O
dehydrogenase None None I-PROTEIN
domains None None O
. None None O

In None None O
the None None O
multivariable None None O
linear None None O
regression None None O
analysis None None O
, None None O
the None None O
MD None None O
of None None O
the None None O
full-field None None O
IVF None None O
showed None None O
positive None None O
associations None None O
with None None O
near None None O
activities None None O
( None None O
β None None O
= None None O
0.05 None None O
; None None O
R2 None None O
= None None O
0.20 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
vision-specific None None O
role None None O
difficulties None None O
( None None O
β None None O
= None None O
0.04 None None O
; None None O
R2 None None O
= None None O
0.19 None None O
; None None O
P None None O
= None None O
.01 None None O
) None None O
, None None O
vision-specific None None O
dependency None None O
( None None O
β None None O
= None None O
0.04 None None O
; None None O
R2 None None O
= None None O
0.20 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
driving None None O
( None None O
β None None O
= None None O
0.05 None None O
; None None O
R2 None None O
= None None O
0.24 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
peripheral None None O
vision None None I-FUNC
( None None O
β None None O
= None None O
0.03 None None O
; None None O
R2 None None O
= None None O
0.18 None None O
; None None O
P None None O
= None None O
.02 None None O
) None None O
, None None O
and None None O
composite None None O
scores None None O
( None None O
β None None O
= None None O
0.04 None None O
; None None O
R2 None None O
= None None O
0.27 None None O
; None None O
P None None O
= None None O
.005 None None O
) None None O
. None None O

The None None O
knee None None O
's None None O
movement None None I-FUNC
from None None O
hyperextension None None O
to None None O
flexion None None O
during None None O
late None None O
stance None None O
meant None None O
the None None O
vertical None None O
push-off None None O
force None None O
that None None O
followed None None O
midstance None None O
was None None O
smaller None None O
than None None O
the None None O
earlier None None O
loading None None O
peak None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
resulting None None O
in None None O
a None None O
flattened None None O
profile None None O
. None None O

Extracellular None None O
purines None None O
, None None O
particularly None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
, None None O
have None None O
been None None O
implicated None None O
in None None O
the None None O
regulation None None O
of None None O
CSC None None O
formation None None O
, None None O
but None None O
currently None None O
, None None O
no None None O
data None None O
on None None O
the None None O
role None None O
of None None O
adenosine None None I-TRANS
and None None O
its None None O
receptors None None I-PROTEIN
in None None O
the None None O
biological None None O
processes None None O
of None None O
CSCs None None O
are None None O
available None None O
. None None O

The None None O
present None None O
study None None O
demonstrated None None O
that None None O
ATP None None I-PROTEIN
synthase None None I-PROTEIN
and None None O
electron None None O
transport None None O
chain None None O
complexes None None O
were None None O
ectopically None None O
expressed None None O
on None None O
the None None O
surface None None O
of None None O
breast None None O
cancer None None O
cells None None O
and None None O
could None None O
serve None None O
as None None O
a None None O
potent None None O
anticancer None None O
target None None O
. None None O

Time-lapse None None O
imaging None None O
revealed None None O
that None None O
TRPM2 None None O
deficiency None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
ischemia-induced None None O
increase None None O
in None None O
the None None O
[ None None O
Zn None None O
( None None O
2+ None None O
) None None O
] None None O
c None None O
but None None O
abolished None None O
the None None O
cytosolic None None O
Zn None None O
( None None O
2+ None None O
) None None O
accumulation None None O
during None None O
reperfusion None None O
as None None O
well None None O
as None None O
ROS-elicited None None O
increases None None O
in None None O
the None None O
[ None None O
Zn None None O
( None None O
2+ None None O
) None None O
] None None O
c. None None O
These None None O
results None None O
provide None None O
the None None O
first None None O
evidence None None O
to None None O
show None None O
a None None O
critical None None O
role None None O
for None None O
TRPM2 None None O
channel None None O
activation None None O
during None None O
reperfusion None None O
in None None O
the None None O
delayed None None O
increase None None O
in None None O
the None None O
[ None None O
Zn None None O
( None None O
2+ None None O
) None None O
] None None O
c None None O
and None None O
CA1 None None I-REGION
pyramidal None None O
neuronal None None O
death None None O
and None None O
identify None None O
TRPM2 None None O
as None None O
a None None O
key None None O
molecule None None O
signaling None None O
ROS None None O
generation None None O
to None None O
postischemic None None O
brain None None O
injury None None O
. None None O

A None None O
disintegrin None None O
and None None O
metalloproteinase None None O
10 None None O
( None None O
ADAM10 None None O
) None None O
is None None O
the None None O
major None None O
α-secretase None None O
that None None O
catalyzes None None O
the None None O
amyloid None None O
precursor None None O
protein None None O
( None None O
APP None None I-TRANS
) None None O
ectodomain None None O
shedding None None O
in None None O
the None None O
brain None None O
and None None O
prevents None None O
amyloid None None O
formation None None O
. None None O

These None None O
results None None O
help None None O
in None None O
understanding None None O
the None None O
mechanism None None O
responsible None None O
for None None O
the None None O
modulation None None O
of None None O
ADAM10 None None O
intracellular None None O
path None None O
, None None O
and None None O
can None None O
constitute None None O
an None None O
innovative None None O
therapeutic None None O
strategy None None O
to None None O
finely None None O
tune None None O
ADAM10 None None O
shedding None None O
activity None None O
towards None None O
APP None None I-TRANS
. None None O

To None None O
investigate None None O
insulin None None I-PROTEIN
release None None O
( None None O
β None None O
cell None None O
function None None O
) None None O
and None None O
glucose None None O
tolerance None None O
following None None O
a None None O
standardized None None O
oral None None O
glucose None None O
tolerance None None O
test None None O
( None None O
OGTT None None O
) None None O
across None None O
kidney None None O
function None None O
strata None None O
. None None O

After None None O
the None None O
OGTT None None O
challenge None None O
, None None O
however None None O
, None None O
β None None O
cell None None O
function None None O
indices None None O
( None None O
area None None O
under None None O
the None None O
curve None None O
for None None O
insulin None None I-PROTEIN
release None None O
, None None O
the None None O
estimated None None O
first None None O
phase None None O
insulin None None I-PROTEIN
release None None O
, None None O
and None None O
the None None O
insulinogenic None None O
index None None O
) None None O
were None None O
incrementally None None O
higher None None O
. None None O

Mixed None None O
models None None O
showed None None O
that None None O
dynamic None None O
insulin None None I-PROTEIN
release None None O
during None None O
the None None O
OGTT None None O
was None None O
inversely None None O
associated None None O
with None None O
kidney None None O
function None None O
, None None O
despite None None O
the None None O
correction None None O
for None None O
each None None O
individual None None O
's None None O
insulin None None I-PROTEIN
sensitivity None None O
or None None O
its None None O
risk None None O
factors None None O
. None None O

As None None O
a None None O
result None None O
, None None O
the None None O
net None None O
balance None None O
between None None O
insulin None None I-PROTEIN
sensitivity None None O
and None None O
β None None O
cell None None O
function None None O
was None None O
preserved None None O
. None None O

The None None O
HSET-Subtest None None O
`` None None O
Imitation None None O
grammatischer None None O
Strukturformen None None O
'' None None O
( None None O
measuring None None O
auditory None None O
short-term None None O
sentence None None O
memory None None I-FUNC
) None None O
exhibited None None O
comparable None None O
high None None O
discriminative None None O
power None None O
( None None O
AUC None None O
: None None O
0.94 None None O
; None None O
p=0.000 None None O
; None None O
95 None None O
% None None O
-CI None None O
: None None O
0.90-0.98 None None O
) None None O
. None None O

By None None O
considering None None O
their None None O
general None None O
development None None O
, None None O
2-year-old None None O
children None None O
with None None O
delayed None None O
speech None None I-FUNC
development None None O
( None None O
late None None O
-talkers None None O
, None None O
LT None None O
) None None O
were None None O
examined None None O
and None None O
described None None O
with None None O
respect None None O
to None None O
linguistic None None O
competence None None O
and None None O
hearing None None O
. None None O

In None None O
addition None None O
to None None O
audiological None None O
tests None None O
( None None O
impedance None None O
testing None None O
, None None O
otoacoustic None None O
emissions None None O
, None None O
reaction None None O
audiometry None None O
) None None O
, None None O
language None None I-FUNC
development None None O
status None None O
test None None O
was None None O
performed None None O
( None None O
clinical None None O
impression None None O
during None None O
examination None None O
, None None O
expressive None None O
vocabulary None None O
: None None O
FRAKIS None None O
, None None O
receptive None None O
competence None None O
: None None O
SETK-2 None None O
) None None O
. None None O

The None None O
clinical None None O
collective None None O
in None None O
this None None O
study None None O
showed None None O
severely None None O
affected None None O
children None None O
with None None O
a None None O
high None None O
percentage None None O
of None None O
other None None O
abnormalities None None O
and None None O
speech None None I-FUNC
perception None None I-FUNC
problems None None O
in None None O
many None None O
cases None None O
. None None O

LT None None O
with None None O
language None None I-FUNC
comprehension None None I-FUNC
problems None None O
require None None O
early None None O
developmental None None O
psychological None None O
investigation None None O
in None None O
order None None O
to None None O
prevent None None O
language None None I-FUNC
and None None O
general None None O
developmental None None O
limitations None None O
. None None O

M1 None None O
polarized None None O
microglia None None O
can None None O
produce None None O
pro-inflammatory None None O
cytokines None None O
, None None O
reactive None None O
oxygen None None O
species None None O
, None None O
and None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
suggesting None None O
that None None O
these None None O
molecules None None O
contribute None None O
to None None O
dysfunction None None O
of None None O
neural None None O
network None None O
in None None O
the None None O
CNS None None O
. None None O

However None None O
, None None O
some None None O
effects None None O
of None None O
NA None None I-TRANS
may None None O
be None None O
mediated None None O
through None None O
lipid-independent None None O
pathways None None O
. None None O

NA None None I-TRANS
exerts None None O
its None None O
anti-atherosclerotic None None O
or None None O
side None None O
effects None None O
via None None O
binding None None O
to None None O
GPR109A None None O
and None None O
receptor None None I-PROTEIN
TRPV1 None None O
. None None O

NA None None I-TRANS
participates None None O
in None None O
several None None O
cellular None None O
pathways None None O
, None None O
including None None O
forkhead None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
sirtuins None None O
, None None O
and None None O
protein None None O
kinase None None O
B None None O
. None None O

To None None O
reveal None None O
the None None O
mechanisms None None O
of None None O
excessive None None O
fatty None None O
deposition None None O
diseases None None O
, None None O
it None None O
is None None O
necessary None None O
to None None O
investigate None None O
the None None O
signaling None None O
pathways None None O
in None None O
the None None O
muscle None None O
, None None O
liver None None O
, None None O
and None None O
adipose None None O
tissue None None O
by None None O
which None None O
NA None None I-TRANS
controls None None O
lipid None None O
metabolism None None O
. None None O

Estrogens None None I-PROTEIN
along None None O
with None None O
their None None O
receptors None None I-PROTEIN
are None None O
required None None O
for None None O
the None None O
normal None None O
physiological None None O
development None None O
of None None O
women None None O
. None None O

Approximately None None O
in None None O
75 None None O
% None None O
of None None O
estrogen None None O
dependent None None O
breast None None O
cancer None None O
cases None None O
estrogen None None I-PROTEIN
receptors None None I-PROTEIN
( None None O
ERs None None O
) None None O
are None None O
held None None O
responsible None None O
. None None O

While None None O
a None None O
number None None O
of None None O
antiestrogen/anti-ER None None O
drugs None None O
including None None O
selective None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
modulators None None O
( None None O
SERMs None None O
) None None O
, None None O
aromatase None None I-PROTEIN
inhibitors None None O
( None None O
AIs None None O
) None None O
and None None O
selective None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
down None None O
regulators None None O
( None None O
SERDs None None O
) None None O
are None None O
used None None O
to None None O
eradicate None None O
breast None None O
cancer None None O
but None None O
their None None O
action None None O
on None None O
Fe None None O
dependent None None O
breast None None O
cancer None None O
complication None None O
is None None O
not None None O
yet None None O
explored None None O
. None None O

Some None None O
amine None None O
analogs None None O
of None None O
pyridazinones None None O
, None None O
pyridazinone- None None O
phenethylamines None None O
and None None O
4,5-fused None None O
pyridazinones None None O
showed None None O
histamine None None I-TRANS
H3R None None O
antagonist None None O
activity None None O
with None None O
significant None None O
affinity None None O
for None None O
rat None None O
and None None O
human None None O
H3R None None O
. None None O

These None None O
amyloid None None O
fibrils None None O
are None None O
associated None None O
with None None O
a None None O
number None None O
of None None O
pathologies None None O
, None None O
especially None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
which None None O
involves None None O
the None None O
aggregation None None O
of None None O
the None None O
Aβ None None O
peptide None None O
. None None O

The None None O
most None None O
important None None O
problems None None O
related None None O
to None None O
diabetes None None O
management None None O
, None None O
such None None O
as None None O
self-monitoring None None O
of None None O
blood None None O
glucose None None O
levels None None O
and None None O
insulin None None I-PROTEIN
injections None None O
, None None O
can None None O
now None None O
be None None O
conquered None None O
due None None O
to None None O
progress None None O
in None None O
nanomedicine None None O
, None None O
which None None O
offers None None O
glucose None None O
nanosensors None None O
, None None O
the None None O
layer-by-layer None None O
technique None None O
, None None O
carbon None None O
nanotubes None None O
, None None O
quantum None None O
dots None None O
, None None O
oral None None O
insulins None None I-PROTEIN
, None None O
microspheres None None O
, None None O
artificial None None O
pancreases None None O
and None None O
nanopumps None None O
. None None O

Fluconazole None None O
, None None O
itraconazole None None O
, None None O
and None None O
voriconazole None None O
were None None O
relatively None None O
less None None O
potent None None O
inhibitors None None O
of None None O
CYP3A5 None None O
than None None O
of None None O
CYP3A4 None None I-PROTEIN
. None None O

Nano-technological None None O
anti-epileptic None None O
drug None None O
( None None O
AED None None O
) None None O
delivery None None O
systems None None O
have None None O
recently None None O
garnered None None O
attention None None I-FUNC
due None None O
to None None O
their None None O
ability None None O
to None None O
cross None None O
the None None O
blood None None O
brain None None O
barrier None None O
, None None O
improved None None O
selectivity None None O
and None None O
potential None None O
for None None O
sustained None None O
drug None None O
delivery None None O
to None None O
the None None O
brain None None O
. None None O

Recently None None O
, None None O
hierarchical None None O
nanostructures None None O
have None None O
attracted None None O
increasing None None O
attention None None I-FUNC
because None None O
of None None O
their None None O
large None None O
specific None None O
surface None None O
area None None O
and None None O
abundant None None O
physical None None O
characteristics None None O
. None None O

Increasing None None O
the None None O
public-health None None O
attention None None I-FUNC
devoted None None O
to None None O
disability None None O
and None None O
identifying None None O
the None None O
factors None None O
associated None None O
with None None O
disability None None O
can None None O
promote None None O
independence None None O
and None None O
social None None O
participation None None O
in None None O
people None None O
with None None O
disabilities None None O
. None None O

Items None None O
assessed None None O
support None None O
for None None O
home None None O
and None None O
workplace None None O
bans None None O
for None None O
cigarettes None None O
and None None O
e-cigarettes None None O
and None None O
associated None None O
risk None None O
perceptions None None I-FUNC
. None None O

Complete None None O
e-cigarette None None O
bans None None O
were None None O
most None None O
strongly None None O
endorsed None None O
when None None O
perceptions None None I-FUNC
of None None O
addictiveness None None O
and None None O
health None None O
risks None None O
were None None O
high None None O
. None None O

The None None O
subacute None None O
use None None O
of None None O
corticosteroids None None O
has None None O
side-effects None None O
such None None O
as None None O
glucose None None O
intolerance None None O
, None None O
dyslipidemia None None O
, None None O
anxiety None None O
, None None O
and None None O
depression None None I-DISEASE
, None None O
which None None O
could None None O
be None None O
halted None None O
with None None O
vitamin None None O
D None None O
, None None O
which None None O
is None None O
an None None O
immunomodulatory None None O
vitamin None None O
. None None O

At None None O
the None None O
end None None O
of None None O
the None None O
therapy None None O
, None None O
the None None O
asthmatic None None O
parameters None None O
such None None O
as None None O
differential None None O
white None None O
blood None None O
cell None None O
counts None None O
, None None O
serum None None O
levels None None O
of None None O
immunoglobulin None None O
E None None O
, None None O
bronchoalveolar None None O
lavaged None None O
fluid None None O
, None None O
and None None O
interleukin-5 None None O
, None None O
as None None O
well None None O
as None None O
serum None None O
levels None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
were None None O
significantly None None O
increased None None O
after None None O
allergen None None O
challenges None None O
in None None O
asthmatic None None O
rats None None O
as None None O
compared None None O
with None None O
the None None O
controls None None O
. None None O

A None None O
commercially None None O
available None None O
assay None None O
for None None O
septin None None O
9 None None O
has None None O
been None None O
developed None None O
with None None O
moderate None None O
sensitivity None None O
( None None O
∼70 None None O
% None None O
) None None O
and None None O
specificity None None O
( None None O
∼90 None None O
% None None O
) None None O
and None None O
a None None O
second None None O
generation None None O
assay None None O
, None None O
Epi None None I-TRANS
proColon None None O
2.0 None None O
( None None O
Epigenomics None None O
AG None None O
) None None O
, None None O
shows None None O
increased None None O
sensitivity None None O
( None None O
∼92 None None O
% None None O
) None None O
. None None O

Materials None None O
with None None O
widely None None O
varying None None O
molecular None None O
topologies None None O
and None None O
exhibiting None None O
liquid None None O
crystalline None None O
properties None None O
have None None O
attracted None None O
considerable None None O
attention None None I-FUNC
in None None O
recent None None O
years None None O
. None None O

The None None O
strategy None None O
developed None None O
here None None O
can None None O
be None None O
extended None None O
to None None O
the None None O
study None None O
of None None O
a None None O
large None None O
variety None None O
of None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
peptidoglycan None None O
morphogenesis None None O
. None None O

This None None O
dismal None None O
outcome None None O
can None None O
partially None None O
be None None O
explained None None O
by None None O
the None None O
resistance None None O
to None None O
currently None None O
available None None O
chemotherapy None None O
regimens None None O
or None None O
the None None O
failure None None O
of None None O
most None None O
anticancer None None O
agents None None O
, None None O
which None None O
prompted None None O
the None None O
development None None O
of None None O
new None None O
and None None O
effective None None O
therapeutic-approaches None None O
, None None O
such None None O
as None None O
inhibitors None None O
of None None O
the None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
. None None O

Increasing None None O
evidence None None O
tends None None O
to None None O
hold None None O
that None None O
humoral None None O
and None None O
cellular None None O
immune None None O
responses None None O
are None None O
a None None O
key None None O
component None None O
of None None O
human None None O
atherosclerosis None None I-DISEASE
development None None O
. None None O

This None None O
review None None O
presents None None O
an None None O
overview None None O
of None None O
the None None O
most None None O
relevant None None O
auto-antibodies None None O
with None None O
regards None None O
to None None O
their None None O
respective None None O
cardiovascular None None O
prognostic None None O
value None None O
in None None O
acute None None O
coronary None None O
syndrome None None O
, None None O
stroke None None I-DISEASE
and None None O
other None None O
cardiomyopathies None None O
, None None O
and None None O
their None None O
potential None None O
pathophysiologic None None O
implication None None O
in None None O
atherogenesis None None O
. None None O

Deletions None None O
and None None O
duplications None None O
of None None O
the None None O
Williams-syndrome None None O
region None None O
have None None O
also None None O
been None None O
associated None None O
with None None O
autism None None O
, None None O
and None None O
with None None O
schizophrenia None None I-DISEASE
, None None O
two None None O
disorders None None O
centrally None None O
involving None None O
social None None I-FUNC
cognition None None I-FUNC
. None None O

Here None None O
we None None O
establish None None O
a None None O
screening None None O
assay None None O
and None None O
criteria None None O
to None None O
identify None None O
post-mortem None None O
brain None None O
samples None None O
containing None None O
well-preserved None None O
synapse None None O
proteomes None None O
, None None O
revealing None None O
that None None O
neocortex None None I-REGION
samples None None O
are None None O
best None None O
preserved None None O
. None None O

We None None O
perform None None O
the None None O
first None None O
purification None None O
and None None O
proteomic None None O
mass None None O
spectrometry None None O
analysis None None O
of None None O
MAGUK None None O
Associated None None O
Signalling None None O
Complexes None None O
( None None O
MASC None None O
) None None O
from None None O
neurosurgical None None O
and None None O
post-mortem None None O
tissue None None O
and None None O
find None None O
genetic None None O
evidence None None O
for None None O
their None None O
involvement None None O
in None None O
over None None O
seventy None None O
human None None O
brain None None I-DISEASE
diseases None None I-DISEASE
. None None O

MADS-box None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
are None None O
involved None None O
in None None O
many None None O
aspects None None O
of None None O
plant None None O
growth None None O
and None None O
development None None O
, None None O
such None None O
as None None O
floral None None O
organ None None O
determination None None O
, None None O
fruit None None O
ripening None None O
, None None O
and None None O
embryonic None None O
development None None O
. None None O

The None None O
accurate None None O
determination None None O
of None None O
the None None O
maximum None None O
turnover None None O
number None None O
and None None O
Michaelis None None O
constant None None O
for None None O
membrane None None O
enzymes None None I-PROTEIN
remains None None O
challenging None None O
. None None O

Social None None O
behavioural None None O
researchers None None O
advocate None None O
multi-pronged None None O
measures None None O
in None None O
similar None None O
situations None None O
: None None O
( None None O
i None None O
) None None O
abolish None None O
incentives None None O
that None None O
spawn None None O
self-serving None None O
bias None None O
; None None O
( None None O
ii None None O
) None None O
enforce None None O
severe None None O
deterrents None None O
for None None O
breaches None None O
of None None O
conduct None None O
; None None O
( None None O
iii None None O
) None None O
value None None O
integrity None None O
; None None O
( None None O
iv None None O
) None None O
strengthen None None O
self-awareness None None I-FUNC
; None None O
and None None O
( None None O
v None None O
) None None O
design None None O
curricula None None O
especially None None O
at None None O
the None None O
trainee None None O
level None None O
to None None O
promote None None O
awareness None None O
of None None O
consequences None None O
to None None O
society None None O
. None None O

© None None O
2014 None None O
The None None O
American None None O
Laryngological None None O
, None None O
Rhinological None None O
and None None O
Otological None None O
Society None None O
, None None O
Inc. None None O
To None None O
investigate None None O
the None None O
correlation None None O
between None None O
BRAF None None O
V600E None None O
mutation None None O
and None None O
anti-epidermal None None O
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
monoclonal None None O
antibodies None None O
( None None O
MoAbs None None O
) None None O
therapeutic None None O
effects None None O
in None None O
metastatic None None O
colorectal None None O
cancer None None O
. None None O

To None None O
evaluate None None O
the None None O
inhibitory None None O
effect None None O
of None None O
Gnaphalium None None O
affine None None O
extracts None None O
on None None O
xanthine None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
XO None None O
) None None O
activity None None O
in None None O
vitro None None O
and None None O
to None None O
analyze None None O
the None None O
mechanism None None O
of None None O
this None None O
effect None None O
. None None O

Utilization None None O
of None None O
the None None O
( None None O
23 None None O
) None None O
Na None None I-TRANS
MR None None O
imaging None None O
will None None O
make None None O
earlier None None O
detection None None O
of None None O
alterations None None O
to None None O
the None None O
patella None None O
cartilage None None O
after None None O
dislocation None None O
possible None None O
and None None O
will None None O
help None None O
prevent None None O
subsequent None None O
disease None None O
due None None O
to None None O
start None None O
adequate None None O
therapy None None O
earlier None None O
in None None O
the None None O
rehabilitation None None O
process None None O
. None None O

In None None O
addition None None O
, None None O
treatment None None O
with None None O
10 None None O
μM None None O
of None None O
RK None None O
also None None O
reduced None None O
mRNA None None O
levels None None O
of None None O
lipogenic None None O
genes None None O
such None None O
as None None O
acetyl-CoA None None I-PROTEIN
carboxylase-1 None None O
( None None O
ACC1 None None O
) None None O
, None None O
fatty None None O
acid None None O
synthase None None O
( None None O
FASN None None O
) None None O
, None None O
and None None O
stearoyl-CoA None None O
desaturase-1 None None O
( None None O
SCD1 None None O
) None None O
. None None O

Patients None None O
with None None O
complete None None O
KD None None O
had None None O
more None None O
frequently None None O
rash None None O
, None None O
changes None None O
on None None O
extremities None None O
and None None O
mucous None None O
membranes None None O
, None None O
as None None O
well None None O
as None None O
higher None None O
serum None None O
bilirubin None None O
, None None O
aminotransferases None None O
, None None O
gamma-glutamyl None None O
transferase None None I-PROTEIN
and None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
levels None None O
. None None O

The None None O
mean None None O
drag None None O
force None None O
was None None O
greater None None O
than None None O
the None None O
mean None None O
lift None None O
force None None O
in None None O
the None None O
middle None None O
part None None O
, None None O
while None None O
the None None O
mean None None O
lift None None O
force None None O
was None None O
greater None None O
than None None O
the None None O
mean None None O
drag None None O
force None None O
in None None O
the None None O
final None None O
part None None O
of None None O
the None None O
underwater None None O
arm None None O
stroke None None I-DISEASE
. None None O

The None None O
cells None None O
were None None O
divided None None O
into None None O
quick None None O
adherent None None O
cells None None O
and None None O
non-quick None None O
adherent None None O
cells None None O
by None None O
type None None O
IV None None O
collagen None None I-PROTEIN
differential None None O
adherent None None O
method None None O
. None None O

The None None O
expression None None O
of None None O
CD29 None None O
, None None O
keratin None None I-PROTEIN
19 None None O
, None None O
keratin None None I-PROTEIN
1 None None O
, None None O
and None None O
keratin None None I-PROTEIN
10 None None O
was None None O
identified None None O
by None None O
immunocytochemical None None O
staining None None O
. None None O

Quick None None O
adherent None None O
cells None None O
showed None None O
positive None None O
expression None None O
of None None O
CD29 None None O
and None None O
keratin None None I-PROTEIN
19 None None O
, None None O
while None None O
non-quick None None O
adherent None None O
cells None None O
showed None None O
positive None None O
expression None None O
of None None O
keratin None None I-PROTEIN
1 None None O
and None None O
keratin None None I-PROTEIN
10 None None O
. None None O

In None None O
recent None None O
years None None O
, None None O
studies None None O
have None None O
revealed None None O
that None None O
besides None None O
metabolism None None O
regulation None None O
, None None O
insulin None None I-PROTEIN
can None None O
also None None O
act None None O
as None None O
a None None O
growth None None O
factor None None O
like None None O
hormone None None O
in None None O
regulating None None O
multiple None None O
processes None None O
and None None O
various None None O
cellular None None O
activities None None O
in None None O
the None None O
process None None O
of None None O
wound None None O
healing None None O
. None None O

Since None None O
both None None O
patients None None O
and None None O
partners None None O
are None None O
affected None None O
by None None O
the None None O
patients None None O
' None None O
disease None None O
and None None O
treatment None None O
, None None O
we None None O
recommend None None O
that None None O
attention None None I-FUNC
is None None O
paid None None O
to None None O
the None None O
couple None None O
instead None None O
of None None O
solely None None O
the None None O
patient None None O
. None None O

CD44-positive None None O
status None None O
was None None O
significantly None None O
correlated None None O
with None None O
human None None O
epidermal None None O
growth None None O
receptor None None I-PROTEIN
2 None None O
( None None O
HER2 None None O
) None None O
-negative None None O
( None None O
p None None O
= None None O
0.023 None None O
) None None O
, None None O
estrogen None None I-PROTEIN
receptor-negative None None O
( None None O
p None None O
= None None O
0.021 None None O
) None None O
, None None O
and None None O
progesterone None None O
receptor-negative None None O
status None None O
( None None O
p None None O
= None None O
0.004 None None O
) None None O
. None None O

As None None O
the None None O
newest None None O
identified None None O
member None None O
of None None O
the None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
( None None O
MMP None None O
) None None O
family None None O
, None None O
the None None O
expression None None O
pattern None None O
and None None O
function None None O
of None None O
epilysin None None O
( None None O
MMP-28 None None O
) None None O
are None None O
still None None O
not None None O
well None None O
understood None None O
. None None O

Six None None O
opsins None None I-PROTEIN
were None None O
included None None O
in None None O
the None None O
rhabdomeric None None O
opsin None None O
group None None O
( None None O
r-opsins None None O
) None None O
. None None O

Other None None O
non-visual None None O
opsin None None O
types None None O
could None None O
participate None None O
to None None O
the None None O
light None None O
perception None None I-FUNC
process None None O
indicating None None O
a None None O
complex None None O
expression None None O
pattern None None O
of None None O
opsins None None I-PROTEIN
in None None O
this None None O
infaunal None None O
brittle None None O
star None None O
. None None O

We None None O
offer None None O
lessons None None O
learnt None None O
and None None O
recommendations None None O
relating None None O
to None None O
( None None O
i None None O
) None None O
modifications None None O
to None None O
the None None O
interview None None O
guide None None O
; None None O
( None None O
ii None None O
) None None O
key None None O
informant None None O
identification None None O
; None None O
( None None O
iii None None O
) None None O
conducting None None O
interviews None None O
to None None O
theoretical None None O
saturation None None O
; None None O
( None None O
iv None None O
) None None O
using None None O
key None None O
informants None None O
to None None O
define None None O
their None None O
community None None O
; None None O
( None None O
v None None O
) None None O
key None None O
informant None None O
's None None O
ability None None O
to None None O
respond None None O
on None None O
behalf None None O
of None None O
the None None O
community None None O
; None None O
( None None O
vi None None I-REGION
) None None O
using None None O
a None None O
qualitative None None O
model None None O
with None None O
a None None O
quantitative None None O
scoring None None O
system None None O
; None None O
and None None O
( None None O
vii None None O
) None None O
the None None O
optimum None None O
application None None O
of None None O
transcript None None O
scoring None None O
. None None O

The None None O
sinonasal None None O
outcome None None O
test-22 None None O
( None None O
SNOT-22 None None O
) None None O
scores None None O
and None None O
immunological None None O
parameters None None O
in None None O
the None None O
specimens None None O
were None None O
analysed None None O
using None None O
a None None O
novel None None O
, None None O
unsupervised None None O
learning None None I-FUNC
method None None O
and None None O
by None None O
conventional None None O
univariate None None O
analysis None None O
. None None O

Growth None None I-PROTEIN
factors None None I-PROTEIN
VEGF None None O
and None None O
GM-CSF None None O
may None None O
be None None O
involved None None O
in None None O
the None None O
immunopathogenesis None None O
of None None O
subjects None None O
with None None O
CRS None None O
and None None O
nasal None None O
polyps None None O
experiencing None None O
exacerbation None None O
. None None O

Peer None None O
reviewed None None O
publications None None O
in None None O
English None None O
language None None I-FUNC
meeting None None O
the None None O
inclusion None None O
criteria None None O
are None None O
eligible None None O
. None None O

Mutations None None O
in None None O
the None None O
RLBP1 None None O
gene None None O
encoding None None I-FUNC
the None None O
cellular None None O
retinaldehyde-binding None None O
protein None None O
( None None O
CRALBP None None O
) None None O
cause None None O
autosomal None None O
recessive None None O
progressive None None O
retinopathy None None O
, None None O
such None None O
as None None O
retinitis None None O
punctata None None O
albescens None None O
( None None O
RPA None None O
) None None O
, None None O
Bothnia-type None None O
dystrophy None None O
( None None O
BD None None O
) None None O
, None None O
Newfoundland None None O
rod-cone None None O
dystrophy None None O
( None None O
NFRCD None None O
) None None O
, None None O
retinitis None None O
pigmentosa None None O
( None None O
RP None None O
) None None O
and None None O
fundus None None O
albipunctatus None None O
( None None O
FA None None O
) None None O
. None None O

Seven None None O
patients None None O
underwent None None O
complete None None O
ophthalmological None None O
examination None None O
including None None O
psychophysical None None O
tests None None O
( None None O
visual None None O
acuity None None O
, None None O
colour None None O
vision None None I-FUNC
, None None O
visual None None O
field None None O
, None None O
dark None None O
adaptation None None O
) None None O
and None None O
electrophysiology None None O
( None None O
Ganzfeld None None O
and None None O
multifocal None None O
ERG None None O
) None None O
. None None O

A None None O
total None None O
of None None O
115 None None O
Chinese None None O
CHB None None O
patients None None O
with None None O
suboptimal None None O
response None None O
to None None O
two None None O
or None None O
more None None O
NA None None I-TRANS
treatments None None O
were None None O
included None None O
in None None O
this None None O
study None None O
. None None O

Alanine None None I-TRANS
aminotransferase None None O
normalization None None O
and None None O
hepatitis None None O
B None None O
e-antigen None None O
seroclearance None None O
occurred None None O
in None None O
77.3 None None O
% None None O
and None None O
23.2 None None O
% None None O
, None None O
respectively None None O
, None None O
after None None O
72-week None None O
TDF None None O
treatment None None O
. None None O

These None None O
consequences None None O
may None None O
be None None O
underappreciated None None O
; None None O
however None None O
, None None O
endothelial None None O
cells None None O
play None None O
a None None O
central None None O
role None None O
in None None O
maintaining None None O
vascular None None O
homeostasis None None O
via None None O
nitric None None I-TRANS
oxide None None I-TRANS
production None None O
. None None O

Nanomedicine None None O
, None None O
in None None O
particular None None O
, None None O
offers None None O
great None None O
potential None None O
in None None O
the None None O
form None None O
of None None O
targeted None None O
drug None None O
delivery None None O
, None None O
via None None O
functionalized None None O
coatings None None O
or None None O
nanocarriers None None O
, None None O
aimed None None O
at None None O
increased None None O
nitric None None I-TRANS
oxide None None I-TRANS
bioavailability None None O
or None None O
reduced None None O
inflammation None None O
. None None O

Special None None O
attention None None I-FUNC
is None None O
paid None None O
on None None O
how None None O
the None None O
presence None None O
of None None O
an None None O
interlayer None None O
of None None O
biomolecules None None O
and None None O
bioreceptors None None O
underneath None None O
the None None O
OSC None None O
impacts None None O
on None None O
the None None O
charge None None O
transport None None O
and None None O
sensing None None O
performance None None O
of None None O
the None None O
device None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
activity None None O
of None None O
two None None O
lysosomal None None O
marker None None O
enzymes None None I-PROTEIN
( None None O
acid None None O
phosphatase None None I-PROTEIN
and None None O
arylsulfatase None None O
) None None O
was None None O
detected None None O
using None None O
cytochemical None None O
experiments None None O
coupled None None O
with None None O
energy-dispersive None None O
X-ray None None O
transmission None None O
electron None None O
microscopy None None O
during None None O
sulfide None None O
and None None O
organic None None O
particle None None O
starvation None None O
. None None O

Surgery None None O
for None None O
CMVR-related None None O
RD None None O
is None None O
associated None None O
with None None O
good None None O
anatomical None None O
outcomes None None O
with None None O
most None None O
eyes None None O
maintaining None None O
or None None O
having None None O
improved None None O
vision None None I-FUNC
. None None O

However None None O
, None None O
it None None O
was None None O
not None None O
until None None O
1921 None None O
that None None O
insulin None None I-PROTEIN
was None None O
purified None None O
, None None O
which None None O
was None None O
used None None O
to None None O
treat None None O
diabetes None None O
in None None O
1922 None None O
. None None O

Since None None O
then None None O
, None None O
increasing None None O
knowledge None None O
were None None O
found None None O
in None None O
insulin None None I-PROTEIN
, None None O
thus None None O
arousing None None O
a None None O
rapid None None O
development None None O
of None None O
its None None O
synthesis None None O
. None None O

Due None None O
to None None O
the None None O
presence None None O
of None None O
immunogenicity None None O
in None None O
animal None None O
insulin None None I-PROTEIN
, None None O
Novo None None O
Nordisk None None O
used None None O
recombinant None None O
DNA None None O
technology None None O
to None None O
synthesize None None O
human None None O
insulin None None I-PROTEIN
and None None O
for None None O
clinical None None O
use None None O
in None None O
1980s None None O
. None None O

Meanwhile None None O
, None None O
insulin None None I-PROTEIN
injections None None O
have None None O
also None None O
been None None O
changed None None O
from None None O
the None None O
ordinary None None O
syringes None None O
to None None O
dedicated None None O
insulin None None I-PROTEIN
syringes None None O
, None None O
from None None O
the None None O
insulin None None I-PROTEIN
pens None None O
to None None O
the None None O
insulin None None I-PROTEIN
pumps None None O
, None None O
and None None O
eventually None None O
to None None O
the None None O
most None None O
advanced None None O
needleless None None O
syringes None None O
. None None O

Both None None O
the None None O
live None None O
pathogen None None O
and None None O
pathogen None None O
fragments None None O
significantly None None O
increased None None O
PPO None None O
, None None O
chitinase None None I-PROTEIN
and None None O
β-1,3-glucanase None None O
activity None None O
in None None O
the None None O
leaves None None O
, None None O
but None None O
only None None O
PPO None None O
activity None None O
was None None O
increased None None O
in None None O
roots None None O
. None None O

In None None O
2008 None None O
and None None O
2013 None None O
, None None O
RFA None None O
was None None O
applied None None O
under None None O
ultrasonographic None None O
guidance None None O
to None None O
two None None O
desmoid None None O
tumours None None O
localized None None O
in None None O
the None None O
dorsal None None I-NEURON
thoracic None None O
wall None None O
. None None O

Anxiety None None O
is None None O
a None None O
common None None O
psychological None None O
disorder None None O
, None None O
often None None O
occurring None None O
in None None O
combination None None O
with None None O
depression None None I-DISEASE
, None None O
but None None O
therapeutic None None O
drugs None None O
with None None O
high None None O
efficacy None None O
and None None O
safety None None O
are None None O
lacking None None O
. None None O

Differences None None O
in None None O
the None None O
size None None O
and None None O
shape None None O
of None None O
anal None None O
and None None O
dorsal None None I-NEURON
fins None None O
were None None O
sex-specific None None O
and None None O
not None None O
related None None O
to None None O
habitat None None O
differences None None O
. None None O

pointedness None None O
) None None O
of None None O
the None None O
dorsal None None I-NEURON
and None None O
anal None None O
fins None None O
is None None O
tightly None None O
correlated None None O
suggesting None None O
that None None O
fins None None O
follow None None O
a None None O
similar None None O
growth None None O
trajectory None None O
as None None O
individuals None None O
become None None O
sexually None None O
mature None None O
. None None O

Efforts None None O
are None None O
underway None None O
to None None O
produce None None O
antimicrobial None None O
peptides None None I-TRANS
in None None O
yellow None None O
mealworms None None O
( None None O
Tenebrio None None O
molitor None None O
) None None O
, None None O
which None None O
can None None O
be None None O
developed None None O
as None None O
more None None O
effective None None O
and None None O
safer None None O
animal None None O
feed None None O
additives None None O
. None None O

While None None O
CNTs-based None None O
products None None O
are None None O
already None None O
being None None O
used None None O
in None None O
textiles None None O
, None None O
polymer None None O
matrices None None O
to None None O
strengthen None None O
materials None None O
, None None O
sports None None O
articles None None O
, None None O
microelectronics None None O
, None None O
energy None None O
storage None None I-FUNC
, None None O
etc. None None O
, None None O
medicinal None None O
products None None O
and None None O
medical None None O
devices None None O
for None None O
in None None O
vivo None None O
application None None O
based None None O
on None None O
CNTs None None O
have None None O
not None None O
been None None O
commercialized None None O
yet None None O
. None None O

Tolvaptan None None O
, None None O
an None None O
oral None None O
arginine None None I-TRANS
vasopressin None None I-TRANS
V2 None None O
receptor None None I-PROTEIN
antagonist None None O
, None None O
became None None O
available None None O
for None None O
hepatic None None O
ascites None None O
. None None O

Tolvaptan None None O
safely None None O
alleviated None None O
fluid None None O
retention None None I-FUNC
caused None None O
by None None O
hepatic None None O
cirrhosis None None O
. None None O

Advantages None None O
include None None O
commercial None None O
availability None None O
and None None O
shelf None None O
storage None None I-FUNC
. None None O

The None None O
photoactive None None O
function None None O
in None None O
opsins None None I-PROTEIN
is None None O
triggered None None O
by None None O
the None None O
ultrafast None None O
isomerization None None O
of None None O
the None None O
retinal None None O
chromophore None None O
around None None O
a None None O
specific None None O
carbon None None O
double None None O
bond None None O
, None None O
leading None None O
to None None O
a None None O
highly None None O
distorted None None O
, None None O
spectrally None None O
red-shifted None None O
photoproduct None None O
. None None O

This None None O
paper None None O
focuses None None O
on None None O
the None None O
ultrafast None None O
11-cis None None O
to None None O
all-trans None None O
isomerization None None O
in None None O
visual None None O
rhodopsins None None I-PROTEIN
, None None O
and None None O
has None None O
a None None O
twofold None None O
goal None None O
: None None O
( None None O
i None None O
) None None O
to None None O
review None None O
the None None O
most None None O
recent None None O
experimental None None O
and None None O
computational None None O
efforts None None O
aimed None None O
at None None O
exposing None None O
the None None O
very None None O
early None None O
phases None None O
of None None O
photoconversion None None O
; None None O
and None None O
( None None O
ii None None O
) None None O
discuss None None O
future None None O
advanced None None O
experiments None None O
and None None O
calculations None None O
that None None O
will None None O
allow None None O
an None None O
even None None O
deeper None None O
understanding None None O
of None None O
the None None O
process None None O
. None None O

Their None None O
functional None None O
role None None O
in None None O
the None None O
activity None None O
of None None O
human None None O
basal None None I-REGION
ganglia None None I-REGION
( None None O
BG None None O
) None None O
is None None O
not None None O
well None None O
known None None O
. None None O

After None None O
the None None O
`` None None O
regression None None O
'' None None O
of None None O
intralaminar None None O
nuclei None None O
activity None None O
( None None O
partial None None O
correlation None None O
) None None O
, None None O
the None None O
functional None None O
connectivity None None O
of None None O
the None None O
caudate None None O
and None None O
putamen None None I-REGION
nuclei None None O
with None None O
other None None O
BG None None O
decreased None None O
( None None O
but None None O
not None None O
with None None O
the None None O
primary None None O
sensorimotor None None O
cortex None None O
) None None O
. None None O

In None None O
this None None O
letter None None O
, None None O
a None None O
remedy None None O
is None None O
proposed None None O
to None None O
this None None O
problem None None O
, None None O
termed None None O
the None None O
slow None None O
growth None None O
memory None None I-FUNC
guessing None None O
( None None O
SGMG None None O
) None None O
approach None None O
. None None O

Endogenous None None O
peptides None None I-TRANS
are None None O
often None None O
functional None None O
within None None O
the None None O
body-and None None O
can None None O
be None None O
both None None O
beneficial None None O
and None None O
detrimental None None O
. None None O

In None None O
this None None O
paper None None O
we None None O
report None None O
on None None O
the None None O
neutral-neutral None None O
reaction None None O
of None None O
the None None O
C3 None None O
carbon None None O
cluster None None O
with None None O
H2S None None I-TRANS
in None None O
solid None None O
inert None None O
argon None None O
at None None O
12 None None O
K None None O
, None None O
conditions None None O
that None None O
mimic None None O
, None None O
in None None O
part None None O
, None None O
the None None O
surfaces None None O
of None None O
interstellar None None O
grains None None O
. None None O

This None None O
complex None None O
, None None O
stabilized None None O
by None None O
an None None O
estimated None None O
7.45 None None O
kJ/mol None None O
( None None O
CCSD None None O
( None None O
T None None O
) None None O
/aug-cc-pVTZ//B3LYP/6-311++G None None O
( None None O
d None None O
, None None O
p None None O
) None None O
level None None O
) None None O
, None None O
is None None O
formed None None O
by None None O
the None None O
interaction None None O
of None None O
a None None O
terminal None None O
carbon None None O
of None None O
C3 None None O
with None None O
a None None O
hydrogen None None O
in None None O
H2S None None I-TRANS
. None None O

The None None O
lipid None None O
phosphatase None None I-PROTEIN
activity None None O
of None None O
the None None O
tumor None None O
suppressor None None O
phosphatase None None I-PROTEIN
and None None O
tensin None None O
homolog None None O
( None None O
PTEN None None O
) None None O
is None None O
enhanced None None O
by None None O
the None None O
presence None None O
of None None O
its None None O
biological None None O
product None None O
, None None O
phosphatidylinositol None None O
4,5-bisphosphate None None O
( None None O
PI None None O
( None None O
4,5 None None O
) None None O
P2 None None O
) None None O
. None None O

The None None O
stress-sensitive None None O
restriction-modification None None O
( None None O
RM None None O
) None None O
system None None O
CglI None None O
from None None O
Corynebacterium None None O
glutamicum None None O
and None None O
the None None O
homologous None None O
NgoAVII None None O
RM None None O
system None None O
from None None O
Neisseria None None O
gonorrhoeae None None O
FA1090 None None O
are None None O
composed None None O
of None None O
three None None O
genes None None O
: None None O
a None None O
DNA None None I-PROTEIN
methyltransferase None None I-PROTEIN
( None None O
M.CglI None None O
and None None O
M.NgoAVII None None O
) None None O
, None None O
a None None O
putative None None O
restriction None None O
endonuclease None None I-PROTEIN
( None None O
R.CglI None None O
and None None O
R.NgoAVII None None O
, None None O
or None None O
R-proteins None None O
) None None O
and None None O
a None None O
predicted None None O
DEAD-family None None O
helicase/ATPase None None O
( None None O
N.CglI None None O
and None None O
N.NgoAVII None None O
or None None O
N-proteins None None O
) None None O
. None None O

Next None None O
, None None O
we None None O
show None None O
that None None O
N-proteins None None O
have None None O
ATPase None None I-PROTEIN
activity None None O
that None None O
is None None O
dependent None None O
on None None O
double-stranded None None O
DNA None None O
and None None O
is None None O
stimulated None None O
by None None O
the None None O
R-proteins None None O
. None None O

Structural None None O
comparison None None O
of None None O
the None None O
B3-like None None O
domains None None O
of None None O
R.NgoAVII None None O
, None None O
EcoRII None None O
, None None O
BfiI None None O
and None None O
the None None O
plant None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
revealed None None O
a None None O
conserved None None O
DNA-binding None None O
surface None None O
comprised None None O
of None None O
N- None None O
and None None O
C-arms None None O
that None None O
together None None O
grip None None O
the None None O
DNA None None O
. None None O

Of None None O
52 None None O
patients None None O
, None None O
NAS None None I-TRANS
was None None O
ameliorated None None O
in None None O
30.8 None None O
% None None O
, None None O
deteriorated None None O
in None None O
30.8 None None O
% None None O
and None None O
remained None None O
unchanged None None O
in None None O
38.4 None None O
% None None O
. None None O

Multivariate None None O
analysis None None O
identified None None O
ALT None None O
non-response None None O
as None None O
a None None O
predictor None None O
of None None O
deterioration None None O
of None None O
NAS None None I-TRANS
( None None O
hazard None None O
ratio None None O
[ None None O
HR None None O
] None None O
, None None O
5.85 None None O
; None None O
P None None O
= None None O
0.031 None None O
) None None O
and None None O
progression None None O
of None None O
liver None None O
fibrosis None None O
( None None O
HR None None O
, None None O
4.50 None None O
; None None O
P None None O
= None None O
0.029 None None O
) None None O
. None None O

In None None O
silico None None O
study None None O
identified None None O
compounds None None O
1 None None O
and None None O
2 None None O
as None None O
potential None None O
inhibitors None None O
of None None O
tyrosinase None None I-PROTEIN
correlating None None O
with None None O
the None None O
observed None None O
antioxidant None None O
activity None None O
in None None O
vitro None None O
. None None O

Testosterone None None O
is None None O
positively None None O
associated None None O
with None None O
short- None None O
and None None O
long-term None None O
verbal None None O
memory None None I-FUNC
( None None O
β None None O
= None None O
0.267 None None O
, None None O
P None None O
= None None O
0.018 None None O
; None None O
β None None O
= None None O
0.326 None None O
, None None O
P None None O
= None None O
0.005 None None O
respectively None None O
) None None O
and None None O
visual None None O
scanning None None O
( None None O
β None None O
= None None O
0.306 None None O
, None None O
P None None O
= None None O
0.008 None None O
) None None O
after None None O
controlling None None O
for None None O
potential None None O
confounders None None O
. None None O

Soil None None O
treated None None O
with None None O
increasing None None O
amendment None None O
doses None None O
( None None O
0 None None O
, None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
5 None None O
% None None O
) None None O
were None None O
analyzed None None O
for None None O
soil None None O
microbiological None None O
parameters None None O
such None None O
as None None O
basal None None O
soil None None O
respiration None None O
and None None O
dehydrogenase None None I-PROTEIN
, None None O
β-glucosidase None None O
, None None O
urease None None I-PROTEIN
, None None O
acid None None O
and None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
, None None O
and None None O
arylsulfatase None None O
activities None None O
. None None O

The None None O
adhesion None None O
inhibition None None O
was None None O
mediated None None O
by None None O
intracellular None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
induction None None O
. None None O

The None None O
phage-displayed None None O
peptide None None O
library None None O
was None None O
used None None O
to None None O
isolate None None O
the None None O
peptides None None I-TRANS
binding None None O
and None None O
internalizing None None O
into None None O
the None None O
HO8910PM None None O
cells None None O
. None None O

The None None O
expression None None O
and None None O
distribution None None O
of None None O
EZH2 None None O
and None None O
p53 None None I-PROTEIN
were None None O
determined None None O
with None None O
reference None None O
to None None O
clinicopathological None None O
features None None O
and None None O
patient None None O
survival None None O
. None None O

In None None O
the None None O
168 None None O
SCC None None O
cases None None O
, None None O
the None None O
positive None None O
rate None None O
of None None O
EZH2 None None O
in None None O
the None None O
cases None None O
with None None O
lymph None None O
node None None O
metastasis None None O
was None None O
82.9 None None O
% None None O
, None None O
and None None O
that None None O
of None None O
p53 None None I-PROTEIN
was None None O
45.7 None None O
% None None O
; None None O
the None None O
positive None None O
rate None None O
of None None O
EZH2/p53 None None O
protein None None O
expression None None O
in None None O
the None None O
cases None None O
with None None O
negative None None O
lymph None None O
nodes None None O
was None None O
70.4 None None O
% None None O
, None None O
and None None O
that None None O
of None None O
p53 None None I-PROTEIN
was None None O
34.7 None None O
% None None O
, None None O
with None None O
a None None O
significant None None O
difference None None O
between None None O
the None None O
two None None O
subgroups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
overall None None O
survival None None O
times None None O
of None None O
EZH2 None None O
( None None O
- None None O
) None None O
p53 None None I-PROTEIN
( None None O
- None None O
) None None O
, None None O
EZH2 None None O
( None None O
+ None None O
) None None O
or None None O
p53 None None I-PROTEIN
( None None O
+ None None O
) None None O
, None None O
and None None O
EZH None None O
( None None O
2+ None None O
) None None O
p53 None None I-PROTEIN
( None None O
+ None None O
) None None O
cases None None O
were None None O
( None None O
72.9 None None O
± None None O
1.1 None None O
) None None O
, None None O
( None None O
68.6 None None O
± None None O
1.8 None None O
) None None O
, None None O
and None None O
( None None O
57.4 None None O
± None None O
3.4 None None O
) None None O
months None None O
, None None O
respectively None None O
, None None O
with None None O
a None None O
significant None None O
difference None None O
among None None O
the None None O
three None None O
subgroups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Both None None O
EZH2 None None O
and None None O
p53 None None I-PROTEIN
proteins None None O
may None None O
play None None O
important None None O
roles None None O
in None None O
the None None O
occurrence None None O
and None None O
development None None O
of None None O
cervical None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Toll-like None None O
receptors None None I-PROTEIN
( None None O
TLRs None None O
) None None O
play None None O
critical None None O
roles None None O
in None None O
the None None O
activation None None O
of None None O
innate None None O
and None None O
adaptive None None O
immune None None O
responses None None O
. None None O

LP None None O
guppies None None O
had None None O
increased None None O
somatic None None O
phosphorus None None O
at None None O
the None None O
end None None O
of None None O
the None None O
experiment None None O
, None None O
possibly None None O
related None None O
to None None O
the None None O
higher None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
in None None O
their None None O
guts None None O
. None None O

Processing None None O
workflows None None O
, None None O
including None None O
complete None None O
proprietary None None O
frameworks None None O
or None None O
combinations None None O
of None None O
modules None None O
from None None O
different None None O
open None None O
source None None O
data None None O
processing None None O
packages None None O
are None None O
described None None O
and None None O
compared None None O
in None None O
terms None None O
of None None O
software None None O
availability None None O
and None None O
usability None None O
, None None O
programming None None O
language None None I-FUNC
, None None O
operating None None O
system None None O
support None None O
, None None O
input/output None None O
data None None O
formats None None O
, None None O
as None None O
well None None O
as None None O
the None None O
main None None O
principles None None O
employed None None O
in None None O
the None None O
algorithms None None O
used None None O
for None None O
identification None None O
and None None O
quantification None None O
. None None O

The None None O
most None None O
common None None O
metal None None O
ion None None O
tags None None O
are None None O
relatively None None O
long None None O
aliphatic None None O
chains None None O
attached None None O
to None None O
the None None O
side None None O
chain None None O
of None None O
a None None O
selected None None O
cysteine None None I-TRANS
residue None None O
with None None O
a None None O
chelating None None O
group None None O
at None None O
the None None O
end None None O
where None None O
it None None O
can None None O
undergo None None O
substantial None None O
internal None None O
motions None None O
, None None O
decreasing None None O
the None None O
accuracy None None O
of None None O
the None None O
method None None O
. None None O

Thus None None O
, None None O
we None None O
developed None None O
a None None O
robust None None O
and None None O
cost-effective None None O
enzymatic None None O
synthesis None None O
of None None O
the None None O
isoleucine None None I-TRANS
precursor None None O
, None None O
2-hydroxy-2- None None O
( None None O
1'- None None O
[ None None O
( None None O
2 None None O
) None None O
H2 None None O
] None None O
, None None O
2'- None None O
[ None None O
( None None O
13 None None O
) None None O
C None None O
] None None O
) None None O
ethyl-3-keto-4- None None O
[ None None O
( None None O
2 None None O
) None None O
H3 None None O
] None None O
butanoic None None O
acid None None O
, None None O
as None None O
well None None O
as None None O
an None None O
incorporation None None O
protocol None None O
that None None O
eliminates None None O
metabolic None None O
leakage None None O
. None None O

Health None None O
profession None None O
educators None None O
have None None O
identified None None O
auscultation None None O
skill None None O
as None None O
a None None O
learning None None I-FUNC
need None None O
for None None O
health None None O
professional None None O
students None None O
. None None O

Both None None O
psychological None None O
distress None None O
and None None O
low None None O
peer None None O
social None None O
support None None O
were None None O
negatively None None O
associated None None O
with None None O
poor None None O
academic None None O
self-perception None None O
, None None O
adjusted None None O
for None None O
local None None O
language None None I-FUNC
proficiency None None O
and None None O
social None None O
support None None O
from None None O
family None None O
. None None O

Mouse None None O
photoreceptor-derived None None O
661 None None O
W None None I-NEURON
cells None None I-NEURON
were None None O
treated None None O
with None None O
the None None O
AT1R None None O
blockers None None O
valsartan None None O
, None None O
losartan None None O
and None None O
candesartan None None O
before None None O
exposure None None O
to None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
. None None O

Pre-treatment None None O
of None None O
661 None None O
W None None I-NEURON
cells None None I-NEURON
with None None O
AT1R None None O
blockers None None O
significantly None None O
decreased None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
-mediated None None O
toxicity None None O
and None None O
reduced None None O
the None None O
ROS None None O
level None None O
. None None O

© None None O
2014 None None O
Wiley None None O
Periodicals None None O
, None None O
Inc. None None O
Nintedanib None None O
( None None O
Ofev None None O
( None None O
® None None O
) None None O
) None None O
is None None O
an None None O
orally None None O
available None None O
, None None O
small None None O
, None None O
multiple None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
developed None None O
by None None O
Boehringer None None O
Ingelheim None None O
for None None O
the None None O
treatment None None O
of None None O
idiopathic None None O
pulmonary None None O
fibrosis None None O
( None None O
IPF None None O
) None None O
and None None O
cancer None None O
. None None O

Journal None None O
of None None O
Advanced None None O
Nursing None None O
published None None O
by None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Cardiovascular None None O
magnetic None None O
resonance None None O
using None None O
displacement None None O
encoding None None I-FUNC
with None None O
stimulated None None O
echoes None None O
( None None O
DENSE None None O
) None None O
is None None O
capable None None O
of None None O
assessing None None O
advanced None None O
measures None None O
of None None O
cardiac None None O
mechanics None None O
such None None O
as None None O
strain None None O
and None None O
torsion None None O
. None None O

A None None O
quasi-monoenergetic None None O
electron None None O
bunch None None O
( None None O
Ne None None I-TRANS
= None None O
1.0 None None O
× None None O
10 None None O
( None None O
-6 None None O
) None None O
C None None O
, None None O
Ee None None O
= None None O
16 None None O
± None None O
0.32 None None O
MeV None None O
) None None O
was None None O
injected None None O
into None None O
a None None O
5-mm-thick None None O
lead None None O
plate None None O
. None None O

It None None O
can None None O
be None None O
used None None O
to None None O
simultaneously None None O
measure None None O
the None None O
poloidal None None O
magnetic None None O
field None None O
Bp None None O
, None None O
electric None None O
field None None O
Er None None O
, None None O
electron None None O
temperature None None O
Te None None O
, None None O
electron None None O
density None None O
ne None None I-TRANS
, None None O
and None None O
ion None None O
temperature None None O
Ti None None O
. None None O

The None None O
DBS None None O
system None None O
covers None None O
plasma None None O
densities None None O
of None None O
0.8 None None O
× None None O
10 None None O
( None None O
13 None None O
) None None O
≤ None None O
ne None None I-TRANS
≤ None None O
1 None None O
× None None O
10 None None O
( None None O
14 None None O
) None None O
cm None None O
( None None O
-3 None None O
) None None O
, None None O
and None None O
provides None None O
access None None O
to None None O
the None None O
FRC None None O
core None None O
( None None O
up None None O
to None None O
the None None O
field None None O
null None None O
) None None O
and None None O
across None None O
the None None O
FRC None None O
separatrix None None O
into None None O
the None None O
scrape-off None None O
layer None None O
plasma None None O
. None None O

Specifically None None O
, None None O
it None None O
is None None O
demonstrated None None O
that None None O
the None None O
new None None O
system None None O
has None None O
a None None O
capability None None O
to None None O
measure None None O
ne None None I-TRANS
profiles None None O
with None None O
plasma None None O
vertical None None O
offsets None None O
of None None O
up None None O
to None None O
±17 None None O
cm None None O
. None None O

These None None O
weight None None O
functions None None O
for None None O
neutron None None O
emission None None O
spectrometry None None O
( None None O
NES None None I-TRANS
) None None O
are None None O
independent None None O
of None None O
the None None O
particular None None O
NES None None I-TRANS
diagnostic None None O
. None None O

By None None O
taking None None O
the None None O
instrumental None None O
response None None O
function None None O
of None None O
TOFOR None None O
into None None O
account None None O
, None None O
we None None O
calculate None None O
time-of-flight None None O
NES None None I-TRANS
weight None None O
functions None None O
that None None O
enable None None O
us None None O
to None None O
directly None None O
determine None None O
the None None O
velocity-space None None O
sensitivity None None O
of None None O
a None None O
given None None O
part None None O
of None None O
a None None O
measured None None O
time-of-flight None None O
spectrum None None O
from None None O
TOFOR None None O
. None None O

The None None O
prototype None None O
NES None None I-TRANS
systems None None O
were None None O
installed None None O
at None None O
J-port None None O
in None None O
KSTAR None None O
in None None O
2012 None None O
. None None O

By None None O
analyzing None None O
about None None O
100 None None O
shots None None O
, None None O
strong None None O
positive None None O
correlation None None O
between None None O
the None None O
O None None O
VI None None I-REGION
and None None O
the None None O
C None None O
IV None None O
emission None None O
intensities None None O
could None None O
be None None O
found None None O
. None None O

The None None O
529 None None O
nm None None O
carbon None None O
VI None None I-REGION
( None None O
n None None O
= None None O
8 None None O
- None None O
7 None None O
transition None None O
) None None O
line None None O
seems None None O
to None None O
be None None O
the None None O
best None None O
choice None None O
for None None O
ion None None O
temperature None None O
and None None O
plasma None None O
rotation None None O
measurements None None O
and None None O
the None None O
considered None None O
hardware None None O
is None None O
listed None None O
. None None O

To None None O
estimate None None O
signals None None O
from None None O
the None None O
soft None None O
X-ray None None O
radiation None None O
power None None O
, None None O
typical None None O
ne None None I-TRANS
, None None O
Te None None O
, None None O
and None None O
argon None None O
impurity None None O
line None None O
radiation None None O
profiles None None O
in None None O
KSTAR None None O
are None None O
chosen None None O
. None None O

Recently None None O
, None None O
research None None O
has None None O
focused None None O
on None None O
stress None None O
hormones None None I-PROTEIN
, None None O
with None None O
cortisol None None O
being None None O
the None None O
most None None O
widely None None O
researched None None O
, None None O
during None None O
the None None O
prodromal None None O
phase None None O
of None None O
psychosis None None O
. None None O

Herbivory None None O
induces None None O
the None None O
activation None None O
of None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
) None None O
, None None O
the None None O
accumulation None None O
of None None O
jasmonates None None O
and None None O
defensive None None O
metabolites None None O
in None None O
damaged None None O
leaves None None O
and None None O
in None None O
distal None None O
undamaged None None O
leaves None None O
. None None O

In None None O
the None None O
wild None None O
tobacco None None O
Nicotiana None None O
attenuata None None O
, None None O
FACs None None O
( None None O
fatty None None O
acid-amino None None O
acid None None O
conjugates None None O
) None None O
in None None O
Manduca None None I-NEURON
sexta None None O
oral None None O
secretions None None O
( None None O
OS None None O
) None None O
are None None O
the None None O
major None None O
elicitors None None O
that None None O
induce None None O
herbivory-specific None None O
signaling None None O
but None None O
their None None O
role None None O
in None None O
systemic None None O
signaling None None O
is None None O
largely None None O
unknown None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
activation None None O
of None None O
SIPK None None O
and None None O
elevation None None O
of None None O
JA None None O
in None None O
specific None None O
systemic None None O
leaves None None O
, None None O
increases None None O
in None None O
the None None O
activity None None O
of None None O
an None None O
important None None O
anti-herbivore None None O
defense None None O
, None None O
trypsin None None I-PROTEIN
proteinase None None O
inhibitor None None O
( None None O
TPI None None O
) None None O
, None None O
were None None O
observed None None O
in None None O
all None None O
systemic None None O
leaves None None O
after None None O
simulated None None O
herbivory None None O
, None None O
suggesting None None O
that None None O
systemic None None O
TPI None None O
induction None None O
does None None O
not None None O
require None None O
SIPK None None O
activation None None O
and None None O
JA None None O
increases None None O
. None None O

CDI None None O
associated None None O
with None None O
thirst None None O
disorder None None O
requires None None O
increased None None O
physician None None O
attention None None I-FUNC
and None None O
patient None None O
awareness None None O
of None None O
potential None None O
complications None None O
. None None O

Serum None None O
NGAL None None O
levels None None O
on None None O
admission None None O
are None None O
associated None None O
with None None O
increased None None O
burden None None O
of None None O
atherosclerosis None None I-DISEASE
in None None O
patients None None O
with None None O
NSTE-ACS None None O
. None None O

We None None O
investigated None None O
the None None O
synthesis None None O
of None None O
electrical None None O
stimulation None None O
patterns None None O
for None None O
functional None None O
movement None None I-FUNC
restoration None None O
in None None O
human None None O
paralyzed None None O
limbs None None O
. None None O

This None None O
synthesis None None O
is None None O
based None None O
on None None O
optimized None None O
functional None None O
electrical None None O
stimulation None None O
( None None O
FES None None O
) None None O
patterns None None O
to None None O
minimize None None O
muscular None None O
energy None None O
consumption None None O
and None None O
movement None None I-FUNC
efficiency None None O
criteria None None O
. None None O

This None None O
device None None O
encompasses None None O
a None None O
controller None None O
unit None None O
that None None O
oversees None None O
the None None O
administration None None O
of None None O
insulin None None I-PROTEIN
micro-boluses None None O
and None None O
continuously None None O
drives None None O
the None None O
pump None None O
based None None O
on None None O
blood None None O
glucose None None O
readings None None O
acquired None None O
in None None O
real None None O
time None None O
. None None O

In None None O
addition None None O
to None None O
promoting None None O
graft None None O
rejection None None O
, None None O
uncontrolled None None O
hypertension None None O
is None None O
a None None O
major None None O
risk None None O
factor None None O
for None None O
atherosclerosis None None I-DISEASE
, None None O
left None None O
ventricular None None O
hypertrophy None None O
, None None O
heart None None O
failure None None O
, None None O
and None None O
premature None None O
death None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
effects None None O
of None None O
extract None None O
from None None O
HL None None O
leaves None None O
( None None O
HLE None None O
) None None O
on None None O
cell None None O
proliferation None None O
and None None O
neuroblast None None O
differentiation None None O
in None None O
the None None O
subgranular None None O
zone None None O
( None None O
SGZ None None O
) None None O
of None None O
the None None O
dentate None None I-REGION
gyrus None None I-REGION
( None None O
DG None None O
) None None O
of None None O
aged None None O
gerbils None None O
. None None O

We None None O
also None None O
observed None None O
changes None None O
in None None O
immunoreactivities None None O
of None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
1 None None O
( None None O
SOD1 None None O
) None None O
and None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
2 None None O
( None None O
SOD2 None None O
) None None O
, None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
, None None O
and None None O
phospho-glycogen None None O
synthase None None O
kinase-3-beta None None O
( None None O
p-GSK-3β None None O
) None None O
to None None O
examine None None O
their None None O
relation None None O
with None None O
neurogenesis None None O
using None None O
immunohistochemistry None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
possible None None O
role None None O
of None None O
cysteine-rich None None O
protein None None O
61 None None O
( None None O
CYR61 None None O
) None None O
, None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
, None None O
androgen None None O
receptor None None I-PROTEIN
( None None O
AR None None O
) None None O
, None None O
interleukin-6 None None O
( None None O
IL-6 None None O
) None None O
, None None O
cytochrome None None O
c None None O
, None None O
caspase-3 None None O
, None None O
and None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
( None None O
PCNA None None O
) None None O
in None None O
the None None O
clinical None None O
progression None None O
of None None O
BPH None None O
. None None O

Molecular None None O
modeling None None O
of None None O
PPDKs None None O
from None None O
divergent None None O
organisms None None O
demonstrates None None O
that None None O
the None None O
orientation None None O
of None None O
the None None O
phosphorylatable None None O
histidine None None I-TRANS
residue None None O
within None None O
the None None O
central None None O
domain None None O
of None None O
PPDK None None O
determines None None O
whether None None O
this None None O
enzyme None None O
promotes None None O
catabolism None None O
or None None O
gluconeogenesis None None O
. None None O

Thus None None O
, None None O
our None None O
aim None None O
is None None O
to None None O
examine None None O
the None None O
effect None None O
of None None O
cystamine None None O
on None None O
the None None O
function None None O
recovery None None O
after None None O
stroke None None I-DISEASE
and None None O
investigate None None O
further None None O
cystamine None None O
mechanisms None None O
. None None O

Cystamine None None O
or None None O
saline None None O
was None None O
administered None None O
intraperitoneally None None O
at None None O
24 None None O
h None None O
after None None O
stroke None None I-DISEASE
. None None O

Cystamine None None O
treatment None None O
significantly None None O
increased None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
levels None None O
and None None O
phosphorylation None None O
of None None O
TrkB None None O
in None None O
brain None None O
after None None O
stroke None None I-DISEASE
. None None O

These None None O
data None None O
provide None None O
evidence None None O
to None None O
investigate None None O
the None None O
promising None None O
utility None None O
of None None O
cystamine None None O
for None None O
therapy None None O
of None None O
stroke None None I-DISEASE
in None None O
a None None O
variety None None O
of None None O
ways None None O
, None None O
acting None None O
principally None None O
through None None O
BDNF/TrkB None None O
pathway None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
findings None None O
imply None None O
that None None O
TOP2 None None O
is None None O
involved None None O
in None None O
the None None O
ALT None None O
pathway None None O
, None None O
perhaps None None O
by None None O
resolving None None O
the None None O
highly None None O
positive None None O
supercoil None None O
structure None None O
at None None O
the None None O
front None None O
of None None O
the None None O
helicase None None I-PROTEIN
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
discuss None None O
the None None O
PTMs None None O
that None None O
occur None None O
on None None O
lysine None None I-TRANS
, None None O
specifically None None O
neddylation None None O
and None None O
sumoylation None None O
, None None O
and None None O
the None None O
proteomic None None O
approaches None None O
that None None O
can None None O
be None None O
applied None None O
for None None O
the None None O
identification None None O
and None None O
quantification None None O
of None None O
these None None O
PTMs None None O
. None None O

Therefore None None O
, None None O
a None None O
meta-analysis None None O
was None None O
conducted None None O
to None None O
elucidate None None O
the None None O
potential None None O
associations None None O
between None None O
dietary None None O
patterns None None O
and None None O
the None None O
risk None None O
of None None O
all-cause None None O
, None None O
CVD None None O
and None None O
stroke None None I-DISEASE
mortality None None O
. None None O

However None None O
, None None O
no None None O
significant None None O
associations None None O
were None None O
observed None None O
between None None O
the None None O
Western/unhealthy None None O
dietary None None O
pattern None None O
and None None O
the None None O
risk None None O
of None None O
all-cause None None O
( None None O
SRRE None None O
= None None O
1·07 None None O
, None None O
95 None None O
% None None O
CI None None O
0·96 None None O
, None None O
1·20 None None O
) None None O
, None None O
CVD None None O
( None None O
SRRE None None O
= None None O
0·99 None None O
, None None O
95 None None O
% None None O
CI None None O
0·91 None None O
, None None O
1·08 None None O
) None None O
and None None O
stroke None None I-DISEASE
( None None O
SRRE None None O
= None None O
0·94 None None O
, None None O
95 None None O
% None None O
CI None None O
0·81 None None O
, None None O
1·10 None None O
) None None O
mortality None None O
. None None O

The None None O
c None None O
to None None O
p None None O
ratios None None O
were None None O
negatively None None O
correlated None None O
with None None O
stage None None O
, None None O
fibrosis None None O
, None None O
bile None None O
duct None None O
loss None None O
, None None O
orcein-positive None None O
granule None None O
deposition None None O
and None None O
hepatitis None None O
activities None None O
in None None O
PBC None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
and None None O
with None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
and None None O
total None None O
bilirubin None None O
levels None None O
at None None O
liver None None O
biopsies None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
P50 None None O
sensory None None O
gating None None O
was None None O
not None None O
related None None O
to None None O
the None None O
other None None O
main None None O
symptoms None None O
of None None O
FM None None O
, None None O
including None None O
fatigue None None O
, None None O
sleep None None O
dysfunction None None O
or None None O
co-morbid None None O
depression None None I-DISEASE
, None None O
nor None None O
to None None O
hypersensitivity None None O
to None None O
noise None None O
or None None O
headache None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
research None None O
project None None O
was None None O
to None None O
explore None None O
the None None O
knowledge None None O
, None None O
perceptions None None I-FUNC
and None None O
experiences None None O
of None None O
remote None None O
dwelling None None O
Indigenous None None O
adults None None O
and None None O
their None None O
health None None O
care None None O
providers None None O
relating None None O
to None None O
hepatitis None None O
B None None O
infection None None O
with None None O
a None None O
view None None O
to None None O
using None None O
this None None O
as None None O
the None None O
evidence None None O
base None None O
to None None O
develop None None O
a None None O
culturally None None O
appropriate None None O
educational None None O
tool None None O
. None None O

Low None None O
levels None None O
of None None O
biomedical None None O
knowledge None None O
about None None O
Hepatitis None None O
B None None O
, None None O
negative None None O
perceptions None None I-FUNC
of None None O
Hepatitis None None O
B None None O
, None None O
communication None None O
( None None O
particularly None None O
language None None I-FUNC
) None None O
and None None O
culture None None O
were None None O
the None None O
major None None O
themes None None O
that None None O
emerged None None O
from None None O
the None None O
data None None O
. None None O

Culturally None None O
appropriate None None O
discussions None None O
in None None O
a None None O
patient None None O
's None None O
first None None O
language None None I-FUNC
using None None O
visual None None O
aids None None O
were None None O
identified None None O
as None None O
vital None None O
to None None O
improving None None O
communication None None O
. None None O

However None None O
, None None O
the None None O
potential None None O
human None None O
health None None O
hazards None None O
posed None None O
by None None O
low-level None None O
chronic None None O
environmental None None O
H2S None None I-TRANS
exposure None None O
are None None O
being None None O
debated None None O
. None None O

While None None O
sparse None None O
, None None O
some None None O
data None None O
also None None O
suggest None None O
potential None None O
ocular None None O
symptoms None None O
and None None O
disorders None None O
associated None None O
with None None O
chronic None None O
ambient None None O
level None None O
H2S None None I-TRANS
exposure None None O
in None None O
adults None None O
( None None O
not None None O
children None None O
) None None O
, None None O
but None None O
the None None O
limited None None O
data None None O
on None None O
H2S None None I-TRANS
exposures None None O
, None None O
co-exposures None None O
and/or None None O
strong None None O
odor None None O
stimulus None None O
of None None O
H2S None None I-TRANS
, None None O
temper None None O
interpretation None None O
. None None O

Median None None O
total None None O
testosterone None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
free None None O
androgen None None O
index None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
insulin None None I-PROTEIN
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
and None None O
homeostasis None None O
model None None O
assessment-insulin None None O
resistance None None O
( None None O
p None None O
= None None O
0.02 None None O
) None None O
were None None O
higher None None O
and None None O
sex None None O
hormone None None O
binding None None O
globulin None None O
( None None O
SBHG None None O
) None None O
( None None O
p None None O
= None None O
0.04 None None O
) None None O
was None None O
lower None None O
in None None O
the None None O
PCOS None None O
group None None O
. None None O

By None None O
use None None O
of None None O
the None None O
EMSA None None O
technique None None O
, None None O
the None None O
chromatin None None O
immunoprecipitation None None O
assay None None O
, None None O
and None None O
the None None O
luciferase None None I-PROTEIN
reporter None None O
system None None O
, None None O
we None None O
demonstrated None None O
that None None O
HSF1 None None O
can None None O
directly None None O
bind None None O
the None None O
HSE None None O
in None None O
the None None O
Dp71 None None O
promoter None None O
region None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
explore None None O
changes None None O
in None None O
the None None O
apple None None O
transcriptome None None O
associated None None O
with None None O
a None None O
flesh None None O
browning None None O
disorder None None O
related None None O
to None None O
controlled None None O
atmosphere None None O
storage None None I-FUNC
using None None O
RNA-sequencing None None O
techniques None None O
. None None O

Additionally None None O
, None None O
a None None O
set None None O
of None None O
novel None None O
browning-specific None None O
differentially None None O
expressed None None O
genes None None O
, None None O
including None None O
pyruvate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
and None None O
1-aminocyclopropane-1-carboxylate None None O
oxidase None None O
, None None O
was None None O
validated None None O
in None None O
apples None None O
stored None None O
for None None O
various None None O
periods None None O
at None None O
different None None O
controlled None None O
atmosphere None None O
conditions None None O
, None None O
giving None None O
rise None None O
to None None O
potential None None O
biomarkers None None O
associated None None O
with None None O
high None None O
risk None None O
of None None O
browning None None O
development None None O
. None None O

The None None O
lived None None O
experience None None O
of None None O
stakeholders None None O
revealed None None O
many None None O
levels None None O
of None None O
emotion None None I-FUNC
, None None O
both None None O
positive None None O
and None None O
heart-rending None None O
. None None O

Participants None None O
reported None None O
challenges None None O
relating None None O
to None None O
understanding None None O
patients None None O
' None None O
needs None None O
, None None O
access None None O
to None None O
consistent None None O
services None None O
within None None O
hospitals None None O
and None None O
the None None O
community None None O
, None None O
time None None O
constraints None None O
, None None O
and None None O
the None None O
strong None None O
emotions None None I-FUNC
evoked None None O
by None None O
this None None O
severe None None O
and None None O
rare None None O
disease None None O
. None None O

Our None None O
discovery None None O
shows None None O
that None None O
complex None None O
cell None None O
behaviors None None O
such None None O
as None None O
the None None O
direction None None O
of None None O
cell None None O
movement None None I-FUNC
are None None O
influenced None None O
by None None O
simple None None O
geometrical None None O
principles None None O
, None None O
which None None O
can None None O
be None None O
utilized None None O
as None None O
the None None O
design None None O
foundation None None O
for None None O
platforms None None O
that None None O
guide None None O
and None None O
sort None None O
cultured None None O
cells None None O
. None None O

We None None O
aimed None None O
to None None O
evaluate None None O
the None None O
accuracy None None O
of None None O
multidetector None None O
computed None None O
tomography None None O
( None None O
MDCT None None O
) None None O
venous None None O
mapping None None O
for None None O
the None None O
localization None None O
of None None O
the None None O
right None None O
adrenal None None I-TRANS
veins None None O
( None None O
RAV None None O
) None None O
in None None O
patients None None O
suffering None None O
from None None O
primary None None O
aldosteronism None None O
. None None O

Results None None O
were None None O
compared None None O
with None None O
RAV None None O
venograms None None O
obtained None None O
during None None O
adrenal None None I-TRANS
vein None None O
sampling None None O
and None None O
corroborated None None O
by None None O
laboratory None None O
testing None None O
of None None O
cortisol None None O
in None None O
selective None None O
RAV None None O
blood None None O
samples None None O
. None None O

Delayed None None O
contrast None None O
enhancement None None O
attributable None None O
to None None O
extension None None O
of None None O
inflammation None None O
was None None O
observed None None O
on None None O
the None None O
aortic None None O
wall None None O
and None None O
aortic None None O
root None None O
( None None O
n=11 None None O
) None None O
, None None O
paravalvular None None O
tissue None None O
( None None O
n=4 None None O
) None None O
, None None O
mitral None None O
valve None None O
( None None O
n=2 None None O
) None None O
, None None O
walls None None O
of None None O
the None None O
cardiac None None O
chambers None None O
( None None O
n=6 None None O
) None None O
, None None O
interventricular None None O
septum None None I-REGION
( None None O
n=3 None None O
) None None O
, None None O
and None None O
wall None None O
of None None O
the None None O
pulmonary None None O
artery None None O
and None None O
superior None None O
mesenteric None None O
artery None None O
( None None O
n=1 None None O
) None None O
. None None O

We None None O
evaluated None None O
telomere None None O
length None None O
in None None O
subjects None None O
with None None O
remitted None None O
and None None O
unremitted None None O
schizophrenia None None I-DISEASE
and None None O
in None None O
control None None O
subjects None None O
. None None O

The None None O
lower None None O
relative None None O
telomere None None O
length None None O
in None None O
unremitted None None O
schizophrenia None None I-DISEASE
subjects None None O
may None None O
thus None None O
indicate None None O
shared None None O
biological None None O
pathways None None O
with None None O
other None None O
neurodegenerative None None O
disorders None None O
that None None O
are None None O
also None None O
characterized None None O
by None None O
increased None None O
cellular None None O
senescence None None O
. None None O

Chronic None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
can None None O
cause None None O
both None None O
acute None None O
and None None O
chronic None None O
health None None O
problems None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
a None None O
60-year-old None None O
man None None O
with None None O
substantial None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
, None None O
who None None O
suffered None None O
cardiac None None O
arrest None None O
after None None O
sudden None None O
withdrawal None None O
of None None O
alcohol None None O
. None None O

Damage None None O
to None None O
the None None O
right None None I-REGION
parietal None None I-REGION
cortex None None I-REGION
often None None O
leads None None O
to None None O
a None None O
syndrome None None O
known None None O
as None None O
unilateral None None O
neglect None None O
in None None O
which None None O
the None None O
patient None None O
fails None None O
to None None O
attend None None O
or None None O
respond None None O
to None None O
stimuli None None O
in None None O
left None None O
space None None O
. None None O

Here None None O
, None None O
we None None O
present None None O
a None None O
computational None None O
model None None O
capable None None O
of None None O
explaining None None O
some None None O
basic None None O
symptoms None None O
of None None O
neglect None None O
( None None O
line None None O
bisection None None O
behaviour None None O
) None None O
, None None O
the None None O
effects None None O
of None None O
prism None None O
adaptation None None O
in None None O
both None None O
healthy None None O
controls None None O
and None None O
neglect None None O
patients None None O
and None None O
the None None O
observed None None O
dissociation None None O
between None None O
action None None O
and None None O
perception None None I-FUNC
following None None O
prisms None None O
. None None O

Intracerebral None None O
hemorrhage None None O
( None None O
ICH None None O
) None None O
is None None O
a None None O
subtype None None O
of None None O
stroke None None I-DISEASE
involving None None O
formation None None O
of None None O
hematoma None None O
within None None O
brain None None O
parenchyma None None O
, None None O
which None None O
accounts None None O
for None None O
8-15 None None O
% None None O
of None None O
all None None O
strokes None None I-DISEASE
in None None O
Western None None O
societies None None O
and None None O
20-30 None None O
% None None O
among None None O
Asian None None O
populations None None O
, None None O
and None None O
has None None O
a None None O
1-year None None O
mortality None None O
rate None None O
& None None O
gt None None O
; None None O
50 None None O
% None None O
. None None O

PPARγ None None O
agonists None None O
have None None O
emerged None None O
as None None O
potential None None O
therapeutic None None O
target None None O
for None None O
stroke None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
determine None None O
association None None O
between None None O
COPD None None O
Assessment None None O
Test None None O
( None None O
CAT None None O
) None None O
and None None O
major None None O
depression None None I-DISEASE
among None None O
clinically None None O
stable None None O
out-patient None None O
COPD None None O
subjects None None O
with None None O
mild None None O
hypoxemia None None O
. None None O

Cases None None O
were None None O
30 None None O
patients None None O
with None None O
major None None O
depression None None I-DISEASE
and None None O
controls None None O
were None None O
30 None None O
patients None None O
without None None O
depression None None I-DISEASE
. None None O

All None None O
possible None None O
predictive None None O
variables None None O
were None None O
included None None O
in None None O
a None None O
multivariate None None O
logistic None None O
regression None None O
model None None O
to None None O
assess None None O
the None None O
association None None O
between None None O
major None None O
depression None None I-DISEASE
and None None O
each None None O
independent None None O
variable None None O
, None None O
while None None O
controlling None None O
for None None O
the None None O
sleep None None O
parameters None None O
. None None O

CAT None None O
score None None O
& None None O
gt None None O
; None None O
20 None None O
was None None O
associated None None O
with None None O
major None None O
depression None None I-DISEASE
, None None O
suggesting None None O
CAT None None O
as None None O
a None None O
predictor None None O
variable None None O
of None None O
major None None O
depression None None I-DISEASE
among None None O
COPD None None O
patients None None O
with None None O
mild None None O
hypoxemia None None O
, None None O
and None None O
indicating None None O
that None None O
an None None O
additional None None O
specific None None O
evaluation None None O
for None None O
the None None O
presence None None O
of None None O
major None None O
depression None None I-DISEASE
should None None O
be None None O
done None None O
. None None O

Many None None O
of None None O
these None None O
children None None O
and None None O
adolescents None None O
, None None O
some None None O
of None None O
whom None None O
will None None O
experience None None O
post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
( None None O
PTSD None None O
) None None O
, None None O
are None None O
submitted None None O
to None None O
health-care None None O
departments None None O
shortly None None O
after None None O
exposure None None O
. None None O

Based None None O
on None None O
epidemiological None None O
data None None O
we None None O
have None None O
calculated None None O
possible None None O
estimates None None O
for None None O
the None None O
present None None O
Danish None None O
prevalence None None O
of None None O
dementia None None I-DISEASE
and None None O
prevalence None None O
projections None None O
through None None O
to None None O
2030 None None O
. None None O

Even None None O
though None None O
results None None O
from None None O
recent None None O
epidemiological None None O
studies None None O
point None None O
to None None O
a None None O
possible None None O
decline None None O
in None None O
incidence None None O
we None None O
expect None None O
the None None O
future None None O
prevalence None None O
of None None O
dementia None None I-DISEASE
to None None O
increase None None O
due None None O
to None None O
an None None O
expected None None O
increase None None O
of None None O
the None None O
elderly None None O
population None None O
. None None O

Venous None None O
air None None O
embolism None None I-DISEASE
( None None O
VAE None None O
) None None O
is None None O
a None None O
well-known None None O
complication None None O
to None None O
trauma None None O
and None None O
various None None O
surgical None None O
, None None O
diagnostic None None O
and None None O
therapeutically None None O
procedures None None O
. None None O

ApoPep-1 None None O
( None None O
CQRPPR None None O
) None None O
was None None O
synthesized None None O
, None None O
and None None O
an None None O
extra None None O
tyrosine None None I-TRANS
residue None None O
was None None O
added None None O
to None None O
its None None O
N-terminal None None O
end None None O
for None None O
radiolabeling None None O
. None None O

At None None O
baseline None None O
, None None O
higher None None O
concentrations None None O
of None None O
glutamate None None I-TRANS
and None None O
beta-endorphin None None O
and None None O
lower None None O
concentrations None None O
of None None O
cortisol None None O
in None None O
CNSP None None O
than None None O
CON None None O
were None None O
found None None O
. None None O

CD4 None None O
( None None O
+ None None O
) None None O
CD25 None None O
( None None O
high None None O
) None None O
FOXP3 None None I-PROTEIN
( None None O
+ None None O
) None None O
Tregs None None O
were None None O
assessed None None O
by None None O
flow-cytometry None None O
at None None O
baseline None None O
and None None O
before None None O
every None None O
subsequent None None O
pulse None None O
and None None O
3-6 None None O
months None None O
after None None O
the None None O
final None None O
pulse None None O
. None None O

The None None O
results None None O
demonstrated None None O
positive None None O
outcomes None None O
following None None O
physical None None O
activity None None O
intervention None None O
for None None O
health-related None None O
quality None None O
of None None O
life None None O
, None None O
depression None None I-DISEASE
, None None O
and None None O
anxiety None None O
. None None O

Soybean None None O
( None None O
Glycine None None I-TRANS
max None None O
L None None O
. None None O

Flower None None O
tissues None None O
also None None O
responded None None O
to None None O
elevated None None O
[ None None O
O3 None None O
] None None O
by None None O
increasing None None O
expression None None O
of None None O
genes None None O
encoding None None I-FUNC
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
( None None O
MMPs None None O
) None None O
. None None O

We None None O
report None None O
the None None O
results None None O
of None None O
an None None O
ultrastructural None None O
study None None O
of None None O
Triton None None O
X-100-extracted None None O
, None None O
Mg-adenosine None None O
triphosphate None None I-TRANS
( None None O
ATP None None O
) None None O
-reactivated None None O
bull None None O
sperm None None O
. None None O

In None None O
a None None O
companion None None O
article None None O
, None None O
we None None O
examined None None O
the None None O
motility None None O
characteristics None None O
induced None None O
in None None O
bull None None O
sperm None None O
models None None O
by None None O
varying None None O
the None None O
concentration None None O
ratio None None O
of None None O
ATP None None O
and None None O
Mg None None O
( None None O
2+ None None O
) None None O
and None None O
the None None O
stabilizing None None O
effect None None O
of None None O
adenosine None None I-TRANS
diphosphate None None O
( None None O
ADP None None O
) None None O
on None None O
coordinated None None O
beating None None O
. None None O

In None None O
total None None O
, None None O
191 None None O
adults None None O
were None None O
asked None None O
whether None None O
or None None O
not None None O
they None None O
expected None None O
child None None O
victims None None O
who None None O
were None None O
testifying None None O
about None None O
sexual None None O
abuse None None O
to None None O
display None None O
sadness None None O
, None None O
fear None None O
, None None O
anger None None O
, None None O
disgust None None O
, None None O
happiness None None O
, None None O
or None None O
a None None O
neutral None None O
demeanor None None O
, None None O
and None None O
how None None O
intensely None None O
the None None O
adults None None O
expected None None O
each None None O
emotion None None I-FUNC
to None None O
be None None O
displayed None None O
. None None O

Of None None O
participants None None O
who None None O
expected None None O
multiple None None O
emotions None None I-FUNC
, None None O
a None None O
combination None None O
of None None O
negative None None O
and None None O
neutral None None O
emotions None None I-FUNC
was None None O
expected None None O
more None None O
from None None O
13-year-old None None O
female None None O
victims None None O
than None None O
from None None O
5-year-old None None O
female None None O
victims None None O
. None None O

To None None O
evaluate None None O
whether None None O
P2X3 None None O
receptors None None I-PROTEIN
( None None O
P2X3R None None O
) None None O
are None None O
expressed None None O
in None None O
the None None O
bladder None None O
urothelium None None O
and None None O
to None None O
determine None None O
their None None O
possible None None O
function None None O
in None None O
modulating None None O
purinergic None None O
detrusor None None O
contractions None None O
in None None O
the None None O
rat None None O
urinary None None O
bladder None None O
. None None O

© None None O
2014 None None O
The None None O
Authors None None O
BJU None None O
International None None O
© None None O
2014 None None O
BJU None None O
International None None O
Published None None O
by None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Fetal None None O
liver None None O
tyrosine None None I-TRANS
kinase None None O
3 None None O
( None None O
FLT3 None None O
) None None O
-internal None None O
tandem None None O
duplications None None O
( None None O
ITDs None None O
) None None O
has None None O
been None None O
used None None O
as None None O
a None None O
powerful None None O
adverse None None O
prognostic None None O
indicator None None O
for None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
in None None O
any None None O
age None None O
group None None O
. None None O

We None None O
also None None O
examine None None O
synthetic None None O
β-sheet None None O
peptides None None I-TRANS
selected None None O
from None None O
a None None O
combinatorial None None O
library None None O
for None None O
their None None O
ability None None O
or None None O
inability None None O
to None None O
form None None O
pores None None O
in None None O
lipid None None O
membranes None None O
. None None O

Due None None O
to None None O
the None None O
cationic None None O
charge None None O
of None None O
the None None O
peptides None None I-TRANS
, None None O
more None None O
favorable None None O
transfer None None O
energies None None O
and None None O
more None None O
stable None None O
binding None None O
were None None O
observed None None O
in None None O
anionic None None O
than None None O
neutral None None O
pores None None O
. None None O

Toll-like None None O
receptors None None I-PROTEIN
( None None O
TLRs None None O
) None None O
can None None O
recognize None None O
microbial None None O
patterns None None O
and None None O
utilize None None O
adaptor None None O
molecules None None O
, None None O
such None None O
as-MyD88 None None O
or None None O
( None None O
TRIF None None O
TIR-domain-containing None None O
adapter-inducing None None O
interferon-β None None O
) None None O
, None None O
to None None O
initiate None None O
downstream None None O
signaling None None O
that None None O
ultimately None None O
affects None None O
the None None O
initiation None None O
of None None O
adaptive None None O
immunity None None O
. None None O

They None None O
received None None O
a None None O
speech None None I-FUNC
re-structuring None None O
intensive None None O
program None None O
( None None O
IP None None O
) None None O
delivered None None O
in None None O
English None None O
only None None O
. None None O

No None None O
significant None None O
difference None None O
in None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
, None None O
pulmonary None None O
embolism None None I-DISEASE
, None None O
or None None O
other None None O
adverse None None O
events None None O
among None None O
the None None O
study None None O
groups None None O
. None None O

FemABX None None O
peptidyl None None O
transferases None None I-PROTEIN
are None None O
involved None None O
in None None O
non-ribosomal None None O
pentaglycine None None O
interpeptide None None O
bridge None None O
biosynthesis None None O
. None None O

As None None O
the None None O
transcription None None O
of None None O
the None None O
murein None None O
hydrolase None None I-PROTEIN
genes None None O
was None None O
up-regulated None None O
in None None O
the None None O
mutant None None O
, None None O
they None None O
most None None O
likely None None O
represent None None O
an None None O
adaption None None O
response None None O
to None None O
the None None O
life None None O
threatening None None O
mutation None None O
. None None O

The None None O
78-hour None None O
curriculum None None O
utilized None None O
traditional None None O
didactic None None O
lectures None None O
, None None O
flipped None None O
classroom None None O
active None None O
learning None None I-FUNC
sessions None None O
, None None O
a None None O
simulated None None O
paging None None O
curriculum None None O
, None None O
simulation None None O
training None None O
, None None O
embalmed None None O
cadaver None None O
anatomical None None O
dissections None None O
, None None O
and None None O
fresh-frozen None None O
cadaver None None O
operative None None O
procedures None None O
. None None O

Student None None O
satisfaction None None O
was None None O
high None None O
for None None O
all None None O
of None None O
the None None O
course None None O
content None None O
, None None O
and None None O
the None None O
active None None O
learning None None I-FUNC
components None None O
of None None O
the None None O
curriculum None None O
( None None O
flipped None None O
classroom None None O
, None None O
simulation None None O
, None None O
and None None O
anatomy None None O
sessions None None O
) None None O
had None None O
higher None None O
scores None None O
than None None O
the None None O
traditional None None O
didactics None None O
in None None O
all None None O
six None None O
categories None None O
of None None O
our None None O
student None None O
satisfaction None None O
survey None None O
. None None O

Sp1-binding None None O
elements None None O
of None None O
UHRF1 None None O
were None None O
identified None None O
at None None O
positions None None O
-664/-505 None None O
of None None O
the None None O
promoter None None O
region None None O
using None None O
the None None O
luciferase None None I-PROTEIN
and None None O
chromatin None None O
immunoprecipitation None None O
assays None None O
. None None O

The None None O
weight None None O
of None None O
the None None O
adrenal None None I-TRANS
glands None None O
in None None O
behaviorally None None O
active None None O
rats None None O
decreased None None O
in None None O
parallel None None O
with None None O
the None None O
decrease None None O
in None None O
blood None None O
corticosterone None None O
. None None O

It None None O
was None None O
hypothesized None None O
that None None O
immunization None None O
with None None O
glutamate-BSA None None O
conjugate None None O
suppresses None None O
activity None None O
of None None O
the None None O
hypothalamic-pituitary-adrenal None None O
feedback None None O
mechanism None None O
underlying None None O
the None None O
production None None O
of None None O
glucocorticoid None None O
hormones None None I-PROTEIN
, None None O
which None None O
is None None O
manifested None None O
in None None O
slightly None None O
increased None None O
ulceration None None O
due None None O
to None None O
attenuation None None O
of None None O
the None None O
gastroprotective None None O
action None None O
of None None O
corticosterone None None O
under None None O
stress None None O
. None None O

The None None O
enzyme None None O
activity None None O
was None None O
increased None None O
3-4 None None O
fold None None O
in None None O
the None None O
adrenal None None I-TRANS
glands None None O
throughout None None O
the None None O
experiment None None O
. None None O

In None None O
long-term None None O
diabetes None None O
( None None O
28 None None O
days None None O
) None None O
, None None O
along None None O
with None None O
reduced None None O
synthesis None None O
of None None O
corticosterone None None O
and None None O
production None None O
of None None O
11-dehydrocorticosterone None None O
in None None O
the None None O
adrenal None None I-TRANS
glands None None O
, None None O
the None None O
extra-adrenal None None O
formation None None O
of None None O
corticosterone None None O
was None None O
activated None None O
as None None O
indicated None None O
by None None O
enhanced None None O
activity None None O
of None None O
the None None O
first None None O
isoform None None O
in None None O
the None None O
liver None None O
and None None O
that None None O
of None None O
the None None O
second None None O
isoform None None O
in None None O
the None None O
kidneys None None O
. None None O

We None None O
studied None None O
the None None O
expression None None O
of None None O
some None None O
CC None None O
chemokines None None O
and None None O
their None None O
receptors None None I-PROTEIN
in None None O
the None None O
synovium None None O
of None None O
patients None None O
with None None O
rheumatoid None None O
arthritis None None O
, None None O
osteoarthrosis None None O
, None None O
and None None O
a None None O
history None None O
of None None O
joint None None O
injury None None O
. None None O

In None None O
1.5 None None O
months None None O
after None None O
modeling None None O
of None None O
streptozotocin-induced None None O
diabetes None None O
mellitus None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
catalase None None I-PROTEIN
activities None None O
decreased None None O
by None None O
40.7 None None O
and None None O
32.0 None None O
% None None O
, None None O
respectively None None O
, None None O
in None None O
comparison None None O
with None None O
the None None O
corresponding None None O
values None None O
in None None O
Wistar None None O
rats None None O
without None None O
diabetes None None O
. None None O

Peptide None None O
NKDTKIAKK-Nle-A None None O
( None None O
562-572 None None O
) None None O
-K None None O
( None None O
Palm None None O
) None None O
A None None O
stimulated None None O
basal None None O
adenylate None None I-PROTEIN
cyclase None None I-PROTEIN
activity None None O
and None None O
reduced None None O
activity None None O
of None None O
the None None O
enzyme None None O
in None None O
testicular None None O
membranes None None O
stimulated None None O
by None None O
chorionic None None O
gonadotropin None None O
. None None O

We None None O
assessed None None O
the None None O
local None None O
residents None None O
' None None O
perceptions None None I-FUNC
of None None O
the None None O
distribution None None O
and None None O
occurrence None None O
of None None O
mosquitoes None None O
using None None O
key None None O
informant None None O
interview None None O
techniques None None O
. None None O

Recent None None O
investigations None None O
have None None O
pointed None None O
out None None O
novel None None O
SSAs None None O
with None None O
a None None O
wider None None O
binding None None O
profile None None O
( None None O
pasireotide None None O
) None None O
, None None O
chimeric None None O
molecules None None O
against None None O
somatostatin None None I-TRANS
receptors None None I-PROTEIN
and None None O
dopamine None None I-TRANS
receptors None None I-PROTEIN
and None None O
the None None O
combination None None O
with None None O
targeted None None O
agents None None O
, None None O
such None None O
as None None O
mTOR None None O
inhibitors None None O
or None None O
antiangiogenic None None O
agents None None O
. None None O

Secondly None None O
, None None O
all None None O
patients None None O
admitted None None O
with None None O
ischemic None None O
stroke None None I-DISEASE
were None None O
retrospectively None None O
screened None None O
to None None O
assess None None O
the None None O
reasons None None O
for None None O
exclusion None None O
to None None O
treatment None None O
and None None O
the None None O
rate None None O
of None None O
thrombolysis None None O
delivered None None O
. None None O

Administration None None O
of None None O
rt-PA None None O
in None None O
an None None O
ED None None O
setting None None O
without None None O
neurological None None O
specialized None None O
stroke None None I-DISEASE
unit None None O
seems None None O
to None None O
be None None O
feasible None None O
and None None O
safe None None O
after None None O
adequate None None O
training None None O
. None None O

In None None O
this None None O
randomised None None O
controlled None None O
clinical None None O
trial None None O
we None None O
aimed None None O
to None None O
test None None O
the None None O
safety None None O
and None None O
therapeutic None None O
efficacy None None O
of None None O
bilateral None None O
theta-burst None None O
stimulation None None O
( None None O
TBS None None O
) None None O
as None None O
an None None O
add-on None None O
therapy None None O
to None None O
standard None None O
treatment None None O
of None None O
major None None O
depression None None I-DISEASE
. None None O

There None None O
was None None O
no None None O
significant None None O
effect None None O
in None None O
the None None O
primary None None O
outcome None None O
measures None None O
( None None O
change None None O
of None None O
the None None O
21-item None None O
Hamilton None None O
Rating None None O
Scale None None O
for None None O
Depression None None I-DISEASE
) None None O
. None None O

This None None O
pilot None None O
study None None O
did None None O
not None None O
reveal None None O
significant None None O
advantages None None O
of None None O
bilateral None None O
TBS None None O
or None None O
rTMS None None O
over None None O
sham None None O
treatment None None O
as None None O
an None None O
add-on None None O
treatment None None O
for None None O
major None None O
depression None None I-DISEASE
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
identify None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
TCR None None O
) None None O
-γδ None None O
( None None O
+ None None O
) None None O
intraepithelial None None O
lymphocytes None None O
( None None O
IELs None None O
) None None O
as None None O
major None None O
targets None None O
of None None O
CT None None O
to None None O
break None None O
tolerance None None O
to None None O
food None None O
allergens None None O
. None None O

To None None O
investigate None None O
persons None None O
with None None O
dementia None None I-DISEASE
and None None O
their None None O
informal None None O
caregivers None None O
' None None O
views None None O
of None None O
inter-sectoral None None O
information None None O
, None None O
communication None None O
and None None O
collaboration None None O
throughout None None O
the None None O
trajectory None None O
of None None O
dementia None None I-DISEASE
care None None O
, None None O
in None None O
eight None None O
European None None O
countries None None O
. None None O

Persons None None O
with None None O
dementia None None I-DISEASE
and None None O
their None None O
informal None None O
caregivers None None O
( None None O
N None None O
= None None O
137 None None O
) None None O
participated None None O
in None None O
focus None None O
group None None O
interviews None None O
during None None O
2011 None None O
. None None O

The None None O
core None None O
finding None None O
was None None O
that None None O
information None None O
, None None O
communication None None O
and None None O
collaboration None None O
were None None O
to None None O
be None None O
focused None None O
on None None O
the None None O
persons None None O
with None None O
dementia None None I-DISEASE
and None None O
the None None O
informal None None O
caregivers None None O
. None None O

As None None O
focus None None O
of None None O
care None None O
is None None O
on None None O
the None None O
person None None O
with None None O
dementia None None I-DISEASE
and None None O
their None None O
informal None None O
caregivers None None O
, None None O
a None None O
dyadic None None O
approach None None O
seems None None O
most None None O
suitable None None O
for None None O
dementia None None I-DISEASE
care None None O
. None None O

Our None None O
work None None O
provides None None O
insight None None O
into None None O
the None None O
biogenesis None None O
of None None O
the None None O
EHM None None O
and None None O
reveals None None O
dynamic None None O
processes None None O
that None None O
recruit None None O
membrane None None O
compartments None None O
and None None O
immune None None O
receptors None None I-PROTEIN
to None None O
this None None O
host-pathogen None None O
interface None None O
. None None O

Herein None None O
we None None O
report None None O
, None None O
for None None O
the None None O
first None None O
time None None O
, None None O
a None None O
case None None O
of None None O
unilateral None None O
adrenal None None I-TRANS
hyperplasia None None O
accompanied None None O
by None None O
hypokalaemic None None O
periodic None None O
paralysis None None O
type None None O
I None None O
resulting None None O
from None None O
a None None O
novel None None O
dominant None None O
mutation None None O
in None None O
CACNA1S None None O
. None None O

A None None O
computed None None O
tomography None None O
( None None O
CT None None O
) None None O
scan None None O
of None None O
the None None O
abdomen None None O
showed None None O
a None None O
nodular None None O
mass None None O
on None None O
the None None O
left None None O
adrenal None None I-TRANS
gland None None O
, None None O
although None None O
laboratory None None O
examination None None O
revealed None None O
the None None O
patient None None O
had None None O
not None None O
developed None None O
primary None None O
aldosteronism None None O
. None None O

The None None O
therapeutic None None O
effect None None O
of None None O
adrenalectomy None None O
indicated None None O
that None None O
unilateral None None O
adrenal None None I-TRANS
hyperplasia None None O
might None None O
make None None O
paralytic None None O
attacks None None O
more None None O
serious None None O
and None None O
more None None O
frequent None None O
by None None O
decreasing None None O
serum None None O
potassium None None O
. None None O

With None None O
this None None O
in None None O
mind None None O
, None None O
over None None O
recent None None O
years None None O
much None None O
attention None None I-FUNC
has None None O
been None None O
given None None O
to None None O
the None None O
development None None O
of None None O
evidence-based None None O
clinical None None O
guidelines None None O
, None None O
staff None None O
education None None O
and None None O
risk None None O
reporting None None O
systems None None O
. None None O

In None None O
this None None O
study None None O
we None None O
set None None O
out None None O
to None None O
assess None None O
staff None None O
perceptions None None I-FUNC
of None None O
safety None None O
and None None O
quality None None O
of None None O
a None None O
maternity None None O
service None None O
and None None O
to None None O
explore None None O
potential None None O
influences None None O
on None None O
service None None O
safety None None O
. None None O

Insulin None None I-PROTEIN
degludec None None O
is None None O
a None None O
new-generation None None O
ultra-long-acting None None O
basal None None O
insulin None None I-PROTEIN
which None None O
offers None None O
a None None O
significantly None None O
more None None O
predictable None None O
glucose-lowering None None O
effect None None O
than None None O
other None None O
long-acting None None O
insulin None None I-PROTEIN
analogues None None O
. None None O

The None None O
combined None None O
data None None O
from None None O
all None None O
trials None None O
showed None None O
a None None O
statistically None None O
significant None None O
reduction None None O
in None None O
the None None O
basal None None O
insulin None None I-PROTEIN
dose None None O
( None None O
MD None None O
-0.042 None None O
, None None O
95 None None O
% None None O
CI None None O
-0.067 None None O
to None None O
-0.018 None None O
, None None O
p None None O
= None None O
0.001 None None O
) None None O
and None None O
the None None O
total None None O
daily None None O
insulin None None I-PROTEIN
dose None None O
( None None O
MD None None O
-0.072 None None O
, None None O
95 None None O
% None None O
CI None None O
0.016 None None O
to None None O
-0.027 None None O
, None None O
p None None O
= None None O
0.002 None None O
) None None O
in None None O
the None None O
degludec None None O
group None None O
compared None None O
to None None O
other None None O
long-acting None None O
analogues None None O
. None None O

In None None O
comparison None None O
with None None O
other None None O
long-acting None None O
analogues None None O
, None None O
treatment None None O
with None None O
insulin None None I-PROTEIN
degludec None None O
was None None O
safe None None O
and None None O
patients None None O
obtained None None O
similar None None O
metabolic None None O
control None None O
expressed None None O
by None None O
HbA1c None None O
and None None O
FPG None None O
levels None None O
with None None O
the None None O
added None None O
benefit None None O
of None None O
a None None O
reduced None None O
basal None None O
and None None O
total None None O
insulin None None I-PROTEIN
dose None None O
. None None O

The None None O
biological None None O
activity None None O
of None None O
collagen None None I-PROTEIN
has None None O
promoted None None O
it None None O
to None None O
be None None O
an None None O
advantageous None None O
biomaterial None None O
for None None O
bone None None O
tissue None None O
engineering None None O
; None None O
however None None O
, None None O
the None None O
mechanical None None O
properties None None O
of None None O
these None None O
scaffolds None None O
are None None O
insufficient None None O
and None None O
the None None O
porous None None O
structures None None O
are None None O
not None None O
stable None None O
in None None O
the None None O
wet None None O
state None None O
. None None O

In None None O
this None None O
work None None O
, None None O
a None None O
three-dimensional None None O
macroporous None None O
bone None None O
scaffold None None O
based None None O
on None None O
collagen None None I-PROTEIN
( None None O
CO None None O
) None None O
fiber None None O
and None None O
bioglass None None O
( None None O
BG None None O
) None None O
is None None O
fabricated None None O
by None None O
a None None O
slurry-dipping None None O
technique None None O
, None None O
and None None O
its None None O
relevant None None O
mechanical None None O
and None None O
biological None None O
properties None None O
are None None O
evaluated None None O
. None None O

Compared None None O
with None None O
CO None None O
scaffold None None O
, None None O
water None None O
absorption None None O
value None None O
of None None O
CO/BG None None O
scaffold None None O
decreases None None O
greatly None None O
from None None O
889 None None O
% None None O
to None None O
52 None None O
% None None O
, None None O
which None None O
significantly None None O
alleviates None None O
the None None O
swelling None None O
behavior None None O
of None None O
collagen None None I-PROTEIN
and None None O
improves None None O
the None None O
stability None None O
of None None O
scaffold None None O
structure None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
used None None O
liposomes None None O
to None None O
transfect None None O
MSCs None None O
with None None O
plasmid None None O
encoding None None I-FUNC
COMP None None O
and None None O
then None None O
induced None None O
the None None O
transfected None None O
MSCs None None O
to None None O
differentiate None None O
in None None O
osteogenic None None O
and None None O
chondrogenic None None O
differentiation None None O
media None None O
containing None None O
BMP-2 None None O
. None None O

Real-time None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
PCR None None O
) None None O
assays None None O
of None None O
osteogenesis-related None None O
markers None None O
( None None O
collagen None None I-PROTEIN
type None None O
I None None O
alpha None None O
1 None None O
, None None O
runt-related None None O
transcription None None O
factor None None O
2 None None O
, None None O
osteopontin None None O
, None None O
bone None None O
gla None None O
protein None None O
) None None O
and None None O
chondrogenesis-related None None O
markers None None O
( None None O
collagen None None I-PROTEIN
type None None O
II None None O
alpha None None O
1 None None O
, None None O
sry-related None None O
high-mobility None None O
group None None O
box None None O
9 None None O
, None None O
Aggrecan None None O
) None None O
was None None O
performed None None O
to None None O
evaluate None None O
the None None O
process None None O
of None None O
cell None None O
differentiation None None O
. None None O

Although None None O
many None None O
preclinical None None O
studies None None O
have None None O
implicated None None O
β3 None None O
integrin None None I-PROTEIN
receptors None None I-PROTEIN
( None None O
αvβ3 None None O
and None None O
αIIbβ3 None None O
) None None O
in None None O
cancer None None O
progression None None O
, None None O
β3 None None O
inhibitors None None O
have None None O
shown None None O
only None None O
modest None None O
efficacy None None O
in None None O
patients None None O
with None None O
advanced None None O
solid None None O
tumours None None O
. None None O

We None None O
show None None O
that None None O
stable None None O
down-regulation None None O
of None None O
tumour None None O
β3 None None O
integrin None None I-PROTEIN
dramatically None None O
impairs None None O
spontaneous None None O
( None None O
but None None O
not None None O
experimental None None O
) None None O
metastasis None None O
to None None O
bone None None O
and None None O
lung None None O
without None None O
affecting None None O
primary None None O
tumour None None O
growth None None O
in None None O
the None None O
mammary None None O
gland None None O
. None None O

Tumour None None O
β3 None None O
integrin None None I-PROTEIN
promoted None None O
migration None None O
, None None O
protease None None O
expression None None O
and None None O
trans-endothelial None None O
migration None None O
in None None O
vitro None None O
and None None O
increased None None O
vascular None None O
dissemination None None O
in None None O
vivo None None O
, None None O
but None None O
was None None O
not None None O
necessary None None O
for None None O
bone None None O
colonization None None O
in None None O
experimental None None O
metastasis None None O
assays None None O
. None None O

In None None O
this None None O
study None None O
we None None O
aimed None None O
to None None O
investigate None None O
the None None O
changes None None O
in None None O
the None None O
levels None None O
of None None O
SIRT2 None None O
, None None O
NFκB None None O
and None None O
FoXO1 None None O
and None None O
oxidative None None O
parameters None None O
of None None O
colonic None None O
mucosa None None O
during None None O
aging None None O
, None None O
and None None O
the None None O
effects None None O
of None None O
exogenous None None O
melatonin None None I-TRANS
( None None O
MLT None None O
) None None O
. None None O

In None None O
conclusion None None O
, None None O
our None None O
findings None None O
suggest None None O
a None None O
suppressive None None O
role None None O
of None None O
melatonin None None I-TRANS
in None None O
the None None O
aging None None O
process None None O
of None None O
colonic None None O
tissue None None O
via None None O
decreasing None None O
SIRT2 None None O
expression None None O
. None None O

To None None O
understand None None O
circadian None None O
disfunction None None O
in None None O
the None None O
age-related None None O
neurodegenerative None None O
disorder None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
, None None O
the None None O
rotenone-induced None None O
PD None None O
( None None O
RIPD None None O
) None None O
male None None O
Wistar None None O
rat None None O
model None None O
was None None O
used None None O
. None None O

There None None O
was None None O
significant None None O
decrease None None O
in None None O
the None None O
mean None None O
24 None None O
h None None O
levels None None O
of None None O
tryptophan None None I-TRANS
, None None O
5-hydroxytryptophan None None I-TRANS
( None None O
5-HTP None None I-TRANS
) None None O
, None None O
serotonin None None I-TRANS
( None None O
5-HT None None I-TRANS
) None None O
, None None O
N-acetyl None None O
serotonin None None I-TRANS
( None None O
NAS None None I-TRANS
) None None O
and None None O
melatonin None None I-TRANS
( None None O
MEL None None O
) None None O
by None None O
approximately None None O
63 None None O
, None None O
51 None None O
, None None O
76 None None O
and None None O
96 None None O
% None None O
respectively None None O
( None None O
p None None O
≤ None None O
0.05 None None O
) None None O
. None None O

As None None O
melatonin None None I-TRANS
, None None O
an None None O
antioxidant None None O
and None None O
an None None O
endogenous None None O
synchronizer None None O
of None None O
rhythm None None O
declined None None O
in None None O
RIPD None None O
male None None O
Wistar None None O
rat None None O
model None None O
, None None O
the None None O
effects None None O
of None None O
melatonin-administration None None O
on None None O
the None None O
rhythmic None None O
expression None None O
of None None O
various None None O
clock None None O
genes None None O
were None None O
studied None None O
. None None O

Postoperative None None O
intermediate None None O
care None None O
enhanced None None O
perceptions None None I-FUNC
of None None O
quality None None O
of None None O
care None None O
, None None O
specifically None None O
in None None O
patients None None O
with None None O
a None None O
perceived None None O
complicated None None O
disease None None O
course None None O
. None None O

Intermediate None None O
care None None O
may None None O
increase None None O
patient None None O
perceptions None None I-FUNC
of None None O
quality None None O
and None None O
safety None None O
of None None O
care None None O
. None None O

There None None O
is None None O
growing None None O
evidence None None O
that None None O
cerebellum None None I-REGION
plays None None O
a None None O
crucial None None O
role None None O
in None None O
cognition None None O
and None None O
emotional None None O
regulation None None O
. None None O

The None None O
objective None None O
of None None O
our None None O
study None None O
was None None O
to None None O
compare None None O
cerebellar None None O
size None None O
between None None O
patients None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
, None None O
and None None O
healthy None None O
controls None None O
in None None O
a None None O
multicenter None None O
sample None None O
. None None O

One None None O
hundred None None O
and None None O
fifteen None None O
patients None None O
with None None O
bipolar None None I-DISEASE
I None None I-DISEASE
disorder None None I-DISEASE
, None None O
32 None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
, None None O
and None None O
52 None None O
healthy None None O
controls None None O
underwent None None O
3 None None O
Tesla None None O
MRI None None O
. None None O

Volumes None None O
of None None O
cerebellar None None I-REGION
cortex None None I-REGION
and None None O
white None None I-REGION
matter None None I-REGION
were None None O
extracted None None O
. None None O

Bilateral None None O
cerebellar None None O
cortical None None O
volumes None None O
were None None O
smaller None None O
in None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
compared None None O
with None None O
patients None None O
with None None O
bipolar None None I-DISEASE
I None None I-DISEASE
disorder None None I-DISEASE
and None None O
healthy None None O
controls None None O
. None None O

No None None O
change None None O
was None None O
evidenced None None O
in None None O
white None None I-REGION
matter None None I-REGION
. None None O

Cerebellar None None O
dysfunction None None O
in None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
if None None O
present None None O
, None None O
appears None None O
to None None O
be None None O
more None None O
subtle None None O
than None None O
a None None O
reduction None None O
in None None O
cerebellar None None O
volume None None O
. None None O

The None None O
performance None None O
of None None O
Whatman None None O
3-MM None None O
filter None None O
papers None None O
for None None O
the None None O
collection None None O
, None None O
drying None None O
, None None O
shipment None None O
and None None O
long-term None None O
storage None None I-FUNC
of None None O
blood None None O
at None None O
ambient None None O
temperature None None O
, None None O
and None None O
for None None O
the None None O
detection None None O
of None None O
African None None O
swine None None O
fever None None O
virus None None O
and None None O
antibodies None None O
was None None O
assessed None None O
. None None O

Pharmacological None None O
tools None None O
combined None None O
with None None O
RNA None None O
interference None None O
demonstrate None None O
that None None O
secretagogin None None O
's None None O
loss None None O
of None None O
function None None O
occludes None None O
adrenocorticotropic None None I-TRANS
hormone None None I-TRANS
release None None O
from None None O
the None None O
pituitary None None O
and None None O
lowers None None O
peripheral None None O
corticosterone None None O
levels None None O
in None None O
response None None O
to None None O
acute None None O
stress None None O
. None None O

We None None O
discovered None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
Bl None None O
( None None O
Bitter None None O
leaf None None O
) None None O
and None None O
Bt None None O
( None None O
Bitter None None O
fruit None None O
) None None O
that None None O
regulate None None O
this None None O
pathway None None O
in None None O
leaves None None O
and None None O
fruits None None O
, None None O
respectively None None O
. None None O

These None None O
studies None None O
show None None O
that None None O
forgetting None None O
from None None O
collective None None O
memory None None I-FUNC
can None None O
be None None O
studied None None O
empirically None None O
, None None O
as None None O
with None None O
forgetting None None O
in None None O
other None None O
forms None None O
of None None O
memory None None I-FUNC
. None None O

Here None None O
, None None O
we None None O
report None None O
that None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
TCR None None O
) None None O
and None None O
costimulatory None None O
signals None None O
imprint None None O
an None None O
early None None O
, None None O
cell-intrinsic None None O
, None None O
division None None O
fate None None O
, None None O
whereby None None O
cells None None O
effectively None None O
count None None O
through None None O
generations None None O
before None None O
returning None None O
automatically None None O
to None None O
a None None O
quiescent None None O
state None None O
. None None O

Signals None None O
from None None O
the None None O
TCR None None O
, None None O
costimulatory None None O
receptors None None I-PROTEIN
, None None O
and None None O
cytokines None None O
add None None O
together None None O
using None None O
a None None O
linear None None O
division None None O
calculus None None O
, None None O
allowing None None O
the None None O
strength None None O
of None None O
a None None O
T None None O
cell None None O
response None None O
to None None O
be None None O
predicted None None O
from None None O
the None None O
sum None None O
of None None O
the None None O
underlying None None O
signal None None O
components None None O
. None None O

ICLs None None O
can None None O
be None None O
repaired None None O
by None None O
the None None O
Fanconi None None O
anemia None None O
( None None O
FA None None O
) None None O
pathway None None O
and None None O
through None None O
FA-independent None None O
processes None None O
involving None None O
the None None O
FAN1 None None O
nuclease None None I-PROTEIN
. None None O

In None None O
vitro None None O
, None None O
this None None O
exonuclease None None I-PROTEIN
mechanism None None O
allows None None O
FAN1 None None O
to None None O
excise None None O
an None None O
ICL None None O
from None None O
one None None O
strand None None O
through None None O
flanking None None O
incisions None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
community-based None None O
survey None None O
was None None O
to None None O
investigate None None O
attitudes None None O
towards None None O
online None None O
self-help None None O
for None None O
eating None None I-DISEASE
disorders None None I-DISEASE
and None None O
the None None O
support None None O
required None None O
whilst None None O
using None None O
such None None O
an None None O
approach None None O
. None None O

Attitudes None None O
towards None None O
online None None O
self-help None None O
( None None O
SH None None O
) None None O
for None None O
eating None None I-DISEASE
disorders None None I-DISEASE
were None None O
very None None O
positive None None O
. None None O

Online None None O
self-help None None O
for None None O
eating None None I-DISEASE
disorders None None I-DISEASE
is None None O
a None None O
desirable None None O
treatment None None O
option None None O
for None None O
many None None O
individuals None None O
. None None O

Fear None None O
to None None O
predictable None None O
threat None None O
and None None O
anxiety None None O
to None None O
unpredictable None None O
threat None None O
reflect None None O
distinct None None O
processes None None O
mediated None None O
by None None O
different None None O
brain None None O
structures None None O
, None None O
the None None O
central None None I-REGION
nucleus None None I-REGION
of None None O
the None None O
amygdala None None I-REGION
and None None O
the None None O
bed None None O
nucleus None None O
of None None O
the None None O
stria None None I-REGION
terminalis None None I-REGION
( None None O
BNST None None O
) None None O
, None None O
respectively None None O
. None None O

Here None None O
, None None O
we None None O
used None None O
stress-enhanced None None O
fear None None O
learning None None I-FUNC
( None None O
SEFL None None O
) None None O
, None None O
an None None O
animal None None O
model None None O
of None None O
the None None O
disorder None None O
, None None O
to None None O
examine None None O
the None None O
role None None O
of None None O
central None None O
IL-1β None None O
in None None O
PTSD None None O
. None None O

There None None O
was None None O
no None None O
increase None None O
in None None O
IL-1β None None O
in None None O
the None None O
basolateral None None O
amygdala None None I-REGION
or None None O
the None None O
perirhinal None None I-REGION
cortex None None I-REGION
. None None O

Here None None O
, None None O
we None None O
examined None None O
the None None O
efficacy None None O
of None None O
dietary None None O
curcumin None None O
at None None O
impairing None None O
the None None O
consolidation None None O
and None None O
reconsolidation None None O
of None None O
a None None O
Pavlovian None None O
fear None None O
memory None None I-FUNC
, None None O
a None None O
widely None None O
studied None None O
animal None None O
model None None O
of None None O
traumatic None None O
memory None None I-FUNC
formation None None O
in None None O
posttraumatic None None O
stress None None O
disorder None None O
( None None O
PTSD None None O
) None None O
. None None O

Next None None O
, None None O
we None None O
show None None O
that None None O
dietary None None O
curcumin None None O
impairs None None O
the None None O
'reconsolidation None None O
' None None O
of None None O
a None None O
recently None None O
formed None None O
auditory None None O
Pavlovian None None O
fear None None O
memory None None I-FUNC
; None None O
fear None None O
memory None None I-FUNC
retrieval None None O
( None None O
reactivation None None O
) None None O
and None None O
postreactivation None None O
( None None O
PR None None O
) None None O
-STM None None O
are None None O
intact None None O
, None None O
whereas None None O
PR-LTM None None O
is None None O
significantly None None O
impaired None None O
. None None O

The None None O
decrease None None O
in None None O
the None None O
energy None None O
absorbed None None O
and None None O
the None None O
dissipation None None O
coefficient None None O
following None None O
repeated None None O
inversions None None O
may None None O
be None None O
due None None O
to None None O
the None None O
slippage None None O
of None None O
collagen None None I-PROTEIN
fibers None None O
. None None O

Data None None O
were None None O
collected None None O
on None None O
172 None None O
patients None None O
with None None O
RCC None None O
and None None O
IVC None None O
( None None O
levels None None O
I-IV None None O
) None None O
venous None None O
tumour None None O
thrombus None None O
who None None O
underwent None None O
radical None None O
nephrectomy None None O
with None None O
tumour None None O
thrombectomy None None O
at None None O
the None None O
Mayo None None O
Clinic None None O
between None None O
2000 None None O
and None None O
2010 None None O
. None None O

PCNL None None O
seems None None O
a None None O
safe None None O
and None None O
effective None None O
option None None O
in None None O
cases None None O
of None None O
a None None O
single None None O
kidney None None O
, None None O
but None None O
it None None O
needs None None O
more None None O
attention None None I-FUNC
in None None O
order None None O
to None None O
prevent None None O
even None None O
minor None None O
complications None None O
that None None O
can None None O
result None None O
in None None O
an None None O
anephric None None O
state None None O
. None None O

However None None O
, None None O
gastrulation None None O
defects None None O
were None None O
associated None None O
with None None O
a None None O
virtual None None O
absence None None O
of None None O
cortical None None O
actin None None I-PROTEIN
in None None O
the None None O
ectodermal None None O
cells None None O
that None None O
face None None O
the None None O
blastocoel None None O
cavity None None O
and None None O
this None None O
was None None O
phenocopied None None O
in None None O
embryos None None O
expressing None None O
dominant-negative None None O
IRF6 None None O
. None None O

In None None O
conclusion None None O
, None None O
we None None O
showed None None O
that None None O
in None None O
mice None None O
RIPK4 None None O
is None None O
implicated None None O
in None None O
cortical None None O
actin None None I-PROTEIN
organization None None O
and None None O
in None None O
E-cadherin None None O
localization None None O
or None None O
function None None O
, None None O
which None None O
can None None O
explain None None O
the None None O
characteristic None None O
epithelial None None O
fusions None None O
observed None None O
in None None O
PPSs None None O
. None None O

Chemical None None O
inhibition None None O
study None None O
and None None O
recombinant None None O
human None None O
P450 None None O
isoforms None None O
analysis None None O
showed None None O
that None None O
CYP3A4 None None I-PROTEIN
was None None O
the None None O
predominant None None O
isoform None None O
involved None None O
in None None O
the None None O
oxidative None None O
metabolism None None O
of None None O
M1-1 None None O
and None None O
M1-2 None None O
. None None O

But None None O
also None None O
the None None O
need None None O
for None None O
a None None O
multidisciplinary None None O
approach None None O
can None None O
make None None O
the None None O
decision None None I-FUNC
making None None I-FUNC
difficult None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
used None None O
paired None None O
bone None None O
biopsies None None O
from None None O
the None None O
femur None None O
shaft None None O
and None None O
blood None None O
samples None None O
from None None O
persons None None O
of None None O
different None None O
ages None None O
to None None O
analyze None None O
age-related None None O
changes None None O
of None None O
plasma None None O
and None None O
memory None None I-FUNC
B None None O
cells None None O
. None None O

The None None O
frequency None None O
of None None O
plasma None None O
and None None O
memory None None I-FUNC
B None None O
cells None None O
from None None O
both None None O
sources None None O
decreased None None O
with None None O
age None None O
, None None O
while None None O
immature None None O
and None None O
naïve None None O
B None None O
cells None None O
were None None O
unaffected None None O
. None None O

With None None O
the None None O
exception None None O
of None None O
cytomegalovirus None None O
, None None O
peripheral None None O
antibody None None O
concentrations None None O
correlated None None O
with None None O
BM None None O
plasma None None O
cells None None O
of None None O
the None None O
same None None O
specificity None None O
, None None O
but None None O
were None None O
independent None None O
of None None O
antigen-specific None None O
peripheral None None O
blood None None O
memory None None I-FUNC
B None None O
cells None None O
. None None O

Researchers None None O
and None None O
funding None None O
agencies None None O
are None None O
increasingly None None O
showing None None O
interest None None O
in None None O
the None None O
application None None O
of None None O
research None None O
findings None None O
and None None O
focusing None None O
attention None None I-FUNC
on None None O
engagement None None O
of None None O
knowledge-users None None O
in None None O
the None None O
research None None O
process None None O
as None None O
a None None O
means None None O
of None None O
increasing None None O
the None None O
uptake None None O
of None None O
research None None O
findings None None O
. None None O

The None None O
nucleotide None None O
sequence None None O
encoding None None I-FUNC
for None None O
the None None O
internal None None O
transcribed None None O
spacer None None O
( None None O
ITS None None O
) None None O
of None None O
the None None O
nuclear None None O
ribosomal None None O
RNA None None O
has None None O
recently None None O
been None None O
proposed None None O
as None None O
a None None O
standard None None O
marker None None O
for None None O
molecular None None O
identification None None O
of None None O
fungi None None O
and None None O
evaluation None None O
of None None O
fungal None None O
diversity None None O
. None None O

Amyloid None None O
β None None O
peptide None None O
( None None O
Aβ None None O
) None None O
immunization None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
patients None None O
has None None O
been None None O
reported None None O
to None None O
induce None None O
amyloid None None O
plaque None None O
removal None None O
, None None O
but None None O
with None None O
little None None O
impact None None O
on None None O
cognitive None None O
decline None None O
. None None O

The None None O
full-length None None O
cDNA None None O
( None None O
2320 None None O
bp None None O
) None None O
encoding None None I-FUNC
a None None O
putative None None O
iron-binding None None O
transferrin None None O
protein None None O
from None None O
Helicoverpa None None O
armigera None None O
was None None O
cloned None None O
and None None O
named None None O
HaTrf None None O
. None None O

To None None O
examine None None O
whether None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
patients None None O
who None None O
stop None None O
cannabis None None O
use None None O
during None None O
a None None O
manic/mixed None None O
episode None None O
have None None O
better None None O
clinical None None O
and None None O
functional None None O
outcomes None None O
than None None O
continued None None O
use None None O
or None None O
never None None O
use None None O
. None None O

MEMBERS None None O
OF None None O
the None None O
photography None None O
group None None O
at None None O
Middleton None None O
Hall None None O
Retirement None None O
Village None None O
in None None O
County None None O
Durham None None O
have None None O
used None None O
their None None O
skills None None O
to None None O
create None None O
a None None O
calendar None None O
to None None O
help None None O
raise None None O
funds None None O
for None None O
the None None O
organisation None None O
's None None O
chosen None None O
charity None None O
, None None O
the None None O
Alzheimer None None I-DISEASE
's None None O
Society None None O
. None None O

MARY None None O
MARSHALL None None O
and None None O
Jane None None O
Gilliard None None O
are None None O
internationally None None O
acclaimed None None O
authors None None O
in None None O
many None None O
aspects None None O
of None None O
dementia None None I-DISEASE
care None None O
. None None O

This None None O
study None None O
matched None None O
1,796 None None O
people None None O
with None None O
a None None O
diagnosis None None O
of None None O
Alzheimer None None I-DISEASE
's None None O
with None None O
7,184 None None O
people None None O
over None None O
the None None O
age None None O
of None None O
66 None None O
who None None O
did None None O
not None None O
have None None O
the None None O
condition None None O
. None None O

Findings None None O
showed None None O
an None None O
association None None O
with None None O
increased None None O
risk None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Delirium None None O
is None None O
a None None O
clinical None None O
syndrome None None O
where None None O
the None None O
patient None None O
has None None O
disturbed None None O
consciousness None None I-FUNC
- None None O
reduced None None O
awareness None None O
of None None O
the None None O
environment None None O
, None None O
reduced None None O
ability None None O
to None None O
focus None None O
, None None O
sustain None None O
or None None O
shift None None O
attention None None I-FUNC
, None None O
cognitive None None O
function None None O
- None None O
difficulty None None O
with None None O
problem None None I-FUNC
solving None None I-FUNC
, None None O
or None None O
memory None None I-FUNC
, None None O
or None None O
perception None None I-FUNC
, None None O
which None None O
can None None O
develop None None O
over None None O
hours None None O
or None None O
days None None O
and None None O
with None None O
symptoms None None O
that None None O
can None None O
fluctuate None None O
over None None O
minutes None None O
, None None O
hours None None O
or None None O
days None None O
. None None O

All None None O
patients None None O
now None None O
have None None O
a None None O
comprehensive None None O
record None None O
of None None O
bowel None None O
movements None None I-FUNC
. None None O

Dementia None None I-DISEASE
care None None O
environments None None O
are None None O
now None None O
home None None O
to None None O
thousands None None O
of None None O
people None None O
who None None O
have None None O
complex None None O
mental None None O
and None None O
physical None None O
health None None O
needs None None O
. None None O

Images None None O
were None None O
evaluated None None O
for None None O
the None None O
following None None O
: None None O
the None None O
presence None None O
of None None O
persistent None None O
vascular None None O
compression None None O
of None None O
the None None O
facial None None I-REGION
nerve None None I-REGION
, None None O
type None None O
of None None O
culprit None None O
vessel None None O
( None None O
artery None None O
or None None O
vein None None O
) None None O
, None None O
name None None O
of None None O
the None None O
culprit None None O
artery None None O
, None None O
segment None None O
of None None O
the None None O
nerve None None O
in None None O
contact None None O
with None None O
the None None O
vessel None None O
, None None O
and None None O
location None None O
of None None O
the None None O
point None None O
of None None O
contact None None O
relative None None O
to None None O
the None None O
existing None None O
surgical None None O
pledget None None O
. None None O

Compression None None O
of None None O
the None None O
attached None None O
segment None None O
( None None O
along None None O
the None None O
ventral None None I-NEURON
surface None None O
of None None O
the None None O
pons None None I-REGION
) None None O
was None None O
identified None None O
in None None O
most None None O
patients None None O
( None None O
58 None None O
% None None O
, None None O
7/12 None None O
) None None O
. None None O

Glucose None None O
nanosensors None None O
are None None O
being None None O
incorporated None None O
in None None O
implantable None None O
devices None None O
that None None O
enable None None O
more None None O
accurate None None O
and None None O
patient-friendly None None O
real-time None None O
tracking None None O
of None None O
blood None None O
glucose None None O
levels None None O
, None None O
and None None O
are None None O
also None None O
providing None None O
the None None O
basis None None O
for None None O
glucose-responsive None None O
nanoparticles None None O
that None None O
better None None O
mimic None None O
the None None O
body None None O
's None None O
physiological None None O
needs None None O
for None None O
insulin None None I-PROTEIN
. None None O

Overactivity None None O
or None None O
contractures None None O
of None None O
the None None O
hamstring None None O
muscles None None O
in None None O
ambulatory None None O
children None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
CP None None O
) None None O
can None None O
lead None None O
to None None O
either None None O
a None None O
jump None None O
gait None None O
( None None O
knee None None O
flexion None None O
associated None None O
with None None O
ankle None None O
plantar None None O
flexion None None O
) None None O
or None None O
a None None O
crouch None None O
gait None None O
( None None O
knee None None O
flexion None None O
associated None None O
with None None O
ankle None None O
dorsiflexion None None O
) None None O
. None None O

However None None O
, None None O
cannabinoid None None O
receptors None None I-PROTEIN
and None None O
TRPV1 None None O
were None None O
not None None O
involved None None O
in None None O
the None None O
hypothermic None None O
effects None None O
of None None O
dipyrone None None O
. None None O

Natural None None O
regeneration None None O
from None None O
these None None O
stands None None O
was None None O
transferred None None O
to None None O
a None None O
common None None O
garden None None O
and None None O
used None None O
to None None O
investigate None None O
the None None O
expression None None O
of None None O
genes None None O
for None None O
abscisic None None O
acid None None O
( None None O
ABA None None O
) None None O
-related None None O
drought None None O
signaling None None O
[ None None O
9-cis-epoxy-dioxygenase None None O
( None None O
NCED None None O
) None None O
, None None O
protein None None O
phosphatase None None I-PROTEIN
2C None None O
( None None O
PP2C None None O
) None None O
, None None O
early None None O
responsive None None O
to None None O
dehydration None None O
( None None O
ERD None None O
) None None O
] None None O
and None None O
stress None None O
protection None None O
[ None None O
ascorbate None None O
peroxidase None None O
( None None O
APX None None O
) None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
( None None O
ALDH None None O
) None None O
, None None O
glutamine None None I-TRANS
amidotransferase None None O
( None None O
GAT None None O
) None None O
] None None O
that None None O
are None None O
involved None None O
in None None O
drought None None O
acclimation None None O
. None None O

We None None O
recently None None O
reported None None O
that None None O
cullin None None O
4B None None O
( None None O
CUL4B None None O
) None None O
, None None O
a None None O
scaffold None None O
protein None None O
that None None O
assembles None None O
CRL4B None None O
ubiquitin None None O
ligase None None I-PROTEIN
complexes None None O
, None None O
is None None O
overexpressed None None O
in None None O
many None None O
types None None O
of None None O
solid None None O
tumours None None O
and None None O
contributes None None O
to None None O
epigenetic None None O
silencing None None O
of None None O
tumour None None O
suppressors None None O
. None None O

Furthermore None None O
, None None O
CRL4B None None O
promoted None None O
the None None O
recruitment None None O
and/or None None O
retention None None I-FUNC
of None None O
PRC2 None None O
at None None O
the None None O
promoters None None O
of None None O
Wnt None None O
antagonists None None O
and None None O
CUL4B None None O
knockdown None None O
decreased None None O
the None None O
retention None None I-FUNC
of None None O
PRC2 None None O
components None None O
as None None O
well None None O
as None None O
H3K27me3 None None O
. None None O

It None None O
is None None O
of None None O
great None None O
importance None None O
to None None O
study None None O
the None None O
physiological None None O
roles None None O
of None None O
enzymes None None I-PROTEIN
in None None O
nature None None O
; None None O
however None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
it None None O
is None None O
not None None O
easily None None O
apparent None None O
. None None O

However None None O
, None None O
it None None O
is None None O
rather None None O
unfortunate None None O
that None None O
the None None O
focus None None O
on None None O
the None None O
use None None O
of None None O
penicillin None None O
acylases None None O
for None None O
industrial None None O
applications None None O
has None None O
stolen None None O
the None None O
spotlight None None O
from None None O
the None None O
study None None O
of None None O
the None None O
importance None None O
of None None O
these None None O
enzymes None None I-PROTEIN
in None None O
natural None None O
metabolism None None O
. None None O

These None None O
enzymes None None I-PROTEIN
are None None O
also None None O
closely None None O
related None None O
to None None O
the None None O
bacterial None None O
signalling None None O
phenomenon None None O
, None None O
quorum None None O
sensing None None O
, None None O
as None None O
detailed None None O
in None None O
this None None O
review None None O
. None None O

We None None O
also None None O
attempt None None O
to None None O
organize None None O
the None None O
available None None O
insights None None O
into None None O
the None None O
possible None None O
in None None O
vivo None None O
role None None O
of None None O
penicillin None None O
acylases None None O
and None None O
related None None O
enzymes None None I-PROTEIN
and None None O
emphasize None None O
the None None O
need None None O
to None None O
refocus None None O
research None None O
efforts None None O
in None None O
this None None O
direction None None O
. None None O

Serum None None O
amyloid None None O
A None None O
( None None O
SAA None None O
) None None O
is None None O
another None None O
major None None O
APP None None I-TRANS
in None None O
dogs None None O
that None None O
is None None O
not None None O
yet None None O
as None None O
widely None None O
used None None O
. None None O

AT2R None None O
overexpression None None O
resulted None None O
in None None O
significantly None None O
reduced None None O
cell None None O
viability None None O
and None None O
subsequently None None O
impaired None None O
glucose-stimulated None None O
insulin None None I-PROTEIN
secretion None None O
( None None O
GSIS None None O
) None None O
function None None O
in None None O
INS-1 None None O
cells None None O
. None None O

Our None None O
findings None None O
suggested None None O
that None None O
AT2R None None O
overexpression None None O
triggers None None O
the None None O
apoptosis None None O
of None None O
INS-1 None None O
cells None None O
and None None O
dysfunction None None O
in None None O
insulin None None I-PROTEIN
secretion None None O
. None None O

Fixed-combination None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
-lowering None None O
medications None None O
simplify None None O
treatment None None O
regimens None None O
for None None O
patients None None O
requiring None None O
2 None None O
ocular None None O
hypotensive None None O
agents None None O
to None None O
maintain None None O
sufficiently None None O
low None None O
IOP None None I-TRANS
. None None O

IOP None None I-TRANS
was None None O
assessed None None O
at None None O
9 None None O
a.m. None None O
and None None O
11 None None O
a.m. None None O
during None None O
week None None O
2 None None O
, None None O
week None None O
6 None None O
, None None O
month None None O
3 None None O
, None None O
and None None O
month None None O
6 None None O
visits None None O
. None None O

Supportive None None O
endpoints None None O
included None None O
mean None None O
IOP None None I-TRANS
, None None O
IOP None None I-TRANS
change None None O
from None None O
baseline None None O
, None None O
and None None O
percentage None None O
of None None O
patients None None O
with None None O
IOP None None I-TRANS
& None None O
lt None None O
; None None O
18 None None O
mmHg None None O
. None None O

The None None O
mean None None O
diurnal None None O
IOP None None I-TRANS
change None None O
from None None O
baseline None None O
with None None O
BBFC None None O
( None None O
least None None O
squares None None O
mean None None O
± None None O
standard None None O
error None None O
-8.5 None None O
± None None O
0.16 None None O
mmHg None None O
) None None O
was None None O
noninferior None None O
to None None O
that None None O
with None None O
BRINZ None None O
+ None None O
BRIM None None O
( None None O
-8.3 None None O
± None None O
0.16 None None O
mmHg None None O
; None None O
mean None None O
difference None None O
-0.1 None None O
mmHg None None O
; None None O
95 None None O
% None None O
CI None None O
-0.5 None None O
to None None O
0.2 None None O
mmHg None None O
) None None O
. None None O

Decreases None None O
from None None O
baseline None None O
& None None O
gt None None O
; None None O
8 None None O
mmHg None None O
were None None O
observed None None O
for None None O
least None None O
squares None None O
mean None None O
diurnal None None O
IOP None None I-TRANS
in None None O
both None None O
groups None None O
as None None O
early None None O
as None None O
week None None O
2 None None O
and None None O
continued None None O
to None None O
the None None O
end None None O
of None None O
the None None O
study None None O
. None None O

Thyroid None None O
function None None O
, None None O
prolactin None None O
, None None O
adrenal None None I-TRANS
, None None O
and None None O
parathyroid None None O
hormone None None O
levels None None O
were None None O
all None None O
normal None None O
. None None O

Post None None O
hoc None None O
meta-regression None None O
analyses None None O
demonstrated None None O
that None None O
larger None None O
SMD None None O
for None None O
sleep None None O
duration None None O
were None None O
identified None None O
for None None O
studies None None O
with None None O
a None None O
greater None None O
age None None O
difference None None O
between None None O
BD None None O
cases None None O
and None None O
controls None None O
( None None O
β=0.22 None None O
; None None O
P=0.03 None None O
) None None O
and None None O
non-significantly None None O
lower None None O
levels None None O
of None None O
residual None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
BD None None O
cases None None O
( None None O
β=-0.13 None None O
; None None O
P=0.07 None None O
) None None O
. None None O

Future None None O
actigraphy None None O
studies None None O
should None None O
pay None None O
attention None None I-FUNC
to None None O
age None None O
matching None None O
and None None O
levels None None O
of None None O
residual None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

A None None O
narrative None None O
review None None O
of None None O
recent None None O
peer-reviewed None None O
literature None None O
( None None O
published None None O
between None None O
1995 None None O
and None None O
2014 None None O
) None None O
was None None O
performed None None O
using None None O
as None None O
the None None O
search None None O
terms None None O
: None None O
Intensive None None O
care None None O
medicine None None O
, None None O
Microbiological None None O
techniques None None O
, None None O
Clinical None None O
laboratory None None O
techniques None None O
, None None O
Diagnosis None None O
, None None O
and None None O
Rapid None None O
diagnosis None None O
, None None O
with None None O
no None None O
language None None I-FUNC
restrictions None None O
. None None O

In None None O
chronic None None O
dermatoses None None O
such None None O
as None None O
eczema None None O
and None None O
psoriasis None None O
, None None O
the None None O
anogenital None None O
area None None O
is None None O
commonly None None O
involved None None O
, None None O
but None None O
often None None O
not None None O
mentioned None None O
by None None O
patients None None O
due None None O
to None None O
feelings None None I-FUNC
of None None O
shame None None O
or None None O
because None None O
skin None None O
changes None None O
in None None O
other None None O
body None None O
areas None None O
are None None O
more None None O
prominent None None O
. None None O

Previously None None O
, None None O
we None None O
reported None None O
that None None O
the None None O
intracellular None None O
bacterial None None O
pathogen None None O
Listeria None None O
monocytogenes None None O
responds None None O
to None None O
low None None O
availability None None O
of None None O
branched-chain None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
BCAAs None None O
) None None O
within None None O
mammalian None None O
cells None None O
by None None O
up-regulating None None O
both None None O
BCAA None None O
biosynthesis None None O
and None None O
virulence None None O
genes None None O
. None None O

Cartilage None None O
can None None O
be None None O
obtained None None O
from None None O
the None None O
septum None None I-REGION
, None None O
ear None None O
, None None O
or None None O
costal None None O
cartilage None None O
when None None O
employing None None O
the None None O
DC-F None None O
technique None None O
. None None O

Levels None None O
of None None O
ADAMTS13 None None O
were None None O
positively None None O
correlated None None O
with None None O
platelet None None O
count None None O
while None None O
inversely None None O
correlated None None O
with None None O
partial None None O
thromboplastin None None O
time None None O
, None None O
serum None None O
ferritin None None I-PROTEIN
, None None O
and None None O
VWF None None O
: None None O
Ag None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
biological None None O
effects None None O
of None None O
carbohydrate None None O
antigens None None O
are None None O
reviewed None None O
in None None O
setting None None O
of None None O
receptors None None I-PROTEIN
and None None O
host None None O
recognition None None O
. None None O

Two None None O
main None None O
uses None None O
of None None O
categories None None O
are None None O
classification None None O
and None None O
feature None None O
inference None None I-FUNC
, None None O
and None None O
category None None O
labels None None O
have None None O
been None None O
widely None None O
shown None None O
to None None O
play None None O
a None None O
dominant None None O
role None None O
in None None O
feature None None O
inference None None I-FUNC
. None None O

The None None O
special-mechanism None None O
hypothesis None None O
is None None O
that None None O
category None None O
labels None None O
, None None O
unlike None None O
other None None O
features None None O
, None None O
trigger None None O
inference None None I-FUNC
decision None None I-FUNC
making None None I-FUNC
in None None O
reference None None O
to None None O
the None None O
category None None O
prototypes None None O
. None None O

Stenosis None None O
of None None O
the None None O
TIPS None None O
was None None O
observed None None O
in None None O
two None None O
children None None O
, None None O
at None None O
9 None None O
months None None O
and None None O
54 None None O
months None None O
follow-up None None O
, None None O
and None None O
thrombosis None None I-DISEASE
was None None O
observed None None O
in None None O
two None None O
children None None O
, None None O
at None None O
7 None None O
months None None O
and None None O
12 None None O
months None None O
follow-up None None O
. None None O

The None None O
lateral None None O
movement None None I-FUNC
of None None O
soil None None O
carbon None None O
has None None O
a None None O
profound None None O
effect None None O
on None None O
the None None O
carbon None None O
budget None None O
of None None O
terrestrial None None O
ecosystems None None O
; None None O
however None None O
, None None O
it None None O
has None None O
never None None O
been None None O
quantified None None O
in None None O
China None None O
, None None O
which None None O
is None None O
one None None O
of None None O
the None None O
strongest None None O
soil None None O
erosion None None O
areas None None O
in None None O
the None None O
world None None O
. None None O

Our None None O
results None None O
showed None None O
that None None O
the None None O
lateral None None O
movement None None I-FUNC
of None None O
soil None None O
carbon None None O
strongly None None O
alters None None O
the None None O
carbon None None O
budget None None O
in None None O
China None None O
, None None O
and None None O
highlighted None None O
the None None O
urgent None None O
need None None O
to None None O
integrate None None O
the None None O
processes None None O
of None None O
soil None None O
erosion None None O
into None None O
the None None O
regional None None O
or None None O
global None None O
carbon None None O
cycle None None O
estimates None None O
. None None O

Still None None O
it None None O
is None None O
important None None O
to None None O
study None None O
nitrate None None O
transport None None O
systems None None O
in None None O
legumes None None O
because None None O
nitrate None None O
intervenes None None O
as None None O
a None None O
signal None None O
in None None O
regulation None None O
of None None O
nodulation None None O
probably None None O
through None None O
nitrate None None O
transporters None None I-PROTEIN
. None None O

Allosteric None None O
synthetic None None O
receptors None None I-PROTEIN
are None None O
difficult None None O
to None None O
access None None O
by None None O
design None None O
. None None O

An None None O
intra-articular None None O
injection None None O
of None None O
ds None None O
miR-210 None None O
was None None O
effective None None O
in None None O
the None None O
healing None None O
of None None O
the None None O
damaged None None O
white None None O
zone None None O
meniscus None None O
through None None O
promotion None None O
of None None O
the None None O
collagen None None I-PROTEIN
type None None O
2 None None O
production None None O
from None None O
meniscus None None O
cells None None O
and None None O
through None None O
upregulated None None O
of None None O
VEGF None None O
and None None O
FGF2 None None O
from None None O
synovial None None O
cells None None O
. None None O

Using None None O
a None None O
reverse None None O
genetics None None O
approach None None O
, None None O
we None None O
isolated None None O
full-length None None O
rice None None O
terpene None None O
synthase None None O
20 None None O
( None None O
OsTPS20 None None O
, None None O
599 None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
69.39 None None O
kDa None None O
) None None O
, None None O
which None None O
was None None O
further None None O
characterized None None O
as None None O
an None None O
( None None O
S None None O
) None None O
-limonene None None O
synthase None None O
by None None O
removing None None O
the None None O
N-terminal None None O
signal None None O
peptide None None O
( None None O
63 None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
of None None O
the None None O
protein None None O
. None None O

Our None None O
aim None None O
is None None O
to None None O
study None None O
the None None O
behavior None None O
of None None O
memory None None I-FUNC
Th None None O
cells None None O
( None None O
Th17 None None O
, None None O
Th17/1 None None O
, None None O
and None None O
Th1 None None O
profiles None None O
) None None O
from None None O
early None None O
rheumatoid None None O
arthritis None None O
( None None O
eRA None None O
) None None O
patients None None O
after None None O
their None None O
in None None O
vitro None None O
activation/expansion None None O
to None None O
provide None None O
information None None O
about None None O
its None None O
contribution None None O
to None None O
RA None None O
chronicity None None O
. None None O

CD4 None None O
( None None O
+ None None O
) None None O
CD45RO None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
from None None O
PBMCs None None O
of None None O
HD None None O
and None None O
eRA None None O
were None None O
activated/expanded None None O
in None None O
vitro None None O
in None None O
the None None O
presence/absence None None O
of None None O
VIP None None I-TRANS
. None None O

VIP None None I-TRANS
decreased None None O
the None None O
mRNA None None O
expression None None O
of None None O
IL-22 None None O
, None None O
IL-2 None None O
, None None O
STAT3 None None O
, None None O
Tbx21 None None O
, None None O
IL-12Rβ2 None None O
, None None O
IL-23R None None O
, None None O
and None None O
IL-21R None None O
in None None O
HD None None O
and None None O
it None None O
decreased None None O
IL-21 None None O
, None None O
IL-2 None None O
, None None O
and None None O
STAT3 None None O
in None None O
eRA None None O
. None None O

VIP None None I-TRANS
is None None O
able None None O
to None None O
modulate None None O
the None None O
pathogenic None None O
profile None None O
, None None O
mostly None None O
in None None O
HD None None O
. None None O

VIP None None I-TRANS
decreases None None O
the None None O
pathogenic None None O
Th17 None None O
, None None O
Th1 None None O
, None None O
and None None O
Th17/1 None None O
profiles None None O
, None None O
mainly None None O
in None None O
healthy None None O
donors None None O
. None None O

No None None O
significant None None O
changes None None O
in None None O
spatial None None O
ability None None O
, None None O
verbal None None O
fluency None None O
, None None O
verbal None None O
memory None None I-FUNC
, None None O
or None None O
executive None None O
function None None O
were None None O
observed None None O
in None None O
any None None O
treatment None None O
arm None None O
compared None None O
to None None O
placebo None None O
even None None O
after None None O
adjustment None None O
for None None O
baseline None None O
cognitive None None O
function None None O
, None None O
age None None O
, None None O
and None None O
education None None O
. None None O

Fibrillarin None None O
depletion None None O
abolished None None O
the None None O
systemic None None O
movement None None I-FUNC
of None None O
RSV None None O
, None None O
but None None O
not None None O
that None None O
of None None O
Tobacco None None O
mosaic None None O
virus None None O
( None None O
TMV None None O
) None None O
and None None O
Potato None None O
virus None None O
X None None O
( None None O
PVX None None O
) None None O
. None None O

Silencing None None O
of None None O
NS3 None None O
alleviated None None O
symptom None None O
severity None None O
and None None O
reduced None None O
RSV None None O
accumulation None None O
, None None O
but None None O
had None None O
no None None O
obvious None None O
effects None None O
on None None O
virus None None O
movement None None I-FUNC
and None None O
the None None O
timing None None O
of None None O
symptom None None O
development None None O
. None None O

Antipsychotics None None O
are None None O
frequently None None O
and None None O
increasingly None None O
prescribed None None O
off-label None None O
for None None O
the None None O
treatment None None O
of None None O
behavioral None None O
and None None O
psychological None None O
symptoms None None O
associated None None O
with None None O
dementia None None I-DISEASE
, None None O
despite None None O
their None None O
modest None None O
efficacy None None O
. None None O

In None None O
addition None None O
, None None O
multiple None None O
key None None O
enzymes None None I-PROTEIN
representing None None O
methylotrophic None None O
and None None O
biosynthetic None None O
pathways None None O
have None None O
been None None O
biochemically None None O
characterized None None O
. None None O

Here None None O
, None None O
we None None O
summarize None None O
the None None O
current None None O
status None None O
of None None O
its None None O
metabolism None None O
and None None O
biochemistry None None O
, None None O
available None None O
genetic None None O
tools None None O
, None None O
and None None O
its None None O
potential None None O
use None None O
in None None O
respect None None O
to None None O
overproduction None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

In None None O
this None None O
article None None O
, None None O
the None None O
DFA-producing None None O
microorganisms None None O
are None None O
summarized None None O
, None None O
relevant None None O
studies None None O
on None None O
various None None O
DFAs-producing None None O
enzymes None None I-PROTEIN
are None None O
reviewed None None O
, None None O
and None None O
especially None None O
, None None O
the None None O
comparisons None None O
of None None O
the None None O
enzymes None None I-PROTEIN
are None None O
presented None None O
in None None O
detail None None O
. None None O

administered None None O
AngII None None O
in None None O
urethane-anesthetized None None O
male None None O
rats None None O
elevates None None O
plasma None None O
adrenaline None None I-TRANS
derived None None O
from None None O
the None None O
adrenal None None I-TRANS
medulla None None O
but None None O
not None None O
noradrenaline None None I-TRANS
with None None O
valsartan- None None O
( None None O
AT1 None None O
receptor None None I-PROTEIN
blocker None None O
) None None O
sensitive None None O
brain None None O
mechanisms None None O
, None None O
( None None O
2 None None O
) None None O
peripheral None None O
AT1 None None O
receptors None None I-PROTEIN
are None None O
not None None O
involved None None O
in None None O
the None None O
AngII-induced None None O
elevation None None O
of None None O
plasma None None O
adrenaline None None I-TRANS
, None None O
although None None O
AngII None None O
induces None None O
both None None O
noradrenaline None None I-TRANS
and None None O
adrenaline None None I-TRANS
secretion None None O
from None None O
bovine None None O
adrenal None None I-TRANS
medulla None None O
cells None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
i.c.v None None O
. None None O

These None None O
patients None None O
presented None None O
with None None O
osteosclerotic None None O
myeloma None None O
( None None O
OSM None None O
, None None O
n None None O
= None None O
13 None None O
) None None O
, None None O
Castleman None None O
's None None O
disease None None O
( None None O
CD None None O
, None None O
n None None O
= None None O
4 None None O
) None None O
, None None O
OSM None None O
with None None O
CD None None O
( None None O
n None None O
= None None O
10 None None O
) None None O
, None None O
and None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
elevation None None O
without None None O
gross None None O
lesions None None O
( None None O
VEGFe None None O
, None None O
n None None O
= None None O
6 None None O
) None None O
, None None O
respectively None None O
. None None O

We None None O
used None None O
laser None None O
capture None None O
microdissection None None O
( None None O
LCM None None O
) None None O
and None None O
next-generation None None O
sequencing None None O
( None None O
NGS None None O
) None None O
to None None O
study None None O
the None None O
specific None None O
miRNA None None O
expression None None O
profiles None None O
in None None O
the None None O
epidermis None None O
( None None O
Epi None None I-TRANS
) None None O
and None None O
dermal None None O
inflammatory None None O
infiltrates None None O
( None None O
RD None None O
) None None O
of None None O
psoriatic None None O
skin None None O
( None None O
N None None O
= None None O
6 None None O
) None None O
. None None O

Peri-trauma None None O
coping None None O
was None None O
assessed None None O
using None None O
ten None None O
selected None None O
items None None O
from None None O
the None None O
`` None None O
How None None O
I None None O
Cope None None O
Under None None O
Pressure None None O
Scale None None O
'' None None O
( None None O
HICUPS None None O
) None None O
, None None O
covering None None O
the None None O
dimensions None None O
of None None O
problem None None I-FUNC
solving None None I-FUNC
, None None O
positive None None O
cognitive None None O
restructuring None None O
, None None O
avoidance None None O
, None None O
support None None O
seeking None None O
, None None O
seeking None None O
understanding None None O
, None None O
and None None O
religious None None O
coping None None O
. None None O

Problem None None I-FUNC
solving None None I-FUNC
and None None O
positive None None O
cognitive None None O
restructuring None None O
were None None O
significantly None None O
associated None None O
with None None O
fewer None None O
PTS None None O
reactions None None O
. None None O

Palmitate None None O
induces None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
apoptosis None None O
in None None O
insulin None None I-PROTEIN
target None None O
tissues None None O
. None None O

To None None O
investigate None None O
the None None O
molecular None None O
mechanism None None O
of None None O
this None None O
effect None None O
, None None O
gene None None O
expression None None O
and None None O
protein None None O
level None None O
of None None O
protein None None O
tyrosine None None I-TRANS
phosphatase None None I-PROTEIN
1B None None O
( None None O
PTP1B None None O
) None None O
were None None O
evaluated None None O
. None None O

We None None O
also None None O
evaluated None None O
the None None O
effect None None O
of None None O
RSG None None O
on None None O
palmitate-induced None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
muscle None None O
cells None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
introduced None None O
RSG None None O
as None None O
an None None O
agent None None O
that None None O
protects None None O
skeletal None None O
muscle None None O
cells None None O
against None None O
palmitate-induced None None O
apoptosis None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Two None None O
short None None O
echo None None O
time None None O
( None None O
20 None None O
ms None None O
) None None O
acquisitions None None O
of None None O
3D None None O
echo None None O
planar None None O
spectroscopic None None O
imaging None None O
at None None O
two None None O
orientations None None O
, None None O
one None None O
in None None O
the None None O
anterior None None I-REGION
commissure-posterior None None O
commissure None None I-REGION
( None None O
AC-PC None None O
) None None O
plane None None O
and None None O
the None None O
second None None O
tilted None None O
in None None O
the None None O
AC-PC None None O
+15° None None O
plane None None O
were None None O
obtained None None O
at None None O
3 None None O
Tesla None None O
in None None O
a None None O
group None None O
of None None O
10 None None O
healthy None None O
volunteers None None O
. None None O

The None None O
numbers None None O
of None None O
AAL None None O
regions None None O
showing None None O
N-acetyl None None O
aspartate None None I-TRANS
( None None O
NAA None None O
) None None O
SD/Mean None None O
ratios None None O
lower None None O
than None None O
30 None None O
% None None O
increased None None O
from None None O
17 None None O
in None None O
the None None O
AC-PC None None O
orientation None None O
and None None O
41 None None O
in None None O
the None None O
AC-PC+15° None None O
orientation None None O
, None None O
to None None O
a None None O
value None None O
of None None O
76 None None O
regions None None O
of None None O
116 None None O
for None None O
the None None O
combined None None O
NAA None None O
maps None None O
. None None O

A None None O
preliminary None None O
study None None O
aimed None None O
to None None O
understand None None O
perceptions None None I-FUNC
and None None O
to None None O
explore None None O
the None None O
level None None O
of None None O
knowledge None None O
about None None O
genetics None None O
in None None O
general None None O
, None None O
eye None None O
genetics None None O
and None None O
gene None None O
therapy None None O
. None None O

Williams-Beuren None None O
syndrome None None O
( None None O
WBS None None O
) None None O
is None None O
a None None O
genetically None None O
defined None None O
neurodevelopmental None None O
disorder None None O
presenting None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
associated None None O
with None None O
a None None O
specific None None O
neurocognitive None None O
profile None None O
characterized None None O
by None None O
anxiety None None O
, None None O
hypersociability None None O
, None None O
poor None None O
visuospatial None None O
skills None None O
and None None O
relatively None None O
preserved None None O
language None None I-FUNC
. None None O

Our None None O
results None None O
indicate None None O
that None None O
, None None O
as None None O
in None None O
other None None O
neurodevelopmental None None O
disorders None None O
, None None O
laterality None None O
is None None O
poorly None None O
defined None None O
in None None O
a None None O
significant None None O
proportion None None O
of None None O
WBS None None O
individuals None None O
, None None O
and None None O
reinforces None None O
the None None O
idea None None O
that None None O
a None None O
correct None None O
definition None None O
of None None O
lateral None None O
preference None None O
is None None O
important None None O
for None None O
cognition None None O
and None None O
language None None I-FUNC
. None None O

The None None O
potential None None O
antidepressant-like None None O
effect None None O
of None None O
acute None None O
SM None None O
and None None O
possible None None O
involvement None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
were None None O
determined None None O
in None None O
male None None O
mice None None O
. None None O

The None None O
quantitative None None O
phase None None O
signal None None O
, None None O
unlike None None O
the None None O
one None None O
provided None None O
by None None O
the None None O
widely None None O
used None None O
phase-contrast None None O
microscope None None O
, None None O
can None None O
be None None O
related None None O
to None None O
relevant None None O
biological None None O
indicators None None O
including None None O
dry None None O
mass None None O
, None None O
cell None None O
volume None None O
regulation None None O
or None None O
transmembrane None None O
water None None O
movements None None I-FUNC
. None None O

We None None O
provide None None O
procedures None None O
for None None O
controlled None None O
laser None None O
targeting None None O
and None None O
an None None O
experimental None None O
approach None None O
for None None O
studying None None O
axonal None None O
repair None None O
in None None O
embryonic None None O
rat None None O
hippocampus None None I-REGION
neurons None None O
. None None O

The None None O
virus None None O
genome None None O
is None None O
a None None O
153-kilobase None None O
pair None None O
( None None O
kbp None None O
) None None O
double-stranded None None O
DNA None None O
molecule None None O
encoding None None I-FUNC
more None None O
than None None O
80 None None O
genes None None O
. None None O

Starting None None O
on None None O
embryonic None None O
day None None O
13 None None O
, None None O
we None None O
collected None None O
precursor None None O
tissues None None O
for None None O
suprachiasmatic None None I-REGION
nucleus None None I-REGION
( None None O
SCN None None O
) None None O
, None None O
liver None None O
and None None O
kidney None None O
from None None O
embryos None None O
carrying None None O
the None None O
circadian None None O
reporter None None O
gene None None O
Per2 None None O
: None None O
:Luc None None O
and None None O
investigated None None O
rhythmicity None None O
and None None O
circadian None None O
traits None None O
of None None O
these None None O
tissues None None O
ex None None O
vivo None None O
. None None O

Machine None None O
learning None None I-FUNC
classification None None O
methods None None O
were None None O
applied None None O
to None None O
quantify None None O
the None None O
acquired None None O
data None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
expression None None O
of None None O
glutamine None None I-TRANS
synthetase None None I-PROTEIN
( None None O
GS None None O
) None None O
in None None O
prostate None None O
cancer None None O
( None None O
PCa None None O
) None None O
and None None O
the None None O
utility None None O
of None None O
[ None None O
¹³N None None O
] None None O
ammonia None None O
positron None None O
emission None None O
tomography/computed None None O
tomography None None O
( None None O
PET/CT None None O
) None None O
in None None O
the None None O
imaging None None O
of None None O
PCa None None O
. None None O

The None None O
expression None None O
of None None O
GS None None O
messenger None None O
ribonucleic None None O
acid None None O
and None None O
protein None None O
also None None O
increased None None O
when None None O
glutamine None None I-TRANS
was None None O
deprived None None O
. None None O

In None None O
turn None None O
, None None O
binary-Y2H None None O
interactions None None O
hold None None O
more None None O
bottleneck None None O
interactions None None O
than None None O
co-complex None None O
interactions None None O
while None None O
both None None O
binary-Y2H None None O
and None None O
co-complex None None O
interactions None None O
are None None O
strongly None None O
enriched None None O
among None None O
co-regulated None None O
proteins None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Lipid None None O
peroxidation None None O
( None None O
LPX None None O
) None None O
, None None O
antioxidant None None O
, None None O
proinflammatory None None O
, None None O
and None None O
arginine None None I-TRANS
metabolic None None O
enzymes None None I-PROTEIN
were None None O
estimated None None O
in None None O
the None None O
wound None None O
excised None None O
on None None O
days None None O
4 None None O
and None None O
10 None None O
post None None O
wounding None None O
. None None O

Biochemical None None O
evaluations None None O
of None None O
LPX None None O
product None None O
( None None O
malondialdehyde None None O
) None None O
, None None O
antioxidant None None O
( None None O
catalase None None I-PROTEIN
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPx None None O
) None None O
) None None O
, None None O
and None None O
pro-inflammatory None None O
( None None O
cyclooxygenase-2 None None O
and None None O
myeloperoxidase None None I-PROTEIN
( None None O
MPO None None O
) None None O
) None None O
enzyme None None O
activities None None O
and None None O
metabolites None None O
( None None O
nitrite None None O
and None None O
urea None None O
) None None O
, None None O
on None None O
days None None O
4 None None O
and None None O
10 None None O
post None None O
wounding None None O
, None None O
confirmed None None O
the None None O
anti-inflammatory None None O
and None None O
antioxidant None None O
properties None None O
of None None O
PE None None O
and None None O
PES None None O
in None None O
this None None O
study None None O
. None None O

idiopathic None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
IPD None None O
) None None O
and None None O
is None None O
technically None None O
based None None O
on None None O
stereotaxy None None O
. None None O

One None None O
examiner None None O
administered None None O
10 None None O
backward None None O
PRT None None O
trials None None O
to None None O
adults None None O
with None None O
Parkinson None None I-DISEASE
disease None None O
( None None O
12 None None O
) None None O
, None None O
multiple None None O
sclerosis None None O
( None None O
14 None None O
) None None O
and None None O
controls None None O
( None None O
12 None None O
) None None O
. None None O

We None None O
further None None O
demonstrate None None O
that None None O
FAM21 None None O
contains None None O
a None None O
functional None None O
monopartite None None O
nuclear None None O
localization None None O
signal None None O
sequence None None O
( None None O
NLS None None O
) None None O
as None None O
well None None O
as None None O
a None None O
CRM1/exportin1-dependent None None O
nuclear None None O
export None None O
signal None None O
( None None O
NES None None I-TRANS
) None None O
, None None O
both None None O
of None None O
which None None O
work None None O
jointly None None O
with None None O
the None None O
N-terminal None None O
head None None O
domain None None O
and None None O
C-terminal None None O
retromer None None O
recruitment None None O
domain None None O
to None None O
regulate None None O
FAM21 None None O
cytosolic None None O
and None None O
nuclear None None O
subcellular None None O
localization None None O
. None None O

Fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
22 None None O
( None None O
FGF22 None None O
) None None O
and None None O
FGF7 None None O
are None None O
postsynaptic-cell-derived None None O
presynaptic None None O
organizers None None O
necessary None None O
for None None O
excitatory None None O
and None None O
inhibitory None None O
presynaptic None None O
differentiation None None O
, None None O
respectively None None O
, None None O
in None None O
the None None O
hippocampus None None I-REGION
. None None O

The None None O
leiomodins None None O
( None None O
Lmod1-3 None None O
) None None O
are None None O
structurally None None O
related None None O
to None None O
Tmod1-4 None None O
and None None O
also None None O
localize None None O
to None None O
actin None None I-PROTEIN
filament None None O
pointed None None O
ends None None O
, None None O
but None None O
in None None O
vitro None None O
biochemical None None O
studies None None O
indicate None None O
that None None O
Lmods None None O
act None None O
instead None None O
as None None O
robust None None O
nucleators None None O
. None None O

Loss None None O
of None None O
Tmod4 None None O
or None None O
Lmod3 None None O
resulted None None O
in None None O
severe None None O
disruption None None O
of None None O
sarcomere None None O
assembly None None O
and None None O
impaired None None O
embryonic None None O
movement None None I-FUNC
. None None O

OnabotulinumtoxinA None None O
( None None O
onabotA None None O
) None None O
has None None O
shown None None O
its None None O
efficacy None None O
over None None O
placebo None None O
in None None O
chronic None None O
migraine None None I-DISEASE
( None None O
CM None None O
) None None O
, None None O
but None None O
clinical None None O
trials None None O
lasted None None O
only None None O
up None None O
to None None O
one None None O
year None None O
. None None O

To None None O
better None None O
understand None None O
the None None O
enzyme-inhibitor None None O
interaction None None O
of None None O
the None None O
most None None O
active None None O
compounds None None O
towards None None O
cholinesterase None None I-PROTEIN
, None None O
molecular None None O
modelling None None O
studies None None O
were None None O
carried None None O
out None None O
. None None O

Investigated None None O
as None None O
inhibitors None None O
of None None O
several None None O
human None None O
carbonic None None I-PROTEIN
anhydrase None None I-PROTEIN
( None None O
hCA None None O
, None None O
EC None None O
4.2.1.1 None None O
) None None O
isoforms None None O
, None None O
i.e None None O
. None None O

In None None O
the None None O
tertiary None None O
benzenesulfonamide None None O
family None None O
, None None O
this None None O
class None None O
of None None O
inhibitors None None O
points None None O
out None None O
a None None O
new None None O
mechanism None None O
of None None O
action None None O
for None None O
human None None O
carbonic None None I-PROTEIN
anhydrase None None I-PROTEIN
II None None O
inhibition None None O
. None None O

Of None None O
172 None None O
children None None O
eligible None None O
for None None O
analysis None None O
, None None O
60 None None O
had None None O
midline None None O
tumors None None O
primarily None None O
localized None None O
to None None O
the None None O
thalamus None None I-REGION
, None None O
hypothalamus None None I-REGION
and None None O
basal None None I-REGION
ganglia None None I-REGION
. None None O

Univariate None None O
analyses None None O
were None None O
undertaken None None O
for None None O
extent None None O
of None None O
resection None None O
, None None O
chemotherapy None None O
regimen None None O
, None None O
anatomic None None O
location None None O
, None None O
histology None None O
, None None O
proliferation None None O
index None None O
, None None O
MGMT None None O
status None None O
and None None O
p53 None None I-PROTEIN
over-expression None None O
. None None O

Hydrazinonicotinamide-annexin None None O
A5 None None O
( None None O
HYNIC-Anx None None O
) None None O
, None None O
a None None O
99m None None O
technetium None None O
( None None O
99mTc None None O
) None None O
-labeled None None O
agent None None O
targeting None None O
phosphatidylserine None None O
, None None O
proved None None O
to None None O
be None None O
sensitive None None O
for None None O
the None None O
detection None None O
of None None O
apoptosis None None O
and None None O
thrombosis None None I-DISEASE
but None None O
is None None O
no None None O
longer None None O
available None None O
for None None O
clinical None None O
use None None O
. None None O

Substance None None I-TRANS
P None None I-TRANS
modulates None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
and None None O
the None None O
excitability None None O
of None None O
sensory None None I-NEURON
neurons None None I-NEURON
in None None O
pain None None O
pathways None None O
. None None O

The None None O
same None None O
cells None None O
were None None O
then None None O
tested None None O
for None None O
modulation None None O
of None None O
action None None O
potential None None O
firing None None O
by None None O
Substance None None I-TRANS
P. None None O
Acid None None O
and None None O
capsaicin None None O
currents None None O
were None None O
more None None O
frequently None None O
encountered None None O
in None None O
the None None O
largest None None O
diameter None None O
neurons None None O
. None None O

Substance None None I-TRANS
P None None I-TRANS
modulated None None O
the None None O
excitability None None O
in None None O
20 None None O
of None None O
72 None None O
cells None None O
tested None None O
( None None O
28 None None O
% None None O
) None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
correlation None None O
between None None O
sensitivity None None O
to None None O
capsaicin None None O
and None None O
to None None O
Substance None None I-TRANS
P. None None O
Excitatory None None O
effects None None O
of None None O
Substance None None I-TRANS
P None None I-TRANS
were None None O
strongly None None O
associated None None O
with None None O
cells None None O
that None None O
had None None O
large None None O
diameters None None O
, None None O
fired None None O
APs None None O
with None None O
large None None O
overshoots None None O
and None None O
slowly None None O
decaying None None O
after None None O
hyperpolarizations None None O
, None None O
and None None O
expressed None None O
acid None None O
currents None None O
at None None O
pH None None O
7 None None O
. None None O

In None None O
contrast None None O
, None None O
neurons None None O
that None None O
exhibited None None O
inhibitory None None O
effects None None O
of None None O
Substance None None I-TRANS
P None None I-TRANS
fired None None O
action None None O
potentials None None O
with None None O
rapidly None None O
decaying None None O
after None None O
hyperpolarizations None None O
. None None O

Ten None None O
types None None O
of None None O
modification None None O
are None None O
currently None None O
supported None None O
, None None O
including None None O
acetylation None None O
, None None O
carbamylation None None O
, None None O
citrullination None None O
, None None O
cysteine None None I-TRANS
oxidation None None O
, None None O
malondialdehyde None None O
adducts None None O
, None None O
methionine None None I-TRANS
oxidation None None O
, None None O
methylation None None O
, None None O
nitration None None O
, None None O
proline None None I-TRANS
hydroxylation None None O
and None None O
phosphorylation None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
action None None O
of None None O
melatonin None None I-TRANS
on None None O
hepatic None None O
differentiation None None O
as None None O
well None None O
as None None O
its None None O
related None None O
signaling None None O
pathways None None O
of None None O
human None None O
dental None None O
pulp None None O
stem None None O
cells None None O
( None None O
hDPSCs None None O
) None None O
and None None O
to None None O
examine None None O
the None None O
therapeutic None None O
effects None None O
of None None O
a None None O
combination None None O
of None None O
melatonin None None I-TRANS
and None None O
hDPSC None None O
transplantation None None O
on None None O
carbon None None O
tetrachloride None None O
( None None O
CCl4 None None O
) None None O
-induced None None O
liver None None O
fibrosis None None O
in None None O
mice None None O
. None None O

Liver None None O
fibrosis None None O
model None None O
was None None O
established None None O
by None None O
injecting None None O
0.5 None None O
mL/kg None None O
CCl4 None None O
followed None None O
by None None O
treatment None None O
with None None O
melatonin None None I-TRANS
( None None O
5 None None O
mg/kg None None O
, None None O
twice None None O
a None None O
week None None O
) None None O
and None None O
hDPSCs None None O
. None None O

Melatonin None None I-TRANS
promoted None None O
hepatic None None O
differentiation None None O
based None None O
on None None O
mRNA None None O
expression None None O
of None None O
differentiation None None O
markers None None O
and None None O
PAS-stained None None O
glycogen-laden None None O
cells None None O
. None None O

Furthermore None None O
, None None O
melatonin None None I-TRANS
activated None None O
p38 None None O
, None None O
extracellular None None O
signal-regulated None None O
kinase None None O
( None None O
ERK None None O
) None None O
, None None O
and None None O
nuclear None None O
factor-κB None None O
( None None O
NF-κB None None O
) None None O
in None None O
hDPSCs None None O
. None None O

Compared None None O
to None None O
treatment None None O
of None None O
CCl4 None None O
-injured None None O
mice None None O
with None None O
either None None O
melatonin None None I-TRANS
or None None O
hDPSC None None O
transplantation None None O
alone None None O
, None None O
the None None O
combination None None O
of None None O
melatonin None None I-TRANS
and None None O
hDPSC None None O
significantly None None O
suppressed None None O
liver None None O
fibrosis None None O
and None None O
restored None None O
ALT None None O
, None None O
AST None None O
, None None O
and None None O
ammonia None None O
levels None None O
. None None O

Combined None None O
treatment None None O
of None None O
grafted None None O
hDPSCs None None O
and None None O
melatonin None None I-TRANS
could None None O
be None None O
a None None O
viable None None O
approach None None O
for None None O
the None None O
treatment None None O
of None None O
liver None None O
cirrhosis None None O
. None None O

Depolarization None None O
of None None O
DRG None None O
neurons None None O
by None None O
a None None O
transient None None O
receptor None None I-PROTEIN
potential None None O
vanilloid None None O
1 None None O
( None None O
TRPV None None O
1 None None O
) None None O
activator None None O
, None None O
capsaicin None None O
was None None O
attenuated None None O
by None None O
E6005 None None O
as None None O
well None None O
as None None O
by None None O
a None None O
3',5'-cyclic None None O
adenosine None None I-TRANS
monophosphate None None O
( None None O
cAMP None None O
) None None O
elevator None None O
, None None O
forskolin None None O
. None None O

There None None O
is None None O
increasing None None O
evidence None None O
suggesting None None O
that None None O
oxidative None None O
stress None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
development None None O
of None None O
many None None O
chronic None None O
and None None O
degenerative None None O
conditions None None O
such None None O
as None None O
diabetic None None O
encephalopathy None None O
and None None O
depression None None I-DISEASE
. None None O

It None None O
was None None O
verified None None O
that None None O
longer None None O
immobility None None O
time None None O
in None None O
diabetic None None O
rats None None O
and None None O
insulin None None I-PROTEIN
plus None None O
clonazepam None None O
treatment None None O
reversed None None O
this None None O
depressive-like None None O
behaviour None None O
. None None O

Delta None None O
EEG-HF-HRV None None O
correlations None None O
in None None O
nonrapid None None O
eye None None O
movement None None I-FUNC
( None None O
NREM None None O
) None None O
sleep None None O
were None None O
modeled None None O
as None None O
whole-night None None O
averages None None O
and None None O
as None None O
continuous None None O
functions None None O
of None None O
time None None O
. None None O

The None None O
dynamic None None O
interplay None None O
between None None O
sleep None None O
and None None O
autonomic None None O
activity None None O
can None None O
be None None O
modeled None None O
across None None O
the None None O
night None None O
to None None O
examine None None O
within- None None O
and None None O
between-participant None None O
differences None None O
including None None O
individuals None None O
with None None O
and None None O
without None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
. None None O

MDM2 None None O
is None None O
a None None O
key None None O
regulator None None O
of None None O
the None None O
p53 None None I-PROTEIN
tumor None None O
suppressor None None O
protein None None O
and None None O
is None None O
overexpressed None None O
in None None O
many None None O
human None None O
cancers None None O
. None None O

The None None O
psychometric None None O
properties None None O
of None None O
the None None O
TRENT None None O
were None None O
explored None None O
for None None O
self- None None O
and None None O
peer-assessment None None O
, None None O
and None None O
pre- None None O
and None None O
post-simulation None None O
environment None None O
mood None None I-FUNC
was None None O
used None None O
to None None O
assess None None O
validity None None O
. None None O

These None None O
are None None O
the None None O
first None None O
results None None O
that None None O
pertain None None O
to None None O
inter- None None O
, None None O
intra-rater None None O
reliability None None O
as None None O
well None None O
as None None O
idiosyncratic None None O
biases None None O
in None None O
NTS None None O
assessment None None O
and None None O
the None None O
first None None O
to None None O
show None None O
that None None O
simulator None None O
performance None None O
can None None O
influence None None O
mood None None I-FUNC
after None None O
assessment None None O
. None None O

The None None O
RCs None None O
of None None O
phenolic None None O
derivatives None None O
, None None O
flavonoids None None O
, None None O
amino None None I-TRANS
acids None None I-TRANS
and None None O
other None None O
anti-oxidant None None O
compounds None None O
were None None O
determined None None O
. None None O

These None None O
genes None None O
include None None O
receptors None None I-PROTEIN
, None None O
signaling None None O
pathways None None O
and None None O
effectors None None O
. None None O

Sections None None O
were None None O
stained None None O
for None None O
CDX2 None None O
, None None O
cytokeratin None None O
20 None None O
( None None O
CK20 None None O
) None None O
, None None O
MUC2 None None O
, None None O
and None None O
p53 None None I-PROTEIN
. None None O

It None None O
was None None O
recently None None O
proposed None None O
that None None O
autonomic None None O
dysfunction None None O
is None None O
triggered None None O
by None None O
oxidation-mediated None None O
inactivation None None O
of None None O
neuronal None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptors None None I-PROTEIN
( None None O
nAChRs None None O
) None None O
, None None O
impairing None None O
synaptic None None O
transmission None None O
in None None O
sympathetic None None O
ganglia None None O
and None None O
resulting None None O
in None None O
autonomic None None O
failure None None O
. None None O

Expression None None O
of None None O
enzymes None None I-PROTEIN
in None None O
the None None O
plant None None O
may None None O
provide None None O
a None None O
cost-effective None None O
option None None O
for None None O
biochemical None None O
conversion None None O
to None None O
biofuel None None O
. None None O

The None None O
aim None None O
of None None O
study None None O
was None None O
to None None O
examine None None O
the None None O
expression None None O
and None None O
diagnostic None None O
implications None None O
of None None O
CA None None O
IX None None I-REGION
in None None O
these None None O
latter None None O
tumours None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
, None None O
in None None O
addition None None O
to None None O
primary None None O
( None None O
25/25 None None O
) None None O
and None None O
metastatic None None O
( None None O
10/11 None None O
) None None O
ccRCC None None O
, None None O
CA None None O
IX None None I-REGION
was None None O
also None None O
expressed None None O
in None None O
breast None None O
( None None O
2/2 None None O
) None None O
, None None O
pulmonary None None O
( None None O
3/5 None None O
) None None O
and None None O
hepatic None None O
( None None O
1/4 None None O
) None None O
clear None None O
cell None None O
carcinoma None None O
, None None O
urothelial None None O
carcinoma None None O
with None None O
clear None None O
cell None None O
change None None O
( None None O
3/6 None None O
) None None O
, None None O
clear None None O
cell None None O
meningioma None None O
( None None O
4/6 None None O
) None None O
and None None O
ependymoma None None O
( None None O
2/3 None None O
) None None O
, None None O
haemangioblastoma None None O
( None None O
10/10 None None O
) None None O
, None None O
and None None O
clear None None O
cell None None O
hidradenoma None None O
( None None O
5/6 None None O
) None None O
. None None O

In None None O
particular None None O
, None None O
CA None None O
IX None None I-REGION
staining None None O
was None None O
often None None O
seen None None O
at None None O
the None None O
periphery None None O
of None None O
necrotic None None O
areas None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
article None None O
is None None O
to None None O
introduce None None O
the None None O
elements None None O
of None None O
the None None O
Ontario None None O
Brain None None O
Institute None None O
to None None O
the None None O
neuroscience None None O
community None None O
: None None O
the None None O
motivation None None O
for None None O
establishing None None O
it None None O
, None None O
the None None O
philosophy None None O
behind None None O
its None None O
creation None None O
, None None O
the None None O
principles None None O
guiding None None O
its None None O
development None None O
, None None O
the None None O
rapid None None O
evolution None None O
of None None O
its None None O
functional None None O
structure None None O
, None None O
the None None O
tools None None O
available None None O
to None None O
achieve None None O
its None None O
vision None None I-FUNC
, None None O
and None None O
the None None O
management None None O
structure None None O
to None None O
ensure None None O
success None None O
. None None O

We None None O
prospectively None None O
collected None None O
the None None O
RAND-36 None None O
, None None O
Center None None O
for None None O
Epidemiologic None None O
Studies None None O
Depression None None I-DISEASE
( None None O
CES-D None None O
) None None O
, None None O
and None None O
Pituitary None None O
QOL None None O
validated None None O
questionnaires None None O
and None None O
patients None None O
' None None O
demographics None None O
, None None O
clinical None None O
presentation None None O
, None None O
endocrine None None O
laboratory None None O
results None None O
, None None O
radiological None None O
studies None None O
, None None O
development None None O
of None None O
complications None None O
and None None O
remission None None O
rates None None O
from None None O
20 None None O
consecutive None None O
acromegalic None None O
patients None None O
who None None O
had None None O
undergone None None O
endoscopic None None O
transphenoidal None None O
surgery None None O
. None None O

The None None O
number None None O
of None None O
c-Fos None None O
protein-like None None O
immunoreactive None None O
( None None O
c-Fos-IR None None O
) None None O
neurons None None O
in None None O
the None None O
spinal None None O
dorsal None None I-NEURON
horn None None O
evoked None None O
by None None O
noxious None None O
stimulation None None O
was None None O
previously None None O
shown None None O
to None None O
be None None O
increased None None O
following None None O
peripheral None None O
nerve None None O
injury None None O
, None None O
and None None O
this None None O
increase None None O
was None None O
proposed None None O
to None None O
reflect None None O
the None None O
neuropathic None None O
pain None None O
state None None O
. None None O

Two None None O
participants None None O
receiving None None O
440 None None O
mg/m None None O
( None None O
2 None None O
) None None O
given None None O
twice None None O
daily None None O
experienced None None O
dose-limiting None None O
toxicities None None O
of None None O
grade None None O
3 None None O
thrombocytopenia None None O
resulting None None O
in None None O
delayed None None O
start None None O
of None None O
course None None O
2 None None O
and None None O
grade None None O
3 None None O
alanine None None I-TRANS
transaminase None None I-PROTEIN
elevation None None O
that None None O
did None None O
not None None O
recover None None O
within None None O
5 None None O
days None None O
. None None O

I None None O
uptake None None O
was None None O
estimated None None O
by None None O
I-uptake None None O
assay None None O
and None None O
gamma None None O
camera None None O
imaging None None O
. None None O

The None None O
perception None None I-FUNC
of None None O
painful None None O
thermal None None O
stimuli None None O
by None None O
sensory None None I-NEURON
neurons None None I-NEURON
is None None O
largely None None O
mediated None None O
by None None O
TRPV1 None None O
. None None O

S1P None None O
acts None None O
on None None O
G-protein None None I-PROTEIN
coupled None None I-PROTEIN
receptors None None I-PROTEIN
that None None O
are None None O
expressed None None O
in None None O
sensory None None I-NEURON
neurons None None I-NEURON
and None None O
sensitize None None O
TRPV1 None None O
channels None None O
towards None None O
thermal None None O
stimuli None None O
. None None O

The None None O
potentiation None None O
of None None O
ICAPS None None O
resulted None None O
from None None O
activation None None O
of None None O
Gαi None None O
through None None O
G-protein None None I-PROTEIN
coupled None None I-PROTEIN
receptors None None I-PROTEIN
for None None O
S1P None None O
. None None O

The None None O
current None None O
data None None O
suggest None None O
that None None O
S1P None None O
sensitized None None O
ICAPS None None O
through None None O
G-protein None None O
coupled None None O
S1P1 None None O
receptor None None I-PROTEIN
activation None None O
of None None O
Gαi-PI3K-PKC-p38 None None O
signaling None None O
pathway None None O
in None None O
sensory None None I-NEURON
neurons None None I-NEURON
. None None O

Our None None O
approach None None O
is None None O
based None None O
on None None O
a None None O
published None None O
framework None None O
that None None O
emphasizes None None O
ethical None None O
reasoning None None I-FUNC
rather None None O
than None None O
topical None None O
knowledge None None O
. None None O

Historical None None O
analogies None None O
from None None O
these None None O
professions None None O
suggest None None O
strategies None None O
for None None O
introducing None None O
trainees None None O
and None None O
orienting None None O
practitioners None None O
both None None O
to None None O
ethical None None O
reasoning None None I-FUNC
and None None O
to None None O
a None None O
code None None O
of None None O
professional None None O
conduct None None O
itself None None O
. None None O

Although None None O
undergraduate None None O
engineering None None O
ethics None None O
courses None None O
often None None O
include None None O
the None None O
development None None O
of None None O
moral None None O
sensitivity None None O
as None None O
a None None O
learning None None I-FUNC
objective None None O
and None None O
the None None O
use None None O
of None None O
active None None O
learning None None I-FUNC
techniques None None O
, None None O
teaching None None O
centers None None O
on None None O
the None None O
transmission None None O
of None None O
cognitive None None O
knowledge None None O
. None None O

The None None O
article None None O
argues None None O
that None None O
the None None O
focus None None O
on None None O
cognitive None None O
learning None None I-FUNC
may None None O
not None None O
promote None None O
, None None O
and None None O
may None None O
even None None O
impair None None O
, None None O
our None None O
efforts None None O
to None None O
foster None None O
moral None None O
sensitivity None None O
. None None O

Evidence None None O
suggested None None O
that None None O
reading None None O
comprehension None None O
in None None O
women None None O
and None None O
men None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
perceived None None O
constraint None None O
in None None O
women None None O
, None None O
may None None O
mediate None None O
some None None O
of None None O
the None None O
association None None O
between None None O
education None None O
and None None O
CHD None None O
risk None None O
. None None O

Frequent None None O
feeds None None O
with None None O
carbohydrate-rich None None O
meals None None O
or None None O
continuous None None O
enteral None None O
feeding None None O
has None None O
been None None O
the None None O
therapy None None O
of None None O
choice None None O
in None None O
glycogen None None O
storage None None I-FUNC
disease None None O
( None None O
Glycogenosis None None O
) None None O
type None None O
III None None O
. None None O

Studies None None O
show None None O
that None None O
manipulating None None O
certain None None O
training None None O
features None None O
in None None O
perceptual None None O
learning None None I-FUNC
determines None None O
the None None O
specificity None None O
of None None O
the None None O
improvement None None O
. None None O

Crowding None None O
, None None O
the None None O
inability None None O
to None None O
recognize None None O
objects None None O
in None None O
a None None O
clutter None None O
, None None O
fundamentally None None O
limits None None O
conscious None None O
visual None None I-FUNC
perception None None I-FUNC
. None None O

Here None None O
we None None O
used None None O
GlassesOff None None O
's None None O
application None None O
for None None O
iDevices None None O
to None None O
train None None O
foveal None None O
vision None None I-FUNC
of None None O
young None None O
participants None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
work None None O
was None None O
to None None O
examine None None O
the None None O
relationships None None O
between None None O
geographical None None O
coordinates None None O
and None None O
the None None O
prevalence None None O
of None None O
winter None None O
depression None None I-DISEASE
( None None O
SADW None None O
) None None O
, None None O
and None None O
to None None O
compare None None O
the None None O
sleep None None O
characteristics None None O
and None None O
chronotype None None O
of None None O
youths None None O
with None None O
and None None O
without None None O
SADW None None O
. None None O

Expression None None O
of None None O
Ki-67 None None O
, None None O
P53 None None I-PROTEIN
and None None O
P27 None None O
was None None O
analyzed None None O
by None None O
immuno-histochemistry None None O
. None None O

De None None O
novo None None O
or None None O
acquired None None O
resistance None None O
to None None O
endocrine None None O
therapy None None O
limits None None O
its None None O
utility None None O
in None None O
a None None O
significant None None O
number None None O
of None None O
estrogen None None I-PROTEIN
receptor-positive None None O
( None None O
ER-positive None None O
) None None O
breast None None O
cancers None None O
. None None O

Integrins None None I-PROTEIN
are None None O
signaling None None O
proteins None None O
that None None O
mediate None None O
cell-cell None None O
and None None O
cell-extracellular None None O
matrix None None O
communication None None O
, None None O
and None None O
their None None O
involvement None None O
in None None O
tooth None None O
development None None O
is None None O
well None None O
known None None O
. None None O

The None None O
glycine None None I-TRANS
at None None O
this None None O
position None None O
in None None O
the None None O
middle None None O
of None None O
the None None O
βI-domain None None O
is None None O
conserved None None O
among None None O
a None None O
wide None None O
range None None O
of None None O
vertebrate None None O
orthologs None None O
and None None O
human None None O
paralogs None None O
. None None O

Data None None O
on None None O
the None None O
perception None None I-FUNC
of None None O
facial None None O
expressions None None O
and None None O
exit None None O
examination None None O
marks None None O
were None None O
obtained None None O
from None None O
144 None None O
( None None O
61 None None O
% None None O
) None None O
females None None O
and None None O
93 None None O
( None None O
39 None None O
% None None O
) None None O
males None None O
with None None O
a None None O
mean None None O
age None None O
of None None O
24.1 None None O
± None None O
1.6 None None O
years None None O
. None None O

Several None None O
oncogenic None None O
signaling None None O
pathways None None O
, None None O
interplaying None None O
with None None O
enzymes None None I-PROTEIN
and None None O
kinases None None I-PROTEIN
involved None None O
in None None O
glucose None None O
metabolism None None O
, None None O
participate None None O
in None None O
the None None O
switch None None O
from None None O
oxidative None None O
phosphorylation None None O
( None None O
OXPHOS None None O
) None None O
to None None O
aerobic None None O
glycolysis None None O
. None None O

ncRNAs None None O
, None None O
especially None None O
miRNAs None None O
and None None O
long None None O
non-coding None None O
RNAs None None O
( None None O
lncRNAs None None O
) None None O
, None None O
may None None O
also None None O
have None None O
great None None O
effect None None O
on None None O
glucose None None O
metabolism None None O
by None None O
targeting None None O
not None None O
only None None O
glycolysis None None O
enzymes None None I-PROTEIN
directly None None O
but None None O
also None None O
oncogenic None None O
signaling None None O
pathways None None O
indirectly None None O
. None None O

In None None O
a None None O
prospective None None O
British None None O
occupational None None O
cohort None None O
with None None O
5-yearly None None O
clinical None None O
examinations None None O
( None None O
n None None O
= None None O
230/5,749 None None O
South None None O
Asian/white None None O
participants None None O
, None None O
age None None O
39-79 None None O
years None None O
at None None O
baseline None None O
) None None O
, None None O
age-related None None O
trajectories None None O
of None None O
fasting None None O
glucose None None O
( None None O
FG None None O
) None None O
and None None O
2 None None O
h None None O
post-load None None O
glucose None None O
( None None O
PLG None None O
) None None O
, None None O
log-transformed None None O
fasting None None O
insulin None None I-PROTEIN
( None None O
FINS None None O
) None None O
and None None O
2 None None O
h None None O
post-load None None O
insulin None None I-PROTEIN
( None None O
PLINS None None O
) None None O
, None None O
HOMA None None O
insulin None None I-PROTEIN
sensitivity None None O
( None None O
HOMA2- None None O
% None None O
S None None O
) None None O
and None None O
HOMA None None O
insulin None None I-PROTEIN
secretion None None O
( None None O
HOMA2- None None O
% None None O
B None None O
) None None O
were None None O
fitted None None O
for None None O
South None None O
Asian None None O
and None None O
white None None O
individuals None None O
who None None O
remained None None O
free None None O
of None None O
diabetes None None O
between None None O
1991 None None O
and None None O
2009 None None O
. None None O

ALM None None O
increased None None O
BF None None O
ADO None None O
and None None O
GABA None None I-TRANS
levels None None O
during None None O
waking None None O
and None None O
mixed None None O
vigilance None None O
states None None O
, None None O
and None None O
preserved None None O
sleep-associated None None O
increases None None O
in None None O
GABA None None I-TRANS
under None None O
low None None O
and None None O
high None None O
sleep None None O
pressure None None O
conditions None None O
. None None O

This None None O
study None None O
evaluated None None O
effects None None O
of None None O
dietary None None O
supplementation None None O
of None None O
sage None None O
( None None O
Salvia None None O
officinalis None None O
) None None O
, None None O
mint None None O
( None None O
Mentha None None O
spicata None None O
) None None O
and None None O
thyme None None O
( None None O
Thymus None None O
vulgaris None None O
) None None O
oils None None O
on None None O
growth None None O
performance None None O
, None None O
lipid None None O
peroxidation None None O
level None None O
( None None O
melondialdehyde None None O
, None None O
MDA None None O
) None None O
and None None O
liver None None O
antioxidant None None O
enzyme None None O
activities None None O
( None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
SOD None None O
; None None O
catalase None None I-PROTEIN
, None None O
CAT None None O
; None None O
glucose-6-phosphate None None O
dehydrogenase None None I-PROTEIN
, None None O
G6PD None None O
; None None O
glutathione None None I-PROTEIN
reductase None None I-PROTEIN
, None None O
GR None None O
; None None O
glutathione-S-transferase None None O
, None None O
GST None None O
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
, None None O
GPx None None O
) None None O
in None None O
rainbow None None O
trout None None O
( None None O
Oncorhynchus None None O
mykiss None None O
) None None O
juveniles None None O
. None None O

Detection None None O
of None None O
genes None None O
encoding None None I-FUNC
antimicrobial None None O
resistance None None O
was None None O
performed None None O
by None None O
PCR None None O
. None None O

During None None O
2009-2011 None None O
, None None O
592 None None O
adults None None O
without None None O
clinical None None O
diabetes None None O
( None None O
fasting None None O
glucose None None O
& None None O
lt None None O
; None None O
7.0 None None O
mmol/L None None O
) None None O
or None None O
known None None O
coronary None None O
heart None None O
disease None None O
or None None O
stroke None None I-DISEASE
were None None O
recruited None None O
. None None O

Genetic None None O
analyses None None O
showed None None O
that None None O
common None None O
environmental None None O
factors None None O
primarily None None O
contributed None None O
to None None O
smoking None None O
initiation None None O
, None None O
while None None O
genetic None None O
factors None None O
explained None None O
a None None O
greater None None O
proportion None None O
of None None O
variance None None O
in None None O
liability None None O
to None None O
nicotine None None I-DISEASE
dependence None None I-DISEASE
. None None O

The None None O
study None None O
involved None None O
17 None None O
adolescents None None O
( None None O
mean None None O
age None None O
14.1 None None O
± None None O
0.27 None None O
, None None O
11 None None O
girls None None O
) None None O
who None None O
were None None O
compared None None O
with None None O
14 None None O
young None None O
adults None None O
( None None O
mean None None O
age None None O
24.24 None None O
± None None O
2.76 None None O
, None None O
7 None None O
women None None O
) None None O
for None None O
measures None None O
of None None O
brain None None O
complexity None None O
( None None O
fractal None None O
dimension None None O
-- None None O
FD None None O
) None None O
, None None O
grey None None I-REGION
matter None None I-REGION
( None None O
GM None None O
) None None O
volume None None O
and None None O
surface-area None None O
of None None O
cortical None None O
ribbon None None O
. None None O

The None None O
results None None O
show None None O
that None None O
the None None O
adults None None O
have None None O
a None None O
lower None None O
cortical None None O
complexity None None O
than None None O
the None None O
adolescents None None O
, None None O
which None None O
was None None O
significant None None O
for None None O
whole None None O
brain None None O
, None None O
left None None O
and None None O
right None None O
hemisphere None None O
, None None O
frontal None None O
and None None O
parietal None None I-REGION
lobes None None I-REGION
for None None O
both None None O
genders None None O
; None None O
and None None O
only None None O
for None None O
males None None O
in None None O
left None None I-REGION
temporal None None I-REGION
lobe None None I-REGION
. None None O

In None None O
the None None O
mechanism None None O
discussion None None O
, None None O
it None None O
was None None O
proved None None O
that None None O
the None None O
fluorescence None None O
quenching None None O
of None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
by None None O
LnW11 None None O
is None None O
initiated None None O
by None None O
complex None None O
formation None None O
. None None O

Cardiovascular None None O
complications None None O
and None None O
markers None None O
of None None O
cardiac None None O
injury None None O
including None None O
creatinine None None O
kinase None None O
( None None O
CK None None O
) None None O
, None None O
CK None None O
iso-enzyme None None O
( None None O
CK-MB None None O
) None None O
, None None O
cardiac None None O
troponin None None O
I None None O
( None None O
cTNI None None O
) None None O
and None None O
brain None None O
natriuretic None None O
peptide None None O
( None None O
BNP None None I-TRANS
) None None O
were None None O
assessed None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
employed None None O
a None None O
knockout None None O
( None None O
KO None None O
) None None O
model None None O
to None None O
investigate None None O
the None None O
contribution None None O
of None None O
enkephalin None None I-TRANS
in None None O
cocaine-induced None None O
behavioral None None O
sensitization None None O
. None None O

On None None O
day None None O
21 None None O
, None None O
microdialysis None None O
measures None None O
of None None O
accumbal None None O
extracellular None None O
dopamine None None I-TRANS
, None None O
Western None None O
blotting None None O
for None None O
GluR1 None None O
AMPA None None O
receptor None None I-PROTEIN
( None None O
AMPAR None None O
) None None O
, None None O
phosphorylated None None O
ERK2 None None O
( None None O
pERK2 None None O
) None None O
, None None O
CREB None None O
( None None O
pCREB None None O
) None None O
, None None O
TrKB None None O
( None None O
pTrkB None None O
) None None O
were None None O
performed None None O
in None None O
brain None None O
areas None None O
relevant None None O
for None None O
sensitization None None O
from None None O
KO None None O
and None None O
WT None None O
and/or None None O
naloxone- None None O
and None None O
vehicle None None O
pre-treated None None O
animals None None O
. None None O

Biochemical None None O
and None None O
histological None None O
evaluations None None O
revealed None None O
significant None None O
accumulation None None O
of None None O
extracellular None None I-PROTEIN
matrix None None I-PROTEIN
proteins None None I-PROTEIN
such None None O
as None None O
glycosaminoglycans None None O
and None None O
collagen None None I-PROTEIN
in None None O
the None None O
50/50 None None O
hydrogel None None O
owing None None O
to None None O
appropriate None None O
tuning None None O
of None None O
hydrogel None None O
degradation None None O
. None None O

Literature None None O
data None None O
indicate None None O
that None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
, None None O
cyclic-AMP None None O
response None None O
element-binding None None O
protein None None O
( None None O
CREB None None O
) None None O
and None None O
phospho-CREB None None O
( None None O
pCREB None None O
) None None O
may None None O
have None None O
a None None O
place None None O
in None None O
depression None None I-DISEASE
. None None O

We None None O
also None None O
tested None None O
the None None O
hypothesis None None O
that None None O
administration None None O
of None None O
herbs None None O
reverses None None O
memory None None I-FUNC
deficits None None O
and None None O
promotes None None O
the None None O
protein None None O
expression None None O
of None None O
BDNF None None O
in None None O
the None None O
mouse None None O
brain None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
adverse None None O
events None None O
such None None O
as None None O
stress None None O
and None None O
depression None None I-DISEASE
can None None O
modulate None None O
the None None O
expression None None O
of None None O
molecular None None O
players None None O
of None None O
cellular None None O
plasticity None None O
in None None O
the None None O
brain None None O
. None None O

Baseline None None O
HUV None None O
in None None O
CRS None None O
( None None O
0.81 None None O
[ None None O
0.13 None None O
] None None O
) None None O
is None None O
lower None None O
than None None O
the None None O
general None None O
U.S. None None O
population None None O
( None None O
0.85 None None O
[ None None O
0.18 None None O
] None None O
) None None O
and None None O
appears None None O
appropriately None None O
positioned None None O
among None None O
other None None O
common None None O
chronic None None O
conditions None None O
including None None O
asthma None None O
( None None O
0.82-0.92 None None O
) None None O
, None None O
migraine None None I-DISEASE
( None None O
0.81-0.91 None None O
) None None O
, None None O
and None None O
seasonal None None O
allergies None None O
( None None O
0.94 None None O
) None None O
. None None O

For None None O
JSE None None O
items None None O
relating None None O
to None None O
emotional None None O
influence None None O
on None None O
medical None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
participants None None O
in None None O
the None None O
arts-making None None O
workshop None None O
changed None None O
more None None O
than None None O
those None None O
in None None O
the None None O
problem-solving None None O
workshop None None O
. None None O

Overall None None O
, None None O
the None None O
immunofluorescence None None O
protocol None None O
for None None O
catalase None None I-PROTEIN
was None None O
evidently None None O
faster None None O
, None None O
cheaper None None O
and None None O
provided None None O
reliable None None O
quantitative None None O
data None None O
that None None O
discriminated None None O
in None None O
the None None O
same None None O
way None None O
the None None O
compared None None O
groups None None O
. None None O

Effect None None O
of None None O
BELE None None O
administrated None None O
for None None O
7 None None O
consecutive None None O
days None None O
was None None O
evaluated None None O
in None None O
mice None None O
by None None O
the None None O
serum None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
, None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ALP None None O
) None None O
, None None O
total None None O
bilirubin None None O
( None None O
TBIL None None O
) None None O
, None None O
albulin None None O
( None None O
ALB None None O
) None None O
, None None O
globulin None None O
( None None O
GLB None None O
) None None O
, None None O
and None None O
total None None O
protein None None O
( None None O
TP None None O
) None None O
levels None None O
, None None O
as None None O
well None None O
as None None O
liver None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
activity None None O
and None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
level None None O
. None None O

We None None O
sought None None O
to None None O
identify None None O
in None None O
adults None None O
the None None O
genetic None None O
determinants None None O
of None None O
fractional None None O
exhaled None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
FeNO None None O
) None None O
levels None None O
and None None O
to None None O
assess None None O
whether None None O
environmental None None O
and None None O
disease-related None None O
factors None None O
influence None None O
these None None O
associations None None O
. None None O

The None None O
most None None O
frequently None None O
identified None None O
factors None None O
had None None O
to None None O
do None None O
with None None O
dissemination None None O
of None None O
guidelines None None O
, None None O
general None None O
practitioners None None O
' None None O
time None None O
constraints None None O
, None None O
the None None O
low None None O
prioritization None None O
of None None O
elderly None None O
patients None None O
with None None O
depression None None I-DISEASE
, None None O
and None None O
the None None O
patients None None O
' None None O
or None None O
relatives None None O
' None None O
wish None None O
for None None O
medication None None O
. None None O

The None None O
cortical None None O
actin None None I-PROTEIN
fringe None None O
assumes None None O
a None None O
central None None O
position None None O
in None None O
the None None O
control None None O
of None None O
clear None None O
zone None None O
formation None None O
and None None O
maintenance None None O
, None None O
given None None O
its None None O
role None None O
in None None O
generating None None O
cytoplasmic None None O
streaming None None O
. None None O

Abstract None None O
Background None None O
: None None O
A None None O
blended None None O
learning None None I-FUNC
can None None O
be None None O
a None None O
useful None None O
learning None None I-FUNC
strategy None None O
to None None O
improve None None O
the None None O
quality None None O
of None None O
fever None None O
and None None O
fever None None O
management None None O
education None None O
for None None O
paediatric None None O
nurses None None O
. None None O

Results/Findings None None O
: None None O
Learning None None I-FUNC
outcomes None None O
did None None O
not None None O
significantly None None O
differ None None O
between None None O
the None None O
two None None O
groups None None O
. None None O

Conclusion None None O
: None None O
A None None O
blended-learning None None O
paediatric None None O
fever None None O
management None None O
program None None O
was None None O
as None None O
effective None None O
as None None O
a None None O
traditional None None O
face-to-face None None O
learning None None I-FUNC
program None None O
. None None O

Small-scale None None O
studies None None O
in None None O
Parkinson None None I-DISEASE
disease None None O
, None None O
a None None O
prototypical None None O
chronic None None O
condition None None O
, None None O
have None None O
suggested None None O
that None None O
delivering None None O
care None None O
using None None O
video None None O
house None None O
calls None None O
is None None O
feasible None None O
, None None O
offers None None O
similar None None O
clinical None None O
outcomes None None O
to None None O
in-person None None O
care None None O
, None None O
and None None O
reduces None None O
travel None None O
burden None None O
. None None O

Approximately None None O
200 None None O
individuals None None O
with None None O
Parkinson None None I-DISEASE
disease None None O
and None None O
their None None O
care None None O
partners None None O
will None None O
be None None O
enrolled None None O
at None None O
20 None None O
centers None None O
throughout None None O
the None None O
United None None O
States None None O
and None None O
followed None None O
for None None O
one None None O
year None None O
. None None O

All None None O
study None None O
activities None None O
are None None O
completed None None O
remotely.The None None O
primary None None O
outcomes None None O
are None None O
: None None O
( None None O
1 None None O
) None None O
feasibility None None O
, None None O
as None None O
measured None None O
by None None O
the None None O
proportion None None O
of None None O
visits None None O
completed None None O
, None None O
and None None O
( None None O
2 None None O
) None None O
quality None None O
of None None O
life None None O
, None None O
as None None O
measured None None O
by None None O
the None None O
39-item None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Questionnaire None None O
. None None O

Connect.Parkinson None None O
will None None O
evaluate None None O
the None None O
feasibility None None O
and None None O
effectiveness None None O
of None None O
using None None O
technology None None O
to None None O
deliver None None O
care None None O
into None None O
the None None O
homes None None O
of None None O
individuals None None O
with None None O
Parkinson None None I-DISEASE
disease None None O
. None None O

I None None O
suggest None None O
that None None O
cognitive-constructivist None None O
learning None None I-FUNC
theory None None O
would None None O
predict None None O
that None None O
a None None O
well-constructed None None O
context-rich None None O
multiple-choice None None O
item None None O
represents None None O
a None None O
complex None None O
problem-solving None None O
exercise None None O
which None None O
activates None None O
a None None O
sequence None None O
of None None O
cognitive None None O
processes None None O
which None None O
closely None None O
parallel None None O
those None None O
required None None O
in None None O
clinical None None O
practice None None O
, None None O
hence None None O
explaining None None O
the None None O
high None None O
validity None None O
of None None O
the None None O
multiple-choice None None O
format None None O
. None None O

The None None O
most None None O
numerous None None O
type None None O
of None None O
lingual None None O
papilla None None O
was None None O
filiform None None O
in None None O
the None None O
South None None O
American None None O
fur None None O
seal None None O
( None None O
SASL None None O
) None None O
and None None O
entire None None O
dorsal None None I-NEURON
lingual None None O
surface None None O
was None None O
covered None None O
by None None O
these None None O
filiform None None O
papillae None None O
but None None O
the None None O
dorsal None None I-NEURON
surface None None O
of None None O
the None None O
tongue None None O
of None None O
the None None O
South None None O
American None None O
sea None None O
lion None None O
was None None O
covered None None O
by None None O
numerous None None O
polygonal None None O
projections None None O
, None None O
which None None O
were None None O
different None None O
in None None O
size None None O
. None None O

There None None O
are None None O
substantial None None O
differences None None O
in None None O
levels None None O
of None None O
nicotine None None I-DISEASE
dependence None None I-DISEASE
by None None O
race None None O
and None None O
ethnic None None O
group None None O
. None None O

Since None None O
2004 None None O
, None None O
guidelines None None O
recommend None None O
long-term None None O
treatment None None O
with None None O
low-molecular-weight None None O
heparin None None O
( None None O
LMWH None None O
) None None O
in None None O
patients None None O
with None None O
cancer None None O
and None None O
pulmonary None None O
embolism None None I-DISEASE
( None None O
PE None None O
) None None O
. None None O

The None None O
perception None None I-FUNC
of None None O
old None None O
age None None O
differs None None O
in None None O
different None None O
societies None None O
and None None O
cultures None None O
: None None O
in None None O
the None None O
Western None None O
societies None None O
, None None O
the None None O
loss None None O
of None None O
youth None None O
, None None O
multiple None None O
losses None None O
of None None O
functions None None O
and None None O
independence None None O
resulting None None O
in None None O
inability None None O
produce None None O
a None None O
social None None O
stigma None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
is None None O
to None None O
explore None None O
how None None O
the None None O
phenomenon None None O
of None None O
dementia None None I-DISEASE
is None None O
perceived None None O
in None None O
ethnically None None O
diverse None None O
groups None None O
and None None O
cultures None None O
. None None O

Search None None O
terms None None O
used None None O
included None None O
anthropology None None O
, None None O
culture None None O
, None None O
ethnic None None O
elderly None None O
and None None O
dementia None None I-DISEASE
. None None O

The None None O
experience None None O
of None None O
dementia None None I-DISEASE
is None None O
not None None O
universal None None O
, None None O
but None None O
is None None O
profoundly None None O
shaped None None O
by None None O
culture None None O
in None None O
which None None O
the None None O
demented None None O
person None None O
lives None None O
. None None O

Sociocultural None None O
conceptualization None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
other None None O
dementias None None I-DISEASE
is None None O
of None None O
growing None None O
interest None None O
in None None O
shaping None None O
the None None O
interpretation None None O
of None None O
the None None O
symptoms None None O
of None None O
dementing None None O
diseases None None O
. None None O

It None None O
was None None O
speculated None None O
that None None O
the None None O
Rht None None O
genes None None O
expressing None None O
defective None None O
DELLA None None O
proteins None None O
might None None O
be None None O
involved None None O
in None None O
water None None O
stress None None O
response None None O
through None None O
modulation None None O
of None None O
cell None None O
wall None None O
stiffness None None O
, None None O
which None None O
influences None None O
its None None O
capacity None None O
for None None O
ions None None O
retention None None I-FUNC
, None None O
and None None O
also None None O
by None None O
their None None O
contribution None None O
to None None O
ROS None None O
detoxification None None O
, None None O
thus None None O
indirectly None None O
stabilizing None None O
cellular None None O
membranes None None O
. None None O

The None None O
sensitivity None None O
of None None O
the None None O
biosensor None None O
was None None O
measured None None O
as None None O
6.93 None None O
meu None None O
A None None O
meu None None O
M None None O
-1 None None O
with None None O
a None None O
sensor None None O
affinity None None O
[ None None O
Km None None O
( None None O
app None None I-TRANS
) None None O
] None None O
of None None O
50 None None O
mu None None O
M None None O
and None None O
95 None None O
percent None None O
reproducibility None None O
after None None O
50 None None O
measurements None None O
. None None O

RAG1 None None O
spans None None O
over None None O
7.0 None None O
kb None None O
, None None O
containing None None O
4 None None O
exons None None O
and None None O
3 None None O
introns None None O
, None None O
and None None O
the None None O
full-length None None O
ORF None None O
is None None O
3207 None None O
bp None None O
, None None O
encoding None None I-FUNC
a None None O
peptide None None O
of None None O
1068 None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

RAG2 None None O
full-length None None O
ORF None None O
is None None O
1062 None None O
bp None None O
, None None O
encodes None None O
a None None O
peptide None None O
of None None O
533 None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
and None None O
lacks None None O
introns None None O
in None None O
the None None O
coding None None O
region None None O
. None None O

In None None O
the None None O
course None None O
of None None O
chronic None None O
ASP None None O
administration None None O
, None None O
the None None O
following None None O
was None None O
observed None None O
: None None O
the None None O
concentration None None O
of None None O
reduced None None O
glutathione None None O
( None None O
GSH None None O
) None None O
and None None O
the None None O
activity None None O
of None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
increased None None O
. None None O

CHEP5 None None O
to None None O
protect None None O
peanut None None O
plants None None O
from None None O
S. None None O
rolfsii None None O
by None None O
ISR None None O
and None None O
the None None O
priming None None O
in None None O
challenged-plants None None O
, None None O
as None None O
evidenced None None O
by None None O
an None None O
increment None None O
in None None O
phenylalanine None None I-TRANS
ammonia-lyase None None O
enzyme None None O
activity None None O
. None None O

Glutamate None None I-TRANS
decarboxylase None None O
( None None O
GAD None None O
) None None O
is None None O
an None None O
enzyme None None O
that None None O
catalyses None None O
the None None O
conversion None None O
of None None O
L-glutamate None None O
into None None O
gamma-aminobutyric None None I-TRANS
acid None None I-TRANS
( None None O
GABA None None I-TRANS
) None None O
, None None O
which None None O
is None None O
a None None O
four-carbon None None O
non-protein None None O
amino None None O
acid None None O
present None None O
in None None O
all None None O
organisms None None O
. None None O

Caspases None None O
are None None O
cysteine None None I-TRANS
proteases None None O
that None None O
are None None O
important None None O
regulators None None O
of None None O
programmed None None O
cell None None O
death None None O
in None None O
animals None None O
. None None O

Calcium None None O
and None None O
hormones None None I-PROTEIN
like None None O
ethylene None None O
and None None O
jasmonic None None O
acid None None O
have None None O
been None None O
shown None None O
to None None O
regulate None None O
plant None None O
antifreeze None None O
activity None None O
. None None O

Casein None None O
kinases None None I-PROTEIN
( None None O
CKs None None O
) None None O
generally None None O
act None None O
as None None O
positive None None O
regulators None None O
in None None O
many None None O
signaling None None O
pathways None None O
in None None O
plants None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
direct None None O
posttranslational None None O
modification None None O
of None None O
PRR37 None None O
mediates None None O
the None None O
genetic None None O
interactions None None O
between None None O
these None None O
two None None O
protein None None O
kinases None None I-PROTEIN
and None None O
PRR37 None None O
. None None O

Heavy None None O
cannabis None None O
users None None O
demonstrated None None O
smaller None None O
hippocampus None None I-REGION
and None None O
amygdala None None I-REGION
volumes None None O
, None None O
but None None O
no None None O
alterations None None O
of None None O
the None None O
orbitofrontal None None O
and None None O
anterior- None None O
and None None O
paracingulate None None O
cortices None None O
, None None O
or None None O
the None None O
pituitary None None I-REGION
gland None None I-REGION
. None None O

To None None O
investigate None None O
whether None None O
performing None None O
a None None O
( None None O
123 None None O
) None None O
I-ioflupane None None O
injection None None O
( None None O
( None None O
123 None None O
) None None O
I-FP-CIT None None O
also None None O
called None None O
DaTSCAN™ None None O
) None None O
single None None O
photon None None O
emission None None O
computed None None O
tomography None None O
( None None O
SPECT None None O
) None None O
scan None None O
in None None O
patients None None O
with None None O
possible None None O
DLB None None O
would None None O
lead None None O
to None None O
a None None O
more None None O
certain None None O
diagnosis None None O
( None None O
probable None None O
DLB None None O
or None None O
non-DLB None None O
dementia None None I-DISEASE
) None None O
. None None O

We None None O
have None None O
tackled None None O
this None None O
problem None None O
of None None O
classifying None None O
chimeric None None O
nodes None None O
using None None O
supervised None None O
machine None None O
learning None None I-FUNC
to None None O
significantly None None O
improve None None O
the None None O
performance None None O
of None None O
MetaVelvet None None O
and None None O
developed None None O
a None None O
new None None O
tool None None O
, None None O
called None None O
MetaVelvet-SL None None O
. None None O

An None None O
ecological None None O
approach None None O
to None None O
place None None O
perception None None I-FUNC
is None None O
also None None O
discussed None None O
. None None O

In None None O
fact None None O
, None None O
exposure None None O
to None None O
natural None None O
environments None None O
protects None None O
people None None O
against None None O
the None None O
impact None None O
of None None O
environmental None None O
stressors None None O
and None None O
offer None None O
physiological None None O
, None None O
emotional None None O
and None None O
attention None None I-FUNC
restoration None None O
more None None O
so None None O
than None None O
urban None None O
environments None None O
. None None O

Natural None None O
environments None None O
elicit None None O
greater None None O
calming None None O
responses None None O
than None None O
urban None None O
environments None None O
, None None O
and None None O
in None None O
relation None None O
to None None O
their None None O
vision None None I-FUNC
there None None O
is None None O
a None None O
general None None O
reduction None None O
of None None O
physiological None None O
symptoms None None O
of None None O
stress None None O
. None None O

Moreover None None O
, None None O
one None None O
can None None O
recover None None O
the None None O
decrease None None O
of None None O
cognitive None None O
performance None None O
associated None None O
with None None O
stress None None O
, None None O
especially None None O
reflected None None O
in None None O
attention None None I-FUNC
tasks None None O
, None None O
through None None O
the None None O
salutary None None O
effect None None O
of None None O
viewing None None O
nature None None O
. None None O

Psychosocial None None O
interventions None None O
are None None O
an None None O
essential None None O
part None None O
of None None O
the None None O
treatment None None O
for None None O
people None None O
with None None O
severe None None O
mental None None O
illness None None O
such None None O
as None None O
schizophrenia None None I-DISEASE
. None None O

This None None O
study None None O
investigates None None O
the None None O
impact None None O
of None None O
occupation-based None None O
motivational None None O
processes None None O
and None None O
social None None O
network None None O
variables None None O
on None None O
the None None O
incidence None None O
of None None O
dementia None None I-DISEASE
over None None O
8 None None O
years None None O
. None None O

Individuals None None O
with None None O
a None None O
higher None None O
frequency None None O
of None None O
social None None O
contact None None O
at None None O
baseline None None O
had None None O
a None None O
significantly None None O
lower None None O
risk None None O
of None None O
dementia None None I-DISEASE
( None None O
HR None None O
: None None O
0.96 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0.91-0.99 None None O
) None None O
, None None O
while None None O
proximity None None O
of None None O
social None None O
contacts None None O
was None None O
not None None O
linked None None O
to None None O
the None None O
risk None None O
of None None O
dementia None None I-DISEASE
( None None O
HR None None O
: None None O
1.03 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0.98-1.08 None None O
) None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
proximity None None O
of None None O
social None None O
contacts None None O
was None None O
linked None None O
to None None O
a None None O
higher None None O
risk None None O
of None None O
dementia None None I-DISEASE
in None None O
individuals None None O
with None None O
high None None O
indices None None O
of None None O
motivational None None O
processes None None O
( None None O
HR None None O
: None None O
1.09 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
1.01-1.19 None None O
) None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
is None None O
the None None O
most None None O
common None None O
form None None O
of None None O
dementia None None I-DISEASE
but None None O
other None None O
neurological None None O
conditions None None O
such None None O
as None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
and None None O
chronic None None O
infections None None O
such None None O
as None None O
syphilis None None O
can None None O
also None None O
lead None None O
to None None O
the None None O
clinical None None O
syndrome None None O
of None None O
dementia None None I-DISEASE
. None None O

From None None O
a None None O
public None None O
health None None O
perspective None None O
, None None O
youth None None O
unemployment None None O
is None None O
a None None O
societal None None O
problem None None O
in None None O
need None None O
of None None O
more None None O
attention None None I-FUNC
and None None O
intervention None None O
in None None O
order None None O
to None None O
prevent None None O
long-term None None O
adverse None None O
health None None O
outcomes None None O
. None None O

Executive None None O
dysfunction None None O
is None None O
a None None O
deficiency None None O
in None None O
skills None None O
of None None O
planning None None O
and None None O
problem None None I-FUNC
solving None None I-FUNC
that None None O
characterizes None None O
many None None O
neuropsychiatric None None O
disorders None None O
. None None O

Towers None None O
Task None None O
data None None O
are None None O
usually None None O
zero-inflated None None O
and None None O
right-censored None None O
, None None O
and None None O
ignoring None None O
these None None O
features None None O
can None None O
result None None O
in None None O
biased None None O
inference None None I-FUNC
for None None O
the None None O
disease None None O
characterization None None O
of None None O
executive None None O
dysfunction None None O
. None None O

Indeed None None O
, None None O
the None None O
introduction None None O
of None None O
MRI None None O
conditional None None O
systems None None O
has None None O
led None None O
to None None O
a None None O
conceptual None None O
shift None None O
in None None O
clinical None None O
decision None None I-FUNC
making-'can None None O
this None None O
patient None None O
undergo None None O
MRI None None O
safely None None O
? None None O
' None None O

The None None O
clinical None None O
cohort None None O
has None None O
been None None O
assessed None None O
four None None O
times None None O
over None None O
a None None O
period None None O
of None None O
8 None None O
years None None O
, None None O
with None None O
retention None None I-FUNC
rates None None O
ranging None None O
between None None O
77 None None O
% None None O
and None None O
85 None None O
% None None O
. None None O

We None None O
report None None O
that None None O
the None None O
addition None None O
of None None O
alkali None None O
ions None None O
( None None O
sodium None None O
or None None O
potassium None None O
) None None O
to None None O
gold None None O
on None None O
KLTL-zeolite None None O
and None None O
mesoporous None None O
MCM-41 None None O
silica None None O
stabilizes None None O
mononuclear None None O
gold None None O
in None None O
Au-O None None O
( None None O
OH None None O
) None None O
x- None None O
( None None O
Na None None I-TRANS
or None None O
K None None O
) None None O
ensembles None None O
. None None O

Although None None O
the None None O
concept None None O
has None None O
attracted None None O
prolonged None None O
attention None None I-FUNC
, None None O
the None None O
mechanisms None None O
by None None O
which None None O
the None None O
habitus None None O
is None None O
fulfilled None None O
remain None None O
unspecified None None O
. None None O

Fetal None None O
( None None O
90 None None O
% None None O
of None None O
full-term None None O
) None None O
IUGR None None O
brains None None O
were None None O
comparable None None O
in None None O
size None None O
to None None O
controls None None O
, None None O
but None None O
have None None O
reduced None None O
expression None None O
of None None O
serotonergic None None O
proteins None None O
and None None O
mRNAs None None O
, None None O
as None None O
well None None O
as None None O
having None None O
fewer None None O
serotonergic None None I-NEURON
neurons None None I-NEURON
. None None O

A None None O
study None None O
examined None None O
how None None O
anhedonic None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
measured None None O
continuously None None O
across None None O
a None None O
wide None None O
range None None O
of None None O
severity None None O
, None None O
influenced None None O
the None None O
physiological None None O
mobilization None None O
of None None O
effort None None O
during None None O
a None None O
cognitive None None O
task None None O
. None None O

The None None O
1974 None None O
Lau None None O
decision None None O
requires None None O
that None None O
U.S. None None O
public None None O
schools None None O
ensure None None O
a None None O
meaningful None None O
education None None O
for None None O
students None None O
learning None None I-FUNC
English None None O
. None None O

Using None None O
nationally None None O
representative None None O
data None None O
from None None O
the None None O
Educational None None O
Longitudinal None None O
Study None None O
( None None O
ELS None None O
) None None O
, None None O
the None None O
effects None None O
of None None O
ESL None None O
placement None None O
on None None O
college None None O
preparatory None None O
course None None O
enrollment None None O
and None None O
academic None None O
achievement None None O
of None None O
language None None I-FUNC
minority None None O
students None None O
are None None O
estimated None None O
, None None O
first None None O
with None None O
fixed None None O
effects None None O
regression None None O
models None None O
and None None O
then None None O
with None None O
multi-level None None O
propensity None None O
score None None O
matching None None O
techniques None None O
. None None O

Perhaps None None O
more None None O
important None None O
, None None O
however None None O
, None None O
no None None O
positive None None O
effects None None O
of None None O
ESL None None O
placement None None O
on None None O
the None None O
achievement None None O
of None None O
language None None I-FUNC
minority None None O
youth None None O
are None None O
found None None O
when None None O
accounting None None O
for None None O
English None None O
proficiency None None O
and None None O
other None None O
potential None None O
covariates None None O
. None None O

This None None O
study None None O
investigated None None O
maternal None None O
psychological None None O
distress None None O
, None None O
perceptions None None I-FUNC
of None None O
social None None O
supports None None O
, None None O
and None None O
parenting None None O
strains None None O
after None None O
the None None O
birth None None O
of None None O
a None None O
very None None O
low None None O
birthweight None None O
( None None O
VLBW None None O
) None None O
infant None None O
. None None O

After None None O
verifying None None O
the None None O
validity None None O
of None None O
scales None None O
and None None O
reliability None None O
in None None O
the None None O
university None None O
students None None O
' None None O
population None None O
, None None O
we None None O
found None None O
that None None O
risk None None O
perception None None I-FUNC
was None None O
associated None None O
with None None O
lower None None O
risk None None O
intake None None O
, None None O
while None None O
risk None None O
attractiveness None None O
was None None O
a None None O
driver None None O
for None None O
it None None O
. None None O

The None None O
results None None O
revealed None None O
that None None O
SNSs None None O
can None None O
increase None None O
students None None O
' None None O
social None None O
capital None None O
in None None O
many None None O
ways None None O
, None None O
such None None O
as None None O
in None None O
the None None O
form None None O
of None None O
peer None None O
support None None O
groups None None O
and None None O
learning None None I-FUNC
environments None None O
, None None O
and None None O
enhance None None O
bonding None None O
and None None O
communality None None O
in None None O
them None None O
. None None O

Such None None O
impairment None None O
occurs None None O
regardless None None O
of None None O
whether None None O
people None None O
collaborate None None O
when None None O
first None None O
experiencing None None O
, None None O
or None None O
encoding None None I-FUNC
, None None O
an None None O
event None None O
( None None O
the None None O
collaborative None None O
encoding None None I-FUNC
deficit None None O
) None None O
, None None O
or None None O
when None None O
retrieving None None O
, None None O
or None None O
remembering None None O
, None None O
the None None O
event None None O
( None None O
the None None O
collaborative None None O
inhibition None None O
effect None None O
) None None O
. None None O

Recent None None O
research None None O
on None None O
the None None O
effects None None O
of None None O
letter None None O
transposition None None O
in None None O
Indo-European None None O
Languages None None I-FUNC
has None None O
shown None None O
that None None O
readers None None O
are None None O
surprisingly None None O
tolerant None None O
of None None O
these None None O
manipulations None None O
in None None O
a None None O
range None None O
of None None O
tasks None None O
. None None O

The None None O
results None None O
show None None O
that None None O
in None None O
spite None None O
of None None O
of None None O
the None None O
neurobiological None None O
noise None None O
involved None None O
in None None O
registering None None O
letter-position None None O
in None None O
all None None O
languages None None I-FUNC
, None None O
flexibility None None O
and None None O
inflexibility None None O
in None None O
coding None None O
letter None None O
order None None O
is None None O
also None None O
shaped None None O
by None None O
the None None O
statistical None None O
orthographic None None O
properties None None O
of None None O
words None None O
in None None O
a None None O
language None None I-FUNC
, None None O
such None None O
as None None O
the None None O
relative None None O
prevalence None None O
of None None O
anagrams None None O
. None None O

Besides None None O
, None None O
MD None None O
increased None None O
protein None None O
damage None None O
in None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
, None None O
amygdala None None I-REGION
, None None O
and None None O
hippocampus None None I-REGION
; None None O
however None None O
, None None O
this None None O
effect None None O
varies None None O
depending None None O
on None None O
the None None O
dose None None O
administered None None O
. None None O

Perceived None None O
reasons None None O
why None None O
older None None O
women None None O
have None None O
sexual None None O
relationships None None O
with None None O
younger None None O
men None None O
included None None O
: None None O
sexual None None O
fulfilment None None O
, None None O
domination None None O
, None None O
reduction None None O
of None None O
stress None None O
, None None O
physical None None O
attraction None None O
, None None O
procreation None None O
, None None O
lack None None O
of None None O
self-control None None O
, None None O
youthful None None O
feeling None None I-FUNC
, None None O
migrancy None None O
, None None O
difficulty None None O
in None None O
finding None None O
partners None None O
of None None O
compatible None None O
age None None O
and None None O
young None None O
men None None O
being None None O
seen None None O
as None None O
not None None O
demanding None None O
. None None O

Given None None O
the None None O
increase None None O
in None None O
sugar None None O
mommy None None O
practices None None O
, None None O
which None None O
may None None O
have None None O
significant None None O
implications None None O
for None None O
the None None O
prevalence None None O
of None None O
HIV/AIDS None None O
, None None O
it None None O
is None None O
necessary None None O
to None None O
understand None None O
the None None O
underlying None None O
perceptions None None I-FUNC
of None None O
these None None O
practices None None O
, None None O
in None None O
order None None O
to None None O
develop None None O
culturally None None O
relevant None None O
and None None O
socially None None O
acceptable None None O
intervention None None O
programmes None None O
. None None O

Michigan-style None None O
learning None None I-FUNC
classifier None None O
systems None None O
( None None O
M-LCSs None None O
) None None O
represent None None O
an None None O
adaptive None None O
and None None O
powerful None None O
class None None O
of None None O
evolutionary None None O
algorithms None None O
which None None O
distribute None None O
the None None O
learned None None O
solution None None O
over None None O
a None None O
sizable None None O
population None None O
of None None O
rules None None O
. None None O

Aging None None O
is None None O
accompanied None None O
by None None O
gradually None None O
increasing None None O
impairment None None O
of None None O
cognitive None None O
abilities None None O
and None None O
constitutes None None O
the None None O
main None None O
risk None None O
factor None None O
of None None O
neurodegenerative None None O
conditions None None O
like None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

Focusing None None O
on None None O
neuronal None None O
polarization None None O
, None None O
neurotransmitter None None I-TRANS
specification None None O
, None None O
axon None None O
guidance None None O
, None None O
and None None O
refinement None None O
of None None O
neuronal None None O
connectivity None None O
, None None O
we None None O
summarize None None O
herein None None O
the None None O
recent None None O
advances None None O
in None None O
understanding None None O
the None None O
features None None O
of None None O
cAMP None None O
signals None None O
and None None O
their None None O
dynamic None None O
interactions None None O
with None None O
calcium None None O
and None None O
cGMP None None O
involved None None O
in None None O
shaping None None O
the None None O
nervous None None O
system None None O
. None None O

Spinal None None O
interneurons None None I-NEURON
can None None O
integrate None None O
diverse None None O
propriospinal None None O
and None None O
supraspinal None None O
inputs None None O
that None None O
trigger None None O
or None None O
modulate None None O
locomotion None None O
and None None O
other None None O
limb None None O
movements None None I-FUNC
. None None O

We None None O
previously None None O
described None None O
a None None O
class None None O
of None None O
spinal None None O
interneurons None None I-NEURON
, None None O
called None None O
transverse None None O
interneurons None None I-NEURON
( None None O
or None None O
T None None O
neurons None None O
) None None O
, None None O
in None None O
adult None None O
turtles None None O
. None None O

In None None O
combination None None O
with None None O
T None None O
neuron None None O
physiological None None O
properties None None O
, None None O
these None None O
dendritic None None O
properties None None O
may None None O
help None None O
integrate None None O
supraspinal None None O
and None None O
propriospinal None None O
inputs None None O
and None None O
generate None None O
and/or None None O
modulate None None O
rhythmic None None O
limb None None O
movements None None I-FUNC
. None None O

The None None O
present None None O
article None None O
discusses None None O
a None None O
region None None O
of None None O
the None None O
hypothalamus None None I-REGION
known None None O
as None None O
the None None O
lateral None None I-REGION
hypothalamic None None I-REGION
area None None I-REGION
( None None O
LHA None None O
) None None O
. None None O

Regions None None O
within None None O
the None None O
LHA None None O
send None None O
dense None None O
projections None None O
to None None O
the None None O
ventral None None I-REGION
tegmental None None I-REGION
area None None I-REGION
( None None O
VTA None None O
) None None O
, None None O
providing None None O
a None None O
pathway None None O
for None None O
the None None O
LHA None None O
to None None O
influence None None O
dopaminergic None None O
systems None None O
generally None None O
recognized None None O
to None None O
be None None O
involved None None O
in None None O
motivated None None O
behaviors None None O
and None None O
their None None O
reinforcement None None O
. None None O

The None None O
LHA None None O
also None None O
receives None None O
inputs None None O
from None None O
brain None None O
areas None None O
involved None None O
in None None O
reward-related None None O
learning None None I-FUNC
and None None O
orexin None None O
neuron None None O
activation None None O
can None None O
become None None O
conditioned None None O
to None None O
environmental None None O
stimuli None None O
that None None O
are None None O
associated None None O
with None None O
rewards None None O
. None None O

The None None O
capacity None None O
to None None O
regulate None None O
emotions None None I-FUNC
is None None O
particularly None None O
important None None O
during None None O
and None None O
after None None O
the None None O
encounter None None O
of None None O
a None None O
stressor None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
explore None None O
how None None O
stress-induced None None O
cortisol None None O
increases None None O
affect None None O
three None None O
different None None O
emotion None None I-FUNC
regulation None None O
strategies None None O
. None None O

These None None O
findings None None O
characterize None None O
the None None O
impact None None O
of None None O
stress None None O
and None None O
sex None None O
on None None O
emotion None None I-FUNC
regulation None None O
and None None O
provide None None O
initial None None O
evidence None None O
that None None O
these None None O
factors None None O
may None None O
interact None None O
. None None O

Future None None O
investigations None None O
should None None O
pay None None O
greater None None O
attention None None I-FUNC
to None None O
adequately None None O
blinded None None O
studies None None O
and None None O
EEG-NF None None O
protocols None None O
that None None O
carefully None None O
control None None O
the None None O
implementation None None O
and None None O
embedding None None O
of None None O
training None None O
. None None O

It None None O
is None None O
still None None O
a None None O
matter None None O
of None None O
debate None None O
which None None O
regions None None O
represent None None O
the None None O
functional None None O
substrate None None O
of None None O
congenital None None O
prosopagnosia None None I-DISEASE
( None None O
CP None None O
) None None O
, None None O
a None None O
condition None None O
characterized None None O
by None None O
a None None O
lifelong None None O
impairment None None O
in None None O
face None None I-FUNC
recognition None None I-FUNC
, None None O
and None None O
affecting None None O
around None None O
2.5 None None O
% None None O
of None None O
the None None O
general None None O
population None None O
. None None O

Using None None O
multi-voxel None None O
pattern None None O
analysis None None O
( None None O
MVPA None None O
) None None O
of None None O
the None None O
fMRI None None O
data None None O
we None None O
demonstrate None None O
that None None O
neural None None O
activity None None O
within None None O
the None None O
`` None None O
core None None O
'' None None O
( None None O
i.e. None None O
, None None O
occipital None None O
face None None O
area None None O
and None None O
fusiform None None O
face None None O
area None None O
) None None O
and None None O
`` None None O
extended None None O
'' None None O
( None None O
i.e. None None O
, None None O
anterior None None O
temporal None None I-REGION
cortex None None I-REGION
) None None O
face None None O
regions None None O
in None None O
CPs None None O
showed None None O
reduced None None O
discriminability None None O
between None None O
faces None None O
and None None O
objects None None O
. None None O

In None None O
contrast None None O
, None None O
discriminability None None O
between None None O
faces None None O
and None None O
bodies/body-parts None None O
and None None O
objects None None O
and None None O
bodies/body-parts None None O
across None None O
the None None O
ventral None None I-NEURON
visual None None O
system None None O
was None None O
typical None None O
in None None O
CPs None None O
. None None O

Our None None O
results None None O
favor None None O
the None None O
hypothesis None None O
which None None O
considers None None O
spatial None None O
working None None I-FUNC
memory None None I-FUNC
as None None O
a None None O
by-product None None O
of None None O
specific None None O
mental None None O
processes None None O
that None None O
engages None None O
common None None O
brain None None O
areas None None O
under None None O
different None None O
network None None O
organizations None None O
. None None O

Fornix None None I-REGION
FA None None O
is None None O
consistently None None O
decreased None None O
in None None O
patients None None O
with None None O
mild None None O
cognitive None None O
impairment None None O
( None None O
MCI None None O
) None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

Reductions None None O
of None None O
FA None None O
at None None O
these None None O
early None None O
stages None None O
, None None O
which None None O
predicted None None O
the None None O
decline None None O
in None None O
memory None None I-FUNC
function None None O
. None None O

Fornix None None I-REGION
also None None O
carries None None O
the None None O
afferent None None O
cholinergic None None O
and None None O
GABAergic None None O
projections None None O
from None None O
the None None O
medial None None O
septal None None I-REGION
nuclei None None I-REGION
and None None O
the None None O
adjacent None None O
diagonal None None I-REGION
band None None I-REGION
back None None O
to None None O
the None None O
medial None None O
temporal None None I-REGION
lobe None None I-REGION
, None None O
interconnecting None None O
the None None O
core None None O
limbic None None O
structures None None O
. None None O

In None None O
keeping None None O
with None None O
that None None O
, None None O
fornix None None I-REGION
FA None None O
is None None O
reduced None None O
in None None O
subjects None None O
with None None O
hippocampal None None O
atrophy None None O
, None None O
correlating None None O
with None None O
memory None None I-FUNC
function None None O
. None None O

While None None O
the None None O
involvement None None O
of None None O
various None None O
molecules None None O
associated None None O
with None None O
the None None O
Sec61 None None O
complex None None O
has None None O
been None None O
thoroughly None None O
characterized None None O
, None None O
little None None O
attention None None I-FUNC
has None None O
been None None O
given None None O
to None None O
the None None O
overall None None O
flux None None O
through None None O
these None None O
channels None None O
. None None O

Thus None None O
, None None O
our None None O
results None None O
support None None O
the None None O
functional None None O
role None None O
of None None O
syllable None None O
units None None O
during None None O
phonological None None O
articulation None None O
in None None O
sign None None O
language None None I-FUNC
production None None O
. None None O

Whether None None O
an None None O
eventual None None O
higher None None O
insulin None None I-PROTEIN
sensitivity None None O
of None None O
female None None O
skeletal None None O
muscle None None O
can None None O
be None None O
related None None O
to None None O
gender-specific None None O
regulation None None O
of None None O
molecular None None O
metabolism None None O
will None None O
be None None O
topic None None O
for None None O
discussion None None O
. None None O

In None None O
particular None None O
, None None O
the None None O
molecular None None O
machinery None None O
for None None O
glucose None None O
and None None O
fatty None None O
acid None None O
oxidative None None O
and None None O
storage None None I-FUNC
capacities None None O
in None None O
skeletal None None O
muscle None None O
and None None O
its None None O
implications None None O
for None None O
substrate None None O
utilization None None O
during None None O
metabolic None None O
situations None None O
of None None O
daily None None O
living None None O
are None None O
discussed None None O
, None None O
emphasizing None None O
their None None O
relevance None None O
for None None O
substrate None None O
choice None None O
in None None O
the None None O
fed None None O
and None None O
fasted None None O
state None None O
, None None O
and None None O
during None None O
periods None None O
of None None O
physical None None O
activity None None O
and None None O
recovery None None O
. None None O

17-β None None O
estradiol None None O
is None None O
the None None O
most None None O
important None None O
female None None O
sex None None O
hormone None None O
, None None O
and None None O
the None None O
identification None None O
of None None O
estradiol None None O
receptors None None I-PROTEIN
in None None O
skeletal None None O
muscle None None O
has None None O
opened None None O
for None None O
a None None O
role None None O
in None None O
regulation None None O
of None None O
substrate None None O
metabolism None None O
. None None O

Investigating None None O
body-weight None None O
perception None None I-FUNC
, None None O
we None None O
found None None O
that None None O
weight None None O
and None None O
adiposity None None O
were None None O
underestimated None None O
by None None O
obese None None O
subjects None None O
, None None O
who None None O
showed None None O
a None None O
greater None None O
disparity None None O
between None None O
perceived None None O
and None None O
actual None None O
adiposity None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Nevertheless None None O
, None None O
chromatin None None O
movement None None I-FUNC
enables None None O
a None None O
flexible None None O
spatial None None O
genome None None O
arrangement None None O
in None None O
plant None None O
nuclei None None O
. None None O

Enucleation-induced None None O
adrenal None None I-TRANS
regeneration None None O
is None None O
a None None O
highly None None O
controlled None None O
process None None O
; None None O
however None None O
, None None O
only None None O
some None None O
elements None None O
involved None None O
in None None O
this None None O
process None None O
have None None O
been None None O
recognized None None O
. None None O

In None None O
regenerating None None O
adrenals None None I-TRANS
we None None O
identified None None O
over None None O
100 None None O
up- None None O
or None None O
downregulated None None O
genes None None O
involved None None O
in None None O
adrenocortical None None O
cell None None O
proliferation None None O
. None None O

Despite None None O
notable None None O
differences None None O
in None None O
mechanisms None None O
of None None O
adrenal None None I-TRANS
and None None O
liver None None O
regeneration None None O
, None None O
in None None O
regenerating None None O
adrenals None None I-TRANS
we None None O
identified None None O
genes None None O
, None None O
the None None O
expression None None O
of None None O
which None None O
is None None O
well None None O
recognized None None O
in None None O
regenerating None None O
liver None None O
. None None O

Vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
is None None O
a None None O
potent None None O
angiogenic None None O
factor None None O
in None None O
solid None None O
tumors None None O
. None None O

85-year-old None None O
gentleman None None O
was None None O
brought None None O
to None None O
the None None O
emergency None None O
room None None O
with None None O
altered None None O
level None None O
of None None O
consciousness None None I-FUNC
after None None O
refusing None None O
to None None O
eat None None O
for None None O
a None None O
week None None O
at None None O
a None None O
skilled None None O
nursing None None O
facility None None O
. None None O

Curcumin None None O
has None None O
long None None O
been None None O
used None None O
to None None O
treat None None O
age-related None None O
diseases None None O
, None None O
such None None O
as None None O
atherosclerosis None None I-DISEASE
and None None O
coronary None None O
heart None None O
disease None None O
. None None O

The None None O
mechanisms None None O
of None None O
herbal None None O
medicines None None O
for None None O
PD None None O
are None None O
associated None None O
with None None O
PG None None O
level None None O
reduction None None O
, None None O
suppression None None O
of None None O
cyclooxygenase-2 None None O
expression None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
activation None None O
and None None O
malondialdehyde None None O
reduction None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
, None None O
and None None O
nuclear None None O
factor-kappa None None O
B None None O
reduction None None O
, None None O
stimulation None None O
of None None O
somatostatin None None I-TRANS
receptor None None I-PROTEIN
, None None O
intracellular None None O
Ca None None O
( None None O
2+ None None O
) None None O
reduction None None O
, None None O
and None None O
recovery None None O
of None None O
phospholipid None None O
metabolism None None O
. None None O

In None None O
male None None O
rats None None O
, None None O
YMJ None None O
treatment None None O
decreased None None O
the None None O
absolute None None O
weights None None O
of None None O
the None None O
epididymides None None O
and None None O
serum None None O
Na None None I-TRANS
levels None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
, None None O
HepG2 None None O
cells None None O
pretreated None None O
with None None O
GBR None None O
extracts None None O
, None None O
rich None None O
in None None O
acylated None None O
steryl None None O
glycoside None None O
( None None O
ASG None None O
) None None O
, None None O
gamma None None O
amino None None O
butyric None None O
acid None None O
GABA None None I-TRANS
) None None O
, None None O
phenolics None None O
or None None O
oryzanol None None O
, None None O
were None None O
incubated None None O
with None None O
hydrogen None None O
peroxide None None O
( None None O
H2O2 None None O
) None None O
and None None O
their None None O
hydroxyl None None O
radical None None O
( None None O
OH None None O
( None None O
• None None O
) None None O
) None None O
scavenging None None O
capacities None None O
and None None O
thiobarbituric None None O
acid-reactive None None O
substances None None O
( None None O
TBARS None None O
) None None O
generation None None O
were None None O
evaluated None None O
. None None O

After None None O
2-week None None O
TN None None O
therapy None None O
, None None O
83 None None O
% None None O
patients None None O
had None None O
more None None O
than None None O
3 None None O
times None None O
bowel None None O
movements None None I-FUNC
per None None O
week None None O
which None None O
was None None O
significantly None None O
different None None O
from None None O
sham-TN None None O
( None None O
P None None O
= None None O
0.01 None None O
) None None O
. None None O

The None None O
arsenal None None O
of None None O
tools None None O
currently None None O
available None None O
to None None O
clinicians None None O
now None None O
includes None None O
inhibitors None None O
of None None O
the None None O
viral None None O
reverse None None O
transcriptase None None O
, None None O
protease None None O
and None None O
integrase None None O
enzymes None None I-PROTEIN
. None None O

As None None O
a None None O
pilot None None O
exploratory None None O
study None None O
, None None O
the None None O
research None None O
design None None O
included None None O
questionnaires None None O
to None None O
assess None None O
the None None O
participants None None O
' None None O
( None None O
children None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
, None None O
parents None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
, None None O
and None None O
therapists None None O
( None None O
n None None O
= None None O
13 None None O
) None None O
) None None O
perceptions None None I-FUNC
on None None O
the None None O
therapeutic None None O
benefit None None O
of None None O
the None None O
dance None None O
program None None O
. None None O

Although None None O
emotion None None I-FUNC
is None None O
always None None O
about None None O
the None None O
here None None O
and None None O
now None None O
, None None O
the None None O
capacity None None O
for None None O
abstract None None O
thought None None O
means None None O
that None None O
the None None O
human None None O
here None None O
and None None O
now None None O
includes None None O
imagination None None O
as None None O
well None None O
as None None O
perception None None I-FUNC
. None None O

Indeed None None O
, None None O
embodied None None O
accounts None None O
will None None O
still None None O
require None None O
structural None None O
accounts None None O
to None None O
determine None None O
why None None O
one None None O
emotion None None I-FUNC
rather None None O
than None None O
another None None O
is None None O
elicited None None O
. None None O

Depressive None None I-DISEASE
symptoms None None I-DISEASE
were None None O
measured None None O
using None None O
the None None O
Patient None None O
Health None None O
Questionnaire None None O
( None None O
PHQ None None O
) None None O
. None None O

Twenty-one None None O
( None None O
35 None None O
% None None O
) None None O
met None None O
the None None O
criteria None None O
for None None O
previously None None O
recognized None None O
depression None None I-DISEASE
( None None O
on None None O
antidepressants None None O
and/or None None O
a None None O
diagnosis None None O
of None None O
depression None None I-DISEASE
in None None O
the None None O
last None None O
12 None None O
months None None O
) None None O
and None None O
17 None None O
( None None O
28.3 None None O
% None None O
) None None O
for None None O
depression None None I-DISEASE
not None None O
previously None None O
recognized None None O
( None None O
PHQ None None O
& None None O
gt None None O
; None None O
4 None None O
) None None O
. None None O

Despite None None O
antidepressant None None O
treatment None None O
12 None None O
participants None None O
( None None O
70.6 None None O
% None None O
of None None O
those None None O
taking None None O
antidepressants None None O
) None None O
still None None O
reported None None O
moderate None None O
to None None O
severe None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
the None None O
time None None O
of None None O
the None None O
study None None O
. None None O

No None None O
association None None O
was None None O
found None None O
between None None O
physical None None O
functioning None None O
( None None O
PCS None None O
) None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

This None None O
study None None O
found None None O
a None None O
high None None O
prevalence None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
both None None O
recognized None None O
and None None O
unrecognized None None O
in None None O
people None None O
with None None O
diabetes None None O
and None None O
foot None None O
ulcers None None O
. None None O

There None None O
was None None O
no None None O
association None None O
between None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
ulcer None None O
outcomes None None O
at None None O
six-months None None O
follow-up None None O
. None None O

A None None O
comprehensive None None O
integrative None None O
strategy None None O
initiated None None O
early None None O
in None None O
the None None O
cognitive None None O
decline None None O
is None None O
perhaps None None O
the None None O
most None None O
effective None None O
method None None O
of None None O
controlling None None O
progression None None O
to None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Cytotoxicity None None O
of None None O
H2S None None I-TRANS
in None None O
neurodegenerative None None O
diseases None None O
may None None O
be None None O
mediated None None O
by None None O
N-methyl-D-aspartate None None O
receptor None None I-PROTEIN
( None None O
NMDAR None None O
) None None O
activation None None O
. None None O

We None None O
observed None None O
that None None O
cytoprotective None None O
effect None None O
of None None O
H2S-releasing None None O
NMDAR None None O
antagonists None None O
correlated None None O
with None None O
their None None O
ability None None O
to None None O
increase None None O
intracellular None None O
sulfane None None O
sulfur None None O
, None None O
but None None O
not None None O
H2S None None I-TRANS
, None None O
levels None None O
. None None O

The None None O
synthesis None None O
of None None O
fluorine-18 None None O
labeled None None O
3-fluoro-5- None None O
[ None None O
( None None O
pyridin-3-yl None None O
) None None O
ethynyl None None O
] None None O
benzonitrile None None O
( None None O
[ None None O
18F None None O
] None None O
FPEB None None O
) None None O
for None None O
imaging None None O
metabotropic None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
subtype None None O
type None None O
5 None None O
( None None O
mGluR5 None None O
) None None O
was None None O
achieved None None O
with None None O
a None None O
commercial None None O
continuous-flow None None O
microfluidics None None O
device None None O
. None None O

To None None O
investigate None None O
panitumumab-IRDye800 None None O
as None None O
an None None O
intraoperative None None O
optical None None O
imaging None None O
agent None None O
for None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
-expressing None None O
cancers None None O
, None None O
we None None O
developed None None O
clinical-quality None None O
panitumumab-IRDye800 None None O
and None None O
evaluated None None O
its None None O
specificity None None O
and None None O
sensitivity None None O
to None None O
visualize None None O
tumors None None O
by None None O
fluorescence None None O
imaging None None O
in None None O
a None None O
variety None None O
of None None O
mouse None None O
xenograft None None O
models None None O
with None None O
different None None O
levels None None O
of None None O
EGFR-expression None None O
. None None O

In None None O
addition None None O
, None None O
biased None None O
attention None None I-FUNC
toward None None O
emotional None None O
information None None O
was None None O
investigated None None O
as None None O
a None None O
mechanism None None O
that None None O
might None None O
underlie None None O
state None None O
rumination None None O
. None None O

In None None O
contrast None None O
, None None O
SR141716A None None O
only None None O
attenuated None None O
the None None O
hypothermic None None O
effects None None O
of None None O
CP55940 None None O
but None None O
not None None O
anandamide None None I-TRANS
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
content None None O
of None None O
antimony None None O
and None None O
other None None O
trace None None O
elements None None O
in None None O
bottled None None O
waters None None O
which None None O
was None None O
kept None None O
in None None O
varied None None O
storage None None I-FUNC
conditions None None O
and None None O
temperatures None None O
. None None O

Storage None None I-FUNC
time None None O
and None None O
temperature None None O
effects None None O
on None None O
the None None O
content None None O
of None None O
some None None O
other None None O
trace None None O
elements None None O
such None None O
as None None O
Al None None O
, None None O
Fe None None O
were None None O
also None None O
significant None None O
( None None O
p None None O
≤ None None O
0.05 None None O
) None None O
. None None O

The None None O
concentration None None O
of None None O
Al None None O
demonstrated None None O
an None None O
increase None None O
in None None O
higher None None O
temperatures None None O
and None None O
storage None None I-FUNC
duration None None O
, None None O
whereas None None O
the None None O
content None None O
of None None O
Fe None None O
demonstrated None None O
no None None O
significant None None O
differences None None O
. None None O

Following None None O
the None None O
first None None O
case None None O
of None None O
a None None O
systemic None None O
air None None O
embolism None None I-DISEASE
due None None O
to None None O
percutaneous None None O
CT-guided None None O
lung None None O
biopsy None None O
in None None O
our None None O
clinic None None O
we None None O
analysed None None O
the None None O
literature None None O
regarding None None O
this None None O
matter None None O
in None None O
view None None O
of None None O
influenceable None None O
or None None O
avoidable None None O
risk None None O
factors None None O
. None None O

The None None O
bound None None O
bilirubin None None O
may None None O
block None None O
the None None O
binding None None O
of None None O
antigenic None None O
peptides None None I-TRANS
to None None O
be None None O
presented None None O
to None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptors None None I-PROTEIN
and None None O
lead None None O
to None None O
suppression None None O
of None None O
the None None O
autoimmune None None O
responses None None O
. None None O

Phosphorylation None None O
of None None O
p53 None None I-PROTEIN
and None None O
Chk1 None None O
and None None O
expression None None O
of None None O
ATF4 None None O
and None None O
CHOP None None O
genes None None O
were None None O
detected None None O
in None None O
IS- None None O
, None None O
PCS- None None O
, None None O
and None None O
PhS-treated None None O
cells None None O
, None None O
but None None O
not None None O
in None None O
IAA-treated None None O
cells None None O
. None None O

Concerns None None O
over None None O
aggravation None None O
of None None O
vasospasm None None O
with None None O
norepinephrine None None I-TRANS
exist None None O
. None None O

To None None O
describe None None O
norepinephrine None None I-TRANS
temporally None None O
related None None O
deterioration None None O
in None None O
neurological None None O
examination None None O
of None None O
two None None O
post-SAH None None O
patients None None O
in None None O
vasospasm None None O
. None None O

We None None O
retrospectively None None O
reviewed None None O
two None None O
charts None None O
of None None O
patients None None O
with None None O
delayed None None O
cerebral None None O
ischemia None None O
( None None O
DCI None None O
) None None O
post-SAH None None O
who None None O
deteriorated None None O
with None None O
norepinephrine None None I-TRANS
infusions None None O
. None None O

We None None O
identified None None O
two None None O
patients None None O
with None None O
DCI None None O
post-SAH None None O
who None None O
deteriorated None None O
during None None O
hypertensive None None O
therapy None None O
with None None O
norepinephrine None None I-TRANS
. None None O

His None None O
exam None None O
improved None None O
on None None O
continuous None None O
milrinone None None O
and None None O
discontinuation None None O
of None None O
norepinephrine None None I-TRANS
. None None O

During None None O
further None None O
deterioration None None O
and None None O
after None None O
angioplasty None None O
, None None O
norepinephrine None None I-TRANS
was None None O
utilized None None O
to None None O
drive None None O
MABP None None O
to None None O
130-140 None None O
mm None None O
Hg None None O
. None None O

After None None O
discontinuation None None O
of None None O
norepinephrine None None I-TRANS
and None None O
continuation None None O
of None None O
milrinone None None O
, None None O
function None None O
dramatically None None O
returned None None O
but None None O
not None None O
to None None O
baseline None None O
. None None O

The None None O
potential None None O
exists None None O
for None None O
worsening None None O
of None None O
DCI None None O
post-SAH None None O
with None None O
hypertensive None None O
therapy None None O
directed None None O
by None None O
norepinephrine None None I-TRANS
. None None O

Development None None O
of None None O
autoantibodies None None O
against None None O
coagulation None None I-PROTEIN
factors None None I-PROTEIN
is None None O
an None None O
uncommon None None O
bleeding None None O
disorder None None O
associated None None O
with None None O
cancer None None O
, None None O
autoimmune None None O
conditions None None O
, None None O
pregnancy None None O
, None None O
or None None O
no None None O
apparent None None O
disease None None O
. None None O

Adalimumab None None O
was None None O
started None None O
in None None O
2010 None None O
, None None O
and None None O
at None None O
the None None O
third None None O
month None None O
of None None O
treatment None None O
, None None O
Ggt None None O
showed None None O
a None None O
rise None None O
of None None O
23 None None O
times None None O
normal None None O
value None None O
( None None O
NV None None O
) None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
2,5 None None O
times None None O
NV None None O
with None None O
AST None None O
and None None O
ALT None None O
with None None O
no None None O
change None None O
. None None O

We None None O
present None None O
the None None O
case None None O
of None None O
a None None O
middle-aged None None O
woman None None O
with None None O
adenocarcinoma None None O
gall None None O
bladder None None O
, None None O
treated None None O
with None None O
postoperative None None O
locoregional None None O
irradiation None None O
following None None O
simple None None O
cholecystectomy None None O
, None None O
who None None O
developed None None O
headache None None O
, None None O
backache None None O
, None None O
vision None None I-FUNC
loss None None O
, None None O
and None None O
multiple None None O
joint None None O
pains None None O
six None None O
years None None O
following None None O
adjuvant None None O
therapy None None O
. None None O

Stroke None None I-DISEASE
has None None O
not None None O
been None None O
reported None None O
as None None O
part None None O
of None None O
its None None O
phenomenology None None O
. None None O

A None None O
57-year-old None None O
man None None O
presented None None O
with None None O
worsening None None O
memory None None I-FUNC
. None None O

MRI None None O
of None None O
the None None O
brain None None O
showed None None O
multiple None None O
acute None None O
ischemic None None O
strokes None None I-DISEASE
. None None O

This None None O
is None None O
the None None O
first None None O
reported None None O
case None None O
in None None O
literature None None O
where None None O
an None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
can None None O
be None None O
attributed None None O
to None None O
Jarisch-Herxheimer None None O
reaction None None O
. None None O

Supportive None None O
therapy None None O
was None None O
started None None O
and None None O
during None None O
the None None O
next None None O
3 None None O
weeks None None O
the None None O
patient None None O
progressively None None O
regained None None O
consciousness None None I-FUNC
and None None O
muscle None None O
strength None None O
and None None O
was None None O
able None None O
to None None O
feed None None O
himself None None O
. None None O

A None None O
25-year-old None None O
infertile None None O
patient None None O
with None None O
a None None O
history None None O
of None None O
bilateral None None O
salpingectomy None None O
, None None O
uterine None None O
septum None None I-REGION
resection None None O
, None None O
and None None O
left None None O
cornual None None O
resection None None O
was None None O
diagnosed None None O
with None None O
heterotopic None None O
pregnancy None None O
in None None O
her None None O
second None None O
in None None O
vitro None None O
fertilization None None O
trial None None O
. None None O

She None None O
suffered None None O
dementia None None I-DISEASE
and None None O
had None None O
a None None O
seizure None None O
in None None O
the None None O
department None None O
resulting None None O
in None None O
a None None O
reduced None None O
GCS None None O
, None None O
making None None O
history None None O
and None None O
examination None None O
difficult None None O
. None None O

In None None O
the None None O
course None None O
of None None O
her None None O
follow-up None None O
, None None O
she None None O
developed None None O
intractable None None O
headaches None None O
, None None O
and None None O
worsening None None O
mood None None I-FUNC
symptoms None None O
and None None O
eventually None None O
exhibited None None O
Psychotic None None O
Features None None O
for None None O
which None None O
psychiatry None None O
became None None O
coinvolved None None O
in None None O
her None None O
care None None O
. None None O

There None None O
is None None O
a None None O
need None None O
to None None O
develop None None O
area None None O
specific None None O
community None None O
based None None O
treatment None None O
services None None O
for None None O
substance None None I-DISEASE
abuse None None I-DISEASE
in None None O
socially None None O
disadvantaged None None O
populations None None O
such None None O
as None None O
urban None None O
resettlement None None O
colonies None None O
. None None O

We None None O
further None None O
showed None None O
that None None O
, None None O
apart None None O
from None None O
maintaining None None O
O2 None None O
homeostasis None None O
, None None O
Hb None None O
and None None O
the None None O
peptides None None I-TRANS
derived None None O
from None None O
it None None O
play None None O
an None None O
indispensable None None O
role None None O
in None None O
the None None O
protection None None O
of None None O
vaginal None None O
epithelium None None O
by None None O
exhibiting None None O
antimicrobial None None O
activity None None O
. None None O

Sperm None None O
motility None None O
and None None O
viability None None O
were None None O
examined None None O
to None None O
evaluate None None O
the None None O
integrity None None O
of None None O
frozen-thawed None None O
sperm None None O
, None None O
and None None O
the None None O
best None None O
extender None None O
was None None O
selected None None O
to None None O
cryopreserve None None O
sperm None None O
from None None O
transgenic None None O
Huntington None None I-DISEASE
's None None O
disease None None O
( None None O
HD None None O
) None None O
rhesus None None O
monkey None None O
. None None O

The None None O
potential None None O
changes None None O
in None None O
water None None O
mobility None None O
accompanying None None O
the None None O
movement None None I-FUNC
of None None O
ions None None O
during None None O
the None None O
propagation None None O
of None None O
action None None O
potentials None None O
along None None O
axonal None None O
tracts None None O
are None None O
taken None None O
into None None O
account None None O
. None None O

Analysis None None O
by None None O
tryptophan None None I-TRANS
fluorescence None None O
quenching None None O
showed None None O
that None None O
FLbR2 None None O
interacts None None O
with None None O
Hb13+ None None O
, None None O
however None None O
the None None O
use None None O
of None None O
ITC None None O
and None None O
IEF None None O
techniques None None O
revealed None None O
that None None O
this None None O
interaction None None O
is None None O
weak None None O
. None None O

Our None None O
results None None O
demonstrated None None O
that None None O
the None None O
RFBE None None O
approach None None O
was None None O
suitable None None O
for None None O
identifying None None O
different None None O
types None None O
of None None O
forearm None None O
movements None None I-FUNC
. None None O

The None None O
prevalence None None O
of None None O
MCI None None O
was None None O
31.5 None None O
% None None O
, None None O
depressive None None O
syndrome None None O
was None None O
29.7 None None O
% None None O
, None None O
and None None O
MCI None None O
with None None O
coexisting None None O
depressive None None O
mood None None I-FUNC
was None None O
9.1 None None O
% None None O
. None None O

Significant None None O
predictors None None O
of None None O
having None None O
a None None O
depressive None None O
mood None None I-FUNC
included None None O
female None None O
gender None None O
, None None O
single None None O
marital None None O
status None None O
, None None O
current None None O
and None None O
past None None O
smoking None None O
status None None O
, None None O
lack None None O
of None None O
physical None None O
activity None None O
, None None O
higher None None O
BMI None None O
and None None O
total None None O
cholesterol None None O
level None None O
, None None O
increased None None O
number None None O
of None None O
comorbidities None None O
, None None O
history None None O
of None None O
hypoglycemia None None I-DISEASE
, None None O
and None None O
insulin None None I-PROTEIN
treatment None None O
. None None O

We None None O
investigated None None O
whether None None O
hypercatabolic None None O
activity None None O
occurred None None O
in None None O
unaffected None None O
arm None None O
muscle None None O
and None None O
whether None None O
supplemented None None O
essential None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
EAAs None None O
) None None O
could None None O
limit None None O
muscle None None O
hypercatabolism None None O
( None None O
MH None None O
) None None O
. None None O

Before None None O
randomization None None O
, None None O
all None None O
patients None None O
had None None O
their None None O
arterial None None O
( None None O
A None None O
) None None O
and None None O
venous None None O
( None None O
V None None O
) None None O
amino None None I-TRANS
acids None None I-TRANS
measured None None O
and None None O
muscle None None O
( None None O
A-V None None O
) None None O
differences None None O
calculated None None O
in None None O
the None None O
unaffected None None O
arm None None O
. None None O

When None None O
compared None None O
to None None O
healthy None None O
controls None None O
, None None O
the None None O
entire None None O
stroke None None I-DISEASE
population None None O
showed None None O
significant None None O
muscle None None O
release None None O
( None None O
=negative None None O
value None None O
A-V None None O
) None None O
of None None O
the None None O
amino None None O
acid None None O
phenylalanine None None I-TRANS
( None None O
phenyl- None None O
) None None O
indicating None None O
a None None O
prevalence None None O
of None None O
MH None None O
. None None O

25 None None O
% None None O
of None None O
mothers None None O
and None None O
33 None None O
% None None O
of None None O
fathers None None O
met None None O
the None None O
criteria None None O
for None None O
at None None O
least None None O
one None None O
psychiatric None None O
disorder None None O
, None None O
with None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
, None None O
BMD None None O
, None None O
and None None O
cluster None None O
B None None O
personality None None I-DISEASE
disorder None None I-DISEASE
being None None O
more None None O
prevalent None None O
. None None O

Cluster None None O
B None None O
personality None None I-DISEASE
disorder None None I-DISEASE
and None None O
substance None None I-DISEASE
dependence None None I-DISEASE
were None None O
more None None O
prevalent None None O
among None None O
fathers None None O
while None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
was None None O
more None None O
prevalent None None O
among None None O
mothers None None O
. None None O

We None None O
investigated None None O
the None None O
possible None None O
radioprotective None None O
role None None O
of None None O
melatonin None None I-TRANS
( None None O
100 None None O
mg/kg None None O
i.p None None O
. None None O
) None None O

The None None O
melatonin None None I-TRANS
pretreated None None O
irradiated None None O
rats None None O
showed None None O
less None None O
change None None O
in None None O
body None None O
weight None None O
as None None O
compared None None O
to None None O
radiation None None O
only None None O
group None None O
. None None O

Secondary None None O
purpose None None O
of None None O
the None None O
study None None O
was None None O
to None None O
identify None None O
the None None O
possible None None O
influencing None None O
factors None None O
for None None O
caregiver None None O
burden None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
a None None O
young None None O
adult-child None None O
caregiver None None O
group None None O
. None None O

Caregivers None None O
' None None O
burden None None O
, None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
and None None O
anxiety None None O
levels None None O
were None None O
assessed None None O
by None None O
using None None O
Zarit None None O
Caregiver None None O
Burden None None O
Scale None None O
( None None O
ZCBS None None O
) None None O
, None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
, None None O
and None None O
State-Trait None None O
Anxiety None None O
Inventory None None O
, None None O
respectively None None O
. None None O

Approximately None None O
one-third None None O
of None None O
the None None O
adult-child None None O
caregivers None None O
had None None O
at None None O
least None None O
mild None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

There None None O
were None None O
positive None None O
correlations None None O
between None None O
caregiving None None O
time None None O
, None None O
severity None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
and None None O
perceived None None O
caregiver None None O
burden None None O
. None None O

Age None None O
, None None O
socioeconomic None None O
level None None O
, None None O
and None None O
marital None None O
status None None O
of None None O
patients None None O
were None None O
affecting None None O
factors None None O
for None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
caregivers None None O
. None None O

The None None O
study None None O
findings None None O
suggest None None O
significant None None O
levels None None O
of None None O
burden None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
even None None O
in None None O
adult-child None None O
caregivers None None O
of None None O
HF None None O
patients None None O
. None None O

Moreover None None O
, None None O
the None None O
available None None O
data None None O
confirms None None O
that None None O
cladribine None None O
, None None O
with None None O
the None None O
participation None None O
of None None O
the None None O
p53 None None I-PROTEIN
protein None None O
, None None O
as None None O
well None None O
as None None O
the None None O
proapoptotic None None O
proteins None None O
from None None O
the None None O
Bcl-2 None None O
family None None O
, None None O
also None None O
induces None None O
the None None O
activation None None O
of None None O
the None None O
intrinsic None None O
apoptosis None None O
pathway None None O
. None None O

Twenty-seven None None O
primary None None O
care None None O
physicians None None O
were None None O
assigned None None O
to None None O
promotion-focused None None O
or None None O
prevention-focused None None O
manipulations None None O
and None None O
compared None None O
on None None O
the None None O
Risk None None O
Taking None None O
Attitudes None None O
in None None O
Medical None None O
Decision None None I-FUNC
Making None None I-FUNC
scale None None O
using None None O
a None None O
randomization None None O
test None None O
. None None O

They None None O
are None None O
able None None O
to None None O
discriminate None None O
between None None O
groups None None O
according None None O
to None None O
their None None O
perception None None I-FUNC
of None None O
oral None None O
health None None O
status None None O
, None None O
but None None O
with None None O
OIDP None None O
detecting None None O
fewer None None O
impacts None None O
on None None O
daily None None O
activities None None O
. None None O

The None None O
L-lactic None None O
acid None None O
biosensor None None O
had None None O
a None None O
good None None O
anti-interference None None O
property None None O
towards None None O
uric None None O
acid None None O
( None None O
UA None None O
) None None O
, None None O
ascorbic None None O
acid None None O
( None None O
AA None None O
) None None O
, None None O
glucose None None O
and None None O
cysteine None None I-TRANS
. None None O

The None None O
mode None None O
of None None O
catalysis None None O
and None None O
encapsulation-based None None O
substrate None None O
selectivity None None O
of None None O
the None None O
host None None O
efficiently None None O
mimic None None O
the None None O
basic None None O
principle None None O
of None None O
operation None None O
observed None None O
in None None O
enzymes None None I-PROTEIN
. None None O

All None None O
cytochrome None None I-PROTEIN
c None None I-PROTEIN
oxidase None None I-PROTEIN
subunit None None O
I None None O
sequences None None O
( None None O
cox1 None None O
gene None None O
; None None O
the None None O
chosen None None O
region None None O
for None None O
zoological None None O
DNA None None O
barcoding None None O
) None None O
present None None O
in None None O
GenBank None None O
for None None O
Annelida None None O
, None None O
as None None O
well None None O
as None None O
for None None O
`` None None O
Polychaeta None None O
'' None None O
, None None O
`` None None O
Oligochaeta None None O
'' None None O
, None None O
and None None O
Hirudinea None None O
separately None None O
, None None O
were None None O
downloaded None None O
and None None O
curated None None O
for None None O
length None None O
, None None O
coverage None None O
and None None O
potential None None O
contaminations None None O
. None None O

Significant None None O
differences None None O
were None None O
observed None None O
among None None O
breast None None O
cancer None None O
and None None O
healthy None None O
blood None None O
samples None None O
in None None O
the None None O
RFLP None None O
pattern None None O
using None None O
AluI None None O
, None None O
HaeIII None None O
and None None O
RsaI None None O
enzymes None None I-PROTEIN
. None None O

There None None O
was None None O
a None None O
noteworthy None None O
reliance None None O
on None None O
students None None O
' None None O
self-rated None None O
perceptions None None I-FUNC
of None None O
their None None O
attitudes None None O
towards None None O
collaborative None None O
practice None None O
collected None None O
through None None O
surveys None None O
, None None O
focus None None O
groups None None O
and None None O
interviews None None O
. None None O

According None None O
to None None O
KEGG None None O
classification None None O
, None None O
the None None O
clusters None None O
for None None O
`` None None O
cysteine None None I-TRANS
and None None O
methionine None None I-TRANS
metabolism None None O
'' None None O
, None None O
`` None None O
energy None None O
'' None None O
, None None O
`` None None O
oxidative None None O
phosphorylation None None O
'' None None O
, None None O
`` None None O
terpenoid None None O
backbone None None O
biosynthesis None None O
'' None None O
, None None O
`` None None O
plant None None O
hormone None None O
signal None None O
transduction None None O
'' None None O
and None None O
`` None None O
copper None None O
, None None O
potassium None None O
transporter None None O
'' None None O
were None None O
significantly None None O
enriched None None O
metabolic None None O
pathways None None O
. None None O

Retention None None I-FUNC
of None None O
adolescent-typical None None O
responsiveness None None O
to None None O
alcohol None None O
in None None O
adult None None O
males None None O
following None None O
adolescent None None O
alcohol None None O
exposure None None O
, None None O
including None None O
enhanced None None O
sensitivity None None O
to None None O
the None None O
socially None None O
facilitating None None O
effects None None O
of None None O
ethanol None None O
following None None O
early None None O
exposure None None O
and None None O
insensitivity None None O
to None None O
the None None O
socially None None O
inhibiting None None O
effects None None O
following None None O
late None None O
adolescent None None O
exposure None None O
, None None O
may None None O
put None None O
these None None O
males None None O
at None None O
risk None None O
for None None O
the None None O
development None None O
of None None O
alcohol-related None None O
disorders None None O
later None None O
in None None O
life None None O
. None None O

Over-nutrition None None O
induces None None O
low-grade None None O
inflammation None None O
that None None O
dampens None None O
insulin None None I-PROTEIN
sensitivity None None O
, None None O
but None None O
the None None O
underlying None None O
molecular None None O
mediators None None O
are None None O
not None None O
fully None None O
understood None None O
. None None O

We None None O
further None None O
show None None O
that None None O
blocking None None O
this None None O
cycle None None O
with None None O
a None None O
FOXO1 None None O
inhibitor None None O
, None None O
an None None O
antioxidant None None O
that None None O
inhibits None None O
FOXO1 None None O
or None None O
IL-1 None None O
receptor None None I-PROTEIN
antagonist None None O
alleviates None None O
chronic None None O
inflammation None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
high-fat None None O
diet None None O
( None None O
HFD None None O
) None None O
-fed None None O
mice None None O
. None None O

It None None O
is None None O
likely None None O
that None None O
monosodium None None O
glutamate None None I-TRANS
( None None O
MSG None None O
) None None O
is None None O
the None None O
excitotoxin None None O
that None None O
has None None O
been None None O
most None None O
commonly None None O
employed None None O
to None None O
characterize None None O
the None None O
process None None O
of None None O
excitotoxicity None None O
and None None O
to None None O
improve None None O
understanding None None O
of None None O
the None None O
ways None None O
that None None O
this None None O
process None None O
is None None O
related None None O
to None None O
several None None O
pathological None None O
conditions None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

Stability None None O
study None None O
of None None O
formulations None None O
resulting None None O
in None None O
faster None None O
and None None O
higher None None O
extent None None O
of None None O
dissolution None None O
and None None O
suitable None None O
mechanical None None O
properties None None O
( None None O
G3 None None O
and None None O
G12 None None O
) None None O
revealed None None O
their None None O
physical None None O
and None None O
chemical None None O
stability None None O
after None None O
three None None O
months None None O
of None None O
storage None None I-FUNC
under None None O
different None None O
conditions None None O
. None None O

We None None O
did None None O
not None None O
restrict None None O
the None None O
search None None O
and None None O
study None None O
selection None None O
with None None O
respect None None O
to None None O
language None None I-FUNC
, None None O
date None None O
of None None O
publication None None O
or None None O
study None None O
setting None None O
. None None O

SIVA1 None None O
promotes None None O
human None None O
double None None O
minute None None O
2 None None O
homolog None None O
( None None O
HDM2 None None O
) None None O
-mediated None None O
p53 None None I-PROTEIN
regulation None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
that None None O
electrical None None O
stimulation None None O
( None None O
ES None None O
) None None O
accelerates None None O
wound None None O
healing None None O
by None None O
upregulating None None O
SIVA1 None None O
and None None O
its None None O
subsequent None None O
ability None None O
to None None O
modulate None None O
p53 None None I-PROTEIN
activities None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
6-formylindolo None None O
[ None None O
3,2-b None None O
] None None O
carbazole None None O
( None None O
FICZ None None O
) None None O
, None None O
a None None O
tryptophan None None I-TRANS
photoproduct None None O
and None None O
endogenous None None O
high-affinity None None O
aryl None None O
hydrocarbon None None O
receptor None None I-PROTEIN
( None None O
AhR None None O
) None None O
agonist None None O
, None None O
acts None None O
as None None O
a None None O
nanomolar None None O
photosensitizer None None O
potentiating None None O
UVA-induced None None O
oxidative None None O
stress None None O
irrespective None None O
of None None O
AhR None None O
ligand None None O
activity None None O
. None None O

Keratinocytes None None O
deficient None None O
in None None O
ACTN1 None None O
exhibit None None O
changes None None O
in None None O
their None None O
actin None None I-PROTEIN
cytoskeleton None None O
organization None None O
, None None O
a None None O
loss None None O
in None None O
front-rear None None O
polarity None None O
, None None O
and None None O
impaired None None O
lamellipodial None None O
dynamics None None O
. None None O

Rather None None O
, None None O
focal None None O
adhesion None None O
proteins None None O
are None None O
arranged None None O
in None None O
a None None O
circle None None O
subjacent None None O
to None None O
cortical None None O
fibers None None O
of None None O
actin None None I-PROTEIN
. None None O

In None None O
summary None None O
, None None O
our None None O
data None None O
suggest None None O
a None None O
mechanism None None O
by None None O
which None None O
ACTN1 None None O
determines None None O
the None None O
motility None None O
of None None O
keratinocytes None None O
by None None O
regulating None None O
the None None O
organization None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
, None None O
focal None None O
adhesion None None O
, None None O
and None None O
hemidesmosome None None O
proteins None None O
complexes None None O
, None None O
thereby None None O
modulating None None O
cell None None O
speed None None O
, None None O
lamellipodial None None O
dynamics None None O
, None None O
and None None O
directed None None O
migration None None O
. None None O

Early-morning None None O
exposure None None O
to None None O
UV None None O
also None None O
produced None None O
maximal None None O
activation None None O
of None None O
ataxia None None O
telangiectasia None None O
mutated None None O
and None None O
Rad3-related None None O
( None None O
Atr None None O
) None None O
-mediated None None O
DNA None None O
damage None None O
checkpoint None None O
signaling None None O
, None None O
including None None O
activation None None O
of None None O
the None None O
tumor None None O
suppressor None None O
p53 None None I-PROTEIN
, None None O
which None None O
is None None O
known None None O
to None None O
control None None O
the None None O
process None None O
of None None O
sunburn None None O
apoptosis None None O
. None None O

The None None O
design None None O
and None None O
synthesis None None O
of None None O
several None None O
new None None O
auristatin None None O
analogues None None O
with None None O
N-terminal None None O
modifications None None O
that None None O
include None None O
amino None None I-TRANS
acids None None I-TRANS
with None None O
α None None O
, None None O
α-disubstituted None None O
carbon None None O
atoms None None O
are None None O
described None None O
, None None O
including None None O
the None None O
discovery None None O
of None None O
our None None O
lead None None O
auristatin None None O
, None None O
PF-06380101 None None O
. None None O

Using None None O
the None None O
results None None O
from None None O
our None None O
experiments None None O
, None None O
we None None O
have None None O
mapped None None O
the None None O
solid/liquid None None O
ternary None None O
phase None None O
diagram None None O
, None None O
determined None None O
the None None O
water None None O
activities None None O
based None None O
on None None O
the None None O
freezing None None O
point None None O
depression None None I-DISEASE
, None None O
and None None O
determined None None O
the None None O
ice/succinic None None O
acid None None O
phase None None O
boundary None None O
as None None O
well None None O
as None None O
the None None O
ternary None None O
eutectic None None O
composition None None O
and None None O
temperature None None O
. None None O

In None None O
a None None O
multivariate None None O
logistic None None O
regression None None O
analysis None None O
, None None O
being None None O
a None None O
male None None O
, None None O
coming None None O
from None None O
a None None O
wealthy None None O
or None None O
quite None None O
well None None O
off None None O
family None None O
background None None O
, None None O
living None None O
in None None O
low None None O
income None None O
or None None O
lower None None O
middle None None O
income None None O
, None None O
weak None None O
beliefs None None O
in None None O
the None None O
importance None None O
of None None O
regular None None O
tooth None None O
brushing None None O
, None None O
depression None None I-DISEASE
and None None O
PTSD None None O
symptoms None None O
, None None O
tobacco None None O
use None None O
and None None O
frequent None None O
gambling None None O
, None None O
low None None O
physical None None O
activity None None O
, None None O
and None None O
low None None O
daily None None O
meal None None O
and None None O
snacks None None O
frequency None None O
were None None O
associated None None O
with None None O
inadequate None None O
tooth None None O
brushing None None O
( None None O
& None None O
lt None None O
; None None O
twice None None O
daily None None O
) None None O
. None None O

To None None O
investigate None None O
the None None O
possible None None O
effect None None O
of None None O
tacrolimus None None O
on None None O
the None None O
development None None O
of None None O
impaired None None O
glucose None None O
tolerance None None O
in None None O
transplant None None O
recipients None None O
, None None O
this None None O
study None None O
focused None None O
on None None O
early None None O
and None None O
second None None O
phase None None O
insulin None None I-PROTEIN
secretion None None O
, None None O
which None None O
may None None O
be None None O
affected None None O
by None None O
reactive None None O
oxygen None None O
species None None O
under None None O
tacrolimus None None O
therapy None None O
. None None O

This None None O
review None None O
addresses None None O
the None None O
need None None O
for None None O
compiling None None O
available None None O
pharmacogenetic None None O
data None None O
in None None O
US None None O
Hispanics None None O
, None None O
discussing None None O
the None None O
prevalence None None O
of None None O
clinically None None O
relevant None None O
polymorphisms None None O
in None None O
pharmacogenes None None O
encoding None None I-FUNC
for None None O
drug-metabolizing None None O
enzymes None None I-PROTEIN
. None None O

Temporal None None I-REGION
lobe None None I-REGION
volumes None None O
were None None O
measured None None O
from None None O
CT None None O
and None None O
from None None O
normative None None O
MR None None O
images None None O
using None None O
the None None O
Cavalieri None None O
method None None O
. None None O

Linear None None O
discrimination None None O
analysis None None O
( None None O
LDA None None O
) None None O
was None None O
used None None O
to None None O
classify None None O
seizure None None O
outcome None None O
by None None O
temporal None None I-REGION
lobe None None I-REGION
volumes None None O
and None None O
normalized None None O
brain None None O
volume None None O
. None None O

A None None O
multivariate None None O
measure None None O
of None None O
the None None O
volume None None O
of None None O
each None None O
temporal None None I-REGION
lobe None None I-REGION
separated None None O
patients None None O
who None None O
were None None O
seizure None None O
free None None O
( None None O
Engel None None O
Class None None O
IA None None O
) None None O
from None None O
those None None O
with None None O
incomplete None None O
seizure None None O
control None None O
( None None O
Engel None None O
Class None None O
IB/IIB None None O
) None None O
with None None O
LDA None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Additionally None None O
, None None O
the None None O
authors None None O
demonstrated None None O
that None None O
age-normalized None None O
whole None None O
brain None None O
volume None None O
, None None O
in None None O
combination None None O
with None None O
temporal None None I-REGION
lobe None None I-REGION
volumes None None O
, None None O
may None None O
further None None O
improve None None O
outcome None None O
prediction None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Furthermore None None O
, None None O
since None None O
the None None O
authors None None O
' None None O
methods None None O
are None None O
modality None None O
independent None None O
, None None O
these None None O
findings None None O
suggest None None O
that None None O
temporal None None I-REGION
lobe None None I-REGION
and None None O
normative None None O
brain None None O
volumes None None O
may None None O
further None None O
be None None O
useful None None O
in None None O
the None None O
selection None None O
of None None O
patients None None O
for None None O
temporal None None I-REGION
lobe None None I-REGION
resection None None O
when None None O
structural None None O
MRI None None O
is None None O
available None None O
. None None O

The None None O
evaluation None None O
of None None O
hydrocephalus None None I-DISEASE
remains None None O
focused None None O
on None None O
ventricular None None O
size None None O
, None None O
yet None None O
the None None O
goal None None O
of None None O
treatment None None O
is None None O
to None None O
allow None None O
for None None O
healthy None None O
brain None None O
development None None O
. None None O

This None None O
study None None O
tests None None O
this None None O
hypothesis None None O
by None None O
comparing None None O
brain None None O
and None None O
fluid None None O
volumes None None O
with None None O
neurocognitive None None O
outcome None None O
in None None O
pediatric None None O
patients None None O
with None None O
hydrocephalus None None I-DISEASE
. None None O

In None None O
this None None O
present None None O
study None None O
, None None O
brain None None O
and None None O
fluid None None O
volumes None None O
were None None O
measured None None O
in None None O
33 None None O
of None None O
these None None O
patients None None O
, None None O
26 None None O
of None None O
whom None None O
required None None O
surgical None None O
treatment None None O
for None None O
hydrocephalus None None I-DISEASE
. None None O

A None None O
combination None None O
of None None O
brain None None O
and None None O
CSF None None O
volumes None None O
appears None None O
to None None O
be None None O
significantly None None O
more None None O
powerful None None O
at None None O
predicting None None O
good None None O
versus None None O
poor None None O
neurocognitive None None O
outcomes None None O
in None None O
patients None None O
with None None O
hydrocephalus None None I-DISEASE
than None None O
either None None O
volume None None O
alone None None O
. None None O

The None None O
authors None None O
further None None O
adapted None None O
this None None O
method None None O
for None None O
use None None O
with None None O
CT None None O
images None None O
of None None O
pediatric None None O
hydrocephalus None None I-DISEASE
and None None O
compared None None O
the None None O
results None None O
with None None O
hand-segmented None None O
data None None O
. None None O

Additionally None None O
, None None O
compared None None O
with None None O
manual None None O
segmentation None None O
the None None O
particle None None O
filter None None O
accurately None None O
segmented None None O
brain None None O
and None None O
fluid None None O
volumes None None O
from None None O
CT None None O
scans None None O
of None None O
5 None None O
pediatric None None O
patients None None O
with None None O
hydrocephalus None None I-DISEASE
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

AAAs None None O
were None None O
induced None None O
in None None O
C57BL/6 None None O
mice None None O
using None None O
porcine None None O
elastase None None I-PROTEIN
. None None O

Five None None O
days None None O
after None None O
elastase None None I-PROTEIN
perfusion None None O
, None None O
100,000 None None O
ADMSCs None None O
were None None O
delivered None None O
through None None O
the None None O
port None None O
to None None O
the None None O
aorta None None O
. None None O

ADMSC None None O
treated None None O
aneurysms None None O
had None None O
a None None O
smaller None None O
diameter None None O
and None None O
less None None O
fragmented None None O
elastin None None I-PROTEIN
versus None None O
saline None None O
controls None None O
. None None O

Histological None None O
staining None None O
indicated None None O
formation None None O
of None None O
an None None O
extracellular None None O
matrix None None O
with None None O
type None None O
II None None O
collagen None None I-PROTEIN
. None None O

Obstetric None None O
trauma None None O
and None None O
injury None None O
to None None O
the None None O
anal None None O
sphincter None None I-REGION
muscles None None I-REGION
are None None O
the None None O
most None None O
common None None O
cause None None O
of None None O
fecal None None O
incontinence None None O
. None None O

Herein None None O
, None None O
we None None O
report None None O
for None None O
the None None O
first None None O
time None None O
that None None O
nanoscale None None O
spinel None None O
LiFeTiO4 None None O
as None None O
a None None O
cathode None None O
material None None O
for None None O
Li-ion None None O
batteries None None O
exhibits None None O
intercalation None None O
pseudocapacitive None None O
Li None None O
( None None O
+ None None O
) None None O
storage None None I-FUNC
behaviour None None O
. None None O

A None None O
fast None None O
and None None O
large-amount None None O
of None None O
Li None None O
( None None O
+ None None O
) None None O
storage None None I-FUNC
( None None O
up None None O
to None None O
1.6 None None O
Li None None O
( None None O
+ None None O
) None None O
per None None O
formula None None O
unit None None O
over None None O
cycling None None O
) None None O
in None None O
the None None O
nanoscale None None O
LiFeTiO4 None None O
host None None O
has None None O
been None None O
achieved None None O
without None None O
compromising None None O
kinetics None None O
. None None O

The None None O
ten-eleven None None O
translocation None None O
enzymes None None I-PROTEIN
catalyze None None O
the None None O
conversion None None O
of None None O
5-methylcytosine None None O
to None None O
5-hydroxymethylcytosine None None O
, None None O
a None None O
distinct None None O
epigenetic None None O
mark None None O
that None None O
has None None O
an None None O
integral None None O
role None None O
in None None O
active None None O
demethylation None None O
. None None O

New None None O
methods None None O
employing None None O
genomic None None O
nucleases None None I-PROTEIN
and None None O
site-specific None None O
epigenetic None None O
regulators None None O
targeted None None O
to None None O
specific None None O
genomic None None O
regions None None O
, None None O
using None None O
either None None O
artificial None None O
DNA-binding None None I-PROTEIN
proteins None None I-PROTEIN
or None None O
RNA-DNA None None O
interactions None None O
, None None O
may None None O
allow None None O
precise None None O
genome None None O
engineering None None O
at None None O
enhancers None None O
. None None O

Several None None O
mechanisms None None O
are None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
latency None None O
including None None O
chromatin None None O
remodeling None None O
by None None O
an None None O
array None None O
of None None O
enzymes None None I-PROTEIN
and None None O
microRNAs None None O
. None None O

We None None O
recently None None O
reported None None O
that None None O
Notch3 None None O
silencing None None O
in None None O
HCC None None O
results None None O
in None None O
p53 None None I-PROTEIN
up-regulation None None O
in None None O
vitro None None O
and None None O
, None None O
therefore None None O
, None None O
we None None O
focused None None O
on None None O
the None None O
mechanisms None None O
that None None O
associate None None O
Notch3 None None O
to None None O
p53 None None I-PROTEIN
protein None None O
expression None None O
. None None O

Tumor None None O
recognition None None O
by None None O
NK None None O
cells None None O
was None None O
found None None O
to None None O
be None None O
partly None None O
triggered None None O
by None None O
molecules None None O
termed None None O
natural None None O
cytotoxic None None O
receptors None None I-PROTEIN
( None None O
NCRs None None O
) None None O
. None None O

Yet None None O
, None None O
the None None O
application None None O
of None None O
such None None O
treatments None None O
to None None O
other None None O
cancers None None O
is None None O
needed None None O
and None None O
dependent None None O
on None None O
the None None O
isolation None None O
of None None O
receptors None None I-PROTEIN
that None None O
could None None O
facilitate None None O
efficient None None O
recognition None None O
of None None O
these None None O
malignancies None None O
. None None O

Consequently None None O
, None None O
we None None O
generated None None O
and None None O
evaluated None None O
several None None O
chimeric None None O
receptors None None I-PROTEIN
based None None O
on None None O
the None None O
extracellular None None O
domain None None O
of None None O
NCR1 None None O
( None None O
NKp46 None None O
) None None O
fused None None O
to None None O
multiple None None O
signaling None None O
moieties None None O
and None None O
assess None None O
their None None O
antitumor None None O
activity None None O
when None None O
retrovirally None None O
expressed None None O
in None None O
T-cells None None O
. None None O

The None None O
percentage None None O
of None None O
ketoprofen None None O
permeated None None O
through None None O
porcine None None O
ear None None O
skin None None O
was None None O
13.7 None None O
, None None O
19.1 None None O
and None None O
12.7 None None O
% None None O
of None None O
the None None O
dose None None O
from None None O
LipoDerm None None O
, None None O
LipoBase None None O
and None None O
PLO None None O
, None None O
respectively None None O
and None None O
decreased None None O
2- None None O
to None None O
3-fold None None O
after None None O
28 None None O
days None None O
of None None O
storage None None I-FUNC
. None None O

In None None O
the None None O
present None None O
paper None None O
, None None O
we None None O
demonstrate None None O
disposal None None O
of None None O
riboflavin None None O
intermediates None None O
by None None O
COG3236 None None O
( None None O
DUF1768 None None O
) None None O
, None None O
a None None O
protein None None O
of None None O
previously None None O
unknown None None O
function None None O
that None None O
is None None O
fused None None O
to None None O
two None None O
different None None O
riboflavin None None O
pathway None None O
enzymes None None I-PROTEIN
in None None O
plants None None O
and None None O
bacteria None None O
( None None O
RIBR None None O
and None None O
RibA None None O
respectively None None O
) None None O
. None None O

Moreover None None O
, None None O
attention None None I-FUNC
is None None O
drawn None None O
to None None O
the None None O
risks None None O
related None None O
to None None O
goods None None O
handled None None O
: None None O
in None None O
particular None None O
, None None O
authors None None O
described None None O
risks None None O
of None None O
asphyxia None None O
or None None O
intoxication None None O
in None None O
restricted None None O
and None None O
poorly None None O
ventilated None None O
areas None None O
such None None O
as None None O
containers None None O
or None None O
ship None None O
holds None None O
. None None O

A None None O
few None None O
years None None O
after None None O
a None None O
series None None O
of None None O
meetings None None O
of None None O
Italian None None O
scientists None None O
were None None O
convened None None O
prior None None O
to None None O
the None None O
unification None None O
of None None O
Italy None None O
, None None O
the None None O
first None None O
women None None O
qualified None None O
in None None O
medicine None None O
and None None O
other None None O
dedicated None None O
women None None O
participated None None O
in None None O
founding None None O
a None None O
movement None None I-FUNC
for None None O
the None None O
improvement None None O
of None None O
living None None O
and None None O
working None None O
conditions None None O
of None None O
women None None O
and None None O
children None None O
in None None O
Italy None None O
. None None O

The None None O
success None None O
achieved None None O
by None None O
the None None O
women None None O
's None None O
movement None None I-FUNC
is None None O
shown None None O
in None None O
the None None O
paper None None O
presented None None O
by None None O
Irene None None O
de None None O
Bonis None None O
`` None None O
Occupational None None O
diseases None None O
among None None O
women None None O
'' None None O
and None None O
published None None O
in None None O
the None None O
proceedings None None O
of None None O
the None None O
fourth None None O
National None None O
Congress None None O
on None None O
Occupational None None O
Diseases None None O
held None None O
in None None O
Rome None None O
, None None O
9-14 None None O
June None None O
1914 None None O
. None None O

The None None O
movement None None I-FUNC
's None None O
engagement None None O
in None None O
the None None O
promotion None None O
of None None O
women None None O
's None None O
occupational None None O
health None None O
at None None O
international None None O
and None None O
national None None O
level None None O
was None None O
successful None None O
but None None O
the None None O
First None None O
World None None O
War None None O
was None None O
to None None O
transform None None O
this None None O
achievement None None O
into None None O
the None None O
women None None O
's None None O
peace None None O
movement None None I-FUNC
. None None O

A None None O
large None None O
potential None None O
window None None O
of None None O
operation None None O
( None None O
3-0.01 None None O
V None None O
) None None O
; None None O
the None None O
excellent None None O
cyclic None None O
stability None None O
, None None O
with None None O
a None None O
capacity None None O
retention None None I-FUNC
of None None O
98 None None O
% None None O
of None None O
the None None O
initial None None O
value None None O
; None None O
and None None O
the None None O
remarkable None None O
rate None None O
capability None None O
( None None O
up None None O
to None None O
100 None None O
C None None O
) None None O
are None None O
the None None O
highlights None None O
of None None O
TiO2/CNS None None O
thin-film None None O
anode None None O
structures None None O
. None None O

Ionizing None None O
radiation None None O
effectively None None O
cross-links None None O
collagen None None I-PROTEIN
into None None O
network None None O
with None None O
enhanced None None O
anti-degradability None None O
and None None O
biocompatibility None None O
, None None O
while None None O
radiation-cross-linked None None O
collagen None None I-PROTEIN
scaffold None None O
lacks None None O
flexibility None None O
, None None O
satisfactory None None O
surface None None O
appearance None None O
, None None O
and None None O
performs None None O
poor None None O
in None None O
cell None None O
penetration None None O
and None None O
ingrowth None None O
. None None O

Compared None None O
with None None O
pure None None O
collagen None None I-PROTEIN
, None None O
scaffolds None None O
with None None O
dextran None None O
demonstrated None None O
more None None O
porous None None O
appearance None None O
, None None O
enhanced None None O
hydrophilicity None None O
while None None O
the None None O
cross-linking None None O
density None None O
was None None O
lower None None O
with None None O
the None None O
consequence None None O
of None None O
larger None None O
pore None None O
size None None O
, None None O
higher None None O
water None None O
uptake None None O
, None None O
as None None O
well None None O
as None None O
reduced None None O
stiffness None None O
. None None O

It None None O
seems None None O
important None None O
to None None O
integrate None None O
these None None O
aspects None None O
, None None O
while None None O
also None None O
paying None None O
attention None None I-FUNC
to None None O
optimizing None None O
co-construction None None O
of None None O
meaning None None O
for None None O
the None None O
person None None O
with None None O
sTBI None None O
in None None O
the None None O
treatment None None O
context None None O
. None None O

Thrombin None None I-PROTEIN
inhibitor None None O
dabigatran None None O
and None None O
factor None None O
Xa None None O
inhibitors None None O
rivaroxaban None None O
, None None O
apixaban None None O
and None None O
edoxaban None None O
form None None O
a None None O
new None None O
class None None O
of None None O
non-vitamin None None O
K None None O
antagonist None None O
oral None None O
anticoagulants None None O
and None None O
have None None O
been None None O
extensively None None O
studied None None O
in None None O
patients None None O
with None None O
venous None None O
thromboembolism None None O
and None None O
atrial None None O
fibrillation None None O
. None None O

Recently None None O
, None None O
we None None O
have None None O
designed None None O
and None None O
synthesized None None O
a None None O
series None None O
of None None O
novel None None O
imidazopyridine None None O
and None None O
imidazopyrazine None None O
derivatives None None O
that None None O
inhibit None None O
Mnk1/2 None None O
kinases None None I-PROTEIN
with None None O
a None None O
potency None None O
in None None O
the None None O
nanomolar None None O
to None None O
micromolar None None O
range None None O
. None None O

Combining None None O
homology None None O
modeling None None O
, None None O
docking None None O
, None None O
molecular None None O
dynamics None None O
simulations None None O
, None None O
and None None O
free None None O
energy None None O
calculations None None O
, None None O
we None None O
find None None O
that None None O
all None None O
compounds None None O
bind None None O
similarly None None O
to None None O
the None None O
active None None O
sites None None O
of None None O
both None None O
kinases None None I-PROTEIN
with None None O
their None None O
imidazopyridine None None O
and None None O
imidazopyrazine None None O
cores None None O
anchored None None O
to None None O
the None None O
hinge None None O
regions None None O
of None None O
the None None O
kinases None None I-PROTEIN
through None None O
hydrogen None None O
bonds None None O
. None None O

Metabolism None None O
of None None O
L-carnitine None None O
by None None O
the None None O
intestinal None None O
microbiome None None O
is None None O
associated None None O
with None None O
atherosclerosis None None I-DISEASE
in None None O
omnivores None None O
but None None O
not None None O
in None None O
vegetarians None None O
, None None O
supporting None None O
CAD None None O
benefits None None O
of None None O
a None None O
plant-based None None O
diet None None O
. None None O

We None None O
found None None O
that None None O
goniolactone None None O
C None None O
preferentially None None O
interacted None None O
with None None O
cellular None None O
systems None None O
that None None O
rely None None O
on None None O
PDGF None None O
signaling None None O
but None None O
not None None O
those None None O
that None None O
rely None None O
on None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
EGF None None O
) None None O
and None None O
basic None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
bFGF None None O
) None None O
signaling None None O
. None None O

Treatment None None O
with None None O
LRC None None O
extract None None O
showed None None O
enhanced None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
and None None O
increased None None O
expression None None O
of None None O
bone None None O
metabolic None None O
markers None None O
Alpl None None O
, None None O
Runx2 None None O
, None None O
and None None O
Bglap None None O
genes None None O
in None None O
both None None O
osteoblastic None None O
cell None None O
lines None None O
. None None O

We None None O
applied None None O
no None None O
language None None I-FUNC
restrictions None None O
. None None O

Very None None O
low None None O
quality None None O
evidence None None O
from None None O
four None None O
studies None None O
indicated None None O
that None None O
exercise None None O
interventions None None O
did None None O
not None None O
appear None None O
to None None O
reduce None None O
symptoms None None O
of None None O
depression None None I-DISEASE
or None None O
increase None None O
physical None None O
activity None None O
. None None O

DMFT None None O
in None None O
permanent None None O
teeth None None O
or None None O
dmft None None O
in None None O
primary None None O
teeth None None O
was None None O
greater None None O
than None None O
one None None O
at None None O
the None None O
start None None O
of None None O
the None None O
study None None O
and None None O
greater None None O
than None None O
one None None O
million None None O
colony-forming None None O
units None None O
of None None O
Streptococcus None None O
mutans None None O
per None None O
millilitre None None O
of None None O
saliva.Although None None O
132 None None O
children None None O
were None None O
still None None O
included None None O
in None None O
the None None O
trial None None O
at None None O
the None None O
two-year None None O
completion None None O
point None None O
, None None O
examination None None O
and None None O
statistical None None O
analysis None None O
was None None O
performed None None O
on None None O
only None None O
the None None O
63 None None O
children None None O
( None None O
31 None None O
in None None O
intervention None None O
group None None O
, None None O
32 None None O
in None None O
control None None O
group None None O
) None None O
who None None O
had None None O
retained None None O
the None None O
beads None None O
( None None O
retention None None I-FUNC
rate None None O
was None None O
47.7 None None O
% None None O
at None None O
two None None O
years None None O
) None None O
. None None O

The None None O
functional None None O
inhibition None None O
of None None O
the None None O
analogues None None O
was None None O
measured None None O
by None None O
an None None O
EWS-FLI1/NR0B1 None None O
reporter None None O
luciferase None None I-PROTEIN
assay None None O
and None None O
a None None O
paired None None O
cell None None O
screening None None O
approach None None O
measuring None None O
effects None None O
on None None O
growth None None O
inhibition None None O
for None None O
human None None O
cells None None O
containing None None O
EWS-FLI1 None None O
( None None O
TC32 None None O
and None None O
TC71 None None O
) None None O
and None None O
control None None O
PANC1 None None O
cell None None O
lines None None O
devoid None None O
of None None O
the None None O
oncoprotein None None O
. None None O

In None None O
contrast None None O
, None None O
a None None O
high None None O
rating None None O
in None None O
pain-VAS None None O
is None None O
more None None O
objective None None O
with None None O
better None None O
repeatability None None O
for None None O
experimental None None O
pain None None O
perception None None I-FUNC
. None None O

Understanding None None O
the None None O
neural None None O
basis None None O
of None None O
consciousness None None I-FUNC
is None None O
fundamental None None O
to None None O
neuroscience None None O
research None None O
. None None O

General None None O
open None None O
quantum None None O
systems None None O
display None None O
memory None None I-FUNC
features None None O
, None None O
their None None O
master None None O
equations None None O
are None None O
non-Markovian None None O
. None None O

Dark None None O
sectors None None O
charged None None O
under None None O
a None None O
new None None O
Abelian None None O
interaction None None O
have None None O
recently None None O
received None None O
much None None O
attention None None I-FUNC
in None None O
the None None O
context None None O
of None None O
dark None None O
matter None None O
models None None O
. None None O

We None None O
demonstrate None None O
that None None O
application None None O
of None None O
an None None O
increasing None None O
shear None None O
field None None O
on None None O
a None None O
glass None None O
leads None None O
to None None O
an None None O
intriguing None None O
dynamic None None O
first-order None None O
transition None None O
in None None O
analogy None None I-FUNC
with None None O
equilibrium None None O
transitions None None O
. None None O

All None None O
these None None O
bromophenol None None O
derivatives None None O
were None None O
tested None None O
against None None O
human None None O
( None None O
h None None O
) None None O
CA None None O
isoenzymes None None O
I None None O
and None None O
II None None O
( None None O
cytosolic None None O
, None None O
ubiquitous None None O
isoforms None None O
) None None O
and None None O
hCA None None O
IX None None I-REGION
and None None O
XII None None O
( None None O
transmembrane None None O
, None None O
tumor-associated None None O
enzymes None None I-PROTEIN
) None None O
. None None O

Ten None None O
trials None None O
examined None None O
study None None O
endpoints None None O
other None None O
than None None O
pain None None O
, None None O
including None None O
anxiety None None O
, None None O
depression None None I-DISEASE
and None None O
quality None None O
of None None O
life None None O
, None None O
but None None O
available None None O
data None None O
were None None O
too None None O
scarce None None O
for None None O
firm None None O
conclusions None None O
to None None O
be None None O
drawn None None O
. None None O

Expression None None O
of None None O
sphingosine None None O
kinase None None O
( None None O
SphK1 None None O
) None None O
, None None O
collagen None None I-PROTEIN
( None None O
Col None None O
) None None O
α1 None None O
( None None O
I None None O
) None None O
, None None O
Col None None O
α1 None None O
( None None O
III None None O
) None None O
, None None O
α-smooth None None O
muscle None None O
actin None None I-PROTEIN
, None None O
and None None O
p-Smad2/3 None None O
was None None O
characterized None None O
by None None O
immunofluorescence None None O
, None None O
real-time None None O
RT-PCR None None O
, None None O
high-content None None O
analysis None None O
, None None O
or None None O
Western None None O
blot None None O
analysis None None O
in None None O
the None None O
fibrotic None None O
liver None None O
, None None O
human None None O
bone None None O
marrow-derived None None O
mesenchymal None None O
stem None None O
cells None None O
, None None O
and None None O
human None None O
hepatogenic None None O
profibrotic None None O
cells None None O
. None None O

TGF-β1 None None O
induced None None O
expression None None O
of None None O
Col None None O
α1 None None O
( None None O
I None None O
) None None O
and None None O
Col None None O
α1 None None O
( None None O
III None None O
) None None O
via None None O
SphK1 None None O
, None None O
which None None O
was None None O
mediated None None O
by None None O
intracellular None None O
S1P None None O
, None None O
independent None None O
of None None O
S1P None None O
receptors None None I-PROTEIN
. None None O

The None None O
nonstructural None None O
protein None None O
1 None None O
( None None O
nsp1 None None O
) None None O
of None None O
CoVs None None O
has None None O
attracted None None O
considerable None None O
attention None None I-FUNC
in None None O
this None None O
regard None None O
as None None O
a None None O
potential None None O
virulence None None O
factor None None O
and None None O
a None None O
target None None O
for None None O
CoV None None O
vaccine None None O
development None None O
because None None O
of None None O
accumulating None None O
evidence None None O
that None None O
point None None O
to None None O
its None None O
role None None O
in None None O
the None None O
downregulation None None O
of None None O
host None None O
innate None None O
immune None None O
responses None None O
to None None O
CoV None None O
infection None None O
. None None O

Other None None O
venom None None O
components None None O
have None None O
drawn None None O
attention None None I-FUNC
as None None O
useful None None O
scaffolds None None O
for None None O
the None None O
development None None O
of None None O
drugs None None O
. None None O

Forty-five None None O
subjects None None O
( None None O
31 None None O
patients None None O
with None None O
neck None None O
pain None None O
, None None O
14 None None O
healthy None None O
controls None None O
) None None O
were None None O
videotaped None None O
while None None O
performing None None O
a None None O
standardized None None O
test None None O
battery None None O
consisting None None O
of None None O
13 None None O
tests None None O
of None None O
active None None O
movement None None I-FUNC
control None None O
. None None O

There None None O
have None None O
been None None O
studies None None O
performed None None O
describing None None O
the None None O
assessment None None O
and None None O
treatment None None O
of None None O
movement None None I-FUNC
control None None O
impairment None None O
problems None None O
and None None O
low None None O
back None None O
pain None None O
. None None O

The None None O
clinical None None O
characteristics None None O
showed None None O
a None None O
group None None O
of None None O
severely None None O
disturbed None None O
patients None None O
, None None O
of None None O
which None None O
78.4 None None O
% None None O
met None None O
criteria None None O
for None None O
borderline None None I-DISEASE
personality None None I-DISEASE
disorder None None I-DISEASE
. None None O

An None None O
integrated None None O
treatment None None O
for None None O
severe None None O
personality None None I-DISEASE
disorders None None I-DISEASE
could None None O
be None None O
effective None None O
in None None O
preventing None None O
reliance None None O
on None None O
readmissions None None O
, None None O
or None None O
prolonged None None O
hospital None None O
stays None None O
, None None O
when None None O
it None None O
is None None O
implemented None None O
by None None O
clinicians None None O
in None None O
ordinary None None O
clinical None None O
settings None None O
. None None O

Microbial None None O
rhodopsins None None I-PROTEIN
are None None O
the None None O
photoreceptive None None O
membrane None None O
proteins None None O
found None None O
in None None O
diverse None None O
microorganisms None None O
from None None O
within None None O
Archaea None None O
, None None O
Eubacteria None None O
, None None O
and None None O
eukaryotes None None O
. None None O

Since None None O
2000 None None O
, None None O
thousands None None O
of None None O
proteorhodopsins None None O
, None None O
genes None None O
of None None O
light-driven None None O
proton None None O
pump None None O
rhodopsins None None I-PROTEIN
, None None O
have None None O
been None None O
identified None None O
from None None O
various None None O
species None None O
of None None O
marine None None O
bacteria None None O
. None None O

Furthermore None None O
, None None O
novel None None O
types None None O
of None None O
rhodopsin None None I-PROTEIN
( None None O
sodium None None O
and None None O
chloride None None O
pumps None None O
) None None O
have None None O
recently None None O
been None None O
discovered None None O
. None None O

A None None O
total None None O
of None None O
510 None None O
subjects None None O
( None None O
93 None None O
% None None O
white None None O
; None None O
58 None None O
% None None O
female None None O
; None None O
mean None None O
age None None O
, None None O
75.3 None None O
years None None O
) None None O
whose None None O
AMD None None O
was None None O
previously None None O
managed None None O
by None None O
anti-vascular None None O
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
intravitreal None None O
injections None None O
. None None O

strain None None O
ADP None None O
, None None O
which None None O
is None None O
initiated None None O
by None None O
atzA None None O
, None None O
encoding None None I-FUNC
atrazine None None O
chlorohydrolase None None O
. None None O

Enhanced None None O
expression None None O
of None None O
p-AtzA None None O
was None None O
obtained None None O
by None None O
using None None O
combinations None None O
of None None O
the None None O
badnavirus None None O
promoter None None O
, None None O
the None None O
maize None None O
alcohol None None I-PROTEIN
dehydrogenase None None I-PROTEIN
first None None O
intron None None O
, None None O
and None None O
the None None O
maize None None O
ubiquitin None None O
promoter None None O
. None None O

Exercise None None O
improved None None O
general None None O
locomotor None None O
and None None O
exploratory None None O
activity None None O
and None None O
resulted None None O
in None None O
significant None None O
reductions None None O
in None None O
full-length None None O
and None None O
hyperphosphorylated None None O
tau None None O
in None None O
the None None O
spinal None None O
cord None None O
and None None O
hippocampus None None I-REGION
as None None O
well None None O
as None None O
a None None O
reduction None None O
in None None O
sarkosyl-insoluble None None O
AT8-tau None None O
in None None O
the None None O
spinal None None O
cord None None O
. None None O

In None None O
rhegmatogenous None None O
retinal None None O
detachment None None O
( None None O
RRD None None O
) None None O
, None None O
intravitreal None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
and None None O
cytokines None None O
may None None O
compromise None None O
post-vitrectomy None None O
outcomes None None O
. None None O

The None None O
recent None None O
resolution None None O
of None None O
G-protein-coupled None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
GPCR None None O
) None None O
structures None None O
in None None O
complex None None O
with None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
bound None None O
to None None O
an None None O
allosteric None None O
modulatory None None O
site None None O
has None None O
renewed None None O
interest None None O
of None None O
the None None O
regulation None None O
of None None O
GPCRs None None O
by None None O
ions None None O
. None None O

Using None None O
cross-sectional None None O
data None None O
, None None O
1,125 None None O
unemployed None None O
adults None None O
were None None O
assessed None None O
using None None O
a None None O
Cognitive None None O
Emotion None None I-FUNC
Regulation None None O
Questionnaire None None O
for None None O
cognitive None None O
coping None None O
and None None O
SF-12 None None O
to None None O
assess None None O
HRQoL None None O
. None None O

Our None None O
findings None None O
suggest None None O
the None None O
potential None None O
value None None O
of None None O
including None None O
assistance None None O
programs None None O
focused None None O
on None None O
cognitive None None O
emotion None None I-FUNC
regulation None None O
strategies None None O
to None None O
complement None None O
current None None O
psychosocial None None O
and None None O
health None None O
approaches None None O
aimed None None O
at None None O
preserving None None O
or None None O
improving None None O
unemployed None None O
people None None O
's None None O
HRQoL None None O
. None None O

This None None O
study None None O
sought None None O
to None None O
summarize None None O
the None None O
findings None None O
of None None O
the None None O
GBD None None O
2010 None None O
( None None O
Global None None O
Burden None None O
of None None O
Diseases None None O
, None None O
Injuries None None O
, None None O
and None None O
Risk None None O
Factors None None O
) None None O
study None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
IS None None O
) None None O
and None None O
to None None O
report None None O
the None None O
impact None None O
of None None O
tobacco None None O
smoking None None O
on None None O
IS None None O
burden None None O
in None None O
specific None None O
countries None None O
. None None O

The None None O
disease None None O
model None None O
of None None O
IE None None O
for None None O
the None None O
GBD None None O
2010 None None O
study None None O
included None None O
IE None None O
death None None O
and None None O
2 None None O
sequelae None None O
: None None O
stroke None None I-DISEASE
and None None O
valve None None O
surgery None None O
. None None O

The None None O
epidemiologic None None O
parameters None None O
of None None O
interest None None O
were None None O
IE None None O
incidence None None O
, None None O
proportions None None O
of None None O
IE None None O
patients None None O
who None None O
developed None None O
stroke None None I-DISEASE
or None None O
underwent None None O
valve None None O
surgery None None O
, None None O
and None None O
case None None O
fatality None None O
. None None O

The None None O
overall None None O
mean None None O
proportion None None O
of None None O
IE None None O
patients None None O
that None None O
developed None None O
stroke None None I-DISEASE
was None None O
0.158 None None O
± None None O
0.091 None None O
, None None O
and None None O
the None None O
mean None None O
proportion None None O
of None None O
patients None None O
that None None O
underwent None None O
valve None None O
surgery None None O
was None None O
0.324 None None O
± None None O
0.188 None None O
. None None O

Placental None None O
growth None None O
factor None None O
( None None O
PLGF None None O
) None None O
has None None O
been None None O
known None None O
to None None O
regulate None None O
pathological None None O
angiogenesis None None O
and None None O
has None None O
been None None O
recently None None O
shown None None O
to None None O
regulate None None O
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
( None None O
MMPs None None O
) None None O
for None None O
extracellular None None O
matrix None None O
degradation None None O
during None None O
neovascularization None None O
. None None O

Challenges None None O
in None None O
diagnosis None None O
, None None O
detection None None O
, None None O
and None None O
risk-stratification None None O
include None None O
difficulties None None O
in None None O
separating None None O
benign None None O
from None None O
high-risk None None O
syncope None None O
and None None O
pinpointing None None O
the None None O
underlying None None O
causes None None O
, None None O
the None None O
detection None None O
of None None O
silent None None O
atrial None None O
fibrillation None None O
in None None O
patients None None O
at None None O
risk None None O
of None None O
stroke None None I-DISEASE
, None None O
and None None O
inadequate None None O
identification None None O
of None None O
sudden-death None None O
risk None None O
. None None O

Medications None None O
to None None O
control None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
are None None O
frequently None None O
preserved None None O
using None None O
benzalkonium None None O
chloride None None O
( None None O
BAK None None O
) None None O
, None None O
which None None O
can None None O
negatively None None O
affect None None O
the None None O
ocular None None O
surface None None O
. None None O

84 None None O
patients None None O
with None None O
IOP None None I-TRANS
≥24 None None O
and None None O
& None None O
lt None None O
; None None O
36 None None O
mmHg None None O
were None None O
randomized None None O
1:1 None None O
to None None O
receive None None O
once-daily None None O
TRAV None None O
or None None O
BIM None None O
for None None O
6 None None O
weeks None None O
followed None None O
by None None O
an None None O
additional None None O
6-week None None O
crossover None None O
period None None O
. None None O

TRAV None None O
was None None O
considered None None O
noninferior None None O
to None None O
BIM None None O
if None None O
the None None O
upper None None O
limit None None O
of None None O
the None None O
95 None None O
% None None O
CI None None O
of None None O
the None None O
between-group None None O
difference None None O
in None None O
mean None None O
IOP None None I-TRANS
was None None O
≤1.5 None None O
mmHg None None O
. None None O

Late-day None None O
IOP-lowering None None O
efficacy None None O
of None None O
BAK-free None None O
TRAV None None O
was None None O
noninferior None None O
to None None O
that None None O
of None None O
BAK None None O
0.02 None None O
% None None O
-preserved None None O
BIM None None O
; None None O
both None None O
reduced None None O
baseline None None O
IOP None None I-TRANS
by None None O
25 None None O
% None None O
. None None O

We None None O
have None None O
estimated None None O
the None None O
prevalence None None O
of None None O
depression None None I-DISEASE
in None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
( None None O
DM2 None None O
) None None O
and None None O
its None None O
relationship None None O
with None None O
sociodemographic None None O
, None None O
lifestyle None None O
and None None O
clinical None None O
variables None None O
. None None O

The None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
were None None O
assessed None None O
using None None O
the None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
( None None O
depression None None I-DISEASE
defined None None O
as None None O
a None None O
BDI None None O
score None None O
& None None O
gt None None O
; None None O
16 None None O
) None None O
and None None O
a None None O
psychiatric None None O
interview None None O
. None None O

A None None O
greater None None O
prevalence None None O
of None None O
depression None None I-DISEASE
was None None O
found None None O
in None None O
women None None O
, None None O
widowers None None O
, None None O
patients None None O
with None None O
obesity None None O
, None None O
those None None O
with None None O
poor None None O
compliance None None O
with None None O
the None None O
prescription None None O
, None None O
those None None O
with None None O
poor None None O
glycemic None None O
control None None O
and None None O
those None None O
who None None O
developed None None O
complications None None O
from None None O
diabetes None None O
. None None O

Depression None None I-DISEASE
is None None O
highly None None O
prevalent None None O
in None None O
patients None None O
with None None O
DM2 None None O
, None None O
especially None None O
in None None O
women None None O
. None None O

Searches None None O
were None None O
limited None None O
to None None O
the None None O
publication None None O
period None None O
1996-May None None O
2014 None None O
and None None O
the None None O
English None None O
language None None I-FUNC
. None None O

We None None O
evaluated None None O
whether None None O
playing None None O
in None None O
lineman None None O
position None None O
is None None O
independently None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
the None None O
presence None None O
and None None O
severity None None O
of None None O
subclinical None None O
atherosclerosis None None I-DISEASE
. None None O

Subclinical None None O
atherosclerosis None None I-DISEASE
was None None O
assessed None None O
using None None O
coronary None None O
artery None None O
calcium None None O
( None None O
CAC None None O
) None None O
scores None None O
in None None O
931 None None O
retired None None O
NFL None None O
players None None O
( None None O
310 None None O
linemen None None O
, None None O
621 None None O
nonlinemen None None O
) None None O
. None None O

We None None O
performed None None O
multivariate None None O
logistic None None O
regression None None O
to None None O
determine None None O
whether None None O
the None None O
lineman None None O
position None None O
is None None O
independently None None O
associated None None O
with None None O
the None None O
presence None None O
and None None O
severity None None O
of None None O
subclinical None None O
atherosclerosis None None I-DISEASE
. None None O

Adjusting None None O
for None None O
demographic None None O
and None None O
metabolic None None O
covariates None None O
, None None O
lineman None None O
status None None O
remained None None O
independently None None O
associated None None O
with None None O
mild None None O
subclinical None None O
atherosclerosis None None I-DISEASE
( None None O
CAC None None O
1 None None O
to None None O
100 None None O
, None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
1.41 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
1.05 None None O
to None None O
2.2 None None O
, None None O
p None None O
= None None O
0.04 None None O
) None None O
and None None O
moderate None None O
to None None O
severe None None O
subclinical None None O
atherosclerosis None None I-DISEASE
( None None O
CAC None None O
≥100 None None O
, None None O
OR None None O
1.67 None None O
, None None O
95 None None O
% None None O
CI None None O
1.05 None None O
to None None O
2.2 None None O
) None None O
. None None O

In None None O
conclusion None None O
, None None O
lineman None None O
status None None O
in None None O
retired None None O
NFL None None O
players None None O
is None None O
associated None None O
with None None O
presence None None O
and None None O
severity None None O
of None None O
subclinical None None O
atherosclerosis None None I-DISEASE
, None None O
which None None O
is None None O
partly None None O
explained None None O
by None None O
race None None O
. None None O

Psychogenic None None O
nonepileptic None None O
seizure None None O
( None None O
PNES None None O
) None None O
and None None O
functional None None O
movement None None I-FUNC
disorder None None O
( None None O
FMD None None O
) None None O
patients None None O
present None None O
to None None O
epileptologists None None O
and None None O
movement None None I-FUNC
disorder None None O
specialists None None O
respectively None None O
, None None O
yet None None O
neurologists None None O
lack None None O
a None None O
neurobiological None None O
perspective None None O
through None None O
which None None O
to None None O
understand None None O
these None None O
enigmatic None None O
groups None None O
. None None O

In None None O
this None None O
perspective None None O
article None None O
, None None O
neuroimaging None None O
studies None None O
in None None O
PNES None None O
and None None O
FMD None None O
are None None O
reviewed None None O
, None None O
and None None O
discussed None None O
using None None O
studies None None O
of None None O
emotional None None O
dysregulation None None O
, None None O
dissociation None None O
and None None O
psychological None None O
trauma None None O
in None None O
the None None O
context None None O
of None None O
motor None None I-FUNC
control None None I-FUNC
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
pharmacologic None None O
inhibition None None O
of None None O
Akt None None O
enables None None O
expansion None None O
of None None O
TIL None None O
with None None O
the None None O
transcriptional None None O
, None None O
metabolic None None O
, None None O
and None None O
functional None None O
properties None None O
characteristic None None O
of None None O
memory None None I-FUNC
T None None O
cells None None O
. None None O

EGFR None None O
is None None O
the None None O
most None None O
common None None O
genetically None None O
altered None None O
oncogene None None O
in None None O
glioblastoma None None O
( None None O
GBM None None O
) None None O
, None None O
but None None O
small-molecule None None O
EGFR None None O
tyrosine None None I-TRANS
kinase None None O
inhibitors None None O
( None None O
TKI None None O
) None None O
have None None O
failed None None O
to None None O
yield None None O
durable None None O
clinical None None O
benefit None None O
. None None O

Central None None O
neurocytomas None None O
( None None O
CNs None None O
) None None O
are None None O
rare None None O
central None None O
nervous None None O
system None None O
tumors None None O
that None None O
occur None None O
in None None O
the None None O
lateral None None I-REGION
ventricles None None I-REGION
. None None O

Central None None O
neurocytoma None None O
( None None O
CN None None O
) None None O
is None None O
a None None O
well-differentiated None None O
tumor None None O
of None None O
neural None None O
cells None None O
occurring None None O
within None None O
the None None O
ventricles None None I-REGION
. None None O

The None None O
rosette-forming None None O
glioneuronal None None O
tumor None None O
of None None O
the None None O
fourth None None I-REGION
ventricle None None I-REGION
and None None O
papillary None None O
glioneuronal None None O
tumor None None O
have None None O
been None None O
newly None None O
classified None None O
as None None O
distinct None None O
disease None None O
entities None None O
. None None O

Patients None None O
performed None None O
a None None O
spirometry None None O
test None None O
and None None O
completed None None O
instruments None None O
that None None O
included None None O
a None None O
Beck None None O
Depression None None I-DISEASE
Inventory-II None None O
, None None O
an None None O
Interpersonal None None O
Support None None O
Evaluation None None O
List None None O
, None None O
and None None O
the None None O
symptom None None O
and None None O
function None None O
scales None None O
of None None O
the None None O
Quality None None O
of None None O
Life None None O
Questionnaire None None O
. None None O

Homozygous None None O
novel None None O
missense None None O
mutation None None O
in None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
3 None None O
. None None O

Myopathic None None O
changes None None O
in None None O
EMG None None O
, None None O
muscle None None O
edema None None O
in None None O
MRI None None O
, None None O
elevated None None O
muscle None None O
enzymes None None I-PROTEIN
and None None O
Jo-1 None None O
positive None None O
antibodies None None O
. None None O

To None None O
determine None None O
whether None None O
the None None O
( None None O
MOUSE None None O
) None None O
NAT1 None None O
and None None O
( None None O
HUMAN None None O
) None None O
NAT2 None None O
enzymes None None I-PROTEIN
are None None O
functionally None None O
equivalent None None O
, None None O
we None None O
expressed None None O
and None None O
purified None None O
( None None O
MOUSE None None O
) None None O
NAT1*1 None None O
and None None O
analysed None None O
its None None O
substrate None None O
specificity None None O
using None None O
a None None O
panel None None O
of None None O
arylamines None None O
and None None O
hydrazines None None O
. None None O

Comparing None None O
( None None O
MOUSE None None O
) None None O
NAT1*1 None None O
with None None O
other None None O
mammalian None None O
NAT None None O
enzymes None None I-PROTEIN
demonstrated None None O
that None None O
the None None O
substrate None None O
profiles None None O
of None None O
( None None O
MOUSE None None O
) None None O
NAT1 None None O
and None None O
( None None O
HUMAN None None O
) None None O
NAT2 None None O
are None None O
less None None O
similar None None O
than None None O
previously None None O
believed None None O
. None None O

Implementation None None O
of None None O
the None None O
PHC None None O
outreach None None O
team None None O
strategy None None O
was None None O
characterised None None O
by None None O
the None None O
following None None O
features None None O
: None None O
1 None None O
) None None O
A None None O
favourable None None O
provincial None None O
context None None O
of None None O
a None None O
well None None O
established None None O
district None None O
and None None O
sub-district None None O
health None None O
system None None O
and None None O
long None None O
standing None None O
values None None O
in None None O
support None None O
of None None O
PHC None None O
; None None O
2 None None O
) None None O
The None None O
forging None None O
of None None O
a None None O
collective None None O
vision None None I-FUNC
for None None O
the None None O
new None None O
strategy None None O
that None None O
built None None O
on None None O
prior None None O
history None None O
and None None O
values None None O
and None None O
that None None O
led None None O
to None None O
distributed None None O
leadership None None O
and None None O
ownership None None O
of None None O
the None None O
new None None O
policy None None O
; None None O
3 None None O
) None None O
An None None O
implementation None None O
strategy None None O
that None None O
ensured None None O
alignment None None O
of None None O
systems None None O
( None None O
information None None O
, None None O
human None None O
resources None None O
) None None O
and None None O
appropriate None None O
sequencing None None O
of None None O
activities None None O
( None None O
planning None None O
, None None O
training None None O
, None None O
piloting None None O
, None None O
household None None O
campaigns None None O
) None None O
; None None O
4 None None O
) None None O
The None None O
privileging None None O
of None None O
'community None None O
dialogues None None O
' None None O
and None None O
local None None O
manager None None O
participation None None O
in None None O
the None None O
early None None O
phases None None O
; None None O
5 None None O
) None None O
The None None O
establishment None None O
of None None O
special None None O
implementation None None O
structures None None O
: None None O
a None None O
PHC None None O
Task None None O
Team None None O
( None None O
chaired None None O
by None None O
a None None O
senior None None O
provincial None None O
manager None None O
) None None O
to None None O
enable None None O
feedback None None O
and None None O
ensure None None O
accountability None None O
, None None O
and None None O
an None None O
NGO None None O
partnership None None O
that None None O
provided None None O
flexible None None O
support None None O
for None None O
implementation None None O
. None None O

Although None None O
implementation None None O
was None None O
not None None O
without None None O
tensions None None O
and None None O
weaknesses None None O
, None None O
particularly None None O
at None None O
the None None O
front-line None None O
of None None O
the None None O
PHC None None O
system None None O
, None None O
the None None O
case None None O
study None None O
highlights None None O
how None None O
a None None O
collective None None O
vision None None I-FUNC
can None None O
facilitate None None O
commitment None None O
to None None O
and None None O
engagement None None O
with None None O
new None None O
policy None None O
in None None O
complex None None O
organisational None None O
environments None None O
. None None O

However None None O
, None None O
bullied None None O
boys None None O
and None None O
girls None None O
reported None None O
similar None None O
scores None None O
for None None O
the None None O
different None None O
subscales None None O
of None None O
the None None O
Child None None O
Perceptions None None I-FUNC
Questionnaire None None O
; None None O
there None None O
were None None O
no None None O
significant None None O
differences None None O
. None None O

The None None O
approach None None O
allows None None O
movement None None I-FUNC
of None None O
dentoalveolar None None O
segments None None O
in None None O
less None None O
time None None O
than None None O
with None None O
conventional None None O
dental None None O
intrusion None None O
using None None O
temporary None None O
skeletal None None O
anchorage None None O
devices None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
household None None O
economic None None O
burden None None O
of None None O
eating None None I-DISEASE
disorders None None I-DISEASE
and None None O
cost-related None None O
non-adherence None None O
to None None O
treatment None None O
in None None O
Australia None None O
. None None O

The None None O
pattern None None O
of None None O
out-of-pocket None None O
expenditure None None O
varied None None O
by None None O
diagnosis None None O
, None None O
with None None O
Bulimia None None I-DISEASE
Nervosa None None I-DISEASE
associated None None O
with None None O
the None None O
highest None None O
total None None O
mean None None O
expenditure None None O
( None None O
per None None O
three None None O
months None None O
) None None O
. None None O

This None None O
study None None O
is None None O
the None None O
first None None O
to None None O
empirically None None O
and None None O
quantitatively None None O
examine None None O
the None None O
household None None O
economic None None O
burden None None O
of None None O
eating None None I-DISEASE
disorders None None I-DISEASE
from None None O
the None None O
patient None None O
perspective None None O
. None None O

Mutation None None O
of None None O
Arabidopsis None None O
DMR1 None None O
, None None O
encoding None None I-FUNC
homoserine None None O
kinase None None O
, None None O
leads None None O
to None None O
elevation None None O
in None None O
homoserine None None O
and None None O
foliar None None O
resistance None None O
to None None O
the None None O
biotrophic None None O
pathogens None None O
Hyaloperonospora None None O
arabidopsidis None None O
and None None O
Oidium None None O
neolycopersici None None O
through None None O
activation None None O
of None None O
an None None O
unidentified None None O
defence None None O
mechanism None None O
. None None O

To None None O
identify None None O
students None None O
who None None O
are None None O
at None None O
risk None None O
for None None O
not None None O
graduating None None O
for None None O
the None None O
purposes None None O
of None None O
providing None None O
appropriate None None O
interventions None None O
, None None O
educators None None O
should None None O
pay None None O
attention None None I-FUNC
to None None O
their None None O
commonly None None O
collected None None O
data None None O
on None None O
attendance None None O
rates None None O
as None None O
a None None O
behavioral None None O
indicator None None O
of None None O
engagement None None O
. None None O

Comparison None None O
of None None O
the None None O
effects None None O
of None None O
camel None None O
thorn None None O
extract None None O
with None None O
those None None O
of None None O
flavonoid None None O
taxifolin None None O
showed None None O
that None None O
the None None O
extract None None O
was None None O
not None None O
inferior None None O
to None None O
taxifolin None None O
in None None O
preventing None None O
the None None O
early None None O
stages None None O
of None None O
aortic None None O
atherosclerosis None None I-DISEASE
caused None None O
by None None O
increased None None O
activity None None O
of None None O
angiotensin-converting None None O
enzyme None None O
. None None O

Insulin None None I-PROTEIN
resistance None None O
( None None O
IR None None O
) None None O
lies None None O
at None None O
the None None O
origin None None O
of None None O
type None None O
2 None None O
diabetes None None O
. None None O

The None None O
key None None O
role None None O
of None None O
APP None None I-TRANS
in None None O
the None None O
pathogenesis None None O
of None None O
Alzheimer None None I-DISEASE
disease None None O
is None None O
well None None O
established None None O
. None None O

Previously None None O
, None None O
APP None None I-TRANS
family None None O
proteins None None O
have None None O
been None None O
implicated None None O
in None None O
synaptic None None O
adhesion None None O
, None None O
and None None O
analysis None None O
of None None O
the None None O
neuromuscular None None O
junction None None O
of None None O
constitutive None None O
APP/APLP2 None None O
mutant None None O
mice None None O
showed None None O
deficits None None O
in None None O
synaptic None None O
morphology None None O
and None None O
neuromuscular None None O
transmission None None O
. None None O

Moreover None None O
, None None O
while None None O
no None None O
gross None None O
alterations None None O
of None None O
brain None None O
morphology None None O
were None None O
detectable None None O
in None None O
NexCre None None O
cDKO None None O
mice None None O
, None None O
quantitative None None O
analysis None None O
of None None O
adult None None O
hippocampal None None O
CA1 None None I-REGION
neurons None None O
revealed None None O
prominent None None O
reductions None None O
in None None O
total None None O
neurite None None O
length None None O
, None None O
dendritic None None O
branching None None O
, None None O
reduced None None O
spine None None O
density None None O
and None None O
reduced None None O
spine None None O
head None None O
volume None None O
. None None O

Collectively None None O
, None None O
our None None O
analysis None None O
reveals None None O
an None None O
essential None None O
role None None O
of None None O
APP None None I-TRANS
family None None O
proteins None None O
in None None O
excitatory None None O
principal None None O
neurons None None O
for None None O
mediating None None O
normal None None O
dendritic None None O
architecture None None O
, None None O
spine None None O
density None None O
and None None O
morphology None None O
, None None O
synaptic None None O
plasticity None None O
and None None O
cognition None None O
. None None O

However None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
two None None O
hitherto None None O
published None None O
families None None O
, None None O
the None None O
cerebellum None None I-REGION
and None None O
its None None O
myelination None None O
are None None O
not None None O
affected None None O
. None None O

Polycystic None None O
ovary None None O
syndrome None None O
( None None O
PCOS None None O
) None None O
is None None O
the None None O
most None None O
prevalent None None O
among None None O
them None None O
, None None O
followed None None O
by None None O
idiopathic None None O
hirsutism None None O
( None None O
IH None None O
) None None O
, None None O
congenital None None O
adrenal None None I-TRANS
hyperplasia None None O
( None None O
CAH None None O
) None None O
, None None O
hyperandrogenic None None O
insulin-resistant None None O
acanthosis None None O
nigricans None None O
( None None O
HAIRAN None None O
) None None O
syndrome None None O
, None None O
and None None O
androgen-secreting None None O
neoplasms None None O
( None None O
ASNs None None O
) None None O
. None None O

Serum None None O
testosterone None None O
independently None None O
increases None None O
risk None None O
for None None O
cardiovascular None None O
disease None None O
( None None O
CVD None None O
) None None O
, None None O
and None None O
correlates None None O
even None None O
with None None O
indices None None O
of None None O
subclinical None None O
atherosclerosis None None I-DISEASE
in None None O
various None None O
populations None None O
of None None O
postmenopausal None None O
women None None O
. None None O

Gene None None O
and None None O
protein None None O
expressions None None O
of None None O
studied None None O
enzymes None None I-PROTEIN
were None None O
determined None None O
by None None O
quantitative None None O
real-time None None O
PCR None None O
and None None O
Western None None O
blot None None O
analysis None None O
. None None O

Growing None None O
and None None O
collecting None None O
an None None O
adequate None None O
number None None O
of None None O
CPCs None None O
demands None None O
complex None None O
culture None None O
media None None O
containing None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
. None None O

The None None O
basis None None O
for None None O
this None None O
assumption None None O
was None None O
the None None O
view None None O
that None None O
all None None O
types None None O
of None None O
movements None None I-FUNC
associated None None O
with None None O
life None None O
must None None O
be None None O
caused None None O
by None None O
the None None O
same None None O
mechanisms None None O
. None None O

The None None O
gut-soluble None None O
proteases None None O
could None None O
contain None None O
trypsin-like None None O
enzymes None None I-PROTEIN
implicated None None O
in None None O
Vip3Aa16 None None O
activation None None O
since None None O
the None None O
proteolysis None None O
was None None O
inhibited None None O
using None None O
specific None None O
protease None None O
inhibitors None None O
. None None O

Among None None O
the None None O
technologies None None O
for None None O
heavy None None O
metal None None O
remediation None None O
, None None O
bioremediation None None O
technology None None O
has None None O
gained None None O
extensive None None O
attention None None I-FUNC
because None None O
of None None O
its None None O
low None None O
processing None None O
costs None None O
and None None O
high None None O
efficiency None None O
. None None O

The None None O
present None None O
study None None O
aimed None None O
to None None O
investigate None None O
and None None O
compare None None O
the None None O
enzymatic None None O
production None None O
of None None O
endophytic None None O
bacteria None None O
isolated None None O
from None None O
healthy None None O
and None None O
brittle None None O
leaf None None O
disease None None O
affected None None O
date None None O
palm None None O
leaves None None O
( None None O
pectinase None None O
, None None O
cellulase None None O
, None None O
lipase None None O
, None None O
and None None O
amylase None None I-PROTEIN
) None None O
. None None O

The None None O
Bacillus None None O
subtilis None None O
JN934392 None None O
strain None None O
isolated None None O
from None None O
healthy None None O
date None None O
palm None None O
leaves None None O
produced None None O
higher None None O
levels None None O
of None None O
amylase None None I-PROTEIN
activity None None O
at None None O
pH None None O
7 None None O
. None None O

Therefore None None O
, None None O
production None None O
of None None O
enzymes None None I-PROTEIN
from None None O
their None None O
natural None None O
producer None None O
is None None O
desirable None None O
. None None O

bisphosphonates None None O
, None None O
selective None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
modulators None None O
and None None O
denosumab None None O
) None None O
, None None O
bone-forming None None O
agents None None O
( None None O
i.e None None O
. None None O

New None None O
compounds None None O
with None None O
well None None O
advanced None None O
clinical None None O
development None None O
include None None O
odanacatib None None O
, None None O
a None None O
selective None None O
inhibitor None None O
of None None O
the None None O
cysteine None None I-TRANS
protease None None O
cathepsin-K None None O
, None None O
and None None O
romosozumab None None O
, None None O
a None None O
monoclonal None None O
antibody None None O
against None None O
sclerostin None None O
. None None O

Special None None O
attention None None I-FUNC
should None None O
be None None O
paid None None O
to None None O
possible None None O
contraindications None None O
of None None O
drugs None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
postmenopausal None None O
or None None O
senile None None O
osteoporosis None None O
. None None O

ITF None None O
promoter None None O
vector None None O
was None None O
stimulated None None O
with None None O
ITF None None O
at None None O
various None None O
concentrations None None O
and None None O
the None None O
luciferase None None I-PROTEIN
activity None None O
was None None O
measured None None O
. None None O

Restriction None None O
endonuclease None None I-PROTEIN
analysis None None O
and None None O
DNA None None O
sequencing None None O
confirmed None None O
that None None O
the None None O
recombinant None None O
plasmid None None O
, None None O
containing None None O
ITF None None O
promoter None None O
, None None O
was None None O
constructed None None O
successfully None None O
. None None O

The None None O
expressions None None O
of None None O
diubiquitin None None O
( None None O
FAT10 None None O
) None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
, None None O
progesterone None None O
receptor None None I-PROTEIN
( None None O
PR None None O
) None None O
and None None O
c-erbB2 None None O
in None None O
50 None None O
cases None None O
of None None O
infitrating None None O
ductal None None O
carcinoma None None O
of None None O
breast None None O
were None None O
detected None None O
by None None O
immunohistochemistry None None O
. None None O

The None None O
serum None None O
levels None None O
of None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
, None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
and None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
were None None O
measured None None O
. None None O

The None None O
levels None None O
of None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
and None None O
myeloperoxidase None None I-PROTEIN
( None None O
MPO None None O
) None None O
were None None O
determined None None O
by None None O
spectrophotometer None None O
; None None O
the None None O
mRNA None None O
expression None None O
of None None O
tumor None None O
necrosis None None O
factor-α None None O
( None None O
TNF-α None None O
) None None O
and None None O
interleukin-1 None None O
beta None None O
( None None O
IL-1β None None O
) None None O
in None None O
the None None O
liver None None O
were None None O
measured None None O
by None None O
real-time None None O
PCR None None O
; None None O
Dickkopf-1 None None O
( None None O
DKK-1 None None O
) None None O
and None None O
beta-catenin None None O
( None None O
β-catenin None None O
) None None O
protein None None O
expression None None O
in None None O
the None None O
liver None None O
were None None O
detected None None O
by None None O
Western None None O
blot None None O
. None None O

The None None O
most None None O
common None None O
complication None None O
were None None O
pulmonary None None O
arterial None None O
hypertension None None O
( None None O
51 None None O
, None None O
27.13 None None O
% None None O
) None None O
, None None O
arrhythmias None None O
( None None O
47 None None O
, None None O
25.00 None None O
% None None O
) None None O
and None None O
severe None None O
heart None None O
failure None None O
( None None O
30 None None O
, None None O
15.96 None None O
% None None O
) None None O
; None None O
the None None O
cardiac None None O
function None None O
of None None O
164 None None O
( None None O
87.23 None None O
% None None O
) None None O
patients None None O
was None None O
at None None O
stage None None O
I-II None None I-REGION
and None None O
5 None None O
( None None O
2.66 None None O
% None None O
) None None O
patients None None O
died None None O
when None None O
discharged None None O
from None None O
hospital None None O
. None None O

To None None O
assess None None O
the None None O
activity None None O
of None None O
cathepsin None None O
D None None O
( None None O
CAT-D None None O
) None None O
and None None O
alpha-1 None None O
antitrypsin None None O
( None None O
AAT None None O
) None None O
in None None O
blood None None O
in None None O
patients None None O
with None None O
hip None None O
or None None O
knee None None O
osteoarthritis None None O
, None None O
and None None O
to None None O
explore None None O
whether None None O
these None None O
two None None O
enzymes None None I-PROTEIN
could None None O
be None None O
served None None O
as None None O
serum None None O
biomarkers None None O
for None None O
cartilage None None O
degeneration None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
difference None None O
in None None O
the None None O
activities None None O
of None None O
2 None None O
enzymes None None I-PROTEIN
between None None O
hip None None O
and None None O
knee None None O
osteoarthritis None None O
( None None O
P None None O
& None None O
gt None None O
; None None O
0.05 None None O
) None None O
. None None O

Iliac None None O
arteriovenous None None O
fistula None None O
( None None O
AVF None None O
) None None O
usually None None O
manifests None None O
in None None O
a None None O
wide None None O
range None None O
of None None O
symptoms None None O
similar None None O
to None None O
typical None None O
deep None None O
venous None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
, None None O
which None None O
often None None O
lead None None O
to None None O
delayed None None O
diagnosis None None O
or None None O
misdiagnosis None None O
. None None O

She None None O
was None None O
initially None None O
diagnosed None None O
as None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
and None None O
the None None O
fi None None O
nal None None O
diagnosis None None O
was None None O
arteriovenous None None O
fistula None None O
. None None O

The None None O
demographic None None O
forces None None O
mean None None O
that None None O
memory None None I-FUNC
services None None O
will None None O
need None None O
to None None O
expand None None O
to None None O
meet None None O
demand None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
contrast None None O
patient None None O
, None None O
family None None O
member None None O
and None None O
professional None None O
experience None None O
of None None O
primary None None O
and None None O
secondary None None O
( None None O
usual None None O
) None None O
care None None O
led None None O
memory None None I-FUNC
services None None O
. None None O

Eleven None None O
( None None O
21 None None O
% None None O
) None None O
of None None O
the None None O
53 None None O
GP None None O
practices None None O
in None None O
Bristol None None O
offered None None O
primary None None O
care None None O
led None None O
dementia None None I-DISEASE
services None None O
. None None O

These None None O
panels None None O
identified None None O
four None None O
main None None O
themes None None O
: None None O
GPs None None O
rarely None None O
make None None O
independent None None O
dementia None None I-DISEASE
diagnosis None None O
; None None O
GPs None None O
and None None O
memory None None I-FUNC
nurses None None O
work None None O
together None None O
; None None O
patients None None O
and None None O
carers None None O
generally None None O
experience None None O
a None None O
high None None O
quality None None O
diagnostic None None O
service None None O
; None None O
an None None O
absence None None O
of None None O
post None None O
diagnostic None None O
support None None O
. None None O

Patients None None O
and None None O
carers None None O
were None None O
generally None None O
satisfied None None O
with None None O
either None None O
primary None None O
or None None O
secondary None None O
care None None O
led None None O
approaches None None O
to None None O
dementia None None I-DISEASE
diagnosis None None O
. None None O

Intracranial None None O
branch None None O
atheromatous None None O
disease None None O
is None None O
a None None O
type None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
that None None O
is None None O
caused None None O
by None None O
narrowing None None O
or None None O
occlusion None None O
of None None O
the None None O
orifice None None O
of None None O
the None None O
penetrating None None O
artery None None O
by None None O
atheromatous None None O
plaque None None O
. None None O

Non-contrast-enhanced None None O
three-dimensional None None O
fast None None O
spin-echo None None O
T1 None None O
imaging None None O
with None None O
variable None None O
flip None None O
angles None None O
and None None O
three-dimensional None None O
fast None None O
imaging None None O
with None None O
steady-state None None O
acquisition None None O
revealed None None O
a None None O
plaque None None O
in None None O
the None None O
dorsal None None I-NEURON
wall None None O
of None None O
the None None O
basilar None None O
artery None None O
that None None O
spread None None O
to None None O
the None None O
origin None None O
of None None O
the None None O
paramedian None None O
pontine None None O
artery None None O
that None None O
branched None None O
toward None None O
the None None O
infarction None None O
. None None O

A None None O
second None None O
study None None O
randomized None None O
70 None None O
patients None None O
with None None O
carotid None None O
atherosclerosis None None I-DISEASE
to None None O
simvastatin None None O
20 None None O
mg/day None None O
, None None O
simvastatin None None O
80 None None O
mg/day None None O
, None None O
or None None O
simvastatin None None O
20 None None O
mg/extended-release None None O
( None None O
ER None None O
) None None O
niacin None None O
2 None None O
g/day None None O
. None None O

In None None O
addition None None O
to None None O
relaying None None O
incoming None None O
electrical None None O
signals None None O
, None None O
spines None None O
can None None O
play None None O
important None None O
roles None None O
in None None O
modifying None None O
these None None O
signals None None O
through None None O
complex None None O
biochemical None None O
processes None None O
and None None O
, None None O
thereby None None O
, None None O
determine None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
formation None None O
. None None O

The None None O
effects None None O
of None None O
transcutaneous None None O
electric None None O
nerve None None O
stimulation None None O
( None None O
TENS None None O
) None None O
and None None O
electroacupuncture None None O
( None None O
EA None None O
) None None O
on None None O
the None None O
cerebral None None I-REGION
cortex None None I-REGION
are None None O
largely None None O
unclear None None O
. None None O

The None None O
neuroprotective None None O
effects None None O
of None None O
menopausal None None O
hormonal None None O
therapy None None O
in None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
have None None O
not None None O
yet None None O
been None None O
clarified None None O
, None None O
and None None O
it None None O
is None None O
not None None O
known None None O
whether None None O
there None None O
is None None O
a None None O
critical None None O
period None None O
. None None O

In None None O
the None None O
substantia None None I-REGION
nigra None None I-REGION
, None None O
ovariectomy None None O
induced None None O
a None None O
decrease None None O
in None None O
levels None None O
of None None O
estrogen None None I-PROTEIN
receptor-α None None O
and None None O
increased None None O
angiotensin None None O
activity None None O
, None None O
NADPH-oxidase None None O
activity None None O
, None None O
and None None O
expression None None O
of None None O
neuroinflammatory None None O
markers None None O
, None None O
which None None O
were None None O
regulated None None O
by None None O
estrogen None None O
administered None None O
immediately None None O
or None None O
6 None None O
weeks None None O
but None None O
not None None O
20 None None O
weeks None None O
after None None O
ovariectomy None None O
. None None O

In None None O
cultures None None O
, None None O
treatment None None O
with None None O
1-methyl-4-phenylpyridinium None None O
induced None None O
an None None O
increase None None O
in None None O
astrocyte-derived None None O
angiotensinogen None None O
and None None O
dopaminergic None None I-NEURON
neuron None None I-NEURON
death None None O
, None None O
which None None O
were None None O
inhibited None None O
by None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
agonists None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
there None None O
is None None O
a None None O
critical None None O
period None None O
for None None O
the None None O
neuroprotective None None O
effect None None O
of None None O
estrogen None None O
against None None O
dopaminergic None None O
cell None None O
death None None O
, None None O
and None None O
local None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
and None None O
renin-angiotensin None None O
system None None O
play None None O
a None None O
major None None O
role None None O
. None None O

A None None O
promising None None O
neuroprotective None None O
strategy None None O
is None None O
glutamate None None I-TRANS
scavenging None None O
, None None O
which None None O
can None None O
be None None O
achieved None None O
by None None O
the None None O
intravenous None None O
administration None None O
of None None O
OxAc None None O
. None None O

Cortical None None O
habituation None None O
in None None O
episodic None None O
migraine None None I-DISEASE
patients None None O
without None None O
medication None None O
overuse None None O
headache None None O
( None None O
MOH None None O
) None None O
, None None O
recorded None None O
by None None O
contingent None None O
negative None None O
variation None None O
( None None O
CNV None None O
) None None O
, None None O
is None None O
often None None O
reduced None None O
compared None None O
with None None O
healthy None None O
controls None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
study None None O
was None None O
to None None O
examine None None O
habituation None None O
characteristics None None O
of None None O
contingent None None O
negative None None O
variation None None O
in None None O
episodic None None O
migraine None None I-DISEASE
patients None None O
suffering None None O
from None None O
short- None None O
and None None O
long-lasting None None O
migraine None None I-DISEASE
compared None None O
to None None O
matched None None O
healthy None None O
controls None None O
. None None O

According None None O
to None None O
DOD None None O
, None None O
the None None O
total None None O
sample None None O
of None None O
migraine None None I-DISEASE
patients None None O
was None None O
divided None None O
into None None O
two None None O
groups None None O
( None None O
group None None O
a None None O
: None None O
DOD None None O
& None None O
lt None None O
; None None O
121 None None O
months None None O
, None None O
n None None O
= None None O
17 None None O
subjects None None O
, None None O
group None None O
b None None O
: None None O
DOD None None O
& None None O
gt None None O
; None None O
120 None None O
months None None O
, None None O
n None None O
= None None O
15 None None O
subjects None None O
) None None O
. None None O

Overall None None O
CNV None None O
and None None O
initial None None O
CNV None None O
differed None None O
significantly None None O
between None None O
migraine None None I-DISEASE
patients None None O
and None None O
controls None None O
, None None O
whereas None None O
the None None O
former None None O
produced None None O
more None None O
negative None None O
amplitudes None None O
. None None O

The None None O
results None None O
are None None O
interpreted None None O
as None None O
`` None None O
maladaptive None None O
plasticity None None O
'' None None O
with None None O
a None None O
risen None None O
intercept None None O
in None None O
long-lasting None None O
migraine None None I-DISEASE
. None None O

Various None None O
neurotransmitters None None I-TRANS
exert None None O
antiapoptotic None None O
, None None O
chemotactic None None O
and None None O
proliferative None None O
effect None None O
on None None O
EC None None O
and None None O
SMC None None O
, None None O
and None None O
modulate None None O
all None None O
the None None O
phases None None O
of None None O
neovascularization None None O
. None None O

The None None O
proposed None None O
operating None None O
rules None None O
would None None O
increase None None O
the None None O
barrage None None O
storage None None I-FUNC
level None None O
during None None O
the None None O
turtle None None O
nesting None None O
season None None O
( None None O
May-July None None O
) None None O
and None None O
then None None O
would None None O
be None None O
allowed None None O
to None None O
reduce None None O
to None None O
a None None O
lower None None O
level None None O
for None None O
incubation None None O
for None None O
the None None O
rest None None O
of None None O
the None None O
year None None O
. None None O

This None None O
article None None O
aims None None O
to None None O
present None None O
the None None O
major None None O
laws None None O
, None None O
directives None None O
, None None O
and None None O
guidelines None None O
with None None O
respect None None O
to None None O
quality None None O
assurance None None O
of None None O
human None None O
genetic None None O
testing None None O
, None None O
paying None None O
careful None None O
attention None None I-FUNC
to None None O
internal None None O
and None None O
external None None O
quality None None O
assurance None None O
. None None O

The None None O
characterization None None O
of None None O
aerosol None None O
acidity None None O
has None None O
received None None O
increased None None O
attention None None I-FUNC
in None None O
recent None None O
years None None O
due None None O
to None None O
its None None O
influence None None O
on None None O
atmospheric None None O
visibility None None O
, None None O
climate None None O
change None None O
and None None O
human None None O
health None None O
. None None O

A None None O
bimodal None None O
distribution None None O
was None None O
observed None None O
for None None O
concentrations None None O
of None None O
SO4 None None O
( None None O
2- None None O
) None None O
, None None O
NO3 None None O
( None None O
- None None O
) None None O
, None None O
Cl None None O
( None None O
- None None O
) None None O
, None None O
K None None O
( None None O
+ None None O
) None None O
and None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
, None None O
whereas None None O
concentrations None None O
of None None O
NH4 None None O
( None None O
+ None None O
) None None O
, None None O
Ca None None O
( None None O
2+ None None O
) None None O
and None None O
Mg None None O
( None None O
2+ None None O
) None None O
showed None None O
a None None O
single None None O
mode None None O
distribution None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
clarify None None O
the None None O
difference None None O
between None None O
perceptions None None I-FUNC
of None None O
injury None None O
and None None O
illness None None O
. None None O

It None None O
was None None O
concluded None None O
that None None O
there None None O
are None None O
themes None None O
unique None None O
to None None O
injury None None O
perceptions None None I-FUNC
that None None O
should None None O
be None None O
recognized None None O
in None None O
research None None O
as None None O
well None None O
as None None O
in None None O
clinical None None O
interventions None None O
. None None O

The None None O
operational None None O
characteristics None None O
of None None O
the None None O
clinical None None O
tests None None O
performed None None O
were None None O
as None None O
follows None None O
: None None O
thumb None None O
index None None O
finger None None O
squeeze None None O
( None None O
96 None None O
% None None O
sensitivity None None O
, None None O
96 None None O
% None None O
accuracy None None O
) None None O
, None None O
Mulder None None O
's None None O
click None None O
( None None O
61 None None O
% None None O
sensitivity None None O
, None None O
62 None None O
% None None O
accuracy None None O
) None None O
, None None O
foot None None O
squeeze None None O
( None None O
41 None None O
% None None O
sensitivity None None O
, None None O
41 None None O
% None None O
accuracy None None O
) None None O
, None None O
plantar None None O
percussion None None O
( None None O
37 None None O
% None None O
sensitivity None None O
, None None O
36 None None O
% None None O
accuracy None None O
) None None O
, None None O
dorsal None None I-NEURON
percussion None None O
( None None O
33 None None O
% None None O
sensitivity None None O
, None None O
26 None None O
% None None O
accuracy None None O
) None None O
, None None O
and None None O
light None None O
touch None None O
and None None O
pin None None O
prick None None O
( None None O
26 None None O
% None None O
sensitivity None None O
, None None O
25 None None O
% None None O
accuracy None None O
) None None O
. None None O

This None None O
risk None None O
is None None O
further None None O
increased None None O
by None None O
disorders None None O
of None None O
bilirubin None None O
binding None None O
to None None O
albumin None None O
, None None O
which None None O
includes None None O
a None None O
reduction None None O
in None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
concentrations None None O
or None None O
in None None O
the None None O
bilirubin-binding None None O
capacity None None O
and None None O
affinity None None O
of None None O
albumin None None O
, None None O
and None None O
the None None O
presence None None O
of None None O
displacing None None O
substances None None O
or None None O
infection None None O
. None None O

Kernicterus None None I-DISEASE
, None None O
the None None O
chronic None None O
and None None O
with None None O
the None None O
most None None O
severe None None O
manifestations None None O
beyond None None O
BIND None None O
, None None O
is None None O
diagnosed None None O
by None None O
the None None O
presence None None O
of None None O
motor None None O
impairments None None O
with None None O
athetosis None None O
, None None O
abnormal None None O
magnetic None None O
resonance None None O
imaging None None O
, None None O
and/or None None O
brainstem None None I-REGION
auditory-evoked None None O
potential None None O
findings None None O
during None None O
infancy None None O
and None None O
childhood None None O
. None None O

We None None O
performed None None O
a None None O
longitudinal None None O
cohort None None O
study None None O
of None None O
365 None None O
HIV-infected None None O
patients None None O
( None None O
24 None None O
% None None O
females None None O
) None None O
was None None O
with None None O
sequential None None O
determinations None None O
of None None O
25OHD None None O
, None None O
serum None None O
parathyroid None None O
hormone None None O
( None None O
PTH None None O
) None None O
, None None O
calcium None None O
, None None O
and None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
. None None O

Immunostaining None None O
of None None O
liver None None O
matrix None None I-PROTEIN
metalloproteinase-8 None None O
( None None O
MMP-8 None None O
) None None O
in None None O
paracetamol None None O
administered None None O
rats None None O
showed None None O
an None None O
increase None None O
in None None O
MMP-8 None None O
expression None None O
in None None O
the None None O
area None None O
of None None O
coagulative None None O
necrosis None None O
surrounding None None O
the None None O
central None None O
vein None None O
of None None O
hepatic None None O
lobules None None O
. None None O

Gene None None O
expression None None O
measurements None None O
revealed None None O
that None None O
paracetamol None None O
decreased None None O
the None None O
expression None None O
of None None O
antioxidant None None O
genes None None O
and None None O
increased None None O
the None None O
expression None None O
of None None O
interleukin-1β None None O
( None None O
IL-1β None None O
) None None O
, None None O
IL-8 None None O
, None None O
tumor None None O
necrosis None None O
factor-α None None O
( None None O
TNF-α None None O
) None None O
and None None O
acute None None I-PROTEIN
phase None None I-PROTEIN
proteins None None I-PROTEIN
. None None O

A None None O
random None None O
sample None None O
of None None O
347 None None O
preschool None None O
children None None O
with None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
was None None O
recruited None None O
from None None O
19 None None O
Special None None O
Child None None O
Care None None O
Centres None None O
in None None O
Hong None None O
Kong None None O
. None None O

Children None None O
with None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
had None None O
less None None O
caries None None O
experiences None None O
than None None O
children None None O
without None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
mean None None O
decayed None None O
, None None O
missing None None O
and None None O
filled None None O
surfaces None None O
and None None O
decayed None None O
surfaces None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Differences None None O
in None None O
oral None None O
health None None O
status None None O
exist None None O
among None None O
preschool None None O
children None None O
with None None O
and None None O
without None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
. None None O

Infant None None O
siblings None None O
of None None O
children None None O
with None None O
an None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
are None None O
at None None O
heightened None None O
genetic None None O
risk None None O
to None None O
develop None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
. None None O

Children None None O
were None None O
assessed None None O
for None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
in None None O
toddlerhood None None O
. None None O

Indeed None None O
, None None O
we None None O
show None None O
that None None O
overexpression None None O
of None None O
the None None O
CCM None None O
complex None None O
, None None O
an None None O
inhibitor None None O
of None None O
β1 None None O
integrin None None I-PROTEIN
activation None None O
, None None O
blocks None None O
endothelial None None O
actin None None I-PROTEIN
rearrangement None None O
and None None O
cell None None O
reorientation None None O
in None None O
response None None O
to None None O
shear None None O
stress None None O
similarly None None O
to None None O
β1 None None O
integrin None None I-PROTEIN
silencing None None O
. None None O

Patients None None O
suffering None None O
from None None O
glycogen None None O
storage None None I-FUNC
disease None None O
V None None O
( None None O
McArdle None None O
disease None None O
) None None O
were None None O
shown None None O
to None None O
have None None O
higher None None O
surface None None O
electrical None None O
activity None None O
in None None O
their None None O
skeletal None None O
muscles None None O
when None None O
exercising None None O
at None None O
the None None O
same None None O
intensity None None O
as None None O
their None None O
healthy None None O
counterparts None None O
, None None O
indicating None None O
more None None O
muscle None None O
fibre None None O
recruitment None None O
. None None O

This None None O
toolkit None None O
requires None None O
no None None O
restriction None None O
enzymes None None I-PROTEIN
besides None None O
BsaI None None O
to None None O
generate None None O
final None None O
constructs None None O
harboring None None O
maize-codon None None O
optimized None None O
Cas9 None None O
and None None O
one None None O
or None None O
more None None O
gRNAs None None O
with None None O
high None None O
efficiency None None O
in None None O
as None None O
little None None O
as None None O
one None None O
cloning None None O
step None None O
. None None O

Cardiovascular None None O
events None None O
and None None O
pain None None O
are None None O
important None None O
factors None None O
related None None O
to None None O
HRQoL None None O
, None None O
social None None O
functioning None None O
and None None O
depression None None I-DISEASE
. None None O

We None None O
analyzed None None O
pre- None None O
and None None O
post-treatment None None O
tumor-infiltrating None None O
immune None None O
cells None None O
( None None O
CD3 None None O
, None None O
CD4 None None O
, None None O
CD8 None None O
, None None O
CD20 None None O
, None None O
CD68 None None O
, None None O
Foxp3 None None I-PROTEIN
) None None O
by None None O
immunohistochemistry None None O
in None None O
a None None O
series None None O
of None None O
121 None None O
breast None None O
cancer None None O
patients None None O
homogeneously None None O
treated None None O
with None None O
neoadjuvant None None O
chemotherapy None None O
. None None O

Sjögren-Larsson None None O
syndrome None None O
( None None O
SLS None None O
) None None O
is None None O
caused None None O
by None None O
defects None None O
in None None O
the None None O
microsomal None None O
fatty None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
( None None O
FALDH None None O
) None None O
leading None None O
to None None O
the None None O
accumulation None None O
of None None O
fatty None None O
alcohols None None O
and None None O
fatty None None O
aldehydes None None O
. None None O

Incorporating None None O
psychosocial None None O
assessment None None O
throughout None None O
the None None O
counseling None None O
session None None O
may None None O
assist None None O
the None None O
individual None None O
in None None O
their None None O
understanding None None O
of None None O
genetic None None O
testing None None O
in None None O
the None None O
context None None O
of None None O
their None None O
support None None O
resources None None O
and None None O
coping None None O
mechanisms None None O
and None None O
may None None O
help None None O
with None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Synaptic None None O
plasticity None None O
and None None O
dendritic None None O
spines None None O
were None None O
normal None None O
in None None O
Cyfip2 None None O
( None None O
+/- None None O
) None None O
hippocampus None None I-REGION
. None None O

In None None O
addition None None O
to None None O
the None None O
spine None None O
changes None None O
at None None O
basal None None O
state None None O
, None None O
metabotropic None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
( None None O
mGluR None None O
) None None O
-induced None None O
dendritic None None O
spine None None O
regulation None None O
was None None O
impaired None None O
in None None O
both None None O
Fmr1 None None O
( None None O
-/y None None O
) None None O
and None None O
Cyfip2 None None O
( None None O
+/- None None O
) None None O
cortical None None O
neurons None None O
. None None O

Testing None None O
additional None None O
models None None O
of None None O
ALS None None O
, None None O
we None None O
find None None O
that None None O
pioglitazone None None O
is None None O
also None None O
neuroprotective None None O
when None None O
FUS None None O
, None None O
but None None O
not None None O
SOD1 None None O
, None None O
is None None O
expressed None None O
in None None O
motor None None I-NEURON
neurons None None I-NEURON
. None None O

Functional None None O
annotation None None O
of None None O
TDFs None None O
that None None O
were None None O
upregulated None None O
suggest None None O
that None None O
the None None O
APR None None O
was None None O
supported None None O
by None None O
transient None None O
recruitment None None O
and None None O
reprogramming None None O
of None None O
processes None None O
like None None O
perception None None I-FUNC
and None None O
recognition None None O
of None None O
pathogen None None O
effector None None O
by None None O
receptors None None I-PROTEIN
, None None O
followed None None O
by None None O
CDPK None None O
and None None O
MAPK None None O
signaling None None O
, None None O
transport None None O
, None None O
metabolism None None O
, None None O
and None None O
energy None None O
release None None O
. None None O

Mamalian None None O
cells None None O
have None None O
been None None O
shown None None O
to None None O
contain None None O
small None None O
, None None O
cationic None None O
, None None O
microbicidal None None O
peptides None None I-TRANS
. None None O

Such None None O
peptides None None I-TRANS
have None None O
been None None O
isolated None None O
both None None O
from None None O
animal None None O
and None None O
human None None O
platelets None None O
and None None O
have None None O
been None None O
termed None None O
platelets None None O
microbicidal None None O
proteins None None O
( None None O
PMP None None O
) None None O
. None None O

Over None None O
the None None O
last None None O
few None None O
decades None None O
, None None O
increasing None None O
attention None None I-FUNC
has None None O
been None None O
paid None None O
to None None O
understanding None None O
the None None O
pathophysiology None None O
, None None O
aetiology None None O
, None None O
prognosis None None O
, None None O
and None None O
treatment None None O
of None None O
elevated None None O
intra-abdominal None None O
pressure None None O
( None None O
IAP None None O
) None None O
in None None O
trauma None None O
, None None O
surgical None None O
, None None O
and None None O
medical None None O
patients None None O
. None None O

Endolysins None None O
are None None O
lytic None None O
enzymes None None I-PROTEIN
encoded None None O
by None None O
bacteriophage None None O
that None None O
represent None None O
an None None O
emerging None None O
class None None O
of None None O
protein None None O
therapeutics None None O
. None None O

The None None O
deduced None None O
MSTN None None O
sequence None None O
contained None None O
functional None None O
sites None None O
similar None None O
to None None O
other None None O
members None None O
of None None O
TGF-β None None O
superfamily None None O
, None None O
including None None O
the None None O
proteolytic None None O
processing None None O
site None None O
and None None O
nine None None O
conserved None None O
cysteines None None I-TRANS
in None None O
the None None O
C-terminal None None O
. None None O

Plasma None None O
lysozyme None None I-PROTEIN
and None None O
alternative None None O
complement None None O
pathway None None O
( None None O
ACH50 None None O
) None None O
activities None None O
as None None O
well None None O
as None None O
nitrogen None None I-TRANS
monoxide None None I-TRANS
( None None O
NO None None O
) None None O
levels None None O
all None None O
increased None None O
significantly None None O
with None None O
the None None O
maximum None None O
levels None None O
being None None O
attained None None O
at None None O
6 None None O
, None None O
6 None None O
and None None O
3 None None O
h None None O
, None None O
respectively None None O
. None None O

Presenting None None O
symptoms None None O
were None None O
predominantly None None O
weight None None O
loss None None O
and None None O
back None None O
pain None None O
with None None O
markedly None None O
elevated None None O
serum None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
median None None O
= None None O
1231 None None O
IU/ml None None O
) None None O
. None None O

The None None O
RPE None None O
cells None None O
exposed None None O
to None None O
to None None O
200 None None O
mM None None O
H2O2 None None O
demonstrated None None O
a None None O
significant None None O
depression None None I-DISEASE
in None None O
the None None O
cell None None O
viability None None O
; None None O
whereas None None O
pre-treatment None None O
with None None O
50 None None O
and None None O
100 None None O
mmol/l None None O
wogonin None None O
could None None O
significantly None None O
improve None None O
the None None O
cell None None O
viability None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
. None None O

In None None O
the None None O
frame None None O
of None None O
the None None O
international None None O
consortium None None O
carrying None None O
out None None O
this None None O
project None None O
our None None O
team None None O
studied None None O
the None None O
genes None None O
encoding None None I-FUNC
families None None O
of None None O
non-coding None None O
RNAs None None O
( None None O
ncRNAs None None O
) None None O
, None None O
concentrating None None O
on None None O
four None None O
classes None None O
: None None O
microRNA None None O
( None None O
miRNA None None O
) None None O
, None None O
ribosomal None None O
RNA None None O
( None None O
rRNA None None O
) None None O
, None None O
small None None O
nuclear None None O
RNA None None O
( None None O
snRNA None None O
) None None O
, None None O
and None None O
in None None O
particular None None O
small None None O
nucleolar None None O
RNA None None O
( None None O
snoRNA None None O
) None None O
and None None O
, None None O
finally None None O
, None None O
transfer None None O
RNA None None O
( None None O
tRNA None None O
) None None O
. None None O

Theoretical None None O
reasoning None None I-FUNC
regarding None None O
the None None O
likely None None O
behavioral None None O
response None None O
to None None O
frequent None None O
measurement None None O
correctly None None O
predicts None None O
domains None None O
most None None O
vulnerable None None O
to None None O
this None None O
possibility None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
while None None O
we None None O
conceptualize None None O
gender None None O
as None None O
a None None O
social None None O
structure None None O
, None None O
we None None O
focus None None O
only None None O
on None None O
the None None O
individual None None O
level None None O
of None None O
analysis None None O
: None None O
testing None None O
the None None O
relative None None O
strength None None O
of None None O
( None None O
maternal None None O
circulating None None O
) None None O
prenatal None None O
hormones None None I-PROTEIN
, None None O
childhood None None O
socialization None None O
, None None O
and None None O
the None None O
power None None O
of None None O
expectations None None O
attached None None O
to None None O
adult None None O
social None None O
roles None None O
( None None O
cultural None None O
interactionist None None O
) None None O
as None None O
explanations None None O
for None None O
women None None O
's None None O
self-reported None None O
feminine None None O
and None None O
masculine None None O
selves None None O
. None None O

Prenatal None None O
hormones None None I-PROTEIN
, None None O
childhood None None O
socialization None None O
, None None O
and None None O
cultural None None O
interactionism None None O
were None None O
all None None O
influential None None O
factors None None O
for None None O
gendered None None O
selves None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
study None None O
is None None O
to None None O
investigate None None O
whether None None O
speaking None None O
other None None O
than None None O
home None None O
languages None None I-FUNC
in None None O
Sub-Saharan None None O
Africa None None O
promotes None None O
generalized None None O
trust None None O
. None None O

Relying None None O
on None None O
data None None O
from None None O
the None None O
Afrobarometer None None O
Project None None O
, None None O
which None None O
provides None None O
information None None O
on None None O
home None None O
and None None O
additional None None O
languages None None I-FUNC
, None None O
the None None O
Index None None O
of None None O
Communication None None O
Potential None None O
( None None O
ICP None None O
) None None O
is None None O
introduced None None O
to None None O
capture None None O
the None None O
linguistic None None O
situation None None O
in None None O
the None None O
20 None None O
sample None None O
countries None None O
. None None O

Results None None O
reveal None None O
that None None O
human None None O
capital None None O
, None None O
migration None None O
background None None O
, None None O
religiosity None None O
, None None O
cultural None None O
values None None O
, None None O
and None None O
perceptions None None I-FUNC
of None None O
discrimination None None O
jointly None None O
account None None O
for None None O
about None None O
40 None None O
% None None O
of None None O
the None None O
employment None None O
variance None None O
between None None O
Muslims None None O
and None None O
non-Muslims None None O
. None None O

This None None O
work None None O
examines None None O
connections None None O
between None None O
two None None O
threads None None O
of None None O
community None None O
residents None None O
' None None O
perceptions None None I-FUNC
of None None O
local None None O
police None None O
legitimacy None None O
, None None O
effectiveness None None O
and None None O
procedural None None O
fairness None None O
, None None O
and None None O
how None None O
those None None O
links None None O
depend None None O
on None None O
race None None O
, None None O
place None None O
, None None O
and None None O
race/place None None O
combinations None None O
. None None O

Further None None O
, None None O
child-reported None None O
protective None None O
factors None None O
of None None O
self-efficacy None None O
, None None O
positive None None O
family None None O
climate None None O
and None None O
social None None O
support None None O
were None None O
associated None None O
with None None O
less None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
baseline None None O
. None None O

Finally None None O
, None None O
family None None O
climate None None O
and None None O
social None None O
support None None O
moderated None None O
the None None O
detrimental None None O
influence None None O
of None None O
parental None None O
psychopathology None None O
on None None O
child None None O
's None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

No None None O
limitations None None O
were None None O
placed None None O
on None None O
length None None O
of None None O
follow-up None None O
, None None O
publication None None O
year None None O
, None None O
or None None O
language None None I-FUNC
. None None O

GABAergic None None O
receptor None None I-PROTEIN
abnormalities None None O
have None None O
been None None O
documented None None O
in None None O
several None None O
major None None O
psychiatric None None O
disorders None None O
including None None O
schizophrenia None None I-DISEASE
, None None O
mood None None I-DISEASE
disorders None None I-DISEASE
, None None O
and None None O
autism None None O
. None None O

FMRP None None O
acts None None O
as None None O
a None None O
translational None None O
repressor None None O
and None None O
, None None O
under None None O
normal None None O
conditions None None O
, None None O
inhibits None None O
metabotropic None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
5 None None O
( None None O
mGluR5 None None O
) None None O
-mediated None None O
signaling None None O
. None None O

Our None None O
laboratory None None O
has None None O
identified None None O
changes None None O
in None None O
mGluR5 None None O
expression None None O
in None None O
autism None None O
, None None O
schizophrenia None None I-DISEASE
, None None O
and None None O
mood None None I-DISEASE
disorders None None I-DISEASE
. None None O

Neurocognitive None None O
deficits None None O
in None None O
schizophrenia None None I-DISEASE
( None None O
SZ None None O
) None None O
are None None O
established None None O
and None None O
the None None O
Consortium None None O
on None None O
the None None O
Genetics None None O
of None None O
Schizophrenia None None I-DISEASE
( None None O
COGS None None O
) None None O
investigated None None O
such None None O
measures None None O
as None None O
endophenotypes None None O
in None None O
family-based None None O
( None None O
COGS-1 None None O
) None None O
and None None O
case-control None None O
( None None O
COGS-2 None None O
) None None O
studies None None O
. None None O

Better None None O
performance None None O
was None None O
most None None O
pronounced None None O
for None None O
spatial None None O
processing None None O
while None None O
emotion None None I-FUNC
identification None None O
had None None O
large None None O
effect None None O
sizes None None O
for None None O
both None None O
accuracy None None O
and None None O
speed None None O
in None None O
both None None O
samples None None O
. None None O

pain None None O
not None None O
controlled None None O
with None None O
analgesia None None O
( None None O
6.7 None None O
% None None O
) None None O
, None None O
hemarthrosis None None O
that None None O
required None None O
arthrocentesis None None O
( None None O
4.4 None None O
% None None O
) None None O
, None None O
fever None None O
( None None O
3.2 None None O
% None None O
) None None O
, None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
( None None O
0.6 None None O
% None None O
) None None O
, None None O
cellulitis None None O
( None None O
0.6 None None O
% None None O
) None None O
, None None O
septic None None O
arthritis None None O
that None None O
required None None O
arthroscopic None None O
debridement None None O
( None None O
0.3 None None O
% None None O
) None None O
, None None O
and None None O
others None None O
( None None O
1.2 None None O
% None None O
) None None O
including None None O
problems None None O
with None None O
immobilization None None O
. None None O

Serious None None O
complications None None O
( None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
, None None O
septic None None O
arthritis None None O
or None None O
need None None O
for None None O
hospital None None O
readmission None None O
) None None O
were None None O
rare None None O
. None None O

With None None O
an None None O
increased None None O
level None None O
of None None O
awareness None None O
of None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
among None None O
the None None O
public None None O
, None None O
there None None O
has None None O
been None None O
an None None O
increase None None O
in None None O
requests None None O
for None None O
sleep None None O
studies None None O
, None None O
and None None O
consequently None None O
, None None O
more None None O
referrals None None O
made None None O
to None None O
sleep None None O
specialists None None O
by None None O
primary None None O
care None None O
physicians None None O
and None None O
other None None O
health None None O
care None None O
providers None None O
. None None O

This None None O
will None None O
facilitate None None O
better None None O
understanding None None O
and None None O
management None None O
of None None O
patients None None O
with None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
and None None O
related None None O
complications None None O
. None None O

Transthyretin None None O
cardiac None None O
amyloidosis None None O
, None None O
particularly None None O
the None None O
type None None O
caused None None O
by None None O
the None None O
mutation None None O
that None None O
replaces None None O
the None None O
amino None None O
acid None None O
valine None None I-TRANS
with None None O
the None None O
amino None None O
acid None None O
isoleucine None None I-TRANS
at None None O
position None None O
122 None None O
( None None O
Val122Ile None None O
) None None O
, None None O
is None None O
most None None O
common None None O
among None None O
African- None None O
Americans None None O
above None None O
65 None None O
years None None O
of None None O
age None None O
. None None O

The None None O
most None None O
frequent None None O
grade-3 None None O
or None None O
grade-4 None None O
adverse None None O
events None None O
were None None O
elevation None None O
of None None O
serum None None O
alanine None None I-TRANS
( None None O
23 None None O
% None None O
) None None O
and None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
20 None None O
% None None O
) None None O
, None None O
and None None O
thrombocytopenia None None O
( None None O
17 None None O
% None None O
) None None O
. None None O

In None None O
liquid None None O
cultures None None O
of None None O
the None None O
fungus None None O
, None None O
tryptophan None None I-TRANS
was None None O
identified None None O
. None None O

Since None None O
Monsanto None None O
developed None None O
the None None O
commercial None None O
process None None O
for None None O
L-DOPA None None I-TRANS
synthesis None None O
for None None O
the None None O
first None None O
time None None O
, None None O
most None None O
of None None O
currently None None O
supplied None None O
L-DOPA None None I-TRANS
has None None O
been None None O
produced None None O
by None None O
the None None O
asymmetric None None O
method None None O
, None None O
especially None None O
asymmetric None None O
hydrogenation None None O
. None None O

Accordingly None None O
, None None O
alternative None None O
biotechnological None None O
approaches None None O
have None None O
been None None O
researched None None O
for None None O
overcoming None None O
the None None O
shortcomings None None O
: None None O
microbial None None O
fermentation None None O
using None None O
microorganisms None None O
with None None O
tyrosinase None None I-PROTEIN
, None None O
tyrosine None None I-TRANS
phenol-lyase None None O
, None None O
or None None O
p-hydroxyphenylacetate None None O
3-hydroxylase None None O
activity None None O
and None None O
enzymatic None None O
conversion None None O
by None None O
immobilized None None O
tyrosinase None None I-PROTEIN
. None None O

Furthermore None None O
, None None O
we None None O
suggest None None O
the None None O
future None None O
potential None None O
of None None O
biotechnological None None O
L-DOPA None None I-TRANS
production None None O
as None None O
an None None O
industrial None None O
process None None O
. None None O

low-medium-high None None O
) None None O
, None None O
however None None O
, None None O
propensity None None O
score None None O
inference None None I-FUNC
requires None None O
extensions None None O
which None None O
have None None O
received None None O
limited None None O
attention None None I-FUNC
. None None O

The None None O
first None None O
two None None O
are None None O
structurally None None O
related None None O
kinases None None I-PROTEIN
whereas None None O
the None None O
third None None O
one None None O
is None None O
a None None O
regulatory None None O
subunit None None O
exhibiting None None O
affinity None None O
for None None O
upstream None None O
activators None None O
modified None None O
by None None O
polyubiquitin None None O
chains None None O
. None None O

This None None O
family None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
is None None O
characterized None None O
by None None O
their None None O
DNA-binding None None O
homeodomain None None O
and None None O
some None None O
members None None O
, None None O
including None None O
Engrailed None None O
, None None O
can None None O
transfer None None O
between None None O
cells None None O
and None None O
regulate None None O
protein None None O
translation None None O
in None None O
addition None None O
to None None O
gene None None O
transcription None None O
. None None O

Early None None O
expression None None O
of None None O
Engrailed None None O
in None None O
dorsal None None I-NEURON
mesencephalon None None I-REGION
contributes None None O
to None None O
the None None O
development None None O
and None None O
organization None None O
of None None O
a None None O
visual None None O
structure None None O
, None None O
the None None O
optic None None O
tectum/superior None None I-REGION
colliculus None None I-REGION
. None None O

Engrailed None None O
regulates None None O
the None None O
expression None None O
of None None O
Ephrin None None O
axon None None O
guidance None None O
cues None None O
in None None O
the None None O
tectum/superior None None I-REGION
colliculus None None I-REGION
. None None O

The None None O
2-year None None O
incidence None None O
of None None O
death None None O
, None None O
infarction None None O
, None None O
and None None O
target None None O
lesion None None O
revascularization None None O
was None None O
14.9 None None O
% None None O
for None None O
paclitaxel-eluting None None O
stents None None O
and None None O
11.5 None None O
% None None O
for None None O
everolimus-eluting None None O
stents None None O
( None None O
P None None O
= None None O
.04 None None O
) None None O
and None None O
the None None O
incidence None None O
of None None O
definite/probable None None O
thrombosis None None I-DISEASE
4.3 None None O
% None None O
and None None O
1.4 None None O
% None None O
, None None O
respectively None None O
( None None O
P None None O
= None None O
.01 None None O
) None None O
. None None O

The None None O
benefit None None O
of None None O
everolimus-eluting None None O
stents None None O
over None None O
paclitaxel-eluting None None O
stents None None O
regarding None None O
stent None None O
thrombosis None None I-DISEASE
was None None O
more None None O
evident None None O
in None None O
the None None O
nonthrombectomy None None O
subgroup None None O
( None None O
5.4 None None O
% None None O
vs None None O
1.4 None None O
% None None O
; None None O
P None None O
= None None O
.01 None None O
) None None O
. None None O

The None None O
last None None O
2 None None O
decades None None O
represent None None O
a None None O
period None None O
of None None O
unparalleled None None O
advancement None None O
in None None O
the None None O
understanding None None O
of None None O
the None None O
pathogenesis None None O
of None None O
Parkinson None None I-DISEASE
disease None None O
( None None O
PD None None O
) None None O
. None None O

Atypical None None O
parkinsonism None None O
comprises None None O
typically None None O
progressive None None I-DISEASE
supranuclear None None I-DISEASE
palsy None None I-DISEASE
, None None O
corticobasal None None O
degeneration None None O
, None None O
and None None O
mutilple None None O
system None None O
atrophy None None O
, None None O
which None None O
are None None O
distinct None None O
pathologic None None O
entities None None O
; None None O
despite None None O
ongoing None None O
research None None O
, None None O
their None None O
cause None None O
and None None O
pathophysiology None None O
are None None O
still None None O
unknown None None O
, None None O
and None None O
there None None O
are None None O
no None None O
biomarkers None None O
or None None O
effective None None O
treatments None None O
available None None O
. None None O

Tremor None None O
is None None O
a None None O
hyperkinetic None None O
movement None None I-FUNC
disorder None None O
characterized None None O
by None None O
rhythmic None None O
oscillations None None O
of None None O
one None None O
or None None O
more None None O
body None None O
parts None None O
. None None O

Essential None None I-DISEASE
tremor None None I-DISEASE
and None None O
parkinsonian None None O
tremor None None O
are None None O
the None None O
most None None O
common None None O
etiologic None None O
subtypes None None O
. None None O

Gilles None None I-DISEASE
de None None I-DISEASE
la None None I-DISEASE
Tourette None None I-DISEASE
syndrome None None I-DISEASE
is None None O
a None None O
common None None O
neuropsychiatric None None O
disorder None None O
spectrum None None O
with None None O
tics None None O
as None None O
the None None O
defining None None O
feature None None O
. None None O

The None None O
dystonias None None O
are None None O
a None None O
group None None O
of None None O
disorders None None O
characterized None None O
by None None O
excessive None None O
involuntary None None O
muscle None None O
contractions None None O
leading None None O
to None None O
abnormal None None O
postures None None O
and/or None None O
repetitive None None O
movements None None I-FUNC
. None None O

However None None O
, None None O
movement None None I-FUNC
disorders None None O
caused None None O
by None None O
other None None O
drugs None None O
are None None O
also None None O
briefly None None O
discussed None None O
. None None O

Although None None O
subgroups None None O
of None None O
these None None O
diseases None None O
lead None None O
to None None O
regional None None O
brain None None O
metal None None O
accumulation None None O
, None None O
mostly None None O
in None None O
globus None None I-REGION
pallidus None None I-REGION
, None None O
which None None O
is None None O
susceptible None None O
to None None O
accumulate None None O
divalent None None O
metal None None O
ions None None O
, None None O
other None None O
subgroups None None O
cause None None O
systemic None None O
metal None None O
accumulation None None O
affecting None None O
the None None O
whole None None O
brain None None O
, None None O
liver None None O
, None None O
and None None O
other None None O
parenchymal None None O
organs None None O
. None None O

At None None O
times None None O
, None None O
however None None O
, None None O
movement None None I-FUNC
disorders None None O
can None None O
be None None O
the None None O
initial None None O
manifestation None None O
of None None O
a None None O
systemic None None O
disease None None O
. None None O

We None None O
conclude None None O
that None None O
afferents None None O
from None None O
the None None O
scalene None None O
muscles None None O
and None None O
diaphragm None None I-REGION
are None None O
insufficient None None O
in None None O
most None None O
subjects None None O
with None None O
SCI None None O
to None None O
evoke None None O
the None None O
usual None None O
inhibition None None O
to None None O
airway None None O
occlusion None None O
and None None O
that None None O
input None None O
from None None O
chest None None O
wall None None O
afferents None None O
below None None O
the None None O
spinal None None O
cord None None O
lesion None None O
may None None O
be None None O
important None None O
for None None O
genesis None None O
of None None O
the None None O
short-latency None None O
inhibition None None O
in None None O
the None None O
able-bodied None None O
subjects None None O
. None None O

The None None O
additional None None O
steps None None O
to None None O
express None None O
and None None O
purify None None O
the None None O
Cse3 None None O
endonuclease None None I-PROTEIN
are None None O
detailed None None O
. None None O

The None None O
convertible None None O
nucleoside None None O
approach None None O
enables None None O
the None None O
attachment None None O
of None None O
nitroxyls None None O
as None None O
paramagnetic None None O
reporters None None O
at None None O
the None None O
exocyclic None None O
amino None None O
groups None None O
of None None O
cytidine None None O
, None None O
adenosine None None I-TRANS
, None None O
and None None O
guanosine None None O
nucleobases None None O
in None None O
synthetic None None O
RNA None None O
. None None O

RNA None None O
and None None O
DNA None None O
carry None None O
out None None O
diverse None None O
functions None None O
in None None O
biology None None O
including None None O
catalysis None None O
, None None O
splicing None None O
, None None O
gene None None O
regulation None None O
, None None O
and None None O
storage None None I-FUNC
of None None O
genetic None None O
information None None O
. None None O

We None None O
pay None None O
particular None None O
attention None None I-FUNC
to None None O
practical None None O
aspects None None O
of None None O
these None None O
studies None None O
, None None O
such None None O
as None None O
careful None None O
preparation None None O
of None None O
samples None None O
with None None O
fixed None None O
free None None O
concentrations None None O
of None None O
cations None None O
in None None O
order None None O
to None None O
avoid None None O
errors None None O
due None None O
to None None O
ion None None O
depletion None None O
effects None None O
that None None O
are None None O
common None None O
in None None O
RNA None None O
systems None None O
. None None O

AdoCbl None None O
( None None O
adenosyl None None O
cobalamin None None O
, None None O
coenzyme None None O
B12 None None O
) None None O
riboswitches None None O
regulate None None O
the None None O
expression None None O
of None None O
enzymes None None I-PROTEIN
and None None O
transporters None None I-PROTEIN
involved None None O
in None None O
bacterial None None O
AdoCbl None None O
biosynthesis None None O
or None None O
uptake None None O
on None None O
a None None O
transcriptional None None O
and/or None None O
translational None None O
level None None O
. None None O

Having None None O
multiple None None O
pregnancies None None O
increases None None O
the None None O
risk None None O
of None None O
HCV-related None None O
HCC None None O
among None None O
Egyptian None None O
women None None O
, None None O
raising None None O
questions None None O
about None None O
the None None O
roles None None O
of None None O
estrogens None None I-PROTEIN
and None None O
other None None O
pregnancy-related None None O
hormones None None I-PROTEIN
in None None O
modulating None None O
HCV None None O
infection None None O
and None None O
its None None O
progression None None O
to None None O
HCC None None O
. None None O

The None None O
basal None None I-REGION
ganglia None None I-REGION
of None None O
the None None O
laboratory None None O
rat None None O
consist None None O
of None None O
a None None O
few None None O
core None None O
regions None None O
that None None O
are None None O
specifically None None O
interconnected None None O
by None None O
efferents None None O
and None None O
afferents None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

The None None O
connectome None None O
data None None O
of None None O
this None None O
meta-study None None O
of None None O
tract-tracing None None O
reports None None O
of None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
are None None O
available None None O
for None None O
further None None O
network None None O
studies None None O
, None None O
the None None O
integration None None O
into None None O
neocortical None None O
connectomes None None O
and None None O
further None None O
extensive None None O
investigations None None O
of None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
dynamics None None O
in None None O
population None None O
simulations None None O
. None None O

An None None O
important None None O
neurodevelopmental None None O
process None None O
during None None O
this None None O
postnatal None None O
period None None O
is None None O
the None None O
maturation None None O
of None None O
the None None O
myelinated None None O
white None None I-REGION
matter None None I-REGION
, None None O
which None None O
facilitates None None O
rapid None None O
communication None None O
across None None O
neural None None O
systems None None O
and None None O
networks None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
profile None None O
of None None O
white None None I-REGION
matter None None I-REGION
myelination None None O
across None None O
the None None O
first None None O
5 None None O
years None None O
of None None O
life None None O
is None None O
strongly None None O
and None None O
specifically None None O
related None None O
to None None O
cognitive None None O
ability None None O
. None None O

By None None O
evaluating None None O
the None None O
neural None None O
networks None None O
subserving None None O
numerical None None O
cognition None None O
in None None O
two None None O
specific None None O
and None None O
substantially None None O
different None None O
numerical None None O
tasks None None O
with None None O
regard None None O
to None None O
both None None O
grey None None I-REGION
matter None None I-REGION
localizations None None O
as None None O
well None None O
as None None O
white None None I-REGION
matter None None I-REGION
tracts None None O
we None None O
( None None O
1 None None O
) None None O
considered None None O
the None None O
possibility None None O
of None None O
additional None None O
memory-related None None O
cortex None None O
areas None None O
crucial None None O
for None None O
arithmetic None None O
fact None None O
retrieval None None O
( None None O
e.g. None None O
, None None O
the None None O
hippocampus None None I-REGION
) None None O
; None None O
( None None O
2 None None O
) None None O
specified None None O
the None None O
functional None None O
involvement None None O
of None None O
prefrontal None None O
areas None None O
in None None O
number None None O
magnitude None None O
processing None None O
, None None O
and None None O
, None None O
finally None None O
; None None O
( None None O
3 None None O
) None None O
identified None None O
the None None O
connections None None O
between None None O
these None None O
anatomo-functional None None O
instantiations None None O
of None None O
the None None O
representations None None O
involved None None O
in None None O
number None None O
magnitude None None O
processing None None O
and None None O
arithmetic None None O
fact None None O
retrieval None None O
employing None None O
probabilistic None None O
fiber None None O
tracking None None O
. None None O

Activity None None O
of None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ALP None None O
) None None O
, None None O
an None None O
early None None O
osteogenesis None None O
marker None None O
, None None O
was None None O
increased None None O
in None None O
the None None O
co-culture None None O
system None None O
compared None None O
to None None O
the None None O
control None None O
single None None O
cultures None None O
, None None O
which None None O
we None None O
also None None O
confirmed None None O
by None None O
ALP None None O
staining None None O
. None None O

Included None None O
diseases None None O
are None None O
ischemic None None O
heart None None O
disease None None O
, None None O
stroke None None I-DISEASE
, None None O
hypertension None None O
, None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
, None None O
colorectal None None O
cancer None None O
, None None O
postmenopausal None None O
breast None None O
cancer None None O
, None None O
endometrial None None O
cancer None None O
, None None O
kidney None None O
cancer None None O
and None None O
osteoarthritis None None O
. None None O

Overexpression None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
, None None O
an None None O
ErbB None None O
family None None O
member None None O
, None None O
is None None O
associated None None O
with None None O
poor None None O
prognosis None None O
in None None O
HNSCC None None O
. None None O

The None None O
first None None O
enzymes None None I-PROTEIN
GTP None None I-PROTEIN
cyclohydrolase None None I-PROTEIN
I None None I-PROTEIN
( None None O
GTPCHI None None O
) None None O
and None None O
aminodeoxychorismate None None O
synthase None None O
( None None O
ADCS None None O
) None None O
in None None O
the None None O
pterin None None O
and None None O
para-aminobenzoate None None O
branches None None O
resulted None None O
in None None O
significant None None O
increase None None O
in None None O
seed None None O
folate None None O
content None None O
, None None O
respectively None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

The None None O
INU1 None None O
gene None None O
encoding None None I-FUNC
an None None O
exo-inulinase None None O
from None None O
the None None O
marine-derived None None O
yeast None None O
Candida None None O
membranifaciens None None O
subsp None None O
. None None O

It None None O
had None None O
an None None O
open None None O
reading None None O
frame None None O
of None None O
1,536 None None O
bp None None O
long None None O
encoding None None I-FUNC
an None None O
inulinase None None O
. None None O

The None None O
cloned None None O
gene None None O
encoded None None O
512 None None O
amino None None O
acid None None O
residues None None O
of None None O
a None None O
protein None None O
with None None O
a None None O
putative None None O
signal None None O
peptide None None O
of None None O
23 None None O
amino None None I-TRANS
acids None None I-TRANS
and None None O
a None None O
calculated None None O
molecular None None O
mass None None O
of None None O
57.8 None None O
kDa None None O
. None None O

Several None None O
stroke None None I-DISEASE
impairment None None O
scales None None O
are None None O
currently None None O
available None None O
for None None O
stroke None None I-DISEASE
patients None None O
but None None O
none None None O
of None None O
them None None O
provide None None O
information None None O
regarding None None O
the None None O
pre-stroke None None O
behavioral None None O
intentions None None O
of None None O
high-risk None None O
stroke None None I-DISEASE
patients None None O
and None None O
their None None O
relatives None None O
. None None O

It None None O
is None None O
suitable None None O
for None None O
use None None O
with None None O
high-risk None None O
stroke None None I-DISEASE
patients None None O
and None None O
their None None O
relatives None None O
to None None O
predict None None O
the None None O
likelihood None None O
of None None O
pre-hospital None None O
delay None None O
. None None O

We None None O
interviewed None None O
ten None None O
stroke None None I-DISEASE
patients None None O
in None None O
a None None O
semi-structured None None O
iterative None None O
process None None O
that None None O
included None None O
interviews None None O
with None None O
experts None None O
, None None O
high-risk None None O
patients None None O
, None None O
and None None O
their None None O
family None None O
members None None O
. None None O

We None None O
identified None None O
five None None O
sub-domains None None O
( None None O
stroke None None I-DISEASE
warning None None O
signs None None O
, None None O
non-treatment None None O
justification None None O
, None None O
symptom None None O
attributions None None O
, None None O
habitual None None O
response None None O
style None None O
, None None O
and None None O
emergency None None O
system None None O
use None None O
) None None O
. None None O

This None None O
SPDBI None None O
scale None None O
is None None O
a None None O
reliable None None O
, None None O
and None None O
valid None None O
measure None None O
of None None O
the None None O
likeliness None None O
of None None O
pre-hospital None None O
delay None None O
in None None O
high-risk None None O
stroke None None I-DISEASE
patients None None O
and None None O
their None None O
family None None O
members None None O
. None None O

This None None O
study None None O
presents None None O
ContextD None None O
, None None O
an None None O
adaptation None None O
of None None O
the None None O
English None None O
ConText None None O
algorithm None None O
to None None O
the None None O
Dutch None None O
language None None I-FUNC
, None None O
and None None O
a None None O
Dutch None None O
clinical None None O
corpus None None O
. None None O

Using None None O
a None None O
Dutch None None O
list None None O
of None None O
medical None None O
terms None None O
extracted None None O
from None None O
the None None O
Unified None None O
Medical None None O
Language None None I-FUNC
System None None O
, None None O
we None None O
identified None None O
medical None None O
terms None None O
in None None O
the None None O
corpus None None O
with None None O
exact None None O
matching None None O
. None None O

Analysis None None O
of None None O
the None None O
promoter None None O
of None None O
PHO84 None None O
encoding None None I-FUNC
a None None O
high None None O
affinity None None O
phosphate None None O
transporter None None O
, None None O
revealed None None O
that None None O
increased None None O
PHO84 None None O
RNA None None O
levels None None O
are None None O
caused None None O
by None None O
both None None O
increased None None O
Pho4-dependent None None O
transcription None None O
and None None O
decreased None None O
RNA None None O
turnover None None O
. None None O

Depression None None I-DISEASE
contributes None None O
negatively None None O
to None None O
health None None O
outcomes None None O
for None None O
both None None O
mothers None None O
and None None O
babies None None O
subsequent None None O
to None None O
stillbirth None None O
. None None O

Approximately None None O
88 None None O
% None None O
reported None None O
depression None None I-DISEASE
( None None O
i.e. None None O
, None None O
score None None O
of None None O
& None None O
gt None None O
; None None O
10 None None O
on None None O
depression None None I-DISEASE
scale None None O
) None None O
. None None O

Of None None O
those None None O
that None None O
reported None None O
using None None O
physical None None O
activity None None O
to None None O
cope None None O
after None None O
stillbirth None None O
, None None O
they None None O
did None None O
so None None O
to None None O
help None None O
with None None O
depression None None I-DISEASE
( None None O
58 None None O
% None None O
) None None O
, None None O
weight None None O
loss None None O
( None None O
55 None None O
% None None O
) None None O
, None None O
and None None O
better None None O
overall None None O
physical None None O
health None None O
( None None O
52 None None O
% None None O
) None None O
. None None O

Women None None O
who None None O
participated None None O
in None None O
physical None None O
activity None None O
after None None O
stillbirth None None O
reported None None O
significantly None None O
lower None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
M None None O
= None None O
15.10 None None O
, None None O
SD None None O
= None None O
5.32 None None O
) None None O
compared None None O
to None None O
women None None O
who None None O
did None None O
not None None O
participate None None O
in None None O
physical None None O
activity None None O
( None None O
M None None O
= None None O
18.06 None None O
, None None O
SD None None O
= None None O
5.57 None None O
; None None O
t None None O
= None None O
-3.45 None None O
, None None O
p None None O
= None None O
.001 None None O
) None None O
. None None O

It None None O
mainly None None O
affects None None O
the None None O
peripheral None None O
nervous None None O
system None None O
, None None O
skin None None O
, None None O
and None None O
certain None None O
other None None O
tissues None None O
such None None O
as None None O
the None None O
reticulo-endothelial None None O
system None None O
, None None O
bones None None O
and None None O
joints None None O
, None None O
mucous None None O
membranes None None O
, None None O
eyes None None O
, None None O
testes None None O
, None None O
muscles None None O
, None None O
and None None O
adrenals None None I-TRANS
. None None O

The None None O
dorsal None None I-NEURON
boundary None None O
of None None O
the None None O
DVC None None O
and None None O
the None None O
ventral None None I-NEURON
border None None O
of None None O
the None None O
SS None None O
were None None O
defined None None O
digitally None None O
. None None O

CUPF None None O
resembles None None O
type None None O
II None None O
A2 None None O
, None None O
Y-duplication None None O
described None None O
by None None O
Effmann None None O
but None None O
differs None None O
significantly None None O
because None None O
it None None O
has None None O
a None None O
normal None None O
functional None None O
dorsal None None I-NEURON
urethra None None O
and None None O
a None None O
ventral None None I-NEURON
hypoplastic None None O
accessory None None O
urethra None None O
. None None O

The None None O
25th None None O
case None None O
in None None O
English None None O
literature None None O
is None None O
reported None None O
with None None O
a None None O
review None None O
of None None O
literature None None O
; None None O
the None None O
addition None None O
of None None O
CUPF None None O
to None None O
Effmann None None O
classification None None O
as None None O
`` None None O
type None None O
II None None O
A2 None None O
, None None O
Y-hypoplastic None None O
ventral None None I-NEURON
urethra None None O
'' None None O
is None None O
proposed None None O
. None None O

Multiloculated None None O
hydrocephalus None None I-DISEASE
may None None O
occur None None O
as None None O
a None None O
consequence None None O
of None None O
intraventricular None None O
hemorrhage None None O
or None None O
infection None None O
and None None O
is None None O
characterized None None O
by None None O
enlargement None None O
of None None O
multiple None None O
noncommunicating None None O
intraventricular None None O
and/or None None O
periventricular None None O
cysts None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
endoscopic None None O
fenestration None None O
may None None O
be None None O
used None None O
as None None O
the None None O
initial None None O
approach None None O
for None None O
treatment None None O
of None None O
multiloculated None None O
hydrocephalus None None I-DISEASE
, None None O
with None None O
craniotomy None None O
and None None O
open None None O
fenestration None None O
used None None O
for None None O
more None None O
severe None None O
or None None O
refractory None None O
cases None None O
. None None O

These None None O
synthesized None None O
membranes None None O
were None None O
further None None O
cross-linked None None O
using None None O
different None None O
cross-linking None None O
agents None None O
for None None O
covalent None None O
immobilization None None O
of None None O
biological None None O
macromolecules None None O
especially None None O
enzymes None None I-PROTEIN
and None None O
in None None O
this None None O
study None None O
, None None O
Bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
and None None O
laccase None None I-PROTEIN
. None None O

The None None O
optimum None None O
temperature None None O
and None None O
pH None None O
were None None O
determined None None O
to None None O
be None None O
50 None None O
°C None None O
and None None O
pH None None O
3 None None O
, None None O
respectively None None O
, None None O
for None None O
both None None O
the None None O
free None None O
and None None O
the None None O
immobilized None None O
enzymes None None I-PROTEIN
. None None O

Moreover None None O
, None None O
species None None O
differences None None O
in None None O
adenosine None None I-TRANS
action None None O
were None None O
found None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
high None None O
adenosine None None I-TRANS
concentrations None None O
, None None O
other None None O
mechanisms None None O
are None None O
activated None None O
and None None O
glucose-induced None None O
insulin None None I-PROTEIN
secretion None None O
is None None O
increased None None O
. None None O

In None None O
mouse None None O
islets None None O
, None None O
low None None O
adenosine None None I-TRANS
concentrations None None O
do None None O
not None None O
significantly None None O
affect None None O
insulin None None I-PROTEIN
secretion None None O
. None None O

It None None O
is None None O
also None None O
known None None O
that None None O
upon None None O
stimulation None None O
of None None O
insulin None None I-PROTEIN
secretion None None O
, None None O
both None None O
rat None None O
and None None O
mouse None None O
islets None None O
release None None O
ATP None None O
. None None O

However None None O
, None None O
mouse None None O
islets None None O
are None None O
unable None None O
to None None O
convert None None O
extracellularly None None O
ATP None None O
to None None O
adenosine None None I-TRANS
and None None O
adenosine None None I-TRANS
arises None None O
from None None O
intracellular None None O
ATP None None O
degradation None None O
. None None O

Therefore None None O
, None None O
secretion None None O
systems None None O
or None None O
chaperone None None I-PROTEIN
proteins None None I-PROTEIN
are None None O
routinely None None O
used None None O
to None None O
assist None None O
in None None O
attaining None None O
high None None O
levels None None O
of None None O
functional None None O
, None None O
soluble None None O
protein None None O
production None None O
. None None O

In None None O
anticipation None None O
of None None O
utilizing None None O
periplasmic None None O
chaperone None None I-PROTEIN
proteins None None I-PROTEIN
to None None O
facilitate None None O
soluble None None O
production None None O
of None None O
immunomodulatory None None O
proteins None None O
in None None O
an None None O
attenuated None None O
strain None None O
of None None O
Salmonella None None O
Typhimurium None None O
, None None O
the None None O
production None None O
of None None O
the None None O
chaperones None None O
was None None O
tested None None O
for None None O
their None None O
effect None None O
on None None O
both None None O
culture None None O
growth None None O
and None None O
bacterial None None O
persistence None None O
in None None O
mouse None None O
tissues None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
in None None O
lung None None O
and None None O
caspase-3 None None O
expressions None None O
in None None O
spleen None None O
were None None O
significantly None None O
lower None None O
in None None O
the None None O
levosimendan-treated None None O
CLP None None O
group None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

( None None O
1 None None O
) None None O
Lower None None O
levels None None O
of None None O
interleukin-1β None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
and None None O
superoxide None None O
, None None O
( None None O
2 None None O
) None None O
attenuation None None O
of None None O
iNOS None None O
and None None O
caspase-3 None None O
expressions None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
decreases None None O
of None None O
neutrophil None None O
infiltration None None O
by None None O
levosimendan None None O
in None None O
peritonitis-induced None None O
sepsis None None O
animals None None O
suggest None None O
that None None O
anti-inflammation None None O
and None None O
anti-apoptosis None None O
effects None None O
of None None O
levosimendan None None O
contribute None None O
to None None O
prolonged None None O
survival None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
retrospective None None O
investigation None None O
is None None O
to None None O
characterize None None O
and None None O
illustrate None None O
the None None O
appearances None None O
of None None O
celiomesenteric None None O
trunk None None O
( None None O
CMT None None O
) None None O
and None None O
hepatosplenomesenteric None None O
trunk None None O
( None None O
HSMT None None O
) None None O
using None None O
CT None None O
with None None O
three-dimensional None None O
volume-rendering None None O
with None None O
attention None None I-FUNC
to None None O
the None None O
proximal None None O
branching None None O
patterns None None O
. None None O

Vasopressors None None O
include None None O
pure None None O
vasoconstrictors None None O
( None None O
phenylephrine None None O
and None None O
vasopressin None None I-TRANS
) None None O
and None None O
inoconstrictors None None O
( None None O
dopamine None None I-TRANS
, None None O
norepinephrine None None I-TRANS
, None None O
and None None O
epinephrine None None I-TRANS
) None None O
. None None O

Recent None None O
large-scale None None O
clinical None None O
trials None None O
have None None O
evaluated None None O
vasopressors None None O
and None None O
determined None None O
that None None O
norepinephrine None None I-TRANS
may None None O
be None None O
preferred None None O
as None None O
a None None O
first-line None None O
therapy None None O
for None None O
a None None O
broad None None O
range None None O
of None None O
shock None None O
states None None O
, None None O
most None None O
notably None None O
septic None None O
shock None None O
. None None O

Respondents None None O
reported None None O
their None None O
perceptions None None I-FUNC
of None None O
the None None O
usefulness None None O
of None None O
RCT None None O
HRQL None None O
outcomes None None O
for None None O
informing None None O
practice None None O
, None None O
their None None O
use None None O
of None None O
HRQL None None O
findings None None O
in None None O
practice None None O
, None None O
barriers/facilitators None None O
to None None O
this None None O
use None None O
, None None O
and None None O
preferences None None O
for None None O
HRQL None None O
data None None O
presentation None None O
in None None O
RCT None None O
publications None None O
. None None O

Oncologists None None O
support None None O
HRQL None None O
findings None None O
from None None O
RCTs None None O
, None None O
but None None O
perceive None None O
important None None O
barriers None None O
to None None O
their None None O
use None None O
in None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
regardless None None O
of None None O
country None None O
or None None O
specialty None None O
. None None O

At None None O
2 None None O
h None None O
after None None O
EA None None O
pretreatment None None O
, None None O
focal None None O
cerebral None None O
ischemic None None O
injury None None O
was None None O
induced None None O
by None None O
transient None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
for None None O
60 None None O
min None None O
in None None O
C57BL/6 None None O
mice None None O
. None None O

Transient None None O
focal None None O
cerebral None None O
ischemia None None O
in None None O
rat None None O
was None None O
induced None None O
with None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
. None None O

JWA None None O
( None None O
Arl6ip5 None None O
) None None O
, None None O
a None None O
homologous None None O
gene None None O
of None None O
glutamate-transporter-associated None None O
protein None None O
3-18 None None O
( None None O
GTRAP3-18 None None O
) None None O
and None None O
addicsin None None O
, None None O
is None None O
highly None None O
expressed None None O
in None None O
hippocampus None None I-REGION
. None None O

In None None O
addition None None O
, None None O
the None None O
increase None None O
of None None O
LTP None None O
amplitude None None O
and None None O
the None None O
decline None None O
of None None O
LTP None None O
threshold None None O
were None None O
observed None None O
in None None O
DG None None O
, None None O
but None None O
not None None O
in None None O
CA1 None None I-REGION
region None None O
, None None O
of None None O
JWA-nKO None None O
mice None None O
compared None None O
to None None O
control None None O
mice None None O
. None None O

We None None O
determined None None O
whether None None O
EE None None O
attenuated None None O
surgery-induced None None O
cognitive None None O
impairment None None O
and None None O
whether None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
and None None O
neurogenesis None None O
played None None O
a None None O
role None None O
in None None O
the None None O
EE None None O
effect None None O
. None None O

Their None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
were None None O
assessed None None O
by None None O
Barnes None None O
maze None None O
, None None O
and None None O
fear None None O
conditioning None None O
started None None O
2 None None O
weeks None None O
after None None O
the None None O
surgery None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
EE None None O
reduces None None O
surgery-induced None None O
impairment None None O
of None None O
learning None None I-FUNC
, None None O
memory None None I-FUNC
, None None O
and None None O
neurogenesis None None O
by None None O
preserving None None O
BDNF None None O
expression None None O
. None None O

The None None O
finding None None O
that None None O
mitochondria None None O
possess None None O
both None None O
a None None O
functional None None O
RAS None None O
and None None O
vitamin None None O
D None None O
receptors None None I-PROTEIN
is None None O
the None None O
starting None None O
point None None O
for None None O
improving None None O
our None None O
understanding None None O
of None None O
the None None O
interaction None None O
of None None O
mitochondria None None O
and None None O
chronic None None O
disease None None O
states None None O
, None None O
which None None O
understanding None None O
should None None O
lead None None O
to None None O
decreases None None O
in None None O
the None None O
chronic None None O
disease None None O
burden None None O
attributable None None O
to None None O
hypertension None None O
, None None O
diabetes None None O
, None None O
or None None O
both None None O
. None None O

This None None O
review None None O
will None None O
cover None None O
novel None None O
immune None None O
cell None None O
subtypes None None O
recently None None O
associated None None O
to None None O
the None None O
disease None None O
including None None O
the None None O
novel None None O
role None None O
of None None O
cytokines None None O
, None None O
toll-like None None O
receptors None None I-PROTEIN
, None None O
and None None O
inflammasomes None None O
in None None O
hypertension None None O
. None None O

Sleep None None O
disturbances None None O
are None None O
almost None None O
twice None None O
as None None O
common None None O
in None None O
women None None O
with None None O
PCOS None None O
compared None None O
with None None O
women None None O
of None None O
similar None None O
age None None O
without None None O
PCOS None None O
, None None O
with None None O
the None None O
association None None O
slightly None None O
accounted None None O
for None None O
by None None O
body None None O
weight None None O
and None None O
, None None O
to None None O
a None None O
greater None None O
extent None None O
, None None O
by None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

Poor None None O
sleep None None O
patterns None None O
increase None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
thus None None O
may None None O
exacerbate None None O
PCOS None None O
symptoms None None O
and None None O
longer-term None None O
risk None None O
of None None O
metabolic None None O
disease None None O
. None None O

Increasing None None O
occurrence None None O
of None None O
difficulty None None O
maintaining None None O
sleep None None O
( None None O
OR None None O
1.92 None None O
95 None None O
% None None O
CI None None O
1.12-3.31 None None O
) None None O
was None None O
mediated None None O
by None None O
obesity None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
together None None O
. None None O

Aromatase None None I-PROTEIN
is None None O
the None None O
key None None O
enzyme None None O
catalyzing None None O
estrogen None None O
biosynthesis None None O
and None None O
is None None O
overexpressed None None O
in None None O
endometriotic None None O
lesions None None O
. None None O

IGF1 None None O
increases None None O
apical None None O
fibronectin None None I-PROTEIN
on None None O
blastocysts None None O
to None None O
increase None None O
attachment None None O
and None None O
invasion None None O
in None None O
an None None O
in None None O
vitro None None O
model None None O
of None None O
implantation None None O
. None None O

Mouse None None O
blastocysts None None O
( None None O
hatched None None O
or None None O
near None None O
completion None None O
of None None O
hatching None None O
) None None O
were None None O
cultured None None O
in None None O
serum None None O
starved None None O
( None None O
SS None None O
) None None O
medium None None O
with None None O
varying None None O
treatments None None O
for None None O
24 None None O
, None None O
48 None None O
or None None O
72 None None O
h. None None O
Treatments None None O
included None None O
10 None None O
ng/ml None None O
IGF1 None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
the None None O
PI3 None None O
kinase None None O
inhibitor None None O
LY294002 None None O
, None None O
an None None O
IGF1 None None O
receptor None None I-PROTEIN
( None None O
IGF1R None None O
) None None O
neutralizing None None O
antibody None None O
or None None O
fibronectin None None I-PROTEIN
. None None O

Fibronectin None None I-PROTEIN
expression None None O
and None None O
localization None None O
in None None O
blastocysts None None O
was None None O
studied None None O
using None None O
immunofluorescence None None O
and None None O
confocal None None O
microscopy None None O
. None None O

This None None O
coincided None None O
with None None O
a None None O
significant None None O
increase None None O
in None None O
blastocyst None None O
outgrowth None None O
in None None O
the None None O
presence None None O
of None None O
IGF1 None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
or None None O
fibronectin None None I-PROTEIN
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
which None None O
was None None O
abolished None None O
by None None O
LY294002 None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

As None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
are None None O
absent None None O
during None None O
embryo None None O
culture None None O
, None None O
their None None O
addition None None O
to None None O
embryo None None O
culture None None O
medium None None O
is None None O
a None None O
potential None None O
avenue None None O
to None None O
improve None None O
IVF None None O
success None None O
. None None O

The None None O
personhood None None O
movement None None I-FUNC
in None None O
dementia None None I-DISEASE
research None None O
has None None O
established None None O
the None None O
theoretical None None O
foundation None None O
for None None O
implementing None None O
cultural None None O
arts None None O
interventions None None O
in None None O
care None None O
practices None None O
. None None O

I None None O
will None None O
argue None None O
that None None O
expanding None None O
on None None O
existing None None O
research None None O
on None None O
poetry None None O
interventions None None O
from None None O
a None None O
health None None O
and None None O
science None None O
perspective None None O
with None None O
a None None O
humanities None None O
approach None None O
will None None O
help None None O
illuminate None None O
how None None O
poetry None None O
works None None O
to None None O
enhance None None O
the None None O
exchange None None O
with None None O
people None None O
with None None O
dementia None None I-DISEASE
. None None O

An None None O
implementation None None O
protocol None None O
for None None O
doll None None O
therapy None None O
for None None O
those None None O
with None None O
dementia None None I-DISEASE
was None None O
developed None None O
and None None O
implemented None None O
with None None O
16 None None O
residents None None O
in None None O
a None None O
dementia None None I-DISEASE
care None None O
center None None O
. None None O

Backgrounds None None O
defined None None O
by None None O
single None None O
deletions None None O
of None None O
metabolically None None O
active None None O
enzymes None None I-PROTEIN
induce None None O
strong None None O
rewiring None None O
when None None O
the None None O
deletion None None O
corresponds None None O
to None None O
a None None O
catabolic None None O
gene None None O
, None None O
evidencing None None O
a None None O
broad None None O
redistribution None None O
of None None O
fluxes None None O
to None None O
alternative None None O
pathways None None O
. None None O

We None None O
searched None None O
PubMed None None O
, None None O
SCOPUS None None O
and None None O
Cochrane None None O
Central None None O
Register None None O
electronic None None O
databases None None O
through None None O
1 None None O
October None None O
2013 None None O
( None None O
including None None O
papers None None O
in None None O
press None None O
at None None O
that None None O
time None None O
) None None O
, None None O
without None None O
language None None I-FUNC
restrictions None None O
. None None O

Our None None O
observation None None O
suggests None None O
that None None O
MS None None O
diagnosis None None O
should None None O
be None None O
taken None None O
into None None O
consideration None None O
in None None O
case None None O
of None None O
cognitive None None O
dysfunction None None O
, None None O
particularly None None O
when None None O
associated None None O
with None None O
slowly None None O
progressive None None O
disease None None O
course None None O
and None None O
severe None None O
cortical None None O
, None None O
cerebellar None None O
and None None O
brainstem None None I-REGION
atrophy None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
other None None O
major None None O
neurological None None O
symptoms None None O
and None None O
signs None None O
. None None O

Understand None None O
the None None O
effect None None O
of None None O
focal None None O
optic None None I-REGION
nerve None None I-REGION
demyelination None None O
on None None O
neighboring None None O
white None None I-REGION
matter None None I-REGION
. None None O

DTI None None O
in None None O
ON None None O
provides None None O
fine None None O
in-vivo None None O
human None None O
model None None O
for None None O
studying None None O
histological None None O
abnormalities None None O
in None None O
normal None None O
appearing None None O
white None None I-REGION
matter None None I-REGION
, None None O
localized None None O
in None None O
close None None O
proximity None None O
to None None O
damaged None None O
bundle None None O
. None None O

Participants None None O
were None None O
administered None None O
affective None None O
trait None None O
measures None None O
( None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
, None None O
Beck None None O
Anxiety None None O
Inventory None None O
) None None O
and None None O
anger None None O
measures None None O
( None None O
the None None O
Spanish None None O
adapted None None O
version None None O
of None None O
the None None O
State-Trait None None O
Anger None None O
Expression None None O
Inventory-2 None None O
) None None O
. None None O

The None None O
binding None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
TFs None None O
) None None O
is None None O
essential None None O
for None None O
gene None None O
expression None None O
. None None O

Remarkably None None O
though None None O
, None None O
by None None O
introducing None None O
the None None O
action None None O
of None None O
topological None None O
enzymes None None I-PROTEIN
such None None O
as None None O
type None None O
I None None O
and None None O
II None None O
topoisomerase None None O
, None None O
most None None O
of None None O
these None None O
defects None None O
can None None O
be None None O
avoided None None O
and None None O
the None None O
result None None O
is None None O
an None None O
ordered None None O
10-nm None None O
chromatin None None O
fibre None None O
. None None O

The None None O
application None None O
of None None O
dynamic None None O
time None None O
warping None None O
( None None O
DTW None None O
) None None O
to None None O
the None None O
correction None None O
of None None O
retention None None I-FUNC
time None None O
shift None None O
in None None O
chromatographic None None O
fingerprints None None O
of None None O
Radix None None O
Puerariae None None O
thomsonii None None O
( None None O
RPT None None O
) None None O
was None None O
studied None None O
. None None O

Because None None O
there None None O
is None None O
retention None None I-FUNC
time None None O
shift None None O
in None None O
the None None O
obtained None None O
fingerprints None None O
, None None O
the None None O
quality None None O
of None None O
these None None O
samples None None O
can None None O
not None None O
be None None O
correctly None None O
evaluated None None O
by None None O
applying None None O
similarity None None O
estimation None None O
and None None O
principal None None O
component None None O
analysis None None O
( None None O
PCA None None O
) None None O
to None None O
the None None O
unaligned None None O
fingerprints None None O
. None None O

After None None O
alignment None None O
, None None O
the None None O
retention None None I-FUNC
time None None O
shift None None O
was None None O
corrected None None O
satisfactorily None None O
and None None O
the None None O
quality None None O
of None None O
these None None O
RPT None None O
samples None None O
was None None O
correctly None None O
evaluated None None O
. None None O

Infiltration None None O
of None None O
both None None O
an None None O
ATPase None None I-PROTEIN
inhibitor None None O
[ None None O
eosin None None O
B None None O
( None None O
EB None None O
) None None O
] None None O
and None None O
a None None O
sucrose None None O
transporter None None O
inhibitor None None O
[ None None O
p-chloromercuribenzene None None O
sulfonate None None O
( None None O
PCMBS None None O
) None None O
] None None O
inhibited None None O
sugar None None O
accumulation None None O
in None None O
the None None O
aril None None O
. None None O

Although None None O
facilitated None None O
diffusion None None O
might None None O
help None None O
sucrose None None O
uptake None None O
from None None O
the None None O
cytosol None None O
to None None O
the None None O
vacuole None None O
in None None O
cultivars None None O
with None None O
high None None O
soluble None None O
invertase None None O
, None None O
membrane None None O
ATPases None None I-PROTEIN
in None None O
the None None O
aril None None O
, None None O
especially None None O
tonoplast None None O
ATPase None None I-PROTEIN
, None None O
are None None O
crucial None None O
for None None O
aril None None O
sugar None None O
accumulation None None O
. None None O

There None None O
were None None O
strong None None O
associations None None O
with None None O
mental None None O
health None None O
admissions None None O
, None None O
especially None None O
dementia None None I-DISEASE
. None None O

The None None O
present None None O
study None None O
was None None O
undertaken None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
zinc None None I-TRANS
supplementation None None O
suppresses None None O
liver None None O
fibrosis None None O
. None None O

Zinc None None I-TRANS
supplementation None None O
was None None O
introduced None None O
4 None None O
weeks None None O
after None None O
BDL None None O
surgery None None O
via None None O
intragastric None None O
administration None None O
once None None O
daily None None O
for None None O
2 None None O
weeks None None O
resulting None None O
in None None O
a None None O
significant None None O
reduction None None O
in None None O
the None None O
collagen None None I-PROTEIN
deposition None None O
in None None O
the None None O
liver None None O
and None None O
an None None O
increase None None O
in None None O
the None None O
survival None None O
rate None None O
. None None O

Therefore None None O
, None None O
the None None O
results None None O
demonstrate None None O
that None None O
zinc None None I-TRANS
supplementation None None O
suppresses None None O
BDL-induced None None O
liver None None O
fibrosis None None O
through None None O
both None None O
inhibiting None None O
collagen None None I-PROTEIN
production None None O
and None None O
enhancing None None O
collagen None None I-PROTEIN
degradation None None O
. None None O

WW None None O
domain-containing None None O
oxidoreductase None None I-PROTEIN
( None None O
WWOX None None O
) None None O
is None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
, None None O
commonly None None O
downregulated None None O
in None None O
various None None O
types None None O
of None None O
tumors None None O
, None None O
including None None O
GBM None None O
. None None O

Of None None O
these None None O
enzymes None None I-PROTEIN
, None None O
PDE2 None None O
shapes None None O
β1 None None O
adrenoceptor-dependent None None O
cardiac None None O
cAMP None None O
signaling None None O
, None None O
both None None O
in None None O
the None None O
right None None O
and None None O
left None None O
ventricular None None O
myocardium None None O
, None None O
but None None O
its None None O
role None None O
in None None O
regulating None None O
β2 None None O
adrenoceptor-mediated None None O
responses None None O
is None None O
less None None O
well None None O
known None None O
. None None O

However None None O
, None None O
low None None O
retention None None I-FUNC
and None None O
survival None None O
of None None O
grafted None None O
MSCs None None O
hinder None None O
its None None O
further None None O
application None None O
. None None O

Development None None O
of None None O
optimal None None O
preventative None None O
and None None O
disease-modifying None None O
approaches None None O
for None None O
atherosclerosis None None I-DISEASE
in None None O
these None None O
patients None None O
will None None O
require None None O
close None None O
collaboration None None O
between None None O
basic None None O
scientists None None O
, None None O
CV None None O
specialists None None O
, None None O
and None None O
rheumatologists None None O
. None None O

When None None O
Notch None None O
signaling None None O
is None None O
activated None None O
, None None O
the None None O
γ-secretase None None O
complex None None O
releases None None O
the None None O
active None None O
intracellular None None O
domains None None O
( None None O
NICD None None O
) None None O
of None None O
their None None O
receptors None None I-PROTEIN
, None None O
which None None O
exert None None O
survival None None O
effects None None O
. None None O

Base None None O
excision None None O
repair None None O
( None None O
BER None None O
) None None O
pathway None None O
is None None O
considered None None O
the None None O
most None None O
active None None O
in None None O
zygotic None None O
DNA None None O
repair None None O
, None None O
but None None O
healthy None None O
oocytes None None O
contain None None O
enzymes None None I-PROTEIN
for None None O
all None None O
repairing None None O
pathways None None O
. None None O

Plant None None O
polyol None None O
dehydrogenases None None I-PROTEIN
are None None O
oxireductases None None O
that None None O
reversibly None None O
oxidize None None O
polyols None None O
into None None O
monosaccharides None None O
. None None O

Simultaneously None None O
, None None O
fructose None None O
reduction None None O
into None None O
polyols None None O
via None None O
mannitol None None O
and None None O
sorbitol None None O
dehydrogenases None None I-PROTEIN
was None None O
stimulated None None O
, None None O
contributing None None O
to None None O
their None None O
higher None None O
intracellular None None O
concentrations None None O
in None None O
water-deficit None None O
stress None None O
. None None O

We None None O
measured None None O
levels None None O
of None None O
serum None None O
antibodies None None O
against None None O
EBV None None O
antigens None None O
, None None O
including None None O
anti-viral None None O
capsid None None O
antigen None None O
( None None O
VCA None None O
) None None O
IgM None None O
, None None O
anti-VCA None None O
IgG None None O
, None None O
anti-early None None O
antigen None None O
( None None O
EA None None O
) None None O
IgM None None O
, None None O
anti-EA None None O
IgG None None O
and None None O
anti-EBV None None O
nuclear None None O
antigen-1 None None O
IgG None None O
, None None O
in None None O
50 None None O
patients None None O
with None None O
NMO None None I-TRANS
( None None O
including None None O
12 None None O
partial None None O
form None None O
with None None O
antiaquaporin None None O
4 None None O
antibodies None None O
) None None O
, None None O
51 None None O
patients None None O
with None None O
MS None None O
, None None O
and None None O
52 None None O
healthy None None O
controls None None O
, None None O
and None None O
cerebrospinal None None O
fluid None None O
( None None O
CSF None None O
) None None O
antibodies None None O
in None None O
37 None None O
patients None None O
with None None O
NMO None None I-TRANS
and None None O
33 None None O
patients None None O
with None None O
MS None None O
with None None O
ELISA None None O
. None None O

The None None O
antibody None None O
titres None None O
were None None O
significantly None None O
higher None None O
in None None O
the None None O
NMO None None I-TRANS
group None None O
than None None O
in None None O
the None None O
MS None None O
( None None O
p=0.005 None None O
) None None O
and None None O
control None None O
( None None O
p=0.005 None None O
) None None O
groups None None O
. None None O

Our None None O
results None None O
raise None None O
the None None O
hypothesis None None O
that None None O
persistent None None O
, None None O
active None None O
EBV None None O
replication None None O
is None None O
present None None O
in None None O
NMO None None I-TRANS
, None None O
and None None O
may None None O
contribute None None O
to None None O
the None None O
immunological None None O
alterations None None O
that None None O
play None None O
a None None O
pathogenetic None None O
role None None O
in None None O
the None None O
disorder None None O
. None None O

The None None O
outsourced None None O
HEPA None None O
programme None None O
had None None O
high None None O
retention None None I-FUNC
and None None O
reasonable None None O
adherence None None O
. None None O

Relationships None None O
between None None O
adherence None None O
to None None O
the None None O
programme None None O
components None None O
and None None O
response None None O
were None None O
not None None O
clear-cut None None O
and None None O
need None None O
further None None O
attention None None I-FUNC
. None None O

The None None O
records None None O
for None None O
90 None None O
consecutive None None O
patients None None O
with None None O
symptomatic None None O
cervical None None O
carotid None None I-DISEASE
artery None None I-DISEASE
stenosis None None I-DISEASE
treated None None O
by None None O
carotid None None O
endarterectomy None None O
( None None O
CEA None None O
) None None O
were None None O
analyzed None None O
retrospectively None None O
. None None O

CT None None O
angiography None None O
revealed None None O
that None None O
ulcer None None O
formation None None O
was None None O
significantly None None O
more None None O
common None None O
and None None O
the None None O
length None None O
of None None O
carotid None None I-DISEASE
artery None None I-DISEASE
stenosis None None I-DISEASE
was None None O
significantly None None O
greater None None O
in None None O
the None None O
octogenarians None None O
. None None O

The None None O
ventricular-peritoneal None None O
shunt None None O
for None None O
hydrocephalus None None I-DISEASE
is None None O
a None None O
well-known None None O
and None None O
established None None O
method None None O
but None None O
is None None O
sometimes None None O
complicated None None O
by None None O
shunt None None O
malfunction None None O
due None None O
to None None O
several None None O
causes None None O
. None None O

Retrosigmoid None None O
lateral None None O
suboccipital None None O
craniectomy None None O
was None None O
performed None None O
, None None O
and None None O
a None None O
soft None None O
yellowish None None O
mass None None O
was None None O
found None None O
to None None O
be None None O
associated None None O
with None None O
the None None O
5th None None O
, None None O
7th None None O
, None None O
and None None O
8th None None O
cranial None None I-REGION
nerves None None I-REGION
, None None O
anterior None None O
inferior None None O
cerebellar None None O
artery None None O
, None None O
and None None O
small None None O
vessels None None O
. None None O

Case None None O
1 None None O
was None None O
a None None O
48-year-old None None O
woman None None O
with None None O
left None None I-REGION
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
and None None O
amygdalar None None O
enlargement None None O
. None None O

Case None None O
2 None None O
was None None O
a None None O
36-year-old None None O
woman None None O
with None None O
multiple None None O
bilateral None None O
subependymal None None O
nodular None None O
heterotopias None None O
, None None O
who None None O
underwent None None O
resection None None O
of None None O
the None None O
left None None O
medial None None O
temporal None None I-REGION
lobe None None I-REGION
including None None O
subependymal None None O
nodular None None O
heterotopias None None O
adjacent None None O
to None None O
the None None O
left None None O
inferior None None O
horn None None O
. None None O

The None None O
article None None O
underscores None None O
the None None O
role None None O
of None None O
assessment None None O
scales None None O
to None None O
optimize None None O
behavioral None None O
management None None O
for None None O
patients None None O
with None None O
dementia None None I-DISEASE
and None None O
discusses None None O
the None None O
value None None O
of None None O
pain None None O
management None None O
to None None O
improve None None O
behavioral None None O
symptoms None None O
. None None O

Force None None O
production None None O
and None None O
maintenance None None O
in None None O
smooth None None O
muscle None None O
is None None O
largely None None O
controlled None None O
by None None O
myosin None None O
regulatory None None O
light None None O
chain None None O
( None None O
RLC None None O
) None None O
phosphorylation None None O
, None None O
which None None O
relies None None O
on None None O
a None None O
balance None None O
between None None O
Ca None None O
( None None O
2+ None None O
) None None O
/calmodulin-dependent None None O
myosin None None O
light None None O
chain None None O
kinase None None O
( None None O
MLCK None None O
) None None O
and None None O
myosin None None O
light None None O
chain None None O
phosphatase None None I-PROTEIN
( None None O
MLCP None None O
) None None O
activities None None O
. None None O

Force None None O
production None None O
and None None O
maintenance None None O
in None None O
smooth None None O
muscle None None O
is None None O
largely None None O
controlled None None O
by None None O
different None None O
signalling None None O
modules None None O
that None None O
fine None None O
tune None None O
myosin None None O
regulatory None None O
light None None O
chain None None O
( None None O
RLC None None O
) None None O
phosphorylation None None O
, None None O
which None None O
relies None None O
on None None O
a None None O
balance None None O
between None None O
Ca None None O
( None None O
2+ None None O
) None None O
/calmodulin-dependent None None O
myosin None None O
light None None O
chain None None O
kinase None None O
( None None O
MLCK None None O
) None None O
and None None O
myosin None None O
light None None O
chain None None O
phosphatase None None I-PROTEIN
( None None O
MLCP None None O
) None None O
activities None None O
. None None O

MYPT1 None None O
is None None O
constitutively None None O
phosphorylated None None O
at None None O
T694 None None O
by None None O
unidentified None None O
kinases None None I-PROTEIN
in None None O
vivo None None O
, None None O
whereas None None O
the None None O
T852 None None O
site None None O
is None None O
phosphorylated None None O
by None None O
RhoA-associated None None O
protein None None O
kinase None None O
( None None O
ROCK None None O
) None None O
. None None O

Compared None None O
to None None O
Ang-II None None O
, None None O
the None None O
caged None None O
Ang-II None None O
analogues None None O
showed None None O
2-3 None None O
orders None None O
of None None O
magnitude None None O
reduced None None O
affinity None None O
toward None None O
both None None O
angiotensin None None O
type-1 None None O
( None None O
AT1R None None O
) None None O
and None None O
type-2 None None O
( None None O
AT2R None None O
) None None O
receptors None None I-PROTEIN
in None None O
competition None None O
binding None None O
assays None None O
, None None O
and None None O
greatly-reduced None None O
potency None None O
in None None O
contraction None None O
assays None None O
of None None O
rat None None O
thoracic None None O
aorta None None O
. None None O

In None None O
vertebrates None None O
, None None O
environmental None None O
temperature None None O
is None None O
detected None None O
by None None O
the None None O
primary None None O
afferents None None O
of None None O
the None None O
somatosensory None None O
neurons None None O
in None None O
the None None O
skin None None O
, None None O
which None None O
express None None O
a None None O
'choir None None O
' None None O
of None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
tuned None None O
to None None O
detect None None O
particular None None O
temperatures None None O
. None None O

The None None O
immune None None O
system None None O
responds None None O
to None None O
hyperthermia None None O
exposure None None O
resulting None None O
in None None O
heat None None O
stroke None None I-DISEASE
by None None O
producing None None O
an None None O
array None None O
of None None O
immunological None None O
proteins None None O
, None None O
such None None O
as None None O
interleukin-6 None None O
( None None O
IL-6 None None O
) None None O
. None None O

We None None O
hypothesized None None O
that None None O
IL-6 None None O
plays None None O
a None None O
protective None None O
role None None O
in None None O
conditions None None O
of None None O
heat None None O
stroke None None I-DISEASE
. None None O

The None None O
role None None O
of None None O
interleukin-6 None None O
( None None O
IL-6 None None O
) None None O
in None None O
hyperthermia None None O
and None None O
heat None None O
stroke None None I-DISEASE
is None None O
poorly None None O
understood None None O
. None None O

Transduction None None O
of None None O
these None None O
diverse None None O
stimuli None None O
into None None O
a None None O
cellular None None O
response None None O
occurs None None O
through None None O
many None None O
different None None O
mechanisms None None O
, None None O
one None None O
being None None O
reorganisation None None O
of None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
. None None O

To None None O
keep None None O
an None None O
appropriate None None O
airflow None None O
to None None O
and None None O
from None None O
the None None O
lungs None None O
under None None O
physiological None None O
conditions None None O
a None None O
precise None None O
neural None None O
co-ordination None None O
of None None O
the None None O
upper None None O
airway None None O
resistance None None O
by None None O
laryngeal None None O
motoneurones None None O
in None None O
the None None O
nucleus None None I-REGION
ambiguus None None I-REGION
is None None O
essential None None O
. None None O

Here None None O
, None None O
using None None O
nerve None None O
and None None O
whole None None O
cell None None O
patch None None O
clamp None None O
recordings None None O
in None None O
in None None O
situ None None O
preparations None None O
of None None O
rats None None O
we None None O
investigated None None O
the None None O
effects None None O
of None None O
CIH None None O
on None None O
the None None O
respiratory None None O
control None None O
of None None O
the None None O
upper None None O
airway None None O
resistance None None O
, None None O
on None None O
the None None O
electrophysiological None None O
properties None None O
of None None O
laryngeal None None O
motoneurones None None O
in None None O
the None None O
nucleus None None I-REGION
ambiguus None None I-REGION
, None None O
and None None O
the None None O
role None None O
of None None O
carotid None None O
body None None O
( None None O
CB None None O
) None None O
afferents None None O
to None None O
the None None O
brainstem None None I-REGION
on None None O
the None None O
underlying None None O
mechanisms None None O
of None None O
these None None O
effects None None O
. None None O

SCFA None None O
receptors None None I-PROTEIN
, None None O
termed None None O
FFA2 None None O
and None None O
FFA3 None None O
, None None O
are None None O
expressed None None O
in None None O
duodenal None None O
enterochromaffin None None O
cells None None O
and None None O
L None None O
cells None None O
, None None O
respectively None None O
. None None O

The None None O
presence None None O
of None None O
SCFA None None O
sensing None None O
in None None O
the None None O
duodenum None None O
with None None O
GLP-2 None None O
and None None O
5-HT None None I-TRANS
signals None None O
further None None O
supports None None O
the None None O
hypothesis None None O
that None None O
luminal None None O
SCFA None None O
in None None O
the None None O
foregut None None O
may None None O
contribute None None O
towards None None O
the None None O
generation None None O
of None None O
functional None None O
symptoms None None O
. None None O

FFA3 None None O
colocalised None None O
with None None O
glucagon-like None None O
peptide None None O
( None None O
GLP None None O
) None None O
-1 None None O
, None None O
whereas None None O
FFA2 None None O
colocalised None None O
with None None O
5-HT None None I-TRANS
. None None O

To None None O
test None None O
the None None O
system None None O
, None None O
we None None O
have None None O
focused None None O
on None None O
the None None O
cardio-respiratory None None O
oscillators None None O
in None None O
the None None O
medulla None None I-REGION
oblongata None None I-REGION
that None None O
modulate None None O
heart None None O
rate None None O
in None None O
phase None None O
with None None O
respiration None None O
to None None O
induce None None O
respiratory None None O
sinus None None O
arrhythmia None None O
( None None O
RSA None None O
) None None O
. None None O

Our None None O
hCPG None None O
comprises None None O
two None None O
neurones None None O
that None None O
antagonise None None O
each None None O
other None None O
to None None O
provide None None O
rhythmic None None O
motor None None O
drive None None O
to None None O
the None None O
vagus None None I-REGION
nerve None None I-REGION
to None None O
slow None None O
the None None O
heart None None O
. None None O

In None None O
rats None None O
, None None O
we None None O
report None None O
on None None O
the None None O
restoration None None O
of None None O
RSA None None O
using None None O
an None None O
hCPG None None O
that None None O
receives None None O
diaphragmatic None None O
electromyography None None O
input None None O
and None None O
use None None O
it None None O
to None None O
stimulate None None O
the None None O
vagus None None I-REGION
nerve None None I-REGION
at None None O
specific None None O
time None None O
points None None O
of None None O
the None None O
respiratory None None O
cycle None None O
to None None O
slow None None O
the None None O
heart None None O
rate None None O
. None None O

Simultaneous None None O
occurrences None None O
of None None O
HSK None None O
and None None O
AAA None None O
have None None O
been None None O
reported None None O
severally None None O
in None None O
the None None O
past None None O
, None None O
and None None O
the None None O
authors None None O
are None None O
paying None None O
attention None None I-FUNC
on None None O
the None None O
ureteral None None O
anomaly None None O
. None None O

As None None O
the None None O
capability None None O
of None None O
mass None None O
spectrometry-based None None O
proteomics None None O
has None None O
matured None None O
, None None O
tens None None O
of None None O
thousands None None O
of None None O
peptides None None I-TRANS
can None None O
be None None O
measured None None O
simultaneously None None O
, None None O
which None None O
has None None O
the None None O
benefit None None O
of None None O
offering None None O
a None None O
systems None None O
view None None O
of None None O
protein None None O
expression None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
a None None O
Bayesian None None O
Proteoform None None O
Quantification None None O
model None None O
( None None O
BP-Quant None None O
) None None O
( None None O
1 None None O
) None None O
that None None O
uses None None O
statistically None None O
derived None None O
peptides None None I-TRANS
signatures None None O
to None None O
identify None None O
peptides None None I-TRANS
that None None O
are None None O
outside None None O
the None None O
dominant None None O
pattern None None O
or None None O
the None None O
existence None None O
of None None O
multiple None None O
overexpressed None None O
patterns None None O
to None None O
improve None None O
relative None None O
protein None None O
abundance None None O
estimates None None O
. None None O

Several None None O
of None None O
the None None O
NEDD4-2 None None O
substrates None None O
include None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
, None None O
such None None O
as None None O
the None None O
epithelial None None O
and None None O
voltage-gated None None I-PROTEIN
sodium None None I-PROTEIN
channels None None I-PROTEIN
. None None O

In None None O
this None None O
article None None O
we None None O
review None None O
the None None O
biology None None O
and None None O
function None None O
of None None O
this None None O
important None None O
ubiquitin-protein None None O
ligase None None I-PROTEIN
and None None O
discuss None None O
its None None O
pathophysiological None None O
significance None None O
. None None O

P38 None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
) None None O
comprise None None O
a None None O
family None None O
of None None O
serine/threonine None None O
protein None None O
kinases None None I-PROTEIN
that None None O
play None None O
important None None O
roles None None O
in None None O
cellular None None O
responses None None O
to None None O
inflammatory None None O
cytokines None None O
and None None O
environmental None None O
stresses None None O
. None None O

The None None O
human None None O
brain None None O
is None None O
characterized None None O
by None None O
an None None O
evolutionarily None None O
new None None O
, None None O
highly None None O
developed None None O
neocortex None None I-REGION
, None None O
which None None O
has None None O
characteristic None None O
connections None None O
with None None O
phylogenically None None O
older None None O
structures None None O
to None None O
enable None None O
adaptation None None O
to None None O
complex None None O
social None None O
environments None None O
. None None O

We None None O
found None None O
that None None O
both None None O
prolonged None None O
maternal None None O
separation None None O
and None None O
neonatal None None O
hypoxia-ischemia None None O
impaired None None O
the None None O
animals None None O
' None None O
spatial None None O
learning None None I-FUNC
and None None O
reference None None O
memory None None I-FUNC
. None None O

Interestingly None None O
, None None O
prolonged None None O
maternal None None O
separation None None O
prior None None O
to None None O
neonatal None None O
hypoxia-ischemia None None O
augmented None None O
the None None O
reference None None O
memory None None I-FUNC
impairments None None O
. None None O

These None None O
are None None O
the None None O
first None None O
data None None O
suggesting None None O
that None None O
an None None O
adverse None None O
postnatal None None O
environmental None None O
manipulation None None O
of None None O
just None None O
6 None None O
days None None O
causes None None O
long-term None None O
effects None None O
on None None O
spatial None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
and None None O
may None None O
render None None O
the None None O
organism None None O
more None None O
vulnerable None None O
to None None O
a None None O
subsequent None None O
insult None None O
. None None O

Cognitive None None O
reappraisal None None O
has None None O
been None None O
associated None None O
with None None O
increased None None O
activation None None O
in None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
PFC None None O
) None None O
and None None O
cingulate None None O
regions None None O
implicated None None O
in None None O
cognitive None None O
control None None O
and None None O
affect None None O
regulation None None O
. None None O

Region-specific None None O
changes None None O
in None None O
glucocorticoid None None O
receptors None None I-PROTEIN
( None None O
GR None None O
) None None O
, None None O
tyrosine None None I-TRANS
hydroxylase None None O
( None None O
TH None None O
) None None O
, None None O
dopamine None None I-TRANS
1 None None O
receptors None None I-PROTEIN
( None None O
DRD1 None None O
) None None O
, None None O
phospho-CREB None None O
( None None O
pCREB None None O
) None None O
and None None O
Ki-67 None None O
expression None None O
were None None O
assessed None None O
in None None O
the None None O
hippocampal None None I-REGION
formation None None I-REGION
, None None O
hypothalamus None None I-REGION
and None None O
mesolimbic None None O
regions None None O
72 None None O
h None None O
following None None O
RSD None None O
. None None O

Acute None None O
SD None None O
enhanced None None O
TH None None O
expression None None O
in None None O
the None None O
ventral None None I-REGION
tegmental None None I-REGION
area None None I-REGION
, None None O
nucleus None None I-REGION
accumbens None None I-REGION
and None None O
A11 None None O
neurons None None O
of None None O
the None None O
hypothalamus None None I-REGION
and None None O
DRD1 None None O
expression None None O
in None None O
the None None O
lateral None None O
hypothalamus None None I-REGION
. None None O

In None None O
contrast None None O
, None None O
repeated None None O
SD None None O
significantly None None O
elevated None None O
GR-ir None None O
at None None O
the None None O
hypothalamic None None O
paraventricular None None O
nucleus None None O
and None None O
CA1 None None I-REGION
and None None O
CA3 None None I-REGION
layers None None O
of None None O
the None None O
hippocampus None None I-REGION
compared None None O
to None None O
all None None O
other None None O
groups None None O
. None None O

We None None O
obtained None None O
from None None O
the None None O
following None None O
diseases None None O
, None None O
gluten None None O
ataxia None None O
, None None O
multiple None None O
sclerosis None None O
, None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
, None None O
schizophrenia None None I-DISEASE
, None None O
attention None None I-DISEASE
deficit None None I-DISEASE
hyperactivity None None I-DISEASE
disorder None None I-DISEASE
, None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
, None None O
headaches None None O
, None None O
irritable None None O
bowel None None O
syndrome None None O
, None None O
fibromyalgia None None O
, None None O
dermatitis None None O
herpetiformis None None O
and None None O
epilepsy None None O
, None None O
studies None None O
in None None O
which None None O
either None None O
a None None O
determination None None O
of None None O
gliadin None None O
was None None O
refered None None O
or None None O
a None None O
treatment None None O
, None None O
with/without None None O
gluten None None O
, None None O
was None None O
applied None None O
and None None O
evaluated None None O
. None None O

The None None O
formulation None None O
involved None None O
self-assembly None None O
of None None O
insulin None None I-PROTEIN
into None None O
nanospheres None None O
( None None O
INS None None O
) None None O
by None None O
a None None O
novel None None O
thermal None None O
induced None None O
phase None None O
separation None None O
method None None O
. None None O

In None None O
vitro None None O
dissolution None None O
studies None None O
showed None None O
that None None O
shell None None O
cross-linked None None O
of None None O
INS None None O
with None None O
EPL None None O
improved None None O
the None None O
release None None O
profiles None None O
of None None O
insulin None None I-PROTEIN
from None None O
the None None O
self-assembled None None O
nanospheres None None O
at None None O
intestinal None None O
pH None None O
. None None O

Compared None None O
to None None O
that None None O
of None None O
INS None None O
, None None O
enteral None None O
administration None None O
of None None O
INS None None O
@ None None O
EPL None None O
at None None O
20 None None O
IU/kg None None O
resulted None None O
in None None O
more None None O
significant None None O
hypoglycemic None None O
effects None None O
in None None O
diabetic None None O
rats None None O
up None None O
to None None O
12 None None O
h. None None O
Accordingly None None O
, None None O
the None None O
results None None O
indicated None None O
that None None O
surface None None O
functional None None O
modification None None O
of None None O
self-assembled None None O
insulin None None I-PROTEIN
nanospheres None None O
with None None O
shell None None O
cross-linked None None O
polycationic None None O
peptide None None O
could None None O
be None None O
a None None O
promising None None O
candidate None None O
for None None O
oral None None O
therapeutic None None O
protein None None O
delivery None None O
. None None O

The None None O
present None None O
study None None O
was None None O
designed None None O
to None None O
assess None None O
the None None O
possible None None O
protective None None O
effects None None O
of None None O
arginine None None I-TRANS
( None None O
Arg None None O
) None None O
against None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
induced None None O
inflammatory None None O
response None None O
in None None O
juvenile None None O
Jian None None O
carp None None O
( None None O
Cyprinus None None O
carpio None None O
var None None O
. None None O

The None None O
cell None None O
viability None None O
, None None O
protein None None O
content None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
were None None O
decreased None None O
by None None O
LPS None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
results None None O
of None None O
the None None O
kinetic None None O
activity None None O
of None None O
CsKSPI None None O
against None None O
trypsin None None I-PROTEIN
was None None O
V None None O
( None None O
max None None O
) None None O
s None None O
= None None O
1.62 None None O
nmol/min None None O
, None None O
K None None O
( None None O
M None None O
) None None O
s None None O
= None None O
0.21 None None O
mM None None O
and None None O
K None None O
( None None O
i None None O
) None None O
s None None O
= None None O
15.37 None None O
nM None None O
. None None O

Overall None None O
, None None O
the None None O
study None None O
indicated None None O
that None None O
the None None O
CsKSPI None None O
was None None O
a None None O
potential None None O
trypsin None None I-PROTEIN
inhibitor None None O
which None None O
involves None None O
in None None O
antimicrobial None None O
activity None None O
. None None O

The None None O
long None None O
known None None O
toxicity None None O
of None None O
free None None O
chromatin None None O
mediated None None O
by None None O
histones None None I-PROTEIN
regained None None O
attention None None I-FUNC
after None None O
discovery None None O
of None None O
neutrophil None None O
extracellular None None O
traps None None O
( None None O
NETs None None O
) None None O
. None None O

This None None O
article None None O
is None None O
part None None O
of None None O
the None None O
Special None None O
Issue None None O
entitled None None O
'The None None O
Nicotinic None None I-PROTEIN
Acetylcholine None None I-TRANS
Receptor None None I-PROTEIN
: None None O
From None None O
Molecular None None O
Biology None None O
to None None O
Cognition None None O
' None None O
. None None O

The None None O
extracellular None None O
matrix None None O
protein None None O
fibronectin None None I-PROTEIN
( None None O
Fn None None O
) None None O
is None None O
known None None O
to None None O
bind None None O
to None None O
the None None O
surface None None O
of None None O
Clostridium None None O
perfringens None None O
cells None None O
. None None O

In None None O
addition None None O
to None None O
nicotinic None None O
receptors None None I-PROTEIN
, None None O
the None None O
opioid None None O
and None None O
endocannabinoid None None O
systems None None O
, None None O
various None None O
signal None None O
transduction None None O
pathways None None O
, None None O
neurotransmitters None None I-TRANS
, None None O
and None None O
neuropeptides None None O
have None None O
been None None O
implicated None None O
in None None O
the None None O
nicotine None None O
withdrawal None None O
syndrome None None O
. None None O

This None None O
article None None O
is None None O
part None None O
of None None O
the None None O
Special None None O
Issue None None O
entitled None None O
'The None None O
Nicotinic None None I-PROTEIN
Acetylcholine None None I-TRANS
Receptor None None I-PROTEIN
: None None O
From None None O
Molecular None None O
Biology None None O
to None None O
Cognition None None O
' None None O
. None None O

In None None O
contrast None None O
, None None O
horizontal None None O
vergence None None O
movements None None I-FUNC
were None None O
consistently None None O
observed None None O
on None None O
all None None O
fixations None None O
in None None O
the None None O
absence None None O
of None None O
a None None O
horizontal None None O
disparity None None O
manipulation None None O
. None None O

Overall None None O
the None None O
present None None O
findings None None O
are None None O
in None None O
agreement None None O
with None None O
the None None O
`` None None O
selective None None O
reweighting None None O
'' None None O
hypothesis None None O
of None None O
perceptual None None O
learning None None I-FUNC
. None None O

We None None O
conducted None None O
a None None O
cross-sectional None None O
analysis None None O
of None None O
8668 None None O
participants None None O
from None None O
the None None O
Atherosclerosis None None I-DISEASE
Risk None None O
in None None O
Communities None None O
( None None O
ARIC None None O
) None None O
Study None None O
, None None O
who None None O
showed None None O
no None None O
clinical None None O
evidence None None O
of None None O
cardiovascular None None O
disease None None O
. None None O

The None None O
adjusted None None O
odds None None O
ratios None None O
( None None O
95 None None O
% None None O
confidence None None O
interval None None O
) None None O
for None None O
elevated None None O
liver None None O
enzymes None None I-PROTEIN
( None None O
vs. None None O
normal None None O
levels None None O
) None None O
with None None O
elevated None None O
hs-cTnT None None O
were None None O
: None None O
1.65 None None O
( None None O
1.28-2.14 None None O
) None None O
for None None O
ALT None None O
, None None O
1.90 None None O
( None None O
1.36-2.68 None None O
) None None O
for None None O
AST None None O
, None None O
and None None O
1.55 None None O
( None None O
1.13-2.12 None None O
) None None O
for None None O
GGT None None O
. None None O

Here None None O
we None None O
explore None None O
a None None O
possible None None O
role None None O
of None None O
the None None O
hepatic None None O
branch None None O
of None None O
the None None O
vagus None None I-REGION
nerve None None I-REGION
in None None O
the None None O
development None None O
of None None O
diet None None O
induced None None O
obesity None None O
and None None O
steatohepatitis None None O
in None None O
Pemt None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Furthermore None None O
, None None O
HV None None O
normalized None None O
the None None O
expression None None O
of None None O
mitochondrial None None O
electron None None O
transport None None O
chain None None O
proteins None None O
and None None O
of None None O
proteins None None O
involved None None O
in None None O
fatty None None O
acid None None O
synthesis None None O
, None None O
acetyl-CoA None None I-PROTEIN
carboxylase None None I-PROTEIN
and None None O
fatty None None O
acid None None O
synthase None None O
in None None O
Pemt None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Neuronal None None O
signals None None O
via None None O
the None None O
hepatic None None O
vagus None None I-REGION
nerve None None I-REGION
contribute None None O
to None None O
the None None O
development None None O
of None None O
steatohepatitis None None O
and None None O
protection None None O
against None None O
obesity None None O
in None None O
HFD None None O
fed None None O
Pemt None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

This None None O
development None None O
includes None None O
the None None O
formation None None O
of None None O
an None None O
efficient None None O
vascular None None O
tissue None None O
which None None O
allows None None O
metabolic None None O
exchanges None None O
between None None O
the None None O
root None None O
and None None O
the None None O
nodule None None O
, None None O
the None None O
formation None None O
of None None O
a None None O
barrier None None O
to None None O
oxygen None None O
diffusion None None O
necessary None None O
for None None O
the None None O
bacterial None None O
nitrogenase None None I-PROTEIN
activity None None O
and None None O
the None None O
enlargement None None O
of None None O
cells None None O
in None None O
the None None O
infection None None O
zone None None O
to None None O
support None None O
the None None O
large None None O
bacterial None None O
population None None O
. None None O

Plant None None O
differentiation None None O
and None None O
bacterial None None O
differentiation None None O
are None None O
controlled None None O
by None None O
reactive None None O
oxygen None None O
and None None O
nitrogen None None O
species None None O
, None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
the None None O
antioxidant None None O
defense None None O
and None None O
antioxidant None None O
compounds None None O
. None None O

Little None None O
is None None O
known None None O
about None None O
the None None O
interrelation None None O
of None None O
the None None O
prostaglandin None None O
E None None O
( None None O
EP None None O
) None None O
receptors None None I-PROTEIN
with None None O
the None None O
prostaglandin None None O
transporter None None O
OATP2A1 None None O
in None None O
the None None O
gastric None None O
mucosa None None O
and None None O
gastric None None O
carcinoma None None O
. None None O

Here None None O
, None None O
we None None O
characterized None None O
the None None O
developmental None None O
role None None O
of None None O
PTP69D None None O
in None None O
the None None O
giant None None O
fiber None None O
( None None O
GF None None O
) None None O
neurons None None O
, None None O
two None None O
interneurons None None I-NEURON
in None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
that None None O
control None None O
the None None O
escape None None O
response None None O
of None None O
the None None O
fly None None O
. None None O

In None None O
addition None None O
, None None O
complementation None None O
studies None None O
and None None O
structure-function None None O
analyses None None O
revealed None None O
that None None O
for None None O
GF None None O
terminal None None O
growth None None O
Cat1 None None O
function None None O
of None None O
PTP69D None None O
requires None None O
the None None O
immunoglobulin None None O
and None None O
the None None O
Cat2 None None O
domains None None O
, None None O
but None None O
not None None O
the None None O
fibronectin None None I-PROTEIN
III None None O
or None None O
the None None O
membrane None None O
proximal None None O
region None None O
domains None None O
. None None O

PGE2 None None O
functions None None O
by None None O
signaling None None O
through None None O
four None None O
EP None None O
receptors None None I-PROTEIN
( None None O
EP1-4 None None O
) None None O
, None None O
resulting None None O
in None None O
several None None O
different None None O
cellular None None O
responses None None O
, None None O
many None None O
of None None O
which None None O
are None None O
pro-tumorigenic None None O
, None None O
and None None O
there None None O
is None None O
growing None None O
interest None None O
in None None O
the None None O
therapeutic None None O
potential None None O
of None None O
targeting None None O
EP4 None None O
and None None O
EP2 None None O
. None None O

15-hydroxyprostaglandin None None O
dehydrogenase None None I-PROTEIN
( None None O
15-PGDH None None O
) None None O
metabolizes None None O
PGE2 None None O
and None None O
silences None None O
the None None O
pathway None None O
in None None O
this None None O
manner None None O
. None None O

The None None O
device None None O
is None None O
a None None O
thin None None O
and None None O
flexible None None O
patch None None O
consisting None None O
of None None O
a None None O
specifically-formulated None None O
porous None None O
collagen None None I-PROTEIN
matrix None None O
, None None O
coated None None O
on None None O
one None None O
side None None O
with None None O
a None None O
thin None None O
protein-binding None None O
layer None None O
. None None O

The None None O
authors None None O
attribute None None O
these None None O
gains None None O
to None None O
interprofessional None None O
collaboration None None O
, None None O
case-based None None O
learning None None I-FUNC
, None None O
and None None O
discipline- None None O
specific None None O
facilitation None None O
. None None O

The None None O
outcomes None None O
strengthen None None O
the None None O
research None None O
that None None O
interprofessional None None O
education None None O
and None None O
case-based None None O
learning None None I-FUNC
are None None O
effective None None O
methods None None O
of None None O
education None None O
. None None O

In None None O
health None None O
professions None None O
education None None O
, None None O
however None None O
, None None O
core None None O
subjects None None O
are None None O
often None None O
obscured None None O
by None None O
the None None O
plethora None None O
of None None O
topics None None O
and None None O
skills None None O
that None None O
must None None O
be None None O
taught None None O
, None None O
rendering None None O
them None None O
largely None None O
implicit None None O
in None None O
the None None O
learning None None I-FUNC
process None None O
. None None O

The None None O
scarcity None None O
of None None O
research None None O
can None None O
be None None O
attributed None None O
to None None O
the None None O
need None None O
for None None O
( None None O
1 None None O
) None None O
explicating None None O
core None None O
subjects None None O
as None None O
the None None O
basis None None O
for None None O
learning None None I-FUNC
, None None O
( None None O
2 None None O
) None None O
language None None I-FUNC
that None None O
describes None None O
professional None None O
education None None O
as None None O
connecting None None O
all None None O
learning None None I-FUNC
to None None O
a None None O
field None None O
's None None O
core None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
research None None O
methods None None O
that None None O
go None None O
beyond None None O
early None None O
phases None None O
of None None O
research None None O
development None None O
, None None O
including None None O
a None None O
conceptual None None O
framework None None O
for None None O
understanding None None O
and None None O
studying None None O
core None None O
subjects None None O
. None None O

The None None O
survey None None O
comprised None None O
18 None None O
questions None None O
to None None O
collect None None O
program None None O
demographic None None O
information None None O
, None None O
program None None O
admissions None None O
requirements None None O
, None None O
and None None O
program None None O
student None None O
retention None None I-FUNC
rates None None O
. None None O

Stepwise None None O
regression None None O
analysis None None O
discovered None None O
three None None O
independent None None O
variables None None O
( None None O
aE=0.15 None None O
) None None O
that None None O
relate None None O
to None None O
dental None None O
hygiene None None O
program None None O
retention None None I-FUNC
rates None None O
. None None O

Computer-assisted None None O
learning None None I-FUNC
( None None O
CAL None None O
) None None O
affords None None O
the None None O
opportunity None None O
to None None O
supplement None None O
face-to-face None None O
teaching None None O
methods None None O
. None None O

One-minute None None O
papers None None O
and None None O
focus None None O
group None None O
discussions None None O
were None None O
administered None None O
to None None O
Cohort None None O
2 None None O
to None None O
gauge None None O
satisfaction None None O
and None None O
perceptions None None I-FUNC
of None None O
the None None O
CAL None None O
modules None None O
. None None O

IL-17 None None O
increased None None O
PB-MSC None None O
migration None None O
in None None O
a None None O
wound None None O
healing None None O
assay None None O
as None None O
well None None O
as None None O
cell None None O
mobilization None None O
from None None O
collagen None None I-PROTEIN
gel None None O
. None None O

Moreover None None O
, None None O
IL-17 None None O
increased None None O
PB-MSC None None O
adhesion None None O
to None None O
endothelial None None O
cells None None O
and None None O
transendothelial None None O
migration None None O
, None None O
as None None O
well None None O
as None None O
increased None None O
the None None O
capacity None None O
of None None O
PB-MSC None None O
adhesion None None O
to None None O
fibronectin None None I-PROTEIN
, None None O
in None None O
an None None O
uPA-dependent None None O
fashion None None O
. None None O

Recent None None O
individual None None O
cell None None O
studies None None O
have None None O
indicated None None O
that None None O
p53 None None I-PROTEIN
activation None None O
is None None O
highly None None O
regulated None None O
in None None O
response None None O
to None None O
stressed None None O
conditions None None O
and None None O
non-stressed None None O
( None None O
normal None None O
proliferating None None O
) None None O
conditions None None O
in None None O
cells None None O
. None None O

In None None O
particular None None O
, None None O
we None None O
found None None O
that None None O
the None None O
core None None O
regulatory None None O
network None None O
consists None None O
of None None O
ATM None None O
, None None O
Mdm2 None None O
, None None O
MdmX None None O
, None None O
Wip1 None None O
and None None O
p53 None None I-PROTEIN
. None None O

Our None None O
results None None O
show None None O
that None None O
the None None O
p53 None None I-PROTEIN
spontaneous None None O
pulses None None O
are None None O
due None None O
to None None O
intrinsic None None O
DNA None None O
double None None O
strand None None O
breaks None None O
in None None O
normal None None O
proliferating None None O
cells None None O
, None None O
and None None O
p53 None None I-PROTEIN
auto-regulation None None O
( None None O
positive None None O
feedback None None O
loop None None O
) None None O
allows None None O
threshold None None O
activation None None O
of None None O
p53 None None I-PROTEIN
in None None O
generating None None O
these None None O
pulses None None O
. None None O

Additionally None None O
, None None O
the None None O
model None None O
makes None None O
testable None None O
predictions None None O
on None None O
pharmacological None None O
intervention None None O
to None None O
reactivate None None O
p53 None None I-PROTEIN
. None None O

The None None O
interactions None None O
of None None O
IGF-1 None None O
with None None O
IGF-1 None None O
receptors None None I-PROTEIN
and None None O
IGF-1 None None O
binding None None O
proteins None None O
( None None O
IGFBPs None None O
) None None O
regulate None None O
IGF-1 None None O
function None None O
. None None O

The None None O
model None None O
can None None O
be None None O
used None None O
to None None O
understand None None O
the None None O
interaction None None O
between None None O
IGF-1 None None O
, None None O
IGFBPs None None O
, None None O
cGP None None O
and None None O
IGF-1 None None O
receptors None None I-PROTEIN
along None None O
with None None O
the None None O
kinetics None None O
of None None O
cell None None O
growth None None O
. None None O

An None None O
implicit None None O
model None None O
of None None O
the None None O
interactions None None O
between None None O
IGF-1 None None O
, None None O
cGP None None O
, None None O
IGFBPs None None O
, None None O
IGF-1 None None O
receptors None None I-PROTEIN
that None None O
included None None O
a None None O
hypothesized None None O
feedback None None O
of None None O
cGP None None O
on None None O
IGF-1 None None O
receptors None None I-PROTEIN
explained None None O
nonlinear None None O
features None None O
of None None O
interaction None None O
between None None O
IGF-1 None None O
and None None O
cGP None None O
not None None O
described None None O
by None None O
the None None O
explicit None None O
model None None O
( None None O
R None None O
( None None O
2 None None O
) None None O
= None None O
0.84 None None O
) None None O
. None None O

Although None None O
the None None O
use None None O
of None None O
drug-eluting None None O
stents None None O
( None None O
DESs None None O
) None None O
in None None O
patients None None O
with None None O
coronary None None O
artery None None O
disease None None O
has None None O
contributed None None O
to None None O
a None None O
significant None None O
reduction None None O
in None None O
in-stent None None O
restenosis None None O
and None None O
repeat None None O
revascularization None None O
, None None O
treating None None O
diffuse None None O
long None None O
lesions None None O
using None None O
DESs None None O
remains None None O
challenging None None O
due None None O
to None None O
the None None O
high None None O
rates None None O
of None None O
in-stent None None O
restenosis None None O
and None None O
stent None None O
thrombosis None None I-DISEASE
. None None O

Using None None O
the None None O
Behavior None None O
Model None None O
for None None O
Vulnerable None None O
Populations None None O
, None None O
we None None O
administered None None O
a None None O
survey None None O
( None None O
n=168 None None O
) None None O
to None None O
assess None None O
predisposing None None O
( None None O
e.g. None None O
, None None O
knowledge None None O
) None None O
, None None O
enabling None None O
( None None O
e.g. None None O
, None None O
trust None None O
) None None O
and None None O
need None None O
factors None None O
( None None O
e.g. None None O
, None None O
risk None None O
perception None None I-FUNC
) None None O
. None None O

There None None O
were None None O
no None None O
significant None None O
differences None None O
between None None O
the None None O
two None None O
groups None None O
regarding None None O
respiratory None None O
distress None None O
syndrome None None O
, None None O
bronchopulmonary None None O
dysplasia None None O
, None None O
intraventricular None None O
hemorrhage None None O
, None None O
periventricular None None I-DISEASE
leukomalacia None None I-DISEASE
, None None O
and None None O
patent None None O
ductus None None O
arteriosus None None O
. None None O

In None None O
the None None O
human None None O
adrenal None None I-TRANS
gland None None O
, None None O
5-HT None None I-TRANS
, None None O
released None None O
by None None O
subcapsular None None O
mast None None O
cells None None O
, None None O
stimulates None None O
corticosteroid None None O
production None None O
through None None O
a None None O
paracrine None None O
mode None None O
of None None O
communication None None O
which None None O
involves None None O
5-HT None None I-TRANS
receptor None None I-PROTEIN
type None None O
4 None None O
( None None O
5-HT4 None None O
) None None O
primarily None None O
located None None O
in None None O
zona None None O
glomerulosa None None O
. None None O

Altogether None None O
, None None O
these None None O
data None None O
support None None O
the None None O
concept None None O
of None None O
adrenal None None I-TRANS
serotonergic None None O
paracrinopathy None None O
and None None O
suggest None None O
that None None O
5-HT None None I-TRANS
and None None O
its None None O
receptors None None I-PROTEIN
may None None O
constitute None None O
valuable None None O
targets None None O
for None None O
pharmacological None None O
treatments None None O
of None None O
primary None None O
adrenal None None I-TRANS
diseases None None O
. None None O

Excessive None None O
exposure None None O
to None None O
estrogen None None O
has None None O
long None None O
been None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
for None None O
developing None None O
breast None None O
cancer None None O
and None None O
anti-estrogen None None O
therapy None None O
is None None O
the None None O
gold None None O
standard None None O
of None None O
care None None O
in None None O
the None None O
treatment None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
α-positive None None O
breast None None O
cancers None None O
. None None O

The None None O
discovery None None O
of None None O
ERβ None None O
, None None O
the None None O
second None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
, None None O
has None None O
added None None O
another None None O
level None None O
of None None O
complexity None None O
to None None O
estrogen None None O
signaling None None O
. None None O

Molecular None None O
mechanisms None None O
governing None None O
the None None O
maintenance None None O
and None None O
proliferation None None O
of None None O
dorsal None None I-NEURON
root None None O
ganglia None None O
( None None O
DRG None None O
) None None O
progenitors None None O
are None None O
largely None None O
unknown None None O
. None None O

Ribosomal None None I-PROTEIN
proteins None None I-PROTEIN
( None None O
rps None None O
) None None O
are None None O
constituents None None O
of None None O
ribosomal None None O
subunits None None O
together None None O
with None None O
the None None O
rRNAs None None O
, None None O
and None None O
the None None O
work None None O
of None None O
the None None O
ribosomes None None O
is None None O
based None None O
on None None O
highly None None O
cooperative None None O
interactions None None O
involving None None O
these None None O
biopolymers None None O
. None None O

We None None O
propose None None O
an None None O
echo None None O
planar None None O
imaging None None O
( None None O
EPI None None I-TRANS
) None None O
distortion None None O
correction None None O
method None None O
( None None O
DR-BUDDI None None O
) None None O
, None None O
specialized None None O
for None None O
diffusion None None O
MRI None None O
, None None O
which None None O
uses None None O
data None None O
acquired None None O
twice None None O
with None None O
reversed None None O
phase None None O
encoding None None I-FUNC
directions None None O
, None None O
often None None O
referred None None O
to None None O
as None None O
blip-up None None O
blip-down None None O
acquisitions None None O
. None None O

miR-181 None None O
has None None O
deleterious None None O
effects None None O
on None None O
stroke None None I-DISEASE
outcome None None O
, None None O
and None None O
reducing None None O
miR-181a None None O
levels None None O
prior None None O
to None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
( None None O
MCAO None None O
) None None O
was None None O
shown None None O
previously None None O
to None None O
be None None O
protective None None O
. None None O

The None None O
ability None None O
to None None O
protect None None O
the None None O
brain None None O
with None None O
post-treatment None None O
with None None O
miR-181a None None O
antagomir None None O
with None None O
long None None O
lasting None None O
effect None None O
makes None None O
this None None O
a None None O
promising None None O
therapeutic None None O
target None None O
and None None O
may None None O
be None None O
an None None O
innovative None None O
and None None O
effective None None O
new None None O
approach None None O
for None None O
stroke None None I-DISEASE
therapy None None O
. None None O

After None None O
vaccination None None O
, None None O
the None None O
number None None O
of None None O
S. None None O
Typhi-specific None None O
plasmablasts None None O
( None None O
878 None None O
ASC/10 None None O
( None None O
6 None None O
) None None O
PBMC None None O
, None None O
95 None None O
% None None O
CI None None O
554-1201 None None O
) None None O
proved None None O
higher None None O
than None None O
in None None O
the None None O
Ty21a None None O
( None None O
339 None None O
ASC/10 None None O
( None None O
6 None None O
) None None O
PBMC None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
Vi None None I-REGION
( None None O
149 None None O
ASC/10 None None O
( None None O
6 None None O
) None None O
PBMC None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
groups None None O
. None None O

A None None O
gut-directed None None O
homing None None O
profile None None O
was None None O
seen None None O
among None None O
O None None O
antigen-specific None None O
and None None O
a None None O
systemic None None O
one None None O
among None None O
Vi None None I-REGION
antigen-specific None None O
plasmablasts None None O
. None None O

Sleep None None O
quality None None O
and None None O
depression None None I-DISEASE
were None None O
measured None None O
with None None O
the None None O
Pittsburgh None None O
Sleep None None O
Quality None None O
Index None None O
( None None O
PSQI None None O
) None None O
and None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
, None None O
version None None O
2 None None O
( None None O
BDI-II None None O
) None None O
. None None O

In None None O
addition None None O
to None None O
a None None O
degradative None None O
role None None O
of None None O
autophagy None None O
in None None O
Aβ None None O
metabolism None None O
we None None O
recently None None O
showed None None O
that None None O
Aβ None None O
secretion None None O
is None None O
inhibited None None O
in None None O
mice None None O
lacking None None O
autophagy-related None None O
gene None None O
7 None None O
( None None O
Atg7 None None O
) None None O
in None None O
excitatory None None O
neurons None None O
in None None O
the None None O
mouse None None O
forebrain None None I-REGION
. None None O

How None None O
do None None O
motor None None O
abilities None None O
relate None None O
to None None O
language None None I-FUNC
in None None O
this None None O
group None None O
? None None O

Results None None O
indicate None None O
that None None O
, None None O
despite None None O
their None None O
fluent None None O
language None None I-FUNC
, None None O
oromotor None None O
praxis None None O
was None None O
impaired None None O
in None None O
WS None None O
relative None None O
to None None O
two None None O
groups None None O
of None None O
typically-developing None None O
children None None O
, None None O
matched None None O
on None None O
either None None O
vocabulary None None O
or None None O
visuospatial None None O
ability None None O
. None None O

In None None O
the None None O
discussion None None O
, None None O
we None None O
turn None None O
to None None O
more None None O
general None None O
issues None None O
of None None O
how None None O
individual None None O
variation None None O
in None None O
oromotor None None O
praxis None None O
may None None O
account None None O
for None None O
differences None None O
in None None O
speech/language None None O
production None None O
abilities None None O
across None None O
developmental None None O
language None None I-DISEASE
disorders None None I-DISEASE
. None None O

Congenital None None O
amusia None None I-DISEASE
is None None O
a None None O
neurogenetic None None O
disorder None None O
that None None O
appears None None O
to None None O
affect None None O
primarily None None O
pitch None None O
and None None O
melody None None O
perception None None I-FUNC
. None None O

The None None O
results None None O
demonstrate None None O
a None None O
pitch-specific None None O
deficit None None O
in None None O
fine None None O
spectro-temporal None None O
information None None O
processing None None O
in None None O
amusia None None I-DISEASE
that None None O
seems None None O
unrelated None None O
to None None O
temporal None None O
or None None O
spectral None None O
coding None None O
in None None O
the None None O
auditory None None O
periphery None None O
. None None O

As None None O
pain None None O
and None None O
quality None None O
of None None O
life None None O
, None None O
rather None None O
than None None O
recurrence None None O
rate None None O
, None None O
gained None None O
the None None O
attention None None I-FUNC
of None None O
clinicians None None O
, None None O
researchers None None O
, None None O
and None None O
patients None None O
, None None O
recent None None O
developments None None O
have None None O
been None None O
focusing None None O
on None None O
different None None O
types None None O
of None None O
absorbable None None O
materials None None O
. None None O

It None None O
is None None O
well None None O
known None None O
that None None O
vaginal None None O
prolapse None None O
may None None O
lead None None O
to None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
and None None O
in None None O
many None None O
studies None None O
repair None None O
of None None O
prolapse None None O
improves None None O
this None None O
dysfunction None None O
. None None O

Surgical None None O
repair None None O
or None None O
reconstruction None None O
of None None O
this None None O
type None None O
of None None O
vaginal None None O
defect None None O
may None None O
be None None O
indicated None None O
if None None O
repair None None O
will None None O
improve None None O
symptoms None None O
of None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
caused None None O
by None None O
vaginal None None O
wall None None O
laxity None None O
. None None O

We None None O
argue None None O
that None None O
promoting None None O
the None None O
reuse None None O
of None None O
virtual None None O
experiments None None O
( None None O
the None None O
in None None O
silico None None O
analogues None None O
of None None O
wet-lab None None O
or None None O
field None None O
experiments None None O
) None None O
would None None O
vastly None None O
improve None None O
the None None O
usefulness None None O
and None None O
relevance None None O
of None None O
computational None None O
models None None O
, None None O
encouraging None None O
critical None None O
scrutiny None None O
of None None O
models None None O
and None None O
serving None None O
as None None O
a None None O
common None None O
language None None I-FUNC
between None None O
modellers None None O
and None None O
experimentalists None None O
. None None O

Atrazine None None O
is None None O
a None None O
phosphodiesterase None None O
inhibitor None None O
and None None O
is None None O
classified None None O
as None None O
an None None O
estrogen None None O
disrupting None None O
compound None None O
because None None O
it None None O
elevates None None O
estrogen None None O
levels None None O
via None None O
induction None None O
of None None O
the None None O
enzyme None None O
aromatase None None I-PROTEIN
. None None O

Consistent None None O
with None None O
these None None O
findings None None O
, None None O
atrazine None None O
exposure None None O
during None None O
T None None O
cell None None O
activation None None O
resulted None None O
in None None O
a None None O
2- None None O
to None None O
5-fold None None O
increase None None O
in None None O
the None None O
frequency None None O
of None None O
Foxp3 None None I-PROTEIN
( None None O
+ None None O
) None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
. None None O

We None None O
could None None O
find None None O
no None None O
evidence None None O
of None None O
an None None O
increase None None O
in None None O
melanopsin None None O
expression None None O
by None None O
quantitative None None O
PCR None None O
in None None O
the None None O
iris None None O
and None None O
ciliary None None O
body None None O
of None None O
aged None None O
retinal None None O
degenerates None None O
and None None O
a None None O
detailed None None O
anatomical None None O
analysis None None O
revealed None None O
a None None O
significant None None O
decline None None O
in None None O
melanopsin-positive None None O
intrinsically None None O
photosensitive None None O
retinal None None O
ganglion None None I-NEURON
cells None None I-NEURON
( None None O
ipRGCs None None O
) None None O
in None None O
rdcl None None O
mice None None O
& None None O
gt None None O
; None None O
1.5 None None O
years None None O
. None None O

Our None None O
results None None O
revealed None None O
that None None O
( None None O
i None None O
) None None O
passive None None O
displacement None None O
of None None O
one None None O
arm None None O
( None None O
displacement None None O
of None None O
the None None O
left None None O
arm None None O
via None None O
a None None O
motorized None None O
manipulandum None None O
moving None None O
at None None O
4°/s None None O
) None None O
influenced None None O
the None None O
velocity None None O
of None None O
the None None O
Kohnstamm None None O
phenomenon None None O
( None None O
forearm None None O
flexion None None O
occurring None None O
shortly None None O
after None None O
the None None O
cessation None None O
of None None O
muscle None None O
contraction None None O
) None None O
in None None O
the None None O
contralateral None None O
arm None None O
and None None O
( None None O
ii None None O
) None None O
mirror None None O
vision None None I-FUNC
had None None O
no None None O
effect None None O
. None None O

In None None O
the None None O
dorsal None None I-NEURON
facial None None O
area None None O
( None None O
DFA None None O
) None None O
of None None O
the None None O
medulla None None O
, None None O
an None None O
activation None None O
of None None O
either None None O
P2 None None O
purinergic None None O
receptor None None I-PROTEIN
or None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
NOS None None I-TRANS
) None None O
results None None O
in None None O
the None None O
release None None O
of None None O
glutamate None None I-TRANS
, None None O
leading None None O
to None None O
an None None O
increase None None O
in None None O
blood None None O
flow None None O
of None None O
the None None O
common None None O
carotid None None O
artery None None O
( None None O
CCA None None O
) None None O
. None None O

Involvement None None O
of None None O
glutamate None None I-TRANS
release None None O
in None None O
these None None O
responses None None O
were None None O
substantiated None None O
by None None O
microdialysis None None O
studies None None O
, None None O
in None None O
which None None O
perfusions None None O
of None None O
ATP None None O
into None None O
the None None O
DFA None None O
increased None None O
the None None O
glutamate None None I-TRANS
concentration None None O
in None None O
dialysates None None O
, None None O
but None None O
co-perfusion None None O
of None None O
ATP None None O
with None None O
L-NAME None None O
or None None O
7-NI None None O
did None None O
not None None O
. None None O

In None None O
conclusion None None O
, None None O
ATP None None O
activation None None O
of None None O
the None None O
P2 None None O
receptor None None I-PROTEIN
in None None O
the None None O
DFA None None O
induced None None O
activation None None O
of None None O
neuronal None None O
NOS/guanylyl None None O
cyclase None None O
, None None O
which None None O
causes None None O
glutamate None None I-TRANS
release None None O
leading None None O
to None None O
an None None O
increase None None O
in None None O
CCA None None O
blood None None O
flow None None O
. None None O

The None None O
mRNA None None O
expression None None O
levels None None O
of None None O
the None None O
corticosteroid None None O
receptors None None I-PROTEIN
mineralocorticoid None None O
( None None O
MR None None O
, None None O
Nr3c2 None None O
) None None O
and None None O
glucocorticoid None None O
( None None O
GR None None O
, None None O
Nr3c1 None None O
) None None O
, None None O
selected None None O
stress None None O
dependent None None O
genes None None O
and None None O
glial None None O
markers None None O
were None None O
analyzed None None O
in None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
, None None O
hippocampus None None I-REGION
and None None O
striatum None None I-REGION
. None None O

Behavioral None None O
alterations None None O
were None None O
accompanied None None O
by None None O
a None None O
decrease None None O
in None None O
the None None O
mRNA None None O
expression None None O
of None None O
GR None None O
and None None O
the None None O
increased None None O
expression None None O
of None None O
Fkbp5 None None O
and None None O
Sgk1 None None O
in None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
, None None O
hippocampus None None I-REGION
and None None O
striatum None None I-REGION
of None None O
DEX-treated None None O
mice None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
the None None O
prolonged None None O
activation None None O
of None None O
GR None None O
receptors None None I-PROTEIN
induced None None O
a None None O
depression-like None None O
state None None O
in None None O
mice None None O
, None None O
activated None None O
stress-related None None O
genes None None O
and None None O
induced None None O
a None None O
decrease None None O
in None None O
the None None O
mRNA None None O
expression None None O
of None None O
GLAST None None O
, None None O
an None None O
astroglial None None O
marker None None O
, None None O
in None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
and None None O
hippocampus None None I-REGION
. None None O

Recombinant None None O
SIRT3 None None O
treatment None None O
resulted None None O
in None None O
increased None None O
expression None None O
of None None O
peroxisome None None O
proliferator None None O
activated None None O
receptor None None I-PROTEIN
( None None O
PPAR None None O
) None None O
-γ None None O
co-activator None None O
1-α None None O
( None None O
PGC-1α None None O
) None None O
and None None O
manganese None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
MnSOD None None O
) None None O
. None None O

At None None O
T1 None None O
, None None O
the None None O
intervention None None O
was None None O
rated None None O
to None None O
be None None O
moderately None None O
to None None O
highly None None O
effective None None O
for None None O
three None None O
performance-related None None O
factors None None O
: None None O
strengthening None None O
muscles None None O
that None None O
support None None O
playing None None O
, None None O
learning None None I-FUNC
techniques None None O
that None None O
support None None O
playing None None O
, None None O
and None None O
posture None None O
. None None O

A None None O
few None None O
studies None None O
have None None O
suggested None None O
a None None O
relationship None None O
between None None O
thyroid None None O
hormones None None I-PROTEIN
and None None O
alcohol None None I-DISEASE
dependence None None I-DISEASE
( None None O
AD None None O
) None None O
such None None O
as None None O
a None None O
blunted None None O
increase None None O
of None None O
thyroid None None O
stimulating None None O
hormone None None O
( None None O
TSH None None O
) None None O
in None None O
response None None O
to None None O
thyrotropin-releasing None None O
hormone None None O
( None None O
TRH None None I-TRANS
) None None O
, None None O
lower None None O
levels None None O
of None None O
circulating None None O
free None None O
triiodothyronine None None O
( None None O
fT3 None None O
) None None O
and None None O
free None None O
thyroxine None None O
( None None O
fT4 None None O
) None None O
levels None None O
and None None O
down None None O
regulation None None O
of None None O
the None None O
TRH None None I-TRANS
receptors None None I-PROTEIN
. None None O

Blood None None O
levels None None O
of None None O
thyroid None None O
hormones None None I-PROTEIN
( None None O
TSH None None O
, None None O
fT3 None None O
and None None O
fT4 None None O
) None None O
were None None O
measured None None O
prior None None O
to None None O
and None None O
at None None O
the None None O
end None None O
of None None O
treatment None None O
. None None O

Balance None None O
can None None O
impact None None O
ACL None None O
injury None None O
risk None None O
and None None O
is None None O
related None None O
to None None O
neuromuscular None None O
control None None O
during None None O
movement None None I-FUNC
. None None O

Point-mutation None None O
of None None O
cysteine None None I-TRANS
codons None None O
indicated None None O
that None None O
cysteine None None I-TRANS
232 None None O
is None None O
involved None None O
in None None O
protein None None O
aggregation None None O
. None None O

It None None O
offers None None O
some None None O
new None None O
features None None O
like None None O
tactile None None O
perception None None I-FUNC
, None None O
open None None O
site None None O
view None None O
, None None O
eye-tracking None None O
control None None O
of None None O
the None None O
camera None None O
, None None O
and None None O
optimal None None O
ergonomics None None O
. None None O

The None None O
Telelap None None O
Alf-X None None O
's None None O
docking None None O
took None None O
less None None O
than None None O
one None None O
minute None None O
, None None O
the None None O
system None None O
was None None O
versatile None None O
during None None O
each None None O
step None None O
of None None O
the None None O
nephrectomy None None O
and None None O
the None None O
operative None None O
times None None O
have None None O
reduced None None O
dramatically None None O
along None None O
the None None O
learning None None I-FUNC
curve None None O
. None None O

PKCε None None O
overexpression None None O
and None None O
activation None None O
: None None O
i None None O
) None None O
reduced None None O
the None None O
expression None None O
levels None None O
of None None O
SMA None None O
and None None O
PECAM None None O
in None None O
endothelial None None O
differentiation None None O
of None None O
PVAT None None O
cells None None O
; None None O
ii None None O
) None None O
completely None None O
abrogated None None O
tubules None None O
formation None None O
in None None O
collagen None None I-PROTEIN
gel None None O
assays None None O
; None None O
iii None None O
) None None O
increased None None O
the None None O
expression None None O
of None None O
p-PAK1 None None O
. None None O

Hydrogen None None I-TRANS
sulfide None None I-TRANS
is None None O
a None None O
mediator None None O
of None None O
IRI None None O
and None None O
can None None O
ameliorate None None O
tissue None None O
injury None None O
in None None O
many None None O
organ None None O
systems None None O
. None None O

We None None O
assessed None None O
the None None O
role None None O
of None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
in None None O
a None None O
rodent None None O
model None None O
of None None O
aortic None None O
occlusion None None O
. None None O

Ten None None O
minutes None None O
before None None O
clamp None None O
release None None O
, None None O
treatment None None O
animals None None O
received None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
( None None O
10 None None O
, None None O
30 None None O
, None None O
or None None O
50 None None O
μg/kg None None O
) None None O
and None None O
control None None O
animals None None O
received None None O
0.9 None None O
% None None O
saline None None O
injected None None O
into None None O
the None None O
retroperitoneum None None O
. None None O

The None None O
procedure None None O
was None None O
identical None None O
to None None O
the None None O
nonrecovery None None O
arm None None O
but None None O
with None None O
a None None O
single None None O
dose None None O
of None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
( None None O
30 None None O
μg/kg None None O
) None None O
and None None O
animals None None O
were None None O
recovered None None O
for None None O
7 None None O
days None None O
. None None O

Hydrogen None None I-TRANS
sulfide None None I-TRANS
has None None O
systemic None None O
and None None O
renal None None O
anti-inflammatory None None O
effects None None O
in None None O
remote None None O
IRI None None O
following None None O
aortic None None O
occlusion None None O
in None None O
rats None None O
. None None O

On None None O
pathology None None O
, None None O
23 None None O
patients None None O
( None None O
41 None None O
% None None O
) None None O
had None None O
small-vessel None None O
atherosclerosis None None I-DISEASE
or None None O
arteriosclerosis None None O
. None None O

WAT None None O
is None None O
involved None None O
in None None O
energy None None O
storage None None I-FUNC
, None None O
whereas None None O
BAT None None O
is None None O
involved None None O
in None None O
energy None None O
expenditure None None O
. None None O

Using None None O
next-generation None None O
amplicon None None O
sequencing None None O
with None None O
the None None O
454 None None O
pyrosequencing None None O
technology None None O
, None None O
we None None O
compiled None None O
a None None O
dataset None None O
consisting None None O
of None None O
42 None None O
nuclear None None O
loci None None O
in None None O
45 None None O
East None None O
African None None O
cichlid None None O
species None None O
, None None O
which None None O
we None None O
subjected None None O
to None None O
maximum None None O
likelihood None None O
and None None O
Bayesian None None O
inference None None I-FUNC
phylogenetic None None O
analyses None None O
. None None O

We None None O
aimed None None O
to None None O
describe None None O
the None None O
difference None None O
between None None O
perceived None None O
versus None None O
measured None None O
CPR None None O
quality None None O
, None None O
and None None O
to None None O
determine None None O
the None None O
impact None None O
of None None O
provider None None O
role None None O
, None None O
real-time None None O
visual None None O
CPR None None O
feedback None None O
and None None O
Just-in-Time None None O
( None None O
JIT None None O
) None None O
CPR None None O
training None None O
on None None O
provider None None O
perceptions None None I-FUNC
. None None O

Healthcare None None O
providers None None O
' None None O
visual None None I-FUNC
perception None None I-FUNC
of None None O
CPR None None O
quality None None O
is None None O
poor None None O
. None None O

Ail None None O
in None None O
nanodiscs None None O
is None None O
capable None None O
of None None O
binding None None O
its None None O
human None None O
ligand None None O
fibronectin None None I-PROTEIN
and None None O
also None None O
yields None None O
high None None O
quality None None O
NMR None None O
spectra None None O
that None None O
reflect None None O
the None None O
proper None None O
fold None None O
. None None O

Data None None O
for None None O
age None None O
, None None O
sex None None O
, None None O
smoking None None O
status None None O
, None None O
alcohol None None O
consumption None None O
, None None O
body None None O
mass None None O
index None None O
, None None O
blood None None O
pressure None None O
, None None O
blood None None O
glucose None None O
, None None O
triglycerides None None O
and None None O
cholesterol None None O
, None None O
and None None O
the None None O
presence None None O
of None None O
chronic None None O
non-communicable None None O
diseases None None O
, None None O
including None None O
diagnosis None None O
of None None O
depression None None I-DISEASE
and None None O
the None None O
presence None None O
of None None O
stress None None O
were None None O
entered None None O
in None None O
medical None None O
records None None O
. None None O

However None None O
, None None O
few None None O
studies None None O
have None None O
examined None None O
changes None None O
in None None O
the None None O
enzymes None None I-PROTEIN
of None None O
the None None O
tricarboxylic None None O
acid None None O
cycle None None O
. None None O

The None None O
present None None O
study None None O
aims None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
lithium None None O
, None None O
valproate None None O
and None None O
sodium None None O
butyrate None None O
, None None O
a None None O
histone None None O
deacetylase None None O
inhibitor None None O
, None None O
on None None O
the None None O
activity None None O
of None None O
tricarboxylic None None O
acid None None O
cycle None None O
enzymes None None I-PROTEIN
in None None O
the None None O
brains None None O
of None None O
rats None None O
subjected None None O
to None None O
an None None O
animal None None O
model None None O
of None None O
mania None None O
induced None None O
by None None O
ouabain None None O
. None None O

Citrate None None O
synthase None None O
, None None O
succinate None None O
dehydrogenase None None I-PROTEIN
, None None O
and None None O
malate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
were None None O
examined None None O
in None None O
the None None O
frontal None None I-REGION
cortex None None I-REGION
and None None O
hippocampus None None I-REGION
. None None O

Ouabain None None O
inhibited None None O
tricarboxylic None None O
acid None None O
cycle None None O
enzymes None None I-PROTEIN
in None None O
the None None O
brain None None O
, None None O
and None None O
valproate None None O
and None None O
sodium None None O
butyrate None None O
but None None O
not None None O
lithium None None O
reversed None None O
this None None O
ouabain-induced None None O
dysfunction None None O
. None None O

In None None O
particular None None O
, None None O
acute None None O
neurotensin None None I-TRANS
receptor None None I-PROTEIN
activation None None O
can None None O
inhibit None None O
conditioned None None O
avoidance None None O
response None None O
( None None O
CAR None None O
) None None O
, None None O
attenuate None None O
phencyclidine None None O
( None None O
PCP None None O
) None None O
-induced None None O
prepulse None None O
inhibition None None O
( None None O
PPI None None O
) None None O
disruptions None None O
, None None O
and None None O
reverse None None O
PCP-induced None None O
hyperlocomotion None None O
. None None O

Since None None O
clinical None None O
administration None None O
of None None O
antipsychotic None None O
therapy None None O
often None None O
requires None None O
a None None O
prolonged None None O
treatment None None O
schedule None None O
, None None O
here None None O
we None None O
assessed None None O
the None None O
effects None None O
of None None O
repeated None None O
activation None None O
of None None O
neurotensin None None I-TRANS
receptors None None I-PROTEIN
using None None O
an None None O
NTS1 None None O
receptor None None I-PROTEIN
selective None None O
agonist None None O
, None None O
PD149163 None None O
, None None O
in None None O
3 None None O
behavioral None None O
tests None None O
of None None O
antipsychotic None None O
activity None None O
. None None O

Peptidomic None None O
analysis None None O
of None None O
host-defense None None O
peptides None None I-TRANS
in None None O
norepinephrine-stimulated None None O
skin None None O
secretions None None O
from None None O
frogs None None O
from None None O
the None None O
Cape None None O
Peninsula None None O
range None None O
resulted None None O
in None None O
the None None O
identification None None O
of None None O
two None None O
magainins None None O
, None None O
two None None O
peptide None None O
glycine-leucine-amide None None O
( None None O
PGLa None None O
) None None O
peptides None None I-TRANS
, None None O
two None None O
xenopsin-precursor None None O
fragment None None O
( None None O
XPF None None O
) None None O
peptides None None I-TRANS
, None None O
nine None None O
caerulein-precursor None None O
fragment None None O
( None None O
CPF None None O
) None None O
peptides None None I-TRANS
, None None O
and None None O
a None None O
peptide None None O
related None None O
to None None O
peptide None None O
glycine-glutamine None None O
( None None O
PGQ None None O
) None None O
previously None None O
found None None O
in None None O
an None None O
extract None None O
of None None O
Xenopus None None O
laevis None None O
stomach None None O
. None None O

Consistent None None O
with None None O
previous None None O
data None None O
, None None O
the None None O
CPF None None O
peptides None None I-TRANS
show None None O
the None None O
greatest None None O
antimicrobial None None O
potency None None O
but None None O
are None None O
hemolytic None None O
. None None O

Conversely None None O
, None None O
PGLa-G3 None None O
, None None O
XPF-G3 None None O
, None None O
and None None O
three None None O
CPF None None O
peptides None None I-TRANS
were None None O
identified None None O
in None None O
the None None O
Kleinmond None None O
frogs None None O
but None None O
not None None O
in None None O
the None None O
Cape None None O
Peninsula None None O
animals None None O
. None None O

Blocking None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
or None None O
aryl None None O
hydrocarbon None None O
receptor None None I-PROTEIN
by None None O
the None None O
antagonist None None O
abolished None None O
the None None O
effects None None O
of None None O
CB126 None None O
on None None O
the None None O
expressions None None O
of None None O
inflammatory None None O
factors None None O
. None None O

NMDA None None O
receptors None None I-PROTEIN
have None None O
been None None O
implicated None None O
in None None O
pathways None None O
of None None O
excitotoxic None None O
damage None None O
to None None O
neurons None None O
and None None O
the None None O
onset None None O
of None None O
high None None O
pressure None None O
neurological None None O
syndrome None None O
( None None O
HPNS None None O
) None None O
in None None O
mammals None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
administration None None O
of None None O
a None None O
soluble None None O
, None None O
intestinal-like None None O
chimeric None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ChimAP None None O
) None None O
improves None None O
the None None O
manifestations None None O
of None None O
HPP None None O
in None None O
Alpl None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Fibronectin None None I-PROTEIN
isoforms None None O
that None None O
include None None O
the None None O
EDA None None O
and None None O
EDB None None O
domains None None O
are None None O
prominent None None O
in None None O
these None None O
fibronectin None None I-PROTEIN
matrices None None O
. None None O

These None None O
changes None None O
are None None O
accompanied None None O
by None None O
an None None O
increase None None O
in None None O
fibronectin None None I-PROTEIN
synthesis None None O
and None None O
fibrillogenesis None None O
. None None O

Our None None O
data None None O
indicate None None O
that None None O
the None None O
interaction None None O
between None None O
the None None O
α4β1 None None O
integrin None None I-PROTEIN
and None None O
the None None O
EDA None None O
domain None None O
of None None O
fibronectin None None I-PROTEIN
helps None None O
to None None O
drive None None O
tissue None None O
fibrosis None None O
by None None O
promoting None None O
a None None O
contractile None None O
phenotype None None O
and None None O
an None None O
increase None None O
in None None O
fibronectin None None I-PROTEIN
synthesis None None O
and None None O
deposition None None O
. None None O

Therefore None None O
, None None O
during None None O
hernia None None O
repair None None O
, None None O
more None None O
attention None None I-FUNC
and None None O
adhesiolysis None None O
is None None O
essential None None O
during None None O
inspection None None O
of None None O
the None None O
inguinal None None O
floor None None O
. None None O

The None None O
study None None O
examined None None O
the None None O
extent None None O
to None None O
which None None O
patients None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
are None None O
involved None None O
in None None O
decisions None None O
regarding None None O
their None None O
treatment None None O
and None None O
whether None None O
they None None O
are None None O
interested None None O
in None None O
ensuring None None O
safety None None O
during None None O
hospitalization None None O
. None None O

The None None O
comparison None None O
of None None O
the None None O
domain None None O
scores None None O
of None None O
population None None O
standards None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
and None None O
the None None O
respondents None None O
with None None O
Crohn None None O
's None None O
disease None None O
revealed None None O
a None None O
difference None None O
in None None O
the None None O
domain None None O
`` None None O
physical None None O
condition None None O
'' None None O
, None None O
where None None O
the None None O
mean None None O
value None None O
was None None O
at None None O
the None None O
limit None None O
of None None O
the None None O
lower None None O
interval None None O
of None None O
the None None O
standard None None O
, None None O
and None None O
in None None O
the None None O
domain None None O
of None None O
`` None None O
independence None None O
'' None None O
. None None O

Our None None O
results None None O
lead None None O
us None None O
to None None O
conclude None None O
that None None O
the None None O
health None None O
care None None O
system None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
needs None None O
to None None O
better None None O
utilize None None O
the None None O
potential None None O
of None None O
trained None None O
nurses None None O
in None None O
the None None O
field None None O
of None None O
community None None O
health None None O
care None None O
. None None O

increased None None O
levels None None O
of None None O
anxiety None None O
and None None O
depression None None I-DISEASE
) None None O
. None None O

Depression None None I-DISEASE
, None None O
anxiety None None O
, None None O
panic None None O
attacks None None O
, None None O
stress None None O
and None None O
post-traumatic None None O
stress None None O
are None None O
the None None O
most None None O
common None None O
symptoms None None O
of None None O
ICD-related None None O
disorders None None O
that None None O
can None None O
negatively None None O
impact None None O
mental None None O
status None None O
. None None O

To None None O
compile None None O
a None None O
proposal None None O
of None None O
the None None O
system None None O
of None None O
taking None None O
complex None None O
prenatal None None O
, None None O
perinatal None None O
and None None O
postnatal None None O
care None None O
of None None O
pregnant None None O
immigrants None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
with None None O
taking None None O
into None None O
account None None O
medical None None O
and None None O
salutogenic None None O
approaches None None O
. None None O

In None None O
the None None O
Czech None None I-TRANS
Republic None None O
, None None O
the None None O
medical None None O
care None None O
is None None O
at None None O
a None None O
higher None None O
level None None O
compared None None O
to None None O
native None None O
countries None None O
. None None O

To None None O
compile None None O
a None None O
proposal None None O
of None None O
the None None O
system None None O
of None None O
taking None None O
complex None None O
prenatal None None O
, None None O
perinatal None None O
and None None O
postnatal None None O
care None None O
of None None O
pregnant None None O
women None None O
and None None O
their None None O
children None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
with None None O
taking None None O
into None None O
account None None O
medical None None O
and None None O
salutogenic None None O
approaches None None O
. None None O

The None None O
study None None O
included None None O
541 None None O
women None None O
from None None O
five None None O
Czech None None I-TRANS
regions None None O
. None None O

This None None O
study None None O
is None None O
part None None O
of None None O
a None None O
project None None O
entitled None None O
the None None O
`` None None O
Health None None O
and None None O
Social None None O
Status None None O
of None None O
Immigrants None None O
and None None O
Asylum None None O
Seekers None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
'' None None O
( None None O
registration None None O
number None None O
OC None None O
10031 None None O
) None None O
, None None O
which None None O
was None None O
started None None O
in None None O
2010 None None O
and None None O
concluded None None O
in None None O
May None None O
2011 None None O
. None None O

The None None O
SSS None None O
study None None O
clearly None None O
revealed None None O
typical None None O
links None None O
among None None O
select None None O
nationalities None None O
living None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
, None None O
and None None O
highlighted None None O
risks None None O
related None None O
to None None O
the None None O
degree None None O
of None None O
integration None None O
( None None O
and None None O
its None None O
relationship None None O
to None None O
social None None O
exclusion None None O
) None None O
. None None O

The None None O
follow-up None None O
study None None O
included None None O
1 None None O
000 None None O
respondents None None O
of None None O
Slovak None None O
, None None O
Vietnamese None None O
, None None O
Ukrainian None None O
, None None O
Russian None None O
and None None O
Polish None None O
nationality None None O
and None None O
is None None O
currently None None O
underway None None O
at None None O
the None None O
Faculty None None O
of None None O
Health None None O
and None None O
Social None None O
Studies None None O
at None None O
the None None O
University None None O
of None None O
South None None O
Bohemia None None O
in None None O
the None None O
Czech None None I-TRANS
Republic None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
paper None None O
explores None None O
the None None O
possibility None None O
of None None O
adapting None None O
the None None O
methodology None None O
to None None O
different None None O
medical None None O
departments None None O
( None None O
surgery None None O
, None None O
stroke None None I-DISEASE
, None None O
and None None O
mental None None O
illness None None O
) None None O
. None None O

Cysteine None None I-TRANS
is None None O
one None None O
of None None O
the None None O
least None None O
abundant None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
yet None None O
it None None O
is None None O
frequently None None O
found None None O
as None None O
a None None O
highly None None O
conserved None None O
residue None None O
within None None O
functional None None O
( None None O
regulatory None None O
, None None O
catalytic None None O
, None None O
or None None O
binding None None O
) None None O
sites None None O
in None None O
proteins None None O
. None None O

Highlighted None None O
in None None O
this None None O
review None None O
are None None O
some None None O
of None None O
the None None O
basic None None O
biophysical None None O
and None None O
biochemical None None O
properties None None O
of None None O
cysteine None None I-TRANS
groups None None O
and None None O
the None None O
equations None None O
that None None O
apply None None O
to None None O
them None None O
, None None O
particularly None None O
with None None O
respect None None O
to None None O
pKa None None O
and None None O
redox None None O
potential None None O
. None None O

Ten None None O
NMOSD None None O
patients None None O
( None None O
40 None None O
% None None O
) None None O
had None None O
brain None None O
lesions None None O
that None None O
did None None O
not None None O
meet None None O
the None None O
Matthews None None O
criteria None None O
( None None O
MS None None O
were None None O
separated None None O
from None None O
NMOSD None None O
by None None O
the None None O
presence None None O
of None None O
at None None O
least None None O
1 None None O
lesion None None O
adjacent None None O
to None None O
the None None O
body None None O
of None None O
the None None O
lateral None None I-REGION
ventricle None None I-REGION
and None None O
in None None O
the None None O
inferior None None O
temporal None None I-REGION
lobe None None I-REGION
; None None O
or None None O
the None None O
presence None None O
of None None O
a None None O
subcortical None None O
U-fiber None None O
lesion None None O
or None None O
a None None O
Dawson None None O
finger-type None None O
lesion None None O
) None None O
. None None O

Enabling None None O
people None None O
with None None O
dementia None None I-DISEASE
and None None O
carers None None O
to None None O
'live None None O
well None None O
' None None O
with None None O
the None None O
condition None None O
is None None O
a None None O
key None None O
United None None O
Kingdom None None O
policy None None O
objective None None O
. None None O

Over None None O
a None None O
two-year None None O
period None None O
, None None O
1500 None None O
people None None O
with None None O
early-stage None None O
dementia None None I-DISEASE
throughout None None O
Great None None O
Britain None None O
will None None O
be None None O
recruited None None O
to None None O
the None None O
study None None O
, None None O
together None None O
with None None O
a None None O
carer None None O
wherever None None O
possible None None O
. None None O

This None None O
will None None O
provide None None O
information None None O
about None None O
the None None O
way None None O
in None None O
which None None O
well-being None None O
, None None O
life None None O
satisfaction None None O
and None None O
quality None None O
of None None O
life None None O
are None None O
affected None None O
by None None O
social None None O
capitals None None O
, None None O
assets None None O
and None None O
resources None None O
, None None O
the None None O
challenges None None O
posed None None O
by None None O
dementia None None I-DISEASE
, None None O
and None None O
the None None O
ways None None O
in None None O
which None None O
people None None O
adjust None None O
to None None O
and None None O
cope None None O
with None None O
these None None O
challenges None None O
. None None O

The None None O
findings None None O
will None None O
lead None None O
to None None O
recommendations None None O
about None None O
what None None O
can None None O
be None None O
done None None O
by None None O
individuals None None O
, None None O
communities None None O
, None None O
health None None O
and None None O
social None None O
care None None O
practitioners None None O
, None None O
care None None O
providers None None O
and None None O
policy-makers None None O
to None None O
improve None None O
the None None O
likelihood None None O
of None None O
living None None O
well None None O
with None None O
dementia None None I-DISEASE
. None None O

A None None O
survey None None O
of None None O
medical None None O
records None None O
was None None O
carried None None O
out None None O
, None None O
collecting None None O
audiological None None O
and None None O
language None None I-FUNC
impairment None None O
diagnostic None None O
data None None O
, None None O
totaling None None O
2424 None None O
individuals None None O
in None None O
the None None O
study None None O
group None None O
. None None O

Different None None O
types None None O
of None None O
biomarkers None None O
, None None O
including None None O
biometric None None O
indices None None O
( None None O
a None None O
condition None None O
factor None None O
K None None O
, None None O
a None None O
gonadosomatic None None O
index None None O
GSI None None O
, None None O
and None None O
a None None O
hepatosomatic None None O
index None None O
HSI None None O
) None None O
, None None O
plasma None None O
levels None None O
of None None O
sex None None I-PROTEIN
steroids None None I-PROTEIN
( None None O
11-ketotestosterone None None O
11-KT None None O
, None None O
testosterone None None O
T None None O
and None None O
estradiol-17β None None O
E2 None None O
) None None O
and None None O
the None None O
histopathology None None O
of None None O
the None None O
gonads None None O
and None None O
liver None None O
, None None O
were None None O
investigated None None O
for None None O
two None None O
different None None O
trophic None None O
levels None None O
of None None O
the None None O
following None None O
two None None O
fish None None O
species None None O
: None None O
the None None O
Guinean None None O
tilapia None None O
Tilapia None None O
guineensis None None O
and None None O
the None None O
African None None O
catfish None None O
Clarias None None O
gariepinus None None O
. None None O

It None None O
seems None None O
that None None O
the None None O
prevailing None None O
climate None None O
conditions None None O
during None None O
the None None O
Maunder None None O
favoured None None O
the None None O
retention None None I-FUNC
of None None O
more None None O
Br None None O
in None None O
marsh None None O
ecosystem None None O
, None None O
ultimately None None O
decreasing None None O
the None None O
biogenic None None O
Br None None O
emissions None None O
to None None O
the None None O
atmosphere None None O
. None None O

Deletion None None O
of None None O
five None None O
amino None None I-TRANS
acids None None I-TRANS
from None None O
the None None O
C-terminal None None O
end None None O
of None None O
FpvI None None O
also None None O
disrupted None None O
interactions None None O
with None None O
FpvR None None O
. None None O

Most None None O
of None None O
these None None O
mutations None None O
as None None O
well None None O
as None None O
deletion None None O
of None None O
thirteen None None O
amino None None I-TRANS
acids None None I-TRANS
from None None O
the None None O
C-terminal None None O
end None None O
of None None O
PvdS None None O
increased None None O
sigma None None O
factor None None O
activity None None O
independent None None O
of None None O
whether None None O
FpvR None None O
was None None O
present None None O
, None None O
suggesting None None O
that None None O
they None None O
increase None None O
either None None O
the None None O
stability None None O
of None None O
PvdS None None O
or None None O
its None None O
affinity None None O
for None None O
core None None O
RNA None None O
polymerase None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
systematically None None O
review None None O
the None None O
management None None O
of None None O
treatment-resistant None None O
depression None None I-DISEASE
in None None O
adolescent None None O
patients None None O
. None None O

Treatment-resistant None None O
depression None None I-DISEASE
was None None O
defined None None O
as None None O
failure None None O
to None None O
respond None None O
to None None O
at None None O
least None None O
one None None O
course None None O
of None None O
psychological None None O
or None None O
pharmacological None None O
treatment None None O
for None None O
depression None None I-DISEASE
with None None O
an None None O
adequate None None O
dosage None None O
, None None O
duration None None O
, None None O
and None None O
appropriate None None O
compliance None None O
during None None O
the None None O
current None None O
illness None None O
episode None None O
. None None O

Approximately None None O
half None None O
of None None O
the None None O
adolescents None None O
who None None O
presented None None O
with None None O
treatment-refractory None None O
depression None None I-DISEASE
responded None None O
to None None O
active None None O
treatment None None O
, None None O
which None None O
suggests None None O
that None None O
practitioners None None O
should None None O
remain None None O
persistent None None O
in None None O
managing None None O
these None None O
challenging None None O
cases None None O
. None None O

Little None None O
research None None O
has None None O
examined None None O
the None None O
support None None O
needs None None O
of None None O
mothers None None O
versus None None O
fathers None None O
of None None O
children None None O
and None None O
adolescents None None O
with None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
. None None O

To None None O
assess None None O
the None None O
accuracy None None O
of None None O
high-resolution None None O
( None None O
HR None None O
) None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
in None None O
diagnosing None None O
early-stage None None O
optic None None I-REGION
nerve None None I-REGION
( None None O
ON None None O
) None None O
invasion None None O
in None None O
a None None O
retinoblastoma None None O
cohort None None O
. None None O

• None None O
Several None None O
physiological None None O
MR None None O
patterns None None O
may None None O
mimic None None O
optic None None I-REGION
nerve None None I-REGION
invasion None None O
. None None O

Published None None O
by None None O
Elsevier None None O
Ireland None None O
Ltd. None None O
Crizotinib None None O
is None None O
the None None O
first None None O
clinically None None O
available None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
that None None O
targets None None O
anaplastic None None O
lymphoma None None O
kinase None None O
( None None O
ALK None None O
) None None O
and None None O
is None None O
associated None None O
with None None O
the None None O
development None None O
of None None O
complex None None O
renal None None O
cysts None None O
. None None O

After None None O
adjusting None None O
for None None O
demographic None None O
variables None None O
, None None O
two None None O
dimensional None None O
measures None None O
showed None None O
significant None None O
inverse None None O
relationships None None O
with None None O
resting None None O
state None None O
connectivity None None O
, None None O
regardless None None O
of None None O
diagnosis None None O
: None None O
1 None None O
) None None O
PGBI-10M None None O
with None None O
amygdala-left None None O
posterior None None O
insula/bilateral None None O
putamen None None I-REGION
; None None O
and None None O
2 None None O
) None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
with None None O
amygdala-right None None O
posterior None None O
insula None None I-REGION
connectivity None None O
. None None O

Resting None None O
state None None O
connectivity None None O
between None None O
amygdala None None I-REGION
and None None O
posterior None None O
insula None None I-REGION
decreased None None O
with None None O
increasing None None O
severity None None O
of None None O
behavioral None None O
and None None O
emotional None None O
dysregulation None None O
and None None O
depression None None I-DISEASE
; None None O
this None None O
suggests None None O
an None None O
intrinsic None None O
functional None None O
uncoupling None None O
of None None O
key None None O
neural None None O
regions None None O
supporting None None O
emotion None None I-FUNC
processing None None O
and None None O
regulation None None O
. None None O

Compared None None O
to None None O
the None None O
control None None O
Arabidopsis None None O
, None None O
the None None O
frozen None None O
leaves None None O
of None None O
JcCBF2-overexpressed None None O
seedlings None None O
grow None None O
stronger None None O
with None None O
less None None O
malondialdehyde None None O
, None None O
smaller None None O
leaf None None O
conductivity None None O
and None None O
activer None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
showing None None O
their None None O
higher None None O
freezing None None O
tolerance None None O
. None None O

The None None O
initial None None O
1GHQ None None O
structure None None O
is None None O
at None None O
odds None None O
with None None O
the None None O
majority None None O
of None None O
existing None None O
biochemical None None O
data None None O
and None None O
the None None O
publication None None O
of None None O
the None None O
3OED None None O
structure None None O
renewed None None O
uncertainty None None O
regarding None None O
the None None O
physiological None None O
relevance None None O
of None None O
1GHQ None None O
, None None O
suggesting None None O
that None None O
crystallization None None O
may None None O
have None None O
been None None O
influenced None None O
by None None O
the None None O
presence None None O
of None None O
zinc None None I-TRANS
acetate None None O
in None None O
the None None O
crystallization None None O
process None None O
. None None O

We None None O
also None None O
observe None None O
that None None O
nonphysiological None None O
zinc None None I-TRANS
ions None None O
enhance None None O
the None None O
formation None None O
of None None O
the None None O
C3d None None O
: None None O
CR2 None None O
complex None None O
at None None O
the None None O
side None None O
face None None O
of None None O
C3d None None O
( None None O
1GHQ None None O
) None None O
through None None O
increases None None O
in None None O
electrostatic None None O
favorability None None O
, None None O
intermolecular None None O
interactions None None O
, None None O
dissociative None None O
character None None O
and None None O
overall None None O
energetic None None O
favorability None None O
. None None O

Evidence None None O
that None None O
thiazolidinediones None None O
( None None O
TZDs None None O
) None None O
increase None None O
fracture None None O
risk None None O
in None None O
women None None O
with None None O
T2DM None None O
has None None O
focused None None O
attention None None I-FUNC
on None None O
the None None O
skeletal None None O
effects None None O
of None None O
treatments None None O
for None None O
diabetes None None O
. None None O

20 None None O
new None None O
NiTi None None O
instruments None None O
were None None O
used None None O
in None None O
the None None O
present None None O
study None None O
( None None O
TF None None O
tip None None O
size None None O
35 None None O
, None None O
0.06 None None O
taper None None O
; None None O
Sybron-Endo None None O
, None None O
Orange None None O
, None None O
CA None None O
, None None O
USA None None O
) None None O
, None None O
divided None None O
into None None O
2 None None O
subgroups None None O
of None None O
10 None None O
instruments None None O
each None None O
, None None O
depending None None O
on None None O
which None None O
movement None None I-FUNC
was None None O
selected None None O
on None None O
the None None O
endodontic None None O
motor None None O
. None None O

The None None O
regenerative None None O
ability None None O
of None None O
olfactory None None I-NEURON
receptor None None I-NEURON
neurons None None I-NEURON
relies None None O
on None None O
specific None None O
glial None None O
cells None None O
, None None O
the None None O
olfactory None None O
and None None O
vomeronasal None None O
axon-surrounding None None O
cells None None O
. None None O

S100 None None O
, None None O
GFAP None None O
and None None O
NCAM None None I-PROTEIN
were None None O
clearly None None O
observed None None O
. None None O

Thus None None O
, None None O
the None None O
dopaminergic None None O
ventral None None I-NEURON
midbrain None None I-REGION
may None None O
contribute None None O
to None None O
the None None O
tonic None None O
activity None None O
in None None O
auditory None None O
cortex None None O
that None None O
has None None O
been None None O
proposed None None O
to None None O
be None None O
involved None None O
in None None O
associating None None O
events None None O
of None None O
auditory None None O
tasks None None O
( None None O
Brosch None None O
et None None O
al None None O
. None None O

This None None O
study None None O
indicates None None O
the None None O
impact None None O
of None None O
nicotine None None O
and None None O
pesticides None None O
( None None O
organochlorine None None O
and None None O
organophosphate None None O
insecticides None None O
used None None O
in None None O
agriculture None None O
) None None O
on None None O
neuronal None None O
α7-nicotinic None None O
acetylcholine None None I-TRANS
receptor None None I-PROTEIN
expression None None O
in None None O
brainstem None None I-REGION
regions None None O
receiving None None O
cholinergic None None O
projections None None O
in None None O
human None None O
perinatal None None O
life None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
presence None None O
of None None O
selected None None O
agricultural None None O
pesticides None None O
in None None O
cerebral None None I-REGION
cortex None None I-REGION
samples None None O
of None None O
the None None O
victims None None O
was None None O
determined None None O
by None None O
specific None None O
analytical None None O
procedures None None O
. None None O

We None None O
detain None None O
that None None O
exposition None None O
to None None O
pesticides None None O
in None None O
pregnancy None None O
produces None None O
homologous None None O
actions None None O
to None None O
those None None O
of None None O
nicotine None None O
on None None O
neuronal None None O
α7-nicotinic None None O
acetylcholine None None I-TRANS
receptor None None I-PROTEIN
, None None O
allowing None None O
to None None O
developmental None None O
alterations None None O
of None None O
brainstem None None I-REGION
vital None None O
centers None None O
in None None O
victims None None O
of None None O
sudden None None O
unexplained None None O
death None None O
. None None O

Based None None O
on None None O
a None None O
broad None None O
analytic None None O
framework None None O
, None None O
423 None None O
participants None None O
diagnosed None None O
with None None O
substance None None I-DISEASE
dependence None None I-DISEASE
only None None O
, None None O
mental None None O
disorders None None O
only None None O
or None None O
co-occurring None None O
disorders None None O
within None None O
a None None O
12-months None None O
period None None O
were None None O
studied None None O
. None None O

Participants None None O
with None None O
dependence None None O
only None None O
and None None O
mental None None O
disorders None None O
only None None O
were None None O
in None None O
contrast None None O
in None None O
terms None None O
of None None O
gender None None O
, None None O
age None None O
, None None O
marital None None O
status None None O
, None None O
self-perception None None O
of None None O
physical None None O
health None None O
, None None O
perception None None I-FUNC
of None None O
the None None O
physical None None O
conditions None None O
of None None O
their None None O
neighbourhood None None O
, None None O
impulsiveness None None O
, None None O
psychological None None O
distress None None O
and None None O
visit None None O
with None None O
a None None O
family None None O
physician None None O
in None None O
previous None None O
12-months None None O
, None None O
while None None O
those None None O
with None None O
co-occurring None None O
disorders None None O
were None None O
in None None O
an None None O
intermediary None None O
position None None O
between None None O
the None None O
other None None O
two None None O
groups None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
is None None O
experimentally None None O
modeled None None O
in None None O
transgenic None None O
( None None O
Tg None None O
) None None O
mice None None O
overexpressing None None O
mutated None None O
forms None None O
of None None O
the None None O
human None None O
amyloid None None O
precursor None None O
protein None None O
either None None O
alone None None O
or None None O
combined None None O
with None None O
mutated None None O
presenilins None None O
and None None O
tau None None O
. None None O

Importantly None None O
, None None O
both None None O
mice None None O
displayed None None O
an None None O
age-related None None O
entorhinal None None I-REGION
cortex None None I-REGION
thinning None None O
and None None O
robust None None O
striatal None None O
atrophy None None O
, None None O
the None None O
latter None None O
associated None None O
with None None O
a None None O
significant None None O
loss None None O
of None None O
synaptophysin None None O
. None None O

Neuropathology None None O
suggests None None O
an None None O
important None None O
role None None O
for None None O
the None None O
locus None None O
coeruleus None None O
( None None O
LC None None O
) None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
pathophysiology None None O
. None None O

We None None O
hypothesize None None O
that None None O
reduced None None O
functional None None O
integration None None O
of None None O
the None None O
LC None None O
reflected None None O
by None None O
lower None None O
brain None None O
functional None None O
connectivity None None O
contributes None None O
to None None O
early None None O
memory None None I-FUNC
dysfunction None None O
. None None O

Connectivity None None O
measures None None O
were None None O
correlated None None O
with None None O
memory None None I-FUNC
scores None None O
. None None O

Our None None O
results None None O
provide None None O
new None None O
evidence None None O
that None None O
the None None O
LC None None O
, None None O
in None None O
interaction None None O
with None None O
the None None O
parahippocampal None None I-REGION
gyrus None None I-REGION
, None None O
may None None O
contribute None None O
to None None O
episodic None None I-FUNC
memory None None I-FUNC
formation None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
found None None O
that None None O
ethanol None None O
improved None None O
the None None O
cognitive None None O
processes None None O
of None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
in None None O
3xTgAD None None O
mice None None O
. None None O

Impaired None None O
olfaction None None I-FUNC
is None None O
another None None O
hallmark None None O
of None None O
AD None None O
tightly None None O
related None None O
to None None O
tau None None O
pathology None None O
in None None O
the None None O
olfactory None None O
pathways None None O
. None None O

Herein None None O
, None None O
we None None O
first None None O
observed None None O
that None None O
human None None O
olfactory None None I-REGION
peduncle None None I-REGION
and None None O
cortex None None O
are None None O
enriched None None O
in None None O
SOM None None O
cells None None O
and None None O
fibers None None O
, None None O
in None None O
aged None None O
postmortem None None O
brains None None O
. None None O

Distinct None None O
molecular None None O
repertoires None None O
of None None O
SOM None None O
peptide None None O
and None None O
receptors None None I-PROTEIN
were None None O
associated None None O
to None None O
sensory None None O
or None None O
cortical None None O
olfactory None None O
processing None None O
structures None None O
. None None O

One None None O
of None None O
these None None O
was None None O
a None None O
premature None None O
stop None None O
codon None None O
that None None O
removed None None O
the None None O
last None None O
101 None None O
amino None None I-TRANS
acids None None I-TRANS
of None None O
the None None O
protein None None O
that None None O
presumably None None O
has None None O
a None None O
negative None None O
effect None None O
on None None O
protein None None O
function None None O
. None None O

However None None O
, None None O
it None None O
is None None O
unclear None None O
whether None None O
oxytocin None None I-TRANS
directly None None O
acts None None O
upon None None O
the None None O
core None None O
face-processing None None O
system None None O
itself None None O
or None None O
indirectly None None O
improves None None O
face None None I-FUNC
recognition None None I-FUNC
via None None O
affective None None O
or None None O
social None None O
salience None None O
mechanisms None None O
. None None O

Participants None None O
in None None O
the None None O
oxytocin None None I-TRANS
condition None None O
outperformed None None O
those None None O
in None None O
the None None O
placebo None None O
condition None None O
on None None O
target-present None None O
trials None None O
, None None O
yet None None O
were None None O
more None None O
likely None None O
to None None O
make None None O
false-positive None None O
errors None None O
on None None O
target-absent None None O
trials None None O
. None None O

These None None O
findings None None O
support None None O
a None None O
social None None O
salience None None O
account None None O
of None None O
the None None O
effects None None O
of None None O
oxytocin None None I-TRANS
on None None O
face None None I-FUNC
recognition None None I-FUNC
and None None O
indicate None None O
that None None O
oxytocin None None I-TRANS
may None None O
impede None None O
face None None I-FUNC
recognition None None I-FUNC
in None None O
certain None None O
scenarios None None O
. None None O

We None None O
developed None None O
a None None O
tool None None O
( None None O
CompareSVM None None O
) None None O
based None None O
on None None O
SVM None None O
to None None O
compare None None O
different None None O
kernel None None O
methods None None O
for None None O
inference None None I-FUNC
of None None O
GRN None None O
. None None O

The None None O
results None None O
obtained None None O
from None None O
CompareSVM None None O
showed None None O
that None None O
accuracy None None O
of None None O
inference None None I-FUNC
method None None O
depends None None O
upon None None O
the None None O
nature None None O
of None None O
experimental None None O
condition None None O
and None None O
size None None O
of None None O
the None None O
network None None O
. None None O

For None None O
network None None O
with None None O
large None None O
number None None O
of None None O
nodes None None O
( None None O
~500 None None O
) None None O
, None None O
choice None None O
of None None O
inference None None I-FUNC
method None None O
depend None None O
upon None None O
nature None None O
of None None O
experimental None None O
condition None None O
. None None O

SF-36 None None O
physical None None O
functioning None None O
and None None O
general None None O
health None None O
perception None None I-FUNC
scores None None O
in None None O
both None None O
groups None None O
were None None O
significantly None None O
lower None None O
in None None O
1 None None O
month None None O
after None None O
surgery None None O
and None None O
were None None O
higher None None O
in None None O
6 None None O
months None None O
after None None O
surgery None None O
, None None O
as None None O
compare None None O
to None None O
before None None O
surgery None None O
. None None O

The None None O
panel None None O
discussed None None O
each None None O
of None None O
the None None O
issues None None O
raised None None O
by None None O
subjects None None O
and None None O
most None None O
terms None None O
were None None O
judged None None O
by None None O
the None None O
panel None None O
as None None O
to None None O
not None None O
require None None O
further None None O
changes None None O
because None None O
the None None O
overall None None O
comprehension None None O
levels None None O
were None None O
relatively None None O
high None None O
and None None O
because None None O
the None None O
translated None None O
terms None None O
were None None O
accurately None None O
rendered None None O
in None None O
the None None O
target None None O
languages None None I-FUNC
. None None O

The None None O
differentially None None O
expressed None None O
proteins None None O
in None None O
the None None O
extraembryonic None None O
tissue None None O
of None None O
SCNT None None O
fetus None None O
included None None O
ATP None None O
or None None O
lipid None None O
binding None None O
proteins None None O
, None None O
antioxidant None None O
proteins None None O
, None None O
translation None None O
elongation None None O
factors None None O
, None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Moreover None None O
, None None O
immunohistochemical None None O
analysis None None O
also None None O
showed None None O
that None None O
the None None O
expression None None O
of None None O
the None None O
catalase None None I-PROTEIN
or None None O
GPX None None O
genes None None O
was None None O
decreased None None O
in None None O
the None None O
extraembryonic None None O
tissue None None O
with None None O
SCNT None None O
fetus None None O
compared None None O
to None None O
those None None O
with None None O
control None None O
fetus None None O
. None None O

Children None None O
with None None O
unilateral None None O
Cerebral None None I-DISEASE
Palsy None None I-DISEASE
( None None O
CP None None O
) None None O
often None None O
show None None O
diminished None None O
awareness None None O
of None None O
the None None O
remaining None None O
capacity None None O
of None None O
their None None O
affected None None O
upper None None O
limb None None O
. None None O

Using None None O
this None None O
data None None O
, None None O
we None None O
developed None None O
a None None O
culturally None None O
and None None O
linguistically None None O
adapted None None O
a None None O
tailored None None O
intervention None None O
that None None O
provides None None O
information None None O
about None None O
HIV None None O
infection None None O
, None None O
treatment None None O
, None None O
and None None O
medication None None O
related None None O
problem None None I-FUNC
solving None None I-FUNC
skills None None O
( None None O
proven None None O
effective None None O
in None None O
English-speaking None None O
populations None None O
) None None O
that None None O
can None None O
be None None O
delivered None None O
using None None O
touch-screen None None O
computers None None O
, None None O
tablets None None O
, None None O
and None None O
smartphones None None O
to None None O
be None None O
tested None None O
in None None O
a None None O
future None None O
study None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
characterize None None O
real-world None None O
treatment None None O
patterns None None O
in None None O
the None None O
prescription None None O
of None None O
antipsychotic None None O
polypharmacy None None O
( None None O
≥ None None O
2 None None O
concurrent None None O
antipsychotics None None O
) None None O
compared None None O
with None None O
antipsychotic None None O
monotherapy None None O
for None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
. None None O

One None None O
quarter None None O
of None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
received None None O
antipsychotic None None O
polypharmacy None None O
. None None O

Moreover None None O
, None None O
Mann-Whitney None None O
test None None O
differentiates None None O
Ca None None O
, None None O
Na None None I-TRANS
, None None O
Zn None None O
, None None O
Sr None None O
, None None O
Co None None O
, None None O
and None None O
Ni None None O
between None None O
minerals None None O
in None None O
oxalate None None O
and None None O
uric None None O
acid None None O
stones None None O
. None None O

The None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
has None None O
all None None O
the None None O
characteristics None None O
of None None O
an None None O
ideal None None O
target None None O
. None None O

Acute None None O
pulmonary None None O
embolism None None I-DISEASE
( None None O
PE None None O
) None None O
can None None O
diminish None None O
patient None None O
quality None None O
of None None O
life None None O
( None None O
QoL None None O
) None None O
. None None O

This None None O
was None None O
a None None O
secondary None None O
analysis None None O
of None None O
an None None O
8-center None None O
, None None O
prospective None None O
randomized None None O
controlled None None O
trial None None O
, None None O
utilizing None None O
multivariate None None O
regression None None O
to None None O
control None None O
for None None O
predefined None None O
predictors None None O
of None None O
worsened None None O
QoL None None O
including None None O
: None None O
age None None O
, None None O
active None None O
malignancy None None O
, None None O
history None None O
of None None O
PE None None O
or None None O
deep None None O
venous None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
, None None O
recurrent None None O
PE None None O
or None None O
DVT None None O
, None None O
chronic None None O
obstructive None None O
pulmonary None None O
disease None None O
and None None O
heart None None O
failure None None O
. None None O

Maintenance None None O
of None None O
endothelial None None O
cell None None O
phenotype None None O
required None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
and None None O
co-culture None None O
with None None O
mouse None None O
proximal None None O
tubular None None O
epithelial None None O
cells None None O
. None None O

Depressive None None I-DISEASE
disorders None None I-DISEASE
are None None O
common None None O
in None None O
children None None O
and None None O
adolescents None None O
and None None O
, None None O
if None None O
left None None O
untreated None None O
, None None O
are None None O
likely None None O
to None None O
recur None None O
in None None O
adulthood None None O
. None None O

To None None O
evaluate None None O
the None None O
effectiveness None None O
of None None O
psychological None None O
therapies None None O
and None None O
antidepressant None None O
medication None None O
, None None O
alone None None O
and None None O
in None None O
combination None None O
, None None O
for None None O
the None None O
treatment None None O
of None None O
depressive None None I-DISEASE
disorder None None I-DISEASE
in None None O
children None None O
and None None O
adolescents None None O
. None None O

We None None O
searched None None O
the None None O
Cochrane None None O
Depression None None I-DISEASE
, None None O
Anxiety None None O
and None None O
Neurosis None None O
Review None None O
Group None None O
's None None O
Specialised None None O
Register None None O
( None None O
CCDANCTR None None O
) None None O
to None None O
11 None None O
June None None O
2014 None None O
. None None O

RCTs None None O
were None None O
eligible None None O
for None None O
inclusion None None O
if None None O
they None None O
compared None None O
i None None O
) None None O
any None None O
psychological None None O
therapy None None O
with None None O
any None None O
antidepressant None None O
medication None None O
, None None O
or None None O
ii None None O
) None None O
a None None O
combination None None O
of None None O
psychological None None O
therapy None None O
and None None O
antidepressant None None O
medication None None O
with None None O
a None None O
psychological None None O
therapy None None O
alone None None O
, None None O
or None None O
an None None O
antidepressant None None O
medication None None O
alone None None O
, None None O
or None None O
iii None None O
) None None O
a None None O
combination None None O
of None None O
psychological None None O
therapy None None O
and None None O
antidepressant None None O
medication None None O
with None None O
a None None O
placebo None None O
or'treatment None None O
as None None O
usual None None O
' None None O
, None None O
or None None O
( None None O
iv None None O
) None None O
a None None O
combination None None O
of None None O
psychological None None O
therapy None None O
and None None O
antidepressant None None O
medication None None O
with None None O
a None None O
psychological None None O
therapy None None O
or None None O
antidepressant None None O
medication None None O
plus None None O
a None None O
placebo.We None None O
included None None O
studies None None O
if None None O
they None None O
involved None None O
participants None None O
aged None None O
between None None O
6 None None O
and None None O
18 None None O
years None None O
, None None O
diagnosed None None O
by None None O
a None None O
clinician None None O
as None None O
having None None O
Major None None I-DISEASE
Depressive None None I-DISEASE
Disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
based None None O
on None None O
Diagnostic None None O
and None None O
Statistical None None O
Manual None None O
( None None O
DSM None None O
) None None O
or None None O
International None None O
Classification None None O
of None None O
Diseases None None O
( None None O
ICD None None O
) None None O
criteria None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
the None None O
available None None O
evidence None None O
, None None O
the None None O
effectiveness None None O
of None None O
these None None O
interventions None None O
for None None O
treating None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
in None None O
children None None O
and None None O
adolescents None None O
can None None O
not None None O
be None None O
established None None O
. None None O

Included None None O
will None None O
be None None O
studies None None O
which None None O
report None None O
quantitative None None O
and/or None None O
qualitative None None O
data None None O
or None None O
review None None O
articles None None O
on None None O
asylum None None O
seekers None None O
in None None O
Germany None None O
, None None O
published None None O
in None None O
German None None O
or None None O
English None None O
language None None I-FUNC
. None None O

Older None None O
adults None None O
of None None O
both None None O
genders None None O
with None None O
five None None O
or None None O
more None None O
years None None O
of None None O
education None None O
, None None O
good None None O
self-rated None None O
health None None O
, None None O
an None None O
absence None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
and None None O
no None None O
family None None O
dysfunction None None O
reported None None O
better None None O
QOL None None O
. None None O

Floating-Harbor None None O
syndrome None None O
is None None O
a None None O
rare None None O
autosomal None None O
dominant None None O
short None None O
stature None None O
syndrome None None O
with None None O
retarded None None O
speech None None I-FUNC
development None None O
, None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
and None None O
dysmorphic None None O
facial None None O
features None None O
. None None O

Although None None O
it None None O
can None None O
not None None O
be None None O
assumed None None O
that None None O
failure None None O
to None None O
self-report None None O
indicates None None O
a None None O
lack None None O
of None None O
awareness None None O
of None None O
CKD None None O
, None None O
our None None O
data None None O
do None None O
suggest None None O
the None None O
need None None O
for None None O
greater None None O
consistency None None O
in None None O
discussions None None O
around None None O
kidney None None O
health None None O
, None None O
with None None O
meaningful None None O
and None None O
relevant None None O
clinical None None O
dialogue None None O
that None None O
is None None O
aligned None None O
with None None O
existing None None O
clinical None None O
encounters None None O
to None None O
enable None None O
shared None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
minimise None None O
anxiety None None O
. None None O

The None None O
mean None None O
change None None O
in None None O
mRSS None None O
at None None O
6 None None O
months None None O
was None None O
not None None O
significantly None None O
different None None O
in None None O
the None None O
IVIG None None O
group None None O
( None None O
-5.3 None None O
± None None O
7.9 None None O
) None None O
compared None None O
to None None O
the None None O
relaxin None None O
trial None None O
( None None O
-4.8 None None O
± None None O
6.99 None None O
, None None O
p None None O
= None None O
0.74 None None O
) None None O
or None None O
MMF None None O
group None None O
( None None O
-3.4 None None O
± None None O
7.4 None None O
, None None O
p None None O
= None None O
0.26 None None O
) None None O
; None None O
however None None O
, None None O
at None None O
12 None None O
months None None O
, None None O
the None None O
mean None None O
change None None O
in None None O
mRSS None None O
was None None O
significantly None None O
better None None O
in None None O
the None None O
IVIG None None O
group None None O
( None None O
-8 None None O
± None None O
8.3 None None O
) None None O
than None None O
in None None O
the None None O
D-pen None None O
( None None O
-2.47 None None O
± None None O
8.6 None None O
, None None O
p None None O
= None None O
0.005 None None O
) None None O
and None None O
collagen None None I-PROTEIN
( None None O
-3.4 None None O
± None None O
7.12 None None O
, None None O
p None None O
= None None O
0.005 None None O
) None None O
groups None None O
, None None O
and None None O
was None None O
comparable None None O
to None None O
the None None O
group None None O
of None None O
primary None None O
MMF None None O
responders None None O
( None None O
-7.1 None None O
± None None O
9 None None O
, None None O
p None None O
= None None O
0.67 None None O
) None None O
. None None O

These None None O
changes None None O
in None None O
RASF None None O
appeared None None O
to None None O
be None None O
related None None O
to None None O
reduced None None O
tumor None None O
necrosis None None O
factor-α None None O
secretion None None O
, None None O
G0/G1 None None O
arrest None None O
, None None O
and None None O
altered None None O
expression None None O
of None None O
various None None O
proteins None None O
including None None O
those None None O
involved None None O
in None None O
angiogenesis None None O
( None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
9 None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
trafficking None None O
) None None O
, None None O
hypoxia None None O
( None None O
hypoxia-inducible None None O
factor-α None None O
, None None O
thioredoxin None None O
domain None None O
containing None None O
5 None None O
) None None O
, None None O
proliferation None None O
( None None O
chromosome None None O
10 None None O
open None None O
reading None None O
frame None None O
116 None None O
) None None O
, None None O
and None None O
inflammation None None O
[ None None O
CCL7 None None O
, None None O
chemokine None None O
( None None O
C-X-C None None O
motif None None O
) None None O
ligand None None O
9 None None O
, None None O
interleukin None None O
26 None None O
] None None O
. None None O

In None None O
the None None O
second None None O
comparison None None O
, None None O
the None None O
pathogen-responsive None None O
TDFs None None O
from None None O
the None None O
partially None None O
resistant None None O
cultivar None None O
were None None O
compared None None O
to None None O
the None None O
cDNA None None O
library None None O
from None None O
inoculated None None O
leaves None None O
of None None O
Rvi6 None None O
( None None O
HcrVf2 None None O
) None None O
-transformed None None O
'Gala None None O
' None None O
lines None None O
( None None O
complete None None O
disease None None O
resistance None None O
) None None O
and None None O
revealed None None O
both None None O
common None None O
physiological None None O
events None None O
, None None O
and None None O
notably None None O
differences None None O
in None None O
the None None O
regulation None None O
of None None O
defense None None O
response None None O
, None None O
the None None O
regulation None None O
of None None O
hydrolase None None I-PROTEIN
activity None None O
, None None O
and None None O
response None None O
to None None O
DNA None None O
damage None None O
. None None O

Dozens None None O
of None None O
randomized None None O
controlled None None O
trials None None O
( None None O
RCTs None None O
) None None O
and None None O
meta-analyses None None O
have None None O
demonstrated None None O
the None None O
efficacy None None O
of None None O
repetitive None None O
transcranial None None O
magnetic None None O
stimulation None None O
( None None O
rTMS None None O
) None None O
for None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
treatment None None O
, None None O
but None None O
there None None O
has None None O
not None None O
been None None O
a None None O
meta-analysis None None O
report None None O
which None None O
evaluates None None O
the None None O
efficacy None None O
and None None O
tolerability None None O
of None None O
rTMS None None O
used None None O
as None None O
an None None O
augmentative None None O
strategy None None O
for None None O
antidepressants None None O
in None None O
treatment-resistant None None O
depression None None I-DISEASE
( None None O
TRD None None O
) None None O
treatment None None O
. None None O

Two None None O
recombinant None None O
arabinosyl None None O
hydrolases None None I-PROTEIN
, None None O
α-L-arabinofuranosidase None None O
from None None O
Geobacillus None None O
sp None None O
. None None O

Based None None O
on None None O
their None None O
unique None None O
modes None None O
of None None O
action None None O
, None None O
both None None O
exo- None None O
and None None O
endo-arabinosyl None None O
hydrolases None None I-PROTEIN
can None None O
work None None O
in None None O
concert None None O
to None None O
catalyze None None O
the None None O
hydrolysis None None O
of None None O
arabinan None None O
to None None O
L-arabinose None None O
. None None O

LGG-treated None None O
mice None None O
were None None O
protected None None O
from None None O
HF None None O
diet-induced None None O
adiposity None None O
and/ None None O
or None None O
insulin None None I-PROTEIN
resistance None None O
when None None O
LGG None None O
was None None O
treated None None O
after None None O
, None None O
not None None O
along None None O
with None None O
, None None O
HF None None O
diet None None O
feeding None None O
. None None O

The None None O
most None None O
widely None None O
investigated None None O
epigenetic None None O
mechanism None None O
is None None O
DNA None None O
methylation None None O
although None None O
also None None O
histone None None O
code None None O
changes None None O
occur None None O
during None None O
the None None O
diverse None None O
steps None None O
of None None O
atherosclerosis None None I-DISEASE
, None None O
such None None O
as None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
vascular None None O
smooth None None O
muscle None None O
cell None None O
( None None O
SMC None None O
) None None O
differentiation None None O
, None None O
and None None O
inflammatory None None O
pathway None None O
activation None None O
. None None O

Furthermore None None O
, None None O
we None None O
also None None O
discuss None None O
the None None O
role None None O
of None None O
non-coding None None O
RNAs None None O
( None None O
ncRNA None None O
) None None O
in None None O
atherosclerosis None None I-DISEASE
. None None O

CXXC5 None None O
is None None O
a None None O
member None None O
of None None O
the None None O
CXXC-type None None O
zinc-finger None None O
domain None None O
containing None None O
protein None None O
family None None O
, None None O
which None None O
is None None O
suggested None None O
to None None O
function None None O
in None None O
gene None None O
transcription None None O
, None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
cytoskeleton None None O
organization None None O
. None None O

Here None None O
, None None O
we None None O
screened None None O
for None None O
the None None O
possible None None O
signaling None None O
pathways None None O
in None None O
which None None O
CXXC5 None None O
might None None O
participate None None O
using None None O
luciferase None None I-PROTEIN
gene None None O
reporters None None O
. None None O

Plant None None O
proline None None I-TRANS
synthesis None None O
depends None None O
on None None O
Δ-pyrroline-5-carboxylate None None O
synthase None None O
( None None O
P5CS None None O
) None None O
gene None None O
. None None O

The None None O
three None None O
orthogonal None None O
encoding None None I-FUNC
gradients None None O
( None None O
through None None O
plane None None O
, None None O
frequency None None O
, None None O
and None None O
phase None None O
) None None O
were None None O
evaluated None None O
independently None None O
in None None O
post-processing None None O
. None None O

Metabolic None None O
syndrome None None O
constitutes None None O
a None None O
constellation None None O
of None None O
findings None None O
including None None O
central None None O
obesity None None O
, None None O
insulin None None I-PROTEIN
resistance/type None None O
2 None None O
diabetes None None O
mellitus None None O
( None None O
DM None None O
) None None O
, None None O
dyslipidemia None None O
and None None O
hypertension None None O
. None None O

Being None None O
central None None O
to None None O
the None None O
development None None O
of None None O
metabolic None None O
syndrome None None O
and None None O
its None None O
other None None O
related None None O
diseases None None O
, None None O
much None None O
focus None None O
has None None O
been None None O
placed None None O
on None None O
identifying None None O
the None None O
mitogenic None None O
effects None None O
of None None O
obesity None None O
and None None O
insulin None None I-PROTEIN
resistance/DM None None O
as None None O
mechanistic None None O
clues None None O
of None None O
the None None O
link None None O
between None None O
metabolic None None O
syndrome None None O
and None None O
cancer None None O
. None None O

Through None None O
variable None None O
activation None None O
of None None O
these None None O
multiple None None O
pathways None None O
, None None O
obesity None None O
and None None O
insulin None None I-PROTEIN
resistance/DM None None O
pre-dispose None None O
to None None O
hematologic None None O
malignancies None None O
, None None O
imposing None None O
the None None O
aggressive None None O
and None None O
chemo-resistant None None O
phenotypes None None O
typically None None O
seen None None O
in None None O
cancer None None O
patients None None O
with None None O
underlying None None O
metabolic None None O
syndrome None None O
. None None O

To None None O
obtain None None O
insights None None O
into None None O
the None None O
effect None None O
of None None O
arginine None None I-TRANS
on None None O
oral None None O
microbial None None O
ecology None None O
, None None O
a None None O
multi-plaque None None O
`` None None O
artificial None None O
mouth None None O
'' None None O
( None None O
MAM None None O
) None None O
biofilm None None O
model None None O
was None None O
inoculated None None O
with None None O
saliva None None O
from None None O
a None None O
healthy None None O
volunteer None None O
and None None O
microcosms None None O
were None None O
grown None None O
for None None O
4 None None O
weeks None None O
with None None O
1.6 None None O
% None None O
( None None O
w/v None None O
) None None O
arginine None None I-TRANS
supplement None None O
( None None O
Arginine None None I-TRANS
) None None O
or None None O
without None None O
( None None O
Control None None O
) None None O
, None None O
samples None None O
were None None O
taken None None O
at None None O
several None None O
time-points None None O
. None None O

The None None O
bacterial None None O
composition None None O
was None None O
determined None None O
by None None O
16S None None O
rRNA None None O
gene None None O
amplicon None None O
sequencing None None O
, None None O
the None None O
presence None None O
and None None O
amount None None O
of None None O
Candida None None O
and None None O
arginine None None I-TRANS
deiminase None None O
system None None O
genes None None O
arcA None None O
and None None O
sagP None None O
by None None O
qPCR None None O
. None None O

The None None O
Arginine None None I-TRANS
microcosms None None O
were None None O
dominated None None O
by None None O
Streptococcus None None O
, None None O
Veillonella None None O
, None None O
and None None O
Neisseria None None O
and None None O
remained None None O
stable None None O
in None None O
time None None O
, None None O
while None None O
the None None O
composition None None O
of None None O
the None None O
Control None None O
microcosms None None O
diverged None None O
significantly None None O
in None None O
time None None O
, None None O
partially None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
Megasphaera None None O
. None None O

The None None O
pH-raising None None O
effect None None O
of None None O
arginine None None I-TRANS
was None None O
confirmed None None O
by None None O
the None None O
pH None None O
and None None O
ammonium None None O
results None None O
. None None O

We None None O
demonstrate None None O
that None None O
supplementation None None O
with None None O
arginine None None I-TRANS
serves None None O
a None None O
health-promoting None None O
function None None O
; None None O
it None None O
enhances None None O
microcosm None None O
resilience None None O
toward None None O
acidification None None O
and None None O
suppresses None None O
outgrowth None None O
of None None O
the None None O
opportunistic None None O
pathogen None None O
Candida None None O
. None None O

Pulmonary None None O
function None None O
tests None None O
showed None None O
a None None O
restrictive None None O
ventilatory None None O
defect None None O
, None None O
with None None O
decreased None None O
carbon None None I-TRANS
monoxide None None I-TRANS
diffusion None None O
capacity None None O
and None None O
marked None None O
hypoxemia None None O
( None None O
PaO2 None None O
61 None None O
mmHg None None O
) None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
dorsal None None I-NEURON
spondylodiscitis None None O
with None None O
a None None O
voluminous None None O
Pott None None O
's None None O
abscess None None O
compressing None None O
the None None O
mediastinal None None O
structures None None O
with None None O
a None None O
risk None None O
of None None O
perforating None None O
into None None O
the None None O
trachea None None O
. None None O

A None None O
key None None O
enzyme None None O
in None None O
the None None O
PCB None None O
catabolic None None O
pathway None None O
is None None O
NAD-dependent None None O
cis-2,3-dihydrobiphenyl-2,3-diol None None O
dehydrogenase None None I-PROTEIN
( None None O
BphB None None O
) None None O
, None None O
for None None O
which None None O
the None None O
crystal None None O
structure None None O
from None None O
Pp None None O
has None None O
been None None O
crystallized None None O
in None None O
apo- None None O
, None None O
NAD-bound None None O
and None None O
biphenyldiol-/NAD-bound None None O
forms None None O
. None None O

Collagen None None I-PROTEIN
hydrogels None None O
have None None O
been None None O
widely None None O
investigated None None O
as None None O
scaffolds None None O
for None None O
vascular None None O
tissue None None O
engineering None None O
due None None O
in None None O
part None None O
to None None O
the None None O
capacity None None O
of None None O
collagen None None I-PROTEIN
to None None O
promote None None O
robust None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
elongation None None O
. None None O

In None None O
the None None O
current None None O
work None None O
, None None O
we None None O
develop None None O
and None None O
characterize None None O
a None None O
sequentially-formed None None O
interpenetrating None None O
network None None O
( None None O
IPN None None O
) None None O
that None None O
retains None None O
the None None O
benefits None None O
of None None O
collagen None None I-PROTEIN
, None None O
but None None O
which None None O
displays None None O
enhanced None None O
mechanical None None O
stiffness None None O
and None None O
strength None None O
, None None O
improved None None O
thromboresistance None None O
, None None O
high None None O
physical None None O
stability None None O
and None None O
resistance None None O
to None None O
contraction None None O
. None None O

These None None O
collagen-PEGDA None None O
IPNs None None O
allow None None O
for None None O
cell None None O
encapsulation None None O
during None None O
the None None O
fabrication None None O
process None None O
with None None O
greater None None O
than None None O
90 None None O
% None None O
cell None None O
viability None None O
via None None O
inclusion None None O
of None None O
cells None None O
within None None O
the None None O
collagen None None I-PROTEIN
hydrogel None None O
precursor None None O
solution None None O
. None None O

The None None O
objectives None None O
of None None O
this None None O
study None None O
were None None O
to None None O
establish None None O
a None None O
non-invasive None None O
imaging None None O
strategy None None O
to None None O
monitor None None O
the None None O
homing None None O
of None None O
transplanted None None O
EPCs None None O
in None None O
diabetic None None O
stroke None None I-DISEASE
mice None None O
and None None O
to None None O
assess None None O
the None None O
effect None None O
of None None O
RWJ None None O
67657 None None O
, None None O
an None None O
inhibitor None None O
of None None O
p38 None None O
MAPK None None O
, None None O
on None None O
the None None O
homing None None O
ability None None O
of None None O
exogenous None None O
EPCs None None O
. None None O

The None None O
signal None None O
of None None O
the None None O
nanoprobe None None O
reached None None O
its None None O
peak None None O
on None None O
day None None O
5 None None O
in None None O
both None None O
magnetic None None O
resonance None None O
imaging None None O
and None None O
near-infrared None None O
fluorescence None None O
imaging None None O
after None None O
EPC None None O
transplantation None None O
in None None O
wild-type None None O
stroke None None I-DISEASE
models None None O
. None None O

However None None O
, None None O
the None None O
signal None None O
intensity None None O
of None None O
diabetic None None O
stroke None None I-DISEASE
models None None O
significantly None None O
increased None None O
after None None O
oral None None O
administration None None O
of None None O
RWJ None None O
67657 None None O
, None None O
indicating None None O
that None None O
more None None O
transplanted None None O
EPCs None None O
migrated None None O
to None None O
the None None O
ischemic None None O
brain None None O
. None None O

The None None O
ability None None O
for None None O
the None None O
MSCs None None O
to None None O
form None None O
tubular None None O
structures None None O
within None None O
the None None O
fibrin None None O
gels None None O
was None None O
directly None None O
dependent None None O
on None None O
the None None O
stoichiometric None None O
ratios None None O
of None None O
thrombin None None I-PROTEIN
and None None O
fibrinogen None None O
and None None O
the None None O
resulting None None O
gel None None O
concentration None None O
, None None O
as None None O
well None None O
as None None O
on None None O
the None None O
presence None None O
of None None O
bFGF None None O
. None None O

The None None O
application None None O
of None None O
ADSCs None None O
delivered None None O
in None None O
the None None O
stiff None None O
fibrin None None O
gels None None O
allowed None None O
for None None O
the None None O
wounds None None O
to None None O
heal None None O
more None None O
quickly None None O
, None None O
as None None O
assessed None None O
by None None O
wound None None O
size None None O
, None None O
amount None None O
of None None O
granulation None None O
tissue None None O
and None None O
collagen None None I-PROTEIN
content None None O
. None None O

In None None O
part None None O
, None None O
this None None O
property None None O
is None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
NAD-dependent None None O
malic None None O
enzymes None None I-PROTEIN
( None None O
NAD-ME None None O
) None None O
with None None O
particular None None O
biochemical None None O
characteristics None None O
. None None O

Indeed None None O
, None None O
by None None O
means None None O
of None None O
molecular None None O
biology None None O
and None None O
immunochemical None None O
techniques None None O
, None None O
we None None O
found None None O
that None None O
truffles None None O
contain None None O
the None None O
major None None O
metabolic None None O
enzymes None None I-PROTEIN
of None None O
the None None O
ECS None None O
, None None O
while None None O
they None None O
do None None O
not None None O
express None None O
the None None O
most None None O
relevant None None O
endocannabinoid-binding None None O
receptors None None I-PROTEIN
. None None O

Overall None None O
, None None O
our None None O
unprecedented None None O
results None None O
suggest None None O
that None None O
anandamide None None I-TRANS
and None None O
ECS None None O
metabolic None None O
enzymes None None I-PROTEIN
have None None O
evolved None None O
earlier None None O
than None None O
endocannabinoid-binding None None O
receptors None None I-PROTEIN
, None None O
and None None O
that None None O
anandamide None None I-TRANS
might None None O
be None None O
an None None O
ancient None None O
attractant None None O
to None None O
truffle None None O
eaters None None O
, None None O
that None None O
are None None O
well-equipped None None O
with None None O
endocannabinoid-binding None None O
receptors None None I-PROTEIN
. None None O

The None None O
mRNA None None O
and None None O
protein None None O
expression None None O
levels None None O
of None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
was None None O
examined None None O
by None None O
reverse None None O
transcriptase None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT-PCR None None O
) None None O
and None None O
Western None None O
blotting None None O
. None None O

Vesicular None None O
glutamate None None I-TRANS
transporters None None I-PROTEIN
( None None O
VGLUTs None None O
) None None O
accumulate None None O
the None None O
neurotransmitter None None I-TRANS
glutamate None None I-TRANS
in None None O
synaptic None None O
vesicles None None O
. None None O

Moreover None None O
, None None O
chloride None None O
competes None None O
with None None O
glutamate None None I-TRANS
at None None O
high None None O
concentrations None None O
. None None O

We None None O
conclude None None O
that None None O
VGLUTs None None O
contain None None O
two None None O
anion None None O
binding None None O
sites None None O
and None None O
one None None O
cation None None O
binding None None O
site None None O
, None None O
allowing None None O
the None None O
transporter None None O
to None None O
adjust None None O
to None None O
the None None O
changing None None O
ionic None None O
conditions None None O
during None None O
vesicle None None O
filling None None O
without None None O
being None None O
dependent None None O
on None None O
other None None O
transporters None None I-PROTEIN
or None None O
channels None None O
. None None O

Current None None O
antipsychotic None None O
drugs None None O
primarily None None O
target None None O
dopamine None None I-TRANS
D2 None None O
receptors None None I-PROTEIN
( None None O
D2Rs None None O
) None None O
, None None O
in None None O
conjunction None None O
with None None O
other None None O
receptors None None I-PROTEIN
such None None O
as None None O
those None None O
for None None O
serotonin None None I-TRANS
. None None O

Identifying None None O
a None None O
specific None None O
D2R None None O
signaling None None O
pathway None None O
that None None O
could None None O
be None None O
targeted None None O
for None None O
antipsychotic None None O
effects None None O
, None None O
without None None O
inducing None None O
EPS None None O
, None None O
would None None O
be None None O
a None None O
significant None None O
improvement None None O
in None None O
the None None O
treatment None None O
of None None O
schizophrenia None None I-DISEASE
. None None O

D2R-DISC1 None None O
complex None None O
levels None None O
are None None O
increased None None O
in None None O
conjunction None None O
with None None O
decreased None None O
GSK-3α/β None None O
( None None O
Ser21/9 None None O
) None None O
phosphorylation None None O
in None None O
both None None O
postmortem None None O
brain None None O
tissue None None O
from None None O
schizophrenia None None I-DISEASE
patients None None O
and None None O
in None None O
Disc1-L100P None None O
mutant None None O
mice None None O
, None None O
an None None O
animal None None O
model None None O
with None None O
behavioral None None O
abnormalities None None O
related None None O
to None None O
schizophrenia None None I-DISEASE
. None None O

The None None O
fiberscope None None O
was None None O
tested None None O
in None None O
mice None None O
coexpressing None None O
ChR2-tdTomato None None O
and None None O
GCaMP5-G None None O
in None None O
cerebellar None None O
interneurons None None I-NEURON
, None None O
delivering None None O
near-cellular None None O
resolution None None O
photoactivation None None O
in None None O
freely None None O
behaving None None O
mice None None O
. None None O

Development None None O
of None None O
neuronal None None O
circuits None None O
is None None O
controlled None None O
by None None O
evolutionarily None None O
conserved None None O
axon None None O
guidance None None O
molecules None None O
, None None O
including None None O
Slits None None O
, None None O
the None None O
repulsive None None O
ligands None None O
for None None O
roundabout None None O
( None None O
Robo None None O
) None None O
receptors None None I-PROTEIN
, None None O
and None None O
Netrin-1 None None O
, None None O
which None None O
mediates None None O
attraction None None O
through None None O
the None None O
DCC None None O
receptor None None I-PROTEIN
. None None O

Unlike None None O
other None None O
Robo None None O
receptors None None I-PROTEIN
, None None O
mammalian None None O
Robo3 None None O
is None None O
not None None O
a None None O
high-affinity None None O
receptor None None I-PROTEIN
for None None O
Slits None None O
because None None O
of None None O
specific None None O
substitutions None None O
in None None O
the None None O
first None None O
immunoglobulin None None O
domain None None O
. None None O

The None None O
level None None O
of None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
and None None O
gamma None None O
glutamyl None None O
transferase None None I-PROTEIN
( None None O
GGT None None O
) None None O
was None None O
found None None O
to None None O
be None None O
increased None None O
in None None O
diabetic None None O
cattle None None O
. None None O

Diabetic None None O
cattle None None O
revealed None None O
significantly None None O
higher None None O
( None None O
P None None O
≤ None None O
0.01 None None O
) None None O
levels None None O
of None None O
erythrocytic None None O
lipid None None O
peroxides None None O
in None None O
comparison None None O
with None None O
other None None O
hyperglycaemic None None O
cattle None None O
and None None O
healthy None None O
controls None None O
whereas None None O
the None None O
level None None O
of None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
and None None O
catalase None None I-PROTEIN
was None None O
found None None O
to None None O
be None None O
significantly None None O
lower None None O
in None None O
diabetes-affected None None O
animals None None O
in None None O
comparison None None O
to None None O
healthy None None O
controls None None O
. None None O

The None None O
10 None None O
to None None O
20-fold None None O
difference None None O
calls None None O
attention None None I-FUNC
to None None O
this None None O
unrecognised None None O
problem None None O
. None None O

Actin None None I-PROTEIN
and None None O
tubulin None None O
are None None O
cytoskeletal None None I-PROTEIN
proteins None None I-PROTEIN
universally None None O
important None None O
for None None O
regulating None None O
many None None O
embryological None None O
processes None None O
but None None O
so None None O
far None None O
studies None None O
in None None O
Nematostella None None O
primarily None None O
focused None None O
on None None O
the None None O
localization None None O
of None None O
these None None O
proteins None None O
in None None O
fixed None None O
embryos None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
analyze None None O
the None None O
effects None None O
of None None O
cyclohexane None None O
inhalation None None O
on None None O
motor None None O
behavior None None O
, None None O
spatial None None I-FUNC
memory None None I-FUNC
, None None O
and None None O
reactive None None O
gliosis None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
adult None None O
mice None None O
. None None O

Remarkably None None O
, None None O
a None None O
significant None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
astrocytes None None O
and None None O
microglia None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
in None None O
the None None O
cytoplasmic None None O
processes None None O
of None None O
these None None O
cells None None O
were None None O
observed None None O
in None None O
the None None O
hippocampal None None O
CA1 None None I-REGION
and None None O
CA3 None None I-REGION
areas None None O
of None None O
cyclohexane-exposed None None O
mice None None O
. None None O

In None None O
summary None None O
, None None O
cyclohexane None None O
exposure None None O
produces None None O
functional None None O
deficits None None O
that None None O
are None None O
associated None None O
with None None O
an None None O
important None None O
increase None None O
in None None O
the None None O
APE1 None None O
expression None None O
as None None O
well None None O
as None None O
the None None O
number None None O
of None None O
astrocytes None None O
and None None O
microglia None None O
cells None None O
and None None O
their None None O
cytoplasmic None None O
complexity None None O
in None None O
the None None O
CA1 None None I-REGION
and None None O
CA3 None None I-REGION
regions None None O
of None None O
the None None O
adult None None O
hippocampus None None I-REGION
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
analyze None None O
the None None O
ability None None O
of None None O
ABCD2 None None O
and None None O
ABCD3 None None O
scores None None O
to None None O
predict None None O
ipsilateral None None O
ischemic None None O
stroke None None I-DISEASE
among None None O
patients None None O
with None None O
symptomatic None None O
50-99 None None O
% None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
. None None O

We None None O
analyzed None None O
the None None O
risk None None O
of None None O
recurrent None None O
ipsilateral None None O
ischemic None None O
stroke None None I-DISEASE
before None None O
carotid None None O
endarterectomy None None O
based None None O
on None None O
each None None O
parameter None None O
of None None O
the None None O
ABCD2 None None O
and None None O
ABCD3 None None O
scores None None O
separately None None O
, None None O
and None None O
for None None O
total None None O
ABCD2 None None O
and None None O
ABCD3 None None O
scores None None O
. None None O

None None None O
of None None O
the None None O
parameters None None O
in None None O
the None None O
ABCD2 None None O
or None None O
ABCD3 None None O
scores None None O
could None None O
alone None None O
predict None None O
all None None O
12 None None O
of None None O
the None None O
ipsilateral None None O
ischemic None None O
strokes None None I-DISEASE
that None None O
occurred None None O
within None None O
2 None None O
days None None O
of None None O
the None None O
presenting None None O
event None None O
, None None O
but None None O
clinical None None O
presentation None None O
tended None None O
to None None O
be None None O
a None None O
statistically None None O
significant None None O
risk None None O
factor None None O
for None None O
recurrent None None O
ipsilateral None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
p None None O
= None None O
0.06 None None O
, None None O
log None None O
rank None None O
test None None O
) None None O
. None None O

We None None O
tested None None O
whether None None O
fear None None O
of None None O
hypoglycemia None None I-DISEASE
is None None O
independently None None O
associated None None O
with None None O
poorer None None O
health-related None None O
quality None None O
of None None O
life None None O
( None None O
HRQOL None None O
) None None O
. None None O

Two None None O
ordinary None None O
least-squares None None O
( None None O
OLS None None O
) None None O
models None None O
of None None O
HRQOL None None O
controlling None None O
for None None O
demographics None None O
and None None O
illness None None O
characteristics None None O
were None None O
specified None None O
, None None O
and None None O
OLS None None O
regression None None O
coefficients None None O
and None None O
statistical None None O
inferences None None I-FUNC
were None None O
compared None None O
. None None O

Model None None O
2 None None O
: None None O
hypoglycemia None None I-DISEASE
symptoms None None O
were None None O
significantly None None O
associated None None O
only None None O
with None None O
SF-12 None None O
MCS None None O
score None None O
. None None O

Hypoglycemia None None I-DISEASE
symptoms None None O
, None None O
Hispanic None None O
ethnicity None None O
, None None O
and None None O
longer None None O
diabetes None None O
duration None None O
were None None O
associated None None O
with None None O
greater None None O
hypoglycemia None None I-DISEASE
fear None None O
. None None O

In None None O
addition None None O
to None None O
the None None O
effect None None O
of None None O
symptomatic None None O
hypoglycemia None None I-DISEASE
on None None O
HRQOL None None O
, None None O
fear None None O
of None None O
hypoglycemia None None I-DISEASE
was None None O
independently None None O
associated None None O
with None None O
lower None None O
overall None None O
health None None O
status None None O
and None None O
mental None None O
and None None O
physical None None O
health None None O
. None None O

Serotonin None None I-TRANS
exhibits None None O
a None None O
vast None None O
repertoire None None O
of None None O
actions None None O
including None None O
cell None None O
proliferation None None O
and None None O
differentiation None None O
. None None O

Persons None None O
with None None O
dementia None None I-DISEASE
receive None None O
health None None O
care None None O
and None None O
social None None O
services None None O
from None None O
a None None O
wide None None O
range None None O
of None None O
professional None None O
care None None O
providers None None O
during None None O
the None None O
disease None None O
trajectory None None O
, None None O
presenting None None O
risks None None O
of None None O
miscommunication None None O
, None None O
duplication None None O
and/or None None O
missed None None O
nursing None None O
interventions None None O
. None None O

Data None None O
were None None O
subjected None None O
to None None O
content None None O
analysis None None O
based None None O
on None None O
the None None O
three None None O
stages None None O
of None None O
dementia None None I-DISEASE
( None None O
early None None O
, None None O
moderate None None O
, None None O
end-of-life None None O
) None None O
. None None O

It None None O
was None None O
clear None None O
that None None O
, None None O
according None None O
to None None O
the None None O
participants None None O
, None None O
best None None O
practice None None O
in None None O
dementia None None I-DISEASE
care None None O
in None None O
Sweden None None O
is None None O
not None None O
achieved None None O
in None None O
every None None O
respect None None O
. None None O

Lack None None O
of None None O
best None None O
practice None None O
strategies None None O
during None None O
these None None O
stages None None O
makes None None O
it None None O
difficult None None O
to None None O
meet None None O
the None None O
needs None None O
of None None O
persons None None O
with None None O
dementia None None I-DISEASE
and None None O
reduce None None O
the None None O
burden None None O
for None None O
next None None O
of None None O
kin None None O
. None None O

Secondary None None O
aims None None O
include None None O
evaluating None None O
which None None O
components None None O
of None None O
the None None O
HEART None None O
Camp None None O
intervention None None O
mediate None None O
the None None O
effects None None O
of None None O
the None None O
intervention None None O
on None None O
adherence None None O
; None None O
evaluating None None O
the None None O
effect None None O
of None None O
HEART None None O
Camp None None O
on None None O
specific None None O
health None None O
outcomes None None O
; None None O
exploring None None O
selected None None O
demographic None None O
variables None None O
( None None O
race None None O
, None None O
gender None None O
, None None O
age None None O
) None None O
as None None O
potential None None O
moderators None None O
of None None O
the None None O
effect None None O
of None None O
the None None O
HEART None None O
Camp None None O
intervention None None O
on None None O
adherence None None O
; None None O
and None None O
exploring None None O
the None None O
perceptions None None I-FUNC
and None None O
experiences None None O
that None None O
contextualize None None O
exercise None None O
adherence None None O
. None None O

Depression None None I-DISEASE
is None None O
a None None O
major None None O
public None None O
health None None O
problem None None O
that None None O
affects None None O
both None None O
individuals None None O
and None None O
society None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
study None None O
were None None O
to None None O
explore None None O
the None None O
association None None O
between None None O
occupational None None O
stress None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
a None None O
group None None O
of None None O
university None None O
teachers None None O
, None None O
and None None O
assess None None O
the None None O
mediating None None O
role None None O
of None None O
psychological None None O
capital None None O
between None None O
these None None O
variables None None O
. None None O

Psychological None None O
capital None None O
partially None None O
mediated None None O
the None None O
relationship None None O
between None None O
occupational None None O
stress None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

Our None None O
results None None O
suggest None None O
that None None O
college None None O
administrators None None O
could None None O
support None None O
the None None O
development None None O
of None None O
psychological None None O
capital None None O
in None None O
their None None O
staff None None O
to None None O
alleviate None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

A None None O
highly None None O
sensitive None None O
electrochemiluminescent None None O
( None None O
ECL None None O
) None None O
biosensor None None O
was None None O
designed None None O
for None None O
the None None O
detection None None O
of None None O
concanavalin None None O
A None None O
( None None O
ConA None None O
) None None O
based None None O
on None None O
glucose None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
GOx None None O
) None None O
as None None O
a None None O
recognition None None O
element None None O
by None None O
carbohydrate-lectin None None O
biospecific None None O
interaction None None O
, None None O
and None None O
poly None None O
( None None O
ethylenimine None None O
) None None O
( None None O
PEI None None O
) None None O
reduced None None O
graphene None None O
and None None O
hollow None None O
gold None None O
nanoparticles None None O
( None None O
HAuNPs None None O
) None None O
as None None O
supporting None None O
matrix None None O
and None None O
signal None None O
amplifier None None O
. None None O

In None None O
this None None O
manuscript None None O
we None None O
briefly None None O
describe None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
( None None O
a None None O
depressive None None O
and None None O
manic None None O
mental None None O
disease None None O
) None None O
, None None O
its None None O
classification None None O
, None None O
its None None O
effects None None O
on None None O
the None None O
patient None None O
, None None O
which None None O
sometimes None None O
include None None O
suicidal None None O
tendencies None None O
, None None O
and None None O
the None None O
drugs None None O
used None None O
for None None O
treatment None None O
. None None O

Attention None None I-FUNC
to None None O
the None None O
direct None None O
and None None O
indirect None None O
effects None None O
of None None O
temperature None None O
on None None O
species None None O
interactions None None O
should None None O
improve None None O
our None None O
ability None None O
to None None O
predict None None O
the None None O
effects None None O
of None None O
climate None None O
change None None O
on None None O
ecological None None O
communities None None O
. None None O

A None None O
highly None None O
interlinked None None O
network None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
TFs None None O
) None None O
orchestrates None None O
the None None O
context-dependent None None O
expression None None O
of None None O
human None None O
genes None None O
. None None O

Meanwhile None None O
, None None O
a None None O
large None None O
body None None O
of None None O
knowledge None None O
on None None O
high-quality None None O
regulatory None None O
interactions None None O
remains None None O
largely None None O
unexplored None None O
, None None O
as None None O
it None None O
is None None O
available None None O
only None None O
in None None O
natural None None O
language None None I-FUNC
descriptions None None O
scattered None None O
over None None O
millions None None O
of None None O
scientific None None O
publications None None O
. None None O

The None None O
spectrin None None O
superfamily None None O
of None None O
proteins None None O
plays None None O
key None None O
roles None None O
in None None O
assembling None None O
the None None O
actin None None I-PROTEIN
cytoskeleton None None O
in None None O
various None None O
cell None None O
types None None O
, None None O
crosslinks None None O
actin None None I-PROTEIN
filaments None None O
, None None O
and None None O
acts None None O
as None None O
scaffolds None None O
for None None O
the None None O
assembly None None O
of None None O
large None None O
protein None None O
complexes None None O
involved None None O
in None None O
structural None None O
integrity None None O
and None None O
mechanosensation None None O
, None None O
as None None O
well None None O
as None None O
cell None None O
signaling None None O
. None None O

We None None O
tested None None O
whether None None O
alcohol None None O
consumption None None O
is None None O
causally None None O
associated None None O
with None None O
depression None None I-DISEASE
and None None O
alcoholism None None O
. None None O

We None None O
performed None None O
observational None None O
and None None O
causal None None O
analyses None None O
using None None O
a None None O
Mendelian None None O
randomization None None O
design None None O
with None None O
antidepressant None None O
medication None None O
use None None O
and None None O
hospitalization/death None None O
, None None O
with None None O
depression None None I-DISEASE
and None None O
alcoholism None None O
as None None O
outcomes None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
the None None O
association None None O
between None None O
increased None None O
alcohol None None O
consumption None None O
and None None O
alcoholism None None O
is None None O
causal None None O
, None None O
without None None O
similar None None O
strong None None O
evidence None None O
for None None O
depression None None I-DISEASE
. None None O

Knockout None None O
mutants None None O
of None None O
global None None O
regulators None None O
confirmed None None O
the None None O
promoter None None O
activity None None O
trend None None O
through None None O
gene None None O
expression None None O
change None None O
for None None O
dehydrogenases None None I-PROTEIN
. None None O

The None None O
results None None O
of None None O
qPCR None None O
revealed None None O
that None None O
genes None None O
encoding None None I-FUNC
FABP3 None None O
, None None O
FASN None None O
, None None O
SCD None None O
, None None O
PLIN2 None None O
, None None O
whey None None O
proteins None None O
( None None O
LALBA None None O
and None None O
BLG None None O
) None None O
, None None O
and None None O
caseins None None O
( None None O
CSN1S1 None None O
, None None O
CSN1S2 None None O
, None None O
CSN2 None None O
and None None O
CSN3 None None O
) None None O
at None None O
100 None None O
and None None O
310 None None O
days None None O
postpartum None None O
increased None None O
significantly None None O
compared None None O
with None None O
the None None O
non-lactating None None O
period None None O
. None None O

Norfloxacin None None O
and None None O
moxifloxacin None None O
suppressed None None O
melanin None None O
biosynthesis None None O
; None None O
antibiotics None None O
were None None O
shown None None O
to None None O
inhibit None None O
cellular None None O
tyrosinase None None I-PROTEIN
activity None None O
and None None O
to None None O
reduce None None O
melanin None None O
content None None O
in None None O
melanocytes None None O
. None None O

The None None O
extent None None O
of None None O
oxidative None None O
stress None None O
in None None O
cells None None O
was None None O
assessed None None O
by None None O
measuring None None O
the None None O
activity None None O
of None None O
antioxidant None None O
enzymes None None I-PROTEIN
: None None O
SOD None None O
, None None O
CAT None None O
, None None O
and None None O
GPx None None O
. None None O

Functional None None O
proteomics None None O
was None None O
used None None O
to None None O
characterize None None O
age-related None None O
changes None None O
in None None O
energy None None O
metabolism None None O
of None None O
different None None O
neuronal None None O
pathways None None O
within None None O
the None None O
cerebellar None None I-REGION
cortex None None I-REGION
of None None O
Wistar None None O
rats None None O
aged None None O
2 None None O
, None None O
6 None None O
, None None O
12 None None O
, None None O
18 None None O
, None None O
and None None O
24 None None O
months None None O
. None None O

Because None None O
most None None O
brain None None O
disorders None None O
are None None O
associated None None O
with None None O
bioenergetic None None O
changes None None O
, None None O
the None None O
maximum None None O
rate None None O
( None None O
Vmax None None O
) None None O
of None None O
selected None None O
enzymes None None I-PROTEIN
of None None O
glycolysis None None O
, None None O
Krebs None None O
' None None O
cycle None None O
, None None O
glutamate None None I-TRANS
and None None O
amino None None I-TRANS
acids None None I-TRANS
metabolism None None O
, None None O
and None None O
acetylcholine None None I-TRANS
catabolism None None O
were None None O
evaluated None None O
. None None O

This None None O
study None None O
represents None None O
a None None O
reliable None None O
model None None O
to None None O
study None None O
in None None O
vivo None None O
( None None O
1 None None O
) None None O
the None None O
physiopathological None None O
molecular None None O
mechanisms None None O
of None None O
some None None O
brain None None I-DISEASE
diseases None None I-DISEASE
dependent None None O
on None None O
energy None None O
metabolism None None O
, None None O
( None None O
2 None None O
) None None O
the None None O
responsiveness None None O
to None None O
noxious None None O
stimuli None None O
, None None O
and None None O
( None None O
3 None None O
) None None O
the None None O
effects None None O
of None None O
drugs None None O
, None None O
discriminating None None O
their None None O
action None None O
sites None None O
at None None O
subcellular None None O
level None None O
on None None O
specific None None O
neuronal None None O
pathways None None O
. None None O

Human None None O
enteric None None O
α-defensins None None O
( None None O
HD5 None None O
and None None O
HD6 None None O
) None None O
, None None O
major None None O
antimicrobial None None O
peptides None None I-TRANS
produced None None O
by None None O
Paneth None None O
cells None None O
in None None O
the None None O
intestine None None O
, None None O
play None None O
important None None O
roles None None O
in None None O
intestinal None None O
innate None None O
immunity None None O
. None None O

The None None O
amount None None O
of None None O
aggrecan None None O
and None None O
type None None O
II None None O
collagen None None I-PROTEIN
was None None O
significantly None None O
decreased None None O
in None None O
the None None O
degenerative None None O
group None None O
. None None O

A None None O
parturient None None O
developed None None O
anterior None None I-DISEASE
spinal None None I-DISEASE
artery None None I-DISEASE
syndrome None None I-DISEASE
after None None O
spinal None None O
anesthesia None None O
for None None O
cesarean None None O
delivery None None O
. None None O

Results None None O
of None None O
network None None O
analysis None None O
suggest None None O
that None None O
SNARE None None O
proteins None None O
of None None O
parasites None None O
and None None O
APP None None I-TRANS
of None None O
humans None None O
may None None O
function None None O
in None None O
the None None O
invasion None None O
of None None O
RBCs None None O
by None None O
parasites None None O
. None None O

Reduction None None O
of None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
is None None O
the None None O
only None None O
known None None O
effective None None O
treatment None None O
for None None O
glaucoma None None O
. None None O

Despite None None O
this None None O
variability None None O
, None None O
evidence None None O
for None None O
the None None O
efficacy None None O
of None None O
IOP None None I-TRANS
reduction None None O
in None None O
glaucoma None None O
is None None O
based None None O
on None None O
studies None None O
designed None None O
to None None O
assess None None O
mean None None O
IOP None None I-TRANS
and None None O
not None None O
IOP None None I-TRANS
variations None None O
. None None O

In None None O
the None None O
interim None None O
, None None O
judicious None None O
selection None None O
of None None O
existing None None O
therapies None None O
can None None O
help None None O
to None None O
minimize None None O
IOP None None I-TRANS
variations None None O
. None None O

However None None O
, None None O
new None None O
technology None None O
to None None O
allow None None O
better None None O
monitoring None None O
of None None O
IOP None None I-TRANS
, None None O
ideally None None O
in None None O
a None None O
continuous None None O
24-hour None None O
manner None None O
, None None O
is None None O
required None None O
to None None O
fully None None O
understand None None O
the None None O
role None None O
of None None O
IOP None None I-TRANS
variations None None O
in None None O
glaucoma None None O
. None None O

Although None None O
all None None O
angle None None O
closure None None O
is None None O
caused None None O
by None None O
iridotrabecular None None O
contact None None O
, None None O
the None None O
cause None None O
of None None O
angle None None O
closure None None O
glaucoma None None O
is None None O
classified None None O
based None None O
on None None O
the None None O
site None None O
of None None O
primary None None O
blockage None None O
of None None O
aqueous None None O
movement None None I-FUNC
from None None O
anterior None None O
to None None O
posterior None None O
: None None O
pupillary None None O
block None None O
, None None O
plateau None None O
iris None None O
, None None O
lens-related None None O
, None None O
and None None O
posterior None None O
causative None None O
factors None None O
. None None O

Selective None None O
laser None None O
trabeculoplasty None None O
( None None O
SLT None None O
) None None O
offers None None O
several None None O
advantages None None O
: None None O
It None None O
effectively None None O
reduces None None O
IOP None None I-TRANS
in None None O
most None None O
patients None None O
with None None O
open-angle None None O
glaucoma None None O
, None None O
it None None O
is None None O
cost-effective None None O
compared None None O
with None None O
eye None None O
drops None None O
, None None O
it None None O
can None None O
be None None O
repeated None None O
if None None O
needed None None O
, None None O
and None None O
it None None O
eliminates None None O
the None None O
issue None None O
of None None O
adherence None None O
to None None O
medications None None O
when None None O
used None None O
as None None O
an None None O
initial None None O
treatment None None O
. None None O

Guarded None None O
external None None O
fistulization None None O
procedures None None O
remain None None O
important None None O
surgical None None O
options None None O
for None None O
patients None None O
who None None O
are None None O
experiencing None None O
progressive None None O
vision None None I-FUNC
loss None None O
caused None None O
by None None O
glaucoma None None O
. None None O

Studies None None O
are None None O
cumulating None None O
to None None O
show None None O
that None None O
very None None O
low None None O
intraocular None None O
pressures None None O
can None None O
both None None O
reduce None None O
glaucomatous None None O
vision None None I-FUNC
loss None None O
and None None O
positively None None O
change None None O
the None None O
rate None None O
of None None O
progression None None O
. None None O

Traditionally None None O
, None None O
invasive None None O
surgical None None O
management None None O
of None None O
glaucoma None None O
is None None O
recommended None None O
when None None O
medication None None O
and/or None None O
laser None None O
trabeculoplasty None None O
fail None None O
to None None O
control None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
. None None O

For None None O
these None None O
reasons None None O
, None None O
a None None O
new None None O
group None None O
of None None O
surgical None None O
procedures None None O
has None None O
emerged None None O
that None None O
seeks None None O
to None None O
decrease None None O
IOP None None I-TRANS
with None None O
lower None None O
associated None None O
rates None None O
of None None O
complications None None O
. None None O

Amyotrophic None None O
lateral None None O
sclerosis None None O
( None None O
ALS None None O
) None None O
is None None O
a None None O
condition None None O
primarily None None O
characterized None None O
by None None O
the None None O
selective None None O
loss None None O
of None None O
upper None None O
and None None O
lower None None O
motor None None I-NEURON
neurons None None I-NEURON
. None None O

Bioidentical None None O
recombinant None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
rhEGF None None O
) None None O
is None None O
available None None O
in None None O
concentrations None None O
and None None O
purity None None O
suitable None None O
for None None O
therapeutic None None O
use None None O
in None None O
long None None O
time None None O
stable None None O
formulations None None O
. None None O

The None None O
study None None O
of None None O
the None None O
phenotypic None None O
characteristics None None O
of None None O
B None None O
lymphocytes None None O
and None None O
the None None O
identification None None O
of None None O
their None None O
surface None None O
receptors None None I-PROTEIN
such None None O
as None None O
BAFF-R None None O
, None None O
TACI None None O
and None None O
BCMA None None O
, None None O
which None None O
are None None O
responsible None None O
of None None O
their None None O
survival None None O
and None None O
maturation None None O
, None None O
have None None O
contributed None None O
to None None O
the None None O
development None None O
of None None O
new None None O
therapeutic None None O
strategies None None O
in None None O
recent None None O
years None None O
. None None O

We None None O
begin None None O
by None None O
illustrating None None O
that None None O
long None None O
before None None O
the None None O
cognitive None None O
revolution None None O
, None None O
social None None O
psychology None None O
focused None None O
on None None O
topics None None O
pertaining None None O
to None None O
what None None O
is None None O
now None None O
known None None O
as None None O
social None None I-FUNC
cognition None None I-FUNC
: None None O
people None None O
's None None O
subjective None None O
interpretations None None O
of None None O
social None None O
situations None None O
and None None O
the None None O
concepts None None O
and None None O
cognitive None None O
processes None None O
underlying None None O
these None None O
interpretations None None O
. None None O

We None None O
suggest None None O
that None None O
social None None I-FUNC
cognition None None I-FUNC
relies None None O
heavily None None O
on None None O
generic None None O
cognition None None O
but None None O
also None None O
on None None O
unique None None O
concepts None None O
( None None O
e.g. None None O
, None None O
agent None None O
, None None O
intentionality None None O
) None None O
and None None O
unique None None O
processes None None O
( None None O
e.g. None None O
, None None O
projection None None O
, None None O
imitation None None O
, None None O
joint None None O
attention None None I-FUNC
) None None O
. None None O

Finally None None O
, None None O
we None None O
comment None None O
on None None O
the None None O
prospects None None O
of None None O
a None None O
recently None None O
developing None None O
approach None None O
to None None O
the None None O
study None None O
of None None O
social None None I-FUNC
cognition None None I-FUNC
( None None O
social None None O
neuroscience None None O
) None None O
and None None O
two None None O
potential None None O
future None None O
directions None None O
( None None O
computational None None O
social None None I-FUNC
cognition None None I-FUNC
and None None O
social-cognitive None None O
robotics None None O
) None None O
. None None O

Frontotemporal None None I-DISEASE
dementia None None I-DISEASE
( None None O
FTD None None O
) None None O
may None None O
present None None O
with None None O
psychiatric None None O
symptoms None None O
, None None O
usually None None O
together None None O
with None None O
neurological None None O
ones None None O
and None None O
in None None O
cases None None O
with None None O
a None None O
family None None O
history None None O
of None None O
dementia None None I-DISEASE
. None None O

Patients None None O
carrying None None O
the None None O
C9Orf72 None None O
mutation None None O
are None None O
likely None None O
to None None O
receive None None O
a None None O
psychiatric None None O
diagnosis None None O
( None None O
mainly None None O
mood None None I-DISEASE
disorder None None I-DISEASE
or None None O
schizophrenia None None I-DISEASE
) None None O
prior None None O
to None None O
correct None None O
diagnosis None None O
; None None O
this None None O
may None None O
be None None O
particularly None None O
problematic None None O
for None None O
those None None O
patients None None O
with None None O
no None None O
neurological None None O
signs None None O
to None None O
orientate None None O
diagnosis None None O
. None None O

Vascular None None O
cognitive None None O
impairment-no None None O
dementia None None I-DISEASE
( None None O
VCIND None None O
) None None O
refers None None O
to None None O
the None None O
early None None O
or None None O
mild None None O
cognitive None None O
impairment None None O
induced None None O
by None None O
cerebral None None O
vascular None None O
injury None None O
. None None O

The None None O
identity None None O
of None None O
flower None None O
organs None None O
is None None O
specified None None O
by None None O
various None None O
MIKC None None O
MADS-box None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
which None None O
act None None O
in None None O
a None None O
combinatorial None None O
manner None None O
. None None O

Several None None O
second None None O
generation None None O
antipsychotics None None O
( None None O
SGAs None None O
) None None O
received None None O
FDA None None O
approval None None O
for None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
in None None O
the None None O
2000s None None O
. None None O

While None None O
the None None O
number None None O
of None None O
patients None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
using None None O
SGAs None None O
nearly None None O
doubled None None O
between None None O
2003 None None O
and None None O
2010 None None O
, None None O
analyses None None O
controlling None None O
for None None O
patient None None O
characteristics None None O
and None None O
the None None O
rise None None O
in None None O
the None None O
bipolar None None O
population None None O
revealed None None O
a None None O
1.2 None None O
% None None O
annual None None O
decline None None O
in None None O
SGA None None O
initiation None None O
during None None O
this None None O
period None None O
. None None O

The None None O
number None None O
of None None O
veterans None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
prescribed None None O
SGAs None None O
is None None O
rising None None O
steadily None None O
, None None O
but None None O
this None None O
increase None None O
appears None None O
primarily None None O
driven None None O
by None None O
a None None O
corresponding None None O
increase None None O
in None None O
the None None O
bipolar None None O
population None None O
. None None O

Bruton None None O
's None None O
tyrosine None None I-TRANS
kinase None None O
( None None O
Btk None None O
) None None O
is None None O
a None None O
member None None O
of None None O
the None None O
Tec None None O
family None None O
of None None O
protein None None O
tyrosine None None I-TRANS
kinases None None I-PROTEIN
involved None None O
in None None O
B None None O
cell None None O
development None None O
and None None O
proliferation None None O
in None None O
neoplastic None None O
human None None O
lymphoid None None O
tissues None None O
. None None O

Learning None None I-FUNC
the None None O
values None None O
and None None O
attitudes None None O
necessary None None O
to None None O
become None None O
a None None O
'doctor None None O
as None None O
a None None O
professional None None O
' None None O
has None None O
traditionally None None O
been None None O
left None None O
largely None None O
to None None O
the None None O
informal None None O
and None None O
hidden None None O
curricula None None O
. None None O

In None None O
2010 None None O
, None None O
as None None O
part None None O
of None None O
a None None O
revision None None O
of None None O
the None None O
fifth None None O
year None None O
curriculum None None O
the None None O
University None None O
of None None O
Bristol None None O
Medical None None O
School None None O
introduced None None O
tutorials None None O
which None None O
focused None None O
on None None O
students None None O
' None None O
achievement None None O
of None None O
the None None O
learning None None I-FUNC
objectives None None O
in None None O
'Tomorrow None None O
's None None O
Doctors None None O
Outcomes None None O
3 None None O
: None None O
the None None O
doctor None None O
as None None O
a None None O
professional None None O
' None None O
. None None O

With None None O
continued None None O
demand None None O
for None None O
increased None None O
accountability None None O
and None None O
transparency None None O
in None None O
medical None None O
education None None O
, None None O
detailed None None O
check-lists None None O
of None None O
specific None None O
learning None None I-FUNC
objectives None None O
will None None O
continue None None O
to None None O
feature None None O
as None None O
a None None O
means None None O
by None None O
which None None O
medical None None O
schools None None O
and None None O
learners None None O
demonstrate None None O
attainment None None O
. None None O

Learner None None O
and None None O
faculty None None O
'buy None None O
in None None O
' None None O
are None None O
imperative None None O
to None None O
the None None O
success None None O
of None None O
curriculum None None O
change None None O
and None None O
vital None None O
if None None O
the None None O
students None None O
are None None O
to None None O
attain None None O
the None None O
intended None None O
learning None None I-FUNC
objectives None None O
. None None O

With None None O
research None None O
findings None None O
indicating None None O
positive None None O
associations None None O
between None None O
teacher-child None None O
interaction None None O
quality None None O
and None None O
children None None O
's None None O
development None None O
and None None O
learning None None I-FUNC
, None None O
many None None O
professional None None O
development None None O
efforts None None O
now None None O
focus None None O
on None None O
improving None None O
the None None O
ways None None O
in None None O
which None None O
teachers None None O
interact None None O
with None None O
children None None O
. None None O

A None None O
third None None O
theme None None O
addressed None None O
how None None O
women None None O
experienced None None O
interventions None None O
and None None O
their None None O
perceptions None None I-FUNC
of None None O
control None None O
over None None O
decision-making None None O
. None None O

Increasing None None O
attention None None I-FUNC
needs None None O
to None None O
be None None O
paid None None O
to None None O
the None None O
impact None None O
of None None O
these None None O
factors None None O
on None None O
women None None O
's None None O
perceptions None None I-FUNC
of None None O
care None None O
during None None O
pregnancy None None O
and None None O
childbirth None None O
. None None O

This None None O
involves None None O
experiences None None O
of None None O
midwives None None O
as None None O
uncaring None None O
, None None O
feelings None None I-FUNC
of None None O
being None None O
suppressed None None O
, None None O
unprotected None None O
and None None O
lacking None None O
safety None None O
, None None O
of None None O
feeling None None I-FUNC
disconnected None None O
and None None O
of None None O
the None None O
body None None O
as None None O
incompetent None None O
in None None O
giving None None O
birth None None O
. None None O

To None None O
date None None O
, None None O
there None None O
are None None O
no None None O
available None None O
studies None None O
on None None O
serum None None O
CHEM None None O
concentrations None None O
in None None O
patients None None O
with None None O
anorexia None None I-DISEASE
nervosa None None I-DISEASE
( None None O
AN None None O
) None None O
, None None O
which None None O
is None None O
recognized None None O
as None None O
a None None O
good None None O
biological None None O
model None None O
of None None O
the None None O
chronic None None O
atrophy None None O
of None None O
adipose None None O
tissue None None O
and None None O
energy None None O
metabolism None None O
disorders None None O
in None None O
humans None None O
. None None O

The None None O
neuroactive None None O
hormone None None O
oxytocin None None I-TRANS
( None None O
OT None None O
) None None O
has None None O
significant None None O
influence None None O
on None None O
human None None O
behavior None None O
, None None O
and None None O
it None None O
has None None O
been None None O
measured None None O
peripherally None None O
in None None O
venous None None O
blood None None O
and None None O
in None None O
saliva None None O
in None None O
many None None O
behavioral None None O
neuroscience None None O
studies None None O
. None None O

Lysine None None I-TRANS
79 None None O
of None None O
histone None None O
H3 None None O
( None None O
H3K79 None None O
) None None O
can None None O
be None None O
methylated None None O
specifically None None O
by None None O
the None None O
Dot1 None None O
family None None O
of None None O
histone None None O
lysine None None I-TRANS
methyltransferases None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
relationships None None O
between None None O
psychopathy None None O
and None None O
impulsive None None O
and None None O
risky None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
by None None O
utilizing None None O
intertemporal None None O
and None None O
probabilistic None None O
choices None None O
for None None O
both None None O
gain None None O
and None None O
loss None None O
, None None O
in None None O
addition None None O
to None None O
the None None O
Iowa None None O
gambling None None O
task None None O
. None None O

Psychiatric None None O
Clinic None None O
, None None O
University None None O
Hospital None None O
, None None O
Hradec None None O
Kralove None None O
and None None O
2nd None None O
Department None None O
of None None O
Internal None None O
Medicine None None O
, None None O
General None None O
University None None O
Hospital None None O
, None None O
Prague None None O
, None None O
Czech None None I-TRANS
Republic None None O
There None None O
was None None O
no None None O
difference None None O
in None None O
relative None None O
hyperaemia None None O
index None None O
as None None O
an None None O
endothelial None None O
function None None O
measure None None O
between None None O
patients None None O
and None None O
controls None None O
( None None O
2.19±0.68 None None O
vs. None None O
1.98±0.57 None None O
, None None O
p=NS None None O
) None None O
and None None O
there None None O
were None None O
also None None O
no None None O
correlations None None O
between None None O
reactive None None O
hyperaemia None None O
index None None O
and None None O
the None None O
traditional None None O
CV None None O
risk None None O
factors None None O
, None None O
illness None None O
duration None None O
or None None O
psychotic None None O
symptoms None None O
. None None O

Self-face None None O
recognition None None I-FUNC
is None None O
one None None O
of None None O
the None None O
most None None O
distinctive None None O
features None None O
in None None O
human None None O
beings None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
establish None None O
whether None None O
differences None None O
in None None O
preference None None O
for None None O
the None None O
similarity None None O
to None None O
the None None O
true None None O
self-face None None O
appearance None None O
could None None O
be None None O
found None None O
between None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
and None None O
a None None O
matched None None O
control None None O
group None None O
. None None O

Among None None O
the None None O
most None None O
widely None None O
cited None None O
and None None O
accepted None None O
alternative None None O
hypotheses None None O
of None None O
anxiety None None O
and None None O
depression None None I-DISEASE
is None None O
dysfunction None None O
of None None O
the None None O
HPA None None O
axis None None O
, None None O
a None None O
system None None O
that None None O
is None None O
central None None O
in None None O
orchestrating None None O
the None None O
stress None None O
response None None O
. None None O

The None None O
idea None None O
of None None O
antioxidant None None O
therapy None None O
attenuating None None O
Alzheimer None None I-DISEASE
disease None None O
( None None O
AD None None O
) None None O
neuropathology None None O
starts None None O
to None None O
be None None O
attractive None None O
. None None O

An None None O
AD-like None None O
model None None O
of None None O
trimethyltin None None O
( None None O
TMT None None O
) None None O
-induced None None O
neurodegeneration None None O
, None None O
targeting None None O
the None None O
hippocampus None None I-REGION
, None None O
involves None None O
neuronal None None O
cell None None O
death None None O
and None None O
cognitive None None O
impairment None None O
. None None O

The None None O
study None None O
was None None O
focused None None O
on None None O
the None None O
effect None None O
of None None O
the None None O
antioxidants None None O
tested None None O
on None None O
learning None None I-FUNC
performance None None O
in None None O
the None None O
Morris None None O
water None None O
maze None None O
( None None O
MWM None None O
) None None O
on None None O
days None None O
21-25 None None O
after None None O
TMT None None O
administration None None O
, None None O
on None None O
biochemical None None O
variables None None O
- None None O
malondyaldehyde None None O
( None None O
MDA None None O
) None None O
and None None O
lysosomal None None O
enzyme None None O
NAGA None None O
in None None O
brain None None O
cortex None None O
and None None O
blood None None O
serum None None O
, None None O
and None None O
on None None O
pyramidal None None O
cell None None O
number None None O
in None None O
the None None O
CA1 None None I-REGION
area None None O
of None None O
the None None O
hippocampus None None I-REGION
on None None O
day None None O
31 None None O
after None None O
TMT None None O
administration None None O
in None None O
adult None None O
male None None O
Wistar None None O
rats None None O
( None None O
n=32 None None O
) None None O
. None None O

Further None None O
, None None O
apparent None None O
reduction None None O
of None None O
pyramidal None None O
cell None None O
number None None O
to None None O
21 None None O
% None None O
in None None O
the None None O
CA1 None None I-REGION
area None None O
of None None O
the None None O
hippocampus None None I-REGION
, None None O
increased None None O
MDA None None O
and None None O
NAGA None None O
activity None None O
in None None O
serum None None O
and None None O
increased None None O
NAGA None None O
activity None None O
in None None O
the None None O
cortex None None O
were None None O
determined None None O
contrary None None O
to None None O
controls None None O
. None None O

SMe1EC2 None None O
apparently None None O
preserved None None O
pyramidal None None O
cell None None O
viability None None O
in None None O
the None None O
CA1 None None I-REGION
area None None O
. None None O

More None None O
attention None None I-FUNC
should None None O
be None None O
paid None None O
to None None O
self-stigma None None O
in None None O
neurotic None None O
patients None None O
, None None O
especially None None O
in None None O
those None None O
with None None O
suicidal None None O
thoughts None None O
and None None O
tendencies None None O
. None None O

The None None O
PHQ-9 None None O
for None None O
de-pression None None O
, None None O
the None None O
Generalized None None I-DISEASE
Anxiety None None I-DISEASE
Disorder None None I-DISEASE
Scale None None O
( None None O
GAD-7 None None O
) None None O
for None None O
anxiety None None O
, None None O
the None None O
Clinical None None O
Global None None O
Impression-Severity None None O
( None None O
CGI-S None None O
) None None O
for None None O
clinical None None O
status None None O
, None None O
and None None O
the None None O
Visual None None O
Analogue None None O
Scale None None O
( None None O
VAS None None O
) None None O
for None None O
health None None O
status None None O
were None None O
utilised None None O
. None None O

The None None O
proportion None None O
of None None O
patients None None O
showing None None O
severe None None O
symptoms None None O
( None None O
65.1 None None O
% None None O
vs. None None O
24.7 None None O
% None None O
) None None O
and None None O
recurrence None None O
of None None O
depression None None I-DISEASE
( None None O
74.6 None None O
% None None O
vs. None None O
49.4 None None O
% None None O
) None None O
, None None O
the None None O
CGI-S None None O
( None None O
4.6 None None O
vs. None None O
4.1 None None O
) None None O
, None None O
the None None O
PHQ-9 None None O
( None None O
16.8 None None O
vs. None None O
11.1 None None O
) None None O
, None None O
and None None O
the None None O
GAD-7 None None O
( None None O
8.3 None None O
vs None None O
6.7 None None O
) None None O
scores None None O
were None None O
significantly None None O
higher None None O
in None None O
PSS None None O
than None None O
in None None O
NPSS None None O
, None None O
while None None O
the None None O
VAS None None O
( None None O
39.4 None None O
vs. None None O
51.2 None None O
) None None O
was None None O
significantly None None O
lower None None O
in None None O
PSS None None O
than None None O
in None None O
NPSS None None O
. None None O

In None None O
addition None None O
, None None O
effects None None O
of None None O
phosphorylation None None O
inhibitors None None O
imply None None O
that None None O
NH4 None None O
( None None O
+ None None O
) None None O
uptake None None O
by None None O
OsAMT1 None None O
; None None O
1 None None O
is None None O
also None None O
modulated None None O
by None None O
tyrosine-specific None None O
protein None None O
kinase None None O
or None None O
calcium-regulated None None O
serine/threonine-specific None None O
protein None None O
phosphatase None None I-PROTEIN
involved None None O
phosphorylation None None O
processes None None O
. None None O

We None None O
report None None O
the None None O
significant None None O
increase None None O
of None None O
the None None O
content None None O
of None None O
free None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
Nicotiana None None O
benthamiana None None O
by None None O
the None None O
co-suppression None None O
of None None O
the None None O
ClpC1 None None O
and None None O
ClpC2 None None O
genes None None O
, None None O
which None None O
are None None O
translated None None O
to None None O
be None None O
the None None O
chaperonic None None O
part None None O
in None None O
the None None O
Clp None None O
protease None None O
at None None O
plastids None None O
. None None O

NbClpC1/C2 None None O
co-suppressed None None O
leaves None None O
accumulated None None O
11.9-fold None None O
more None None O
free None None O
amino None None I-TRANS
acids None None I-TRANS
than None None O
the None None O
GFP-silenced None None O
leaves None None O
. None None O

The None None O
loosely None None O
packed None None O
mesophyll None None O
cells None None O
and None None O
abnormal None None O
vascular None None O
bundles None None O
in None None O
the None None O
leaves None None O
suggested None None O
structural None None O
problems None None O
associated None None O
with None None O
translocation None None O
of None None O
free None None O
amino None None I-TRANS
acids None None I-TRANS
to None None O
sink None None O
tissues None None O
. None None O

β-Cyclodextrin-hemin None None O
complex-induced None None O
tomato None None O
lateral None None O
root None None O
formation None None O
was None None O
associated None None O
with None None O
nitric None None I-TRANS
oxide None None I-TRANS
and None None O
heme None None O
oxygenase None None O
1 None None O
by None None O
modulating None None O
cell None None O
cycle None None O
regulatory None None O
genes None None O
. None None O

Because None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
is None None O
involved None None O
in None None O
LR None None O
formation None None O
, None None O
the None None O
correlation None None O
of None None O
β-CDH None None O
with None None O
NO None None O
and None None O
HO1 None None O
was None None O
investigated None None O
. None None O

This None None O
low None None O
percentage None None O
may None None O
relate None None O
to None None O
the None None O
perception None None I-FUNC
of None None O
lower None None O
yield None None O
for None None O
surgical None None O
ablation None None O
, None None O
especially None None O
in None None O
patients None None O
with None None O
complex None None O
clinical None None O
presentations None None O
. None None O

We None None O
also None None O
observed None None O
a None None O
strong None None O
negative None None O
correlation None None O
between None None O
CT None None O
and None None O
drive None None O
for None None O
thinness None None O
in None None O
extrastriate None None O
regions None None O
involved None None O
in None None O
body None None O
perception None None I-FUNC
. None None O

Besides None None O
chronic None None O
stress None None O
, None None O
chronic None None O
pain None None O
is None None O
a None None O
prevalent None None O
determinant None None O
for None None O
depression None None I-DISEASE
. None None O

Here None None O
, None None O
we None None O
compared None None O
the None None O
role None None O
of None None O
the None None O
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
( None None O
ACC None None O
) None None O
and None None O
the None None O
posterior None None O
insular None None O
cortex None None O
in None None O
the None None O
anxiodepressive None None O
, None None O
sensory None None O
, None None O
and None None O
affective None None O
aspects None None O
of None None O
chronic None None O
pain None None O
. None None O

Furthermore None None O
, None None O
the None None O
ACC None None O
appears None None O
as None None O
a None None O
critical None None O
hub None None O
for None None O
mood None None I-DISEASE
disorders None None I-DISEASE
, None None O
including None None O
for None None O
the None None O
anxiodepressive None None O
consequences None None O
of None None O
chronic None None O
pain None None O
, None None O
and None None O
thus None None O
constitutes None None O
an None None O
important None None O
target None None O
for None None O
divulging None None O
the None None O
underlying None None O
mechanism None None O
. None None O

The None None O
CeA None None O
receives None None O
dense None None O
inputs None None O
from None None O
cortical None None O
regions None None O
, None None O
is None None O
the None None O
major None None O
output None None O
region None None O
of None None O
the None None O
amygdala None None I-REGION
, None None O
is None None O
primarily None None O
GABAergic None None O
( None None O
inhibitory None None O
) None None O
, None None O
and None None O
expresses None None O
high None None O
levels None None O
of None None O
prostress None None O
and None None O
antistress None None O
peptides None None I-TRANS
. None None O

We None None O
discuss None None O
neurotransmission None None O
in None None O
the None None O
CeA None None O
as None None O
a None None O
potential None None O
integrative None None O
hub None None O
between None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
and None None O
alcohol None None O
use None None O
disorder None None O
, None None O
which None None O
are None None O
commonly None None O
co-occurring None None O
in None None O
humans None None O
. None None O

Many None None O
schizophrenia None None I-DISEASE
risk None None O
loci None None O
converge None None O
on None None O
the None None O
synaptic None None O
glutamate None None I-TRANS
signaling None None O
network None None O
. None None O

Gray None None O
matter None None O
homogenates None None O
were None None O
prepared None None O
from None None O
auditory None None O
cortex None None O
gray None None O
matter None None O
of None None O
22 None None O
schizophrenia None None I-DISEASE
and None None O
23 None None O
matched None None O
control None None O
subjects None None O
, None None O
a None None O
subset None None O
of None None O
whom None None O
had None None O
been None None O
previously None None O
assessed None None O
for None None O
dendritic None None O
spine None None O
density None None O
. None None O

Synaptic None None O
protein None None O
co-expression None None O
was None None O
significantly None None O
decreased None None O
in None None O
schizophrenia None None I-DISEASE
with None None O
the None None O
exception None None O
of None None O
a None None O
small None None O
group None None O
of None None O
postsynaptic None None O
density None None O
proteins None None O
, None None O
whose None None O
co-expression None None O
increased None None O
and None None O
inversely None None O
correlated None None O
with None None O
spine None None O
density None None O
in None None O
schizophrenia None None I-DISEASE
subjects None None O
. None None O

The None None O
tartrate-resistant None None O
acid None None O
phosphatase None None I-PROTEIN
5b None None O
level None None O
increased None None O
more None None O
slowly None None O
at None None O
4 None None O
months None None O
after None None O
surgery None None O
than None None O
at None None O
2 None None O
months None None O
after None None O
surgery None None O
in None None O
the None None O
VK3-treated None None O
groups None None O
. None None O

Recent None None O
human None None O
studies None None O
have None None O
indicated None None O
that None None O
neurodevelopmental None None O
disabilities None None O
, None None O
learning None None I-FUNC
disorders None None O
, None None O
memory None None I-FUNC
impairment None None O
, None None O
and None None O
mood None None I-FUNC
disturbance None None O
are None None O
common None None O
in None None O
IUGR None None O
offspring None None O
. None None O

Meanwhile None None O
, None None O
many None None O
studies None None O
have None None O
shown None None O
that None None O
moderate None None O
food None None O
restriction None None O
enhances None None O
spatial None None O
learning None None I-FUNC
and None None O
improves None None O
mood None None I-FUNC
disturbance None None O
in None None O
adult None None O
humans None None O
and None None O
animals None None O
. None None O

Offspring None None O
had None None O
low None None O
birth None None O
weight None None O
and None None O
delayed None None O
development None None O
of None None O
physical None None O
and None None O
coordinated None None O
movement None None I-FUNC
. None None O

Abnormal None None O
eye None None O
movements None None I-FUNC
also None None O
are None None O
common None None O
in None None O
multiple None None O
sclerosis None None O
, None None O
but None None O
quantitative None None O
assessment None None O
methods None None O
that None None O
can None None O
be None None O
applied None None O
in None None O
practice None None O
and None None O
clinical None None O
trials None None O
are None None O
not None None O
readily None None O
available None None O
. None None O

We None None O
review None None O
data None None O
and None None O
principles None None O
to None None O
help None None O
us None None O
understand None None O
the None None O
importance None None O
of None None O
vision None None I-FUNC
as None None O
a None None O
model None None O
for None None O
outcomes None None O
assessment None None O
in None None O
clinical None None O
practice None None O
and None None O
therapeutic None None O
trials None None O
in None None O
multiple None None O
sclerosis None None O
. None None O

However None None O
, None None O
fruit None None O
set None None O
and None None O
adult None None O
fitness None None O
decreased None None O
with None None O
decreasing None None O
patch None None O
size None None O
, None None O
with None None O
an None None O
estimated None None O
mean None None O
lifetime None None O
inbreeding None None O
depression None None I-DISEASE
of None None O
0.9 None None O
( None None O
obtained None None O
by None None O
comparing None None O
F None None O
values None None O
in None None O
adults None None O
and None None O
progenies None None O
) None None O
. None None O

MET None None O
did None None O
not None None O
change None None O
the None None O
basal None None O
phosphorylation None None O
status None None O
of None None O
insulin None None I-PROTEIN
receptor None None I-PROTEIN
signaling None None O
molecules None None O
. None None O

Combined None None O
with None None O
terahertz None None O
time-domain None None O
spectroscopy None None O
, None None O
the None None O
feasibility None None O
of None None O
fast None None O
and None None O
reliable None None O
diagnosis None None O
of None None O
cervical None None O
carcinoma None None O
by None None O
a None None O
fuzzy None None O
rule-building None None O
expert None None O
system None None O
( None None O
FuRES None None O
) None None O
and None None O
a None None O
fuzzy None None O
optimal None None O
associative None None O
memory None None I-FUNC
( None None O
FOAM None None O
) None None O
had None None O
been None None O
studied None None O
. None None O

Vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
and None None O
IL-6 None None O
decreased None None O
by None None O
a None None O
median None None O
of None None O
334 None None O
and None None O
2 None None O
pg/ml None None O
respectively None None O
. None None O

Namely None None O
, None None O
the None None O
thalamus None None I-REGION
can None None O
be None None O
thought None None O
of None None O
as None None O
a None None O
hub None None O
for None None O
cortico-cortical None None O
interactions None None O
, None None O
and None None O
these None None O
transthalamic None None O
cortico-cortical None None O
interactions None None O
were None None O
found None None O
to None None O
play None None O
a None None O
part None None O
in None None O
internal None None O
motor None None O
monitoring None None O
. None None O

For None None O
example None None O
, None None O
one None None O
way None None O
to None None O
impair None None O
these None None O
interactions None None O
is None None O
by None None O
interfering None None O
with None None O
the None None O
ability None None O
of None None O
the None None O
thalamus None None I-REGION
to None None O
display None None O
bursts None None O
of None None O
firing None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
argue None None O
that None None O
elevated None None O
striatal None None O
dopaminergic None None O
activity None None O
in None None O
schizophrenia None None I-DISEASE
attenuates None None O
nigrothalamic None None O
GABAergic None None O
inputs None None O
, None None O
and None None O
thereby None None O
reduces None None O
burst None None O
propensity None None O
of None None O
the None None O
mediodorsal None None O
( None None O
MD None None O
) None None O
thalamic None None O
nucleus None None O
in None None O
schizophrenia None None I-DISEASE
, None None O
with None None O
the None None O
ultimate None None O
result None None O
of None None O
reduced None None O
transthalamic None None O
cortico-cortical None None O
communication None None O
, None None O
relative None None O
disconnection None None O
between None None O
functionally None None O
associated None None O
cortical None None O
areas None None O
and None None O
to None None O
psychosis None None O
. None None O

Autism None None I-DISEASE
Spectrum None None I-DISEASE
Disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
symptoms None None O
have None None O
been None None O
hypothesized None None O
to None None O
result None None O
from None None O
altered None None O
brain None None O
connectivity None None O
. None None O

Here None None O
, None None O
we None None O
review None None O
the None None O
evidence None None O
for None None O
impaired None None O
white None None I-REGION
matter None None I-REGION
connectivity None None O
as None None O
a None None O
neural None None O
substrate None None O
for None None O
socio-emotional None None O
dysfunction None None O
in None None O
ASD None None O
. None None O

Seventy-two None None O
published None None O
DTI None None O
studies None None O
examining None None O
white None None I-REGION
matter None None I-REGION
microstructure None None O
in None None O
ASD None None O
were None None O
reviewed None None O
. None None O

Several None None O
DTI None None O
studies None None O
reported None None O
microstructural None None O
differences None None O
indicative None None O
of None None O
developmental None None O
alterations None None O
in None None O
white None None I-REGION
matter None None I-REGION
organization None None O
, None None O
and None None O
potentially None None O
myelination None None O
, None None O
in None None O
ASD None None O
. None None O

While None None O
alterations None None O
of None None O
the None None O
uncinate None None I-REGION
fasciculus None None I-REGION
and None None O
frontal None None O
and None None O
temporal None None O
thalamic None None O
projections None None O
have None None O
been None None O
associated None None O
with None None O
social None None O
symptoms None None O
in None None O
ASD None None O
, None None O
few None None O
studies None None O
examined None None O
association None None O
of None None O
tract None None O
microstructure None None O
with None None O
core None None O
impairment None None O
in None None O
this None None O
disorder None None O
. None None O

We None None O
focus None None O
our None None O
attention None None I-FUNC
on None None O
adsorbed None None O
protein None None O
monolayers None None O
upon None None O
a None None O
solid None None O
surface None None O
using None None O
a None None O
thermodynamic None None O
and None None O
kinetic None None O
analytical None None O
development None None O
. None None O

To None None O
better None None O
prepare None None O
for None None O
this None None O
transition None None O
, None None O
it None None O
is None None O
essential None None O
that None None O
all None None O
matriculants None None O
to None None O
surgery None None O
residency None None O
successfully None None O
complete None None O
a None None O
preparatory None None O
course None None O
of None None O
blended None None O
learning None None I-FUNC
that None None O
specifically None None O
addresses None None O
essential None None O
components None None O
of None None O
quality None None O
care None None O
and None None O
patient None None O
safety None None O
before None None O
the None None O
start None None O
of None None O
their None None O
training None None O
. None None O

Because None None O
these None None O
two None None O
systems None None O
are None None O
highly None None O
coordinated None None O
, None None O
we None None O
measured None None O
expression None None O
of None None O
prototypic None None O
obesogenic None None O
and None None O
immunogenic None None O
genes None None O
in None None O
freshly None None O
harvested None None O
PBMC None None O
from None None O
controls None None O
and None None O
participants None None O
with None None O
schizophrenia None None I-DISEASE
. None None O

Retention None None I-FUNC
of None None O
technical None None O
skill None None O
is None None O
suspect None None O
, None None O
unless None None O
sequential None None O
learning None None I-FUNC
experiences None None O
are None None O
provided None None O
. None None O

Increased None None O
inflammation None None O
, None None O
endothelial None None O
dysfunction None None O
, None None O
and None None O
structural None None O
brain None None O
abnormalities None None O
have None None O
been None None O
reported None None O
in None None O
both None None O
schizophrenia None None I-DISEASE
and None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
but None None O
the None None O
relationships None None O
between None None O
these None None O
factors None None O
are None None O
unknown None None O
. None None O

We None None O
measured None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
( None None O
vWf None None O
) None None O
as None None O
a None None O
marker None None O
of None None O
endothelial None None O
cell None None O
activation None None O
and None None O
six None None O
inflammatory None None O
markers None None O
( None None O
tumor None None O
necrosis None None O
factor-receptor None None I-PROTEIN
1 None None O
, None None O
osteoprotegerin None None O
, None None O
interleukin-1-receptor None None I-PROTEIN
antagonist None None O
, None None O
interleukin-6 None None O
, None None O
C-reactive None None O
protein None None O
, None None O
CD40 None None O
ligand None None O
) None None O
in None None O
plasma None None O
and None None O
16 None None O
brain None None O
structures None None O
obtained None None O
from None None O
MRI None None O
scans None None O
of None None O
356 None None O
individuals None None O
( None None O
schizophrenia None None I-DISEASE
spectrum None None O
; None None O
n=121 None None O
, None None O
affective None None O
spectrum None None O
; None None O
n=95 None None O
, None None O
healthy None None O
control None None O
subjects None None O
; None None O
n=140 None None O
) None None O
. None None O

There None None O
was None None O
a None None O
positive None None O
association None None O
( None None O
p=2.5×10 None None O
( None None O
-4 None None O
) None None O
) None None O
between None None O
plasma None None O
levels None None O
of None None O
vWf None None O
and None None O
total None None O
volume None None O
of None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
which None None O
remained None None O
significant None None O
after None None O
correction None None O
for None None O
multiple None None O
testing None None O
. None None O

After None None O
adjusting None None O
for None None O
diagnosis None None O
and None None O
antipsychotic None None O
medication None None O
, None None O
vWf None None O
remained None None O
significantly None None O
associated None None O
with None None O
increased None None O
basal None None I-REGION
ganglia None None I-REGION
volume None None O
( None None O
p=0.008 None None O
) None None O
, None None O
in None None O
particular None None O
the None None O
right None None I-REGION
globus None None I-REGION
pallidus None None I-REGION
( None None O
p=3.7×10 None None O
( None None O
-4 None None O
) None None O
) None None O
. None None O

Our None None O
results None None O
show None None O
a None None O
strong None None O
positive None None O
correlation None None O
between None None O
vWf None None O
levels None None O
and None None O
basal None None I-REGION
ganglia None None I-REGION
volume None None O
, None None O
in None None O
particular None None O
globus None None I-REGION
pallidus None None I-REGION
, None None O
independent None None O
of None None O
diagnosis None None O
. None None O

Fatigue None None O
, None None O
insomnia None None O
, None None O
depression None None I-DISEASE
symptoms None None I-DISEASE
, None None O
as None None O
well None None O
as None None O
fatigue None None O
cognitions None None O
were None None O
assessed None None O
in None None O
participants None None O
( None None O
36 None None O
% None None O
females None None O
; None None O
age None None O
& None None O
gt None None O
; None None O
18 None None O
years None None O
, None None O
N=115 None None O
) None None O
with None None O
chronic None None O
HCV None None O
infection None None O
at None None O
a None None O
tertiary None None O
hepatitis None None O
clinic None None O
. None None O

Comorbidities None None O
and None None O
fatigue None None O
perceptions None None I-FUNC
accounted None None O
for None None O
61 None None O
% None None O
of None None O
the None None O
variation None None O
of None None O
fatigue None None O
. None None O

The None None O
tumor None None O
included None None O
2 None None O
types None None O
of None None O
poorly None None O
differentiated None None O
tumor None None O
cells None None O
and None None O
was None None O
immunohistochemically None None O
positive None None O
for None None O
the None None O
NUT-specific None None O
antigen None None O
, None None O
epithelial None None O
membrane None None O
antigen None None O
( None None O
EMA None None O
) None None O
, None None O
cluster None None O
of None None O
differentiation None None O
99 None None O
( None None O
CD99 None None O
) None None O
antigen None None O
, None None O
CD45RO None None O
antigen None None O
, None None O
keratins None None I-PROTEIN
, None None O
p63 None None O
, None None O
and None None O
p40 None None O
. None None O

Cathepsin None None O
X None None O
( None None O
CTSX None None O
, None None O
also None None O
called None None O
cathepsin None None O
Z/P None None O
) None None O
is None None O
a None None O
cysteine None None I-TRANS
protease None None O
that None None O
still None None O
plays None None O
an None None O
unknown None None O
role None None O
in None None O
human None None O
cancer None None O
. None None O

Although None None O
collagen None None I-PROTEIN
pentapeptide None None O
( None None O
Lys-Thr-Thr-Lys-Ser None None O
, None None O
KTTKS None None O
) None None O
has None None O
received None None O
a None None O
great None None O
deal None None O
of None None O
attention None None I-FUNC
owing None None O
to None None O
its None None O
collagen None None I-PROTEIN
biosynthesis-stimulating None None O
effects None None O
, None None O
its None None O
enzymatic None None O
instability None None O
in None None O
the None None O
skin None None O
is None None O
an None None O
obstacle None None O
to None None O
effective None None O
topical None None O
application None None O
. None None O

They None None O
also None None O
had None None O
high None None O
stability None None O
against None None O
proteolytic None None O
enzymes None None I-PROTEIN
in None None O
rat None None O
skin None None O
. None None O

The None None O
in None None O
vitro None None O
anti-inflammatory None None O
activity None None O
of None None O
compounds None None O
1 None None O
and None None O
2 None None O
was None None O
evaluated None None O
by None None O
measuring None None O
their None None O
ability None None O
in None None O
suppressing None None O
superoxide None None O
anion None None O
generation None None O
and None None O
elastase None None I-PROTEIN
release None None O
in None None O
fMLP/CB-induced None None O
human None None O
neutrophils None None O
. None None O

By None None O
whole-exome None None O
and None None O
candidate None None O
gene None None O
sequencing None None O
, None None O
we None None O
identified None None O
11 None None O
individuals None None O
from None None O
9 None None O
families None None O
carrying None None O
compound None None O
heterozygous None None O
or None None O
homozygous None None O
mutations None None O
in None None O
GTPBP3 None None O
, None None O
encoding None None I-FUNC
the None None O
mitochondrial None None O
GTP-binding None None O
protein None None O
3 None None O
. None None O

In None None O
contrast None None O
to None None O
individuals None None O
with None None O
mutations None None O
in None None O
MTO1 None None O
, None None O
the None None O
protein None None O
product None None O
of None None O
which None None O
is None None O
predicted None None O
to None None O
participate None None O
in None None O
the None None O
generation None None O
of None None O
the None None O
same None None O
modification None None O
, None None O
most None None O
individuals None None O
with None None O
GTPBP3 None None O
mutations None None O
developed None None O
neurological None None O
symptoms None None O
and None None O
MRI None None O
involvement None None O
of None None O
thalamus None None I-REGION
, None None O
putamen None None I-REGION
, None None O
and None None O
brainstem None None I-REGION
resembling None None O
Leigh None None O
syndrome None None O
. None None O

Advances None None O
in None None O
understanding None None O
the None None O
etiology None None O
of None None O
Parkinson None None I-DISEASE
disease None None O
have None None O
been None None O
driven None None O
by None None O
the None None O
identification None None O
of None None O
causative None None O
mutations None None O
in None None O
families None None O
. None None O

Post None None O
mortem None None O
studies None None O
demonstrated None None O
that None None O
loss None None O
of None None O
RAB39B None None O
resulted None None O
in None None O
pathologically None None O
confirmed None None O
Parkinson None None I-DISEASE
disease None None O
. None None O

The None None O
loss None None O
of None None O
RAB39B None None O
results None None O
in None None O
dysregulation None None O
of None None O
α-synuclein None None O
homeostasis None None O
and None None O
a None None O
spectrum None None O
of None None O
neuropathological None None O
features None None O
that None None O
implicate None None O
RAB39B None None O
in None None O
the None None O
pathogenesis None None O
of None None O
Parkinson None None I-DISEASE
disease None None O
and None None O
potentially None None O
other None None O
neurodegenerative None None O
disorders None None O
. None None O

This None None O
protein None None O
interacts None None O
with None None O
elastin None None I-PROTEIN
fibers None None O
and None None O
the None None O
microfibrillar None None O
network None None O
. None None O

Functional None None O
analyses None None O
performed None None O
on None None O
both None None O
affected None None O
individual None None O
's None None O
cells None None I-NEURON
and None None O
in None None O
vitro None None O
models None None O
showed None None O
that None None O
these None None O
two None None O
mutations None None O
caused None None O
pure None None O
or None None O
partial None None O
haploinsufficiency None None O
. None None O

The None None O
finding None None O
of None None O
aquaglyceroporin-9 None None O
in None None O
the None None O
basolateral None None O
surface None None O
of None None O
the None None O
hepatocyte None None O
accounted None None O
for None None O
the None None O
rapid None None O
entry None None O
of None None O
mannitol None None O
into None None O
hepatocytes None None O
and None None O
its None None O
exclusion None None O
from None None O
water None None O
movement None None I-FUNC
in None None O
the None None O
ductules None None O
where None None O
aquaporin-1 None None O
is None None O
present None None O
. None None O

An None None O
acute None None O
bout None None O
of None None O
exercise None None O
increases None None O
skeletal None None O
muscle None None O
glucose None None O
uptake None None O
, None None O
while None None O
chronic None None O
exercise None None O
training None None O
improves None None O
mitochondrial None None O
function None None O
, None None O
increases None None O
mitochondrial None None O
biogenesis None None O
, None None O
and None None O
increases None None O
the None None O
expression None None O
of None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
proteins None None O
and None None O
numerous None None O
metabolic None None O
genes None None O
. None None O

Accordingly None None O
, None None O
class None None O
activities None None O
must None None O
capitalize None None O
on None None O
this None None O
inherently None None O
energetic None None O
and None None O
curious None None O
nature None None O
so None None O
that None None O
learning None None I-FUNC
becomes None None O
a None None O
lifelong None None O
activity None None O
where None None O
students None None O
take None None O
initiative None None O
for None None O
learning None None I-FUNC
, None None O
are None None O
skilled None None O
in None None O
learning None None I-FUNC
, None None O
and None None O
want None None O
to None None O
learn None None O
new None None O
things None None O
. None None O

The None None O
flipped None None O
exam None None O
was None None O
a None None O
collaborative None None O
, None None O
group None None O
effort None None O
, None None O
and None None O
learning None None I-FUNC
was None None O
interactive None None O
. None None O

This None None O
required None None O
students None None O
to None None O
actively None None O
search None None O
for None None O
content None None O
and None None O
context None None O
, None None O
dynamically None None O
making None None O
connections None None O
between None None O
what None None O
they None None O
knew None None O
and None None O
what None None O
they None None O
learned None None O
, None None O
grappling None None O
with None None O
complexity None None O
, None None O
uncertainty None None O
, None None O
and None None O
ambiguity None None I-FUNC
, None None O
and None None O
finally None None O
discovering None None O
answers None None O
to None None O
important None None O
questions None None O
. None None O

The None None O
acceptance None None O
of None None O
this None None O
new None None O
learning None None I-FUNC
method None None O
was None None O
examined None None O
in None None O
the None None O
present None None O
pilot None None O
study None None O
. None None O

Learning None None I-FUNC
activities None None O
include None None O
1 None None O
) None None O
displaying None None O
the None None O
recruitment None None O
of None None O
muscle None None O
fibers None None O
with None None O
increasing None None O
force None None O
development None None O
; None None O
2 None None O
) None None O
the None None O
measurement None None O
of None None O
conduction None None O
velocity None None O
of None None O
motor None None O
nerves None None O
; None None O
3 None None O
) None None O
the None None O
assessment None None O
of None None O
reflex None None O
delay None None O
and None None O
demonstration None None O
of None None O
Jendrassik None None O
's None None O
maneuver None None O
; None None O
and None None O
4 None None O
) None None O
a None None O
Hoffman None None O
reflex None None O
experiment None None O
that None None O
illustrates None None O
the None None O
composition None None O
of None None O
mixed None None O
nerves None None O
and None None O
the None None O
differential None None O
excitability None None O
thresholds None None O
of None None O
fibers None None O
within None None O
the None None O
same None None O
nerve None None O
, None None O
thus None None O
aiding None None O
an None None O
understanding None None O
of None None O
the None None O
reflex None None O
nature None None O
of None None O
muscle None None O
control None None O
. None None O

The None None O
results None None O
can None None O
then None None O
provide None None O
an None None O
ideal None None O
platform None None O
for None None O
a None None O
discovery None None O
learning None None I-FUNC
session/tutorial None None O
on None None O
how None None O
the None None O
central None None O
nervous None None O
system None None O
controls None None O
muscles None None O
, None None O
giving None None O
insights None None O
on None None O
how None None O
supraspinal None None O
control None None O
interacts None None O
with None None O
reflexes None None O
to None None O
give None None O
smooth None None O
, None None O
precise None None O
muscular None None O
activation None None O
. None None O

These None None O
variables None None O
include None None O
heart None None O
rate None None O
, None None O
cardiac None None O
output None None O
, None None O
stroke None None I-DISEASE
volume None None O
, None None O
total None None O
peripheral None None O
resistance None None O
, None None O
and None None O
arterial None None O
pressures None None O
( None None O
mean None None O
, None None O
diastolic None None O
, None None O
and None None O
systolic None None O
) None None O
. None None O

Statistical None None O
analysis None None O
of None None O
the None None O
data None None O
generated None None O
for None None O
each None None O
of None None O
these None None O
four None None O
maneuvers None None O
allows None None O
the None None O
students None None O
to None None O
consider None None O
the None None O
factors None None O
that None None O
contribute None None O
to None None O
the None None O
diving None None O
response None None O
, None None O
such None None O
as None None O
the None None O
temperature None None O
of None None O
the None None O
water None None O
and None None O
the None None O
location None None O
of None None O
the None None O
sensory None None O
receptors None None I-PROTEIN
that None None O
initiate None None O
the None None O
response None None O
. None None O

We None None O
present None None O
the None None O
first None None O
preliminary None None O
inventory None None O
of None None O
Trichoptera None None O
taxa None None O
in None None O
the None None O
Aegean None None O
and None None O
Adriatic None None O
Sea None None O
basins None None O
in None None O
Kosovo None None O
that None None O
have None None O
previously None None O
received None None O
poor None None O
and None None O
fragmentary None None O
attention None None I-FUNC
. None None O

Basic None None O
helix-loop-helix None None O
( None None O
bHLH None None O
) None None O
proteins None None O
comprise None None O
a None None O
large None None O
superfamily None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
which None None O
are None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
various None None O
developmental None None O
processes None None O
. None None O

This None None O
article None None O
initially None None O
examines None None O
the None None O
most None None O
commonly None None O
proposed None None O
positions None None O
on None None O
when None None O
a None None O
human None None O
being None None O
dies None None O
those None None O
of None None O
cardiopulmonary None None O
death None None O
, None None O
whole None None O
brain None None O
death None None O
, None None O
brainstem None None I-REGION
death None None O
and None None O
higher None None O
brain None None O
death None None O
and None None O
for None None O
each None None O
describes None None O
scenarios None None O
that None None O
provide None None O
counter-intuitive None None O
results None None O
. None None O

The None None O
variables None None O
measured None None O
were None None O
the None None O
latency None None O
time None None O
to None None O
step None None O
into None None O
the None None O
dark None None O
compartment None None O
of None None O
the None None O
apparatus None None O
and None None O
the None None O
learning None None I-FUNC
criterion None None O
( None None O
remaining None None O
in None None O
the None None O
illuminated None None O
compartment None None O
for None None O
at None None O
least None None O
180 None None O
sec None None O
) None None O
. None None O

After None None O
21 None None O
days None None O
of None None O
treatment None None O
, None None O
the None None O
juice None None O
dose-dependently None None O
prolonged None None O
the None None O
latency None None O
time None None O
at None None O
the None None O
retention None None I-FUNC
tests None None O
, None None O
the None None O
effect None None O
being None None O
significant None None O
at None None O
doses None None O
of None None O
5 None None O
ml/kg None None O
and None None O
10 None None O
ml/kg None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
Aronia None None O
melanocarpa None None O
fruit None None O
juice None None O
could None None O
improve None None O
memory None None I-FUNC
in None None O
rats None None O
. None None O

To None None O
explore None None O
the None None O
effect None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
on None None O
the None None O
gene None None O
expression None None O
of None None O
hepatic None None O
TNF-α None None O
and None None O
IL-1β None None O
by None None O
crush None None O
injury None None O
of None None O
rat None None O
's None None O
soft None None O
tissues None None O
. None None O

This None None O
polymer None None O
is None None O
degraded None None O
by None None O
enzymes None None I-PROTEIN
called None None O
chitinases None None I-PROTEIN
which None None O
are None None O
a None None O
part None None O
of None None O
the None None O
glycoside None None O
hydrolase None None I-PROTEIN
family None None O
. None None O

At None None O
present None None O
many None None O
microbial None None O
sources None None O
are None None O
being None None O
explored None None O
and None None O
tapped None None O
for None None O
chitinase None None I-PROTEIN
production None None O
which None None O
includes None None O
potential None None O
fungal None None O
cultures None None O
. None None O

The None None O
present None None O
review None None O
focuses None None O
on None None O
recent None None O
advances None None O
in None None O
fungal None None O
chitinases None None I-PROTEIN
, None None O
containing None None O
a None None O
short None None O
introduction None None O
to None None O
types None None O
of None None O
chitinases None None I-PROTEIN
, None None O
their None None O
fermentative None None O
production None None O
, None None O
purification None None O
and None None O
characterization None None O
and None None O
molecular None None O
cloning None None O
and None None O
expression None None O
. None None O

The None None O
kinetics None None O
of None None O
immobilized None None O
enzymes None None I-PROTEIN
can None None O
not None None O
be None None O
analyzed None None O
by None None O
means None None O
of None None O
the None None O
simple None None O
Michaelis-Menten None None O
concept None None O
, None None O
which None None O
generally None None O
fails None None O
to None None O
describe None None O
the None None O
immobilized None None O
state None None O
due None None O
to None None O
both None None O
its None None O
probable None None O
barriers None None O
, None None O
and None None O
because None None O
the None None O
active None None O
concentration None None O
of None None O
the None None O
enzyme None None O
approaches None None O
, None None O
or None None O
even None None O
exceeds None None O
this None None O
of None None O
its None None O
substrate None None O
( None None O
s None None O
) None None O
. None None O

Likewise None None O
, None None O
immobilization None None O
is None None O
often None None O
a None None O
key None None O
method None None O
in None None O
optimizing None None O
the None None O
operational None None O
performance None None O
of None None O
enzymes None None I-PROTEIN
, None None O
in None None O
both None None O
laboratory None None O
and None None O
industrial None None O
scale None None O
, None None O
and None None O
affects None None O
considerably None None O
the None None O
kinetics None None O
in None None O
non-aqueous None None O
and None None O
non-conventional None None O
media None None O
due None None O
to None None O
several None None O
issues None None O
as None None O
the None None O
structural None None O
changes None None O
of None None O
the None None O
enzyme None None O
molecule None None O
, None None O
the None None O
heterogeneity None None O
of None None O
the None None O
system None None O
, None None O
and None None O
the None None O
partial None None O
or None None O
total None None O
absence None None O
of None None O
water None None O
. None None O

In None None O
vitro None None O
experiments None None O
carried None None O
out None None O
with None None O
DEHP None None O
( None None O
0.1-100 None None O
microM None None O
) None None O
induced None None O
proliferations None None O
( None None O
E-screen None None O
assay None None O
) None None O
in None None O
human None None O
estrogen None None I-PROTEIN
receptors-alpha None None O
( None None O
ERalpha None None O
) None None O
positive None None O
MCF-7 None None O
and None None O
ERalpha None None O
negative None None O
MDA-MB-231 None None O
breast None None O
cancer None None O
cells None None O
irrespective None None O
of None None O
their None None O
ERa None None O
status None None O
. None None O

A None None O
rapid None None O
detection None None O
( None None O
within None None O
10 None None O
min None None O
) None None O
of None None O
phenol None None O
constituents None None O
from None None O
winery None None O
effluents None None O
was None None O
achieved None None O
by None None O
bioconjugate None None O
, None None O
when None None O
compared None None O
to None None O
tyrosinases None None I-PROTEIN
and None None O
gold None None O
nanoparticles None None O
independently None None O
. None None O

As None None O
with None None O
any None None O
lignocellulosic None None O
biomass None None O
, None None O
sorghum None None O
also None None O
requires None None O
pretreatment None None O
which None None O
increases None None O
its None None O
susceptibility None None O
to None None O
hydrolysis None None O
by None None O
enzymes None None I-PROTEIN
for None None O
generating None None O
sugars None None O
which None None O
can None None O
be None None O
further None None O
fermented None None O
to None None O
alcohol None None O
. None None O

The None None O
activity None None O
of None None O
some None None O
luminal None None O
enzymes None None I-PROTEIN
from None None O
microbial None None O
origin None None O
like None None O
a-amylase None None O
, None None O
gluco-amylase None None O
, None None O
proteinase None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
and None None O
beta-glucuronidase None None O
were None None O
also None None O
elevated None None O
in None None O
hypoxic None None O
condition None None O
. None None O

For None None O
cost None None O
effective None None O
production None None O
of None None O
laccase None None I-PROTEIN
enzyme None None O
( None None O
benzenediol None None O
: None None O
oxygen None None O
oxidoreductase None None I-PROTEIN
) None None O
from None None O
P. None None O
ostreatus None None O
MTCC None None O
1802 None None O
through None None O
solid None None O
sate None None O
fermentation None None O
, None None O
physico-chemical None None O
parameters None None O
such None None O
as None None O
temperature None None O
( None None O
20-35 None None O
degrees None None O
C None None O
) None None O
, None None O
incubation None None O
period None None O
( None None O
9-17 None None O
days None None O
) None None O
and None None O
substrate None None O
( None None O
Neem None None O
bark None None O
and None None O
wheat None None O
bran None None O
, None None O
in None None O
various None None O
ratios None None O
, None None O
w/w None None O
) None None O
were None None O
optimized None None O
first None None O
by None None O
one None None O
parameter None None O
at None None O
time None None O
approach None None O
and None None O
then None None O
obtained None None O
optimum None None O
conditions None None O
were None None O
considered None None O
as None None O
zero None None O
level None None O
in None None O
evolutionary None None O
optimization None None O
factorial None None O
design None None O
technique None None O
. None None O

The None None O
results None None O
obtained None None O
could None None O
be None None O
a None None O
base None None O
line None None O
for None None O
industrial None None O
scale None None O
production None None O
of None None O
laccase None None I-PROTEIN
. None None O

Among None None O
the None None O
growth None None O
hormones None None I-PROTEIN
used None None O
, None None O
1 None None O
mg/L None None O
2 None None O
, None None O
4-D None None O
showed None None O
best None None O
callusing None None O
. None None O

Chlorophyll None None O
a None None O
and None None O
b None None O
and None None O
total None None O
chlorophyll None None O
, None None O
proline None None I-TRANS
and None None O
total None None O
phenolic None None O
contents None None O
, None None O
total None None O
peroxidase None None O
and None None O
catalase None None I-PROTEIN
activities None None O
increased None None O
under None None O
stress None None O
conditions None None O
suggesting None None O
the None None O
tolerance None None O
of None None O
callus None None O
to None None O
drought None None O
stress None None O
. None None O

The None None O
biocontrol None None O
potential None None O
of None None O
NII None None O
1006 None None O
strain None None O
may None None O
be None None O
correlated None None O
significantly None None O
with None None O
their None None O
ability None None O
to None None O
produce None None O
antibiotics None None O
as None None O
well None None O
as None None O
extracellular None None O
hydrolytic None None I-PROTEIN
enzymes None None I-PROTEIN
particularly None None O
chitinolytic None None O
enzyme None None O
. None None O

The None None O
protein None None O
modified None None O
monolithic None None O
column None None O
in None None O
affinity None None O
capillary None None O
electrochromatography None None O
( None None O
CEC None None O
) None None O
has None None O
attracted None None O
considerable None None O
attention None None I-FUNC
over None None O
the None None O
past None None O
decades None None O
because None None O
of None None O
its None None O
great None None O
enantioseparation None None O
ability None None O
. None None O

A None None O
pepsin None None I-PROTEIN
functionalized None None O
organic None None O
polymer None None O
monolith None None O
was None None O
prepared None None O
by None None O
covalently None None O
bonded None None O
pepsin None None I-PROTEIN
to None None O
poly None None O
( None None O
GMA-co-EDMA None None O
) None None O
monolith None None O
with None None O
glutaraldehyde None None O
as None None O
a None None O
spacer None None O
based None None O
on None None O
the None None O
activity None None O
of None None O
epoxide None None O
group None None O
. None None O

A None None O
method None None O
for None None O
the None None O
simultaneous None None O
determination None None O
of None None O
indole-3-acetic None None O
acid None None O
, None None O
N6- None None O
( None None O
2-isopentenyl None None O
) None None O
adenosine None None I-TRANS
, None None O
N6- None None O
( None None O
2-isopentenyl None None O
) None None O
adenine None None O
, None None O
trans-zeatin None None O
riboside None None O
, None None O
zeatin None None O
, None None O
strigolactone None None O
, None None O
abscisic None None O
acid None None O
, None None O
salicylic None None O
acid None None O
, None None O
gibberellin None None O
A3 None None O
and None None O
jasmonic None None O
acid None None O
in None None O
five None None O
different None None O
parts None None O
of None None O
main None None O
branch None None O
, None None O
lateral None None O
branch None None O
, None None O
primary None None O
leaf None None O
, None None O
secondary None None O
leaf None None O
and None None O
stem None None O
of None None O
Sargasum None None O
fusiforme None None O
( None None O
Hary None None O
. None None O
) None None O

The None None O
extract None None O
was None None O
further None None O
purified None None O
on None None O
a None None O
carbon/ None None O
NH2 None None I-TRANS
cartridge None None O
with None None O
elution None None O
solvents None None O
of None None O
acetonitrile/toluene None None O
( None None O
3:1 None None O
, None None O
v/v None None O
) None None O
. None None O

To None None O
clone None None O
cDNA None None O
encoding None None I-FUNC
troponin None None O
T None None O
of None None O
Schistosoma None None O
japonicum None None O
( None None O
SjTnT None None O
) None None O
, None None O
and None None O
evaluate None None O
the None None O
protective None None O
efficacy None None O
induced None None O
by None None O
recombinant None None O
SjTnT None None O
in None None O
BALB/c None None O
mice None None O
against None None O
S. None None O
japonicum None None O
challenge None None O
infection None None O
. None None O

To None None O
investigate None None O
the None None O
relationship None None O
between None None O
p53 None None I-PROTEIN
, None None O
COX-2 None None O
, None None O
Bax None None O
, None None O
c-myc None None I-PROTEIN
genes None None O
and None None O
colorectal None None O
carcinoma None None O
complicated None None O
with None None O
chronic None None O
schistosomiasis None None O
. None None O

The None None O
tissue None None O
microarray None None O
techniques None None O
and None None O
immunohistochemistry None None O
method None None O
were None None O
used None None O
in None None O
all None None O
the None None O
patients None None O
to None None O
detect None None O
the None None O
expressions None None O
of None None O
p53 None None I-PROTEIN
, None None O
COX-2 None None O
, None None O
Bax None None O
and None None O
c-myc None None I-PROTEIN
proteins None None O
. None None O

The None None O
positive None None O
rate None None O
of None None O
c-myc None None I-PROTEIN
expression None None O
in None None O
the None None O
schistosomiasis None None O
group None None O
was None None O
higher None None O
than None None O
that None None O
in None None O
the None None O
non-schistosomiasis None None O
group None None O
, None None O
with None None O
a None None O
significant None None O
difference None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
but None None O
the None None O
positive None None O
expression None None O
level None None O
was None None O
lower None None O
than None None O
that None None O
in None None O
the None None O
non-schistosomiasis None None O
group None None O
, None None O
and None None O
there None None O
was None None O
a None None O
significant None None O
difference None None O
between None None O
the None None O
two None None O
groups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

The None None O
schistosome None None O
chronic None None O
infection None None O
may None None O
cause None None O
a None None O
persistent None None O
low None None O
level None None O
expression None None O
of None None O
c-myc None None I-PROTEIN
gene None None O
. None None O

The None None O
related None None O
literature None None O
published None None O
from None None O
2008 None None O
to None None O
2012 None None O
was None None O
searched None None O
from None None O
the None None O
databases None None O
of None None O
CNKI None None O
, None None O
VIP None None I-TRANS
and None None O
Wanfang None None O
and None None O
then None None O
screened None None O
by None None O
the None None O
exclusion None None O
criteria None None O
. None None O

It None None O
consists None None O
of None None O
: None None O
( None None O
1 None None O
) None None O
radioprotectors None None O
which None None O
realize None None O
their None None O
radiation None None O
protective None None O
effect None None O
at None None O
the None None O
physical None None O
, None None O
chemical None None O
and None None O
biochemical None None O
levels None None O
in None None O
the None None O
course None None O
of None None O
the None None O
energy None None O
absorption None None O
of None None O
ionizing None None O
radiation None None O
via None None O
partial None None O
neutralization None None O
of None None O
the None None O
`` None None O
oxygen None None O
effect None None O
'' None None O
as None None O
a None None O
radiobiological None None O
phenomenon None None O
; None None O
( None None O
2 None None O
) None None O
radiomitigators None None O
, None None O
which None None O
realize None None O
their None None O
effect None None O
at None None O
the None None O
system None None O
level None None O
by None None O
accelerating None None O
the None None O
post-radiation None None O
recovery None None O
of None None O
radiosensitive None None O
tissues None None O
through None None O
an None None O
activation None None O
of None None O
proinflammatory None None O
signaling None None O
pathways None None O
and None None O
an None None O
increase None None O
of None None O
secretion None None O
of None None O
hematopoietic None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
, None None O
are None None O
used None None O
in None None O
the None None O
early None None O
period None None O
after None None O
exposure None None O
to None None O
radiation None None O
prior None None O
to None None O
the None None O
development None None O
of None None O
clinical None None O
manifestations None None O
of None None O
acute None None O
radiation None None O
damage None None O
as None None O
drugs None None O
of None None O
emergency None None O
and None None O
early None None O
treatment None None O
for None None O
radiation None None O
injuries None None O
; None None O
( None None O
3 None None O
) None None O
radiomodulators None None O
-- None None O
pharmaceutical None None O
drugs None None O
and None None O
food None None O
nutritional None None O
supplements None None O
which None None O
elevate None None O
the None None O
resistance None None O
of None None O
the None None O
organism None None O
to None None O
adverse None None O
environmental None None O
factors None None O
, None None O
including None None O
mutagenic None None O
effects None None O
of None None O
exposure None None O
to None None O
low-dose None None O
ionizing None None O
radiation None None O
, None None O
by None None O
means None None O
of None None O
modulating None None O
the None None O
gene None None O
expression None None O
through None None O
`` None None O
substrate None None O
'' None None O
maintenance None None O
of None None O
adaptive None None O
changes None None O
resulting None None O
in None None O
an None None O
increased None None O
antioxidant None None O
protection None None O
of None None O
the None None O
organism None None O
; None None O
( None None O
4 None None O
) None None O
pharmaceutical None None O
drugs None None O
to None None O
protect None None O
against None None O
the None None O
incorporation None None O
of None None O
technogenic None None O
radionu- None None O
clides None None O
into None None O
the None None O
organism None None O
; None None O
( None None O
5 None None O
) None None O
pharmaceutical None None O
drugs None None O
to None None O
prevent None None O
( None None O
arrest None None O
) None None O
manifestations None None O
of None None O
the None None O
primary None None O
response None None O
to None None O
radiation None None O
. None None O

The None None O
study None None O
was None None O
aimed None None O
at None None O
experimental None None O
evaluating None None O
the None None O
efficacy None None O
of None None O
experimental None None O
wound None None O
collagen None None I-PROTEIN
coverings None None O
`` None None O
Sangvikol None None O
'' None None O
, None None O
`` None None O
Gemasept None None O
'' None None O
, None None O
`` None None O
Kolotsil None None O
'' None None O
and None None O
`` None None O
Biatravm None None O
'' None None O
for None None O
treatment None None O
of None None O
deep None None O
radiation None None O
burns None None O
which None None O
form None None O
at None None O
combined None None O
radiation None None O
injures None None O
. None None O

It None None O
is None None O
established None None O
that None None O
wound None None O
collagen None None I-PROTEIN
coverings None None O
are None None O
well None None O
modeled None None O
on None None O
a None None O
wound None None O
, None None O
absorb None None O
excess None None O
exudate None None O
, None None O
maintain None None O
optimum None None O
humidity None None O
in None None O
a None None O
wound None None O
; None None O
protect None None O
a None None O
wound None None O
from None None O
infection None None O
, None None O
and None None O
medicinal None None O
fillers None None O
contribute None None O
to None None O
the None None O
activation None None O
of None None O
reparative None None O
processes None None O
in None None O
the None None O
irradiated None None O
skin None None O
. None None O

It None None O
is None None O
shown None None O
in None None O
experiments None None O
on None None O
the None None O
rats None None O
subjected None None O
to None None O
gamma-radiation None None O
at None None O
various None None O
doses None None O
that None None O
preventive None None O
introduction None None O
of None None O
exogenous None None O
melatonin None None I-TRANS
reduces None None O
the None None O
quantity None None O
ofchromosomal None None O
aberrations None None O
in None None O
cells None None O
ofbone None None O
marrow None None O
and None None O
decreases None None O
the None None O
expression None None O
of None None O
oxidative None None O
stress None None O
. None None O

The None None O
latter None None O
are None None O
differentiated None None O
in None None O
3 None None O
principal None None O
groups None None O
: None None O
radioprotectors None None O
, None None O
radiomodificators None None O
( None None O
these None None O
are None None O
able None None O
to None None O
have None None O
a None None O
positive None None O
effect None None O
when None None O
administered None None O
preliminary None None O
, None None O
before None None O
the None None O
exposure None None O
, None None O
or None None O
provide None None O
a None None O
delayed None None O
nonspecific None None O
protection None None O
after None None O
the None None O
exposure None None O
-- None None O
urgent None None O
therapy None None O
) None None O
and None None O
hemopoietic None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
demanding None None O
course None None O
administration None None O
. None None O

It None None O
includes None None O
urgent None None O
administration None None O
of None None O
the None None O
cytokine None None O
combination None None O
( None None O
betaleukine None None O
and None None O
thrombopoietin None None O
) None None O
with None None O
subsequent None None O
supportive None None O
therapy None None O
and None None O
a None None O
hemopoietic None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
course None None O
. None None O

Both None None O
analogues None None O
demonstrated None None O
similar None None O
sensitivity None None O
towards None None O
denaturing None None O
agents None None O
: None None O
addition None None O
of None None O
2.0 None None O
M None None O
ofguanidine None None O
chloride None None O
resulted None None O
in None None O
the None None O
complete None None O
inactivation None None O
of None None O
both None None O
enzymes None None I-PROTEIN
. None None O

It None None O
is None None O
shown None None O
that None None O
the None None O
protein None None I-PROTEIN
C-activating None None O
activity None None O
of None None O
the None None O
micromycete None None O
in None None O
a None None O
solid-state None None O
culture None None O
was None None O
1.5-3.5 None None O
times None None O
higher None None O
than None None O
in None None O
a None None O
submerged None None O
culture None None O
( None None O
as None None O
calculated None None O
per None None O
milliliter None None O
of None None O
culture None None O
medium None None O
) None None O
. None None O

A None None O
laccase None None I-PROTEIN
from None None O
the None None O
culture None None O
filtrate None None O
of None None O
Phellinus None None O
linteus None None O
MTCC-1175 None None O
has None None O
been None None O
purified None None O
to None None O
homogeneity None None O
. None None O

Using None None O
2,6-dimethoxyphenol None None O
, None None O
2,2 None None O
' None None O
[ None None O
azino-bis- None None O
( None None O
3-ethylbonzthiazoline-6-sulphonic None None O
acid None None O
) None None O
diammonium None None O
salt None None O
] None None O
( None None O
ABTS None None O
) None None O
and None None O
4-hydroxy-3,5-dimethoxybenzaldehyde None None O
azine None None O
as None None O
the None None O
substrates None None O
, None None O
the None None O
Kin None None O
, None None O
kcat None None O
and None None O
kt/Km None None O
values None None O
of None None O
the None None O
laccase None None I-PROTEIN
were None None O
found None None O
to None None O
be None None O
160 None None O
microM None None O
, None None O
6.85 None None O
s None None O
( None None O
-1 None None O
) None None O
, None None O
4.28 None None O
x None None O
10 None None O
( None None O
4 None None O
) None None O
M None None O
( None None O
-1 None None O
) None None O
s None None O
( None None O
-1 None None O
) None None O
, None None O
42 None None O
microM None None O
, None None O
6.85 None None O
s None None O
( None None O
-1 None None O
) None None O
, None None O
16.3 None None O
x None None O
10 None None O
( None None O
4 None None O
) None None O
M None None O
( None None O
-1 None None O
) None None O
s None None O
( None None O
-1 None None O
) None None O
and None None O
92 None None O
microM None None O
, None None O
6.85 None None O
s None None O
( None None O
-1 None None O
) None None O
, None None O
7.44 None None O
x None None O
10 None None O
( None None O
4 None None O
) None None O
M None None O
( None None O
-1 None None O
) None None O
s None None O
( None None O
-1 None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
Nobel None None O
Prize None None O
for None None O
Chemistry None None O
in None None O
2012 None None O
was None None O
awarded None None O
to None None O
Robert None None O
Lefkowitz None None O
and None None O
Bryan None None O
Kobilka None None O
`` None None O
for None None O
studies None None O
in None None O
G-protein-coupled None None I-PROTEIN
receptors None None I-PROTEIN
'' None None O
( None None O
GPCR None None O
) None None O
. None None O

In None None O
these None None O
studies None None O
, None None O
unique None None O
approaches None None O
for None None O
purification None None O
and None None O
crystallization None None O
of None None O
other None None O
receptors None None I-PROTEIN
were None None O
developed None None O
. None None O

There None None O
was None None O
studied None None O
action None None O
of None None O
aliphatic None None O
alcohols None None O
( None None O
ethanol None None O
, None None O
propanol None None O
, None None O
isopropanol None None O
, None None O
n-butanol None None O
, None None O
isobutanol None None O
, None None O
secbutanol None None O
, None None O
tretbetanol None None O
) None None O
and None None O
pH None None O
on None None O
various None None O
kinds None None O
of None None O
reactional None None O
capability None None O
the None None O
serum None None O
cholinesterase None None I-PROTEIN
. None None O

The None None O
fact None None O
that None None O
the None None O
presence None None O
of None None O
alcohols None None O
did None None O
not None None O
affect None None O
parameters None None O
of None None O
the None None O
reverse None None O
cholinesterase None None I-PROTEIN
inhibition None None O
with None None O
onium None None O
ions None None O
tetramethylammonium None None O
and None None O
choline None None O
allows None None O
suggesting None None O
the None None O
absence None None O
of None None O
effect None None O
solvents None None O
on None None O
specific None None O
acetylcholine None None I-TRANS
sorption None None O
in None None O
the None None O
enzyme None None O
active None None O
center None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
work None None O
was None None O
to None None O
examine None None O
the None None O
effect None None O
of None None O
diazoxide None None O
, None None O
an None None O
activator None None O
of None None O
mitochondrial None None O
ATP-dependent None None O
potassium None None I-PROTEIN
channels None None I-PROTEIN
, None None O
on None None O
mitochondrial None None O
physiology None None O
and None None O
cell None None O
survival None None O
in None None O
the None None O
presence None None O
of None None O
Cd2+ None None O
. None None O

The None None O
protective None None O
effect None None O
of None None O
diazoxide None None O
was None None O
completely None None O
suppressed None None O
by None None O
increasing None None O
duration None None O
of None None O
incubation None None O
of None None O
the None None O
cells None None O
with None None O
Cd2+ None None O
, None None O
and None None O
partially None None O
by None None O
addition None None O
to None None O
the None None O
assay None None O
medium None None O
of None None O
5-hydroxyde- None None O
canoic None None O
acid None None O
( None None O
100 None None O
or None None O
300 None None O
microM None None O
) None None O
, None None O
a None None O
blocker None None O
of None None O
mitochondrial None None O
ATP-dependent None None O
potassium None None I-PROTEIN
channels None None I-PROTEIN
. None None O

The None None O
aim None None O
this None None O
study None None O
was None None O
to None None O
develop None None O
a None None O
new None None O
model None None O
of None None O
schizophrenia None None I-DISEASE
by None None O
oral None None O
Levodopa None None O
+ None None O
Carbidopa None None O
( None None O
LC None None O
) None None O
administration None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
LC None None O
introduction None None O
to None None O
rats None None O
may None None O
be None None O
used None None O
as None None O
an None None O
alternative None None O
dopaminergic None None O
animal None None O
model None None O
of None None O
schizophrenia None None I-DISEASE
. None None O

By None None O
using None None O
methods None None O
of None None O
Real-Time None None O
PCR None None O
, None None O
immunocytochemistry None None O
, None None O
image None None O
analysis None None O
, None None O
and None None O
study None None O
of None None O
interatrial None None O
septum None None I-REGION
, None None O
we None None O
have None None O
established None None O
that None None O
a None None O
gradual None None O
increase None None O
of None None O
intensity None None O
of None None O
infestation None None O
with None None O
Cryptosporidium None None O
parvum None None O
oocytes None None O
causes None None O
sharp None None O
changes None None O
corresponding None None O
to None None O
the None None O
`` None None O
all None None O
or None None O
nothing None None O
'' None None O
response None None O
. None None O

At None None O
the None None O
intermediate None None O
and None None O
severe None None O
infestation None None O
, None None O
in None None O
the None None O
interatrial None None O
septum None None I-REGION
the None None O
foramen None None O
ovale None None O
was None None O
visualized None None O
and None None O
there None None O
were None None O
observed None None O
cardiac None None O
atrophy None None O
and None None O
a None None O
strong None None O
shift None None O
of None None O
ration None None O
of None None O
expression None None O
of None None O
myosin None None O
heavy None None O
chains None None O
toward None None O
the None None O
low-velocity None None O
beta None None O
chain None None O
. None None O

Our None None O
results None None O
can None None O
be None None O
interest None None O
to None None O
evolutionary None None O
biologists None None O
and None None O
physicians None None O
, None None O
as None None O
they None None O
show None None O
importance None None O
of None None O
knowledge None None O
of None None O
evolutionary-comparative None None O
investigations None None O
for None None O
the None None O
search None None O
for None None O
novel None None O
risk None None O
factors None None O
of None None O
heart None None O
diseases None None O
and None None O
demonstrate None None O
interconnection None None O
between None None O
gastroenteritis None None O
, None None O
pathology None None O
of None None O
interatrial None None O
septum None None I-REGION
, None None O
and None None O
a None None O
change None None O
of None None O
composition None None O
of None None O
the None None O
main None None O
contractile None None O
proteins None None O
in None None O
cardiomyocytes None None O
. None None O

Ras None None O
gene None None O
products None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
processes None None O
of None None O
cellular None None O
proliferation None None O
and None None O
differentiation None None O
and None None O
are None None O
controlled None None O
by None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinases None None I-PROTEIN
. None None O

In None None O
the None None O
latter None None O
, None None O
morphogenetic None None O
movements None None I-FUNC
manifested None None O
themselves None None O
as None None O
gastrulation None None O
, None None O
during None None O
which None None O
the None None O
germ None None O
layers None None O
and None None O
the None None O
digestive None None O
system None None O
formed None None O
. None None O

alpha-L-Rhamnosidase None None O
of None None O
E. None None O
erubescens None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
alpha-L-rhamnnosidase None None O
of None None O
C. None None O
albidus None None O
, None None O
contained None None O
higher None None O
levels None None O
of None None O
lysine None None I-TRANS
, None None O
arginine None None I-TRANS
, None None O
threonine None None I-TRANS
, None None O
alanine None None I-TRANS
, None None O
isoleucine None None I-TRANS
, None None O
leucine None None I-TRANS
, None None O
tyrosine None None I-TRANS
, None None O
phenylalanine None None I-TRANS
. None None O

A None None O
significant None None O
percentage None None O
of None None O
hydrophobic None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
which None None O
is None None O
31 None None O
and None None O
34 None None O
% None None O
of None None O
the None None O
total None None O
content None None O
, None None O
and None None O
the None None O
presence None None O
of None None O
the None None O
carbohydrate None None O
component None None O
are None None O
essential None None O
in None None O
stabilization None None O
of None None O
enzymes None None I-PROTEIN
molecule None None O
. None None O

The None None O
hippocampal None None O
slices None None O
( None None O
layer None None O
stratum None None I-REGION
pyramidale None None I-REGION
, None None O
CA1 None None I-REGION
, None None O
Nissl None None O
's None None O
stain None None O
) None None O
obtained None None O
from None None O
mice None None O
exhibiting None None O
seizures None None O
revealed None None O
a None None O
large None None O
number None None O
of None None O
modified None None O
cells None None O
( None None O
24.7 None None O
+/- None None O
2.1 None None O
% None None O
) None None O
. None None O

The None None O
data None None O
obtained None None O
indicate None None O
that None None O
modified None None O
neurons None None O
are None None O
the None None O
result None None O
of None None O
seizures None None O
suffered None None O
by None None O
the None None O
animals None None O
in None None O
the None None O
course None None O
of None None O
PTZ None None O
kindling None None O
, None None O
and None None O
that None None O
the None None O
blockade None None O
of None None O
NMDA None None O
glutamate None None I-TRANS
receptors None None I-PROTEIN
can None None O
suppress None None O
manifestations None None O
of None None O
seizures None None O
and None None O
the None None O
accompanying None None O
morphological None None O
changes None None O
of None None O
hippocampal None None O
neurons None None O
. None None O

The None None O
double None None O
immunofluorescence None None O
method None None O
shows None None O
the None None O
presence None None O
of None None O
AGRP-immunoreactive None None O
processes None None O
around None None O
the None None O
bodies None None O
of None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
. None None O

The None None O
data None None O
indicate None None O
possible None None O
direct None None O
inhibitory None None O
action None None O
of None None O
AGRP None None O
on None None O
tyrosine None None I-TRANS
hydroxylase None None O
level None None O
in None None O
dopaminergic None None O
brain None None O
neurons None None O
and None None O
its None None O
role None None O
as None None O
a None None O
modulator None None O
of None None O
the None None O
functional None None O
activity None None O
of None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
. None None O

Imipramine None None O
and None None O
fluoxetine None None O
effectively None None O
reduce None None O
the None None O
stated None None O
behavioral None None O
disorders None None O
, None None O
their None None O
effectiveness None None O
corresponds None None O
to None None O
the None None O
results None None O
of None None O
clinical None None O
studies None None O
and None None O
the None None O
data None None O
received None None O
from None None O
other None None O
models None None O
of None None O
depression None None I-DISEASE
. None None O

On None None O
the None None O
other None None O
-- None None O
are None None O
original None None O
, None None O
as None None O
they None None O
reflect None None O
the None None O
assimilation None None O
of None None O
child None None O
articulations None None O
implemented None None O
in None None O
the None None O
Russian None None O
language None None I-FUNC
. None None O

Catecholamines None None I-TRANS
and None None O
NO None None O
deficiency None None O
play None None O
a None None O
substantial None None O
role None None O
in None None O
the None None O
development None None O
of None None O
cold None None O
hypertension None None O
, None None O
but None None O
these None None O
are None None O
not None None O
involved None None O
in None None O
acclimatization None None O
cardiac None None O
hypertrophy None None O
. None None O

Catecholamines None None I-TRANS
, None None O
aldosterone None None O
and None None O
angiotensin None None O
II None None O
are None None O
not None None O
involved None None O
in None None O
cold None None O
hypertrophy None None O
of None None O
heart None None O
. None None O

Thyroid None None O
hormones None None I-PROTEIN
play None None O
substantial None None O
role None None O
in None None O
the None None O
development None None O
of None None O
cold None None O
hypertension None None O
and None None O
cardiac None None O
hypertrophy None None O
. None None O

The None None O
review None None O
provides None None O
evidence None None O
that None None O
: None None O
1 None None O
) None None O
genes None None O
encoding None None I-FUNC
key None None O
elements None None O
of None None O
the None None O
brain None None O
serotonergic None None O
system None None O
( None None O
tryptophan None None I-TRANS
hydroxylase-2 None None O
, None None O
5-HT1A None None O
and None None O
5-HT2A None None O
receptors None None I-PROTEIN
) None None O
are None None O
implicated None None O
in None None O
the None None O
effect None None O
ofBDNF None None O
; None None O
2 None None O
) None None O
acute None None O
central None None O
administration None None O
of None None O
BDNF None None O
produced None None O
long-term None None O
ameliorative None None O
effects None None O
on None None O
some None None O
animal None None O
models None None O
of None None O
genetically None None O
defined None None O
behavior None None O
disorders None None O
; None None O
3 None None O
) None None O
BDNF None None O
decreased None None O
behavioral None None O
disorders None None O
induced None None O
by None None O
prenatal None None O
stress None None O
and None None O
ethanol None None O
exposure None None O
and None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
treatment None None O
of None None O
epigenetically None None O
defined None None O
pathological None None O
behavior None None O
. None None O

Leptin None None O
is None None O
the None None O
best None None O
characterized None None O
adipokine None None O
involved None None O
in None None O
energy None None O
metabolism None None O
and None None O
inflammatory None None O
status None None O
, None None O
being None None O
associated None None O
with None None O
the None None O
development None None O
of None None O
a None None O
number None None O
of None None O
diseases None None O
, None None O
including None None O
atherosclerosis None None I-DISEASE
, None None O
diabetes None None O
, None None O
certain None None O
cancers None None O
and None None O
immune-mediated None None O
processes None None O
. None None O

Moreover None None O
there None None O
are None None O
the None None O
evidences None None O
that None None O
leptin None None O
influences None None O
receptor None None I-PROTEIN
signalling None None O
as None None O
well None None O
as None None O
the None None O
synthesis None None O
and None None O
releasing None None O
of None None O
several None None O
neurotransmitters None None I-TRANS
. None None O

In None None O
the None None O
present None None O
work None None O
we None None O
have None None O
studied None None O
the None None O
effects None None O
of None None O
p53 None None I-PROTEIN
on None None O
the None None O
proliferation None None O
and None None O
differentiation None None O
of None None O
neural None None O
progenitor None None O
cells None None O
( None None O
NPC None None O
) None None O
in None None O
mouse None None O
hippocampal None None O
organotypic None None O
culture None None O
. None None O

Obtained None None O
data None None O
demonstrated None None O
that None None O
the None None O
injections None None O
of None None O
PFT None None O
did None None O
not None None O
affect None None O
on None None O
the None None O
amount None None O
of None None O
phospho-H3 None None O
positive None None O
cells None None O
in None None O
the None None O
subgranular None None O
zone None None O
of None None O
hippocampus None None I-REGION
. None None O

Thus None None O
, None None O
obtained None None O
data None None O
revealed None None O
that None None O
p53 None None I-PROTEIN
is None None O
an None None O
important None None O
factor None None O
of None None O
neuronal None None O
differentiation None None O
and None None O
, None None O
probably None None O
, None None O
p53 None None I-PROTEIN
action None None O
is None None O
mediated None None O
by None None O
cell None None O
cycle None None O
regulator None None O
protein None None O
such None None O
as None None O
Pim-1 None None O
and None None O
Phbl None None O
. None None O

The None None O
effect None None O
of None None O
insulin None None I-PROTEIN
on None None O
contractility None None O
of None None O
directly None None O
stimulated None None O
skeletal None None O
muscles None None O
was None None O
studied None None O
in None None O
experiments None None O
in None None O
isolated None None O
preparations None None O
of None None O
rat None None O
fast None None O
, None None O
extensor None None O
digitorum None None O
longus None None O
( None None O
m. None None O
EDL None None O
) None None O
, None None O
slow None None O
, None None O
soleus None None O
( None None O
m. None None O
SOL None None O
) None None O
and None None O
mixed None None O
, None None O
diaphragm None None I-REGION
muscles None None O
. None None O

Insulin None None I-PROTEIN
( None None O
0.5-10 None None O
nM None None O
) None None O
decreased None None O
muscle None None O
twitch None None O
force None None O
. None None O

Insulin None None I-PROTEIN
did None None O
not None None O
affect None None O
strength None None O
of None None O
isotonic None None O
KCL- None None O
or None None O
caffeine-induced None None O
muscle None None O
contractures None None O
, None None O
but None None O
decreased None None O
second None None O
and None None O
increased None None O
first None None O
and None None O
third None None O
phases None None O
of None None O
extracellularly None None O
recorded None None O
muscle None None O
fiber None None O
APs None None O
. None None O

Apparently None None O
, None None O
the None None O
process None None O
of None None O
accumulation None None O
of None None O
Ca2+ None None O
in None None O
the None None O
cytoplasm None None O
of None None O
the None None O
respiratory None None O
center None None O
's None None O
cells None None I-NEURON
was None None O
slowed None None O
after None None O
the None None O
Na2EDTA None None O
injection None None O
to None None O
hypothermal None None O
rats None None O
in None None O
the None None O
bloodstream None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
aerobic None None O
exercise None None O
ameliorates None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
inflammation None None O
and None None O
mitochondrial None None O
dysfunction None None O
which None None O
play None None O
important None None O
roles None None O
in None None O
the None None O
development None None O
of None None O
cardiovascular None None O
disease None None O
. None None O

This None None O
study None None O
aims None None O
to None None O
understand None None O
the None None O
roles None None O
of None None O
hydrogen None None O
and None None O
carbon None None I-TRANS
monoxide None None I-TRANS
during None None O
the None None O
desulfurization None None O
process None None O
in None None O
a None None O
coal None None O
gasification None None O
system None None O
that None None O
H2S None None I-TRANS
of None None O
the None None O
syngas None None O
was None None O
removed None None O
by None None O
Fe2O3/SiO2 None None O
sorbents None None O
. None None O

The None None O
formation None None O
of None None O
COS None None O
occurs None None O
when None None O
the None None O
feeding None None O
gas None None O
is None None O
blended None None O
with None None O
CO None None O
and None None O
H2S None None I-TRANS
, None None O
or None None O
CO2 None None O
and None None O
H2S None None I-TRANS
. None None O

Our None None O
chemical None None O
characterization None None O
of None None O
a None None O
commercial None None O
sample None None O
of None None O
NAs None None I-TRANS
showed None None O
it None None O
to None None O
contain None None O
in None None O
order None None O
of None None O
abundance None None O
, None None O
1-ring None None O
& None None O
gt None None O
; None None O
2-ring None None O
& None None O
gt None None O
; None None O
acyclic None None O
& None None O
gt None None O
; None None O
3-ring None None O
acids None None O
( None None O
∼84 None None O
% None None O
) None None O
. None None O

The None None O
current None None O
study None None O
demonstrates None None O
that None None O
splenectomy None None O
prior None None O
to None None O
experimental None None O
stroke None None I-DISEASE
eliminates None None O
sex None None O
differences None None O
in None None O
infarct None None O
volume None None O
and None None O
activated None None O
brain None None O
monocytes/microglia None None O
. None None O

This None None O
study None None O
provides None None O
new None None O
information None None O
about None None O
the None None O
sex None None O
specific None None O
mechanisms None None O
of None None O
the None None O
peripheral None None O
immune None None O
response None None O
in None None O
neurodegeneration None None O
after None None O
stroke None None I-DISEASE
and None None O
demonstrates None None O
the None None O
need None None O
for None None O
representation None None O
of None None O
both None None O
sexes None None O
in None None O
basic None None O
and None None O
clinical None None O
stroke None None I-DISEASE
research None None O
. None None O

The None None O
formation None None O
of None None O
active None None O
GCs None None O
from None None O
the None None O
`` None None O
adrenal None None I-TRANS
'' None None O
-like None None O
pathway None None O
was None None O
observed None None O
with None None O
some None None O
lung None None O
explants None None O
and None None O
primary None None O
epithelial None None O
cell None None O
cultures None None O
. None None O

Our None None O
results None None O
demonstrated None None O
that None None O
the None None O
orexinergic None None O
neurons None None O
of None None O
R. None None O
schneideri None None O
are None None O
located None None O
in None None O
the None None O
suprachiasmatic None None I-REGION
nucleus None None I-REGION
of None None O
the None None O
diencephalon None None I-REGION
. None None O

We None None O
conclude None None O
that None None O
in None None O
the None None O
toad None None O
R. None None O
schneideri None None O
, None None O
orexinergic None None O
neurons None None O
are None None O
located None None O
in None None O
the None None O
suprachiasmatic None None I-REGION
nucleus None None I-REGION
and None None O
that None None O
OX1R None None O
contributes None None O
to None None O
hypercarbic None None O
and None None O
hypoxic None None O
chemoreflexes None None O
. None None O

Study None None O
3 None None O
replicated None None O
the None None O
positive None None O
effect None None O
of None None O
state None None O
orientation None None O
on None None O
positive None None O
emotions None None I-FUNC
with None None O
an None None O
experimental None None O
induction None None O
of None None O
action None None O
vs. None None O
state None None O
orientation None None O
. None None O

The None None O
bladders None None O
were None None O
dissected None None O
and None None O
embedded None None O
in None None O
paraffin None None O
, None None O
from None None O
which None None O
5-μm None None O
thick None None O
sections None None O
were None None O
obtained None None O
and None None O
stained None None O
with None None O
: None None O
Masson None None O
's None None O
trichrome None None O
, None None O
to None None O
quantify None None O
connective None None O
and None None O
smooth None None O
muscle None None O
tissue None None O
; None None O
Weigert None None O
's None None O
resorcin None None O
fuchsin None None O
, None None O
to None None O
observe None None O
elastic None None O
fibers None None O
; None None O
picrosirius None None O
red None None O
with None None O
polarization None None O
, None None O
to None None O
observe None None O
collagen None None I-PROTEIN
; None None O
and None None O
anti-beta None None O
III None None O
tubulin None None O
antibody None None O
, None None O
to None None O
observe None None O
the None None O
bladder None None O
nerves None None O
. None None O

The None None O
histological None None O
analysis None None O
of None None O
the None None O
smooth None None O
muscle None None O
, None None O
collagen None None I-PROTEIN
, None None O
nerves None None O
and None None O
connective None None O
tissue None None O
of None None O
the None None O
developing None None O
bladders None None O
revealed None None O
that None None O
there None None O
are None None O
no None None O
gender None None O
differences None None O
during None None O
weeks None None O
13-23 None None O
of None None O
gestation None None O
. None None O

A None None O
total None None O
of None None O
51 None None O
patients None None O
with None None O
narcolepsy None None I-DISEASE
and None None O
35 None None O
healthy None None O
controls None None O
responded None None O
to None None O
questionnaires None None O
regarding None None O
subjectively None None O
perceived None None O
attention None None I-FUNC
deficits None None O
, None None O
sleepiness None None O
, None None O
anxiety None None O
and None None O
depression None None I-DISEASE
. None None O

Patients None None O
rated None None O
their None None O
level None None O
of None None O
attention None None I-FUNC
in None None O
everyday None None O
situations None None O
to None None O
be None None O
relatively None None O
poor None None O
. None None O

The None None O
subjective None None O
ratings None None O
of None None O
attention None None I-FUNC
deficits None None O
significantly None None O
correlated None None O
with None None O
ratings None None O
of None None O
momentary None None O
sleepiness None None O
, None None O
anxiety None None O
, None None O
and None None O
depression None None I-DISEASE
, None None O
but None None O
not None None O
with None None O
objectively None None O
measured None None O
cognitive None None O
performance None None O
. None None O

The None None O
present None None O
study None None O
showed None None O
that None None O
sleepiness None None O
and None None O
depression None None I-DISEASE
, None None O
more None None O
than None None O
objective None None O
cognitive None None O
deficits None None O
, None None O
might None None O
play None None O
a None None O
role None None O
in None None O
the None None O
subjectively None None O
perceived None None O
attention None None I-FUNC
deficits None None O
of None None O
patients None None O
with None None O
narcolepsy None None I-DISEASE
. None None O

In None None O
the None None O
experimental None None O
arm None None O
, None None O
matched None None O
unrelated None None O
HCT None None O
in None None O
first None None O
remission None None O
was None None O
offered None None O
also None None O
to None None O
patients None None O
with None None O
an None None O
FLT3-ITD None None O
( None None O
FMS-like None None O
tyrosine None None I-TRANS
kinase None None O
3-internal None None O
tandem None None O
duplication None None O
) None None O
allelic None None O
ratio None None O
& None None O
gt None None O
; None None O
0.8 None None O
, None None O
poor None None O
day None None O
+15 None None O
marrow None None O
blast None None O
clearance None None O
and None None O
adverse None None O
karyotypes None None O
. None None O

The None None O
increase None None O
in None None O
acetylcholine None None I-TRANS
yielded None None O
by None None O
pyridostigmine None None O
( None None O
PYR None None O
) None None O
, None None O
an None None O
acetylcholinesterase None None I-PROTEIN
inhibitor None None O
, None None O
was None None O
evaluated None None O
for None None O
its None None O
effect None None O
on None None O
the None None O
haemodynamic None None O
responses-mean None None O
arterial None None O
pressure None None O
( None None O
MAP None None O
) None None O
and None None O
heart None None O
rate None None O
( None None O
HR None None O
) None None O
-and None None O
their None None O
nycthemeral None None O
oscillation None None O
in None None O
mice None None O
before None None O
and None None O
one None None O
week None None O
after None None O
myocardial None None O
infarction None None O
( None None O
MI None None O
) None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
PI3K/Akt None None O
activator None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor-1 None None O
( None None O
IGF-1 None None O
) None None O
attenuated None None O
lethality None None O
of None None O
FZD None None O
in None None O
HepG2 None None O
cells None None O
. None None O

Also None None O
, None None O
it None None O
is None None O
unknown None None O
whether None None O
retention None None I-FUNC
rate None None O
differs None None O
when None None O
clips None None O
are None None O
applied None None O
to None None O
ulcerated None None O
rather None None O
than None None O
normal None None O
mucosa None None O
. None None O

QuickClip2Long None None O
had None None O
the None None O
lowest None None O
retention None None I-FUNC
rate None None O
on None None O
normal None None O
mucosa None None O
. None None O

The None None O
Resolution None None O
and None None O
Instinct None None O
clips None None O
have None None O
comparable None None O
retention None None I-FUNC
rates None None O
and None None O
both None None O
appeared None None O
to None None O
be None None O
better None None O
than None None O
the None None O
QuickClip2Long None None O
on None None O
normal None None O
mucosa-simulated None None O
ulcers None None O
; None None O
however None None O
this None None O
did None None O
not None None O
reach None None O
statistical None None O
significance None None O
. None None O

Phospholipase None None I-PROTEIN
C None None I-PROTEIN
epsilon None None O
1 None None O
( None None O
PLCE1 None None O
) None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
carcinogenesis None None O
and None None O
progression None None O
of None None O
several None None O
types None None O
of None None O
cancers None None O
. None None O

Nursing None None O
student None None O
persistence None None O
, None None O
retention None None I-FUNC
, None None O
and None None O
success None None O
are None None O
universally None None O
desired None None O
outcomes None None O
yet None None O
remain None None O
elusive None None O
and None None O
challenging None None O
worldwide None None O
. None None O

Jeffreys None None O
's None None O
Nursing None None O
Universal None None O
Retention None None I-FUNC
and None None O
Success None None O
( None None O
NURS None None O
) None None O
model None None O
presents None None O
a None None O
globally-applicable None None O
framework None None O
for None None O
examining None None O
the None None O
multidimensional None None O
factors None None O
that None None O
affect None None O
undergraduate None None O
and None None O
graduate None None O
nursing None None O
student None None O
retention None None I-FUNC
and None None O
success None None O
in None None O
order None None O
to None None O
make None None O
a None None O
positive None None O
difference None None O
. None None O

We None None O
enrolled None None O
21 None None O
patients None None O
with None None O
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
( None None O
TLE None None O
) None None O
, None None O
with None None O
and None None O
without None None O
hippocampal None None O
lesions None None O
( None None O
TLE None None O
( None None O
+ None None O
) None None O
=12 None None O
; None None O
TLE None None O
( None None O
- None None O
) None None O
=9 None None O
, None None O
respectively None None O
) None None O
, None None O
11 None None O
patients None None O
with None None O
extratemporal None None I-DISEASE
epilepsy None None I-DISEASE
( None None O
ETE None None O
) None None O
and None None O
29 None None O
controls None None O
( None None O
NC None None O
) None None O
. None None O

Regression None None O
analyses None None O
confirmed None None O
that None None O
a None None O
hippocampal None None O
lesion None None O
was None None O
particularly None None O
disruptive None None O
to None None O
consolidation None None O
over None None O
the None None O
first None None O
24h None None O
, None None O
and None None O
that None None O
seizures None None O
were None None O
associated None None O
with None None O
memory None None I-FUNC
decline None None O
over None None O
longer None None O
delays None None O
. None None O

In None None O
this None None O
regard None None O
, None None O
we None None O
also None None O
present None None O
an None None O
overview None None O
of None None O
the None None O
existing None None O
and None None O
more None None O
relevant None None O
molecules None None O
, None None O
with None None O
a None None O
special None None O
attention None None I-FUNC
to None None O
the None None O
historical None None O
development None None O
of None None O
their None None O
pharmacological None None O
properties None None O
and None None O
structures None None O
, None None O
as None None O
well None None O
as None None O
a None None O
brief None None O
summary None None O
of None None O
clinical None None O
trials None None O
involving None None O
PARP None None O
inhibitors None None O
. None None O

Some None None O
of None None O
these None None O
compounds None None O
like None None O
those None None O
targeted None None O
to None None O
entry None None O
and None None O
mitotic None None O
kinases None None I-PROTEIN
, None None O
mitotic None None O
kinesins/motor None None O
proteins None None O
, None None O
and None None O
multiprotein None None O
complexes None None O
have None None O
been None None O
evaluated None None O
in None None O
vitro None None O
and None None O
in None None O
animal None None O
models None None O
, None None O
and None None O
some None None O
of None None O
them None None O
have None None O
reached None None O
clinical None None O
trials None None O
. None None O

Observational None None O
study None None O
included None None O
consecutive None None O
patients None None O
with None None O
ischemic None None O
stroke None None I-DISEASE
younger None None O
than None None O
55 None None O
years None None O
( None None O
2007-2012 None None O
) None None O
. None None O

Stroke None None I-DISEASE
severity None None O
was None None O
measured None None O
by None None O
the None None O
National None None O
Institutes None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
( None None O
NIHSS None None O
) None None O
, None None O
and None None O
the None None O
three-month None None O
stroke None None I-DISEASE
outcome None None O
by None None O
the None None O
modified None None O
Rankin None None O
Scale None None O
( None None O
mRS None None O
) None None O
. None None O

Overall None None O
255 None None O
stroke None None I-DISEASE
patients None None O
were None None O
included None None O
, None None O
22 None None O
( None None O
8.6 None None O
% None None O
) None None O
with None None O
APS None None O
. None None O

In None None O
summary None None O
, None None O
the None None O
present None None O
study None None O
demonstrated None None O
that None None O
isoquercitrin None None O
inhibits None None O
human None None O
pancreatic None None O
cancer None None O
progression None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
and None None O
that None None O
its None None O
molecular None None O
mechanism None None O
may None None O
be None None O
closely None None O
related None None O
to None None O
opioid None None O
receptors None None I-PROTEIN
and None None O
to None None O
the None None O
activation None None O
of None None O
the None None O
mitogen-activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
signalling None None O
pathway None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
cyclic None None O
Arginine‑Glycine‑Aspartic None None O
acid‑D‑Tyrosine‑Lysine None None O
[ None None O
c None None O
( None None O
RGDyK None None O
) None None O
] None None O
, None None O
that None None O
has None None O
a None None O
high None None O
binding None None O
affinity None None O
to None None O
integrin None None I-PROTEIN
αvβ3 None None O
receptors None None I-PROTEIN
, None None O
that None None O
are None None O
overexpressed None None O
in None None O
glioblastoma None None O
cancers None None O
, None None O
was None None O
employed None None O
as None None O
a None None O
novel None None O
approach None None O
to None None O
target None None O
cancer None None O
by None None O
delivering None None O
therapeutic None None O
molecules None None O
intracellularly None None O
. None None O

The None None O
specific None None O
binding None None O
affinity None None O
of None None O
the None None O
Arginine‑Glycine‑Aspartic None None O
acid None None I-TRANS
( None None O
RGD None None O
) None None O
micelles None None O
, None None O
to None None O
the None None O
integrin None None I-PROTEIN
receptor None None I-PROTEIN
, None None O
enhanced None None O
the None None O
intracellular None None O
accumulation None None O
of None None O
DTX None None O
, None None O
and None None O
markedly None None O
increased None None O
its None None O
cytotoxic None None O
efficacy None None O
. None None O

However None None O
, None None O
most None None O
current None None O
studies None None O
on None None O
the None None O
theoretic None None O
and None None O
numerical None None O
models None None O
of None None O
wind-blown None None O
sand None None O
movement None None I-FUNC
only None None O
consider None None O
ideal None None O
conditions None None O
such None None O
as None None O
steady None None O
wind None None O
velocity None None O
, None None O
flat None None O
sand None None O
surface None None O
, None None O
etc None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
propose None None O
a None None O
numerical None None O
model None None O
for None None O
the None None O
coupling None None O
effect None None O
between None None O
wind None None O
flow None None O
and None None O
saltating None None O
sand None None O
particles None None O
to None None O
simulate None None O
wind-blown None None O
sand None None O
movement None None I-FUNC
over None None O
the None None O
slope None None O
surface None None O
and None None O
use None None O
the None None O
SIMPLE None None O
algorithm None None O
to None None O
calculate None None O
wind None None O
flow None None O
and None None O
simulate None None O
sands None None O
transport None None O
by None None O
tracking None None O
sand None None O
particle None None O
trajectories None None O
. None None O

There None None O
are None None O
several None None O
risk None None O
factors None None O
or None None O
determinants None None O
of None None O
stroke None None I-DISEASE
and None None O
other None None O
cardiovascular None None O
diseases None None O
that None None O
are None None O
modifiable None None O
and None None O
have None None O
been None None O
shown None None O
to None None O
reduce None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
in None None O
at-risk None None O
persons None None O
. None None O

Further None None O
, None None O
this None None O
paper None None O
will None None O
examine None None O
the None None O
relationship None None O
of None None O
WT1 None None O
with None None O
CD97 None None O
, None None O
a None None O
gene None None O
that None None O
codes None None O
for None None O
an None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
family None None O
member None None O
, None None O
an None None O
adhesion None None O
G-protein-coupled None None I-PROTEIN
receptor None None I-PROTEIN
, None None O
thought None None O
to None None O
promote None None O
tumor None None O
invasiveness None None O
and None None O
migration None None O
. None None O

Particular None None O
attention None None I-FUNC
has None None O
been None None O
dedicated None None O
in None None O
the None None O
last None None O
years None None O
to None None O
the None None O
end None None O
of None None O
life None None O
( None None O
EOL None None O
) None None O
period None None O
in None None O
cancer None None O
patients None None O
for None None O
both None None O
ethical None None O
and None None O
socioeconomic None None O
issues None None O
. None None O

The None None O
peptides None None I-TRANS
increased None None O
in None None O
both None None O
serum None None O
and None None O
cardiac None None O
tissue None None O
homogenates None None O
in None None O
animals None None O
treated None None O
with None None O
DOX None None O
compared None None O
to None None O
the None None O
other None None O
groups None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
DCA None None O
induces None None O
apoptosis None None O
in None None O
gastric None None O
carcinoma None None O
cells None None O
through None None O
activation None None O
of None None O
an None None O
intrinsic None None O
mitochondrial‑dependent None None O
pathway None None O
, None None O
in None None O
which None None O
p53 None None I-PROTEIN
is None None O
involved None None O
. None None O

The None None O
present None None O
study None None O
suggests None None O
and None None O
describes None None O
the None None O
application None None O
of None None O
a None None O
delivery None None O
system None None O
for None None O
antisense None None O
oligonucleotides None None O
against None None O
mRNA None None O
encoding None None I-FUNC
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
proteins None None O
α None None O
and None None O
β None None O
. None None O

Therefore None None O
, None None O
it None None O
was None None O
concluded None None O
that None None O
PEPO None None O
successfully None None O
alleviated None None O
hepatic None None O
fibrosis None None O
induced None None O
by None None O
CCl4 None None O
and None None O
reversed None None O
the None None O
effects None None O
of None None O
hepatotoxicity None None O
by None None O
regulating None None O
the None None O
serum None None O
levels None None O
of None None O
enzymes None None I-PROTEIN
and None None O
decreasing None None O
the None None O
expression None None O
levels None None O
of None None O
CTGF None None O
, None None O
TGF‑β1 None None O
and None None O
NF‑κB None None O
in None None O
liver None None O
tissues None None O
. None None O

Pathological None None O
examination None None O
of None None O
resected None None O
surgical None None O
specimens None None O
from None None O
RRSO None None O
revealed None None O
that None None O
some None None O
serous None None O
ovarian None None O
carcinomas None None O
originated None None O
from None None O
fimbriae None None O
of None None O
the None None O
uterine None None O
tube None None O
, None None O
showing None None O
focal None None O
p53 None None I-PROTEIN
overexpression None None O
( None None O
p53 None None I-PROTEIN
signature None None O
) None None O
in None None O
the None None O
tubal None None O
epithelium None None O
. None None O

Because None None O
this None None O
technique None None O
does None None O
not None None O
require None None O
the None None O
urologist None None O
to None None O
overcome None None O
a None None O
steep None None O
and None None O
long None None O
learning None None I-FUNC
curve None None O
, None None O
a None None O
dramatic None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
RARP None None O
surgeries None None O
was None None O
observed None None O
in None None O
recent None None O
years None None O
and None None O
RARP None None O
has None None O
rapidly None None O
gained None None O
acceptance None None O
in None None O
the None None O
Japanese None None O
urological None None O
community None None O
after None None O
its None None O
introduction None None O
in None None O
Japan None None O
in None None O
2006 None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
present None None O
the None None O
current None None O
state None None O
of None None O
RARP None None O
and None None O
a None None O
critical None None O
evaluation None None O
of None None O
the None None O
learning None None I-FUNC
curves None None O
associated None None O
with None None O
performing None None O
RARP None None O
as None None O
well None None O
as None None O
published None None O
oncological None None O
, None None O
continence None None O
, None None O
and None None O
potency None None O
outcomes None None O
. None None O

The None None O
biggest None None O
advantage None None O
of None None O
robotic None None O
surgery None None O
is None None O
the None None O
remarkably None None O
free None None O
movement None None I-FUNC
of None None O
joint-equipped None None O
robotic None None O
forceps None None O
under None None O
3-dimensional None None O
high None None O
vision None None I-FUNC
. None None O

However None None O
, None None O
pregabalin None None O
, None None O
duloxetine None None O
, None None O
and None None O
oxycodone None None O
should None None O
be None None O
administered None None O
with None None O
specific None None O
attention None None I-FUNC
on None None O
the None None O
potential None None O
side None None O
effects None None O
. None None O

However None None O
, None None O
attention None None I-FUNC
has None None O
to None None O
paid None None O
to None None O
the None None O
onset None None O
of None None O
hypocalcemia None None O
when None None O
determining None None O
the None None O
optimal None None O
dosage None None O
, None None O
especially None None O
since None None O
data None None O
and None None O
methods None None O
on None None O
its None None O
prevention None None O
are None None O
limited None None O
. None None O

Data None None O
from None None O
patients None None O
with None None O
eating None None I-DISEASE
disorders None None I-DISEASE
( None None O
n None None O
= None None O
292 None None O
) None None O
, None None O
psychiatric None None O
outpatients None None O
( None None O
n None None O
= None None O
140 None None O
) None None O
and None None O
normal None None O
controls None None O
( None None O
n None None O
= None None O
648 None None O
) None None O
, None None O
all None None O
females None None O
, None None O
were None None O
used None None O
to None None O
study None None O
the None None O
internal None None O
consistency None None O
, None None O
the None None O
discriminative None None O
ability None None O
, None None O
and None None O
the None None O
sensitivity None None O
and None None O
specificity None None O
of None None O
the None None O
inventory None None O
using None None O
preliminary None None O
cut-offs None None O
for None None O
each None None O
subscale None None O
and None None O
diagnosis None None O
separately None None O
. None None O

Anorexia None None I-DISEASE
nervosa None None I-DISEASE
was None None O
significantly None None O
discriminated None None O
from None None O
bulimia None None I-DISEASE
nervosa None None I-DISEASE
and None None O
eating None None I-DISEASE
disorder None None I-DISEASE
not None None O
otherwise None None O
specified None None O
on None None O
the None None O
Eating None None I-DISEASE
Disorder None None I-DISEASE
Risk None None O
Scales None None O
. None None O

Drive None None O
for None None O
Thinness None None O
is None None O
the None None O
second None None O
best None None O
predictor None None O
for None None O
an None None O
eating None None I-DISEASE
disorder None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
research None None O
the None None O
relationship None None O
between None None O
childhood None None O
trauma None None O
, None None O
self-esteem None None O
, None None O
and None None O
levels None None O
of None None O
depression None None I-DISEASE
and None None O
anxiety None None O
in None None O
substance-dependent None None O
( None None O
SD None None O
) None None O
people None None O
. None None O

All None None O
other None None O
data None None O
was None None O
collected None None O
using None None O
a None None O
semi-structured None None O
socio-demographic None None O
questionnaire None None O
, None None O
the None None O
Childhood None None O
Trauma None None O
Questionnaire None None O
( None None O
CTQ None None O
) None None O
, None None O
the None None O
Rosenberg None None O
Self None None O
Esteem None None O
Scale None None O
( None None O
RSES None None O
) None None O
, None None O
the None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
( None None O
BDI None None O
) None None O
and None None O
the None None O
Beck None None O
Anxiety None None O
Inventory None None O
( None None O
BAI None None O
) None None O
. None None O

This None None O
study None None O
showed None None O
high None None O
levels None None O
of None None O
childhood None None O
traumatic None None O
experiences None None O
for None None O
SD None None O
people None None O
and None None O
indicates None None O
that None None O
there None None O
may None None O
be None None O
a None None O
relationship None None O
between None None O
these None None O
experiences None None O
and None None O
their None None O
levels None None O
of None None O
self-esteem None None O
, None None O
depression None None I-DISEASE
and None None O
anxiety None None O
. None None O

For None None O
the None None O
first None None O
time None None O
PAH None None O
mass None None O
deposited None None O
in None None O
the None None O
bay None None O
sediments None None O
has None None O
been None None O
estimated None None O
and None None O
shall None None O
serve None None O
as None None O
base None None O
for None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
source None None O
abatement None None O
. None None O

Azelnidipine None None O
is None None O
a None None O
unique None None O
dihydropyridine None None O
calcium None None O
channel None None O
blocker None None O
with None None O
selectivity None None O
for None None O
L-type None None O
calcium None None I-PROTEIN
channels None None I-PROTEIN
that None None O
has None None O
been None None O
launched None None O
for None None O
the None None O
treatment None None O
of None None O
hypertension None None O
. None None O

High None None O
blood None None O
pressure None None O
is None None O
associated None None O
with None None O
many None None O
metabolic None None O
disorders None None O
, None None O
including None None O
glucose None None O
intolerance None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Recent None None O
studies None None O
have None None O
demonstrated None None O
that None None O
azelnidipine None None O
could None None O
improve None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
glucose None None O
tolerance None None O
by None None O
potentially None None O
inhibiting None None O
sympathetic None None O
nerve None None O
activity None None O
. None None O

If None None O
metastasectomy None None O
or None None O
tyrosine None None I-TRANS
kinase None None O
inhibitors None None O
( None None O
TKIs None None O
) None None O
fail None None O
, None None O
interventional None None O
ablation None None O
techniques None None O
are None None O
considered None None O
. None None O

However None None O
, None None O
this None None O
mechanism None None O
is None None O
abolished None None O
during None None O
non-rapid None None O
eye None None O
movement None None I-FUNC
( None None O
NREM None None O
) None None O
sleep None None O
. None None O

PW None None O
and None None O
adult None None O
animals None None O
were None None O
fear None None O
conditioned None None O
and None None O
exposed None None O
to None None O
the None None O
elevated None None O
platform None None O
stress None None O
paradigm None None O
, None None O
and None None O
extinction None None O
and None None O
long-term None None I-FUNC
potentiation None None I-FUNC
were None None O
examined None None O
. None None O

We None None O
show None None O
that None None O
exposure None None O
to None None O
stress None None O
is None None O
associated None None O
with None None O
reduction None None O
of None None O
fear None None O
and None None O
enhanced None None O
induction None None O
of None None O
long-term None None I-FUNC
potentiation None None I-FUNC
( None None O
LTP None None O
) None None O
in None None O
PW None None O
pups None None O
, None None O
in None None O
contrast None None O
to None None O
its None None O
effects None None O
in None None O
adult None None O
animals None None O
. None None O

Diosgenin None None O
inhibited None None O
Akt None None O
phosphorylation None None O
and None None O
upregulated None None O
p21 None None O
and None None O
p27 None None O
expression None None O
, None None O
but None None O
did None None O
not None None O
alter None None O
the None None O
expression None None O
of None None O
p53 None None I-PROTEIN
, None None O
suggesting None None O
diosgenin-induced None None O
upregulation None None O
of None None O
p21 None None O
and None None O
p57 None None O
is None None O
p53-independent None None O
in None None O
HCC None None O
cells None None O
. None None O

LY379268 None None O
protected None None O
Sternberger None None O
monoclonal None None O
incorporated None None O
antibody-32 None None O
( None None O
SMI-32 None None O
) None None O
( None None O
+ None None O
) None None O
motor None None I-NEURON
neurons None None I-NEURON
against None None O
excitotoxic None None O
death None None O
in None None O
mixed None None O
cultures None None O
of None None O
spinal None None O
cord None None O
cells None None O
, None None O
and None None O
its None None O
action None None O
was None None O
abrogated None None O
by None None O
anti-GDNF None None O
antibodies None None O
. None None O

At None None O
day None None O
40 None None O
of None None O
treatment None None O
, None None O
LY379268 None None O
enhanced None None O
spinal None None O
cord None None O
levels None None O
of None None O
GDNF None None O
and None None O
GLT-1 None None O
, None None O
and None None O
rescued None None O
spinal None None O
cord None None O
motor None None I-NEURON
neurons None None I-NEURON
, None None O
as None None O
assessed None None O
by None None O
stereologic None None O
counting None None O
of None None O
SMI-32 None None O
( None None O
+ None None O
) None None O
cells None None O
. None None O

Amyloid-β None None O
( None None O
Aβ None None O
) None None O
deposition None None O
and None None O
tau-dependent None None O
pathology None None O
are None None O
key None None O
features None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

PITL None None O
is None None O
based None None O
on None None O
the None None O
site-selective None None O
N-terminus None None O
dimethylation None None O
labeling None None O
of None None O
peptide None None O
α-N-termini None None O
and None None O
the None None O
free None None O
ε-amino None None O
group None None O
of None None O
lysines None None I-TRANS
, None None O
resulting None None O
in None None O
the None None O
partially None None O
isobaric None None O
labeling None None O
of None None O
peptides None None I-TRANS
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
measured None None O
barriers None None O
, None None O
caregiver None None O
adherence None None O
to None None O
PRN None None O
analgesic None None O
regimens None None O
, None None O
and None None O
patient None None O
health None None O
outcomes None None O
( None None O
pain None None O
, None None O
depression None None I-DISEASE
, None None O
quality None None O
of None None O
life None None O
[ None None O
QoL None None O
] None None O
) None None O
. None None O

Laboratory None None O
chemistries None None O
( None None O
intact None None O
parathyroid None None O
hormone None None O
, None None O
Na None None I-TRANS
, None None O
K None None O
, None None O
Ca None None O
, None None O
P None None O
, None None O
arterial None None O
blood None None O
gas None None O
) None None O
were None None O
obtained None None O
before None None O
surgery None None O
and None None O
at None None O
2 None None O
time None None O
points None None O
during None None O
surgery None None O
. None None O

Angioedema None None O
has None None O
been None None O
reported None None O
to None None O
occur None None O
after None None O
administering None None O
intravenous None None O
recombinant None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
with None None O
an None None O
incidence None None O
of None None O
1.3 None None O
% None None O
-5.1 None None O
% None None O
in None None O
patients None None O
with None None O
acute None None O
stroke None None I-DISEASE
. None None O

Hematoxylin None None O
and None None O
eosin None None O
staining None None O
was None None O
performed None None O
on None None O
the None None O
hepatic None None O
tissues None None O
of None None O
the None None O
rats None None O
to None None O
observe None None O
the None None O
fibrosis None None O
or None None O
cirrhosis None None O
, None None O
and None None O
western None None O
blot None None O
analysis None None O
was None None O
employed None None O
to None None O
detect None None O
α‑smooth None None O
muscle None None O
actin None None I-PROTEIN
and None None O
desmin None None O
protein None None O
expression None None O
. None None O

Remarkably None None O
, None None O
there None None O
is None None O
less None None O
information None None O
available None None O
on None None O
the None None O
topic None None O
of None None O
the None None O
effect None None O
of None None O
ECT None None O
on None None O
the None None O
patient None None O
's None None O
perception None None I-FUNC
of None None O
their None None O
sleep None None O
. None None O

Recent None None O
studies None None O
have None None O
demonstrated None None O
that None None O
baicalin None None O
treatment None None O
increases None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
( None None O
ALP None None O
) None None O
and None None O
osteoprotegerin None None O
secretion None None O
by None None O
osteoblasts None None O
. None None O

Finally None None O
, None None O
the None None O
effect None None O
of None None O
baicalin None None O
on None None O
hair None None O
growth None None O
in None None O
vivo None None O
was None None O
examined None None O
by None None O
topical None None O
application None None O
of None None O
baicalin None None O
on None None O
the None None O
shaved None None O
dorsal None None I-NEURON
skin None None O
of None None O
C57BL/6 None None O
mice None None O
. None None O

Phylogenetic None None O
analysis None None O
shows None None O
that None None O
the None None O
novel None None O
PLA2 None None O
from None None O
B. None None O
nigroviridis None None O
venom None None O
is None None O
basal None None O
to None None O
the None None O
branch None None O
including None None O
all None None O
the None None O
homologous None None O
PLA2 None None O
enzymes None None I-PROTEIN
described None None O
in None None O
rattlesnakes None None O
, None None O
and None None O
more None None O
distant None None O
from None None O
PLA2s None None O
from None None O
Bothriechis None None O
species None None O
. None None O

We None None O
installed None None O
a None None O
server None None O
at None None O
the None None O
Information None None O
Technology None None O
Center None None O
of None None O
the None None O
University None None O
of None None O
Toyama None None O
with None None O
a None None O
high-security None None O
firewall None None O
and None None O
online None None O
storage None None I-FUNC
software None None O
( None None O
Proself None None O
) None None O
for None None O
receipt None None O
and None None O
transfer None None O
of None None O
data None None O
. None None O

Sharing None None O
of None None O
data None None O
via None None O
NAS None None I-TRANS
allows None None O
cardiovascular None None O
physicians None None O
and None None O
surgeons None None O
to None None O
communicate None None O
safely None None O
and None None O
effectively None None O
, None None O
leading None None O
to None None O
successful None None O
building None None O
of None None O
a None None O
heart None None O
team None None O
. None None O

The None None O
herinia None None O
port None None O
size None None O
was None None O
large None None O
, None None O
and None None O
the None None O
defect None None O
of None None O
diaphragm None None I-REGION
was None None O
successfully None None O
repaired None None O
by None None O
both None None O
direct None None O
closure None None O
and None None O
mesh None None O
reconstruction None None O
. None None O

Enhanced None None O
computed None None O
tomography None None O
( None None O
CT None None O
) None None O
showed None None O
massive None None O
liquid None None O
retention None None I-FUNC
of None None O
the None None O
left None None O
thorax None None O
, None None O
but None None O
no None None O
aortic None None O
dissection None None O
or None None O
aneurysms None None O
. None None O

We None None O
also None None O
mentioned None None O
an None None O
ambiguity None None I-FUNC
of None None O
the None None O
term None None O
, None None O
'' None None O
giant None None O
'' None None O
regarding None None O
the None None O
size None None O
and None None O
weight None None O
of None None O
myxoma None None O
. None None O

A None None O
55-year-old None None O
male None None O
taxi None None O
driver None None O
visited None None O
our None None O
hospital None None O
because None None O
of None None O
a None None O
left None None O
dorsal None None I-NEURON
tumor None None O
. None None O

Complete None None O
or None None O
partial None None O
loss None None O
of None None O
sensation None None I-FUNC
is None None O
often None None O
reported None None O
by None None O
patients None None O
who None None O
have None None O
experienced None None O
nerve None None O
trauma None None O
during None None O
implant None None O
surgery None None O
. None None O

Mechanical None None O
complications None None O
associated None None O
with None None O
implant-supported None None O
overdentures None None O
and None None O
implant-supported None None O
removable None None O
partial None None O
dentures None None O
are None None O
loss None None O
of None None O
retention None None I-FUNC
of None None O
attachment None None O
systems None None O
, None None O
the None None O
need None None O
to None None O
replace None None O
retention None None I-FUNC
elements None None O
and None None O
to None None O
reline None None O
or None None O
repair None None O
the None None O
resin None None O
portion None None O
of None None O
the None None O
denture None None O
, None None O
and None None O
implant None None O
fracture None None O
. None None O

The None None O
neuromodulation None None O
of None None O
motor None None O
excitability None None O
has None None O
been None None O
shown None None O
to None None O
improve None None O
functional None None O
movement None None I-FUNC
in None None O
people None None O
with None None O
central None None O
nervous None None O
system None None O
damage None None O
. None None O

In None None O
a None None O
close None None O
analogy None None I-FUNC
, None None O
performance None None O
of None None O
nanocrystal None None O
( None None O
NC None None O
) None None O
based None None O
devices None None O
depends None None O
on None None O
the None None O
perfection None None O
of None None O
interfaces None None O
formed None None O
between None None O
NC None None O
layers None None O
. None None O

The None None O
expression None None O
of None None O
ERS None None O
chaperones None None O
( None None O
glucose-regulated None None O
protein None None O
78 None None O
( None None O
GRP78 None None O
) None None O
, None None O
X-box None None O
binding None None O
protein None None O
l None None O
( None None O
XBP1 None None O
) None None O
, None None O
cysteine None None I-TRANS
aspartate None None I-TRANS
specific None None O
protease-12 None None O
( None None O
caspase-12 None None O
) None None O
, None None O
and None None O
growth None None O
arrest None None O
and None None O
DNA None None O
damage-inducible None None O
gene None None O
153 None None O
( None None O
Gadd153/CHOP None None O
) None None O
was None None O
analyzed None None O
by None None O
immunohistochemistry None None O
staining None None O
, None None O
and None None O
osteoblast None None O
apoptosis None None O
was None None O
determined None None O
by None None O
TUNEL None None O
staining None None O
and None None O
flow None None O
cytometry None None O
. None None O

Attention None None I-FUNC
has None None O
been None None O
more None None O
recently None None O
focused None None O
on None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
inhibitors None None O
( None None O
EGFR None None O
TKIs None None O
) None None O
as None None O
well None None O
as None None O
cyclo-oxygenase None None O
2 None None O
( None None O
COX-2 None None O
) None None O
inhibitors None None O
with None None O
early None None O
studies None None O
showing None None O
encouraging None None O
responses None None O
but None None O
rather None None O
poor None None O
tolerance None None O
to None None O
therapy None None O
. None None O

Differential None None O
diagnosis None None O
of None None O
severe None None O
progressive None None O
dementia None None I-DISEASE
includes None None O
a None None O
wide None None O
spectrum None None O
of None None O
inflammatory None None O
and None None O
neurodegenerative None None O
diseases None None O
. None None O

Complementary None None O
blood None None O
testing None None O
revealed None None O
a None None O
positive None None O
result None None O
for None None O
antineural None None O
antibodies None None O
to None None O
Contactin-associated None None O
protein None None O
2 None None O
( None None O
CASPR2 None None O
) None None O
and None None O
the None None O
patient None None O
received None None O
treatment None None O
for None None O
CASPR2 None None O
autoimmune None None O
encephalitis None None I-DISEASE
. None None O

We None None O
believe None None O
, None None O
however None None O
, None None O
that None None O
potentially None None O
treatable None None O
causes None None O
of None None O
dementia None None I-DISEASE
should None None O
aggressively None None O
sought None None O
out None None O
and None None O
subsequently None None O
treated None None O
in None None O
an None None O
attempt None None O
to None None O
curtail None None O
the None None O
course None None O
of None None O
disease None None O
and None None O
ultimately None None O
reduce None None O
the None None O
rate None None O
of None None O
mortality None None O
. None None O

Emerging None None O
evidence None None O
indicates None None O
that None None O
the None None O
enhanced None None O
activity None None O
of None None O
dorsal None None I-NEURON
horn None None O
neurons None None O
requires None None O
communication None None O
with None None O
glia None None O
and None None O
microglia None None O
, None None O
cells None None O
that None None O
are None None O
physiologically None None O
involved None None O
in None None O
neuronal None None O
wellbeing None None O
. None None O

Based None None O
on None None O
OspB None None O
and None None O
OspF None None O
similarity None None O
( None None O
both None None O
effectors None None O
share None None O
similar None None O
transcription None None I-PROTEIN
regulation None None I-PROTEIN
, None None O
temporal None None O
secretion None None O
into None None O
host None None O
cells None None O
and None None O
nuclear None None O
localization None None O
) None None O
we None None O
hypothesized None None O
that None None O
OspB None None O
and None None O
OspF None None O
effectors None None O
may None None O
form None None O
a None None O
pair None None O
aimed None None O
at None None O
modulating None None O
the None None O
host None None O
cell None None O
response None None O
throughout None None O
the None None O
infection None None O
process None None O
, None None O
with None None O
opposite None None O
effects None None O
. None None O

Five None None O
levels None None O
of None None O
compressive None None O
pressure None None O
from None None O
171 None None O
to None None O
313 None None O
kPa None None O
were None None O
applied None None O
for None None O
5s None None O
to None None O
fuse None None O
the None None O
colons None None O
under None None O
radiofrequency None None O
power None None O
of None None O
160 None None O
W None None O
, None None O
and None None O
then None None O
the None None O
collagen None None I-PROTEIN
denaturation None None O
of None None O
the None None O
fused None None O
region None None O
was None None O
examined None None O
by None None O
transmission None None O
electron None None O
microscopy None None O
. None None O

Transmission None None O
electron None None O
micrographs None None O
showed None None O
that None None O
increased None None O
compressive None None O
pressure None None O
led None None O
to None None O
thicker None None O
denatured None None O
collagen None None I-PROTEIN
fibrils None None O
and None None O
wider None None O
gaps None None O
between None None O
each None None O
collagen None None I-PROTEIN
fibril None None O
. None None O

The None None O
aims None None O
of None None O
this None None O
quasi-experimental None None O
before-and-after None None O
study None None O
were None None O
to None None O
first None None O
determine None None O
whether None None O
the None None O
use None None O
of None None O
eye None None O
tracking None None O
technology None None O
combined None None O
with None None O
video None None O
debriefing None None O
techniques None None O
has None None O
the None None O
potential None None O
to None None O
improve None None O
the None None O
quality None None O
of None None O
feedback None None O
and None None O
enhance None None O
situation None None O
awareness None None O
( None None O
SA None None O
) None None O
in None None O
simulated None None O
settings None None O
and None None O
second None None O
to None None O
determine None None O
students None None O
' None None O
satisfaction None None O
towards None None O
simulated None None O
learning None None I-FUNC
. None None O

Eye None None O
tracking None None O
glasses None None O
video None None O
recorded None None O
the None None O
scenarios None None O
and None None O
tracked None None O
right None None O
eye None None O
movement None None I-FUNC
. None None O

Participants None None O
reported None None O
greater None None O
insight None None O
into None None O
their None None O
performance None None O
and None None O
were None None O
satisfied None None O
with None None O
simulated None None O
learning None None I-FUNC
. None None O

Three None None O
new None None O
saikosaponin None None O
analogs None None O
, None None O
comastomasaponins None None O
I-K None None O
( None None O
1-3 None None O
) None None O
, None None O
were None None O
isolated None None O
from None None O
the None None O
aerial None None O
portions None None O
of None None O
Comastomapedunculatum None None O
. None None O

A None None O
total None None O
of None None O
207 None None O
volunteer None None O
participants None None O
answered None None O
stress None None O
questionnaire None None O
and None None O
gave None None O
peripheral None None O
blood None None O
cells None None O
for None None O
identification None None O
of None None O
SNPs None None O
in None None O
genes None None O
coding None None O
for None None O
glucocorticoid None None O
receptor None None I-PROTEIN
( None None O
GR None None O
) None None O
, None None O
beta None None O
2 None None O
adrenergic None None O
receptor None None I-PROTEIN
( None None O
B2AR None None O
) None None O
, None None O
interferon-gamma None None O
receptors None None I-PROTEIN
( None None O
IFNGR1 None None O
, None None O
IFNGR2 None None O
) None None O
, None None O
and None None O
interleukin-4 None None O
receptor None None I-PROTEIN
( None None O
IL4R None None O
) None None O
. None None O

The None None O
study None None O
seeks None None O
to None None O
investigate None None O
how None None O
the None None O
duration None None O
of None None O
storage None None I-FUNC
of None None O
cryopreserved None None O
human None None O
cadaveric None None O
iliac None None O
arteries None None O
impacts None None O
their None None O
mechanical None None O
, None None O
structural None None O
and None None O
microbiological None None O
properties None None O
as None None O
compared None None O
to None None O
their None None O
fresh None None O
sample None None O
. None None O

The None None O
prevalence None None O
of None None O
morbidities None None O
in None None O
SH None None O
subjects None None O
include None None O
ischaemic None None O
heart None None O
disease None None O
( None None O
16.8 None None O
% None None O
) None None O
, None None O
heart None None O
failure None None O
( None None O
8.9 None None O
% None None O
) None None O
, None None O
tachyarrhythmias None None O
( None None O
13.3 None None O
% None None O
) None None O
, None None O
any None None O
cardiovascular None None O
disease None None O
( None None O
28 None None O
% None None O
) None None O
, None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
( None None O
28 None None O
% None None O
) None None O
, None None O
osteoporosis None None O
( None None O
28 None None O
% None None O
) None None O
, None None O
and None None O
any None None O
fracture None None O
( None None O
15.9 None None O
% None None O
) None None O
. None None O

In None None O
particular None None O
, None None O
the None None O
Mn None None O
complex None None O
of None None O
the None None O
ligand None None O
containing None None O
a None None O
4-quinoline None None O
group None None O
in None None O
its None None O
side None None O
arm None None O
which None None O
, None None O
as None None O
it None None O
happens None None O
in None None O
the None None O
MnSOD None None O
enzymes None None I-PROTEIN
, None None O
has None None O
a None None O
water None None O
molecule None None O
coordinated None None O
to None None O
the None None O
metal None None O
ion None None O
that None None O
shows None None O
the None None O
lowest None None O
toxicity None None O
and None None O
highest None None O
functional None None O
efficiency None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

Luciferase None None I-PROTEIN
assays None None O
showed None None O
that None None O
this None None O
medium None None O
contained None None O
a None None O
large None None O
amount None None O
of None None O
active None None O
TGF-β None None O
. None None O

Activated None None O
RhoA None None O
, None None O
proline-rich None None O
tyrosine None None I-TRANS
kinase-2 None None O
( None None O
Pyk2 None None O
) None None O
and None None O
cofilin None None O
induced None None O
by None None O
CCL19 None None O
were None None O
elevated None None O
, None None O
and None None O
increased None None O
RhoA None None O
, None None O
Pyk2 None None O
and None None O
cofilin None None O
activity None None O
was None None O
eliminated None None O
by None None O
CCR7mAb None None O
, None None O
RhoA/ROCK None None O
and None None O
Pyk2 None None O
inhibitors None None O
, None None O
indicating None None O
involvement None None O
of None None O
the None None O
RhoA/ROCK-Pyk2-cofilin None None O
cascade None None O
. None None O

A None None O
simple None None O
and None None O
low-cost None None O
solution None None O
combustion None None O
method None None O
was None None O
used None None O
to None None O
prepare None None O
Eu None None O
( None None O
3+ None None O
) None None O
( None None O
1-11mol None None O
% None None O
) None None O
doped None None O
Zn2TiO4 None None O
nanophosphors None None O
at None None O
500°C None None O
using None None O
zinc None None I-TRANS
nitrates None None O
as None None O
precursors None None O
and None None O
oxalyl None None O
di-hydrazide None None O
( None None O
ODH None None O
) None None O
as None None O
fuel None None O
. None None O

On None None O
immunohistochemical None None O
analysis None None O
, None None O
the None None O
lesional None None O
cells None None O
indicated None None O
diffuse None None O
positive None None O
staining None None O
for None None O
vimentin None None O
and None None O
factor None None O
XIIIa None None O
and None None O
focal None None O
positive None None O
staining None None O
for None None O
CD34 None None O
, None None O
but None None O
did None None O
not None None O
indicate None None O
positive None None O
staining None None O
for None None O
other None None O
pertinent None None O
antigens None None O
such None None O
as None None O
cytokeratins None None O
, None None O
calretinin None None O
, None None O
desmin None None O
, None None O
α-smooth None None O
muscle None None O
actin None None I-PROTEIN
, None None O
ALK None None O
, None None O
and None None O
estrogen None None O
and None None O
progesterone None None O
receptors None None I-PROTEIN
as None None O
well None None O
as None None O
IgG4 None None O
in None None O
plasma None None O
cells None None O
. None None O

Instead None None O
, None None O
light None None O
and None None O
electron None None O
microscopic None None O
analyses None None O
reveal None None O
axonal None None O
pathology None None O
in None None O
the None None O
spinal None None O
dorsal None None I-NEURON
horn None None O
and None None O
spinothalamic None None O
tract None None O
concurrent None None O
with None None O
the None None O
induction None None O
and None None O
maintenance None None O
of None None O
nociceptive None None O
hypersensitivity None None O
. None None O

The None None O
endoplasmic None None O
reticulum None None O
aminopeptidase None None O
1 None None O
( None None O
ERAP1 None None O
) None None O
performs None None O
a None None O
major None None O
role None None O
in None None O
antigen None None O
processing None None O
, None None O
trimming None None O
N-terminally None None O
extended None None O
peptides None None I-TRANS
to None None O
the None None O
final None None O
epitope None None O
for None None O
presentation None None O
by None None O
major None None O
histocompatibility None None O
complex None None O
class None None O
I None None O
molecules None None O
. None None O

Recent None None O
evidence None None O
examining None None O
the None None O
trimming None None O
activity None None O
of None None O
polymorphic None None O
ERAP1 None None O
highlights None None O
its None None O
role None None O
in None None O
generating None None O
peptides None None I-TRANS
for None None O
loading None None O
onto None None O
and None None O
stabilizing None None O
HLA-B27 None None O
, None None O
and None None O
the None None O
consequent None None O
alterations None None O
in None None O
the None None O
interaction None None O
of None None O
specific None None O
NK None None O
cell None None O
receptors None None I-PROTEIN
, None None O
and None None O
the None None O
activation None None O
of None None O
the None None O
unfolded None None O
protein None None O
response None None O
as None None O
important None None O
in None None O
the None None O
mechanism None None O
of None None O
disease None None O
pathogenesis None None O
. None None O

This None None O
is None None O
similarly None None O
the None None O
case None None O
for None None O
depression None None I-DISEASE
developing None None O
during None None O
interferon-α None None O
( None None O
IFN-α None None O
) None None O
therapy None None O
. None None O

Two None None O
nights None None O
of None None O
polysomnography None None O
with None None O
quantitative None None O
electroencephalogram None None O
( None None O
EEG None None O
) None None O
were None None O
obtained None None O
in None None O
24 None None O
adult None None O
, None None O
euthymic None None O
subjects None None O
-- None None O
all None None O
subsequently None None O
treated None None O
with None None O
IFN-α None None O
for None None O
hepatitis None None O
C. None None O
Every None None O
2 None None O
weeks None None O
, None None O
a None None O
Beck None None O
Depression None None I-DISEASE
Inventory-II None None O
( None None O
BDI-II None None O
) None None O
score None None O
was None None O
obtained None None O
, None None O
and None None O
the None None O
maximal None None O
increase None None O
in None None O
BDI-II None None O
from None None O
pre-treatment None None O
baseline None None O
-- None None O
excluding None None O
the None None O
sleep None None O
question None None O
-- None None O
was None None O
determined None None O
. None None O

Most None None O
other None None O
sleep None None O
parameters None None O
-- None None O
including None None O
total None None O
sleep None None O
time None None O
and None None O
percentage None None O
of None None O
time None None O
in None None O
slow None None O
wave None None O
sleep None None O
-- None None O
were None None O
not None None O
associated None None O
with None None O
subsequent None None O
changes None None O
in None None O
depression None None I-DISEASE
. None None O

As None None O
most None None O
other None None O
aspects None None O
of None None O
sleep None None O
were None None O
not None None O
associated None None O
with None None O
resilience None None O
or None None O
vulnerability None None O
, None None O
sleep None None O
interventions None None O
to None None O
prevent None None O
depression None None I-DISEASE
may None None O
need None None O
to None None O
specifically None None O
target None None O
these None None O
specific None None O
sleep None None O
parameters None None O
. None None O

Potential None None O
relevant None None O
studies None None O
were None None O
searched None None O
for None None O
in None None O
PubMed None None O
, None None O
Springerlink None None O
, None None O
Wiley None None O
, None None O
EBSCO None None O
, None None O
Ovid None None O
, None None O
Web None None O
of None None O
Science None None O
, None None O
Wanfang None None O
databases None None O
, None None O
China None None O
National None None O
Knowledge None None O
Infrastructure None None O
( None None O
CNKI None None O
) None None O
databases None None O
and None None O
VIP None None I-TRANS
databases None None O
. None None O

In None None O
the None None O
normothermia+ischemia None None O
groups None None O
, None None O
a None None O
significant None None O
delayed None None O
neuronal None None O
death None None O
was None None O
observed None None O
in None None O
the None None O
stratum None None I-REGION
pyramidale None None I-REGION
( None None O
SP None None O
) None None O
of None None O
the None None O
hippocampal None None O
CA1 None None I-REGION
region None None O
( None None O
CA1 None None I-REGION
) None None O
5 None None O
days None None O
after None None O
ischemia-reperfusion None None O
. None None O

Based None None O
on None None O
our None None O
findings None None O
, None None O
we None None O
suggest None None O
that None None O
an None None O
experimentally None None O
hyperthermic None None O
pre-condition None None O
before None None O
cerebral None None O
ischemic None None O
insult None None O
produces None None O
more None None O
extensive None None O
neuronal None None O
damage None None O
and None None O
glial None None O
activation None None O
in None None O
the None None O
ischemic None None O
hippocampus None None I-REGION
. None None O

Patients None None O
with None None O
chronic None None O
migraine None None I-DISEASE
with None None O
medication None None O
overuse None None O
( None None O
CM-MO None None O
) None None O
have None None O
decreased None None O
quality None None O
of None None O
life None None O
( None None O
QoL None None O
) None None O
and None None O
increased None None O
disability None None O
: None None O
the None None O
degree None None O
to None None O
which None None O
these None None O
outcomes None None O
are None None O
connected None None O
to None None O
disease None None O
severity None None O
and None None O
the None None O
pattern None None O
of None None O
MO None None O
towards None None O
disease None None O
severity None None O
are None None O
unclear None None O
. None None O

The None None O
results None None O
from None None O
the None None O
present None None O
study None None O
open None None O
the None None O
possibility None None O
of None None O
using None None O
flavonoids None None O
for None None O
potential None None O
new None None O
therapeutic None None O
strategies None None O
for None None O
sporadic None None O
dementia None None I-DISEASE
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Migraine None None I-DISEASE
is None None O
a None None O
common None None O
chronic None None O
neurological None None O
disorder None None O
with None None O
still None None O
largely None None O
unknown None None O
pathogenesis None None O
. None None O

Two None None O
hundred None None O
patients None None O
with None None O
migraine None None I-DISEASE
and None None O
200 None None O
controls None None O
were None None O
enrolled None None O
in None None O
this None None O
study None None O
. None None O

TNF-α-308 None None O
GA None None O
, None None O
AA None None O
genotypes None None O
and None None O
A None None O
allele None None O
or None None O
AA None None O
genotype None None O
were None None O
associated None None O
with None None O
increased None None O
risk None None O
of None None O
migraine None None I-DISEASE
with None None O
aura None None O
( None None O
MA None None O
) None None O
and None None O
migraine None None I-DISEASE
without None None I-DISEASE
aura None None I-DISEASE
( None None O
MO None None O
) None None O
respectively None None O
; None None O
this None None O
was None None O
more None None O
significant None None O
in None None O
female None None O
patients None None O
with None None O
MA None None O
than None None O
in None None O
males None None O
. None None O

TNF-α None None O
levels None None O
were None None O
higher None None O
in None None O
patients None None O
with None None O
migraine None None I-DISEASE
, None None O
MA None None O
, None None O
or None None O
MO None None O
than None None O
in None None O
controls None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Images None None O
of None None O
the None None O
diaphragm None None I-REGION
, None None O
liver None None O
, None None O
and None None O
spleen None None O
were None None O
obtained None None O
using None None O
2-dimensional None None O
ultrasound None None O
. None None O

Acceptable None None O
agreement None None O
was None None O
not None None O
present None None O
for None None O
intubated None None O
and None None O
all None None O
patients None None O
for None None O
diaphragmatic None None O
and None None O
solid None None O
organ None None O
movement None None I-FUNC
. None None O

The None None O
medial None None O
and None None O
middle None None O
thirds None None O
may None None O
be None None O
used None None O
interchangeably None None O
to None None O
assess None None O
hemidiaphragm None None O
movement None None I-FUNC
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
interaction None None O
between None None O
these None None O
enzymes None None I-PROTEIN
. None None O

The None None O
results None None O
suggested None None O
that None None O
CYP3A5 None None O
does None None O
not None None O
affect None None O
CYP3A4 None None I-PROTEIN
expression None None O
directly None None O
. None None O

A None None O
luciferase None None I-PROTEIN
reporter None None O
assay None None O
indicated None None O
that None None O
this None None O
attenuation None None O
was None None O
due None None O
to None None O
a None None O
decrease None None O
in None None O
CYP3A4 None None I-PROTEIN
promoter None None O
activity None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
current None None O
study None None O
demonstrated None None O
that None None O
CYP3A5 None None O
may None None O
affect None None O
CYP3A4 None None I-PROTEIN
at None None O
the None None O
transcriptional None None O
level None None O
and None None O
may None None O
thus None None O
modify None None O
CYP3A4 None None I-PROTEIN
expression None None O
and None None O
activity None None O
in None None O
the None None O
presence None None O
of None None O
substrates None None O
and None None O
inducers None None O
. None None O

Proteinaceous None None O
inclusions None None O
in None None O
nerve None None O
cells None None O
and None None O
glia None None O
are None None O
a None None O
defining None None O
neuropathological None None O
hallmark None None O
in None None O
a None None O
variety None None O
of None None O
neurodegenerative None None O
diseases None None O
, None None O
including None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
progressive None None I-DISEASE
supranuclear None None I-DISEASE
palsy None None I-DISEASE
( None None O
PSP None None O
) None None O
, None None O
and None None O
corticobasal None None O
degeneration None None O
( None None O
CBD None None O
) None None O
. None None O

Although None None O
initial None None O
colposcopic None None O
training None None O
did None None O
not None None O
influence None None O
the None None O
probability None None O
to None None O
use None None O
colposcopy None None O
at None None O
the None None O
time None None O
of None None O
excision None None O
, None None O
the None None O
probability None None O
of None None O
performing None None O
excisions None None O
immediately None None O
after None None O
a None None O
colposcopic None None O
examination None None O
or None None O
under None None O
direct None None O
colposcopic None None O
vision None None I-FUNC
was None None O
significantly None None O
increased None None O
by None None O
the None None O
monthly None None O
practice None None O
of None None O
30 None None O
or None None O
more None None O
colposcopic None None O
examinations None None O
( None None O
AOR None None O
: None None O
3.34 None None O
; None None O
95 None None O
% None None O
CI None None O
: None None O
1.54-7.26 None None O
and None None O
AOR None None O
: None None O
2.16 None None O
; None None O
95 None None O
% None None O
CI None None O
: None None O
1.08-4.34 None None O
, None None O
respectively None None O
) None None O
and None None O
by None None O
the None None O
monthly None None O
practice None None O
of None None O
5 None None O
or None None O
more None None O
excisional None None O
therapies None None O
( None None O
AOR None None O
: None None O
3.06 None None O
; None None O
95 None None O
% None None O
CI None None O
: None None O
1.42-6.56 None None O
and None None O
AOR None None O
: None None O
3.03 None None O
; None None O
95 None None O
% None None O
: None None O
1.54-5.96 None None O
, None None O
respectively None None O
) None None O
. None None O

Autosomal None None O
recessive None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
( None None O
ID None None O
) None None O
is None None O
genetically None None O
heterogeneous None None O
and None None O
most None None O
of None None O
the None None O
genes None None O
causing None None O
it None None O
remain None None O
undiscovered None None O
. None None O

Above None None O
all None None O
, None None O
the None None O
two-photon None None O
absorption None None O
( None None O
2PA None None O
) None None O
cross-section None None O
values None None O
( None None O
σ None None O
) None None O
were None None O
enhanced None None O
by None None O
coordination None None O
with None None O
zinc None None I-TRANS
and None None O
influenced None None O
by None None O
halide None None O
ions None None O
, None None O
reaching None None O
up None None O
to None None O
2583 None None O
GM None None O
( None None O
X None None O
= None None O
Br None None O
) None None O
. None None O

It None None O
is None None O
found None None O
that None None O
water None None O
is None None O
a None None O
less None None O
favorable None None O
solvent None None O
for None None O
these None None O
polymers None None O
than None None O
for None None O
peptides None None I-TRANS
. None None O

Recently None None O
, None None O
sphingolipid None None O
metabolizing None None O
enzymes None None I-PROTEIN
have None None O
emerged None None O
as None None O
important None None O
targets None None O
of None None O
many None None O
chemotherapeutics None None O
and None None O
DNA None None O
damaging None None O
agents None None O
and None None O
therefore None None O
play None None O
significant None None O
roles None None O
in None None O
mediating None None O
the None None O
physiological None None O
response None None O
of None None O
the None None O
cell None None O
to None None O
DNA None None O
damage None None O
. None None O

In None None O
an None None O
effort None None O
to None None O
develop None None O
micronutrient-dense None None O
chickpea None None O
lines None None O
, None None O
a None None O
study None None O
to None None O
examine None None O
the None None O
variability None None O
and None None O
to None None O
identify None None O
SNP None None O
alleles None None O
associated None None O
with None None O
seed None None O
iron None None O
and None None O
zinc None None I-TRANS
concentrations None None O
was None None O
conducted None None O
using None None O
94 None None O
diverse None None O
accessions None None O
of None None O
chickpea None None O
. None None O

In None None O
the None None O
current None None O
set None None O
of None None O
germplasm None None O
, None None O
zinc None None I-TRANS
is None None O
negatively None None O
correlated None None O
with None None O
grain None None O
yield None None O
across None None O
all None None O
locations None None O
and None None O
years None None O
; None None O
whereas None None O
the None None O
negative None None O
correlation None None O
between None None O
iron None None O
and None None O
grain None None O
yield None None O
was None None O
only None None O
significant None None O
at None None O
the None None O
Elrose None None O
locality None None O
. None None O

One None None O
SNP None None O
located None None O
on None None O
chromosome None None O
1 None None O
( None None O
chr1 None None O
) None None O
is None None O
associated None None O
with None None O
both None None O
iron None None O
and None None O
zinc None None I-TRANS
concentrations None None O
. None None O

Two None None O
additional None None O
SNP None None O
loci None None O
, None None O
one None None O
on None None O
chr6 None None O
and None None O
the None None O
other None None O
on None None O
chr7 None None O
, None None O
were None None O
also None None O
found None None O
to None None O
be None None O
associated None None O
with None None O
iron None None O
and None None O
zinc None None I-TRANS
concentrations None None O
, None None O
respectively None None O
. None None O

The None None O
levels None None O
of None None O
expression None None O
of None None O
ephrinB2 None None O
, None None O
VEGF None None O
, None None O
CD105 None None O
and None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
9 None None O
( None None O
MMP9 None None O
) None None O
protein None None O
were None None O
measured None None O
by None None O
western None None O
blotting None None O
, None None O
and None None O
messenger None None O
RNA None None O
( None None O
mRNA None None O
) None None O
levels None None O
were None None O
measured None None O
using None None O
real-time None None O
PCR None None O
. None None O

Premature None None I-DISEASE
ejaculation None None I-DISEASE
( None None O
PE None None O
) None None O
is None None O
the None None O
most None None O
common None None O
male None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
effects None None O
of None None O
glyphosate None None O
on None None O
the None None O
immunoglobulin None None O
M None None O
( None None O
IgM None None O
) None None O
, None None O
complement None None O
C3 None None O
( None None O
C3 None None O
) None None O
, None None O
and None None O
lysozyme None None I-PROTEIN
( None None O
LYZ None None O
) None None O
in None None O
the None None O
kidney None None O
of None None O
common None None O
carp None None O
exposed None None O
to None None O
52.08 None None O
or None None O
104.15mgL None None O
( None None O
-1 None None O
) None None O
of None None O
glyphosate None None O
for None None O
168h None None O
. None None O

In None None O
another None None O
part None None O
, None None O
lead None None O
was None None O
administered None None O
to None None O
rats None None O
for None None O
32 None None O
days None None O
and None None O
after None None O
evaluating None None O
criteria None None O
of None None O
diabetes None None O
, None None O
the None None O
activity None None O
of None None O
gluconeogenesis None None O
and None None O
glycogenolysis None None O
enzymes None None I-PROTEIN
, None None O
and None None O
markers None None O
of None None O
oxidative None None O
stress None None O
and None None O
inflammation None None O
were None None O
measured None None O
in None None O
the None None O
liver None None O
. None None O

Chronic None None O
exposure None None O
to None None O
lead None None O
can None None O
disrupt None None O
glucose None None O
homeostasis None None O
by None None O
affecting None None O
pancreas None None O
and None None O
liver None None O
mainly None None O
through None None O
induction None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Treatment None None O
of None None O
cells None None O
with None None O
calcium None None O
citrate None None O
( None None O
10-100μM None None O
) None None O
significantly None None O
reduced None None O
the None None O
generation None None O
of None None O
intracellular None None O
reactive None None O
oxygen None None O
species None None O
and None None O
increased None None O
the None None O
activities None None O
of None None O
the None None O
antioxidant None None O
enzymes None None I-PROTEIN
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
catalase None None I-PROTEIN
, None None O
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
in None None O
LPS-stimulated None None O
macrophages None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
difference None None O
between None None O
the None None O
control None None O
and None None O
infertile None None O
dromedaries None None O
in None None O
seminal None None O
plasma None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPx None None O
) None None O
activity None None O
( None None O
15.04 None None O
± None None O
1.14 None None O
vs. None None O
4.55 None None O
± None None O
0.96 None None O
nmol/min/mL None None O
, None None O
respectively None None O
) None None O
and None None O
both None None O
phospholipase None None O
A2 None None O
( None None O
sPLA2 None None O
; None None O
50.66 None None O
± None None O
6.28 None None O
vs. None None O
23.56 None None O
± None None O
4.29 None None O
pg/mL None None O
, None None O
respectively None None O
) None None O
and None None O
testosterone None None O
concentrations None None O
( None None O
732.14 None None O
± None None O
57.12 None None O
vs. None None O
396.36 None None O
± None None O
79.34 None None O
pg/mL None None O
, None None O
respectively None None O
) None None O
. None None O

Eight None None O
subjects None None O
moved None None O
( None None O
self-paced None None O
) None None O
light None None O
or None None O
heavy None None O
products None None O
( None None O
0.2 None None O
and None None O
3.0 None None O
kg None None O
) None None O
from None None O
a None None O
central None None O
product None None O
bin None None O
to None None O
an None None O
inner None None O
or None None O
outer None None O
order None None O
bin None None O
( None None O
at None None O
60 None None O
or None None O
150 None None O
cm None None O
) None None O
on None None O
the None None O
left None None O
or None None O
right None None O
side None None O
of None None O
the None None O
workstation None None O
, None None O
while None None O
movements None None I-FUNC
were None None O
recorded None None O
. None None O

Protein None None O
molecules None None O
immobilized None None O
on None None O
biomaterial None None O
surfaces None None O
are None None O
performed None None O
based None None O
on None None O
oriented None None O
conjugation None None O
or None None O
replaced None None O
mimicking None None O
peptides None None I-TRANS
. None None O

UXT None None O
, None None O
also None None O
termed None None O
androgen None None O
receptor None None I-PROTEIN
trapped None None O
clone‑27 None None O
, None None O
is None None O
an None None O
α‑class None None O
prefoldin‑type None None O
chaperone None None O
that None None O
acts None None O
as None None O
a None None O
coregulator None None O
for None None O
various None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
including None None O
nuclear None None O
factor‑κB None None O
and None None O
androgen None None O
receptor None None I-PROTEIN
( None None O
AR None None O
) None None O
. None None O

Mothers None None O
that None None O
were None None O
unaware None None O
of None None O
HPV None None O
were None None O
significantly None None O
more None None O
likely None None O
to None None O
conduct None None O
the None None O
interview None None O
in None None O
a None None O
language None None I-FUNC
other None None O
than None None O
English None None O
and None None O
to None None O
lack None None O
health None None O
insurance None None O
for None None O
their None None O
daughters None None O
. None None O

The None None O
associations None None O
between None None O
lack None None O
of None None O
awareness None None O
and None None O
use None None O
of None None O
a None None O
language None None I-FUNC
other None None O
than None None O
English None None O
, None None O
as None None O
well None None O
as None None O
lack None None O
of None None O
health None None O
insurance None None O
for None None O
their None None O
daughter None None O
indicate None None O
the None None O
need None None O
for None None O
HPV None None O
vaccine None None O
outreach None None O
efforts None None O
tailored None None O
to None None O
ethnic None None O
minority None None O
communities None None O
in None None O
the None None O
U.S None None O
. None None O

Dysfunction None None O
of None None O
the None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
family None None O
, None None O
is None None O
the None None O
key None None O
process None None O
in None None O
tumorigenesis None None O
, None None O
and None None O
anti-EGFR None None O
therapeutic None None O
strategies None None O
such None None O
as None None O
cetuximab None None O
therapy None None O
now None None O
are None None O
used None None O
in None None O
the None None O
treatment None None O
of None None O
cancer None None O
. None None O

Alantolactone None None O
effectively None None O
suppressed None None O
both None None O
constitutive None None O
and None None O
inducible None None O
STAT3 None None O
activation None None O
at None None O
tyrosine None None I-TRANS
705 None None O
. None None O

Alantolactone None None O
significantly None None O
inhibits None None O
STAT3 None None O
activation None None O
with None None O
a None None O
marginal None None O
effect None None O
on None None O
MAPKs None None O
and None None O
on None None O
NF-κB None None O
transcription None None O
; None None O
however None None O
, None None O
this None None O
effect None None O
is None None O
not None None O
mediated None None O
by None None O
inhibiting None None O
STAT3 None None O
upstream None None O
kinases None None I-PROTEIN
. None None O

Urea-induced None None O
denaturation None None O
of None None O
OVA None None O
produced None None O
a None None O
transition None None O
, None None O
characterized None None O
by None None O
the None None O
start- None None O
, None None O
the None None O
mid- None None O
and None None O
the None None O
end-points None None O
at None None O
3.2 None None O
M None None O
, None None O
5.9/5.6 None None O
M None None O
and None None O
8.5/8.0 None None O
M None None O
urea None None O
, None None O
respectively None None O
, None None O
when None None O
studied None None O
by None None O
MRE222nm None None O
and None None O
tryptophan None None I-TRANS
fluorescence None None O
measurements None None O
. None None O

Our None None O
study None None O
focused None None O
on None None O
dynamic None None O
changes None None O
of None None O
metanephrine None None O
( None None O
MN None None O
) None None O
, None None O
normetanephrine None None O
( None None O
NMN None None O
) None None O
, None None O
cytokines None None O
, None None O
and None None O
spleen None None O
volume None None O
in None None O
the None None O
rat None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
( None None O
MCAO None None O
) None None O
model None None O
. None None O

Deletion None None O
of None None O
alaT None None O
and None None O
avtA None None O
encoding None None I-FUNC
the None None O
transaminases None None O
and None None O
introduction None None O
of None None O
an None None O
attenuated None None O
mutant None None O
of None None O
acetohydroxyacid None None O
synthase None None O
( None None O
AHAS None None O
) None None O
increased None None O
both None None O
L-serine None None O
production None None O
level None None O
( None None O
26.23 None None O
g/L None None O
) None None O
and None None O
its None None O
productivity None None O
( None None O
0.27 None None O
g/L/h None None O
) None None O
. None None O

The None None O
modification None None O
decreased None None O
the None None O
metabolic None None O
flow None None O
towards None None O
the None None O
branched-chain None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
BCAAs None None O
) None None O
and None None O
induced None None O
to None None O
shift None None O
it None None O
towards None None O
L-serine None None O
production None None O
. None None O

Such None None O
high-temperature None None O
processing None None O
requires None None O
development None None O
of None None O
thermostable None None O
enzymes None None I-PROTEIN
. None None O

Here None None O
we None None O
report None None O
on None None O
the None None O
influence None None O
of None None O
the None None O
reduced None None O
activity None None O
of None None O
succinate None None O
dehydrogenase None None I-PROTEIN
in None None O
Y. None None O
lipolytica None None O
on None None O
its None None O
ability None None O
to None None O
produce None None O
succinate None None O
. None None O

At None None O
the None None O
neurochemical None None O
level None None O
, None None O
young None None O
EE None None O
rats None None O
showed None None O
higher None None O
hippocampal None None O
glutamate None None I-TRANS
and None None O
GABA None None I-TRANS
concentrations None None O
, None None O
and None None O
DA None None O
turnover None None O
in None None O
VS None None O
, None None O
which None None O
correlated None None O
with None None O
RM None None O
performance None None O
. None None O

These None None O
results None None O
challenge None None O
the None None O
assumption None None O
that None None O
mature None None O
adult None None O
animals None None O
are None None O
always None None O
worse None None O
in None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
tasks None None O
. None None O

Recent None None O
efforts None None O
to None None O
identify None None O
the None None O
molecules None None O
that None None O
are None None O
involved None None O
in None None O
the None None O
maintenance None None O
of None None O
long-term None None O
memories None None O
in None None O
mammals None None O
have None None O
focused None None O
attention None None I-FUNC
on None None O
atypical None None O
isoforms None None O
of None None O
protein None None O
kinase None None O
C None None O
( None None O
PKC None None O
) None None O
. None None O

We None None O
show None None O
that None None O
systemic None None O
injections None None O
of None None O
either None None O
chelerythrine None None O
or None None O
ZIP None None O
erase None None O
long-term None None O
olfactory None None O
memories None None O
in None None O
the None None O
cockroach None None O
, None None O
but None None O
have None None O
no None None O
effect None None O
on None None O
memory None None I-FUNC
acquisition None None O
during None None O
conditioning None None O
. None None O

Genetic None None O
correction None None O
of None None O
patient-derived None None O
induced None None O
pluripotent None None O
stem None None O
cells None None O
( None None O
iPSCs None None O
) None None O
by None None O
TALENs None None O
or None None O
CRISPR-Cas9 None None O
holds None None O
promise None None O
for None None O
DMD None None O
gene None None O
therapy None None O
; None None O
however None None O
, None None O
the None None O
safety None None O
of None None O
such None None O
nuclease None None I-PROTEIN
treatment None None O
must None None O
be None None O
determined None None O
. None None O

To None None O
restore None None O
the None None O
dystrophin None None I-PROTEIN
protein None None O
, None None O
we None None O
performed None None O
three None None O
correction None None O
methods None None O
( None None O
exon None None O
skipping None None O
, None None O
frameshifting None None O
, None None O
and None None O
exon None None O
knockin None None O
) None None O
in None None O
DMD-patient-derived None None O
iPSCs None None O
, None None O
and None None O
found None None O
that None None O
exon None None O
knockin None None O
was None None O
the None None O
most None None O
effective None None O
approach None None O
. None None O

Finally None None O
, None None O
we None None O
differentiated None None O
the None None O
corrected None None O
iPSCs None None O
toward None None O
skeletal None None O
muscle None None O
cells None None O
and None None O
successfully None None O
detected None None O
the None None O
expression None None O
of None None O
full-length None None O
dystrophin None None I-PROTEIN
protein None None O
. None None O

Androgens None None I-PROTEIN
are None None O
widely None None O
used None None O
for None None O
treating None None O
Fanconi None None O
anemia None None O
( None None O
FA None None O
) None None O
and None None O
other None None O
human None None O
bone None None O
marrow None None O
failure None None O
syndromes None None O
, None None O
but None None O
their None None O
mode None None O
of None None O
action None None O
remains None None O
incompletely None None O
understood None None O
. None None O

Emotional None None O
awareness None None O
( None None O
i.e. None None O
, None None O
attention None None I-FUNC
to None None O
and None None O
clarity None None O
of None None O
emotions None None I-FUNC
) None None O
is None None O
associated None None O
with None None O
a None None O
wide None None O
range None None O
of None None O
outcomes None None O
. None None O

Emotional None None O
awareness None None O
( None None O
i.e. None None O
, None None O
attention None None I-FUNC
to None None O
and None None O
clarity None None O
of None None O
emotions None None I-FUNC
) None None O
was None None O
measured None None O
with None None O
self-report None None O
in None None O
a None None O
sample None None O
of None None O
44 None None O
individuals None None O
diagnosed None None O
with None None O
either None None O
schizophrenia None None I-DISEASE
or None None O
schizoaffective None None I-DISEASE
disorder None None I-DISEASE
. None None O

For None None O
the None None O
sample None None O
as None None O
a None None O
whole None None O
, None None O
individuals None None O
with None None O
higher None None O
levels None None O
of None None O
attention None None I-FUNC
to None None O
emotion None None I-FUNC
tended None None O
to None None O
have None None O
more None None O
severe None None O
delusions None None O
. None None O

Neuronal None None O
T-type None None O
voltage-gated None None O
Ca None None O
( None None O
2+ None None O
) None None O
channels None None O
are None None O
reported None None O
to None None O
have None None O
physiological None None O
roles None None O
that None None O
include None None O
regulation None None O
of None None O
burst None None O
firing None None O
, None None O
Ca None None O
( None None O
2+ None None O
) None None O
oscillations None None O
, None None O
and None None O
neurotransmitter None None I-TRANS
release None None O
. None None O

We None None O
used None None O
Ni None None O
( None None O
2+ None None O
) None None O
to None None O
explore None None O
the None None O
role None None O
of None None O
axonal None None O
T-type None None O
channels None None O
in None None O
dopamine None None I-TRANS
( None None O
DA None None O
) None None O
release None None O
in None None O
mouse None None O
striatum None None I-REGION
, None None O
but None None O
identified None None O
significant None None O
off-target None None O
effects None None O
on None None O
DA None None O
uptake None None O
. None None O

We None None O
investigated None None O
the None None O
abundance None None O
of None None O
biofilms None None O
occurring None None O
on None None O
needles None None O
of None None O
the None None O
common None None O
yew None None O
( None None O
Taxus None None O
baccata None None O
) None None O
in None None O
the None None O
city None None O
of None None O
Prague None None O
, None None O
Czech None None I-TRANS
Republic None None O
. None None O

Temporal None None I-DISEASE
lobe None None I-DISEASE
epilepsy None None I-DISEASE
( None None O
TLE None None O
) None None O
is None None O
the None None O
most None None O
common None None O
form None None O
of None None O
acquired None None O
epilepsy None None O
in None None O
adult None None O
. None None O

Sensory None None O
information None None O
coming None None O
from None None O
climbing None None O
fiber None None O
and None None O
mossy None None O
fiber-granule None None O
cell None None O
pathways None None O
, None None O
generates None None O
motor-related None None O
outputs None None O
according None None O
to None None O
internal None None O
rules None None O
of None None O
integration None None O
and None None O
computation None None O
in None None O
the None None O
cerebellar None None I-REGION
cortex None None I-REGION
. None None O

These None None O
results None None O
indicate None None O
that None None O
the None None O
cerebellar None None O
granule None None O
cells None None O
transfer None None O
the None None O
high-fidelity None None O
sensory None None O
information None None O
from None None O
mossy None None O
fibers None None O
, None None O
which None None O
is None None O
cut-off None None O
by None None O
molecular None None O
layer None None O
interneurons None None I-NEURON
( None None O
MLIs None None O
) None None O
. None None O

All None None O
circadian None None O
rhythms None None O
, None None O
especially None None O
temperature None None O
rhythm None None O
showed None None O
a None None O
phase-advance None None O
, None None O
associated None None O
with None None O
reverse None None O
melatonin None None I-TRANS
secretion None None O
. None None O

Taking None None O
in None None O
consideration None None O
the None None O
reverse None None O
melatonin None None I-TRANS
secretion None None O
and None None O
the None None O
phase-advanced None None O
temperature None None O
rhythm None None O
, None None O
which None None O
is None None O
driven None None O
by None None O
the None None O
suprachiasmatic None None I-REGION
nucleus None None I-REGION
, None None O
we None None O
hypothesize None None O
that None None O
the None None O
central None None O
clock None None O
is None None O
more None None O
sensitive None None O
to None None O
afternoon None None O
than None None O
to None None O
morning None None O
melatonin None None I-TRANS
. None None O

chronaesthesia None None O
) None None O
corroborates None None O
the None None O
phase None None O
response None None O
curve None None O
of None None O
melatonin None None I-TRANS
secretion None None O
to None None O
exogenous None None O
melatonin None None I-TRANS
. None None O

Carbon None None I-TRANS
monoxide None None I-TRANS
( None None O
CO None None O
) None None O
is None None O
neuroprotective None None O
in None None O
various None None O
models None None O
of None None O
brain None None O
injury None None O
, None None O
but None None O
the None None O
precise None None O
mechanisms None None O
for None None O
this None None O
are None None O
yet None None O
to None None O
be None None O
established None None O
. None None O

Administration None None O
of None None O
Hemin None None O
( None None O
a None None O
CO None None O
donor None None O
) None None O
in None None O
FS None None O
rats None None O
alleviated None None O
the None None O
neuronal None None O
damage None None O
, None None O
reduced None None O
neuronal None None O
apoptosis None None O
, None None O
upregulated None None O
GRP78 None None O
expression None None O
, None None O
decreased None None O
CHOP None None O
, None None O
and None None O
increased None None O
p-PERK None None O
and None None O
p-eIF2α None None O
expression None None O
in None None O
the None None O
hippocampus None None I-REGION
, None None O
compared None None O
to None None O
FS None None O
control None None O
rats None None O
. None None O

This None None O
study None None O
explains None None O
how None None O
water None None O
molecules None None O
mediate None None O
the None None O
adsorption None None O
of None None O
charged None None O
amino None None I-TRANS
acids None None I-TRANS
showing None None O
that None None O
protonated None None O
amino None None I-TRANS
acids None None I-TRANS
are None None O
chemically None None O
adsorbed None None O
much None None O
more None None O
strongly None None O
than None None O
de-protonated None None O
Asp None None O
. None None O

Memory None None I-FUNC
comprises None None O
acquisition None None O
, None None O
consolidation None None O
and None None O
retrieval None None O
of None None O
information None None O
. None None O

It None None O
is None None O
well None None O
demonstrated None None O
that None None O
sex None None O
hormones None None I-PROTEIN
, None None O
mainly None None O
estrogen None None O
, None None O
impact None None O
cognitive None None O
function None None O
. None None O

There None None O
are None None O
many None None O
contradictory None None O
results None None O
regarding None None O
the None None O
role None None O
of None None O
progesterone None None O
in None None O
memory None None I-FUNC
. None None O

In None None O
multivariate None None O
analysis None None O
among None None O
men None None O
lack None None O
of None None O
non-organised None None O
religious None None O
activity None None O
( None None O
odds None None O
ratio=OR None None O
0.85 None None O
, None None O
confidence None None O
interval=CI None None O
0.77-0.95 None None O
) None None O
, None None O
lower None None O
dietary None None O
risk None None O
knowledge None None O
( None None O
OR=0.64 None None O
, None None O
CI=0.41-0.99 None None O
) None None O
, None None O
tobacco None None O
use None None O
( None None O
OR=2.23 None None O
, None None O
CI=1.14-4.38 None None O
) None None O
, None None O
and None None O
suffering None None O
from None None O
depression None None I-DISEASE
( None None O
OR=1.59 None None O
, None None O
CI=1.00-2.47 None None O
) None None O
were None None O
associated None None O
with None None O
overweight/obesity None None O
, None None O
and None None O
younger None None O
age None None O
( None None O
OR=0.32 None None O
, None None O
CI=0.12-0.90 None None O
) None None O
, None None O
lives None None O
away None None O
from None None O
parents None None O
or None None O
guardians None None O
( None None O
OR=1.79 None None O
, None None O
CI=1.04-3.07 None None O
) None None O
, None None O
healthy None None O
dietary None None O
practices None None O
( None None O
OR=1.95 None None O
, None None O
CI=1.02-3.72 None None O
) None None O
and None None O
9 None None O
or None None O
more None None O
hours None None O
sleep None None O
duration None None O
( None None O
OR=0.28 None None O
, None None O
CI=0.09-0.96 None None O
) None None O
were None None O
associated None None O
with None None O
central None None O
obesity None None O
. None None O

Polysomnography None None O
was None None O
conducted None None O
and None None O
morning None None O
levels None None O
of None None O
glucose None None O
and None None O
insulin None None I-PROTEIN
were None None O
measured None None O
and None None O
IR None None O
was None None O
determined None None O
from None None O
the None None O
blood None None O
samples None None O
collected None None O
early None None O
in None None O
the None None O
morning None None O
after None None O
overnight None None O
fast None None O
. None None O

Effects None None O
of None None O
severity None None O
of None None O
OSA None None O
defined None None O
by None None O
apnea None None O
hypopnea None None O
index None None O
( None None O
AHI None None O
) None None O
and None None O
oxygen None None O
desaturation None None O
index None None O
( None None O
ODI None None O
) None None O
on None None O
glucose None None O
, None None O
insulin None None I-PROTEIN
, None None O
and None None O
HOMA-IR None None O
were None None O
analyzed None None O
. None None O

The None None O
current None None O
study None None O
investigated None None O
the None None O
influence None None O
of None None O
a None None O
plaintiff None None O
's None None O
weight None None O
and None None O
the None None O
location None None O
of None None O
an None None O
accident None None O
on None None O
a None None O
simulated None None O
jury None None O
's None None O
perceptions None None I-FUNC
of None None O
plaintiff None None O
's None None O
personal None None O
responsibility None None O
for None None O
an None None O
accident None None O
. None None O

Participants None None O
were None None O
significantly None None O
more None None O
likely None None O
to None None O
report None None O
the None None O
plaintiff None None O
's None None O
weight None None O
entered None None O
into None None O
their None None O
perceptions None None I-FUNC
of None None O
personal None None O
responsibility None None O
when None None O
they None None O
viewed None None O
the None None O
overweight None None O
plaintiff None None O
compared None None O
to None None O
the None None O
thin None None O
plaintiff None None O
. None None O

The None None O
weight None None O
of None None O
a None None O
plaintiff None None O
may None None O
affect None None O
juror None None O
perceptions None None I-FUNC
of None None O
personal None None O
responsibility None None O
particularly None None O
if None None O
the None None O
juror None None O
possesses None None O
self-reported None None O
weight None None O
bias None None O
. None None O

Following None None O
drug None None O
withdrawl None None O
, None None O
the None None O
morphological None None O
changes None None O
of None None O
the None None O
frontal None None I-REGION
lobe None None I-REGION
cells None None O
were None None O
examined None None O
by None None O
hematoxylin None None O
and None None O
eosin None None O
( None None O
H None None O
& None None O
amp None None O
; None None O
E None None O
) None None O
staining None None O
. None None O

Reverse None None O
transcription‑polymerase None None O
chain None None O
reaction None None O
( None None O
RT‑PCR None None O
) None None O
and None None O
western None None O
blotting None None O
methods None None O
were None None O
applied None None O
to None None O
detect None None O
the None None O
mRNA None None O
and None None O
protein None None O
expression None None O
levels None None O
of None None O
Bcl‑2 None None O
and None None O
Bax None None O
, None None O
respectively None None O
, None None O
in None None O
the None None O
frontal None None I-REGION
lobe None None I-REGION
. None None O

In None None O
the None None O
present None None O
work None None O
, None None O
we None None O
developed None None O
NanoLuc None None O
as None None O
a None None O
sensitive None None O
bioluminescent None None O
reporter None None O
to None None O
measure None None O
quantitatively None None O
the None None O
internalization None None O
of None None O
cell None None O
membrane None None O
receptors None None I-PROTEIN
, None None O
based None None O
on None None O
the None None O
pH None None O
dependence None None O
of None None O
the None None O
reporter None None O
activity None None O
. None None O

The None None O
authors None None O
' None None O
institution None None O
previously None None O
reported None None O
a None None O
69 None None O
% None None O
rate None None O
of None None O
crude None None O
local None None O
control None None O
for None None O
surgical None None O
management None None O
of None None O
lateral None None I-REGION
ventricle None None I-REGION
metastases None None O
at None None O
the None None O
University None None O
of None None O
Texas None None O
MD None None O
Anderson None None O
Cancer None None O
Center None None O
. None None O

Most None None O
lesions None None O
were None None O
located None None O
in None None O
the None None O
lateral None None I-REGION
ventricles None None I-REGION
( None None O
n None None O
= None None O
25 None None O
, None None O
83.3 None None O
% None None O
) None None O
and None None O
were None None O
treated None None O
to None None O
a None None O
median None None O
dose None None O
of None None O
20 None None O
Gy None None O
( None None O
range None None O
14-20 None None O
Gy None None O
) None None O
. None None O

The None None O
Philips None None O
Pinnacle None None O
( None None O
version None None O
9.2 None None O
) None None O
program None None O
was None None O
used None None O
for None None O
planning None None O
of None None O
VMAS None None O
, None None O
using None None O
the None None O
SmartArc None None O
optimization None None O
algorithm None None O
for None None O
delivery None None O
on None None O
a None None O
Varian None None O
iX None None I-REGION
linear None None O
accelerator None None O
. None None O

The None None O
authors None None O
reviewed None None O
the None None O
radiological None None O
data None None O
and None None O
clinical None None O
records None None O
for None None O
14 None None O
patients None None O
who None None O
had None None O
consecutively None None O
undergone None None O
GKS None None O
for None None O
a None None O
facial None None I-REGION
nerve None None I-REGION
schwannoma None None O
. None None O

After None None O
GKS None None O
, None None O
facial None None I-REGION
nerve None None I-REGION
function None None O
improved None None O
in None None O
2 None None O
patients None None O
, None None O
remained None None O
unchanged None None O
in None None O
9 None None O
patients None None O
, None None O
and None None O
worsened None None O
in None None O
3 None None O
patients None None O
. None None O

GKS None None O
might None None O
be None None O
a None None O
good None None O
primary None None O
treatment None None O
option None None O
for None None O
patients None None O
with None None O
a None None O
small- None None O
to None None O
medium-sized None None O
facial None None I-REGION
nerve None None I-REGION
schwannoma None None O
when None None O
facial None None I-REGION
nerve None None I-REGION
function None None O
and None None O
hearing None None O
are None None O
relatively None None O
preserved None None O
. None None O

Neuroimaging None None O
analyses None None O
indicated None None O
tumor None None O
growth None None O
in None None O
42 None None O
patients None None O
, None None O
hydrocephalus None None I-DISEASE
in None None O
10 None None O
patients None None O
with None None O
vestibular None None O
schwannoma None None O
, None None O
cystic None None O
formation None None O
with None None O
mass None None O
effect None None O
in None None O
7 None None O
patients None None O
, None None O
and None None O
tumor None None O
hemorrhage None None O
in None None O
13 None None O
patients None None O
, None None O
of None None O
whom None None O
10 None None O
had None None O
pituitary None None O
adenoma None None O
. None None O

From None None O
2006 None None O
through None None O
2011 None None O
, None None O
the None None O
authors None None O
conducted None None O
a None None O
retrospective None None O
review None None O
of None None O
106 None None O
cases None None O
of None None O
primary None None O
or None None O
secondary None None O
trigeminal None None O
neuralgia None None O
consecutively None None O
treated None None O
with None None O
GKS None None O
targeting None None O
the None None O
dorsal None None I-NEURON
root None None O
entry None None O
zone None None O
( None None O
DREZ None None O
) None None O
for None None O
which None None O
a None None O
maximal None None O
dose None None O
of None None O
90 None None O
Gy None None O
and None None O
a None None O
20 None None O
% None None O
isodose None None O
line None None O
to None None O
the None None O
brainstem None None I-REGION
were None None O
used None None O
. None None O

To None None O
evaluate None None O
individual None None O
anatomical None None O
variations None None O
among None None O
trigeminal None None I-REGION
nerves None None I-REGION
, None None O
the None None O
authors None None O
used None None O
3 None None O
parameters None None O
: None None O
the None None O
length None None O
of None None O
the None None O
trigeminal None None I-REGION
nerve None None I-REGION
in None None O
the None None O
cistern None None O
( None None O
nerve None None O
length None None O
) None None O
, None None O
the None None O
length None None O
of None None O
the None None O
target None None O
between None None O
the None None O
radiation None None O
shot None None O
and None None O
the None None O
brainstem None None I-REGION
( None None O
targeting None None O
length None None O
) None None O
, None None O
and None None O
the None None O
ratio None None O
between None None O
nerve None None O
length None None O
and None None O
targeting None None O
length None None O
( None None O
targeting None None O
ratio None None O
) None None O
. None None O

After None None O
treating None None O
cells None None O
with None None O
bortezomib None None O
or None None O
dexamethasone None None O
, None None O
the None None O
expression None None O
of None None O
PGC-1α None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
2 None None O
( None None O
SOD-2 None None O
) None None O
and None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
was None None O
examined None None O
by None None O
RT-PCR None None O
. None None O

To None None O
study None None O
the None None O
mechanism None None O
of None None O
gene None None O
transcription None None I-PROTEIN
regulation None None I-PROTEIN
by None None O
response None None O
regulator None None O
PhoP None None O
, None None O
we None None O
identified None None O
a None None O
high-affinity None None O
DNA None None O
sequence None None O
for None None O
PhoP None None O
binding None None O
using None None O
systematic None None O
evolution None None O
of None None O
ligands None None O
by None None O
exponential None None O
enrichment None None O
. None None O

The None None O
artificial None None O
pancreas None None O
is None None O
an None None O
emerging None None O
technology None None O
for None None O
the None None O
treatment None None O
of None None O
type None None O
1 None None O
diabetes None None O
and None None O
two None None O
configurations None None O
have None None O
been None None O
proposed None None O
: None None O
single-hormone None None O
( None None O
insulin None None I-PROTEIN
alone None None O
) None None O
and None None O
dual-hormone None None O
( None None O
insulin None None I-PROTEIN
and None None O
glucagon None None I-TRANS
) None None O
. None None O

We None None O
did None None O
a None None O
randomised None None O
crossover None None O
trial None None O
of None None O
dual-hormone None None O
artificial None None O
pancreas None None O
, None None O
single-hormone None None O
artificial None None O
pancreas None None O
, None None O
and None None O
conventional None None O
insulin None None I-PROTEIN
pump None None O
therapy None None O
( None None O
continuous None None O
subcutaneous None None O
insulin None None I-PROTEIN
infusion None None O
) None None O
in None None O
participants None None O
aged None None O
12 None None O
years None None O
or None None O
older None None O
with None None O
type None None O
1 None None O
diabetes None None O
. None None O

During None None O
visits None None O
when None None O
the None None O
patient None None O
used None None O
the None None O
single-hormone None None O
artificial None None O
pancreas None None O
, None None O
insulin None None I-PROTEIN
was None None O
delivered None None O
based None None O
on None None O
glucose None None O
sensor None None O
readings None None O
and None None O
a None None O
predictive None None O
dosing None None O
algorithm None None O
. None None O

During None None O
conventional None None O
insulin None None I-PROTEIN
pump None None O
therapy None None O
visits None None O
, None None O
patients None None O
received None None O
continuous None None O
subcutaneous None None O
insulin None None I-PROTEIN
infusion None None O
. None None O

The None None O
mean None None O
difference None None O
in None None O
time None None O
spent None None O
in None None O
the None None O
target None None O
range None None O
between None None O
single-hormone None None O
artificial None None O
pancreas None None O
and None None O
conventional None None O
insulin None None I-PROTEIN
pump None None O
therapy None None O
was None None O
11 None None O
% None None O
( None None O
17 None None O
; None None O
p=0·002 None None O
) None None O
and None None O
between None None O
dual-hormone None None O
artificial None None O
pancreas None None O
and None None O
conventional None None O
insulin None None I-PROTEIN
pump None None O
therapy None None O
was None None O
12 None None O
% None None O
( None None O
21 None None O
; None None O
p=0·00011 None None O
) None None O
. None None O

There None None O
were None None O
52 None None O
hypoglycaemic None None O
events None None O
with None None O
conventional None None O
insulin None None I-PROTEIN
pump None None O
therapy None None O
( None None O
12 None None O
of None None O
which None None O
were None None O
symptomatic None None O
) None None O
, None None O
13 None None O
with None None O
the None None O
single-hormone None None O
artificial None None O
pancreas None None O
( None None O
five None None O
of None None O
which None None O
were None None O
symptomatic None None O
) None None O
, None None O
and None None O
nine None None O
with None None O
the None None O
dual-hormone None None O
artificial None None O
pancreas None None O
( None None O
0 None None O
of None None O
which None None O
were None None O
symptomatic None None O
) None None O
; None None O
the None None O
number None None O
of None None O
nocturnal None None O
hypoglycaemic None None O
events None None O
was None None O
13 None None O
( None None O
0 None None O
symptomatic None None O
) None None O
, None None O
0 None None O
, None None O
and None None O
0 None None O
, None None O
respectively None None O
. None None O

This None None O
original None None O
expression None None O
panel None None O
of None None O
human None None O
placental None None O
drug None None O
transporters None None I-PROTEIN
should None None O
help None None O
to None None O
understand None None O
transplacental None None O
drug None None O
transfer None None O
and None None O
to None None O
ensure None None O
more None None O
rational None None O
drug None None O
use None None O
during None None O
pregnancy None None O
. None None O

To None None O
compare None None O
the None None O
cognitive None None O
profiles None None O
of None None O
AJ None None O
with None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
with None None O
and None None O
without None None O
LRRK2 None None O
G2019S None None O
mutations None None O
using None None O
a None None O
comprehensive None None O
neuropsychological None None O
battery None None O
. None None O

The None None O
association None None O
between None None O
G2019S None None O
mutation None None O
status None None O
( None None O
predictor None None O
) None None O
and None None O
each None None O
neuropsychological None None O
test None None O
( None None O
outcome None None O
) None None O
was None None O
assessed None None O
using None None O
linear None None O
regression None None O
models None None O
adjusted None None O
for None None O
PIGD None None O
motor None None O
phenotype None None O
, None None O
site None None O
, None None O
sex None None O
, None None O
age None None O
, None None O
disease None None O
duration None None O
, None None O
education None None O
, None None O
Unified None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Rating None None O
Scale None None O
( None None O
UPDRS None None O
) None None O
Part None None O
III None None O
, None None O
levodopa None None O
equivalent None None O
dose None None O
, None None O
and None None O
Geriatric None None O
Depression None None I-DISEASE
Score None None O
( None None O
GDS None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
the None None O
rapid None None O
improvement None None O
of None None O
a None None O
primary None None O
hit None None O
against None None O
matrix None None I-PROTEIN
metalloproteinase-14 None None O
using None None O
this None None O
approach None None O
. None None O

In None None O
addition None None O
to None None O
its None None O
conventional None None O
transcription None None I-PROTEIN
regulation None None I-PROTEIN
activity None None O
in None None O
the None None O
nucleus None None O
, None None O
RXRα None None O
can None None O
act None None O
in None None O
the None None O
cytoplasm None None O
to None None O
modulate None None O
important None None O
biological None None O
processes None None O
, None None O
such None None O
as None None O
mitochondria-dependent None None O
apoptosis None None O
, None None O
inflammation None None O
, None None O
and None None O
phosphatidylinositol None None O
3-kinase None None O
( None None O
PI3K None None O
) None None O
/AKT-mediated None None O
cell None None O
survival None None O
. None None O

Dielectric None None O
barrier None None O
discharge None None O
( None None O
DBD None None O
) None None O
devices None None O
generate None None O
air None None O
plasma None None O
above None None O
the None None O
skin None None O
containing None None O
active None None O
and None None O
reactive None None O
species None None O
including None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
. None None O

First None None O
, None None O
visceral None None O
adiposity None None O
, None None O
leptin None None O
, None None O
insulin None None I-PROTEIN
, None None O
and None None O
angiotensin None None O
II None None O
have None None O
been None None O
identified None None O
as None None O
potential None None O
culprits None None O
in None None O
obesity-induced None None O
sympathoexcitation None None O
in None None O
males None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
baicalein None None O
has None None O
potential None None O
for None None O
use None None O
as None None O
a None None O
therapeutic None None O
drug None None O
for None None O
the None None O
treatment None None O
of None None O
various None None O
neurodegenerative None None O
diseases None None O
, None None O
including None None O
prion None None I-DISEASE
diseases None None I-DISEASE
. None None O

Disease None None O
modifying None None O
functions None None O
may None None O
also None None O
complement None None O
analgesic None None O
and None None O
anti-spastic None None O
effects None None O
of None None O
cannabis None None O
, None None O
its None None O
constituents None None O
, None None O
and None None O
of None None O
'endocannabinoid None None O
enhancing None None O
' None None O
drugs None None O
or None None O
nutricals None None O
like None None O
inhibitors None None O
of None None O
fatty None None O
acid None None O
amide None None O
hydrolase None None I-PROTEIN
. None None O

Stable None None O
nanomimics-polymersomes None None O
presenting None None O
receptors None None I-PROTEIN
required None None O
for None None O
parasite None None O
attachment None None O
to None None O
host None None O
cells-were None None O
designed None None O
to None None O
efficiently None None O
interrupt None None O
the None None O
life None None O
cycle None None O
of None None O
the None None O
parasite None None O
by None None O
inhibiting None None O
invasion None None O
. None None O

They None None O
exhibited None None O
efficacies None None O
of None None O
more None None O
than None None O
2 None None O
orders None None O
of None None O
magnitude None None O
higher None None O
than None None O
the None None O
soluble None None O
form None None O
of None None O
the None None O
receptor None None I-PROTEIN
, None None O
which None None O
can None None O
be None None O
explained None None O
by None None O
multivalent None None O
interactions None None O
of None None O
several None None O
receptors None None I-PROTEIN
on None None O
one None None O
nanomimic None None O
with None None O
multiple None None O
ligands None None O
on None None O
the None None O
infective None None O
parasite None None O
. None None O

PE None None O
directly None None O
reduced None None O
the None None O
enzyme None None O
activity None None O
of None None O
tyrosinase None None I-PROTEIN
in None None O
a None None O
cell-free None None O
assay None None O
. None None O

The None None O
redesigning None None O
of None None O
industrially None None O
useful None None O
enzymes None None I-PROTEIN
for None None O
improving None None O
their None None O
performance None None O
has None None O
become None None O
a None None O
challenge None None O
because None None O
bioinformatics None None O
databases None None O
have None None O
been None None O
revealing None None O
new None None O
facts None None O
on None None O
a None None O
day-to-day None None O
basis None None O
. None None O

Hydrolases None None I-PROTEIN
are None None O
employed None None O
in None None O
pharmaceutical None None O
, None None O
biofuel None None O
, None None O
detergent None None O
, None None O
food None None O
and None None O
feed None None O
industries None None O
that None None O
significantly None None O
contribute None None O
to None None O
the None None O
global None None O
annual None None O
revenue None None O
, None None O
and None None O
therefore None None O
, None None O
the None None O
emphasis None None O
has None None O
been None None O
on None None O
engineering None None O
them None None O
. None None O

This None None O
review None None O
focuses None None O
on None None O
the None None O
recent None None O
developments None None O
in None None O
improving None None O
the None None O
characteristics None None O
of None None O
various None None O
biotechnologically None None O
important None None O
enzymes None None I-PROTEIN
. None None O

Compared None None O
to None None O
their None None O
naïve None None O
T None None O
cell None None O
counterparts None None O
, None None O
memory None None I-FUNC
T None None O
cells None None O
possess None None O
unique None None O
characteristics None None O
that None None O
endow None None O
them None None O
with None None O
the None None O
ability None None O
to None None O
quickly None None O
and None None O
robustly None None O
respond None None O
to None None O
foreign None None O
antigens None None O
. None None O

Significant None None O
progress None None O
has None None O
been None None O
made None None O
over None None O
the None None O
past None None O
several None None O
decades None None O
contributing None None O
to None None O
our None None O
understanding None None O
of None None O
memory None None I-FUNC
T None None O
cell None None O
generation None None O
, None None O
their None None O
distinct None None O
biology None None O
, None None O
and None None O
their None None O
detrimental None None O
impact None None O
in None None O
clinical None None O
and None None O
animal None None O
models None None O
of None None O
transplantation None None O
. None None O

Formation None None O
and None None O
properties None None O
of None None O
Langmuir None None O
films None None O
of None None O
thiacalix None None O
[ None None O
4 None None O
] None None O
arene None None O
( None None O
TCA None None O
) None None O
derivatives None None O
containing None None O
N-donor None None O
groups None None O
on None None O
the None None O
lower None None O
rim None None O
( None None O
Y═O None None O
( None None O
CH2 None None O
) None None O
3CN None None O
; None None O
OCH2CN None None O
; None None O
NH2 None None I-TRANS
; None None O
OCH2ArCN-p None None O
) None None O
in None None O
1,3-alternate None None O
conformation None None O
on None None O
aqueous None None O
subphase None None O
and None None O
solid None None O
substrates None None O
have None None O
been None None O
studied None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
A549 None None O
cells None None O
were None None O
treated None None O
with None None O
different None None O
concentrations None None O
of None None O
Wnt1 None None O
and None None O
the None None O
results None None O
indicated None None O
that None None O
the None None O
mRNA None None O
and None None O
protein None None O
expression None None O
levels None None O
of None None O
vimentin None None O
, None None O
α‑smooth None None O
muscle None None O
actin None None I-PROTEIN
( None None O
α‑SMA None None O
) None None O
and None None O
collagen None None I-PROTEIN
Ⅰ None None O
gradully None None O
increased None None O
and None None O
those None None O
of None None O
E‑cadherin None None O
gradully None None O
decreased None None O
in None None O
a None None O
concentration‑dependent None None O
manner None None O
. None None O

The None None O
mRNA None None O
and None None O
protein None None O
expression None None O
levels None None O
of None None O
of None None O
vimentin None None O
, None None O
α‑SMA None None O
and None None O
collagen None None I-PROTEIN
Ⅰ None None O
increased None None O
significantly None None O
, None None O
whereas None None O
those None None O
of None None O
E‑cadherin None None O
decreased None None O
significantly None None O
. None None O

Bronchoalveolar None None O
fluid None None O
was None None O
obtained None None O
7 None None O
days None None O
after None None O
treatment None None O
with None None O
bleomycin None None O
and None None O
the None None O
A549 None None O
cells None None O
were None None O
incubated None None O
for None None O
48 None None O
h. None None O
An None None O
increase None None O
in None None O
the None None O
expression None None O
levels None None O
of None None O
the None None O
mesenchymal None None O
markers None None O
, None None O
α‑SMA None None O
, None None O
vimentin None None O
and None None O
collagen None None I-PROTEIN
Ⅰ None None O
, None None O
and None None O
a None None O
concomitant None None O
decrease None None O
in None None O
the None None O
expression None None O
of None None O
the None None O
epithelial None None O
marker None None O
, None None O
E‑cadherin None None O
were None None O
observed None None O
. None None O

In None None O
the None None O
second None None O
part None None O
of None None O
this None None O
study None None O
, None None O
different None None O
supervised None None O
machine None None O
learning None None I-FUNC
( None None O
ML None None O
) None None O
techniques None None O
were None None O
investigated None None O
, None None O
including None None O
k-nearest None None O
neighbour None None O
( None None O
KNN None None O
) None None O
, None None O
random None None O
forest None None O
( None None O
RF None None O
) None None O
and None None O
support None None O
vector None None O
machines None None O
with None None O
linear None None O
( None None O
SVML None None O
) None None O
and None None O
radial None None O
basis None None O
function None None O
kernels None None O
( None None O
SVMR None None O
) None None O
. None None O

Several None None O
studies None None O
have None None O
shown None None O
that None None O
glycine None None I-TRANS
transporter None None O
1 None None O
( None None O
GlyT1 None None O
) None None O
inhibitors None None O
have None None O
anxiolytic None None O
actions None None O
. None None O

Here None None O
, None None O
we None None O
clarified None None O
which None None O
glycine None None I-TRANS
receptor None None I-PROTEIN
is None None O
the None None O
main None None O
contributor None None O
to None None O
the None None O
anxiolytic None None O
effects None None O
of None None O
GlyT1 None None O
inhibitors None None O
by None None O
using None None O
maternal None None O
separation-induced None None O
ultrasonic None None O
vocalization None None O
( None None O
USV None None O
) None None O
by None None O
rat None None O
pups None None O
as None None O
an None None O
index None None O
of None None O
anxiety None None O
. None None O

To None None O
systematically None None O
review None None O
musculoskeletal None None O
physiotherapists None None O
' None None O
perceptions None None I-FUNC
regarding None None O
the None None O
use None None O
of None None O
psychological None None O
interventions None None O
within None None O
physiotherapy None None O
practice None None O
. None None O

Full None None O
text None None O
qualitative None None O
, None None O
quantitative None None O
and None None O
mixed None None O
methodology None None O
studies None None O
published None None O
in None None O
English None None O
language None None I-FUNC
investigating None None O
musculoskeletal None None O
physiotherapists None None O
' None None O
perceptions None None I-FUNC
regarding None None O
their None None O
use None None O
of None None O
psychological None None O
interventions None None O
within None None O
physiotherapy None None O
practice None None O
. None None O

The None None O
role None None O
of None None O
limbic/prefrontal/striatal None None O
circuitry None None O
in None None O
behavioral None None O
activation None None O
and None None O
effort-related None None O
functions None None O
is None None O
examined None None O
, None None O
and None None O
the None None O
utility None None O
of None None O
behavioral None None O
tasks None None O
of None None O
effort-based None None O
decision None None I-FUNC
making None None I-FUNC
as None None O
models None None O
of None None O
motivational None None O
symptoms None None O
is None None O
discussed None None O
. None None O

In None None O
this None None O
study None None O
, None None O
155 None None O
PD None None O
patients None None O
without None None O
dementia None None I-DISEASE
or None None O
cognitive None None O
impairment None None O
underwent None None O
: None None O
i. None None O
the None None O
ICD None None O
diagnoses None None O
, None None O
using None None O
the None None O
Questionnaire None None O
for None None O
Impulsive-Compulsive None None O
Disorders None None O
, None None O
ii None None O
. None None O

Lipoxygenases None None O
form None None O
a None None O
family None None O
of None None O
lipid None None O
peroxidizing None None O
enzymes None None I-PROTEIN
and None None O
human None None O
lipoxygenase None None O
isoforms None None O
have None None O
been None None O
implicated None None O
in None None O
the None None O
pathogenesis None None O
of None None O
inflammatory None None O
, None None O
hyperproliferative None None O
( None None O
cancer None None O
) None None O
and None None O
neurodegenerative None None O
diseases None None O
. None None O

In None None O
this None None O
review None None O
we None None O
are None None O
summarizing None None O
the None None O
current None None O
knowledge None None O
on None None O
the None None O
distribution None None O
of None None O
lipoxygenases None None O
in None None O
living None None O
single None None O
and None None O
multicellular None None O
organisms None None O
with None None O
particular None None O
emphasis None None O
to None None O
higher None None O
vertebrates None None O
and None None O
will None None O
also None None O
focus None None O
on None None O
the None None O
genetic None None O
diversity None None O
of None None O
enzymes None None I-PROTEIN
and None None O
receptors None None I-PROTEIN
involved None None O
in None None O
human None None O
leukotriene None None O
signaling None None O
. None None O

Depression None None I-DISEASE
and None None O
health-related None None O
quality None None O
of None None O
life None None O
( None None O
HRQL None None O
) None None O
were None None O
assessed None None O
among None None O
the None None O
three None None O
groups None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
severity None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
increased None None O
in None None O
Group None None O
I None None O
as None None O
compared None None O
to None None O
the None None O
other None None O
two None None O
groups None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Prior None None O
parental None None O
discipline None None O
, None None O
including None None O
corporal None None O
punishment None None O
( None None O
B=0.55 None None O
, None None O
P=.008 None None O
) None None O
, None None O
as None None O
well None None O
as None None O
the None None O
frequency None None O
( None None O
B=0.73 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
duration None None O
of None None O
punishment None None O
( None None O
B=0.33 None None O
, None None O
P=.02 None None O
) None None O
were None None O
strong None None O
predictors None None O
of None None O
increased None None O
depressive None None I-DISEASE
symptom None None I-DISEASE
severity None None O
. None None O

Children None None O
develop None None O
distinct None None O
morbidities None None O
related None None O
to None None O
the None None O
off-target None None O
effects None None O
of None None O
tyrosine None None I-TRANS
kinase None None O
inhibitors None None O
. None None O

The None None O
treatment None None O
of None None O
retinoblastoma None None O
is None None O
multidisciplinary None None O
and None None O
is None None O
designed None None O
primarily None None O
to None None O
save None None O
life None None O
and None None O
preserve None None O
vision None None I-FUNC
. None None O

Intravenous None None O
thrombolysis None None O
for None None O
ischaemic None None O
stroke None None I-DISEASE
remains None None O
underused None None O
worldwide None None O
. None None O

In None None O
2008-09 None None O
, None None O
we None None O
designed None None O
the None None O
Tyrol None None O
Stroke None None I-DISEASE
Pathway None None O
, None None O
which None None O
provided None None O
information None None O
campaigns None None O
for None None O
the None None O
public None None O
and None None O
standardised None None O
the None None O
entire None None O
treatment None None O
pathway None None O
from None None O
stroke None None I-DISEASE
onset None None O
to None None O
outpatient None None O
rehabilitation None None O
. None None O

We None None O
hope None None O
that None None O
these None None O
results None None O
will None None O
guide None None O
health None None O
authorities None None O
and None None O
stroke None None I-DISEASE
physicians None None O
elsewhere None None O
when None None O
implementing None None O
similar None None O
programmes None None O
for None None O
patients None None O
with None None O
stroke None None I-DISEASE
. None None O

The None None O
appearance None None O
of None None O
different None None O
types None None O
of None None O
SD None None O
was None None O
more None None O
pronounced None None O
in None None O
the None None O
lowering None None O
phase None None O
than None None O
in None None O
the None None O
raising None None O
phase None None O
of None None O
arm None None O
movements None None I-FUNC
. None None O

The None None O
RRCB None None O
proved None None O
to None None O
be None None O
feasible None None O
and None None O
accepted None None O
( None None O
86 None None O
% None None O
retention None None I-FUNC
, None None O
28 None None O
out None None O
of None None O
24 None None O
completers None None O
) None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
IL-1β-induced None None O
memory None None I-FUNC
impairment None None O
in None None O
brain None None O
is None None O
mediated None None O
by None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
( None None O
H2S None None I-TRANS
) None None O
synthesized None None O
by None None O
cystathionine None None O
beta-synthase None None O
( None None O
CBS None None O
) None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
a None None O
series None None O
of None None O
novel None None O
highly None None O
functionalized None None O
spiropyrrolidine-oxindoles None None O
have None None O
been None None O
synthesized None None O
through None None O
1,3-dipolar None None O
cycloaddition None None O
of None None O
an None None O
azomethine None None O
ylide None None O
formed None None O
from None None O
isatin None None O
and None None O
various None None O
amino None None I-TRANS
acids None None I-TRANS
such None None O
as None None O
sarcosine None None O
, None None O
proline None None I-TRANS
and None None O
thioproline None None O
with None None O
the None None O
dipolarophile None None O
( None None O
E None None O
) None None O
-3- None None O
( None None O
1,3-diphenyl-1H-pyrazol-4-yl None None O
) None None O
-2- None None O
( None None O
1H-indole-3-carbonyl None None O
) None None O
acrylonitrile None None O
under None None O
optimized None None O
conditions None None O
. None None O

The None None O
kharif None None O
, None None O
rabi None None O
and None None O
net None None O
sown None None O
area None None O
were None None O
aggregated None None O
at None None O
10 None None O
km None None O
× None None O
10 None None O
km None None O
grid None None O
on None None O
annual None None O
basis None None O
for None None O
entire None None O
India None None O
and None None O
CV None None O
was None None O
computed None None O
at None None O
each None None O
grid None None I-NEURON
cell None None I-NEURON
using None None O
temporal None None O
spatially-aggregated None None O
area None None O
as None None O
input None None O
. None None O

After None None O
measurement None None O
of None None O
auditory None None O
brainstem None None I-REGION
responses None None O
( None None O
ABRs None None O
) None None O
, None None O
the None None O
animals None None O
were None None O
sacrificed None None O
3 None None O
weeks None None O
after None None O
packing None None O
placement None None O
for None None O
histological None None O
observation None None O
. None None O

All None None O
patients None None O
were None None O
treated None None O
by None None O
prednisolone None None O
alone None None O
, None None O
and None None O
their None None O
facial None None I-REGION
nerve None None I-REGION
recovered None None O
to None None O
HB None None O
grade None None O
I None None O
after None None O
3 None None O
weeks None None O
to None None O
2 None None O
months None None O
without None None O
any None None O
sequelae None None O
. None None O

In None None O
the None None O
EMA None None O
description None None O
the None None O
nanowire None None O
DOS None None O
is None None O
rendered None None O
as None None O
a None None O
series None None O
of None None O
sharply None None O
rising None None O
peaks None None O
having None None O
slowly None None O
decaying None None O
tails None None O
, None None O
with None None O
characteristic None None O
peak None None O
height None None O
and None None O
spacing None None O
, None None O
all None None O
being None None O
classifiable None None O
in None None O
the None None O
language None None I-FUNC
of None None O
atomic None None O
orbital None None O
momenta None None O
1S None None O
, None None O
1P None None O
, None None O
1D None None O
, None None O
etc None None O
. None None O

Since None None O
2000 None None O
sirtuins None None O
( None None O
SIRT1-7 None None O
) None None O
have None None O
gained None None O
growing None None O
attention None None I-FUNC
for None None O
their None None O
connections None None O
with None None O
many None None O
biological None None O
processes None None O
such None None O
as None None O
cellular None None O
metabolism None None O
regulation None None O
, None None O
neuroprotection None None O
, None None O
apoptosis None None O
, None None O
inflammation None None O
, None None O
and None None O
cancer None None O
progression None None O
. None None O

Accordingly None None O
, None None O
this None None O
study None None O
investigated None None O
visual None None O
function None None O
and None None O
color None None O
perception None None I-FUNC
in None None O
adolescents None None O
with None None O
ADHD None None O
using None None O
color None None O
Visual None None O
Evoked None None O
Potentials None None O
( None None O
cVEP None None O
) None None O
, None None O
which None None O
provides None None O
an None None O
objective None None O
measure None None O
of None None O
color None None O
perception None None I-FUNC
. None None O

Background None None O
Patterns None None O
of None None O
population None None O
susceptibility None None O
to None None O
sexually None None O
transmissible None None O
infections None None O
may None None O
be None None O
influenced None None O
by None None O
various None None O
social None None O
determinants None None O
of None None O
health None None O
, None None O
however None None O
these None None O
receive None None O
relatively None None O
little None None O
attention None None I-FUNC
. None None O

The None None O
effects None None O
of None None O
CGE None None O
on None None O
the None None O
phosphatidylinositol None None O
3‑kinase None None O
( None None O
PI3K None None O
) None None O
/Akt None None O
pathway None None O
and None None O
mitogen‑activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
) None None O
were None None O
assessed None None O
by None None O
immunoblotting None None O
. None None O

Each None None O
group None None O
consisted None None O
of None None O
24 None None O
rats None None O
and None None O
each None None O
group None None O
was None None O
divided None None O
into None None O
four None None O
subgroups None None O
according None None O
to None None O
the None None O
indicated None None O
reperfusion None None O
times None None O
of None None O
12 None None O
, None None O
24 None None O
, None None O
48 None None O
and None None O
72 None None O
h. None None O
The None None O
morphological None None O
changes None None O
of None None O
the None None O
cortical None None O
tissue None None O
and None None O
the None None O
cellular None None O
apoptosis None None O
were None None O
determined None None O
using None None O
hematoxylin None None O
and None None O
eosin None None O
staining None None O
and None None O
the None None O
terminal None None O
deoxynucleotidyl None None O
transferase None None I-PROTEIN
dUTP None None O
nick None None O
end None None O
labeling None None O
method None None O
, None None O
respectively None None O
. None None O

Subsequently None None O
, None None O
we None None O
demonstrated None None O
that None None O
overexpression None None O
of None None O
CRY1 None None O
inhibited None None O
the None None O
basal None None O
concentration None None O
of None None O
cyclic None None O
adenosine None None I-TRANS
monophosphate None None O
( None None O
cAMP None None O
) None None O
, None None O
leading None None O
to None None O
decreased None None O
protein None None O
kinase None None O
A None None O
activity None None O
, None None O
which None None O
resulted None None O
in None None O
decreased None None O
phosphorylation None None O
of None None O
p65 None None O
. None None O

Secondary None None O
end None None O
points None None O
reported None None O
included None None O
VMA None None O
release None None O
over None None O
time None None O
, None None O
total None None O
posterior None None O
vitreous None None O
detachment None None O
( None None O
PVD None None O
) None None O
, None None O
change None None O
in None None O
visual None None O
acuity None None O
from None None O
baseline None None O
, None None O
and None None O
number None None O
of None None O
anti-vascular None None O
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
injections None None O
. None None O

This None None O
approach None None O
, None None O
analyte None None O
retention None None I-FUNC
and None None O
matrix None None O
removal None None O
, None None O
enabled None None O
the None None O
assessment None None O
of None None O
iron None None O
( None None O
III None None O
) None None O
and None None O
total None None O
iron None None O
content None None O
in None None O
fresh None None O
waters None None O
and None None O
high None None O
salinity None None O
coastal None None O
waters None None O
with None None O
direct None None O
sample None None O
introduction None None O
, None None O
in None None O
the None None O
range None None O
of None None O
20.0-100 None None O
µg/L None None O
. None None O

The None None O
study None None O
allowed None None O
us None None O
to None None O
identify None None O
some None None O
potent None None O
5-HT1A None None O
receptor None None I-PROTEIN
ligands None None O
with None None O
additional None None O
moderate None None O
affinity None None O
for None None O
5-HT2A None None O
, None None O
5-HT7 None None O
and None None O
dopamine None None I-TRANS
D2 None None O
receptors None None I-PROTEIN
. None None O

Compounds None None O
9 None None O
, None None O
12 None None O
and None None O
13 None None O
showed None None O
features None None O
of None None O
agonists None None O
of None None O
pre- None None O
and/or None None O
post-synaptic None None O
5-HT1A None None O
receptors None None I-PROTEIN
, None None O
whereas None None O
14 None None O
was None None O
classified None None O
as None None O
an None None O
antagonist None None O
of None None O
postsynaptic None None O
sites None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
most None None O
neutropenic None None O
children None None O
need None None O
neither None None O
antibiotic None None O
prophylaxis None None O
nor None None O
extensive None None O
medical None None O
attention None None I-FUNC
. None None O

The None None O
valence None None O
of None None O
the None None O
stimuli None None O
( None None O
positive None None O
, None None O
negative None None O
and None None O
neutral None None O
words None None O
that None None O
could None None O
be None None O
either None None O
semantically None None O
related None None O
or None None O
unrelated None None O
) None None O
as None None O
well None None O
as None None O
the None None O
type None None O
of None None O
encoding None None I-FUNC
task None None O
( None None O
focused None None O
on None None O
either None None O
familiarity None None O
or None None O
emotionality None None O
) None None O
was None None O
manipulated None None O
. None None O

Importantly None None O
, None None O
this None None O
advantage None None O
was None None O
modulated None None O
by None None O
the None None O
encoding None None I-FUNC
task None None O
, None None O
as None None O
it None None O
was None None O
reliable None None O
only None None O
in None None O
the None None O
task None None O
which None None O
focused None None O
on None None O
emotionality None None O
. None None O

In None None O
this None None O
work None None O
we None None O
demonstrate None None O
for None None O
the None None O
first None None O
time None None O
that None None O
GH- None None O
and None None O
secretoneurin None None O
( None None O
SN None None O
) None None O
immunoreactivity None None O
( None None O
the None None O
secretogranin None None O
II None None O
( None None O
SgII None None O
) None None O
fragment None None O
) None None O
are None None O
similarly None None O
present None None O
in None None O
retinal None None O
ganglion None None I-NEURON
cells None None I-NEURON
( None None O
RGCs None None O
) None None O
, None None O
which None None O
is None None O
an None None O
extrapituitary None None O
site None None O
of None None O
GH None None O
expression None None O
, None None O
and None None O
in None None O
quail None None O
QNR/D None None O
cells None None O
, None None O
which None None O
provide None None O
an None None O
experimental None None O
RGC None None O
model None None O
. None None O

To None None O
this None None O
end None None O
, None None O
immature None None O
Atlantic None None O
salmon None None O
postsmolts None None O
received None None O
testosterone None None O
( None None O
T None None O
) None None O
, None None O
adrenosterone None None O
( None None O
OA None None O
, None None O
which None None O
is None None O
converted None None O
in None None O
vivo None None O
into None None O
11-ketotestosterone None None O
, None None O
11-KT None None O
) None None O
or None None O
a None None O
combination None None O
of None None O
the None None O
two None None O
androgens None None I-PROTEIN
( None None O
T+OA None None O
) None None O
. None None O

Both None None O
androgens None None I-PROTEIN
down-regulated None None O
testicular None None O
amh None None O
and None None O
increased None None O
igf3 None None O
transcript None None O
levels None None O
after None None O
1 None None O
week None None O
of None None O
treatment None None O
, None None O
but None None O
effects None None O
on None None O
growth None None O
factor None None O
gene None None O
expression None None O
required None None O
sustained None None O
androgen None None O
stimulation None None O
and None None O
faded None None O
out None None O
in None None O
the None None O
groups None None O
with None None O
the None None O
decreasing None None O
T None None O
plasma None None O
levels None None O
. None None O

This None None O
review None None O
focuses None None O
on None None O
the None None O
medicinal None None O
chemistry None None O
efforts None None O
directed None None O
toward None None O
the None None O
identification None None O
of None None O
competitive None None O
and None None O
noncompetitive None None O
antagonists None None O
of None None O
glutamate None None I-TRANS
at None None O
group None None O
II None None O
metabotropic None None O
glutamate None None I-TRANS
receptors None None I-PROTEIN
( None None O
mGluRII None None O
: None None O
mGlu2/3 None None O
and None None O
mGlu2 None None O
) None None O
. None None O

Cytokines None None O
, None None O
IDO None None O
, None None O
and None None O
tryptophan None None I-TRANS
( None None O
Trp None None O
) None None O
catabolites None None O
were None None O
analyzed None None O
by None None O
enzyme-linked None None O
immunosorbent None None O
assay None None O
, None None O
western None None O
blot None None O
, None None O
and None None O
liquid None None O
chromatography-electrospray None None O
ionization None None O
tandem None None O
mass None None O
spectrometry None None O
, None None O
respectively None None O
. None None O

This None None O
treatment None None O
upregulated None None O
the None None O
hippocampal None None O
contents None None O
of None None O
Trp None None O
and None None O
5-HT None None I-TRANS
but None None O
did None None O
not None None O
influence None None O
5-HT None None I-TRANS
turnover None None O
. None None O

DXS None None O
reduced None None O
IDO None None O
activity None None O
to None None O
shift None None O
the None None O
balance None None O
of None None O
the None None O
Kyn/5-HT None None O
pathway None None O
toward None None O
the None None O
5-HT None None I-TRANS
pathway None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
applied None None O
an None None O
ultra None None O
high None None O
performance None None O
liquid None None O
chromatography/time-of-flight None None O
mass None None O
spectrometry None None O
( None None O
UHPLC/TOF-MS None None O
) None None O
-based None None O
lipidomics None None O
method None None O
to None None O
analyze None None O
the None None O
global None None O
lipid None None O
profiles None None O
of None None O
hypothyroidism None None O
in None None O
rat None None O
cerebellum None None I-REGION
. None None O

In None None O
addition None None O
, None None O
we None None O
confirmed None None O
that None None O
H2O2 None None O
activated None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
( None None O
MAPKs None None O
) None None O
, None None O
such None None O
as None None O
extracellular None None O
signal-regulated None None O
kinase None None O
( None None O
ERK None None O
) None None O
, None None O
c-Jun None None O
NH2-terminal None None O
kinase None None O
( None None O
JNK None None O
) None None O
and None None O
p38 None None O
MAPK None None O
. None None O

The None None O
cellular None None O
element None None O
of None None O
these None None O
strategies None None O
is None None O
limited None None O
, None None O
however None None O
, None None O
by None None O
poor None None O
efficiency None None O
of None None O
delivery None None O
and None None O
retention None None I-FUNC
of None None O
therapeutic None None O
cells None None O
in None None O
target None None O
sites None None O
. None None O

To None None O
do None None O
so None None O
, None None O
we None None O
engineered None None O
an None None O
artificial None None O
collagen-specific None None O
anchor None None O
( None None O
ACSA None None O
) None None O
that None None O
is None None O
able None None O
to None None O
specifically None None O
bind None None O
collagen None None I-PROTEIN
I None None O
. None None O

The None None O
binding None None O
specificity None None O
of None None O
the None None O
ACSA None None O
was None None O
achieved None None O
by None None O
employing None None O
variable None None O
regions None None O
of None None O
a None None O
monoclonal None None O
antibody None None O
that None None O
recognizes None None O
a None None O
unique None None O
epitope None None O
present None None O
in None None O
human None None O
collagen None None I-PROTEIN
I None None O
. None None O

We None None O
determined None None O
that None None O
the None None O
ACSA None None O
was None None O
localized None None O
within None None O
cell None None O
membranes None None O
and None None O
interacted None None O
with None None O
its None None O
intended None None O
target None None O
, None None O
that None None O
is None None O
, None None O
collagen None None I-PROTEIN
I None None O
. None None O

We None None O
have None None O
also None None O
demonstrated None None O
that None None O
the None None O
presence None None O
of None None O
the None None O
ACSA None None O
did None None O
not None None O
interfere None None O
with None None O
cell None None O
proliferation None None O
, None None O
the None None O
biosynthesis None None O
of None None O
endogenous None None O
collagen None None I-PROTEIN
I None None O
, None None O
or None None O
the None None O
biological None None O
functions None None O
of None None O
native None None O
collagen None None I-PROTEIN
receptors None None I-PROTEIN
. None None O

If None None O
successful None None O
, None None O
the None None O
ACSA None None O
approach None None O
to None None O
deliver None None O
cells None None O
will None None O
serve None None O
as None None O
an None None O
outline None None O
for None None O
developing None None O
cell None None O
delivery None None O
methods None None O
that None None O
target None None O
other None None O
elements None None O
of None None O
extracellular None None O
matrices None None O
, None None O
including None None O
other None None O
collagen None None I-PROTEIN
types None None O
, None None O
laminins None None O
, None None O
and None None O
fibronectins None None I-PROTEIN
. None None O

Participants None None O
with None None O
SPD None None O
had None None O
greater None None O
volume None None O
of None None O
the None None O
ventral None None I-REGION
striatum None None I-REGION
bilaterally None None O
; None None O
and None None O
reduced None None O
cortical None None O
thickness None None O
in None None O
right None None O
hemisphere None None O
frontal None None O
areas None None O
, None None O
and None None O
greater None None O
thickness None None O
of None None O
the None None O
cuneus None None I-REGION
bilaterally None None O
compared None None O
to None None O
HPD None None O
and None None O
control None None O
participants None None O
. None None O

Catechol-O-methyltransferase None None O
( None None O
COMT None None O
) None None O
activity None None O
in None None O
the None None O
medial None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
mPFC None None O
) None None O
has None None O
been None None O
shown None None O
to None None O
influence None None O
cognitive None None O
abilities None None O
by None None O
modifying None None O
dopamine None None I-TRANS
clearance None None O
. None None O

Conversely None None O
, None None O
recombinant None None O
COMT None None O
administration None None O
totally None None O
impaired None None O
learning None None I-FUNC
. None None O

The None None O
experimental None None O
and None None O
computational None None O
results None None O
show None None O
that None None O
learning None None I-FUNC
performance None None O
can None None O
be None None O
deeply None None O
influenced None None O
by None None O
COMT None None O
manipulations None None O
in None None O
the None None O
mPFC None None O
. None None O

This None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
potential None None O
enhancing None None O
effect None None O
of None None O
heat None None O
stress None None O
on None None O
mental None None O
fatigue None None O
progression None None O
during None None O
sustained None None O
attention None None I-FUNC
task None None O
using None None O
arterial None None O
spin None None O
labeling None None O
( None None O
ASL None None O
) None None O
imaging None None O
. None None O

Specifically None None O
, None None O
increased None None O
CBF None None O
mainly None None O
gathered None None O
in None None O
thalamic-brainstem None None O
area None None O
while None None O
decreased None None O
CBF None None O
predominantly None None O
located None None O
in None None O
fronto-parietal None None O
areas None None O
, None None O
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
, None None O
posterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
, None None O
and None None O
medial None None O
frontal None None I-REGION
cortex None None I-REGION
. None None O

Specifically None None O
, None None O
higher None None O
CBF None None O
and None None O
enhanced None None O
rising None None O
trend None None O
were None None O
presented None None O
in None None O
superior None None I-REGION
parietal None None I-REGION
lobe None None I-REGION
, None None O
precuneus None None I-REGION
, None None O
posterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
and None None O
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
, None None O
while None None O
lower None None O
CBF None None O
or None None O
inhibited None None O
rising None None O
trend None None O
was None None O
found None None O
in None None O
dorsolateral None None O
frontal None None I-REGION
cortex None None I-REGION
, None None O
medial None None O
frontal None None I-REGION
cortex None None I-REGION
, None None O
inferior None None O
parietal None None I-REGION
lobe None None I-REGION
and None None O
thalamic-brainstem None None O
areas None None O
. None None O

These None None O
findings None None O
may None None O
provide None None O
proof None None O
for None None O
such None None O
a None None O
view None None O
: None None O
heat None None O
stress None None O
has None None O
a None None O
potential None None O
fatigue-enhancing None None O
effect None None O
when None None O
individual None None O
is None None O
performing None None O
highly None None O
cognition-demanding None None O
attention None None I-FUNC
task None None O
. None None O

Mice None None O
were None None O
housed None None O
with None None O
or None None O
without None None O
a None None O
running None None O
wheels None None O
for None None O
30 None None O
days None None O
then None None O
tested None None O
for None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
on None None O
the None None O
plus None None O
water None None O
maze None None O
, None None O
adapted None None O
for None None O
multiple None None O
strains None None O
, None None O
and None None O
rotarod None None O
test None None O
of None None O
motor None None O
performance None None O
. None None O

Taken None None O
together None None O
, None None O
results None None O
demonstrate None None O
that None None O
despite None None O
different None None O
levels None None O
of None None O
neurogenesis None None O
, None None O
memory None None I-FUNC
performance None None O
and None None O
motor None None O
coordination None None O
in None None O
these None None O
mouse None None O
strains None None O
, None None O
all None None O
strains None None O
have None None O
the None None O
capacity None None O
to None None O
increase None None O
neurogenesis None None O
and None None O
improve None None O
learning None None I-FUNC
on None None O
the None None O
water None None O
maze None None O
through None None O
voluntary None None O
wheel None None O
running None None O
. None None O

Considering None None O
the None None O
primary None None O
neuropathology None None O
of None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
involving None None O
the None None O
frontal None None I-REGION
lobe None None I-REGION
system None None O
, None None O
patients None None O
with None None O
PD None None O
are None None O
expected None None O
to None None O
exhibit None None O
deficits None None O
in None None O
ToM None None O
and None None O
social None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Consistent None None O
with None None O
previous None None O
findings None None O
, None None O
patients None None O
with None None O
PD None None O
were None None O
impaired None None O
in None None O
the None None O
affective None None O
ToM None None O
task None None O
, None None O
and None None O
when None None O
making None None O
decisions None None O
under None None O
ambiguity None None I-FUNC
and None None O
in None None O
risk None None O
situations None None O
. None None O

However None None O
, None None O
the None None O
final None None O
capital None None O
in None None O
the None None O
GDT None None O
was None None O
correlated None None O
with None None O
memory None None I-FUNC
impairment None None O
. None None O

This None None O
Editorial None None O
provides None None O
an None None O
historical None None O
excursus None None O
of None None O
old None None O
and None None O
new-entry None None O
molecules None None O
in None None O
migraine None None I-DISEASE
therapeutic None None O
area None None O
. None None O

The None None O
development None None O
of None None O
new None None O
acute None None O
and None None O
preventative None None O
compounds None None O
, None None O
such None None O
as None None O
5HT None None O
( None None O
serotonin None None I-TRANS
) None None O
1F None None O
receptor None None I-PROTEIN
( None None O
5-HT1F None None O
) None None O
agonist None None O
lasmiditan None None O
, None None O
calcitonin None None I-TRANS
gene None None O
related None None O
peptide None None O
( None None O
CGRP None None O
) None None O
peptide None None O
receptor None None I-PROTEIN
antagonists None None O
, None None O
anti-CGRP None None O
monoclonal None None O
antibodies None None O
( None None O
LY2951742 None None O
, None None O
ALD403 None None O
, None None O
LBR101 None None O
) None None O
and None None O
anti-CGRP-r None None O
monoclonal None None O
antibody None None O
( None None O
AMG334 None None O
) None None O
, None None O
is None None O
warranted None None O
and None None O
might None None O
be None None O
soon None None O
completed None None O
in None None O
order None None O
to None None O
offer None None O
new None None O
opportunities None None O
to None None O
migraine None None I-DISEASE
patients None None O
. None None O

The None None O
formation None None O
of None None O
specialized None None O
metabolites None None O
enables None None O
plants None None O
to None None O
respond None None O
to None None O
biotic None None O
and None None O
abiotic None None O
stresses None None O
, None None O
but None None O
requires None None O
the None None O
sequential None None O
action None None O
of None None O
multiple None None O
enzymes None None I-PROTEIN
. None None O

In None None O
the None None O
SCL-90-R None None O
, None None O
clinically None None O
significant None None O
scores None None O
for None None O
anxiety None None O
, None None O
phobic None None O
anxiety None None O
and None None O
depression None None I-DISEASE
were None None O
found None None O
in None None O
55 None None O
% None None O
, None None O
51 None None O
% None None O
, None None O
and None None O
44 None None O
% None None O
of None None O
the None None O
mefloquine None None O
group None None O
. None None O

Data None None O
indicated None None O
that None None O
subjects None None O
experiencing None None O
acute None None O
mefloquine None None O
adverse None None O
side None None O
effects None None O
may None None O
develop None None O
long-term None None O
mental None None O
health None None O
problems None None O
with None None O
a None None O
decreased None None O
sense None None O
of None None O
global None None O
quality None None O
of None None O
life None None O
with None None O
lack None None O
of None None O
energy None None O
, None None O
nervousness None None O
, None None O
and None None O
depression None None I-DISEASE
. None None O

The None None O
β-amyloid None None O
precursor None None O
protein None None O
cleavage None None O
enzyme None None O
( None None O
BACE None None O
) None None O
has None None O
been None None O
conceived None None O
to None None O
be None None O
an None None O
attractive None None O
therapeutic None None O
target None None O
to None None O
control None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

As None None O
these None None O
individuals None None O
are None None O
also None None O
characterized None None O
by None None O
elevated None None O
levels None None O
of None None O
doubt None None O
regarding None None O
internal None None O
states None None O
, None None O
the None None O
causal None None O
relationship None None O
between None None O
doubt None None O
and None None O
accurate None None O
perception None None I-FUNC
remained None None O
unclear None None O
. None None O

The None None O
release None None O
of None None O
MTX None None O
is None None O
facilitated None None O
by None None O
use None None O
of None None O
proteolytic None None O
enzymes None None I-PROTEIN
and None None O
higher None None O
pHs None None O
. None None O

Morning None None O
plasma None None O
and None None O
CSF None None O
cortisol None None O
concentrations None None O
were None None O
obtained None None O
from None None O
the None None O
subjects None None O
with None None O
AD None None O
dementia None None I-DISEASE
, None None O
mild None None O
cognitive None None O
impairment None None O
of None None O
AD None None O
type None None O
( None None O
MCI-AD None None O
) None None O
, None None O
MCI None None O
of None None O
other None None O
type None None O
( None None O
MCI-O None None O
) None None O
, None None O
and None None O
controls None None O
with None None O
normal None None O
cognition None None O
included None None O
in None None O
a None None O
multicenter None None O
study None None O
from None None O
the None None O
German None None O
Dementia None None I-DISEASE
Competence None None O
Network None None O
. None None O

CSF None None O
cortisol None None O
concentrations None None O
were None None O
increased None None O
in None None O
the None None O
subjects None None O
with None None O
AD None None O
dementia None None I-DISEASE
or None None O
MCI-AD None None O
compared None None O
with None None O
subjects None None O
with None None O
MCI-O None None O
or None None O
normal None None O
cognition None None O
. None None O

We None None O
have None None O
measured None None O
plasma None None O
progranulin None None O
and None None O
interleukin-6 None None O
in None None O
230 None None O
patients None None O
with None None O
frontotemporal None None O
lobar None None O
degeneration None None O
( None None O
FTLD None None O
) None None O
, None None O
104 None None O
patients None None O
with None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
and None None O
161 None None O
control None None O
subjects None None O
. None None O

Despite None None O
growing None None O
research None None O
on None None O
emotion None None I-FUNC
regulation None None O
( None None O
ER None None O
) None None O
strategies None None O
and None None O
psychopathology None None O
, None None O
research None None O
has None None O
primarily None None O
focused None None O
on None None O
identifying None None O
one-to-one None None O
associations None None O
between None None O
ER None None O
strategies None None O
and None None O
symptoms None None O
. None None O

We None None O
utilised None None O
latent None None O
class None None O
analysis None None O
to None None O
identify None None O
distinct None None O
repertoires None None O
of None None O
ER None None O
strategies None None O
, None None O
and None None O
their None None O
links None None O
with None None O
various None None O
psychopathology None None O
domains None None O
( None None O
i.e. None None O
, None None O
anxiety None None O
, None None O
depression None None I-DISEASE
, None None O
disordered None None O
eating None None O
, None None O
borderline None None O
personality None None O
) None None O
. None None O

Cytosine None None O
methylation None None O
( None None O
5-methylcytosine None None O
, None None O
5meC None None O
) None None O
in None None O
the None None O
CpG-rich None None O
regions None None O
of None None O
the None None O
mammalian None None O
genome None None O
is None None O
an None None O
important None None O
epigenetic None None O
mechanism None None O
playing None None O
roles None None O
in None None O
transcription None None I-PROTEIN
regulation None None I-PROTEIN
and None None O
genomic None None O
stability None None O
. None None O

In None None O
this None None O
paper None None O
we None None O
introduce None None O
a None None O
new None None O
data None None O
model None None O
better None None O
suited None None O
for None None O
high-dimensional None None O
data None None O
storage None None I-FUNC
and None None O
querying None None O
, None None O
optimized None None O
for None None O
database None None O
scalability None None O
and None None O
performance None None O
. None None O

It None None O
is None None O
becoming None None O
clear None None O
that None None O
addressing None None O
the None None O
`` None None O
classical None None O
'' None None O
risk None None O
factors None None O
for None None O
atherosclerosis None None I-DISEASE
does None None O
not None None O
entirely None None O
reduce None None O
the None None O
risk None None O
of None None O
cardiovascular None None O
events None None O
. None None O

Since None None O
inflammation None None O
is None None O
a None None O
hallmark None None O
of None None O
atherosclerosis None None I-DISEASE
, None None O
tests None None O
for None None O
pro-inflammatory None None O
biomarkers None None O
have None None O
been None None O
introduced None None O
such None None O
as None None O
for None None O
hsCRP None None O
, None None O
fibrinogen None None O
and None None O
IL-6 None None O
, None None O
with None None O
many None None O
more None None O
at None None O
different None None O
stages None None O
of None None O
development None None O
. None None O

The None None O
down-regulated None None O
genes None None O
are None None O
involved None None O
in None None O
amino None None O
acid None None O
, None None O
cofactor None None O
, None None O
and None None O
vitamin None None O
metabolism None None O
, None None O
and None None O
also None None O
include None None O
ABC None None O
transporters None None I-PROTEIN
. None None O

Within None None O
this None None O
group None None O
, None None O
the None None O
top None None O
five None None O
leading None None O
causes None None O
of None None O
DALYs None None O
were None None O
: None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
, None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
migraine None None I-DISEASE
, None None O
substance-use None None O
disorders None None O
, None None O
and None None O
anxiety None None I-DISEASE
disorder None None I-DISEASE
, None None O
which None None O
accounted None None O
for None None O
70.9 None None O
% None None O
of None None O
all None None O
DALYs None None O
due None None O
to None None O
neuropsychiatric None None O
disorders None None O
. None None O

Mental None None O
and None None O
substance-use None None O
disorders None None O
accounted None None O
for None None O
22.4 None None O
% None None O
of None None O
total None None O
YLDs None None O
, None None O
with None None O
depression None None I-DISEASE
being None None O
the None None O
most None None O
disabling None None O
disorder None None O
. None None O

A None None O
single-nucleotide None None O
polymorphism None None O
( None None O
SNP None None O
) None None O
in None None O
the None None O
promoter None None O
of None None O
the None None O
Mdm2 None None O
gene None None O
( None None O
Mdm2 None None O
( None None O
SNP309-G None None O
) None None O
) None None O
results None None O
in None None O
an None None O
increased None None O
Mdm2 None None O
expression None None O
, None None O
partial None None O
attenuation None None O
of None None O
the None None O
p53 None None I-PROTEIN
pathway None None O
and None None O
accelerated None None O
tumor None None O
development None None O
. None None O

AOM None None O
did None None O
not None None O
significantly None None O
induce None None O
stabilization None None O
of None None O
wild-type None None O
p53 None None I-PROTEIN
or None None O
activate None None O
p53 None None I-PROTEIN
downstream None None O
targets None None O
following None None O
AOM None None O
treatment None None O
, None None O
regardless None None O
of None None O
the None None O
genotype None None O
. None None O

Together None None O
these None None O
results None None O
suggest None None O
the None None O
Mdm2 None None O
( None None O
SNP309- None None O
) None None O
( None None O
G None None O
) None None O
allele None None O
significantly None None O
impacts None None O
CRC None None O
through None None O
mechanisms None None O
outside None None O
the None None O
p53 None None I-PROTEIN
pathway None None O
. None None O

A None None O
substitution None None O
of None None O
aspartate None None I-TRANS
to None None O
valine None None I-TRANS
at None None O
amino None None O
acid None None O
816 None None O
( None None O
D816V None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
commonly None None O
found None None O
oncogenic None None O
c-Kit None None O
mutations None None O
and None None O
is None None O
found None None O
in None None O
& None None O
gt None None O
; None None O
90 None None O
% None None O
of None None O
cases None None O
of None None O
mastocytosis None None O
and None None O
less None None O
commonly None None O
in None None O
germ-cell None None O
tumors None None O
, None None O
core-binding None None O
factor None None O
acute None None O
myeloid None None O
leukemia None None O
and None None O
mucosal None None O
melanomas None None O
. None None O

Using None None O
in None None O
vitro None None O
bioengineering None None O
models None None O
in None None O
conjunction None None O
with None None O
molecular None None O
cell None None O
biology None None O
tools None None O
, None None O
we None None O
found None None O
that None None O
fluid None None O
shear None None O
( None None O
2 None None O
dyn/cm None None O
( None None O
2 None None O
) None None O
) None None O
markedly None None O
upregulates None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
12 None None O
( None None O
MMP-12 None None O
) None None O
expression None None O
and None None O
its None None O
activity None None O
in None None O
human None None O
chondrosarcoma None None O
cells None None O
. None None O

This None None O
study None None O
reveals None None O
a None None O
novel None None O
mechanism None None O
of None None O
control None None O
of None None O
cell None None O
proliferation None None O
by None None O
LRH-1 None None O
regulating None None O
CDKN1A None None O
transcription None None O
in None None O
breast None None O
cancer None None O
cells None None O
, None None O
independent None None O
of None None O
ERα None None O
and None None O
p53 None None I-PROTEIN
status None None O
. None None O

At None None O
the None None O
molecular None None O
level None None O
, None None O
the None None O
antitumorigenic None None O
effect None None O
of None None O
SOX30 None None O
is None None O
mediated None None O
by None None O
directly None None O
binding None None O
to None None O
CACTTTG None None O
( None None O
+115 None None O
to None None O
+121 None None O
) None None O
of None None O
p53 None None I-PROTEIN
promoter None None O
region None None O
and None None O
activating None None O
p53 None None I-PROTEIN
transcription None None O
, None None O
suggesting None None O
that None None O
SOX30 None None O
is None None O
a None None O
novel None None O
transcriptional None None O
activating None None O
factor None None O
of None None O
p53 None None I-PROTEIN
. None None O

Overall None None O
, None None O
these None None O
findings None None O
demonstrate None None O
that None None O
SOX30 None None O
is None None O
a None None O
novel None None O
epigenetic None None O
silenced None None O
tumor None None O
suppressor None None O
acting None None O
through None None O
direct None None O
regulation None None O
of None None O
p53 None None I-PROTEIN
transcription None None O
and None None O
expression None None O
. None None O

Genes None None O
coding None None O
for None None O
two None None O
oxidative None None O
phosphorylation None None O
reactions None None O
( None None O
cytochrome None None I-PROTEIN
c None None I-PROTEIN
oxidase None None I-PROTEIN
and None None O
ubiquinol None None O
cytochrome None None O
c None None O
reductase None None O
) None None O
were None None O
identified None None O
by None None O
the None None O
model-based None None O
simulation None None O
as None None O
potential None None O
deletion None None O
targets None None O
for None None O
enhancing None None O
ethanol None None O
production None None O
and None None O
maintaining None None O
acceptable None None O
overall None None O
growth None None O
rate None None O
in None None O
oxygen-limited None None O
conditions None None O
. None None O

The None None O
results None None O
have None None O
also None None O
permitted None None O
the None None O
identification None None O
of None None O
transcriptional None None O
regulators None None O
and None None O
changes None None O
in None None O
metabolic None None O
pathways None None O
related None None O
to None None O
the None None O
catabolism None None O
and None None O
anabolism None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
or None None O
nucleotides None None O
. None None O

To None None O
report None None O
two None None O
cases None None O
of None None O
microbial None None O
keratitis None None O
with None None O
subsequent None None O
corneal None None O
perforation None None O
immediately None None O
following None None O
corneal None None O
collagen None None I-PROTEIN
crosslinking None None O
( None None O
CXL None None O
) None None O
. None None O

Natural None None O
three None None O
dimensional None None O
( None None O
3D None None O
) None None O
ECM None None O
hydrogels None None O
, None None O
such None None O
as None None O
collagen None None I-PROTEIN
or None None O
hyaluronic None None O
acid None None O
, None None O
feature None None O
many None None O
of None None O
the None None O
chemical None None O
and None None O
physical None None O
properties None None O
of None None O
tissue None None O
, None None O
yet None None O
, None None O
these None None O
systems None None O
have None None O
limitations None None O
including None None O
the None None O
inability None None O
to None None O
independently None None O
control None None O
biophysical None None O
properties None None O
such None None O
as None None O
stiffness None None O
and None None O
pore None None O
size None None O
. None None O

We None None O
achieve None None O
this None None O
by None None O
mechanically None None O
loading None None O
collagen None None I-PROTEIN
hydrogels None None O
covalently-conjugated None None O
to None None O
a None None O
polydimethylsiloxane None None O
( None None O
PDMS None None O
) None None O
membrane None None O
to None None O
induce None None O
hydrogel None None O
stiffening None None O
. None None O

Next None None O
, None None O
to None None O
enhance None None O
cell None None O
specificity None None O
, None None O
a None None O
guiding None None O
unit None None O
of None None O
c None None O
( None None O
RGDyK None None O
) None None O
peptide None None O
conjugated None None O
adamantane None None O
( None None O
Ad-RGD None None O
) None None O
as None None O
prototypical None None O
system None None O
, None None O
is None None O
incorporated None None O
on None None O
the None None O
surface None None O
of None None O
Rhod-SP None None O
@ None None O
MSN-CD None None O
to None None O
target None None O
integrin None None I-PROTEIN
αvβ3 None None O
and None None O
αvβ5 None None O
overexpressed None None O
on None None O
cancer None None O
cells None None O
. None None O

We None None O
identified None None O
individuals None None O
with None None O
a None None O
first None None O
diagnosis None None O
of None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
those None None O
without None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
from None None O
Jan None None O
1 None None O
, None None O
1996 None None O
, None None O
to None None O
Dec None None O
31 None None O
, None None O
2012 None None O
, None None O
from None None O
The None None O
Health None None O
Improvement None None O
Network None None O
UK None None O
primary None None O
care None None O
database None None O
. None None O

We None None O
report None None O
the None None O
incidence None None O
of None None O
symptoms None None O
recorded None None O
in None None O
more None None O
than None None O
1 None None O
% None None O
of None None O
cases None None O
per None None O
1000 None None O
person-years None None O
and None None O
incidence None None O
risk None None O
ratios None None O
( None None O
RRs None None O
) None None O
for None None O
individuals None None O
with None None O
and None None O
without None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
at None None O
2 None None O
, None None O
5 None None O
, None None O
and None None O
10 None None O
years None None O
before None None O
diagnosis None None O
. None None O

At None None O
5 None None O
years None None O
before None None O
diagnosis None None O
, None None O
compared None None O
with None None O
controls None None O
( None None O
n=25,544 None None O
) None None O
, None None O
patients None None O
who None None O
went None None O
on None None O
to None None O
develop None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
n=4769 None None O
) None None O
had None None O
a None None O
higher None None O
incidence None None O
of None None O
tremor None None O
( None None O
RR None None O
13·70 None None O
, None None O
95 None None O
% None None O
CI None None O
7·82-24·31 None None O
) None None O
, None None O
balance None None O
impairments None None O
( None None O
2·19 None None O
, None None O
1·09-4·16 None None O
) None None O
, None None O
constipation None None O
( None None O
2·24 None None O
, None None O
2·04-2·46 None None O
) None None O
, None None O
hypotension None None O
( None None O
3·23 None None O
, None None O
1·85-5·52 None None O
) None None O
, None None O
erectile None None O
dysfunction None None O
( None None O
1·30 None None O
, None None O
1·11-1·51 None None O
) None None O
, None None O
urinary None None O
dysfunction None None O
( None None O
1·96 None None O
, None None O
1·34-2·80 None None O
) None None O
, None None O
dizziness None None O
( None None O
1·99 None None O
, None None O
1·67-2·37 None None O
) None None O
, None None O
fatigue None None O
( None None O
1·56 None None O
, None None O
1·27-1·91 None None O
) None None O
, None None O
depression None None I-DISEASE
( None None O
1·76 None None O
, None None O
1·41-2·17 None None O
) None None O
, None None O
and None None O
anxiety None None O
( None None O
1·41 None None O
, None None O
1·09-1·79 None None O
) None None O
. None None O

A None None O
range None None O
of None None O
prediagnostic None None O
features None None O
can None None O
be None None O
detected None None O
several None None O
years None None O
before None None O
diagnosis None None O
of None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
in None None O
primary None None O
care None None O
. None None O

Parkinson None None I-DISEASE
's None None O
UK None None O
. None None O

In None None O
the None None O
present None None O
research None None O
we None None O
examined None None O
whether None None O
the None None O
psychological None None O
meaning None None O
of None None O
people None None O
's None None O
categorisation None None O
goals None None O
affects None None O
facial None None O
muscle None None O
activity None None O
in None None O
response None None O
to None None O
facial None None O
expressions None None O
of None None O
emotion None None I-FUNC
. None None O

We None None O
predicted None None O
that None None O
participants None None O
would None None O
respond None None O
differentially None None O
to None None O
the None None O
emotional None None O
faces None None O
when None None O
the None None O
categorisation None None O
criteria None None O
allowed None None O
for None None O
inferences None None I-FUNC
about None None O
a None None O
target None None O
's None None O
thoughts None None O
, None None O
feelings None None I-FUNC
or None None O
behaviour None None O
( None None O
i.e. None None O
, None None O
when None None O
categorising None None O
extraversion None None O
) None None O
, None None O
but None None O
not None None O
when None None O
these None None O
lacked None None O
any None None O
social None None O
meaning None None O
( None None O
i.e. None None O
, None None O
when None None O
categorising None None O
light None None O
frequency None None O
) None None O
. None None O

The None None O
synthesis None None O
of None None O
different None None O
kinds None None O
of None None O
magnetic None None O
nanoparticles None None O
( None None O
MNPs None None O
) None None O
has None None O
attracted None None O
much None None O
attention None None I-FUNC
. None None O

Amylase None None I-PROTEIN
levels None None O
were None None O
increased None None O
and None None O
ultrasonographic None None O
evaluation None None O
revealed None None O
bilateral None None O
parotitis None None O
. None None O

Was None None O
demonstrated None None O
involvement None None O
of None None O
all None None O
fasciculus None None I-REGION
of None None O
the None None O
plexus None None O
in None None O
51.46 None None O
% None None O
. None None O

The None None O
phosphorylation None None O
of None None O
key None None O
proteins None None O
balanced None None O
by None None O
protein None None O
kinases None None I-PROTEIN
and None None O
phosphatases None None I-PROTEIN
are None None O
implicated None None O
in None None O
the None None O
regulation None None O
of None None O
cell None None O
cycle None None O
and None None O
apoptosis None None O
of None None O
malignant None None O
cells None None O
and None None O
influences None None O
anticancer None None O
drug None None O
actions None None O
. None None O

Using None None O
genome-wide None None O
expression None None O
profiles None None O
, None None O
we None None O
predicted None None O
key None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
downregulated None None O
nuclear None None O
factor None None O
of None None O
activated None None O
T-cells None None O
, None None O
cytoplasmic None None O
1 None None O
( None None O
NFATc1 None None O
) None None O
, None None O
a None None O
master None None O
transcription None None O
factor None None O
for None None O
osteoclastogenesis None None O
. None None O

A None None O
partial None None O
silencing None None O
of None None O
NFATc1 None None O
allowed None None O
a None None O
selection None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
were None None O
likely None None O
to None None O
be None None O
located None None O
upstream None None O
of None None O
NFATc1 None None O
. None None O

Collectively None None O
, None None O
a None None O
systems-biology None None O
approach None None O
allows None None O
the None None O
prediction None None O
of None None O
a None None O
RANKL-salubrinal/guanabenz-NFATc1 None None O
regulatory None None O
axis None None O
, None None O
and None None O
in None None O
vitro None None O
assays None None O
validate None None O
an None None O
involvement None None O
of None None O
AP-1 None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
in None None O
suppression None None O
of None None O
osteoclastogenesis None None O
. None None O

Binding None None O
peptides None None I-TRANS
( None None O
BPs None None O
) None None O
were None None O
introduced None None O
representing None None O
sequences None None O
critical None None O
for None None O
Cdc42 None None O
docking None None O
on None None O
a None None O
specific None None O
partner None None O
. None None O

Proteins None None O
like None None O
p53 None None I-PROTEIN
, None None O
H3K18 None None O
, None None O
PAF53 None None O
, None None O
NPM1 None None O
and None None O
GABP-β1 None None O
are None None O
the None None O
known None None O
substrates None None O
for None None O
the None None O
deacetylase None None O
activity None None O
of None None O
SIRT7 None None O
, None None O
thereby None None O
making None None O
it None None O
a None None O
key None None O
mediator None None O
of None None O
many None None O
cellular None None O
activities None None O
. None None O

We None None O
previously None None O
showed None None O
that None None O
KAI1 None None O
physically None None O
and None None O
functionally None None O
crosstalks None None O
with None None O
the None None O
tumor-biologically None None O
relevant None None O
integrin None None I-PROTEIN
αvβ3 None None O
, None None O
thereby None None O
suppressing None None O
ovarian None None O
cancer None None O
cell None None O
migration None None O
and None None O
proliferation None None O
. None None O

Whereas None None O
KAI1 None None O
diminished None None O
cell None None O
proliferative None None O
activity None None O
, None None O
KAI1-splice None None O
prominently None None O
enhanced None None O
cell None None O
proliferation None None O
concomitant None None O
with None None O
elevated None None O
transcription None None O
and None None O
cell-surface None None O
expression None None O
of None None O
the None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
. None None O

We None None O
elevated None None O
the None None O
target None None O
genes None None O
of None None O
miR29b None None O
through None None O
software None None O
predictions None None O
and None None O
a None None O
luciferase None None I-PROTEIN
report None None O
assay None None O
. None None O

MiR-29b None None O
promoted None None O
OSCC None None O
cell None None O
migration None None O
and None None O
downregulated None None O
CX3CL1 None None O
, None None O
a None None O
cell-cell None None O
adhesion None None I-PROTEIN
regulator None None O
, None None O
which None None O
plays None None O
an None None O
essential None None O
role None None O
in None None O
miR-29b-regulated None None O
OSCC None None O
cell None None O
migration None None O
machinery None None O
. None None O

Arginine None None I-TRANS
has None None O
been None None O
proven None None O
effective None None O
for None None O
eluting None None O
bound None None O
antibodies None None O
from None None O
the None None O
4-MEP None None O
resin None None O
column None None O
. None None O

Arginine None None I-TRANS
was None None O
found None None O
to None None O
efficiently None None O
reduce None None O
antibody None None O
adsorption None None O
onto None None O
4-MEP None None O
resin None None O
more None None O
than None None O
solvents None None O
containing None None O
guanidine None None O
, None None O
urea None None O
and None None O
NaCl None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
attraction None None O
between None None O
BGG None None O
and None None O
4-MEP None None O
is None None O
based None None O
on None None O
hydrophobic None None O
interactions None None O
that None None O
can None None O
be None None O
weakened None None O
by None None O
arginine None None I-TRANS
or None None O
the None None O
organic None None O
solvents None None O
. None None O

Molecular None None O
dynamics None None O
simulations None None O
used None None O
to None None O
illuminate None None O
the None None O
mechanism None None O
of None None O
binding None None O
of None None O
an None None O
arginine None None I-TRANS
molecule None None O
to None None O
a None None O
4-MEP None None O
resin None None O
ligand None None O
molecule None None O
showed None None O
that None None O
the None None O
alkyl None None O
chain None None O
of None None O
the None None O
arginine None None I-TRANS
side None None O
chain None None O
primarily None None O
interacts None None O
with None None O
the None None O
pyridine None None O
ring None None O
of None None O
the None None O
4-MEP None None O
resin None None O
ligand None None O
through None None O
hydrophobic None None O
interactions None None O
. None None O

The None None O
hydrophobic None None O
interaction None None O
of None None O
the None None O
arginine None None I-TRANS
side None None O
chain None None O
with None None O
the None None O
pyridine None None O
ring None None O
reduces None None O
the None None O
attraction None None O
between None None O
the None None O
antibodies None None O
and None None O
4-MEP None None O
, None None O
leading None None O
to None None O
the None None O
efficient None None O
dissociation None None O
of None None O
the None None O
antibodies None None O
from None None O
the None None O
4-MEP None None O
resin None None O
in None None O
the None None O
presence None None O
of None None O
arginine-containing None None O
solutions None None O
. None None O

This None None O
movement None None I-FUNC
of None None O
the None None O
gradient None None O
has None None O
a None None O
focusing None None O
effect None None O
on None None O
the None None O
analyte None None O
bands None None O
, None None O
limiting None None O
band None None O
broadening None None O
in None None O
the None None O
column None None O
. None None O

The None None O
obtained None None O
results None None O
indicate None None O
that None None O
the None None O
newly None None O
developed None None O
fiber None None O
is None None O
a None None O
feasible None None O
, None None O
selective None None O
, None None O
green None None O
, None None O
and None None O
cost-effective None None O
microextraction None None O
medium None None O
and None None O
could None None O
be None None O
successfully None None O
applied None None O
for None None O
extraction None None O
and None None O
determination None None O
of None None O
naphthalene-derived None None O
plant None None O
hormones None None I-PROTEIN
in None None O
complex None None O
matrices None None O
. None None O

The None None O
retention None None I-FUNC
times None None O
of None None O
the None None O
analytes None None O
in None None O
matrix None None O
spiked None None O
controls None None O
were None None O
within None None O
± None None O
0.06 None None O
min None None O
of None None O
the None None O
average None None O
retention None None I-FUNC
times None None O
of None None O
the None None O
corresponding None None O
analytes None None O
in None None O
calibration None None O
standards None None O
. None None O

Several None None O
questionnaires None None O
are None None O
available None None O
to None None O
evaluate None None O
illness None None O
perceptions None None I-FUNC
in None None O
patients None None O
, None None O
such None None O
as None None O
the None None O
illness None None O
perception None None I-FUNC
questionnaire None None O
revised None None O
( None None O
IPQ-R None None O
) None None O
and None None O
the None None O
brief None None O
version None None O
( None None O
Brief None None O
IPQ None None O
) None None O
. None None O

The None None O
manuscript None None O
by None None O
R. None None O
Punith None None O
and None None O
J. None None O
Seetharamappa None None O
( None None O
http None None O
: None None O
//dx.doi.org/10.1016/j.saa.201202.038 None None O
) None None O
presents None None O
the None None O
interaction None None O
between None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
from None None O
human None None O
( None None O
HAS None None O
) None None O
and None None O
from None None O
bovine None None O
( None None O
BSA None None O
) None None O
with None None O
a None None O
drug None None O
called None None O
Anastrozole None None O
( None None O
AZ None None O
) None None O
. None None O

The None None O
corresponding None None O
data None None O
are None None O
modeled None None O
and None None O
analyzed None None O
quantitatively None None O
, None None O
the None None O
merits None None O
of None None O
the None None O
respective None None O
approach None None O
discussed None None O
and None None O
inferences None None I-FUNC
made None None O
with None None O
respect None None O
to None None O
future None None O
design None None O
improvements None None O
. None None O

Following None None O
a None None O
breakfast None None O
to None None O
reduce None None O
hunger None None O
, None None O
youth None None O
participated None None O
in None None O
a None None O
computerized None None O
visual None None O
probe None None O
task None None O
of None None O
sustained None None O
attention None None I-FUNC
that None None O
assessed None None O
reaction None None O
time None None O
to None None O
pairs None None O
of None None O
pictures None None O
consisting None None O
of None None O
high None None O
palatable None None O
foods None None O
, None None O
low None None O
palatable None None O
foods None None O
, None None O
and None None O
neutral None None O
household None None O
objects None None O
. None None O

Changes None None O
in None None O
expression None None O
levels None None O
of None None O
ghrelin None None O
, None None O
GOAT None None O
and None None O
GHS-R1a None None O
mRNAs None None O
were None None O
also None None O
examined None None O
in None None O
different None None O
brain None None O
regions None None O
( None None O
pituitary None None O
, None None O
hypothalamus None None I-REGION
, None None O
thalamus None None I-REGION
, None None O
cerebellum None None I-REGION
, None None O
cerebral None None I-REGION
cortex None None I-REGION
, None None O
olfactory None None I-REGION
bulb None None I-REGION
, None None O
midbrain None None I-REGION
and None None O
medulla None None I-REGION
oblongata None None I-REGION
) None None O
. None None O

GHS-R1a None None O
expression None None O
was None None O
detected None None O
in None None O
all None None O
brain None None O
regions None None O
, None None O
and None None O
age-dependent None None O
changes None None O
were None None O
observed None None O
in None None O
the None None O
pituitary None None O
and None None O
cerebellum None None I-REGION
. None None O

Here None None O
we None None O
introduce None None O
an None None O
enzyme-free None None O
and None None O
colorimetric None None O
detection None None O
strategy None None O
for None None O
small None None O
molecule None None O
adenosine None None I-TRANS
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
established None None O
a None None O
melanogenesis None None O
regulation None None O
assay None None O
system None None O
using None None O
a None None O
fluorescent None None O
protein None None O
reporter None None O
combined None None O
with None None O
the None None O
promoters None None O
for None None O
the None None O
microphthalmia-associated None None O
transcription None None O
factor None None O
( None None O
MITF None None O
) None None O
, None None O
tyrosinase None None I-PROTEIN
( None None O
Tyr None None O
) None None O
and None None O
dopachrome None None O
tautomerase None None O
( None None O
Dct None None O
) None None O
genes None None O
in None None O
MeWo None None O
human None None O
melanoma None None O
cells None None O
. None None O

These None None O
results None None O
clearly None None O
indicate None None O
that None None O
Blon_0625 None None O
is None None O
a None None O
multi-functional None None O
glycoside None None O
hydrolase None None I-PROTEIN
which None None O
retains None None O
the None None O
activity None None O
of None None O
BGL None None O
, None None O
XYL None None O
, None None O
and None None O
also None None O
α-l-arabinofuranosidase None None O
. None None O

Results None None O
from None None O
evaluation None None O
of None None O
biochemical None None O
activities None None O
of None None O
the None None O
fiber-enzyme None None O
assemble None None O
showed None None O
that None None O
nitriation None None O
with None None O
the None None O
nitric/sulfuric None None O
acid None None O
ratio None None O
( None None O
v/v None None O
, None None O
10:1 None None O
) None None O
and None None O
silanization None None O
treatment None None O
delivered None None O
desirable None None O
enzyme None None O
activity None None O
and None None O
long-term None None O
storage None None I-FUNC
stability None None O
, None None O
showing None None O
great None None O
promising None None O
toward None None O
future None None O
large-scale None None O
applications None None O
. None None O

Bacterial None None O
laccases None None I-PROTEIN
show None None O
low None None O
activities None None O
but None None O
can None None O
be None None O
of None None O
biotechnological None None O
interest None None O
due None None O
to None None O
industrially None None O
suitable None None O
characteristics None None O
such None None O
as None None O
thermostability None None O
and None None O
tolerance None None O
to None None O
alkaline None None O
pH None None O
. None None O

Interestingly None None O
, None None O
the None None O
`` None None O
typical None None O
'' None None O
laccase None None I-PROTEIN
inhibitor None None O
, None None O
sodium None None O
azide None None O
, None None O
had None None O
no None None O
significant None None O
inhibitory None None O
effect None None O
on None None O
the None None O
activity None None O
of None None O
SLAC-M298F None None O
, None None O
which None None O
also None None O
exhibited None None O
increased None None O
resistance None None O
to None None O
inhibition None None O
by None None O
sulfhydryl None None O
compounds None None O
. None None O

Among None None O
cold-active None None O
enzymes None None I-PROTEIN
, None None O
lipases None None O
offer None None O
a None None O
great None None O
potential None None O
in None None O
detergent None None O
, None None O
cosmetic None None O
, None None O
biofuel None None O
and None None O
food None None O
or None None O
feed None None O
industries None None O
. None None O

For None None O
efficient None None O
hydrolysis None None O
of None None O
softwood None None O
, None None O
it None None O
was None None O
necessary None None O
to None None O
add None None O
supplementary None None O
enzymes None None I-PROTEIN
to None None O
hydrolyze None None O
both None None O
mannan None None O
and None None O
MOS None None O
to None None O
less None None O
inhibitory None None O
product None None O
, None None O
mannose None None O
. None None O

In None None O
this None None O
study None None O
, None None O
a None None O
novel None None O
glucose None None O
biosensor None None O
was None None O
fabricated None None O
by None None O
reconstitutional None None O
immobilization None None O
of None None O
glucose None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
GOx None None O
) None None O
onto None None O
a None None O
poly None None O
( None None O
glycidyl None None O
methacrylate-co-vinylferrocene None None O
) None None O
( None None O
poly None None O
( None None O
GMA-co-VFc None None O
) None None O
) None None O
film None None O
coated None None O
pencil None None O
graphite None None O
electrode None None O
( None None O
PGE None None O
) None None O
. None None O

Three None None O
patients None None O
with None None O
intractable None None O
Tourette None None I-DISEASE
syndrome None None I-DISEASE
( None None O
TS None None O
) None None O
underwent None None O
thalamic None None O
deep None None O
brain None None O
stimulation None None O
( None None O
DBS None None O
) None None O
. None None O

The None None O
present None None O
study None None O
in None None O
three None None O
cases None None O
with None None O
TS None None O
shows None None O
that None None O
spontaneous None None O
tics None None O
in None None O
TS None None O
are None None O
preceded None None O
by None None O
repetitive None None O
coherent None None O
thalamo-cortical None None O
discharges None None O
, None None O
indicating None None O
that None None O
preceding None None O
a None None O
tic None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
circuits None None O
are None None O
`` None None O
charged None None O
up None None O
'' None None O
, None None O
ultimately None None O
leading None None O
to None None O
a None None O
motor None None O
tic None None O
. None None O

Once None None O
believed None None O
to None None O
be None None O
a None None O
passive None None O
process None None O
, None None O
it None None O
is None None O
now None None O
recognized None None O
that None None O
vascular None None O
calcification None None O
is None None O
a None None O
complex None None O
and None None O
highly None None O
regulated None None O
process None None O
that None None O
involves None None O
activation None None O
of None None O
cellular None None O
signaling None None O
pathways None None O
, None None O
circulating None None O
inhibitors None None O
of None None O
calcification None None O
, None None O
genetic None None O
factors None None O
, None None O
and None None O
hormones None None I-PROTEIN
. None None O

Plants None None O
impaired None None O
in None None O
jasmonate None None O
and/or None None O
ethylene None None O
signaling None None O
are None None O
susceptible None None O
to None None O
infections None None O
by None None O
necrotrophic None None O
fungi None None O
, None None O
suggesting None None O
that None None O
these None None O
two None None O
hormones None None I-PROTEIN
are None None O
both None None O
required None None O
for None None O
defense None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
calculated None None O
multiple None None O
physicochemical None None O
and None None O
secondary None None O
structural None None O
parameters None None O
of None None O
protein None None O
sequences None None O
, None None O
including None None O
length None None O
, None None O
hydrophobicity None None O
, None None O
the None None O
amount None None O
of None None O
secondary None None O
structure None None O
, None None O
the None None O
number None None O
of None None O
intrinsically None None O
disordered None None O
regions None None O
( None None O
IDRs None None O
) None None O
and None None O
the None None O
predicted None None O
presence None None O
of None None O
transmembrane None None O
helices None None O
and None None O
signal None None O
peptides None None I-TRANS
, None None O
using None None O
a None None O
total None None O
of None None O
208,333 None None O
protein None None O
sequences None None O
from None None O
the None None O
genomes None None O
of None None O
six None None O
representative None None O
plant None None O
species None None O
, None None O
Arabidopsis None None O
thaliana None None O
, None None O
Glycine None None I-TRANS
max None None O
( None None O
soybean None None O
) None None O
, None None O
Populus None None O
trichocarpa None None O
( None None O
poplar None None O
) None None O
, None None O
Oryza None None O
sativa None None O
( None None O
rice None None O
) None None O
, None None O
Physcomitrella None None O
patens None None O
( None None O
moss None None O
) None None O
and None None O
Cyanidioschyzon None None O
merolae None None O
( None None O
alga None None O
) None None O
. None None O

To None None O
address None None O
the None None O
lack None None O
of None None O
culturally None None O
and None None O
geographically None None O
relevant None None O
health None None O
information None None O
, None None O
a None None O
community-university None None O
partnership None None O
was None None O
formed None None O
to None None O
develop None None O
, None None O
implement None None O
, None None O
and None None O
evaluate None None O
Aboriginal None None O
Community None None O
Learning None None I-FUNC
Centres None None O
( None None O
CLCs None None O
) None None O
. None None O

Technological None None O
access None None O
provided None None O
by None None O
the None None O
CLCs None None O
increased None None O
capacity None None O
for None None O
learning None None I-FUNC
and None None O
collective None None O
community None None O
initiatives None None O
, None None O
as None None O
well None None O
as None None O
building None None O
community None None O
leads None None O
' None None O
skills None None O
, None None O
knowledge None None O
, None None O
and None None O
self-efficacy None None O
. None None O

Since None None O
1997 None None O
, None None O
our None None O
team None None O
has None None O
utilized None None O
CBPR None None O
approaches None None O
to None None O
improve None None O
health None None O
service None None O
delivery None None O
for None None O
persons None None O
with None None O
dementia None None I-DISEASE
and None None O
their None None O
caregivers None None O
in None None O
rural None None O
and None None O
remote None None O
settings None None O
. None None O

A None None O
multistage None None O
approach None None O
initiated None None O
an None None O
ongoing None None O
CBPR None None O
research None None O
program None None O
in None None O
rural None None O
dementia None None I-DISEASE
care None None O
and None None O
shaped None None O
its None None O
direction None None O
based None None O
on None None O
stakeholders None None O
' None None O
recommendation None None O
to None None O
prioritize None None O
both None None O
community None None O
and None None O
facility-based None None O
care None None O
. None None O

We None None O
conducted None None O
one-on-one None None O
interviews None None O
and None None O
focus None None O
groups None None O
with None None O
community None None O
consultants None None O
to None None O
assess None None O
their None None O
perceptions None None I-FUNC
of None None O
the None None O
partnership None None O
using None None O
a None None O
tailored None None O
version None None O
of None None O
a None None O
previously None None O
developed None None O
individual None None O
and None None O
focus None None O
group None None O
interview None None O
instrument None None O
. None None O

The None None O
key None None O
themes None None O
that None None O
emerged None None O
from None None O
the None None O
interactive None None O
sessions None None O
stressed None None O
the None None O
importance None None O
of None None O
building None None O
relationships None None O
and None None O
trust None None O
; None None O
mutual None None O
use None None O
and None None O
sharing None None O
of None None O
data None None O
; None None O
and None None O
acquiring None None O
knowledge None None O
, None None O
skills None None O
, None None O
and None None O
abilities None None O
to None None O
enable None None O
sustainable None None O
research None None O
partnerships None None O
with None None O
AI None None O
communitiesConclusions None None O
: None None O
Innovative None None O
, None None O
dynamic None None O
, None None O
and None None O
strategic None None O
collaborative None None O
methods None None O
of None None O
Appreciative None None O
Inquiry None None O
and None None O
the None None O
World None None O
Café None None O
can None None O
served None None O
to None None O
engage None None O
people None None O
in None None O
a None None O
constructive None None O
dialogue None None O
to None None O
create None None O
a None None O
shared None None O
vision None None I-FUNC
and None None O
plan None None O
for None None O
more None None O
meaningful None None O
research None None O
partnerships None None O
based None None O
on None None O
principles None None O
of None None O
equity None None O
and None None O
social None None O
justice None None O
, None None O
essential None None O
for None None O
the None None O
elimination None None O
of None None O
health None None O
disparities None None O
. None None O

The None None O
pancreatic None None O
digestive None None O
enzymes None None I-PROTEIN
require None None O
an None None O
alkaline None None O
milieu None None O
for None None O
proper None None O
function None None O
, None None O
and None None O
lowering None None O
the None None O
pH None None O
disables None None O
their None None O
activity None None O
. None None O

Partial None None O
diabetic None None O
rats None None O
were None None O
treated None None O
with None None O
vanadium None None O
and None None O
insulin None None I-PROTEIN
injection None None O
and None None O
their None None O
effects None None O
on None None O
BC None None O
ultrastructure None None O
are None None O
studied None None O
. None None O

Animals None None O
were None None O
randomly None None O
divided None None O
to None None O
control None None O
( None None O
CD None None O
) None None O
, None None O
vanadium-treated None None O
( None None O
1 None None O
mg/mL None None O
VOSO4 None None O
+ None None O
5H2O None None O
in None None O
base None None O
solution None None O
, None None O
VTD None None O
) None None O
and None None O
insulin-treated None None O
( None None O
80 None None O
U/kg/day None None O
NPH None None O
insulin None None I-PROTEIN
injection None None O
, None None O
ITD None None O
) None None O
diabetic None None O
groups None None O
. None None O

Intermittent None None O
tail None None O
blood None None O
samples None None O
were None None O
taken None None O
for None None O
measurements None None O
of None None O
blood None None O
glucose None None O
( None None O
BG None None O
) None None O
and None None O
plasma None None O
insulin None None I-PROTEIN
( None None O
PI None None O
) None None O
. None None O

Hyperglycemia None None O
worsened None None O
in None None O
CD None None O
and None None O
repaired None None O
in None None O
ITD None None O
shortly None None O
after None None O
insulin None None I-PROTEIN
withdrawal None None O
. None None O

BC None None O
had None None O
pyknotic None None O
nuclei None None O
, None None O
vacuolated None None O
cytoplasm None None O
and None None O
few None None O
tiny None None O
insulin None None I-PROTEIN
secretory None None O
granules None None O
. None None O

BC None None O
had None None O
well-developed None None O
endoplasmic None None O
reticulum None None O
, None None O
many None None O
insulin None None I-PROTEIN
secretory None None O
granules None None O
and None None O
mitochondria None None O
. None None O

The None None O
trophic None None O
actions None None O
of None None O
vanadium None None O
in None None O
diabetic None None O
rats None None O
effectively None None O
renovated None None O
beta None None O
cell None None O
ultrastructure None None O
and None None O
prevented None None O
pancreatic None None O
islets None None O
atrophy None None O
, None None O
whereas None None O
the None None O
relief None None O
of None None O
glucotoxicity None None O
seen None None O
with None None O
insulin None None I-PROTEIN
treatment None None O
could None None O
repair None None O
some None None O
beta None None O
cells None None O
and None None O
partially None None O
prevented None None O
islet None None O
atrophy None None O
. None None O

This None None O
peculiar None None O
course None None O
of None None O
the None None O
vein None None O
might None None O
predispose None None O
it None None O
for None None O
thrombosis None None I-DISEASE
in None None O
case None None O
of None None O
pancreatitis None None O
. None None O

Erlotinib None None O
is None None O
a None None O
selective None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
used None None O
as None None O
a None None O
target None None O
therapy None None O
against None None O
non-small None None O
lung None None O
cancer None None O
and None None O
advanced None None O
pancreatic None None O
cancer None None O
. None None O

Parents None None O
and None None O
teachers None None O
reported None None O
on None None O
children None None O
's None None O
socio-emotional None None O
and None None O
behavioral None None O
skills None None O
with None None O
the None None O
Devereux None None O
Early None None O
Childhood None None O
Assessment None None O
( None None O
DECA None None O
) None None O
, None None O
while None None O
children None None O
's None None O
pre-academic None None O
skills None None O
( None None O
cognitive None None O
, None None O
motor None None O
, None None O
and None None O
language None None I-FUNC
) None None O
were None None O
assessed None None O
directly None None O
with None None O
the None None O
Learning None None I-FUNC
Accomplishment None None O
Profile None None O
Diagnostic None None O
( None None O
LAP-D None None O
) None None O
at None None O
the None None O
beginning None None O
and None None O
end None None O
of None None O
their None None O
four-year-old None None O
pre-K None None O
year None None O
. None None O

The None None O
aim None None O
was None None O
to None None O
evaluate None None O
the None None O
effect None None O
of None None O
seeds None None O
of None None O
B. None None O
crassifolia None None O
on None None O
insulin None None I-PROTEIN
release None None O
from None None O
the None None O
pancreatic None None O
beta None None O
cells None None O
in None None O
streptozotocininduced None None O
diabetic None None O
rats None None O
. None None O

Insulin None None I-PROTEIN
level None None O
; None None O
insulin None None I-PROTEIN
sensitivity None None O
index None None O
, None None O
insulin None None I-PROTEIN
content None None O
in None None O
pancreas None None O
, None None O
malonaldehyde None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
contents None None O
, None None O
oxidative None None O
stress None None O
parameters None None O
were None None O
assayed None None O
. None None O

To None None O
determine None None O
the None None O
insulin None None I-PROTEIN
releasing None None O
activity None None O
, None None O
after None None O
extract None None O
treatment None None O
, None None O
the None None O
pancreas None None O
was None None O
excised None None O
. None None O

The None None O
extract None None O
decreased None None O
serum None None O
glucose None None O
in None None O
streptozotocin-induced None None O
diabetic None None O
rats None None O
and None None O
increased None None O
insulin None None I-PROTEIN
release None None O
from None None O
the None None O
beta None None O
cells None None O
of None None O
the None None O
pancreas None None O
. None None O

Natural None None O
products None None O
from None None O
plants None None O
have None None O
received None None O
considerable None None O
attention None None I-FUNC
in None None O
recent None None O
years None None O
due None None O
to None None O
their None None O
diverse None None O
pharmacological None None O
properties None None O
, None None O
including None None O
antioxidants None None O
and None None O
hepatoprotective None None O
activities None None O
. None None O

The None None O
effects None None O
of None None O
AEPA None None O
on None None O
biomarkers None None O
of None None O
oxidative None None O
damage None None O
( None None O
lipid None None O
peroxidation None None O
) None None O
and None None O
antioxidant None None O
enzymes None None I-PROTEIN
namely None None O
, None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
, None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPx None None O
) None None O
and None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
( None None O
GST None None O
) None None O
were None None O
measured None None O
in None None O
liver None None O
post None None O
mitochondrial None None O
fraction None None O
. None None O

The None None O
activities None None O
of None None O
antioxidant None None O
enzymes None None I-PROTEIN
, None None O
levels None None O
of None None O
malondialdehyde None None O
and None None O
protein None None O
carbonyls None None O
were None None O
also None None O
decreased None None O
dose-dependently None None O
in None None O
the None None O
AEPA-treated None None O
rats None None O
. None None O

Thus None None O
iron None None O
deficiency None None O
anemia None None O
during None None O
pregnancy None None O
in None None O
well-educated None None O
set None None O
up None None O
needs None None O
more None None O
attention None None I-FUNC
by None None O
the None None O
concerned None None O
authorities None None O
. None None O

The None None O
anti-arthritic None None O
activity None None O
of None None O
HEAC None None O
was None None O
assessed None None O
based None None O
on None None O
the None None O
ability None None O
of None None O
HEAC None None O
to None None O
alter None None O
the None None O
paw None None O
edema None None O
diameter None None O
, None None O
body None None O
weight None None O
, None None O
full None None O
blood None None O
count None None O
, None None O
renal None None O
and None None O
liver None None O
function None None O
markers None None O
, None None O
glycoprotein None None O
, None None O
lysosomal None None O
enzymes None None I-PROTEIN
and None None O
possible None None O
antioxidant None None O
potential None None O
in None None O
the None None O
arthritic None None O
rats None None O
. None None O

The None None O
mechanism None None O
of None None O
the None None O
compounds None None O
on None None O
inhibiting None None O
heterotypic None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
were None None O
further None None O
explored None None O
by None None O
determining None None O
the None None O
expression None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
, None None O
Intercellular None None O
adhesion None None O
molecule None None O
1 None None O
( None None O
ICAM-1 None None O
) None None O
, None None O
αv-integrin None None O
, None None O
β1-integrin None None O
and None None O
β5-integrin None None O
by None None O
western None None O
blotting None None O
assay None None O
. None None O

The None None O
anti-inflammatory None None O
activity None None O
of None None O
P. None None O
capensis None None O
extracts None None O
was None None O
evaluated None None O
against None None O
both None None O
cyclooxygenase None None O
enzymes None None I-PROTEIN
( None None O
COX None None O
1 None None O
and None None O
2 None None O
) None None O
. None None O

To None None O
understand None None O
the None None O
neuroprotective None None O
effects None None O
of None None O
honeybee None None O
propolis None None O
, None None O
glutamine None None I-TRANS
synthetase None None I-PROTEIN
( None None O
GS None None O
) None None O
activity None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
, None None O
thiobarbituric None None O
acid None None O
reactive None None O
substances None None O
( None None O
TBARS None None O
) None None O
and None None O
total None None O
antioxidant None None O
status None None O
( None None O
TAS None None O
) None None O
were None None O
studied None None O
in None None O
different None None O
brain None None O
regions-cerebral None None O
cortex None None I-REGION
( None None O
CC None None O
) None None O
, None None O
cerebellum None None I-REGION
( None None O
CB None None O
) None None O
and None None O
brain None None O
stem None None O
( None None O
BS None None O
) None None O
of None None O
rats None None O
supplemented None None O
with None None O
propolis None None O
and None None O
subjected None None O
to None None O
kainic None None O
acid None None O
( None None O
KA None None O
) None None O
mediated None None O
excitotoxicity None None O
. None None O

Three None None O
variants None None O
of None None O
primary None None O
progressive None None O
aphasia None None I-DISEASE
( None None O
PPA None None O
) None None O
, None None O
distinguished None None O
by None None O
language None None I-FUNC
performance None None O
and None None O
supportive None None O
patterns None None O
of None None O
atrophy None None O
on None None O
imaging None None O
, None None O
have None None O
different None None O
clinical None None O
courses None None O
and None None O
the None None O
prognoses None None O
for None None O
specific None None O
functions None None O
. None None O

Progressive None None O
atrophy None None O
in None None O
focal None None O
areas None None O
surrounding None None O
left None None I-REGION
temporal None None I-REGION
pole None None I-REGION
and None None O
left None None O
inferior None None O
temporal None None I-REGION
cortex None None I-REGION
, None None O
and None None O
right None None O
homologous None None O
area None None O
is None None O
closely None None O
related None None O
to None None O
progressive None None O
decline None None O
in None None O
auditory None None O
word None None O
comprehension None None O
. None None O

Initial None None O
mechanistic None None O
studies None None O
in None None O
Caki-1 None None O
cells None None O
in None None O
vitro None None O
coupled None None O
with None None O
studies None None O
of None None O
their None None O
inhibitory None None O
properties None None O
on None None O
a None None O
panel None None O
of None None O
35 None None O
kinases None None I-PROTEIN
of None None O
oncological None None O
interest None None O
indicate None None O
that None None O
these None None O
compounds None None O
inhibit None None O
protein None None O
kinases None None I-PROTEIN
of None None O
the None None O
AKT None None O
and None None O
MAPKAPK None None O
families None None O
with None None O
a None None O
higher None None O
selectivity None None O
toward None None O
MAPKAPK3 None None O
( None None O
IC503 None None O
= None None O
91 None None O
nM None None O
, None None O
IC505 None None O
= None None O
117 None None O
nM None None O
) None None O
. None None O

Electrocatalysis None None O
coupled None None O
with None None O
DNA-mediated None None O
charge None None O
transport None None O
has None None O
enabled None None O
specific None None O
and None None O
sensitive None None O
detection None None O
of None None O
lesions None None O
, None None O
mismatches None None O
and None None O
DNA-binding None None I-PROTEIN
proteins None None I-PROTEIN
. None None O

Stress None None O
generation None None O
was None None O
examined None None O
as None None O
a None None O
potential None None O
mechanism None None O
to None None O
explain None None O
the None None O
association None None O
between None None O
personality None None O
traits None None O
, None None O
especially None None O
negative None None O
emotionality None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

These None None O
hypothesized None None O
processes None None O
were None None O
evaluated None None O
in None None O
a None None O
prospective None None O
daily None None O
diary None None O
study None None O
in None None O
which None None O
young None None O
adults None None O
( None None O
N=210 None None O
) None None O
completed None None O
baseline None None O
measures None None O
of None None O
personality None None O
, None None O
dysfunctional None None O
attitudes None None O
, None None O
negative None None O
cognitive None None O
style None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

Negative None None O
Emotionality-Stress None None O
Reaction None None O
( None None O
NEM-SR None None O
) None None O
predicted None None O
initial None None O
levels None None O
and None None O
trajectories None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
stressors None None O
over None None O
time None None O
. None None O

Both None None O
dysfunctional None None O
attitudes None None O
and None None O
negative None None O
cognitive None None O
style None None O
interacted None None O
with None None O
these None None O
additional None None O
stressors None None O
to None None O
predict None None O
prospective None None O
fluctuations None None O
of None None O
daily None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

The None None O
vast None None O
majority None None O
of None None O
patients None None O
with None None O
symptoms None None O
suggestive None None O
of None None O
PAD None None O
have None None O
atherosclerosis None None I-DISEASE
often None None O
associated None None O
with None None O
conventional None None O
vascular None None O
risk None None O
factors None None O
such None None O
as None None O
smoking None None O
, None None O
diabetes None None O
, None None O
dyslipidemia None None O
, None None O
and None None O
inflammation None None O
. None None O

Peripheral None None O
arterial None None O
disease None None O
( None None O
PAD None None O
) None None O
describes None None O
the None None O
clinical None None O
manifestations None None O
of None None O
atherosclerosis None None I-DISEASE
affecting None None O
the None None O
circulation None None O
in None None O
the None None O
legs None None O
. None None O

Antiplatelet None None O
agents None None O
and None None O
anticoagulants None None O
may None None O
be None None O
used None None O
to None None O
reduce None None O
the None None O
incidence None None O
of None None O
acute None None O
events None None O
related None None O
to None None O
thrombosis None None I-DISEASE
. None None O

In None None O
vitro None None O
studies None None O
improve None None O
the None None O
production None None O
of None None O
human None None O
recombinant None None O
proteins None None O
, None None O
such None None O
as None None O
insulin None None I-PROTEIN
( None None O
INS None None O
) None None O
, None None O
growth None None O
hormone None None O
( None None O
GH None None O
) None None O
, None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor-1 None None O
( None None O
IGF-1 None None O
) None None O
and None None O
erythropoietin None None O
( None None O
EPO None None O
) None None O
, None None O
which None None O
could None None O
have None None O
therapeutic None None O
application None None O
. None None O

Reactive None None O
oxygen None None O
species None None O
are None None O
produced None None O
during None None O
anaerobic None None O
exercise None None O
mostly None None O
by None None O
Fe None None O
ions None None O
released None None O
into None None O
plasma None None O
and None None O
endothelial/muscle None None O
xanthine None None I-PROTEIN
oxidase None None I-PROTEIN
activation None None O
that None None O
generates None None O
uric None None O
acid None None O
( None None O
UA None None O
) None None O
as None None O
the None None O
endpoint None None O
metabolite None None O
. None None O

The None None O
dynamic None None O
resistance None None O
warm-up None None O
method None None O
was None None O
found None None O
to None None O
cause None None O
changes None None O
in None None O
the None None O
kinematics None None O
of None None O
jumping None None O
movements None None I-FUNC
, None None O
as None None O
well None None O
as None None O
an None None O
increase None None O
in None None O
jump None None O
height None None O
values None None O
. None None O

[ None None O
Purpose None None O
] None None O
The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
effects None None O
of None None O
unstable None None O
surface None None O
training None None O
( None None O
UST None None O
) None None O
on None None O
walking None None O
ability None None O
in None None O
chronic None None O
stroke None None I-DISEASE
patients None None O
. None None O

[ None None O
Conclusion None None O
] None None O
The None None O
results None None O
of None None O
the None None O
study None None O
suggest None None O
that None None O
UST None None O
is None None O
an None None O
effective None None O
method None None O
for None None O
improvement None None O
of None None O
walking None None O
ability None None O
in None None O
chronic None None O
stroke None None I-DISEASE
patients None None O
. None None O

[ None None O
Purpose None None O
] None None O
Cerebral None None I-DISEASE
palsy None None I-DISEASE
is None None O
a None None O
disorder None None O
that None None O
affects None None O
balance None None O
in None None O
the None None O
sitting None None O
position None None O
. None None O

In None None O
order None None O
to None None O
improve None None O
trunk None None O
control None None O
sensory-motor None None O
control None None I-FUNC
training None None O
is None None O
carried None None O
out None None O
on None None O
an None None O
unstable None None O
surface None None O
. None None O

Before None None O
using None None O
the None None O
TTS None None O
for None None O
training None None O
children None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
experiments None None O
were None None O
conducted None None O
with None None O
healthy None None O
adult None None O
subjects None None O
and None None O
the None None O
TTS None None O
to None None O
gather None None O
basic None None O
data None None O
for None None O
its None None O
improvement None None O
. None None O

[ None None O
Purpose None None O
] None None O
The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
recovery None None O
process None None O
of None None O
standing None None O
postural None None O
control None None O
in None None O
hemiplegia None None O
after None None O
stroke None None I-DISEASE
. None None O

[ None None O
Purpose None None O
] None None O
The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
psychometric None None O
properties None None O
of None None O
the None None O
lower None None O
extremity None None O
subscale None None O
of None None O
the None None O
Fugl-Meyer None None O
Assessment None None O
lower None None O
extremity None None O
( None None O
FMA-LE None None O
) None None O
for None None O
community-dwelling None None O
hemiplegic None None O
stroke None None I-DISEASE
patients None None O
. None None O

Anxiety None None O
and None None O
depression None None I-DISEASE
showed None None O
a None None O
significant None None O
interaction None None O
effect None None O
between None None O
groups None None O
. None None O

[ None None O
Subjects None None O
and None None O
Methods None None O
] None None O
In None None O
total None None O
, None None O
46 None None O
stroke None None I-DISEASE
patients None None O
and None None O
37 None None O
age-matched None None O
healthy None None O
subjects None None O
were None None O
recruited None None O
for None None O
the None None O
study None None O
. None None O

[ None None O
Results None None O
] None None O
The None None O
control None None O
of None None O
postural None None O
stability None None O
during None None O
standing None None O
with None None O
active None None O
head None None O
rotation None None O
was None None O
significantly None None O
decreased None None O
in None None O
the None None O
stroke None None I-DISEASE
group None None O
as None None O
compared None None O
with None None O
the None None O
healthy None None O
group None None O
with None None O
both None None O
the None None O
eyes None None O
open None None O
and None None O
closed None None O
. None None O

[ None None O
Conclusion None None O
] None None O
The None None O
findings None None O
suggest None None O
that None None O
postural None None O
instability None None O
is None None O
increased None None O
in None None O
stroke None None I-DISEASE
patients None None O
during None None O
active None None O
head None None O
rotation None None O
, None None O
and None None O
therefore None None O
, None None O
vestibular None None O
function None None O
in None None O
relation None None O
to None None O
head None None O
rotation None None O
might None None O
be None None O
reduced None None O
in None None O
stroke None None I-DISEASE
patients None None O
. None None O

The None None O
subjects None None O
in None None O
this None None O
group None None O
demonstrated None None O
higher None None O
levels None None O
of None None O
acceptance None None O
of None None O
injuries None None O
during None None O
the None None O
rehabilitation None None O
period None None O
than None None O
the None None O
other None None O
groups None None O
, None None O
devotion None None O
to None None O
rehabilitation None None O
, None None O
and None None O
awareness None None O
of None None O
the None None O
recovery None None O
in None None O
competitive None None O
performance None None O
and None None O
a None None O
feeling None None I-FUNC
of None None O
personal None None O
growth None None O
. None None O

[ None None O
Purpose None None O
] None None O
The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
changes None None O
in None None O
function None None O
and None None O
balance None None O
after None None O
Kinesio None None O
Taping None None O
application None None O
in None None O
stroke None None I-DISEASE
patients None None O
. None None O

[ None None O
Purpose None None O
] None None O
This None None O
study None None O
examined None None O
the None None O
effects None None O
of None None O
stair None None O
gait None None O
exercise None None O
on None None O
the None None O
static None None O
balance None None O
ability None None O
of None None O
chronic None None O
stroke None None I-DISEASE
patients None None O
. None None O

Combining None None O
mental None None O
practice None None O
with None None O
physical None None O
practice None None O
may None None O
be None None O
a None None O
more None None O
effective None None O
treatment None None O
strategy None None O
than None None O
physical None None O
training None None O
alone None None O
for None None O
hand None None O
recovery None None O
in None None O
stroke None None I-DISEASE
patients None None O
. None None O

This None None O
study None None O
designed None None O
to None None O
assess None None O
the None None O
behavior None None O
of None None O
IL-1β None None O
through None None O
newly None None O
diagnosed None None O
patients None None O
, None None O
different None None O
responders None None O
groups None None O
( None None O
optimal None None O
, None None O
suboptimal None None O
and None None O
failure None None O
cytogenetic None None O
response None None O
) None None O
and None None O
advanced None None O
stages None None O
( None None O
acceleration None None O
and None None O
crisis None None O
groups None None O
) None None O
of None None O
CML None None O
Iraqi None None O
patients None None O
whom None None O
receiving None None O
Imatinib None None O
mesylate None None O
( None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
) None None O
, None None O
trying None None O
to None None O
elucidate None None O
the None None O
role None None O
of None None O
immunity None None O
in None None O
pathophysiology None None O
of None None O
CML None None O
disease None None O
development None None O
and None None O
treatments None None O
. None None O

Mean None None O
serum None None O
ferritin None None I-PROTEIN
was None None O
486.54 None None O
± None None O
640.0 None None O
ng/ml None None O
( None None O
15-4,554 None None O
) None None O
. None None O

Nine None None O
patients None None O
had None None O
a None None O
serum None None O
ferritin None None I-PROTEIN
of None None O
≥1,000 None None O
ng/ml None None O
. None None O

Serum None None O
ferritin None None I-PROTEIN
did None None O
not None None O
correlate None None O
with None None O
age None None O
, None None O
total None None O
number None None O
of None None O
BTs None None O
splenectomy None None O
status None None O
or None None O
BT None None O
in None None O
last None None O
one None None O
year None None O
( None None O
p None None O
& None None O
gt None None O
; None None O
0.05 None None O
) None None O
. None None O

Age None None O
, None None O
BT None None O
and None None O
splenectomized None None O
status None None O
did None None O
not None None O
affect None None O
ferritin None None I-PROTEIN
level None None O
. None None O

to None None O
contribute None None O
to None None O
ferritin None None I-PROTEIN
level None None O
and None None O
hence None None O
iron None None O
load None None O
in None None O
TI None None O
patients None None O
. None None O

The None None O
effects None None O
of None None O
buffy None None O
coat None None O
removal None None O
on None None O
the None None O
efficiency None None O
of None None O
leukofiltration None None O
, None None O
storage None None I-FUNC
parameters None None O
of None None O
leukofiltered None None O
packed None None O
red None None O
blood None None O
cells None None O
and None None O
feasibility None None O
of None None O
prestorage None None O
leukofiltration None None O
were None None O
also None None O
assessed None None O
. None None O

Levels None None O
of None None O
K None None O
( None None O
+ None None O
) None None O
, None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
and None None O
hemolysis None None O
were None None O
assessed None None O
in None None O
all None None O
the None None O
units None None O
weekly None None O
, None None O
post None None O
leukofiltration None None O
. None None O

Leukofiltered None None O
PRBC None None O
showed None None O
lesser None None O
elevation None None O
of None None O
K None None O
( None None O
+ None None O
) None None O
, None None O
LDH None None O
and None None O
hemolysis None None O
towards None None O
the None None O
end None None O
of None None O
the None None O
storage None None I-FUNC
period None None O
as None None O
compared None None O
to None None O
their None None O
unfiltered None None O
counterparts None None O
. None None O

Buffy None None O
coat None None O
removal None None O
prior None None O
to None None O
filtration None None O
improves None None O
the None None O
efficiency None None O
of None None O
leukofilter None None O
and None None O
aids None None O
in None None O
improving None None O
the None None O
storage None None I-FUNC
of None None O
red None None O
cells None None O
in None None O
terms None None O
of None None O
hemolysis None None O
. None None O

Platelet None None O
count None None O
, None None O
prothrombin None None O
time None None O
( None None O
PT None None O
) None None O
, None None O
activated None None O
partial None None O
thromboplastin None None O
time None None O
( None None O
APTT None None O
) None None O
, None None O
thrombin None None I-PROTEIN
time None None O
( None None O
TT None None O
) None None O
, None None O
Fibrinogen None None O
and None None O
D-dimer None None O
levels None None O
were None None O
measured None None O
immediately None None O
, None None O
24 None None O
h None None O
and None None O
7 None None O
days None None O
after None None O
operation None None O
and None None O
compared None None O
with None None O
the None None O
baseline None None O
preoperative None None O
values None None O
. None None O

The None None O
current None None O
study None None O
was None None O
initiated None None O
to None None O
determine None None O
the None None O
prevalence None None O
of None None O
activated None None O
protein None None I-PROTEIN
C None None I-PROTEIN
( None None O
APC None None O
) None None O
resistance None None O
, None None O
factor None None O
V None None O
Leiden None None O
and None None O
antiphospholipid None None O
antibodies None None O
( None None O
APA None None O
) None None O
in None None O
Iraqi None None O
women None None O
with None None O
recurrent None None O
fetal None None O
loss None None O
( None None O
RFL None None O
) None None O
, None None O
and None None O
evaluate None None O
the None None O
outcome None None O
of None None O
intervention None None O
in None None O
those None None O
with None None O
such None None O
states None None O
. None None O

Seventy-one None None O
Korean None None O
NTG None None O
patients None None O
with None None O
low None None O
IOP None None I-TRANS
( None None O
the None None O
highest None None O
IOP None None I-TRANS
& None None O
lt None None O
; None None O
15 None None O
mmHg None None O
, None None O
40 None None O
patients None None O
) None None O
and None None O
high None None O
IOP None None I-TRANS
( None None O
the None None O
lowest None None O
IOP None None I-TRANS
& None None O
gt None None O
; None None O
15 None None O
mmHg None None O
, None None O
31 None None O
patients None None O
) None None O
were None None O
included None None O
in None None O
this None None O
study None None O
. None None O

The None None O
prevalence None None O
of None None O
self-reported None None O
Raynaud None None O
phenomenon None None O
was None None O
significantly None None O
higher None None O
in None None O
the None None O
low None None O
IOP None None I-TRANS
group None None O
( None None O
33.0 None None O
% None None O
) None None O
than None None O
the None None O
high None None O
IOP None None I-TRANS
group None None O
( None None O
10.3 None None O
% None None O
, None None O
p None None O
= None None O
0.04 None None O
) None None O
. None None O

However None None O
, None None O
the None None O
prevalence None None O
of None None O
Raynaud None None O
phenomenon None None O
was None None O
higher None None O
in None None O
the None None O
low None None O
IOP None None I-TRANS
groups None None O
. None None O

The None None O
potential None None O
role None None O
of None None O
gonadal None None O
hormones None None I-PROTEIN
is None None O
discussed None None O
based None None O
on None None O
the None None O
female None None O
predominance None None O
in None None O
IBS None None O
and None None O
the None None O
correlation None None O
between None None O
IBS None None O
symptoms None None O
and None None O
hormonal None None O
status None None O
. None None O

Gonadal None None O
hormones None None I-PROTEIN
, None None O
in None None O
particular None None O
estrogens None None I-PROTEIN
, None None O
can None None O
significantly None None O
modulate None None O
various None None O
clinical None None O
manifestations None None O
of None None O
IBS None None O
, None None O
including None None O
alterations None None O
in None None O
GI None None O
motility None None O
and None None O
visceral None None O
hypersensitivity None None O
. None None O

The None None O
modulatory None None O
effects None None O
of None None O
estrogens None None I-PROTEIN
on None None O
visceral None None O
pain None None O
may None None O
result None None O
from None None O
interactions None None O
with None None O
numerous None None O
neurotransmitters None None I-TRANS
at None None O
different None None O
levels None None O
of None None O
the None None O
brain-gut None None O
axis None None O
, None None O
with None None O
a None None O
pivotal None None O
role None None O
of None None O
estrogens None None I-PROTEIN
' None None O
interactions None None O
with None None O
the None None O
serotonin None None I-TRANS
and None None O
corticotropin-releasing None None O
factor None None O
( None None O
CRF None None O
) None None O
signaling None None O
systems None None O
. None None O

Gymnasts None None O
with None None O
the None None O
best None None O
results None None O
in None None O
coordination None None O
and None None O
motor None None O
learning None None I-FUNC
tests None None O
went None None O
on None None O
to None None O
achieve None None O
better None None O
competition None None O
results None None O
in None None O
three- None None O
year None None O
time None None O
. None None O

It None None O
was None None O
predicted None None O
that None None O
the None None O
use None None O
of None None O
movement None None I-FUNC
outcome None None O
instructions None None O
could None None O
enhance None None O
the None None O
learning None None I-FUNC
of None None O
a None None O
serial None None O
skill None None O
as None None O
previously None None O
supported None None O
in None None O
studies None None O
examining None None O
the None None O
acquisition None None O
of None None O
discrete None None O
and None None O
continuous None None O
skills None None O
. None None O

Key None None O
PointsMovement None None O
outcome None None O
( None None O
MO None None O
) None None O
instructions None None O
have None None O
a None None O
positive None None O
impact None None O
on None None O
learning None None I-FUNC
a None None O
serial None None O
task None None O
, None None O
especially None None O
in None None O
kicking None None O
actions.More None None O
functional None None O
coordination None None O
during None None O
movement None None I-FUNC
executions None None O
for None None O
MO None None O
participants.Benefits None None O
for None None O
MO None None O
instructions None None O
may None None O
be None None O
individual None None O
specific None None O
. None None O

The None None O
goal None None O
of None None O
the None None O
present None None O
review None None O
is None None O
to None None O
therefore None None O
scrutinize None None O
what None None O
is None None O
currently None None O
known None None O
regarding None None O
students None None O
' None None O
learning None None I-FUNC
during None None O
their None None O
participation None None O
in None None O
Sport None None O
Education None None O
. None None O

While None None O
research None None O
on None None O
the None None O
impact None None O
of None None O
Sport None None O
Education None None O
on None None O
students None None O
' None None O
learning None None I-FUNC
, None None O
as None None O
well None None O
as None None O
teachers None None O
' None None O
and None None O
students None None O
' None None O
perceptions None None I-FUNC
about None None O
student None None O
learning None None I-FUNC
has None None O
shown None None O
students None None O
' None None O
improvements None None O
during None None O
the None None O
participation None None O
in None None O
Sport None None O
Education None None O
seasons None None O
, None None O
there None None O
is None None O
still None None O
considerable None None O
variance None None O
in None None O
these None None O
results None None O
. None None O

These None None O
inconsistent None None O
results None None O
can None None O
be None None O
explained None None O
by None None O
factors None None O
not None None O
considered None None O
in None None O
the None None O
Sport None None O
Education None None O
research None None O
, None None O
such None None O
as None None O
the None None O
effect None None O
of None None O
time None None O
on None None O
students None None O
' None None O
learning None None I-FUNC
and None None O
the None None O
control None None O
of None None O
the None None O
teaching-learning None None O
process None None O
within None None O
Sport None None O
Education None None O
units None None O
. None None O

Future None None O
research None None O
should None None O
define None None O
, None None O
implement None None O
, None None O
and None None O
evaluate None None O
protocols None None O
for None None O
student-coaches None None O
' None None O
preparation None None O
in None None O
order None None O
to None None O
understand None None O
the None None O
influence None None O
of None None O
this None None O
issue None None O
on None None O
students None None O
' None None O
learning None None I-FUNC
as None None O
well None None O
as None None O
consider None None O
the None None O
implementation None None O
of None None O
hybrid None None O
approaches None None O
. None None O

These None None O
differences None None O
included None None O
: None None O
1 None None O
) None None O
decreased None None O
external None None O
rotation None None O
of None None O
contralateral None None O
hip None None O
, None None O
hence None None O
a None None O
decreased None None O
hip None None O
contribution None None O
to None None O
'turn None None O
out None None O
' None None O
; None None O
2 None None O
) None None O
increased None None O
contralateral None None O
knee None None O
adduction None None O
and None None O
internal None None O
rotation None None O
; None None O
3 None None O
) None None O
an None None O
apparent None None O
synchronicity None None O
in None None O
the None None O
contralateral None None O
lower None None O
limb None None O
of None None O
the None None O
decreased None None O
hip None None O
external None None O
rotation None None O
and None None O
increased None None O
knee None None O
adduction None None O
; None None O
and None None O
4 None None O
) None None O
minimal None None O
use None None O
of None None O
ankle None None O
plantar/dorsiflexion None None O
movement None None I-FUNC
for None None O
symptomatic None None O
side None None O
. None None O

Serum None None O
insulin None None I-PROTEIN
, None None O
IGF-1 None None O
, None None O
GH None None O
, None None O
and None None O
cortisol None None O
were None None O
not None None O
differentially None None O
affected None None O
( None None O
p None None O
& None None O
gt None None O
; None None O
0.05 None None O
) None None O
. None None O

Key None None O
pointsIn None None O
response None None O
to None None O
42 None None O
days None None O
of None None O
heavy None None O
resistance None None O
training None None O
and None None O
either None None O
SizeOn None None O
Maximum None None O
Performance None None O
or None None O
protein/carbohydrate/creatine None None O
supplementation None None O
, None None O
similar None None O
increases None None O
in None None O
muscle None None O
mass None None O
and None None O
strength None None O
in None None O
both None None O
groups None None O
occurred None None O
; None None O
however None None O
, None None O
the None None O
increases None None O
were None None O
not None None O
different None None O
between None None O
supplement None None O
groups.The None None O
supplementation None None O
of None None O
SizeOn None None O
Maximum None None O
Performance None None O
had None None O
no None None O
preferential None None O
effect None None O
on None None O
augmenting None None O
serum None None O
insulin None None I-PROTEIN
, None None O
IGF-1 None None O
, None None O
and None None O
GH None None O
, None None O
or None None O
in None None O
decreasing None None O
cortisol.While None None O
resistance None None O
training None None O
was None None O
effective None None O
in None None O
increasing None None O
total None None O
creatine None None O
content None None O
in None None O
skeletal None None O
muscle None None O
, None None O
myofibrillar None None O
protein None None O
, None None O
and None None O
the None None O
content None None O
of None None O
total None None O
IRS-1 None None O
and None None O
Akt None None O
, None None O
it None None O
was None None O
not None None O
preferentially None None O
due None None O
to None None O
SizeOn None None O
Maximum None None O
Performance None None O
supplementation.At None None O
the None None O
daily None None O
dose None None O
of None None O
50 None None O
g None None O
, None None O
SizeOn None None O
Maximum None None O
Performance None None O
supplementation None None O
for None None O
42 None None O
days None None O
combined None None O
with None None O
resistance None None O
training None None O
does None None O
not None None O
increases None None O
muscle None None O
mass None None O
and None None O
strength None None O
due None None O
to None None O
its None None O
ability None None O
to None None O
elevate None None O
serum None None O
hormones None None I-PROTEIN
and None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
or None None O
in None None O
its None None O
ability None None O
to None None O
augment None None O
skeletal None None O
muscle None None O
signaling None None O
pathway None None O
markers None None O
indicative None None O
of None None O
muscle None None O
protein None None O
synthesis None None O
when None None O
compared None None O
to None None O
an None None O
equivalent None None O
daily None None O
dose None None O
of None None O
protein/carbohydrate/creatine None None O
. None None O

The None None O
present None None O
study None None O
aimed None None O
to None None O
investigate None None O
whether None None O
facial None None O
electromyography None None O
( None None O
EMG None None O
) None None O
recordings None None O
reflect None None O
the None None O
perception None None I-FUNC
of None None O
effort None None O
and None None O
primary None None O
active None None O
lower None None O
limb None None O
muscle None None O
activity None None O
during None None O
incremental None None O
workload None None O
cycling None None O
. None None O

To None None O
do None None O
so None None O
, None None O
we None None O
examined None None O
the None None O
content None None O
and None None O
distribution None None O
of None None O
myosin None None O
heavy None None O
chain None None O
( None None O
MyHC None None O
) None None O
isoforms None None O
in None None O
the None None O
rat None None O
soleus None None O
muscle None None O
fiber None None O
, None None O
the None None O
activity None None O
of None None O
CaN None None O
and None None O
expression None None O
of None None O
NFATc1 None None O
in None None O
these None None O
fibers None None O
, None None O
and None None O
changes None None O
in None None O
the None None O
expression None None O
of None None O
nerve None None O
growth None None O
factor None None O
( None None O
NGF None None O
) None None O
, None None O
brain-derived None None O
neurotrophic None None O
factor None None O
( None None O
BDNF None None O
) None None O
and None None O
neutrophin-3 None None O
( None None O
NT-3 None None O
) None None O
in None None O
the None None O
soleus None None O
and None None O
striatum None None I-REGION
following None None O
high-and None None O
medium-intensity None None O
aerobic None None O
treadmill None None O
training None None O
. None None O

We None None O
used None None O
ATPase None None I-PROTEIN
staining None None O
to None None O
identify None None O
the None None O
muscle None None O
fiber None None O
type None None O
I None None O
and None None O
II None None O
, None None O
SDS-PAGE None None O
to None None O
separate None None O
and None None O
analyze None None O
the None None O
isoforms None None O
MyHCI None None O
, None None O
MyHCIIA None None O
, None None O
MyHCIIB None None O
and None None O
MyHCIIx None None O
, None None O
and None None O
performed None None O
western None None O
blots None None O
to None None O
determine None None O
the None None O
expression None None O
of None None O
NFATc1 None None O
, None None O
NGF None None O
, None None O
BDNF None None O
and None None O
NT-3 None None O
. None None O

Eight None None O
weeks None None O
of None None O
moderate- None None O
and None None O
high-intensity None None O
aerobic None None O
exercise None None O
induced None None O
the None None O
expression None None O
of None None O
NGF None None O
, None None O
BDNF None None O
and None None O
NT-3 None None O
in None None O
the None None O
soleus None None O
muscle None None O
and None None O
the None None O
striatum None None I-REGION
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
with None None O
the None None O
most None None O
significant None None O
increase None None O
in None None O
the None None O
H-Ex None None O
group None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Heat None None O
stress None None O
, None None O
which None None O
strongly None None O
affects None None O
plant None None O
performance None None O
and None None O
often None None O
results None None O
in None None O
reduced None None O
vegetative None None O
growth None None O
and None None O
yields None None O
depression None None I-DISEASE
, None None O
has None None O
become None None O
an None None O
increasingly None None O
serious None None O
global None None O
problem None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
discuss None None O
the None None O
current None None O
knowledge None None O
of None None O
the None None O
potential None None O
molecular None None O
mechanisms None None O
, None None O
mediating None None O
abnormal None None O
cardiac None None O
development None None O
in None None O
non-syndromic None None O
and None None O
isolated None None O
CHD None None O
, None None O
including None None O
mutations None None O
in None None O
cardiac None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
the None None O
role None None O
of None None O
somatic None None O
mutations None None O
and None None O
epigenetic None None O
alterations None None O
as None None O
well None None O
as None None O
the None None O
influence None None O
of None None O
gene-environment None None O
interactions None None O
. None None O

The None None O
largest None None O
changes None None O
are None None O
seen None None O
as None None O
advantages None None O
in None None O
executive None None O
control None None O
, None None O
a None None O
set None None O
of None None O
processes None None O
responsible None None O
for None None O
controlled None None O
attention None None I-FUNC
, None None O
inhibition None None O
, None None O
and None None O
shifting None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
examine None None O
some None None O
of None None O
the None None O
evidence None None O
for None None O
these None None O
findings None None O
and None None O
explain None None O
their None None O
relation None None O
to None None O
bilingual None None O
language None None I-FUNC
use None None O
. None None O

Due None None O
to None None O
a None None O
shift None None O
toward None None O
home None None O
and None None O
community-based None None O
care None None O
there None None O
will None None O
be None None O
an None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
family None None O
caregivers None None O
caring None None O
for None None O
persons None None O
with None None O
dementia None None I-DISEASE
. None None O

Currently None None O
there None None O
is None None O
a None None O
paucity None None O
of None None O
research None None O
that None None O
examines None None O
the None None O
dementia None None I-DISEASE
caregiving None None O
experience None None O
from None None O
the None None O
perspective None None O
of None None O
bereaved None None O
caregivers None None O
or None None O
that None None O
presents None None O
the None None O
complete None None O
caregiving None None O
journey None None O
. None None O

This None None O
study None None O
utilized None None O
qualitative None None O
description None None O
to None None O
describe None None O
the None None O
overall None None O
dementia None None I-DISEASE
caregiving None None O
journey None None O
as None None O
told None None O
by None None O
11 None None O
bereaved None None O
caregivers None None O
. None None O

Findings None None O
from None None O
this None None O
work None None O
contribute None None O
new None None O
understanding None None O
to None None O
the None None O
literature None None O
around None None O
the None None O
unique None None O
perspective None None O
of None None O
bereaved None None O
caregivers None None O
, None None O
while None None O
presenting None None O
the None None O
overall None None O
dementia None None I-DISEASE
caregiving None None O
journey None None O
. None None O

Additionally None None O
, None None O
the None None O
use None None O
of None None O
retention None None I-FUNC
sutures None None O
, None None O
closure None None O
of None None O
the None None O
open None None O
abdomen None None O
, None None O
and None None O
reinforcement None None O
after None None O
component None None O
separation None None O
are None None O
examined None None O
using None None O
current None None O
literature None None O
. None None O

Furthermore None None O
, None None O
laparoscopic None None O
ventral None None I-NEURON
mesh None None O
rectopexy None None O
has None None O
emerged None None O
as None None O
a None None O
procedure None None O
that None None O
could None None O
potentially None None O
fill None None O
this None None O
role None None O
and None None O
is None None O
rapidly None None O
becoming None None O
the None None O
procedure None None O
of None None O
choice None None O
for None None O
the None None O
surgical None None O
treatment None None O
of None None O
pelvic None None O
organ None None O
prolapse None None O
. None None O

Lysozyme None None I-PROTEIN
, None None O
an None None O
antibacterial None None O
enzyme None None O
, None None O
was None None O
used None None O
as None None O
a None None O
stabilizing None None O
ligand None None O
for None None O
the None None O
synthesis None None O
of None None O
fairly None None O
uniform None None O
silver None None O
nanoparticles None None O
adopting None None O
various None None O
strategies None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
case None None O
report None None O
is None None O
to None None O
describe None None O
a None None O
patient None None O
with None None O
brain None None I-DISEASE
infarction None None I-DISEASE
due None None O
to None None O
recanalization None None O
of None None O
an None None O
occluded None None O
vertebral None None O
artery None None O
( None None O
VA None None O
) None None O
following None None O
closed None None O
reduction None None O
and None None O
open None None O
fixation None None O
of None None O
cervical None None O
spinal None None O
dislocation None None O
and None None O
to None None O
discuss None None O
the None None O
management None None O
of None None O
asymptomatic None None O
VA None None O
injuries None None O
associated None None O
with None None O
spine None None O
trauma None None O
. None None O

After None None O
surgery None None O
, None None O
supraspinal None None O
symptoms None None O
such None None O
as None None O
left None None O
horizontal None None O
nystagmus None None O
and None None O
left None None O
homonymous None None O
hemianopsia None None O
led None None O
to None None O
cranial None None O
computed None None O
tomography None None O
and None None O
magnetic None None O
resonance None None O
imaging None None O
, None None O
which None None O
showed None None O
left-side None None O
cerebellar None None O
infarction None None O
in None None O
the None None O
posterior None None O
inferior None None O
cerebellar None None O
artery None None O
territory None None O
and None None O
right-side None None O
posterior None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
infarction None None I-DISEASE
. None None O

Although None None O
there None None O
are None None O
some None None O
reports None None O
described None None O
where None None O
management None None O
with None None O
observation None None O
alone None None O
seems None None O
safe None None O
, None None O
serious None None O
attention None None I-FUNC
should None None O
be None None O
given None None O
to None None O
the None None O
VA None None O
injury None None O
caused None None O
by None None O
cervical None None O
spine None None O
trauma None None O
. None None O

All None None O
established None None O
languages None None I-FUNC
, None None O
spoken None None O
or None None O
signed None None O
, None None O
make None None O
a None None O
distinction None None O
between None None O
nouns None None O
and None None O
verbs None None O
. None None O

Here None None O
we None None O
ask None None O
whether None None O
handshape None None O
type None None O
is None None O
used None None O
to None None O
mark None None O
the None None O
noun-verb None None O
distinction None None O
in None None O
a None None O
gesture None None O
system None None O
invented None None O
by None None O
a None None O
deaf None None O
child None None O
who None None O
does None None O
not None None O
have None None O
access None None O
to None None O
a None None O
usable None None O
model None None O
of None None O
either None None O
spoken None None O
or None None O
signed None None O
language None None I-FUNC
. None None O

Thus None None O
, None None O
unlike None None O
users None None O
of None None O
established None None O
and None None O
emerging None None O
languages None None I-FUNC
, None None O
the None None O
homesigner None None O
is None None O
a None None O
producer None None O
of None None O
his None None O
system None None O
but None None O
does None None O
not None None O
receive None None O
it None None O
from None None O
others None None O
. None None O

The None None O
noun-verb None None O
distinction None None O
is None None O
thus None None O
so None None O
fundamental None None O
to None None O
language None None I-FUNC
that None None O
it None None O
can None None O
arise None None O
in None None O
a None None O
homesign None None O
system None None O
not None None O
shared None None O
with None None O
others None None O
. None None O

Here None None O
we None None O
have None None O
a None None O
closer None None O
look None None O
at None None O
the None None O
progression None None O
of None None O
irradiated None None O
cells None None O
through None None O
S-phase None None O
in None None O
dependence None None O
of None None O
their None None O
p53 None None I-PROTEIN
status None None O
. None None O

It None None O
is None None O
clear None None O
from None None O
the None None O
experiments None None O
presented None None O
here None None O
that None None O
p53 None None I-PROTEIN
does None None O
play None None O
a None None O
role None None O
for None None O
the None None O
progress None None O
of None None O
cells None None O
through None None O
the None None O
S-phase None None O
after None None O
X-ray None None O
exposure None None O
, None None O
but None None O
the None None O
exact None None O
mechanisms None None O
by None None O
which None None O
replicon None None O
initiation None None O
and None None O
elongation None None O
is None None O
controlled None None O
in None None O
irradiated None None O
cells None None O
remain None None O
to None None O
be None None O
elucidated None None O
. None None O

Human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
( None None O
HER2 None None O
) None None O
positive None None O
breast None None O
cancer None None O
is None None O
an None None O
entity None None O
with None None O
aggressive None None O
behaviour None None O
. None None O

Androgen None None O
or None None O
male None None O
hormones None None I-PROTEIN
are None None O
critical None None O
for None None O
the None None O
development None None O
and None None O
maintenance None None O
of None None O
male None None O
characteristics None None O
and None None O
numerous None None O
EDCs None None O
exist None None O
in None None O
the None None O
environment None None O
with None None O
the None None O
potential None None O
to None None O
disrupt None None O
androgen None None O
action None None O
. None None O

Use None None O
of None None O
reporter None None O
genes None None O
such None None O
as None None O
bacterial None None O
luciferase None None I-PROTEIN
( None None O
lux None None O
) None None O
and None None O
green None None O
fluorescent None None O
protein None None O
( None None O
gfp None None O
) None None O
has None None O
significantly None None O
improved None None O
speed None None O
and None None O
sensitivity None None O
of None None O
detection None None O
. None None O

The None None O
incidence None None O
of None None O
hypoglycemia None None I-DISEASE
and None None O
glycemic None None O
changes None None O
in None None O
relation None None O
to None None O
the None None O
adjustment None None O
of None None O
doses None None O
of None None O
antidiabetic None None O
agents None None O
, None None O
diet None None O
, None None O
and None None O
physical None None O
activity None None O
during None None O
Ramadan None None O
was None None O
also None None O
evaluated None None O
. None None O

Those None None O
who None None O
were None None O
hospitalized None None O
for None None O
diabetic None None O
ketoacidosis None None O
or None None O
severe None None O
hypoglycemia None None I-DISEASE
a None None O
month None None O
prior None None O
to None None O
Ramadan None None O
or None None O
were None None O
given None None O
short-term None None O
corticosteroid None None O
therapy None None O
were None None O
excluded None None O
. None None O

In None None O
addition None None O
, None None O
their None None O
rate None None O
of None None O
hypoglycemia None None I-DISEASE
was None None O
minimal None None O
. None None O

Compared None None O
with None None O
control None None O
, None None O
the None None O
ratio None None O
of None None O
heart-weight None None O
to None None O
body-weight None None O
and None None O
the None None O
serum None None O
levels None None O
of None None O
SOD None None O
and None None O
GSH None None O
in None None O
the None None O
BPS None None O
group None None O
significantly None None O
increased None None O
, None None O
the None None O
expression None None O
of None None O
p38 None None O
MAPK None None O
, None None O
the None None O
serum None None O
levels None None O
of None None O
MDA None None O
, None None O
TGF-β1 None None O
, None None O
TNF-α None None O
, None None O
HIF-1α None None O
, None None O
MMP-9 None None O
, None None O
caspase-3 None None O
, None None O
BNP None None I-TRANS
, None None O
ANP None None O
, None None O
and None None O
heart None None O
Bax None None O
expression None None O
significantly None None O
decreased None None O
, None None O
and None None O
heart None None O
Bcl-2 None None O
expression None None O
significantly None None O
increased None None O
. None None O

Surgical None None O
stress None None O
, None None O
intraoperative None None O
trauma None None O
, None None O
or None None O
laceration None None O
of None None O
the None None O
chorda None None O
tympani None None O
nerve None None O
with None None O
a None None O
resultant None None O
retrograde None None O
facial None None I-REGION
nerve None None I-REGION
edema None None O
can None None O
all None None O
be None None O
provoking None None O
etiological None None O
factors None None O
. None None O

Gingival None None O
epithelial None None O
cells None None O
participate None None O
in None None O
innate None None O
immunity None None O
by None None O
producing None None O
a None None O
range None None O
of None None O
antimicrobial None None O
peptides None None I-TRANS
to None None O
protect None None O
the None None O
host None None O
against None None O
oral None None O
pathogens None None O
. None None O

The None None O
women None None O
were None None O
asked None None O
about None None O
social None None O
problem-solving None None O
, None None O
and None None O
mental None None O
health None None O
symptoms None None O
of None None O
depression None None I-DISEASE
, None None O
anxiety None None O
, None None O
and None None O
PTSD None None O
as None None O
well None None O
as None None O
behavioral None None O
functioning None None O
of None None O
their None None O
children None None O
. None None O

Exposure None None O
of None None O
adult None None O
flies None None O
to None None O
HEDF None None O
caused None None O
mitochondrial None None O
dysfunction None None O
, None None O
overproduction None None O
of None None O
ROS None None O
, None None O
and None None O
alterations None None O
in None None O
the None None O
activity None None O
of None None O
detoxifying None None O
enzymes None None I-PROTEIN
GST None None O
, None None O
SOD None None O
and None None O
CAT None None O
. None None O

In None None O
parallel None None O
, None None O
alterations None None O
in None None O
cholinesterase None None I-PROTEIN
activity None None O
and None None O
impairments None None O
in None None O
negative None None O
geotaxis None None O
behavior None None O
were None None O
observed None None O
. None None O

A None None O
confirmatory None None O
factor None None O
analysis None None O
was None None O
performed None None O
on None None O
the None None O
results None None O
of None None O
SCL-90 None None O
filled None None O
by None None O
1,195 None None O
patients None None O
with None None O
heroin None None I-DISEASE
dependence None None I-DISEASE
entering None None O
TC None None O
treatment None None O
. None None O

The None None O
17-item None None O
Hamilton None None O
Depression None None I-DISEASE
Rating None None O
Scale None None O
( None None O
HAM-D None None O
) None None O
was None None O
used None None O
to None None O
decide None None O
whether None None O
a None None O
patient None None O
should None None O
be None None O
assigned None None O
to None None O
the None None O
remitted None None O
or None None O
non-remitted None None O
group None None O
. None None O

To None None O
separate None None O
correlations None None O
from None None O
causative None None O
effects None None O
, None None O
the None None O
expression None None O
levels None None O
of None None O
19 None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
perturbed None None O
under None None O
cellobiose None None O
conditions None None O
were None None O
modulated None None O
, None None O
and None None O
the None None O
three None None O
strongest None None O
promoters None None O
under None None O
cellobiose None None O
conditions None None O
were None None O
applied None None O
to None None O
fine-tune None None O
expression None None O
of None None O
the None None O
heterologous None None O
cellobiose-utilizing None None O
pathway None None O
. None None O

Herein None None O
, None None O
the None None O
two None None O
different None None O
folding None None O
states None None O
of None None O
mammalian None None O
genomes None None O
are None None O
reviewed None None O
and None None O
then None None O
models None None O
are None None O
discussed None None O
wherein None None O
instructions None None O
for None None O
cell None None O
type-specific None None O
genome None None O
folding None None O
are None None O
locally None None O
encoded None None O
in None None O
the None None O
linear None None O
genome None None O
and None None O
transmitted None None O
through None None O
mitosis None None O
, None None O
e.g. None None O
, None None O
as None None O
open None None O
chromatin None None O
sites None None O
with None None O
or None None O
without None None O
continuous None None O
binding None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

In None None O
this None None O
model None None O
, None None O
no None None O
explicit None None O
epigenetic None None O
memory None None I-FUNC
for None None O
cell None None O
type-specific None None O
chromosome None None O
folding None None O
is None None O
required None None O
. None None O

At None None O
a None None O
memory None None I-FUNC
clinic None None O
, None None O
247 None None O
referred None None O
consecutive None None O
patients None None O
with None None O
AD None None O
were None None O
monitored None None O
during None None O
12.6 None None O
± None None O
1.6 None None O
years None None O
. None None O

The None None O
AD None None O
pathology None None O
that None None O
independently None None O
predicted None None O
an None None O
early None None O
death None None O
caused None None O
by None None O
dementia None None I-DISEASE
was None None O
cerebral None None O
inflammation None None O
( None None O
sVCAM-1 None None O
; None None O
HR None None O
, None None O
1.32 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.07-1.64 None None O
) None None O
. None None O

When None None O
examining None None O
death None None O
caused None None O
by None None O
dementia None None I-DISEASE
and None None O
related None None O
causes None None O
( None None O
vascular None None O
diseases None None O
and None None O
infections None None O
) None None O
, None None O
age None None O
( None None O
HR None None O
, None None O
1.23 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.04-1.46 None None O
) None None O
and None None O
cerebrovascular None None O
pathology None None O
( None None O
white-matter None None O
lesions None None O
: None None O
HR None None O
, None None O
1.17 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.01-1.36 None None O
; None None O
and None None O
CSF/serum None None O
albumin None None I-PROTEIN
ratio None None O
: None None O
HR None None O
, None None O
1.16 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.001-1.34 None None O
) None None O
were None None O
also None None O
significant None None O
risk None None O
factors None None O
in None None O
addition None None O
to None None O
the None None O
previous None None O
variables None None O
. None None O

In None None O
terms None None O
of None None O
cardiovascular None None O
events None None O
special None None O
attention None None I-FUNC
may None None O
be None None O
given None None O
to None None O
calcium None None O
supplements None None O
. None None O

The None None O
relaxation None None O
times None None O
in None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
, None None O
thalamus None None I-REGION
and None None O
white None None I-REGION
matter None None I-REGION
were None None O
evaluated None None O
. None None O

The None None O
central None None O
neck None None O
compartment None None O
( None None O
level None None O
VI None None I-REGION
) None None O
lymph None None O
nodes None None O
are None None O
at None None O
the None None O
greatest None None O
risk None None O
of None None O
metastases None None O
from None None O
PTC None None O
, None None O
but None None O
the None None O
role None None O
of None None O
central None None O
neck None None O
dissection None None O
( None None O
CND None None O
) None None O
remains None None O
controversial None None O
, None None O
particularly None None O
in None None O
PTC None None O
without None None O
clinical None None O
cervical None None O
lymph None None O
node None None O
metastasis None None O
( None None O
cN0 None None O
) None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
the None None O
expression None None O
of None None O
p53 None None I-PROTEIN
, None None O
mouse None None O
double None None O
minute None None O
2 None None O
homolog None None O
( None None O
MDM2 None None O
) None None O
, None None O
eukaryotic None None O
translation None None O
initiation None None O
factor None None O
4E None None O
( None None O
eIF4E None None O
) None None O
, None None O
and None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
were None None O
investigated None None O
in None None O
nasopharyngeal None None O
carcinoma None None O
( None None O
NPC None None O
) None None O
, None None O
and None None O
the None None O
correlation None None O
between None None O
their None None O
expression None None O
and None None O
clinicopathological None None O
characteristics None None O
and None None O
prognosis None None O
was None None O
analyzed None None O
. None None O

Streptavidin-peroxidase None None O
immunohistochemistry None None O
was None None O
used None None O
to None None O
evaluate None None O
the None None O
expression None None O
of None None O
p53 None None I-PROTEIN
, None None O
MDM2 None None O
, None None O
eIF4E None None O
and None None O
EGFR None None O
in None None O
NPC None None O
biopsy None None O
specimens None None O
, None None O
and None None O
the None None O
association None None O
between None None O
their None None O
expression None None O
and None None O
clinical None None O
parameters None None O
and None None O
survival None None O
was None None O
analyzed None None O
. None None O

p53 None None I-PROTEIN
( None None O
χ2,20.322 None None O
; None None O
P=0.001 None None O
) None None O
and None None O
EGFR None None O
( None None O
χ2,8.337 None None O
; None None O
P=0.005 None None O
) None None O
expression None None O
were None None O
found None None O
to None None O
correlate None None O
with None None O
T None None O
stage None None O
, None None O
whereas None None O
MDM2 None None O
( None None O
χ2,16.361 None None O
; None None O
P=0.001 None None O
) None None O
expression None None O
was None None O
found None None O
to None None O
correlate None None O
with None None O
lymph None None O
node None None O
metastasis None None O
. None None O

The None None O
Cox None None O
proportional-hazards None None O
regression None None O
model None None O
revealed None None O
that None None O
p53 None None I-PROTEIN
( None None O
β None None O
, None None O
-0.455 None None O
; None None O
χ2,5.491 None None O
; None None O
P=0.019 None None O
) None None O
and None None O
EGFR None None O
( None None O
β None None O
, None None O
3.93 None None O
; None None O
χ2 None None O
, None None O
11.95 None None O
; None None O
P=0.001 None None O
) None None O
expression None None O
were None None O
independent None None O
prognostic None None O
factors None None O
. None None O

Epithelial-to-mesenchymal None None O
transition None None O
( None None O
EMT None None O
) None None O
, None None O
which None None O
may None None O
be None None O
stimulated None None O
by None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor-I None None O
( None None O
IGF-I None None O
) None None O
is None None O
involved None None O
in None None O
the None None O
metastasis None None O
of None None O
numerous None None O
tumors None None O
; None None O
however None None O
, None None O
the None None O
molecular None None O
mechanism None None O
by None None O
which None None O
IGF-I None None O
may None None O
induce None None O
tumor None None O
cell None None O
EMT None None O
remains None None O
to None None O
be None None O
elucidated None None O
in None None O
gastric None None O
cancer None None O
. None None O

Subsequent None None O
to None None O
the None None O
use None None O
of None None O
Pifithrin-α None None O
, None None O
a None None O
specific None None O
inhibitor None None O
of None None O
p53 None None I-PROTEIN
activation None None O
, None None O
increased None None O
MDM2 None None O
expression None None O
was None None O
observed None None O
in None None O
the None None O
LIRR1-overexpressing None None O
cells None None O
, None None O
suggesting None None O
that None None O
LIRR1 None None O
could None None O
mediate None None O
the None None O
DNA None None O
damage None None O
response None None O
( None None O
DDR None None O
) None None O
signaling None None O
in None None O
a None None O
p53-dependent None None O
manner None None O
. None None O

In None None O
addition None None O
, None None O
a None None O
5-ethynyl-2'-deoxyuridine None None O
retention None None I-FUNC
assay None None O
and None None O
flow None None O
cytometry None None O
analysis None None O
were None None O
used None None O
to None None O
detect None None O
the None None O
effect None None O
of None None O
let-7g/i None None O
on None None O
the None None O
proliferation None None O
and None None O
apoptosis None None O
of None None O
BEL-7402 None None O
cells None None O
, None None O
respectively None None O
. None None O

Specific None None O
indicators None None O
of None None O
mitochondrial None None O
dysfunction None None O
, None None O
a None None O
reduction None None O
in None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
generation None None O
, None None O
the None None O
inner None None O
mitochondrial None None O
membrane None None O
potential None None O
, None None O
augmentation None None O
of None None O
reactive None None O
oxygen None None O
species None None O
production None None O
and None None O
cytochrome None None O
c None None O
were None None O
also None None O
detected None None O
in None None O
the None None O
mitochondria None None O
following None None O
treatment None None O
with None None O
BDMC None None O
. None None O

The None None O
activity None None O
of None None O
the None None O
key None None O
enzymes None None I-PROTEIN
in None None O
polyamine None None O
catabolism None None O
was None None O
detected None None O
using None None O
chemiluminescence None None O
. None None O

Furthermore None None O
, None None O
lactic None None O
acid None None O
, None None O
choline None None O
, None None O
glucose None None O
, None None O
proline None None I-TRANS
, None None O
valine None None I-TRANS
, None None O
isoleucine None None I-TRANS
, None None O
aspartic None None I-TRANS
acid None None I-TRANS
and None None O
2-hydroxybutyric None None O
acid None None O
demonstrated None None O
VIP None None I-TRANS
& None None O
gt None None O
; None None O
1 None None O
in None None O
the None None O
PLS-D None None O
model None None O
and None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
with None None O
ANOVA None None O
. None None O

No None None O
morphological None None O
changes None None O
were None None O
observed None None O
in None None O
the None None O
myoepithelial None None O
cells None None O
cultured None None O
in None None O
fibronectin None None I-PROTEIN
protein None None O
under None None O
stimulation None None O
from None None O
either None None O
tumor-conditioned None None O
medium None None O
. None None O

No None None O
significant None None O
difference None None O
in None None O
FGF-2 None None O
mRNA None None O
expression None None O
was None None O
detected None None O
when None None O
the None None O
cells None None O
were None None O
cultured None None O
either None None O
in None None O
the None None O
tumor-conditioned None None O
medium None None O
or None None O
in None None O
the None None O
fibronectin None None I-PROTEIN
substratum None None O
. None None O

The None None O
present None None O
study None None O
examined None None O
the None None O
role None None O
of None None O
the None None O
PRDI-BF1-RIZ None None O
( None None O
PR None None O
) None None O
domain None None O
of None None O
tumor None None O
suppressor None None O
retinoblastoma None None O
protein-interacting None None O
zinc None None I-TRANS
finger None None O
gene None None O
1 None None O
( None None O
RIZ1 None None O
) None None O
as None None O
an None None O
anticancer None None O
domain None None O
and None None O
its None None O
ability None None O
to None None O
induce None None O
apoptosis None None O
in None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
ESCC None None O
) None None O
cells None None O
. None None O

Western None None O
blotting None None O
was None None O
performed None None O
to None None O
detect None None O
the None None O
protein None None O
expression None None O
levels None None O
of None None O
PDCD5 None None O
, None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
IGF None None O
) None None O
-1 None None O
and None None O
the None None O
EMT None None O
marker None None O
, None None O
Snail None None O
. None None O

The None None O
PDCD5 None None O
transfected None None O
cells None None O
showed None None O
higher None None O
sensitivity None None O
to None None O
cisplatin None None O
treatment None None O
than None None O
the None None O
HepG2-Neo None None O
cells None None O
, None None O
with None None O
a None None O
higher None None O
p53 None None I-PROTEIN
protein None None O
expression None None O
level None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
changes None None O
to None None O
the None None O
expression None None O
levels None None O
of None None O
fragile None None O
histidine None None I-TRANS
triad None None O
( None None O
FHIT None None O
) None None O
, None None O
breast None None O
cancer None None O
type None None O
2 None None O
susceptibility None None O
protein None None O
( None None O
BRCA2 None None O
) None None O
, None None O
MutL None None O
homolog None None O
1 None None O
( None None O
MLH1 None None O
) None None O
and None None O
tumour None None O
protein None None O
53 None None O
( None None O
p53 None None I-PROTEIN
) None None O
exhibited None None O
by None None O
families None None O
with None None O
a None None O
history None None O
of None None O
oesophageal None None O
cancer None None O
in None None O
a None None O
region None None O
that None None O
has None None O
a None None O
high None None O
incidence None None O
of None None O
oesophageal None None O
cancer None None O
, None None O
and None None O
to None None O
determine None None O
the None None O
association None None O
of None None O
these None None O
changes None None O
with None None O
the None None O
cancer None None O
history None None O
of None None O
the None None O
families None None O
. None None O

However None None O
, None None O
FHIT None None O
, None None O
p53 None None I-PROTEIN
, None None O
BRCA2 None None O
and None None O
MLH1 None None O
expression None None O
demonstrated None None O
no None None O
significant None None O
affect None None O
on None None O
clinicopathological None None O
changes None None O
, None None O
such None None O
as None None O
oesophageal None None O
cancerous None None O
tissue None None O
differentiation None None O
, None None O
the None None O
degree None None O
of None None O
infiltration None None O
and None None O
cancer None None O
cell None None O
metastasis None None O
. None None O

Additionally None None O
, None None O
it None None O
was None None O
found None None O
that None None O
the None None O
hydrogen None None I-TRANS
sulfide None None I-TRANS
concentration None None O
in None None O
the None None O
serum None None O
of None None O
sulfur-treated None None O
mice None None O
was None None O
increased None None O
by None None O
4.73 None None O
% None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

In None None O
all None None O
samples None None O
, None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
and None None O
K-Ras None None O
mutational None None O
analysis None None O
was None None O
also None None O
performed None None O
. None None O

Nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
is None None O
a None None O
signaling None None O
molecule None None O
, None None O
which None None O
is None None O
involved None None O
in None None O
inflammation None None O
and None None O
carcinogenesis None None O
. None None O

The None None O
present None None O
study None None O
investigates None None O
the None None O
effect None None O
of None None O
pro-inflammatory None None O
cytokine-induced None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
production None None O
and None None O
iNOS None None O
expression None None O
on None None O
the None None O
invasion None None O
of None None O
human None None O
colorectal None None O
adenocarcinoma None None O
HT-29 None None O
cells None None O
, None None O
and None None O
the None None O
effect None None O
of None None O
extract None None O
from None None O
Cnidii None None O
Rhizoma None None O
on None None O
NO None None O
production None None O
and None None O
the None None O
invasiveness None None O
of None None O
HT-29 None None O
cells None None O
. None None O

However None None O
, None None O
the None None O
experimentally None None O
validated None None O
data None None O
of None None O
genes None None O
, None None O
miRNA None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
TFs None None O
) None None O
can None None O
not None None O
be None None O
found None None O
in None None O
a None None O
unified None None O
form None None O
, None None O
which None None O
makes None None O
it None None O
challenging None None O
to None None O
decipher None None O
the None None O
regulatory None None O
mechanisms None None O
. None None O

SMI None None O
homework None None O
scores None None O
accounted None None O
for None None O
increases None None O
in None None O
recall None None O
of None None O
important None None O
events None None O
and None None O
plausible None None O
inferences None None I-FUNC
, None None O
suggesting None None O
that None None O
consistent None None O
practice None None O
and None None O
feedback None None O
with None None O
story None None O
mapping None None O
could None None O
contribute None None O
to None None O
important None None O
recall None None O
gains None None O
. None None O

As None None O
anticancer None None O
effects None None O
of None None O
similar None None O
extracts None None O
have None None O
been None None O
reported None None O
in None None O
several None None O
cancers None None O
, None None O
we None None O
investigated None None O
whether None None O
PL-ES None None O
and None None O
PL-I-ES None None O
might None None O
have None None O
such None None O
anticancer None None O
activities None None O
on None None O
a None None O
variety None None O
of None None O
human None None O
cancer None None O
cells None None O
in None None O
vitro None None O
. None None O

PL-I-ES None None O
( None None O
100 None None O
µg/mL None None O
) None None O
was None None O
effective None None O
on None None O
only None None O
four None None O
cancer None None O
cells None None O
but None None O
its None None O
higher None None O
concentration None None O
at None None O
250 None None O
µg/mL None None O
led None None O
to None None O
a None None O
significant None None O
( None None O
25-90 None None O
% None None O
) None None O
growth None None O
reduction None None O
in None None O
seven None None O
cancer None None O
cells None None O
. None None O

Moreover None None O
, None None O
enzymatic None None O
assays None None O
for None None O
caspase-3 None None O
( None None O
Csp-3 None None O
) None None O
and None None O
caspase-9 None None O
( None None O
Csp-9 None None O
) None None O
, None None O
the None None O
pro-apoptotic None None O
regulators None None O
, None None O
showed None None O
that None None O
both None None O
enzymes None None I-PROTEIN
were None None O
significantly None None O
activated None None O
by None None O
PL-ES None None O
or None None O
PL-I-ES None None O
, None None O
indicating None None O
that None None O
cell None None O
death None None O
due None None O
to None None O
oxidative None None O
stress None None O
was None None O
more None None O
likely None None O
associated None None O
with None None O
apoptosis None None O
. None None O

Occlusion None None O
of None None O
the None None O
artery None None O
of None None O
Percheron None None O
( None None O
AOP None None O
) None None O
is None None O
presumed None None O
to None None O
cause None None O
this None None O
specific None None O
stroke None None I-DISEASE
syndrome None None O
. None None O

Here None None O
we None None O
described None None O
a None None O
70-year-old None None O
male None None O
patient None None O
who None None O
presented None None O
with None None O
acute None None O
disturbance None None O
of None None O
consciousness None None I-FUNC
due None None O
to None None O
acute None None O
bilateral None None O
paramedian None None O
thalamo-mesencephalic None None O
infarction None None O
secondary None None O
to None None O
AOP None None O
occlusion None None O
. None None O

Results None None O
of None None O
the None None O
current None None O
study None None O
may None None O
be None None O
used None None O
to None None O
guide None None O
development None None O
of None None O
CI None None O
devices None None O
and None None O
in None None O
efforts None None O
to None None O
improve None None O
speech None None I-FUNC
and None None O
language None None I-FUNC
of None None O
children None None O
wearing None None O
CIs None None O
. None None O

Facial None None I-REGION
nerve None None I-REGION
palsy None None O
was None None O
found None None O
in None None O
35.5 None None O
% None None O
of None None O
the None None O
cases None None O
( None None O
11 None None O
cases None None O
) None None O
. None None O

The None None O
purposes None None O
of None None O
this None None O
study None None O
were None None O
to None None O
determine None None O
the None None O
effect None None O
of None None O
caffeic None None O
acid None None O
on None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
β1-induced None None O
myofibroblast None None O
differentiation None None O
and None None O
collagen None None I-PROTEIN
production None None O
, None None O
and None None O
to None None O
determine None None O
whether None None O
caffeic None None O
acid None None O
is None None O
involved None None O
in None None O
the None None O
antioxidant None None O
effect None None O
in None None O
nasal None None O
polyp-derived None None O
fibroblasts None None O
( None None O
NPDFs None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
α-smooth None None O
muscle None None O
actin None None I-PROTEIN
( None None O
SMA None None O
) None None O
, None None O
collagen None None I-PROTEIN
types None None O
I None None O
and None None O
III None None O
, None None O
and None None O
Nox4 None None O
mRNA None None O
was None None O
determined None None O
by None None O
a None None O
reverse None None O
transcription-polymerase None None O
chain None None O
reaction None None O
, None None O
and None None O
the None None O
expression None None O
of None None O
α-SMA None None O
protein None None O
was None None O
determined None None O
by None None O
actin None None I-PROTEIN
ned None None O
by None None O
immunofluorescence None None O
microscopy None None O
. None None O

The None None O
expression None None O
of None None O
α-SMA None None O
and None None O
production None None O
of None None O
collagen None None I-PROTEIN
were None None O
significantly None None O
increased None None O
following None None O
TGF-β1 None None O
treatment None None O
. None None O

Caffeic None None O
acid None None O
may None None O
inhibit None None O
TGF-β1-induced None None O
differentiation None None O
of None None O
fibroblasts None None O
into None None O
myofibroblasts None None O
and None None O
collagen None None I-PROTEIN
production None None O
by None None O
regulating None None O
ROS None None O
. None None O

The None None O
threshold None None O
stimuli None None O
evoking None None O
sensation None None I-FUNC
and None None O
eliciting None None O
laryngeal None None O
adductor None None O
reflex None None O
were None None O
recorded None None O
. None None O

We None None O
assessed None None O
the None None O
clinical None None O
outcomes None None O
of None None O
dorsal None None I-NEURON
release None None O
of None None O
the None None O
first None None O
extensor None None O
compartment None None O
for None None O
the None None O
treatment None None O
of None None O
de None None O
Quervain None None O
's None None O
disease None None O
using None None O
the None None O
disabilities None None O
of None None O
the None None O
arm None None O
, None None O
shoulder None None O
and None None O
hand None None O
( None None O
DASH None None O
) None None O
score None None O
. None None O

All None None O
patients None None O
had None None O
a None None O
positive None None O
Finkelstein None None O
test None None O
and None None O
localized None None O
tenderness None None O
over None None O
the None None O
first None None O
dorsal None None I-NEURON
compartment None None O
. None None O

A None None O
2-cm-long None None O
transverse None None O
skin None None O
incision None None O
was None None O
made None None O
over None None O
the None None O
first None None O
extensor None None O
compartment None None O
and None None O
the None None O
dorsal None None I-NEURON
retinaculum None None O
covering None None O
the None None O
extensor None None O
pollicis None None O
brevis None None O
was None None O
incised None None O
longitudinally None None O
. None None O

There None None O
were None None O
no None None O
postoperative None None O
complications None None O
such None None O
as None None O
subluxation None None O
of None None O
the None None O
tendon None None O
of None None O
the None None O
first None None O
dorsal None None I-NEURON
compartment None None O
or None None O
injury None None O
to None None O
the None None O
sensory None None O
branch None None O
of None None O
the None None O
radial None None O
nerve None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
identify None None O
the None None O
risk None None O
factors None None O
for None None O
anterior None None O
knee None None O
pain None None O
in None None O
patients None None O
with None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
. None None O

Approximately None None O
12.6 None None O
% None None O
of None None O
ambulatory None None O
patients None None O
with None None O
spastic None None I-DISEASE
cerebral None None I-DISEASE
palsy None None I-DISEASE
were None None O
found None None O
to None None O
have None None O
anterior None None O
knee None None O
pain None None O
in None None O
our None None O
hospital-based None None O
cohort None None O
study None None O
. None None O

There None None O
are None None O
few None None O
comparative None None O
studies None None O
about None None O
the None None O
optimal None None O
method None None O
of None None O
pneumatic None None O
compression None None O
to None None O
prevent None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
. None None O

We None None O
report None None O
a None None O
13-year-old None None O
boy None None O
who None None O
presented None None O
with None None O
a None None O
14-month None None O
history None None O
of None None O
a None None O
fixed None None O
elbow None None O
with None None O
no None None O
movement None None I-FUNC
and None None O
a None None O
palpable None None O
bony None None O
mass None None O
in None None O
the None None O
anterior None None O
aspect None None O
of None None O
the None None O
elbow None None O
. None None O

The None None O
presently None None O
using None None O
drugs None None O
can None None O
impose None None O
a None None O
variety None None O
of None None O
side-effects None None O
including None None O
cardiac None None O
toxicity None None O
, None None O
hypopiesia None None O
, None None O
sexual None None I-DISEASE
dysfunction None None I-DISEASE
, None None O
body None None O
weight None None O
gain None None O
, None None O
and None None O
sleep None None I-DISEASE
disorder None None I-DISEASE
. None None O

Elderly None None O
people None None O
with None None O
this None None O
impairment None None O
represent None None O
an None None O
at-risk None None O
group None None O
for None None O
the None None O
development None None O
of None None O
dementia None None I-DISEASE
. None None O

According None None O
to None None O
the None None O
results None None O
, None None O
96 None None O
cases None None O
( None None O
45.3 None None O
% None None O
) None None O
suffered None None O
from None None O
mild None None O
( None None O
MMSE≥22 None None O
) None None O
, None None O
110 None None O
cases None None O
( None None O
51.9 None None O
% None None O
) None None O
from None None O
moderate None None O
( None None O
11≤MMSE≤21 None None O
) None None O
and None None O
6 None None O
cases None None O
( None None O
2.8 None None O
% None None O
) None None O
from None None O
severe None None O
cognitive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MMSE≤10 None None O
) None None O
. None None O

In None None O
the None None O
next None None O
set None None O
, None None O
formalin None None O
tests None None O
were None None O
carried None None O
out None None O
in None None O
companion None None O
with None None O
injection None None O
of None None O
Naloxone None None O
Hydrochloride None None O
, None None O
a None None O
non-selective None None O
antagonist None None O
of None None O
opioid None None O
receptors None None I-PROTEIN
, None None O
pre-formalin None None O
injection None None O
and None None O
30 None None O
and None None O
45 None None O
minutes None None O
post None None O
formalin None None O
injection None None O
. None None O

In None None O
this None None O
study None None O
, None None O
electrooculography None None O
( None None O
EOG None None O
) None None O
was None None O
utilized None None O
to None None O
investigate None None O
memory None None I-FUNC
recall None None O
accessibility None None O
via None None O
eye None None O
movement None None I-FUNC
patterns None None O
. None None O

Lateral None None O
hypothalamus None None I-REGION
, None None O
as None None O
the None None O
main None None O
niche None None O
of None None O
orexin None None O
neurons None None O
with None None O
extensive None None O
projections None None O
, None None O
is None None O
involved None None O
in None None O
sleep None None O
and None None O
wakefulness None None O
and None None O
so None None O
it None None O
affects None None O
the None None O
excitability None None O
of None None O
the None None O
brain None None O
. None None O

infusion None None O
increased None None O
hippocampal None None O
glutamate None None I-TRANS
content None None O
, None None O
it None None O
did None None O
not None None O
change None None O
PTZ None None O
induced None None O
convulsive None None O
intensity None None O
. None None O

According None None O
to None None O
the None None O
interaction None None O
between None None O
zinc None None I-TRANS
and None None O
opioidergic None None O
system None None O
activity None None O
, None None O
this None None O
study None None O
has None None O
investigated None None O
the None None O
effect None None O
of None None O
new None None O
kind None None O
of None None O
zinc None None I-TRANS
supplement None None O
, None None O
nano None None O
zinc None None I-TRANS
oxide None None O
( None None O
nZnO None None O
) None None O
, None None O
in None None O
compared None None O
to None None O
its None None O
conventional None None O
form None None O
( None None O
cZnO None None O
) None None O
, None None O
in None None O
presence None None O
and None None O
absence None None O
of None None O
opioidergic None None O
system None None O
activity None None O
on None None O
acute None None O
pain None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
difference None None O
in None None O
median None None O
maximal None None O
thickness None None O
of None None O
intima-media None None O
in None None O
the None None O
carotid None None O
of None None O
group None None O
I None None O
compare None None O
to None None O
group None None O
II None None O
in None None O
patients None None O
with None None O
and None None O
without None None O
elevated None None O
liver None None O
enzymes None None I-PROTEIN
( None None O
in None None O
both None None O
groups None None O
, None None O
0.6 None None O
mm None None O
, None None O
p= None None O
0.402 None None O
) None None O
. None None O

Because None None O
this None None O
mechanism None None O
does None None O
not None None O
require None None O
the None None O
action None None O
of None None O
insulin None None I-PROTEIN
, None None O
dapagliflozin None None O
rarely None None O
causes None None O
hypoglycemia None None I-DISEASE
and None None O
is None None O
effective None None O
in None None O
patients None None O
both None None O
early None None O
and None None O
late None None O
in None None O
the None None O
course None None O
of None None O
their None None O
disease None None O
. None None O

In None None O
contrast None None O
, None None O
older None None O
adults None None O
had None None O
better None None O
memory None None I-FUNC
for None None O
the None None O
story None None O
's None None O
content None None O
and None None O
structure None None O
if None None O
they None None O
had None None O
previously None None O
retold None None O
the None None O
story None None O
accurately None None O
. None None O

In None None O
summary None None O
, None None O
retellings None None O
exerted None None O
a None None O
greater None None O
effect None None O
on None None O
memory None None I-FUNC
in None None O
older None None O
, None None O
compared None None O
with None None O
younger None None O
, None None O
adults None None O
. None None O

A None None O
number None None O
of None None O
the None None O
cytokines None None O
released None None O
by None None O
the None None O
elongating None None O
conceptuses None None O
stimulate None None O
inducible None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
such None None O
as None None O
nuclear None None O
factor None None O
kappa None None O
B None None O
( None None O
NFKB None None O
) None None O
potentially None None O
regulating None None O
the None None O
maternal None None O
uterine None None O
proinflammatory None None O
and None None O
immune None None O
response None None O
. None None O

Somatoform None None I-DISEASE
disorder None None I-DISEASE
appeared None None O
120 None None O
% None None O
more None None O
often None None O
in None None O
patients None None O
after None None O
cardiac None None O
catheterisation None None O
in None None O
comparison None None O
to None None O
the None None O
normal None None O
population None None O
. None None O

If None None O
the None None O
frontal None None O
edge None None O
of None None O
the None None O
tumour None None O
showed None None O
serosa None None O
and None None O
the None None O
dorsal None None I-NEURON
plane None None O
perirectal None None O
fat None None O
than None None O
the None None O
tumour None None O
was None None O
located None None O
in None None O
the None None O
`` None None O
rectosigmoid None None O
'' None None O
. None None O

Angiotensin None None O
II None None O
, None None O
atrial None None O
natriuretic None None O
peptide None None O
and None None O
intrarenal None None O
dopamine None None I-TRANS
play None None O
a None None O
pivotal None None O
role None None O
in None None O
this None None O
interactive None None O
network None None O
. None None O

Mean None None O
factor None None I-PROTEIN
XII None None I-PROTEIN
level None None O
was None None O
109.1 None None O
± None None O
35.7 None None O
% None None O
( None None O
range None None O
: None None O
9-200 None None O
) None None O
. None None O

Mean None None O
factor None None I-PROTEIN
XII None None I-PROTEIN
level None None O
was None None O
44.8 None None O
± None None O
13.1 None None O
, None None O
and None None O
levels None None O
ranged None None O
between None None O
9 None None O
and None None O
60 None None O
in None None O
this None None O
group None None O
. None None O

Remaining None None O
1164 None None O
( None None O
92.6 None None O
% None None O
) None None O
women None None O
had None None O
factor None None I-PROTEIN
XII None None I-PROTEIN
levels None None O
≥ None None O
60 None None O
% None None O
. None None O

Previous None None O
studies None None O
have None None O
reported None None O
that None None O
greater None None O
activation None None O
of None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
was None None O
observed None None O
during None None O
self-initiated None None O
movements None None I-FUNC
than None None O
during None None O
externally None None O
triggered None None O
movements None None I-FUNC
. None None O

In None None O
addition None None O
, None None O
the None None O
FPPFC None None O
plays None None O
a None None O
role None None O
in None None O
coordinating None None O
lateral None None O
prefrontal None None I-REGION
cortex None None I-REGION
. None None O

There None None O
has None None O
always None None O
been None None O
concern None None O
in None None O
determining None None O
the None None O
relationship None None O
between None None O
orthodontic None None O
tooth None None O
movement None None I-FUNC
and None None O
the None None O
consequent None None O
biological None None O
costs None None O
to None None O
the None None O
periodontium None None O
and None None O
tooth None None O
root None None O
. None None O

This None None O
patient None None O
was None None O
diagnosed None None O
with None None O
moderate None None O
factor None None I-PROTEIN
VIII None None I-PROTEIN
deficiency None None O
with None None O
a None None O
coagulation None None O
time None None O
within None None O
the None None O
normal None None O
range None None O
. None None O

Although None None O
vascular None None O
involvement None None O
, None None O
including None None O
venous None None O
and None None O
arteries None None O
of None None O
any None None O
size None None O
, None None O
is None None O
a None None O
usual None None O
manifestation None None O
, None None O
cases None None O
with None None O
pulmonary None None O
thrombosis None None I-DISEASE
as None None O
the None None O
initial None None O
symptom None None O
are None None O
not None None O
common None None O
in None None O
the None None O
absence None None O
of None None O
pulmonary None None O
artery None None O
aneurysm None None O
( None None O
PAA None None O
) None None O
. None None O

The None None O
following None None O
biomarkers None None O
were None None O
measured None None O
at None None O
the None None O
baseline None None O
and None None O
every None None O
3 None None O
months None None O
: None None O
bone-specific None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
, None None O
N-terminal None None O
telopeptide None None O
of None None O
type None None O
I None None O
collagen None None I-PROTEIN
corrected None None O
for None None O
creatinine None None O
, None None O
parathyroid None None O
hormone None None O
, None None O
BMD None None O
of None None O
the None None O
lumbar None None O
spine None None O
, None None O
and None None O
physical None None O
parameters None None O
evaluated None None O
according None None O
to None None O
the None None O
SF-36v2 None None O
Health None None O
Survey None None O
. None None O

The None None O
tumor None None O
invaded None None O
perithyroid None None O
soft None None O
tissues None None O
in None None O
6 None None O
patients None None O
and None None O
central None None O
neck None None O
( None None O
level None None O
VI None None I-REGION
) None None O
lymph None None O
nodes None None O
in None None O
3 None None O
. None None O

Our None None O
approach None None O
uses None None O
a None None O
highly None None O
accurate None None O
mechanical None None O
model None None O
of None None O
tube None None O
interactions None None O
, None None O
which None None O
is None None O
important None None O
since None None O
small None None O
movements None None I-FUNC
of None None O
the None None O
tip None None O
position None None O
may None None O
require None None O
large None None O
changes None None O
in None None O
the None None O
shape None None O
of None None O
the None None O
device None None O
's None None O
shaft None None O
. None None O

Fragile None None O
X None None O
syndrome None None O
( None None O
FXS None None O
) None None O
is None None O
the None None O
most None None O
common None None O
single None None O
gene None None O
cause None None O
of None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
and None None O
it None None O
is None None O
characterized None None O
by None None O
a None None O
CGG None None O
expansion None None O
of None None O
more None None O
than None None O
200 None None O
repeats None None O
in None None O
the None None O
FMR1 None None O
gene None None O
, None None O
leading None None O
to None None O
methylation None None O
of None None O
the None None O
promoter None None O
and None None O
gene None None O
silencing None None O
. None None O

The None None O
premutation None None O
causes None None O
primary None None O
ovarian None None O
insufficiency None None O
in None None O
approximately None None O
20 None None O
% None None O
of None None O
females None None O
, None None O
psychiatric None None O
problems None None O
( None None O
including None None O
depression None None I-DISEASE
and/or None None O
anxiety None None O
) None None O
in None None O
approximately None None O
50 None None O
% None None O
of None None O
carriers None None O
and None None O
a None None O
neurodegenerative None None O
disorder None None O
, None None O
the None None O
fragile None None O
X-associated None None O
tremor None None O
ataxia None None O
syndrome None None O
( None None O
FXTAS None None O
) None None O
, None None O
in None None O
approximately None None O
40 None None O
% None None O
of None None O
males None None O
and None None O
16 None None O
% None None O
of None None O
females None None O
later None None O
in None None O
life None None O
. None None O

Tourette None None I-DISEASE
syndrome None None I-DISEASE
( None None O
TS None None O
) None None O
is None None O
a None None O
heritable None None O
neuropsychiatric None None O
disorder None None O
commonly None None O
complicated None None O
by None None O
obsessions None None O
and None None O
compulsions None None O
, None None O
but None None O
defined None None O
by None None O
frequent None None O
unwanted None None O
movements None None I-FUNC
( None None O
motor None None O
tics None None O
) None None O
and None None O
vocalizations None None O
( None None O
phonic None None O
tics None None O
) None None O
that None None O
develop None None O
in None None O
childhood None None O
or None None O
adolescence None None O
. None None O

Inspired None None O
by None None O
the None None O
Fifth None None O
International None None O
Scientific None None O
Symposium None None O
on None None O
Tourette None None I-DISEASE
Syndrome None None I-DISEASE
, None None O
the None None O
articles None None O
in None None O
this None None O
special None None O
issue None None O
review None None O
advances None None O
in None None O
the None None O
phenomenology None None O
, None None O
epidemiology None None O
, None None O
genetics None None O
, None None O
pathophysiology None None O
, None None O
and None None O
treatment None None O
of None None O
TS None None O
. None None O

For None None O
many None None O
medical None None O
conditions None None O
, None None O
including None None O
Tourette None None I-DISEASE
syndrome None None I-DISEASE
, None None O
there None None O
are None None O
true None None O
cases None None O
that None None O
have None None O
not None None O
been None None O
previously None None O
diagnosed None None O
due None None O
to None None O
problems None None O
of None None O
access None None O
to None None O
appropriate None None O
clinical None None O
services None None O
. None None O

We None None O
reviewed None None O
11 None None O
community None None O
surveys None None O
in None None O
children None None O
with None None O
Tourette None None I-DISEASE
syndrome None None I-DISEASE
( None None O
TS None None O
) None None O
published None None O
since None None O
2000 None None O
. None None O

Community None None O
samples None None O
and None None O
large None None O
clinically-ascertained None None O
samples None None O
consistently None None O
show None None O
high None None O
rates None None O
of None None O
ADHD None None O
, None None O
disruptive None None O
behavior None None O
and None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
in None None O
children None None O
with None None O
TS None None O
. None None O

Vascular None None I-PROTEIN
Endothelial None None I-PROTEIN
Growth None None I-PROTEIN
Factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
and None None O
its None None O
receptors None None I-PROTEIN
play None None O
an None None O
important None None O
role None None O
in None None O
angiogenesis-dependent None None O
tumors None None O
. None None O

Human None None O
VEGF-A None None O
gene None None O
consists None None O
of None None O
eight None None O
exons None None O
that None None O
undergoes None None O
alternative None None O
exon None None O
splicing None None O
and None None O
produce None None O
five None None O
different None None O
proteins None None O
consisting None None O
of None None O
121 None None O
, None None O
145 None None O
, None None O
165 None None O
, None None O
189 None None O
and None None O
206 None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
named None None O
VEGF121 None None O
, None None O
VEGF145 None None O
, None None O
VEGF165 None None O
, None None O
VEGF189 None None O
, None None O
and None None O
VEGF206 None None O
) None None O
. None None O

In None None O
this None None O
research None None O
the None None O
effect None None O
of None None O
vitamin None None O
B1 None None O
and None None O
B6 None None O
on None None O
cyanocobalamin None None O
stability None None O
in None None O
commercial None None O
light None None O
protected None None O
parenteral None None O
formulations None None O
and None None O
upon None None O
adding None None O
stabilizing None None O
agents None None O
will None None O
be None None O
investigated None None O
and None None O
best None None O
formulation None None O
composition None None O
and None None O
proper None None O
storage None None I-FUNC
condition None None O
will None None O
be None None O
introduced None None O
. None None O

Sixty-six None None O
samples None None O
of None None O
fruit None None O
juices None None O
were None None O
analyzed None None O
, None None O
and None None O
fourteen None None O
amino None None I-TRANS
acids None None I-TRANS
were None None O
identified None None O
and None None O
determined None None O
in None None O
the None None O
sampled None None O
fruit None None O
juices None None O
. None None O

In None None O
general None None O
, None None O
determining None None O
the None None O
amount None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
and None None O
comparing None None O
sample None None O
amino None None I-TRANS
acids None None I-TRANS
profiles None None O
with None None O
the None None O
standard None None O
values None None O
seems None None O
to None None O
be None None O
an None None O
indicator None None O
for None None O
quality None None O
control None None O
. None None O

Levels None None O
of None None O
plasma None None O
B-type None None I-TRANS
natriuretic None None I-TRANS
peptide None None I-TRANS
, None None O
serum None None O
sodium None None O
, None None O
potassium None None O
, None None O
creatinine None None O
, None None O
and None None O
estimated None None O
glomerular None None O
filtration None None O
rate None None O
were None None O
measured None None O
before None None O
administration None None O
of None None O
tolvaptan None None O
or None None O
carperitide None None O
at None None O
baseline None None O
, None None O
the None None O
time None None O
of None None O
discharge None None O
, None None O
and None None O
one None None O
year None None O
after None None O
discharge None None O
. None None O

This None None O
is None None O
a None None O
retrospective None None O
study None None O
performed None None O
from None None O
our None None O
stroke None None I-DISEASE
registry None None O
using None None O
deidentified None None O
patient None None O
information None None O
. None None O

Consecutive None None O
AIS None None O
patients None None O
presenting None None O
to None None O
our None None O
PSC None None O
from None None O
July None None O
2008 None None O
to None None O
December None None O
of None None O
2010 None None O
were None None O
identified None None O
from None None O
our None None O
prospectively None None O
collected None None O
stroke None None I-DISEASE
registry None None O
. None None O

Further None None O
study None None O
on None None O
the None None O
role None None O
of None None O
substance None None I-DISEASE
abuse None None I-DISEASE
in None None O
time None None O
to None None O
ED None None O
arrival None None O
, None None O
tPA None None O
use None None O
, None None O
and None None O
outcome None None O
in None None O
AIS None None O
patients None None O
is None None O
warranted None None O
. None None O

Two None None O
monocytic None None O
[ None None O
CD14 None None O
( None None O
+ None None O
) None None O
CD15 None None O
( None None O
- None None O
) None None O
CD11b None None O
( None None O
+ None None O
) None None O
CD33 None None O
( None None O
+ None None O
) None None O
HLA-DR None None O
( None None O
- None None O
) None None O
Lin None None O
( None None O
- None None O
) None None O
and None None O
CD14 None None O
( None None O
+ None None O
) None None O
CD15 None None O
( None None O
+ None None O
) None None O
CD11b None None O
( None None O
+ None None O
) None None O
CD33 None None O
( None None O
+ None None O
) None None O
HLA-DR None None O
( None None O
- None None O
) None None O
Lin None None O
( None None O
- None None O
) None None O
] None None O
and None None O
a None None O
granulocytic None None O
[ None None O
CD14 None None O
( None None O
- None None O
) None None O
CD15 None None O
( None None O
+ None None O
) None None O
CD11b None None O
( None None O
+ None None O
) None None O
CD33 None None O
( None None O
+ None None O
) None None O
HLA-DR None None O
( None None O
- None None O
) None None O
Lin None None O
( None None O
- None None O
) None None O
] None None O
subpopulations None None O
of None None O
MDSCs None None O
were None None O
identified None None O
, None None O
expressing None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
, None None O
and None None O
reactive None None O
oxygen None None O
species None None O
, None None O
respectively None None O
. None None O

Cognitive None None O
control None None O
is None None O
critical None None O
for None None O
efficiently None None O
using None None O
the None None O
limited None None O
resources None None O
in None None O
working None None I-FUNC
memory None None I-FUNC
. None None O

We None None O
trained None None O
monkeys None None O
in None None O
a None None O
visual None None O
matching-to-sample None None O
paradigm None None O
with None None O
a None None O
post-sample None None O
memory None None I-FUNC
cue None None O
. None None O

Infrequent None None O
probe None None O
trials None None O
on None None O
which None None O
monkeys None None O
were None None O
given None None O
tests None None O
of None None O
the None None O
type None None O
not None None O
cued None None O
on None None O
that None None O
trial None None O
were None None O
used None None O
to None None O
assess None None O
whether None None O
memory None None I-FUNC
was None None O
under None None O
cognitive None None O
control None None O
. None None O

Again None None O
, None None O
memory None None I-FUNC
for None None O
expected None None O
memory None None I-FUNC
tests None None O
was None None O
superior None None O
to None None O
that None None O
on None None O
unexpected None None O
tests None None O
. None None O

Basic None None O
research None None O
has None None O
found None None O
that None None O
high None None O
levels None None O
of None None O
catecholamine None None O
release None None O
during None None O
stress None None O
rapidly None None O
impair None None O
the None None O
top-down None None O
cognitive None None O
functions None None O
of None None O
the None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
PFC None None O
) None None O
, None None O
while None None O
strengthening None None O
the None None O
emotional None None O
and None None O
habitual None None O
responses None None O
of None None O
the None None O
amygdala None None I-REGION
and None None O
basal None None I-REGION
ganglia None None I-REGION
. None None O

High None None O
levels None None O
of None None O
NE None None I-TRANS
release None None O
during None None O
stress None None O
engage None None O
low None None O
affinity None None O
alpha-1 None None O
adrenoceptors None None O
, None None O
( None None O
and None None O
likely None None O
beta-1 None None O
adrenoceptors None None O
) None None O
, None None O
which None None O
rapidly None None O
reduce None None O
the None None O
firing None None O
of None None O
PFC None None O
neurons None None O
, None None O
but None None O
strengthen None None O
amygdala None None I-REGION
function None None O
. None None O

Clinical None None O
studies None None O
have None None O
found None None O
that None None O
blocking None None O
alpha-1 None None O
receptors None None I-PROTEIN
with None None O
prazosin None None O
, None None O
or None None O
stimulating None None O
alpha-2A None None O
receptors None None I-PROTEIN
with None None O
guanfacine None None O
or None None O
clonidine None None O
can None None O
be None None O
useful None None O
in None None O
reducing None None O
the None None O
symptoms None None O
of None None O
PTSD None None O
. None None O

Therefore None None O
, None None O
bacterial None None O
mtlD None None O
gene None None O
coding None None O
for None None O
mannitol None None O
1-phosphate None None O
dehydrogenase None None I-PROTEIN
under None None O
the None None O
control None None O
of None None O
constitutive None None O
promoter None None O
CaMV35S None None O
was None None O
introduced None None O
and None None O
overexpressed None None O
in None None O
the None None O
peanut None None O
cv None None O
. None None O

The None None O
morphological None None O
characteristics None None O
of None None O
the None None O
lingual None None O
papillae None None O
of None None O
Sprague None None O
Dowley None None O
rats None None O
, None None O
three-dimensional None None O
SEM None None O
images None None O
, None None O
and None None O
the None None O
types None None O
of None None O
papillae None None O
on None None O
the None None O
dorsal None None I-NEURON
surface None None O
were None None O
similar None None O
to None None O
those None None O
reported None None O
previously None None O
in None None O
other None None O
rodent None None O
mammals None None O
. None None O

Among None None O
other None None O
metal None None O
nanoparticles None None O
, None None O
zinc None None I-TRANS
oxide None None O
nanoparticles None None O
are None None O
very None None O
much None None O
important None None O
due None None O
to None None O
their None None O
utilization None None O
in None None O
gas None None O
sensors None None O
, None None O
biosensors None None O
, None None O
cosmetics None None O
, None None O
drug-delivery None None O
systems None None O
, None None O
and None None O
so None None O
forth None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
finding None None O
of None None O
putative None None O
genes None None O
of None None O
multidrug None None O
resistance None None O
efflux None None O
pump None None O
and None None O
ATP-binding None None O
cassette None None O
transporters None None I-PROTEIN
in None None O
this None None O
strain None None O
suggests None None O
a None None O
multidrug None None O
resistant None None O
phenotype None None O
. None None O

Multivariate None None O
analysis None None O
showed None None O
the None None O
risk None None O
factors None None O
for None None O
incisional None None O
hernia None None O
were None None O
female None None O
( None None O
p=0.0014 None None O
) None None O
, None None O
distal None None O
colon None None O
and None None O
rectal None None O
cancer None None O
( None None O
p=0.0038 None None O
) None None O
, None None O
high None None O
body None None O
mass None None O
index None None O
( None None O
p=0.0055 None None O
) None None O
and None None O
lower None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
p=0.0081 None None O
) None None O
. None None O

Although None None O
expressing None None O
adequate None None O
levels None None O
of None None O
functional None None O
tumor None None O
necrosis None None O
factor-related None None O
apoptosis-inducing None None O
ligand None None O
( None None O
TRAIL None None O
) None None O
receptors None None I-PROTEIN
DR4/DR5 None None O
, None None O
significant None None O
proportion None None O
of None None O
esophageal None None O
cancer None None O
cells None None O
exhibit None None O
resistance None None O
to None None O
the None None O
cytotoxic None None O
effect None None O
of None None O
this None None O
ligand None None O
. None None O

Ramosetron None None O
is None None O
a None None O
new None None O
selective None None O
5-hydroxytryptamine None None I-TRANS
type None None O
3 None None O
( None None O
5-HT3 None None O
) None None O
receptor None None I-PROTEIN
antagonist None None O
that None None O
reportedly None None O
has None None O
more None None O
potent None None O
antiemetic None None O
effects None None O
than None None O
other None None O
5-HT3 None None O
receptor None None I-PROTEIN
antagonists None None O
. None None O

This None None O
study None None O
was None None O
performed None None O
to None None O
evaluate None None O
any None None O
improvement None None O
in None None O
the None None O
nutritional None None O
state None None O
and None None O
clinical None None O
symptoms None None O
in None None O
patients None None O
with None None O
liver None None O
failure None None O
and None None O
advanced None None O
cirrhosis None None O
after None None O
consumption None None O
of None None O
a None None O
liver None None O
diet None None O
with None None O
restricted None None O
energy None None O
and None None O
protein None None O
, None None O
in None None O
combination None None O
with None None O
a None None O
branched None None O
chain None None O
amino None None I-TRANS
acids None None I-TRANS
( None None O
BCAA None None O
) None None O
-enriched None None O
elemental None None O
diet None None O
. None None O

The None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ALP None None O
) None None O
, None None O
and None None O
albumin None None O
( None None O
ALB None None O
) None None O
levels None None O
were None None O
tested None None O
and None None O
the None None O
survival None None O
time None None O
was None None O
recorded None None O
. None None O

Patients None None O
undergoing None None O
combined None None O
splenectomy None None O
and None None O
hepatectomy None None O
needed None None O
longer None None O
surgery None None O
time None None O
and None None O
hospital None None O
stay None None O
time None None O
, None None O
and None None O
transfused None None O
much None None O
more None None O
blood None None O
intraoperatively None None O
( None None O
p=0.07 None None O
, None None O
0.03 None None O
, None None O
and None None O
0.02 None None O
) None None O
, None None O
and None None O
also None None O
experienced None None O
more None None O
portal None None O
vein None None O
thrombosis None None I-DISEASE
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

P53 None None I-PROTEIN
and None None O
Bcl-2 None None O
protein None None O
expression None None O
were None None O
estimated None None O
in None None O
the None None O
sera None None O
and None None O
in None None O
liver None None O
tissues None None O
of None None O
45 None None O
HCC None None O
cases None None O
using None None O
ELISA None None O
and None None O
immunohistochemistry None None O
. None None O

Serum None None O
p53 None None I-PROTEIN
antigen None None O
in None None O
HCC None None O
patients None None O
( None None O
0.46±0.331ng/ml None None O
) None None O
showed None None O
significant None None O
elevation None None O
than None None O
healthy None None O
individuals None None O
( None None O
0.24±0.11ng/ml None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Bcl-2 None None O
showed None None O
a None None O
positive None None O
linear None None O
correlation None None O
with None None O
p53 None None I-PROTEIN
in None None O
the None None O
sera None None O
of None None O
carcinoma None None O
patients None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

However None None O
, None None O
a None None O
positive None None O
linear None None O
correlation None None O
was None None O
found None None O
between None None O
bcl-2 None None O
and None None O
p53 None None I-PROTEIN
suggesting None None O
that None None O
bcl-2/p53 None None O
co-expression None None O
pattern None None O
may None None O
be None None O
of None None O
value None None O
in None None O
the None None O
development None None O
of None None O
more None None O
effective None None O
medical None None O
therapies None None O
in None None O
HCC None None O
. None None O

We None None O
observed None None O
no None None O
significant None None O
difference None None O
in None None O
the None None O
analysis None None O
of None None O
the None None O
post-operative None None O
hemoglobin None None O
, None None O
liver None None O
enzymes None None I-PROTEIN
, None None O
residual None None O
liver None None O
size None None O
, None None O
size None None O
of None None O
tumor None None O
resected None None O
, None None O
need None None O
for None None O
postoperative None None O
monitoring None None O
in None None O
ICU None None O
stay None None O
, None None O
length None None O
of None None O
hospital None None O
stay None None O
and None None O
blood None None O
loss None None O
. None None O

For None None O
older None None O
patients None None O
who None None O
undergo None None O
a None None O
radical None None O
gastrectomy None None O
for None None O
gastric None None O
cancer None None O
, None None O
the None None O
surgeon None None O
must None None O
pay None None O
meticulous None None O
attention None None I-FUNC
to None None O
the None None O
transection None None O
and None None O
mobilization None None O
of None None O
the None None O
duodenum None None O
in None None O
order None None O
to None None O
prevent None None O
duodenal None None O
stump None None O
leakage None None O
. None None O

Transient None None O
lower None None O
esophageal None None O
sphincter None None O
relaxation None None O
inhibitors None None O
, None None O
i.e. None None O
, None None O
gamma-aminobutyric None None I-TRANS
acid None None I-TRANS
B None None O
receptor None None I-PROTEIN
agonists None None O
, None None O
baclofen None None O
, None None O
and None None O
metabotropic None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
5 None None O
antagonists None None O
, None None O
ADX10059 None None O
, None None O
were None None O
tried None None O
in None None O
resistant None None O
cases None None O
, None None O
but None None O
caused None None O
central None None O
nervous None None O
and None None O
hepatic None None O
side None None O
effects None None O
, None None O
respectively None None O
. None None O

Serum None None O
p53 None None I-PROTEIN
Abs None None O
was None None O
assessed None None O
by None None O
( None None O
ELISA None None O
) None None O
. None None O

Serum None None O
P53 None None I-PROTEIN
Abs None None O
was None None O
significantly None None O
( None None O
p=0.01 None None O
) None None O
increased None None O
with None None O
the None None O
progression None None O
of None None O
child None None O
score None None O
but None None O
there None None O
was None None O
no None None O
significant None None O
difference None None O
with None None O
regard None None O
to None None O
age None None O
, None None O
sex None None O
, None None O
tumor None None O
size None None O
or None None O
serum None None O
liver None None O
profile None None O
. None None O

P53 None None I-PROTEIN
Abs None None O
could None None O
be None None O
regarded None None O
as None None O
a None None O
specific None None O
biomarker None None O
for None None O
cancer None None O
process None None O
and None None O
its None None O
use None None O
in None None O
combination None None O
with None None O
AFP None None O
may None None O
increase None None O
the None None O
diagnostic None None O
sensitivity None None O
of None None O
HCC None None O
. None None O

Multivariate None None O
logistic None None O
regression None None O
showed None None O
that None None O
the None None O
independent None None O
risk None None O
factors None None O
for None None O
mortality None None O
are None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
level None None O
& None None O
lt None None O
; None None O
3.0 None None O
mg/ None None O
dL None None O
( None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
= None None O
17.6 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
= None None O
1.4-224.6 None None O
, None None O
P None None O
= None None O
0.027 None None O
) None None O
and None None O
septic None None O
shock None None O
( None None O
OR None None O
= None None O
37.5 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
3.6-386.7 None None O
, None None O
P None None O
= None None O
0.002 None None O
) None None O
. None None O

If None None O
the None None O
indications None None O
for None None O
combined None None O
Billroth None None O
II None None O
with None None O
Braun None None O
anastomosis None None O
are None None O
strictly None None O
controlled None None O
, None None O
and None None O
more None None O
attention None None I-FUNC
is None None O
paid None None O
to None None O
perioperatively None None O
support None None O
, None None O
combined None None O
Billroth None None O
II None None O
with None None O
Braun None None O
anastomosis None None O
can None None O
prolong None None O
the None None O
life None None O
span None None O
of None None O
the None None O
patients None None O
with None None O
gastric None None O
cancer None None O
rather None None O
than None None O
increase None None O
the None None O
surgical None None O
complications None None O
and None None O
the None None O
mortality None None O
. None None O

A None None O
total None None O
of None None O
394 None None O
stage None None O
I-III None None O
surgical None None O
gastric None None O
cancer None None O
patients None None O
who None None O
were None None O
detected None None O
of None None O
immunohistochemical None None O
( None None O
IHC None None O
) None None O
HER2 None None O
expression None None O
postoperatively None None O
were None None O
included None None O
in None None O
this None None O
retrospective None None O
study None None O
. None None O

Zinc None None I-TRANS
finger None None O
protein None None O
139 None None O
( None None O
ZNF139 None None O
) None None O
gene None None O
is None None O
proved None None O
play None None O
an None None O
important None None O
role None None O
in None None O
gastric None None O
cancer None None O
. None None O

Here None None O
, None None O
we None None O
identified None None O
Itch None None O
as None None O
the None None O
E3 None None O
ubiquitin None None O
ligase None None I-PROTEIN
for None None O
ASPP2 None None O
. None None O

We None None O
demonstrated None None O
the None None O
presence None None O
of None None O
exosome-associated None None O
Aβ None None O
in None None O
the None None O
cerebrospinal None None O
fluid None None O
( None None O
CSF None None O
) None None O
of None None O
cynomolgus None None O
monkeys None None O
and None None O
APP None None I-TRANS
transgenic None None O
mice None None O
. None None O

To None None O
evaluate None None O
the None None O
evolution None None O
of None None O
facial None None O
edema None None O
in None None O
the None None O
postoperative None None O
period None None O
after None None O
alveolar None None O
graft None None O
surgeries None None O
performed None None O
with None None O
collagen None None I-PROTEIN
membrane None None O
soaked None None O
with None None O
recombinant None None O
human None None O
bone None None O
morphogenetic None None O
protein-2 None None O
( None None O
rhBMP-2 None None O
) None None O
in None None O
individuals None None O
with None None O
cleft None None O
lip None None O
and None None O
palate None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
is None None O
to None None O
report None None O
the None None O
incidence None None O
of None None O
amblyopia None None I-DISEASE
and None None O
its None None O
risk None None O
factors None None O
in None None O
children None None O
with None None O
isolated None None O
metopic None None O
craniosynostosis None None O
. None None O

Ophthalmologic None None O
records None None O
were None None O
reviewed None None O
for None None O
diagnoses None None O
of None None O
amblyopia None None I-DISEASE
, None None O
strabismus None None O
, None None O
and None None O
refractive None None O
error None None O
. None None O

The None None O
incidence None None O
of None None O
amblyopia None None I-DISEASE
and None None O
its None None O
risk None None O
factors None None O
found None None O
in None None O
our None None O
study None None O
are None None O
higher None None O
than None None O
the None None O
rate None None O
found None None O
in None None O
the None None O
clinically None None O
normal None None O
pediatric None None O
population None None O
. None None O

Amblyopia None None I-DISEASE
is None None O
best None None O
treated None None O
early None None O
in None None O
life None None O
to None None O
achieve None None O
a None None O
successful None None O
outcome None None O
. None None O

We None None O
tested None None O
independent None None O
and None None O
interactive None None O
effects None None O
of None None O
Apolipoprotein None None O
E None None O
( None None O
ApoE None None O
) None None O
and None None O
pulse None None O
pressure None None O
( None None O
PP None None O
) None None O
concurrently None None O
and None None O
longitudinally None None O
across None None O
9 None None O
years None None O
( None None O
3 None None O
waves None None O
) None None O
of None None O
episodic None None O
( None None O
EM None None O
) None None O
and None None O
semantic None None I-FUNC
memory None None I-FUNC
( None None O
SM None None O
) None None O
data None None O
from None None O
the None None O
Victoria None None O
Longitudinal None None O
Study None None O
. None None O

First None None O
, None None O
the None None O
best None None O
fitting None None O
memory None None I-FUNC
model None None O
was None None O
2 None None O
single None None O
latent None None O
variables None None O
for None None O
EM None None O
and None None O
SM None None O
, None None O
each None None O
exhibiting None None O
configural None None O
, None None O
metric None None O
, None None O
and None None O
partial None None O
scalar None None O
invariance None None O
. None None O

We None None O
investigated None None O
the None None O
role None None O
of None None O
p230 None None O
and None None O
its None None O
interacting None None O
protein None None O
, None None O
microtubule None None O
actin None None I-PROTEIN
crosslinking None None O
protein None None O
1 None None O
( None None O
MACF1 None None O
) None None O
, None None O
in None None O
amino None None O
acid None None O
starvation-induced None None O
membrane None None O
transport None None O
. None None O

The None None O
metabolite None None O
profile None None O
revealed None None O
that None None O
the None None O
simulated None None O
heat None None O
wave None None O
induced None None O
a None None O
switch None None O
in None None O
stress None None O
protecting None None O
compounds None None O
from None None O
proline None None I-TRANS
to None None O
polyols None None O
. None None O

Close None None O
attention None None I-FUNC
to None None O
infection None None O
in None None O
PD None None O
patients None None O
with None None O
relatively None None O
lower None None O
fT4 None None O
levels None None O
should None None O
be None None O
considered None None O
. None None O

An None None O
additional None None O
level None None O
of None None O
complexity None None O
has None None O
been None None O
found None None O
within None None O
PKS-based None None O
pathways None None O
where None None O
the None None O
PKS None None O
is None None O
fused None None O
to None None O
a None None O
single None None O
module None None O
nonribosomal None None O
peptide None None O
synthetase None None O
( None None O
NRPS None None O
) None None O
to None None O
synthesize None None O
polyketides None None O
conjugated None None O
to None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

We None None O
shortlisted None None O
at None None O
least None None O
12 None None O
enzymes None None I-PROTEIN
for None None O
which None None O
there None None O
was None None O
no None None O
corresponding None None O
deposition None None O
in None None O
PDB None None O
, None None O
reflecting None None O
that None None O
their None None O
crystal None None O
structures None None O
are None None O
yet None None O
to None None O
be None None O
solved None None O
! None None O

Due None None O
to None None O
the None None O
unavailability None None O
of None None O
any None None O
crystal None None O
structure None None O
of None None O
Glutamate None None I-TRANS
synthase None None O
in None None O
PDB None None O
, None None O
we None None O
generated None None O
the None None O
3D None None O
structure None None O
by None None O
homology None None O
modeling None None O
. None None O

The None None O
active None None O
site None None O
of None None O
Glutamate None None I-TRANS
synthase None None O
was None None O
identified None None O
by None None O
not None None O
only None None O
superimposing None None O
the None None O
template None None O
structure None None O
( None None O
PDB None None O
ID None None O
: None None O
1E0A None None O
) None None O
over None None O
each None None O
other None None O
but None None O
also None None O
by None None O
the None None O
Parallel-ProBiS None None O
algorithm None None O
. None None O

A None None O
sensitive None None O
and None None O
specific None None O
LC-MS/MS None None O
method None None O
for None None O
the None None O
quantification None None O
of None None O
arachidonic None None O
acid None None O
, None None O
prostaglandin None None O
E2 None None O
, None None O
thromboxane None None O
B2 None None O
, None None O
anandamide None None I-TRANS
, None None O
2-arachidonoylglycerol None None O
, None None O
noladin None None O
ether None None O
, None None O
lineoyl None None O
ethanolamide None None O
, None None O
oleoyl None None O
ethanolamide None None O
, None None O
palmitoyl None None O
ethanolamide None None O
, None None O
steroyl None None O
ethanolamide None None O
, None None O
aldosterone None None O
, None None O
cortisol None None O
, None None O
dehydroepiandrosterone None None O
, None None O
progesterone None None O
, None None O
and None None O
testosterone None None O
in None None O
human None None O
plasma None None O
was None None O
developed None None O
and None None O
validated None None O
. None None O

Extensive None None O
experimental None None O
study None None O
shows None None O
that None None O
FFNN None None O
trained None None O
with None None O
developed None None O
learning None None I-FUNC
algorithm None None O
, None None O
achieves None None O
low None None O
prediction None None O
error None None O
and None None O
good None None O
generalization None None O
quality None None O
regardless None None O
of None None O
outliers None None O
' None None O
presence None None O
in None None O
training None None O
data None None O
. None None O

Self-assembled None None O
antimicrobial None None O
peptides None None I-TRANS
have None None O
evolved None None O
from None None O
the None None O
area None None O
of None None O
antimicrobial None None O
peptides None None I-TRANS
. None None O

Self-assembled None None O
peptides None None I-TRANS
harness None None O
a None None O
`` None None O
bottom-up None None O
'' None None O
approach None None O
, None None O
whereby None None O
the None None O
primary None None O
peptide None None O
sequence None None O
may None None O
be None None O
modified None None O
with None None O
natural None None O
and None None O
unnatural None None O
amino None None I-TRANS
acids None None I-TRANS
to None None O
produce None None O
an None None O
inherently None None O
antimicrobial None None O
hydrogel None None O
. None None O

pH None None O
, None None O
enzymes None None I-PROTEIN
) None None O
and None None O
therefore None None O
allow None None O
local None None O
, None None O
targeted None None O
antimicrobial None None O
therapy None None O
at None None O
the None None O
site None None O
of None None O
infection None None O
. None None O

This None None O
article None None O
reviews None None O
an None None O
area None None O
of None None O
increasing None None O
interest None None O
, None None O
namely None None O
self-assembled None None O
peptides None None I-TRANS
and None None O
their None None O
potential None None O
therapeutic None None O
applications None None O
as None None O
innovative None None O
hydrogels None None O
and None None O
biomaterials None None O
in None None O
the None None O
prevention None None O
of None None O
biofilm-related None None O
infection None None O
. None None O

Cellulose None None O
nanocrystals None None O
( None None O
CNCs None None O
) None None O
continue None None O
to None None O
gain None None O
increasing None None O
attention None None I-FUNC
in None None O
the None None O
materials None None O
community None None O
as None None O
sustainable None None O
nanoparticles None None O
with None None O
unique None None O
chemical None None O
and None None O
mechanical None None O
properties None None O
. None None O

Although None None O
there None None O
is None None O
controversial None None O
evidence None None O
about None None O
the None None O
effect None None O
of None None O
methamphetamine None None O
and None None O
MDMA None None O
on None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
in None None O
laboratory None None O
animals None None O
, None None O
results None None O
from None None O
published None None O
papers None None O
demonstrate None None O
that None None O
amphetamines None None O
cause None None O
long-term None None O
impairment None None O
of None None O
cognitive None None O
functions None None O
. None None O

In None None O
humans None None O
, None None O
there None None O
is None None O
a None None O
considerable None None O
body None None O
of None None O
evidence None None O
indicating None None O
that None None O
methamphetamine None None O
and None None O
MDMA None None O
seriously None None O
disrupt None None O
memory None None I-FUNC
and None None O
learning None None I-FUNC
processes None None O
. None None O

Abstract None None O
Effective None None O
vaccination None None O
against None None O
intracellular None None O
pathogens None None O
, None None O
such None None O
as None None O
tuberculosis None None O
( None None O
TB None None O
) None None O
, None None O
relies None None O
on None None O
the None None O
generation None None O
and None None O
maintenance None None O
of None None O
CD4 None None O
memory None None I-FUNC
T None None O
cells None None O
. None None O

This None None O
review None None O
discusses None None O
how None None O
the None None O
persistence None None O
of None None O
antigen None None O
, None None O
the None None O
location None None O
of None None O
memory None None I-FUNC
cells None None O
, None None O
and None None O
their None None O
multifunctional None None O
ability None None O
shape None None O
the None None O
CD4 None None O
memory None None I-FUNC
T None None O
cell None None O
response None None O
against None None O
TB None None O
. None None O

ID None None O
is None None O
able None None O
to None None O
interact None None O
with None None O
the None None O
larger None None O
DNA-binding None None O
basic None None O
helix-loop-helix None None O
( None None O
bHLH None None O
) None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
, None None O
but None None O
due None None O
to None None O
the None None O
lack None None O
of None None O
the None None O
basic None None O
domain None None O
required None None O
for None None O
DNA None None O
binding None None O
, None None O
ID None None O
traps None None O
bHLH None None O
proteins None None O
in None None O
non-functional None None O
complexes None None O
. None None O

Keratin None None I-PROTEIN
intermediate None None O
filament None None O
proteins None None O
are None None O
well None None O
established None None O
as None None O
major None None O
cytoskeletal None None O
players None None O
in None None O
maintaining None None O
epithelial None None O
integrity None None O
. None None O

Disruption None None O
of None None O
the None None O
keratin None None I-PROTEIN
cytoskeleton None None O
by None None O
mutations None None O
or None None O
its None None O
reorganization None None O
following None None O
posttranslational None None O
modifications None None O
can None None O
render None None O
epithelia None None O
susceptible None None O
to None None O
tissue None None O
damage None None O
and None None O
various None None O
stresses None None O
, None None O
while None None O
loss None None O
of None None O
keratin None None I-PROTEIN
expression None None O
is None None O
a None None O
hallmark None None O
of None None O
epithelial-mesenchymal None None O
transition None None O
( None None O
EMT None None O
) None None O
. None None O

Based None None O
on None None O
selected None None O
examples None None O
, None None O
we None None O
will None None O
discuss None None O
how None None O
cell-specific None None O
expression None None O
of None None O
keratin None None I-PROTEIN
isotypes None None O
affects None None O
cytoarchitecture None None O
and None None O
cell None None O
behavior None None O
. None None O

Next None None O
, None None O
we None None O
discuss None None O
pathomechanisms None None O
of None None O
epidermal None None O
keratin None None I-PROTEIN
disorders None None O
in None None O
the None None O
light None None O
of None None O
novel None None O
data None None O
. None None O

To None None O
date None None O
, None None O
the None None O
existence None None O
of None None O
immortal None None O
strands None None O
remains None None O
contentious None None O
with None None O
published None None O
evidence None None O
arguing None None O
in None None O
favour None None O
of None None O
and None None O
against None None O
the None None O
retention None None I-FUNC
of None None O
an None None O
immortal None None O
strand None None O
by None None O
asymmetrically None None O
dividing None None O
SCs None None O
. None None O

Endothelial None None O
cell None None O
senescence None None O
is None None O
associated None None O
with None None O
vascular None None O
diseases None None O
, None None O
such None None O
as None None O
atherosclerosis None None I-DISEASE
. None None O

Abstract None None O
Focal None None O
adhesion None None O
kinase None None O
( None None O
FAK None None O
) None None O
is None None O
a None None O
non-receptor None None I-PROTEIN
protein None None O
tyrosine None None I-TRANS
kinase None None O
that None None O
is None None O
highly None None O
expressed None None O
or None None O
activated None None O
in None None O
many None None O
human None None O
cancers None None O
. None None O

However None None O
, None None O
their None None O
therapeutic None None O
effects None None O
are None None O
hampered None None O
by None None O
severe None None O
side None None O
effects None None O
, None None O
such None None O
as None None O
muscle None None O
weakness None None O
, None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
fat None None O
redistribution None None O
, None None O
and None None O
osteoporosis None None O
. None None O

The None None O
transfection None None O
process None None O
has None None O
been None None O
subdivided None None O
into None None O
separate None None O
steps None None O
and None None O
here None None O
special None None O
emphasis None None O
is None None O
given None None O
to None None O
peptides None None I-TRANS
that None None O
have None None O
been None None O
designed None None O
to None None O
optimize None None O
these None None O
steps None None O
individually None None O
. None None O

Abstract None None O
Estrogen None None O
affects None None O
transcriptional None None O
status None None O
by None None O
activating None None O
its None None O
corresponding None None O
nuclear None None O
receptor None None I-PROTEIN
, None None O
the None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
. None None O

In None None O
addition None None O
to None None O
modified None None O
lipoprotein None None O
uptake None None O
, None None O
these None None O
proteins None None O
are None None O
also None None O
known None None O
to None None O
regulate None None O
apoptotic None None O
cell None None O
clearance None None O
, None None O
initiate None None O
signal None None O
transduction None None O
, None None O
and None None O
serve None None O
as None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
for None None O
pathogens None None O
. None None O

The None None O
present None None O
review None None O
focuses None None O
on None None O
the None None O
involvement None None O
of None None O
SRs None None O
in None None O
atherosclerosis None None I-DISEASE
, None None O
thrombosis None None I-DISEASE
, None None O
and None None O
other None None O
cardiovascular None None O
diseases None None O
. None None O

With None None O
respect None None O
to None None O
the None None O
regulation None None O
of None None O
RNA None None O
transcripts None None O
, None None O
the None None O
concept None None O
of None None O
RNA None None O
regulons None None O
, None None O
which None None O
- None None O
by None None O
analogy None None I-FUNC
with None None O
DNA None None O
regulons None None O
in None None O
bacteria None None O
- None None O
refers None None O
to None None O
the None None O
coordinated None None O
control None None O
of None None O
functionally None None O
related None None O
RNA None None O
molecules None None O
, None None O
has None None O
emerged None None O
as None None O
a None None O
unifying None None O
theory None None O
that None None O
describes None None O
the None None O
logic None None O
of None None O
regulatory None None O
RNA-protein None None O
interactions None None O
in None None O
eukaryotes None None O
. None None O

The None None O
TGF-β None None O
superfamily None None O
members None None O
signal None None O
via None None O
specific None None O
serine/threonine None None O
kinase None None O
receptors None None I-PROTEIN
and None None O
their None None O
nuclear None None O
effectors None None O
termed None None O
Smad None None O
proteins None None O
as None None O
well None None O
as None None O
through None None O
non-Smad None None O
pathways None None O
, None None O
which None None O
explain None None O
their None None O
pleiotropic None None O
effects None None O
in None None O
self-renewal None None O
and None None O
differentiation None None O
of None None O
stem None None O
cells None None O
. None None O

Abstract None None O
Orexin None None O
peptides None None I-TRANS
and None None O
their None None O
cognate None None O
receptors None None I-PROTEIN
were None None O
discovered None None O
14 None None O
years None None O
ago None None O
. None None O

The None None O
persistence None None O
of None None O
antigen-specific None None O
antibody None None O
titers None None O
over None None O
a None None O
protective None None O
threshold None None O
, None None O
and None None O
the None None O
ability None None O
to None None O
exibit None None O
a None None O
'recall None None O
response None None O
' None None O
to None None O
a None None O
subsequent None None O
encounter None None O
with None None O
an None None O
antigen None None O
have None None O
long None None O
been None None O
the None None O
only None None O
measurable None None O
correlates None None O
of None None O
vaccine None None O
take None None O
and None None O
immune None None O
memory None None I-FUNC
development None None O
, None None O
suffering None None O
from None None O
the None None O
disadvantage None None O
of None None O
relying None None O
on None None O
long-term None None O
monitoring None None O
of None None O
the None None O
immune None None O
response None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
discuss None None O
recent None None O
data None None O
and None None O
hypotheses None None O
on None None O
early None None O
correlates None None O
of None None O
the None None O
development None None O
of None None O
immune None None O
memory None None I-FUNC
, None None O
with None None O
special None None O
emphasis None None O
on None None O
the None None O
gene None None O
expression None None O
signatures None None O
that None None O
underlie None None O
the None None O
self-renewal None None O
ability None None O
of None None O
some None None O
lymphocyte None None O
subsets None None O
, None None O
and None None O
their None None O
similarities None None O
with None None O
gene None None O
expression None None O
signatures None None O
in None None O
stem None None O
cells None None O
. None None O

Cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
tissue None None O
invasion None None O
are None None O
also None None O
characteristics None None O
of None None O
malignant None None O
tumors None None O
and None None O
patterns None None O
of None None O
methylation None None O
similar None None O
to None None O
that None None O
seen None None O
in None None O
trophoblast None None O
are None None O
found None None O
in None None O
various None None O
tumor None None O
types None None O
. None None O

Abstract None None O
Glucocorticoids None None O
, None None O
recognized None None O
as None None O
stress-related None None O
steroid None None I-PROTEIN
hormones None None I-PROTEIN
secreted None None O
from None None O
adrenal None None I-TRANS
glands None None O
, None None O
have None None O
multiple None None O
roles None None O
in None None O
brain None None O
function None None O
. None None O

In None None O
the None None O
present None None O
review None None O
, None None O
we None None O
show None None O
an None None O
overview None None O
of None None O
the None None O
current None None O
knowledge None None O
concerning None None O
the None None O
impact None None O
of None None O
glucocorticoids None None O
on None None O
behavior None None O
in None None O
animal None None O
models None None O
of None None O
depression None None I-DISEASE
, None None O
and None None O
on None None O
cell None None O
survival None None O
and None None O
function None None O
in None None O
the None None O
CNS None None O
. None None O

The None None O
mismatch None None O
is None None O
recognized None None O
by None None O
T4 None None O
endonuclease None None I-PROTEIN
VII None None O
and None None O
nicked None None O
on None None O
the None None O
3 None None O
' None None O
side None None O
. None None O

The None None O
residual None None O
nick None None O
is None None O
ligated None None O
by None None O
DNA None None I-PROTEIN
ligase None None I-PROTEIN
( None None O
gp30 None None O
) None None O
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
that None None O
dynamic None None O
regulation None None O
of None None O
chromatin None None O
structure None None O
occurs None None O
in None None O
response None None O
to None None O
neuronal None None O
stimulation None None O
associated None None O
with None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
. None None O

Studies None None O
in None None O
animal None None O
models None None O
have None None O
used None None O
genetic None None O
and None None O
pharmacological None None O
methods None None O
to None None O
manipulate None None O
the None None O
epigenetic None None O
machinery None None O
in None None O
the None None O
brain None None O
during None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
formation None None O
. None None O

Analysis None None O
of None None O
animal None None O
models None None O
has None None O
also None None O
implicated None None O
epigenetic None None O
mechanisms None None O
in None None O
impaired None None O
cognition None None O
associated None None O
with None None O
aging None None O
, None None O
neurodegenerative None None O
disease None None O
, None None O
and None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
( None None O
ID None None O
) None None O
. None None O

This None None O
review None None O
provides None None O
an None None O
overview None None O
of None None O
chromatin None None O
modifications None None O
that None None O
are None None O
implicated None None O
in None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
and None None O
discusses None None O
the None None O
role None None O
of None None O
chromatin None None O
modifying None None O
proteins None None O
in None None O
learning-induced None None O
transcriptional None None O
regulation None None O
and None None O
human None None O
cognitive None None I-DISEASE
disorders None None I-DISEASE
. None None O

Consequently None None O
, None None O
aberrant None None O
levels None None O
of None None O
neurosteroids None None O
have None None O
been None None O
implicated None None O
in None None O
numerous None None O
disorders None None O
, None None O
including None None O
, None None O
but None None O
not None None O
limited None None O
to None None O
, None None O
anxiety None None O
, None None O
neurodegenerative None None O
diseases None None O
, None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
, None None O
epilepsy None None O
, None None O
and None None O
depression None None I-DISEASE
. None None O

Despite None None O
its None None O
extreme None None O
stability None None O
, None None O
elastin None None I-PROTEIN
can None None O
be None None O
degraded None None O
by None None O
several None None O
enzymes None None I-PROTEIN
termed None None O
elastases None None I-PROTEIN
. None None O

As None None O
a None None O
consequence None None O
, None None O
elastin None None I-PROTEIN
fragmentation None None O
resulting None None O
in None None O
the None None O
generation None None O
of None None O
elastin None None I-PROTEIN
peptides None None I-TRANS
is None None O
one None None O
of None None O
the None None O
hallmarks None None O
of None None O
aging None None O
. None None O

The None None O
second None None O
part None None O
of None None O
this None None O
review None None O
is None None O
focused None None O
on None None O
the None None O
available None None O
evidence None None O
concerning None None O
the None None O
pathogenetic None None O
consequences None None O
of None None O
aluminium None None O
overload None None O
in None None O
human None None O
health None None O
, None None O
with None None O
particular None None O
attention None None I-FUNC
to None None O
its None None O
putative None None O
role None None O
in None None O
bone None None O
and None None O
neurodegenerative None None O
human None None O
diseases None None O
. None None O

Evidence None None O
has None None O
accumulated None None O
indicating None None O
that None None O
TCP None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
are None None O
the None None O
main None None O
regulators None None O
of None None O
plant None None O
form None None O
and None None O
architecture None None O
and None None O
constitute None None O
a None None O
tool None None O
through None None O
which None None O
evolution None None O
shapes None None O
plant None None O
diversity None None O
. None None O

Also None None O
important None None O
, None None O
the None None O
possible None None O
role None None O
of None None O
TCP None None O
proteins None None O
as None None O
integrators None None O
of None None O
plant None None O
developmental None None O
responses None None O
to None None O
the None None O
environment None None O
has None None O
deserved None None O
little None None O
attention None None I-FUNC
. None None O

The None None O
Src None None O
family None None O
kinases None None I-PROTEIN
Yes None None O
, None None O
Fyn None None O
, None None O
and None None O
c-Src None None O
play None None O
a None None O
pivotal None None O
role None None O
in None None O
regulating None None O
diverse None None O
liver None None O
functions None None O
such None None O
as None None O
bile None None O
flow None None O
, None None O
proteolysis None None O
, None None O
apoptosis None None O
, None None O
and None None O
proliferation None None O
and None None O
are None None O
regulated None None O
by None None O
anisoosmotic None None O
cell None None O
volume None None O
changes None None O
, None None O
death None None O
receptor None None I-PROTEIN
ligands None None O
, None None O
and None None O
bile None None O
acids None None O
. None None O

In None None O
contrast None None O
, None None O
hepatocyte None None O
shrinkage None None O
generates None None O
an None None O
almost None None O
instantaneous None None O
oxidative None None O
stress None None O
response None None O
that None None O
triggers None None O
the None None O
activation None None O
of None None O
c-Jun None None O
N-terminal None None O
kinase None None O
and None None O
the None None O
Src None None O
family None None O
kinases None None I-PROTEIN
Fyn None None O
and None None O
Yes None None O
. None None O

This None None O
review None None O
will None None O
discuss None None O
the None None O
role None None O
of None None O
Src None None O
family None None O
kinases None None I-PROTEIN
in None None O
the None None O
regulation None None O
of None None O
liver None None O
function None None O
with None None O
emphasis None None O
on None None O
their None None O
role None None O
in None None O
osmo-signaling None None O
and None None O
bile None None O
acid None None O
signaling None None O
. None None O

They None None O
take None None O
part None None O
in None None O
a None None O
plethora None None O
of None None O
metal None None O
ion-related None None O
events None None O
( None None O
from None None O
detoxification None None O
to None None O
homeostasis None None O
, None None O
storage None None I-FUNC
, None None O
and None None O
delivery None None O
) None None O
, None None O
in None None O
a None None O
wide None None O
range None None O
of None None O
stress None None O
responses None None O
, None None O
and None None O
in None None O
different None None O
pathological None None O
processes None None O
( None None O
tumorigenesis None None O
, None None O
neurodegeneration None None O
, None None O
and None None O
inflammation None None O
) None None O
. None None O

In None None O
mammalian None None O
kidney None None O
, None None O
MT1/MT2 None None O
interact None None O
with None None O
megalin None None O
and None None O
related None None O
receptors None None I-PROTEIN
, None None O
and None None O
with None None O
the None None O
transporter None None O
transthyretin None None O
. None None O

Interaction None None O
with None None O
ferritin None None I-PROTEIN
and None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
are None None O
also None None O
documented None None O
. None None O

As None None O
some None None O
of None None O
these None None O
proteins None None O
are None None O
involved None None O
in None None O
cell None None O
cycle None None O
and None None O
proliferation None None O
control None None O
( None None O
p53 None None I-PROTEIN
, None None O
nuclear None None O
factor None None O
κB None None O
, None None O
and None None O
PKCμ None None O
) None None O
, None None O
they None None O
are None None O
considered None None O
in None None O
the None None O
context None None O
of None None O
oncogenesis None None O
and None None O
tumor None None O
progression None None O
. None None O

Although None None O
the None None O
BIRs None None O
are None None O
responsible None None O
for None None O
binding None None O
to None None O
caspases None None O
, None None O
the None None O
RING None None O
domain None None O
can None None O
act None None O
as None None O
a None None O
ubiquitin-E3 None None O
ligase None None I-PROTEIN
, None None O
leading None None O
to None None O
ubiquitylation None None O
of None None O
IAPs None None O
themselves None None O
and None None O
their None None O
pro-apoptotic None None O
IAP None None O
counterparts None None O
such None None O
as None None O
caspases None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
the None None O
results None None O
against None None O
the None None O
function None None O
of None None O
IAPs None None O
as None None O
a None None O
NEDD8-E3 None None O
ligase None None I-PROTEIN
are None None O
also None None O
suggested None None O
. None None O

To None None O
understand None None O
elastin None None I-PROTEIN
regulation None None O
during None None O
normal None None O
development None None O
, None None O
we None None O
describe None None O
the None None O
role None None O
of None None O
various None None O
elastic None None O
fiber None None O
accessory None None O
proteins None None O
. None None O

A None None O
wide None None O
variety None None O
of None None O
environmental None None O
cues None None O
, None None O
including None None O
inflammatory None None O
cytokines None None O
, None None O
ligands None None O
for None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
and None None O
endogenous None None O
danger None None O
signals None None O
, None None O
activate None None O
the None None O
inducible None None O
transcription None None O
factor None None O
nuclear None None O
factor-κB None None O
( None None O
NF-κB None None O
) None None O
, None None O
which None None O
is None None O
a None None O
central None None O
regulator None None O
of None None O
inflammatory None None O
and None None O
immune None None O
responses None None O
. None None O

Interestingly None None O
, None None O
the None None O
late None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
penicillin None None O
biosynthesis None None O
, None None O
and None None O
the None None O
isopenicillin None None O
N None None O
epimerization None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
cephalosporin None None O
biosynthesis None None O
are None None O
located None None O
inside None None O
peroxisomes None None O
in None None O
the None None O
producer None None O
fungi None None O
Penicillium None None O
chrysogenum None None O
and None None O
Acremonium None None O
chrysogenum None None O
. None None O

We None None O
found None None O
that None None O
various None None O
environmental None None O
agents None None O
, None None O
as None None O
well None None O
as None None O
endogenous None None O
compounds None None O
such None None O
as None None O
methionine None None I-TRANS
sulfoxide None None O
( None None O
MetO None None O
) None None O
, None None O
generate None None O
methyl None None O
radicals None None O
and None None O
modify None None O
dC None None O
to None None O
form None None O
5-methyl-dC None None O
in None None O
DNA None None O
in None None O
vitro None None O
. None None O

Their None None O
physiological None None O
ligands None None O
are None None O
the None None O
tachykinins None None O
, None None O
which None None O
, None None O
in None None O
the None None O
mammalian None None O
gut None None O
, None None O
correspond None None O
to None None O
substance None None I-TRANS
P None None I-TRANS
, None None O
neurokinin None None I-TRANS
A None None I-TRANS
, None None O
and None None O
neurokinin None None I-TRANS
B None None I-TRANS
. None None O

The None None O
availability None None O
of None None O
specific None None O
antibodies None None O
has None None O
allowed None None O
identifying None None O
the None None O
sites None None O
of None None O
distribution None None O
of None None O
the None None O
neurokinin None None O
receptors None None I-PROTEIN
in None None O
the None None O
gut None None O
, None None O
and None None O
important None None O
differences None None O
have None None O
been None None O
found None None O
among None None O
cell None None O
types None None O
and None None O
animal None None O
species None None O
. None None O

Papain-like None None O
cysteine None None I-TRANS
peptidases None None I-PROTEIN
are None None O
a None None O
diverse None None O
family None None O
of None None O
peptidases None None I-PROTEIN
found None None O
in None None O
most None None O
known None None O
organisms None None O
. None None O

Other None None O
organisms None None O
can None None O
utilize None None O
papain-like None None O
peptidases None None I-PROTEIN
for None None O
different None None O
purposes None None O
and None None O
they None None O
are None None O
often None None O
part None None O
of None None O
host-pathogen None None O
interactions None None O
. None None O

This None None O
review None None O
presents None None O
a None None O
state-of-the-art None None O
description None None O
of None None O
the None None O
structure None None O
and None None O
phylogeny None None O
of None None O
papain-like None None O
peptidases None None I-PROTEIN
as None None O
well None None O
as None None O
an None None O
overview None None O
of None None O
their None None O
physiological None None O
and None None O
pathological None None O
functions None None O
in None None O
humans None None O
and None None O
in None None O
other None None O
organisms None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
is None None O
the None None O
most None None O
common None None O
neurodegenerative None None O
disease None None O
of None None O
the None None O
brain None None O
, None None O
which None None O
has None None O
devastating None None O
effects None None O
on None None O
patients None None O
and None None O
loved None None O
ones None None O
. None None O

Studies None None O
using None None O
ET None None O
antagonists None None O
show None None O
that None None O
activation None None O
of None None O
ETA None None O
receptors None None I-PROTEIN
in None None O
the None None O
brain None None O
vascular None None O
smooth None None O
muscle None None O
induces None None O
vasospasm None None O
after None None O
stroke None None I-DISEASE
. None None O

Activation None None O
of None None O
ETB None None O
receptors None None I-PROTEIN
stimulates None None O
astrocytic None None O
production None None O
of None None O
these None None O
permeability None None O
factors None None O
. None None O

ETs None None O
promote None None O
the None None O
induction None None O
of None None O
reactive None None O
astrocytes None None O
through None None O
ETB None None O
receptors None None I-PROTEIN
. None None O

Recent None None O
studies None None O
have None None O
shown None None O
high None None O
expression None None O
of None None O
ETB None None O
receptors None None I-PROTEIN
in None None O
neural None None O
progenitors None None O
. None None O

Selenium None None O
is None None O
an None None O
essential None None O
trace None None O
element None None O
that None None O
is None None O
incorporated None None O
into None None O
25 None None O
human None None O
proteins None None O
as None None O
the None None O
amino None None O
acid None None O
selenocysteine None None I-TRANS
( None None O
Sec None None O
) None None O
. None None O

Improved None None O
synthesis None None O
of None None O
2'-deoxyadenosine None None O
using None None O
Escherichia None None O
coli None None O
overexpressing None None O
some None None O
enzymes None None I-PROTEIN
and None None O
gram-scale None None O
chemical None None O
synthesis None None O
of None None O
2'-deoxynucleoside None None O
5'-triphosphates None None O
reported None None O
recently None None O
are None None O
described None None O
in None None O
this None None O
review None None O
. None None O

Abstract None None O
Sterol None None O
regulatory None None O
element-binding None None O
proteins None None O
( None None O
SREBPs None None O
) None None O
are None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
regulate None None O
a None None O
wide None None O
variety None None O
of None None O
genes None None O
involved None None O
in None None O
cholesterol None None O
and None None O
fatty None None O
acid None None O
synthesis None None O
. None None O

LfcinB None None O
is None None O
able None None O
to None None O
modulate None None O
the None None O
effects None None O
cytokines None None O
such None None O
as None None O
IL-1 None None O
and None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
2 None None O
as None None O
well None None O
as None None O
promote None None O
specific None None O
cartilage None None O
anabolic None None O
factors None None O
. None None O

Plant None None O
phospholipase None None I-PROTEIN
As None None I-PROTEIN
( None None O
PLAs None None O
) None None O
are None None O
a None None O
complex None None O
group None None O
of None None O
enzymes None None I-PROTEIN
that None None O
catalyze None None O
the None None O
release None None O
of None None O
free None None O
fatty None None O
acids None None O
from None None O
phospholipids None None O
. None None O

Two None None O
specific None None O
genes None None O
or None None O
genetic None None O
loci None None O
, None None O
namely None None O
sasX None None O
and None None O
the None None O
arginine None None I-TRANS
catabolic None None O
mobile None None O
element None None O
( None None O
ACME None None O
) None None O
, None None O
could None None O
recently None None O
be None None O
linked None None O
to None None O
the None None O
epidemiological None None O
success None None O
of None None O
MRSA None None O
clones None None O
, None None O
supporting None None O
the None None O
notion None None O
that None None O
colonization None None O
factors None None O
play None None O
a None None O
crucial None None O
role None None O
in None None O
MRSA None None O
outbreaks None None O
. None None O

ACME None None O
contains None None O
an None None O
arc None None O
arginine None None I-TRANS
deiminase None None O
gene None None O
cluster None None O
promoting None None O
the None None O
survival None None O
of None None O
MRSA None None O
in None None O
the None None O
acidic None None O
skin None None O
environment None None O
, None None O
in None None O
addition None None O
to None None O
a None None O
polyamine None None O
resistance None None O
gene None None O
that None None O
deals None None O
with None None O
the None None O
increased None None O
production None None O
of None None O
toxic None None O
polyamines None None O
by None None O
the None None O
host None None O
that None None O
is None None O
prompted None None O
by None None O
arc None None O
. None None O

In None None O
contrast None None O
, None None O
empathic None None O
accuracy None None O
involves None None O
the None None O
integration None None O
of None None O
a None None O
multitude None None O
of None None O
such None None O
inferences None None I-FUNC
from None None O
diverse None None O
sources None None O
of None None O
information None None O
that None None O
are None None O
available None None O
in None None O
everyday None None O
interactions None None O
( None None O
e.g. None None O
, None None O
facial None None O
and None None O
bodily None None O
expressions None None O
, None None O
prosody None None O
, None None O
communication None None O
content None None O
, None None O
situational None None O
context None None O
, None None O
etc None None O
. None None O
) None None O
. None None O

In None None O
these None None O
interactions None None O
, None None O
older None None O
women None None O
were None None O
only None None O
less None None O
empathically None None O
accurate None None O
than None None O
younger None None O
women None None O
when None None O
judging None None O
their None None O
interaction None None O
partner None None O
's None None O
negative None None O
feelings None None I-FUNC
and None None O
when None None O
judging None None O
thoughts None None O
that None None O
accompanied None None O
experiences None None O
of None None O
negative None None O
affect None None O
. None None O

In None None O
addition None None O
, None None O
EBNA1 None None O
and None None O
FoxA None None O
, None None O
when None None O
associated None None O
with None None O
mitotic None None O
chromatin None None O
may None None O
`` None None O
bookmark None None O
'' None None O
active None None O
genes None None O
and None None O
ensure None None O
their None None O
reactivation None None O
in None None O
postmitotic None None O
cells None None O
( None None O
epigenetic None None O
memory None None I-FUNC
) None None O
. None None O

Although None None O
there None None O
is None None O
increasing None None O
evidence None None O
that None None O
aberrant None None O
expression None None O
of None None O
those None None O
enzymes None None I-PROTEIN
which None None O
control None None O
protein None None O
arginine None None I-TRANS
methylation None None O
contribute None None O
to None None O
carcinogenesis None None O
, None None O
their None None O
de-regulation None None O
by None None O
oncogenic None None O
viruses None None O
in None None O
primary None None O
cells None None O
has None None O
yet None None O
to None None O
be None None O
reported None None O
. None None O

The None None O
current None None O
study None None O
examined None None O
relationships None None O
among None None O
self-reported None None O
depression None None I-DISEASE
severity None None O
, None None O
posttraumatic None None O
stress None None O
disorder None None O
( None None O
PTSD None None O
) None None O
symptom None None O
severity None None O
, None None O
and None None O
grade None None O
point None None O
average None None O
( None None O
GPA None None O
) None None O
among None None O
student None None O
servicemembers None None O
and None None O
veterans None None O
. None None O

More None None O
severe None None O
depression None None I-DISEASE
was None None O
associated None None O
with None None O
turning None None O
in None None O
assignments None None O
late None None O
( None None O
beta None None O
weight None None O
= None None O
0.171 None None O
, None None O
p None None O
= None None O
0.03 None None O
) None None O
, None None O
failed None None O
exams None None O
( None None O
beta None None O
weight None None O
= None None O
0.188 None None O
, None None O
p None None O
= None None O
0.02 None None O
) None None O
, None None O
and None None O
skipped None None O
classes None None O
( None None O
beta None None O
weight None None O
= None None O
0.254 None None O
, None None O
p None None O
= None None O
0.01 None None O
) None None O
. None None O

MEDLINE None None O
, None None O
EMBASE None None O
, None None O
Cochrane None None O
Central None None O
Register None None O
of None None O
Controlled None None O
Trials None None O
, None None O
Cochrane None None O
Methodology None None O
Register None None O
, None None O
Health None None O
Technology None None O
Assessments None None O
, None None O
and None None O
Database None None O
of None None O
Abstracts None None O
of None None O
Reviews None None O
of None None O
Effects None None O
( None None O
Ovid None None O
interface None None O
) None None O
, None None O
Grey None None I-REGION
Matters None None I-REGION
, None None O
Google None None O
Scholar None None O
, None None O
and None None O
personal None None O
records None None O
were None None O
searched None None O
for None None O
CPGs None None O
on None None O
the None None O
HDPs None None O
( None None O
Jan/03 None None O
to None None O
Nov/13 None None O
) None None O
in None None O
English None None O
, None None O
French None None O
, None None O
Dutch None None O
, None None O
or None None O
German None None O
. None None O

The None None O
most None None O
pertinent None None O
idea None None O
is None None O
self-organization None None O
in None None O
analogy None None I-FUNC
to None None O
evolution None None O
in None None O
nature None None O
, None None O
which None None O
created None None O
the None None O
key-lock None None O
principle None None O
. None None O

In None None O
a None None O
fifth None None O
community None None O
sample None None O
of None None O
North None None O
American None None O
participants None None O
acquired None None O
using None None O
Amazon None None O
Mechanical None None O
Turk None None O
, None None O
the None None O
PPI-R-40 None None O
showed None None O
similarly None None O
high None None O
convergent None None O
correlations None None O
, None None O
demonstrating None None O
stability None None O
across None None O
language None None I-FUNC
, None None O
culture None None O
, None None O
and None None O
data-collection None None O
method None None O
. None None O

2015 None None O
APA None None O
, None None O
all None None O
rights None None O
reserved None None O
Patients None None O
with None None O
the None None O
22q11-deletion None None O
syndrome None None O
( None None O
22q11DS None None O
) None None O
are None None O
at None None O
an None None O
increased None None O
risk None None O
of None None O
developing None None O
schizophrenia None None I-DISEASE
. None None O

However None None O
, None None O
excessive None None O
generalization None None O
of None None O
such None None O
memories None None O
, None None O
characterized None None O
by None None O
a None None O
failure None None O
to None None O
discriminate None None O
dangerous None None O
from None None O
safe None None O
stimuli None None O
, None None O
is None None O
common None None O
in None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

We None None O
identified None None O
distinct None None O
neuronal None None O
populations None None O
in None None O
the None None O
lateral None None O
amygdala None None I-REGION
( None None O
LA None None O
) None None O
of None None O
rats None None O
that None None O
signaled None None O
generalized None None O
versus None None O
cue-specific None None O
associations None None O
and None None O
determined None None O
how None None O
their None None O
distributions None None O
switched None None O
during None None O
fear None None O
generalization None None O
. None None O

These None None O
results None None O
provide None None O
a None None O
cellular None None O
basis None None O
in None None O
the None None O
amygdala None None I-REGION
for None None O
the None None O
alteration None None O
of None None O
emotional None None O
states None None O
from None None O
normal None None O
to None None O
pathological None None O
fear None None O
. None None O

We None None O
observed None None O
that None None O
activation None None O
in None None O
visual None None O
and None None O
prefrontal None None O
executive None None O
control None None O
areas None None O
was None None O
positively None None O
correlated None None O
with None None O
fixation None None O
duration None None O
, None None O
whereas None None O
activation None None O
in None None O
ventral None None I-NEURON
areas None None O
associated None None O
with None None O
scene None None O
encoding None None I-FUNC
and None None O
medial None None O
superior None None O
frontal None None O
and None None O
paracentral None None O
regions None None O
associated None None O
with None None O
changing None None O
action None None O
plans None None O
was None None O
negatively None None O
correlated None None O
with None None O
fixation None None O
duration None None O
. None None O

As None None O
we None None O
explore None None O
a None None O
scene None None O
, None None O
our None None O
eye None None O
movements None None I-FUNC
add None None O
global None None O
patterns None None O
of None None O
motion None None O
to None None O
the None None O
retinal None None O
image None None O
, None None O
complicating None None O
visual None None O
motion None None O
produced None None O
by None None O
self-motion None None O
or None None O
moving None None O
objects None None O
. None None O

Although None None O
it None None O
is None None O
well None None O
established None None O
that None None O
stress None None O
can None None O
disrupt None None O
complex None None O
cognitive None None O
functions None None O
, None None O
relatively None None O
little None None O
is None None O
known None None O
about None None O
how None None O
it None None O
influences None None O
visual None None O
processing None None O
, None None O
especially None None O
in None None O
terms None None O
of None None O
visual None None O
selective None None I-FUNC
attention None None I-FUNC
. None None O

A None None O
great None None O
deal None None O
of None None O
prior None None O
research None None O
has None None O
examined None None O
the None None O
relation None None O
between None None O
estimates None None O
of None None O
working None None I-FUNC
memory None None I-FUNC
and None None O
cognitive None None O
abilities None None O
. None None O

The None None O
current None None O
study None None O
explored None None O
whether None None O
individual None None O
differences None None O
in None None O
working None None I-FUNC
memory None None I-FUNC
delay None None O
activity None None O
would None None O
be None None O
a None None O
significant None None O
predictor None None O
of None None O
cognitive None None O
abilities None None O
. None None O

During None None O
two None None O
working None None I-FUNC
memory None None I-FUNC
change None None O
detection None None O
tasks None None O
, None None O
we None None O
acquired None None O
EEG None None O
data None None O
and None None O
examined None None O
the None None O
contralateral None None O
delay None None O
activity None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
individual None None O
differences None None O
in None None O
working None None I-FUNC
memory None None I-FUNC
delay None None O
activity None None O
predict None None O
individual None None O
differences None None O
in None None O
a None None O
broad None None O
range None None O
of None None O
cognitive None None O
abilities None None O
, None None O
and None None O
this None None O
is None None O
because None None O
of None None O
both None None O
differences None None O
in None None O
the None None O
number None None O
of None None O
items None None O
that None None O
can None None O
be None None O
maintained None None O
and None None O
the None None O
ability None None O
to None None O
control None None O
access None None O
to None None O
working None None I-FUNC
memory None None I-FUNC
. None None O

Evidence None None O
implicates None None O
ventral None None I-NEURON
parieto-premotor None None O
cortices None None O
in None None O
representing None None O
the None None O
goal None None O
of None None O
grasping None None O
independent None None O
of None None O
the None None O
movements None None I-FUNC
or None None O
effectors None None O
involved None None O
[ None None O
Umilta None None O
, None None O
M. None None O
A. None None O
, None None O
Escola None None O
, None None O
L. None None O
, None None O
Intskirveli None None O
, None None O
I. None None O
, None None O
Grammont None None O
, None None O
F. None None O
, None None O
Rochat None None O
, None None O
M. None None O
, None None O
Caruana None None O
, None None O
F. None None O
, None None O
et None None O
al None None O
. None None O

Modern None None O
technologies None None O
that None None O
enable None None O
arbitrary None None O
causal None None O
relationships None None O
between None None O
hand None None O
movements None None I-FUNC
and None None O
tool None None O
actions None None O
provide None None O
a None None O
strong None None O
test None None O
of None None O
this None None O
hypothesis None None O
. None None O

Neurology None None O
, None None O
50 None None O
, None None O
1253-1259 None None O
, None None O
1998 None None O
] None None O
, None None O
we None None O
detected None None O
greater None None O
activity None None O
in None None O
the None None O
vicinity None None O
of None None O
the None None O
anterior None None O
intraparietal None None I-REGION
sulcus None None I-REGION
( None None O
aIPS None None O
) None None O
during None None O
manual None None O
grasp None None O
versus None None O
reach None None O
. None None O

Elife None None O
, None None O
2 None None O
, None None O
e00425 None None O
, None None O
2013 None None O
; None None O
Jacobs None None O
, None None O
S. None None O
, None None O
Danielmeier None None O
, None None O
C. None None O
, None None O
& None None O
amp None None O
; None None O
Frey None None O
, None None O
S. None None O
H. None None O
Human None None O
anterior None None O
intraparietal None None O
and None None O
ventral None None I-NEURON
premotor None None O
cortices None None O
support None None O
representations None None O
of None None O
grasping None None O
with None None O
the None None O
hand None None O
or None None O
a None None O
novel None None O
tool None None O
. None None O

This None None O
supports None None O
the None None O
hypothesis None None O
that None None O
the None None O
cerebellum None None I-REGION
predicts None None O
the None None O
forthcoming None None O
sensory None None O
consequences None None O
of None None O
volitional None None O
actions None None O
[ None None O
Blakemore None None O
, None None O
S. None None O
J. None None O
, None None O
Frith None None O
, None None O
C. None None O
D. None None O
, None None O
& None None O
amp None None O
; None None O
Wolpert None None O
, None None O
D. None None O
M. None None O
The None None O
cerebellum None None I-REGION
is None None O
involved None None O
in None None O
predicting None None O
the None None O
sensory None None O
consequences None None O
of None None O
action None None O
. None None O

We None None O
conclude None None O
that None None O
grasp-selective None None O
responses None None O
in None None O
the None None O
human None None O
aIPS None None O
and None None O
premotor None None O
cortex None None O
depend None None O
on None None O
the None None O
existence None None O
of None None O
nonarbitrary None None O
causal None None O
relationships None None O
between None None O
hand None None O
movements None None I-FUNC
and None None O
end-effector None None O
actions None None O
. None None O

A None None O
number None None O
of None None O
central None None O
cellular None None O
signaling None None O
pathways None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
have None None O
been None None O
implied None None O
in None None O
the None None O
control None None O
of None None O
EMT None None O
and None None O
metastasis None None O
formation None None O
, None None O
among None None O
them None None O
signal None None O
originating None None O
from None None O
the None None O
activation None None O
of None None O
the None None O
transforming None None O
growth None None O
factor None None O
β None None O
( None None O
TGFβ None None O
) None None O
, None None O
epithelial None None O
growth None None O
factor None None O
, None None O
Wnt None None O
, None None O
Notch None None O
, None None O
and None None O
Hedgehog None None O
pathways None None O
. None None O

The None None O
process None None O
, None None O
however None None O
, None None O
is None None O
not None None O
irreversible None None O
, None None O
and None None O
pluripotency None None O
can None None O
be None None O
reestablished None None O
in None None O
terminally None None O
differentiated None None O
cells None None O
through None None O
the None None O
expression None None O
of None None O
the None None O
reprogramming None None O
factors None None O
( None None O
RFs None None O
) None None O
octamer-binding None None O
transcription None None O
factor None None O
3/4 None None O
( None None O
Oct4 None None O
) None None O
, None None O
sex-determining None None O
region None None O
Y None None O
box None None O
2 None None O
( None None O
Sox2 None None O
) None None O
, None None O
Krüppel-like None None O
factor None None O
4 None None O
( None None O
Klf4 None None O
) None None O
, None None O
and None None O
c-Myc None None I-PROTEIN
. None None O

The None None O
progeny None None O
of None None O
these None None O
cloned None None O
mice None None O
harboring None None O
a None None O
rearranged None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
loci None None O
specific None None O
for None None O
NKT None None O
cells None None O
, None None O
Vα14-Jα18 None None O
, None None O
possess None None O
an None None O
increased None None O
number None None O
of None None O
NKT None None O
cells None None O
in None None O
the None None O
primary None None O
as None None O
well None None O
as None None O
in None None O
the None None O
secondary None None O
lymphoid None None O
organs None None O
. None None O

Abstract None None O
Hydrocephalus None None I-DISEASE
is None None O
the None None O
result None None O
of None None O
an None None O
imbalance None None O
between None None O
the None None O
formation None None O
and None None O
drainage None None O
of None None O
cerebrospinal None None O
fluid None None O
( None None O
CSF None None O
) None None O
, None None O
characterized None None O
by None None O
an None None O
elevation None None O
of None None O
the None None O
CSF None None O
pressure None None O
within None None O
the None None O
brain None None O
. None None O

The None None O
importance None None O
of None None O
the None None O
local None None O
activity None None O
of None None O
steroid None None O
11β-hydroxysteroid None None O
dehydrogenase None None I-PROTEIN
( None None O
11β-HSD None None O
) None None O
of None None O
both None None O
types None None O
for None None O
regulation None None O
of None None O
the None None O
actual None None O
corticosteroid None None O
concentration None None O
is None None O
emphasized None None O
, None None O
and None None O
an None None O
original None None O
method None None O
for None None O
determination None None O
of None None O
cortisol/cortisone None None O
concentration None None O
in None None O
CSF None None O
is None None O
described None None O
. None None O

Abstract None None O
Introduction None None O
: None None O
A None None O
clinical None None O
study None None O
was None None O
conducted None None O
to None None O
determine None None O
steroidal None None O
hormone None None O
cascade None None O
in None None O
the None None O
blood None None O
to None None O
relate None None O
them None None O
to None None O
mental None None O
performance None None O
with None None O
the None None O
Clinician-Administered None None O
PTSD None None O
scale None None O
( None None O
CAPS None None O
) None None O
, None None O
serum None None O
lipid None None O
concentrations None None O
, None None O
and None None O
steroidal None None O
hormones None None I-PROTEIN
, None None O
particularly None None O
cortisol None None O
, None None O
testosterone None None O
, None None O
estradiol None None O
, None None O
dehydroepiandrosterone None None O
( None None O
DHEA None None O
) None None O
, None None O
and None None O
pregnenolone None None O
, None None O
in None None O
treatment-resistant None None O
male None None O
veterans None None O
with None None O
combat-related None None O
chronic None None O
posttraumatic None None O
stress None None O
disorder None None O
( None None O
PTSD None None O
) None None O
before None None O
and None None O
after None None O
consumption None None O
of None None O
a None None O
special None None O
fermented None None O
soy None None O
formulation None None O
( None None O
FSWW08 None None O
) None None O
. None None O

FSWW08 None None O
increased None None O
blood None None O
levels None None O
of None None O
steroids None None O
, None None O
such None None O
as None None O
testosterone None None O
, None None O
estradiol None None O
, None None O
and None None O
particularly None None O
the None None O
adrenal None None I-TRANS
hormones None None I-PROTEIN
cortisol None None O
and None None O
androstenediol None None O
. None None O

SHRs None None O
are None None O
ligand-dependent None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
that None None O
are None None O
predominantly None None O
localized None None O
in None None O
the None None O
cytoplasm None None O
in None None O
the None None O
absence None None O
of None None O
their None None O
appropriate None None O
ligand None None O
. None None O

Importantly None None O
, None None O
the None None O
newly None None O
synthesized None None O
and None None O
unliganded None None O
receptors None None I-PROTEIN
bind None None O
stepwise None None O
with None None O
chaperones None None O
then None None O
being None None O
associated None None O
in None None O
a None None O
dynamic None None O
chaperone None None O
heterocomplex None None O
, None None O
including None None O
heat None None O
shock None None O
proteins None None O
. None None O

Abstract None None O
Various None None O
findings None None O
implicate None None O
sex None None O
hormones None None I-PROTEIN
in None None O
prostate None None O
growth None None O
and None None O
development None None O
and None None O
also None None O
in None None O
prostate None None O
carcinogenesis None None O
. None None O

Steroid None None I-PROTEIN
hormones None None I-PROTEIN
testosterone None None O
( None None O
T None None O
) None None O
, None None O
free None None O
testosterone None None O
( None None O
fT None None O
) None None O
, None None O
and None None O
estradiol None None O
( None None O
E2 None None O
) None None O
, None None O
and None None O
binding None None O
protein None None O
SHBG None None O
levels None None O
were None None O
measured None None O
in None None O
762 None None O
men None None O
undergoing None None O
prostate None None O
biopsy None None O
due None None O
to None None O
suspect None None O
PSA None None O
serum None None O
levels None None O
. None None O

All None None O
hormones None None I-PROTEIN
except None None O
E2 None None O
and None None O
tumor None None O
markers None None O
correlated None None O
significantly None None O
with None None O
age None None O
( None None O
T None None O
: None None O
ρ=-0.09 None None O
; None None O
fT None None O
: None None O
ρ=-0.27 None None O
; None None O
SHBG None None O
: None None O
ρ=0.21 None None O
; None None O
PSA None None O
: None None O
ρ=0.32 None None O
; None None O
and None None O
fPSA None None O
% None None O
: None None O
ρ=0.22 None None O
) None None O
. None None O

Addition None None O
of None None O
hormones None None I-PROTEIN
and None None O
SHBG None None O
to None None O
a None None O
baseline None None O
marker None None O
model None None O
including None None O
PSA None None O
, None None O
fPSA None None O
% None None O
, None None O
and None None O
age None None O
improved None None O
cancer None None O
prediction None None O
in None None O
three None None O
multivariate None None O
classification None None O
methods None None O
; None None O
however None None O
, None None O
the None None O
improvement None None O
was None None O
minimal None None O
. None None O

Abstract None None O
Background None None O
: None None O
The None None O
prostate None None O
gland None None O
synthesizes None None O
a None None O
host None None O
of None None O
hormones None None I-PROTEIN
, None None O
prostaglandins None None O
and None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Abstract None None O
Background None None O
: None None O
To None None O
detect None None O
genes None None O
associated None None O
with None None O
the None None O
expression None None O
of None None O
ESR1 None None O
and None None O
PGR None None O
- None None O
as None None O
well None None O
as None None O
of None None O
their None None O
protein None None O
products None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
and None None O
progesterone None None O
receptor None None I-PROTEIN
( None None O
PR None None O
) None None O
- None None O
221 None None O
de-identified None None O
invasive None None O
ductal None None O
carcinomas None None O
of None None O
the None None O
breast None None O
were None None O
investigated None None O
. None None O

Adipocyte None None O
diameter None None O
, None None O
basal None None O
lipolysis None None O
, None None O
and None None O
heparin-releasable None None O
lipoprotein None None I-PROTEIN
lipase None None I-PROTEIN
activity None None O
were None None O
measured None None O
. None None O

Trichostatin None None O
A None None O
( None None O
TSA None None O
) None None O
reduced None None O
the None None O
level None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
alpha None None O
( None None O
ERα None None O
) None None O
and None None O
adding None None O
it None None O
24 None None O
h None None O
before None None O
adding None None O
OHT None None O
prevented None None O
dome None None O
formation None None O
. None None O

One None None O
of None None O
the None None O
breakthroughs None None O
in None None O
breast None None O
cancer None None O
treatment None None O
is None None O
the None None O
discovery None None O
of None None O
aromatase None None I-PROTEIN
inhibitors None None O
( None None O
AIs None None O
) None None O
in None None O
the None None O
early None None O
1970s None None O
. None None O

Adjuvant None None O
hormonal None None O
therapy None None O
, None None O
with None None O
antiestrogens None None O
( None None O
AE None None O
) None None O
such None None O
as None None O
tamoxifen None None O
and None None O
fulvestrant None None O
, None None O
is None None O
highly None None O
effective None None O
in None None O
the None None O
treatment None None O
of None None O
estrogen None None I-PROTEIN
receptor-positive None None O
( None None O
ER+ None None O
) None None O
breast None None O
cancers None None O
and None None O
is None None O
largely None None O
responsible None None O
for None None O
the None None O
increase None None O
in None None O
survival None None O
rates None None O
seen None None O
in None None O
the None None O
past None None O
four None None O
decades None None O
. None None O

The None None O
other None None O
family None None O
members None None O
of None None O
glycoprotein None None O
hormone None None O
receptors None None I-PROTEIN
, None None O
such None None O
as None None O
leutinizing None None O
hormone None None O
receptor None None I-PROTEIN
( None None O
LHR None None O
) None None O
, None None O
human None None O
chorionic None None O
gonadotropin None None O
( None None O
hCG None None O
) None None O
, None None O
and None None O
follicle-stimulating None None O
hormone None None O
( None None O
FSH None None O
) None None O
are None None O
known None None O
to None None O
be None None O
expressed None None O
in None None O
nonendocrine None None O
tissues None None O
including None None O
human None None O
breast None None O
cancer None None O
and None None O
regulate None None O
proliferation None None O
and None None O
differentiation None None O
. None None O

For None None O
this None None O
study None None O
, None None O
patients None None O
with None None O
stages None None O
I-III None None O
breast None None O
cancers None None O
and None None O
adjacent None None O
noncancerous None None O
tissues None None O
were None None O
prospectively None None O
accrued None None O
and None None O
analyzed None None O
. None None O

Investigation None None O
of None None O
the None None O
presence None None O
of None None O
these None None O
enzymes None None I-PROTEIN
in None None O
human None None O
tissues None None O
could None None O
be None None O
carried None None O
out None None O
on None None O
commercially None None O
available None None O
human None None O
tissue None None O
arrays None None O
with None None O
use None None O
of None None O
antibodies None None O
specific None None O
to None None O
CYP7B1 None None O
and None None O
11β-HSD1 None None O
for None None O
immunohistochemistry None None O
. None None O

The None None O
seminal None None O
plasma None None O
also None None O
contains None None O
significant None None O
amounts None None O
of None None O
cortisol None None O
, None None O
which None None O
influences None None O
the None None O
androgen None None O
biosynthesis None None O
through None None O
its None None O
receptors None None I-PROTEIN
in None None O
the None None O
Leydig None None O
cells None None O
. None None O

Manufacturers None None O
of None None O
immunoanalytical None None O
kits None None O
should None None O
take None None O
into None None O
account None None O
the None None O
potential None None O
adverse None None O
effects None None O
of None None O
autoantibodies None None O
against None None O
thyroid None None O
hormones None None I-PROTEIN
when None None O
measuring None None O
the None None O
results None None O
of None None O
immunoassay None None O
determination None None O
of None None O
the None None O
free None None O
fraction None None O
of None None O
these None None O
hormones None None I-PROTEIN
. None None O

In None None O
target None None O
tissues None None O
, None None O
T None None O
is None None O
also None None O
biotransformed None None O
to None None O
the None None O
A-ring-reduced None None O
metabolites None None O
3α,5α-androstanediol None None O
( None None O
3α,5α-diol None None O
) None None O
and None None O
3β,5α-androstanediol None None O
( None None O
3β,5α-diol None None O
) None None O
, None None O
which None None O
are None None O
potent None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
agonists None None O
; None None O
however None None O
, None None O
their None None O
biological None None O
role None None O
in None None O
bone None None O
has None None O
not None None O
been None None O
completely None None O
elucidated None None O
. None None O

Osteoblast None None O
function None None O
was None None O
assessed None None O
by None None O
determining None None O
cell None None O
DNA None None O
, None None O
cell-associated None None O
osteocalcin None None O
, None None O
and None None O
calcium None None O
content None None O
, None None O
as None None O
well None None O
as None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
and None None O
Alp1 None None O
gene None None O
expression None None O
. None None O

The None None O
breast None None O
tumor None None O
PR None None O
before None None O
treatment None None O
and None None O
serum None None O
insulin-like None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
I None None O
( None None O
∂IGF-1 None None O
) None None O
, None None O
steroids None None O
, None None O
steroid-binding None None O
proteins None None O
, None None O
and None None O
insulin None None I-PROTEIN
before None None O
and None None O
during None None O
treatment None None O
were None None O
measured None None O
in None None O
17 None None O
postmenopausal None None O
women None None O
with None None O
breast None None O
cancer None None O
who None None O
were None None O
treated None None O
sequentially None None O
with None None O
tamoxifen None None O
40 None None O
mg/day None None O
followed None None O
by None None O
MA None None O
160 None None O
mg/day None None O
in None None O
alternating None None O
3-month None None O
periods None None O
. None None O

With None None O
stem-cell-based None None O
therapy None None O
gaining None None O
worldwide None None O
attention None None I-FUNC
, None None O
we None None O
explore None None O
the None None O
role None None O
of None None O
steroids None None O
in None None O
modulating None None O
MSCs None None O
for None None O
clinical None None O
and None None O
therapeutic None None O
purposes None None O
. None None O

Within None None O
the None None O
adipose None None O
tissue None None O
, None None O
the None None O
transcriptional None None O
feedback None None O
regulation None None O
between None None O
clock None None O
genes None None O
and None None O
nuclear None None O
hormone None None O
receptors None None I-PROTEIN
, None None O
together None None O
with None None O
direct None None O
protein None None O
associations None None O
among None None O
these None None O
molecules None None O
, None None O
ensures None None O
the None None O
expression None None O
of None None O
metabolic None None O
genes None None O
at None None O
the None None O
appropriate None None O
time None None O
. None None O

The None None O
effects None None O
are None None O
mediated None None O
through None None O
the None None O
nuclear None None O
receptors None None I-PROTEIN
that None None O
alter None None O
the None None O
expression None None O
of None None O
a None None O
wide None None O
variety None None O
of None None O
genes None None O
through None None O
the None None O
mechanisms None None O
that None None O
are None None O
similar None None O
to None None O
those None None O
seen None None O
in None None O
the None None O
other None None O
cells None None O
. None None O

Furthermore None None O
, None None O
some None None O
enzymatic None None O
processes None None O
are None None O
affected None None O
by None None O
these None None O
hormones None None I-PROTEIN
only None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
other None None O
hormones None None I-PROTEIN
such None None O
as None None O
growth None None O
hormone None None O
( None None O
GH None None O
) None None O
or None None O
insulin None None I-PROTEIN
. None None O

The None None O
glucocorticoids None None O
enhance None None O
the None None O
leptin None None O
release None None O
, None None O
while None None O
reducing None None O
that None None O
of None None O
the None None O
inflammatory None None O
adipokines None None O
and None None O
stimulating None None O
that None None O
of None None O
the None None O
lipoprotein None None I-PROTEIN
lipase None None I-PROTEIN
( None None O
LPL None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
insulin None None I-PROTEIN
. None None O

However None None O
, None None O
recent None None O
work None None O
suggests None None O
that None None O
, None None O
at None None O
least None None O
in None None O
mice None None O
, None None O
the None None O
reduction None None O
in None None O
the None None O
osteocalcin None None O
release None None O
by None None O
the None None O
osteoblasts None None O
in None None O
the None None O
presence None None O
of None None O
the None None O
glucocorticoids None None O
accounts None None O
for None None O
much None None O
of None None O
the None None O
in None None O
vivo None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

However None None O
, None None O
adipose None None O
tissue None None O
is None None O
also None None O
a None None O
site None None O
of None None O
androgen None None O
and None None O
estrogen None None O
synthesis None None O
; None None O
androgens None None I-PROTEIN
convert None None O
to None None O
estrogens None None I-PROTEIN
in None None O
these None None O
tissues None None O
, None None O
and None None O
adipose None None O
tissue None None O
is None None O
also None None O
a None None O
reservoir None None O
of None None O
steroids None None O
that None None O
act None None O
locally None None O
in None None O
a None None O
paracrine None None O
and None None O
intracrine None None O
manner None None O
. None None O

This None None O
review None None O
integrates None None O
studies None None O
on None None O
the None None O
effects None None O
of None None O
androgens None None I-PROTEIN
and None None O
estrogens None None I-PROTEIN
in None None O
the None None O
developmental None None O
programming None None O
of None None O
adipose None None O
tissue None None O
function None None O
in None None O
early None None O
life None None O
and None None O
addresses None None O
the None None O
contributions None None O
of None None O
local None None O
androgen None None O
and None None O
estrogen None None O
metabolism None None O
on None None O
adipose None None O
tissue None None O
function None None O
in None None O
adults None None O
. None None O

Breast None None O
and None None O
nonbreast None None O
fat None None O
both None None O
produce None None O
estrogens None None I-PROTEIN
and None None O
cytokines None None O
that None None O
may None None O
promote None None O
the None None O
growth None None O
of None None O
small None None O
breast None None O
cancers None None O
making None None O
them None None O
appear None None O
earlier None None O
. None None O

Dehydroepiandrosterone None None O
( None None O
DHEA None None O
) None None O
and None None O
its None None O
sulfate None None O
ester None None O
, None None O
DHEAS None None O
, None None O
are None None O
the None None O
major None None O
circulating None None O
adrenal None None I-TRANS
steroids None None O
and None None O
serve None None O
as None None O
substrates None None O
for None None O
sex None None O
hormone None None O
biosynthesis None None O
. None None O

DHEA None None O
has None None O
been None None O
shown None None O
to None None O
modulate None None O
insulin None None I-PROTEIN
signaling None None O
pathways None None O
, None None O
enhance None None O
glucose None None O
uptake None None O
in None None O
adipocytes None None O
, None None O
and None None O
increase None None O
insulin None None I-PROTEIN
sensitivity None None O
in None None O
patients None None O
with None None O
DHEA None None O
deficiency None None O
or None None O
abnormal None None O
glucose None None O
tolerance None None O
. None None O

The None None O
mechanisms None None O
underlying None None O
DHEA None None O
actions None None O
in None None O
adipose None None O
tissue None None O
are None None O
still None None O
unclear None None O
; None None O
however None None O
, None None O
they None None O
involve None None O
nuclear None None O
receptors None None I-PROTEIN
such None None O
as None None O
androgen None None O
receptor None None I-PROTEIN
and None None O
peroxisome None None O
proliferator-activated None None O
receptors None None I-PROTEIN
γ None None O
and None None O
α None None O
. None None O

Vitamin None None O
A None None O
, None None O
ingested None None O
either None None O
as None None O
retinol None None O
or None None O
β-carotene None None O
from None None O
animal- None None O
or None None O
plant-derived None None O
foods None None O
respectively None None O
, None None O
is None None O
a None None O
nutrient None None O
essential None None O
for None None O
many None None O
biological None None O
functions None None O
such None None O
as None None O
embryonic None None O
development None None O
, None None O
vision None None I-FUNC
, None None O
immune None None O
response None None O
, None None O
tissue None None O
remodeling None None O
, None None O
and None None O
metabolism None None O
. None None O

Lipid None None O
droplets None None O
( None None O
LDs None None O
) None None O
are None None O
the None None O
organelles None None O
for None None O
intracellular None None O
triacylglycerol None None O
( None None O
TAG None None O
) None None O
storage None None I-FUNC
and None None O
are None None O
present None None O
in None None O
all None None O
eukaryotic None None O
cells None None O
. None None O

LDs None None O
consist None None O
of None None O
a None None O
TAG None None O
core None None O
surrounded None None O
by None None O
a None None O
phospholipid None None O
monolayer None None O
and None None O
an None None O
array None None O
of None None O
associated None None O
proteins None None O
that None None O
determine None None O
size None None O
, None None O
stability None None O
, None None O
inter-droplet None None O
interaction None None O
, None None O
and None None O
lipid None None O
storage None None I-FUNC
capacity None None O
. None None O

For None None O
example None None O
, None None O
estradiol None None O
signals None None O
via None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
to None None O
regulate None None O
the None None O
levels None None O
of None None O
PLIN1 None None O
and None None O
the None None O
lipase None None O
ATGL None None O
controlling None None O
LD None None O
size None None O
and None None O
total None None O
lipid None None O
accumulation None None O
. None None O

The None None O
estrogen-related None None O
receptors None None I-PROTEIN
( None None O
ERRα None None O
, None None O
β None None O
, None None O
and None None O
γ None None O
) None None O
are None None O
orphan None None O
members None None O
of None None O
the None None O
nuclear None None O
receptor None None I-PROTEIN
superfamily None None O
. None None O

Investigations None None O
performed None None O
in None None O
recent None None O
years None None O
in None None O
rodents None None O
and None None O
humans None None O
provided None None O
evidence None None O
that None None O
the None None O
stroma-vascular None None O
cells None None O
contribute None None O
to None None O
the None None O
conversion None None O
of None None O
steroid None None I-PROTEIN
hormones None None I-PROTEIN
in None None O
AT None None O
and None None O
are None None O
also None None O
steroid None None O
targets None None O
. None None O

Adipocytes None None O
are None None O
specialized None None O
cells None None O
that None None O
function None None O
to None None O
store None None O
energy None None O
in None None O
the None None O
form None None O
of None None O
lipids None None O
, None None O
predominantly None None O
triglycerides None None O
( None None O
TGs None None O
) None None O
, None None O
and None None O
as None None O
a None None O
regulatory None None O
system None None O
contributing None None O
to None None O
metabolic None None O
homoeostasis None None O
through None None O
the None None O
production None None O
and None None O
secretion None None O
of None None O
hormones None None I-PROTEIN
and None None O
cytokines None None O
. None None O

More None None O
recently None None O
, None None O
the None None O
epidemic None None O
rise None None O
in None None O
the None None O
incidence None None O
of None None O
maternal None None O
obesity None None O
has None None O
seen None None O
the None None O
attention None None I-FUNC
of None None O
the None None O
DOHaD None None O
field None None O
turn None None O
toward None None O
identifying None None O
the None None O
impact None None O
on None None O
the None None O
offspring None None O
of None None O
exposure None None O
to None None O
an None None O
excess None None O
nutrient None None O
supply None None O
in None None O
early None None O
life None None O
. None None O

The None None O
cortisol None None O
regenerating None None O
enzyme None None O
11β-hydroxysteroid None None O
dehydrogenase None None I-PROTEIN
type None None O
1 None None O
( None None O
11β-HSD1 None None O
) None None O
amplifies None None O
tissue None None O
glucocorticoid None None O
levels None None O
, None None O
particularly None None O
in None None O
the None None O
liver None None O
and None None O
adipose None None O
tissue None None O
. None None O

These None None O
results None None O
have None None O
been None None O
surprising None None O
, None None O
as None None O
cortisol None None O
production None None O
rates None None O
by None None O
11β-HSD1 None None O
are None None O
at None None O
least None None O
equivalent None None O
to None None O
that None None O
of None None O
the None None O
adrenal None None I-TRANS
glands None None O
. None None O

Chronic None None O
overnutrition None None O
and None None O
lack None None O
of None None O
physical None None O
activity None None O
result None None O
in None None O
excess None None O
deposition None None O
of None None O
adipose None None O
tissue None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
which None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
the None None O
pathophysiology None None O
of None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
( None None O
DM2 None None O
) None None O
and None None O
associated None None O
cardiovascular None None O
disease None None O
( None None O
CVD None None O
) None None O
. None None O

In None None O
turn None None O
, None None O
ROS None None O
and None None O
pro-inflammatory None None O
adipokines None None O
cause None None O
resistance None None O
to None None O
the None None O
metabolic None None O
actions None None O
of None None O
insulin None None I-PROTEIN
in None None O
several None None O
tissues None None O
including None None O
cardiovascular None None O
and None None O
adipose None None O
tissue None None O
. None None O

Because None None O
of None None O
the None None O
known None None O
effects None None O
of None None O
energy None None O
restriction None None O
to None None O
increase None None O
activity None None O
of None None O
the None None O
hypothalamo-pitutiary None None O
adrenal None None I-TRANS
( None None O
HPA None None O
) None None O
axis None None O
in None None O
lean None None O
humans None None O
and None None O
animals None None O
, None None O
and None None O
because None None O
increases None None O
in None None O
circulating None None O
glucocorticoid None None O
levels None None O
could None None O
potentially None None O
contribute None None O
to None None O
adverse None None O
body None None O
compositional None None O
changes None None O
with None None O
obesity None None O
treatments None None O
, None None O
we None None O
conducted None None O
a None None O
systematic None None O
PubMed None None O
search None None O
to None None O
determine None None O
whether None None O
HPA None None O
axis None None O
activation None None O
also None None O
occurs None None O
in None None O
response None None O
to None None O
energy None None O
restriction None None O
in None None O
obese None None O
humans None None O
and None None O
animals None None O
. None None O

These None None O
findings None None O
parallel None None O
studies None None O
on None None O
short- None None O
or None None O
long-term None None O
energy None None O
restriction None None O
in None None O
obese None None O
rodents None None O
, None None O
with None None O
most None None O
studies None None O
showing None None O
increases None None O
in None None O
circulating None None O
corticosterone None None O
concentrations None None O
, None None O
and None None O
no None None O
change None None O
or None None O
actual None None O
increases None None O
in None None O
hypothalamic None None O
expression None None O
of None None O
corticotropin-releasing None None O
hormone None None O
, None None O
urocortin None None O
3 None None O
or None None O
their None None O
receptors None None I-PROTEIN
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
will None None O
focus None None O
on None None O
discussing None None O
the None None O
role None None O
of None None O
estrogen None None O
signaling None None O
in None None O
regulating None None O
adipocyte None None O
differentiation None None O
, None None O
metabolism None None O
and None None O
its None None O
endocrine None None O
function None None O
with None None O
a None None O
focus None None O
on None None O
the None None O
possible None None O
underlying None None O
molecular None None O
mechanisms None None O
mediated None None O
by None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
α None None O
and None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
β. None None O
Polycystic None None O
ovary None None O
syndrome None None O
( None None O
PCOS None None O
) None None O
is None None O
a None None O
common None None O
condition None None O
characterized None None O
by None None O
reproductive None None O
and None None O
hyperandrogenic None None O
features None None O
and None None O
is None None O
often None None O
associated None None O
with None None O
obesity None None O
and None None O
metabolic None None O
dysfunction None None O
. None None O

Furthermore None None O
, None None O
PCOS None None O
per None None O
se None None O
( None None O
independent None None O
of None None O
its None None O
frequent None None O
association None None O
with None None O
obesity None None O
) None None O
often None None O
confers None None O
cardiometabolic None None O
risk None None O
( None None O
including None None O
insulin None None I-PROTEIN
resistance None None O
) None None O
, None None O
and None None O
its None None O
concurrence None None O
with None None O
obesity None None O
often None None O
represents None None O
a None None O
metabolic None None O
`` None None O
double-whammy None None O
'' None None O
from None None O
the None None O
adverse None None O
effects None None O
of None None O
PCOS None None O
and None None O
obesity None None O
. None None O

Much None None O
of None None O
the None None O
coordinated None None O
regulation None None O
of None None O
whole-body None None O
glucose None None O
homeostasis None None O
results None None O
from None None O
the None None O
regulation None None O
of None None O
lipid None None O
storage None None I-FUNC
and None None O
release None None O
by None None O
adipose None None O
tissue None None O
and None None O
efficient None None O
switching None None O
between None None O
glucose None None O
oxidation None None O
and None None O
fatty None None O
acid None None O
oxidation None None O
in None None O
skeletal None None O
muscle None None O
. None None O

After None None O
the None None O
discovery None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
beta None None O
in None None O
many None None O
organs None None O
, None None O
and None None O
confirmation None None O
of None None O
its None None O
presence None None O
in None None O
the None None O
brain None None O
, None None O
many None None O
researchers None None O
raised None None O
the None None O
question None None O
of None None O
whether None None O
ERβ-specific None None O
ligands None None O
may None None O
be None None O
novel None None O
therapeutic None None O
agents None None O
for None None O
treatment None None O
of None None O
menopausal None None O
complaints None None O
with None None O
the None None O
desirable None None O
effects None None O
of None None O
estrogen None None O
but None None O
without None None O
increased None None O
risk None None O
of None None O
tumor None None O
incidence None None O
. None None O

At None None O
present None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
beta-selective None None O
ligands None None O
do None None O
not None None O
seem None None O
to None None O
be None None O
active None None O
in None None O
models None None O
of None None O
prevention None None O
or None None O
reversal None None O
of None None O
osteoporosis None None O
. None None O

They None None O
act None None O
either None None O
in None None O
an None None O
endocrine None None O
manner None None O
, None None O
where None None O
they None None O
reach None None O
their None None O
target None None O
cells None None O
via None None O
the None None O
bloodstream None None O
or None None O
a None None O
paracrine None None O
manner None None O
, None None O
as None None O
co-transmitters None None O
modulating None None O
the None None O
function None None O
of None None O
neurotransmitters None None I-TRANS
. None None O

In None None O
recent None None O
years None None O
, None None O
several None None O
studies None None O
have None None O
documented None None O
that None None O
human None None O
skin None None O
expresses None None O
several None None O
functional None None O
receptors None None I-PROTEIN
for None None O
NP None None O
, None None O
such None None O
as None None O
corticotropin-releasing None None O
hormone None None O
, None None O
melanocortins None None O
, None None O
β-endorphin None None O
, None None O
vasoactive None None O
intestinal None None O
polypeptide None None O
, None None O
neuropeptide None None I-TRANS
Y None None I-TRANS
and None None O
calcitonin None None I-TRANS
gene-related None None O
peptide None None O
. None None O

Phytoestrogens None None O
- None None O
primarily None None O
the None None O
isoflavones None None O
genistein None None O
, None None O
daidzein None None O
and None None O
coumestrol None None O
, None None O
stemming None None O
from None None O
soy None None O
( None None O
Glycine None None I-TRANS
max None None O
) None None O
or None None O
red None None O
clover None None O
( None None O
Trifolium None None O
pratense None None O
) None None O
- None None O
were None None O
suggested None None O
to None None O
have None None O
the None None O
desired None None O
but None None O
not None None O
the None None O
undesired None None O
effects None None O
of None None O
estrogens None None I-PROTEIN
. None None O

In None None O
a None None O
narrow None None O
dose None None O
range None None O
they None None O
have None None O
beneficial None None O
effects None None O
on None None O
climacteric None None O
complaints None None O
, None None O
which None None O
are None None O
due None None O
to None None O
several None None O
compounds None None O
with None None O
dopaminergic None None O
, None None O
noradrenergic None None O
, None None O
serotoninergic None None O
and None None O
GABAergic None None O
actions None None O
that None None O
act None None O
together None None O
in None None O
the None None O
hypothalamus None None I-REGION
. None None O

Abstract None None O
This None None O
paper None None O
will None None O
review None None O
the None None O
effect None None O
of None None O
aging None None O
on None None O
glucose None None O
metabolism None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
pancreas None None O
and None None O
in None None O
peripheral None None O
tissues None None O
and None None O
how None None O
melatonin None None I-TRANS
administration None None O
could None None O
affect None None O
these None None O
parameters None None O
. None None O

Melatonin None None I-TRANS
administration None None O
was None None O
able None None O
to None None O
reduce None None O
these None None O
age-related None None O
alterations None None O
, None None O
decreasing None None O
plasma None None O
insulin None None I-PROTEIN
levels None None O
and None None O
increasing None None O
its None None O
pancreatic None None O
content None None O
in None None O
SAMP8 None None O
mice None None O
. None None O

Conversely None None O
, None None O
in None None O
SAMP8 None None O
mice None None O
, None None O
melatonin None None I-TRANS
treatment None None O
decreased None None O
the None None O
expression None None O
of None None O
glucagon None None I-TRANS
, None None O
GLUT2 None None O
, None None O
somatostatin None None I-TRANS
and None None O
insulin None None I-PROTEIN
. None None O

The None None O
present None None O
study None None O
has None None O
shown None None O
that None None O
aging None None O
is None None O
associated None None O
with None None O
significant None None O
alterations None None O
in None None O
the None None O
relative None None O
expression None None O
of None None O
pancreatic None None O
genes None None O
involved None None O
in None None O
both None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
glucose None None O
metabolism None None O
and None None O
that None None O
these None None O
are None None O
associated None None O
with None None O
an None None O
increase None None O
in None None O
inflammation None None O
and None None O
oxidative None None O
stress None None O
. None None O

By None None O
doing None None O
so None None O
, None None O
insulin None None I-PROTEIN
resistance None None O
is None None O
diminished None None O
and None None O
plasma None None O
insulin None None I-PROTEIN
is None None O
reduced None None O
, None None O
enhancing None None O
insulin None None I-PROTEIN
pancreatic None None O
content None None O
and None None O
reducing None None O
plasma None None O
glucose None None O
levels None None O
and None None O
HOMA None None O
index None None O
. None None O

Our None None O
results None None O
show None None O
that None None O
physiological None None O
concentrations None None O
of None None O
oestrogens None None O
activate None None O
the None None O
expression None None O
of None None O
manganese None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
by None None O
oestrogen None None O
receptors None None I-PROTEIN
and None None O
the None None O
mitogen-activated None None O
protein None None O
kinase None None O
and None None O
nuclear None None O
factor None None O
kappa None None O
B None None O
pathway None None O
. None None O

Thus None None O
, None None O
melatonin None None I-TRANS
administration None None O
as None None O
a None None O
single None None O
therapy None None O
can None None O
maintain None None O
the None None O
full None None O
function None None O
of None None O
the None None O
brain None None O
mitochondria None None O
during None None O
the None None O
early None None O
events None None O
of None None O
aging None None O
, None None O
a None None O
finding None None O
that None None O
has None None O
important None None O
consequences None None O
in None None O
the None None O
pathophysiology None None O
of None None O
brain None None O
senescence None None O
. None None O

The None None O
concomitant None None O
administration None None O
of None None O
melatonin None None I-TRANS
( None None O
25 None None O
μg/mL None None O
of None None O
drinking None None O
water None None O
) None None O
normalized None None O
the None None O
abnormally None None O
high None None O
LH None None O
levels None None O
but None None O
did None None O
not None None O
affect None None O
the None None O
inhibited None None O
testosterone None None O
secretion None None O
found None None O
in None None O
fructose- None None O
or None None O
high-fat-fed None None O
rats None None O
. None None O

Melatonin None None I-TRANS
significantly None None O
blunted None None O
the None None O
body None None O
weight None None O
and None None O
systolic None None O
BP None None O
increase None None O
, None None O
the None None O
increase None None O
in None None O
the None None O
AUC None None O
of None None O
glycemia None None O
after None None O
an None None O
IPGTT None None O
, None None O
and None None O
the None None O
changes None None O
in None None O
circulating None None O
lipid None None O
profile None None O
and None None O
uric None None O
acid None None O
found None None O
in None None O
both None None O
MS None None O
models None None O
. None None O

Indeed None None O
, None None O
the None None O
role None None O
of None None O
epigenetic None None O
machinery None None O
in None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
processes None None O
is None None O
well None None O
documented None None O
. None None O

The None None O
specific None None O
roles None None O
of None None O
Notch None None O
in None None O
adult None None O
brain None None O
plasticity None None O
and None None O
neurological None None O
disorders None None O
have None None O
begun None None O
to None None O
be None None O
unraveled None None O
in None None O
recent None None O
years None None O
, None None O
and None None O
pieces None None O
of None None O
experimental None None O
evidence None None O
suggest None None O
that None None O
Notch None None O
is None None O
operative None None O
in None None O
diverse None None O
brain None None O
pathologies None None O
including None None O
tumorigenesis None None O
, None None O
stroke None None I-DISEASE
, None None O
and None None O
neurological None None O
disorders None None O
such None None O
as None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
Down None None O
syndrome None None O
, None None O
and None None O
multiple None None O
sclerosis None None O
. None None O

These None None O
proteins None None O
are None None O
not None None O
targeted None None O
to None None O
limited None None O
and None None O
specific None None O
receptors None None I-PROTEIN
to None None O
execute None None O
specific None None O
missions None None O
, None None O
but None None O
manipulate None None O
a None None O
vast None None O
number None None O
of None None O
biomolecules None None O
in None None O
the None None O
network None None O
by None None O
serving None None O
as None None O
a None None O
molecular None None O
hub None None O
at None None O
the None None O
center None None O
. None None O

Among None None O
them None None O
, None None O
MurD None None O
is None None O
responsible None None O
for None None O
the None None O
ATP-dependent None None O
addition None None O
of None None O
d-glutamic None None O
acid None None I-TRANS
to None None O
UDP-MurNAc-l-Ala None None O
, None None O
a None None O
reaction None None O
which None None O
involves None None O
acyl-phosphate None None O
and None None O
tetrahedral None None O
intermediates None None O
. None None O

Escherichia None None O
coli None None O
MurD None None O
has None None O
been None None O
the None None O
first None None O
Mur None None O
ligase None None I-PROTEIN
for None None O
which None None O
the None None O
tridimensional None None O
( None None O
3D None None O
) None None O
structure None None O
was None None O
solved None None O
. None None O

One None None O
well-known None None O
example None None O
is None None O
the None None O
amplification None None O
of None None O
the None None O
dihydrofolate None None I-PROTEIN
reductase None None I-PROTEIN
gene None None O
observed None None O
in None None O
methotrexate-resistant None None O
cells None None O
. None None O

sHSPs None None O
do None None O
not None None O
actively None None O
refold None None O
incorporated None None O
peptides None None I-TRANS
therefore None None O
they None None O
are None None O
sometimes None None O
referred None None O
to None None O
as None None O
holdases None None O
. None None O

However None None O
, None None O
regulating None None O
or None None O
analyzing None None O
the None None O
structures None None O
of None None O
folding None None O
intermediates None None O
of None None O
peptides None None I-TRANS
and None None O
proteins None None O
continues None None O
to None None O
be None None O
a None None O
difficult None None O
problem None None O
. None None O

Indeed None None O
, None None O
Cgs None None O
are None None O
the None None O
main None None O
protein None None O
component None None O
of None None O
the None None O
vesicular None None O
matrix None None O
in None None O
LDCV None None O
, None None O
and None None O
they None None O
are None None O
involved None None O
in None None O
the None None O
concentration None None O
of None None O
soluble None None O
species None None O
like None None O
neurotransmitters None None I-TRANS
and None None O
calcium None None O
. None None O

The None None O
importance None None O
of None None O
selenium None None O
for None None O
organisms None None O
can None None O
be None None O
explained None None O
by None None O
its None None O
existence None None O
as None None O
selenocysteine None None I-TRANS
in None None O
the None None O
catalytic None None O
centers None None O
of None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
and None None O
thioredoxin None None I-PROTEIN
reductase None None I-PROTEIN
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
Cox5a None None O
hypermethylation None None O
was None None O
associated None None O
with None None O
downregulation None None O
of None None O
Cox5a None None O
expression None None O
at None None O
the None None O
mRNA None None O
and None None O
protein None None O
level None None O
, None None O
and None None O
a None None O
reduction None None O
in None None O
mitochondrial None None O
complex None None O
IV None None O
activity None None O
and None None O
ATP None None O
content None None O
in None None O
HFD-induced None None O
insulin None None I-PROTEIN
resistant None None O
rats None None O
compared None None O
to None None O
controls None None O
. None None O

These None None O
novel None None O
observations None None O
indicate None None O
that None None O
Cox5a None None O
hypermethylation None None O
is None None O
associated None None O
with None None O
mitochondrial None None O
dysfunction None None O
in None None O
skeletal None None O
muscle None None O
of None None O
HFD-induced None None O
insulin None None I-PROTEIN
resistant None None O
rats None None O
. None None O

Using None None O
a None None O
standardized None None O
, None None O
validated None None O
, None None O
computerized None None O
eye None None O
tracking None None O
protocol None None O
, None None O
fixation None None O
, None None O
saccades None None O
, None None O
and None None O
smooth None None O
pursuit None None O
eye None None O
movements None None I-FUNC
were None None O
measured None None O
just None None O
prior None None O
to None None O
intervention None None O
and None None O
immediately None None O
postintervention None None O
. None None O

This None None O
study None None O
demonstrated None None O
that None None O
neither None None O
1.5 None None O
nor None None O
2.0 None None O
ATA None None O
equivalent None None O
HBO2 None None O
had None None O
an None None O
effect None None O
on None None O
postconcussive None None O
eye None None O
movement None None I-FUNC
abnormalities None None O
after None None O
mild None None O
TBI None None O
when None None O
compared None None O
with None None O
a None None O
sham-control None None O
. None None O

Furthermore None None O
, None None O
the None None O
association None None O
of None None O
different None None O
co-occurrence None None O
patterns None None O
with None None O
enzymes None None I-PROTEIN
reducing None None O
nitric None None I-TRANS
oxide None None I-TRANS
to None None O
N2O None None O
encoded None None O
by None None O
nor None None O
genes None None O
was None None O
examined None None O
. None None O

We None None O
localized None None O
transcripts None None O
encoding None None I-FUNC
targeted None None O
proteins None None O
by None None O
in None None O
situ None None O
hybridization None None O
, None None O
quantified None None O
expression None None O
of None None O
immune- None None O
, None None O
apoptosis- None None O
, None None O
and None None O
gonad-related None None O
genes None None O
with None None O
quantitative None None O
real-time None None O
PCR None None O
, None None O
and None None O
performed None None O
gonadal None None O
histology None None O
and None None O
whole-mount None None O
immunohistochemistry None None O
for None None O
Bcl2-interacting-killer None None O
( None None O
Bik None None O
) None None O
pro-apoptotic None None O
protein None None O
. None None O

Like None None O
chemotherapy None None O
, None None O
everolimus None None O
did None None O
not None None O
alter None None O
emotional None None O
reactivity None None O
, None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
performances None None O
, None None O
but None None O
in None None O
contrast None None O
to None None O
chemotherapy None None O
, None None O
did None None O
not None None O
affect None None O
behavioral None None O
flexibility None None O
or None None O
reactivity None None O
to None None O
novelty None None O
. None None O

In None None O
conclusion None None O
, None None O
two None None O
weeks None None O
daily None None O
everolimus None None O
treatment None None O
at None None O
the None None O
clinical None None O
dose None None O
did None None O
not None None O
evoke None None O
alteration None None O
of None None O
cognitive None None O
performances None None O
evaluated None None O
in None None O
hippocampal- None None O
and None None O
prefrontal None None I-REGION
cortex-dependent None None O
tasks None None O
that None None O
would None None O
persist None None O
at None None O
one None None O
to None None O
four None None O
weeks None None O
after None None O
the None None O
end None None O
of None None O
the None None O
treatment None None O
completion None None O
. None None O

Thus None None O
, None None O
chimeric None None O
constructs None None O
bearing None None O
the None None O
alternative None None O
alleles None None O
( None None O
G None None O
& None None O
gt None None O
; None None O
A None None O
) None None O
were None None O
assayed None None O
alone None None O
or None None O
in None None O
cotransfection None None O
with None None O
the None None O
miRNA None None O
mimics None None O
, None None O
with None None O
dual None None O
luciferase None None I-PROTEIN
reporter None None O
assay None None O
in None None O
non-MPM None None O
Met-5A None None O
cells None None O
. None None O

We None None O
identified None None O
patients None None O
with None None O
lung None None O
adenocarcinomas None None O
harboring None None O
BRAF None None O
mutations None None O
between None None O
2009 None None O
and None None O
2013 None None O
detected None None O
using None None O
a None None O
mass None None O
spectrometry-based None None O
polymerase None None O
chain None None O
reaction None None O
genotyping None None O
assay None None O
of None None O
hot-spot None None O
mutations None None O
involving None None O
codons None None O
corresponding None None O
to None None O
amino None None I-TRANS
acids None None I-TRANS
V600 None None O
, None None O
D594 None None O
, None None O
and None None O
G469 None None O
of None None O
BRAF None None O
. None None O

Mutations None None O
in None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
tended None None O
to None None O
be None None O
frequent None None O
in None None O
patients None None O
with None None O
G None None O
allele None None O
at None None O
the None None O
rs4953354 None None O
, None None O
compared None None O
with None None O
those None None O
with None None O
other None None O
genotypes None None O
. None None O

The None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
crizotinib None None O
is None None O
an None None O
effective None None O
therapy None None O
for None None O
patients None None O
with None None O
cancers None None O
harboring None None O
rearrangements None None O
of None None O
the None None O
anaplastic None None O
lymphoma None None O
kinase None None O
( None None O
ALK None None O
) None None O
gene None None O
. None None O

Among None None O
HIV-infected None None O
women None None O
, None None O
perinatal None None O
depression None None I-DISEASE
compromises None None O
clinical None None O
, None None O
maternal None None O
, None None O
and None None O
child None None O
health None None O
outcomes None None O
. None None O

Depression None None I-DISEASE
symptom None None I-DISEASE
severity None None O
was None None O
measured None None O
using None None O
a None None O
modified None None O
Hopkins None None O
Symptom None None O
Checklist None None O
15 None None O
, None None O
with None None O
scores None None O
ranging None None O
from None None O
1 None None O
to None None O
4 None None O
. None None O

Linear None None O
regression None None O
with None None O
generalized None None O
estimating None None O
equations None None O
was None None O
used None None O
to None None O
compare None None O
mean None None O
depression None None I-DISEASE
scores None None O
over None None O
the None None O
3 None None O
periods None None O
. None None O

Findings None None O
were None None O
consistent None None O
when None None O
assessing None None O
probable None None O
depression None None I-DISEASE
. None None O

Barriers None None O
to None None O
safer None None O
conception None None O
counseling None None O
included None None O
provider None None O
assumptions None None O
of None None O
HIV None None O
seroconcordance None None O
, None None O
low None None O
knowledge None None O
of None None O
safer None None O
conception None None O
strategies None None O
, None None O
personal None None O
feelings None None I-FUNC
toward None None O
PLWH None None O
having None None O
children None None O
, None None O
and None None O
challenges None None O
to None None O
tailoring None None O
safer None None O
sex None None O
messages None None O
. None None O

Greater None None O
understanding None None O
of None None O
the None None O
relationship None None O
between None None O
HIV None None O
status None None O
and None None O
disrespect None None O
and None None O
abuse None None O
during None None O
childbirth None None O
is None None O
required None None O
to None None O
design None None O
interventions None None O
to None None O
promote None None O
women None None O
's None None O
rights None None O
and None None O
to None None O
increase None None O
uptake None None O
of None None O
and None None O
retention None None I-FUNC
in None None O
health None None O
services None None O
; None None O
however None None O
, None None O
few None None O
comparative None None O
studies None None O
of None None O
women None None O
living None None O
with None None O
HIV None None O
( None None O
WLWH None None O
) None None O
and None None O
HIV-negative None None O
women None None O
exist None None O
. None None O

Yet None None O
, None None O
the None None O
common None None O
problems None None O
with None None O
implementation None None O
are None None O
related None None O
to None None O
delayed None None O
or None None O
incomplete None None O
integration None None O
of None None O
higher None None O
level None None O
health None None O
systems None None O
functions None None O
: None None O
lack None None O
of None None O
coordinated None None O
leadership None None O
and None None O
unified None None O
national None None O
integration None None O
policies None None O
; None None O
separate None None O
financing None None O
streams None None O
for None None O
SRH None None O
and None None O
HIV None None O
services None None O
and None None O
inadequate None None O
health None None O
worker None None O
training None None O
, None None O
supervision None None O
and None None O
retention None None I-FUNC
. None None O

At None None O
the None None O
end None None O
of None None O
this None None O
study None None O
, None None O
we None None O
were None None O
able None None O
to None None O
demonstrate None None O
that None None O
the None None O
histological None None O
and None None O
electron None None O
microscopic None None O
findings None None O
on None None O
a None None O
skin None None O
biopsy None None O
may None None O
be None None O
an None None O
indicator None None O
of None None O
the None None O
likelihood None None O
of None None O
identifying None None O
a None None O
pathogenic None None O
mutation None None O
in None None O
type None None O
1 None None O
collagen None None I-PROTEIN
genes None None O
. None None O

Retinal None None O
arteriolar None None O
diameter None None O
, None None O
cerebral None None O
WM None None O
microstructural None None O
integrity None None O
, None None O
waist None None O
circumference None None O
, None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Several None None O
peptides None None I-TRANS
that None None O
prevent None None O
NO None None O
production None None O
by None None O
interacting None None O
with None None O
CaM None None O
have None None O
been None None O
isolated None None O
in None None O
the None None O
cutaneous None None O
secretions None None O
of None None O
Australian None None O
amphibians None None O
, None None O
and None None O
are None None O
thought None None O
to None None O
serve None None O
as None None O
a None None O
defense None None O
mechanism None None O
against None None O
predators None None O
. None None O

Isothermal None None O
titration None None O
calorimetry None None O
was None None O
used None None O
to None None O
determine None None O
thermodynamic None None O
parameters None None O
of None None O
the None None O
binding None None O
interactions None None O
and None None O
revealed None None O
that None None O
all None None O
the None None O
peptides None None I-TRANS
bind None None O
to None None O
CaM None None O
in None None O
a None None O
similar None None O
fashion None None O
, None None O
with None None O
the None None O
peptide None None O
encapsulated None None O
between None None O
the None None O
two None None O
lobes None None O
of None None O
CaM None None O
. None None O

Abstract None None O
Steroid None None I-PROTEIN
hormones None None I-PROTEIN
modulate None None O
expression None None O
of None None O
enzymes None None I-PROTEIN
that None None O
metabolize None None O
xenobiotics None None O
, None None O
including None None O
dietary None None O
supplements None None O
. None None O

This None None O
and None None O
other None None O
similar None None O
outbreaks None None O
indicate None None O
that None None O
contamination None None O
of None None O
water None None O
storage None None I-FUNC
tanks None None O
can None None O
lead None None O
to None None O
large None None O
outbreaks None None O
of None None O
Campylobacter None None O
enteritis None None O
. None None O

Epithelial None None O
cells None None O
of None None O
the None None O
cornea None None O
and None None O
the None None O
conjunctiva None None O
constitutively None None O
produce None None O
antimicrobial None None O
peptides None None I-TRANS
; None None O
however None None O
, None None O
the None None O
production None None O
of None None O
defensins None None O
by None None O
other None None O
cell None None O
types None None O
located None None O
around None None O
the None None O
eye None None O
has None None O
not None None O
been None None O
investigated None None O
. None None O

The None None O
intracellular None None O
survival None None O
of None None O
each None None O
mycobacterium None None O
, None None O
the None None O
production None None O
of None None O
cytokines None None O
and None None O
the None None O
changes None None O
on None None O
the None None O
distribution None None O
of None None O
the None None O
actin None None I-PROTEIN
filaments None None O
during None None O
the None None O
infection None None O
were None None O
also None None O
analyzed None None O
. None None O

Costs None None O
and None None O
benefits None None O
of None None O
the None None O
immune None None O
response None None O
have None None O
attracted None None O
considerable None None O
attention None None I-FUNC
in None None O
the None None O
last None None O
years None None O
among None None O
evolutionary None None O
biologists None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
conformation None None O
, None None O
aggregation None None O
stability None None O
and None None O
proteinase None None I-PROTEIN
K None None I-PROTEIN
( None None O
PK None None O
) None None O
-sensitivity None None O
of None None O
small None None O
and None None O
large None None O
PrPSc None None O
aggregates None None O
of None None O
mouse-adapted None None O
prion None None O
strains None None O
. None None O

Furthermore None None O
, None None O
we None None O
showed None None O
that None None O
small None None O
PrPSc None None O
aggregates None None O
of None None O
the None None O
Chandler None None O
scrapie None None I-DISEASE
strain None None O
have None None O
greater None None O
resistance None None O
to None None O
PK None None O
digestion None None O
and None None O
aggregation-denaturation None None O
than None None O
large None None O
PrPSc None None O
aggregates None None O
of None None O
this None None O
strain None None O
. None None O

Matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
( None None O
MMPs None None O
) None None O
represent None None O
a None None O
large None None O
family None None O
of None None O
over None None O
twenty None None O
different None None O
secreted None None O
or None None O
membrane-bound None None O
endopeptidases None None O
, None None O
involved None None O
in None None O
many None None O
physiological None None O
( None None O
embryogenesis None None O
, None None O
precursor None None O
or None None O
stem None None O
cell None None O
mobilization None None O
, None None O
tissue None None O
remodeling None None O
during None None O
wound None None O
healing None None O
, None None O
etc None None O
. None None O

In None None O
the None None O
last None None O
few None None O
years None None O
, None None O
it None None O
has None None O
been None None O
fully None None O
elucidated None None O
that None None O
these None None O
molecules None None O
have None None O
many None None O
other None None O
functions None None O
, None None O
mainly None None O
related None None O
to None None O
the None None O
immune None None O
response None None O
, None None O
in None None O
consideration None None O
of None None O
their None None O
effects None None O
on None None O
cytokines None None O
, None None O
hormones None None I-PROTEIN
and None None O
chemokines None None O
. None None O

Mouse None None O
serum None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
levels None None O
were None None O
greatest None None O
for None None O
mice None None O
infected None None O
with None None O
H. None None O
microstoma None None O
only None None O
but None None O
did None None O
not None None O
vary None None O
with None None O
number None None O
of None None O
scolices None None O
; None None O
no None None O
change None None O
in None None O
mouse None None O
serum None None O
alanine None None I-TRANS
transaminase None None I-PROTEIN
levels None None O
was None None O
observed None None O
. None None O

β-defensins None None O
are None None O
small None None O
cationic None None O
antimicrobial None None O
peptides None None I-TRANS
secreted None None O
by None None O
diverse None None O
cell None None O
types None None O
including None None O
colonic None None O
epithelial None None O
cells None None O
. None None O

Altogether None None O
, None None O
our None None O
study None None O
reports None None O
an None None O
essential None None O
role None None O
of None None O
PrP2 None None O
in None None O
collective None None O
migration None None O
process None None O
of None None O
the None None O
primordium None None O
and None None O
in None None O
neuromast None None O
formation None None O
, None None O
further None None O
implicating None None O
a None None O
role None None O
for None None O
prion None None O
protein None None O
in None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
. None None O

The None None O
negative None None O
effects None None O
of None None O
mild None None O
traumatic None None O
brain None None O
injury None None O
( None None O
mTBI None None O
) None None O
on None None O
attention None None I-FUNC
are None None O
well None None O
established None None O
. None None O

The None None O
current None None O
study None None O
examined None None O
the None None O
behavioural None None O
and None None O
electrophysiological None None O
impact None None O
of None None O
mTBI None None O
on None None O
consistent None None O
practice None None O
of None None O
a None None O
neuropsychological None None O
test None None O
of None None O
attention None None I-FUNC
. None None O

These None None O
executive None None O
attention None None I-FUNC
demands None None O
did None None O
not None None O
appear None None O
to None None O
ease None None O
with None None O
consistent None None O
practice None None O
in None None O
the None None O
mTBI None None O
group None None O
, None None O
who None None O
also None None O
endorsed None None O
more None None O
concussion-related None None O
symptoms None None O
. None None O

Eph None None O
receptors None None I-PROTEIN
, None None O
the None None O
largest None None O
family None None O
of None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinases None None I-PROTEIN
, None None O
control None None O
cell-cell None None O
adhesion/de-adhesion None None O
, None None O
cell None None O
morphology None None O
and None None O
cell None None O
positioning None None O
through None None O
interaction None None O
with None None O
cell None None O
surface None None O
ephrin None None O
ligands None None O
. None None O

Prosody None None O
can None None O
be None None O
described None None O
as None None O
the None None O
rhythmic None None O
, None None O
dynamic None None O
, None None O
and None None O
melodic None None O
aspects None None O
of None None O
language None None I-FUNC
. None None O

A None None O
large None None O
percentage None None O
of None None O
Swedish None None O
children None None O
with None None O
language None None I-FUNC
impairment None None O
show None None O
prosodic None None O
problems None None O
to None None O
some None None O
extent None None O
. None None O

In None None O
the None None O
study None None O
, None None O
10 None None O
children None None O
with None None O
phonological None None O
language None None I-FUNC
impairment None None O
and None None O
14 None None O
children None None O
with None None O
phonological-grammatical None None O
language None None I-FUNC
impairment None None O
from None None O
4 None None O
; None None O
3 None None O
to None None O
6 None None O
; None None O
2 None None O
years None None O
of None None O
age None None O
participated None None O
. None None O

The None None O
group None None O
with None None O
phonological None None O
language None None I-FUNC
impairment None None O
received None None O
higher None None O
scores None None O
in None None O
all None None O
variables None None O
, None None O
compared None None O
to None None O
the None None O
group None None O
with None None O
phonological-grammatical None None O
language None None I-FUNC
impairment None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
examine None None O
the None None O
feasibility None None O
and None None O
acceptability None None O
of None None O
routine None None O
screening None None O
for None None O
alcohol None None O
misuse None None O
in None None O
a None None O
small None None O
sample None None O
of None None O
older None None O
people None None O
with None None O
cognitive None None O
impairment None None O
receiving None None O
services None None O
in None None O
memory None None I-FUNC
clinics None None O
. None None O

Ten None None O
service None None O
users None None O
older None None O
than None None O
65 None None O
with None None O
a None None O
diagnosis None None O
of None None O
cognitive None None O
impairment None None O
( None None O
i.e. None None O
, None None O
mild None None O
cognitive None None O
impairment None None O
or None None O
dementia None None I-DISEASE
) None None O
took None None O
part None None O
in None None O
the None None O
study None None O
. None None O

While None None O
there None None O
were None None O
some None None O
challenges None None O
( None None O
e.g. None None O
, None None O
arithmetic None None O
, None None O
recall None None O
, None None O
language None None I-FUNC
problems None None O
) None None O
, None None O
these None None O
challenges None None O
could None None O
be None None O
overcome None None O
with None None O
the None None O
aid None None O
of None None O
the None None O
person None None O
administering None None O
the None None O
screening None None O
tool None None O
using None None O
standardized None None O
techniques None None O
for None None O
assessment None None O
administration None None O
. None None O

The None None O
process None None O
of None None O
completing None None O
alcohol None None O
screening None None O
tools None None O
with None None O
older None None O
adults None None O
receiving None None O
services None None O
at None None O
memory None None I-FUNC
clinics None None O
may None None O
increase None None O
awareness None None O
of None None O
the None None O
potential None None O
impact None None O
of None None O
alcohol None None O
on None None O
cognitive None None O
functioning None None O
and None None O
provide None None O
practitioners None None O
with None None O
an None None O
opportunity None None O
to None None O
educate None None O
service None None O
users None None O
about None None O
the None None O
ways None None O
that None None O
their None None O
drinking None None O
is None None O
affecting None None O
their None None O
memory None None I-FUNC
. None None O

Respondents None None O
exhibited None None O
a None None O
consistent None None O
vision None None I-FUNC
of None None O
doorstep None None O
services None None O
with None None O
regard None None O
to None None O
the None None O
Project None None O
and None None O
CHPS None None O
. None None O

Phosphorylation None None O
of None None O
p66Shc None None O
at None None O
serine None None I-TRANS
36 None None O
and None None O
levels None None O
of None None O
p66Shc None None O
in None None O
mitochondria None None O
and None None O
cytosol None None O
were None None O
measured None None O
. None None O

Nudix None None O
hydrolases None None I-PROTEIN
comprise None None O
a None None O
large None None O
gene None None O
family None None O
of None None O
twenty None None O
nine None None O
members None None O
in None None O
Arabidopsis None None O
, None None O
each None None O
containing None None O
a None None O
conserved None None O
motif None None O
capable None None O
of None None O
hydrolyzing None None O
specific None None O
substrates None None O
like None None O
ADP-glucose None None O
and None None O
NADH None None O
. None None O

However None None O
, None None O
patient None None O
perceptions None None I-FUNC
about None None O
barriers None None O
experienced None None O
while None None O
seeking None None O
care None None O
for None None O
post-discharge None None O
SSI None None O
have None None O
not None None O
been None None O
assessed None None O
in None None O
depth None None O
. None None O

Developmental None None I-DISEASE
Coordination None None I-DISEASE
Disorder None None I-DISEASE
( None None O
DCD None None O
) None None O
has None None O
been None None O
shown None None O
to None None O
co-occur None None O
with None None O
behavioral None None O
and None None O
language None None I-FUNC
problems None None O
in None None O
school-aged None None O
children None None O
, None None O
but None None O
little None None O
is None None O
known None None O
as None None O
to None None O
when None None O
these None None O
problems None None O
begin None None O
to None None O
emerge None None O
, None None O
or None None O
if None None O
they None None O
are None None O
inherent None None O
in None None O
children None None O
with None None O
DCD None None O
. None None O

Two None None O
hundred None None O
and None None O
fourteen None None O
children None None O
( None None O
mean None None O
age None None O
4years None None O
11months None None O
, None None O
SD None None O
9.8months None None O
, None None O
103 None None O
male None None O
) None None O
performed None None O
the None None O
Movement None None I-FUNC
Assessment None None O
Battery None None O
for None None O
Children None None O
2nd None None O
Edition None None O
( None None O
MABC-2 None None O
) None None O
. None None O

Auditory None None O
comprehension None None O
and None None O
expressive None None O
communication None None O
were None None O
examined None None O
using None None O
the None None O
Preschool None None O
Language None None I-FUNC
Scales None None O
4th None None O
Edition None None O
( None None O
PLS-4 None None O
) None None O
. None None O

Preschool None None O
children None None O
with None None O
diminished None None O
motor None None O
coordination None None O
( None None O
n=37 None None O
) None None O
were None None O
found None None O
to None None O
have None None O
lower None None O
language None None I-FUNC
scores None None O
, None None O
higher None None O
externalizing None None O
behaviors None None O
in None None O
the None None O
form None None O
of None None O
increased None None O
aggression None None O
, None None O
as None None O
well None None O
as None None O
increased None None O
withdrawn None None O
and None None O
other None None O
behavior None None O
symptoms None None O
compared None None O
with None None O
their None None O
typically None None O
developing None None O
peers None None O
. None None O

The None None O
level None None O
of None None O
continuous None None O
glucose None None O
monitoring None None O
( None None O
CGM None None O
) None None O
accuracy None None O
needed None None O
for None None O
insulin None None I-PROTEIN
dosing None None O
using None None O
sensor None None O
values None None O
( None None O
i.e. None None O
, None None O
the None None O
level None None O
of None None O
accuracy None None O
permitting None None O
non-adjunct None None O
CGM None None O
use None None O
) None None O
is None None O
a None None O
topic None None O
of None None O
ongoing None None O
debate None None O
. None None O

A None None O
combination None None O
of None None O
archival None None O
data None None O
( None None O
parallel None None O
CGM None None O
, None None O
insulin None None I-PROTEIN
pump None None O
, None None O
self-monitoring None None O
of None None O
blood None None O
glucose None None O
[ None None O
SMBG None None O
] None None O
records None None O
, None None O
and None None O
meals None None O
for None None O
56 None None O
pump None None O
users None None O
with None None O
type None None O
1 None None O
diabetes None None O
) None None O
and None None O
in None None O
silico None None O
experiments None None O
was None None O
used None None O
to None None O
`` None None O
replay None None O
'' None None O
real-life None None O
treatment None None O
scenarios None None O
and None None O
relate None None O
sensor None None O
error None None O
to None None O
glycemic None None O
outcomes None None O
. None None O

These None None O
segments None None O
were None None O
replayed None None O
at None None O
seven None None O
sensor None None O
accuracy None None O
levels None None O
( None None O
mean None None O
absolute None None O
relative None None O
differences None None O
[ None None O
MARDs None None O
] None None O
of None None O
3-22 None None O
% None None O
) None None O
testing None None O
six None None O
scenarios None None O
: None None O
insulin None None I-PROTEIN
dosing None None O
using None None O
sensor None None O
values None None O
, None None O
threshold None None O
, None None O
and None None O
predictive None None O
alarms None None O
, None None O
each None None O
without None None O
or None None O
with None None O
considering None None O
CGM None None O
trend None None O
arrows None None O
. None None O

Using None None O
CGM None None O
for None None O
insulin None None I-PROTEIN
dosing None None O
decisions None None O
is None None O
feasible None None O
below None None O
a None None O
certain None None O
level None None O
of None None O
sensor None None O
error None None O
, None None O
estimated None None O
in None None O
silico None None O
at None None O
MARD=10 None None O
% None None O
. None None O

In None None O
the None None O
following None None O
6 None None O
trials None None O
, None None O
vision None None I-FUNC
was None None O
occluded None None O
and None None O
subjects None None O
stood None None O
under None None O
various None None O
conditions None None O
of None None O
vibration/no None None O
vibration None None O
of None None O
the None None O
lumbar None None O
spine None None O
or None None O
m. None None O
Triceps None None O
Surae None None O
( None None O
TSM None None O
) None None O
on None None O
firm None None O
surface None None O
and None None O
on None None O
foam None None O
surface None None O
. None None O

This None None O
study None None O
shows None None O
that None None O
riding None None O
on None None O
a None None O
horse None None O
can None None O
generate None None O
movement None None I-FUNC
patterns None None O
in None None O
the None None O
human None None O
pelvis None None O
that None None O
emulate None None O
many None None O
, None None O
but None None O
not None None O
all None None O
, None None O
characteristics None None O
of None None O
those None None O
during None None O
natural None None O
walking None None O
. None None O

Expression None None O
of None None O
key None None O
biomarkers None None O
, None None O
including None None O
endocrine None None O
receptors None None I-PROTEIN
, None None O
HER2 None None O
and None None O
proliferation None None O
markers None None O
, None None O
appears None None O
to None None O
be None None O
different None None O
in None None O
younger None None O
patients None None O
and None None O
young None None O
women None None O
are None None O
more None None O
likely None None O
to None None O
harbor None None O
a None None O
genetic None None O
predisposition None None O
. None None O

Although None None O
research None None O
has None None O
demonstrated None None O
that None None O
donors None None O
often None None O
make None None O
their None None O
decision None None O
based None None O
on None None O
moral None None O
reasoning None None I-FUNC
rather None None O
than None None O
balancing None None O
risks None None O
and None None O
benefits None None O
, None None O
providing None None O
them None None O
with None None O
accurate None None O
, None None O
uniform None None O
information None None O
remains None None O
crucial None None O
because None None O
donors None None O
report None None O
feeling None None I-FUNC
misinformed None None O
about None None O
or None None O
unprepared None None O
for None None O
donation None None O
. None None O

Specifically None None O
, None None O
it None None O
is None None O
already None None O
clear None None O
that None None O
endocrine None None O
system None None O
acts None None O
by None None O
secreting None None O
vasopressin None None I-TRANS
( None None O
AVP None None O
) None None O
, None None O
oxytocin None None I-TRANS
( None None O
OT None None O
) None None O
and None None O
angiotensin None None O
II None None O
( None None O
ANG None None O
II None None O
) None None O
, None None O
and None None O
that None None O
gaseous None None O
molecules None None O
, None None O
such None None O
as None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
and None None O
carbon None None I-TRANS
monoxide None None I-TRANS
( None None O
CO None None O
) None None O
, None None O
play None None O
an None None O
important None None O
role None None O
in None None O
modulating None None O
the None None O
neurohypophyseal None None O
secretion None None O
as None None O
well None None O
as None None O
ANG None None O
II None None O
production None None O
and None None O
thirst None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
aimed None None O
to None None O
investigate None None O
whether None None O
H2S None None I-TRANS
and None None O
its None None O
interaction None None O
with None None O
NO None None O
system None None O
could None None O
participate None None O
in None None O
the None None O
modulatory None None O
responses None None O
of None None O
thirst None None O
and None None O
hormonal None None O
secretion None None O
induced None None O
by None None O
fluid None None O
deprivation None None O
. None None O

Surprisingly None None O
, None None O
24-h None None O
water None None O
deprivation None None O
increased None None O
the None None O
activity None None O
of None None O
sulfide-generating None None O
enzymes None None I-PROTEIN
in None None O
the None None O
medial None None O
basal None None O
hypothalamus None None I-REGION
( None None O
MBH None None O
) None None O
. None None O

We None None O
thus None None O
suggest None None O
that None None O
H2S None None I-TRANS
system None None O
has None None O
an None None O
important None None O
role None None O
in None None O
the None None O
modulation None None O
of None None O
hormonal None None O
and None None O
behavioral None None O
responses None None O
induced None None O
by None None O
24-h None None O
fluid None None O
deprivation None None O
. None None O

Further None None O
molecular None None O
analysis None None O
revealed None None O
that None None O
the None None O
expression None None O
of None None O
four None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
Sp1 None None O
, None None O
c-Myc None None I-PROTEIN
, None None O
NF-κB None None O
and None None O
USF2 None None O
, None None O
which None None O
are None None O
located None None O
in None None O
the None None O
proximate None None O
promoter None None O
region None None O
( None None O
-1126 None None O
to None None O
-47 None None O
) None None O
of None None O
hTERT None None O
, None None O
was None None O
also None None O
suppressed None None O
by None None O
ATO None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
D. None None O
gliroides None None O
did None None O
not None None O
display None None O
NST None None O
in None None O
response None None O
to None None O
Norepinephrine None None I-TRANS
. None None O

The None None O
sweating None None O
rate None None O
remained None None O
abnormally None None O
low None None O
under None None O
conditions None None O
of None None O
moderate None None O
heat None None O
stress None None O
, None None O
rising None None O
significantly None None O
( None None O
110 None None O
gm None None O
( None None O
-2 None None O
) None None O
h None None O
( None None O
-1 None None O
) None None O
) None None O
without None None O
evidence None None O
of None None O
stabilization None None O
, None None O
only None None O
when None None O
tendency None None O
for None None O
heat None None O
storage None None I-FUNC
occurred None None O
. None None O

Therefore None None O
, None None O
the None None O
goal None None O
of None None O
this None None O
study None None O
was None None O
to None None O
verify None None O
the None None O
effect None None O
of None None O
passive None None O
heat None None O
loading None None O
( None None O
PHL None None O
) None None O
on None None O
the None None O
expression None None O
of None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor-21 None None O
( None None O
FGF21 None None O
) None None O
and None None O
free None None O
fatty None None O
acids None None O
( None None O
FFAs None None O
) None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
found None None O
that None None O
afatinib None None O
, None None O
a None None O
small None None O
molecule None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
( None None O
TKI None None O
) None None O
targeting None None O
EGFR None None O
, None None O
HER-2 None None O
and None None O
HER-4 None None O
, None None O
reversed None None O
the None None O
chemoresistance None None O
mediated None None O
by None None O
ABCG2 None None O
in None None O
vitro None None O
, None None O
but None None O
had None None O
no None None O
effect None None O
on None None O
that None None O
mediated None None O
by None None O
multidrug None None O
resistance None None O
protein None None O
ABCB1 None None O
and None None O
ABCC1 None None O
. None None O

Mechanistic None None O
investigations None None O
exhibited None None O
that None None O
afatinib None None O
significantly None None O
inhibited None None O
ATPase None None I-PROTEIN
activity None None O
of None None O
ABCG2 None None O
and None None O
downregulated None None O
expression None None O
level None None O
of None None O
ABCG2 None None O
, None None O
which None None O
resulted None None O
in None None O
the None None O
suppression None None O
of None None O
efflux None None O
activity None None O
of None None O
ABCG2 None None O
in None None O
parallel None None O
to None None O
the None None O
increase None None O
of None None O
intracellular None None O
accumulation None None O
of None None O
ABCG2 None None O
substrate None None O
anticancer None None O
agents None None O
. None None O

Serine None None I-TRANS
and None None O
glycine None None I-TRANS
are None None O
amino None None I-TRANS
acids None None I-TRANS
that None None O
provide None None O
the None None O
essential None None O
precursors None None O
for None None O
the None None O
synthesis None None O
of None None O
proteins None None O
, None None O
nucleic None None O
acids None None O
and None None O
lipids None None O
. None None O

Our None None O
analysis None None O
highlighted None None O
the None None O
relevance None None O
of None None O
PHGDH None None O
and None None O
SHMT2 None None O
expression None None O
as None None O
prognostic None None O
factor None None O
for None None O
breast None None O
cancer None None O
, None None O
revealing None None O
a None None O
substantial None None O
ability None None O
of None None O
these None None O
enzymes None None I-PROTEIN
to None None O
predict None None O
patient None None O
survival None None O
outcome None None O
. None None O

Although None None O
these None None O
observations None None O
require None None O
further None None O
investigations None None O
they None None O
might None None O
suggest None None O
a None None O
selective None None O
requirement None None O
of None None O
some None None O
enzymes None None I-PROTEIN
in None None O
specific None None O
cancer None None O
types None None O
, None None O
recommending None None O
more None None O
cautions None None O
in None None O
the None None O
development None None O
of None None O
novel None None O
translational None None O
opportunities None None O
and None None O
biomarker None None O
identification None None O
of None None O
human None None O
cancers None None O
. None None O

Within None None O
the None None O
prostate None None O
of None None O
PTEN-deficient None None O
mice None None O
, None None O
there None None O
is None None O
a None None O
progressive None None O
pattern None None O
of None None O
ERα None None O
expression None None O
: None None O
low None None O
in None None O
benign None None O
glands None None O
, None None O
moderate None None O
in None None O
tumors None None O
within None None O
the None None O
dorsal None None I-NEURON
, None None O
lateral None None O
and None None O
ventral None None I-NEURON
lobes None None O
, None None O
and None None O
high None None O
in None None O
tumors None None O
within None None O
the None None O
anterior None None O
prostate None None O
. None None O

Finally None None O
, None None O
ERα None None O
knockdown None None O
reduces None None O
the None None O
levels None None O
of None None O
the None None O
MYC None None O
protein None None O
and None None O
lowers None None O
the None None O
sensitivity None None O
of None None O
cellular None None O
proliferation None None O
to None None O
glucose None None O
withdrawal None None O
, None None O
which None None O
correlates None None O
with None None O
decreased None None O
expression None None O
of None None O
the None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
GLUT1 None None O
. None None O

A None None O
survey None None O
provided None None O
insights None None O
into None None O
participants None None O
' None None O
knowledge None None O
and None None O
perceptions None None I-FUNC
of None None O
sexual None None O
health None None O
, None None O
STIs None None O
and None None O
healthy None None O
relationships None None O
. None None O

The None None O
human None None O
pyruvate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
complex None None O
( None None O
PDC None None O
) None None O
comprises None None O
three None None O
principal None None O
catalytic None None O
components None None O
for None None O
its None None O
mission None None O
: None None O
E1 None None O
, None None O
E2 None None O
, None None O
and None None O
E3 None None O
. None None O

The None None O
PDC None None O
is None None O
subject None None O
to None None O
regulation None None O
at None None O
E1 None None O
by None None O
serine None None I-TRANS
phosphorylation None None O
by None None O
four None None O
kinases None None I-PROTEIN
( None None O
PDK1-4 None None O
) None None O
, None None O
an None None O
inactivation None None O
reversed None None O
by None None O
the None None O
action None None O
of None None O
two None None O
phosphatases None None I-PROTEIN
( None None O
PDP1 None None O
and None None O
-2 None None O
) None None O
. None None O

Bacterial None None O
histidine None None I-TRANS
kinases None None I-PROTEIN
( None None O
HKs None None O
) None None O
are None None O
promising None None O
targets None None O
for None None O
novel None None O
antibacterials None None O
. None None O

Retrospective None None O
cohort None None O
study None None O
of None None O
167 None None O
patients None None O
consecutively None None O
diagnosed None None O
as None None O
having None None O
anti-NMDAR None None O
encephalitis None None I-DISEASE
between None None O
May None None O
1 None None O
, None None O
2008 None None O
, None None O
and None None O
January None None O
31 None None O
, None None O
2013 None None O
. None None O

Percentage None None O
of None None O
patients None None O
with None None O
anti-NMDAR None None O
encephalitis None None I-DISEASE
and None None O
elevated None None O
CXCL13 None None O
in None None O
CSF None None O
. None None O

Seventy None None O
percent None None O
of None None O
patients None None O
with None None O
early-stage None None O
anti-NMDAR None None O
encephalitis None None I-DISEASE
had None None O
increased None None O
CSF None None O
CXCL13 None None O
concentration None None O
that None None O
correlated None None O
with None None O
intrathecal None None O
NMDAR-antibody None None O
synthesis None None O
. None None O

CXCL13 None None O
is None None O
a None None O
potentially None None O
useful None None O
biomarker None None O
of None None O
treatment None None O
response None None O
and None None O
outcome None None O
in None None O
anti-NMDAR None None O
encephalitis None None I-DISEASE
. None None O

Domain-general None None O
theories None None O
of None None O
autism None None O
rest None None O
on None None O
evidence None None O
that None None O
the None None O
disorder None None O
impacts None None O
not None None O
only None None O
social None None O
communication None None O
skills None None O
but None None O
also None None O
nonsocial None None O
functions None None O
such None None O
as None None O
memory None None I-FUNC
. None None O

Here None None O
we None None O
tested None None O
school-age None None O
children None None O
with None None O
high-functioning None None O
autism None None O
( None None O
ASD None None O
) None None O
and None None O
IQ None None O
, None None O
and None None O
age-matched None None O
comparison None None O
children None None O
on None None O
a None None O
visual None None O
long-term None None I-FUNC
memory None None I-FUNC
task None None O
involving None None O
more None None O
than None None O
100 None None O
photographs None None O
of None None O
objects None None O
, None None O
faces None None O
, None None O
cats None None O
, None None O
houses None None O
, None None O
and None None O
abstract None None O
stimuli None None O
. None None O

Data None None O
supported None None O
the None None O
presence None None O
of None None O
a None None O
high-capacity None None O
and None None O
high-precision None None O
visual None None I-FUNC
memory None None I-FUNC
in None None O
children None None O
with None None O
ASD None None O
. None None O

When None None O
more None None O
exemplars None None O
per None None O
category None None O
were None None O
encoded None None O
, None None O
category None None O
memory None None I-FUNC
improved None None O
, None None O
but None None O
exemplar None None O
memory None None I-FUNC
declined None None O
. None None O

Our None None O
study None None O
provided None None O
no None None O
evidence None None O
that None None O
visual None None I-FUNC
memory None None I-FUNC
in None None O
general None None O
, None None O
and None None O
face None None O
memory None None I-FUNC
in None None O
particular None None O
, None None O
is None None O
impaired None None O
in None None O
children None None O
with None None O
ASD None None O
. None None O

The None None O
study None None O
has None None O
a None None O
direct None None O
implication None None O
to None None O
Alzheimer None None I-DISEASE
Disease None None O
as None None O
the None None O
results None None O
invoke None None O
a None None O
new None None O
mechanism None None O
to None None O
prevent None None O
Aβ None None O
fibrillation None None O
. None None O

Activation None None O
of None None O
the None None O
Wnt None None O
pathway None None O
by None None O
treatment None None O
with None None O
Wnt3a-conditioned None None O
medium None None O
or None None O
glycogen None None O
synthase None None O
kinase None None O
3β None None O
inhibitors None None O
, None None O
such None None O
as None None O
SB-216763 None None O
and None None O
6-bromoindirubin-3'-oxime None None O
, None None O
delays None None O
the None None O
progression None None O
of None None O
cellular None None O
senescence None None O
as None None O
shown None None O
by None None O
the None None O
decrease None None O
in None None O
the None None O
senescence None None O
effectors None None O
p53 None None I-PROTEIN
and None None O
pRb None None O
, None None O
lowered None None O
senescence-associated None None O
β-galactosidase None None O
activity None None O
, None None O
and None None O
increased None None O
telomerase None None O
activity None None O
. None None O

Intravenous None None O
insulin None None I-PROTEIN
infusion None None O
represents None None O
the None None O
first None None O
and None None O
most None None O
adequate None None O
therapeutic None None O
approach None None O
for None None O
sustained None None O
hyperglycemia None None O
, None None O
but None None O
this None None O
can None None O
provide None None O
only None None O
a None None O
short-term None None O
solution None None O
. None None O

We None None O
compared None None O
outcomes None None O
of None None O
veteran None None O
patients None None O
provided None None O
with None None O
comprehensive None None O
rehabilitation None None O
with None None O
those None None O
provided None None O
with None None O
consultative None None O
rehabilitation None None O
services None None O
postacute None None O
stroke None None I-DISEASE
using None None O
propensity None None O
scores None None O
. None None O

However None None O
, None None O
there None None O
is None None O
no None None O
comparative None None O
study None None O
, None None O
so None None O
far None None O
, None None O
to None None O
evaluate None None O
the None None O
learning None None I-FUNC
curve None None O
between None None O
robotic None None O
and None None O
laparoscopic None None O
rectal None None O
cancer None None O
surgeries None None O
. None None O

Cumulative None None O
sum None None O
( None None O
CUSUM None None O
) None None O
was None None O
used None None O
to None None O
evaluate None None O
the None None O
learning None None I-FUNC
curve None None O
. None None O

The None None O
perioperative None None O
clinicopathologic None None O
characteristics None None O
were None None O
compared None None O
by None None O
phases None None O
and None None O
surgical None None O
procedures.According None None O
to None None O
CUSUM None None O
, None None O
the None None O
learning None None I-FUNC
curve None None O
of None None O
robotic None None O
LAR None None O
was None None O
the None None O
44th None None O
case None None O
and None None O
laparoscopic None None O
LAR None None O
was None None O
the None None O
41st None None O
case None None O
. None None O

Pathologic None None O
outcomes None None O
were None None O
not None None O
significantly None None O
different None None O
in None None O
both None None O
procedures None None O
and None None O
phases.The None None O
learning None None I-FUNC
curve None None O
of None None O
robotic None None O
LAR None None O
for None None O
rectal None None O
cancer None None O
was None None O
similar None None O
to None None O
laparoscopic None None O
LAR None None O
, None None O
and None None O
the None None O
clinicopathologic None None O
outcomes None None O
were None None O
similar None None O
in None None O
both None None O
the None None O
procedures None None O
. None None O

Per None None O
protocol None None O
analysis None None O
demonstrated None None O
that None None O
sMVS None None O
treatment None None O
was None None O
associated None None O
with None None O
a None None O
decline None None O
in None None O
ferritin None None I-PROTEIN
( None None O
-24.4 None None O
± None None O
70.1 None None O
μg/L None None O
) None None O
and None None O
vitamin None None O
B12 None None O
( None None O
-45.9 None None O
± None None O
150.3 None None O
pmol/L None None O
) None None O
over None None O
12 None None O
months None None O
, None None O
whereas None None O
in None None O
WLS None None O
Forte None None O
patients None None O
, None None O
ferritin None None I-PROTEIN
remained None None O
stable None None O
( None None O
+3.2 None None O
± None None O
93.2 None None O
μg/L None None O
) None None O
and None None O
vitamin None None O
B12 None None O
increased None None O
significantly None None O
( None None O
+55.1 None None O
± None None O
144.2 None None O
pmol/L None None O
) None None O
. None None O

The None None O
safety None None O
, None None O
tolerability None None O
, None None O
and None None O
efficacy None None O
data None None O
for None None O
antipsychotic None None O
drugs None None O
used None None O
in None None O
the None None O
acute None None O
phase None None O
of None None O
stroke None None I-DISEASE
are None None O
limited None None O
. None None O

Patients None None O
were None None O
tracked None None O
for None None O
1 None None O
month None None O
from None None O
the None None O
time None None O
of None None O
their None None O
first None None O
hospitalization None None O
for None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

After None None O
adjustment None None O
for None None O
the None None O
covariates None None O
, None None O
antipsychotics None None O
users None None O
before None None O
ischemic None None O
stroke None None I-DISEASE
are None None O
associated None None O
with None None O
a None None O
73 None None O
% None None O
decrease None None O
in None None O
the None None O
rate None None O
of None None O
mortality None None O
( None None O
OR None None O
0.27 None None O
; None None O
95 None None O
% None None O
CI None None O
0.23-0.31 None None O
) None None O
. None None O

The None None O
benefit None None O
on None None O
lower None None O
mortality None None O
was None None O
found None None O
not None None O
only None None O
among None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
who None None O
had None None O
received None None O
antipsychotics None None O
previously None None O
but None None O
also None None O
among None None O
patients None None O
who None None O
start None None O
antipsychotics None None O
after None None O
their None None O
stroke None None I-DISEASE
. None None O

Nevertheless None None O
, None None O
extensive None None O
parallel None None O
work None None O
in None None O
the None None O
Drosophila None None O
midgut None None O
shows None None O
that None None O
intestinal None None O
epithelium None None O
damage None None O
induces None None O
inflammatory None None O
signals None None O
and None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
acting None None O
mainly None None O
in None None O
a None None O
paracrine None None O
manner None None O
to None None O
induce None None O
intestinal None None O
stem None None O
cell None None O
proliferation None None O
and None None O
tumor None None O
formation None None O
when None None O
genetically None None O
predisposed None None O
. None None O

Therefore None None O
, None None O
recent None None O
work None None O
on None None O
Drosophila None None O
host None None O
defense None None O
to None None O
infection None None O
by None None O
expanding None None O
its None None O
main None None O
focus None None O
on None None O
systemic None None O
immunity None None O
signaling None None O
pathways None None O
to None None O
include None None O
the None None O
study None None O
of None None O
organ None None O
homeostasis None None O
in None None O
health None None O
and None None O
disease None None O
shapes None None O
a None None O
new None None O
notion None None O
that None None O
epithelially None None O
emanating None None O
cytokines None None O
and None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
can None None O
directly None None O
act None None O
on None None O
the None None O
intestinal None None O
stem None None O
cell None None O
niche None None O
to None None O
promote None None O
`` None None O
regenerative None None O
inflammation None None O
'' None None O
and None None O
potentially None None O
cancer None None O
. None None O

These None None O
three None None O
, None None O
negative-sense None None O
single-stranded None None O
RNA None None O
viruses None None O
, None None O
are None None O
hosted None None O
by None None O
fruit None None O
bats None None O
and None None O
use None None O
EphrinB2 None None O
receptors None None I-PROTEIN
for None None O
entry None None O
into None None O
cells None None O
. None None O

Trypan None None O
Blue None None O
staining None None O
and None None O
TUNEL None None O
assay None None O
were None None O
done None None O
at None None O
selected None None O
concentrations None None O
of None None O
NE None None I-TRANS
. None None O

We None None O
show None None O
that None None O
at None None O
50 None None O
μM None None O
NE None None I-TRANS
, None None O
there None None O
occurs None None O
a None None O
transition None None O
from None None O
cellular None None O
hypertrophy None None O
towards None None O
death None None O
. None None O

In None None O
these None None O
cells None None O
, None None O
E2 None None O
was None None O
formed None None O
from None None O
E1S None None O
and None None O
E1 None None O
, None None O
while None None O
androstenedione None None O
was None None O
not None None O
converted None None O
to None None O
estrogens None None I-PROTEIN
. None None O

Previous None None O
exposure None None O
to None None O
hyperglycemic None None O
conditions None None O
accelerates None None O
a None None O
decline None None O
in None None O
cellular None None O
function None None O
through None None O
metabolic None None O
memory None None I-FUNC
despite None None O
normalization None None O
of None None O
glycemic None None O
control None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
epigenetic-related None None O
metabolic None None O
memory None None I-FUNC
may None None O
also None None O
underlie None None O
differences None None O
in None None O
wound None None O
healing None None O
phenotypes None None O
and None None O
can None None O
potentially None None O
identify None None O
therapeutic None None O
targets None None O
. None None O

Previously None None O
, None None O
we None None O
described None None O
replication None None O
timing None None O
on None None O
human None None O
chromosome None None O
21q None None O
in None None O
the None None O
THP-1 None None O
human None None O
cell None None O
line None None O
( None None O
2n None None O
= None None O
46 None None O
, None None O
XY None None O
) None None O
and None None O
showed None None O
that None None O
several None None O
genes None None O
associated None None O
with None None O
neural None None O
diseases None None O
, None None O
such None None O
as None None O
the None None O
neuronal None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
subunit None None O
GluR-5 None None O
( None None O
GRIK1 None None O
) None None O
and None None O
amyloid None None O
precursor None None O
protein None None O
( None None O
APP None None I-TRANS
) None None O
, None None O
were None None O
located None None O
in None None O
regions None None O
where None None O
replication None None O
timing None None O
transitioned None None O
from None None O
early None None O
to None None O
late None None O
S None None O
phase None None O
. None None O

Analysis None None O
of None None O
selected None None O
large None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
genes None None O
( None None O
& None None O
gt None None O
; None None O
200 None None O
kb None None O
) None None O
, None None O
and None None O
of None None O
APP None None I-TRANS
, None None O
showed None None O
that None None O
their None None O
precise None None O
replication None None O
timing None None O
patterns None None O
differed None None O
among None None O
the None None O
cell None None O
lines None None O
. None None O

It None None O
argues None None O
that None None O
unhistoricist None None O
queer None None O
theory None None O
has None None O
recently None None O
drawn None None O
attention None None I-FUNC
to None None O
this None None O
closed/open None None O
interrelationship None None O
by None None O
inadvertently None None O
raising None None O
( None None O
a None None O
) None None O
doubts None None O
about None None O
the None None O
irreducible None None O
openness None None O
of None None O
queer None None O
; None None O
( None None O
b None None O
) None None O
questions None None O
about None None O
its None None O
fundamentalism None None O
; None None O
and None None O
( None None O
c None None O
) None None O
reservations None None O
about None None O
its None None O
ability None None O
to None None O
handle None None O
the None None O
re-emerging None None O
issues None None O
of None None O
consonances None None O
between None None O
sexual None None O
concepts None None O
across None None O
history None None O
and None None O
the None None O
importance None None O
, None None O
usages None None O
, None None O
and None None O
allure None None O
of None None O
sexual None None O
identities None None O
. None None O

The None None O
porous None None O
microspheres None None O
were None None O
fabricated None None O
by None None O
a None None O
modified None None O
double None None O
emulsion None None O
method None None O
with None None O
bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
as None None O
porogen None None O
. None None O

Cells None None O
were None None O
exposed None None O
to None None O
different None None O
concentrations None None O
( None None O
1-100 None None O
μg/ml None None O
) None None O
of None None O
Mo-NPs None None O
( None None O
size None None O
40 None None O
nm None None O
) None None O
for None None O
24 None None O
and None None O
48 None None O
h. None None O
After None None O
the None None O
exposure None None O
, None None O
different None None O
cytotoxicity None None O
assays None None O
( None None O
3- None None O
( None None O
4 None None O
, None None O
5-dimethylthiazol-2-yl None None O
) None None O
-2 None None O
, None None O
5-diphenyl None None O
tetrazolium None None O
bromide None None O
, None None O
MTT None None O
; None None O
neutral None None O
red None None O
uptake None None O
, None None O
NRU None None O
; None None O
and None None O
cellular None None O
morphology None None O
) None None O
and None None O
oxidative None None O
stress None None O
markers None None O
( None None O
lipid None None O
peroxidation None None O
, None None O
LPO None None O
; None None O
glutathione None None O
, None None O
GSH None None O
; None None O
and None None O
catalase None None I-PROTEIN
) None None O
were None None O
studied None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
synthesis None None O
of None None O
cyclic None None O
arginine-glycine-aspartic None None O
acid None None I-TRANS
( None None O
RGD None None O
) None None O
peptide-conjugated None None O
generation None None O
5 None None O
( None None O
G5 None None O
) None None O
poly None None O
( None None O
amidoamine None None O
) None None O
dendrimers None None O
for None None O
anticancer None None O
drug None None O
encapsulation None None O
and None None O
targeted None None O
therapy None None O
of None None O
cancer None None O
cells None None O
overexpressing None None O
αvβ3 None None O
integrins None None I-PROTEIN
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
describe None None O
the None None O
method None None O
of None None O
dorsal None None I-NEURON
multiple None None O
plating None None O
without None None O
the None None O
routine None None O
use None None O
of None None O
transarticular None None O
screws None None O
, None None O
and None None O
to None None O
report None None O
on None None O
the None None O
ability None None O
of None None O
plate None None O
fixation None None O
to None None O
maintain None None O
alignment None None O
comparable None None O
to None None O
that None None O
of None None O
transarticular None None O
screw None None O
fixation None None O
in None None O
15 None None O
patients None None O
. None None O

Deep None None O
venous None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
of None None O
the None None O
upper None None O
extremity None None O
is None None O
uncommon None None O
compared None None O
with None None O
DVT None None O
of None None O
the None None O
lower None None O
extremity None None O
. None None O

This None None O
article None None O
describes None None O
a None None O
case None None O
of None None O
superficial None None O
venous None None O
thrombosis None None I-DISEASE
that None None O
mimicked None None O
DVT None None O
in None None O
the None None O
surgical None None O
( None None O
right None None O
) None None O
arm None None O
of None None O
a None None O
recreational None None O
baseball None None O
player None None O
after None None O
suprapectoral None None O
biceps None None O
tenodesis None None O
for None None O
a None None O
painful None None O
superior None None O
labrum None None O
anterior-posterior None None O
lesion None None O
. None None O

It None None O
is None None O
important None None O
for None None O
clinicians None None O
to None None O
understand None None O
the None None O
distinction None None O
between None None O
superficial None None O
venous None None O
thrombosis None None I-DISEASE
and None None O
DVT None None O
in None None O
the None None O
upper None None O
extremity None None O
because None None O
the None None O
physical None None O
findings None None O
, None None O
treatment None None O
, None None O
and None None O
prognosis None None O
for None None O
these None None O
2 None None O
entities None None O
differ None None O
in None None O
the None None O
following None None O
ways None None O
: None None O
( None None O
1 None None O
) None None O
superficial None None O
venous None None O
thrombosis None None I-DISEASE
may None None O
be None None O
accompanied None None O
by None None O
a None None O
cord None None O
, None None O
but None None O
DVT None None O
is None None O
associated None None O
with None None O
more None None O
generalized None None O
swelling None None O
; None None O
( None None O
2 None None O
) None None O
superficial None None O
venous None None O
thrombosis None None I-DISEASE
requires None None O
symptomatic None None O
treatment None None O
only None None O
, None None O
whereas None None O
DVT None None O
requires None None O
anticoagulation None None O
; None None O
and None None O
( None None O
3 None None O
) None None O
superficial None None O
venous None None O
thrombosis None None I-DISEASE
typically None None O
resolves None None O
with None None O
few None None O
sequelae None None O
, None None O
whereas None None O
upper-extremity None None O
DVT None None O
increases None None O
the None None O
risk None None O
of None None O
future None None O
DVT None None O
. None None O

In None None O
the None None O
current None None O
work None None O
, None None O
we None None O
explored None None O
the None None O
conformational None None O
diversity None None O
of None None O
FabH None None O
enzymes None None I-PROTEIN
to None None O
understand None None O
the None None O
determinants None None O
of None None O
diverse None None O
interaction None None O
specificity None None O
across None None O
Gram-positive None None O
and None None O
Gram-negative None None O
bacteria None None O
. None None O

These None None O
insights None None O
will None None O
potentially None None O
facilitate None None O
the None None O
rational None None O
design None None O
and None None O
development None None O
of None None O
antibacterial None None O
inhibitors None None O
against None None O
FabH None None O
enzymes None None I-PROTEIN
. None None O

Many None None O
studies None None O
reported None None O
significant None None O
pain None None O
relief None None O
by None None O
rTMS None None O
, None None O
especially None None O
high-frequency None None O
stimulation None None O
over None None O
the None None O
primary None None I-REGION
motor None None I-REGION
cortex None None I-REGION
performed None None O
in None None O
consecutive None None O
treatment None None O
sessions None None O
. None None O

This None None O
effect None None O
could None None O
be None None O
sufficiently None None O
mimicked None None O
by None None O
exogenous None None O
norepinephrine None None I-TRANS
and None None O
blocked None None O
by None None O
the None None O
β-antagonist None None O
propranolol None None O
. None None O

Norepinephrine None None I-TRANS
also None None O
abrogated None None O
sunitinib-induced None None O
inhibition None None O
of None None O
cancer None None O
cell None None O
migration None None O
, None None O
but None None O
had None None O
no None None O
effect None None O
on None None O
direct None None O
anti-proliferative None None O
activity None None O
of None None O
sunitinib None None O
on None None O
cancer None None O
cells None None O
. None None O

A None None O
similar None None O
pattern None None O
for None None O
glutamate None None I-TRANS
was None None O
only None None O
observed None None O
in None None O
males None None O
. None None O

Our None None O
kinetics None None O
profiling None None O
approach None None O
complements None None O
the None None O
existing None None O
enzyme-coupled None None O
byproduct-release None None O
assays None None O
, None None O
unraveling None None O
new None None O
mechanistic None None O
insights None None O
of None None O
substrate None None O
activation/channeling None None O
in None None O
NRPS None None O
enzymes None None I-PROTEIN
. None None O

However None None O
, None None O
changing None None O
the None None O
relative None None O
attention None None I-FUNC
that None None O
actors None None O
and None None O
observers None None O
pay None None O
to None None O
these None None O
factors None None O
can None None O
reverse None None O
the None None O
effects None None O
of None None O
the None None O
actors None None O
' None None O
synchronous None None O
behavior None None O
on None None O
conformity None None O
. None None O

We None None O
also None None O
find None None O
that None None O
activating None None O
an None None O
alternative None None O
goal None None O
decreases None None O
the None None O
attractiveness None None O
of None None O
socially None None O
warm None None O
activities None None O
when None None O
people None None O
are None None O
feeling None None I-FUNC
cold None None O
( None None O
Experiment None None O
3 None None O
) None None O
. None None O

Experiment None None O
4 None None O
further None None O
investigated None None O
the None None O
mechanism None None O
behind None None O
the None None O
influence None None O
of None None O
incompatibility None None O
versus None None O
compatibility None None O
between None None O
motivational None None O
orientation None None O
and None None O
valence None None O
on None None O
distance None None O
perception None None I-FUNC
. None None O

Furthermore None None O
, None None O
perceptual None None O
estimates None None O
were None None O
correlated None None O
with None None O
the None None O
activity None None O
of None None O
the None None O
Behavioral None None O
Inhibition None None O
System None None O
( None None O
BIS None None O
) None None O
and None None O
the None None O
activity None None O
of None None O
the None None O
Behavioral None None O
Activation None None O
System None None O
( None None O
BAS None None O
) None None O
relative None None O
to None None O
the None None O
BIS None None O
, None None O
further None None O
suggesting None None O
that None None O
goal-related None None O
motivation None None O
may None None O
be None None O
associated None None O
with None None O
perception None None I-FUNC
. None None O

These None None O
findings None None O
fill None None O
an None None O
important None None O
gap None None O
in None None O
the None None O
responsiveness None None O
literature None None O
and None None O
highlight None None O
the None None O
utility None None O
of None None O
considering None None O
person-context None None O
factors None None O
in None None O
emotion None None I-FUNC
interpretation None None O
and None None O
responsiveness None None O
processes None None O
. None None O

The None None O
short None None O
rib-polydactyly None None O
syndromes None None O
are None None O
a None None O
heterogeneous None None O
group None None O
of None None O
lethal None None O
autosomal None None O
recessive None None O
disorders None None O
( None None O
SRP None None O
I-IV None None O
) None None O
, None None O
which None None O
result None None O
from None None O
cellular None None O
ciliary None None O
dysfunction None None O
during None None O
embryogenesis None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
transcutaneous None None O
vagus None None I-REGION
nerve None None I-REGION
stimulation None None O
( None None O
tVNS None None O
) None None O
on None None O
neural None None O
oscillatory None None O
patterns None None O
. None None O

The None None O
primary None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
perceptual None None O
sensation None None I-FUNC
produced None None O
by None None O
bipolar None None O
electrical None None O
stimulation None None O
of None None O
auditory None None O
brainstem None None I-REGION
implant None None O
( None None O
ABI None None O
) None None O
electrodes None None O
with None None O
the None None O
morphology None None O
of None None O
electrically None None O
evoked None None O
responses None None O
elicited None None O
by None None O
the None None O
same None None O
bipolar None None O
stimulus None None O
in None None O
the None None O
same None None O
unanesthetized None None O
, None None O
postsurgical None None O
state None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
sensations None None I-FUNC
elicited None None O
by None None O
monopolar None None O
higher-rate None None O
pulse-train None None O
stimuli None None O
similar None None O
to None None O
that None None O
used None None O
in None None O
processor None None O
programming None None O
were None None O
measured None None O
for None None O
all None None O
electrodes None None O
in None None O
the None None O
ABI None None O
array None None O
and None None O
classified None None O
using None None O
the None None O
same None None O
categories None None O
. None None O

Sensations None None I-FUNC
were None None O
classified None None O
for None None O
33 None None O
bipolar None None O
pairs None None O
as None None O
follows None None O
: None None O
21 None None O
pairs None None O
were None None O
auditory None None O
, None None O
6 None None O
were None None O
mixed None None O
, None None O
5 None None O
were None None O
side None None O
effect None None O
, None None O
and None None O
1 None None O
was None None O
no None None O
sensation None None I-FUNC
. None None O

The None None O
presence None None O
of None None O
other None None O
waves None None O
in None None O
the None None O
early-latency None None O
response None None O
such None None O
as None None O
N1 None None O
or None None O
P2 None None O
or None None O
a None None O
positive None None O
wave None None O
after None None O
4 None None O
msec None None O
did None None O
not None None O
distinguish None None O
between None None O
only None None O
auditory None None O
or None None O
only None None O
nonauditory None None O
sensations None None I-FUNC
. None None O

When None None O
bipolar None None O
sensations None None I-FUNC
were None None O
compared None None O
with None None O
monopolar None None O
sensations None None I-FUNC
for None None O
the None None O
21 None None O
bipolar None None O
pairs None None O
categorized None None O
as None None O
auditory None None O
, None None O
7 None None O
pairs None None O
had None None O
monopolar None None O
sensations None None I-FUNC
of None None O
auditory None None O
for None None O
both None None O
electrodes None None O
, None None O
9 None None O
pairs None None O
had None None O
only None None O
one None None O
electrode None None O
with None None O
a None None O
monopolar None None O
sensation None None I-FUNC
of None None O
auditory None None O
, None None O
with None None O
the None None O
remainder None None O
having None None O
neither None None O
electrode None None O
as None None O
auditory None None O
. None None O

When None None O
monopolar None None O
stimulation None None O
was None None O
compared None None O
with None None O
evoked None None O
potential None None O
morphology None None O
elicited None None O
by None None O
bipolar None None O
stimulation None None O
, None None O
P3 None None O
and None None O
the None None O
eMLR None None O
were None None O
more None None O
likely None None O
to None None O
be None None O
present None None O
when None None O
one None None O
or None None O
both None None O
of None None O
the None None O
electrodes None None O
in None None O
the None None O
bipolar None None O
pair None None O
elicited None None O
an None None O
auditory None None O
or None None O
mixed None None O
sensation None None I-FUNC
with None None O
monopolar None None O
stimulation None None O
and None None O
were None None O
less None None O
likely None None O
to None None O
occur None None O
when None None O
neither None None O
of None None O
the None None O
electrodes None None O
had None None O
an None None O
auditory None None O
monopolar None None O
sensation None None I-FUNC
. None None O

ABI None None O
electrodes None None O
that None None O
are None None O
associated None None O
with None None O
auditory None None O
sensations None None I-FUNC
elicited None None O
by None None O
bipolar None None O
stimulation None None O
are None None O
more None None O
likely None None O
to None None O
elicit None None O
evoked None None O
responses None None O
with None None O
a None None O
P3 None None O
wave None None O
or None None O
a None None O
middle-latency None None O
wave None None O
. None None O

Unsanitary None None O
conditions None None O
during None None O
harvesting None None O
, None None O
drying None None O
, None None O
packing None None O
and None None O
storage None None I-FUNC
in None None O
production None None O
and None None O
processing None None O
of None None O
cereals None None O
can None None O
effect None None O
mycotoxin None None O
contamination None None O
. None None O

When None None O
compared None None O
with None None O
N-UC-MSCs None None O
, None None O
GDM-UC-MSCs None None O
showed None None O
decreased None None O
cell None None O
growth None None O
and None None O
earlier None None O
cellular None None O
senescence None None O
with None None O
accumulation None None O
of None None O
p16 None None O
and None None O
p53 None None I-PROTEIN
, None None O
even None None O
though None None O
they None None O
expressed None None O
similar None None O
levels None None O
of None None O
CD105 None None O
, None None O
CD90 None None O
, None None O
and None None O
CD73 None None O
MSC None None O
marker None None O
proteins None None O
. None None O

At None None O
baseline None None O
as None None O
predictive None None O
biomarkers None None O
we None None O
identified None None O
2 None None O
peptides None None I-TRANS
- None None O
m/z None None O
6411 None None O
, None None O
4075 None None O
- None None O
as None None O
significantly None None O
up-regulated None None O
in None None O
responders None None O
to None None O
chemotherapy None None O
and None None O
4 None None O
peaks None None O
- None None O
m/z None None O
5900 None None O
, None None O
12544 None None O
, None None O
49124 None None O
and None None O
11724 None None O
- None None O
significantly None None O
up-regulated None None O
in None None O
longer None None O
vs None None O
shorter None None O
responders None None O
to None None O
vemurafenib None None O
. None None O

Three None None O
experiments None None O
are None None O
reported None None O
, None None O
investigating None None O
the None None O
effects None None O
of None None O
using None None O
1 None None O
or None None O
2 None None O
hands None None O
when None None O
making None None O
convergent None None O
low None None O
index None None O
of None None O
difficulty None None O
( None None O
ID None None O
) None None O
and None None O
visually None None O
controlled None None O
movements None None I-FUNC
( None None O
2 None None O
hands None None O
meeting None None O
together None None O
) None None O
. None None O

Movements None None I-FUNC
made None None O
with None None O
low None None O
ID None None O
showed None None O
a None None O
small None None O
effect None None O
of None None O
1- None None O
or None None O
2-handed None None O
movements None None I-FUNC
, None None O
with None None O
the None None O
effective None None O
amplitude None None O
of None None O
the None None O
movement None None I-FUNC
being None None O
reduced None None O
by None None O
about None None O
20 None None O
% None None O
when None None O
2 None None O
hands None None O
were None None O
used None None O
. None None O

This None None O
Drosophila None None O
ADD None None O
domain None None O
is None None O
highly None None O
similar None None O
in None None O
structure None None O
and None None O
in None None O
the None None O
amino None None I-TRANS
acids None None I-TRANS
which None None O
mediate None None O
the None None O
histone None None O
tail None None O
contacts None None O
to None None O
the None None O
ADD None None O
domain None None O
of None None O
hATRX None None O
as None None O
shown None None O
by None None O
3D None None O
modeling None None O
. None None O

Correlations None None O
between None None O
serum None None O
markers None None O
[ None None O
IgG4 None None O
, None None O
soluble None None O
IL-2 None None O
receptor None None I-PROTEIN
( None None O
sIL-2R None None O
) None None O
, None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
, None None O
and None None O
C-reactive None None O
protein None None O
( None None O
CRP None None O
) None None O
] None None O
and None None O
TLG None None O
concomitant None None O
with None None O
FDG-PET/CT None None O
scans None None O
were None None O
investigated None None O
. None None O

Overall None None O
, None None O
we None None O
discriminated None None O
five None None O
out None None O
of None None O
six None None O
prion None None O
strains None None O
, None None O
while None None O
two None None O
different None None O
scrapie None None I-DISEASE
strains None None O
showed None None O
identical None None O
PrPSc None None O
types None None O
. None None O

Human None None O
prion None None I-DISEASE
diseases None None I-DISEASE
, None None O
including None None O
sporadic None None O
, None None O
familial None None O
, None None O
and None None O
acquired None None O
forms None None O
such None None O
as None None O
Creutzfeldt-Jakob None None O
disease None None O
( None None O
CJD None None O
) None None O
, None None O
are None None O
caused None None O
by None None O
prions None None O
in None None O
which None None O
an None None O
abnormal None None O
prion None None O
protein None None O
( None None O
PrPSc None None O
) None None O
derived None None O
from None None O
its None None O
normal None None O
cellular None None O
isoform None None O
( None None O
PrPC None None O
) None None O
is None None O
the None None O
only None None O
known None None O
component None None O
. None None O

Like None None O
other None None O
forms None None O
of None None O
human None None O
prion None None I-DISEASE
disease None None I-DISEASE
, None None O
the None None O
pathogenesis None None O
of None None O
VPSPr None None O
also None None O
currently None None O
remains None None O
unclear None None O
. None None O

Various None None O
studies None None O
on None None O
curcumin None None O
demonstrate None None O
promise None None O
for None None O
the None None O
prevention None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
inhibition None None O
of None None O
PrPres None None O
accumulation None None O
. None None O

We None None O
collected None None O
blood None None O
samples None None O
for None None O
measurement None None O
of None None O
plasma None None O
GABA None None I-TRANS
concentrations None None O
before None None O
the None None O
operation None None O
and None None O
on None None O
POD None None O
1 None None O
and None None O
2 None None O
. None None O

The None None O
mean None None O
plasma None None O
GABA None None I-TRANS
concentration None None O
on None None O
POD None None O
2 None None O
was None None O
significantly None None O
lower None None O
in None None O
patients None None O
with None None O
delirium None None O
than None None O
in None None O
those None None O
without None None O
delirium None None O
. None None O

Plasma None None O
GABA None None I-TRANS
level None None O
on None None O
POD None None O
2 None None O
has None None O
a None None O
significant None None O
independent None None O
association None None O
with None None O
postoperative None None O
delirium None None O
. None None O

Changes None None O
in None None O
nanoparticle None None O
size None None O
and None None O
shape None None O
due None None O
to None None O
particle-particle None None O
interactions None None O
( None None O
i.e. None None O
, None None O
aggregation None None O
or None None O
agglomeration None None O
) None None O
may None None O
significantly None None O
alter None None O
particle None None O
mobility None None O
and None None O
retention None None I-FUNC
in None None O
porous None None O
media None None O
. None None O

The None None O
model None None O
was None None O
verified None None O
through None None O
comparison None None O
of None None O
model None None O
simulations None None O
to None None O
published None None O
results None None O
of None None O
an None None O
experimental None None O
and None None O
Eulerian None None O
modeling None None O
study None None O
( None None O
Raychoudhury None None O
et None None O
al. None None O
, None None O
2012 None None O
) None None O
of None None O
carboxymethyl None None O
cellulose None None O
( None None O
CMC None None O
) None None O
-modified None None O
nano-sized None None O
zero-valent None None O
iron None None O
particle None None O
( None None O
nZVI None None O
) None None O
transport None None O
and None None O
retention None None I-FUNC
in None None O
water-saturated None None O
sand None None O
columns None None O
. None None O

Using None None O
ensemble None None O
classification None None O
learning None None I-FUNC
method-Rotation None None O
Forest None None O
and None None O
ReliefF None None O
feature-selection None None O
technique None None O
for None None O
selecting None None O
the None None O
optimal None None O
subset None None O
of None None O
salient None None O
features None None O
, None None O
the None None O
best None None O
model None None O
with None None O
selected None None O
features None None O
can None None O
achieve None None O
87.1 None None O
% None None O
sensitivity None None O
, None None O
83.6 None None O
% None None O
specificity None None O
, None None O
and None None O
85.3 None None O
% None None O
accuracy None None O
, None None O
with None None O
0.71 None None O
Matthews None None O
correlation None None O
coefficient None None O
( None None O
mcc None None O
) None None O
on None None O
a None None O
tenfold None None O
stratified None None O
cross-validation None None O
test None None O
. None None O

In None None O
this None None O
age None None O
of None None O
rapidly None None O
developing None None O
online None None O
learning None None I-FUNC
, None None O
the None None O
advent None None O
of None None O
a None None O
series None None O
of None None O
talks None None O
and None None O
supplementary None None O
material None None O
devoted None None O
to None None O
genetics None None O
in None None O
agriculture None None O
from None None O
Henry None None O
Stewart None None O
Talks None None O
( None None O
http None None O
: None None O
//hstalks.com/main/browse_talks.php None None O
? None None O
r=776 None None O
& None None O
amp None None O
; None None O
c=252 None None O
) None None O
is None None O
welcome None None O
indeed None None O
. None None O

Coronary None None O
stenting None None O
is None None O
one None None O
of None None O
the None None O
most None None O
commonly None None O
used None None O
approaches None None O
to None None O
open None None O
coronary None None O
arteries None None O
blocked None None O
due None None O
to None None O
atherosclerosis None None I-DISEASE
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
microscale None None O
processes None None O
during None None O
the None None O
initiation None None O
of None None O
stent None None O
thrombosis None None I-DISEASE
. None None O

Today None None O
it None None O
is None None O
`` None None O
en None None O
vogue None None O
'' None None O
to None None O
oppose None None O
the None None O
use None None O
of None None O
GMO None None O
plants None None O
not None None O
only None None O
in None None O
the None None O
environmental- None None O
and None None O
consumer-protection None None O
movement None None I-FUNC
, None None O
the None None O
Green None None O
and None None O
the None None O
Social None None O
Democratic None None O
Party None None O
in None None O
Germany None None O
, None None O
but None None O
also None None O
in None None O
the None None O
conservative None None O
parties None None O
of None None O
the None None O
political None None O
spectrum None None O
. None None O

In None None O
our None None O
study None None O
on None None O
the None None O
role None None O
of None None O
hormones None None I-PROTEIN
in None None O
gall None None O
induction None None O
by None None O
the None None O
aphid None None O
Tetraneura None None O
nigriabdominalis None None O
, None None O
it None None O
was None None O
found None None O
that None None O
feedback None None O
regulation None None O
related None None O
to None None O
auxin None None O
and None None O
cytokinin None None O
activity None None O
is None None O
absent None None O
in None None O
gall None None O
tissues None None O
, None None O
even None None O
though None None O
the None None O
aphids None None O
contain None None O
higher None None O
concentrations None None O
of None None O
those None None O
phytohormones None None O
than None None O
do None None O
plant None None O
tissues None None O
. None None O

Those None None O
with None None O
elevated None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
were None None O
more None None O
likely None None O
to None None O
frequently None None O
engage None None O
in None None O
cigarette- None None O
and None None O
prescription/other None None O
drug-use None None O
coping None None O
. None None O

The None None O
current None None O
study None None O
aims None None O
to None None O
examine None None O
discrepancies None None O
in None None O
parents None None O
' None None O
and None None O
college None None O
students None None O
' None None O
perceptions None None I-FUNC
of None None O
alcohol None None O
risk None None O
and None None O
the None None O
role None None O
of None None O
perceived None None O
risk None None O
in None None O
predicting None None O
parents None None O
' None None O
intentions None None O
to None None O
discuss None None O
alcohol None None O
with None None O
their None None O
child None None O
. None None O

DEAD-box None None O
RNA None None O
helicases None None I-PROTEIN
( None None O
DDXs None None O
) None None O
have None None O
been None None O
reported None None O
to None None O
participate None None O
in None None O
viral None None O
replication None None O
and None None O
host None None O
innate None None O
immune None None O
response None None O
. None None O

Our None None O
data None None O
imply None None O
that None None O
DDX3X None None O
, None None O
a None None O
member None None O
of None None O
DEAD-box None None O
RNA None None O
helicase None None I-PROTEIN
, None None O
is None None O
necessary None None O
for None None O
IFN None None O
production None None O
and None None O
could None None O
inhibit None None O
DENV None None O
replication None None O
. None None O

The None None O
unique None None O
architecture None None O
of None None O
the None None O
active None None O
site None None O
of None None O
Thermobifida None None O
fusca None None O
truncated None None O
hemoglobin None None O
( None None O
Tf-trHb None None O
) None None O
and None None O
other None None O
globins None None O
belonging None None O
to None None O
the None None O
same None None O
family None None O
has None None O
stimulated None None O
extensive None None O
studies None None O
aimed None None O
at None None O
understanding None None O
the None None O
interplay None None O
between None None O
iron-bound None None O
ligands None None O
and None None O
distal None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

Previous None None O
research None None O
has None None O
studied None None O
the None None O
impact None None O
of None None O
Level None None O
II None None O
concealed None None O
soft None None O
body None None O
armor None None O
( None None O
SBA None None O
) None None O
on None None O
the None None O
augmentation None None O
of None None O
heat None None O
storage None None I-FUNC
in None None O
a None None O
hot None None O
environment None None O
simulating None None O
a None None O
typical None None O
summer None None O
day None None O
in None None O
the None None O
southeastern None None O
United None None O
States None None O
( None None O
wet None None O
bulb None None O
globe None None O
temperature None None O
[ None None O
WBGT None None O
] None None O
= None None O
30°C None None O
) None None O
and None None O
noted None None O
a None None O
significant None None O
difference None None O
between None None O
macro- None None O
and None None O
micro-WBGTs None None O
. None None O

The None None O
first None None O
52 None None O
amino None None I-TRANS
acids None None I-TRANS
of None None O
N-terminus None None O
are None None O
unessential None None O
for None None O
toxicity None None O
. None None O

Several None None O
of None None O
these None None O
factors None None O
are None None O
known None None O
, None None O
such None None O
as None None O
family None None O
history None None O
of None None O
RA None None O
, None None O
high None None O
birth None None O
weight None None O
, None None O
smoking None None O
, None None O
silica None None O
exposure None None O
, None None O
alcohol None None O
nonuse None None O
, None None O
obesity None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
rheumatoid None None O
factor None None O
, None None O
anti-citrullinated None None O
protein None None O
antibody None None O
, None None O
and None None O
genetic None None O
variants None None O
such None None O
as None None O
the None None O
shared None None O
epitope None None O
and None None O
protein None None O
tyrosine None None I-TRANS
phosphatase None None I-PROTEIN
nonreceptor None None I-PROTEIN
type None None O
22 None None O
. None None O

By None None O
contrast None None O
, None None O
when None None O
presentation None None O
is None None O
blocked None None O
, None None O
pointing None None O
has None None O
inhibitory None None O
effects None None O
on None None O
memory None None I-FUNC
( None None O
Dodd None None O
& None None O
amp None None O
; None None O
Shumborski None None O
, None None O
2009 None None O
; None None O
Rossi-Arnaud None None O
et None None O
al. None None O
, None None O
2012 None None O
) None None O
. None None O

We None None O
proposed None None O
that None None O
the None None O
negative None None O
effects None None O
might None None O
be None None O
accounted None None O
for None None O
by None None O
the None None O
simultaneous None None O
recruitment None None O
of None None O
attention None None I-FUNC
resources None None O
in None None O
the None None O
planning None None O
and None None O
execution None None O
of None None O
pointing None None O
movements None None I-FUNC
. None None O

The None None O
long-term None None O
safety None None O
, None None O
tolerability None None O
, None None O
and None None O
efficacy None None O
of None None O
high-dose None None O
13.3 None None O
mg/24 None None O
h None None O
rivastigmine None None O
patch None None O
in None None O
severe None None O
Alzheimer None None I-DISEASE
disease None None O
was None None O
evaluated None None O
in None None O
a None None O
24-week None None O
, None None O
open-label None None O
extension None None O
to None None O
the None None O
double-blind None None O
ACTION None None O
study None None O
. None None O

Magnetic None None O
resonance None None O
imaging None None O
, None None O
F-18 None None O
fluorodeoxyglucose None None O
positron None None O
emission None None O
tomography None None O
markers None None O
, None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Assessment None None O
Scale-cognitive None None O
subscale None None O
were None None O
compared None None O
in None None O
terms None None O
of None None O
effect None None O
size None None O
and None None O
statistical None None O
power None None O
over None None O
different None None O
follow-up None None O
periods None None O
in None None O
2 None None O
MCI None None O
groups None None O
, None None O
selected None None O
from None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
Disease None None I-DISEASE
Neuroimaging None None O
Initiative None None O
data None None O
set None None O
based None None O
on None None O
cerebrospinal None None O
fluid None None O
( None None O
abnormal None None O
cerebrospinal None None O
fluid None None O
Aβ1-42 None None O
concentration-ABETA+ None None O
) None None O
or None None O
magnetic None None O
resonance None None O
imaging None None O
evidence None None O
of None None O
Alzheimer None None I-DISEASE
disease None None O
( None None O
positivity None None O
to None None O
hippocampal None None O
atrophy-HIPPO+ None None O
) None None O
. None None O

To None None O
investigate None None O
factors None None O
shaping None None O
the None None O
delivery None None O
of None None O
acute None None O
inpatient None None O
stroke None None I-DISEASE
therapy None None O
( None None O
i.e None None O
. None None O

We None None O
present None None O
the None None O
case None None O
of None None O
a None None O
14-year-old None None O
female None None O
who None None O
experienced None None O
several None None O
episodes None None O
of None None O
reversible None None O
altered None None O
mental None None O
status None None O
triggered None None O
by None None O
hypoglycemia None None I-DISEASE
. None None O

Insulinoma None None O
, None None O
a None None O
rare None None O
, None None O
differentiated None None O
, None None O
and None None O
functioning None None O
neuroendocrine None None O
tumor None None O
of None None O
the None None O
pancreas None None O
overproduces None None O
insulin None None I-PROTEIN
, None None O
thus None None O
leading None None O
to None None O
hypoglycemic None None O
episodes None None O
. None None O

In None None O
epithelial None None O
collective None None O
migration None None O
, None None O
leader None None O
and None None O
follower None None O
cells None None O
migrate None None O
while None None O
maintaining None None O
cell-cell None None O
adhesion None None I-PROTEIN
and None None O
tissue None None O
polarity None None O
. None None O

Recently None None O
, None None O
perovskite-based None None O
systems None None O
have None None O
been None None O
attracting None None O
a None None O
large None None O
amount None None O
of None None O
research None None O
attention None None I-FUNC
, None None O
where None None O
the None None O
highest None None O
performing None None O
devices None None O
employ None None O
a None None O
small None None O
molecule None None O
( None None O
2,2',7,7'-tetrakis None None O
( None None O
N None None O
, None None O
N-di-p-methoxyphenyl-amine None None O
) None None O
-9,9'-spirobifluorene None None O
) None None O
( None None O
Spiro-OMeTAD None None O
) None None O
hole None None O
transporter None None O
. None None O

To None None O
examine None None O
the None None O
importance None None O
of None None O
EGFR None None O
signalling None None O
to None None O
gastric None None O
pathology None None O
, None None O
this None None O
study None None O
investigated None None O
whether None None O
treatment None None O
of None None O
Mongolian None None O
gerbils None None O
with None None O
a None None O
selective None None O
EGFR None None O
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
, None None O
EKB-569 None None O
, None None O
altered None None O
gastric None None O
pathology None None O
in None None O
chronic None None O
H. None None O
pylori None None O
infection None None O
. None None O

Mammals None None O
do None None O
not None None O
have None None O
the None None O
enzymes None None I-PROTEIN
required None None O
to None None O
metabolize None None O
oxalate None None O
and None None O
rely None None O
on None None O
their None None O
gut None None O
microbiota None None O
for None None O
this None None O
function None None O
. None None O

Amino None None I-TRANS
acids None None I-TRANS
extracted None None O
from None None O
BACTRAP None None O
( None None O
® None None O
) None None O
-grown None None O
cells None None O
showed None None O
significant None None O
( None None O
13 None None O
) None None O
C-enrichments None None O
with None None O
( None None O
13 None None O
) None None O
C-fractions None None O
of None None O
up None None O
to None None O
30.4 None None O
% None None O
for None None O
naphthalene None None O
and None None O
3.8 None None O
% None None O
for None None O
fluorene None None O
, None None O
thus None None O
providing None None O
evidence None None O
for None None O
the None None O
in None None O
situ None None O
biodegradation None None O
and None None O
assimilation None None O
of None None O
those None None O
PAHs None None O
at None None O
the None None O
field None None O
site None None O
. None None O

While None None O
both None None O
larva None None O
and None None O
adult None None O
Drosophila None None O
have None None O
central None None O
nervous None None O
systems None None O
, None None O
not None None O
much None None O
is None None O
known None None O
about None None O
how None None O
neurotransmitter None None I-TRANS
tissue None None O
content None None O
changes None None O
through None None O
development None None O
. None None O

Tyramine None None I-TRANS
and None None O
octopamine None None I-TRANS
content None None O
varied None None O
between None None O
life None None O
stages None None O
, None None O
with None None O
almost None None O
no None None O
octopamine None None I-TRANS
being None None O
present None None O
in None None O
the None None O
pupa None None O
, None None O
while None None O
tyramine None None I-TRANS
levels None None O
in None None O
the None None O
pupa None None O
were None None O
very None None O
high None None O
. None None O

After None None O
severe None None O
brain None None O
injury None None O
, None None O
this None None O
treatment None None O
might None None O
trigger None None O
recovery None None O
from None None O
altered None None O
states None None O
of None None O
consciousness None None I-FUNC
, None None O
improve None None O
cognition None None O
and None None O
facilitate None None O
rehabilitation None None O
. None None O

A None None O
new None None O
strategy None None O
for None None O
the None None O
manufacture None None O
of None None O
a None None O
turn-on None None O
fluorescent None None O
molecularly None None O
imprinted None None O
polymer None None O
( None None O
CdTe/SiO2/MIP None None O
) None None O
receptor None None I-PROTEIN
for None None O
detecting None None O
tyrosine None None I-TRANS
phosphopeptide None None O
( None None O
pTyr None None O
peptide None None O
) None None O
was None None O
proposed None None O
. None None O

Bovine None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
is None None O
chosen None None O
as None None O
the None None O
nucleation None None O
templates None None O
to None None O
synthesize None None O
Pt-based None None O
peroxidase None None O
nanomimetics None None O
with None None O
the None None O
average None None O
diameter None None O
of None None O
2.0nm None None O
. None None O

The None None O
resulted None None O
complex None None O
CP None None O
@ None None O
Cu None None O
can None None O
serve None None O
as None None O
a None None O
turn-on None None O
fluorescent None None O
probe None None O
for None None O
the None None O
detection None None O
of None None O
histidine None None I-TRANS
and None None O
histidine None None I-TRANS
rich None None O
proteins None None O
in None None O
broad None None O
pH None None O
application None None O
range None None O
. None None O

Moreover None None O
, None None O
CP None None O
@ None None O
Cu None None O
has None None O
potential None None O
for None None O
imaging None None O
histidine None None I-TRANS
in None None O
vitro None None O
experiments None None O
and None None O
has None None O
promise None None O
in None None O
real None None O
sample None None O
applications None None O
with None None O
great None None O
validity None None O
. None None O

Herein None None O
, None None O
an None None O
electrochemical None None O
biosensor None None O
was None None O
fabricated None None O
for None None O
DNA None None O
demethylase None None O
detection None None O
based None None O
on None None O
DNA None None O
demethylation None None O
triggered None None O
endonuclease None None I-PROTEIN
BstUI None None O
and None None O
Exonuclease None None I-PROTEIN
III None None O
digestion None None O
. None None O

Then None None O
, None None O
the None None O
remained None None O
fragment None None O
of None None O
DNA-DNA None None O
duplex None None O
was None None O
further None None O
cleaved None None O
by None None O
exonuclease None None I-PROTEIN
III None None O
and None None O
led None None O
to None None O
increased None None O
electrochemical None None O
signal None None O
. None None O

With None None O
the None None O
presence None None O
of None None O
three None None O
ingeniously None None O
designed None None O
hairpin None None O
structures None None O
and None None O
Exonuclease None None I-PROTEIN
III None None O
( None None O
Exo None None O
III None None O
) None None O
, None None O
the None None O
target None None O
DNA None None O
can None None O
trigger None None O
two None None O
independent None None O
cycles None None O
of None None O
reactions None None O
: None None O
hairpin None None O
assembly None None O
reaction None None O
and None None O
Exo None None O
III None None O
cleavage None None O
reaction None None O
, None None O
which None None O
are None None O
designed None None O
to None None O
initiate None None O
target None None O
DNA None None O
recycling None None O
amplification None None O
and None None O
reporter None None O
DNA None None O
amplification None None O
, None None O
respectively None None O
. None None O

In None None O
this None None O
feature None None O
article None None O
, None None O
we None None O
focused None None O
attention None None I-FUNC
on None None O
the None None O
strategies None None O
of None None O
SNP None None O
genotyping None None O
based None None O
on None None O
biosensors None None O
, None None O
including None None O
nucleic None None O
acid None None O
analogs None None O
, None None O
surface None None O
ligation None None O
reaction None None O
, None None O
single None None O
base None None O
extension None None O
, None None O
mismatch None None O
binding None None O
protein None None O
, None None O
molecular None None O
beacon None None O
, None None O
rolling None None O
circle None None O
amplification None None O
, None None O
and None None O
strand-displacement None None O
amplification None None O
. None None O

The None None O
phosphorylation-actuated None None O
λ None None O
exonuclease None None I-PROTEIN
reaction None None O
will None None O
cleave None None O
the None None O
stem None None O
of None None O
the None None O
hairpin None None O
to None None O
yield None None O
a None None O
single-stranded None None O
DNA None None O
, None None O
which None None O
is None None O
unable None None O
to None None O
combine None None O
with None None O
SGI None None O
and None None O
as None None O
a None None O
result None None O
, None None O
the None None O
FRET None None O
signal None None O
would None None O
decrease None None O
gradually None None O
in None None O
correlation None None O
to None None O
the None None O
T4 None None O
PNK None None O
activity None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
target None None O
protein None None O
, None None O
taking None None O
folate None None O
receptor None None I-PROTEIN
( None None O
FR None None O
) None None O
as None None O
the None None O
model None None O
protein None None O
in None None O
this None None O
study None None O
, None None O
its None None O
binding None None O
with None None O
folate None None O
can None None O
protect None None O
the None None O
probe None None O
DNA None None O
from None None O
exonuclease None None I-PROTEIN
I-catalyzed None None O
degradation None None O
, None None O
thus None None O
the None None O
probe None None O
DNA None None O
can None None O
be None None O
immobilized None None O
onto None None O
the None None O
electrode None None O
surface None None O
through None None O
the None None O
hybridization None None O
with None None O
capture None None O
DNA None None O
, None None O
triggering None None O
HCR None None O
on None None O
the None None O
electrode None None O
surface None None O
. None None O

We None None O
chose None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
marker None None O
β-amyloid None None O
40 None None O
( None None O
Aβ40 None None O
) None None O
as None None O
model None None O
peptide None None O
, None None O
and None None O
detected None None O
the None None O
interaction None None O
between None None O
it None None O
and None None O
its None None O
inhibitors None None O
KLVFFK6 None None O
by None None O
SPRi None None O
. None None O

Interaction None None O
between None None O
other None None O
lower None None O
molecular None None O
weight None None O
peptides None None I-TRANS
was None None O
detected None None O
via None None O
PRX None None O
surface None None O
, None None O
and None None O
the None None O
relatively None None O
weak None None O
interactions None None O
( None None O
KD=1.73×10 None None O
( None None O
-4 None None O
) None None O
M None None O
) None None O
between None None O
LPFFD None None O
( None None O
Mw=0.6kDa None None O
) None None O
and None None O
amylin20-29 None None O
( None None O
Mw=1.0kDa None None O
) None None O
are None None O
successfully None None O
detected None None O
. None None O

Experiment None None O
3 None None O
employed None None O
a None None O
cueing None None O
paradigm None None O
that None None O
purposefully None None O
directed None None O
attention None None I-FUNC
away None None O
from None None O
centre None None O
to None None O
determine None None O
whether None None O
pseudoneglect None None O
was None None O
influenced None None O
by None None O
overt None None O
attentional None None O
orienting None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
covert None None O
attention None None I-FUNC
toward None None O
upper None None O
space None None O
distractors None None O
recruits None None O
additional None None O
right None None O
hemisphere None None O
activation None None O
, None None O
leading None None O
existing None None O
leftward None None O
biases None None O
to None None O
be None None O
accentuated None None O
. None None O

In None None O
particular None None O
, None None O
executive None None O
dysfunction None None O
is None None O
recognized None None O
as None None O
a None None O
core None None O
deficit None None O
of None None O
NF1 None None O
, None None O
including None None O
impairments None None O
in None None O
executive None None O
attention None None I-FUNC
and None None O
inhibitory None None O
control None None O
. None None O

Finally None None O
, None None O
we None None O
run None None O
correlation None None O
analyses None None O
to None None O
identify None None O
the None None O
relationship None None O
between None None O
inhibitory None None O
control None None O
, None None O
levels None None O
of None None O
neurotransmitters None None I-TRANS
, None None O
and None None O
EEG None None O
markers None None O
of None None O
neural None None O
function None None O
. None None O

MRS None None O
data None None O
revealed None None O
a None None O
reduction None None O
in None None O
medial None None O
frontal None None O
GABA+/tCr None None O
( None None O
total None None O
Creatine None None O
) None None O
levels None None O
in None None O
the None None O
NF1 None None O
group None None O
, None None O
in None None O
parallel None None O
with None None O
the None None O
already None None O
reported None None O
reduced None None O
occipital None None O
GABA None None I-TRANS
levels None None O
. None None O

Notably None None O
, None None O
medial None None O
frontal None None O
but None None O
not None None O
occipital None None O
GABA None None I-TRANS
levels None None O
correlated None None O
with None None O
general None None O
intellectual None None O
abilities None None O
( None None O
IQ None None O
) None None O
in None None O
NF1 None None O
, None None O
and None None O
inhibitory None None O
control None None O
in None None O
both None None O
groups None None O
. None None O

Glucose-stimulated None None O
insulin None None I-PROTEIN
secretion None None O
( None None O
GSIS None None O
) None None O
is None None O
a None None O
highly None None O
regulated None None O
process None None O
involving None None O
complex None None O
interaction None None O
of None None O
multiple None None O
factors None None O
. None None O

The None None O
role None None O
of None None O
KCNQ1 None None O
channel None None O
in None None O
insulin None None I-PROTEIN
secretion None None O
has None None O
been None None O
explored None None O
by None None O
previous None None O
work None None O
in None None O
clonal None None O
pancreatic None None O
β-cells None None O
but None None O
has None None O
yet None None O
to None None O
be None None O
investigated None None O
in None None O
the None None O
context None None O
of None None O
primary None None O
islets None None O
as None None O
well None None O
as None None O
intact None None O
animals None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
we None None O
examined None None O
KCNQ1 None None O
expression None None O
in None None O
pancreas None None O
and None None O
intestine None None O
from None None O
normal None None O
mice None None O
and None None O
then None None O
investigated None None O
the None None O
effects None None O
of None None O
chromanol None None O
293B None None O
, None None O
a None None O
KCNQ1 None None O
channel None None O
inhibitor None None O
, None None O
on None None O
insulin None None I-PROTEIN
secretion None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

These None None O
data None None O
not None None O
only None None O
provided None None O
new None None O
evidence None None O
for None None O
the None None O
participation None None O
of None None O
KCNQ1 None None O
in None None O
GSIS None None O
at None None O
the None None O
level None None O
of None None O
pancreatic None None O
islet None None O
and None None O
intact None None O
animal None None O
but None None O
also None None O
indicated None None O
the None None O
potential None None O
linking None None O
role None None O
of None None O
GLP-1 None None O
between None None O
KCNQ1 None None O
and None None O
insulin None None I-PROTEIN
secretion None None O
. None None O

Purity None None O
and None None O
viability None None O
percentages None None O
were None None O
not None None O
significantly None None O
different None None O
among None None O
any None None O
of None None O
the None None O
analyzed None None O
digestion None None O
enzymes None None I-PROTEIN
. None None O

In None None O
conclusion None None O
, None None O
our None None O
MTC None None O
meta-analysis None None O
suggests None None O
that None None O
the None None O
digestion None None O
enzymes None None I-PROTEIN
currently None None O
being None None O
used None None O
for None None O
islet None None O
isolation None None O
works None None O
with None None O
similar None None O
efficiency None None O
regarding None None O
islet None None O
yield None None O
, None None O
purity None None O
and None None O
viability None None O
; None None O
however None None O
, None None O
Vitacyte None None O
and None None O
Serva None None O
NB1 None None O
enzymes None None I-PROTEIN
seem None None O
to None None O
be None None O
associated None None O
with None None O
an None None O
improved None None O
SI None None O
as None None O
compared None None O
with None None O
Liberase None None O
MTF None None O
. None None O

Type None None O
2 None None O
diabetes None None O
is None None O
associated None None O
with None None O
dementia None None I-DISEASE
risk None None O
, None None O
but None None O
evidence None None O
is None None O
limited None None O
for None None O
possible None None O
associations None None O
of None None O
diabetes None None O
and None None O
prediabetes None None O
with None None O
cognitive None None O
decline None None O
. None None O

Uranium None None O
commonly None None O
exists None None O
in None None O
aqueous None None O
solutions None None O
in None None O
the None None O
form None None O
of None None O
its None None O
oxo None None O
ion None None O
, None None O
uranyl None None O
( None None O
U None None O
( None None O
VI None None I-REGION
) None None O
O2 None None O
( None None O
2+ None None O
) None None O
) None None O
. None None O

Global None None O
gene None None O
expression None None O
analysis None None O
of None None O
MYC None None O
knockdown None None O
in None None O
ASC None None O
enriched None None O
for None None O
functional None None O
pathways None None O
related None None O
to None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
, None None O
cytoskeletal None None O
remodeling None None O
, None None O
and None None O
transcriptional None None O
components None None O
of None None O
adipogenesis None None O
. None None O

FVB None None O
mice None None O
treated None None O
with None None O
post-therapy None None O
CCI-779 None None O
have None None O
significant None None O
improvements None None O
in None None O
salivary None None O
gland None None O
physiology None None O
as None None O
determined None None O
by None None O
stimulated None None O
salivary None None O
flow None None O
rates None None O
, None None O
proliferation None None O
indices None None O
and None None O
amylase None None I-PROTEIN
production None None O
and None None O
secretion None None O
. None None O

Using None None O
4-methylumbelliferyl-β-D-N None None O
, None None O
N None None O
' None None O
, None None O
N″-triacetylchitotrioside None None O
( None None O
4-MU-GlcNAc3 None None O
) None None O
as None None O
a None None O
substrate None None O
, None None O
an None None O
acidic None None O
chitinase None None I-PROTEIN
was None None O
purified None None O
from None None O
seeds None None O
of None None O
black None None O
soybean None None O
( None None O
Glycine None None I-TRANS
max None None O
Tainan None None O
no None None O
. None None O

The None None O
purified None None O
chitinase None None I-PROTEIN
was None None O
a None None O
monomeric None None O
enzyme None None O
with None None O
molecular None None O
mass None None O
of None None O
20.1 None None O
kDa None None O
and None None O
isoelectric None None O
point None None O
of None None O
4.34 None None O
. None None O

Ca2+ None None O
waves None None O
in None None O
polarized None None O
epithelia None None O
are None None O
initiated None None O
by None None O
inositol None None O
1,4,5-trisphosphate None None O
receptors None None I-PROTEIN
( None None O
InsP3Rs None None O
) None None O
, None None O
and None None O
these None None O
waves None None O
begin None None O
in None None O
the None None O
apical None None O
region None None O
because None None O
InsP3Rs None None O
are None None O
targeted None None O
to None None O
the None None O
ER None None O
adjacent None None O
to None None O
the None None O
apical None None O
membrane None None O
. None None O

In None None O
an None None O
inflammatory None None O
setting None None O
, None None O
these None None O
cells None None O
produce None None O
high None None O
amounts None None O
of None None O
inflammatory None None O
cytokines None None O
, None None O
chemokines None None O
and None None O
redox None None O
mediators None None O
such None None O
as None None O
reactive None None O
oxygen None None O
species None None O
or None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
. None None O

Furthermore None None O
, None None O
dimerization None None O
of None None O
PKA None None O
RI None None O
was None None O
paralleled None None O
by None None O
enhanced None None O
activity None None O
of None None O
PKA None None O
as None None O
shown None None O
by None None O
the None None O
phosphorylation None None O
of None None O
vasodilator-stimulated None None O
phosphoprotein None None O
( None None O
VASP None None O
) None None O
at None None O
serine None None I-TRANS
157 None None O
that None None O
was None None O
independent None None O
of None None O
the None None O
formation None None O
of None None O
cyclic None None O
AMP None None O
. None None O

Consequently None None O
, None None O
the None None O
treatment None None O
of None None O
inflammatory None None O
diseases None None O
with None None O
anti-oxidants None None O
or None None O
NOS None None I-TRANS
inhibitors None None O
may None None O
alter None None O
PKA None None O
activity None None O
. None None O

Glucagon-like None None O
peptide None None O
1 None None O
( None None O
GLP-1 None None O
) None None O
is None None O
secreted None None O
from None None O
enteroendocrine None None O
L-cells None None O
in None None O
response None None O
to None None O
oral None None O
nutrient None None O
intake None None O
and None None O
elicits None None O
glucose-stimulated None None O
insulin None None I-PROTEIN
secretion None None O
while None None O
suppressing None None O
glucagon None None I-TRANS
secretion None None O
. None None O

GLP-1 None None O
receptors None None I-PROTEIN
agonists None None O
have None None O
been None None O
a None None O
substantial None None O
change None None O
in None None O
treatment None None O
of None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
, None None O
and None None O
its None None O
weekly None None O
administration None None O
has None None O
broken None None O
pre-established None None O
schemes None None O
. None None O

It None None O
can None None O
be None None O
concluded None None O
that None None O
exenatide None None O
BID None None O
shows None None O
a None None O
hypoglycemic None None O
effect None None O
similar None None O
to None None O
other None None O
treatments None None O
for None None O
type None None O
2 None None O
DM None None O
but None None O
adding None None O
significant None None O
weight None None O
loss None None O
with None None O
low None None O
incidence None None O
of None None O
hypoglycemia None None I-DISEASE
. None None O

The None None O
wide None None O
ubiquity None None O
of None None O
GLP-1 None None O
receptors None None I-PROTEIN
in None None O
the None None O
body None None O
has None None O
stimulated None None O
the None None O
search None None O
for None None O
different None None O
extrapancreatic None None O
actions None None O
of None None O
GLP-1 None None O
and None None O
its None None O
receptor None None I-PROTEIN
agonists None None O
. None None O

Also None None O
, None None O
native None None O
and None None O
GLP-1 None None O
receptor None None I-PROTEIN
agonists None None O
have None None O
demonstrated None None O
significant None None O
beneficial None None O
effects None None O
on None None O
liver None None O
steatosis None None O
and None None O
fibrosis None None O
and None None O
on None None O
neuronal None None O
protection None None O
in None None O
experimental None None O
models None None O
of None None O
Alzheimer None None I-DISEASE
, None None O
and None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
as None None O
well None None O
as None None O
on None None O
cerebral None None O
ischaemia None None O
. None None O

And None None O
, None None O
if None None O
you None None O
want None None O
to None None O
know None None O
if None None O
you None None O
got None None O
a None None O
good None None O
night None None O
's None None O
sleep None None O
last None None O
night None None O
, None None O
well None None O
, None None O
now None None O
there None None O
's None None O
also None None O
an None None O
app None None I-TRANS
for None None O
that None None O
. None None O

It None None O
is None None O
estimated None None O
that None None O
a None None O
large None None O
population None None O
of None None O
people None None O
who None None O
suffer None None O
from None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
is None None O
unaware None None O
of None None O
the None None O
condition None None O
and None None O
remains None None O
undiagnosed None None O
[ None None O
1 None None O
] None None O
, None None O
creating None None O
a None None O
need None None O
( None None O
and None None O
desire None None O
) None None O
to None None O
self-monitor None None O
. None None O

They None None O
were None None O
the None None O
first None None O
to None None O
show None None O
the None None O
existence None None O
of None None O
rapid None None O
eye None None O
movement None None I-FUNC
( None None O
REM None None O
) None None O
sleep None None O
? None None O
commonly None None O
associated None None O
with None None O
? None None O
dreaming None None O
? None None O
and None None O
began None None O
the None None O
process None None O
of None None O
opening None None O
our None None O
eyes None None O
to None None O
the None None O
complex None None O
physiological None None O
processes None None O
that None None O
occur None None O
during None None O
sleep None None O
. None None O

One None None O
of None None O
the None None O
most None None O
important None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
is None None O
obstructive None None O
sleep None None O
apnea None None O
( None None O
OSA None None O
) None None O
. None None O

If None None O
left None None O
untreated None None O
, None None O
alterations None None O
in None None O
the None None O
function None None O
of None None O
the None None O
autonomic None None O
nervous None None O
system None None O
and None None O
a None None O
chronic None None O
inflammatory None None O
state None None O
result None None O
, None None O
contributing None None O
to None None O
the None None O
risk None None O
of None None O
heart None None O
disease None None O
, None None O
stroke None None I-DISEASE
, None None O
glucose None None O
intolerance None None O
, None None O
and None None O
hypertension None None O
in None None O
adulthood None None O
. None None O

The None None O
instability None None O
of None None O
this None None O
feedback None None O
loop None None O
is None None O
one None None O
of None None O
the None None O
key None None O
factors None None O
contributing None None O
to None None O
a None None O
number None None O
of None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
, None None O
including None None O
Cheyne None None O
? None None O
Stokes None None O
respiration None None O
and None None O
obstructive None None O
sleep None None O
apnea None None O
( None None O
OSA None None O
) None None O
. None None O

In None None O
recent None None O
years None None O
, None None O
a None None O
number None None O
of None None O
techniques None None O
that None None O
bring None None O
together None None O
concepts None None O
from None None O
signal None None O
processing None None O
, None None O
control None None O
theory None None O
, None None O
and None None O
machine None None O
learning None None I-FUNC
have None None O
proven None None O
effective None None O
for None None O
estimating None None O
the None None O
overall None None O
loop None None O
gain None None O
of None None O
the None None O
respiratory None None O
control None None O
system None None O
( None None O
see None None O
Figure None None O
1 None None O
) None None O
and None None O
its None None O
major None None O
components None None O
, None None O
chemoreflex None None O
gain None None O
and None None O
plant None None O
gain None None O
, None None O
from None None O
noninvasive None None O
time-series None None O
measurements None None O
of None None O
ventilation None None O
and None None O
blood None None O
gases None None O
. None None O

Its None None O
influence None None O
on None None O
human None None O
behavior None None O
and None None O
mood None None I-FUNC
can None None O
reach None None O
levels None None O
whose None None O
limits None None O
are None None O
still None None O
unknown None None O
, None None O
especially None None O
in None None O
everything None None O
related None None O
to None None O
perception None None I-FUNC
, None None O
where None None O
the None None O
whole None None O
nervous None None O
system None None O
is None None O
involved None None O
. None None O

Main None None O
outcome None None O
measures None None O
were None None O
CH None None O
, None None O
CRF None None O
, None None O
Goldmann-correlated None None O
intraocular None None O
pressure None None O
( None None O
IOPg None None O
) None None O
, None None O
corneal-compensated None None O
IOP None None I-TRANS
( None None O
IOPcc None None O
) None None O
, None None O
and None None O
Goldmann None None O
applanation None None O
tonometry None None O
measurements None None O
performed None None O
preoperatively None None O
and None None O
at None None O
postoperative None None O
week None None O
1 None None O
and None None O
months None None O
1 None None O
, None None O
3 None None O
, None None O
and None None O
6 None None O
. None None O

Although None None O
separate None None O
theories None None O
relate None None O
ACC None None O
function None None O
variously None None O
to None None O
conflict None None O
monitoring None None O
, None None O
reward None None O
processing None None O
, None None O
action None None O
selection None None O
, None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
and None None O
more None None O
, None None O
damage None None O
to None None O
the None None O
ACC None None O
mostly None None O
spares None None O
performance None None O
on None None O
tasks None None O
that None None O
exercise None None O
these None None O
functions None None O
, None None O
indicating None None O
that None None O
they None None O
are None None O
not None None O
in None None O
fact None None O
unique None None O
to None None O
the None None O
ACC None None O
. None None O

In None None O
this None None O
study None None O
we None None O
develop None None O
a None None O
computational None None O
model None None O
of None None O
the None None O
rodent None None O
medial None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
that None None O
accounts None None O
for None None O
the None None O
behavioral None None O
sequelae None None O
of None None O
ACC None None O
damage None None O
, None None O
unifies None None O
many None None O
of None None O
the None None O
cognitive None None O
functions None None O
attributed None None O
to None None O
it None None O
, None None O
and None None O
provides None None O
a None None O
solution None None O
to None None O
an None None O
outstanding None None O
question None None O
in None None O
cognitive None None O
control None None O
research-how None None O
the None None O
control None None O
system None None O
determines None None O
and None None O
motivates None None O
what None None O
tasks None None O
to None None O
perform None None O
. None None O

According None None O
to None None O
this None None O
position None None O
, None None O
the None None O
ACC None None O
utilizes None None O
reward None None O
information None None O
to None None O
select None None O
tasks None None O
that None None O
are None None O
then None None O
accomplished None None O
through None None O
top-down None None O
control None None O
over None None O
action None None O
selection None None O
by None None O
the None None O
striatum None None I-REGION
. None None O

With None None O
institutional None None O
review None None O
board None None O
( None None O
Cleveland None None O
, None None O
Ohio None None O
) None None O
approval None None O
and None None O
waiver None None O
of None None O
written/informed None None O
consent None None O
, None None O
the None None O
anesthesia None None O
records None None O
of None None O
adult None None O
patients None None O
undergoing None None O
noncardiac None None O
surgery None None O
from None None O
2005 None None O
to None None O
2011 None None O
at None None O
the None None O
Cleveland None None O
Clinic None None O
were None None O
queried None None O
using None None O
a None None O
novel None None O
electronic None None O
search None None O
protocol None None O
developed None None O
to None None O
identify None None O
potential None None O
hypersensitivity None None O
reactions None None O
: None None O
cardiovascular None None O
collapse None None O
defined None None O
as None None O
systolic None None O
arterial None None O
blood None None O
pressure None None O
less None None O
than None None O
50 None None O
mmHg None None O
; None None O
administration None None O
of None None O
epinephrine None None I-TRANS
; None None O
administration None None O
of None None O
diphenhydramine None None O
; None None O
physician None None O
comments None None O
in None None O
the None None O
anesthesia None None O
record None None O
suggestive None None O
of None None O
hypersensitivity None None O
reactions None None O
; None None O
laboratory None None O
tests None None O
for None None O
histamine None None I-TRANS
, None None O
tryptase None None O
, None None O
or None None O
immunoglobulin-E None None O
within None None O
24 None None O
h None None O
of None None O
surgery None None O
; None None O
and None None O
International None None O
Classification None None O
of None None O
Diseases None None O
, None None O
Ninth None None O
Revision None None O
, None None O
codes None None O
suggestive None None O
of None None O
hypersensitivity None None O
reactions None None O
. None None O

Persons None None O
with None None O
dementia None None I-DISEASE
( None None O
PWD None None O
) None None O
are None None O
known None None O
to None None O
have None None O
difficulty None None O
with None None O
participation None None O
and None None O
focus None None O
during None None O
physical None None O
activity None None O
. None None O

VR None None O
training None None O
is None None O
well None None O
tolerated None None O
in None None O
a None None O
single None None O
research None None O
participant None None O
with None None O
dementia None None I-DISEASE
and None None O
is None None O
an None None O
engaging None None O
medium None None O
for None None O
participation None None O
in None None O
exercise None None O
. None None O

We None None O
performed None None O
post None None O
hoc None None O
analysis None None O
of None None O
data None None O
integrated None None O
from None None O
4 None None O
double-blind None None O
studies None None O
of None None O
tadalafil None None O
5 None None O
mg None None O
and None None O
placebo None None O
once None None O
daily None None O
in None None O
742 None None O
and None None O
735 None None O
men None None O
, None None O
respectively None None O
, None None O
45 None None O
years None None O
old None None O
or None None O
older None None O
with None None O
total None None O
I-PSS None None O
13 None None O
or None None O
greater None None O
. None None O

I-PSS None None O
was None None O
assessed None None O
at None None O
weeks None None O
4 None None O
, None None O
8 None None O
and None None O
12 None None O
in None None O
all None None O
studies None None O
, None None O
week None None O
1 None None O
in None None O
2 None None O
and None None O
week None None O
2 None None O
in None None O
1 None None O
. None None O

Pars None None O
distalis-derived None None O
TSH None None O
( None None O
PD-TSH None None O
) None None O
stimulates None None O
the None None O
thyroid None None O
gland None None O
to None None O
produce None None O
thyroid None None O
hormones None None I-PROTEIN
( None None O
THs None None O
) None None O
, None None O
whereas None None O
pars None None O
tuberalis-derived None None O
TSH None None O
( None None O
PT-TSH None None O
) None None O
acts None None O
on None None O
the None None O
hypothalamus None None I-REGION
to None None O
regulate None None O
seasonal None None O
physiology None None O
and None None O
behavior None None O
. None None O

Mass None None O
spectrometry None None O
identification None None O
of None None O
SUUR-associated None None O
proteins None None O
identified None None O
the None None O
replicative None None O
helicase None None I-PROTEIN
member None None O
CDC45 None None O
as None None O
a None None O
SUUR-associated None None O
protein None None O
, None None O
supporting None None O
a None None O
role None None O
for None None O
SUUR None None O
directly None None O
at None None O
replication None None O
forks None None O
. None None O

An None None O
evolutionarily None None O
conserved None None O
unfolded None None O
protein None None O
response None None O
( None None O
UPR None None O
) None None O
component None None O
, None None O
IRE1 None None O
, None None O
cleaves None None O
XBP1/HAC1 None None O
introns None None O
in None None O
order None None O
to None None O
generate None None O
spliced None None O
mRNAs None None O
that None None O
are None None O
translated None None O
into None None O
potent None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
heterochromatic None None O
silencing None None O
, None None O
which None None O
we None None O
find None None O
is None None O
governed None None O
by None None O
histone None None I-PROTEIN
methyltransferases None None I-PROTEIN
G9a None None O
( None None O
KMT1C None None O
) None None O
and None None O
GLP None None O
( None None O
KMT1D None None O
) None None O
, None None O
is None None O
essential None None O
for None None O
stochastic None None O
and None None O
singular None None O
olfactory None None O
receptor None None I-PROTEIN
( None None O
OR None None O
) None None O
expression None None O
. None None O

However None None O
, None None O
it None None O
remains None None O
unclear None None O
how None None O
the None None O
precise None None O
firing None None O
patterns None None O
of None None O
medial None None O
entorhinal None None I-REGION
cortex None None I-REGION
( None None O
MEC None None O
) None None O
cells None None O
influence None None O
hippocampal None None O
physiology None None O
and None None O
hippocampus-dependent None None O
behavior None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
obligate None None O
intracellular None None O
Chlamydia None None O
downregulate None None O
the None None O
central None None O
tumor None None O
suppressor None None O
p53 None None I-PROTEIN
in None None O
human None None O
cells None None O
. None None O

The None None O
stabilization None None O
of None None O
p53 None None I-PROTEIN
in None None O
human None None O
cells None None O
severely None None O
impaired None None O
chlamydial None None O
development None None O
and None None O
caused None None O
the None None O
loss None None O
of None None O
infectious None None O
particle None None O
formation None None O
. None None O

Increased None None O
expression None None O
of None None O
the None None O
PPP None None O
key None None O
enzyme None None O
glucose-6-phosphate None None O
dehydrogenase None None I-PROTEIN
rescued None None O
the None None O
inhibition None None O
of None None O
chlamydial None None O
growth None None O
induced None None O
by None None O
DNA None None O
damage None None O
or None None O
stabilized None None O
p53 None None I-PROTEIN
. None None O

With None None O
this None None O
approach None None O
, None None O
we None None O
successfully None None O
identified None None O
multiple None None O
molecularly None None O
distinct None None O
dopamine None None I-TRANS
neuron None None O
subtypes None None O
and None None O
localized None None O
them None None O
in None None O
the None None O
adult None None O
mouse None None O
brain None None O
. None None O

Another None None O
Aldh1a1+ None None O
subtype None None O
, None None O
located None None O
in None None O
the None None O
substantia None None I-REGION
nigra None None I-REGION
, None None O
is None None O
especially None None O
vulnerable None None O
in None None O
the None None O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine None None O
( None None O
MPTP None None O
) None None O
model None None O
of None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
show None None O
that None None O
HCF-1 None None O
recruitment None None O
to None None O
numerous None None O
E2F-bound None None O
promoters None None O
is None None O
mediated None None O
by None None O
the None None O
concerted None None O
action None None O
of None None O
zinc None None I-TRANS
finger None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
THAP11 None None O
and None None O
ZNF143 None None O
, None None O
rather None None O
than None None O
E2F None None O
proteins None None O
directly None None O
. None None O

Proteins None None O
and None None O
ribonucleoproteins None None O
containing None None O
a None None O
nuclear None None O
export None None O
signal None None O
( None None O
NES None None I-TRANS
) None None O
assemble None None O
with None None O
the None None O
exportin None None O
Xpo1p None None O
( None None O
yeast None None O
CRM1 None None O
) None None O
and None None O
Gsp1p-GTP None None O
( None None O
yeast None None O
Ran-GTP None None O
) None None O
in None None O
the None None O
nucleus None None O
and None None O
exit None None O
through None None O
the None None O
nuclear None None O
pore None None O
complex None None O
. None None O

Transcriptional None None O
changes None None O
suggest None None O
that None None O
derepression None None O
of None None O
the None None O
nuclear None None O
receptors None None I-PROTEIN
PPARα None None O
, None None O
PPARγ None None O
, None None O
and None None O
LXRα None None O
in None None O
aged None None O
mouse None None O
liver None None O
leads None None O
to None None O
activation None None O
of None None O
targets None None O
regulating None None O
lipid None None O
synthesis None None O
and None None O
storage None None I-FUNC
, None None O
whereas None None O
age-dependent None None O
changes None None O
in None None O
nucleosome None None O
occupancy None None O
are None None O
associated None None O
with None None O
binding None None O
sites None None O
for None None O
both None None O
known None None O
regulators None None O
( None None O
forkhead None None O
factors None None O
and None None O
nuclear None None O
receptors None None I-PROTEIN
) None None O
and None None O
candidates None None O
associated None None O
with None None O
nuclear None None O
lamina None None O
( None None O
Hdac3 None None O
and None None O
Srf None None O
) None None O
implicated None None O
to None None O
govern None None O
metabolic None None O
function None None O
of None None O
aging None None O
liver None None O
. None None O

We None None O
have None None O
recently None None O
found None None O
that None None O
overexpression None None O
of None None O
a None None O
chromosome None None O
21-encoded None None O
microRNA-155 None None O
results None None O
in None None O
decreased None None O
levels None None O
of None None O
the None None O
membrane None None O
trafficking None None O
component None None O
, None None O
SNX27 None None O
, None None O
diminishing None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
recycling None None O
and None None O
thereby None None O
impairing None None O
synaptic None None O
functions None None O
in None None O
DS None None O
. None None O

Instead None None O
, None None O
TRF2 None None O
binds None None O
and None None O
transactivates None None O
the None None O
promoter None None O
of None None O
the None None O
angiogenic None None O
tyrosine None None I-TRANS
kinase None None O
platelet-derived None None O
growth None None O
factor None None O
receptor None None I-PROTEIN
β None None O
( None None O
PDGFRβ None None O
) None None O
. None None O

In None None O
human None None O
neuroblastoma None None O
cells None None O
, None None O
either None None O
blockade None None O
of None None O
ARG1 None None O
or None None O
benzodiazepine-mediated None None O
activation None None O
of None None O
GABA-A None None O
receptors None None I-PROTEIN
induced None None O
apoptosis None None O
and None None O
inhibited None None O
mitogenic None None O
signaling None None O
through None None O
AKT None None O
and None None O
MAPK None None O
. None None O

Expression None None O
of None None O
CD161 None None O
hence None None O
identifies None None O
a None None O
transcriptional None None O
and None None O
functional None None O
phenotype None None O
, None None O
shared None None O
across None None O
human None None O
T None None O
lymphocytes None None O
and None None O
independent None None O
of None None O
both None None O
T None None I-PROTEIN
cell None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
TCR None None O
) None None O
expression None None O
and None None O
cell None None O
lineage None None O
. None None O

However None None O
, None None O
when None None O
human None None O
neutrophils None None O
were None None O
`` None None O
stalled None None O
'' None None O
by None None O
simultaneously None None O
blocking None None O
actin None None I-PROTEIN
and None None O
myosin None None O
dynamics None None O
, None None O
they None None O
maintained None None O
the None None O
gradient None None O
of None None O
responsiveness None None O
to None None O
chemoattractant None None O
and None None O
also None None O
displayed None None O
noise-driven None None O
PIP3 None None O
flashes None None O
on None None O
the None None O
basal None None O
membrane None None O
, None None O
localized None None O
toward None None O
the None None O
front None None O
. None None O

In None None O
terms None None O
of None None O
pain None None O
perception None None I-FUNC
, None None O
LC None None O
performed None None O
through None None O
1 None None O
port None None O
does None None O
not None None O
offer None None O
advantages None None O
when None None O
compared None None O
with None None O
2 None None O
or None None O
3 None None O
ports None None O
. None None O

The None None O
cells None None O
were None None O
treated None None O
for None None O
2 None None O
hours None None O
, None None O
4 None None O
hours None None O
, None None O
6 None None O
hours None None O
, None None O
and None None O
24 None None O
hours None None O
, None None O
respectively None None O
, None None O
using None None O
10 None None O
drugs None None O
including None None O
epirubicin None None O
( None None O
EPI None None I-TRANS
) None None O
, None None O
cisplatin None None O
( None None O
DDP None None O
) None None O
, None None O
mitomycin-C None None O
( None None O
MMC None None O
) None None O
, None None O
oxaliplatin None None O
( None None O
OXA None None O
) None None O
, None None O
hydroxycamptothecin None None O
( None None O
HCPT None None O
) None None O
, None None O
5-fluorouracil None None O
( None None O
5-FU None None O
) None None O
, None None O
gemcitabine None None O
( None None O
GEM None None O
) None None O
, None None O
docetaxel None None O
( None None O
DTX None None O
) None None O
, None None O
thiotepa None None O
( None None O
TSPA None None O
) None None O
, None None O
and None None O
pemetrexed None None O
disodium None None O
( None None O
PEM None None O
) None None O
in None None O
4 None None O
concentrations None None O
of None None O
HHCM None None O
( None None O
5 None None O
% None None O
, None None O
10 None None O
% None None O
, None None O
25 None None O
% None None O
, None None O
and None None O
50 None None O
% None None O
, None None O
respectively None None O
) None None O
mimicking None None O
the None None O
scenario None None O
of None None O
TACE None None O
and None None O
were None None O
assessed None None O
using None None O
3- None None O
( None None O
4,5-dimethylthiazol-2-yl None None O
) None None O
-2,5-diphenyltetrazolium None None O
bromide None None O
( None None O
MTT None None O
) None None O
assay None None O
. None None O

The None None O
sensitive None None O
drugs None None O
with None None O
inhibition None None O
rates None None O
more None None O
than None None O
30 None None O
% None None O
were None None O
EPI None None I-TRANS
, None None O
MMC None None O
, None None O
HCPT None None O
, None None O
OXA None None O
, None None O
and None None O
PEM None None O
in None None O
4 None None O
types None None O
of None None O
HHCMs None None O
. None None O

There None None O
were None None O
no None None O
differences None None O
in None None O
serum None None O
MDA None None O
levels None None O
among None None O
the None None O
4 None None O
groups None None O
, None None O
and None None O
serum None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
and None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
activities None None O
were None None O
significantly None None O
higher None None O
in None None O
the None None O
IR1 None None O
( None None O
P None None O
= None None O
0.026 None None O
and None None O
P None None O
= None None O
0.018 None None O
, None None O
respectively None None O
) None None O
and None None O
IR6 None None O
( None None O
P None None O
= None None O
0.000 None None O
and None None O
P None None O
= None None O
0.002 None None O
, None None O
respectively None None O
) None None O
groups None None O
than None None O
in None None O
the None None O
DIR1 None None O
and None None O
DIR6 None None O
groups None None O
. None None O

Progression None None O
of None None O
KRAS None None O
wild-type None None O
rectal None None O
cancer None None O
after None None O
chemotherapy None None O
suggested None None O
that None None O
each None None O
clone None None O
from None None O
rectal None None O
and None None O
sigmoid None None O
colon None None O
cancer None None O
might None None O
have None None O
a None None O
different None None O
sensitivity None None O
to None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
antibody None None O
. None None O

No None None O
thrombosis None None I-DISEASE
was None None O
found None None O
within None None O
group None None O
C None None O
, None None O
and None None O
the None None O
stumps None None O
were None None O
free None None O
of None None O
neuroma None None O
formation None None O
. None None O

One None None O
week None None O
prior None None O
to None None O
the None None O
elective None None O
surgery None None O
he None None O
presented None None O
with None None O
upper None None O
gastrointestinal None None O
bleeding None None O
for None None O
which None None O
he None None O
was None None O
admitted None None O
, None None O
diagnosed None None O
by None None O
a None None O
gastroenterologist None None O
as None None O
bleeding None None O
duodenal None None O
ulcer None None O
and None None O
treated None None O
by None None O
local None None O
epinephrine None None I-TRANS
injection None None O
and None None O
blood None None O
transfusion None None O
. None None O

As None None O
a None None O
consequence None None O
, None None O
the None None O
gut None None O
microbiota None None O
produces None None O
metabolites None None O
from None None O
a None None O
large None None O
range None None O
of None None O
molecules None None O
that None None O
host None None O
's None None O
enzymes None None I-PROTEIN
are None None O
not None None O
able None None O
to None None O
convert None None O
. None None O

The None None O
cells None None O
that None None O
line None None O
the None None O
mucosa None None O
of None None O
the None None O
human None None O
gastrointestinal None None O
tract None None O
( None None O
GI None None O
, None None O
that None None O
is None None O
, None None O
oral None None O
cavity None None O
, None None O
oesophagus None None O
, None None O
stomach None None O
, None None O
small None None O
intestine None None O
, None None O
large None None O
intestine None None O
, None None O
and None None O
rectum None None O
) None None O
are None None O
constantly None None O
challenged None None O
by None None O
adverse None None O
micro-environmental None None O
factors None None O
, None None O
such None None O
as None None O
different None None O
pH None None O
, None None O
enzymes None None I-PROTEIN
, None None O
and None None O
bacterial None None O
flora None None O
. None None O

To None None O
counteract None None O
the None None O
hostile None None O
microenvironment None None O
, None None O
the None None O
GI None None O
epithelia None None O
react None None O
by None None O
speeding None None O
cell None None O
exfoliation None None O
( None None O
the None None O
GI None None O
mucosa None None O
has None None O
a None None O
turnover None None O
time None None O
of None None O
two None None O
to None None O
three None None O
days None None O
) None None O
, None None O
by None None O
increasing None None O
peristalsis None None O
, None None O
by None None O
eliminating None None O
bacteria None None O
through None None O
secretion None None O
of None None O
plasma None None O
cell-immunoglobulins None None O
and None None O
by None None O
increasing None None O
production None None O
of None None O
natural None None O
antibacterial None None O
compounds None None O
, None None O
such None None O
as None None O
defensin-5 None None O
and None None O
lysozyme None None I-PROTEIN
. None None O

The None None O
molecular None None O
mechanisms None None O
connected None None O
to None None O
the None None O
crosstalk None None O
between None None O
the None None O
intraluminal None None O
bacterial None None O
flora None None O
and None None O
the None None O
production None None O
of None None O
lysozyme None None I-PROTEIN
released None None O
by None None O
the None None O
GI None None O
mucosae None None O
, None None O
are None None O
discussed None None O
. None None O

The None None O
potential None None O
use None None O
of None None O
lysozyme None None I-PROTEIN
to None None O
treat None None O
infectious None None O
diseases None None O
is None None O
receiving None None O
much None None O
attention None None I-FUNC
. None None O

They None None O
have None None O
been None None O
identified None None O
as None None O
self-replicating None None O
proteinaceous None None O
agents None None O
responsible None None O
for None None O
the None None O
onset None None O
of None None O
rare None None O
and None None O
fatal None None O
neurodegenerative None None O
disorders-known None None O
as None None O
transmissible None None O
spongiform None None O
encephalopathies None None O
, None None O
or None None O
prion None None I-DISEASE
diseases-which None None O
affect None None O
humans None None O
and None None O
other None None O
animal None None O
species None None O
. None None O

As None None O
more None None O
detailed None None O
information None None O
on None None O
gut None None O
microbiota None None O
complexity None None O
and None None O
functional None None O
diversity None None O
accumulates None None O
, None None O
we None None O
are None None O
learning None None I-FUNC
more None None O
about None None O
how None None O
diet-microbiota None None O
interactions None None O
can None None O
influence None None O
the None None O
immune None None O
system None None O
within None None O
and None None O
outside None None O
the None None O
gut None None O
and None None O
host None None O
health None None O
in None None O
general None None O
. None None O

Many None None O
universities None None O
have None None O
implemented None None O
depressive None None I-DISEASE
symptom None None I-DISEASE
screening None None O
programs None None O
and None None O
the None None O
number None None O
of None None O
students None None O
identified None None O
as None None O
in None None O
need None None O
of None None O
services None None O
following None None O
screening None None O
greatly None None O
exceeds None None O
available None None O
mental None None O
health None None O
resources None None O
. None None O

Students None None O
( None None O
n=262 None None O
) None None O
who None None O
reported None None O
elevated None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
both None None O
an None None O
initial None None O
screening None None O
and None None O
baseline None None O
assessment None None O
( None None O
n=150 None None O
) None None O
were None None O
invited None None O
to None None O
participate None None O
in None None O
telephone-based None None O
follow-up None None O
assessments None None O
4 None None O
, None None O
8 None None O
, None None O
and None None O
12 None None O
months None None O
post-baseline None None O
. None None O

Baseline None None O
social None None O
disconnection None None O
and None None O
negative None None O
feedback-seeking None None O
both None None O
significantly None None O
predicted None None O
membership None None O
in None None O
the None None O
persistently None None O
elevated None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
course None None O
. None None O

Screening None None O
cut-points None None O
on None None O
social None None O
disconnection None None O
and None None O
negative None None O
feedback-seeking None None O
measures None None O
can None None O
reduce None None O
the None None O
number None None O
of None None O
cases None None O
identified None None O
as None None O
needing None None O
mental None None O
health None None O
services None None O
while None None O
retaining None None O
the None None O
majority None None O
of None None O
cases None None O
who None None O
will None None O
experience None None O
a None None O
persistent None None O
depressive None None I-DISEASE
symptom None None I-DISEASE
course None None O
. None None O

In None None O
this None None O
review None None O
we None None O
will None None O
highlight None None O
recent None None O
progress None None O
with None None O
plant-based None None O
production None None O
of None None O
polyhydroxyalkanoates None None O
( None None O
PHAs None None O
) None None O
, None None O
silk None None O
, None None O
elastin None None I-PROTEIN
, None None O
collagen None None I-PROTEIN
, None None O
and None None O
cyanophycin None None O
with None None O
an None None O
emphasis None None O
on None None O
the None None O
synthesis None None O
of None None O
poly None None O
[ None None O
( None None O
R None None O
) None None O
-3-hydroxybutyrate None None O
] None None O
( None None O
PHB None None O
) None None O
, None None O
a None None O
renewable None None O
biodegradable None None O
PHA None None O
polymer None None O
with None None O
potential None None O
commercial None None O
applications None None O
in None None O
plastics None None O
, None None O
chemicals None None O
, None None O
and None None O
feed None None O
markets None None O
. None None O

Together None None O
with None None O
other None None O
sequence-specific None None O
nucleases None None I-PROTEIN
, None None O
CRISPR/Cas9 None None O
is None None O
a None None O
game-changing None None O
technology None None O
that None None O
is None None O
poised None None O
to None None O
revolutionise None None O
basic None None O
research None None O
and None None O
plant None None O
breeding None None O
. None None O

Several None None O
limitations None None O
of None None O
( None None O
18 None None O
) None None O
F None None O
and None None O
other None None O
non-metallic None None O
isotopes None None O
have None None O
been None None O
emphasized None None O
by None None O
the None None O
development None None O
of None None O
macromolecular None None O
biotargeting None None O
agents None None O
for None None O
cancer None None O
, None None O
including None None O
peptides None None I-TRANS
, None None O
antibodies None None O
, None None O
fragments None None O
and None None O
oligonucleotides None None O
, None None O
which None None O
typically None None O
have None None O
biological None None O
half-lives None None O
that None None O
are None None O
much None None O
longer None None O
than None None O
the None None O
radioactive None None O
half-life None None O
of None None O
( None None O
18 None None O
) None None O
F. None None O
Based None None O
on None None O
the None None O
( None None O
18 None None O
) None None O
F-FDG None None O
success None None O
story None None O
, None None O
we None None O
can None None O
wonder None None O
whether None None O
all None None O
critical None None O
criteria None None O
are None None O
or None None O
can None None O
be None None O
fulfilled None None O
for None None O
the None None O
radiometallated None None O
bioconjugates None None O
to None None O
start None None O
out None None O
from None None O
the None None O
crowd None None O
and None None O
which None None O
metals None None O
have None None O
the None None O
best None None O
chance None None O
of None None O
success None None O
. None None O

Thus None None O
, None None O
a None None O
large None None O
three-dimensional None None O
space None None O
is None None O
made None None O
available None None O
for None None O
oil None None O
storage None None I-FUNC
. None None O

After None None O
a None None O
course None None O
of None None O
physiotherapy None None O
he None None O
regained None None O
full None None O
range None None O
of None None O
pain None None O
free None None O
movements None None I-FUNC
. None None O

We None None O
can None None O
confirm None None O
that None None O
PET/CT None None O
for None None O
somatostatin None None I-TRANS
receptor None None I-PROTEIN
imaging None None O
shows None None O
good None None O
sensitivity None None O
in None None O
detecting None None O
neuroendocrine None None O
neoplasms None None O
and None None O
should None None O
be None None O
preferred None None O
for None None O
diagnostic None None O
, None None O
if None None O
available None None O
. None None O

Bilateral None None O
adrenal None None I-TRANS
haemorrhage None None O
is None None O
a None None O
rare None None O
, None None O
but None None O
serious None None O
, None None O
illness None None O
carrying None None O
an None None O
estimated None None O
15 None None O
% None None O
mortality None None O
. None None O

The None None O
main None None O
pathophysiology None None O
of None None O
gynecomastia None None O
is None None O
alteration None None O
in None None O
the None None O
balance None None O
between None None O
the None None O
stimulatory None None O
effect None None O
of None None O
estrogen None None O
and None None O
the None None O
inhibitory None None O
effects None None O
of None None O
androgens None None I-PROTEIN
on None None O
the None None O
development None None O
of None None O
the None None O
breast None None O
. None None O

We None None O
present None None O
a None None O
case None None O
of None None O
a None None O
complex None None O
ventral None None I-NEURON
hernia None None O
that None None O
was None None O
laparoscopically None None O
repaired None None O
using None None O
a None None O
new None None O
FDA None None O
cleared None None O
laparoscopic None None O
biologic None None O
graft None None O
. None None O

A None None O
few None None O
months None None O
later None None O
, None None O
he None None O
required None None O
umbilical None None O
herniorrhaphy None None O
, None None O
but None None O
he None None O
did None None O
not None None O
respond None None O
to None None O
attempts None None O
to None None O
raise None None O
his None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
antigen None None O
and None None O
activity None None O
levels None None O
using None None O
conventional None None O
therapies None None O
, None None O
including None None O
desmopressin None None O
, None None O
cryoprecipitate None None O
, None None O
intravenous None None O
immunoglobulin None None O
, None None O
and None None O
Von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
concentrate None None O
. None None O

Most None None O
of None None O
the None None O
choriocarcinomas None None O
are None None O
normally None None O
arising None None O
in None None O
the None None O
gestational None None O
trophoblast None None O
, None None O
gonads None None O
and None None O
, None None O
less None None O
frequently None None O
, None None O
mediastinum None None O
, None None O
pineal None None I-REGION
gland None None O
and None None O
retroperitoneum None None O
. None None O

Despite None None O
permanent None None O
increase None None O
in None None O
learning None None I-FUNC
curves None None O
and None None O
new None None O
approaches None None O
in None None O
laparoscopic None None O
techniques None None O
, None None O
bile None None O
duct None None O
injuries None None O
still None None O
remain None None O
twice None None O
as None None O
frequent None None O
as None None O
in None None O
the None None O
conventional None None O
open None None O
approach None None O
. None None O

Retroperitoneal None None O
sarcomas None None O
have None None O
rarely None None O
been None None O
reported None None O
to None None O
secrete None None O
insulin-growth None None O
factor None None O
II None None O
( None None O
IGF-II None None O
) None None O
and None None O
produce None None O
an None None O
enigmatic None None O
hypoglycemia None None I-DISEASE
. None None O

The None None O
authors None None O
present None None O
the None None O
case None None O
of None None O
hypoglycemia None None I-DISEASE
due None None O
to None None O
an None None O
IGF-II-secreting None None O
retroperitoneal None None O
sarcoma None None O
that None None O
was None None O
successfully None None O
treated None None O
by None None O
complete None None O
surgical None None O
resection None None O
. None None O

Steroid None None O
and None None O
growth None None O
hormone None None O
therapies None None O
also None None O
have None None O
efficacy None None O
to None None O
treat None None O
this None None O
hypoglycemia None None I-DISEASE
in None None O
some None None O
patients None None O
. None None O

The None None O
findings None None O
of None None O
this None None O
case None None O
report None None O
and None None O
review None None O
of None None O
the None None O
literature None None O
support None None O
a None None O
primary None None O
role None None O
for None None O
complete None None O
tumor None None O
resection None None O
to None None O
address None None O
tumor-induced None None O
hypoglycemia None None I-DISEASE
. None None O

Brain None None O
magnetic None None O
resonance None None O
imaging None None O
confirmed None None O
a None None O
cerebrovascular None None I-DISEASE
accident None None I-DISEASE
. None None O

A None None O
clinical None None O
diagnosis None None O
of None None O
paradoxical None None O
embolism None None I-DISEASE
was None None O
made None None O
and None None O
she None None O
was None None O
subsequently None None O
referred None None O
to None None O
the None None O
cardiologists None None O
for None None O
angiographic None None O
closure None None O
of None None O
the None None O
PFO None None O
. None None O

The None None O
present None None O
study None None O
aimed None None O
to None None O
evaluate None None O
whether None None O
right None None O
subclavian None None O
vein None None O
( None None O
SCV None None O
) None None O
catheter None None O
insertion None None O
depth None None O
can None None O
be None None O
predicted None None O
reliably None None O
by None None O
the None None O
distances None None O
from None None O
the None None O
SCV None None O
insertion None None O
site None None O
to None None O
the None None O
ipsilateral None None O
clavicular None None O
notch None None O
directly None None O
( None None O
denoted None None O
as None None O
I-IC None None O
) None None O
, None None O
via None None O
the None None O
top None None O
of None None O
the None None O
SCV None None O
arch None None O
, None None O
or None None O
via None None O
the None None O
clavicle None None O
( None None O
denoted None None O
as None None O
I-T-IC None None O
and None None O
I-C-IC None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
I-IC None None O
, None None O
I-T-IC None None O
, None None O
and None None O
I-C-IC None None O
distances None None O
in None None O
each None None O
case None None O
were None None O
measured None None O
after None None O
ultrasound-guided None None O
SCV None None O
catheter None None O
insertion None None O
. None None O

L None None O
differed None None O
from None None O
the None None O
I-T-IC None None O
, None None O
I-C-IC None None O
, None None O
and None None O
I-IC None None O
distances None None O
by None None O
0.14±0.53 None None O
, None None O
2.19±1.17 None None O
, None None O
and None None O
-0.45±0.68cm None None O
, None None O
respectively None None O
. None None O

The None None O
mean None None O
I-IC None None O
was None None O
significantly None None O
shorter None None O
than None None O
L None None O
, None None O
while None None O
the None None O
mean None None O
I-C-IC None None O
was None None O
significantly None None O
longer None None O
. None None O

The None None O
I-T-IC None None O
distance None None O
may None None O
be None None O
a None None O
reliable None None O
bedside None None O
predictor None None O
of None None O
the None None O
optimal None None O
insertion None None O
length None None O
for None None O
a None None O
right None None O
SCV None None O
cannulation None None O
. None None O

A None None O
prospective None None O
, None None O
randomized None None O
and None None O
double-blind None None O
study None None O
was None None O
planned None None O
to None None O
identify None None O
the None None O
optimum None None O
dose None None O
of None None O
esmolol None None O
infusion None None O
to None None O
suppress None None O
the None None O
increase None None O
in None None O
bispectral None None O
index None None O
values None None O
and None None O
the None None O
movement None None I-FUNC
and None None O
hemodynamic None None O
responses None None O
to None None O
tracheal None None O
intubation None None O
. None None O

Incidence None None O
of None None O
movement None None I-FUNC
response None None O
and None None O
the None None O
ΔBIS None None O
max None None O
values None None O
were None None O
comparable None None O
in None None O
Group None None O
Es250 None None O
and None None O
Group None None O
Es150 None None O
, None None O
but None None O
these None None O
values None None O
were None None O
significantly None None O
higher None None O
in None None O
Group None None O
Es50 None None O
than None None O
in None None O
the None None O
other None None O
two None None O
groups None None O
. None None O

In None None O
total None None O
, None None O
eight None None O
hydrophobic None None O
residues None None O
in None None O
the None None O
core None None O
of None None O
DSD None None O
were None None O
replaced None None O
by None None O
eight None None O
cysteine None None I-TRANS
residues None None O
that None None O
serve None None O
as None None O
ligands None None O
to None None O
the None None O
[ None None O
4Fe-4S None None O
] None None O
clusters None None O
. None None O

To None None O
evaluate None None O
the None None O
efficacy None None O
of None None O
transcervical None None O
intralesional None None O
vasopressin None None I-TRANS
injection None None O
to None None O
submucous None None O
myoma None None O
in None None O
hysteroscopic None None O
myomectomy None None O
from None None O
2011 None None O
to None None O
2014 None None O
. None None O

Forty None None O
premenopausal None None O
women None None O
with None None O
symptomatic None None O
submucous None None O
myoma None None O
requiring None None O
hysteroscopic None None O
myomectomy None None O
were None None O
randomized None None O
to None None O
transcervical None None O
intralesional None None O
vasopressin None None I-TRANS
injection None None O
or None None O
placebo None None O
in None None O
a None None O
4:4 None None O
ratio None None O
. None None O

There None None O
were None None O
significant None None O
reductions None None O
in None None O
the None None O
median None None O
volume None None O
of None None O
fluid None None O
used None None O
( None None O
4,200 None None O
mL None None O
[ None None O
range None None O
1,300-21,000 None None O
mL None None O
] None None O
compared None None O
with None None O
9,800 None None O
mL None None O
( None None O
range None None O
1,500-23,000 None None O
mL None None O
; None None O
P=.004 None None O
) None None O
and None None O
fluid None None O
intravasation None None O
( None None O
0 None None O
mL None None O
[ None None O
range None None O
0-3,100 None None O
] None None O
compared None None O
with None None O
300 None None O
mL None None O
[ None None O
range None None O
-150-3,150 None None O
mL None None O
; None None O
P=.029 None None O
) None None O
in None None O
the None None O
vasopressin None None I-TRANS
group None None O
. None None O

The None None O
operative None None O
surgeon None None O
rated None None O
that None None O
95 None None O
% None None O
of None None O
the None None O
vasopressin None None I-TRANS
group None None O
had None None O
`` None None O
minimal None None O
'' None None O
bleeding None None O
compared None None O
with None None O
36.8 None None O
% None None O
in None None O
the None None O
placebo None None O
group None None O
. None None O

Transcervical None None O
intralesional None None O
vasopressin None None I-TRANS
injection None None O
in None None O
hysteroscopic None None O
myomectomy None None O
did None None O
not None None O
reduce None None O
operative None None O
time None None O
but None None O
did None None O
reduce None None O
volume None None O
of None None O
inflow None None O
fluid None None O
, None None O
fluid None None O
intravasation None None O
, None None O
intraoperative None None O
blood None None O
loss None None O
, None None O
and None None O
improving None None O
visual None None O
clarity None None O
. None None O

To None None O
systematically None None O
identify None None O
the None None O
number None None O
of None None O
applications None None O
( None None O
`` None None O
apps None None I-TRANS
'' None None O
) None None O
compatible None None O
with None None O
the None None O
iPhone None None O
and None None O
the None None O
iPad None None O
that None None O
are None None O
potentially None None O
useful None None O
to None None O
obstetrician-gynecologists None None O
( None None O
ob-gyns None None O
) None None O
. None None O

A None None O
master None None O
list None None O
of None None O
unique None None O
apps None None I-TRANS
was None None O
created None None O
and None None O
the None None O
apps None None I-TRANS
were None None O
divided None None O
into None None O
categories None None O
and None None O
subcategories None None O
. None None O

Of None None O
these None None O
unique None None O
apps None None I-TRANS
, None None O
242 None None O
apps None None I-TRANS
( None None O
13.3 None None O
% None None O
) None None O
were None None O
considered None None O
potentially None None O
useful None None O
to None None O
ob-gyns None None O
. None None O

Less None None O
than None None O
15 None None O
% None None O
of None None O
apps None None I-TRANS
found None None O
were None None O
considered None None O
potentially None None O
useful None None O
to None None O
ob-gyns None None O
. None None O

Although None None O
researchers None None O
increased None None O
the None None O
statistical None None O
rigor None None O
of None None O
their None None O
approaches None None O
over None None O
the None None O
past None None O
15 None None O
years None None O
, None None O
researchers None None O
' None None O
ability None None O
to None None O
draw None None O
causal None None O
inferences None None I-FUNC
has None None O
been None None O
limited None None O
because None None O
the None None O
studies None None O
are None None O
based None None O
on None None O
nonexperimental None None O
designs None None O
. None None O

The None None O
current None None O
study None None O
addressed None None O
whether None None O
the None None O
learning None None I-FUNC
system None None O
imposes None None O
a None None O
constraint None None O
that None None O
favors None None O
word None None O
forms None None O
beginning None None O
with None None O
a None None O
consonant None None O
onset None None O
over None None O
those None None O
beginning None None O
with None None O
an None None O
onsetless None None O
sub-syllable None None O
, None None O
by None None O
examining None None O
infants None None O
' None None O
segmentation None None O
of None None O
vowel-initial None None O
non-words None None O
in None None O
French None None O
liaison None None O
. None None O

Cadmium None None O
, None None O
Sr None None O
and None None O
Zn None None O
are None None O
enriched None None O
in None None O
willow None None O
and None None O
Cs None None O
, None None O
Na None None I-TRANS
and None None O
Tl None None O
in None None O
heather None None O
. None None O

Moreover None None O
, None None O
by None None O
integrating None None O
GIS None None O
functionalities None None O
and None None O
Multi None None O
Criteria None None O
Decision None None O
Analysis None None O
( None None O
MCDA None None O
) None None O
techniques None None O
, None None O
it None None O
allows None None O
to None None O
: None None O
i None None O
) None None O
deal None None O
with None None O
several None None O
sources None None O
and None None O
multiple None None O
impacted None None O
receptors None None I-PROTEIN
within None None O
the None None O
area None None O
of None None O
concern None None O
; None None O
ii None None O
) None None O
identify None None O
different None None O
receptors None None I-PROTEIN
' None None O
vulnerability None None O
levels None None O
according None None O
to None None O
specific None None O
groundwater None None O
uses None None O
; None None O
iii None None O
) None None O
assess None None O
the None None O
risks None None O
posed None None O
by None None O
all None None O
contamination None None O
sources None None O
in None None O
the None None O
area None None O
; None None O
and None None O
iv None None O
) None None O
provide None None O
a None None O
risk-based None None O
ranking None None O
of None None O
the None None O
contamination None None O
sources None None O
that None None O
can None None O
threaten None None O
the None None O
achievement None None O
of None None O
the None None O
groundwater None None O
good None None O
quality None None O
status None None O
. None None O

Among None None O
the None None O
32 None None O
sources None None O
analyzed None None O
in None None O
the None None O
case None None O
study None None O
, None None O
three None None O
sources None None O
received None None O
the None None O
highest None None O
relevance None None O
score None None O
, None None O
due None None O
to None None O
the None None O
medium-high None None O
relative None None O
risks None None O
estimated None None O
for None None O
Chromium None None O
( None None O
VI None None I-REGION
) None None O
and None None O
Perchloroethylene None None O
. None None O

The None None O
potent None None O
physical None None O
adsorption None None O
of None None O
Epirubicin None None O
to None None O
nanodiamonds None None O
creates None None O
a None None O
rapidly None None O
synthesized None None O
and None None O
stable None None O
nanodiamond-drug None None O
complex None None O
that None None O
promotes None None O
endocytic None None O
uptake None None O
and None None O
enhanced None None O
tumor None None O
cell None None O
retention None None I-FUNC
. None None O

α-TTP None None O
is None None O
a None None O
key None None O
protein None None O
responsible None None O
for None None O
selection None None O
and None None O
retention None None I-FUNC
of None None O
RRR-α-tocopherol None None O
, None None O
the None None O
most None None O
active None None O
isoform None None O
of None None O
vitamin None None O
E None None O
in None None O
superior None None O
animals None None O
. None None O

Structural None None O
modifications None None O
of None None O
plant None None O
hormones None None I-PROTEIN
are None None O
required None None O
to None None O
improve None None O
their None None O
biological None None O
performance None None O
and None None O
their None None O
specificity None None O
to None None O
allow None None O
commercial None None O
application None None O
. None None O

Based None None O
on None None O
research None None O
on None None O
expertise None None O
and None None O
text None None O
comprehension None None O
, None None O
we None None O
investigated None None O
whether None None O
the None None O
abstractness None None O
or None None O
the None None O
cohesion None None O
of None None O
experts None None O
' None None O
and None None O
intermediates None None O
' None None O
explanations None None O
accounted None None O
for None None O
novices None None O
' None None O
learning None None I-FUNC
. None None O

In None None O
Study None None O
2 None None O
, None None O
we None None O
investigated None None O
novices None None O
' None None O
processing None None O
while None None O
learning None None I-FUNC
with None None O
experts None None O
' None None O
and None None O
intermediates None None O
' None None O
explanations None None O
. None None O

Experiment None None O
2 None None O
experimentally None None O
increased None None O
the None None O
salience None None O
of None None O
manipulative None None O
intent None None O
of None None O
the None None O
advertiser None None O
, None None O
and None None O
showed None None O
that None None O
moving None None O
music None None O
reduces None None O
inferences None None I-FUNC
of None None O
manipulative None None O
intent None None O
, None None O
leading None None O
in None None O
turn None None O
to None None O
increased None None O
behavioral None None O
intentions None None O
. None None O

Moving None None O
music None None O
did None None O
not None None O
increase None None O
memory None None I-FUNC
performance None None O
, None None O
beliefs None None O
, None None O
and None None O
explicit None None O
attitudes None None O
, None None O
suggesting None None O
that None None O
the None None O
influence None None O
is None None O
affect-based None None O
rather None None O
cognition-based None None O
. None None O

A None None O
pathogenomics None None O
approach None None O
, None None O
by None None O
coupling None None O
of None None O
pan-genomic None None O
analysis None None O
of None None O
multiple None None O
isolates None None O
with None None O
sequencing None None O
of None None O
experimentally None None O
attenuated None None O
highly None None O
pathogenic None None O
Leptospira None None O
, None None O
has None None O
resulted None None O
in None None O
the None None O
functional None None O
inference None None I-FUNC
of None None O
virulence None None O
factors None None O
. None None O

Gut None None O
microbes None None O
are None None O
known None None O
to None None O
play None None O
various None None O
roles None None O
in None None O
insects None None O
such None None O
as None None O
digestion None None O
of None None O
inaccessible None None O
nutrients None None O
, None None O
synthesis None None O
of None None O
deficient None None O
amino None None I-TRANS
acids None None I-TRANS
, None None O
and None None O
interaction None None O
with None None O
ecological None None O
environments None None O
, None None O
including None None O
host None None O
plants None None O
. None None O

Sexual None None I-DISEASE
dysfunction None None I-DISEASE
can None None O
occur None None O
after None None O
pouch None None O
surgery None None O
, None None O
particularly None None O
in None None O
those None None O
with None None O
pouch None None O
failure None None O
. None None O

Local None None O
T-cell None None O
activation None None O
has None None O
been None None O
hypothesized None None O
to None None O
account None None O
for None None O
increased None None O
FOXP3 None None I-PROTEIN
expression None None O
in None None O
colon None None O
lamina None None O
propria None None O
( None None O
LP None None O
) None None O
T None None O
cells None None O
. None None O

Thus None None O
, None None O
at None None O
steady None None O
state None None O
, None None O
only None None O
a None None O
minority None None O
of None None O
FOXP3 None None I-PROTEIN
, None None O
and None None O
particularly None None O
Helios None None O
, None None O
T None None O
cells None None O
share None None O
a None None O
T-cell None None O
receptor None None I-PROTEIN
sequence None None O
with None None O
FOXP3 None None I-PROTEIN
effector None None O
populations None None O
in None None O
the None None O
colon None None O
LP None None O
, None None O
even None None O
in None None O
UC None None O
, None None O
revealing None None O
distinct None None O
clonal None None O
origins None None O
for None None O
LP None None O
regulatory None None O
T None None O
cell None None O
and None None O
effector None None O
T None None O
cells None None O
in None None O
humans None None O
. None None O

the None None O
central None None O
amygdala None None I-REGION
( None None O
CeA None None O
) None None O
and None None O
the None None O
dorsal None None I-NEURON
raphe None None O
( None None O
DR None None O
) None None O
, None None O
both None None O
containing None None O
high None None O
levels None None O
of None None O
OXT None None O
receptors None None I-PROTEIN
( None None O
OXTRs None None O
) None None O
and None None O
constituting None None O
important None None O
nodes None None O
of None None O
the None None O
neural None None O
circuitry None None O
related None None O
to None None O
aggression None None O
. None None O

Although None None O
some None None O
mediators None None O
play None None O
pivotal None None O
roles None None O
in None None O
the None None O
development None None O
and None None O
maintenance None None O
of None None O
inflammatory None None O
hyperalgesia None None O
by None None O
affecting None None O
the None None O
functional None None O
properties None None O
of None None O
tetrodotoxin-resistant None None O
( None None O
TTX-R None None O
) None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
channels None None O
, None None O
the None None O
roles None None O
of None None O
tissue None None O
acidosis None None O
in None None O
nociceptive None None O
transmission None None O
mediated None None O
by None None O
TTX-R None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
channels None None O
are None None O
largely None None O
unknown None None O
. None None O

Acidic None None O
pH None None O
decreased None None O
the None None O
peak None None O
amplitude None None O
of None None O
TTX-R None None O
I None None O
( None None O
Na None None I-TRANS
) None None O
in None None O
a None None O
pH-dependent None None O
manner None None O
, None None O
but None None O
weak None None O
acid None None O
( None None O
≥pH None None O
6.0 None None O
) None None O
had None None O
a None None O
minor None None O
inhibitory None None O
effect None None O
on None None O
the None None O
TTX-R None None O
I None None O
( None None O
Na None None I-TRANS
) None None O
. None None O

In None None O
addition None None O
, None None O
acidic None None O
pH None None O
had None None O
little None None O
effect None None O
on None None O
the None None O
use-dependent None None O
inhibition None None O
, None None O
and None None O
significantly None None O
retarded None None O
the None None O
development None None O
of None None O
inactivation None None O
and None None O
accelerated None None O
the None None O
recovery None None O
from None None O
inactivation None None O
of None None O
TTX-R None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
channels None None O
. None None O

Given None None O
that None None O
both None None O
tissue None None O
acidosis None None O
and None None O
inflammatory None None O
mediators None None O
in None None O
inflamed None None O
or None None O
injured None None O
tissues None None O
act None None O
synergistically None None O
to None None O
promote None None O
nociceptive None None O
transmission None None O
by None None O
affecting None None O
the None None O
functional None None O
properties None None O
of None None O
TTX-R None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
channels None None O
, None None O
these None None O
channels None None O
would None None O
be None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
a None None O
good None None O
target None None O
to None None O
treat None None O
inflammatory None None O
pain None None O
. None None O

II None None O
achieved None None O
a None None O
speech None None I-FUNC
perception None None I-FUNC
for None None O
numbers None None O
of None None O
95 None None O
% None None O
( None None O
65 None None O
dB None None O
) None None O
and None None O
50 None None O
% None None O
( None None O
65 None None O
dB None None O
) None None O
for None None O
monosyllables None None O
. None None O

Sphingolipids None None O
are None None O
a None None O
highly None None O
conserved None None O
lipid None None O
component None None O
of None None O
cell None None O
membranes None None O
involved None None O
in None None O
the None None O
formation None None O
of None None O
lipid None None O
raft None None O
domains None None O
that None None O
house None None O
many None None O
of None None O
the None None O
receptors None None I-PROTEIN
and None None O
cell-to-cell None None O
signaling None None O
factors None None O
involved None None O
in None None O
regulating None None O
cell None None O
division None None O
, None None O
maturation None None O
, None None O
and None None O
terminal None None O
differentiation None None O
. None None O

Here None None O
, None None O
sleep None None O
electroencephalography None None O
( None None O
EEG None None O
) None None O
was None None O
recorded None None O
during None None O
a None None O
40-h None None O
multiple None None O
nap None None O
protocol None None O
, None None O
and None None O
working None None I-FUNC
memory None None I-FUNC
performance None None O
was None None O
assessed None None O
by None None O
the None None O
n-back None None O
task None None O
10 None None O
times None None O
before None None O
and None None O
after None None O
each None None O
scheduled None None O
nap None None O
sleep None None O
episode None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
genotype-driven None None O
differences None None O
in None None O
sleep None None O
depend None None O
on None None O
circadian None None O
phase None None O
: None None O
heterozygous None None O
participants None None O
were None None O
awake None None O
longer None None O
and None None O
slept None None O
less None None O
at None None O
the None None O
end None None O
of None None O
the None None O
biological None None O
day None None O
, None None O
while None None O
they None None O
exhibited None None O
longer None None O
non None None O
rapid None None O
eye None None O
movement None None I-FUNC
( None None O
NREM None None O
) None None O
sleep None None O
and None None O
slow None None O
wave None None O
sleep None None O
concomitant None None O
with None None O
reduced None None O
power None None O
between None None O
8-16 None None O
Hz None None O
at None None O
the None None O
end None None O
of None None O
the None None O
biological None None O
night None None O
. None None O

Moreover None None O
, None None O
REM None None O
sleep None None O
duration None None O
benefitted None None O
working None None I-FUNC
memory None None I-FUNC
particularly None None O
when None None O
occurring None None O
in None None O
the None None O
early None None O
morning None None O
hours None None O
and None None O
specifically None None O
in None None O
heterozygous None None O
individuals None None O
. None None O

They None None O
further None None O
indicate None None O
that None None O
REM None None O
sleep None None O
, None None O
being None None O
under None None O
strong None None O
circadian None None O
control None None O
, None None O
boosts None None O
working None None I-FUNC
memory None None I-FUNC
performance None None O
according None None O
to None None O
genotype None None O
in None None O
a None None O
time-of-day None None O
dependent None None O
manner None None O
. None None O

The None None O
unique None None O
cellular None None O
and None None O
vascular None None O
architecture None None O
of None None O
the None None O
adult None None O
ventricular-subventricular None None O
zone None None I-REGION
( None None O
V/SVZ None None O
) None None O
neurogenic None None O
niche None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
regulating None None O
neural None None O
stem None None O
cell None None O
function None None O
. None None O

Using None None O
whole-mount None None O
preparation None None O
of None None O
the None None O
lateral None None I-REGION
ventricle None None I-REGION
wall None None O
, None None O
we None None O
examined None None O
the None None O
architecture None None O
of None None O
neural None None O
stem None None O
cells None None O
and None None O
blood None None O
vessels None None O
in None None O
the None None O
V/SVZ None None O
of None None O
adult None None O
mouse None None O
over None None O
the None None O
course None None O
of None None O
3 None None O
months None None O
after None None O
onset None None O
of None None O
focal None None O
cerebral None None O
ischemia None None O
. None None O

Vascular None None O
volume None None O
in None None O
the None None O
V/SVZ None None O
was None None O
augmented None None O
from None None O
3 None None O
% None None O
of None None O
the None None O
total None None O
volume None None O
prior None None O
to None None O
stroke None None I-DISEASE
to None None O
6 None None O
% None None O
at None None O
90 None None O
days None None O
after None None O
stroke None None I-DISEASE
. None None O

These None None O
data None None O
indicate None None O
that None None O
stroke None None I-DISEASE
induces None None O
long-term None None O
alterations None None O
of None None O
the None None O
neural None None O
stem None None O
cell None None O
and None None O
vascular None None O
architecture None None O
of None None O
the None None O
adult None None O
V/SVZ None None O
neurogenic None None O
niche None None O
. None None O

With None None O
the None None O
gradual None None O
aging None None O
of None None O
the None None O
population None None O
, None None O
geriatric None None O
depression None None I-DISEASE
has None None O
become None None O
a None None O
major None None O
public None None O
health None None O
issue None None O
in None None O
China None None O
owing None None O
to None None O
its None None O
overall None None O
upward None None O
trend None None O
and None None O
associated None None O
negative None None O
socio-economic None None O
impact None None O
. None None O

Among None None O
these None None O
participants None None O
, None None O
majority None None O
were None None O
currently None None O
married None None O
, None None O
had None None O
attended None None O
elementary None None O
school None None O
or None None O
less None None O
, None None O
had None None O
an None None O
average None None O
annual None None O
family None None O
income None None O
of None None O
less None None O
than None None O
3000 None None O
Yuan/person None None O
, None None O
had None None O
strong None None O
religious None None O
beliefs None None O
while None None O
10.61 None None O
% None None O
( None None O
2.77 None None O
% None None O
in None None O
urban None None O
and None None O
23.60 None None O
% None None O
in None None O
rural None None O
area None None O
) None None O
had None None O
geriatric None None O
depression None None I-DISEASE
( None None O
5.91 None None O
% None None O
among None None O
male None None O
and None None O
14.58 None None O
% None None O
among None None O
females None None O
) None None O
. None None O

Religious None None O
belief None None O
( None None O
AOR None None O
= None None O
3.92 None None O
, None None O
95 None None O
% None None O
CI None None O
1.18-13.03 None None O
) None None O
, None None O
satisfaction None None O
regarding None None O
quality None None O
of None None O
life None None O
( None None O
AOR None None O
= None None O
0.53 None None O
, None None O
95 None None O
% None None O
CI None None O
0.37-0.84 None None O
) None None O
and None None O
income None None O
( None None O
AOR None None O
= None None O
0.75 None None O
, None None O
95 None None O
% None None O
CI None None O
0.35-1.60 None None O
) None None O
, None None O
suffering None None O
from None None O
more None None O
chronic None None O
diseases None None O
( None None O
AOR None None O
= None None O
1.70 None None O
, None None O
95 None None O
% None None O
CI None None O
1.42-2.04 None None O
) None None O
, None None O
experiencing None None O
three None None O
or None None O
more None None O
negative None None O
events None None O
( None None O
AOR None None O
= None None O
1.72 None None O
, None None O
95 None None O
% None None O
CI None None O
0.92-3.22 None None O
) None None O
and None None O
lack None None O
of None None O
ability None None O
to None None O
take None None O
self-care None None O
( None None O
AOR None None O
= None None O
2.20 None None O
, None None O
95 None None O
% None None O
CI None None O
1.09-4.48 None None O
) None None O
were None None O
all None None O
associated None None O
with None None O
having None None O
geriatric None None O
depression None None I-DISEASE
with None None O
or None None O
without None None O
adjustment None None O
for None None O
gender None None O
, None None O
education None None O
and None None O
occupation None None O
. None None O

Dynamic None None O
combinatorial None None O
chemistry None None O
was None None O
used None None O
to None None O
generate None None O
a None None O
set None None O
of None None O
receptors None None I-PROTEIN
for None None O
peptides None None I-TRANS
containing None None O
methylated None None O
lysine None None I-TRANS
( None None O
KMen None None O
, None None O
n None None O
= None None O
0-3 None None O
) None None O
and None None O
study None None O
the None None O
contribution None None O
of None None O
electrostatic None None O
effects None None O
and None None O
pocket None None O
depth None None O
to None None O
binding None None O
affinity None None O
and None None O
selectivity None None O
. None None O

The None None O
widespread None None O
thioredoxin None None O
superfamily None None O
enzymes None None I-PROTEIN
typically None None O
share None None O
the None None O
following None None O
features None None O
: None None O
a None None O
characteristic None None O
α-β None None O
fold None None O
, None None O
the None None O
presence None None O
of None None O
a None None O
Cys-X-X-Cys None None O
( None None O
or None None O
Cys-X-X-Ser None None O
) None None O
redox-active None None O
motif None None O
, None None O
and None None O
a None None O
proline None None I-TRANS
in None None O
the None None O
cis None None O
configuration None None O
abutting None None O
the None None O
redox-active None None O
site None None O
in None None O
the None None O
tertiary None None O
structure None None O
. None None O

However None None O
, None None O
crystal None None O
structures None None O
show None None O
that None None O
the None None O
Cys-X-X-Cys None None O
of None None O
the None None O
second None None O
domain None None O
is None None O
buried None None O
and None None O
that None None O
the None None O
adjacent None None O
proline None None I-TRANS
is None None O
in None None O
the None None O
trans None None O
, None None O
rather None None O
than None None O
the None None O
cis None None O
isomer None None O
. None None O

The None None O
Eps1p None None O
structures None None O
thus None None O
expand None None O
the None None O
documented None None O
diversity None None O
of None None O
the None None O
PDI None None O
oxidoreductase None None I-PROTEIN
family None None O
and None None O
demonstrate None None O
that None None O
conserved None None O
sequence None None O
motifs None None O
in None None O
common None None O
folds None None O
do None None O
not None None O
guarantee None None O
structural None None O
or None None O
functional None None O
conservation None None O
. None None O

Obesity None None O
is None None O
a None None O
major None None O
risk None None O
factor None None O
for None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
type-2 None None O
diabetes None None O
. None None O

Therefore None None O
, None None O
the None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
whether None None O
LT None None O
production None None O
was None None O
associated None None O
with None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
other None None O
metabolic None None O
parameters None None O
in None None O
a None None O
cohort None None O
of None None O
obese None None O
subjects None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
confirm None None O
the None None O
previously None None O
established None None O
notion None None O
of None None O
chronic None None O
low None None O
grade None None O
inflammation None None O
in None None O
obesity None None O
and None None O
further None None O
suggests None None O
a None None O
role None None O
for None None O
the None None O
LT None None O
pathway None None O
in None None O
obesity-associated None None O
development None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
humans None None O
. None None O

No None None O
differences None None O
in None None O
mean None None O
plasma None None O
substance None None I-TRANS
P None None I-TRANS
concentrations None None O
between None None O
treatment None None O
groups None None O
were None None O
observed None None O
( None None O
p None None O
= None None O
0.67 None None O
) None None O
. None None O

Our None None O
results None None O
demonstrated None None O
that None None O
early-passage None None O
pBMSCs None None O
are None None O
more None None O
potent None None O
in None None O
expressing None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
and None None O
displayed None None O
higher None None O
differentiation None None O
ability None None O
, None None O
and None None O
middle-passage None None O
pBMSCs None None O
transfected None None O
with None None O
Oct4 None None O
improved None None O
the None None O
developmental None None O
efficiency None None O
of None None O
NT None None O
embryos None None O
, None None O
suggesting None None O
that None None O
high None None O
Oct4 None None O
expression None None O
cells None None O
are None None O
more None None O
efficient None None O
as None None O
NT None None O
donors None None O
. None None O

After None None O
a None None O
differentiation None None O
protocol None None O
mimicking None None O
pancreatic None None O
development None None O
, None None O
HDDC None None O
populations None None O
contained None None O
about None None O
2 None None O
% None None O
of None None O
immature None None O
insulin-producing None None O
cells None None O
and None None O
showed None None O
glucose-unresponsive None None O
insulin None None I-PROTEIN
secretion None None O
. None None O

In None None O
renal None None O
tubular None None O
cells None None O
, None None O
TGF-β1 None None O
administration None None O
upregulated None None O
SHROOM3 None None O
expression None None O
in None None O
a None None O
β-catenin/TCF7L2-mediated None None O
manner None None O
, None None O
while None None O
SHROOM3 None None O
in None None O
turn None None O
facilitated None None O
canonical None None O
TGF-β1 None None O
signaling None None O
and None None O
increased None None O
α1 None None O
collagen None None I-PROTEIN
( None None O
COL1A1 None None O
) None None O
expression None None O
. None None O

Inflammation None None O
in None None O
response None None O
to None None O
excess None None O
low-density None None O
lipoproteins None None O
in None None O
the None None O
blood None None O
is None None O
an None None O
important None None O
driver None None O
of None None O
atherosclerosis None None I-DISEASE
development None None O
. None None O

However None None O
, None None O
LXR None None O
also None None O
upregulates None None O
the None None O
expression None None O
of None None O
sterol None None O
regulatory None None O
element-binding None None O
protein None None O
1c None None O
( None None O
SREBP-1c None None O
) None None O
, None None O
leading None None O
to None None O
increased None None O
hepatic None None O
triglyceride None None O
synthesis None None O
, None None O
an None None O
independent None None O
risk None None O
factor None None O
for None None O
atherosclerosis None None I-DISEASE
. None None O

Moreover None None O
, None None O
targeting None None O
the None None O
interaction None None O
between None None O
TRAP80 None None O
and None None O
LXR None None O
should None None O
facilitate None None O
the None None O
development None None O
of None None O
potential None None O
LXR None None O
agonists None None O
that None None O
effectively None None O
prevent None None O
atherosclerosis None None I-DISEASE
. None None O

Metabolic None None O
profiling None None O
revealed None None O
that None None O
pyruvate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
PDH None None O
) None None O
is None None O
a None None O
key None None O
bifurcation None None O
point None None O
between None None O
T None None O
cell None None O
glycolytic None None O
and None None O
oxidative None None O
metabolism None None O
. None None O

Long-term None None I-FUNC
potentiation None None I-FUNC
( None None O
LTP None None O
) None None O
of None None O
synaptic None None O
strength None None O
between None None O
hippocampal None None O
neurons None None O
is None None O
associated None None O
with None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
, None None O
and None None O
LTP None None O
dysfunction None None O
is None None O
thought None None O
to None None O
underlie None None O
memory None None I-FUNC
loss None None O
. None None O

While None None O
the None None O
nondecaying None None O
nature None None O
of None None O
LTP None None O
is None None O
thought None None O
to None None O
depend None None O
on None None O
protein None None O
synthesis None None O
and None None O
contribute None None O
to None None O
memory None None I-FUNC
maintenance None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
mechanisms None None O
and None None O
roles None None O
of None None O
decaying None None O
LTP None None O
. None None O

These None None O
results None None O
strongly None None O
suggest None None O
that None None O
an None None O
active None None O
process None None O
that None None O
involves None None O
AMPAR None None O
endocytosis None None O
mediates None None O
the None None O
decay None None O
of None None O
LTP None None O
and None None O
that None None O
inhibition None None O
of None None O
this None None O
process None None O
can None None O
prolong None None O
the None None O
longevity None None O
of None None O
LTP None None O
as None None O
well None None O
as None None O
memory None None I-FUNC
under None None O
both None None O
physiological None None O
and None None O
pathological None None O
conditions None None O
. None None O

Here None None O
we None None O
compare None None O
Sendai-viral None None O
( None None O
SeV None None O
) None None O
, None None O
episomal None None O
( None None O
Epi None None I-TRANS
) None None O
and None None O
mRNA None None O
transfection None None O
mRNA None None O
methods None None O
using None None O
a None None O
number None None O
of None None O
criteria None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
evaluate None None O
the None None O
extent None None O
of None None O
inflammation None None O
and None None O
the None None O
influence None None O
of None None O
glycemic None None O
control None None O
in None None O
the None None O
early None None O
phases None None O
of None None O
atherosclerosis None None I-DISEASE
in None None O
childhood None None O
type None None O
1 None None O
diabetes None None O
. None None O

Serum None None O
biochemical None None O
factors None None O
, None None O
including None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
and None None O
gamma-glutamyl None None O
transferase None None I-PROTEIN
( None None O
GGT None None O
) None None O
, None None O
were None None O
determined None None O
. None None O

The None None O
interaction None None O
effects None None O
between None None O
serum None None O
hepatic None None O
enzymes None None I-PROTEIN
and None None O
alcohol None None O
intake None None O
on None None O
baPWV None None O
were None None O
further None None O
evaluated None None O
. None None O

Further None None O
analyses None None O
revealed None None O
that None None O
the None None O
proportional None None O
associations None None O
between None None O
serum None None O
levels None None O
of None None O
hepatic None None O
enzymes None None I-PROTEIN
and None None O
baPWV None None O
were None None O
striking None None O
in None None O
the None None O
subjects None None O
without None None O
alcohol None None O
intake None None O
but None None O
not None None O
in None None O
those None None O
with None None O
alcohol None None O
intake None None O
. None None O

Normal None None O
findings None None O
that None None O
were None None O
scored None None O
were None None O
: None None O
gray-white None None O
differentiation None None O
of None None O
the None None O
brain None None O
, None None O
collapse None None O
of None None O
the None None O
ventricles None None I-REGION
, None None O
air None None O
in None None O
the None None O
orbit None None O
, None None O
fluid None None O
accumulation None None O
in None None O
the None None O
frontal None None O
and None None O
maxillary None None O
sinuses None None O
, None None O
and None None O
air None None O
in None None O
vessels None None O
of None None O
head None None O
and None None O
neck None None O
. None None O

Since None None O
Sallis None None O
and None None O
McKenzie None None O
's None None O
seminal None None O
article None None O
in None None O
1991 None None O
outlining None None O
physical None None O
education None None O
's None None O
role None None O
in None None O
public None None O
health None None O
, None None O
increased None None O
attention None None I-FUNC
has None None O
been None None O
given None None O
to None None O
promoting None None O
youth None None O
physical None None O
activity None None O
in None None O
schools None None O
. None None O

To None None O
investigate None None O
the None None O
effects None None O
of None None O
different None None O
head None None O
positions None None O
in None None O
the None None O
lateral None None O
decubitus None None O
posture None None O
on None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
. None None O

We None None O
assessed None None O
differences None None O
in None None O
the None None O
IOP None None I-TRANS
of None None O
the None None O
dependent None None O
and None None O
nondependent None None O
eyes None None O
in None None O
the None None O
lateral None None O
decubitus None None O
positions None None O
with None None O
different None None O
head None None O
positions None None O
. None None O

Low None None O
head None None O
position None None O
significantly None None O
increased None None O
the None None O
IOP None None I-TRANS
of None None O
dependent None None O
eyes None None O
, None None O
compared None None O
with None None O
the None None O
neutral None None O
or None None O
high None None O
head None None O
positions None None O
in None None O
lateral None None O
decubitus None None O
posture None None O
. None None O

Proper None None O
adjustment None None O
of None None O
the None None O
height None None O
of None None O
a None None O
pillow None None O
may None None O
help None None O
mitigate None None O
IOP None None I-TRANS
elevations None None O
resulting None None O
from None None O
lying None None O
on None None O
the None None O
side None None O
with None None O
a None None O
low None None O
pillow None None O
or None None O
with None None O
no None None O
pillow None None O
. None None O

Compared None None O
to None None O
quality None None O
specifications None None O
for None None O
bias None None O
, None None O
hemoglobin None None O
, None None O
hematocrit None None O
, None None O
albumin None None O
and None None O
total None None O
proteins None None O
exhibited None None O
meaningful None None O
increases None None O
from None None O
supine None None O
to None None O
sitting None None O
, None None O
whereas None None O
meaningful None None O
increases None None O
were None None O
observed None None O
for None None O
hemoglobin None None O
, None None O
hematocrit None None O
, None None O
albumin None None O
, None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ALP None None O
) None None O
, None None O
amylase None None I-PROTEIN
, None None O
aspartate None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
) None None O
, None None O
total None None O
bilirubin None None O
, None None O
calcium None None O
, None None O
total None None O
and None None O
high-density None None O
lipoprotein None None O
( None None O
HDL None None O
) None None O
cholesterol None None O
, None None O
gamma-glutamyl None None O
transferase None None I-PROTEIN
( None None O
GGT None None O
) None None O
, None None O
glucose None None O
, None None O
lactate None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
LDH None None O
) None None O
, None None O
magnesium None None O
, None None O
total None None O
protein None None O
and None None O
triglycerides None None O
from None None O
sitting None None O
to None None O
standing None None O
. None None O

Class None None O
I None None O
myosins None None O
can None None O
sense None None O
cellular None None O
mechanical None None O
forces None None O
and None None O
function None None O
as None None O
tension-sensitive None None O
anchors None None O
or None None O
transporters None None I-PROTEIN
. None None O

A None None O
series None None O
of None None O
structurally None None O
related None None O
jatrophane None None O
diterpenoids None None O
( None None O
1-6 None None O
) None None O
, None None O
including None None O
the None None O
new None None O
euphosquamosins None None O
A-C None None O
( None None O
4-6 None None O
) None None O
, None None O
was None None O
purified None None O
from None None O
the None None O
Iranian None None O
spurge None None O
Euphorbia None None O
squamosa None None O
and None None O
evaluated None None O
for None None O
its None None O
capacity None None O
to None None O
inhibit None None O
drug None None O
efflux None None O
by None None O
multidrug None None O
transporters None None I-PROTEIN
of None None O
Candida None None O
albicans None None O
. None None O

Anti-inflammatory None None O
activity None None O
of None None O
new None None O
metabolites None None O
to None None O
inhibit None None O
the None None O
superoxide None None O
anion None None O
generation None None O
and None None O
elastase None None I-PROTEIN
release None None O
in None None O
N-formyl-methionyl-leucyl None None O
phenylalanine/cytochalasin None None O
B None None O
( None None O
FMLP/CB None None O
) None None O
-induced None None O
human None None O
neutrophil None None O
cells None None O
and None None O
cytotoxicity None None O
of None None O
both None None O
new None None O
compounds None None O
toward None None O
five None None O
cancer None None O
cell None None O
lines None None O
were None None O
reported None None O
. None None O

Major None None O
regulators None None O
of None None O
SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
ATPase None None I-PROTEIN
( None None O
SERCA2a None None O
) None None O
are None None O
the None None O
phosphorylation None None O
status None None O
of None None O
a None None O
regulatory None None O
protein None None O
, None None O
phospholamban None None O
, None None O
and None None O
SERCA2a None None O
expression None None O
, None None O
which None None O
are None None O
diminished None None O
in None None O
the None None O
failing None None O
heart None None O
. None None O

Therefore None None O
, None None O
we None None O
tested None None O
the None None O
hypothesis None None O
that None None O
taurine None None O
deficiency None None O
leads None None O
to None None O
alterations None None O
in None None O
SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
ATPase None None I-PROTEIN
activity None None O
related None None O
to None None O
reduced None None O
phospholamban None None O
phosphorylation None None O
and None None O
expression None None O
of None None O
SERCA2a None None O
. None None O

However None None O
, None None O
the None None O
reduction None None O
in None None O
SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
ATPase None None I-PROTEIN
activity None None O
was None None O
not None None O
caused None None O
by None None O
reduced None None O
SERCA2a None None O
expression None None O
. None None O

The None None O
findings None None O
support None None O
the None None O
observation None None O
that None None O
taurine None None O
deficient None None O
hearts None None O
develop None None O
systolic None None O
and None None O
diastolic None None O
defects None None O
related None None O
to None None O
reduced None None O
SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
ATPase None None I-PROTEIN
activity None None O
, None None O
a None None O
change None None O
mediated None None O
in None None O
part None None O
by None None O
reduced None None O
phospholamban None None O
phosphorylation None None O
. None None O

The None None O
addition None None O
of None None O
phosphatase None None I-PROTEIN
to None None O
the None None O
patch None None O
pipette None None O
rescued None None O
TASK-1 None None O
current None None O
from None None O
myocytes None None O
isolated None None O
from None None O
AF None None O
hearts None None O
, None None O
indicating None None O
that None None O
the None None O
change None None O
in None None O
current None None O
is None None O
phosphorylation None None O
dependent None None O
. None None O

The None None O
IV None None O
anesthetic None None O
, None None O
propofol None None O
, None None O
when None None O
administered None None O
as None None O
fat None None O
emulsion-based None None O
formulation None None O
( None None O
Diprivan None None O
) None None O
promotes None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
but None None O
the None None O
direct None None O
effects None None O
of None None O
propofol None None O
and None None O
its None None O
solvent None None O
, None None O
Intralipid None None O
, None None O
on None None O
cardiac None None O
insulin None None I-PROTEIN
resistance None None O
are None None O
unknown None None O
. None None O

GLUT4 None None O
trafficking None None O
and None None O
phosphorylations None None O
of None None O
insulin None None I-PROTEIN
receptor None None I-PROTEIN
substrate-1 None None O
( None None O
IRS-1 None None O
) None None O
at None None O
Ser307 None None O
( None None O
h312 None None O
) None None O
, None None O
Ser1100 None None O
( None None O
h1101 None None O
) None None O
, None None O
and None None O
Tyr608 None None O
( None None O
hTyr612 None None O
) None None O
were None None O
measured None None O
. None None O

Those None None O
diagnosed None None O
with None None O
a None None O
personality None None I-DISEASE
disorder None None I-DISEASE
were None None O
significantly None None O
more None None O
impaired None None O
at None None O
follow-up None None O
than None None O
those None None O
without None None O
. None None O

The None None O
treatment None None O
outcome None None O
of None None O
depression None None I-DISEASE
was None None O
poorer None None O
for None None O
the None None O
group None None O
with None None O
Axis None None O
II None None O
disorders None None O
compared None None O
to None None O
those None None O
without None None O
. None None O

Special None None O
attention None None I-FUNC
should None None O
be None None O
paid None None O
to None None O
Axis None None O
II None None O
traits None None O
when None None O
planning None None O
and None None O
conducting None None O
the None None O
treatment None None O
of None None O
adolescent None None O
depression None None I-DISEASE
. None None O

The None None O
main None None O
objective None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
test None None O
an None None O
association None None O
between None None O
CYP2D6 None None I-PROTEIN
polymorphism None None O
and None None O
mental None None O
and None None O
personality None None I-DISEASE
disorders None None I-DISEASE
among None None O
suicide None None O
attempters None None O
. None None O

Suicide None None O
attempters None None O
were None None O
divided None None O
into None None O
four None None O
groups None None O
according None None O
to None None O
their None None O
number None None O
of None None O
CYP2D6 None None I-PROTEIN
active None None O
genes None None O
( None None O
zero None None O
, None None O
one None None O
, None None O
and None None O
two None None O
or None None O
more None None O
) None None O
. None None O

Suicide None None O
attempters None None O
carrying None None O
two None None O
or None None O
more None None O
active None None O
CYP2D6 None None I-PROTEIN
genes None None O
were None None O
more None None O
likely None None O
to None None O
be None None O
diagnosed None None O
with None None O
at None None O
least None None O
one None None O
personality None None I-DISEASE
disorder None None I-DISEASE
than None None O
those None None O
with None None O
one None None O
or None None O
zero None None O
CYP2D6 None None I-PROTEIN
active None None O
genes None None O
. None None O

Experimental None None O
results None None O
showed None None O
that None None O
zinc None None I-TRANS
( None None O
Zn None None O
) None None O
had None None O
the None None O
greatest None None O
bioaccessible None None O
fraction None None O
, None None O
recorded None None O
as None None O
an None None O
average None None O
of None None O
608.53 None None O
mg/kg None None O
, None None O
followed None None O
in None None O
order None None O
of None None O
decreasing None None O
concentration None None O
by None None O
129.80 None None O
mg/kg None None O
lead None None O
( None None O
Pb None None O
) None None O
, None None O
56.77 None None O
mg/kg None None O
copper None None O
( None None O
Cu None None O
) None None O
, None None O
34.03 None None O
mg/kg None None O
chromium None None O
( None None O
Cr None None O
) None None O
, None None O
22.05 None None O
mg/kg None None O
nickel None None O
( None None O
Ni None None O
) None None O
, None None O
13.17 None None O
mg/kg None None O
arsenic None None O
( None None O
As None None O
) None None O
and None None O
2.77 None None O
mg/kg None None O
cadmium None None O
( None None O
Cd None None O
) None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
work None None O
is None None O
to None None O
investigate None None O
placebo None None O
response None None O
rates None None O
in None None O
placebo-controlled None None O
randomized None None O
clinical None None O
trials None None O
( None None O
RCTs None None O
) None None O
of None None O
pharmacological None None O
therapy None None O
in None None O
bipolar None None O
depression None None I-DISEASE
( None None O
BPD None None O
) None None O
and None None O
to None None O
identify None None O
predictors None None O
of None None O
placebo None None O
response None None O
and None None O
clinical None None O
trial None None O
outcome None None O
in None None O
BPD None None O
. None None O

The None None O
neuroanatomy None None O
of None None O
language None None I-FUNC
lateralization None None O
and None None O
the None None O
corresponding None None O
synchronous None None O
functional None None O
connectivity None None O
( None None O
FC None None O
) None None O
in None None O
handedness None None O
cohorts None None O
are None None O
not None None O
, None None O
however None None O
, None None O
fully None None O
understood None None O
. None None O

Our None None O
findings None None O
suggest None None O
that None None O
LH None None O
have None None O
atypical None None O
connectivity None None O
in None None O
the None None O
language None None I-FUNC
network None None O
, None None O
with None None O
an None None O
enhanced None None O
role None None O
of None None O
the None None O
STG None None O
, None None O
findings None None O
which None None O
provide None None O
novel None None O
insights None None O
into None None O
the None None O
structural None None O
and None None O
functional None None O
substrates None None O
underlying None None O
the None None O
atypical None None O
language None None I-FUNC
development None None O
of None None O
left-handed None None O
individuals None None O
. None None O

Behavioural None None O
variant None None O
frontotemporal None None I-DISEASE
dementia None None I-DISEASE
( None None O
bvFTD None None O
) None None O
is None None O
a None None O
debilitating None None O
neurodegenerative None None O
disorder None None O
characterized None None O
by None None O
frontal None None O
and None None O
temporal None None I-REGION
lobe None None I-REGION
atrophy None None O
primarily None None O
affecting None None O
social None None I-FUNC
cognition None None I-FUNC
and None None O
emotion None None I-FUNC
, None None O
including None None O
loss None None O
of None None O
empathy None None O
. None None O

Cognitive None None O
and None None O
emotional None None I-FUNC
empathy None None I-FUNC
deficits None None O
have None None O
been None None O
associated None None O
with None None O
bvFTD None None O
; None None O
however None None O
, None None O
little None None O
is None None O
known None None O
regarding None None O
the None None O
performance None None O
of None None O
patients None None O
with None None O
bvFTD None None O
on None None O
behavioural None None O
measures None None O
of None None O
emotional None None I-FUNC
empathy None None I-FUNC
, None None O
and None None O
whether None None O
empathic None None O
responses None None O
differ None None O
for None None O
negative None None O
versus None None O
positive None None O
stimuli None None O
. None None O

Lastly None None O
, None None O
the None None O
MET None None O
and None None O
IRI None None O
measures None None O
of None None O
emotional None None I-FUNC
empathy None None I-FUNC
were None None O
found None None O
to None None O
be None None O
significantly None None O
correlated None None O
within None None O
the None None O
bvFTD None None O
group None None O
. None None O

Further None None O
, None None O
a None None O
generalized None None O
emotional None None I-FUNC
processing None None I-FUNC
impairment None None O
for None None O
negative None None O
stimuli None None O
was None None O
observed None None O
, None None O
which None None O
could None None O
contribute None None O
to None None O
the None None O
emotional None None I-FUNC
empathy None None I-FUNC
deficit None None O
. None None O

Piperine None None O
, None None O
the None None O
pungent None None O
alkaloid None None O
of None None O
black None None O
pepper None None O
, None None O
and None None O
several None None O
of None None O
its None None O
derivatives None None O
are None None O
modulators None None O
of None None O
γ-amino None None O
butyric None None O
acid None None O
type None None O
A None None O
( None None O
GABAA None None O
) None None O
receptors None None I-PROTEIN
. None None O

Patients None None O
in None None O
a None None O
`` None None O
one-stop None None O
'' None None O
service None None O
( None None O
ACC None None O
; None None O
N None None O
= None None O
89 None None O
) None None O
vs None None O
those None None O
in None None O
standard None None O
care None None O
clinics None None O
( None None O
CDC None None O
; None None O
N None None O
= None None O
243 None None O
) None None O
were None None O
compared None None O
on None None O
HIV None None O
treatment None None O
and None None O
retention None None I-FUNC
in None None O
care None None O
outcomes None None O
. None None O

Acupuncture None None O
is None None O
frequently None None O
advocated None None O
as None None O
an None None O
adjunct None None O
treatment None None O
during None None O
stroke None None I-DISEASE
rehabilitation None None O
. None None O

Randomized None None O
controlled None None O
trials None None O
( None None O
RCT None None O
) None None O
on None None O
acupuncture None None O
treating None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
were None None O
searched None None O
from None None O
the None None O
following None None O
databases None None O
: None None O
PubMed None None O
, None None O
EMBASE None None O
, None None O
Cochrane None None O
Library None None O
, None None O
CNKI None None O
, None None O
CMB None None O
and None None O
VIP None None I-TRANS
from None None O
inception None None O
to None None O
October None None O
2013 None None O
. None None O

Current None None O
evidence None None O
provisionally None None O
demonstrates None None O
that None None O
acupuncture None None O
treatment None None O
is None None O
superior None None O
to None None O
either None None O
non-acupuncture None None O
or None None O
conventional None None O
therapy None None O
for None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
. None None O

Here None None O
we None None O
addressed None None O
this None None O
question None None O
by None None O
investigating None None O
with None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
the None None O
haemodynamic None None O
response None None O
during None None O
executive-type None None O
processing None None O
using None None O
a None None O
phonological None None O
verbal None None O
fluency None None O
and None None O
a None None O
working None None I-FUNC
memory None None I-FUNC
task None None O
in None None O
VPT-born None None O
young None None O
adults None None O
who None None O
had None None O
experienced None None O
differing None None O
degrees None None O
of None None O
neonatal None None O
brain None None O
injury None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
during None None O
the None None O
n-back None None O
task None None O
and None None O
as None None O
working None None I-FUNC
memory None None I-FUNC
load None None O
increased None None O
, None None O
the None None O
PVH+VD None None O
group None None O
showed None None O
less None None O
engagement None None O
of None None O
the None None O
frontal None None I-REGION
cortex None None I-REGION
than None None O
the None None O
UPVH None None O
group None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
low None None O
PS None None O
may None None O
involve None None O
an None None O
imbalance None None O
in None None O
processing None None O
distinct None None O
emotional None None O
inputs None None O
, None None O
with None None O
greater None None O
reactivity None None O
to None None O
aversive None None O
information None None O
in None None O
regions None None O
involved None None O
in None None O
avoidance None None O
behaviour None None O
( None None O
amygdala None None I-REGION
, None None O
OFC None None O
) None None O
and None None O
dampened None None O
response None None O
to None None O
positive None None O
and None None O
neutral None None O
stimuli None None O
across None None O
circuits None None O
subserving None None O
motivated None None O
behaviour None None O
( None None O
striatum None None I-REGION
, None None O
hippocampus None None I-REGION
, None None O
amygdala None None I-REGION
) None None O
. None None O

These None None O
findings None None O
in None None O
non-depressed None None O
subjects None None O
point None None O
to None None O
a None None O
neural None None O
mechanism None None O
whereby None None O
some None None O
individuals None None O
are None None O
more None None O
likely None None O
to None None O
show None None O
systematic None None O
negative None None O
emotional None None O
biases None None O
, None None O
as None None O
frequently None None O
observed None None O
in None None O
depression None None I-DISEASE
. None None O

Cetuximab None None O
, None None O
a None None O
chimeric None None O
monoclonal None None O
antibody None None O
developed None None O
for None None O
targeting None None O
the None None O
Epidermal None None I-PROTEIN
Growth None None I-PROTEIN
Factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
, None None O
has None None O
been None None O
intensively None None O
used None None O
to None None O
treat None None O
cancer None None O
patients None None O
with None None O
metastatic None None O
colorectal None None O
cancer None None O
and None None O
head None None O
and None None O
neck None None O
cancer None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
the None None O
scaffold None None O
protein None None O
AMBRA1 None None O
, None None O
a None None O
member None None O
of None None O
the None None O
autophagy None None O
signalling None None O
network None None O
and None None O
a None None O
downstream None None O
target None None O
of None None O
mTOR None None O
, None None O
regulates None None O
cell None None O
proliferation None None O
by None None O
facilitating None None O
the None None O
dephosphorylation None None O
and None None O
degradation None None O
of None None O
the None None O
proto-oncogene None None O
c-Myc None None I-PROTEIN
. None None O

As None None O
expected None None O
, None None O
such None None O
a None None O
de-regulation None None O
of None None O
c-Myc None None I-PROTEIN
correlates None None O
with None None O
increased None None O
tumorigenesis None None O
in None None O
AMBRA1-defective None None O
systems None None O
, None None O
thus None None O
supporting None None O
a None None O
role None None O
for None None O
AMBRA1 None None O
as None None O
a None None O
haploinsufficient None None O
tumour None None O
suppressor None None O
gene None None O
. None None O

The None None O
sequential None None O
secretion None None O
of None None O
insulin None None I-PROTEIN
and None None O
glucagon None None I-TRANS
delicately None None O
maintains None None O
glucose None None O
homeostasis None None O
by None None O
inhibiting None None O
or None None O
enhancing None None O
hepatic None None O
gluconeogenesis None None O
during None None O
postprandial None None O
or None None O
fasting None None O
states None None O
, None None O
respectively None None O
. None None O

Herein None None O
, None None O
we None None O
reveal None None O
that None None O
the None None O
early None None O
growth None None O
response None None O
gene-1 None None O
( None None O
Egr-1 None None O
) None None O
can None None O
be None None O
transiently None None O
activated None None O
by None None O
glucagon None None I-TRANS
in None None O
hepatocytes None None O
, None None O
which None None O
mediates None None O
glucagon-regulated None None O
gluconeogenesis None None O
by None None O
increasing None None O
the None None O
expression None None O
of None None O
gluconeogenesis None None O
genes None None O
. None None O

The None None O
mechanism None None O
analysis None None O
demonstrated None None O
that None None O
Egr-1 None None O
can None None O
directly None None O
bind None None O
to None None O
the None None O
promoter None None O
of None None O
C/EBPa None None O
and None None O
regulate None None O
the None None O
expression None None O
of None None O
gluconeogenesis None None O
genes None None O
in None None O
the None None O
later None None O
phase None None O
of None None O
glucagon None None I-TRANS
stimulation None None O
. None None O

Consistent None None O
with None None O
findings None None O
in None None O
other None None O
organs None None O
, None None O
loss None None O
of None None O
JAM-A None None O
decreased None None O
β1 None None O
integrin None None I-PROTEIN
expression None None O
and None None O
impaired None None O
filamentous None None O
actin None None I-PROTEIN
formation None None O
. None None O

FGAL None None O
inhibited None None O
and None None O
rightward None None O
shifted None None O
Phe-induced None None O
cumulative None None O
contraction‑response None None O
curves None None O
, None None O
indicating None None O
a None None O
noncompetitive None None O
antagonism None None O
of None None O
α1 None None O
adrenergic None None O
receptors None None I-PROTEIN
. None None O

FGAL None None O
inhibited None None O
and None None O
rightward None None O
shifted None None O
CaCl2-induced None None O
cumulative None None O
contraction-response None None O
curves None None O
in None None O
both None None O
depolarizing None None O
medium None None O
( None None O
high None None O
K+ None None O
) None None O
and None None O
in None None O
the None None O
presence None None O
of None None O
verapamil None None O
and None None O
phenylephrine None None O
, None None O
suggesting None None O
inhibition None None O
of None None O
Ca2+ None None O
influx None None O
through None None O
voltage-gated None None I-PROTEIN
calcium None None I-PROTEIN
channels None None I-PROTEIN
( None None O
CaV None None O
) None None O
and None None O
receptor None None I-PROTEIN
operated None None O
channels None None O
( None None O
ROCs None None O
) None None O
, None None O
respectively None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
full-length None None O
cDNA None None O
encoding None None I-FUNC
HMGS None None O
was None None O
isolated None None O
from None None O
Tripterygium None None O
wilfordii None None O
( None None O
abbreviated None None O
TwHMGS None None O
, None None O
GenBank None None O
accession None None O
number None None O
: None None O
KM978213 None None O
) None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
improve None None O
the None None O
antitumor None None O
activity None None O
and None None O
reduce None None O
the None None O
side None None O
effects None None O
of None None O
irinotecan None None O
( None None O
2 None None O
) None None O
, None None O
novel None None O
prodrugs None None O
of None None O
SN-38 None None O
( None None O
3 None None O
) None None O
were None None O
prepared None None O
by None None O
conjugating None None O
amino None None I-TRANS
acids None None I-TRANS
or None None O
dipeptides None None O
to None None O
the None None O
10-hydroxyl None None O
group None None O
of None None O
SN-38 None None O
via None None O
a None None O
carbamate None None O
linkage None None O
. None None O

As None None O
a None None O
proof None None O
of None None O
concept None None O
, None None O
we None None O
used None None O
insulin None None I-PROTEIN
as None None O
the None None O
target None None O
molecule None None O
to None None O
reveal None None O
in None None O
solution None None O
. None None O

Intra-accumbal None None O
infusion None None O
of None None O
the None None O
α1-adrenergic None None O
agonist None None O
methoxamine None None O
, None None O
which None None O
has None None O
comparable None None O
affinity None None O
for None None O
α1A- None None O
, None None O
α1B- None None O
and None None O
α1D-adrenoceptor None None O
subtypes None None O
, None None O
fails None None O
to None None O
alter None None O
noradrenaline None None I-TRANS
efflux None None O
but None None O
reduces None None O
dopamine None None I-TRANS
efflux None None O
in None None O
the None None O
nucleus None None I-REGION
accumbens None None I-REGION
of None None O
rats None None O
. None None O

The None None O
present None None O
study None None O
also None None O
provides None None O
in-vivo None None O
neurochemical None None O
evidence None None O
indicating None None O
that None None O
concomitant None None O
, None None O
but None None O
not None None O
separate None None O
, None None O
activation None None O
of None None O
the None None O
α1A- None None O
, None None O
α1B- None None O
and None None O
α1D-adrenoceptors None None O
in None None O
the None None O
nucleus None None I-REGION
accumbens None None I-REGION
is None None O
required None None O
for None None O
α1-adrenergic None None O
inhibition None None O
of None None O
accumbal None None O
dopaminergic None None O
activity None None O
. None None O

This None None O
article None None O
presents None None O
a None None O
single None None O
case None None O
study None None O
on None None O
the None None O
feasibility None None O
of None None O
using None None O
a None None O
low-cost None None O
and None None O
portable None None O
vision-based None None O
system None None O
( None None O
a None None O
Microsoft None None O
Kinect None None O
sensor None None O
) None None O
to None None O
monitor None None O
changes None None O
in None None O
movement None None I-FUNC
patterns None None O
before None None O
and None None O
after None None O
a None None O
total None None O
hip None None O
replacement None None O
surgery None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
develop None None O
and None None O
describe None None O
the None None O
technique None None O
of None None O
piezoelectric None None O
surgery None None O
for None None O
dorsal None None I-NEURON
laminectomy None None O
and None None O
to None None O
assess None None O
its None None O
clinical None None O
safety None None O
in None None O
normal None None O
sheep None None O
. None None O

Following None None O
technique None None O
development None None O
, None None O
six None None O
live None None O
sheep None None O
underwent None None O
a None None O
piezoelectric None None O
( None None O
n None None O
= None None O
6 None None O
) None None O
two-level None None O
dorsal None None I-NEURON
laminectomy None None O
at None None O
L2-L3 None None O
and None None O
L4-L5 None None O
( None None O
PiezoL2-3,4-5 None None O
) None None O
, None None O
and None None O
another None None O
30 None None O
live None None O
sheep None None O
underwent None None O
a None None O
three-level None None O
laminectomy None None O
at None None O
L1 None None O
, None None O
L3 None None O
, None None O
and None None O
L5 None None O
( None None O
PiezoL1,3,5 None None O
) None None O
for None None O
a None None O
total None None O
of None None O
102 None None O
laminectomy None None O
sites None None O
. None None O

Dorsal None None I-NEURON
laminectomy None None O
was None None O
safely None None O
and None None O
accurately None None O
performed None None O
in None None O
35/36 None None O
study None None O
sheep None None O
using None None O
a None None O
Piezoelectric None None O
surgical None None O
instrument None None O
. None None O

Subjectively None None O
, None None O
PiezoL None None O
was None None O
easy None None O
to None None O
perform None None O
and None None O
with None None O
a None None O
rapid None None O
learning None None I-FUNC
curve None None O
. None None O

Based None None O
on None None O
our None None O
study None None O
, None None O
PiezoL None None O
is None None O
considered None None O
a None None O
safe None None O
and None None O
viable None None O
technique None None O
for None None O
performing None None O
ovine None None O
dorsal None None I-NEURON
laminectomy None None O
in None None O
the None None O
preclinical None None O
research None None O
setting None None O
. None None O

Differential None None O
reactivity None None O
of None None O
genes None None O
to None None O
androgens None None I-PROTEIN
and None None O
thyroid None None O
hormone None None O
in None None O
ARKO None None O
mice None None O
may None None O
shed None None O
light None None O
on None None O
the None None O
mechanism None None O
of None None O
androgen None None O
action None None O
in None None O
the None None O
SMG None None O
. None None O

Complications None None O
and None None O
parameters None None O
such None None O
as None None O
feeling None None I-FUNC
of None None O
pop None None O
during None None O
tenotomy None None O
and None None O
ankle None None O
dorsiflexion None None O
during None None O
tenotomy None None O
were None None O
also None None O
compared None None O
. None None O

There None None O
was None None O
no None None O
statistically None None O
significant None None O
difference None None O
between None None O
the None None O
two None None O
groups None None O
in None None O
their None None O
ankle None None O
joint None None O
dorsiflexion None None O
, None None O
feeling None None I-FUNC
of None None O
pop None None O
, None None O
and None None O
final None None O
follow-up None None O
Dimeglio None None O
score None None O
. None None O

Complications None None O
such None None O
as None None O
navicular None None O
dorsal None None I-NEURON
subluxation None None O
and None None O
valgus None None O
overcorrection None None O
were None None O
less None None O
common None None O
in None None O
group None None O
2 None None O
. None None O

In None None O
part None None O
, None None O
this None None O
is None None O
attributable None None O
to None None O
insufficient None None O
attention None None I-FUNC
being None None O
paid None None O
to None None O
the None None O
social None None O
and None None O
governance None None O
processes None None O
that None None O
drive None None O
decisions None None O
and None None O
can None None O
undermine None None O
their None None O
implementation None None O
. None None O

However None None O
, None None O
the None None O
effective None None O
application None None O
of None None O
SES None None O
models None None O
has None None O
been None None O
limited None None O
by None None O
the None None O
insufficient None None O
attention None None I-FUNC
given None None O
to None None O
governance None None O
influences None None O
. None None O

The None None O
results None None O
of None None O
toxicogenomic None None O
data None None O
indicated None None O
that None None O
: None None O
( None None O
1 None None O
) None None O
TBT None None O
cotreatment None None O
rescued None None O
the None None O
embryos None None O
from None None O
decreased None None O
hatching None None O
ratio None None O
caused None None O
by None None O
BaP None None O
alone None None O
, None None O
while None None O
the None None O
alteration None None O
of None None O
gene None None O
expression None None O
( None None O
in None None O
this None None O
article None None O
the None None O
phrase None None O
gene None None O
expression None None O
is None None O
used None None O
as None None O
a None None O
synonym None None O
to None None O
gene None None O
transcription None None O
, None None O
although None None O
in None None O
is None None O
acknowledged None None O
that None None O
gene None None O
expression None None O
can None None O
also None None O
be None None O
regulated None None O
by None None O
, None None O
e.g. None None O
, None None O
translation None None O
and None None O
mRNA None None O
or None None O
protein None None O
stability None None O
) None None O
relative None None O
to None None O
zebrafish None None O
hatching None None O
in None None O
the None None O
BaP None None O
groups None None O
was None None O
resumed None None O
by None None O
the None None O
cotreatment None None O
with None None O
TBT None None O
; None None O
( None None O
2 None None O
) None None O
BaP None None O
cotreatment None None O
decreased None None O
TBT-mediated None None O
dorsal None None I-NEURON
curvature None None O
, None None O
and None None O
alleviated None None O
the None None O
perturbation None None O
of None None O
Notch None None O
pathway None None O
caused None None O
by None None O
TBT None None O
alone None None O
; None None O
( None None O
3 None None O
) None None O
cotreatment None None O
with None None O
TBT None None O
decreased None None O
BaP-mediated None None O
bradycardia None None O
, None None O
which None None O
might None None O
be None None O
due None None O
to None None O
that None None O
TBT None None O
cotreatment None None O
alleviated None None O
the None None O
perturbation None None O
in None None O
expression None None O
of None None O
genes None None O
related None None O
to None None O
cardiac None None O
muscle None None O
cell None None O
development None None O
and None None O
calcium None None O
handling None None O
caused None None O
by None None O
BaP None None O
alone None None O
; None None O
4 None None O
) None None O
TBT None None O
cotreatment None None O
brought None None O
an None None O
antagonistic None None O
effect None None O
on None None O
the None None O
BaP-mediated None None O
oxidative None None O
stress None None O
and None None O
DNA None None O
damage None None O
. None None O

Concentrations None None O
of None None O
metals None None O
were None None O
measured None None O
with None None O
AAS None None O
( None None O
copper None None O
- None None O
Cu None None O
, None None O
iron None None O
- None None O
Fe None None O
, None None O
magnesium None None O
- None None O
Mg None None O
, None None O
zinc None None I-TRANS
- None None O
Zn None None O
) None None O
and None None O
CV-AAS None None O
( None None O
mercury None None O
- None None O
Hg None None O
) None None O
. None None O

Higher None None O
phosphorus None None O
retention None None I-FUNC
efficiencies None None O
were None None O
observed None None O
in None None O
the None None O
second None None O
and None None O
third None None O
layers None None O
of None None O
sediment None None O
from None None O
days None None O
10 None None O
to None None O
20 None None O
with None None O
the None None O
ORC None None O
. None None O

The None None O
microbial None None O
activities None None O
of None None O
the None None O
sediment None None O
samples None None O
demonstrated None None O
that None None O
both None None O
the None None O
dehydrogenase None None I-PROTEIN
activity None None O
( None None O
DHA None None O
) None None O
and None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
activity None None O
( None None O
APA None None O
) None None O
in None None O
the None None O
upper None None O
sediment None None O
layer None None O
increased None None O
with None None O
the None None O
ORC None None O
treatment None None O
, None None O
which None None O
indicated None None O
that None None O
the None None O
mineralization None None O
of None None O
P None None O
was None None O
accelerated None None O
and None None O
the None None O
microbial None None O
biomass None None O
was None None O
increased None None O
. None None O

During None None O
study None None O
period None None O
, None None O
results None None O
showed None None O
that None None O
rainfall None None O
was None None O
the None None O
main None None O
factor None None O
of None None O
maintenance None None O
hydraulic None None O
conditions None None O
, None None O
while None None O
evapotranspiration None None O
was None None O
driver None None O
of None None O
variations None None O
in None None O
water None None O
storage None None I-FUNC
level None None O
. None None O

Due None None O
to None None O
the None None O
short None None O
hydraulic None None O
retention None None I-FUNC
time None None O
, None None O
effluents None None O
of None None O
these None None O
septic None None O
tanks None None O
are None None O
still None None O
highly None None O
polluted None None O
, None None O
and None None O
there None None O
is None None O
usually None None O
high None None O
accumulation None None O
of None None O
septic None None O
tank None None O
sludge None None O
or None None O
septage None None O
containing None None O
high None None O
levels None None O
of None None O
organics None None O
and None None O
pathogens None None O
that None None O
requires None None O
frequent None None O
desludging None None O
and None None O
subsequent None None O
treatment None None O
. None None O

We None None O
first None None O
isolated None None O
the None None O
full-length None None O
cDNA None None O
encoding None None I-FUNC
LeAPL1 None None O
( None None O
GenBank None None O
Accession None None O
No None None O
. None None O

KJ603243 None None O
) None None O
; None None O
they None None O
contained None None O
open None None O
reading None None O
frames None None O
of None None O
1554 None None O
bp None None O
( None None O
57.7-kDa None None O
polypeptide None None O
of None None O
517 None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
and None None O
1578 None None O
bp None None O
( None None O
57.0 None None O
kDa None None O
polypeptide None None O
of None None O
525 None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
, None None O
respectively None None O
. None None O

IbOr None None O
plants None None O
exhibited None None O
increased None None O
carotenoid None None O
levels None None O
( None None O
up None None O
to None None O
7-fold None None O
) None None O
in None None O
their None None O
storage None None I-FUNC
roots None None O
compared None None O
to None None O
wild None None O
type None None O
( None None O
WT None None O
) None None O
plants None None O
, None None O
as None None O
revealed None None O
by None None O
HPLC None None O
analysis None None O
. None None O

The None None O
yields None None O
of None None O
storage None None I-FUNC
roots None None O
and None None O
aerial None None O
parts None None O
of None None O
IbOr None None O
plants None None O
and None None O
WT None None O
plants None None O
were None None O
not None None O
significantly None None O
different None None O
under None None O
field None None O
cultivation None None O
. None None O

Towards None None O
this None None O
goal None None O
we None None O
used None None O
four None None O
contrasting None None O
soybean None None O
( None None O
Glycine None None I-TRANS
max None None O
) None None O
genotypes None None O
( None None O
PI None None O
567690 None None O
-- None None O
drought None None O
tolerant None None O
, None None O
Pana None None O
-- None None O
drought None None O
susceptible None None O
, None None O
PI None None O
408105A None None O
-- None None O
flooding None None O
tolerant None None O
, None None O
S99-2281 None None O
-- None None O
flooding None None O
susceptible None None O
) None None O
grown None None O
under None None O
greenhouse None None O
conditions None None O
and None None O
compared None None O
genotypic None None O
responses None None O
to None None O
drought None None O
and None None O
flooding None None O
at None None O
the None None O
physiological None None O
, None None O
biochemical None None O
, None None O
and None None O
cellular None None O
level None None O
. None None O

Multipotent None None O
mesenchymal None None O
stromal None None O
cells None None O
( None None O
MSC None None O
) None None O
are None None O
receiving None None O
increased None None O
attention None None I-FUNC
for None None O
their None None O
non-progenitor None None O
immunomodulatory None None O
potential None None O
. None None O

Although None None O
some None None O
instruments None None O
have None None O
been None None O
developed None None O
to None None O
study None None O
spatial None None O
short-term None None I-FUNC
memory None None I-FUNC
in None None O
real None None O
environments None None O
, None None O
there None None O
are None None O
no None None O
instruments None None O
that None None O
are None None O
specifically None None O
designed None None O
to None None O
assess None None O
visuospatial None None O
short-term None None I-FUNC
memory None None I-FUNC
in None None O
an None None O
attractive None None O
way None None O
to None None O
children None None O
. None None O

Hence None None O
, None None O
we None None O
suggest None None O
that None None O
the None None O
ARSM None None O
task None None O
has None None O
high None None O
verisimilitude None None O
with None None O
spatial None None O
short-term None None I-FUNC
memory None None I-FUNC
skills None None O
in None None O
real None None O
life None None O
. None None O

Iron None None O
deficiency None None O
anemia None None O
was None None O
defined None None O
when None None O
serum None None O
iron None None O
and None None O
ferritin None None I-PROTEIN
levels None None O
are None None O
below None None O
10 None None O
µmol/l None None O
and None None O
15 None None O
µg/dl None None O
, None None O
respectively None None O
. None None O

However None None O
, None None O
this None None O
effect None None O
was None None O
not None None O
associated None None O
with None None O
evidence None None O
of None None O
translocation None None O
into None None O
the None None O
haemocoel None None O
of None None O
the None None O
entire None None O
protein None None O
, None None O
where None None O
the None None O
receptors None None I-PROTEIN
of None None O
TnBVANK1 None None O
are None None O
putatively None None O
located None None O
. None None O

The None None O
remaining None None O
NMJs None None O
had None None O
intermittent None None O
( None None O
4 None None O
% None None O
) None None O
or None None O
complete None None O
( None None O
18 None None O
% None None O
) None None O
failure None None O
of None None O
neurotransmitter None None I-TRANS
release None None O
in None None O
response None None O
to None None O
50 None None O
Hz None None O
nerve None None O
stimulation None None O
, None None O
presumably None None O
due None None O
to None None O
blocked None None O
action None None O
potential None None O
entry None None O
into None None O
the None None O
nerve None None O
terminal None None O
, None None O
which None None O
may None None O
arise None None O
from None None O
nerve None None O
terminal None None O
swelling None None O
and None None O
thinning None None O
. None None O

Recent None None O
studies None None O
proposed None None O
that None None O
accumulation None None O
of None None O
oxidative None None O
stress None None O
is None None O
involved None None O
in None None O
the None None O
etiology None None O
of None None O
stress None None O
induced None None O
depression None None I-DISEASE
and None None O
anxiety None None O
. None None O

The None None O
number None None O
of None None O
ligand-receptor None None I-PROTEIN
pairs None None O
increases None None O
with None None O
the None None O
dynamic None None O
segregation None None O
of None None O
ligands None None O
and None None O
receptors None None I-PROTEIN
toward None None O
the None None O
adhesion None None O
zone None None O
causing None None O
an None None O
out-of-plane None None O
deformation None None O
of None None O
the None None O
membrane None None O
. None None O

Carotenoid-dependent None None O
coloration None None O
has None None O
attracted None None O
considerable None None O
attention None None I-FUNC
in None None O
this None None O
context None None O
, None None O
because None None O
investing None None O
carotenoids None None O
in None None O
coloration None None O
has None None O
to None None O
be None None O
traded None None O
off None None O
against None None O
its None None O
physiological None None O
functions None None O
; None None O
carotenoids None None O
are None None O
antioxidants None None O
and None None O
increase None None O
immunocompetence None None O
. None None O

Folate-conjugated None None O
cryptophane None None O
was None None O
developed None None O
for None None O
targeting None None O
cryptophane None None O
to None None O
membrane-bound None None O
folate None None O
receptors None None I-PROTEIN
that None None O
are None None O
overexpressed None None O
in None None O
many None None O
human None None O
cancers None None O
. None None O

Experiments None None O
with None None O
mutant None None O
strains None None O
lacking None None O
mitochondrial None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
sod-2 None None O
) None None O
showed None None O
oxidative None None O
stress None None O
for None None O
two None None O
FeOx None None O
and None None O
Fe None None O
( None None O
3+ None None O
) None None O
-ions None None O
, None None O
however None None O
, None None O
revealed None None O
that None None O
it None None O
was None None O
not None None O
the None None O
predominant None None O
mechanism None None O
of None None O
toxicity None None O
. None None O

Here None None O
, None None O
we None None O
extend None None O
the None None O
concept None None O
of None None O
van None None O
der None None O
Waals None None O
heterojunctions None None O
to None None O
semiconducting None None O
p-type None None O
single-walled None None O
carbon None None O
nanotube None None O
( None None O
s-SWCNT None None O
) None None O
and None None O
n-type None None O
amorphous None None O
indium None None O
gallium None None O
zinc None None I-TRANS
oxide None None O
( None None O
a-IGZO None None O
) None None O
thin None None O
films None None O
that None None O
can None None O
be None None O
solution-processed None None O
or None None O
sputtered None None O
with None None O
high None None O
spatial None None O
uniformity None None O
at None None O
the None None O
wafer None None O
scale None None O
. None None O

Of None None O
interest None None O
, None None O
high None None O
Zva None None O
remained None None O
associated None None O
with None None O
reduced None None O
survival None None O
as None None O
compared None None O
to None None O
low None None O
Zva None None O
, None None O
in None None O
patients None None O
with None None O
normal None None O
LV None None O
stroke None None I-DISEASE
volume None None O
, None None O
but None None O
was None None O
no None None O
longer None None O
significant None None O
in None None O
low None None O
flow None None O
patients None None O
( None None O
p=0.98 None None O
) None None O
. None None O

Quil None None O
A None None O
was None None O
resolved None None O
as None None O
three None None O
peaks None None O
with None None O
retention None None I-FUNC
times None None O
of None None O
4.1 None None O
, None None O
5.5 None None O
and None None O
6.4 None None O
min None None O
with None None O
a None None O
detector None None O
temperature None None O
of None None O
30 None None O
°C None None O
and None None O
with None None O
water-acetonitrile None None O
and None None O
0.01 None None O
% None None O
formic None None O
acid None None O
as None None O
the None None O
mobile None None O
phase None None O
. None None O

These None None O
autoantibodies None None O
and None None O
their None None O
subclasses None None O
have None None O
received None None O
increasing None None O
attention None None I-FUNC
by None None O
medical None None O
community None None O
due None None O
to None None O
their None None O
association None None O
with None None O
recurrent None None O
venous None None O
thrombosis None None I-DISEASE
, None None O
fetal None None O
loss None None O
and None None O
thrombocytopenia None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
histidine None None I-TRANS
based None None O
pseudobioaffinity None None O
adsorbents None None O
have None None O
been None None O
used None None O
for None None O
the None None O
selective None None O
adsorption None None O
and None None O
separation None None O
of None None O
anti-double None None O
stranded None None O
DNA None None O
( None None O
anti-dsDNA None None O
) None None O
, None None O
anticardiolipin None None O
( None None O
aCL None None O
) None None O
and None None O
anti-β2-glycoprotein-I None None O
( None None O
anti-β2-GPI None None O
) None None O
antibodies None None O
from None None O
sera None None O
of None None O
patients None None O
with None None O
SLE None None O
. None None O

Three None None O
of None None O
the None None O
peptides None None I-TRANS
were None None O
localized None None O
in None None O
subdomain-1 None None O
and None None O
2 None None O
. None None O

This None None O
revealed None None O
that None None O
AAS None None O
and None None O
AGE None None O
modifies None None O
an None None O
essential None None O
BCP None None O
catalytic None None O
cysteine None None I-TRANS
residue None None O
and None None O
suggests None None O
a None None O
role None None O
for None None O
allicin None None O
as None None O
a None None O
general None None O
electrophilic None None O
reagent None None O
that None None O
targets None None O
protein None None O
thiols None None O
. None None O

This None None O
augmentation None None O
therapy None None O
might None None O
be None None O
useful None None O
for None None O
the None None O
treatment None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

Excluded None None O
were None None O
studies None None O
describing None None O
patients None None O
with None None O
hemorrhagic None None O
stroke None None I-DISEASE
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
propose None None O
graph None None O
inference None None I-FUNC
methods None None O
to None None O
remove None None O
extracolonic None None O
components None None O
to None None O
achieve None None O
a None None O
high None None O
quality None None O
segmentation None None O
. None None O

Encoding None None I-FUNC
the None None O
panorama None None O
video None None O
with None None O
state-of-the-art None None O
HECV None None O
and None None O
representing None None O
occlusions None None O
with None None O
simple None None O
spatiotemporal None None O
ancillary None None O
information None None O
STOP None None O
achieves None None O
high-compression None None O
ratio None None O
and None None O
good None None O
visual None None O
quality None None O
with None None O
competitive None None O
results None None O
with None None O
respect None None O
to None None O
competing None None O
techniques None None O
. None None O

Images None None O
of None None O
facial None None O
expressions None None O
are None None O
often None None O
captured None None O
from None None O
various None None O
views None None O
as None None O
a None None O
result None None O
of None None O
either None None O
head None None O
movements None None I-FUNC
or None None O
variable None None O
camera None None O
position None None O
. None None O

We None None O
show None None O
that None None O
this None None O
model None None O
outperforms None None O
the None None O
state-of-the-art None None O
methods None None O
for None None O
multiview None None O
and None None O
view-invariant None None O
facial None None O
expression None None O
classification None None O
, None None O
and None None O
several None None O
state-of-the-art None None O
methods None None O
for None None O
multiview None None O
learning None None I-FUNC
and None None O
feature None None O
fusion None None O
. None None O

We None None O
model None None O
the None None O
relationship None None O
between None None O
a None None O
viewer None None O
and None None O
a None None O
display None None O
by None None O
considering None None O
two None None O
main None None O
aspects None None O
of None None O
visual None None I-FUNC
perception None None I-FUNC
, None None O
i.e. None None O
, None None O
scaling None None O
factor None None O
and None None O
perceptual None None O
blur None None O
radius None None O
. None None O

Bouncing None None O
a None None O
ball None None O
with None None O
a None None O
racket None None O
is None None O
a None None O
hybrid None None O
rhythmic-discrete None None O
motor None None O
task None None O
, None None O
combining None None O
continuous None None O
rhythmic None None O
racket None None O
movements None None I-FUNC
with None None O
discrete None None O
impact None None O
events None None O
. None None O

Studies None None O
suggested None None O
that None None O
rhythmic None None O
and None None O
discrete None None O
movements None None I-FUNC
are None None O
governed None None O
by None None O
different None None O
control None None O
mechanisms None None O
at None None O
different None None O
levels None None O
of None None O
the None None O
Central None None O
Nervous None None O
System None None O
. None None O

We None None O
performed None None O
an None None O
experiment None None O
with None None O
thirty None None O
healthy None None O
subjects None None O
and None None O
found None None O
that None None O
the None None O
most None None O
effective None None O
training None None O
condition None None O
depended None None O
on None None O
the None None O
degree None None O
of None None O
rhythmicity None None O
: None None O
Haptic None None O
guidance None None O
seems None None O
to None None O
hamper None None O
learning None None I-FUNC
of None None O
continuous None None O
rhythmic None None O
tasks None None O
, None None O
but None None O
it None None O
seems None None O
to None None O
promote None None O
learning None None I-FUNC
for None None O
repetitive None None O
tasks None None O
that None None O
resemble None None O
discrete None None O
movements None None I-FUNC
. None None O

However None None O
, None None O
the None None O
annotation None None O
by None None O
medical None None O
doctors None None O
for None None O
training None None O
and None None O
evaluation None None O
purposes None None O
is None None O
a None None O
difficult None None O
and None None O
time-consuming None None O
task None None O
, None None O
which None None O
restricts None None O
the None None O
supervised None None O
learning None None I-FUNC
phase None None O
to None None O
specific None None O
CBIR None None O
problems None None O
of None None O
well-defined None None O
clinical None None O
applications None None O
. None None O

Our None None O
method None None O
first None None O
infers None None O
the None None O
relation None None O
between None None O
patients None None O
by None None O
using None None O
information None None I-FUNC
retrieval None None I-FUNC
techniques None None O
to None None O
determine None None O
the None None O
textual None None O
distances None None O
between None None O
patient None None O
radiology None None O
reports None None O
. None None O

We None None O
propose None None O
a None None O
linear None None O
combination None None O
of None None O
nonlinear None None O
kinematic None None O
features None None O
to None None O
model None None O
wrist None None O
movement None None I-FUNC
, None None O
and None None O
propose None None O
an None None O
approach None None O
to None None O
learn None None O
feature None None O
thresholds None None O
and None None O
weights None None O
using None None O
high-level None None O
labels None None O
of None None O
overall None None O
movement None None I-FUNC
quality None None O
provided None None O
by None None O
a None None O
therapist None None O
. None None O

Thus None None O
, None None O
we None None O
hypothesized None None O
that None None O
simultaneous None None O
blockade None None O
of None None O
the None None O
ET-A None None O
and None None O
-B None None O
receptors None None I-PROTEIN
would None None O
protect None None O
the None None O
kidney None None O
during None None O
RVD None None O
. None None O

Stroke None None I-DISEASE
is None None O
responsible None None O
for None None O
high None None O
morbidity None None O
and None None O
mortality None None O
. None None O

Plasma None None O
D-dimer None None O
measurement None None O
is None None O
the None None O
first None None O
diagnostic None None O
test None None O
performed None None O
in None None O
patients None None O
with None None O
a None None O
non-high None None O
or None None O
an None None O
unlikely None None O
clinical None None O
probability None None O
of None None O
pulmonary None None O
embolism None None I-DISEASE
( None None O
PE None None O
) None None O
but None None O
its None None O
clinical None None O
usefulness None None O
is None None O
limited None None O
in None None O
elderly None None O
patients None None O
due None None O
to None None O
a None None O
low None None O
specificity None None O
in None None O
this None None O
subgroup None None O
. None None O

This None None O
study None None O
indicated None None O
that None None O
male None None O
gender None None O
, None None O
studying None None O
in None None O
college None None O
and None None O
vocational None None O
schools None None O
, None None O
illicit None None O
substance None None O
use None None O
, None None O
poor None None O
economic None None O
conditions None None O
, None None O
having None None O
a None None O
diagnosed None None O
illness None None O
and None None O
risk None None O
of None None O
developing None None O
depression None None I-DISEASE
can None None O
be None None O
risk None None O
factors None None O
for None None O
unintentional None None O
injuries None None O
among None None O
university None None O
students None None O
. None None O

This None None O
stress None None O
may None None O
cause None None O
anxiety None None O
, None None O
depression None None I-DISEASE
and None None O
post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
( None None O
PTSD None None O
) None None O
, None None O
which None None O
impairs None None O
their None None O
recovery None None O
. None None O

Hence None None O
, None None O
effects None None O
of None None O
a None None O
cutaneous None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
releasing None None O
patch None None O
( None None O
NitroSense None None O
Derma None None O
Protect None None O
) None None O
were None None O
evaluated None None O
in None None O
subjects None None O
with None None O
DPN None None O
. None None O

Patients None None O
received None None O
24 None None O
mg None None O
patches None None O
( None None O
each None None O
patch None None O
releases None None O
around None None O
9 None None O
nmol/cm2/min None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
) None None O
for None None O
3 None None O
hrs None None O
, None None O
every None None O
other None None O
day None None O
during None None O
a None None O
3 None None O
wks None None O
period None None O
, None None O
or None None O
indistinguishable None None O
placebo None None O
patches None None O
. None None O

Present None None O
results None None O
highlight None None O
utility None None O
of None None O
NitroSense None None O
Derma None None O
Protect None None O
as None None O
controllable None None O
nitric None None I-TRANS
oxide None None I-TRANS
source None None O
for None None O
patients None None O
with None None O
DPN None None O
. None None O

To None None O
develop None None O
ethnicity None None O
specific None None O
reference None None O
limits None None O
for None None O
insulin None None I-PROTEIN
levels None None O
in None None O
a None None O
normoglycaemic None None O
healthy None None O
Indian None None O
cohort None None O
in None None O
order None None O
to None None O
derive None None O
a None None O
clinical None None O
cut None None O
off None None O
for None None O
hyperinsulinaemia None None O
as None None O
an None None O
effective None None O
screening None None O
tool None None O
for None None O
predicting None None O
future None None O
risk None None O
of None None O
metabolic None None O
and None None O
cardiovascular None None O
disease None None O
. None None O

Reference None None O
limits None None O
for None None O
insulin None None I-PROTEIN
in None None O
normoglycemic None None O
Indians None None O
needs None None O
to None None O
be None None O
revised None None O
to None None O
2.7-17 None None O
uIU/ None None O
ml None None O
. None None O

Inferior None None O
vena None None O
cava None None O
[ None None O
IVC None None O
] None None O
thrombosis None None I-DISEASE
is None None O
a None None O
rare None None O
complication None None O
of None None O
acute None None O
pancreatitis None None O
. None None O

We None None O
discuss None None O
the None None O
pathogenesis None None O
, None None O
clinical None None O
features None None O
and None None O
management None None O
of None None O
IVC None None O
thrombosis None None I-DISEASE
complicating None None O
acute None None O
and None None O
chronic None None O
pancreatitis None None O
in None None O
brief None None O
. None None O

Septic None None O
cavernous None None I-DISEASE
sinus None None I-DISEASE
thrombosis None None I-DISEASE
is None None O
a None None O
rare None None O
clinical None None O
condition None None O
. None None O

Furthermore None None O
, None None O
perception None None I-FUNC
of None None O
susceptibility None None O
to None None O
HPV None None O
infection None None O
by None None O
daughters None None O
was None None O
significantly None None O
associated None None O
with None None O
acceptance None None O
of None None O
the None None O
vaccines None None O
( None None O
p None None O
= None None O
0.0001 None None O
) None None O
. None None O

Examined None None O
the None None O
level None None O
of None None O
serum None None O
lipid None None O
, None None O
plasma None None O
glucose None None O
, None None O
serum None None O
insulin None None I-PROTEIN
, None None O
insulin None None I-PROTEIN
sensitivity None None O
index None None O
, None None O
and None None O
the None None O
activity None None O
of None None O
hexokinase None None O
and None None O
pyruvate None None O
kinase None None O
. None None O

The None None O
content None None O
of None None O
hydroxyproline None None O
( None None O
HYP None None O
) None None O
and None None O
the None None O
activities None None O
of None None O
catalase None None I-PROTEIN
( None None O
CAT None None O
) None None O
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GSH-Px None None O
) None None O
were None None O
detected None None O
by None None O
using None None O
the None None O
kits None None O
. None None O

Haplotype None None O
analysis None None O
revealed None None O
an None None O
association None None O
ofAVPRIA None None O
C*S- None None O
and None None O
C*L-haplotype None None O
( None None O
rs11174811 None None O
and None None O
RS1 None None O
, None None O
respectively None None O
) None None O
and None None O
increased None None O
( None None O
PFDR= None None O
0.016 None None O
) None None O
or None None O
decreased None None O
( None None O
PFDR None None O
= None None O
0.031 None None O
) None None O
Extraversion None None O
( None None O
EPI None None I-TRANS
) None None O
in None None O
Bashkirs None None O
, None None O
respectively None None O
. None None O

The None None O
influence None None O
of None None O
suppression None None O
of None None O
the None None O
expression None None O
of None None O
the None None O
Drosophila None None O
insulin-like None None O
receptor None None I-PROTEIN
gene None None O
( None None O
InR None None O
) None None O
in None None O
corpus None None O
allatum None None O
( None None O
the None None O
gland-synthesizing None None O
juvenile None None O
hormone None None O
) None None O
on None None O
octopamine None None I-TRANS
and None None O
juvenile None None O
hormone None None O
metabolism None None O
and None None O
on None None O
the None None O
development None None O
of None None O
the None None O
stress-reaction None None O
in None None O
Drosophila None None O
melanogaster None None O
females None None O
was None None O
studied None None O
. None None O

It None None O
was None None O
mentioned None None O
that None None O
a None None O
decrease None None O
in None None O
InR None None O
gene None None O
expression None None O
in None None O
corpus None None O
allatum None None O
does None None O
not None None O
influence None None O
the None None O
activity None None O
of None None O
OA-dependent None None O
N-acetyltransferase None None O
( None None O
the None None O
enzyme None None O
that None None O
degrades None None O
octopamine None None I-TRANS
) None None O
. None None O

The None None O
algorithm None None O
of None None O
postsynaptic None None O
excitatory None None O
glutamatergic None None O
synapses None None O
plasticity None None O
analyzed None None O
, None None O
which None None O
leads None None O
to None None O
the None None O
modification None None O
and None None O
storage None None I-FUNC
for None None O
a None None O
long None None O
time None None O
, None None O
the None None O
efficiency None None O
of None None O
synaptic None None O
transmission None None O
-- None None O
ong-term None None O
potentiation None None O
, None None O
long-term None None I-FUNC
depression None None I-DISEASE
. None None O

Described None None O
the None None O
molecular None None O
and None None O
cellular None None O
mechanisms None None O
of None None O
the None None O
trafficking None None O
of None None O
GABAA None None O
( None None O
- None None O
) None None O
receptors None None I-PROTEIN
and None None O
its None None O
role None None O
in None None O
the None None O
dynamic None None O
modulation None None O
of None None O
neuronal None None O
inhibition None None O
. None None O

Deactualization None None O
of None None O
neural None None O
network None None O
, None None O
which None None O
is None None O
implemented None None O
at None None O
the None None O
molecular None None O
level None None O
by None None O
the None None O
mechanism None None O
of None None O
internalization None None O
specific None None O
cluster None None O
of None None O
GABAA None None O
( None None O
- None None O
) None None O
receptor None None I-PROTEIN
, None None O
is None None O
a None None O
pro-ess None None O
of None None O
transferring None None O
from None None O
stage None None O
of None None O
working None None O
or None None O
random None None O
access None None O
memory None None I-FUNC
in None None O
the None None O
storage None None I-FUNC
stage None None O
. None None O

These None None O
data None None O
indicate None None O
the None None O
joint None None O
participation None None O
of None None O
serotonine None None O
and None None O
sex None None I-PROTEIN
steroids None None I-PROTEIN
in None None O
the None None O
regulation None None O
of None None O
the None None O
neuroedocrine None None O
function None None O
of None None O
Amygdala None None I-REGION
, None None O
which None None O
have None None O
a None None O
modulating None None O
effect None None O
on None None O
the None None O
secretion None None O
and None None O
release None None O
gonadotropine None None O
centers None None O
and None None O
sexual None None O
behavior None None O
centers None None O
in None None O
the None None O
hypothalamic None None O
area None None O
of None None O
the None None O
brain None None O
. None None O

Systematizes None None O
the None None O
data None None O
on None None O
the None None O
role None None O
of None None O
serotonin None None I-TRANS
and None None O
sex None None I-PROTEIN
steroids None None I-PROTEIN
in None None O
the None None O
mechanisms None None O
involved None None O
in None None O
the None None O
stress None None O
response None None O
of None None O
Amygdala None None I-REGION
, None None O
and None None O
its None None O
participation None None O
in None None O
the None None O
formation None None O
of None None O
mood None None I-FUNC
, None None O
emotions None None I-FUNC
and None None O
the None None O
genesis None None O
of None None O
depression None None I-DISEASE
. None None O

Special None None O
attention None None I-FUNC
is None None O
paid None None O
to None None O
relatively None None O
new None None O
line None None O
of None None O
investigations None None O
that None None O
is None None O
called None None O
`` None None O
music None None O
of None None O
the None None O
brain None None O
'' None None O
and None None O
deals None None O
with None None O
transformation None None O
of None None O
bioelectric None None O
processes None None O
of None None O
human None None O
organism None None O
into None None O
music None None O
. None None O

With None None O
autism None None O
, None None O
OS None None O
markers None None O
are None None O
found None None O
almost None None O
in None None O
every None None O
research None None O
, None None O
whilst None None O
with None None O
schizophrenia None None I-DISEASE
, None None O
the None None O
OS None None O
data None None O
are None None O
contradictory None None O
. None None O

The None None O
model None None O
is None None O
realized None None O
as None None O
an None None O
ordinary None None O
differential None None O
equation None None O
system None None O
, None None O
supposing None None O
induction None None O
of None None O
antioxidant None None O
protection None None O
enzymes None None I-PROTEIN
being None None O
mediated None None O
by None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
, None None O
with None None O
the None None O
subsequent None None O
decrease None None O
of None None O
ROS None None O
content None None O
in None None O
a None None O
cell None None O
. None None O

Our None None O
study None None O
explains None None O
the None None O
inconsistency None None O
of None None O
clinical None None O
data None None O
of None None O
OS None None O
in None None O
schizophrenia None None I-DISEASE
and None None O
suggests None None O
a None None O
novel None None O
criterion None None O
for None None O
discriminative None None O
cytogenetic None None O
diagnostics None None O
of None None O
schizophrenia None None I-DISEASE
and None None O
IA None None O
, None None O
as None None O
well None None O
as None None O
allows None None O
to None None O
assume None None O
that None None O
antioxidant None None O
therapy None None O
should None None O
be None None O
effective None None O
only None None O
for None None O
children None None O
with None None O
low None None O
number None None O
of None None O
active None None O
RG None None O
copies None None O
. None None O

In None None O
the None None O
current None None O
paper None None O
a None None O
review None None O
of None None O
the None None O
role None None O
of None None O
GSK-3b None None O
in None None O
mechanisms None None O
of None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
is None None O
presented None None O
. None None O

The None None O
data None None O
on None None O
participation None None O
of None None O
GSK-3b None None O
in None None O
regulation None None O
of None None O
NMDA-dependent None None O
long-term None None I-FUNC
depression None None I-DISEASE
and None None O
potentiation None None O
, None None O
and None None O
the None None O
possible None None O
mechanisms None None O
of None None O
enzyme None None O
's None None O
influence None None O
through None None O
NMDA None None O
receptors None None I-PROTEIN
and None None O
AMPA None None O
endocytosis None None O
are None None O
shown None None O
. None None O

The None None O
study None None O
presents None None O
the None None O
interdisciplinary None None O
approach None None O
to None None O
the None None O
analysis None None O
of None None O
the None None O
brain None None O
mechanisms None None O
of None None O
learning None None I-FUNC
difficulties None None O
in None None O
primary None None O
schoolchildren None None O
. None None O

EEG None None O
recordings None None O
of None None O
children None None O
with None None O
ADHD None None O
symptoms None None O
more None None O
frequently None None O
, None None O
as None None O
compared None None O
to None None O
children None None O
with None None O
typical None None O
development None None O
, None None O
contained None None O
EEG None None O
patterns None None O
of None None O
the None None O
fronto-thalamic None None O
system None None O
non-optimal None None O
functioning None None O
, None None O
reflected None None O
in None None O
frontal None None O
theta None None O
waves None None O
( None None O
FTW None None O
) None None O
, None None O
right None None O
hemisphere None None O
local None None O
electrical None None O
activity None None O
( None None O
EA None None O
) None None O
deviations None None O
and None None O
EEG None None O
patterns None None O
associated None None O
with None None O
the None None O
general None None O
activation None None O
deficit None None O
arising None None O
from None None O
the None None O
brainstem None None I-REGION
reticular None None I-REGION
formation None None I-REGION
( None None O
DA None None O
) None None O
. None None O

Two None None O
groups None None O
of None None O
right-handed None None O
volunteers None None O
( None None O
18-25 None None O
and None None O
35-60 None None O
years None None O
old None None O
) None None O
reproduced None None O
the None None O
memorized None None O
sequence None None O
of None None O
six None None O
movements None None I-FUNC
by None None O
the None None O
right None None O
hand None None O
or None None O
by None None O
the None None O
left None None O
one None None O
. None None O

According None None O
to None None O
the None None O
hypothesis None None O
about None None O
hemispheric None None O
specialization None None O
in None None O
coding None None O
of None None O
movement None None I-FUNC
information None None O
( None None O
right None None O
hemisphere None None O
specialization None None O
on None None O
absolute None None O
positional None None O
coding None None O
, None None O
the None None O
left None None O
one None None O
-- None None O
on None None O
relative None None O
vector None None O
coding None None O
, None None O
i.e None None O
. None None O

The None None O
reduction None None O
of None None O
memory None None I-FUNC
capacity None None O
apparently None None O
can None None O
be None None O
explained None None O
by None None O
the None None O
reduction None None O
of None None O
role None None O
of None None O
the None None O
left None None O
hemisphere None None O
in None None O
functioning None None O
of None None O
the None None O
short-term None None O
motor None None O
memory None None I-FUNC
owing None None O
to None None O
age-dependent None None O
reduction None None O
of None None O
hemispheric None None O
asymmetry None None O
. None None O

Perception None None I-FUNC
of None None O
dissonant None None O
chords None None O
in None None O
non-musicians None None O
was None None O
accompanied None None O
by None None O
increase None None O
of None None O
lower None None O
theta None None O
activity None None O
over None None O
right None None O
anterior None None O
regions None None O
, None None O
while None None O
consonant None None O
chords None None O
induced None None O
greater None None O
theta None None O
activity None None O
over None None O
left None None O
anterior None None O
regions None None O
; None None O
this None None O
pattern None None O
of None None O
asymmetrical None None O
activation None None O
was None None O
not None None O
observed None None O
in None None O
musicians None None O
. None None O

The None None O
obtained None None O
results None None O
reflect None None O
more None None O
efficient None None O
musical None None O
harmony None None O
processing None None O
and None None O
, None None O
possibly None None O
, None None O
less None None O
emotional None None O
perception None None I-FUNC
of None None O
chords None None O
in None None O
musicians None None O
. None None O

Besides None None O
, None None O
47.7 None None O
% None None O
of None None O
the None None O
raphe None None I-REGION
nuclei None None I-REGION
serotoninergic None None O
neurons None None O
under None None O
study None None O
showed None None O
positive None None O
correlation None None O
between None None O
their None None O
impulse None None O
activity None None O
and None None O
the None None O
spectral None None O
power None None O
density None None O
of None None O
beta-rhythm None None O
. None None O

Both None None O
groups None None O
were None None O
subjected None None O
to None None O
chronic None None O
mild None None O
stress None None O
during None None O
30 None None O
days None None O
and None None O
tested None None O
for None None O
depressive None None O
behaviour None None O
( None None O
forced None None O
swim None None O
test None None O
, None None O
32 None None O
% None None O
glucose None None O
solution None None O
consumption None None O
test None None O
) None None O
, None None O
anxiety None None O
( None None O
elevated None None O
plus None None O
maze None None O
) None None O
and None None O
learning None None I-FUNC
( None None O
AA None None O
test None None O
) None None O
. None None O

Application None None O
of None None O
high-speed None None O
video None None O
recording None None O
of None None O
food-procuring None None O
movements None None I-FUNC
in None None O
rats None None O
( None None O
obtaining None None O
food None None O
from None None O
a None None O
narrow None None O
horizontal None None O
tube None None O
) None None O
is None None O
described None None O
. None None O

This None None O
method None None O
expands None None O
the None None O
view None None O
both None None O
the None None O
single None None O
phases None None O
of None None O
food-procuring None None O
movement None None I-FUNC
, None None O
and None None O
the None None O
nature None None O
of None None O
their None None O
execution None None O
. None None O

The None None O
study None None O
of None None O
a None None O
combined None None O
effect None None O
of None None O
isoproterenol None None O
and None None O
2-methylthio-ATP None None O
showed None None O
that None None O
an None None O
increase None None O
in None None O
the None None O
sympathetic None None O
regulatory None None O
effects None None O
on None None O
the None None O
heart None None O
of None None O
21-day-old None None O
animals None None O
, None None O
against None None O
the None None O
background None None O
of None None O
a None None O
high None None O
functional None None O
activity None None O
of None None O
β-adrenergic None None O
receptors None None I-PROTEIN
and None None O
P2X None None O
receptors None None I-PROTEIN
of None None O
the None None O
heart None None O
, None None O
a None None O
combined None None O
administration None None O
of None None O
the None None O
agonists None None O
led None None O
to None None O
a None None O
mutually None None O
complementing None None O
effect None None O
of None None O
an None None O
increase None None O
in None None O
the None None O
myocardial None None O
contractility None None O
. None None O

Five None None O
outcome None None O
measures None None O
representing None None O
physical None None O
, None None O
mental None None O
, None None O
and None None O
social None None O
function None None O
were None None O
included None None O
: None None O
activities None None O
of None None O
daily None None O
living None None O
( None None O
ADLs None None O
) None None O
, None None O
symptoms None None O
of None None O
depression None None I-DISEASE
, None None O
feelings None None I-FUNC
of None None O
anxiety None None O
, None None O
social None None O
participation None None O
, None None O
and None None O
social None None O
support None None O
interactions None None O
. None None O

Experimental None None O
studies None None O
in None None O
animal None None O
models None None O
of None None O
metabolic None None O
diseases None None O
have None None O
also None None O
revealed None None O
that None None O
activation None None O
of None None O
PPARs None None O
protects None None O
against None None O
the None None O
vascular None None O
complications None None O
of None None O
diabetes None None O
, None None O
hypertension None None O
, None None O
atherosclerosis None None I-DISEASE
, None None O
myocardial None None O
infarction None None O
and None None O
stroke None None I-DISEASE
, None None O
through None None O
exerting None None O
their None None O
anti-inflammatory None None O
, None None O
anti-atherogenic None None O
and None None O
antioxidant None None O
effects None None O
. None None O

However None None O
, None None O
the None None O
importance None None O
of None None O
silent None None O
markers None None O
of None None O
small None None O
vessel None None O
disease None None O
, None None O
including None None O
white None None I-REGION
matter None None I-REGION
hyperintensities None None O
of None None O
presumed None None O
vascular None None O
origin None None O
, None None O
has None None O
not None None O
been None None O
assessed None None O
so None None O
far None None O
. None None O

Atahualpa None None O
residents None None O
aged None None O
≥ None None O
60 None None O
years None None O
were None None O
identified None None O
during None None O
a None None O
door-to-door None None O
survey None None O
and None None O
invited None None O
to None None O
undergo None None O
brain None None O
magnetic None None O
resonance None None O
imaging None None O
for None None O
identification None None O
and None None O
grading None None O
white None None I-REGION
matter None None I-REGION
hyperintensities None None O
and None None O
other None None O
markers None None O
of None None O
small None None O
vessel None None O
disease None None O
. None None O

Out None None O
of None None O
258 None None O
enrolled None None O
persons None None O
( None None O
mean None None O
age None None O
, None None O
70 None None O
± None None O
8 None None O
years None None O
; None None O
59 None None O
% None None O
women None None O
) None None O
, None None O
172 None None O
( None None O
67 None None O
% None None O
) None None O
had None None O
white None None I-REGION
matter None None I-REGION
hyperintensities None None O
, None None O
which None None O
were None None O
moderate None None O
to None None O
severe None None O
in None None O
63 None None O
. None None O

Prevalence None None O
and None None O
correlates None None O
of None None O
white None None I-REGION
matter None None I-REGION
hyperintensities None None O
in None None O
elders None None O
living None None O
in None None O
rural None None O
Ecuador None None O
is None None O
almost None None O
comparable None None O
with None None O
that None None O
reported None None O
from None None O
industrialized None None O
nations None None O
, None None O
reinforcing None None O
the None None O
concept None None O
that None None O
the None None O
burden None None O
of None None O
small None None O
vessel None None O
disease None None O
is None None O
on None None O
the None None O
rise None None O
in None None O
underserved None None O
Latin None None O
American None None O
populations None None O
. None None O

Specialized None None O
receptors None None I-PROTEIN
( None None O
RAGE None None O
, None None O
Galectin None None O
3… None None O
) None None O
bind None None O
AGE None None O
. None None O

Diabetic None None O
retinopathy None None O
is None None O
related None None O
to None None O
excessive None None O
secretion None None O
of None None O
vascular None None O
growth None None O
factor None None O
( None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
[ None None O
VEGF None None O
] None None O
) None None O
. None None O

The None None O
importance None None O
of None None O
the None None O
preanalytic None None O
phase None None O
is None None O
often None None O
not None None O
given None None O
the None None O
necessary None None O
attention None None I-FUNC
, None None O
although None None O
the None None O
validity None None O
of None None O
the None None O
results None None O
and None None O
consequent None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
medical None None O
management None None O
of None None O
animal None None O
patients None None O
would None None O
likely None None O
be None None O
improved None None O
if None None O
the None None O
quality None None O
of None None O
specimens None None O
submitted None None O
to None None O
the None None O
laboratory None None O
was None None O
optimized None None O
. None None O

To None None O
replicate None None O
, None None O
in None None O
Zambia None None O
, None None O
a None None O
recent None None O
global None None O
study None None O
by None None O
the None None O
WHO None None O
, None None O
which None None O
reported None None O
that None None O
the None None O
odds None None O
of None None O
depression None None I-DISEASE
were None None O
not None None O
increased None None O
in None None O
African None None O
people None None O
with None None O
diabetes None None O
, None None O
and None None O
to None None O
explore None None O
the None None O
sociodemographic None None O
and None None O
clinical None None O
factors None None O
associated None None O
with None None O
depression None None I-DISEASE
. None None O

Compared None None O
with None None O
control None None O
subjects None None O
( None None O
mean None None O
± None None O
sd None None O
Major None None O
Depression None None I-DISEASE
Inventory None None O
score None None O
15.10 None None O
± None None O
9.19 None None O
) None None O
, None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
were None None O
significantly None None O
more None None O
common None None O
in None None O
patients None None O
with None None O
diabetes None None O
( None None O
mean None None O
± None None O
sd None None O
Major None None O
Depression None None I-DISEASE
Inventory None None O
score None None O
19.12 None None O
± None None O
8.95 None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Contrary None None O
to None None O
the None None O
WHO None None O
study None None O
, None None O
we None None O
found None None O
that None None O
depression None None I-DISEASE
was None None O
a None None O
common None None O
comorbid None None O
health None None O
problem None None O
among None None O
Zambian None None O
people None None O
with None None O
diabetes None None O
. None None O

Low None None O
serum None None O
levels None None O
of None None O
vitamin None None O
D None None O
have None None O
been None None O
associated None None O
with None None O
depression None None I-DISEASE
in None None O
non-stroke None None O
subjects None None O
. None None O

In None None O
total None None O
, None None O
189 None None O
patients None None O
with None None O
acute None None O
ischaemic None None O
stroke None None I-DISEASE
were None None O
consecutively None None O
recruited None None O
. None None O

The None None O
17-item None None O
Hamilton None None O
Depression None None I-DISEASE
Scale None None O
was None None O
used None None O
for None None O
screening None None O
for None None O
the None None O
existence None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
1 None None O
month None None O
after None None O
stroke None None I-DISEASE
. None None O

Today None None O
, None None O
administering None None O
rTPA None None O
thrombolytic None None O
therapy None None O
within None None O
the None None O
first None None O
hours None None O
of None None O
a None None O
stroke None None I-DISEASE
is None None O
the None None O
only None None O
validated None None O
drug None None O
therapy None None O
for None None O
improving None None O
the None None O
spontaneous None None O
-- None None O
and None None O
most None None O
of None None O
the None None O
time None None O
incomplete None None O
-- None None O
recovery None None O
of None None O
neurological None None O
functions None None O
post-stroke None None O
. None None O

The None None O
question None None O
of None None O
whether None None O
lesioned-brain None None O
plasticity None None O
can None None O
be None None O
modulated None None O
by None None O
external None None O
factors None None O
like None None O
pharmacological None None O
agents None None O
is None None O
now None None O
addressed None None O
in None None O
the None None O
hope None None O
of None None O
improving None None O
recovery None None O
and None None O
reducing None None O
the None None O
chronic None None O
impairments None None O
of None None O
stroke None None I-DISEASE
patients None None O
. None None O

This None None O
resulted None None O
in None None O
a None None O
transition None None O
from None None O
Type None None O
II None None O
to None None O
Type None None O
I-like None None O
membrane None None O
protein None None O
crystals None None O
and None None O
improved None None O
diffraction None None O
to None None O
2.44 None None O
Å None None O
resolution None None O
. None None O

Nedd4-family None None O
ubiquitin None None O
ligases None None I-PROTEIN
are None None O
key None None O
regulators None None O
of None None O
cell None None O
surface None None O
receptor None None I-PROTEIN
signaling None None O
. None None O

In None None O
schizophrenia None None I-DISEASE
, None None O
medication None None O
adherence None None O
is None None O
critical None None O
to None None O
achieve None None O
better None None O
patient None None O
outcomes None None O
and None None O
to None None O
avoid None None O
relapses None None O
, None None O
which None None O
are None None O
responsible None None O
for None None O
a None None O
significant None None O
proportion None None O
of None None O
total None None O
healthcare None None O
costs None None O
for None None O
this None None O
chronic None None O
illness None None O
. None None O

A None None O
discrete None None O
event None None O
simulation None None O
( None None O
DES None None O
) None None O
model None None O
was None None O
developed None None O
from None None O
a None None O
Spanish None None O
healthcare None None O
system None None O
perspective None None O
to None None O
estimate None None O
clinical None None O
and None None O
economic None None O
outcomes None None O
for None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
over None None O
a None None O
five-year None None O
period None None O
. None None O

A None None O
total None None O
of None None O
40 None None O
patients None None O
were None None O
randomized None None O
to None None O
receive None None O
a None None O
bolus None None O
of None None O
propofol None None O
( None None O
0.5 None None O
mg/kg None None O
; None None O
n None None O
= None None O
20 None None O
) None None O
or None None O
thiamylal None None O
( None None O
1.5 None None O
mg/kg None None O
; None None O
n None None O
= None None O
20 None None O
) None None O
to None None O
increase None None O
anesthetic None None O
depth None None O
when None None O
the None None O
surgeon None None O
found None None O
patient None None O
movement None None I-FUNC
intraoperatively None None O
. None None O

This None None O
study None None O
highlights None None O
the None None O
toxic None None O
effect None None O
of None None O
AlCl3 None None O
on None None O
the None None O
brain None None O
which None None O
may None None O
affects None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
and None None O
seems None None O
to None None O
be None None O
different None None O
according None None O
to None None O
dose None None O
and None None O
duration None None O
of None None O
exposure None None O
. None None O

Among None None O
many None None O
such None None O
condensed None None O
heterocycles None None O
, None None O
pyrazoloquinazolines None None O
have None None O
managed None None O
to None None O
hold None None O
the None None O
attention None None I-FUNC
of None None O
many None None O
researchers None None O
, None None O
owing None None O
to None None O
the None None O
broad None None O
spectrum None None O
of None None O
activities None None O
they None None O
portray None None O
. None None O

No None None O
significant None None O
differences None None O
were None None O
found None None O
in None None O
attitude None None O
towards None None O
follow-up None None O
, None None O
patient None None O
satisfaction None None O
, None None O
anxiety None None O
and None None O
depression None None I-DISEASE
, None None O
alternative None None O
health None None O
care None None O
use None None O
or None None O
local None None O
recurrences None None O
between None None O
the None None O
risk None None O
groups None None O
. None None O

As None None O
compared None None O
to None None O
controls None None O
, None None O
GD-HUVEC None None O
exhibited None None O
enhanced None None O
monocyte None None O
adhesion None None O
and None None O
vascular None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecule-1 None None O
( None None O
VCAM-1 None None O
) None None O
and None None O
intercellular None None O
adhesion None None O
molecule-1 None None O
( None None O
ICAM-1 None None O
) None None O
expression None None O
and None None O
exposure None None O
on None None O
plasma None None O
membrane None None O
after None None O
tumour None None O
necrosis None None O
factor-alpha None None O
( None None O
TNF-α None None O
) None None O
stimulation None None O
( None None O
Western None None O
blot None None O
, None None O
flow None None O
cytometer None None O
) None None O
. None None O

More None None O
recently None None O
, None None O
with None None O
the None None O
availability None None O
of None None O
sequence None None O
data None None O
and None None O
advanced None None O
experimental None None O
techniques None None O
, None None O
the None None O
focus None None O
of None None O
attention None None I-FUNC
has None None O
shifted None None O
toward None None O
the None None O
study None None O
of None None O
evolutionary None None O
trajectories None None O
and None None O
the None None O
overall None None O
layout None None O
of None None O
protein None None O
fitness None None O
landscapes None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
illustrate None None O
recent None None O
developments None None O
in None None O
this None None O
area None None O
, None None O
and None None O
outline None None O
a None None O
roadmap None None O
for None None O
improved None None O
selection None None O
inference None None I-FUNC
. None None O

Armodafinil None None O
and None None O
the None None O
mood None None I-FUNC
stabilizer None None O
carbamazepine None None O
are None None O
both None None O
inducers None None O
of None None O
and None None O
substrates None None O
for None None O
cytochrome None None O
P450 None None O
( None None O
CYP3A4 None None I-PROTEIN
) None None O
. None None O

Systemic None None O
exposure None None O
to None None O
the None None O
metabolites None None O
of None None O
these None None O
agents None None O
that None None O
are None None O
formed None None O
via None None O
CYP3A4 None None I-PROTEIN
were None None O
increased None None O
after None None O
pretreatment None None O
in None None O
each None None O
group None None O
. None None O

Systemic None None O
exposure None None O
to None None O
both None None O
carbamazepine None None O
and None None O
armodafinil None None O
was None None O
reduced None None O
after None None O
pretreatment None None O
with None None O
the None None O
other None None O
drug None None O
; None None O
systemic None None O
exposure None None O
to None None O
the None None O
metabolites None None O
of None None O
each None None O
drug None None O
, None None O
which None None O
are None None O
formed None None O
via None None O
CYP3A4 None None I-PROTEIN
, None None O
was None None O
increased None None O
. None None O

Acute None None O
thromboembolic None None O
and None None O
bleeding None None O
events None None O
, None None O
as None None O
well None None O
as None None O
long-term None None O
consequences None None O
of None None O
stroke None None I-DISEASE
, None None O
intracranial None None O
hemorrhage None None O
, None None O
and None None O
acute None None O
myocardial None None O
infarction None None O
, None None O
were None None O
tracked None None O
. None None O

The None None O
differences None None O
between None None O
dabigatran None None O
and None None O
apixaban None None O
were None None O
modest None None O
but None None O
consistent None None O
in None None O
sensitivity None None O
analyses None None O
, None None O
with None None O
the None None O
directionality None None O
only None None O
changing None None O
at None None O
the None None O
limits None None O
of None None O
the None None O
CIs None None O
for None None O
the None None O
relative None None O
risks None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
or None None O
intracranial None None O
hemorrhage None None O
or None None O
when None None O
assuming None None O
that None None O
both None None O
treatment None None O
discontinuation None None O
and None None O
post-event None None O
disability None None O
rates None None O
differ None None O
by None None O
drug None None O
. None None O

Encenicline None None O
( None None O
EVP-6124 None None O
) None None O
is None None O
a None None O
selective None None O
α7 None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptor None None I-PROTEIN
partial None None O
agonist None None O
being None None O
developed None None O
for None None O
cognitive None None O
impairment None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
schizophrenia None None I-DISEASE
. None None O

The None None O
distribution None None O
of None None O
patients None None O
across None None O
each None None O
possible None None O
combination None None O
of None None O
scores None None O
on None None O
the None None O
HAS-BLED None None O
scale None None O
( None None O
evidence None None O
of None None O
hypertension None None O
, None None O
abnormal None None O
renal None None O
or None None O
liver None None O
function None None O
, None None O
stroke None None I-DISEASE
, None None O
bleeding None None O
, None None O
labile None None O
INR None None O
, None None O
age None None O
& None None O
gt None None O
; None None O
65 None None O
years None None O
, None None O
and None None O
drugs None None O
or None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
or None None O
dependence None None O
) None None O
and None None O
the None None O
CHA2DS2-VASc None None O
scale None None O
( None None O
CHADS2 None None O
[ None None O
congestive None None O
heart None None O
failure None None O
, None None O
hypertension None None O
, None None O
age None None O
≥75 None None O
years None None O
, None None O
diabetes None None O
mellitus None None O
, None None O
prior None None O
stroke None None I-DISEASE
or None None O
transient None None O
ischemic None None O
attack None None O
or None None O
thromboembolism None None O
] None None O
with None None O
additional None None O
nonmajor None None O
stroke None None I-DISEASE
risk None None O
factors None None O
, None None O
including None None O
age None None O
65-74 None None O
years None None O
, None None O
female None None O
sex None None O
, None None O
and None None O
vascular None None O
disease None None O
) None None O
was None None O
generated None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
ITPs None None O
' None None O
perceptions None None I-FUNC
of None None O
their None None O
communication None None O
proficiency None None O
and None None O
the None None O
resultant None None O
impact None None O
on None None O
patient None None O
safety None None O
. None None O

Screening None None O
for None None O
depression None None I-DISEASE
is None None O
an None None O
effective None None O
way None None O
to None None O
increase None None O
early None None O
recognition None None O
, None None O
and None None O
there None None O
is None None O
an None None O
opportunity None None O
to None None O
utilize None None O
pharmacists None None O
' None None O
skills None None O
and None None O
accessibility None None O
to None None O
do None None O
this None None O
. None None O

The None None O
specific None None O
objectives None None O
were None None O
to None None O
: None None O
( None None O
1 None None O
) None None O
develop None None O
a None None O
depression None None I-DISEASE
screening None None O
training None None O
program None None O
to None None O
aid None None O
pharmacists None None O
in None None O
the None None O
screening None None O
and None None O
risk None None O
assessment None None O
of None None O
depression None None I-DISEASE
in None None O
community None None O
pharmacy None None O
, None None O
( None None O
2 None None O
) None None O
assess None None O
the None None O
feasibility None None O
of None None O
pharmacists None None O
using None None O
a None None O
screening None None O
tool None None O
for None None O
depression None None I-DISEASE
, None None O
( None None O
3 None None O
) None None O
assess None None O
pharmacists None None O
' None None O
perspectives None None O
on None None O
the None None O
ease None None O
of None None O
use None None O
of None None O
different None None O
screening None None O
tools None None O
in None None O
the None None O
community None None O
pharmacy None None O
setting None None O
and None None O
( None None O
4 None None O
) None None O
investigate None None O
the None None O
barriers None None O
and None None O
facilitators None None O
to None None O
pharmacists None None O
performing None None O
screening None None O
and None None O
risk None None O
assessment None None O
services None None O
for None None O
depression None None I-DISEASE
in None None O
community None None O
pharmacy None None O
. None None O

A None None O
training None None O
program None None O
on None None O
depression None None I-DISEASE
was None None O
developed None None O
and None None O
delivered None None O
to None None O
the None None O
pharmacists None None O
, None None O
followed None None O
by None None O
an None None O
eight None None O
week None None O
data None None O
collection None None O
period None None O
during None None O
which None None O
pharmacists None None O
conducted None None O
patient None None O
screenings None None O
for None None O
depression None None I-DISEASE
. None None O

Pharmacy None None O
based None None O
depression None None I-DISEASE
screening None None O
programs None None O
have None None O
the None None O
potential None None O
to None None O
increase None None O
the None None O
early None None O
detection None None O
of None None O
depression None None I-DISEASE
which None None O
may None None O
lead None None O
to None None O
early None None O
intervention None None O
, None None O
and None None O
potentially None None O
contribute None None O
to None None O
easing None None O
the None None O
enormous None None O
disease None None O
burden None None O
associated None None O
with None None O
depression None None I-DISEASE
. None None O

Alien None None O
control None None O
phenomena None None O
are None None O
symptoms None None O
reported None None O
by None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
whereby None None O
feelings None None I-FUNC
of None None O
control None None O
and None None O
ownership None None O
of None None O
thoughts None None O
and None None O
movements None None I-FUNC
are None None O
lost None None O
. None None O

Thought None None O
insertion None None O
( None None O
TI None None O
) None None O
was None None O
associated None None O
with None None O
reduced None None O
activation None None O
of None None O
networks None None O
supporting None None O
language None None I-FUNC
, None None O
movement None None I-FUNC
, None None O
and None None O
self-related None None O
processing None None O
. None None O

Both None None O
experiences None None O
involved None None O
a None None O
reduction None None O
in None None O
activity None None O
of None None O
left None None O
supplementary None None O
motor None None O
area None None O
( None None O
SMA None None O
) None None O
and None None O
were None None O
associated None None O
with None None O
altered None None O
functional None None O
connectivity None None O
( None None O
FC None None O
) None None O
between None None O
SMA None None O
and None None O
brain None None O
regions None None O
involved None None O
in None None O
language None None I-FUNC
processing None None O
and None None O
movement None None I-FUNC
implementation None None O
. None None O

To None None O
test None None O
for None None O
the None None O
link None None O
between None None O
frontal None None O
midline None None O
DMN None None O
activity None None O
and None None O
self-relevant None None O
processing None None O
we None None O
measured None None O
neuronal None None O
activity None None O
( None None O
single-neurons None None O
' None None O
firing None None O
rates None None O
) None None O
in None None O
human None None O
subcallosal None None O
cingulate None None I-REGION
cortex None None I-REGION
( None None O
SCC None None O
) None None O
in None None O
the None None O
course None None O
of None None O
Deep None None O
Brain None None O
Stimulation None None O
surgery None None O
. None None O

In None None O
addition None None O
, None None O
adolescents None None O
' None None O
and None None O
mothers None None O
' None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
parenting None None O
efficacy None None O
after None None O
childbirth None None O
were None None O
linked None None O
to None None O
profile None None O
membership None None O
, None None O
such None None O
that None None O
the None None O
Harmonious-Adolescent None None O
Primary None None O
profile None None O
reported None None O
the None None O
most None None O
positive None None O
adjustment None None O
patterns None None O
, None None O
whereas None None O
profiles None None O
with None None O
high None None O
coparental None None O
conflict None None O
( None None O
i.e. None None O
, None None O
Conflictual None None O
Coparenting None None O
and None None O
Conflictual-Adolescent None None O
Primary None None O
profiles None None O
) None None O
showed None None O
the None None O
least None None O
positive None None O
adjustment None None O
patterns None None O
. None None O

But None None O
the None None O
clinical None None O
application None None O
of None None O
VIP None None I-TRANS
has None None O
been None None O
limited None None O
for None None O
the None None O
easy None None O
in None None O
vivo None None O
digestion None None O
. None None O

Finally None None O
, None None O
these None None O
two None None O
classifiers None None O
were None None O
used None None O
to None None O
predict None None O
the None None O
bioactivities None None O
of None None O
novel None None O
VIPs None None I-TRANS
, None None O
without None None O
experimental None None O
activities None None O
, None None O
which None None O
were None None O
suggested None None O
for None None O
experimental None None O
research None None O
groups None None O
to None None O
test None None O
their None None O
bioactivities None None O
and None None O
the None None O
possible None None O
practical None None O
applications None None O
in None None O
future None None O
. None None O

The None None O
blood None None O
coagulation None None O
cascade None None O
represents None None O
an None None O
attractive None None O
target None None O
for None None O
antithrombotic None None O
drug None None O
development None None O
, None None O
and None None O
recent None None O
studies None None O
have None None O
attempted None None O
to None None O
identify None None O
oral None None O
anticoagulants None None O
with None None O
inhibitory None None O
activity None None O
for None None O
enzymes None None I-PROTEIN
in None None O
this None None O
cascade None None O
, None None O
with None None O
particular None None O
attention None None I-FUNC
focused None None O
on None None O
thrombin None None I-PROTEIN
and None None O
factor None None O
Xa None None O
( None None O
fXa None None O
) None None O
as None None O
typical None None O
targets None None O
. None None O

The None None O
potential None None O
utility None None O
of None None O
designed None None O
bivalent None None O
ligands None None O
as None None O
targeting None None O
agents None None O
for None None O
cancer None None O
diagnosis None None O
and/or None None O
therapy None None O
can None None O
be None None O
evaluated None None O
by None None O
determining None None O
their None None O
binding None None O
to None None O
the None None O
corresponding None None O
receptors None None I-PROTEIN
. None None O

While None None O
peptides None None I-TRANS
are None None O
promising None None O
as None None O
probes None None O
and None None O
therapeutics None None O
, None None O
targeting None None O
intracellular None None O
proteins None None O
will None None O
require None None O
greater None None O
understanding None None O
of None None O
highly None None O
structured None None O
, None None O
cell-internalized None None O
scaffolds None None O
. None None O

Peptides None None I-TRANS
are None None O
of None None O
great None None O
interest None None O
to None None O
be None None O
used None None O
as None None O
vaccine None None O
antigens None None O
due None None O
to None None O
their None None O
safety None None O
, None None O
ease None None O
of None None O
manufacturing None None O
and None None O
specificity None None O
in None None O
generating None None O
immune None None O
response None None O
. None None O

However None None O
, None None O
peptides None None I-TRANS
alone None None O
are None None O
poorly None None O
immunogenic None None O
, None None O
which None None O
demand None None O
co-administration None None O
with None None O
strong None None O
adjuvant None None O
to None None O
enhance None None O
their None None O
immunogenicity None None O
. None None O

Thus None None O
inhibition None None O
of None None O
this None None O
complex None None O
is None None O
a None None O
viable None None O
target None None O
for None None O
numerous None None O
acute None None O
and None None O
chronic None None O
neurodegenerative None None O
diseases None None O
involving None None O
tau None None O
protein None None O
, None None O
including None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

To None None O
examine None None O
their None None O
specificity None None O
and None None O
selectivity None None O
, None None O
all None None O
inhibitors None None O
were None None O
tested None None O
with None None O
human None None O
α1,3-fucosyltransferase None None O
IX None None I-REGION
and None None O
Helicobacter None None O
pylori None None O
α1,3-fucosyltransferase None None O
, None None O
which None None O
is None None O
to None None O
date None None O
the None None O
only None None O
α1,3-fucosyltransferase None None O
with None None O
a None None O
known None None O
high None None O
resolution None None O
structure None None O
. None None O

In None None O
that None None O
regard None None O
, None None O
acetylated None None O
GDP-galactose None None O
derivative None None O
Ac-3 None None O
turned None None O
out None None O
to None None O
inhibit None None O
H. None None O
pylori None None O
α1,3-fucosyltransferase None None O
but None None O
not None None O
human None None O
fucosyltransferase None None O
IX None None I-REGION
, None None O
whereas None None O
GDP-6-amino-β-l-fucose None None O
17 None None O
showed None None O
an None None O
appreciably None None O
better None None O
inhibitory None None O
effect None None O
on None None O
fucosyltransferase None None O
IX None None I-REGION
activity None None O
than None None O
on None None O
that None None O
of None None O
H. None None O
pylori None None O
fucosyltransferase None None O
. None None O

Myeloperoxidase None None I-PROTEIN
( None None O
MPO None None O
) None None O
produces None None O
hypohalous None None O
acids None None O
as None None O
a None None O
key None None O
component None None O
of None None O
the None None O
innate None None O
immune None None O
response None None O
; None None O
however None None O
, None None O
release None None O
of None None O
these None None O
acids None None O
extracellularly None None O
results None None O
in None None O
inflammatory None None O
cell None None O
and None None O
tissue None None O
damage None None O
. None None O

In None None O
this None None O
study None None O
, None None O
a None None O
promising None None O
compound None None O
34 None None O
, None None O
with None None O
a None None O
c-Met None None O
IC50 None None O
value None None O
of None None O
1.04nM None None O
, None None O
was None None O
identified None None O
as None None O
a None None O
multitargeted None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
inhibitor None None O
. None None O

A None None O
novel None None O
series None None O
of None None O
8-amino None None O
imidazo None None O
[ None None O
1,2-a None None O
] None None O
pyrazine None None O
derivatives None None O
has None None O
been None None O
developed None None O
as None None O
inhibitors None None O
of None None O
the None None O
VirB11 None None O
ATPase None None I-PROTEIN
HP0525 None None O
, None None O
a None None O
key None None O
component None None O
of None None O
the None None O
bacterial None None O
type None None O
IV None None O
secretion None None O
system None None O
. None None O

Adverse None None O
clinical None None O
outcomes None None O
included None None O
cerebrovascular None None I-DISEASE
accident None None I-DISEASE
( None None O
CVA None None O
) None None O
, None None O
transient None None O
ischaemic None None O
attack None None O
( None None O
TIA None None O
) None None O
, None None O
loss None None O
of None None O
vision None None I-FUNC
, None None O
vascular None None O
lesions None None O
( None None O
carotid None None O
, None None O
femoral None None O
, None None O
renal None None O
, None None O
coronary None None O
, None None O
or None None O
other None None O
vessels None None O
) None None O
requiring None None O
stenting None None O
, None None O
angioplasty None None O
, None None O
or None None O
other None None O
surgical None None O
intervention None None O
, None None O
aortic None None O
valve None None O
replacement None None O
, None None O
end-stage None None O
renal None None O
failure None None O
or None None O
death None None O
. None None O

Seven None None O
days None None O
later None None O
, None None O
the None None O
patient None None O
presented None None O
acute None None O
ocular None None O
pain None None O
, None None O
loss None None O
of None None O
acuity None None O
for None None O
color None None O
, None None O
blurred None None O
vision None None I-FUNC
, None None O
photophobia None None O
, None None O
redness None None O
and None None O
short None None O
progressive None None O
visual None None O
loss None None O
in None None O
the None None O
right None None O
eye None None O
. None None O

For None None O
behavioural None None O
studies None None O
, None None O
drug None None O
effects None None O
were None None O
tested None None O
in None None O
male None None O
Sprague-Dawley None None O
rats None None O
implanted None None O
with None None O
electrodes None None O
targeting None None O
the None None O
medial None None I-REGION
forebrain None None I-REGION
bundle None None I-REGION
and None None O
trained None None O
to None None O
lever-press None None O
for None None O
electrical None None O
brain None None O
stimulation None None O
. None None O

Dapagliflozin None None O
, None None O
a None None O
selective None None O
sodium-glucose None None O
cotransporter-2 None None O
inhibitor None None O
, None None O
reduces None None O
hyperglycaemia None None O
by None None O
increasing None None O
glucosuria None None O
independently None None O
of None None O
insulin None None I-PROTEIN
, None None O
representing None None O
a None None O
novel None None O
approach None None O
in None None O
T2DM None None O
. None None O

Different None None O
ammonia None None O
assimilation None None O
strategies None None O
were None None O
exhibited None None O
by None None O
the None None O
archaeal None None O
communities None None O
: None None O
X. None None O
testudinaria None None O
, None None O
H. None None O
erectus None None O
and None None O
sediment None None O
archaeal None None O
communities None None O
were None None O
enriched None None O
for None None O
glutamate None None I-TRANS
dehydrogenase None None I-PROTEIN
with None None O
mixed None None O
specificity None None O
( None None O
NAD None None I-TRANS
( None None O
P None None O
) None None O
( None None O
+ None None O
) None None O
) None None O
pathways None None O
, None None O
while None None O
archaeal None None O
planktonic None None O
communities None None O
were None None O
enriched None None O
for None None O
specific None None O
glutamate None None I-TRANS
dehydrogenase None None I-PROTEIN
( None None O
NADP None None O
( None None O
+ None None O
) None None O
) None None O
and None None O
glutamate None None I-TRANS
synthase None None O
pathways None None O
. None None O

The None None O
ability None None O
to None None O
use None None O
cognitive None None O
emotion None None I-FUNC
regulation None None O
strategies None None O
such None None O
as None None O
reappraisal None None O
may None None O
be None None O
a None None O
core None None O
component None None O
of None None O
emotional None None O
competence None None O
across None None O
development None None O
, None None O
but None None O
due None None O
to None None O
methodological None None O
challenges None None O
in None None O
measuring None None O
such None None O
strategies None None O
, None None O
they None None O
are None None O
rarely None None O
studied None None O
in None None O
young None None O
children None None O
. None None O

The None None O
association None None O
between None None O
the None None O
LPP None None O
and None None O
emotion None None I-FUNC
regulatory None None O
capacity None None O
in None None O
children None None O
is None None O
unknown None None O
. None None O

Next None None O
they None None O
completed None None O
a None None O
disappointing None None O
and None None O
a None None O
frustrating None None O
task None None O
during None None O
which None None O
emotion None None I-FUNC
regulation None None O
strategies None None O
were None None O
observed None None O
. None None O

These None None O
findings None None O
provide None None O
observation-based None None O
evidence None None O
that None None O
the None None O
LPP None None O
may None None O
be None None O
a None None O
viable None None O
neurosignature None None O
for None None O
emotion None None I-FUNC
regulatory None None O
capacity None None O
in None None O
children None None O
. None None O

Transcranial None None O
magnetic None None O
resonance None None O
imaging-guided None None O
high-intensity None None O
focused None None O
ultrasound None None O
( None None O
MRgHIFU None None O
) None None O
is None None O
gaining None None O
attention None None I-FUNC
as None None O
a None None O
potent None None O
substitute None None O
for None None O
surgical None None O
intervention None None O
in None None O
the None None O
treatment None None O
of None None O
neurologic None None O
disorders None None O
. None None O

Focused None None O
ultrasound None None O
sonication None None O
destroyed None None O
tissues None None O
by None None O
focusing None None O
a None None O
high-energy None None O
beam None None O
on None None O
the None None O
ventralis None None O
intermedius None None O
nucleus None None O
of None None O
the None None O
thalamus None None I-REGION
. None None O

Thalamic None None O
MRgHIFU None None O
had None None O
substantial None None O
therapeutic None None O
effects None None O
on None None O
patients None None O
, None None O
based None None O
on None None O
MRgHIFU-mediated None None O
improvements None None O
in None None O
movement None None I-FUNC
control None None O
and None None O
significant None None O
changes None None O
in None None O
brain None None O
mu None None O
rhythms None None O
. None None O

Accordingly None None O
, None None O
we None None O
hypothesized None None O
that None None O
the None None O
CSF None None O
phenomenon None None O
is None None O
a None None O
form None None O
of None None O
atherosclerosis None None I-DISEASE
including None None O
both None None O
small None None O
vessels None None O
and None None O
epicardial None None O
coronary None None O
arteries None None O
. None None O

The None None O
overuse None None O
model None None O
promoted None None O
behavioral None None O
changes None None O
and None None O
increased None None O
creatine None None O
kinase None None O
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
activity None None O
, None None O
as None None O
well None None O
as None None O
the None None O
levels None None O
of None None O
superoxide None None O
, None None O
nitrotyrosine None None O
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
thiobarbituric None None O
acid None None O
reactive None None O
substance None None O
, None None O
carbonyl None None O
, None None O
tumor None None O
necrosis None None O
factor None None O
α None None O
and None None O
interleukin-6 None None O
. None None O

Catalase None None I-PROTEIN
activity None None O
remained None None O
unchanged None None O
and None None O
the None None O
glutathione None None O
level None None O
increased None None O
significantly None None O
after None None O
exposure None None O
to None None O
AuNPs None None O
plus None None O
ultrasound None None O
. None None O

We None None O
suggest None None O
that None None O
the None None O
efficacy None None O
of None None O
TU None None O
is None None O
dependent None None O
on None None O
its None None O
ability None None O
to None None O
limit None None O
the None None O
upregulation None None O
of None None O
neurokinin-1 None None O
receptor None None I-PROTEIN
, None None O
substance None None I-TRANS
P None None I-TRANS
, None None O
tumor None None O
necrosis None None O
factor-α None None O
and None None O
interleukin-6 None None O
around None None O
the None None O
injured None None O
sciatic None None O
nerve None None O
. None None O

The None None O
diagnosis None None O
of None None O
ILA None None O
was None None O
based None None O
on None None O
exclusion None None O
of None None O
other None None O
causes None None O
of None None O
white None None I-REGION
matter None None I-REGION
changes None None O
seen None None O
on None None O
magnetic None None O
resonance None None O
imaging None None O
. None None O

Here None None O
we None None O
identify None None O
the None None O
plastid None None O
proteomes None None O
of None None O
two None None O
diatoms None None O
, None None O
Thalassiosira None None O
pseudonana None None O
and None None O
Phaeodactylum None None O
tricornutum None None O
, None None O
using None None O
a None None O
customized None None O
prediction None None O
tool None None O
( None None O
ASAFind None None O
) None None O
that None None O
identifies None None O
nuclear-encoded None None O
plastid None None O
proteins None None O
in None None O
algae None None O
with None None O
secondary None None O
plastids None None O
of None None O
the None None O
red None None O
lineage None None O
based None None O
on None None O
the None None O
output None None O
of None None O
SignalP None None O
and None None O
the None None O
identification None None O
of None None O
conserved None None O
'ASAFAP None None O
' None None O
motifs None None O
and None None O
transit None None O
peptides None None I-TRANS
. None None O

NAFLD None None O
was None None O
referred None None O
as None None O
fatty None None O
liver None None O
with None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
levels None None O
≧31 None None O
IU/L None None O
in None None O
this None None O
study None None O
. None None O

Furthermore None None O
, None None O
hDPSC-derived None None O
dopaminergic None None O
and None None O
spinal None None O
motor None None I-NEURON
neuron None None I-NEURON
cells None None O
after None None O
induction None None O
expressed None None O
a None None O
higher None None O
density None None O
of None None O
neuron None None O
cell None None O
markers None None O
than None None O
those None None O
before None None O
induction None None O
. None None O

Published None None O
by None None O
Elsevier None None O
B.V. None None O
Non-adherence None None O
with None None O
antipsychotic None None O
medication None None O
is None None O
a None None O
frequently None None O
occurring None None O
problem None None O
, None None O
particularly None None O
among None None O
patients None None O
with None None O
psychotic None None I-DISEASE
disorders None None I-DISEASE
. None None O

However None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
application None None O
of None None O
CM None None O
on None None O
medication None None O
adherence None None O
in None None O
patients None None O
with None None O
psychotic None None I-DISEASE
disorders None None I-DISEASE
. None None O

The None None O
current None None O
study None None O
is None None O
a None None O
randomized None None O
controlled None None O
trial None None O
concerning None None O
the None None O
effectiveness None None O
of None None O
a None None O
CM None None O
procedure None None O
called None None O
'Money None None O
for None None O
Medication None None O
' None None O
( None None O
M4M None None O
) None None O
, None None O
aimed None None O
at None None O
improving None None O
adherence None None O
with None None O
antipsychotic None None O
depot None None O
medication None None O
in None None O
psychotic None None I-DISEASE
disorder None None I-DISEASE
patients None None O
. None None O

This None None O
RCT None None O
assesses None None O
the None None O
effectiveness None None O
and None None O
side-effects None None O
of None None O
financial None None O
incentives None None O
in None None O
improving None None O
adherence None None O
with None None O
antipsychotic None None O
depot None None O
medication None None O
in None None O
patients None None O
with None None O
psychotic None None I-DISEASE
disorders None None I-DISEASE
. None None O

The None None O
present None None O
review None None O
discusses None None O
some None None O
general None None O
questions None None O
, None None O
including None None O
the None None O
properties None None O
of None None O
excitation None None O
at None None O
depolarizing None None O
GABAergic None None O
synapse None None O
and None None O
shunting None None O
inhibition None None O
by None None O
depolarizing None None O
GABA None None I-TRANS
; None None O
technical None None O
issues None None O
in None None O
exploration None None O
of None None O
depolarizing None None O
GABA None None I-TRANS
using None None O
various None None O
techniques None None O
and None None O
preparations None None O
, None None O
including None None O
the None None O
developmental None None O
aspects None None O
of None None O
traumatic None None O
injury None None O
and None None O
what None None O
is None None O
known None None O
( None None O
or None None O
rather None None O
unknown None None O
) None None O
on None None O
the None None O
actions None None O
of None None O
GABA None None I-TRANS
in None None O
vivo None None O
; None None O
complex None None O
roles None None O
of None None O
depolarizing None None O
GABA None None I-TRANS
in None None O
developmental None None O
epilepsies None None O
, None None O
including None None O
a None None O
contribution None None O
of None None O
depolarizing None None O
GABA None None I-TRANS
to None None O
enhanced None None O
excitability None None O
in None None O
the None None O
immature None None O
networks None None O
, None None O
caused None None O
by None None O
repetitive None None O
seizures None None O
accumulation None None O
of None None O
intracellular None None O
chloride None None O
concentration None None O
that None None O
increases None None O
excitatory None None O
GABA None None I-TRANS
power None None O
and None None O
its None None O
synchronizing None None O
proconvulsive None None O
effects None None O
, None None O
and None None O
correction None None O
of None None O
chloride None None O
homeostasis None None O
as None None O
a None None O
potential None None O
strategy None None O
to None None O
treat None None O
neonatal None None O
seizures None None O
. None None O

Numerous None None O
clinical None None O
studies None None O
have None None O
shown None None O
a None None O
correlation None None O
between None None O
increased None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
( None None O
MMP None None O
) None None O
/a None None O
disintegrin None None O
and None None O
metalloproteinase None None O
( None None O
ADAM None None O
) None None O
activity None None O
and None None O
poor None None O
outcome None None O
of None None O
cancer None None O
. None None O

Given None None O
the None None O
limitations None None O
of None None O
this None None O
method None None O
, None None O
the None None O
objective None None O
of None None O
the None None O
current None None O
study None None O
was None None O
to None None O
reexamine None None O
the None None O
excitability None None O
of None None O
motoneurons None None O
in None None O
chronic None None O
stroke None None I-DISEASE
survivors None None O
by None None O
estimating None None O
reflex None None O
latency None None O
using None None O
single None None O
motor None None O
unit None None O
discharge None None O
. None None O

We None None O
applied None None O
tendon None None O
taps None None O
of None None O
different None None O
amplitudes None None O
on None None O
the None None O
biceps None None O
tendons None None O
of None None O
both None None O
arms None None O
of None None O
the None None O
stroke None None I-DISEASE
survivors None None O
. None None O

Stroke None None I-DISEASE
is None None O
the None None O
fourth None None O
leading None None O
cause None None O
of None None O
death None None O
in None None O
the None None O
United None None O
States None None O
. None None O

The None None O
gaps None None O
for None None O
patients None None O
diagnosed None None O
with None None O
a None None O
stroke None None I-DISEASE
are None None O
the None None O
availability None None O
of None None O
physicians None None O
who None None O
specialize None None O
in None None O
stroke None None I-DISEASE
care None None O
and None None O
access None None O
to None None O
evidence-based None None O
stroke None None I-DISEASE
care None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
article None None O
is None None O
to None None O
describe None None O
how None None O
the None None O
implementation None None O
of None None O
a None None O
hub None None O
and None None O
spoke None None O
model None None O
using None None O
telemedicine None None O
has None None O
assisted None None O
in None None O
increasing None None O
patient None None O
access None None O
to None None O
neurology None None O
expertise None None O
and None None O
receiving None None O
evidence-based None None O
treatment None None O
of None None O
recombinant None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
, None None O
thereby None None O
improving None None O
patient None None O
outcomes None None O
. None None O

We None None O
examined None None O
hospital None None O
surveillance None None O
data None None O
captured None None O
by None None O
the None None O
Atherosclerosis None None I-DISEASE
Risk None None O
in None None O
Communities None None O
Study None None O
from None None O
January None None O
1 None None O
, None None O
2005 None None O
, None None O
to None None O
December None None O
31 None None O
, None None O
2010 None None O
. None None O

Over None None O
6 None None O
years None None O
, None None O
15,461 None None O
( None None O
weighted None None O
) None None O
hospitalized None None O
events None None O
for None None O
ADHF None None O
( None None O
59 None None O
% None None O
HFrEF None None O
) None None O
occurred None None O
in None None O
the None None O
catchment None None O
of None None O
the None None O
Atherosclerosis None None I-DISEASE
Risk None None O
in None None O
Communities None None O
, None None O
based None None O
on None None O
3,309 None None O
sampled None None O
events None None O
. None None O

Notably None None O
, None None O
compared None None O
with None None O
patients None None O
without None None O
previous None None O
AF None None O
, None None O
patients None None O
with None None O
previous None None O
AF None None O
at None None O
baseline None None O
had None None O
increased None None O
rates None None O
of None None O
stroke None None I-DISEASE
and None None O
mortality None None O
at None None O
1-year None None O
follow-up None None O
( None None O
2.1 None None O
% None None O
vs None None O
9.6 None None O
% None None O
, None None O
p None None O
= None None O
0.01 None None O
, None None O
and None None O
8.2 None None O
% None None O
vs None None O
34.9 None None O
% None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
; None None O
respectively None None O
) None None O
. None None O

In None None O
conclusion None None O
, None None O
previous None None O
AF None None O
at None None O
baseline None None O
but None None O
not None None O
NOAF None None O
significantly None None O
increases None None O
stroke None None I-DISEASE
and None None O
mortality None None O
rates None None O
after None None O
TAVI None None O
. None None O

The None None O
prognostic None None O
implications None None O
of None None O
flow None None O
, None None O
assessed None None O
by None None O
stroke None None I-DISEASE
volume None None O
index None None O
( None None O
SVi None None O
) None None O
, None None O
and None None O
left None None O
ventricular None None O
( None None O
LV None None O
) None None O
global None None O
longitudinal None None O
strain None None O
on None None O
survival None None O
of None None O
patients None None O
with None None O
low-gradient None None O
severe None None O
aortic None None O
stenosis None None O
( None None O
AS None None O
) None None O
and None None O
preserved None None O
LV None None O
ejection None None O
fraction None None O
are None None O
debated None None O
. None None O

End None None O
points None None O
were None None O
in-hospital None None O
, None None O
30-day None None O
, None None O
and None None O
1-year None None O
all-cause None None O
mortality None None O
, None None O
stroke None None I-DISEASE
, None None O
myocardial None None O
infarction None None O
, None None O
major None None O
bleeding None None O
, None None O
and None None O
major None None O
vascular None None O
complications None None O
. None None O

This None None O
is None None O
a None None O
retrospective None None O
single-center None None O
study None None O
of None None O
1,458 None None O
consecutive None None O
patients None None O
hospitalized None None O
with None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
or None None O
transient None None O
ischemic None None O
attack None None O
who None None O
underwent None None O
TEE None None O
for None None O
evaluation None None O
of None None O
a None None O
suspected None None O
cardioembolic None None O
cause None None O
. None None O

In None None O
conclusion None None O
, None None O
in None None O
patients None None O
with None None O
suspected None None O
cardioembolic None None O
stroke None None I-DISEASE
, None None O
TEE None None O
findings None None O
led None None O
to None None O
a None None O
change None None O
in None None O
management None None O
in None None O
16.7 None None O
% None None O
of None None O
patients None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
depression None None I-DISEASE
and None None O
anxiety None None O
are None None O
associated None None O
with None None O
electrocardiographic None None O
( None None O
ECG None None O
) None None O
repolarization None None O
abnormalities None None O
in None None O
the None None O
Multi-Ethnic None None O
Study None None O
of None None O
Atherosclerosis None None I-DISEASE
( None None O
MESA None None O
) None None O
, None None O
a None None O
cohort None None O
free None None O
of None None O
symptomatic None None O
cardiovascular None None O
disease None None O
. None None O

The None None O
divergent None None O
associations None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
trait None None O
anxiety None None O
with None None O
ECG None None O
T-wave None None O
inversions None None O
were None None O
similar None None O
in None None O
men None None O
and None None O
women None None O
, None None O
and None None O
these None None O
associations None None O
were None None O
present None None O
across None None O
the None None O
racial None None O
and None None O
ethnic None None O
subgroups None None O
( None None O
non-Hispanic None None O
white None None O
, None None O
African-American None None O
, None None O
Hispanic None None O
, None None O
and None None O
Chinese None None O
) None None O
. None None O

Negative None None O
emotions None None I-FUNC
may None None O
have None None O
a None None O
differential None None O
impact None None O
on None None O
cardiovascular None None O
mortality None None O
through None None O
unique None None O
relations None None O
with None None O
cardiac None None O
repolarization None None O
. None None O

Vimentin None None O
was None None O
negative None None O
in None None O
the None None O
primary None None O
lesion None None O
of None None O
the None None O
AT None None O
, None None O
as None None O
well None None O
as None None O
in None None O
the None None O
metastasis None None O
found None None O
in None None O
the None None O
adrenal None None I-TRANS
gland None None O
. None None O

Secondary None None O
outcome None None O
measures None None O
were None None O
fasting None None O
plasma None None O
glucose None None O
( None None O
FPG None None O
) None None O
, None None O
post-prandial None None O
blood None None O
glucose None None O
( None None O
PPG None None O
) None None O
, None None O
HbA1c None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
HOMA-IR None None O
) None None O
. None None O

However None None O
, None None O
clinical None None O
association None None O
between None None O
serum None None O
ferritin None None I-PROTEIN
level None None O
and None None O
IR None None O
remained None None O
unclear None None O
. None None O

Cox None None O
proportional None None O
hazards None None O
models None None O
were None None O
used None None O
to None None O
measure None None O
the None None O
hazard None None O
ratios None None O
( None None O
HRs None None O
) None None O
of None None O
baseline None None O
serum None None O
ferritin None None I-PROTEIN
levels None None O
on None None O
IR None None O
. None None O

The None None O
development None None O
rate None None O
of None None O
IR None None O
increased None None O
in None None O
proportion None None O
to None None O
the None None O
baseline None None O
serum None None O
ferritin None None I-PROTEIN
levels None None O
( None None O
quartile None None O
1 None None O
: None None O
16.7 None None O
% None None O
, None None O
quartile None None O
2 None None O
: None None O
18.5 None None O
% None None O
, None None O
quartile None None O
3 None None O
: None None O
19.9 None None O
% None None O
, None None O
quartile None None O
4 None None O
: None None O
25.5 None None O
% None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Elevated None None O
serum None None O
ferritin None None I-PROTEIN
level None None O
was None None O
independently None None O
associated None None O
with None None O
the None None O
future None None O
development None None O
of None None O
IR None None O
in None None O
Korean None None O
men None None O
. None None O

Membrane None None O
proteins None None O
destined None None O
for None None O
degradation None None O
, None None O
such None None O
as None None O
misfolded None None O
proteins None None O
or None None O
activated None None O
receptors None None I-PROTEIN
, None None O
are None None O
usually None None O
ubiquitinated None None O
and None None O
sorted None None O
into None None O
the None None O
intraluminal None None O
vesicles None None O
( None None O
ILVs None None O
) None None O
of None None O
prevacuolar None None O
compartments/multivesicular None None O
bodies None None O
( None None O
PVCs/MVBs None None O
) None None O
, None None O
which None None O
then None None O
fuse None None O
with None None O
vacuoles/lysosomes None None O
to None None O
deliver None None O
their None None O
contents None None O
to None None O
the None None O
lumen None None O
for None None O
degradation None None O
by None None O
luminal None None O
proteases None None O
. None None O

These None None O
correlates None None O
have None None O
been None None O
observed None None O
at None None O
the None None O
level None None O
of None None O
single-unit None None O
firing None None O
and None None O
in None None O
measurements None None O
of None None O
phasic None None O
DA None None O
release None None O
in None None O
ventral None None I-REGION
striatum None None I-REGION
( None None O
VS None None O
) None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
a None None O
class None None O
of None None O
segmentally None None O
arrayed None None O
local None None O
interneurons None None I-NEURON
( None None O
period-positive None None O
median None None O
segmental None None O
interneurons None None I-NEURON
, None None O
or None None O
PMSIs None None O
) None None O
regulates None None O
the None None O
speed None None O
of None None O
peristaltic None None O
locomotion None None O
in None None O
Drosophila None None O
larvae None None O
. None None O

Calcium None None O
imaging None None O
showed None None O
that None None O
PMSIs None None O
are None None O
rhythmically None None O
active None None O
during None None O
peristalsis None None O
with None None O
a None None O
short None None O
time None None O
delay None None O
in None None O
relation None None O
to None None O
motor None None I-NEURON
neurons None None I-NEURON
. None None O

Self-reported None None O
sleep None None O
disturbances None None O
and None None O
established None None O
risk None None O
factors None None O
for None None O
dementia None None I-DISEASE
were None None O
measured None None O
in None None O
men None None O
at None None O
ages None None O
50 None None O
( None None O
n None None O
= None None O
1574 None None O
) None None O
and None None O
70 None None O
( None None O
n None None O
= None None O
1029 None None O
) None None O
years None None O
. None None O

In None None O
addition None None O
, None None O
plasma None None O
levels None None O
of None None O
β-amyloid None None O
( None None O
Aβ None None O
) None None O
peptides None None I-TRANS
1-40 None None O
and None None O
1-42 None None O
were None None O
measured None None O
at None None O
ages None None O
70 None None O
, None None O
77 None None O
, None None O
and None None O
82 None None O
years None None O
. None None O

Binary None None O
logistic None None O
regression None None O
showed None None O
the None None O
increased None None O
risk None None O
for None None O
both None None O
dementia None None I-DISEASE
( None None O
+114 None None O
% None None O
) None None O
and None None O
AD None None O
( None None O
+192 None None O
% None None O
) None None O
were None None O
highest None None O
when None None O
sleep None None O
disturbance None None O
was None None O
reported None None O
at None None O
age None None O
70 None None O
years None None O
( None None O
both None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
Bax None None O
and None None O
phosphorylated None None O
protein None None O
of None None O
p53 None None I-PROTEIN
was None None O
detected None None O
using None None O
Western None None O
blotting None None O
analyses None None O
and None None O
immunofluorescence None None O
staining None None O
. None None O

Increases None None O
in None None O
CYP2E1 None None I-PROTEIN
activity None None O
and None None O
its None None O
expression None None O
were None None O
augmented None None O
after None None O
hepatic None None O
IR None None O
in None None O
ED-fed None None O
animals None None O
, None None O
but None None O
were None None O
attenuated None None O
by None None O
GdCl3 None None O
. None None O

To None None O
study None None O
the None None O
disagreement None None O
between None None O
self-reported None None O
suicidal None None O
ideation None None O
( None None O
SR-SI None None O
) None None O
and None None O
clinician-ascertained None None O
suicidal None None O
ideation None None O
( None None O
CA-SI None None O
) None None O
and None None O
its None None O
correlation None None O
with None None O
depression None None I-DISEASE
and None None O
anxiety None None O
severity None None O
in None None O
patients None None O
with None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
or None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
( None None O
BPD None None O
) None None O
. None None O

SR-SI None None O
was None None O
extracted None None O
from None None O
the None None O
16 None None O
Item None None O
Quick None None O
Inventory None None O
of None None O
Depression None None I-DISEASE
Symptomatology None None O
Self-Report None None O
( None None O
QIDS-SR-16 None None O
) None None O
item None None O
12 None None O
. None None O

Depression None None I-DISEASE
and None None O
anxiety None None O
severity None None O
were None None O
measured None None O
with None None O
the None None O
QIDS-SR-16 None None O
and None None O
Zung None None O
Self-Rating None None O
Anxiety None None O
Scale None None O
. None None O

The None None O
disagreement None None O
was None None O
positively None None O
correlated None None O
to None None O
depression None None I-DISEASE
severity None None O
in None None O
both None None O
MDD None None O
and None None O
BPD None None O
with None None O
a None None O
correlation None None O
coefficient None None O
R None None O
( None None O
2 None None O
) None None O
= None None O
0.40 None None O
and None None O
0.79 None None O
, None None O
respectively None None O
, None None O
but None None O
was None None O
only None None O
positively None None O
correlated None None O
to None None O
anxiety None None O
severity None None O
in None None O
BPD None None O
with None None O
a None None O
R None None O
( None None O
2 None None O
) None None O
= None None O
0.46 None None O
. None None O

Among None None O
overweight None None O
girls None None O
who None None O
reported None None O
weekly None None O
binge None None O
eating None None O
at None None O
Time None None O
2 None None O
, None None O
those None None O
who None None O
overvalued None None O
weight None None O
were None None O
at None None O
greater None None O
risk None None O
of None None O
having None None O
more None None O
severe None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
odds None None O
ratio None None O
, None None O
10.4 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.3-85.6 None None O
) None None O
. None None O

Thyroid None None O
hormones None None I-PROTEIN
have None None O
a None None O
significant None None O
impact None None O
on None None O
heart None None O
function None None O
, None None O
mediated None None O
by None None O
genomic None None O
and None None O
non-genomic None None O
effects None None O
. None None O

Thyroid None None O
hormones None None I-PROTEIN
upregulate None None O
the None None O
expression None None O
of None None O
the None None O
sarcoplasmic None None O
reticulum None None O
calcium-activated None None O
ATPase None None I-PROTEIN
and None None O
downregulate None None O
the None None O
expression None None O
of None None O
phospholamban None None O
. None None O

Basic None None O
information None None O
about None None O
CFTR None None I-PROTEIN
mutations None None O
classes None None O
and None None O
new None None O
treatments None None O
is None None O
needed None None O
if None None O
we None None O
are None None O
to None None O
deal None None O
properly None None O
with None None O
the None None O
new None None O
CF None None O
era None None O
. None None O

VX-770 None None O
is None None O
a None None O
new None None O
drug None None O
available None None O
to None None O
treat None None O
CF None None O
patients None None O
with None None O
some None None O
class None None O
III None None O
CFTR None None I-PROTEIN
mutations None None O
and None None O
other None None O
drugs None None O
are None None O
being None None O
studied None None O
regarding None None O
other None None O
classes None None O
. None None O

Clinical None None O
trials None None O
have None None O
showed None None O
good None None O
evaluation None None O
of None None O
some None None O
drugs None None O
so None None O
far None None O
, None None O
but None None O
clinical None None O
response None None O
is None None O
a None None O
wide None None O
spectrum None None O
yet None None O
to None None O
be None None O
analyzed None None O
: None None O
CFTR None None I-PROTEIN
mutations None None O
spectrum None None O
, None None O
costs None None O
related None None O
to None None O
the None None O
treatment None None O
with None None O
new None None O
drugs None None O
( None None O
for None None O
VX-770 None None O
therapy None None O
) None None O
, None None O
variability None None O
of None None O
CF None None O
clinical None None O
expression None None O
, None None O
limitations None None O
to None None O
test None None O
in None None O
vitro None None O
drugs None None O
, None None O
absence None None O
of None None O
good None None O
clinical None None O
markers None None O
to None None O
evaluate None None O
drug None None O
response None None O
, None None O
absence None None O
of None None O
long-term None None O
studies None None O
and None None O
with None None O
patients None None O
below None None O
six None None O
years None None O
old None None O
, None None O
multidrug None None O
treatment None None O
used None None O
to None None O
improve None None O
the None None O
expression None None O
response None None O
, None None O
and None None O
finally None None O
, None None O
the None None O
most None None O
important None None O
problem None None O
, None None O
who None None O
will None None O
benefit None None O
from None None O
the None None O
new None None O
drugs None None O
therapy None None O
, None None O
are None None O
issues None None O
that None None O
constitute None None O
a None None O
barrier None None O
that None None O
should None None O
be None None O
overcome None None O
. None None O

APJ None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
occurrence None None O
and None None O
development None None O
of None None O
cardiovascular None None O
and None None O
metabolic None None O
diseases None None O
including None None O
atherosclerosis None None I-DISEASE
( None None O
AS None None O
) None None O
, None None O
coronary None None O
heart None None O
disease None None O
( None None O
CAD None None O
) None None O
, None None O
heart None None O
failure None None O
( None None O
HF None None O
) None None O
, None None O
pulmonary None None O
arterial None None O
hypertension None None O
( None None O
PAH None None O
) None None O
, None None O
myocardial None None O
hypertrophy None None O
and None None O
atrial None None O
fibrillation None None O
, None None O
especially None None O
hypertension None None O
. None None O

Given None None O
the None None O
role None None O
of None None O
apelin/APJ None None O
in None None O
hypertension None None O
and None None O
other None None O
cardiovascular None None O
diseases None None O
, None None O
we None None O
believe None None O
that None None O
the None None O
peptides None None I-TRANS
and None None O
compounds None None O
based None None O
on None None O
APJ None None O
will None None O
be None None O
developed None None O
for None None O
treatment None None O
of None None O
these None None O
diseases None None O
. None None O

Results None None O
showed None None O
: None None O
first None None O
, None None O
that None None O
the None None O
level None None O
of None None O
activity None None O
within None None O
the None None O
inferior None None I-REGION
parietal None None I-REGION
lobule None None I-REGION
and None None O
MT/V5/EBA None None O
( None None O
extrastriate None None O
body None None O
area None None O
) None None O
, None None O
areas None None O
constitutive None None O
of None None O
the None None O
AON None None O
, None None O
was None None O
independent None None O
of None None O
the None None O
gymnasts None None O
' None None O
physical None None O
condition None None O
. None None O

The None None O
equal None None O
contribution None None O
of None None O
MT/V5/EBA None None O
and None None O
inferior None None I-REGION
parietal None None I-REGION
lobule None None I-REGION
during None None O
the None None O
observation None None O
of None None O
movements None None I-FUNC
the None None O
gymnasts None None O
were None None O
able None None O
or None None O
unable None None O
to None None O
practice None None O
suggests None None O
respectively None None O
that None None O
physical None None O
provisional None None O
incapacity None None O
does None None O
not None None O
interfere None None O
with None None O
the None None O
perceptual None None O
processing None None O
of None None O
body None None O
shape None None O
and None None O
motion None None O
information None None O
, None None O
and None None O
that None None O
motor None None O
expertise None None O
may None None O
prevent None None O
the None None O
decay None None O
of None None O
sensorimotor None None O
representations None None O
. None None O

Neurocognition None None O
may None None O
constitute None None O
one None None O
of None None O
the None None O
numerous None None O
factors None None O
that None None O
mediate None None O
the None None O
reciprocal None None O
influences None None O
between None None O
personality None None O
and None None O
depression None None I-DISEASE
. None None O

Twenty None None O
participants None None O
with None None O
self-reported None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
18 None None O
control None None O
participants None None O
were None None O
selected None None O
based None None O
on None None O
their None None O
BDI-II None None O
scores None None O
. None None O

The None None O
participants None None O
who None None O
self-reported None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
had None None O
higher None None O
HA None None O
, None None O
lower None None O
SD None None O
and None None O
higher None None O
anxiety None None O
compared None None O
to None None O
controls None None O
. None None O

Individuals None None O
with None None O
self-reported None None O
depression None None I-DISEASE
showed None None O
reduced None None O
ERPs None None O
amplitudes None None O
for None None O
happiness None None O
. None None O

Personality None None O
dimensions None None O
influence None None O
the None None O
neurocognitive None None O
processing None None O
of None None O
emotional None None O
faces None None O
in None None O
individuals None None O
with None None O
self-reported None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
which None None O
may None None O
constitute None None O
a None None O
cognitive None None O
vulnerability None None O
to None None O
depression None None I-DISEASE
. None None O

In None None O
order None None O
to None None O
investigate None None O
visual None None O
responses None None O
, None None O
we None None O
examined None None O
visual None None O
evoked None None O
potentials None None O
( None None O
VEPs None None O
) None None O
and None None O
behavioral None None O
responses None None O
to None None O
visual None None O
stimuli None None O
in None None O
vegetative None None O
patients None None O
during None None O
recovery None None O
to None None O
consciousness None None I-FUNC
. None None O

Our None None O
findings None None O
show None None O
the None None O
improvement None None O
of None None O
visual None None O
responding None None O
with None None O
recovery None None O
from None None O
the None None O
vegetative None None O
state None None O
to None None O
consciousness None None I-FUNC
. None None O

Hallux None None O
movement None None I-FUNC
, None None O
tibialis None None O
anterior None None O
maximum None None O
EMG None None O
amplitude None None O
and None None O
pain None None O
felt None None O
by None None O
the None None O
participant None None O
for None None O
each None None O
stroke None None I-DISEASE
were None None O
recorded None None O
. None None O

The None None O
change None None O
in None None O
hallux None None O
angle None None O
was None None O
significantly None None O
correlated None None O
with None None O
the None None O
duration None None O
of None None O
the None None O
stroke None None I-DISEASE
( None None O
R None None O
( None None O
2 None None O
) None None O
=0.18 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
maximum None None O
( None None O
R None None O
( None None O
2 None None O
) None None O
=0.14 None None O
, None None O
P=0.01 None None O
) None None O
and None None O
average None None O
( None None O
R None None O
( None None O
2 None None O
) None None O
=0.17 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
force None None O
used None None O
to None None O
elicit None None O
the None None O
reflex None None O
. None None O

The None None O
transcriptional None None O
profiles None None O
of None None O
pro-inflammatory None None O
cytokines None None O
, None None O
chemokines None None O
, None None O
antimicrobial None None O
peptides None None I-TRANS
and None None O
Toll-like None None O
receptors None None I-PROTEIN
were None None O
evaluated None None O
by None None O
RT-PCR None None O
and None None O
ELISA None None O
in None None O
tissue None None O
homogenates None None O
. None None O

The None None O
goal None None O
of None None O
immunotherapy None None O
is None None O
to None None O
marshal None None O
the None None O
specificity None None O
and None None O
long-term None None I-FUNC
memory None None I-FUNC
of None None O
the None None O
adaptive None None O
immune None None O
response None None O
to None None O
achieve None None O
durable None None O
tumor None None O
regression None None O
and None None O
possible None None O
cure None None O
, None None O
although None None O
, None None O
to None None O
date None None O
, None None O
this None None O
has None None O
been None None O
achieved None None O
in None None O
only None None O
a None None O
small None None O
subset None None O
of None None O
patients None None O
. None None O

These None None O
include None None O
administration None None O
of None None O
exogenous None None O
cytokines None None O
or None None O
therapeutic None None O
vaccines None None O
to None None O
increase None None O
the None None O
frequency None None O
of None None O
tumor-specific None None O
T None None O
cells None None O
, None None O
adoptive None None O
transfer None None O
of None None O
tumor-specific None None O
immune None None O
effector None None O
cells None None O
, None None O
and None None O
, None None O
more None None O
recently None None O
, None None O
the None None O
application None None O
of None None O
a None None O
variety None None O
of None None O
immune None None O
checkpoint None None O
inhibitors None None O
and None None O
agonists None None O
of None None O
co-stimulatory None None O
receptors None None I-PROTEIN
to None None O
overcome None None O
tumor-induced None None O
immune-suppressive None None O
mechanisms None None O
. None None O

This None None O
review None None O
highlights None None O
some None None O
of None None O
the None None O
most None None O
common None None O
causes None None O
of None None O
foot None None O
and None None O
ankle None None O
pain None None O
in None None O
the None None O
child None None O
, None None O
with None None O
specific None None O
attention None None I-FUNC
to None None O
demographics None None O
, None None O
etiologies None None O
, None None O
diagnostic None None O
workup None None O
, None None O
and None None O
treatment None None O
options None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
SFN None None O
alleviates None None O
GalN/LPS-induced None None O
liver None None O
injury None None O
, None None O
possibly None None O
by None None O
exerting None None O
antioxidant None None O
, None None O
anti-inflammatory None None O
, None None O
and None None O
antiapoptotic None None O
effects None None O
and None None O
modulating None None O
certain None None O
antioxidant None None O
defense None None O
enzymes None None I-PROTEIN
. None None O

Leucine None None I-TRANS
is None None O
a None None O
key None None O
amino None None O
acid None None O
for None None O
initiating None None O
translation None None O
in None None O
muscle None None O
cells None None O
, None None O
but None None O
the None None O
dose-dependent None None O
effects None None O
of None None O
leucine None None I-TRANS
on None None O
intracellular None None O
signaling None None O
are None None O
poorly None None O
characterized None None O
. None None O

We None None O
hypothesized None None O
that None None O
a None None O
leucine None None I-TRANS
`` None None O
threshold None None O
'' None None O
exists None None O
, None None O
which None None O
represents None None O
the None None O
minimum None None O
stimulus None None O
required None None O
to None None O
initiate None None O
mTOR None None O
signaling None None O
in None None O
muscle None None O
cells None None O
. None None O

However None None O
, None None O
only None None O
p70S6k None None O
( None None O
Thr389 None None O
) None None O
exhibited None None O
a None None O
dose-dependent None None O
response None None O
to None None O
leucine None None I-TRANS
with None None O
all None None O
treatments None None O
higher None None O
than None None O
control None None O
( None None O
~4-fold None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
at None None O
least None None O
5 None None O
mM None None O
higher None None O
than None None O
the None None O
1.5-mM None None O
concentration None None O
( None None O
1.2-fold None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.02 None None O
) None None O
. None None O

Seven None None O
days None None O
of None None O
exposure None None O
to None None O
0.5 None None O
, None None O
1.5 None None O
, None None O
5.0 None None O
, None None O
and None None O
16.5 None None O
mM None None O
leucine None None I-TRANS
resulted None None O
in None None O
an None None O
increase None None O
in None None O
cell None None O
size None None O
in None None O
at None None O
least None None O
5 None None O
mM None None O
treatments None None O
( None None O
~1.6-fold None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
vs None None O
control None None O
) None None O
. None None O

The None None O
phosphorylation None None O
of None None O
p70S6k None None O
( None None O
Thr389 None None O
) None None O
follows None None O
a None None O
leucine None None I-TRANS
dose-response None None O
relationship None None O
, None None O
although None None O
this None None O
was None None O
not None None O
reflected None None O
by None None O
the None None O
acute None None O
protein None None O
synthetic None None O
response None None O
. None None O

Sulforaphane None None O
increases None None O
antioxidant None None O
enzymes None None I-PROTEIN
including None None O
NAD None None I-TRANS
( None None O
P None None O
) None None O
H None None O
quinone None None O
oxidoreductase None None I-PROTEIN
and None None O
heme None None O
oxygenase None None O
I None None O
and None None O
inhibits None None O
inflammatory None None O
cytokines None None O
. None None O

The None None O
study None None O
aims None None O
to None None O
compare None None O
in None None O
vitro None None O
stain None None O
resistance None None O
, None None O
color None None O
stability None None O
, None None O
gloss None None O
, None None O
and None None O
gloss None None O
retention None None I-FUNC
of None None O
a None None O
nano-filled None None O
resin-modified None None O
glass None None O
ionomers None None O
( None None O
RMGIs None None O
) None None O
to None None O
a None None O
traditional None None O
RMGI None None O
and None None O
resin-based None None O
composites None None O
( None None O
RBCs None None O
) None None O
. None None O

After None None O
storage None None I-FUNC
, None None O
specimens None None O
were None None O
cleaned None None O
and None None O
L*a*b* None None O
and None None O
gloss None None O
measurements None None O
were None None O
remeasured None None O
. None None O

After None None O
storage None None I-FUNC
, None None O
the None None O
materials None None O
ranked None None O
: None None O
Filtek None None O
= None None O
Clearfil None None O
& None None O
gt None None O
; None None O
Ketac None None O
& None None O
gt None None O
; None None O
Fuji None None O
in None None O
water None None O
, None None O
and None None O
Filtek None None O
& None None O
gt None None O
; None None O
Clearfil None None O
& None None O
gt None None O
; None None O
Ketac None None O
& None None O
gt None None O
; None None O
Fuji None None O
in None None O
staining None None O
solution None None O
. None None O

Prevalence None None O
of None None O
high None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
ranged None None O
from None None O
low None None O
of None None O
22.3 None None O
% None None O
( None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
, None None O
20.4-24.3 None None O
) None None O
to None None O
high None None O
of None None O
38.0 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
, None None O
35.2-41.0 None None O
) None None O
among None None O
those None None O
of None None O
Mexican None None O
or None None O
Puerto None None O
Rican None None O
background None None O
, None None O
respectively None None O
. None None O

Serotonin None None I-TRANS
or None None O
5-hydroxytryptamine None None I-TRANS
( None None O
5-HT None None I-TRANS
) None None O
is None None O
a None None O
neurotransmitter None None I-TRANS
and None None O
hormone None None O
that None None O
contributes None None O
to None None O
the None None O
regulation None None O
of None None O
various None None O
physiological None None O
functions None None O
by None None O
its None None O
actions None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
and None None O
in None None O
the None None O
respective None None O
organ None None O
systems None None O
. None None O

These None None O
gut-resident None None O
cells None None O
produce None None O
much None None O
more None None O
5-HT None None I-TRANS
than None None O
all None None O
neuronal None None O
and None None O
other None None O
sources None None O
combined None None O
, None None O
establishing None None O
EC None None O
cells None None O
as None None O
the None None O
main None None O
source None None O
of None None O
this None None O
biogenic None None O
amine None None O
in None None O
the None None O
human None None O
body None None O
. None None O

Alterations None None O
in None None O
5-HT None None I-TRANS
signalling None None O
have None None O
been None None O
described None None O
in None None O
inflammatory None None O
conditions None None O
of None None O
the None None O
gut None None O
, None None O
such None None O
as None None O
inflammatory None None O
bowel None None O
disease None None O
. None None O

Based None None O
on None None O
searches None None O
for None None O
terms None None O
such None None O
as None None O
'5-HT None None O
' None None O
, None None O
'EC None None O
cell None None O
' None None O
, None None O
'immune None None O
cells None None O
' None None O
and None None O
'inflammation None None O
' None None O
in None None O
pubmed.gov None None O
as None None O
well None None O
as None None O
by None None O
utilizing None None O
pertinent None None O
reviews None None O
, None None O
the None None O
current None None O
review None None O
aims None None O
to None None O
provide None None O
an None None O
update None None O
on None None O
the None None O
role None None O
of None None O
5-HT None None I-TRANS
in None None O
biological None None O
functions None None O
with None None O
a None None O
particular None None O
focus None None O
on None None O
immune None None O
activation None None O
and None None O
inflammation None None O
. None None O

We None None O
observed None None O
significant None None O
differences None None O
among None None O
the None None O
Amicus None None O
, None None O
Optia None None O
, None None O
and None None O
Spectra None None O
regarding None None O
PRE None None O
( None None O
79.8 None None O
± None None O
8.2 None None O
, None None O
82.9 None None O
± None None O
5.8 None None O
, None None O
and None None O
70.4 None None O
± None None O
8.2 None None O
% None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
volume None None O
of None None O
anticoagulant None None O
infused None None O
( None None O
542 None None O
± None None O
196 None None O
, None None O
687 None None O
± None None O
120 None None O
, None None O
and None None O
647 None None O
± None None O
111 None None O
mL None None O
; None None O
p None None O
= None None O
0.002 None None O
) None None O
, None None O
volume None None O
of None None O
Ca-Mg None None O
solution None None O
infused None None O
( None None O
81 None None O
± None None O
28 None None O
, None None O
56 None None O
± None None O
16 None None O
, None None O
and None None O
63 None None O
± None None O
15 None None O
mL None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
absolute None None O
change None None O
of None None O
ionic None None O
Ca None None O
( None None O
-0.04 None None O
± None None O
0.13 None None O
, None None O
-0.05 None None O
± None None O
0.12 None None O
, None None O
and None None O
-0.19 None None O
± None None O
0.16 None None O
mmol/L None None O
; None None O
p None None O
= None None O
0.002 None None O
) None None O
, None None O
and None None O
absolute None None O
change None None O
of None None O
Na None None I-TRANS
( None None O
1.18 None None O
± None None O
1.97 None None O
, None None O
1.02 None None O
± None None O
1.93 None None O
, None None O
and None None O
3.71 None None O
± None None O
1.98 None None O
mEq/L None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

The None None O
estimated None None O
( None None O
95 None None O
% None None O
CI None None O
) None None O
inpatient None None O
care None None O
costs None None O
( None None O
in None None O
2012 None None O
pounds None None O
sterling None None O
) None None O
in None None O
the None None O
event None None O
year None None O
for None None O
the None None O
example None None O
of None None O
a None None O
60-year-old None None O
man None None O
were None None O
: None None O
non-fatal None None O
ischaemic None None O
heart None None O
disease None None O
£9767 None None O
( None None O
£7038-£12 None None O
696 None None O
) None None O
; None None O
amputation None None O
£9546 None None O
( None None O
£6416-£13 None None O
463 None None O
) None None O
; None None O
non-fatal None None O
stroke None None I-DISEASE
£6805 None None O
( None None O
£3856-£10 None None O
278 None None O
) None None O
; None None O
non-fatal None None O
myocardial None None O
infarction None None O
£6379 None None O
( None None O
£4290-£8339 None None O
) None None O
; None None O
fatal None None O
stroke None None I-DISEASE
£3954 None None O
( None None O
£2012-£6428 None None O
) None None O
; None None O
fatal None None O
ischaemic None None O
heart None None O
disease None None O
£3766 None None O
( None None O
£746-£5512 None None O
) None None O
; None None O
heart None None O
failure None None O
£3191 None None O
( None None O
£1678-4903 None None O
) None None O
; None None O
fatal None None O
myocardial None None O
infarction None None O
£1521 None None O
( None None O
£647-£2670 None None O
) None None O
; None None O
and None None O
blindness None None O
in None None O
one None None O
eye None None O
£1355 None None O
( None None O
£415-£2655 None None O
) None None O
. None None O

Costs None None O
of None None O
non-inpatient None None O
healthcare None None O
in None None O
the None None O
event None None O
year None None O
were None None O
: None None O
amputation None None O
£2699 None None O
( None None O
£1409-£4126 None None O
) None None O
; None None O
blindness None None O
in None None O
one None None O
eye None None O
£1790 None None O
( None None O
£878-£3056 None None O
) None None O
; None None O
non-fatal None None O
stroke None None I-DISEASE
£1019 None None O
( None None O
£770-£1499 None None O
) None None O
; None None O
nonfatal None None O
myocardial None None O
infarction None None O
£1963 None None O
( None None O
£794-£1157 None None O
) None None O
; None None O
heart None None O
failure None None O
£979 None None O
( None None O
£708-£1344 None None O
) None None O
; None None O
non-fatal None None O
ischaemic None None O
heart None None O
disease None None O
£864 None None O
( None None O
£718-£1014 None None O
) None None O
; None None O
and None None O
cataract None None O
extraction None None O
£700 None None O
( None None O
£619-£780 None None O
) None None O
. None None O

At None None O
9 None None O
years None None O
of None None O
age None None O
, None None O
asymptomatic None None O
schwannomas None None O
of None None O
the None None O
cranial None None I-REGION
nerves None None I-REGION
were None None O
discovered None None O
: None None O
cranial None None I-REGION
nerves None None I-REGION
X None None O
( None None O
left None None O
) None None O
, None None O
XI None None O
( None None O
left None None O
) None None O
, None None O
and None None O
VIII None None O
( None None O
bilateral None None O
) None None O
. None None O

Natural None None O
variation None None O
between None None O
the None None O
winter None None O
and None None O
summer None None O
annual None None O
Arabidopsis None None O
ecotypes None None O
Cvi None None O
and None None O
Bur None None O
was None None O
exploited None None O
to None None O
investigate None None O
the None None O
expression None None O
of None None O
genes None None O
involved None None O
in None None O
chromatin None None O
remodelling None None O
via None None O
histone None None O
2B None None O
( None None O
H2B None None O
) None None O
ubiquitination/de-ubiquitination None None O
and None None O
histone None None O
acetylation/deacetylation None None O
, None None O
the None None O
repressive None None O
histone None None O
methyl None None O
transferases None None I-PROTEIN
CURLY None None O
LEAF None None O
( None None O
CLF None None O
) None None O
and None None O
SWINGER None None O
( None None O
SWN None None O
) None None O
, None None O
and None None O
the None None O
gene None None O
silencing None None O
repressor None None O
ROS1 None None O
( None None O
REPRESSOR None None O
OF None None O
SILENCING1 None None O
) None None O
and None None O
promoter None None O
of None None O
silencing None None O
KYP/SUVH4 None None O
( None None O
KRYPTONITE None None O
) None None O
, None None O
during None None O
dormancy None None O
cycling None None O
in None None O
the None None O
SSB None None O
. None None O

MPS None None O
III None None O
presents None None O
with None None O
progressive None None O
mental None None O
deterioration None None O
, None None O
speech None None I-FUNC
delay None None O
and None None O
behavioural None None O
problems None None O
with None None O
subtle None None O
somatic None None O
features None None O
, None None O
which None None O
can None None O
often None None O
lead None None O
to None None O
misdiagnosis None None O
with None None O
idiopathic None None O
developmental/speech None None O
delay None None O
, None None O
attention None None I-FUNC
deficit/hyperactivity None None O
disorder None None O
or None None O
autism None None O
. None None O

The None None O
patient None None O
developed None None O
normally None None O
until None None O
the None None O
age None None O
of None None O
2 None None O
years None None O
when None None O
he None None O
was None None O
referred None None O
to None None O
a None None O
paediatric None None O
neurologist None None O
for None None O
suspected None None O
motor None None O
and None None O
speech None None I-FUNC
delay None None O
. None None O

We None None O
strongly None None O
recommend None None O
screening None None O
for None None O
MPS None None O
III None None O
in None None O
children None None O
with None None O
severe None None O
behavioural None None O
abnormalities None None O
with None None O
hyperactivity None None O
, None None O
psychomotor None None O
or None None O
speech None None I-FUNC
deterioration None None O
and None None O
failure None None O
to None None O
achieve None None O
early None None O
developmental None None O
milestones None None O
particularly None None O
with None None O
facial None None O
dysmorphism None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
stomach None None O
'senses None None O
' None None O
the None None O
composition None None O
of None None O
the None None O
gastric None None O
content None None O
and None None O
this None None O
information None None O
is None None O
passed None None O
via None None O
the None None O
vagal None None O
nerve None None O
to None None O
the None None O
lateral None None O
hypothalamus None None I-REGION
and None None O
the None None O
limbic None None O
system None None O
, None None O
most None None O
likely None None O
as None None O
palatability None None O
signals None None O
that None None O
influence None None O
eating None None O
behaviour None None O
. None None O

Receptors None None I-PROTEIN
that None None O
respond None None O
to None None O
macronutrient None None O
content None None O
or None None O
gastric None None O
wall None None O
tension None None O
influence None None O
appetite None None O
and None None O
meal None None O
related None None O
hormone None None O
responses None None O
. None None O

Brain None None O
areas None None O
such None None O
as None None O
thalamus None None I-REGION
, None None O
amygdala None None I-REGION
, None None O
putamen None None I-REGION
and None None O
praecuneus None None O
are None None O
activated None None O
by None None O
the None None O
ingestion None None O
of None None O
food None None O
. None None O

Pre-mucosal None None O
defence None None O
mechanisms None None O
include None None O
secreted None None O
acid None None O
( None None O
HCl None None O
0.1 None None O
mmol/L None None O
) None None O
and None None O
pepsin None None I-PROTEIN
, None None O
which None None O
are None None O
capable None None O
of None None O
denaturing None None O
tissue None None O
. None None O

Sleep None None O
duration None None O
was None None O
derived None None O
using None None O
a None None O
combination None None O
of None None O
questionnaire None None O
and None None O
objective None None O
heart None None O
rate None None O
and None None O
movement None None I-FUNC
sensing None None O
in None None O
the None None O
UK None None O
ADDITION-Plus None None O
study None None O
( None None O
2002-2007 None None O
) None None O
. None None O

Oxidative None None O
stress None None O
and None None O
inflammatory None None O
reaction None None O
due None None O
to None None O
OSA None None O
have None None O
seldom None None O
been None None O
studied None None O
in None None O
stable None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
. None None O

The None None O
present None None O
study None None O
demonstrated None None O
that None None O
a None None O
preferentially None None O
adaptive None None O
antioxidative None None O
response None None O
to None None O
hypoxia None None O
emerges None None O
, None None O
and None None O
the None None O
role None None O
of None None O
OSA None None O
with None None O
respect None None O
to None None O
inflammatory None None O
reaction None None O
is None None O
attenuated None None O
, None None O
in None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
with None None O
OSA None None O
. None None O

A None None O
significant None None O
group None None O
× None None O
time None None O
interaction None None O
was None None O
found None None O
for None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
and None None O
the None None O
physical None None O
and None None O
psychological None None O
domains None None O
of None None O
QoL None None O
. None None O

The None None O
introduction None None O
of None None O
lysine None None I-TRANS
residue None None O
at None None O
VP2 None None O
131 None None O
position None None O
that None None O
allows None None O
cell None None O
culture None None O
adaptation None None O
of None None O
FMDV None None O
serotype None None O
A None None O
could None None O
be None None O
exploited None None O
for None None O
the None None O
generation None None O
of None None O
vaccine None None O
seed None None O
stocks None None O
with None None O
improved None None O
growth None None O
properties None None O
in None None O
BHK-21 None None O
cell None None O
line None None O
. None None O

Participants None None O
were None None O
classified None None O
with None None O
executive None None O
or None None O
memory None None I-FUNC
dysfunction None None O
based None None O
on None None O
standardized None None O
score None None O
cutoffs None None O
( None None O
& None None O
lt None None O
; None None O
16th None None O
percentile None None O
) None None O
for None None O
the None None O
Color None None O
Trails None None O
Test None None O
and None None O
Selective None None O
Reminding None None O
Test None None O
. None None O

Of None None O
the None None O
613 None None O
participants None None O
, None None O
331 None None O
( None None O
54 None None O
% None None O
) None None O
had None None O
executive None None O
dysfunction None None O
, None None O
202 None None O
( None None O
33 None None O
% None None O
) None None O
had None None O
memory None None I-FUNC
dysfunction None None O
, None None O
and None None O
96 None None O
( None None O
16 None None O
% None None O
) None None O
had None None O
both None None O
. None None O

This None None O
early None None O
learning None None I-FUNC
leads None None O
to None None O
increased None None O
neural None None O
specialization None None O
for None None O
previously None None O
unfamiliar None None O
face None None O
or None None O
object None None O
groups None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
early None None O
individual-level None None O
learning None None I-FUNC
results None None O
in None None O
long-lasting None None O
process-specific None None O
effects None None O
, None None O
which None None O
benefit None None O
categories None None O
that None None O
continue None None O
to None None O
be None None O
perceived None None O
and None None O
recognized None None O
at None None O
the None None O
individual None None O
level None None O
( None None O
e.g None None O
. None None O

We None None O
describe None None O
11 None None O
individuals None None O
with None None O
clinical None None O
features None None O
of None None O
5q31.3 None None O
microdeletion None None O
syndrome None None O
and None None O
de None None O
novo None None O
mutations None None O
in None None O
PURA None None O
, None None O
encoding None None I-FUNC
transcriptional None None O
activator None None O
protein None None O
Pur-α None None O
, None None O
within None None O
the None None O
critical None None O
region None None O
. None None O

Acute None None O
encephalopathy None None O
with None None O
biphasic None None O
seizures None None O
and None None O
late None None O
reduced None None O
diffusion None None O
( None None O
AESD None None O
) None None O
is None None O
a None None O
very None None O
rare None None O
encephalopathy None None O
subtype None None O
which None None O
is None None O
characterized None None O
by None None O
biphasic None None O
seizures None None O
and None None O
disturbance None None O
of None None O
consciousness None None I-FUNC
in None None O
the None None O
acute None None O
stage None None O
followed None None O
in None None O
the None None O
subacute None None O
stage None None O
by None None O
restricted None None O
diffusion None None O
in None None O
the None None O
subcortical None None O
white None None I-REGION
matter None None I-REGION
and None None O
finally None None O
resulting None None O
in None None O
cerebral None None O
atrophy None None O
on None None O
magnetic None None O
resonance None None O
imaging None None O
. None None O

Three None None O
data None None O
sources None None O
were None None O
used None None O
: None None O
participant None None O
observation None None O
of None None O
an None None O
NP None None O
and None None O
a None None O
CNS None None O
for None None O
18 None None O
hours None None O
each None None O
over None None O
a None None O
3-week None None O
period None None O
; None None O
CNS None None O
and None None O
NP None None O
diaries None None O
recording None None O
strategies None None O
, None None O
barriers None None O
, None None O
and None None O
facilitators None None O
to None None O
the None None O
implementation None None O
process None None O
; None None O
and None None O
interviews None None O
with None None O
members None None O
of None None O
the None None O
interdisciplinary None None O
team None None O
to None None O
explore None None O
perceptions None None I-FUNC
about None None O
the None None O
NP None None O
and None None O
CNS None None O
role None None O
in None None O
implementing None None O
the None None O
pain None None O
protocol None None O
. None None O

The None None O
study None None O
recruitment None None O
and None None O
retention None None I-FUNC
rates None None O
were None None O
92 None None O
% None None O
and None None O
91 None None O
% None None O
, None None O
respectively None None O
. None None O

Graduates None None O
from None None O
Problem/Context None None O
Based None None O
Learning None None I-FUNC
( None None O
CBL None None O
) None None O
undergraduate None None O
nursing None None O
programs None None O
often None None O
express None None O
concern None None O
that None None O
they None None O
may None None O
not None None O
be None None O
as None None O
well None None O
prepared None None O
for None None O
transition None None O
to None None O
graduate None None O
nursing None None O
practice None None O
as None None O
their None None O
colleagues None None O
from None None O
more None None O
traditional None None O
lecture-based None None O
programs None None O
. None None O

Epidemiological None None O
data None None O
suggest None None O
at None None O
least None None O
one None None O
in None None O
five None None O
humans None None O
are None None O
at None None O
risk None None O
of None None O
zinc None None I-TRANS
deficiency None None O
. None None O

Phytate None None O
, None None O
a None None O
potent None None O
indigestible None None O
ligand None None O
for None None O
zinc None None I-TRANS
prevents None None O
it None None O
's None None O
absorption None None O
. None None O

Plasma None None O
zinc None None I-TRANS
is None None O
insensitive None None O
to None None O
early None None O
zinc None None I-TRANS
deficiency None None O
. None None O

Early None None O
effects None None O
of None None O
zinc None None I-TRANS
deficiency None None O
are None None O
chemical None None O
, None None O
functional None None O
and None None O
may None None O
be None None O
`` None None O
hidden None None O
'' None None O
. None None O

In None None O
both None None O
studies None None O
the None None O
presence None None O
of None None O
zinc None None I-TRANS
deficiency None None O
was None None O
proven None None O
by None None O
functional None None O
responses None None O
to None None O
controlled None None O
zinc None None I-TRANS
treatment None None O
. None None O

In None None O
the None None O
women None None O
memory None None I-FUNC
, None None O
reasoning None None I-FUNC
, None None O
and None None O
eye-hand None None O
coordination None None O
were None None O
significantly None None O
affected None None O
. None None O

At None None O
the None None O
end None None O
of None None O
the None None O
study None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
increase None None O
in None None O
the None None O
serum None None O
retinol None None O
level None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.03 None None O
) None None O
, None None O
serum None None O
zinc None None I-TRANS
level None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.03 None None O
) None None O
, None None O
IGF-1 None None O
hormone None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.04 None None O
) None None O
and None None O
Z-score None None O
height None None O
for None None O
age None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
bone None None O
age None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
and None None O
gamma None None O
globulin None None O
level None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.04 None None O
) None None O
and None None O
a None None O
significant None None O
decrease None None O
in None None O
the None None O
amount None None O
of None None O
infection/inflammation None None O
measured None None O
by None None O
CRP None None O
level None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
combined None None O
vitamin None None O
A None None O
and None None O
zinc None None I-TRANS
supplementation None None O
reduces None None O
the None None O
risk None None O
of None None O
infection None None O
and None None O
increases None None O
linear None None O
growth None None O
among None None O
children None None O
, None None O
and None None O
thus None None O
may None None O
play None None O
a None None O
key None None O
role None None O
in None None O
controlling None None O
infection None None O
and None None O
stunted None None O
growth None None O
for None None O
children None None O
under None None O
five None None O
years None None O
old None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
postgraduate None None O
critical None None O
care None None O
nursing None None O
students None None O
' None None O
attitudes None None O
to None None O
, None None O
and None None O
engagement None None O
with None None O
, None None O
Team-Based None None O
Learning None None I-FUNC
( None None O
TBL None None O
) None None O
. None None O

Students None None O
' None None O
attitudes None None O
to None None O
learning None None I-FUNC
within None None O
teams None None O
( None None O
Team None None O
Experience None None O
Questionnaire None None O
) None None O
and None None O
student None None O
engagement None None O
( None None O
observed None None O
and None None O
self-reports None None O
) None None O
. None None O

There None None O
were None None O
significant None None O
changes None None O
in None None O
students None None O
' None None O
attitudes None None O
to None None O
learning None None I-FUNC
within None None O
teams None None O
including None None O
increases None None O
in None None O
overall None None O
satisfaction None None O
with None None O
team None None O
experience None None O
, None None O
team None None O
impact None None O
on None None O
quality None None O
of None None O
learning None None I-FUNC
, None None O
team None None O
impact None None O
on None None O
clinical None None O
reasoning None None I-FUNC
ability None None O
and None None O
professional None None O
development None None O
. None None O

In None None O
turn None None O
, None None O
these None None O
factors None None O
enhanced None None O
nurses None None O
' None None O
professional None None O
skills None None O
in None None O
teamwork None None O
, None None O
communication None None O
, None None O
problem None None I-FUNC
solving None None I-FUNC
and None None O
higher None None O
order None None O
critical None None O
thinking None None O
. None None O

We None None O
theorized None None O
that None None O
unmet None None O
dental None None O
need None None O
would None None O
be None None O
positively None None O
associated None None O
with None None O
not None None O
having None None O
a None None O
medical None None O
home None None O
and None None O
having None None O
characteristics None None O
of None None O
more None None O
severe None None O
ASD None None O
( None None O
eg None None O
, None None O
parent None None O
reported None None O
severe None None O
ASD None None O
, None None O
an None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
communication None None O
, None None O
or None None O
behavior None None O
difficulties None None O
) None None O
. None None O

Children None None O
with None None O
ASD None None O
with None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
or None None O
greater None None O
communication None None O
or None None O
behavioral None None O
difficulties None None O
had None None O
greater None None O
odds None None O
of None None O
unmet None None O
dental None None O
need None None O
than None None O
those None None O
with None None O
ASD None None O
without None None O
these None None O
characteristics None None O
. None None O

( None None O
211 None None O
) None None O
At None None O
was None None O
recovered None None O
by None None O
dry None None O
distillation None None O
, None None O
and None None O
80 None None O
% None None O
of None None O
the None None O
produced None None O
( None None O
211 None None O
) None None O
At None None O
was None None O
successfully None None O
obtained None None O
in None None O
dry None None O
Na None None I-TRANS
( None None O
211 None None O
) None None O
At None None O
form None None O
within None None O
2h None None O
from None None O
the None None O
end None None O
of None None O
bombardment None None O
( None None O
EOB None None O
) None None O
. None None O

Stroke None None I-DISEASE
is None None O
a None None O
major None None O
cause None None O
of None None O
morbidity None None O
and None None O
mortality None None O
and None None O
up None None O
to None None O
15-20 None None O
% None None O
of None None O
ischemic None None O
strokes None None I-DISEASE
can None None O
be None None O
attributed None None O
to None None O
atherosclerotic None None O
internal None None O
carotid None None O
artery None None O
disease None None O
. None None O

Review None None O
of None None O
current None None O
strategies None None O
for None None O
managing None None O
asymptomatic None None O
carotid None None O
disease None None O
Those None None O
favouring None None O
a None None O
pro-interventional None None O
approach None None O
argue None None O
that None None O
: None None O
( None None O
i None None O
) None None O
until None None O
new None None O
randomised None None O
trials None None O
demonstrate None None O
that None None O
best None None O
medical None None O
therapy None None O
( None None O
BMT None None O
) None None O
is None None O
better None None O
than None None O
CEA None None O
or None None O
carotid None None O
artery None None O
stenting None None O
( None None O
CAS None None O
) None None O
in None None O
preventing None None O
stroke None None I-DISEASE
, None None O
guidelines None None O
of None None O
practice None None O
should None None O
remain None None O
unchanged None None O
; None None O
( None None O
ii None None O
) None None O
strokes None None I-DISEASE
secondary None None O
to None None O
carotid None None O
thromboembolism None None O
harboured None None O
a None None O
potentially None None O
treatable None None O
asymptomatic None None O
lesion None None O
prior None None O
to None None O
the None None O
event None None O
. None None O

These None None O
may None None O
be None None O
grouped None None O
broadly None None O
into None None O
3 None None O
discrete None None O
categories None None O
: None None O
( None None O
1 None None O
) None None O
attention None None I-FUNC
to None None O
the None None O
sleep-wake None None O
cycle None None O
, None None O
( None None O
2 None None O
) None None O
addition None None O
of None None O
personal None None O
to None None O
augment None None O
the None None O
experience None None O
and None None O
( None None O
3 None None O
) None None O
incorporation None None O
of None None O
formal None None O
educational None None O
elements None None O
to None None O
night None None O
rotations None None O
. None None O

To None None O
examine None None O
demographic None None O
and None None O
behavioural None None O
correlates None None O
of None None O
unhealthy None None O
snack-food None None O
consumption None None O
among None None O
Australian None None O
secondary-school None None O
students None None O
and None None O
the None None O
association None None O
between None None O
their None None O
perceptions None None I-FUNC
of None None O
availability None None O
, None None O
convenience None None O
and None None O
intake None None O
with None None O
consumption None None O
. None None O

We None None O
established None None O
that None None O
PAR None None O
, None None O
as None None O
a None None O
prototype None None O
compound None None O
, None None O
suppressed None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
- None None O
and None None O
tumour None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
-α-induced None None O
increases None None O
in None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
( None None O
MMP None None O
) None None O
-1 None None O
, None None O
MMP-3 None None O
, None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
, None None O
and None None O
interleukin None None O
( None None O
IL None None O
) None None O
-1β None None O
mRNA None None O
in None None O
chondrocytes None None O
. None None O

The None None O
rate None None O
of None None O
orthodontic None None O
tooth None None O
movement None None I-FUNC
is None None O
chiefly None None O
determined None None O
by None None O
the None None O
remodeling None None O
of None None O
tissues None None O
surrounding None None O
the None None O
roots None None O
; None None O
this None None O
in None None O
turn None None O
is None None O
under None None O
the None None O
control None None O
of None None O
molecular None None O
mechanisms None None O
regulating None None O
cellular None None O
behaviors None None O
in None None O
the None None O
alveolar None None O
bone None None O
and None None O
periodontal None None O
ligament None None O
. None None O

The None None O
review None None O
also None None O
shows None None O
directions None None O
for None None O
future None None O
studies None None O
to None None O
develop None None O
more None None O
clinically None None O
applicable None None O
methods None None O
to None None O
accelerate None None O
orthodontic None None O
tooth None None O
movement None None I-FUNC
. None None O

) None None O
, None None O
whereas None None O
the None None O
ICG None None O
control None None O
dye None None O
failed None None O
to None None O
demonstrate None None O
similar None None O
retention None None I-FUNC
within None None O
the None None O
tumor None None O
bed None None O
( None None O
0.0003 None None O
MSOT None None O
a.u None None O
. None None O
) None None O
. None None O

We None None O
assessed None None O
the None None O
association None None O
of None None O
this None None O
SNP None None O
with None None O
the None None O
development None None O
of None None O
lipoatrophy/dyslipidemia None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
these None None O
patients None None O
and None None O
measured None None O
carotid None None O
intima None None O
thickening None None O
which None None O
is None None O
a None None O
surrogate None None O
marker None None O
for None None O
chronic None None O
cardiac None None O
morbidity None None O
. None None O

Patients None None O
with None None O
lipodystrophy None None O
demonstrated None None O
a None None O
higher None None O
likelihood None None O
of None None O
the None None O
development None None O
of None None O
metabolic None None O
syndrome None None O
as None None O
evident None None O
by None None O
increased None None O
insulin None None I-PROTEIN
sensitivity None None O
and None None O
increased None None O
percentage None None O
( None None O
% None None O
) None None O
β None None O
cell None None O
function None None O
. None None O

Our None None O
study None None O
validates None None O
the None None O
association None None O
of None None O
the None None O
TNF-α None None O
238G/A None None O
SNP None None O
allelic None None O
variant None None O
with None None O
the None None O
development None None O
of None None O
HIV- None None O
lipodystrophy None None O
via None None O
the None None O
modulation None None O
of None None O
TNF-α None None O
production None None O
, None None O
which None None O
contributes None None O
to None None O
dyslipidemia None None O
, None None O
increased None None O
lipolysis None None O
, None None O
increased None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
altered None None O
differentiation None None O
of None None O
adipocytes None None O
and None None O
increased None None O
carotid None None O
intima None None O
thickness None None O
. None None O

The None None O
discussion None None O
is None None O
part None None O
of None None O
a None None O
larger None None O
programme None None O
of None None O
research None None O
that None None O
focuses None None O
ethnographic None None O
attention None None I-FUNC
on None None O
nurses None None O
' None None O
activating None None O
technological None None O
managerial None None O
improvement None None O
strategies None None O
. None None O

as None None O
well None None O
as None None O
attention None None I-FUNC
was None None O
provided None None O
to None None O
the None None O
neuroprotective None None O
effect None None O
of None None O
vitamin None None O
E None None O
( None None O
VE None None O
) None None O
. None None O

Oral None None O
administration None None O
of None None O
VE None None O
attenuated None None O
the None None O
neurotoxic None None O
effects None None O
of None None O
DM None None O
through None None O
improvement None None O
of None None O
oxidative None None O
status None None O
, None None O
DNA None None O
fragmentation None None O
percentage None None O
and None None O
suppressing None None O
the None None O
expression None None O
level None None O
of None None O
CYP2E1 None None I-PROTEIN
, None None O
TP53 None None O
and None None O
COX2 None None O
genes None None O
. None None O

To None None O
examine None None O
the None None O
association None None O
between None None O
medical None None O
student None None O
perception None None I-FUNC
of None None O
their None None O
public None None O
health None None O
and None None O
community None None O
medicine None None O
instruction None None O
and None None O
practice None None O
location None None O
in None None O
a None None O
Health None None O
Professional None None O
Shortage None None O
Area None None O
. None None O

Findings None None O
suggest None None O
an None None O
association None None O
between None None O
perceptions None None I-FUNC
of None None O
public None None O
health None None O
and None None O
community None None O
medicine None None O
instruction None None O
and None None O
practice None None O
location None None O
. None None O

As None None O
the None None O
Public None None O
Health None None O
Accreditation None None O
Board None None O
( None None O
PHAB None None O
) None None O
launched None None O
the None None O
nation None None O
's None None O
only None None O
accreditation None None O
program None None O
for None None O
state None None O
, None None O
local None None O
, None None O
tribal None None O
, None None O
and None None O
territorial None None O
health None None O
departments None None O
in None None O
September None None O
2011 None None O
, None None O
attention None None I-FUNC
to None None O
the None None O
issues None None O
facing None None O
the None None O
public None None O
health None None O
workforce None None O
in None None O
these None None O
health None None O
departments None None O
was None None O
included None None O
. None None O

To None None O
review None None O
the None None O
findings None None O
from None None O
the None None O
outcome None None O
evaluation None None O
of None None O
the None None O
first None None O
nine None None O
classes None None O
of None None O
AEF None None O
alumni None None O
with None None O
particular None None O
attention None None I-FUNC
to None None O
how None None O
the None None O
fellowship None None O
affected None None O
alumni None None O
careers None None O
, None None O
mentors None None O
' None None O
careers None None O
, None None O
host None None O
site None None O
agency None None O
capacity None None O
, None None O
and None None O
competencies None None O
of None None O
the None None O
applied None None O
epidemiology None None O
workforce None None O
. None None O

Jugular None None O
blood None None O
samples None None O
were None None O
taken None None O
at None None O
15-min None None O
intervals None None O
for None None O
plasma None None O
hormones None None I-PROTEIN
and None None O
metabolites None None O
analysis None None O
. None None O

Insulin None None I-PROTEIN
plus None None O
GLP-1 None None O
infusion None None O
induced None None O
a None None O
greater None None O
increase None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
in None None O
plasma None None O
concentrations None None O
of None None O
insulin None None I-PROTEIN
and None None O
triglyceride None None O
( None None O
TG None None O
) None None O
, None None O
but None None O
decreased None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
glucagon None None I-TRANS
, None None O
total None None O
cholesterol None None O
( None None O
T-Cho None None O
) None None O
, None None O
NEAA None None O
and None None O
UN None None O
plasma None None O
concentrations None None O
. None None O

In None None O
conclusion None None O
, None None O
GLP-1 None None O
exerts None None O
extrapancreatic None None O
roles None None O
in None None O
ruminants None None O
not None None O
only None None O
insulin-independent None None O
but None None O
probably None None O
, None None O
in None None O
contrast None None O
to None None O
non-ruminants None None O
, None None O
antagonistic None None O
to None None O
insulin None None I-PROTEIN
effects None None O
. None None O

We None None O
conducted None None O
semi-structured None None O
interviews None None O
using None None O
a None None O
topic None None O
guide None None O
based None None O
on None None O
a None None O
literature None None O
review None None O
and None None O
findings None None O
from None None O
our None None O
previous None None O
study None None O
, None None O
which None None O
explored None None O
the None None O
perspectives None None O
of None None O
healthcare None None O
professionals None None O
about None None O
insulin None None I-PROTEIN
initiation None None O
and None None O
management None None O
. None None O

Participants None None O
discussed None None O
not None None O
only None None O
their None None O
concerns None None O
about None None O
insulin None None I-PROTEIN
therapy None None O
, None None O
but None None O
also None None O
their None None O
views None None O
and None None O
beliefs None None O
about None None O
the None None O
necessity None None O
of None None O
insulin None None I-PROTEIN
. None None O

The None None O
South None None O
Asian None None O
and None None O
white None None O
participants None None O
had None None O
similar None None O
concerns None None O
, None None O
but None None O
these None None O
were None None O
sometimes None None O
greater None None O
in None None O
South None None O
Asian None None O
participants None None O
, None None O
because None None O
of None None O
the None None O
influence None None O
of None None O
negative None None O
views None None O
and None None O
experiences None None O
of None None O
other None None O
insulin None None I-PROTEIN
users None None O
. None None O

Furthermore None None O
, None None O
they None None O
should None None O
be None None O
aware None None O
of None None O
how None None O
an None None O
individual None None O
's None None O
social None None O
context None None O
can None None O
influence None None O
his/her None None O
perceptions None None I-FUNC
about None None O
the None None O
necessity None None O
of None None O
insulin None None I-PROTEIN
as None None O
well None None O
as None None O
their None None O
concerns None None O
, None None O
and None None O
that None None O
this None None O
influence None None O
may None None O
be None None O
greater None None O
in None None O
some None None O
South None None O
Asian None None O
populations None None O
. None None O

The None None O
cerebellum None None I-REGION
resides None None O
in None None O
the None None O
posterior None None O
cranial None None O
fossa None None O
dorsal None None I-NEURON
to None None O
the None None O
brainstem None None I-REGION
and None None O
has None None O
diverse None None O
connections None None O
to None None O
the None None O
cerebrum None None I-REGION
, None None O
brain None None O
stem None None O
, None None O
and None None O
spinal None None O
cord None None O
. None None O

Its None None O
circuitry None None O
is None None O
critically None None O
involved None None O
in None None O
motor None None I-FUNC
control None None I-FUNC
and None None O
motor None None O
learning None None I-FUNC
, None None O
and None None O
its None None O
role None None O
in None None O
nonmotor None None O
cognitive None None O
and None None O
affective None None O
functions None None O
is None None O
becoming None None O
increasingly None None O
recognized None None O
. None None O

Advanced None None O
neuroimaging None None O
modalities None None O
have None None O
revealed None None O
cerebellar None None O
changes None None O
in None None O
both None None O
common None None O
and None None O
rare None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
. None None O

The None None O
human None None O
cerebellum None None I-REGION
is None None O
composed None None O
of None None O
2 None None O
hemispheres None None O
and None None O
a None None O
narrow None None O
medial None None O
section None None O
( None None O
vermis None None I-REGION
) None None O
. None None O

The None None O
cerebellum None None I-REGION
possesses None None O
widespread None None O
outgoing None None O
connections None None O
. None None O

This None None O
article None None O
provides None None O
an None None O
overview None None O
of None None O
the None None O
intra-axial None None O
tumors None None O
that None None O
affect None None O
the None None O
cerebellum None None I-REGION
, None None O
which None None O
can None None O
be None None O
categorized None None O
by None None O
location None None O
and None None O
age None None O
. None None O

A None None O
physician None None O
is None None O
often None None O
faced None None O
with None None O
the None None O
task None None O
of None None O
identifying None None O
the None None O
few None None O
cases None None O
in None None O
which None None O
cerebellar None None O
stroke None None I-DISEASE
is None None O
the None None O
underlying None None O
cause None None O
instead None None O
. None None O

Large None None O
infarctions None None O
or None None O
the None None O
ones None None O
with None None O
hemorrhagic None None O
conversion None None O
can None None O
lead None None O
to None None O
tissue None None O
swelling None None O
and None None O
complications None None O
such None None O
as None None O
obstructive None None I-DISEASE
hydrocephalus None None I-DISEASE
and None None O
brainstem None None I-REGION
compression None None O
. None None O

Thus None None O
, None None O
the None None O
hematoma None None O
and None None O
its None None O
associated None None O
swelling None None O
can None None O
cause None None O
obstructive None None I-DISEASE
hydrocephalus None None I-DISEASE
and None None O
brainstem None None I-REGION
compression None None O
, None None O
in None None O
severe None None O
cases None None O
contributing None None O
to None None O
early None None O
mortality None None O
, None None O
but None None O
outcome None None O
can None None O
be None None O
good None None O
if None None O
surgical None None O
intervention None None O
is None None O
appropriately None None O
timed None None O
. None None O

The None None O
cerebellum None None I-REGION
is None None O
involved None None O
in None None O
the None None O
control None None O
of None None O
all None None O
eye None None O
movements None None I-FUNC
, None None O
in None None O
their None None O
real-time None None O
, None None O
immediate None None O
modulation None None O
, None None O
and None None O
in None None O
their None None O
long-term None None O
adaptive None None O
calibration None None O
. None None O

But None None O
it None None O
is None None O
also None None O
because None None O
the None None O
cerebellum None None I-REGION
acts None None O
primarily None None O
as None None O
a None None O
rather None None O
subtle None None O
modulator None None O
of None None O
neurocognitive None None O
processes None None O
. None None O

For None None O
a None None O
long None None O
time None None O
, None None O
cerebellum None None I-REGION
was None None O
only None None O
known None None O
for None None O
its None None O
role None None O
in None None O
movement None None I-FUNC
coordination None None O
and None None O
until None None O
recently None None O
, None None O
its None None O
role None None O
in None None O
non-motor None None O
brain None None O
function None None O
was None None O
largely None None O
ignored None None O
. None None O

This None None O
article None None O
aims None None O
to None None O
review None None O
the None None O
current None None O
evidences None None O
supporting None None O
the None None O
role None None O
of None None O
the None None O
cerebellum None None I-REGION
in None None O
the None None O
pathophysiology None None O
of None None O
psychiatric None None O
disorders None None O
, None None O
including None None O
studies None None O
using None None O
volumetric None None O
and/or None None O
functional None None O
imaging None None O
techniques None None O
, None None O
genetic None None O
and None None O
molecular None None O
studies None None O
, None None O
and None None O
clinical None None O
reports None None O
. None None O

This None None O
article None None O
discusses None None O
the None None O
diagnosis None None O
and None None O
differential None None O
diagnosis None None O
of None None O
viral None None O
, None None O
bacterial None None O
, None None O
fungal None None O
, None None O
and None None O
prion None None O
pathogens None None O
affecting None None O
the None None O
cerebellum None None I-REGION
in None None O
patterns None None O
predictable None None O
by None None O
pace None None O
of None None O
illness None None O
and None None O
by None None O
involved None None O
neuroanatomic None None O
structures None None O
. None None O

No None None O
difference None None O
was None None O
observed None None O
in None None O
gene None None O
expression None None O
for None None O
oestrogen-β None None O
and None None O
progesterone None None O
receptors None None I-PROTEIN
in None None O
melasma-affected None None O
skin None None O
compared None None O
with None None O
adjacent None None O
healthy None None O
skin None None O
. None None O

Judicious None None O
use None None O
of None None O
tear None None O
substitutes None None O
and None None O
expedited None None O
tarsorrhaphy None None O
is None None O
crucial None None O
to None None O
restoration None None O
of None None O
useful None None O
vision None None I-FUNC
in None None O
these None None O
children None None O
. None None O

The None None O
medical None None O
records None None O
of None None O
children None None O
under None None O
10 None None O
years None None O
of None None O
age None None O
surgically None None O
treated None None O
for None None O
PCG None None O
from None None O
2003 None None O
to None None O
2012 None None O
were None None O
retrospectively None None O
reviewed None None O
to None None O
identify None None O
patients None None O
with None None O
IOP None None I-TRANS
of None None O
≤12 None None O
mm None None O
Hg None None O
with None None O
a None None O
minimum None None O
of None None O
6 None None O
months None None O
' None None O
follow-up None None O
. None None O

In None None O
24 None None O
eyes None None O
IOP None None I-TRANS
was None None O
controlled None None O
by None None O
1 None None O
trabeculotomy None None O
, None None O
with None None O
6 None None O
eyes None None O
requiring None None O
antiglaucoma None None O
medication None None O
; None None O
in None None O
5 None None O
eyes None None O
, None None O
by None None O
2 None None O
trabeculotomies None None O
, None None O
without None None O
medication None None O
; None None O
and None None O
in None None O
3 None None O
eyes None None O
, None None O
by None None O
2 None None O
trabeculotomies None None O
plus None None O
1 None None O
with None None O
mitomycin-C None None O
and None None O
2 None None O
eyes None None O
requiring None None O
antiglaucomatous None None O
medication None None O
. None None O

Controlling None None O
IOP None None I-TRANS
had None None O
a None None O
positive None None O
effect None None O
on None None O
the None None O
CCT None None O
, None None O
HCD None None O
, None None O
and None None O
AL None None O
in None None O
patients None None O
with None None O
congenital None None O
glaucoma None None O
. None None O

Quantitative None None O
ophthalmic None None O
testing None None O
of None None O
visual None None O
acuity None None O
, None None O
color None None O
vision None None I-FUNC
, None None O
automated None None O
visual None None O
field None None O
sensitivity None None O
, None None O
optic None None I-REGION
nerve None None I-REGION
pallor None None O
and None None O
cupping None None O
, None None O
and None None O
retinal None None O
nerve None None O
fiber None None O
layer None None O
( None None O
RNFL None None O
) None None O
thickness None None O
assessed None None O
by None None O
optical None None O
coherence None None O
tomography None None O
( None None O
OCT None None O
) None None O
was None None O
performed None None O
in None None O
18 None None O
subjects None None O
5-25 None None O
years None None O
of None None O
age None None O
. None None O

Subnormal None None O
visual None None O
acuity None None O
was None None O
detected None None O
in None None O
89 None None O
% None None O
of None None O
subjects None None O
, None None O
color None None O
vision None None I-FUNC
deficits None None O
in None None O
94 None None O
% None None O
, None None O
visual None None O
field None None O
defects None None O
in None None O
100 None None O
% None None O
, None None O
optic None None O
disk None None O
pallor None None O
in None None O
94 None None O
% None None O
, None None O
abnormally None None O
large None None O
optic None None I-REGION
nerve None None I-REGION
cup None None O
: None None O
disk None None O
ratio None None O
in None None O
33 None None O
% None None O
, None None O
thinned None None O
RNFL None None O
in None None O
100 None None O
% None None O
, None None O
afferent None None O
pupillary None None O
defects None None O
in None None O
61 None None O
% None None O
, None None O
cataracts None None O
in None None O
22 None None O
% None None O
, None None O
nystagmus None None O
in None None O
39 None None O
% None None O
, None None O
and None None O
strabismus None None O
in None None O
39 None None O
% None None O
of None None O
subjects None None O
. None None O

We None None O
present None None O
a None None O
4.8-year-old None None O
female None None O
with None None O
grade None None O
3 None None O
lipemia None None O
retinalis None None O
due None None O
to None None O
lipoprotein None None I-PROTEIN
lipase None None I-PROTEIN
deficiency None None O
, None None O
an None None O
abnormal None None O
electroretinogram None None O
, None None O
and None None O
bilateral None None O
decreased None None O
visual None None O
acuity None None O
. None None O

© None None O
2014 None None O
The None None O
Authors None None O
The None None O
Plant None None O
Journal None None O
published None None O
by None None O
Society None None O
for None None O
Experimental None None O
Biology None None O
and None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
We None None O
used None None O
contrast-enhanced None None O
ultrasound None None O
( None None O
CEUS None None O
) None None O
to None None O
estimate None None O
the None None O
effect None None O
of None None O
an None None O
increase None None O
in None None O
mean None None O
arterial None None O
pressure None None O
( None None O
MAP None None O
) None None O
induced None None O
by None None O
noradrenaline None None I-TRANS
infusion None None O
on None None O
renal None None O
microvascular None None O
cortical None None O
perfusion None None O
in None None O
critically None None O
ill None None O
patients None None O
. None None O

Luminal None None O
delivery None None O
of None None O
solutions None None O
containing None None O
amino None None I-TRANS
acids None None I-TRANS
or None None O
polyethylene None None O
glycols None None O
( None None O
PEGs None None O
) None None O
may None None O
improve None None O
preservation None None O
results None None O
and None None O
reduce None None O
this None None O
injury None None O
. None None O

Luminal None None O
PEG None None O
and None None O
glutamine None None I-TRANS
delay None None O
epithelial None None O
breakdown None None O
and None None O
preserve None None O
several None None O
important None None O
mucosal None None O
features None None O
during None None O
extended None None O
IP None None O
. None None O

Platelets None None O
, None None O
once None None O
considered None None O
mediators None None O
of None None O
hemostasis None None O
and None None O
thrombosis None None I-DISEASE
, None None O
are None None O
now None None O
known None None O
to None None O
be None None O
involved None None O
in None None O
wound None None O
healing None None O
, None None O
inflammation None None O
, None None O
cardiovascular None None O
diseases None None O
, None None O
diabetes None None O
, None None O
arthritis None None O
, None None O
and None None O
cancer None None O
. None None O

This None None O
study None None O
used None None O
functional None None O
MRI None None O
( None None O
fMRI None None O
) None None O
to None None O
examine None None O
a None None O
novel None None O
aspect None None O
of None None O
emotion None None I-FUNC
regulation None None O
in None None O
adolescent None None O
development None None O
: None None O
whether None None O
age None None O
predicts None None O
differences None None O
in None None O
both None None O
the None None O
concurrent None None O
and None None O
lasting None None O
effects None None O
of None None O
emotion None None I-FUNC
regulation None None O
on None None O
amygdala None None I-REGION
response None None O
. None None O

During None None O
re-presentation None None O
, None None O
older None None O
individuals None None O
continued None None O
to None None O
show None None O
lasting None None O
reductions None None O
in None None O
the None None O
amygdala None None I-REGION
response None None O
to None None O
aversive None None O
stimuli None None O
they None None O
had None None O
previously None None O
reappraised None None O
, None None O
an None None O
effect None None O
mediated None None O
by None None O
rostrolateral None None O
PFC None None O
. None None O

We None None O
investigated None None O
whether None None O
cytokine None None O
secretion None None O
was None None O
accompanied None None O
by None None O
cytosolic-to-nuclear None None O
NFκB None None O
translocation None None O
and None None O
whether None None O
endothelial None None O
cell None None I-PROTEIN
adhesion/migration None None O
was None None O
altered None None O
by None None O
released None None O
cytokines None None O
. None None O

Media None None O
conditioned None None O
by None None O
LPS-stimulated-Müller None None O
cells None None O
induced None None O
leukocyte-endothelial None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
and None None O
endothelial None None O
cell None None O
migration None None O
, None None O
which None None O
was None None O
attenuated None None O
by None None O
( None None O
+ None None O
) None None O
-PTZ None None O
treatment None None O
. None None O

Venous None None O
thromboembolism None None O
( None None O
VTE None None O
) None None O
is None None O
a None None O
potentially None None O
fatal None None O
condition None None O
and None None O
includes None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
and None None O
pulmonary None None O
embolism None None I-DISEASE
. None None O

Reperfusion None None O
therapies None None O
, None None O
such None None O
as None None O
intravenous None None O
thrombolysis None None O
or None None O
endovascular None None O
and None None O
interventional None None O
procedures None None O
, None None O
fit None None O
within None None O
the None None O
existing None None O
stroke None None I-DISEASE
system None None O
of None None O
care None None O
. None None O

Up None None O
to None None O
88 None None O
% None None O
of None None O
strokes None None I-DISEASE
are None None O
ischemic None None O
in None None O
nature None None O
. None None O

The None None O
time None None O
course None None O
of None None O
clinically None None O
significant None None O
fatigue None None O
in None None O
the None None O
first None None O
year None None O
after None None O
stroke None None I-DISEASE
is None None O
uncertain None None O
. None None O

We None None O
recruited None None O
patients None None O
with None None O
a None None O
recent None None O
acute None None O
stroke None None I-DISEASE
. None None O

Clinically None None O
significant None None O
fatigue None None O
affected None None O
a None None O
third None None O
of None None O
patients None None O
one None None O
month None None O
after None None O
stroke None None I-DISEASE
. None None O

Published None None O
by None None O
Elsevier None None O
Inc. None None O
A None None O
growing None None O
body None None O
of None None O
studies None None O
consistently None None O
demonstrates None None O
that None None O
social None None O
responsiveness None None O
toward None None O
others None None O
is None None O
influenced None None O
by None None O
the None None O
neurohormone None None O
oxytocin None None I-TRANS
. None None O

Thus None None O
, None None O
we None None O
investigated None None O
whether None None O
oxytocin None None I-TRANS
administration None None O
influences None None O
the None None O
self-attribution None None O
of None None O
positive None None O
and None None O
negative None None O
adjectives None None O
at None None O
the None None O
early None None O
, None None O
effortful None None O
stage None None O
of None None O
self-related None None O
information None None O
processing None None O
. None None O

oxytocin None None I-TRANS
or None None O
a None None O
placebo None None O
in None None O
a None None O
randomized None None O
double-blind None None O
study None None O
before None None O
completing None None O
a None None O
sorting None None O
task None None O
, None None O
in None None O
which None None O
they None None O
were None None O
instructed None None O
to None None O
co-classify None None O
, None None O
as None None O
fast None None O
as None None O
possible None None O
, None None O
positive None None O
and None None O
negative None None O
adjectives None None O
into None None O
either None None O
self None None O
or None None O
non-self None None O
categories None None O
. None None O

The None None O
present None None O
findings None None O
demonstrate None None O
that None None O
oxytocin None None I-TRANS
administration None None O
influences None None O
the None None O
early None None O
stage None None O
of None None O
self-related None None O
information None None O
processing None None O
and None None O
suggests None None O
that None None O
the None None O
oxytocinergic None None O
system None None O
might None None O
be None None O
involved None None O
in None None O
psychopathological None None O
conditions None None O
characterized None None O
by None None O
a None None O
negative None None O
representation None None O
of None None O
self None None O
. None None O

Eosinophilia None None O
as None None O
well None None O
as None None O
a None None O
variety None None O
of None None O
other None None O
biologic None None O
markers None None O
, None None O
for None None O
example None None O
, None None O
Th2 None None O
cytokines None None O
, None None O
peripheral None None O
blood None None O
periostin None None O
, None None O
and None None O
LT None None O
enzymes None None I-PROTEIN
and None None O
receptors None None I-PROTEIN
, None None O
are None None O
associated None None O
with None None O
AERD None None O
both None None O
in None None O
the None None O
blood None None O
and None None O
in None None O
respiratory None None O
mucosa None None O
. None None O

A None None O
multiple None None O
regression None None O
analysis None None O
showed None None O
that None None O
the None None O
sputum None None O
eosinophil None None O
ratio None None O
and None None O
exhaled None None O
nitric None None I-TRANS
oxide None None I-TRANS
were None None O
independently None None O
correlated None None O
with None None O
E-I None None O
LF None None O
, None None O
P None None O
= None None O
.0003 None None O
and None None O
P None None O
= None None O
.032 None None O
, None None O
respectively None None O
. None None O

Jumping None None O
to None None O
conclusions None None O
( None None O
JTC None None O
) None None O
is None None O
a None None O
probabilistic None None I-FUNC
reasoning None None I-FUNC
bias None None O
and None None O
is None None O
thought None None O
to None None O
contribute None None O
to None None O
delusion None None O
formation None None O
. None None O

We None None O
aimed None None O
to None None O
examine None None O
the None None O
rostral None None O
prefrontal None None I-REGION
cortex None None I-REGION
( None None O
rPFC None None O
) None None O
activity None None O
with None None O
functional None None O
near None None O
ınfrared None None O
spectroscopy None None O
during None None O
a None None O
modified None None O
version None None O
of None None O
the None None O
Beads None None O
in None None O
a None None O
Jar None None O
Task None None O
( None None O
BIJT None None O
) None None O
in None None O
subjects None None O
with None None O
persecutory None None O
delusions None None O
( None None O
N=25 None None O
) None None O
. None None O

Patients None None O
with None None O
schizophrenia None None I-DISEASE
( None None O
SZ None None O
) None None O
often None None O
make None None O
aberrant None None O
cause None None O
and None None O
effect None None O
inferences None None I-FUNC
in None None O
non-social None None O
and None None O
social None None O
situations None None O
. None None O

In None None O
the None None O
patients None None O
group None None O
, None None O
fMRI None None O
revealed None None O
greater None None O
BOLD-responses None None O
, None None O
during None None O
both None None O
physical None None O
and None None O
social None None O
causality None None O
judgements None None O
( None None O
group×task None None O
interaction None None O
) None None O
, None None O
in None None O
the None None O
left None None I-REGION
inferior None None I-REGION
frontal None None I-REGION
gyrus None None I-REGION
( None None O
L.IFG None None O
) None None O
. None None O

This None None O
shunt None None O
could None None O
be None None O
reversed None None O
with None None O
a None None O
norepinephrine None None I-TRANS
infusion None None O
, None None O
resulting None None O
in None None O
improved None None O
oxygenation None None O
. None None O

The None None O
higher None None O
norepinephrine/epinephrine None None O
ratio None None O
noted None None O
in None None O
the None None O
single-drug None None O
group None None O
may None None O
be None None O
implicated None None O
in None None O
lower None None O
adrenal None None I-TRANS
sympathetic None None O
activity None None O
. None None O

Receiver None None O
operating None None O
characteristic None None O
( None None O
ROC None None O
) None None O
curve None None O
analysis None None O
for None None O
preoperative None None O
urine None None O
epinephrine None None I-TRANS
levels None None O
showed None None O
good None None O
performance None None O
for None None O
prediction None None O
of None None O
high None None O
lactate None None O
levels None None O
[ None None O
& None None O
gt None None O
; None None O
2 None None O
mmol/L None None O
, None None O
area None None O
under None None O
the None None O
curve None None O
( None None O
AUC None None O
) None None O
=0.800 None None O
] None None O
, None None O
whereas None None O
ROC None None O
for None None O
preoperative None None O
urine None None O
norepinephrine None None I-TRANS
levels None None O
showed None None O
no None None O
predictive None None O
performance None None O
for None None O
high None None O
lactate None None O
levels None None O
. None None O

Simulation-based None None O
education None None O
using None None O
deliberate None None O
practice None None O
may None None O
result None None O
in None None O
improved None None O
intraoperative None None O
handoff None None O
communication None None O
and None None O
retention None None I-FUNC
of None None O
skills None None O
at None None O
one None None O
year None None O
. None None O

To None None O
investigate None None O
whether None None O
melatonin None None I-TRANS
administered None None O
intraoperatively None None O
reduced None None O
pain None None O
following None None O
laparoscopic None None O
cholecystectomy None None O
. None None O

Ten None None O
mg None None O
of None None O
intravenous None None O
( None None O
IV None None O
) None None O
melatonin None None I-TRANS
or None None O
placebo None None O
were None None O
administered None None O
at None None O
the None None O
time None None O
of None None O
surgical None None O
incision None None O
. None None O

Mean None None O
change None None O
from None None O
baseline None None O
to None None O
52 None None O
weeks None None O
was None None O
similar None None O
for None None O
ranibizumab None None O
0.5q4 None None O
and None None O
intravitreal None None O
aflibercept None None O
2q8 None None O
across None None O
all None None O
12 None None O
subscales None None O
, None None O
with None None O
the None None O
greatest None None O
improvements None None O
noted None None O
for None None O
mental None None O
health None None O
and None None O
general None None O
vision None None I-FUNC
( None None O
9.0-11.6 None None O
points None None O
, None None O
both None None O
treatments None None O
, None None O
both None None O
studies None None O
) None None O
. None None O

AKB-9778 None None O
is None None O
a None None O
small-molecule None None O
competitive None None O
inhibitor None None O
of None None O
vascular None None O
endothelial-protein None None O
tyrosine None None I-TRANS
phosphatase None None I-PROTEIN
( None None O
VE-PTP None None O
) None None O
that None None O
promotes None None O
Tie2 None None O
activation None None O
and None None O
reduces None None O
vascular None None O
leakage None None O
and None None O
neovascularization None None O
in None None O
mouse None None O
models None None O
. None None O

No None None O
safety None None O
concerns None None O
were None None O
identified None None O
after None None O
systemic None None O
administration None None O
of None None O
AKB-9778 None None O
for None None O
4 None None O
weeks None None O
in None None O
patients None None O
with None None O
DME None None O
, None None O
and None None O
doses None None O
of None None O
15 None None O
mg None None O
or None None O
more None None O
twice None None O
daily None None O
reduced None None O
macular None None O
edema None None O
and None None O
improved None None O
vision None None I-FUNC
in None None O
some None None O
patients None None O
. None None O

In None None O
vitro None None O
, None None O
sarcoid None None O
derived None None O
fibroblasts None None O
are None None O
invasive None None O
and None None O
express None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
( None None O
MMP None None O
) None None O
-1 None None O
, None None O
-2 None None O
and None None O
-9 None None O
. None None O

No None None O
difference None None O
in None None O
renal None None O
failure None None O
, None None O
cancer None None O
, None None O
memory None None I-FUNC
impairment None None O
, None None O
or None None O
hemorrhagic None None O
stroke None None I-DISEASE
was None None O
observed None None O
, None None O
although None None O
there None None O
were None None O
few None None O
events None None O
in None None O
these None None O
categories None None O
. None None O

A None None O
`` None None O
learning None None I-FUNC
health None None O
care None None O
system None None O
'' None None O
, None None O
as None None O
outlined None None O
in None None O
a None None O
recent None None O
Institute None None O
of None None O
Medicine None None O
report None None O
, None None O
harnesses None None O
real-time None None O
clinical None None O
data None None O
to None None O
continuously None None O
measure None None O
and None None O
improve None None O
clinical None None O
care None None O
. None None O

To None None O
align None None O
more None None O
closely None None O
with None None O
the None None O
goals None None O
of None None O
a None None O
learning None None I-FUNC
health None None O
care None None O
system None None O
, None None O
we None None O
present None None O
the None None O
novel None None O
design None None O
and None None O
initial None None O
results None None O
of None None O
the None None O
Veterans None None O
Affairs None None O
( None None O
VA None None O
) None None O
Clinical None None O
Assessment None None O
, None None O
Reporting None None O
, None None O
and None None O
Tracking None None O
( None None O
CART None None O
) None None O
program-a None None O
national None None O
clinical None None O
quality None None O
program None None O
for None None O
VA None None O
cardiac None None O
catheterization None None O
laboratories None None O
that None None O
harnesses None None O
real-time None None O
clinical None None O
data None None O
to None None O
support None None O
clinical None None O
care None None O
and None None O
quality-monitoring None None O
efforts None None O
. None None O

Reconstructing None None O
scans None None O
is None None O
a None None O
viable None None O
way None None O
of None None O
correcting None None O
minor None None O
movement None None I-FUNC
artifacts None None O
. None None O

Patients None None O
experiencing None None O
a None None O
femoral None None O
neck None None O
fracture None None O
presented None None O
with None None O
better None None O
preserved None None O
renal None None O
function None None O
( None None O
eGFR None None O
) None None O
and None None O
lower None None O
C-terminal None None O
fragment None None O
of None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor-23 None None O
( None None O
cFGF-23 None None O
) None None O
concentrations None None O
compared None None O
to None None O
those None None O
with None None O
trochanteric None None O
fractures None None O
. None None O

In None None O
recipients None None O
, None None O
variation None None O
in None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPX1 None None O
) None None O
and None None O
NRF-2 None None O
( None None O
NFE2L2 None None O
) None None O
was None None O
significantly None None O
associated None None O
with None None O
PGD None None O
( None None O
P None None O
= None None O
.01 None None O
for None None O
both None None O
) None None O
. None None O

We None None O
assessed None None O
the None None O
postoperative None None O
neurocognitive None None O
function None None O
after None None O
temporal None None O
lobectomy None None O
in None None O
children None None O
with None None O
temporal None None I-DISEASE
lobe None None I-DISEASE
epilepsy None None I-DISEASE
. None None O

Twenty None None O
children None None O
underwent None None O
resection None None O
of None None O
either None None O
dominant None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
or None None O
nondominant None None O
( None None O
n None None O
= None None O
12 None None O
) None None O
temporal None None I-REGION
lobes None None I-REGION
, None None O
and None None O
their None None O
median None None O
age None None O
at None None O
surgery None None O
was None None O
12.8 None None O
± None None O
3.2 None None O
years None None O
. None None O

Intelligence None None O
quotient None None O
( None None O
IQ None None O
) None None O
and None None O
memory None None I-FUNC
quotient None None O
scores None None O
remained None None O
stable None None O
during None None O
a None None O
3.6-year None None O
median None None O
follow-up None None O
in None None O
these None None O
children None None O
after None None O
the None None O
surgery None None O
. None None O

Early None None O
surgical None None O
treatment None None O
in None None O
children None None O
with None None O
intractable None None O
seizures None None O
of None None O
temporal None None I-REGION
lobe None None I-REGION
origin None None O
may None None O
result None None O
in None None O
better None None O
neurocognitive None None O
outcomes None None O
. None None O

Intelligence None None O
quotient None None O
was None None O
normal None None O
, None None O
but None None O
psychologic None None O
tests None None O
revealed None None O
depressed None None O
mood None None I-FUNC
. None None O

The None None O
report None None O
reveals None None O
that None None O
the None None O
temporal None None I-REGION
lobe None None I-REGION
calcifications None None O
and None None O
the None None O
consequent None None O
epileptic None None O
seizures None None O
can None None O
appear None None O
even None None O
very None None O
early None None O
. None None O

Loss-of-function None None O
mutations None None O
might None None O
thus None None O
result None None O
in None None O
complex None None O
paroxysmal None None O
diseases None None O
such None None O
as None None O
epilepsy None None I-DISEASE
syndromes None None I-DISEASE
or None None O
movement None None I-FUNC
disorders None None O
. None None O

Neurological None None O
examination None None O
revealed None None O
generalized None None O
dystonic None None O
and None None O
frequent None None O
athetoid None None O
movements None None I-FUNC
of None None O
the None None O
arms None None O
, None None O
trunk None None O
, None None O
and None None O
neck None None O
. None None O

Both None None O
transient None None O
paroxysmal None None O
tonic None None O
upward None None O
gaze None None O
and None None O
Angelman None None O
syndrome None None O
have None None O
been None None O
associated None None O
with None None O
dopaminergic None None I-NEURON
neurons None None I-NEURON
. None None O

The None None O
observed None None O
, None None O
reversible None None O
effect None None O
on None None O
vision None None I-FUNC
is None None O
most None None O
probably None None O
caused None None O
by None None O
pressure None None O
exerted None None O
by None None O
the None None O
medial None None O
part None None O
of None None O
the None None O
cyst None None O
on None None O
the None None O
left None None I-REGION
optic None None I-REGION
nerve None None I-REGION
. None None O

Alternating None None O
hemiplegia None None O
of None None O
childhood None None O
and None None O
rapid-onset None None O
dystonia None None O
parkinsonism None None O
are None None O
two None None O
separate None None O
movement None None I-FUNC
disorders None None O
with None None O
different None None O
dominant None None O
mutations None None O
in None None O
the None None O
same None None O
sodium-potassium None None O
transporter None None O
ATPase None None I-PROTEIN
subunit None None O
gene None None O
, None None O
ATP1A3 None None O
. None None O

However None None O
, None None O
laughter None None O
is None None O
a None None O
social None None O
emotion None None I-FUNC
, None None O
occurring None None O
most None None O
often None None O
in None None O
interactions None None O
, None None O
where None None O
it None None O
is None None O
associated None None O
with None None O
bonding None None O
, None None O
agreement None None O
, None None O
affection None None O
, None None O
and None None O
emotional None None O
regulation None None O
. None None O

Indicators None None O
of None None O
feasibility None None O
included None None O
recruitment None None O
rates None None O
of None None O
family None None O
practices None None O
, None None O
participants None None O
and None None O
facilitators None None O
, None None O
as None None O
well None None O
as None None O
feasibility None None O
and None None O
retention None None I-FUNC
rates None None O
in None None O
the None None O
FLIP None None O
program None None O
and None None O
study None None O
protocols None None O
. None None O

The None None O
trial None None O
protocol None None O
was None None O
acceptable None None O
to None None O
practices None None O
and None None O
participants None None O
and None None O
had None None O
a None None O
95 None None O
% None None O
participant None None O
retention None None I-FUNC
rate None None O
over None None O
the None None O
6 None None O
months None None O
( None None O
56/59 None None O
) None None O
. None None O

SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
pump None None O
( None None O
SERCA None None O
) None None O
( None None O
SR None None O
Ca None None O
( None None O
2+ None None O
) None None O
ATPase None None I-PROTEIN
) None None O
was None None O
not None None O
affected None None O
. None None O

The None None O
effect None None O
is None None O
mediated None None O
by None None O
the None None O
inhibition None None O
of None None O
Ca None None O
( None None O
2+ None None O
) None None O
influx None None O
via None None O
LTCC None None O
, None None O
and None None O
partially None None O
opposed None None O
by None None O
the None None O
inhibition None None O
of None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
/Ca None None O
( None None O
2+ None None O
) None None O
exchange None None O
. None None O

Herein None None O
, None None O
we None None O
sought None None O
to None None O
determine None None O
the None None O
extent None None O
to None None O
which None None O
measures None None O
of None None O
depression None None I-DISEASE
severity None None O
and None None O
cognitive None None O
dysfunction None None O
were None None O
associated None None O
with None None O
perceived None None O
global None None O
disability None None O
, None None O
workplace None None O
performance None None O
and None None O
quality None None O
of None None O
life None None O
. None None O

Measures None None O
of None None O
workplace None None O
function None None O
, None None O
global None None O
disability None None O
, None None O
depression None None I-DISEASE
severity None None O
, None None O
cognitive None None O
function None None O
, None None O
and None None O
quality None None O
of None None O
life None None O
were None None O
employed None None O
. None None O

Perceived None None O
global None None O
disability None None O
was None None O
significantly None None O
predicted None None O
by None None O
clinical None None O
ratings None None O
of None None O
depression None None I-DISEASE
severity None None O
( None None O
β=0.54 None None O
) None None O
, None None O
and None None O
perceived None None O
inattention None None O
( None None O
β=0.24 None None O
) None None O
, None None O
accounting None None O
for None None O
37 None None O
% None None O
of None None O
the None None O
variance None None O
. None None O

Finally None None O
, None None O
both None None O
clinical None None O
ratings None None O
of None None O
depression None None I-DISEASE
severity None None O
( None None O
β=-0.54 None None O
) None None O
, None None O
and None None O
perceived None None O
inattention None None O
( None None O
β=-0.18 None None O
) None None O
were None None O
significant None None O
inverse None None O
predictors None None O
of None None O
perceived None None O
quality None None O
of None None O
life None None O
, None None O
accounting None None O
for None None O
34 None None O
% None None O
of None None O
the None None O
variance None None O
. None None O

Conversely None None O
, None None O
total None None O
depression None None I-DISEASE
symptom None None I-DISEASE
severity None None O
accounts None None O
for None None O
a None None O
greater None None O
degree None None O
of None None O
variability None None O
in None None O
global None None O
measures None None O
of None None O
disability None None O
relative None None O
to None None O
cognitive None None O
measures None None O
. None None O

It None None O
has None None O
been None None O
studied None None O
mainly None None O
in None None O
the None None O
area None None O
of None None O
schizophrenia None None I-DISEASE
with None None O
few None None O
studies None None O
addressing None None O
other None None O
disorders None None O
. None None O

The None None O
hypothesis None None O
was None None O
that None None O
in None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
level None None O
of None None O
awareness None None O
may None None O
be None None O
associated None None O
with None None O
numerous None None O
factors None None O
including None None O
neurocognitive None None O
function None None O
, None None O
structural None None O
changes None None O
in None None O
the None None O
frontal None None I-REGION
lobes None None I-REGION
and None None O
hippocampus None None I-REGION
evaluated None None O
by None None O
MRI None None O
, None None O
neurocognitive None None O
status None None O
, None None O
severity None None O
of None None O
mania None None O
and None None O
other None None O
psychiatric None None O
symptoms None None O
and None None O
comorbid None None O
alcoholism None None O
. None None O

Hypotheses None None O
concerning None None O
the None None O
relationships None None O
between None None O
degree None None O
of None None O
unawareness None None O
and None None O
possible None None O
contributors None None O
to None None O
its None None O
development None None O
including None None O
comorbid None None O
alcoholism None None O
, None None O
cognitive None None O
dysfunction None None O
and None None O
structural None None O
reduction None None O
of None None O
gray None None O
matter None None O
in None None O
the None None O
frontal None None O
region None None O
and None None O
hippocampus None None I-REGION
, None None O
were None None O
not None None O
associated None None O
with None None O
degree None None O
of None None O
unawareness None None O
but None None O
symptoms None None O
of None None O
mania None None O
were None None O
significantly None None O
associated None None O
. None None O

The None None O
study None None O
findings None None O
illustrate None None O
that None None O
women None None O
in None None O
monogamous None None O
relationships None None O
have None None O
a None None O
low None None O
perception None None I-FUNC
of None None O
STI- None None O
and None None O
HIV-related None None O
risk None None O
. None None O

Methionine None None I-TRANS
dependence None None O
is None None O
the None None O
only None None O
known None None O
general None None O
metabolic None None O
defect None None O
in None None O
cancer None None O
. None None O

In None None O
order None None O
to None None O
exploit None None O
the None None O
cancer-specific None None O
metabolic None None O
defect None None O
of None None O
methionine None None I-TRANS
dependence None None O
, None None O
methioninases None None O
were None None O
developed None None O
. None None O

Dual None None O
RAAS None None O
inhibition None None O
with None None O
ACE None None O
inhibitors None None O
plus None None O
ARBs None None O
or None None O
ACE None None O
inhibitors None None O
plus None None O
direct None None O
renin None None I-PROTEIN
inhibitors None None O
has None None O
failed None None O
to None None O
improve None None O
cardiovascular None None O
or None None O
renal None None O
outcomes None None O
but None None O
has None None O
predisposed None None O
patients None None O
to None None O
serious None None O
adverse None None O
events None None O
. None None O

COX None None O
enzymes None None I-PROTEIN
are None None O
constitutively None None O
expressed None None O
in None None O
the None None O
kidneys None None O
and None None O
function None None O
to None None O
maintain None None O
a None None O
homeostatic None None O
environment None None O
in None None O
terms None None O
of None None O
maintaining None None O
the None None O
glomerular None None O
filtration None None O
rate None None O
, None None O
blood None None O
pressure None None O
, None None O
sodium None None O
, None None O
water None None O
, None None O
and None None O
osmotic None None O
regulation None None O
. None None O

Obesity None None O
also None None O
worsens None None O
glucose None None O
intolerance None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
as None None O
risk None None O
factors None None O
for None None O
CKD None None O
. None None O

10-20-30 None None O
increased None None O
VO2max None None O
but None None O
did None None O
not None None O
influence None None O
muscle None None O
fiber None None O
area None None O
, None None O
distribution None None O
or None None O
capillarization None None O
, None None O
whereas None None O
the None None O
expression None None O
of None None O
the None None O
pro-angiogenic None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
was None None O
lowered None None O
by None None O
22 None None O
% None None O
. None None O

Additional None None O
comorbidities None None O
included None None O
epilepsy None None O
( None None O
twelve None None O
) None None O
, None None O
hemiparesis None None O
( None None O
eight None None O
) None None O
, None None O
headaches None None O
( None None O
eight None None O
) None None O
, None None O
and None None O
vision None None I-FUNC
deficits None None O
( None None O
six None None O
) None None O
. None None O

Stimulant None None O
medication None None O
may None None O
be None None O
a None None O
safe None None O
and None None O
effective None None O
intervention None None O
for None None O
Sturge-Weber None None O
syndrome None None O
children None None O
with None None O
attention None None I-FUNC
issues/attention None None O
deficit None None I-DISEASE
hyperactivity None None I-DISEASE
disorder None None I-DISEASE
. None None O

Seven None None O
infants None None O
with None None O
moderate-to-severe None None O
watershed None None O
injury None None O
exhibited None None O
the None None O
following None None O
outcomes None None O
: None None O
normal None None O
( None None O
three None None O
) None None O
, None None O
mild None None O
language None None I-FUNC
delay None None O
( None None O
two None None O
) None None O
, None None O
mild None None O
hemiplegic None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
( None None O
one None None O
) None None O
, None None O
and None None O
epilepsy None None O
( None None O
one None None O
) None None O
. None None O

Individuals None None O
who None None O
are None None O
diagnosed None None O
with None None O
congenital None None O
insensitivity None None O
to None None O
pain None None O
usually None None O
present None None O
severely None None O
impaired None None O
pain None None O
perception None None I-FUNC
, None None O
and None None O
in None None O
some None None O
cases None None O
, None None O
they None None O
also None None O
manifest None None O
a None None O
decreased None None O
sense None None O
of None None O
smell None None O
( None None O
anosmia None None O
) None None O
. None None O

Both None None O
the None None O
activities None None O
of None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
NaR None None O
) None None O
and None None O
nitrite None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
NiR None None O
) None None O
per None None O
total None None O
mass None None O
of None None O
ruminal None None O
bacteria None None O
were None None O
increased None None O
by None None O
nitrate None None O
feeding None None O
. None None O

While None None O
p53 None None I-PROTEIN
binds None None O
to None None O
the None None O
promoter None None O
and None None O
increases None None O
the None None O
gene None None O
expression None None O
of None None O
Mdm2 None None O
, None None O
MDM2 None None O
protein None None O
directly None None O
binds None None O
to None None O
p53 None None I-PROTEIN
and None None O
inhibits None None O
its None None O
activity None None O
. None None O

Since None None O
there None None O
are None None O
few None None O
reviews None None O
covering None None O
the None None O
structure- None None O
activity None None O
relationship None None O
analysis None None O
of None None O
recent None None O
p53-MDM2 None None O
inhibitors None None O
reported None None O
from None None O
2011 None None O
to None None O
the None None O
present None None O
time None None O
, None None O
in None None O
this None None O
review None None O
, None None O
attentions None None I-FUNC
are None None O
focused None None O
on None None O
the None None O
development None None O
of None None O
p53-MDM2 None None O
inhibitors None None O
published None None O
from None None O
2011 None None O
to None None O
the None None O
present None None O
time None None O
. None None O

Circular None None O
peptides None None I-TRANS
which None None O
have None None O
been None None O
identified None None O
in None None O
bacteria None None O
, None None O
fungi None None O
, None None O
plants None None O
and None None O
some None None O
mammals None None O
but None None O
not None None O
in None None O
humans None None O
display None None O
exceptional None None O
stability None None O
and None None O
potent None None O
bioactivities None None O
. None None O

Because None None O
P2X None None O
receptors None None I-PROTEIN
have None None O
been None None O
implicated None None O
in None None O
neurological None None O
, None None O
inflammatory None None O
and None None O
cardiovascular None None O
diseases None None O
, None None O
they None None O
constitute None None O
promising None None O
drug None None O
targets None None O
. None None O

GH None None O
is None None O
secreted None None O
in None None O
a None None O
pulsatile None None O
manner None None O
from None None O
the None None O
pituitary None None I-REGION
gland None None I-REGION
, None None O
but None None O
GH None None O
pulsatility None None O
is None None O
not None None O
routinely None None O
assessed None None O
clinically None None O
. None None O

Cystoid None None O
macular None None O
edema None None O
observed None None O
on None None O
SD None None O
OCT None None O
in None None O
very None None O
preterm None None O
infants None None O
screened None None O
for None None O
ROP None None O
is None None O
associated None None O
with None None O
poorer None None O
language None None I-FUNC
and None None O
motor None None O
skills None None O
at None None O
18 None None O
to None None O
24 None None O
months None None O
corrected None None O
age None None O
. None None O

Patients None None O
aged None None O
18 None None O
to None None O
85 None None O
years None None O
with None None O
previous None None O
intraocular None None O
surgery None None O
or None None O
refractory None None O
glaucoma None None O
and None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
of None None O
≥18 None None O
mmHg None None O
in None None O
whom None None O
glaucoma None None O
drainage None None O
implant None None O
( None None O
GDI None None O
) None None O
surgery None None O
was None None O
planned None None O
were None None O
randomized None None O
to None None O
implantation None None O
of None None O
an None None O
AGV None None O
or None None O
a None None O
BGI None None O
. None None O

At None None O
5 None None O
years None None O
, None None O
IOP None None I-TRANS
( None None O
mean None None O
± None None O
standard None None O
deviation None None O
[ None None O
SD None None O
] None None O
) None None O
was None None O
14.7±4.4 None None O
mmHg None None O
in None None O
the None None O
AGV None None O
group None None O
and None None O
12.7±4.5 None None O
mmHg None None O
in None None O
the None None O
BGI None None O
group None None O
( None None O
P None None O
= None None O
0.015 None None O
) None None O
. None None O

Eleven None None O
eyes None None O
in None None O
the None None O
AGV None None O
group None None O
( None None O
20 None None O
% None None O
of None None O
AGV None None O
failures None None O
) None None O
experienced None None O
persistent None None O
hypotony None None O
, None None O
explantation None None O
of None None O
implant None None O
, None None O
or None None O
loss None None O
of None None O
light None None O
perception None None I-FUNC
compared None None O
with None None O
22 None None O
eyes None None O
( None None O
47 None None O
% None None O
of None None O
failures None None O
) None None O
in None None O
the None None O
BGI None None O
group None None O
. None None O

Currently None None O
, None None O
there None None O
is None None O
a None None O
movement None None I-FUNC
toward None None O
earlier None None O
identification None None O
and None None O
treatment None None O
of None None O
small None None O
melanomas None None O
using None None O
clinical None None O
factors None None O
predictive None None O
of None None O
malignant None None O
potential None None O
, None None O
in None None O
keeping None None O
with None None O
similar None None O
philosophy None None O
regarding None None O
other None None O
cancers None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
affected None None O
eye None None O
had None None O
worse None None O
mean None None O
CDVA None None O
( None None O
1.14±0.79 None None O
logarithm None None O
of None None O
the None None O
minimum None None O
angle None None O
of None None O
resolution None None O
[ None None O
logMAR None None O
] None None O
vs. None None O
0.35±0.46 None None O
logMAR None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.0005 None None O
) None None O
, None None O
higher None None O
mean None None O
IOP None None I-TRANS
( None None O
19.2±7.2 None None O
vs. None None O
14.7±3.6 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.0005 None None O
) None None O
, None None O
higher None None O
C/D None None O
ratio None None O
( None None O
0.54±0.22 None None O
vs. None None O
0.51±0.20 None None O
, None None O
P=0.006 None None O
) None None O
, None None O
greater None None O
mean None None O
number None None O
of None None O
glaucoma None None O
medication None None O
classes None None O
( None None O
1.4±1.4 None None O
vs. None None O
0.5±1.1 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.0005 None None O
) None None O
, None None O
worse None None O
MD None None O
( None None O
-13.83±6.89 None None O
decibels None None O
[ None None O
dB None None O
] None None O
vs. None None O
-6.59±6.63 None None O
dB None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.0005 None None O
) None None O
, None None O
and None None O
worse None None O
mean None None O
RNFL None None O
thickness None None O
( None None O
69.2±26.3 None None O
vs. None None O
82.4±13.7 None None O
, None None O
P=0.001 None None O
) None None O
. None None O

Five-year None None O
results None None O
suggest None None O
focal/grid None None O
laser None None O
treatment None None O
at None None O
the None None O
initiation None None O
of None None O
intravitreal None None O
ranibizumab None None O
is None None O
no None None O
better None None O
than None None O
deferring None None O
laser None None O
treatment None None O
for None None O
≥24 None None O
weeks None None O
in None None O
eyes None None O
with None None O
DME None None O
involving None None O
the None None O
central None None O
macula None None O
with None None O
vision None None I-FUNC
impairment None None O
. None None O

Most None None O
eyes None None O
treated None None O
with None None O
ranibizumab None None O
and None None O
either None None O
prompt None None O
or None None O
deferred None None O
laser None None O
maintain None None O
vision None None I-FUNC
gains None None O
obtained None None O
by None None O
the None None O
first None None O
year None None O
through None None O
5 None None O
years None None O
with None None O
little None None O
additional None None O
treatment None None O
after None None O
3 None None O
years None None O
. None None O

A None None O
questionnaire None None O
gauging None None O
knowledge None None O
of None None O
, None None O
attitudes None None O
toward None None O
, None None O
and None None O
perceptions None None I-FUNC
regarding None None O
peer None None O
review None None O
was None None O
distributed None None O
to None None O
all None None O
staff None None O
radiologists None None O
at None None O
a None None O
large None None O
academic None None O
hospital None None O
. None None O

The None None O
investigation None None O
of None None O
physicians None None O
' None None O
attitudes None None O
toward None None O
and None None O
perceptions None None I-FUNC
about None None O
peer None None O
review None None O
is None None O
important None None O
for None None O
understanding None None O
the None None O
potential None None O
impact None None O
not None None O
only None None O
on None None O
patient None None O
care None None O
but None None O
also None None O
on None None O
radiologists None None O
' None None O
relationships None None O
and None None O
psychology None None O
in None None O
the None None O
workplace None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
both None None O
devices None None O
in None None O
bruxism None None I-DISEASE
therapy None None O
; None None O
EMG None None O
activity None None O
levels None None O
during None None O
postural None None O
activity None None O
and None None O
maximum None None O
voluntary None None O
contraction None None O
of None None O
the None None O
superficial None None O
temporal None None O
and None None O
masseter None None O
muscles None None O
were None None O
compared None None O
before None None O
and None None O
after None None O
30 None None O
days None None O
of None None O
treatment None None O
. None None O

To None None O
examine None None O
the None None O
association None None O
between None None O
depression None None I-DISEASE
and None None O
impaired None None O
glucose None None O
regulation None None O
, None None O
newly None None O
diagnosed None None O
diabetes None None O
and None None O
previously None None O
diagnosed None None O
diabetes None None O
in None None O
middle-aged None None O
and None None O
elderly None None O
Chinese None None O
people None None O
, None None O
and None None O
whether None None O
depression None None I-DISEASE
was None None O
associated None None O
with None None O
different None None O
treatment None None O
regimens None None O
or None None O
durations None None O
of None None O
diabetes None None O
. None None O

The None None O
self-reported None None O
depression None None I-DISEASE
rating None None O
scale None None O
Patient None None O
Health None None O
Questionnaire None None O
9 None None O
( None None O
PHQ-9 None None O
) None None O
was None None O
used None None O
to None None O
diagnose None None O
probable None None O
and None None O
sub-threshold None None O
depression None None I-DISEASE
. None None O

Compared None None O
with None None O
participants None None O
with None None O
normal None None O
glucose None None O
regulation None None O
, None None O
those None None O
with None None O
previously None None O
diagnosed None None O
diabetes None None O
had None None O
increased None None O
odds None None O
of None None O
probable None None O
depression None None I-DISEASE
[ None None O
odds None None O
ratio None None O
( None None O
OR None None O
) None None O
= None None O
1.61 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
1.39-1.87 None None O
] None None O
and None None O
sub-threshold None None O
depression None None I-DISEASE
( None None O
OR None None O
= None None O
1.14 None None O
, None None O
95 None None O
% None None O
CI None None O
1.06-1.24 None None O
) None None O
, None None O
after None None O
adjustment None None O
for None None O
multiple None None O
confounding None None O
factors None None O
. None None O

Among None None O
those None None O
with None None O
previously None None O
diagnosed None None O
diabetes None None O
, None None O
insulin None None I-PROTEIN
treatment None None O
was None None O
associated None None O
with None None O
greater None None O
odds None None O
of None None O
depression None None I-DISEASE
compared None None O
with None None O
no None None O
treatment None None O
or None None O
oral None None O
anti-diabetic None None O
medicine None None O
. None None O

Patients None None O
receiving None None O
insulin None None I-PROTEIN
were None None O
more None None O
likely None None O
to None None O
have None None O
depression None None I-DISEASE
than None None O
those None None O
not None None O
receiving None None O
treatment None None O
or None None O
being None None O
treated None None O
with None None O
oral None None O
anti-diabetic None None O
medicine None None O
. None None O

For None None O
patients None None O
with None None O
dementia None None I-DISEASE
, None None O
abuse None None O
ranges None None O
from None None O
subtle None None O
scams None None O
to None None O
outright None None O
physical None None O
violence None None O
. None None O

The None None O
stages None None O
of None None O
dementia None None I-DISEASE
-- None None O
mild None None O
cognitive None None O
impairment None None O
, None None O
mild None None O
dementia None None I-DISEASE
, None None O
moderate None None O
dementia None None I-DISEASE
, None None O
and None None O
severe None None O
dementia None None I-DISEASE
-- None None O
lend None None O
themselves None None O
to None None O
varied None None O
presentations None None O
of None None O
abuse None None O
. None None O

Previous None None O
studies None None O
have None None O
shown None None O
that None None O
striatal None None O
dopamine None None I-TRANS
transporter None None O
density None None O
is None None O
positively None None O
correlated None None O
with None None O
the None None O
cognitive None None O
performance None None O
of None None O
healthy None None O
volunteers None None O
. None None O

Single-photon None None O
emission None None O
computed None None O
tomography None None O
with None None O
[ None None O
( None None O
99m None None O
) None None O
Tc None None O
] None None O
TRODAT-1 None None O
as None None O
a None None O
ligand None None O
was None None O
used None None O
to None None O
measure None None O
striatal None None O
dopamine None None I-TRANS
transporter None None O
levels None None O
in None None O
20 None None O
opioid-dependent None None O
individuals None None O
and None None O
20 None None O
age- None None O
and None None O
sex-matched None None O
healthy None None O
controls None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
in None None O
human None None O
, None None O
repeated None None O
opioid None None O
exposure None None O
reduces None None O
striatal None None O
dopamine None None I-TRANS
transporter None None O
density None None O
, None None O
which None None O
can None None O
be None None O
associated None None O
with None None O
non-perseverative None None O
errors None None O
. None None O

Primary None None O
endpoint None None O
was None None O
cardiovascular None None O
death None None O
, None None O
secondary None None O
were None None O
: None None O
non None None O
fatal None None O
myocardial None None O
infarction None None O
; None None O
coronary None None O
revascularization None None O
; None None O
cerebrovascular None None I-DISEASE
accidents None None I-DISEASE
and None None O
safety None None O
endpoints None None O
. None None O

However None None O
, None None O
such None None O
an None None O
approach None None O
would None None O
violate None None O
the None None O
ethical None None O
principles None None O
of None None O
autonomy None None O
and None None O
maleficence None None O
, None None O
and None None O
would None None O
run None None O
counter None None O
to None None O
the None None O
movement None None I-FUNC
toward None None O
patient-centered None None O
care None None O
. None None O

Immunoglobulins None None O
, None None O
keratin None None I-PROTEIN
proteins None None O
, None None O
fibronectin None None I-PROTEIN
, None None O
lactotransferrin None None O
precursor None None O
, None None O
14-3-3 None None O
protein None None O
zeta/delta None None O
, None None O
neutrophil None None O
defensin None None O
3 None None O
and None None O
alpha-actinin None None O
exhibited None None O
fluctuations None None O
in None None O
levels None None O
. None None O

The None None O
current None None O
study None None O
examined None None O
visual None None I-FUNC
attention None None I-FUNC
biases None None O
in None None O
8-year-old None None O
children None None O
who None None O
were None None O
part None None O
of None None O
the None None O
Bucharest None None O
Early None None O
Intervention None None O
Project None None O
( None None O
BEIP None None O
) None None O
. None None O

Research None None O
assessing None None O
attention None None I-FUNC
biases None None O
in None None O
children None None O
experiencing None None O
early None None O
environmental None None O
stress None None O
may None None O
refine None None O
our None None O
understanding None None O
of None None O
the None None O
mechanisms None None O
underlying None None O
risk None None O
for None None O
later None None O
psychiatric None None O
and None None O
social None None O
disorders None None O
and None None O
inform None None O
prevention None None O
efforts None None O
. None None O

The None None O
most None None O
common None None O
grade None None O
3 None None O
or None None O
4 None None O
adverse None None O
events None None O
were None None O
neutropenia None None O
( None None O
38 None None O
[ None None O
35 None None O
% None None O
] None None O
of None None O
110 None None O
patients None None O
) None None O
, None None O
muscle None None O
pain None None O
( None None O
ten None None O
[ None None O
9 None None O
% None None O
] None None O
) None None O
, None None O
rash None None O
( None None O
eight None None O
[ None None O
7 None None O
% None None O
] None None O
) None None O
, None None O
cough None None O
, None None O
dyspnoea None None O
, None None O
or None None O
other None None O
pulmonary None None O
symptoms None None O
( None None O
five None None O
[ None None O
5 None None O
% None None O
] None None O
) None None O
, None None O
fatigue None None O
( None None O
five None None O
[ None None O
5 None None O
% None None O
] None None O
) None None O
, None None O
thrombosis None None I-DISEASE
( None None O
five None None O
[ None None O
5 None None O
% None None O
] None None O
) None None O
, None None O
and None None O
thrombocytopenia None None O
( None None O
four None None O
[ None None O
4 None None O
% None None O
] None None O
) None None O
. None None O

Rhizomelic None None O
chondrodysplasia None None O
punctata None None O
( None None O
RCDP None None O
) None None O
is None None O
a None None O
group None None O
of None None O
disorders None None O
with None None O
overlapping None None O
clinical None None O
features None None O
including None None O
rhizomelia None None O
, None None O
chondrodysplasia None None O
punctata None None O
, None None O
coronal None None O
clefts None None O
, None None O
cervical None None O
dysplasia None None O
, None None O
congenital None None O
cataracts None None O
, None None O
profound None None O
postnatal None None O
growth None None O
retardation None None O
, None None O
severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
and None None O
seizures None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
identification None None O
of None None O
mutations None None O
in None None O
another None None O
gene None None O
in None None O
plasmalogen None None O
biosynthesis None None O
, None None O
fatty None None O
acyl-CoA None None O
reductase None None O
1 None None O
( None None O
FAR1 None None O
) None None O
, None None O
in None None O
two None None O
families None None O
affected None None O
by None None O
severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
early-onset None None O
epilepsy None None O
, None None O
microcephaly None None O
, None None O
congenital None None O
cataracts None None O
, None None O
growth None None O
retardation None None O
, None None O
and None None O
spasticity None None O
. None None O

We None None O
thus None None O
expand None None O
the None None O
spectrum None None O
of None None O
clinical None None O
features None None O
associated None None O
with None None O
defects None None O
in None None O
plasmalogen None None O
biosynthesis None None O
to None None O
include None None O
FAR1 None None O
deficiency None None O
as None None O
a None None O
cause None None O
of None None O
syndromic None None O
severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
with None None O
cataracts None None O
, None None O
epilepsy None None O
, None None O
and None None O
growth None None O
retardation None None O
but None None O
without None None O
rhizomelia None None O
. None None O

Here None None O
we None None O
report None None O
the None None O
identification None None O
of None None O
causal None None O
mutations None None O
in None None O
Sorting None None O
Nexin None None O
14 None None O
( None None O
SNX14 None None O
) None None O
found None None O
in None None O
seven None None O
affected None None O
individuals None None O
from None None O
three None None O
unrelated None None O
consanguineous None None O
families None None O
who None None O
presented None None O
with None None O
recessively None None O
inherited None None O
moderate-severe None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
cerebellar None None I-DISEASE
ataxia None None I-DISEASE
, None None O
early-onset None None O
cerebellar None None O
atrophy None None O
, None None O
sensorineural None None O
hearing None None O
loss None None O
, None None O
and None None O
the None None O
distinctive None None O
association None None O
of None None O
progressively None None O
coarsening None None O
facial None None O
features None None O
, None None O
relative None None O
macrocephaly None None O
, None None O
and None None O
the None None O
absence None None O
of None None O
seizures None None O
. None None O

Our None None O
findings None None O
indicate None None O
an None None O
essential None None O
role None None O
for None None O
SNX14 None None O
in None None O
neural None None O
development None None O
and None None O
function None None O
, None None O
particularly None None O
in None None O
development None None O
and None None O
maturation None None O
of None None O
the None None O
cerebellum None None I-REGION
. None None O

We None None O
performed None None O
homozygosity None None O
mapping None None O
and None None O
whole-exome None None O
sequencing None None O
in None None O
a None None O
Sardinian None None O
family None None O
with None None O
two None None O
affected None None O
children None None O
and None None O
identified None None O
a None None O
homozygous None None O
frameshift None None O
mutation None None O
, None None O
c.571dupA None None O
( None None O
p.Ile191Asnfs None None O
( None None O
∗ None None O
) None None O
6 None None O
) None None O
, None None O
in None None O
CKAP2L None None O
, None None O
encoding None None I-FUNC
the None None O
protein None None O
cytoskeleton-associated None None O
protein None None O
2-like None None O
( None None O
CKAP2L None None O
) None None O
. None None O

The None None O
depression None None I-DISEASE
module None None O
of None None O
the None None O
Patient None None O
Health None None O
Questionnaire-9 None None O
( None None O
PHQ-9 None None O
) None None O
is None None O
a None None O
widely None None O
used None None O
depression None None I-DISEASE
screening None None O
instrument None None O
in None None O
nonpsychiatric None None O
settings None None O
. None None O

The None None O
algorithm None None O
was None None O
the None None O
originally None None O
proposed None None O
scoring None None O
method None None O
to None None O
screen None None O
for None None O
depression None None I-DISEASE
. None None O

We None None O
performed None None O
a None None O
systematic None None O
review None None O
of None None O
diagnostic None None O
accuracy None None O
studies None None O
of None None O
the None None O
PHQ-9 None None O
using None None O
the None None O
algorithm None None O
scoring None None O
method None None O
to None None O
detect None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
. None None O

These None None O
helicases None None I-PROTEIN
and None None O
their None None O
regulation None None O
help None None O
maintain None None O
genome None None O
stability None None O
during None None O
DNA None None O
replication None None O
and None None O
repair None None O
. None None O

In None None O
vivo None None O
impairment None None O
of None None O
this None None O
regulatory None None O
mechanism None None O
compensates None None O
for None None O
the None None O
inactivation None None O
of None None O
another None None O
fork None None O
regression None None O
helicase None None I-PROTEIN
and None None O
increases None None O
reliance None None O
on None None O
joint None None O
DNA None None O
structure None None O
removal None None O
or None None O
avoidance None None O
. None None O

A None None O
7 None None O
years-old None None O
female None None O
patient None None O
with None None O
normal None None O
development None None O
until None None O
the None None O
age None None O
12 None None O
months None None O
, None None O
developed None None O
Rett None None O
like None None O
clinical None None O
picture None None O
( None None O
psychomotor None None O
regression None None O
, None None O
microcephaly None None O
, None None O
stereotypic None None O
hands None None O
movements None None I-FUNC
in None None O
the None None O
midline None None O
, None None O
hyperventilation None None O
episodes None None O
) None None O
present None None O
at None None O
the None None O
onset None None O
of None None O
her None None O
condition None None O
( None None O
age None None O
18 None None O
months None None O
) None None O
, None None O
features None None O
still None None O
present None None O
at None None O
the None None O
initial None None O
evaluation None None O
in None None O
our None None O
clinic None None O
at None None O
age None None O
5 None None O
years None None O
. None None O

Autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
is None None O
often None None O
described None None O
as None None O
comprising None None O
an None None O
unusual None None O
brain None None O
growth None None O
pattern None None O
and None None O
aberrant None None O
brain None None O
lateralization None None O
. None None O

To None None O
increase None None O
the None None O
power None None O
of None None O
nasal None None O
potential None None O
difference None None O
( None None O
NPD None None O
) None None O
as None None O
a None None O
biomarker None None O
of None None O
CFTR None None I-PROTEIN
function None None O
, None None O
improvement None None O
of None None O
its None None O
repeatability None None O
is None None O
needed None None O
. None None O

Standard None None O
diffusion None None O
based None None O
fractional None None O
anisotropy None None O
and None None O
apparent None None O
diffusion None None O
coefficient None None O
values None None O
were None None O
significantly None None O
altered None None O
in None None O
patients None None O
versus None None O
controls None None O
in None None O
the None None O
middle None None I-REGION
cerebellar None None I-REGION
peduncles None None I-REGION
and None None O
central None None O
pons None None I-REGION
. None None O

Previously None None O
, None None O
sulfasalazine None None O
has None None O
been None None O
shown None None O
to None None O
prevent None None O
release None None O
of None None O
glutamate None None I-TRANS
from None None O
glioma None None O
cells None None O
and None None O
prevent None None O
GAS None None O
in None None O
rodent None None O
models None None O
. None None O

PPAR None None O
gamma None None O
agonists None None O
are None None O
known None None O
to None None O
upregulate None None O
functional None None O
EAAT2 None None O
expression None None O
in None None O
astrocytes None None O
and None None O
prevent None None O
excitotoxicity None None O
caused None None O
by None None O
glutamate None None I-TRANS
excess None None O
. None None O

The None None O
use None None O
of None None O
intravenous None None O
thrombolytic None None O
therapy None None O
for None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
is None None O
associated None None O
with None None O
improved None None O
outcomes None None O
. None None O

Affected None None O
males None None O
with None None O
the None None O
classic None None O
phenotype None None O
develop None None O
renal None None O
, None None O
cardiac None None O
, None None O
and None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
and None None O
die None None O
prematurely None None O
. None None O

We None None O
report None None O
a None None O
38-year-old None None O
man None None O
with None None O
acute None None O
aphasia None None I-DISEASE
and None None O
a None None O
left None None O
M2 None None O
segment None None O
of None None O
the None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
thrombus None None O
with None None O
no None None O
recanalization None None O
who None None O
was None None O
finally None None O
diagnosed None None O
with None None O
Fabry None None O
disease None None O
after None None O
left None None O
ventricular None None O
hypertrophy None None O
of None None O
undetermined None None O
cause None None O
had None None O
been None None O
identified None None O
. None None O

High-resolution None None O
three-dimensional None None O
T1-weighted None None O
fast None None O
spoiled None None O
gradient None None O
recalled None None O
echo None None O
MRI None None O
were None None O
obtained None None O
from None None O
11 None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
before None None O
and None None O
after None None O
insulin None None I-PROTEIN
therapy None None O
. None None O

Regional None None O
cortical None None O
thinning None None O
was None None O
demonstrated None None O
in None None O
the None None O
middle None None I-REGION
temporal None None I-REGION
gyrus None None I-REGION
, None None O
posterior None None I-REGION
cingulate None None I-REGION
gyrus None None I-REGION
, None None O
precuneus None None I-REGION
, None None O
right None None O
lateral None None O
occipital None None I-REGION
gyrus None None I-REGION
and None None O
entorhinal None None I-REGION
cortex None None I-REGION
bilaterally None None O
for None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
compared None None O
with None None O
normal None None O
controls None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
insulin None None I-PROTEIN
therapy None None O
may None None O
have None None O
recovering None None O
effects None None O
on None None O
the None None O
brain None None O
cortex None None O
in None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
. None None O

The None None O
sum None None O
of None None O
the None None O
Unified None None O
Parkinson None None I-DISEASE
Disease None None O
Rating None None O
Scale None None O
( None None O
UPDRS None None O
) None None O
axial None None O
score None None O
for None None O
the None None O
`` None None O
on None None O
'' None None O
state None None O
was None None O
lower None None O
in None None O
the None None O
RBD None None O
group None None O
than None None O
in None None O
the None None O
non-RBD None None O
group None None O
after None None O
DBS None None O
( None None O
p None None O
= None None O
0.029 None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
hypothesized None None O
that None None O
the None None O
contact None None O
lens None None O
modified None None O
with None None O
an None None O
HA-binding None None O
peptide None None O
( None None O
HABpep None None O
) None None O
could None None O
locally None None O
bind None None O
and None None O
concentrate None None O
exogenous None None O
HA None None O
present None None O
in None None O
eyedrops None None O
to None None O
the None None O
modified None None O
contact None None O
lens None None O
surface None None O
, None None O
which None None O
exhibited None None O
superior None None O
water None None O
retention None None I-FUNC
. None None O

Bound None None O
HA None None O
and None None O
its None None O
retention None None I-FUNC
over None None O
time None None O
on None None O
the None None O
modified None None O
surfaces None None O
were None None O
evaluated None None O
by None None O
fluorescence None None O
measurements None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
explore None None O
applying None None O
CNNs None None O
to None None O
large None None O
vocabulary None None O
continuous None None O
speech None None I-FUNC
recognition None None I-FUNC
( None None O
LVCSR None None O
) None None O
tasks None None O
. None None O

Third None None O
, None None O
given None None O
the None None O
importance None None O
of None None O
sequence None None O
training None None O
for None None O
speech None None I-FUNC
tasks None None O
, None None O
we None None O
introduce None None O
a None None O
strategy None None O
to None None O
use None None O
ReLU+dropout None None O
during None None O
Hessian-free None None O
sequence None None O
training None None O
of None None O
CNNs None None O
. None None O

In None None O
1 None None O
patient None None O
, None None O
low None None O
wall None None O
shear None None O
stress None None O
was None None O
found None None O
in None None O
the None None O
left None None O
limb None None O
of None None O
the None None O
Y-graft None None O
, None None O
corresponding None None O
to None None O
the None None O
location None None O
of None None O
subsequent None None O
thrombosis None None I-DISEASE
in None None O
the None None O
patient None None O
. None None O

Although None None O
the None None O
development None None O
of None None O
thrombosis None None I-DISEASE
is None None O
multifactorial None None O
, None None O
the None None O
occurrence None None O
in None None O
1 None None O
patient None None O
suggests None None O
that None None O
simulations None None O
should None None O
not None None O
solely None None O
consider None None O
the None None O
hepatic None None O
blood None None O
flow None None O
distribution None None O
but None None O
also None None O
aim None None O
to None None O
avoid None None O
low None None O
wall None None O
shear None None O
stress None None O
in None None O
the None None O
limbs None None O
. None None O

There None None O
were None None O
no None None O
significant None None O
differences None None O
between None None O
the None None O
antegrade None None O
cerebral None None O
perfusion None None O
and None None O
hypothermic None None O
circulatory None None O
arrest/retrograde None None O
cerebral None None O
perfusion None None O
groups None None O
with None None O
regard None None O
to None None O
30-day None None O
mortality None None O
( None None O
3.2 None None O
% None None O
vs None None O
4.0 None None O
% None None O
) None None O
, None None O
hospital None None O
mortality None None O
( None None O
6.0 None None O
% None None O
vs None None O
7.1 None None O
% None None O
) None None O
, None None O
incidence None None O
of None None O
stroke None None I-DISEASE
( None None O
6.7 None None O
% None None O
vs None None O
8.6 None None O
% None None O
) None None O
, None None O
or None None O
transient None None O
neurologic None None O
disorder None None O
( None None O
4.1 None None O
% None None O
vs None None O
4.4 None None O
% None None O
) None None O
. None None O

Intensive None None O
glucose None None O
control None None O
can None None O
lead None None O
to None None O
mortality None None O
among None None O
critically None None O
ill None None O
adults None None O
because None None O
of None None O
episodic None None O
, None None O
moderate None None O
hypoglycemia None None I-DISEASE
. None None O

Glucose None None O
control None None O
was None None O
achieved None None O
with None None O
intravenous None None O
insulin None None I-PROTEIN
infusion None None O
with None None O
a None None O
strict None None O
glucose None None O
monitoring None None O
protocol None None O
. None None O

Evidence None None O
suggests None None O
a None None O
major None None O
role None None O
for None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
. None None O

We None None O
investigated None None O
whether None None O
left None None O
ventricular None None O
assist None None O
device-related None None O
shear None None O
stress None None O
and None None O
a None None O
disintegrin None None O
and None None O
metalloproteinase None None O
with None None O
a None None O
thrombospondin None None O
type None None O
1 None None O
motif None None O
, None None O
member None None O
13 None None O
( None None O
ADAMTS-13 None None O
, None None O
the None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
protease None None O
) None None O
altered None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
metabolism None None O
. None None O

von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
multimers None None O
and None None O
degradation None None O
fragments None None O
were None None O
characterized None None O
with None None O
electrophoresis None None O
and None None O
immunoblotting None None O
. None None O

Normal None None O
human None None O
blood None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
was None None O
cycled None None O
in None None O
a None None O
laboratory None None O
vortexer None None O
( None None O
∼2400 None None O
rpm None None O
, None None O
shear None None O
stress None None O
∼175 None None O
dyne/cm None None O
( None None O
2 None None O
) None None O
, None None O
4 None None O
hours None None O
) None None O
to None None O
reproduce None None O
the None None O
pathologic None None O
degradation None None O
of None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
that None None O
occurs None None O
during None None O
left None None O
ventricular None None O
assist None None O
device None None O
support None None O
. None None O

von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
multimers None None O
and None None O
11 None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
degradation None None O
fragments None None O
were None None O
characterized None None O
with None None O
electrophoresis None None O
and None None O
immunoblotting None None O
. None None O

Normal None None O
human None None O
blood None None O
exposed None None O
to None None O
supraphysiologic None None O
shear None None O
stress None None O
in None None O
the None None O
vortexer None None O
demonstrated None None O
the None None O
same None None O
profile None None O
of None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
degradation None None O
fragments None None O
as None None O
in None None O
a None None O
patient None None O
with None None O
a None None O
left None None O
ventricular None None O
assist None None O
device None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
supraphysiologic None None O
shear None None O
stress None None O
, None None O
ADAMTS-13 None None O
completely None None O
eliminated None None O
large None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
multimers None None O
and None None O
generated None None O
statistically None None O
significant None None O
amounts None None O
of None None O
11/11 None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
degradation None None O
fragments None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
. None None O

Supraphysiologic None None O
shear None None O
stress None None O
alone None None O
causes None None O
physical None None O
demolition None None O
of None None O
large None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
multimers None None O
into None None O
smaller None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
multimers None None O
. None None O

ADAMTS-13 None None O
may None None O
be None None O
a None None O
therapeutic None None O
target None None O
to None None O
reduce None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
degradation None None O
and None None O
bleeding None None O
complications None None O
in None None O
patients None None O
with None None O
a None None O
left None None O
ventricular None None O
assist None None O
device None None O
. None None O

We None None O
hypothesize None None O
that None None O
Cten None None O
may None None O
mediate None None O
invasion None None O
of None None O
lung None None O
cancer None None O
cells None None O
provided None None O
by None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
via None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
. None None O

Chemical None None O
inhibition None None O
of None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
was None None O
used None None O
to None None O
evaluate None None O
the None None O
effect None None O
on None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor-induced None None O
Cten None None O
expression None None O
. None None O

Stimulation None None O
of None None O
lung None None O
cancer None None O
cells None None O
with None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
activated None None O
the None None O
signal None None O
transducer None None O
and None None O
activator None None O
of None None O
transcription None None O
3 None None O
pathway None None O
and None None O
induced None None O
expression None None O
of None None O
Cten None None O
in None None O
all None None O
cell None None O
lines None None O
. None None O

There None None O
was None None O
no None None O
mortality None None O
, None None O
stroke None None I-DISEASE
, None None O
renal None None O
failure None None O
, None None O
or None None O
reoperation None None O
for None None O
bleeding None None O
. None None O

The None None O
main None None O
objective None None O
of None None O
the None None O
Genetic None None O
Loci None None O
and None None O
the None None O
Burden None None O
of None None O
Atherosclerotic None None O
Lesions None None O
study None None O
is None None O
to None None O
assemble None None O
comprehensive None None O
biological None None O
networks None None O
of None None O
atherosclerosis None None I-DISEASE
using None None O
advanced None None O
cardiovascular None None O
imaging None None O
for None None O
phenotyping None None O
, None None O
a None None O
panomic None None O
approach None None O
to None None O
identify None None O
underlying None None O
genomic None None O
, None None O
proteomic None None O
, None None O
metabolomic None None O
, None None O
and None None O
lipidomic None None O
underpinnings None None O
, None None O
analyzed None None O
by None None O
systems None None O
biology-driven None None O
bioinformatics None None O
. None None O

A None None O
multivariable None None O
model None None O
obtained None None O
with None None O
the None None O
use None None O
of None None O
logistic None None O
binary None None O
regression None None O
analysis None None O
showed None None O
that None None O
waist None None O
circumference None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
had None None O
no None None O
influence None None O
over None None O
IVF-ICSI None None O
outcomes None None O
, None None O
but None None O
a None None O
higher None None O
number None None O
of None None O
follicles None None O
, None None O
lower None None O
serum None None O
progesterone None None O
levels None None O
on None None O
the None None O
day None None O
before None None O
α-hCG None None O
administration None None O
, None None O
and None None O
lower None None O
FFL None None O
concentrations None None O
were None None O
significantly None None O
associated None None O
with None None O
a None None O
higher None None O
probability None None O
of None None O
having None None O
a None None O
live None None O
birth None None O
. None None O

High None None O
FFL None None O
levels None None O
were None None O
associated None None O
with None None O
abdominal None None O
obesity None None O
, None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
and None None O
a None None O
lower None None O
live None None O
birth None None O
rate None None O
after None None O
IVF-ICSI None None O
. None None O

Hypothalamic None None O
expression None None O
of None None O
leptin None None O
receptor None None I-PROTEIN
( None None O
ObRb None None O
) None None O
, None None O
estrogen None None I-PROTEIN
receptor-α None None O
( None None O
ER-α None None O
) None None O
, None None O
and None None O
GnRH None None O
protein None None O
was None None O
altered None None O
in None None O
an None None O
age-dependent None None O
manner None None O
with None None O
increased None None O
ObRb None None O
and None None O
ER-α None None O
expression None None O
in None None O
P1 None None O
LBW None None O
hypothalami None None O
and None None O
a None None O
reversal None None O
of None None O
this None None O
expression None None O
pattern None None O
in None None O
adult None None O
LBW None None O
hypothalami None None O
. None None O

Serotonin None None I-TRANS
reuptake None None O
inhibitors None None O
( None None O
SRI None None O
) None None O
and None None O
serotonin None None I-TRANS
and None None O
norepinephrine None None I-TRANS
reuptake None None O
inhibitors None None O
( None None O
SNRI None None O
) None None O
have None None O
demonstrated None None O
a None None O
rather None None O
robust None None O
efficacy None None O
for None None O
the None None O
treatment None None O
of None None O
most None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

The None None O
objective None None O
of None None O
our None None O
paper None None O
is None None O
to None None O
review None None O
relevant None None O
studies None None O
for None None O
the None None O
pharmacologic None None O
management None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
resistant None None O
to None None O
the None None O
first None None O
line None None O
treatment None None O
. None None O

An None None O
adequate None None O
trial None None O
for None None O
a None None O
SRI None None O
in None None O
the None None O
treatment None None O
of None None O
obsessive-compulsive None None I-DISEASE
disorder None None I-DISEASE
( None None O
OCD None None O
) None None O
should None None O
continue None None O
for None None O
at None None O
least None None O
12 None None O
weeks None None O
. None None O

Several None None O
trials None None O
have None None O
highlighted None None O
the None None O
efficacy None None O
of None None O
antipsychotics None None O
as None None O
an None None O
add-on None None O
to None None O
SRI None None O
in None None O
treatment-resistant None None O
OCD None None O
such None None O
as None None O
haloperidol None None O
more None None O
so None None O
when None None O
comorbid None None O
with None None O
a None None O
tic None None I-DISEASE
disorder None None I-DISEASE
, None None O
or None None O
risperidone None None O
that None None O
can None None O
reduce None None O
OCD None None O
as None None O
well None None O
as None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
. None None O

One None None O
double-blind None None O
placebo-controlled None None O
study None None O
was None None O
conducted None None O
to None None O
investigate None None O
treatment-resistant None None O
social None None I-DISEASE
phobia None None I-DISEASE
showing None None O
no None None O
benefit None None O
of None None O
pindolol None None O
add-on None None O
paroxetine None None O
. None None O

Hence None None O
, None None O
there None None O
is None None O
a None None O
crucial None None O
need None None O
for None None O
larger None None O
double-blind None None O
placebo-controlled None None O
trials None None O
for None None O
resistant None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

Schemas None None O
represent None None O
a None None O
stable None None O
vision None None I-FUNC
of None None O
oneself None None O
. None None O

The None None O
intensity None None O
of None None O
the None None O
5 None None O
domains None None O
inside None None O
each None None O
class None None O
of None None O
patients None None O
could None None O
guide None None O
the None None O
clinical None None O
interpretation None None O
, None None O
specifically None None O
for None None O
personality None None I-DISEASE
disorders None None I-DISEASE
. None None O

The None None O
prevalence None None O
of None None O
depressive None None O
or None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
may None None O
also None None O
be None None O
increased None None O
in None None O
these None None O
children None None O
. None None O

The None None O
connections None None O
between None None O
hallucinations None None O
, None None O
mood None None I-DISEASE
disorders None None I-DISEASE
and None None O
negative None None O
symptoms None None O
are None None O
often None None O
difficult None None O
to None None O
live None None O
with None None O
for None None O
the None None O
nearest None None O
and None None O
dearest None None O
. None None O

Finally None None O
, None None O
the None None O
views None None O
of None None O
Alzheimer None None I-DISEASE
and None None O
his None None O
student None None O
Schuppius None None O
are None None O
described None None O
: None None O
their None None O
understanding None None O
of None None O
pseudodementia None None O
is None None O
open None None O
to None None O
psychoanalytic None None O
concepts None None O
( None None O
1914 None None O
) None None O
. None None O

Thus None None O
, None None O
Schuppius None None O
's None None O
article None None O
under None None O
the None None O
tutoring None None O
of None None O
Aloïs None None O
Alzheimer None None I-DISEASE
offers None None O
a None None O
double None None O
testimony None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
it None None O
exposes None None O
a None None O
hidden None None O
aspect None None O
of None None O
Aloïs None None O
Alzheimer None None I-DISEASE
: None None O
a None None O
brilliant None None O
histopathologist None None O
capable None None O
of None None O
interest None None O
for None None O
psychodynamic None None O
mechanisms None None O
. None None O

Topologically None None O
, None None O
we None None O
can None None O
even None None O
define None None O
its None None O
emergence None None O
in None None O
the None None O
Breslau None None O
's None None O
university None None O
and None None O
psychiatric None None O
clinic None None O
in None None O
which None None O
Wernicke None None O
, None None O
Stertz None None O
, None None O
Bonhoeffer None None O
and None None O
Alzheimer None None I-DISEASE
himself None None O
, None None O
promoted None None O
it None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
intervention None None O
is None None O
to None None O
promote None None O
communication None None O
within None None O
the None None O
group None None O
through None None O
sharing None None O
their None None O
interests None None O
and None None O
emotions None None I-FUNC
, None None O
and None None O
to None None O
enhance None None O
the None None O
understanding None None O
of None None O
social None None O
situations None None O
. None None O

This None None O
study None None O
included None None O
16 None None O
individuals None None O
with None None O
high-functioning None None O
autism/Asperger None None O
syndrome None None I-DISEASE
. None None O

This None None O
type None None O
of None None O
intervention None None O
seems None None O
to None None O
be None None O
an None None O
interesting None None O
therapeutic None None O
indication None None O
for None None O
individuals None None O
with None None O
high-functioning None None O
autism/Asperger None None O
syndrome None None I-DISEASE
. None None O

The None None O
importance None None O
of None None O
enzymes None None I-PROTEIN
as None None O
biotechnological None None O
catalysts None None O
for None None O
paper None None O
industry None None O
is None None O
now None None O
recognized None None O
. None None O

A None None O
slight None None O
decrease None None O
in None None O
tear None None O
strength None None O
was None None O
observed None None O
with None None O
enzymes None None I-PROTEIN
C1 None None O
and None None O
C4 None None O
at None None O
pH None None O
7 None None O
while None None O
the None None O
most None None O
decrease None None O
in None None O
tear None None O
was None None O
observed None None O
after None None O
C2 None None O
, None None O
C3 None None O
, None None O
C5 None None O
treatments None None O
. None None O

Owing None None O
to None None O
their None None O
biocompatibility None None O
, None None O
biodegradability None None O
, None None O
and None None O
controllable None None O
properties None None O
, None None O
wood None None O
mimetic None None O
hydrogel None None O
beads None None O
can None None O
be None None O
used None None O
to None None O
immobilize None None O
various None None O
enzymes None None I-PROTEIN
for None None O
applications None None O
in None None O
the None None O
biomedical None None O
, None None O
bioelectronic None None O
, None None O
and None None O
biocatalytic None None O
fields None None O
. None None O

The None None O
non-specific None None O
action None None O
of None None O
pepsin None None I-PROTEIN
on None None O
guar None None O
galactomannan None None O
( None None O
GG None None O
) None None O
resulted None None O
in None None O
selective None None O
removal None None O
of None None O
galactose None None O
residues None None O
, None None O
leading None None O
to None None O
the None None O
formation None None O
of None None O
galactose None None O
- None None O
depleted None None O
guar None None O
galactomannan None None O
( None None O
GDGG None None O
) None None O
with None None O
decrease None None O
in None None O
Mw None None O
and None None O
change None None O
in None None O
G None None O
: None None O
M None None O
ratio None None O
of None None O
1:3.4 None None O
, None None O
thus None None O
mimicking None None O
that None None O
of None None O
locust None None O
bean None None O
gum None None O
( None None O
LBG None None O
) None None O
. None None O

Thus None None O
, None None O
debranching None None O
of None None O
guar None None O
galactomannan None None O
by None None O
the None None O
catalytic None None O
action None None O
of None None O
pepsin None None I-PROTEIN
is None None O
beneficial None None O
for None None O
improved None None O
functional None None O
properties None None O
and None None O
diversified None None O
applications None None O
. None None O

Injectable None None O
tyramine None None I-TRANS
modified None None O
hyaluronic None None O
acid None None O
( None None O
HA-Tyr None None O
) None None O
hydrogels None None O
which None None O
are None None O
bio-orthogonally None None O
cross-linked None None O
with None None O
horseradish None None O
peroxidase None None O
( None None O
HRP None None O
) None None O
and None None O
hydrogen None None O
peroxide None None O
( None None O
H2O2 None None O
) None None O
are None None O
excellent None None O
candidate None None O
biomaterials None None O
for None None O
drug None None O
delivery None None O
, None None O
regenerative None None O
medicine None None O
and None None O
tissue None None O
engineering None None O
. None None O

The None None O
moderate None None O
negative None None O
correlation None None O
pairs None None O
( None None O
rp None None O
) None None O
between None None O
remaining None None O
Alcian None None O
blue None None O
and None None O
amount None None O
of None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
adsorbed None None O
on None None O
EPS None None O
from None None O
strains None None O
TN114 None None O
and None None O
PP803 None None O
were None None O
-0.652 None None O
and None None O
-0.609 None None O
. None None O

EPS None None O
from None None O
strain None None O
PP803 None None O
had None None O
a None None O
higher None None O
efficiency None None O
in None None O
removing None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
than None None O
the None None O
EPS None None O
from None None O
strain None None O
TN114 None None O
based None None O
on None None O
their None None O
EC50 None None O
values None None O
( None None O
1.79 None None O
and None None O
1.49 None None O
mg/mL None None O
for None None O
TN114 None None O
and None None O
PP803 None None O
, None None O
respectively None None O
) None None O
. None None O

Overall None None O
results None None O
suggested None None O
that None None O
EPS None None O
is None None O
a None None O
key None None O
factor None None O
that None None O
our None None O
strains None None O
used None None O
to None None O
bind None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
allowing None None O
their None None O
survival None None O
in None None O
high None None O
NaCl None None O
concentrations None None O
. None None O

Effect None None O
of None None O
storage None None I-FUNC
time None None O
and None None O
plasticizers None None O
on None None O
the None None O
structural None None O
stability None None O
of None None O
melt None None O
processed None None O
TPS None None O
was None None O
investigated None None O
. None None O

XRD None None O
analysis None None O
highlights None None O
major None None O
changes None None O
in None None O
the None None O
microstructure None None O
of None None O
plasticized None None O
starch None None O
, None None O
and None None O
dependence None None O
of None None O
crystalline None None O
type None None O
and None None O
degree None None O
of None None O
crystallinity None None O
mainly None None O
on None None O
the None None O
plasticizer None None O
composition None None O
and None None O
storage None None I-FUNC
time None None O
. None None O

In None None O
this None None O
study None None O
, None None O
cellulose/Mn3O4 None None O
composites None None O
were None None O
successfully None None O
fabricated None None O
using None None O
four None None O
types None None O
of None None O
alkalis None None O
( None None O
urea None None O
( None None O
CO None None O
( None None O
NH2 None None I-TRANS
) None None O
2 None None O
) None None O
, None None O
hexamethylenetetramine None None O
( None None O
( None None O
CH2 None None O
) None None O
6N4 None None O
, None None O
HMT None None O
) None None O
, None None O
NaOH None None O
, None None O
and None None O
KOH None None O
) None None O
by None None O
an None None O
environmentally-friendly None None O
sonochemistry None None O
method None None O
. None None O

Although None None O
this None None O
addition None None O
caused None None O
an None None O
increase None None O
in None None O
the None None O
viscosity None None O
, None None O
the None None O
resulting None None O
adhesive None None O
retained None None O
both None None O
good None None O
mobility None None O
and None None O
viscosity None None O
stability None None O
during None None O
storage None None I-FUNC
. None None O

Oral None None O
administration None None O
of None None O
COS None None O
inhibited None None O
inflammation None None O
in None None O
the None None O
colonic None None O
mucosa None None O
by None None O
suppression None None O
of None None O
myeloperoxidase None None I-PROTEIN
activation None None O
in None None O
inflammatory None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
activation None None O
of None None O
nuclear None None O
factor-kappa None None O
B None None O
, None None O
cyclooxygenase-2 None None O
, None None O
and None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
. None None O

These None None O
results None None O
suggested None None O
that None None O
enzyme None None O
reaction None None O
mechanisms None None O
, None None O
including None None O
the None None O
sizes None None O
of None None O
the None None O
binding None None O
sites None None O
and None None O
the None None O
reaction None None O
patterns None None O
of None None O
the None None O
two None None O
enzymes None None I-PROTEIN
, None None O
contributed None None O
to None None O
the None None O
differences None None O
in None None O
the None None O
RS None None O
contents None None O
obtained None None O
using None None O
different None None O
methods None None O
of None None O
RS None None O
analysis None None O
. None None O

5 None None O
% None None O
w/w None None O
glycine None None I-TRANS
and None None O
proline None None I-TRANS
decreased None None O
the None None O
glass None None O
transition None None O
temperature None None O
( None None O
Tg None None O
) None None O
of None None O
maltodextrins None None O
from None None O
102.6±2.0°C None None O
to None None O
73.1±1.4°C None None O
and None None O
76.1±0.7°C None None O
, None None O
respectively None None O
; None None O
meanwhile None None O
the None None O
binary None None O
mixture None None O
made None None O
with None None O
lysine None None I-TRANS
had None None O
a None None O
Tg None None O
value None None O
of None None O
83.6±2.2°C None None O
. None None O

The None None O
addition None None O
of None None O
glycine None None I-TRANS
and None None O
proline None None I-TRANS
resulted None None O
effective None None O
in None None O
reducing None None O
the None None O
elastic None None O
modulus None None O
( None None O
about None None O
50 None None O
% None None O
) None None O
and None None O
tensile None None O
strength None None O
( None None O
about None None O
three None None O
times None None O
) None None O
and None None O
, None None O
therefore None None O
, None None O
can None None O
be None None O
used None None O
to None None O
increase None None O
the None None O
film None None O
ductility None None O
. None None O

Ac2-26 None None O
resulted None None O
entrapped None None O
into None None O
chitosan None None O
hydrogel None None O
matrix None None O
that None None O
prevented None None O
its None None O
release None None O
, None None O
whereas None None O
such None None O
interaction None None O
in None None O
alginate None None O
hydrogel None None O
slowed None None O
down None None O
peptide None None O
diffusion None None O
enabling None None O
its None None O
sustained None None O
release None None O
till None None O
72 None None O
h. None None O
In None None O
vivo None None O
wound None None O
healing None None O
studies None None O
conducted None None O
on None None O
mice None None O
dorsal None None I-NEURON
wounds None None O
indicate None None O
that None None O
after None None O
the None None O
9th None None O
day None None O
of None None O
post None None O
wounding None None O
Ac2-26/alginate None None O
hydrogels None None O
could None None O
significantly None None O
accelerate None None O
wound None None O
healing None None O
, None None O
with None None O
complete None None O
closure None None O
of None None O
the None None O
wound None None O
on None None O
day None None O
14th None None O
. None None O

To None None O
examine None None O
the None None O
suitability None None O
of None None O
these None None O
fiber None None O
blends None None O
for None None O
heart None None O
patches None None O
, None None O
their None None O
morphology None None O
, None None O
as None None O
well None None O
as None None O
their None None O
physical None None O
, None None O
chemical None None O
, None None O
and None None O
mechanical None None O
properties None None O
were None None O
measured None None O
before None None O
examining None None O
their None None O
biocompatibility None None O
through None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
. None None O

The None None O
present None None O
study None None O
aimed None None O
at None None O
examining None None O
the None None O
effect None None O
of None None O
Mindfulness-Based None None O
Cognitive None None O
Therapy None None O
( None None O
MBCT None None O
) None None O
in None None O
decreasing None None O
depression None None I-DISEASE
symptoms None None I-DISEASE
in None None O
dully None None O
diagnosed None None O
males None None O
( None None O
drug None None O
dependent None None O
males None None O
with None None O
co-morbid None None O
depression None None I-DISEASE
) None None O
.An None None O
experimental None None O
research None None O
design None None O
with None None O
pre- None None O
and None None O
post-tests None None O
and None None O
a None None O
control None None O
group None None O
was None None O
used None None O
. None None O

The None None O
results None None O
suggested None None O
that None None O
MBCT None None O
did None None O
contribute None None O
to None None O
a None None O
significant None None O
decrease None None O
in None None O
the None None O
depression None None I-DISEASE
symptoms None None I-DISEASE
of None None O
the None None O
dully None None O
diagnosed None None O
individuals None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
association None None O
of None None O
obsessive None None O
beliefs None None O
, None None O
obsessive-compulsive None None I-DISEASE
disorder None None I-DISEASE
severity None None O
and None None O
metacognitive None None O
beliefs None None O
to None None O
the None None O
quality None None O
of None None O
life None None O
in None None O
patients None None O
with None None O
obsessive-compulsive None None I-DISEASE
disorder None None I-DISEASE
( None None O
OCD None None O
) None None O
. None None O

With None None O
culture None None O
progression None None O
and None None O
development None None O
of None None O
gametocytes None None O
, None None O
parasitic None None O
release None None O
of None None O
the None None O
glycolytic None None O
end None None O
products None None O
lactate None None O
, None None O
pyruvate None None O
, None None O
alanine None None I-TRANS
, None None O
and None None O
glycerol None None O
, None None O
were None None O
found None None O
to None None O
be None None O
dramatically None None O
reduced None None O
whilst None None O
acetate None None O
release None None O
was None None O
greatly None None O
increased None None O
. None None O

Besides None None O
, None None O
concerning None None O
Oncotype None None O
DX™ None None O
and None None O
MammaPrint None None O
( None None O
® None None O
) None None O
, None None O
new None None O
data None None O
do None None O
not None None O
allow None None O
to None None O
conclude None None O
neither None None O
to None None O
their None None O
complementary None None O
clinical None None O
information None None O
to None None O
other None None O
clinicopathological None None O
existing None None O
biomarkers None None O
nor None None O
to None None O
a None None O
favorable None None O
cost-efficiency None None O
ratio None None O
in None None O
therapeutic None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
this None None O
because None None O
of None None O
the None None O
methodological None None O
weakness None None O
and None None O
uncertainty None None O
that None None O
are None None O
identified None None O
in None None O
the None None O
selected None None O
studies None None O
. None None O

Spontaneous None None O
spleen None None O
rupture None None O
with None None O
no None None O
recent None None O
report None None O
of None None O
trauma None None O
is None None O
an None None O
extremely None None O
rare None None O
and None None O
life-threatening None None O
cause None None O
of None None O
intraperitoneal None None O
hemorrhage.We None None O
present None None O
the None None O
first None None O
case None None O
of None None O
an None None O
atraumatic None None O
pathological None None O
splenic None None O
rupture None None O
following None None O
alteplase None None O
thrombolysis None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

The None None O
serum None None O
samples None None O
were None None O
obtained None None O
at None None O
3 None None O
time-points None None O
for None None O
rtPA None None O
group None None O
( None None O
time-point None None O
0 None None O
: None None O
1st-4th None None O
hour None None O
of None None O
stroke None None I-DISEASE
; None None O
time-point None None O
1 None None O
- None None O
immediately None None O
after None None O
rtPA None None O
administration None None O
; None None O
time-point None None O
2 None None O
- None None O
on None None O
day None None O
5-7 None None O
from None None O
stroke None None I-DISEASE
onset None None O
) None None O
. None None O

In None None O
accordance None None O
with None None O
the None None O
hypothesis None None O
of None None O
a None None O
shared None None O
, None None O
common None None O
pathophysiological None None O
mechanism None None O
in None None O
both None None O
TGA None None O
and None None O
migraine None None I-DISEASE
, None None O
neuromuscular None None O
transmission None None O
( None None O
NMT None None O
) None None O
abnormalities None None O
previously None None O
found None None O
in None None O
migraine None None I-DISEASE
were None None O
also None None O
suspected None None O
in None None O
TGA None None O
. None None O

The None None O
role None None O
of None None O
channelopathy None None O
with None None O
NMT None None O
dysfunction None None O
in None None O
the None None O
pathogenesis None None O
of None None O
TGA None None O
is None None O
rather None None O
unlikely None None O
, None None O
whereas None None O
subclinical None None O
NMT None None O
abnormalities None None O
were None None O
certainly None None O
proven None None O
in None None O
migraine None None I-DISEASE
. None None O

There None None O
were None None O
several None None O
studies None None O
that None None O
showed None None O
impaired None None O
antioxidant None None O
defense None None O
system None None O
( None None O
ADS None None O
) None None O
enzymes None None I-PROTEIN
expression None None O
or None None O
activity None None O
in None None O
AD None None O
patients None None O
. None None O

We None None O
evaluated None None O
association None None O
between None None O
chosen None None O
SNPs None None O
of None None O
the None None O
enzymes None None I-PROTEIN
of None None O
the None None O
ADS None None O
and None None O
risk None None O
of None None O
AD None None O
. None None O

Papillary None None O
tumor None None O
of None None O
the None None O
pineal None None I-REGION
region None None O
( None None O
PTPR None None O
) None None O
was None None O
introduced None None O
to None None O
the None None O
WHO None None O
classification None None O
in None None O
2007 None None O
. None None O

The None None O
main None None O
clinical None None O
features None None O
include None None O
bilateral None None O
vestibulopathy None None O
, None None O
cerebellar None None I-DISEASE
ataxia None None I-DISEASE
and None None O
sensory None None O
neuropathy None None O
. None None O

Right-sided None None O
lesions None None O
very None None O
rarely None None O
lead None None O
to None None O
pure None None O
alexia None None I-DISEASE
in None None O
right-handed None None O
individuals None None O
. None None O

Functional None None O
magnetic None None O
resonance None None O
imaging None None O
revealed None None O
right-hemisphere None None O
dominance None None O
for None None O
language None None I-FUNC
as None None O
well None None O
as None None O
bilateral None None O
reading-related None None O
activity None None O
in None None O
the None None O
fusiform None None O
gyri None None O
. None None O

MRI None None O
of None None O
the None None O
brain None None O
showed None None O
diffuse None None O
, None None O
hyperintensive None None O
in None None O
T2 None None O
, None None O
poorly None None O
defined None None O
lesions None None O
in None None O
the None None O
white None None I-REGION
matter None None I-REGION
. None None O

In None None O
tumor None None O
models None None O
, None None O
both None None O
wild None None O
type None None O
and None None O
mutant None None O
p53 None None I-PROTEIN
proteins None None O
show None None O
aggregation None None O
kinetics None None O
and None None O
morphology None None O
similar None None O
to None None O
those None None O
of None None O
classical None None O
amyloidogenic None None O
proteins None None O
, None None O
such None None O
as None None O
-amyloid None None O
peptide None None O
and None None O
-synuclein None None O
. None None O

So None None O
far None None O
, None None O
amyloidogenic None None O
p53 None None I-PROTEIN
mutations None None O
have None None O
been None None O
implicated None None O
in None None O
more None None O
than None None O
ten None None O
different None None O
types None None O
of None None O
cancer None None O
, None None O
suggesting None None O
a None None O
connection None None O
between None None O
p53 None None I-PROTEIN
aggregation None None O
and None None O
cancer None None O
. None None O

Here None None O
, None None O
we None None O
summarize None None O
recent None None O
findings None None O
on None None O
carcinogenic None None O
aggregation None None O
of None None O
wild None None O
type None None O
p53 None None I-PROTEIN
and None None O
its None None O
clinical None None O
mutants None None O
, None None O
structure-dependent None None O
amyloidogenesis None None O
of None None O
p53 None None I-PROTEIN
, None None O
and None None O
several None None O
promising None None O
strategies None None O
based None None O
on None None O
inhibition None None O
of None None O
p53 None None I-PROTEIN
aggregation None None O
are None None O
also None None O
discussed None None O
. None None O

A None None O
substantive None None O
literature None None O
has None None O
accumulated None None O
implicating None None O
sphingolipids None None O
, None None O
in None None O
particular None None O
ceramides None None O
, None None O
as None None O
mediators None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
in None None O
metabolic None None O
syndrome None None O
. None None O

Diminished None None O
sulfation None None O
of None None O
heparan None None O
sulfate None None O
resulted None None O
in None None O
enhanced None None O
chemokine None None O
expression None None O
; None None O
increased None None O
macrophages None None O
in None None O
plaques None None O
; None None O
increased None None O
expression None None O
of None None O
ACAT2 None None O
, None None O
a None None O
key None None O
enzyme None None O
in None None O
cholesterol None None O
ester None None O
storage None None I-FUNC
; None None O
and None None O
increased None None O
foam None None O
cell None None O
conversion None None O
. None None O

Evidence None None O
suggests None None O
that None None O
the None None O
neighbourhood None None O
environment None None O
impacts None None O
the None None O
risk None None O
of None None O
depression None None I-DISEASE
, None None O
but None None O
few None None O
studies None None O
have None None O
investigated None None O
this None None O
effect None None O
in None None O
those None None O
with None None O
diabetes None None O
. None None O

Material None None O
deprivation None None O
was None None O
associated None None O
with None None O
increased None None O
risk None None O
of None None O
depression None None I-DISEASE
, None None O
particularly None None O
in None None O
participants None None O
who None None O
were None None O
older None None O
or None None O
retired None None O
. None None O

Clinicians None None O
are None None O
encouraged None None O
to None None O
consider None None O
the None None O
neighbourhood None None O
environment None None O
of None None O
their None None O
patients None None O
when None None O
assessing None None O
the None None O
risk None None O
of None None O
depression None None I-DISEASE
. None None O

The None None O
LXR-regulated None None O
E3 None None O
ubiquitin None None O
ligase None None I-PROTEIN
IDOL None None O
controls None None O
LDLR None None O
receptor None None I-PROTEIN
stability None None O
independent None None O
of None None O
SREBP None None O
and None None O
PCSK9 None None O
, None None O
but None None O
its None None O
relevance None None O
to None None O
plasma None None O
lipid None None O
levels None None O
is None None O
unknown None None O
. None None O

Cockayne None None O
syndrome None None O
( None None O
CS None None O
) None None O
is None None O
an None None O
accelerated None None O
aging None None O
disorder None None O
characterized None None O
by None None O
progressive None None O
neurodegeneration None None O
caused None None O
by None None O
mutations None None O
in None None O
genes None None O
encoding None None I-FUNC
the None None O
DNA None None O
repair None None O
proteins None None O
CS None None O
group None None O
A None None O
or None None O
B None None O
( None None O
CSA None None O
or None None O
CSB None None O
) None None O
. None None O

Notably None None O
, None None O
β-hydroxybutyrate None None O
levels None None O
are None None O
increased None None O
by None None O
the None None O
high-fat None None O
diet None None O
, None None O
and None None O
β-hydroxybutyrate None None O
, None None O
PARP None None O
inhibition None None O
, None None O
or None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
supplementation None None O
can None None O
activate None None O
SIRT1 None None O
and None None O
rescue None None O
CS-associated None None O
phenotypes None None O
. None None O

This None None O
study None None O
connects None None O
two None None O
emerging None None O
longevity None None O
metabolites None None O
, None None O
β-hydroxybutyrate None None O
and None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
, None None O
through None None O
the None None O
deacetylase None None O
SIRT1 None None O
and None None O
suggests None None O
possible None None O
interventions None None O
for None None O
CS None None O
. None None O

Corpora None None O
amylacea None None O
( None None O
CoA None None O
) None None O
are None None O
present None None O
in None None O
about None None O
60 None None O
% None None O
of None None O
atrophic None None O
hippocampi None None O
resected None None O
from None None O
patients None None O
with None None O
drug None None O
resistant None None O
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
( None None O
DRTLE None None O
) None None O
. None None O

The None None O
objective None None O
is None None O
to None None O
measure None None O
the None None O
presence None None O
, None None O
distribution None None O
and None None O
density None None O
of None None O
CoA None None O
in None None O
the None None O
lateral None None O
temporal None None I-REGION
lobes None None I-REGION
of None None O
patients None None O
with None None O
DRTLE None None O
and None None O
focal None None O
cortical None None O
dysplasia None None O
( None None O
FCD None None O
) None None O
, None None O
also None None O
examining None None O
how None None O
CoA None None O
density None None O
may None None O
be None None O
linked None None O
to None None O
demographic None None O
and None None O
clinical None None O
traits None None O
. None None O

The None None O
meningeal None None O
surface None None O
( None None O
MS None None O
) None None O
was None None O
involved None None O
in None None O
all None None O
cases None None O
, None None O
and None None O
8 None None O
cases None None O
displayed None None O
CoA None None O
in None None O
the None None O
cerebral None None O
parenchyma None None O
( None None O
white None None I-REGION
matter None None I-REGION
) None None O
and None None O
around None None O
blood None None O
vessels None None O
. None None O

Patients None None O
with None None O
DRTLE None None O
and None None O
a None None O
primary None None O
lesion None None O
( None None O
hippocampal None None O
sclerosis None None O
, None None O
tumour None None O
, None None O
vascular None None O
malformation None None O
) None None O
associated None None O
with None None O
mild None None O
FCD None None O
were None None O
shown None None O
to None None O
have None None O
CoA None None O
deposits None None O
in None None O
the None None O
neocortex None None I-REGION
. None None O

The None None O
distal None None O
radius None None O
can None None O
be None None O
approached None None O
dorsally None None O
by None None O
releasing None None O
the None None O
third None None O
dorsal None None I-NEURON
compartment None None O
and None None O
continuing None None O
the None None O
dissection None None O
subperiosteally None None O
. None None O

All None None O
proteins None None O
encoded None None O
by None None O
the None None O
ORFs None None O
of None None O
the None None O
P1 None None O
virus None None O
are None None O
less None None O
than None None O
50 None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
length None None O
, None None O
except None None O
that None None O
encoded None None O
by None None O
ORF1 None None O
( None None O
113 None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
. None None O

E2F4 None None O
activity None None O
stratification None None O
was None None O
highly None None O
predictive None None O
of None None O
patient None None O
outcome None None O
, None None O
and None None O
our None None O
results None None O
remained None None O
robust None None O
even None None O
when None None O
controlling None None O
for None None O
many None None O
factors None None O
including None None O
patient None None O
age None None O
, None None O
tumor None None O
size None None O
, None None O
grade None None O
, None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
status None None O
, None None O
lymph None None O
node None None O
( None None O
LN None None O
) None None O
status None None O
, None None O
whether None None O
the None None O
patient None None O
received None None O
adjuvant None None O
therapy None None O
, None None O
and None None O
the None None O
patient None None O
's None None O
other None None O
prognostic None None O
indices None None O
such None None O
as None None O
Adjuvant None None O
! None None O

Increasing None None O
severity None None O
of None None O
COPD None None O
was None None O
associated None None O
with None None O
lower None None O
RVEDV None None O
( None None O
p None None O
= None None O
0.004 None None O
) None None O
and None None O
lower None None O
RV None None O
stroke None None I-DISEASE
volume None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

A None None O
greater None None O
percentage None None O
of None None O
emphysema None None O
also None None O
was None None O
associated None None O
with None None O
lower None None O
RVEDV None None O
( None None O
p None None O
= None None O
0.005 None None O
) None None O
and None None O
stroke None None I-DISEASE
volume None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
as None None O
was None None O
the None None O
presence None None O
of None None O
centrilobular None None O
and None None O
paraseptal None None O
emphysema None None O
. None None O

Until None None O
recently None None O
, None None O
the None None O
vitamin None None O
K None None O
antagonists None None O
( None None O
VKAs None None O
, None None O
e.g. None None O
, None None O
warfarin None None O
) None None O
were None None O
the None None O
only None None O
oral None None O
anticoagulants None None O
available None None O
, None None O
acting None None O
by None None O
decreased None None O
synthesis None None O
of None None O
vitamin None None O
K-dependent None None O
coagulation None None I-PROTEIN
factors None None I-PROTEIN
( None None O
II None None O
, None None O
VI None None I-REGION
, None None O
IX None None I-REGION
, None None O
and None None O
X None None O
) None None O
. None None O

The None None O
limitations None None O
of None None O
VKAs None None O
led None None O
to None None O
development None None O
of None None O
a None None O
new None None O
class None None O
of None None O
drugs None None O
collectively None None O
defined None None O
as None None O
non-VKA None None O
oral None None O
anticoagulants None None O
( None None O
NOACs None None O
) None None O
, None None O
which None None O
included None None O
direct None None O
thrombin None None I-PROTEIN
inhibitors None None O
( None None O
dabigatran None None O
) None None O
and None None O
factor None None O
Xa None None O
inhibitors None None O
( None None O
rivaroxaban None None O
, None None O
apixaban None None O
, None None O
and None None O
edoxaban None None O
) None None O
. None None O

Screening None None O
for None None O
geriatric None None O
conditions None None O
such None None O
as None None O
memory None None I-FUNC
loss None None O
, None None O
fall None None O
risk None None O
, None None O
and None None O
depression None None I-DISEASE
may None None O
contribute None None O
to None None O
the None None O
prevention None None O
of None None O
adverse None None O
physical None None O
and None None O
mental None None O
comorbidities None None O
, None None O
unnecessary None None O
hospitalizations None None O
, None None O
and None None O
premature None None O
nursing None None O
home None None O
admissions None None O
. None None O

The None None O
goals None None O
of None None O
the None None O
program None None O
were None None O
to None None O
improve None None O
early None None O
identification None None O
of None None O
at-risk None None O
individuals None None O
and None None O
ensure None None O
appropriate None None O
follow-up None None O
for None None O
memory None None I-FUNC
loss None None O
, None None O
fall None None O
risk None None O
, None None O
and None None O
depression None None I-DISEASE
; None None O
facilitate None None O
discussion None None O
about None None O
prevention None None O
, None None O
diagnosis None None O
, None None O
and None None O
treatment None None O
of None None O
these None None O
conditions None None O
; None None O
implement None None O
strategies None None O
to None None O
reduce None None O
risks None None O
for None None O
these None None O
conditions None None O
; None None O
and None None O
increase None None O
access None None O
to None None O
screening None None O
and None None O
expand None None O
preventive None None O
health None None O
services None None O
for None None O
older None None O
adults None None O
. None None O

Individuals None None O
with None None O
severe None None O
antisocial None None O
behaviour None None O
often None None O
demonstrate None None O
abnormalities None None O
or None None O
difficulties None None O
in None None O
emotion None None I-FUNC
processing None None O
. None None O

We None None O
therefore None None O
conducted None None O
a None None O
brain-based None None O
study None None O
of None None O
emotion None None I-FUNC
processing None None O
in None None O
juvenile None None O
offenders None None O
. None None O

The None None O
early None None O
posterior None None O
negativity None None O
( None None O
EPN None None O
) None None O
and None None O
the None None O
late None None O
positive None None O
potential None None O
( None None O
LPP None None O
) None None O
components None None O
were None None O
used None None O
as None None O
indices None None O
of None None O
emotion None None I-FUNC
processing None None O
. None None O

In None None O
line None None O
with None None O
normal None None O
emotion None None I-FUNC
processing None None O
, None None O
the None None O
LPP None None O
was None None O
significantly None None O
enhanced None None O
following None None O
unpleasant None None O
images None None O
for None None O
non-offenders None None O
. None None O

The None None O
findings None None O
indicated None None O
that None None O
this None None O
brain-based None None O
hypo-reactivity None None O
occurred None None O
during None None O
a None None O
late None None O
stage None None O
of None None O
cognitive None None O
processing None None O
and None None O
was None None O
not None None O
a None None O
consequence None None O
of None None O
atypical None None O
early None None O
visual None None I-FUNC
attention None None I-FUNC
or None None O
perception None None I-FUNC
. None None O

When None None O
tumor None None O
compartment None None O
and None None O
levels None None O
of None None O
miR-21 None None O
expression None None O
were None None O
considered None None O
, None None O
significant None None O
associations None None O
with None None O
poor None None O
clinical None None O
outcome None None O
were None None O
detected None None O
exclusively None None O
in None None O
tumor None None O
epithelia None None O
from None None O
estrogen None None I-PROTEIN
receptor- None None O
and/or None None O
progesterone None None O
receptor-positive None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2-negative None None O
cases None None O
[ None None O
recurrence-free None None O
survival None None O
: None None O
HR None None O
, None None O
3.67 None None O
( None None O
P None None O
= None None O
0.006 None None O
) None None O
; None None O
BC-specific None None O
survival None None O
: None None O
HR None None O
, None None O
5.13 None None O
( None None O
P None None O
= None None O
0.002 None None O
) None None O
] None None O
and None None O
in None None O
tumor None None O
stroma None None O
from None None O
TNBC None None O
cases None None O
[ None None O
recurrence-free None None O
survival None None O
: None None O
HR None None O
, None None O
2.59 None None O
( None None O
P None None O
= None None O
0.013 None None O
) None None O
; None None O
BC-specific None None O
survival None None O
: None None O
HR None None O
, None None O
3.37 None None O
( None None O
P None None O
= None None O
0.003 None None O
) None None O
] None None O
. None None O

Type None None O
I None None O
collagen None None I-PROTEIN
proin None None O
pro-in None None O
expression None None O
in None None O
a None None O
damaged None None O
supraspinatus None None O
tendon None None O
is None None O
thought None None O
to None None O
be None None O
dependent None None O
on None None O
the None None O
distance None None O
from None None O
the None None O
edge None None O
of None None O
the None None O
tear None None O
and None None O
the None None O
local None None O
expression None None O
of None None O
pro-inflammatory None None O
, None None O
anti-proliferative None None O
, None None O
and None None O
pro-proliferative None None O
cytokines None None O
. None None O

The None None O
expression None None O
of None None O
type None None O
I None None O
collagen None None I-PROTEIN
is None None O
dependent None None O
on None None O
the None None O
distance None None O
from None None O
the None None O
edge None None O
of None None O
the None None O
torn None None O
supraspinatus None None O
tendon None None O
, None None O
the None None O
balance None None O
between None None O
anti-proliferative None None O
IFN-γ None None O
and None None O
pro-proliferative None None O
IL-4 None None O
and None None O
IL-13 None None O
, None None O
and None None O
the None None O
expression None None O
of None None O
pro-inflammatory None None O
IL-1β None None O
. None None O

Among None None O
the None None O
inclusion None None O
criteria None None O
were None None O
preoperative None None O
estimates None None O
of None None O
C-reactive None None O
protein None None O
and None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
. None None O

Overall None None O
, None None O
fibromyalgia None None O
women None None O
showed None None O
a None None O
worse None None O
status None None O
in None None O
pain None None O
, None None O
fatigue None None O
, None None O
health-related None None O
quality None None O
of None None O
life None None O
, None None O
depression None None I-DISEASE
, None None O
and None None O
anxiety None None O
than None None O
controls None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

No None None O
differences None None O
between None None O
fibromyalgia None None O
and None None O
controls None None O
were None None O
observed None None O
in None None O
cognitive None None O
and None None O
memory None None I-FUNC
performance None None O
, None None O
except None None O
for None None O
delayed None None O
recall None None O
, None None O
but None None O
the None None O
observed None None O
effect None None O
size None None O
was None None O
low None None O
( None None O
~0.25 None None O
) None None O
. None None O

Glucose None None I-PROTEIN
transporter None None I-PROTEIN
1 None None O
deficiency None None O
syndrome None None O
( None None O
OMIM None None O
606777 None None O
) None None O
is None None O
a None None O
treatable None None O
epileptic None None O
encephalopathy None None O
caused None None O
by None None O
mutations None None O
in None None O
the None None O
SLC2A1 None None O
gene None None O
( None None O
OMIM None None O
138140 None None O
) None None O
causing None None O
impaired None None O
glucose None None O
transport None None O
into None None O
the None None O
brain None None O
. None None O

We None None O
describe None None O
an None None O
8-year-old None None O
boy None None O
with None None O
glucose None None I-PROTEIN
transporter None None I-PROTEIN
1 None None O
deficiency None None O
syndrome None None O
whose None None O
clinical None None O
presentation None None O
was None None O
dominated None None O
by None None O
hemiplegic None None O
migraines None None I-DISEASE
that None None O
resolved None None O
with None None O
institution None None O
of None None O
a None None O
modified None None O
Atkins None None O
diet None None O
. None None O

For None None O
each None None O
patient None None O
, None None O
a None None O
formal None None O
ophthalmologic None None O
examination None None O
, None None O
an None None O
Amsler None None O
grid None None O
test None None O
, None None O
an None None O
automated None None O
visual None None O
field None None O
( None None O
central None None O
20° None None O
) None None O
, None None O
a None None O
color None None O
vision None None I-FUNC
test None None O
( None None O
15 None None O
Hue None None O
) None None O
, None None O
a None None O
full None None O
field None None O
, None None O
a None None O
pattern None None O
and None None O
a None None O
multifocal None None O
electroretinogram None None O
as None None O
well None None O
as None None O
flash None None O
and None None O
pattern None None O
visual None None O
evoked None None O
potentials None None O
( None None O
Métrovision© None None O
) None None O
were None None O
performed None None O
. None None O

The None None O
pathophysiology None None O
of None None O
this None None O
phenomenon None None O
, None None O
however None None O
, None None O
remains None None O
unclear None None O
; None None O
the None None O
hypothesis None None O
of None None O
a None None O
lower None None O
threshold None None O
for None None O
perception None None I-FUNC
of None None O
entoptic None None O
images None None O
can None None O
not None None O
entirely None None O
account None None O
for None None O
the None None O
reported None None O
symptoms None None O
. None None O

23 None None O
hamstring None None O
auto-graft None None O
ACL-reconstructed None None O
men None None O
( None None O
mean None None O
age None None O
: None None O
27.2 None None O
standard None None O
deviation None None O
7.5 None None O
years None None O
, None None O
BMI None None O
: None None O
25.4 None None O
standard None None O
deviation None None O
3.2 None None O
time None None O
since None None O
surgery None None O
: None None O
27 None None O
standard None None O
deviation None None O
7 None None O
months None None O
) None None O
completed None None O
KOOS-questionnaire None None O
and None None O
an None None O
objective None None O
test-battery None None O
: None None O
( None None O
i None None O
) None None O
one-leg None None O
maximal None None O
jump None None O
for None None O
distance None None O
( None None O
OLJD None None O
) None None O
, None None O
isometric None None O
maximal None None O
voluntary None None O
contraction None None O
( None None O
MVC None None O
) None None O
for None None O
( None None O
ii None None O
) None None O
knee None None O
extensors None None O
and None None O
( None None O
iii None None O
) None None O
flexors None None O
, None None O
and None None O
( None None O
iv None None O
) None None O
maximal None None O
counter None None O
movement None None I-FUNC
jump None None O
( None None O
CMJ None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
was None None O
expected None None O
that None None O
the None None O
variations None None O
of None None O
parameters None None O
of None None O
carbon None None O
chemistry None None O
may None None O
affect None None O
the None None O
inference None None I-FUNC
of None None O
the None None O
best None None O
model None None O
on None None O
calcification None None O
responses None None O
to None None O
these None None O
parameters None None O
between None None O
Bayesian None None O
modeling None None O
approach None None O
and None None O
classical None None O
statistical None None O
one None None O
even None None O
under None None O
stable None None O
pCO2 None None O
values None None O
with None None O
low None None O
variations None None O
. None None O

Eleven None None O
individuals None None O
with None None O
chronic None None O
hemiparesis None None O
( None None O
mean None None O
lesion None None O
time None None O
of None None O
19.64 None None O
months None None O
) None None O
after None None O
unilateral None None O
and None None O
non-recurrent None None O
stroke None None I-DISEASE
underwent None None O
training None None O
based None None O
on None None O
PNF None None O
method None None O
for None None O
twelve None None O
sessions None None O
, None None O
being None None O
evaluated None None O
for None None O
motor None None O
function None None O
- None None O
using None None O
the None None O
Stroke None None I-DISEASE
Rehabilitation None None O
Assessment None None O
of None None O
Movement None None I-FUNC
( None None O
STREAM None None O
) None None O
instrument None None O
; None None O
functionality None None O
, None None O
by None None O
the None None O
Functional None None O
Independence None None O
Measure None None O
( None None O
FIM None None O
) None None O
; None None O
and None None O
gait None None O
kinematic None None O
( None None O
using None None O
the None None O
Qualisys None None O
Motion None None O
Capture None None O
System None None O
) None None O
, None None O
at None None O
baseline None None O
and None None O
post-training None None O
. None None O

Data None None O
showed None None O
significant None None O
changes None None O
in None None O
motor None None O
function None None O
and None None O
functionality None None O
after None None O
training None None O
, None None O
suggesting None None O
that None None O
this None None O
program None None O
can None None O
be None None O
useful None None O
for None None O
rehabilitation None None O
of None None O
chronic None None O
stroke None None I-DISEASE
survivors None None O
. None None O

The None None O
present None None O
study None None O
investigated None None O
the None None O
existence None None O
of None None O
a None None O
relationship None None O
between None None O
depression None None I-DISEASE
and None None O
body None None O
posture None None O
in None None O
40 None None O
women None None O
, None None O
aged None None O
between None None O
20 None None O
and None None O
30 None None O
years None None O
, None None O
who None None O
had None None O
normal None None O
body None None O
mass None None O
indices None None O
( None None O
or None None O
were None None O
underweight None None O
) None None O
and None None O
absence None None O
of None None O
neurological None None O
, None None O
psychiatric None None O
, None None O
or None None O
musculoskeletal None None O
disorders None None O
. None None O

The None None O
degree None None O
of None None O
depression None None I-DISEASE
was None None O
rated None None O
on None None O
analogue None None O
scales None None O
representing None None O
current None None O
and None None O
usual None None O
depression None None I-DISEASE
and None None O
current None None O
and None None O
usual None None O
sadness None None O
and None None O
by None None O
the None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
. None None O

Consequently None None O
, None None O
postural None None O
assessment None None O
and None None O
treatment None None O
may None None O
assist None None O
in None None O
diagnosing None None O
and None None O
treating None None O
depression None None I-DISEASE
. None None O

Therefore None None O
, None None O
the None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
feasibility None None O
and None None O
acceptance None None O
of None None O
holistic None None O
exercise None None O
among None None O
people None None O
with None None O
dementia None None I-DISEASE
. None None O

They None None O
were None None O
enjoyment None None O
, None None O
relaxation None None O
, None None O
keeping None None O
active None None O
, None None O
social None None O
interaction None None O
, None None O
pain None None O
relief None None O
, None None O
learning None None I-FUNC
something None None O
new None None O
and None None O
intention None None O
to None None O
continue None None O
, None None O
respectively None None O
. None None O

Left None None I-REGION
inferior None None I-REGION
frontal None None I-REGION
gyrus None None I-REGION
( None None O
IFG None None O
) None None O
, None None O
a None None O
key None None O
region None None O
of None None O
the None None O
mirror-neuron None None O
system None None O
, None None O
gets None None O
lesioned None None O
in None None O
Broca None None O
's None None O
aphasia None None I-DISEASE
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
report None None O
a None None O
case None None O
of None None O
poststroke None None O
subject None None O
with None None O
Broca None None O
's None None O
aphasia None None I-DISEASE
, None None O
who None None O
exhibited None None O
an None None O
inadvertent None None O
and None None O
significant None None O
improvement None None O
in None None O
speech None None I-FUNC
after None None O
MT None None O
for None None O
the None None O
paretic None None O
upper None None O
limb None None O
. None None O

He None None O
received None None O
a None None O
total None None O
absence None None O
of None None O
spontaneous None None O
speech None None I-FUNC
, None None O
writing None None O
, None None O
and None None O
naming None None O
. None None O

20 None None O
physiotherapy None None O
students None None O
with None None O
episodic None None O
migraines None None I-DISEASE
and None None O
20 None None O
age- None None O
and None None O
sex None None O
matched None None O
healthy None None O
controls None None O
were None None O
included None None O
in None None O
this None None O
observational None None O
case-control None None O
study None None O
. None None O

No None None O
significant None None O
differences None None O
were None None O
found None None O
in None None O
neck None None O
ROM None None O
measurements None None O
and None None O
FHP None None O
between None None O
the None None O
migraine None None I-DISEASE
and None None O
control None None O
groups None None O
. None None O

Significant None None O
differences None None O
were None None O
found None None O
in None None O
the None None O
prevalence None None O
of None None O
active None None O
and None None O
latent None None O
MTrPs None None O
between None None O
the None None O
migraine None None I-DISEASE
and None None O
control None None O
subjects None None O
in None None O
the None None O
right None None O
trapezius None None O
( None None O
χ None None O
( None None O
2 None None O
) None None O
= None None O
11.649 None None O
, None None O
p None None O
= None None O
0.003 None None O
) None None O
and None None O
right None None O
sternocleidomastoid None None O
( None None O
χ None None O
( None None O
2 None None O
) None None O
= None None O
8.485 None None O
, None None O
p None None O
= None None O
0.014 None None O
) None None O
. None None O

This None None O
little None None O
attention None None I-FUNC
depends None None O
on None None O
the None None O
fact None None O
that None None O
these None None O
fasciae None None O
vary None None O
in None None O
thickness None None O
and None None O
composition None None O
, None None O
especially None None O
at None None O
the None None O
cervical None None O
level None None O
. None None O

To None None O
assess None None O
the None None O
immediate None None O
effects None None O
on None None O
the None None O
electrical None None O
activity None None O
of None None O
the None None O
transversus None None O
abdominis/internal None None O
oblique None None O
( None None O
TrA/IO None None O
) None None O
muscle None None O
during None None O
rapid None None O
voluntary None None O
upper None None O
limb None None O
movements None None I-FUNC
before None None O
and None None O
after None None O
a None None O
sacroiliac None None O
joint None None O
( None None O
SIJ None None O
) None None O
manipulation None None O
. None None O

The None None O
SIJ None None O
manipulation None None O
immediately None None O
improved None None O
the None None O
electrical None None O
activity None None O
of None None O
the None None O
TrA/IO None None O
muscle None None O
during None None O
rapid None None O
voluntary None None O
upper None None O
limb None None O
movements None None I-FUNC
, None None O
suggesting None None O
improved None None O
segment None None O
stability None None O
and None None O
an None None O
increment None None O
to None None O
the None None O
afferent None None O
stimuli None None O
in None None O
order None None O
to None None O
affect None None O
the None None O
motor None None O
response None None O
. None None O

We None None O
hypothesized None None O
that None None O
geographically None None O
isolating None None O
EDs None None O
would None None O
prevent None None O
migratory None None O
contamination None None O
in None None O
a None None O
CRT None None O
designed None None O
to None None O
increase None None O
ED None None O
delivery None None O
of None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
( None None O
tPA None None O
) None None O
in None None O
stroke None None I-DISEASE
( None None O
the None None O
INSTINCT None None O
trial None None O
) None None O
. None None O

After None None O
covariate None None O
adjustment None None O
, None None O
erythropoietin None None O
was None None O
not None None O
associated None None O
with None None O
beta-cell None None O
function None None O
, None None O
insulin None None I-PROTEIN
sensitivity None None O
, None None O
or None None O
glycemia None None O
at None None O
either None None O
3- None None O
or None None O
12-months None None O
postpartum None None O
. None None O

Postoperative None None O
morbidity None None O
consisted None None O
of None None O
one None None O
postoperative None None O
stroke None None I-DISEASE
with None None O
no None None O
late None None O
sequelae None None O
. None None O

However None None O
, None None O
a None None O
VATS None None O
lobectomy None None O
of None None O
the None None O
right None None O
upper None None O
or None None O
right None None O
middle None None O
lobe None None O
revealed None None O
no None None O
difference None None O
in None None O
forced None None O
vital None None O
capacity None None O
( None None O
-1.21 None None O
% None None O
versus None None O
-1.45 None None O
% None None O
; None None O
p None None O
= None None O
0.88 None None O
) None None O
or None None O
the None None O
diffusion None None O
capacity None None O
of None None O
carbon None None I-TRANS
monoxide None None I-TRANS
( None None O
-3.99 None None O
% None None O
versus None None O
-2.45 None None O
% None None O
; None None O
p None None O
= None None O
0.61 None None O
) None None O
compared None None O
with None None O
VATS None None O
sublobar None None O
resection None None O
after None None O
12 None None O
months None None O
. None None O

Thereafter None None O
, None None O
histology None None O
of None None O
kidney None None O
, None None O
liver None None O
, None None O
and None None O
hippocampus None None I-REGION
was None None O
performed None None O
. None None O

Histologic None None O
evaluation None None O
revealed None None O
that None None O
laminar None None O
flow None None O
produced None None O
significant None None O
cellular None None O
edema None None O
in None None O
the None None O
kidney None None O
and None None O
hippocampus None None I-REGION
. None None O

Postoperative None None O
mortality None None O
and None None O
postoperative None None O
stroke None None I-DISEASE
were None None O
significantly None None O
increased None None O
in None None O
patients None None O
with None None O
POAF None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.0001 None None O
in None None O
both None None O
cases None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
stimulation None None O
of None None O
the None None O
lateral None None O
septum None None I-REGION
in None None O
the None None O
absence None None O
of None None O
a None None O
seizure None None O
resulted None None O
in None None O
cortical None None O
deactivation None None O
with None None O
slow None None O
oscillations None None O
. None None O

But None None O
how None None O
does None None O
subcortical None None O
stimulation None None O
cause None None O
slow None None O
wave None None O
activity None None O
in None None O
frontal None None I-REGION
cortex None None I-REGION
? None None O

acetylcholine None None I-TRANS
) None None O
change None None O
in None None O
cortex None None O
during None None O
the None None O
excitation None None O
of None None O
inhibitory None None O
projection None None O
nuclei None None O
? None None O

In None None O
contrast None None O
, None None O
the None None O
choline None None O
signal None None O
and None None O
local None None O
field None None O
potential None None O
in None None O
frontal None None I-REGION
cortex None None I-REGION
had None None O
no None None O
significant None None O
changes None None O
when None None O
stimulating None None O
the None None O
hippocampus None None I-REGION
, None None O
but None None O
showed None None O
increased None None O
choline None None O
and None None O
decreased None None O
slow None None O
wave None None O
activity None None O
with None None O
an None None O
arousal None None O
stimulus None None O
produced None None O
by None None O
toe None None O
pinch None None O
. None None O

For None None O
multiparous None None O
women None None O
, None None O
not None None O
having None None O
had None None O
personal None None O
feelings None None I-FUNC
resolved None None O
following None None O
their None None O
previous None None O
birth None None O
and None None O
negative None None O
experiences None None O
of None None O
last None None O
birth None None O
influenced None None O
current None None O
expectations None None O
for None None O
their None None O
upcoming None None O
birth None None O
. None None O

Available None None O
participants None None O
completed None None O
the None None O
Eating None None I-DISEASE
Disorder None None I-DISEASE
Examination None None O
as None None O
well None None O
as None None O
self-report None None O
measures None None O
of None None O
self-esteem None None O
and None None O
depression None None I-DISEASE
at None None O
2 None None O
to None None O
4 None None O
years None None O
posttreatment None None O
. None None O

Clinical None None O
trial None None O
registration None None O
information-Effectiveness None None O
of None None O
Family-Based None None O
Versus None None O
Individual None None O
Psychotherapy None None O
in None None O
Treating None None O
Adolescents None None O
With None None O
Anorexia None None I-DISEASE
Nervosa None None I-DISEASE
; None None O
http None None O
: None None O
//www.clinicaltrials.gov/ None None O
; None None O
NCT00149786 None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
efficacy None None O
of None None O
adjunctive None None O
child- None None O
and None None O
family-focused None None O
cognitive-behavioral None None O
therapy None None O
( None None O
CFF-CBT None None O
) None None O
to None None O
psychotherapy None None O
as None None O
usual None None O
( None None O
control None None O
) None None O
for None None O
mood None None I-FUNC
symptom None None O
severity None None O
and None None O
global None None O
functioning None None O
in None None O
children None None O
with None None O
BD None None O
. None None O

Fasting None None O
metabolic None None O
parameters None None O
increased None None O
significantly None None O
with None None O
risperidone None None O
( None None O
glucose None None O
[ None None O
3.8 None None O
] None None O
mg/dL None None O
, None None O
insulin None None I-PROTEIN
[ None None O
4.9 None None O
] None None O
mU/L None None O
, None None O
homeostasis None None O
model None None O
assessment None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
[ None None O
HOMA-IR None None O
: None None O
1.2 None None O
] None None O
, None None O
triglycerides None None O
[ None None O
15.6 None None O
] None None O
mg/dL None None O
) None None O
, None None O
and None None O
olanzapine None None O
( None None O
glucose None None O
[ None None O
5.0 None None O
] None None O
mg/dL None None O
, None None O
total None None O
cholesterol None None O
[ None None O
21.2 None None O
] None None O
mg/dL None None O
, None None O
and None None O
low-density None None O
lipoprotein None None O
cholesterol None None O
[ None None O
44.6 None None O
] None None O
mg/dL None None O
) None None O
, None None O
but None None O
not None None O
with None None O
quetiapine None None O
or None None O
in None None O
healthy None None O
control None None O
participants None None O
. None None O

However None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
developmental None None O
trajectory None None O
of None None O
irritability None None O
or None None O
how None None O
child None None O
irritability None None O
interacts None None O
with None None O
maternal None None O
depression None None I-DISEASE
. None None O

Moreover None None O
, None None O
paternal None None O
depression None None I-DISEASE
and None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
, None None O
as None None O
well None None O
as None None O
maternal None None O
drug None None O
and None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
, None None O
were None None O
also None None O
risk None None O
factors None None O
for None None O
membership None None O
in None None O
the None None O
more None None O
severe None None O
irritability None None O
classes None None O
. None None O

Conversely None None O
, None None O
mother None None O
depression None None I-DISEASE
at None None O
child None None O
ages None None O
1 None None O
and None None O
3 None None O
years None None O
is None None O
associated None None O
with None None O
increased None None O
child None None O
irritability None None O
at None None O
3 None None O
and None None O
5 None None O
. None None O

Maternal None None O
depression None None I-DISEASE
and None None O
child None None O
irritability None None O
influence None None O
each None None O
other None None O
bidirectionally None None O
, None None O
particularly None None O
early None None O
in None None O
development None None O
. None None O

As None None O
compared None None O
to None None O
the None None O
utility None None O
of None None O
early None None O
emerging None None O
social None None O
communicative None None O
risk None None O
markers None None O
for None None O
predicting None None O
a None None O
later None None O
diagnosis None None O
of None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
( None None O
ASD None None O
) None None O
, None None O
less None None O
is None None O
known None None O
about None None O
the None None O
relevance None None O
of None None O
early None None O
patterns None None O
of None None O
restricted None None O
and None None O
repetitive None None O
behaviors None None O
. None None O

Observational None None O
coding None None O
of None None O
repetitive None None O
object None None O
manipulation None None O
and None None O
stereotyped None None O
motor None None O
behaviors None None O
in None None O
digital None None O
recordings None None O
of None None O
the None None O
Communication None None O
and None None O
Symbolic None None O
Behavior None None O
Scales None None O
was None None O
conducted None None O
using None None O
the None None O
Repetitive None None O
and None None O
Stereotyped None None O
Movement None None I-FUNC
Scales None None O
for None None O
3 None None O
groups None None O
of None None O
12-month-olds None None O
: None None O
low-risk None None O
infants None None O
( None None O
LR None None O
, None None O
n None None O
= None None O
53 None None O
) None None O
; None None O
high-familial-risk None None O
infants None None O
who None None O
did None None O
not None None O
meet None None O
diagnostic None None O
criteria None None O
for None None O
ASD None None O
at None None O
24 None None O
months None None O
( None None O
HR-negative None None O
, None None O
n None None O
= None None O
75 None None O
) None None O
; None None O
and None None O
high-familial-risk None None O
infants None None O
who None None O
met None None O
diagnostic None None O
criteria None None O
for None None O
ASD None None O
at None None O
24 None None O
months None None O
( None None O
HR-ASD None None O
, None None O
n None None O
= None None O
30 None None O
) None None O
. None None O

To None None O
address None None O
this None None O
gap None None O
, None None O
we None None O
scanned None None O
36 None None O
patients None None O
with None None O
pediatric None None O
OCD None None O
compared None None O
to None None O
27 None None O
healthy None None O
controls None None O
, None None O
aged None None O
8 None None O
to None None O
19 None None O
years None None O
, None None O
with None None O
diffusion None None O
tensor None None O
imaging None None O
( None None O
DTI None None O
) None None O
to None None O
measure None None O
fractional None None O
anisotropy None None O
( None None O
FA None None O
) None None O
, None None O
an None None O
index None None O
of None None O
white None None I-REGION
matter None None I-REGION
coherence None None O
. None None O

Patients None None O
with None None O
OCD None None O
showed None None O
more None None O
pronounced None None O
age-related None None O
increases None None O
in None None O
FA None None O
than None None O
controls None None O
in None None O
regions None None O
of None None O
interest None None O
, None None O
as None None O
well None None O
as None None O
several None None O
other None None O
white None None I-REGION
matter None None I-REGION
tracts None None O
. None None O

Our None None O
findings None None O
support None None O
theories None None O
of None None O
atypical None None O
FSTC None None O
maturation None None O
in None None O
pediatric None None O
OCD None None O
by None None O
providing None None O
the None None O
first None None O
evidence None None O
for None None O
altered None None O
trajectories None None O
of None None O
white None None I-REGION
matter None None I-REGION
development None None O
in None None O
anterior None None O
corpus None None I-REGION
callosum None None I-REGION
, None None O
anterior None None O
cingulum None None I-REGION
bundle None None I-REGION
, None None O
and None None O
ALIC None None O
in None None O
young None None O
patients None None O
. None None O

Given None None O
the None None O
ageing None None O
population None None O
and None None O
complex None None O
care None None O
needs None None O
of None None O
aged None None O
care None None O
facility None None O
residents None None O
, None None O
exacerbated None None O
by None None O
the None None O
high None None O
prevalence None None O
of None None O
dementia None None I-DISEASE
, None None O
the None None O
healthcare None None O
workforce None None O
's None None O
ability None None O
to None None O
meet None None O
older None None O
people None None O
's None None O
care None None O
needs None None O
is None None O
paramount None None O
. None None O

The None None O
intervention None None O
facility None None O
placement None None O
programme None None O
led None None O
to None None O
mentors None None O
and None None O
students None None O
being None None O
well None None O
prepared None None O
for None None O
the None None O
placement None None O
and None None O
to None None O
students None None O
experiencing None None O
enhanced None None O
teaching None None O
and None None O
learning None None I-FUNC
derived None None O
from None None O
high None None O
levels None None O
of None None O
mentor None None O
support None None O
and None None O
increased None None O
autonomy None None O
. None None O

They None None O
were None None O
stable None None O
in None None O
labelling None None O
milieu None None O
, None None O
in None None O
human None None O
plasma None None O
and None None O
in None None O
the None None O
presence None None O
of None None O
histidine None None I-TRANS
. None None O

Glucose-6-phosphate None None O
dehydrogenase None None I-PROTEIN
( None None O
G6PD None None O
) None None O
deficiency None None O
is None None O
highly None None O
prevalent None None O
in None None O
southern None None O
China None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Although None None O
rarely None None O
seen None None O
, None None O
bilateral None None O
anteromedial None None O
infarction None None O
of None None O
the None None O
pons None None I-REGION
demonstrates None None O
the None None O
characteristic None None O
`` None None O
heart None None O
appearance None None O
'' None None O
sign None None O
on None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
. None None O

This None None O
typical None None O
pattern None None O
can None None O
be None None O
attributed None None O
to None None O
atherosclerotic None None O
or None None O
thrombotic None None O
involvement None None O
of None None O
bilateral None None O
paramedian None None O
and None None O
short None None O
circumferential None None O
pontine None None O
arteries None None O
supplying None None O
the None None O
anteromedial None None O
pons None None I-REGION
. None None O

Recognizing None None O
the None None O
`` None None O
heart None None O
appearance None None O
'' None None O
sign None None O
in None None O
a None None O
stroke-like None None O
episode None None O
may None None O
be None None O
helpful None None O
in None None O
differentiating None None O
bilateral None None O
anteromedial None None O
pontine None None O
infarction None None O
from None None O
other None None O
pathologic None None O
processes None None O
involving None None O
the None None O
pons None None I-REGION
. None None O

The None None O
primary None None O
outcome None None O
measure None None O
was None None O
the None None O
Stroop None None O
Test None None O
, None None O
a None None O
cognitive None None O
test None None O
of None None O
selective None None I-FUNC
attention None None I-FUNC
and None None O
conflict None None O
resolution None None O
. None None O

Mood None None I-FUNC
, None None O
functional None None O
capacity None None O
, None None O
and None None O
general None None O
balance None None O
and None None O
mobility None None O
were None None O
additional None None O
secondary None None O
outcome None None O
measures None None O
. None None O

Improved None None O
selective None None I-FUNC
attention None None I-FUNC
and None None O
conflict None None O
resolution None None O
was None None O
significantly None None O
associated None None O
with None None O
functional None None O
capacity None None O
at None None O
6 None None O
months None None O
( None None O
r None None O
= None None O
.39 None None O
; None None O
P None None O
= None None O
.04 None None O
) None None O
. None None O

Thus None None O
, None None O
clinicians None None O
should None None O
consider None None O
prescribing None None O
exercise None None O
and None None O
recreational None None O
activities None None O
in None None O
the None None O
cognitive None None O
rehabilitation None None O
of None None O
chronic None None O
stroke None None I-DISEASE
survivors None None O
. None None O

Subjects None None O
comprised None None O
58 None None O
patients None None O
with None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
who None None O
underwent None None O
both None None O
3-D None None O
ultrasound None None O
imaging None None O
and None None O
MRA None None O
. None None O

Real-time None None O
3-D None None O
B None None O
mode None None O
images None None O
demonstrated None None O
plaque None None O
and None None O
vessel None None O
movement None None I-FUNC
. None None O

Ultrasound None None O
imaging None None O
was None None O
necessary None None O
to None None O
detect None None O
mild None None O
stenosis None None O
, None None O
ulcerated None None O
plaque None None O
, None None O
or None None O
mobile None None O
plaque None None O
in None None O
comparison None None O
with None None O
MRA None None O
, None None O
and None None O
3-D None None O
ultrasound None None O
imaging None None O
was None None O
useful None None O
to None None O
recognize None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
and None None O
flow None None O
pattern None None O
as None None O
a None None O
total None None O
structure None None O
by None None O
static None None O
and None None O
real-time None None O
3-D None None O
demonstration None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Stroke-bypass None None O
transportation None None O
to None None O
the None None O
stroke None None I-DISEASE
center None None O
by None None O
paramedics None None O
is None None O
important None None O
to None None O
maximize None None O
the None None O
efficiency None None O
of None None O
intravenous None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
( None None O
iv-tPA None None O
) None None O
therapy None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Ischemic None None O
stroke None None I-DISEASE
is None None O
one None None O
of None None O
the None None O
leading None None O
causes None None O
of None None O
morbidity None None O
and None None O
mortality None None O
worldwide None None O
and None None O
characterized None None O
by None None O
defective None None O
angiogenesis None None O
. None None O

However None None O
, None None O
delivery None None O
of None None O
peptides None None I-TRANS
into None None O
the None None O
brain None None O
parenchyma None None O
has None None O
been None None O
hampered None None O
by None None O
the None None O
presence None None O
of None None O
the None None O
blood-brain None None O
barrier None None O
( None None O
BBB None None O
) None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Addressing None None O
the None None O
needs None None O
to None None O
achieve None None O
the None None O
highest None None O
standards None None O
at None None O
multidisciplinary None None O
team None None O
meetings None None O
at None None O
the None None O
Stroke None None I-DISEASE
Unit None None O
of None None O
Broomfield None None O
Hospital None None O
, None None O
an None None O
electronic None None O
version None None O
is None None O
applied None None O
instead None None O
of None None O
the None None O
traditional None None O
paper None None O
model None None O
. None None O

This None None O
also None None O
enables None None O
the None None O
stroke None None I-DISEASE
team None None O
to None None O
retrieve None None O
old None None O
information None None O
anywhere None None O
in None None O
the None None O
hospital None None O
, None None O
electronically None None O
, None None O
from None None O
previous None None O
documentations None None O
to None None O
compare None None O
progress None None O
of None None O
rehabilitation None None O
. None None O

This None None O
initiative None None O
commenced None None O
in None None O
late None None O
April None None O
2013 None None O
and None None O
the None None O
first None None O
clinical None None O
outcome None None O
assessments None None O
performed None None O
at None None O
the None None O
beginning None None O
of None None O
September None None O
2013 None None O
, None None O
enabling None None O
the None None O
stroke None None I-DISEASE
team None None O
to None None O
assess None None O
rehabilitation None None O
activities None None O
and None None O
achievements None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Stroke None None I-DISEASE
is None None O
a None None O
global None None O
health None None O
problem None None O
. None None O

Obtaining None None O
country-specific None None O
information None None O
could None None O
enable None None O
us None None O
to None None O
develop None None O
targeted None None O
programs None None O
to None None O
improve None None O
stroke None None I-DISEASE
care None None O
. None None O

There None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
income None None O
classification None None O
and None None O
access None None O
and None None O
affordability None None O
of None None O
head None None O
computed None None O
tomography None None O
scan None None O
( None None O
ρ None None O
= None None O
.215 None None O
, None None O
P None None O
= None None O
.002 None None O
) None None O
, None None O
transthoracic None None O
echocardiogram None None O
( None None O
ρ None None O
= None None O
.181 None None O
, None None O
P None None O
= None None O
.012 None None O
) None None O
, None None O
extracranial None None O
carotid None None O
Doppler None None O
ultrasound None None O
( None None O
ρ None None O
= None None O
.312 None None O
, None None O
P None None O
≤ None None O
.000 None None O
) None None O
, None None O
cardiac None None O
telemetry None None O
( None None O
ρ None None O
= None None O
.353 None None O
, None None O
P None None O
≤ None None O
.000 None None O
) None None O
, None None O
and None None O
stroke None None I-DISEASE
treatments None None O
such None None O
as None None O
intravenous None None O
thrombolysis None None O
( None None O
ρ None None O
= None None O
.276 None None O
, None None O
P None None O
≤ None None O
.001 None None O
) None None O
, None None O
and None None O
carotid None None O
endarterectomy None None O
( None None O
ρ None None O
= None None O
.214 None None O
, None None O
P None None O
≤ None None O
.004 None None O
) None None O
; None None O
stroke None None I-DISEASE
quality None None O
measures None None O
such None None O
as None None O
venous None None O
thromboembolism None None O
prophylaxis None None O
during None None O
hospital None None O
stay None None O
( None None O
ρ None None O
= None None O
.163 None None O
, None None O
P None None O
≤ None None O
.022 None None O
) None None O
, None None O
discharge None None O
from None None O
hospital None None O
on None None O
antithrombotic None None O
therapy None None O
( None None O
ρ None None O
= None None O
.266 None None O
, None None O
P None None O
≤ None None O
.000 None None O
) None None O
, None None O
consideration None None O
for None None O
acute None None O
thrombolytic None None O
therapy None None O
( None None O
ρ None None O
= None None O
.358 None None O
, None None O
P None None O
≤ None None O
.000 None None O
) None None O
, None None O
and None None O
antithrombotic None None O
therapy None None O
prescribed None None O
by None None O
end None None O
of None None O
hospital None None O
day None None O
2 None None O
( None None O
ρ None None O
= None None O
.334 None None O
, None None O
P None None O
≤ None None O
.000 None None O
) None None O
. None None O

Our None None O
study None None O
shows None None O
that None None O
it None None O
is None None O
possible None None O
to None None O
get None None O
an None None O
overview None None O
of None None O
stroke None None I-DISEASE
treatment None None O
measures None None O
in None None O
different None None O
countries None None O
by None None O
conducting None None O
an None None O
internet-based None None O
survey None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Few None None O
studies None None O
have None None O
examined None None O
the None None O
association None None O
of None None O
an None None O
absent None None O
A1 None None O
segment None None O
and None None O
ischemic None None O
stroke None None I-DISEASE
outcome None None O
. None None O

We None None O
compared None None O
patients None None O
with None None O
absent None None O
A1 None None O
to None None O
patients None None O
with None None O
bilateral None None O
A1 None None O
segments None None O
in None None O
terms None None O
of None None O
demographics None None O
, None None O
stroke None None I-DISEASE
severity None None O
( None None O
as None None O
measured None None O
by None None O
National None None O
Institute None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
[ None None O
NIHSS None None O
] None None O
) None None O
, None None O
vascular None None O
distribution None None O
, None None O
and None None O
in-hospital None None O
mortality None None O
using None None O
the None None O
chi-square None None O
test None None O
and None None O
logistic None None O
regression None None O
. None None O

The None None O
median None None O
volume None None O
of None None O
the None None O
infracted None None O
tissue None None O
was None None O
similar None None O
across None None O
the None None O
groups None None O
even None None O
when None None O
it None None O
was None None O
stratified None None O
according None None O
to None None O
the None None O
Treatment None None O
of None None O
Acute None None O
Stroke None None I-DISEASE
Trial None None O
classification None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

No None None O
prior None None O
infarcts None None O
were None None O
noted None None O
in None None O
the None None O
thalamus None None I-REGION
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Clip None None O
and None None O
Coil None None O
were None None O
performed None None O
in None None O
141 None None O
and None None O
80 None None O
patients None None O
, None None O
respectively None None O
; None None O
Clip None None O
for None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
AN None None O
and None None O
Coil None None O
for None None O
paraclinoid None None O
or None None O
basilar None None O
apex None None O
AN None None O
. None None O

This None None O
study None None O
is None None O
aimed None None O
at None None O
establishing None None O
whether None None O
the None None O
telephone None None O
administration None None O
of None None O
the None None O
PROject None None O
of None None O
Stroke None None I-DISEASE
unIt None None O
ITaly None None O
( None None O
PROSIT None None O
) None None O
audit None None O
questionnaire None None O
is None None O
reliable None None O
compared None None O
with None None O
direct None None O
face-to-face None None O
interview None None O
. None None O

We None None O
found None None O
a None None O
perfect None None O
agreement None None O
for None None O
stroke None None I-DISEASE
units None None O
identification None None O
between None None O
the None None O
2 None None O
different None None O
audit None None O
modalities None None O
( None None O
K None None O
= None None O
1.00 None None O
; None None O
standard None None O
error None None O
[ None None O
SE None None O
] None None O
, None None O
1.525 None None O
) None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Poststroke None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
have None None O
prospectively None None O
predicted None None O
impairment None None O
of None None O
health-related None None O
quality None None O
of None None O
life None None O
( None None O
HRQOL None None O
) None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
impact None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
1 None None O
and None None O
3 None None O
months None None O
after None None O
stroke None None I-DISEASE
on None None O
the None None O
3-month None None O
poststroke None None O
HRQOL None None O
and None None O
to None None O
investigate None None O
the None None O
influence None None O
of None None O
the None None O
HRQOL None None O
measured None None O
at None None O
1 None None O
month None None O
after None None O
stroke None None I-DISEASE
on None None O
these None None O
relationships None None O
. None None O

A None None O
psychiatrist None None O
assessed None None O
the None None O
presence None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
using None None O
the None None O
31-item None None O
version None None O
of None None O
the None None O
Hamilton None None O
Rating None None O
Scale None None O
for None None O
Depression None None I-DISEASE
and None None O
the None None O
HRQOL None None O
was None None O
assessed None None O
with None None O
the None None O
36-item None None O
Short-Form None None O
Health None None O
Survey None None O
from None None O
the None None O
Medical None None O
Outcomes None None O
Study None None O
. None None O

We None None O
found None None O
an None None O
association None None O
between None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
1 None None O
month None None O
and None None O
HRQOL None None O
at None None O
3 None None O
months None None O
after None None O
the None None O
stroke None None I-DISEASE
; None None O
however None None O
, None None O
this None None O
association None None O
was None None O
not None None O
significant None None O
when None None O
adjusting None None O
for None None O
the None None O
1 None None O
month None None O
poststroke None None O
HRQOL None None O
. None None O

Current None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
at None None O
3 None None O
months None None O
are None None O
important None None O
for None None O
HRQOL None None O
at None None O
3 None None O
months None None O
after None None O
stroke None None I-DISEASE
; None None O
however None None O
, None None O
regarding None None O
the None None O
prospective None None O
prediction None None O
, None None O
HRQOL None None O
at None None O
1 None None O
month None None O
is None None O
the None None O
most None None O
relevant None None O
factor None None O
. None None O

Between None None O
1 None None O
January None None O
, None None O
2004 None None O
, None None O
and None None O
31 None None O
December None None O
, None None O
2010 None None O
, None None O
415 None None O
patients None None O
were None None O
treated None None O
with None None O
recombinant None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
at None None O
the None None O
Department None None O
of None None O
Neurology None None O
, None None O
University None None O
of None None O
Debrecen None None O
. None None O

A None None O
more None None O
efficient None None O
health None None O
care None None O
program None None O
should None None O
be None None O
implemented None None O
after None None O
stroke None None I-DISEASE
to None None O
maintain None None O
the None None O
favorable None None O
effect None None O
of None None O
thrombolysis None None O
in None None O
the None None O
long None None O
term None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Additionally None None O
, None None O
the None None O
neurologic None None O
deficits None None O
, None None O
brain None None I-DISEASE
edemas None None I-DISEASE
, None None O
and None None O
cell None None O
death None None O
that None None O
followed None None O
ICH None None O
were None None O
quantitatively None None O
analyzed None None O
. None None O

Thus None None O
, None None O
the None None O
present None None O
study None None O
demonstrates None None O
that None None O
edaravone None None O
has None None O
scavenging None None O
properties None None O
that None None O
attenuate None None O
neurologic None None O
behavioral None None O
deficits None None O
and None None O
brain None None I-DISEASE
edema None None I-DISEASE
in None None O
the None None O
early None None O
period None None O
of None None O
ICH None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Patients None None O
with None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
or None None O
transient None None O
ischemic None None O
attack None None O
were None None O
included None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

We None None O
aimed None None O
to None None O
test None None O
the None None O
outcome-predictive None None O
power None None O
of None None O
routine None None O
fasting None None O
glucose None None O
( None None O
FG None None O
) None None O
obtained None None O
at None None O
second None None O
day None None O
after None None O
onset None None O
in None None O
intravenous None None O
thrombolysis None None O
( None None O
IVT None None O
) None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
AIS None None O
) None None O
patients None None O
. None None O

There None None O
is None None O
a None None O
paucity None None O
of None None O
data None None O
from None None O
South None None O
Asia None None O
where None None O
stroke None None I-DISEASE
is None None O
highly None None O
prevalent None None O
. None None O

Methylenetetrahydrofolate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
MTHFR None None O
) None None O
is None None O
an None None O
important None None O
enzyme None None O
, None None O
which None None O
regulates None None O
homocysteine None None O
metabolism None None O
, None None O
and None None O
some None None O
polymorphisms None None O
of None None O
gene None None O
encoding None None I-FUNC
this None None O
enzyme None None O
are None None O
associated None None O
with None None O
a None None O
decreased None None O
activity None None O
of None None O
the None None O
enzyme None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Cerebral None None O
microbleeds None None O
( None None O
CMBs None None O
) None None O
are None None O
small None None O
dot-like None None O
lesions None None O
appearing None None O
as None None O
hyposignals None None O
on None None O
gradient None None O
echo None None O
( None None O
GRE None None O
) None None O
T2* None None O
magnetic None None O
resonance None None O
( None None O
MR None None O
) None None O
sequences None None O
, None None O
whereas None None O
the None None O
leukoaraiosis None None O
( None None O
LA None None O
) None None O
indicates None None O
the None None O
presence None None O
of None None O
patchy None None O
areas None None O
of None None O
hypersignal None None O
on None None O
fluid-attenuated None None O
inversion None None O
recovery None None O
( None None O
FLAIR None None O
) None None O
MR None None O
sequences None None O
in None None O
the None None O
periventricular None None O
white None None I-REGION
matter None None I-REGION
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Atahualpa None None O
residents None None O
60 None None O
years None None O
of None None O
age None None O
or None None O
more None None O
were None None O
identified None None O
during None None O
a None None O
door-to-door None None O
survey None None O
and None None O
invited None None O
to None None O
undergo None None O
magnetic None None O
resonance None None O
imaging None None O
for None None O
identification None None O
of None None O
SVD None None O
markers None None O
, None None O
including None None O
white None None I-REGION
matter None None I-REGION
hyperintensities None None O
( None None O
WMHs None None O
) None None O
, None None O
strokes None None I-DISEASE
, None None O
and None None O
deep None None O
microbleeds None None O
. None None O

Of None None O
these None None O
, None None O
172 None None O
patients None None O
( None None O
67 None None O
% None None O
) None None O
had None None O
WMH None None O
, None None O
40 None None O
patients None None O
( None None O
16 None None O
% None None O
) None None O
had None None O
SVD-related None None O
strokes None None I-DISEASE
, None None O
and None None O
23 None None O
patients None None O
( None None O
9 None None O
% None None O
) None None O
had None None O
deep None None O
microbleeds None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

The None None O
spinal None None O
cord None None O
tissue None None O
samples None None O
were None None O
harvested None None O
to None None O
analyze None None O
tissue None None O
concentrations None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
, None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
activity None None O
, None None O
xanthine None None I-PROTEIN
oxidase None None I-PROTEIN
activity None None O
, None None O
total None None O
antioxidant None None O
capacity None None O
, None None O
and None None O
total None None O
oxidant None None O
status None None O
and None None O
to None None O
perform None None O
histopathological None None O
examination None None O
. None None O

A None None O
total None None O
of None None O
185 None None O
cases None None O
( None None O
130 None None O
ischemic None None O
stroke None None I-DISEASE
) None None O
were None None O
analyzed None None O
. None None O

Identification None None O
of None None O
these None None O
higher None None O
risk None None O
stroke None None I-DISEASE
and None None O
TIA None None O
cases None None O
for None None O
more None None O
intensive None None O
cardiac None None O
monitoring None None O
may None None O
improve None None O
stroke None None I-DISEASE
secondary None None O
prevention None None O
practices None None O
. None None O

Data None None O
from None None O
the None None O
Australian None None O
Longitudinal None None O
Study None None O
on None None O
Women None None O
's None None O
Health None None O
were None None O
used None None O
to None None O
compare None None O
12-year None None O
survival None None O
rates None None O
in None None O
older None None O
women None None O
with None None O
prevalent None None O
stroke None None I-DISEASE
, None None O
incident None None O
stroke None None I-DISEASE
, None None O
and None None O
no None None O
stroke None None I-DISEASE
. None None O

The None None O
`` None None O
no None None O
stroke None None I-DISEASE
'' None None O
group None None O
was None None O
used None None O
as None None O
the None None O
reference None None O
category None None O
in None None O
all None None O
statistical None None O
models None None O
. None None O

At None None O
survey None None O
2 None None O
in None None O
1999 None None O
, None None O
a None None O
further None None O
3 None None O
% None None O
reported None None O
having None None O
a None None O
stroke None None I-DISEASE
between None None O
1996 None None O
and None None O
1999 None None O
( None None O
incident None None O
stroke None None I-DISEASE
) None None O
. None None O

Age-adjusted None None O
hazards None None O
ratios None None O
( None None O
HRs None None O
) None None O
were None None O
: None None O
1.64 None None O
( None None O
1.43-1.89 None None O
) None None O
for None None O
the None None O
`` None None O
prevalent None None O
stroke None None I-DISEASE
'' None None O
group None None O
and None None O
2.29 None None O
( None None O
1.97-2.66 None None O
) None None O
for None None O
the None None O
`` None None O
incident None None O
stroke None None I-DISEASE
'' None None O
group None None O
. None None O

Adjusting None None O
for None None O
demographic None None O
and None None O
lifestyle None None O
factors None None O
did None None O
not None None O
make None None O
any None None O
further None None O
difference None None O
to None None O
the None None O
relationship None None O
between None None O
stroke None None I-DISEASE
and None None O
survival None None O
. None None O

This None None O
study None None O
highlights None None O
the None None O
long-term None None O
impacts None None O
of None None O
stroke None None I-DISEASE
on None None O
life None None O
expectancy None None O
and None None O
the None None O
importance None None O
of None None O
comorbidities None None O
and None None O
other None None O
lifestyle None None O
factors None None O
in None None O
affecting None None O
poststroke None None O
survival None None O
. None None O

We None None O
evaluated None None O
the None None O
number None None O
and None None O
location None None O
of None None O
MBs None None O
, None None O
severity None None O
of None None O
lacune None None O
and None None O
leukoaraiosis None None O
( None None O
LA None None O
) None None O
, None None O
and None None O
etiologic None None O
subtype None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Among None None O
696 None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
, None None O
162 None None O
patients None None O
( None None O
23.3 None None O
% None None O
) None None O
had None None O
MBs None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Although None None O
the None None O
first None None O
step None None O
toward None None O
effective None None O
primary None None O
prevention None None O
of None None O
stroke None None I-DISEASE
is None None O
awareness None None O
of None None O
its None None O
risk None None O
factors None None O
, None None O
there None None O
is None None O
limited None None O
information None None O
on None None O
knowledge None None O
of None None O
these None None O
risk None None O
factors None None O
among None None O
Nigerians None None O
at None None O
increased None None O
risk None None O
. None None O

Using None None O
an None None O
interviewer-administered None None O
questionnaire None None O
in None None O
a None None O
cross-sectional None None O
design None None O
, None None O
high-risk None None O
patients None None O
( None None O
defined None None O
as None None O
those None None O
with None None O
a None None O
diagnosis None None O
of None None O
hypertension None None O
and/or None None O
diabetes None None O
) None None O
attending None None O
the None None O
specialist None None O
medical None None O
outpatient None None O
clinics None None O
of None None O
the None None O
University None None O
of None None O
Ilorin None None O
Teaching None None O
Hospital None None O
were None None O
requested None None O
to None None O
mention None None O
all None None O
the None None O
stroke None None I-DISEASE
risk None None O
factors None None O
they None None O
knew None None O
. None None O

Factors None None O
found None None O
to None None O
be None None O
significantly None None O
associated None None O
with None None O
ability None None O
to None None O
correctly None None O
mention None None O
at None None O
least None None O
1 None None O
stroke None None I-DISEASE
risk None None O
factor None None O
were None None O
younger None None O
age None None O
( None None O
& None None O
lt None None O
; None None O
55 None None O
years None None O
) None None O
, None None O
more None None O
than None None O
12 None None O
years None None O
of None None O
formal None None O
education None None O
, None None O
family None None O
history None None O
of None None O
stroke None None I-DISEASE
, None None O
urban None None O
residence None None O
, None None O
and None None O
previous None None O
health None None O
education None None O
on None None O
stroke None None I-DISEASE
. None None O

In None None O
this None None O
report None None O
, None None O
the None None O
clinical None None O
features None None O
of None None O
patients None None O
with None None O
epilepsy None None O
were None None O
evaluated None None O
for None None O
assessing None None O
the None None O
predictive None None O
factors None None O
of None None O
epilepsy None None O
in None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
. None None O

Analysis None None O
of None None O
patient None None O
background None None O
characteristics None None O
revealed None None O
a None None O
significantly None None O
higher None None O
incidence None None O
of None None O
epilepsy None None O
in None None O
patients None None O
with None None O
high None None O
modified None None O
Rankin None None O
Scale None None O
( None None O
mRS None None O
) None None O
scores None None O
, None None O
high None None O
cerebrovascular None None O
attack None None O
scores None None O
, None None O
onset None None O
age None None O
of None None O
3 None None O
years None None O
or None None O
less None None O
, None None O
early None None O
seizures None None O
, None None O
cortical None None O
involvement None None O
, None None O
stroke None None I-DISEASE
subtype None None O
, None None O
and None None O
diffuse None None O
brain None None O
atrophy None None O
. None None O

For None None O
prediction None None O
of None None O
epilepsy None None O
in None None O
moyamoya None None I-DISEASE
disease None None I-DISEASE
, None None O
MDERS None None O
is None None O
a None None O
simple None None O
and None None O
convenient None None O
assessment None None O
scale None None O
. None None O

Concomitant None None O
treatment None None O
with None None O
an None None O
angiotension None None O
converting None None O
enzyme None None O
inhibitor None None O
( None None O
ACEi None None O
) None None O
and None None O
localization None None O
of None None O
infarction None None O
in None None O
the None None O
territory None None O
of None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
seem None None O
to None None O
be None None O
associated None None O
with None None O
a None None O
higher None None O
risk None None O
of None None O
this None None O
complication None None O
. None None O

The None None O
National None None O
Institutes None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
score None None O
at None None O
admission None None O
ranged None None O
from None None O
6 None None O
to None None O
24 None None O
( None None O
median None None O
12.5 None None O
) None None O
. None None O

Orolingual None None O
angioedema None None O
is None None O
a None None O
potential None None O
complication None None O
of None None O
which None None O
treating None None O
physicians None None O
in None None O
stroke None None I-DISEASE
units None None O
need None None O
to None None O
be None None O
aware None None O
, None None O
even None None O
in None None O
those None None O
cases None None O
without None None O
history None None O
of None None O
ACEi None None O
treatment None None O
and None None O
without None None O
infarction None None O
in None None O
the None None O
territory None None O
of None None O
the None None O
middle None None I-DISEASE
cerebral None None I-DISEASE
artery None None I-DISEASE
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Patients None None O
with None None O
symptoms None None O
that None None O
impersonate None None O
a None None O
stroke None None I-DISEASE
but None None O
are None None O
later None None O
found None None O
to None None O
have None None O
an None None O
alternate None None O
diagnosis None None O
are None None O
termed None None O
stroke None None I-DISEASE
mimics None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
is None None O
to None None O
describe None None O
the None None O
characteristics None None O
, None None O
safety None None O
, None None O
and None None O
outcomes None None O
of None None O
stroke None None I-DISEASE
mimic None None O
patients None None O
treated None None O
with None None O
t-PA None None O
within None None O
4.5 None None O
hours None None O
. None None O

Stroke None None I-DISEASE
mimics None None O
were None None O
determined None None O
by None None O
review None None O
of None None O
clinical None None O
and None None O
imaging None None O
findings None None O
. None None O

We None None O
identified None None O
38 None None O
stroke None None I-DISEASE
mimic None None O
( None None O
12 None None O
% None None O
) None None O
and None None O
285 None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
88 None None O
% None None O
) None None O
t-PA-treated None None O
patients None None O
. None None O

There None None O
were None None O
no None None O
differences None None O
in None None O
race None None O
, None None O
baseline None None O
stroke None None I-DISEASE
scale None None O
, None None O
or None None O
onset None None O
to None None O
treatment None None O
time None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

The None None O
use None None O
of None None O
stent None None O
retrievers None None O
for None None O
mechanical None None O
thrombectomy None None O
in None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
may None None O
induce None None O
significant None None O
vasospasm None None O
, None None O
which None None O
at None None O
the None None O
early None None O
phases None None O
of None None O
reperfusion None None O
may None None O
be None None O
crucial None None O
for None None O
rethrombosis None None O
of None None O
the None None O
recanalized None None O
vessel None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Over None None O
the None None O
last None None O
4 None None O
decades None None O
, None None O
rates None None O
of None None O
stroke None None I-DISEASE
occurrence None None O
in None None O
low- None None O
and None None O
middle-income None None O
countries None None O
( None None O
LMIC None None O
) None None O
have None None O
roughly None None O
doubled None None O
, None None O
whereas None None O
they None None O
have None None O
substantively None None O
decreased None None O
in None None O
high-income None None O
countries None None O
. None None O

This None None O
article None None O
proposes None None O
a None None O
theory-based None None O
integrated None None O
blood None None O
pressure None None O
( None None O
BP None None O
) None None O
self-management None None O
intervention None None O
called None None O
Phone-based None None O
Intervention None None O
under None None O
Nurse None None O
Guidance None None O
after None None O
Stroke None None I-DISEASE
( None None O
PINGS None None O
) None None O
that None None O
could None None O
be None None O
tested None None O
among None None O
hospitalized None None O
stroke None None I-DISEASE
patients None None O
with None None O
poorly None None O
controlled None None O
hypertension None None O
encountered None None O
in None None O
SSA None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Warfarin None None O
, None None O
a None None O
vitamin None None O
K None None O
epoxide None None O
reductase None None O
inhibitor None None O
, None None O
is None None O
the None None O
oral None None O
anticoagulant None None O
most None None O
commonly None None O
used None None O
to None None O
reduce None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
in None None O
patients None None O
with None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
. None None O

The None None O
emergence None None O
of None None O
newer None None O
classes None None O
of None None O
oral None None O
anticoagulants None None O
will None None O
offer None None O
therapeutic None None O
alternatives None None O
to None None O
reduce None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
in None None O
patients None None O
with None None O
AF None None O
. None None O

Copyright None None O
© None None O
2014 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Sixty-four None None O
patients None None O
were None None O
taking None None O
aspirin None None O
before None None O
the None None O
stroke None None I-DISEASE
. None None O

Collagen-induced None None O
thromboxane None None O
A2 None None O
( None None O
TXA2 None None O
) None None O
synthesis None None O
, None None O
ADP None None O
( None None O
adenosine None None I-TRANS
diphosphate None None O
) None None O
-induced None None O
aggregation None None O
, None None O
and None None O
occlusion None None O
time None None O
( None None O
PF-100 None None O
) None None O
were None None O
measured None None O
. None None O

Mean None None O
age None None O
was None None O
69.7 None None O
± None None O
11.5 None None O
years None None O
, None None O
and None None O
baseline None None O
median None None O
National None None O
Institute None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
score None None O
was None None O
15 None None O
( None None O
range None None O
, None None O
8-24 None None O
) None None O
. None None O

Successful None None O
recanalization None None O
, None None O
as None None O
defined None None O
by None None O
a None None O
thrombolysis None None O
in None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
flow None None O
grade None None O
of None None O
2b None None O
or None None O
3 None None O
, None None O
was None None O
achieved None None O
in None None O
40 None None O
patients None None O
( None None O
81.6 None None O
% None None O
) None None O
. None None O

Copyright None None O
© None None O
2014 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

The None None O
Alberta None None O
Stroke None None I-DISEASE
Program None None O
Early None None O
Computed None None O
Tomography None None O
Score None None O
( None None O
ASPECTS None None O
) None None O
was None None O
determined None None O
on None None O
noncontrast None None O
CT None None O
and None None O
computed None None O
tomography None None O
angiography None None O
source None None O
images None None O
( None None O
CTA-SI None None O
) None None O
. None None O

Given None None O
the None None O
uncertainty None None O
whether None None O
LVO None None O
has None None O
the None None O
same None None O
significance None None O
in None None O
mild None None O
and None None O
severe None None O
stroke None None I-DISEASE
, None None O
we None None O
compared None None O
functional None None O
outcomes None None O
after None None O
intravenous None None O
thrombolysis None None O
, None None O
based None None O
on None None O
severity None None O
and None None O
LVO None None O
. None None O

LVO None None O
was None None O
associated None None O
with None None O
worse None None O
outcome None None O
in None None O
severe None None O
stroke None None I-DISEASE
( None None O
age-adjusted None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
of None None O
favorable None None O
outcome None None O
, None None O
.42 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
, None None O
.19-.93 None None O
; None None O
P None None O
= None None O
.033 None None O
) None None O
and None None O
mortality None None O
( None None O
age-adjusted None None O
OR None None O
, None None O
3.52 None None O
; None None O
95 None None O
% None None O
CI None None O
, None None O
1.08-11.48 None None O
; None None O
P None None O
= None None O
.037 None None O
) None None O
. None None O

LVO None None O
is None None O
associated None None O
with None None O
worse None None O
functional None None O
outcome None None O
and None None O
mortality None None O
in None None O
severe None None O
stroke None None I-DISEASE
after None None O
intravenous None None O
thrombolysis None None O
. None None O

Copyright None None O
© None None O
2014 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

We None None O
examined None None O
the None None O
benefit None None O
of None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
( None None O
tPA None None O
) None None O
, None None O
delivered None None O
as None None O
part None None O
of None None O
usual None None O
stroke None None I-DISEASE
management None None O
, None None O
on None None O
patient-reported None None O
outcomes None None O
and None None O
health None None O
care None None O
utilization None None O
. None None O

Data None None O
were None None O
collected None None O
from None None O
surveys None None O
6 None None O
months None None O
after None None O
stroke None None I-DISEASE
using None None O
standardized None None O
patient-reported None None O
outcome None None O
measures None None O
and None None O
questions None None O
about None None O
health None None O
care None None O
utilization None None O
. None None O

Patients None None O
were None None O
matched None None O
on None None O
stroke None None I-DISEASE
severity None None O
, None None O
age None None O
, None None O
race None None O
, None None O
and None None O
gender None None O
. None None O

Thus None None O
, None None O
use None None O
of None None O
tPA None None O
provides None None O
a None None O
large None None O
benefit None None O
to None None O
the None None O
daily None None O
lives None None O
of None None O
people None None O
with None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

We None None O
found None None O
no None None O
differences None None O
in None None O
the None None O
clinical None None O
presentation None None O
of None None O
stroke None None I-DISEASE
between None None O
the None None O
sexes None None O
, None None O
except None None O
that None None O
men None None O
were None None O
more None None O
likely None None O
to None None O
have None None O
postural None None O
instability None None O
and None None O
females None None O
were None None O
more None None O
likely None None O
to None None O
have None None O
dysphagia None None O
. None None O

Copyright None None O
© None None O
2014 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Atherosclerotic None None O
disease None None O
accounts None None O
for None None O
20 None None O
% None None O
-30 None None O
% None None O
of None None O
strokes None None I-DISEASE
in None None O
the None None O
general None None O
population None None O
. None None O

Herein None None O
, None None O
we None None O
describe None None O
a None None O
unique None None O
case None None O
of None None O
acute None None O
embolic None None O
stroke None None I-DISEASE
in None None O
a None None O
young None None O
adult None None O
patient None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
a None None O
large None None O
clot None None O
in None None O
the None None O
right None None O
common None None O
and None None O
internal None None O
carotid None None O
arteries None None O
, None None O
as None None O
a None None O
result None None O
of None None O
an None None O
extrinsic None None O
cause None None O
. None None O

Copyright None None O
© None None O
2014 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Secondary None None O
outcomes None None O
were None None O
motion-related None None O
pain None None O
( None None O
Visual None None O
Analogue None None O
Scale None None O
, None None O
VAS None None O
) None None O
and None None O
cervical None None O
range None None O
of None None O
motion None None O
( None None O
ROM None None O
, None None O
recorded None None O
by None None O
means None None O
of None None O
an None None O
ultrasonic None None O
3D None None O
movement None None I-FUNC
analysis None None O
system None None O
) None None O
. None None O

The None None O
combination None None O
of None None O
acupuncture None None O
and None None O
stretching None None O
could None None O
represent None None O
a None None O
suitable None None O
treatment None None O
option None None O
to None None O
improve None None O
cervical None None O
movement None None I-FUNC
behavior None None O
and None None O
reduce None None O
trigger None None O
point None None O
pain None None O
in None None O
the None None O
short-term None None O
. None None O

The None None O
changes None None O
on None None O
the None None O
fasting None None O
plasma None None O
glucose None None O
( None None O
FBG None None O
) None None O
, None None O
2-h None None O
postprandial None None O
blood None None O
glucose None None O
after None None O
a None None O
75 None None O
g None None O
oral None None O
glucose None None O
load None None O
( None None O
P2BG None None O
) None None O
, None None O
glycated None None O
hemoglobin None None O
( None None O
HbA1c None None O
) None None O
, None None O
blood None None O
urea None None O
nitrogen None None O
( None None O
BUN None None O
) None None O
, None None O
serum None None O
creatinine None None O
( None None O
SCr None None O
) None None O
, None None O
total None None O
cholesterol None None O
( None None O
TC None None O
) None None O
and None None O
aspartate None None I-TRANS
transaminase None None I-PROTEIN
( None None O
AST None None O
) None None O
were None None O
compared None None O
before None None O
and None None O
after None None O
the None None O
treatment None None O
. None None O

A None None O
few None None O
patients None None O
( None None O
n=7 None None O
) None None O
reduced None None O
the None None O
dose None None O
of None None O
the None None O
hypoglycemic None None O
agents None None O
in None None O
response None None O
to None None O
repeated None None O
hypoglycemia None None I-DISEASE
during None None O
the None None O
treatment None None O
. None None O

The None None O
levels None None O
of None None O
tumor None None O
necrosis None None O
factor-alpha None None O
( None None O
TNF-α None None O
) None None O
, None None O
interleukine-1β None None O
( None None O
IL-1β None None O
) None None O
, None None O
interleukine-10 None None O
( None None O
IL-10 None None O
) None None O
, None None O
matrix None None I-PROTEIN
metalloproteinase-1 None None O
( None None O
MMP-1 None None O
) None None O
and None None O
-13 None None O
( None None O
MMP-13 None None O
) None None O
were None None O
measured None None O
with None None O
human None None O
ELISA None None O
kits None None O
. None None O

St None None O
John None None O
's None None O
wort None None O
( None None O
SJW None None O
) None None O
is None None O
one None None O
of None None O
the None None O
most None None O
commonly None None O
used None None O
complementary None None O
medicines None None O
( None None O
CM None None O
) None None O
for None None O
the None None O
self-treatment None None O
of None None O
depression None None I-DISEASE
which None None O
can None None O
be None None O
accessed None None O
with None None O
or None None O
without None None O
health None None O
professional None None O
advice None None O
. None None O

Three None None O
themes None None O
emerged None None O
as None None O
to None None O
why None None O
participants None None O
used None None O
SJW None None O
- None None O
ease None None O
of None None O
access None None O
of None None O
SJW None None O
, None None O
perceptions None None I-FUNC
of None None O
effectiveness None None O
and None None O
safety None None O
of None None O
SJW None None O
enabling None None O
control None None O
over None None O
its None None O
use None None O
, None None O
and None None O
the None None O
perceived None None O
benefits None None O
of None None O
using None None O
a None None O
natural None None O
product None None O
. None None O

People None None O
use None None O
many None None O
self-care None None O
strategies None None O
to None None O
manage None None O
symptoms None None O
of None None O
depression None None I-DISEASE
, None None O
including None None O
more None None O
severe None None O
symptoms None None O
. None None O

showed None None O
potential None None O
effects None None O
towards None None O
the None None O
hyperlipidemia-related None None O
targets None None O
: None None O
HMG-CoA None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
HMGR None None O
) None None O
, None None O
squalene None None O
synthase None None O
( None None O
SQS None None O
) None None O
, None None O
oxidosqualene None None O
cyclase None None O
( None None O
OSC None None O
) None None O
, None None O
cholesteryl None None O
ester None None O
transfer None None O
protein None None O
( None None O
CETP None None O
) None None O
, None None O
liver None None O
X None None O
receptor None None I-PROTEIN
( None None O
LXR None None O
) None None O
, None None O
farnesoid None None O
X None None O
receptor None None I-PROTEIN
( None None O
FXR None None O
) None None O
and None None O
peroxisome None None O
proliferator-activated None None O
receptors None None I-PROTEIN
( None None O
PPARα None None O
and None None O
PPARγ None None O
) None None O
. None None O

The None None O
present None None O
study None None O
explored None None O
participants None None O
' None None O
perceptions None None I-FUNC
of None None O
the None None O
consent None None O
process None None O
in None None O
a None None O
sham None None O
controlled None None O
acupressure None None O
trial None None O
which None None O
did None None O
not None None O
explicitly None None O
indicate None None O
participants None None O
may None None O
receive None None O
a None None O
sham None None O
intervention None None O
. None None O

Target None None O
diseases None None O
and/or None None O
symptoms None None O
were None None O
dementia None None I-DISEASE
, None None O
severe None None O
mental None None O
illness None None O
such None None O
as None None O
schizophrenia None None I-DISEASE
, None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
and None None O
major None None O
depression None None I-DISEASE
, None None O
frail None None O
elderly None None O
in None None O
nursing None None O
home None None O
, None None O
and None None O
hemiplegic None None O
patients None None O
after None None O
stroke None None I-DISEASE
. None None O

Although None None O
there None None O
was None None O
insufficient None None O
evidence None None O
in None None O
the None None O
studies None None O
of None None O
HT None None O
due None None O
to None None O
poor None None O
methodological None None O
and None None O
reporting None None O
quality None None O
and None None O
heterogeneity None None O
, None None O
HT None None O
may None None O
be None None O
an None None O
effective None None O
treatment None None O
for None None O
mental None None O
and None None O
behavioral None None O
disorders None None O
such None None O
as None None O
dementia None None I-DISEASE
, None None O
schizophrenia None None I-DISEASE
, None None O
depression None None I-DISEASE
, None None O
and None None O
terminal-care None None O
for None None O
cancer None None O
. None None O

All None None O
transfusion None None O
services None None O
now None None O
operate None None O
in None None O
an None None O
environment None None O
of None None O
ever-increasing None None O
regulatory None None O
controls None None O
encompassing None None O
all None None O
aspects None None O
of None None O
blood None None O
collection None None O
, None None O
processing None None O
and None None O
storage None None I-FUNC
. None None O

In None None O
this None None O
article None None O
, None None O
we None None O
will None None O
discuss None None O
the None None O
current None None O
standards None None O
required None None O
for None None O
the None None O
manufacture None None O
of None None O
blood None None O
, None None O
starting None None O
from None None O
blood None None O
collection None None O
, None None O
through None None O
processing None None O
and None None O
on None None O
to None None O
storage None None I-FUNC
. None None O

Consequently None None O
, None None O
although None None O
iron None None O
stores None None O
( None None O
predominantly None None O
ferritin None None I-PROTEIN
) None None O
may None None O
be None None O
normal None None O
, None None O
the None None O
transport None None O
of None None O
iron None None O
either None None O
from None None O
the None None O
gastrointestinal None None O
tract None None O
or None None O
iron None None O
stores None None O
to None None O
the None None O
bone None None O
marrow None None O
is None None O
inhibited None None O
, None None O
leading None None O
to None None O
a None None O
state None None O
of None None O
'functional None None O
' None None O
iron None None O
deficiency None None O
and None None O
subsequent None None O
anaemia None None O
. None None O

Although None None O
blood None None O
collection None None O
and None None O
administration None None O
is None None O
safer None None O
and None None O
more None None O
efficient None None O
than None None O
ever None None O
before None None O
, None None O
red None None O
cells None None O
undergo None None O
multiple None None O
metabolic None None O
and None None O
structural None None O
changes None None O
during None None O
storage None None I-FUNC
that None None O
may None None O
compromise None None O
their None None O
functionality None None O
and None None O
viability None None O
following None None O
transfusion None None O
. None None O

In None None O
the None None O
current None None O
review None None O
, None None O
we None None O
begin None None O
with None None O
an None None O
in-depth None None O
overview None None O
of None None O
the None None O
pathophysiological None None O
mechanisms None None O
underlying None None O
red None None O
cell None None O
storage None None I-FUNC
, None None O
with None None O
a None None O
focus None None O
on None None O
altered None None O
metabolism None None O
, None None O
oxidative None None O
stress None None O
and None None O
red None None O
cell None None O
membrane None None O
damage None None O
. None None O

Aprotinin None None O
acts None None O
to None None O
inactivate None None O
free None None O
plasmin None None I-PROTEIN
, None None O
but None None O
with None None O
little None None O
effect None None O
on None None O
bound None None O
plasmin None None I-PROTEIN
, None None O
whereas None None O
the None None O
lysine None None I-TRANS
analogues None None O
are None None O
designed None None O
to None None O
prevent None None O
excessive None None O
plasmin None None I-PROTEIN
formation None None O
by None None O
fitting None None O
into None None O
plasminogen None None O
's None None O
lysine-binding None None O
site None None O
to None None O
prevent None None O
the None None O
binding None None O
of None None O
plasminogen None None O
to None None O
fibrin None None O
. None None O

Bridging None None O
therapy None None O
for None None O
patients None None O
on None None O
warfarin None None O
should None None O
be None None O
considered None None O
for None None O
those None None O
at None None O
highest None None O
risk None None O
of None None O
thrombosis None None I-DISEASE
, None None O
whereas None None O
it None None O
may None None O
not None None O
be None None O
necessary None None O
for None None O
those None None O
on None None O
non-vitamin None None O
K None None O
antagonist None None O
oral None None O
anticoagulant None None O
drugs None None O
given None None O
the None None O
reduced None None O
time None None O
off None None O
anticoagulation None None O
and None None O
their None None O
more None None O
predictable None None O
pharmacokinetics None None O
. None None O

Previous None None O
studies None None O
indicate None None O
that None None O
at None None O
least None None O
some None None O
aspects None None O
of None None O
audiovisual None None O
speech None None I-FUNC
perception None None I-FUNC
are None None O
impaired None None O
in None None O
children None None O
with None None O
specific None None O
language None None I-FUNC
impairment None None O
( None None O
SLI None None O
) None None O
. None None O

By None None O
combining None None O
electrophysiological None None O
and None None O
behavioral None None O
measures None None O
, None None O
we None None O
examined None None O
perception None None I-FUNC
of None None O
both None None O
audiovisually None None O
congruent None None O
and None None O
audiovisually None None O
incongruent None None O
speech None None I-FUNC
in None None O
school-age None None O
children None None O
with None None O
a None None O
history None None O
of None None O
SLI None None O
( None None O
H-SLI None None O
) None None O
, None None O
their None None O
typically None None O
developing None None O
( None None O
TD None None O
) None None O
peers None None O
, None None O
and None None O
adults None None O
. None None O

In None None O
the None None O
second None None O
experiment None None O
, None None O
participants None None O
watched None None O
videos None None O
of None None O
audivisually None None O
incongruent None None O
syllables None None O
created None None O
to None None O
elicit None None O
the None None O
so-called None None O
McGurk None None O
illusion None None O
( None None O
with None None O
an None None O
auditory None None O
'pa None None O
' None None O
dubbed None None O
onto None None O
a None None O
visual None None O
articulation None None O
of None None O
'ka None None O
' None None O
, None None O
and None None O
the None None O
expectant None None O
perception None None I-FUNC
being None None O
that None None O
of None None O
'ta None None O
' None None O
if None None O
audiovisual None None O
integration None None O
took None None O
place None None O
) None None O
. None None O

Some None None O
of None None O
these None None O
factors None None O
include None None O
a None None O
stable None None O
fixation None None O
construct None None O
, None None O
nutritional None None O
status None None O
, None None O
good None None O
surgical None None O
technique None None O
, None None O
and None None O
good None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Several None None O
in None None O
vitro None None O
studies None None O
have None None O
shown None None O
that None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
promote None None O
the None None O
regeneration None None O
of None None O
bone None None O
, None None O
cartilage None None O
, None None O
and None None O
tendons None None O
. None None O

Despite None None O
promising None None O
early None None O
studies None None O
treating None None O
chronic None None O
wounds None None O
with None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
, None None O
results None None O
with None None O
traditional None None O
bolus None None O
dosing None None O
of None None O
a None None O
single None None O
growth None None O
factor None None O
have None None O
yielded None None O
insignificant None None O
results None None O
. None None O

Advances None None O
in None None O
tissue None None O
engineering None None O
and None None O
regenerative None None O
medicine None None O
have None None O
provided None None O
technologies None None O
capable None None O
of None None O
delivering None None O
multiple None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
in None None O
a None None O
spatially None None O
oriented None None O
approach None None O
. None None O

With None None O
improved None None O
delivery None None O
systems None None O
, None None O
treatment None None O
of None None O
chronic None None O
wounds None None O
with None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
has None None O
the None None O
potential None None O
to None None O
accelerate None None O
healing None None O
in None None O
a None None O
manner None None O
not None None O
previously None None O
realized None None O
with None None O
traditional None None O
delivery None None O
approaches None None O
. None None O

The None None O
infiltrate None None O
was None None O
mainly None None O
composed None None O
of None None O
CD68 None None O
( None None O
+ None None O
) None None O
CD163 None None O
( None None O
+ None None O
) None None O
myeloperoxidase None None I-PROTEIN
( None None O
+ None None O
) None None O
myeloid None None O
cell None None O
nuclear None None O
differentiation None None O
antigen None None O
( None None O
+ None None O
) None None O
CD117 None None O
( None None O
- None None O
) None None O
CD15 None None O
( None None O
- None None O
) None None O
CD34 None None O
( None None O
- None None O
) None None O
, None None O
a None None O
phenotype None None O
suggestive None None O
of None None O
M2-like None None O
macrophages None None O
. None None O

A None None O
keyword None None O
search None None O
from None None O
electronic None None O
databases None None O
and None None O
a None None O
review None None O
of None None O
state None None O
legislation None None O
related None None O
to None None O
BMI None None O
surveillance None None O
and None None O
screening None None O
were None None O
used None None O
to None None O
identify None None O
relevant None None O
literature None None O
and None None O
data None None O
focused None None O
on None None O
surveillance None None O
and None None O
screening None None O
policies None None O
, None None O
BMI None None O
report None None O
cards None None O
, None None O
and None None O
parental None None O
perceptions None None I-FUNC
of None None O
BMI None None O
screenings None None O
and None None O
their None None O
child None None O
's None None O
weight None None O
status None None O
[ None None O
corrected None None O
] None None O
. None None O

Many None None O
substances None None O
( None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
and None None O
hormones None None I-PROTEIN
) None None O
have None None O
osteoinduction None None O
properties None None O
and None None O
when None None O
added None None O
to None None O
some None None O
osteoconduction None None O
biomaterial None None O
they None None O
accelerate None None O
bone None None O
neoformation None None O
properties None None O
. None None O

With None None O
dietary None None O
energy None None O
increasing None None O
the None None O
activities None None O
of None None O
lipoprotein None None I-PROTEIN
lipase None None I-PROTEIN
( None None O
LPL None None O
) None None O
, None None O
fatty None None O
acid None None O
synthase None None O
( None None O
FAS None None O
) None None O
and None None O
acetyl-CoA None None I-PROTEIN
carboxylase None None I-PROTEIN
( None None O
ACC None None O
) None None O
significantly None None O
increased None None O
, None None O
whereas None None O
hormone-sensitive None None O
lipase None None O
( None None O
HSL None None O
) None None O
and None None O
carnitine None None O
palmitoyltransferase-1 None None O
( None None O
CPT-1 None None O
) None None O
significantly None None O
diminished None None O
. None None O

Fasting None None O
serum None None O
glucose None None O
, None None O
androgens None None I-PROTEIN
, None None O
FSH None None O
, None None O
LH None None O
, None None O
SHBG None None O
, None None O
insulin None None I-PROTEIN
, None None O
AMH None None O
, None None O
apelin-36 None None O
, None None O
adiponectin None None O
, None None O
leptin None None O
and None None O
omentin-1 None None O
were None None O
measured None None O
. None None O

The None None O
rise None None O
to None None O
leadership None None O
positions None None O
in None None O
surgery None None O
often None None O
requires None None O
scaling None None O
a None None O
steep None None O
pyramid None None I-REGION
. None None O

Some None None O
of None None O
the None None O
qualities None None O
young None None O
surgeons None None O
must None None O
possess None None O
to None None O
ascend None None O
the None None O
leadership None None O
pyramid None None I-REGION
are None None O
summarized None None O
by None None O
the None None O
`` None None O
HOPES None None O
'' None None O
of None None O
leadership None None O
: None None O
Honesty None None O
, None None O
recognition None None O
of None None O
Opportunity None None O
, None None O
having None None O
a None None O
Plan None None O
, None None O
knowing None None O
your None None O
Environment None None O
, None None O
and None None O
Self-assessment None None O
. None None O

Neuroendocrine None None O
( None None O
NE None None I-TRANS
) None None O
tumors None None O
commonly None None O
afflict None None O
patients None None O
with None None O
multiple None None O
endocrine None None O
neoplasia None None O
type None None O
1 None None O
( None None O
MEN1 None None O
) None None O
. None None O

The None None O
role None None O
of None None O
metastasectomy None None O
of None None O
NE None None I-TRANS
tumors None None O
in None None O
MEN1 None None O
patients None None O
is None None O
not None None O
clearly None None O
defined None None O
. None None O

Seated None None O
movement None None I-FUNC
and None None O
postural None None O
responses None None O
were None None O
transduced None None O
with None None O
a None None O
sensitive None None O
accelerometer None None O
attached None None O
to None None O
the None None O
underside None None O
of None None O
a None None O
low-mass None None O
cantilevered None None O
chair None None O
. None None O

Major None None O
adverse None None O
cardiovascular None None O
events None None O
( None None O
MACE None None O
[ None None O
death None None O
, None None O
heart None None O
failure None None O
hospitalization None None O
, None None O
atrial None None O
fibrillation None None O
, None None O
and None None O
stroke None None I-DISEASE
] None None O
) None None O
were None None O
compared None None O
between None None O
those None None O
with None None O
and None None O
without None None O
a None None O
PSW None None O
, None None O
in None None O
both None None O
EF None None O
groups None None O
. None None O

A None None O
national None None O
risk None None O
assessment None None O
is None None O
already None None O
available None None O
for None None O
intersex None None O
in None None O
fish None None O
arising None None O
from None None O
estrogens None None I-PROTEIN
under None None O
current None None O
flow None None O
conditions None None O
. None None O

Early None None O
stent None None O
thrombosis None None I-DISEASE
was None None O
significantly None None O
greater None None O
with None None O
bivalirudin None None O
compared None None O
with None None O
heparin None None O
( None None O
RR None None O
1.61 None None O
[ None None O
1.18-2.20 None None O
] None None O
, None None O
p=0.003 None None O
) None None O
, None None O
especially None None O
in None None O
patients None None O
undergoing None None O
primary None None O
PCI None None O
( None None O
2.15 None None O
[ None None O
1.15-4.03 None None O
] None None O
, None None O
p=0.02 None None O
) None None O
. None None O

The None None O
final None None O
Rapid None None O
Upper None None O
Limb None None O
Assessment None None O
score None None O
for None None O
the None None O
patient None None O
turning None None O
movement None None I-FUNC
was None None O
found None None O
to None None O
be None None O
higher None None O
than None None O
for None None O
the None None O
bending None None O
down None None O
movement None None I-FUNC
. None None O

Long None None O
term None None O
exposure None None O
to None None O
dexamethasone None None O
( None None O
Dx None None O
) None None O
is None None O
associated None None O
with None None O
brain None None O
damage None None O
especially None None O
in None None O
the None None O
hippocampus None None I-REGION
via None None O
the None None O
oxidative None None O
stress None None O
pathway None None O
. None None O

This None None O
study None None O
has None None O
examined None None O
the None None O
effects None None O
of None None O
a None None O
CL None None O
extract None None O
on None None O
the None None O
densities None None O
of None None O
cresyl None None O
violet None None O
positive None None O
neurons None None O
and None None O
glial None None O
fibrillary None None O
acidic None None O
protein None None O
immunoreactive None None O
( None None O
GFAP-ir None None O
) None None O
astrocytes None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
Dx None None O
treated None None O
male None None O
rats None None O
. None None O

once None None O
daily None None O
) None None O
significantly None None O
reduced None None O
the None None O
densities None None O
of None None O
cresyl None None O
violet None None O
positive None None O
neurons None None O
in None None O
the None None O
sub-areas None None O
CA1 None None I-REGION
, None None O
CA3 None None I-REGION
and None None O
the None None O
dentate None None I-REGION
gyrus None None I-REGION
, None None O
but None None O
not None None O
in None None O
the None None O
CA2 None None I-REGION
area None None O
. None None O

was None None O
found None None O
to None None O
significantly None None O
restore None None O
neuronal None None O
densities None None O
in None None O
the None None O
CA1 None None I-REGION
and None None O
dentate None None I-REGION
gyrus None None I-REGION
. None None O

In None None O
normal None None O
pancreas None None O
labeling None None O
with None None O
antiphosphorylated None None O
ERK1/2 None None O
( None None O
pERK1/2 None None O
) None None O
antibody None None O
was None None O
mainly None None O
confined None None O
to None None O
islets None None O
of None None O
Langerhans None None O
in None None O
close None None O
overlapping None None O
with None None O
insulin None None I-PROTEIN
containing None None O
cells None None O
. None None O

It None None O
should None None O
be None None O
noted None None O
that None None O
the None None O
localization None None O
of None None O
all None None O
three None None O
kinases None None I-PROTEIN
was None None O
mainly None None O
in None None O
the None None O
cell None None O
nuclei None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
using None None O
inhibitors None None O
to None None O
protein None None O
kinases None None I-PROTEIN
may None None O
attenuate None None O
the None None O
progression None None O
of None None O
the None None O
disease None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
distribution None None O
density None None O
and None None O
immunoreactive None None O
( None None O
IR None None O
) None None O
intensity None None O
of None None O
5-hydroxytryptamine None None I-TRANS
( None None O
5-HT None None I-TRANS
) None None O
, None None O
gastrin None None I-TRANS
( None None O
GAS None None O
) None None O
, None None O
somatostatin None None I-TRANS
( None None O
SS None None O
) None None O
, None None O
pancreatic None None I-TRANS
polypeptide None None I-TRANS
( None None O
PP None None O
) None None O
, None None O
neuropeptide None None I-TRANS
Y None None I-TRANS
( None None O
NPY None None I-TRANS
) None None O
and None None O
glucagon None None I-TRANS
( None None O
GLU None None O
) None None O
IR None None O
cells None None O
in None None O
the None None O
skin None None O
of None None O
the None None O
bullfrog None None O
Rana None None O
catesbeiana None None O
during None None O
periods None None O
of None None O
activity None None O
and None None O
hibernation None None O
. None None O

In None None O
dorsal None None I-NEURON
skin None None O
, None None O
the None None O
density None None O
of None None O
the None None O
GHs-IR None None O
cells None None O
in None None O
mucous None None O
glands None None O
was None None O
higher None None O
than None None O
that None None O
in None None O
epidermis None None O
except None None O
for None None O
GAS-IR None None O
cells None None O
. None None O

During None None O
hibernation None None O
, None None O
the None None O
density None None O
of None None O
the None None O
six None None O
types None None O
of None None O
GHs-IR None None O
cells None None O
and None None O
the None None O
IR None None O
intensity None None O
of None None O
GAS None None O
, None None O
SS None None O
, None None O
NPY None None I-TRANS
and None None O
GLU-IR None None O
cells None None O
in None None O
the None None O
epidermis None None O
of None None O
dorsal None None I-NEURON
skin None None O
increased None None O
significantly None None O
. None None O

The None None O
capacity None None O
to None None O
diagnosys None None O
, None None O
quantify None None O
and None None O
evaluate None None O
movement None None I-FUNC
beyond None None O
the None None O
general None None O
confines None None O
of None None O
a None None O
clinical None None O
environment None None O
under None None O
effectiveness None None O
conditions None None O
may None None O
alleviate None None O
rampant None None O
strain None None O
on None None O
limited None None O
, None None O
expensive None None O
and None None O
highly None None O
specialized None None O
medical None None O
resources None None O
. None None O

Genes None None O
encoding None None I-FUNC
heat None None O
shock None None O
proteins None None O
and None None O
general None None O
stress None None O
resistance None None O
proteins None None O
showed None None O
transcriptional None None O
surges None None O
after None None O
1 None None O
sec None None O
of None None O
SHS None None O
treatment None None O
at None None O
200°C None None O
, None None O
with None None O
parallel None None O
induction None None O
of None None O
stress-related None None O
regulator None None O
genes None None O
including None None O
rpoE None None O
, None None O
rpoS None None O
, None None O
and None None O
rpoH None None O
. None None O

Practicing None None O
SK None None O
& None None O
amp None None O
; None None O
P None None O
for None None O
six None None O
weeks None None O
led None None O
to None None O
improvement None None O
in None None O
mean±SD None None O
score None None O
of None None O
study None None O
participants None None O
in None None O
GAF None None O
, None None O
anxiety None None O
( None None O
ANX None None O
) None None O
, None None O
depressed None None O
mood None None I-FUNC
( None None O
DEP None None O
) None None O
, None None O
positive None None O
well None None O
being None None O
( None None O
PWB None None O
) None None O
, None None O
general None None O
health None None O
( None None O
GH None None O
) None None O
, None None O
self None None O
control None None O
( None None O
SC None None O
) None None O
, None None O
vitality None None O
( None None O
VT None None O
) None None O
and None None O
total None None O
positive None None O
general None None O
well None None O
being None None O
( None None O
PGWB None None O
) None None O
. None None O

SK None None O
& None None O
amp None None O
; None None O
P None None O
also None None O
causes None None O
significant None None O
reduction None None O
in None None O
anxiety None None O
and None None O
depression None None I-DISEASE
levels None None O
. None None O

In None None O
the None None O
Wechsler None None O
Intelligence None None O
Scale None None O
for None None O
children None None O
, None None O
a None None O
lower None None O
score None None O
was None None O
observed None None O
for None None O
the None None O
ASD None None O
group None None O
than None None O
for None None O
the None None O
TD None None O
group None None O
in None None O
Picture None None O
concept None None O
, None None O
which None None O
is None None O
a None None O
subscale None None O
of None None O
perceptual None None O
reasoning None None I-FUNC
. None None O

Apolipoprotein None None O
E4 None None O
gene None None O
is None None O
associated None None O
with None None O
increased None None O
risk None None O
of None None O
dementia None None I-DISEASE
with None None O
comorbid None None O
diabetes None None O
mellitus None None O
. None None O

We None None O
assessed None None O
relative None None O
telomere None None O
length None None O
and None None O
apolipoprotein None None O
E None None O
genotype None None O
in None None O
subjects None None O
with None None O
dementia None None I-DISEASE
( None None O
n=70 None None O
) None None O
and None None O
cognitively None None O
normal None None O
control None None O
groups None None O
( None None O
n=55 None None O
) None None O
with None None O
and None None O
without None None O
comorbid None None O
diabetes None None O
mellitus None None O
type None None O
2 None None O
. None None O

Apolipoprotein None None O
E4 None None O
allele None None O
frequency None None O
was None None O
highest None None O
in None None O
dementia None None I-DISEASE
with None None O
comorbid None None O
diabetes None None O
mellitus None None O
type None None O
2 None None O
( None None O
0.26 None None O
) None None O
. None None O

The None None O
findings None None O
suggest None None O
that None None O
relative None None O
telomere None None O
length None None O
is None None O
unrelated None None O
to None None O
apolipoprotein None None O
E4 None None O
genotype None None O
in None None O
dementia None None I-DISEASE
and None None O
cognitive None None O
normal None None O
subjects None None O
with None None O
or None None O
without None None O
comorbid None None O
diabetes None None O
mellitus None None O
type None None O
2 None None O
. None None O

This None None O
study None None O
aims None None O
to None None O
investigate None None O
the None None O
mediational None None O
effects None None O
of None None O
adaptive None None O
and None None O
maladaptive None None O
rumination None None O
in None None O
the None None O
relationship None None O
between None None O
illness None None O
perception None None I-FUNC
and None None O
negative None None O
emotions None None I-FUNC
( None None O
depression None None I-DISEASE
, None None O
anxiety None None O
and None None O
stress None None O
) None None O
in None None O
male None None O
and None None O
female None None O
patients None None O
( None None O
N=110 None None O
) None None O
suffering None None O
from None None O
depressive None None I-DISEASE
disorders None None I-DISEASE
. None None O

However None None O
, None None O
no None None O
mediating None None O
effects None None O
of None None O
adaptive None None O
rumination None None O
were None None O
found None None O
in None None O
the None None O
relationship None None O
between None None O
illness None None O
perception None None I-FUNC
and None None O
negative None None O
emotion None None I-FUNC
. None None O

It None None O
also None None O
mediated None None O
the None None O
relationship None None O
between None None O
perceived None None O
identity None None O
and None None O
emotional None None O
representation None None O
of None None O
illness None None O
and None None O
negative None None O
emotions None None I-FUNC
in None None O
females None None O
. None None O

The None None O
Scale None None O
for None None O
Assessment None None O
of None None O
Somatic None None O
Symptoms None None O
( None None O
Chaturvedi None None O
et None None O
al. None None O
, None None O
1987 None None O
) None None O
and None None O
a None None O
Visual None None O
Analogue None None O
Scale None None O
( None None O
VAS None None O
) None None O
for None None O
stress None None O
and None None O
job None None O
satisfaction None None O
perception None None I-FUNC
were None None O
used None None O
to None None O
collect None None O
data None None O
. None None O

Somatic None None O
symptoms None None O
positively None None O
correlated None None O
( None None O
r=0.302 None None O
) None None O
with None None O
stress None None O
perception None None I-FUNC
and None None O
negatively None None O
correlated None None O
( None None O
r=-0.231 None None O
) None None O
with None None O
perceived None None O
job None None O
satisfaction None None O
, None None O
while None None O
perceived None None O
stress None None O
and None None O
perceived None None O
job None None O
satisfaction None None O
were None None O
negatively None None O
correlated None None O
( None None O
r=-0.460 None None O
, None None O
p=0.000 None None O
) None None O
. None None O

Altogether None None O
, None None O
164 None None O
patients None None O
( None None O
83 None None O
% None None O
) None None O
had None None O
alcohol None None I-DISEASE
dependence None None I-DISEASE
and None None O
24 None None O
patients None None O
( None None O
12 None None O
% None None O
) None None O
had None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
. None None O

In None None O
view None None O
of None None O
the None None O
clinical None None O
importance None None O
of None None O
the None None O
adherence None None O
issues None None O
in None None O
schizophrenia None None I-DISEASE
management None None O
, None None O
a None None O
consensus None None O
group None None O
of None None O
experienced None None O
local None None O
psychiatrists None None O
and None None O
nurse None None O
specialists None None O
gathered None None O
to None None O
outline None None O
a None None O
number None None O
of None None O
consensus None None O
statements None None O
for None None O
clinicians None None O
to None None O
consider None None O
enhancing None None O
adherence None None O
in None None O
their None None O
patients None None O
. None None O

Using None None O
a None None O
modified None None O
Delphi None None O
method None None O
, None None O
published None None O
literature None None O
and None None O
published None None O
guidelines None None O
regarding None None O
the None None O
management None None O
of None None O
schizophrenia None None I-DISEASE
were None None O
reviewed None None O
by None None O
the None None O
full None None O
panel None None O
during None None O
the None None O
group None None O
meeting None None O
. None None O

They None None O
include None None O
areas None None O
on None None O
adherence None None O
assessment None None O
and None None O
definition None None O
, None None O
treatment None None O
strategies None None O
in None None O
enhancing None None O
adherence None None O
, None None O
and None None O
treatment None None O
considerations None None O
at None None O
specific None None O
phases None None O
of None None O
schizophrenia None None I-DISEASE
. None None O

The None None O
isometric None None O
contraction None None O
study None None O
revealed None None O
that None None O
both None None O
nifedipine None None O
( None None O
Cav None None O
1.2 None None O
channel None None O
blocker None None O
) None None O
and None None O
NS11021 None None O
( None None O
KCa None None O
1.1 None None O
channel None None O
activator None None O
) None None O
induced None None O
concentration-dependent None None O
vasorelaxation None None O
in None None O
MAs None None O
precontracted None None O
with None None O
noradrenaline None None I-TRANS
. None None O

In None None O
Drosophila None None O
, None None O
commissural None None O
axons None None O
sense None None O
the None None O
midline None None O
attractants None None O
Netrin None None O
A None None O
and None None O
B None None O
( None None O
Net None None O
) None None O
through None None O
Frazzled None None O
( None None O
Fra None None O
) None None O
receptors None None I-PROTEIN
. None None O

Altogether None None O
, None None O
our None None O
results None None O
indicate None None O
that None None O
contact-mediated None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
via None None O
Fmi None None O
acts None None O
in None None O
addition None None O
to None None O
the None None O
Net/Fra None None O
guidance None None O
system None None O
during None None O
axon None None O
pathfinding None None O
across None None O
the None None O
midline None None O
, None None O
underlining None None O
the None None O
importance None None O
of None None O
PCP None None O
molecules None None O
during None None O
vertebrates None None O
and None None O
invertebrates None None O
midline None None O
development None None O
. None None O

Psychophysical None None O
evidence None None O
suggests None None O
that None None O
the None None O
perception None None I-FUNC
of None None O
the None None O
motion None None O
and None None O
color None None O
of None None O
moving None None O
stimuli None None O
are None None O
determined None None O
separately None None O
in None None O
the None None O
human None None O
brain None None O
. None None O

The None None O
mineral None None O
meliphanite None None O
( None None O
Ca None None O
, None None O
Na None None I-TRANS
) None None O
2Be None None O
[ None None O
( None None O
Si None None O
, None None O
Al None None O
) None None O
2O6 None None O
( None None O
F None None O
, None None O
OH None None O
) None None O
] None None O
is None None O
a None None O
crystalline None None O
sodium None None O
calcium None None O
beryllium None None O
silicate None None O
which None None O
has None None O
the None None O
potential None None O
to None None O
be None None O
used None None O
as None None O
piezoelectric None None O
material None None O
and None None O
for None None O
other None None O
ferroelectric None None O
applications None None O
. None None O

EDS None None O
analysis None None O
shows None None O
a None None O
material None None O
with None None O
high None None O
concentrations None None O
of None None O
Si None None O
and None None O
Ca None None O
and None None O
low None None O
amounts None None O
of None None O
Na None None I-TRANS
, None None O
Al None None O
and None None O
F. None None O
Beryllium None None O
was None None O
not None None O
detected None None O
. None None O

The None None O
total None None O
variance None None O
explained None None O
by None None O
the None None O
regression None None O
model None None O
was None None O
0.56 None None O
for None None O
`` None None O
Frequency None None O
of None None O
incident None None O
reporting None None O
'' None None O
and None None O
0.26 None None O
for None None O
`` None None O
Overall None None O
perception None None I-FUNC
of None None O
safety None None O
'' None None O
. None None O

Isolated None None O
TR None None O
can None None O
be None None O
severe None None O
and None None O
is None None O
associated None None O
with None None O
excess None None O
mortality None None O
and None None O
morbidity None None O
, None None O
warranting None None O
heightened None None O
attention None None I-FUNC
to None None O
diagnosis None None O
and None None O
quantitation None None O
. None None O

Recently None None O
developed None None O
antiplatelet None None O
agents None None O
( None None O
prasugrel None None O
, None None O
ticagrelor None None O
, None None O
cangrelor None None O
and None None O
elinogrel None None O
) None None O
efficiently None None O
antagonize None None O
P2Y12 None None O
receptor None None I-PROTEIN
, None None O
a None None O
key None None O
platelet None None O
activating None None O
signaling None None O
pathway None None O
, None None O
and None None O
thereby None None O
inhibit None None O
aggregation None None O
induced None None O
by None None O
mediators None None O
such None None O
as None None O
ADP None None O
, None None O
collagen None None I-PROTEIN
, None None O
thrombin None None I-PROTEIN
and None None O
TXA2 None None O
. None None O

Hypercholesterolemic None None O
patients None None O
with None None O
HTN None None O
who None None O
used None None O
the None None O
cholesterol- None None O
lowering None None O
drugs None None O
HMG-CoA None None I-PROTEIN
reductase None None I-PROTEIN
inhibitors None None O
( None None O
statins None None O
) None None O
had None None O
improved None None O
FMD None None O
with None None O
a None None O
reduction None None O
in None None O
cholesterol None None O
levels None None O
and None None O
no None None O
significant None None O
change None None O
in None None O
blood None None O
pressure None None O
( None None O
BP None None O
) None None O
. None None O

Problem None None O
gamblers None None O
with None None O
and None None O
without None None O
ADHD None None O
did None None O
not None None O
differ None None O
on None None O
demographic None None O
characteristics None None O
or None None O
the None None O
rate None None O
of None None O
other None None O
psychiatric None None O
disorders None None O
, None None O
depression None None I-DISEASE
scores None None O
, None None O
nicotine None None O
and None None O
alcohol None None O
consumption None None O
, None None O
and None None O
body None None O
mass None None O
index None None O
. None None O

Monoclonal None None O
antibodies None None O
( None None O
mAbs None None O
) None None O
and None None O
their None None O
directly None None O
derived None None O
cell-based None None O
application None None O
known None None O
as None None O
chimeric None None O
antigen None None O
receptors None None I-PROTEIN
( None None O
CARs None None O
) None None O
ensue None None O
from None None O
the None None O
need None None O
to None None O
develop None None O
novel None None O
therapeutic None None O
strategies None None O
that None None O
retain None None O
high None None O
anti-tumor None None O
activity None None O
, None None O
but None None O
carry None None O
reduced None None O
toxicity None None O
compared None None O
to None None O
conventional None None O
chemo- None None O
and None None O
radiotherapies None None O
. None None O

In None None O
those None None O
who None None O
had None None O
taken None None O
an None None O
adenosine None None I-TRANS
disphosphate None None O
( None None O
ADP None None O
) None None O
-receptor None None I-PROTEIN
antagonist None None O
within None None O
5 None None O
days None None O
( None None O
n=173 None None O
) None None O
, None None O
these None None O
results None None O
were None None O
amplified None None O
, None None O
and None None O
additionally None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
cost None None O
saving None None O
( None None O
median None None O
cost None None O
, None None O
A=£1738.53 None None O
, None None O
B=£1736.96 None None O
, None None O
C=£3191.80 None None O
p=0.006 None None O
) None None O
. None None O

Serum None None O
and None None O
tissue None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
and None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
levels None None O
in None None O
the None None O
cilostazol-treated None None O
group None None O
( None None O
group None None O
III None None O
) None None O
were None None O
higher None None O
compared None None O
with None None O
the None None O
ischemia-reperfusion None None O
group None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Patients None None O
were None None O
randomized None None O
by None None O
computer None None O
into None None O
2 None None O
equal None None O
groups None None O
: None None O
Vasopressin None None I-TRANS
or None None O
control None None O
. None None O

The None None O
drug None None O
was None None O
administered None None O
continually None None O
during None None O
surgery None None O
while None None O
patients None None O
needed None None O
catecholamines None None I-TRANS
. None None O

Vasopressin None None I-TRANS
infusion None None O
has None None O
been None None O
used None None O
to None None O
treat None None O
catecholamine-unresponsive None None O
shock None None O
. None None O

The None None O
Geriatric None None O
Depression None None I-DISEASE
and None None O
the None None O
Hachinski None None O
Ischemia None None O
scales None None O
were None None O
used None None O
to None None O
identify None None O
the None None O
presence None None O
of None None O
clinical None None O
depression None None I-DISEASE
and None None O
vascular None None I-DISEASE
dementia None None I-DISEASE
, None None O
respectively None None O
. None None O

Although None None O
our None None O
recent None None O
analysis None None O
performed None None O
well None None O
in None None O
terms None None O
of None None O
RF None None O
predictive None None O
power None None O
for None None O
a None None O
25-component None None O
learning None None I-FUNC
set None None O
( None None O
for None None O
both None None O
Q-MS None None O
and None None O
TOF-MS None None O
detection None None O
) None None O
, None None O
large None None O
physically None None O
unrealistic None None O
negative None None O
ECN None None O
and None None O
carbon None None O
number None None O
equivalent None None O
( None None O
CNE None None O
) None None O
values None None O
were None None O
noted None None O
for None None O
TOF-MS None None O
detection None None O
, None None O
e.g. None None O
, None None O
ECN None None O
( None None O
acetic None None O
acid None None O
) None None O
=-16.96 None None O
. None None O

It None None O
was None None O
observed None None O
that None None O
the None None O
sensor None None O
could None None O
successfully None None O
differentiate None None O
cadmium None None O
ions None None O
from None None O
interferents None None O
( None None O
magnesium None None O
salts None None O
, None None O
zinc None None I-TRANS
salts None None O
, None None O
etc None None O
. None None O
) None None O
. None None O

Thus None None O
, None None O
it None None O
can None None O
be None None O
a None None O
powerful None None O
tool None None O
for None None O
facilitating None None O
decision None None I-FUNC
making None None I-FUNC
during None None O
routine None None O
colonoscopy None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
paper None None O
is None None O
to None None O
assess None None O
the None None O
role None None O
of None None O
people None None O
's None None O
perception None None I-FUNC
in None None O
disaster None None O
management None None O
. None None O

The None None O
study None None O
revealed None None O
that None None O
community None None O
members None None O
did None None O
not None None O
share None None O
uniform None None O
perceptions None None I-FUNC
. None None O

Strengthening None None O
social None None O
networks None None O
and None None O
integrating None None O
communities None None O
' None None O
perceptions None None I-FUNC
in None None O
intervention None None O
mechanisms None None O
were None None O
identified None None O
as None None O
possible None None O
ways None None O
of None None O
managing None None O
future None None O
landslide None None O
disasters None None O
. None None O

Data None None O
collection None None O
was None None O
performed None None O
by None None O
two None None O
independent None None O
reviewers None None O
in None None O
October None None O
2012 None None O
, None None O
with None None O
the None None O
search None None O
strategy None None O
formulated None None O
by None None O
crossing None None O
descriptors None None O
and None None O
relevant None None O
terms None None O
to None None O
the None None O
topic None None O
in None None O
English None None O
, None None O
Portuguese None None O
and None None O
Spanish None None O
languages None None I-FUNC
. None None O

We None None O
discuss None None O
here None None O
toroidal None None O
pore None None O
formation None None O
by None None O
peptides None None I-TRANS
including None None O
melittin None None O
, None None O
protegrin None None O
, None None O
and None None O
Alzheimer None None I-DISEASE
's None None O
Aβ1-41 None None O
, None None O
as None None O
well None None O
as None None O
by None None O
PFPs None None O
from None None O
several None None O
evolutionarily None None O
unrelated None None O
families None None O
: None None O
the None None O
colicin/Bcl-2 None None O
grouping None None O
including None None O
the None None O
pro-apoptotic None None O
protein None None O
Bax None None O
, None None O
actinoporins None None O
derived None None O
from None None O
sea None None O
anemones None None O
, None None O
and None None O
the None None O
membrane None None O
attack None None O
complex-perforin/cholesterol None None O
dependent None None O
cytolysin None None O
( None None O
MACPF/CDC None None O
) None None O
set None None O
of None None O
proteins None None O
. None None O

In None None O
the None None O
first None None O
part None None O
of None None O
this None None O
series None None O
, None None O
we None None O
explored None None O
one None None O
mechanism None None O
for None None O
generating None None O
ultrasensitivity None None O
, None None O
zero-order None None O
ultrasensitivity None None O
, None None O
where None None O
the None None O
saturation None None O
of None None O
two None None O
converting None None O
enzymes None None I-PROTEIN
allows None None O
the None None O
output None None O
to None None O
switch None None O
from None None O
low None None O
to None None O
high None None O
over None None O
a None None O
tight None None O
range None None O
of None None O
input None None O
levels None None O
. None None O

An None None O
analysis None None O
of None None O
petiole None None O
exudates None None O
from None None O
wild-type None None O
leaves None None O
revealed None None O
that None None O
N None None O
from None None O
urea None None O
accounted None None O
for None None O
& None None O
gt None None O
; None None O
13 None None O
% None None O
of None None O
amino None None O
acid None None O
N. None None O
Urea None None O
export None None O
from None None O
senescent None None O
leaves None None O
further None None O
increased None None O
in None None O
ureG-2 None None O
deletion None None O
mutants None None O
lacking None None O
urease None None I-PROTEIN
activity None None O
. None None O

Eleven None None O
patients None None O
were None None O
diagnosed None None O
with None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
and None None O
adjustment None None I-DISEASE
disorder None None I-DISEASE
and None None O
were None None O
classed None None O
as None None O
depressive None None O
patients None None O
. None None O

However None None O
, None None O
many None None O
antimicrobial None None O
agents None None O
also None None O
have None None O
biological None None O
activities None None O
stemming None None O
from None None O
their None None O
interactions None None O
with None None O
host None None O
receptors None None I-PROTEIN
and None None O
effects None None O
on None None O
host None None O
inflammatory None None O
responses None None O
and None None O
other None None O
human None None O
or None None O
bacterial None None O
cellular None None O
biological None None O
pathways None None O
. None None O

In None None O
this None None O
study None None O
, None None O
fibril None None O
formation None None O
of None None O
peptides None None I-TRANS
containing None None O
the None None O
critical None None O
sequences None None O
for None None O
tau None None O
aggregation None None O
VQIINK None None O
and None None O
a None None O
plausible None None O
serine None None I-TRANS
phosphorylation None None O
site None None O
of None None O
tau None None O
at None None O
its None None O
C-terminal None None O
was None None O
investigated None None O
. None None O

After None None O
combining None None O
both None None O
structural None None O
motifs None None O
, None None O
a None None O
new None None O
lead None None O
compound None None O
was None None O
identified None None O
that None None O
inhibited None None O
T None None O
Ag None None O
ATPase None None I-PROTEIN
activity None None O
with None None O
an None None O
IC50 None None O
of None None O
50 None None O
μM None None O
. None None O

c-myc None None I-PROTEIN
G-quadruplex None None O
DNA None None O
, None None O
which None None O
plays None None O
a None None O
central None None O
role None None O
in None None O
tumor None None O
progression None None O
and None None O
resistance None None O
, None None O
has None None O
been None None O
extensively None None O
investigated None None O
as None None O
potential None None O
target None None O
of None None O
antitumor None None O
drugs None None O
. None None O

When None None O
dealt None None O
with None None O
5 None None O
, None None O
the None None O
strength None None O
of None None O
CD None None O
signal None None O
attributed None None O
to None None O
c-myc None None I-PROTEIN
G4 None None O
DNA None None O
is None None O
decreased None None O
and None None O
the None None O
FRET None None O
melting None None O
point None None O
of None None O
c-myc None None I-PROTEIN
G4 None None O
DNA None None O
is None None O
increased None None O
. None None O

As None None O
a None None O
result None None O
, None None O
the None None O
replication None None O
of None None O
c-myc None None I-PROTEIN
oligomers None None O
is None None O
blocked None None O
by None None O
5 None None O
. None None O

Insomnia None None O
symptoms None None O
also None None O
occur None None O
in None None O
other None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
, None None O
but None None O
it None None O
is None None O
not None None O
known None None O
to None None O
what None None O
extent None None O
it None None O
is None None O
related None None O
to None None O
dysfunctional None None O
thinking None None O
about None None O
sleep None None O
. None None O

The None None O
following None None O
groups None None O
were None None O
included None None O
: None None O
34 None None O
patients None None O
with None None O
primary None None O
insomnia None None O
( None None O
PI None None O
) None None O
, None None O
30 None None O
patients None None O
with None None O
sleep None None O
apnea None None O
syndrome None None O
( None None O
SAS None None O
) None None O
, None None O
31 None None O
patients None None O
with None None O
restless None None O
legs None None O
syndrome None None O
( None None O
RLS None None O
) None None O
, None None O
26 None None O
patients None None O
with None None O
SAS None None O
comorbid None None O
with None None O
RLS None None O
( None None O
SAS None None O
+ None None O
RLS None None O
) None None O
, None None O
and None None O
24 None None O
patients None None O
with None None O
idiopathic None None O
hypersomnia None None O
or None None O
narcolepsy None None I-DISEASE
. None None O

The None None O
DBAS None None O
scores None None O
were None None O
compared None None O
across None None O
the None None O
different None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
and None None O
correlated None None O
with None None O
polysomnographic None None O
( None None O
PSG None None O
) None None O
variables None None O
, None None O
subjective None None O
sleep None None O
parameters None None O
, None None O
scores None None O
of None None O
the None None O
Beck None None O
Depression None None I-DISEASE
Inventory None None O
( None None O
BDI None None O
) None None O
, None None O
and None None O
the None None O
Regensburg None None O
Insomnia None None O
Scale None None O
( None None O
RIS None None O
; None None O
measuring None None O
psychological None None O
symptoms None None O
of None None O
insomnia None None O
) None None O
. None None O

Furthermore None None O
, None None O
these None None O
drugs None None O
can None None O
induce None None O
other None None O
side None None O
effects None None O
associated None None O
with None None O
higher None None O
cardiovascular None None O
morbidity None None O
and None None O
mortality None None O
, None None O
such None None O
as None None O
insulin None None I-PROTEIN
resistance None None O
, None None O
diabetes None None O
or None None O
metabolic None None O
syndrome None None O
. None None O

The None None O
expression None None O
levels None None O
of None None O
17 None None O
transcripts None None O
, None None O
including None None O
cytosolic None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
and None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
A4-4 None None O
were None None O
increased None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
, None None O
whereas None None O
23 None None O
genes None None O
including None None O
adiponectin None None O
, None None O
neonatal None None O
Fc None None O
receptor None None I-PROTEIN
and None None O
tumor None None O
necrosis None None O
factor None None O
ligand None None O
superfamily None None O
member None None O
5 None None O
were None None O
decreased None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
in None None O
FS10 None None O
. None None O

By None None O
understanding None None O
its None None O
root None None O
causes None None O
, None None O
interventions None None O
can None None O
be None None O
tailored None None O
to None None O
minimize None None O
moral None None O
distress None None O
with None None O
the None None O
ultimate None None O
goal None None O
of None None O
enhancing None None O
patient None None O
care None None O
, None None O
staff None None O
satisfaction None None O
, None None O
and None None O
retention None None I-FUNC
. None None O

The None None O
expression None None O
of None None O
the None None O
antiapoptotic None None O
protein None None O
Bcl-2 None None O
, None None O
pro-apoptotic None None O
protein None None O
Bax None None O
, None None O
and None None O
the None None O
mediator None None O
of None None O
angiogenesis None None O
vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
were None None O
also None None O
investigated None None O
. None None O

IV None None O
fibrinolysis None None O
is None None O
the None None O
only None None O
approved None None O
treatment None None O
in None None O
ischemic None None O
stroke None None I-DISEASE
but None None O
is None None O
very None None O
often None None O
contraindicated None None O
in None None O
these None None O
situations None None O
. None None O

We None None O
report None None O
the None None O
case None None O
of None None O
two None None O
patients None None O
who None None O
were None None O
admitted None None O
in None None O
emergency None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
with None None O
contraindication None None O
to None None O
IV None None O
fibrinolysis None None O
( None None O
cardioversion None None O
for None None O
atrial None None O
fibrillation None None O
under None None O
anticoagulation None None O
; None None O
24 None None O
hours None None O
after None None O
carotid None None O
surgery None None O
) None None O
. None None O

After None None O
validation None None O
of None None O
IV None None O
fibrinolysis None None O
within None None O
4.5 None None O
hours None None O
after None None O
stroke None None I-DISEASE
onset None None O
, None None O
techniques None None O
of None None O
mechanical None None O
thrombectomy None None O
have None None O
gradually None None O
been None None O
developed None None O
, None None O
either None None O
as None None O
a None None O
complementary None None O
treatment None None O
or None None O
as None None O
an None None O
alternative None None O
in None None O
the None None O
case None None O
of None None O
CI None None O
to None None O
fibrinolysis None None O
. None None O

This None None O
will None None O
permit None None O
the None None O
rapid None None O
establishment None None O
of None None O
a None None O
clinico-radiological None None O
report None None O
for None None O
selecting None None O
stroke None None I-DISEASE
patients None None O
eligible None None O
for None None O
a None None O
procedure None None O
of None None O
recanalization None None O
by None None O
thrombolysis None None O
and/or None None O
mechanical None None O
thrombectomy None None O
. None None O

All None None O
physiological None None O
heart None None O
murmurs None None O
were None None O
systolic None None O
and None None O
low-grade None None O
( None None O
I-III/VI None None O
) None None O
. None None O

PF4 None None O
deficiency None None O
aggravates None None O
liver None None O
IRI None None O
, None None O
as None None O
shown None None O
by None None O
higher None None O
serum None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
ALT None None O
) None None O
levels None None O
and None None O
Suzuki None None O
scores None None O
. None None O

The None None O
progressive None None O
nature None None O
of None None O
heart None None O
failure None None O
( None None O
HF None None O
) None None O
coupled None None O
with None None O
high None None O
mortality None None O
and None None O
poor None None O
quality None None O
of None None O
life None None O
mandates None None O
greater None None O
attention None None I-FUNC
to None None O
palliative None None O
care None None O
as None None O
a None None O
routine None None O
component None None O
of None None O
advanced None None O
HF None None O
management None None O
. None None O

Cells None None O
identified None None O
using None None O
cytosolic None None O
enzyme None None O
aldehyde None None O
dehydrogenase None None I-PROTEIN
( None None O
ALDH None None O
) None None O
may None None O
benefit None None O
patients None None O
with None None O
severe None None O
PAD None None O
but None None O
has None None O
not None None O
been None None O
studied None None O
in None None O
patients None None O
with None None O
claudication None None O
. None None O

The None None O
primary None None O
end None None O
point None None O
is None None O
the None None O
time None None O
to None None O
first None None O
occurrence None None O
of None None O
cardiovascular None None O
death None None O
, None None O
myocardial None None O
infarction None None O
, None None O
stroke None None I-DISEASE
, None None O
definite None None O
stent None None O
thrombosis None None I-DISEASE
, None None O
urgent None None O
revascularization None None O
, None None O
and None None O
bleeding None None O
complications None None O
( None None O
Bleeding None None O
Academic None None O
Research None None O
Consortium None None O
definition None None O
2 None None O
, None None O
3 None None O
, None None O
or None None O
5 None None O
) None None O
. None None O

The None None O
tradeoff None None O
between None None O
stent None None O
thrombosis None None I-DISEASE
( None None O
ST None None O
) None None O
and None None O
major None None O
bleeding None None O
( None None O
MB None None O
) None None O
of None None O
12- None None O
versus None None O
6-month None None O
dual None None O
antiplatelet None None O
therapy None None O
( None None O
DAPT None None O
) None None O
after None None O
coronary None None O
stent None None O
implantation None None O
has None None O
not None None O
been None None O
clearly None None O
defined None None O
. None None O

We None None O
performed None None O
a None None O
systematic None None O
review None None O
to None None O
determine None None O
the None None O
frequency None None O
of None None O
detection None None O
of None None O
new None None O
cardiac None None O
findings None None O
in None None O
patients None None O
with None None O
cryptogenic None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
IS None None O
) None None O
undergoing None None O
transesophageal None None O
echocardiography None None O
( None None O
TEE None None O
) None None O
. None None O

We None None O
sought None None O
to None None O
compare None None O
N-terminal None None O
pro-B-type None None O
natriuretic None None I-TRANS
peptide None None I-TRANS
( None None O
NT-pro-BNP None None O
) None None O
and None None O
echocardiography-derived None None O
pulmonary None None O
artery None None O
systolic None None O
pressure None None O
( None None O
PASP None None O
) None None O
levels None None O
in None None O
a None None O
high-altitude None None O
population-based None None O
study None None O
in None None O
Peru None None O
with None None O
and None None O
without None None O
chronic None None O
exposure None None O
to None None O
biomass None None O
fuel None None O
smoke None None O
. None None O

The None None O
learning None None I-FUNC
curve None None O
is None None O
short None None O
and None None O
additional None None O
tricks None None O
can None None O
be None None O
learnt None None O
to None None O
improve None None O
success None None O
. None None O

The None None O
medical None None O
records None None O
of None None O
all None None O
children None None O
( None None O
aged None None O
& None None O
lt None None O
; None None O
18 None None O
years None None O
) None None O
who None None O
presented None None O
to None None O
the None None O
emergency None None O
room None None O
with None None O
acute None None O
urinary None None O
retention None None I-FUNC
from None None O
2000 None None O
to None None O
2012 None None O
were None None O
reviewed None None O
. None None O

Data None None O
were None None O
collected None None O
on None None O
patient None None O
demographics None None O
and None None O
cause None None O
, None None O
treatment None None O
, None None O
and None None O
outcome None None O
of None None O
the None None O
urinary None None O
retention None None I-FUNC
. None None O

Causes None None O
of None None O
urinary None None O
retention None None I-FUNC
were None None O
mechanical None None O
obstruction None None O
in None None O
14 None None O
patients None None O
( None None O
25 None None O
% None None O
) None None O
, None None O
infection None None O
or None None O
inflammation None None O
in None None O
10 None None O
( None None O
18 None None O
% None None O
) None None O
, None None O
fecal None None O
impaction None None O
in None None O
7 None None O
( None None O
13 None None O
% None None O
) None None O
, None None O
neurologic None None O
disorders None None O
in None None O
6 None None O
( None None O
11 None None O
% None None O
) None None O
, None None O
gynecologic None None O
disorders None None O
in None None O
4 None None O
( None None O
7 None None O
% None None O
) None None O
, None None O
and None None O
behavioral None None O
processes None None O
in None None O
3 None None O
patients None None O
( None None O
5 None None O
% None None O
) None None O
; None None O
12 None None O
patients None None O
( None None O
21 None None O
% None None O
) None None O
were None None O
idiopathic None None O
. None None O

To None None O
examine None None O
the None None O
effects None None O
of None None O
neostigmine None None O
, None None O
an None None O
acetylcholinesterase None None I-PROTEIN
inhibitor None None O
that None None O
has None None O
been None None O
used None None O
to None None O
treat None None O
impaired None None O
bladder None None O
emptying None None O
on None None O
diabetic None None O
rat None None O
urinary None None O
bladder None None O
smooth None None O
muscle None None O
. None None O

Streptozotocin-diabetic None None O
( None None O
12 None None O
weeks None None O
) None None O
bladder None None O
tissue None None O
activity None None O
compared None None O
with None None O
control None None O
was None None O
assessed None None O
by None None O
using None None O
electrical None None O
field None None O
stimulation None None O
( None None O
EFS None None O
) None None O
in None None O
the None None O
presence None None O
and None None O
absence None None O
of None None O
the None None O
cholinesterase None None I-PROTEIN
inhibitor None None O
, None None O
neostigmine None None O
. None None O

These None None O
may None None O
include None None O
( None None O
i None None O
) None None O
reframing None None O
the None None O
way None None O
we None None O
think None None O
about None None O
the None None O
comorbidities None None O
of None None O
epilepsy None None O
, None None O
( None None O
ii None None O
) None None O
more None None O
precisely None None O
characterizing None None O
the None None O
cognitive None None O
and None None O
behavioral None None O
phenotypes None None O
of None None O
electroclinical None None I-DISEASE
syndromes None None I-DISEASE
, None None O
( None None O
iii None None O
) None None O
more None None O
carefully None None O
mapping None None O
the None None O
longitudinal None None O
trajectory None None O
of None None O
cognitive None None O
and None None O
behavioral None None O
features None None O
relative None None O
to None None O
the None None O
timing None None O
of None None O
seizures None None O
, None None O
and None None O
( None None O
iv None None O
) None None O
considering None None O
the None None O
links None None O
between None None O
cognitive None None O
, None None O
behavioral None None O
, None None O
and None None O
neurological None None O
phenotypes None None O
in None None O
the None None O
new None None O
classification None None O
scheme None None O
. None None O

Glycyrrhizin None None O
( None None O
Gly None None I-TRANS
) None None O
has None None O
been None None O
reported None None O
as None None O
an None None O
inhibitor None None O
of None None O
extracellular None None O
HMGB1 None None O
( None None O
high-mobility None None O
group None None O
box None None O
1 None None O
protein None None O
) None None O
cytokine None None O
's None None O
activity None None O
, None None O
and None None O
protects None None O
spinal None None O
cord None None O
, None None O
liver None None O
, None None O
heart None None O
and None None O
brain None None O
against None None O
ischemia-reperfusion-induced None None O
injury None None O
in None None O
rats None None O
. None None O

Intraperitoneal None None O
administration None None O
of None None O
Gly None None I-TRANS
( None None O
60mg/kg None None O
) None None O
significantly None None O
reduced None None O
the None None O
levels None None O
of None None O
serum None None O
TNF-α None None O
and None None O
IL-1β None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
Gly None None I-TRANS
possesses None None O
an None None O
anti-inflammation None None O
effect None None O
to None None O
protect None None O
the None None O
remote None None O
organs None None O
from None None O
burn-induced None None O
injury None None O
. None None O

Albumin None None O
and None None O
other None None O
plasma None None I-PROTEIN
proteins None None I-PROTEIN
are None None O
reduced None None O
, None None O
leading None None O
to None None O
increased None None O
free None None O
fraction None None O
of None None O
phenytoin None None O
, None None O
resulting None None O
in None None O
greater None None O
clearance None None O
and None None O
a None None O
lower None None O
total None None O
drug None None O
concentration None None O
. None None O

Loss None None O
of None None O
consciousness None None I-FUNC
is None None O
associated None None O
with None None O
high None None O
rates None None O
of None None O
intracranial None None O
bleeding None None O
. None None O

While None None O
headache None None O
is None None O
a None None O
common None None O
emergency None None O
department None None O
chief None None O
complaint None None O
, None None O
cerebral None None I-DISEASE
venous None None I-DISEASE
sinus None None I-DISEASE
thrombosis None None I-DISEASE
( None None O
CVST None None O
) None None O
is None None O
an None None O
infrequently None None O
encountered None None O
cause None None O
of None None O
headache None None O
and None None O
is None None O
often None None O
not None None O
included None None O
in None None O
emergency None None O
physicians None None O
' None None O
differential None None O
diagnoses None None O
for None None O
headache None None O
. None None O

A None None O
27-year-old None None O
female None None O
presented None None O
to None None O
our None None O
emergency None None O
department None None O
with None None O
headache None None O
, None None O
blurred None None O
vision None None I-FUNC
, None None O
and None None O
vomiting None None O
a None None O
day None None O
after None None O
being None None O
diagnosed None None O
with None None O
acute None None O
otitis None None O
media None None O
. None None O

We None None O
describe None None O
techniques None None O
that None None O
medical None None O
educators None None O
can None None O
use None None O
when None None O
leading None None O
teaching None None O
sessions None None O
to None None O
foster None None O
engagement None None O
and None None O
encourage None None O
self-directed None None O
learning None None I-FUNC
, None None O
based None None O
on None None O
current None None O
literature None None O
and None None O
evidence None None O
about None None O
learning None None I-FUNC
. None None O

Complexes None None O
with None None O
carboxylate None None O
ligands None None O
that None None O
contain None None O
maleimide None None O
and None None O
naphthalimide None None O
derived None None O
partial None None O
structures None None O
were None None O
synthesized None None O
, None None O
characterized None None O
and None None O
investigated None None O
for None None O
inhibition None None O
of None None O
the None None O
tumor-relevant None None O
enzyme None None O
thioredoxin None None I-PROTEIN
reductase None None I-PROTEIN
and None None O
antiproliferative None None O
effects None None O
in None None O
cancer None None O
cells None None O
. None None O

While None None O
important None None O
efforts None None O
were None None O
made None None O
in None None O
the None None O
development None None O
of None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
tracers None None O
for None None O
the None None O
in None None O
vivo None None O
molecular None None O
diagnosis None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
very None None O
few None None O
investigations None None O
to None None O
develop None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
MRI None None O
) None None O
probes None None O
were None None O
performed None None O
. None None O

This None None O
perturbation None None O
of None None O
mother-conceptus None None O
energy None None O
partitioning None None O
stimulated None None O
fetal None None O
pancreatic None None O
β-cell None None O
and None None O
adipocyte None None O
hyperplasia None None O
, None None O
thereby None None O
inducing None None O
an None None O
enduring None None O
competitive None None O
dominance None None O
of None None O
adipocytes None None O
over None None O
other None None O
tissues None None O
in None None O
the None None O
acquisition None None O
and None None O
sequestering None None O
of None None O
nutrient None None O
energy None None O
via None None O
intensified None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
hyperplastic None None O
adiposity None None O
. None None O

By None None O
the None None O
late None None O
20th None None O
century None None O
, None None O
a None None O
metabolic None None O
tipping None None O
point None None O
was None None O
reached None None O
at None None O
which None None O
the None None O
postprandial None None O
insulin None None I-PROTEIN
response None None O
was None None O
so None None O
intense None None O
, None None O
the None None O
relative None None O
number None None O
of None None O
adipocytes None None O
so None None O
large None None O
, None None O
and None None O
inactivity None None O
so None None O
pervasive None None O
that None None O
the None None O
competitive None None O
dominance None None O
of None None O
adipocytes None None O
in None None O
the None None O
sequestering None None O
of None None O
nutrient None None O
energy None None O
was None None O
inevitable None None O
and None None O
obesity None None O
was None None O
unavoidable None None O
. None None O

Seventeen None None O
of None None O
34 None None O
patients None None O
with None None O
PHACE None None O
syndrome None None O
and None None O
signs None None O
or None None O
symptoms None None O
of None None O
dysphagia None None O
or None None O
speech None None I-FUNC
or None None O
language None None I-FUNC
problems None None O
were None None O
included None None O
for None None O
analysis None None O
. None None O

Speech None None I-FUNC
or None None O
language None None I-FUNC
delay None None O
was None None O
noted None None O
in None None O
16 None None O
; None None O
posterior None None O
fossa None None O
abnormalities None None O
and None None O
lip None None O
or None None O
oropharynx None None O
hemangiomas None None O
were None None O
the None None O
most None None O
commonly None None O
seen None None O
associated None None O
finding None None O
in None None O
this None None O
group None None O
. None None O

A None None O
subset None None O
of None None O
individuals None None O
with None None O
PHACE None None O
syndrome None None O
experience None None O
dysphagia None None O
, None None O
speech None None I-FUNC
delay None None O
, None None O
or None None O
language None None I-FUNC
delay None None O
. None None O

Although None None O
this None None O
descriptive None None O
study None None O
was None None O
not None None O
comprehensive None None O
enough None None O
to None None O
examine None None O
prevalence None None O
, None None O
the None None O
high None None O
incidence None None O
of None None O
dysphagia None None O
and None None O
speech None None I-FUNC
and None None O
language None None I-FUNC
delay None None O
seen None None O
in None None O
our None None O
cohort None None O
warrants None None O
future None None O
prospective None None O
studies None None O
to None None O
further None None O
investigate None None O
the None None O
association None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
movement None None I-FUNC
of None None O
mitochondria None None O
and None None O
the None None O
spatiotemporal None None O
dynamics None None O
of None None O
the None None O
cortical None None O
F-actin None None O
network None None O
were None None O
directly None None O
visualized None None O
in None None O
vivo None None O
. None None O

Published None None O
by None None O
Elsevier None None O
B.V. None None O
Our None None O
previous None None O
study None None O
showed None None O
that None None O
3,3'-diselenodipropionic None None O
acid None None O
( None None O
DSePA None None O
) None None O
, None None O
a None None O
simple None None O
, None None O
stable None None O
, None None O
and None None O
water-soluble None None O
organoselenium None None O
exhibiting None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
( None None O
GPx None None O
) None None O
-like None None O
activity None None O
offered None None O
good None None O
radioprotection None None O
under None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
conditions None None O
. None None O

Activation None None O
of None None O
Toll-like None None O
receptors None None I-PROTEIN
( None None O
TLRs None None O
) None None O
signaling None None O
by None None O
intestinal None None O
microflora-derived None None O
bacterial None None O
products None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
injury None None O
defence None None O
for None None O
the None None O
host None None O
. None None O

To None None O
determine None None O
the None None O
effect None None O
of None None O
tiletamine-zolazepam None None O
( None None O
TZ None None O
) None None O
on None None O
canine None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
. None None O

Following None None O
preanesthetic None None O
baseline None None O
readings None None O
of None None O
IOP None None I-TRANS
, None None O
each None None O
dog None None O
received None None O
IV None None O
TZ None None O
and None None O
then None None O
the None None O
IOP None None I-TRANS
values None None O
were None None O
measured None None O
every None None O
10 None None O
min None None O
for None None O
40 None None O
min None None O
in None None O
all None None O
treatments None None O
. None None O

This None None O
could None None O
be None None O
an None None O
option None None O
for None None O
induction None None O
or None None O
surgical None None O
procedures None None O
in None None O
dogs None None O
with None None O
ophthalmic None None O
problems None None O
when None None O
an None None O
increase None None O
in None None O
IOP None None I-TRANS
is None None O
undesirable None None O
. None None O

TNFα None None O
converges None None O
as None None O
a None None O
non-selective None None O
stimulant None None O
of None None O
HSPC None None O
activity None None O
and None None O
both None None O
cytokines None None O
synergize None None O
with None None O
other None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
in None None O
promoting None None O
differentiation None None O
. None None O

ACACA None None O
, None None O
FASN None None O
, None None O
LPL None None O
, None None O
CD36 None None O
, None None O
FABP3 None None O
, None None O
SCD1 None None O
and None None O
SCD5 None None O
) None None O
and None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
SREBF1 None None O
and None None O
PPARG None None O
) None None O
, None None O
or None None O
in None None O
the None None O
constituent None None O
FA None None O
of None None O
mammary None None O
tissue None None O
. None None O

Directions None None O
for None None O
change None None O
were None None O
identified None None O
, None None O
including None None O
improved None None O
electronic None None O
data None None O
collection None None O
and None None O
communication None None O
systems None None O
, None None O
reporting None None O
of None None O
service None None O
delivery None None O
and None None O
outcomes None None O
between None None O
states None None O
and None None O
territories None None O
, None None O
professional None None O
collaboration None None O
, None None O
service None None O
co-location None None O
and None None O
interprofessional None None O
learning None None I-FUNC
and None None O
development None None O
. None None O

In None None O
contrast None None O
to None None O
hominin None None O
encephalization None None O
, None None O
the None None O
final None None O
Pleistocene None None O
and None None O
Holocene None None O
reduction None None O
in None None O
cranial None None O
volume None None O
has None None O
attracted None None O
very None None O
little None None O
attention None None I-FUNC
and None None O
remains None None O
unexplained None None O
. None None O

means None None O
of None None O
storing None None O
memory None None I-FUNC
outside None None O
the None None O
brain None None O
. None None O

Other None None O
genes None None O
were None None O
reported None None O
for None None O
their None None O
role None None O
as None None O
protective/risk None None O
factors None None O
in None None O
complex None None O
diseases None None O
such None None O
as None None O
multiple None None O
sclerosis None None O
, None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
and None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

The None None O
antibacterial None None O
activity None None O
of None None O
the None None O
CFS None None O
precipitated None None O
with None None O
40 None None O
% None None O
ammonium None None O
sulfate None None O
( None None O
AS None None O
) None None O
remained None None O
even None None O
after None None O
treatment None None O
at None None O
60 None None O
and None None O
100 None None O
°C None None O
, None None O
at None None O
pH None None O
4 None None O
and None None O
10 None None O
and None None O
with None None O
proteolytic None None O
enzymes None None I-PROTEIN
, None None O
detergents None None O
and None None O
heavy None None O
metals None None O
. None None O

In None None O
addition None None O
to None None O
stable None None O
and None None O
cyclic None None O
subtilosin None None O
A None None O
, None None O
a None None O
mixture None None O
of None None O
many None None O
extracellular None None O
antibacterial None None O
peptides None None I-TRANS
was None None O
also None None O
detected None None O
in None None O
the None None O
KKU213 None None O
culture None None O
. None None O

Adults None None O
with None None O
congenital None None O
heart None None O
disease None None O
require None None O
lifelong None None O
surveillance None None O
, None None O
follow-up None None O
imaging None None O
, None None O
and None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
by None None O
appropriately None None O
trained None None O
and None None O
familiar None None O
physicians None None O
and None None O
extenders None None O
. None None O

Thus None None O
, None None O
in None None O
an None None O
effort None None O
to None None O
generate None None O
an None None O
evidence None None O
base None None O
for None None O
communication None None O
about None None O
shared None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
informed None None O
consent None None O
for None None O
vascular None None O
surgery None None O
patients None None O
and None None O
their None None O
surrogates None None O
, None None O
we None None O
defined None None O
the None None O
incidence None None O
, None None O
risks None None O
, None None O
and None None O
outcomes None None O
of None None O
postoperative None None O
cardiac None None O
arrest None None O
after None None O
primary None None O
vascular None None O
surgery None None O
procedures None None O
. None None O

Further None None O
research None None O
into None None O
how None None O
to None None O
best None None O
communicate None None O
risk None None O
, None None O
to None None O
elicit None None O
patient None None O
preferences None None O
, None None O
and None None O
to None None O
engage None None O
in None None O
shared None None O
decision None None I-FUNC
making None None I-FUNC
is None None O
needed None None O
. None None O

Fourth None None O
, None None O
vascular None None O
cannulation None None O
performance None None O
of None None O
the None None O
systems None None O
was None None O
compared None None O
, None None O
studying None None O
cannulation None None O
time None None O
, None None O
Imperial None None O
College None None O
Complex None None O
Cannulation None None O
Scoring None None O
Tool None None O
score None None O
, None None O
and None None O
the None None O
number None None O
of None None O
wall None None O
hits None None O
and None None O
catheter None None O
movements None None I-FUNC
within None None O
rigid None None O
studies None None O
. None None O

We None None O
identified None None O
306,438 None None O
patients None None O
operated None None O
on None None O
for None None O
PAD None None O
, None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
, None None O
and None None O
abdominal None None O
aortic None None O
aneurysm None None O
. None None O

Nonelective None None O
admissions None None O
were None None O
more None None O
common None None O
among None None O
SNPH None None O
patients None None O
who None None O
presented None None O
with None None O
more None None O
advanced None None O
PAD None None O
( None None O
P None None O
& None None O
gt None None O
; None None O
.05 None None O
) None None O
and None None O
symptomatic None None O
carotid None None I-DISEASE
stenosis None None I-DISEASE
( None None O
P None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
. None None O

Reactivation None None O
( None None O
RP None None O
) None None O
can None None O
return None None O
a None None O
memory None None I-FUNC
to None None O
an None None O
unstable None None O
state None None O
, None None O
from None None O
which None None O
it None None O
must None None O
be None None O
restabilized None None O
( None None O
reconsolidated None None O
) None None O
if None None O
it None None O
is None None O
to None None O
persist None None O
. None None O

The None None O
N-methyl-d-aspartate None None O
( None None O
NMDA None None O
) None None O
partial None None O
agonist None None O
d-cycloserine None None O
( None None O
DCS None None O
) None None O
may None None O
promote None None O
memory None None I-FUNC
destabilization None None O
. None None O

Individuals None None O
with None None O
PTSD None None O
were None None O
randomized None None O
as None None O
follows None None O
: None None O
Study None None O
One None None O
: None None O
propranolol None None O
with None None O
memory None None I-FUNC
reactivation None None O
( None None O
n=10 None None O
) None None O
or None None O
without None None O
reactivation None None O
( None None O
n=8 None None O
) None None O
; None None O
Study None None O
Two None None O
: None None O
reactivation None None O
mifepristone None None O
( None None O
n=13 None None O
) None None O
, None None O
non-reactivation None None O
( None None O
NRP None None O
) None None O
mifepristone None None O
( None None O
n=15 None None O
) None None O
, None None O
or None None O
double None None O
placebo None None O
( None None O
PL None None O
) None None O
( None None O
n=15 None None O
) None None O
; None None O
Study None None O
Three None None O
: None None O
reactivation None None O
mifepristone None None O
plus None None O
d-cycloserine None None O
( None None O
n=16 None None O
) None None O
, None None O
or None None O
two None None O
placebos None None O
( None None O
n=15 None None O
) None None O
. None None O

A None None O
week None None O
later None None O
they None None O
engaged None None O
in None None O
script-driven None None O
traumatic None None O
mental None None I-FUNC
imagery None None I-FUNC
, None None O
while None None O
heart None None O
rate None None O
( None None O
HR None None O
) None None O
, None None O
skin None None O
conductance None None O
( None None O
SC None None O
) None None O
, None None O
and None None O
facial None None O
electromyogram None None O
( None None O
EMG None None O
) None None O
responses None None O
were None None O
measured None None O
. None None O

Various None None O
lines None None O
of None None O
evidence None None O
suggest None None O
that None None O
appetite-related None None O
neuropeptides None None O
in None None O
the None None O
hypothalamus None None I-REGION
are None None O
regulated None None O
by None None O
adiposity None None O
signals None None O
such None None O
as None None O
leptin None None O
and None None O
insulin None None I-PROTEIN
in None None O
mammals None None O
. None None O

Hypothalamic None None O
NPY None None I-TRANS
mRNA None None O
levels None None O
were None None O
significantly None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
decreased None None O
after None None O
14 None None O
days None None O
of None None O
age None None O
, None None O
whereas None None O
hypothalamic None None O
POMC None None I-TRANS
mRNA None None O
levels None None O
were None None O
significantly None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
increased None None O
at None None O
28 None None O
days None None O
of None None O
age None None O
. None None O

We None None O
next None None O
examined None None O
the None None O
correlation None None O
of None None O
hypothalamic None None O
NPY None None I-TRANS
and None None O
POMC None None I-TRANS
mRNA None None O
levels None None O
and None None O
several None None O
parameters None None O
at None None O
28 None None O
days None None O
of None None O
age None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
the None None O
gene None None O
expressions None None O
of None None O
NPY None None I-TRANS
and None None O
POMC None None I-TRANS
do None None O
not None None O
depend None None O
on None None O
adiposity None None O
in None None O
chickens None None O
, None None O
at None None O
least None None O
in None None O
28-day-old None None O
layer None None O
chickens None None O
. None None O

Although None None O
various None None O
guidelines None None O
have None None O
been None None O
developed None None O
for None None O
the None None O
management None None O
of None None O
these None None O
patients None None O
, None None O
issues None None O
around None None O
antimicrobial-related None None O
considerations None None O
in None None O
critically None None O
ill None None O
patients None None O
require None None O
further None None O
evidence-based None None O
attention None None I-FUNC
. None None O

The None None O
emergency None None O
physician None None O
must None None O
be None None O
aware None None O
of None None O
the None None O
ethical None None O
and None None O
medico-legal None None O
parameters None None O
that None None O
govern None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Therefore None None O
the None None O
authors None None O
investigate None None O
the None None O
usefulness None None O
of None None O
participant None None O
and None None O
informant None None O
SCCs None None O
in None None O
predicting None None O
change None None O
in None None O
cognition None None O
, None None O
functional None None O
abilities None None O
, None None O
and None None O
diagnostic None None O
classification None None O
of None None O
mild None None O
cognitive None None O
impairment None None O
or None None O
dementia None None I-DISEASE
in None None O
a None None O
community-dwelling None None O
sample None None O
over None None O
4 None None O
years None None O
. None None O

An None None O
informant None None O
completed None None O
a None None O
baseline None None O
questionnaire None None O
that None None O
included None None O
15 None None O
memory None None I-FUNC
and None None O
4 None None O
nonmemory None None O
SCC None None O
questions None None O
relating None None O
to None None O
the None None O
participant None None O
. None None O

Informant-related None None O
memory None None I-FUNC
questions None None O
were None None O
associated None None O
with None None O
global None None O
cognitive None None O
and None None O
functional None None O
decline None None O
and None None O
with None None O
diagnostic None None O
conversion None None O
over None None O
4 None None O
years None None O
. None None O

Older None None O
participants None None O
completed None None O
baseline None None O
measures None None O
of None None O
memory None None I-FUNC
and None None O
executive None None O
function None None O
, None None O
health None None O
, None None O
and None None O
baseline None None O
and None None O
post-treatment None None O
Hamilton None None O
Depression None None I-DISEASE
Scales None None O
( None None O
HAM-D None None O
) None None O
in None None O
a None None O
12-week None None O
trial None None O
comparing None None O
psychotherapies None None O
( None None O
problem-solving None None O
vs. None None O
supportive None None O
; None None O
N None None O
= None None O
46 None None O
) None None O
. None None O

Psychotherapies None None O
that None None O
support None None O
or None None O
improve None None O
the None None O
executive None None O
skill None None O
of None None O
switching None None O
may None None O
augment None None O
treatment None None O
response None None O
for None None O
older None None O
patients None None O
exhibiting None None O
executive None None O
dysfunction None None O
in None None O
depression None None I-DISEASE
. None None O

Published None None O
by None None O
Elsevier None None O
Inc. None None O
Depression None None I-DISEASE
is None None O
an None None O
important None None O
precursor None None O
to None None O
dementia None None I-DISEASE
, None None O
but None None O
less None None O
is None None O
known None None O
about None None O
the None None O
role None None O
dementia None None I-DISEASE
plays None None O
in None None O
altering None None O
the None None O
course None None O
of None None O
depression None None I-DISEASE
. None None O

Prospective None None O
cohort None None O
study None None O
using None None O
the None None O
longitudinal None None O
Uniform None None O
Data None None O
Set None None O
of None None O
the None None O
National None None O
Alzheimer None None I-DISEASE
's None None O
Coordinating None None O
Center None None O
( None None O
2005-2013 None None O
) None None O
. None None O

27,776 None None O
subjects None None O
with None None O
dementia None None I-DISEASE
, None None O
MCI None None O
, None None O
or None None O
normal None None O
cognition None None O
. None None O

Rates None None O
of None None O
depression None None I-DISEASE
were None None O
significantly None None O
higher None None O
in None None O
subjects None None O
with None None O
MCI None None O
and None None O
dementia None None I-DISEASE
compared None None O
with None None O
those None None O
with None None O
normal None None O
cognition None None O
at None None O
index None None O
visit None None O
. None None O

In None None O
the None None O
subjects None None O
without None None O
depression None None I-DISEASE
at None None O
the None None O
index None None O
visit None None O
( None None O
N None None O
= None None O
18,842 None None O
) None None O
, None None O
those None None O
with None None O
MCI None None O
and None None O
dementia None None I-DISEASE
had None None O
higher None None O
probabilities None None O
of None None O
depression None None I-DISEASE
diagnosis None None O
2 None None O
years None None O
post None None O
index None None O
visit None None O
than None None O
those None None O
with None None O
normal None None O
cognition None None O
: None None O
MCI None None O
= None None O
21.7 None None O
% None None O
, None None O
dementia None None I-DISEASE
= None None O
24.7 None None O
% None None O
, None None O
normal None None O
cognition None None O
= None None O
10.5 None None O
% None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
efforts None None O
to None None O
effectively None None O
engage None None O
and None None O
treat None None O
older None None O
adults None None O
with None None O
dementia None None I-DISEASE
will None None O
need None None O
also None None O
to None None O
address None None O
co-occurring None None O
depression None None I-DISEASE
. None None O

Our None None O
previous None None O
results None None O
indicated None None O
that None None O
TLR4 None None O
increased None None O
the None None O
DNA None None O
damage None None O
response None None O
induced None None O
by None None O
TiO2 None None O
NPs None None O
, None None O
due None None O
to None None O
enhanced None None O
NP None None O
uptake None None O
into None None O
the None None O
cytoplasm None None O
, None None O
whereas None None O
TLR3 None None O
expression None None O
decreased None None O
the None None O
DNA None None O
damage None None O
response None None O
induced None None O
by None None O
TiO2 None None O
NPs None None O
because None None O
of None None O
NP None None O
retention None None I-FUNC
in None None O
the None None O
endosome None None O
. None None O

This None None O
methodology None None O
gives None None O
promising None None O
results None None O
in None None O
the None None O
analysis None None O
of None None O
water None None O
saturated None None O
samples None None O
as None None O
the None None O
limited None None O
amount None None O
of None None O
sorbents None None O
reduces None None O
water None None O
retention None None I-FUNC
. None None O

Molecular None None O
docking None None O
of None None O
the None None O
two None None O
peptides None None I-TRANS
to None None O
the None None O
Fc None None O
fragment None None O
simultaneously None None O
showed None None O
that None None O
FYWHCLDE None None O
( None None O
1 None None O
) None None O
stood None None O
still None None O
but None None O
FYCHTIDE None None O
( None None O
3 None None O
) None None O
shifted None None O
aside None None O
the None None O
CH2CH3 None None O
inter-domain None None O
. None None O

One None None O
runs None None O
a None None O
test None None O
mixture None None O
containing None None O
20 None None O
standards None None O
on None None O
a None None O
standard None None O
stationary None None O
phase None None O
and None None O
enters None None O
their None None O
gradient None None O
retention None None I-FUNC
times None None O
into None None O
open-source None None O
software None None O
available None None O
at None None O
www.measureyourgradient.org None None O
. None None O

Furthermore None None O
, None None O
a None None O
method None None O
to None None O
accurately None None O
predict None None O
retention None None I-FUNC
times None None O
of None None O
specific None None O
lipid None None O
components None None O
for None None O
this None None O
type None None O
of None None O
chromatography None None O
is None None O
presented None None O
. None None O

Unexpectedly None None O
, None None O
the None None O
recovery None None O
rates None None O
for None None O
several None None O
γ-glutamyl None None O
peptides None None I-TRANS
in None None O
the None None O
serum None None O
samples None None O
were None None O
quite None None O
low None None O
, None None O
whereas None None O
values None None O
for None None O
some None None O
γ-glutamyl None None O
peptides None None I-TRANS
in None None O
the None None O
liver None None O
samples None None O
were None None O
highly None None O
elevated None None O
. None None O

© None None O
2014 None None O
John None None O
Wiley None None O
& None None O
amp None None O
; None None O
Sons None None O
Ltd. None None O
Research None None O
on None None O
animals None None O
, None None O
infants None None O
, None None O
children None None O
, None None O
and None None O
adults None None O
provides None None O
evidence None None O
that None None O
distinct None None O
cognitive None None O
systems None None O
underlie None None O
navigation None None O
and None None O
object None None I-FUNC
recognition None None I-FUNC
. None None O

To None None O
evaluate None None O
a None None O
group-based None None O
self-management None None O
program None None O
( None None O
SMP None None O
) None None O
delivered None None O
as None None O
part None None O
of None None O
a None None O
quality None None O
improvement None None O
program None None O
, None None O
Co-Creating None None O
Health None None O
, None None O
for None None O
patients None None O
living None None O
with None None O
one None None O
of None None O
four None None O
long-term None None O
conditions None None O
( None None O
LTCs None None O
) None None O
: None None O
chronic None None O
obstructive None None O
pulmonary None None O
disease None None O
, None None O
depression None None I-DISEASE
, None None O
diabetes None None O
, None None O
and None None O
musculoskeletal None None O
pain None None O
. None None O

Patients None None O
' None None O
anxiety None None O
( None None O
ES None None O
0.37 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
and None None O
depression None None I-DISEASE
( None None O
ES None None O
0.31 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
significantly None None O
improved None None O
. None None O

The None None O
development None None O
of None None O
human None None O
body None None O
perception None None I-FUNC
has None None O
long None None O
been None None O
investigated None None O
, None None O
but None None O
little None None O
is None None O
known None None O
about None None O
its None None O
early None None O
origins None None O
. None None O

We None None O
now None None O
show None None O
that None None O
the None None O
amount None None O
of None None O
heterochromatin None None O
protein None None O
1γ None None O
( None None O
HP1γ None None O
) None None O
increases None None O
during None None O
neuronal None None O
maturation None None O
in None None O
the None None O
mouse None None O
neocortex None None I-REGION
. None None O

Operative None None O
interventions None None O
in None None O
the None None O
elderly None None O
require None None O
coordinated None None O
attention None None I-FUNC
to None None O
the None None O
specific None None O
requirements None None O
of None None O
the None None O
aged None None O
. None None O

The None None O
methanol None None O
extract None None O
of None None O
A. None None O
arguta None None O
( None None O
20 None None O
μg/mL None None O
) None None O
stems None None O
lowered None None O
nitric None None I-TRANS
oxide None None I-TRANS
production None None O
in None None O
LPS-stimulated None None O
Raw None None O
264.7 None None O
cells None None O
by None None O
40 None None O
% None None O
. None None O

Among None None O
the None None O
5 None None O
layers None None O
, None None O
the None None O
chloroform None None O
layer None None O
had None None O
the None None O
greatest None None O
inhibitory None None O
effect None None O
on None None O
LPS-stimulated None None O
nitric None None I-TRANS
oxide None None I-TRANS
production None None O
and None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
mRNA None None O
expression None None O
in None None O
Raw None None O
264.7 None None O
cells None None O
. None None O

This None None O
was None None O
accompanied None None O
with None None O
the None None O
reduced None None O
phosphorylation None None O
of None None O
mitogen-activated None None O
protein None None O
kinases None None I-PROTEIN
including None None O
extracellular None None O
signal-regulated None None O
protein None None O
kinase None None O
1/2 None None O
, None None O
c-Jun None None O
N-terminal None None O
protein None None O
kinase None None O
, None None O
and None None O
p38 None None O
. None None O

Labour None None O
is None None O
more None None O
likely None None O
to None None O
be None None O
prolonged None None O
and None None O
dysfunctional None None O
, None None O
leading None None O
to None None O
the None None O
requirements None None O
for None None O
higher None None O
doses None None O
of None None O
oxytocin None None I-TRANS
and None None O
increased None None O
risks None None O
of None None O
operative None None O
deliveries None None O
and None None O
morbidity None None O
. None None O

Inhibition-induced None None O
plasticity None None O
occurs None None O
in None None O
a None None O
cortical None None O
network None None O
, None None O
known None None O
to None None O
be None None O
crucial None None O
for None None O
tinnitus None None O
perception None None I-FUNC
. None None O

The None None O
detection None None O
was None None O
carried None None O
out None None O
after None None O
the None None O
modification None None O
of None None O
carbon None None O
screen None None O
printed None None O
electrodes None None O
( None None O
SPEs None None O
) None None O
by None None O
immobilization None None O
of None None O
sarcosine None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
SOX None None O
) None None O
on None None O
the None None O
electrode None None O
surface None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
we None None O
have None None O
synthesized None None O
hyperbranched None None O
polyester None None O
microspheres None None O
with None None O
carboxylic None None O
acid None None O
functional None None O
groups None None O
( None None O
HBPE-CA None None O
) None None O
and None None O
developed None None O
a None None O
label-free None None O
electrochemical None None O
aptamer None None O
biosensor None None O
using None None O
thrombin-binding None None O
aptamer None None O
( None None O
TBA None None O
) None None O
as None None O
receptor None None I-PROTEIN
for None None O
the None None O
measurement None None O
of None None O
thrombin None None I-PROTEIN
in None None O
whole None None O
blood None None O
. None None O

Binding None None O
of None None O
the None None O
thrombin None None I-PROTEIN
at None None O
the None None O
modified None None O
ITO None None O
electrode None None O
surface None None O
greatly None None O
restrained None None O
access None None O
of None None O
electrons None None O
for None None O
a None None O
redox None None O
probe None None O
of None None O
[ None None O
Fe None None O
( None None O
CN None None O
) None None O
6 None None O
] None None O
( None None O
3-/4- None None O
) None None O
. None None O

Control None None O
experiments None None O
were None None O
also None None O
carried None None O
out None None O
by None None O
using None None O
bull None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
BSA None None O
) None None O
and None None O
lysozyme None None I-PROTEIN
in None None O
the None None O
absence None None O
of None None O
thrombin None None I-PROTEIN
. None None O

Research None None O
is None None O
scarce None None O
and None None O
successful None None O
interventions None None O
are None None O
lacking.To None None O
evaluate None None O
the None None O
effect None None O
of None None O
a None None O
group-based None None O
Cognitive None None O
Behavioural None None O
Therapy None None O
( None None O
CBT None None O
) None None O
intervention None None O
in None None O
relation None None O
to None None O
headache None None O
, None None O
pain None None O
perception None None I-FUNC
, None None O
psychological None None O
symptoms None None O
and None None O
quality None None O
of None None O
life None None O
in None None O
patients None None O
with None None O
CPTH None None O
. None None O

In None None O
contrast None None O
, None None O
mean None None O
serum None None O
levels None None O
of None None O
albumin None None O
, None None O
ferritin None None I-PROTEIN
and None None O
haemoglobin None None O
were None None O
all None None O
lower None None O
in None None O
cases None None O
( None None O
p None None O
= None None O
0.008 None None O
, None None O
p None None O
= None None O
0.043 None None O
and None None O
p None None O
= None None O
0.016 None None O
, None None O
respectively None None O
) None None O
. None None O

Our None None O
cases None None O
exhibited None None O
higher None None O
levels None None O
of None None O
iPTH None None O
and None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
than None None O
control None None O
patients None None O
, None None O
reinforcing None None O
the None None O
role None None O
of None None O
secondary None None O
hyperparathyroidism None None O
in None None O
tendon None None O
weakening None None O
. None None O

Our None None O
previous None None O
studies None None O
suggested None None O
that None None O
RBM5 None None O
expression None None O
was None None O
negatively None None O
correlated None None O
with None None O
the None None O
expression None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
in None None O
non-small None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
tissues None None O
. None None O

The None None O
linear None None O
regression None None O
showed None None O
a None None O
negative None None O
association None None O
between None None O
delta None None O
( None None O
% None None O
) None None O
adiponectin None None O
and None None O
delta None None O
( None None O
% None None O
) None None O
insulin None None I-PROTEIN
( None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
interdisciplinary None None O
therapy None None O
models None None O
that None None O
included None None O
aerobic None None O
plus None None O
strength None None O
training None None O
were None None O
more None None O
effective None None O
than None None O
only None None O
aerobic None None O
training None None O
to None None O
improve None None O
lipid None None O
profile None None O
and None None O
insulin None None I-PROTEIN
sensitivity None None O
, None None O
as None None O
well None None O
as None None O
the None None O
inflammatory None None O
state None None O
by None None O
increasing None None O
adiponectin None None O
. None None O

Prolonged None None O
seizures None None O
and None None O
status None None I-DISEASE
epilepticus None None I-DISEASE
are None None O
common None None O
neurological None None O
medical None None O
emergencies None None O
. None None O

We None None O
have None None O
detected None None O
six None None O
novel None None O
ZEB1 None None O
mutations None None O
; None None O
c.1749_1750del None None O
; None None O
p. None None O
( None None O
Pro584* None None O
) None None O
and None None O
c.1717_1718del None None O
; None None O
p. None None O
( None None O
Val573Phefs*12 None None O
) None None O
in None None O
two None None O
Czech None None I-TRANS
families None None O
, None None O
c.1176dup None None O
; None None O
p. None None O
( None None O
Ala393Serfs*19 None None O
) None None O
, None None O
c.1100C None None O
& None None O
gt None None O
; None None O
A None None O
; None None O
p. None None O
( None None O
Ser367* None None O
) None None O
, None None O
c.627del None None O
; None None O
p. None None O
( None None O
Phe209Leufs*11 None None O
) None None O
in None None O
three None None O
British None None O
families None None O
and None None O
a None None O
splice None None O
site None None O
mutation None None O
, None None O
c.685-2A None None O
& None None O
gt None None O
; None None O
G None None O
, None None O
in None None O
a None None O
patient None None O
of None None O
Sri None None O
Lankan None None O
origin None None O
. None None O

This None None O
prospective None None O
, None None O
observational None None O
, None None O
single-hospital None None O
study None None O
involved None None O
104 None None O
non-anemic None None O
pregnant None None O
women None None O
, None None O
divided None None O
into None None O
4 None None O
groups None None O
based None None O
on None None O
the None None O
quartile None None O
values None None O
for None None O
ferritin None None I-PROTEIN
at None None O
the None None O
first None None O
trimester None None O
of None None O
pregnancy None None O
. None None O

We None None O
observed None None O
that None None O
ferritin None None I-PROTEIN
levels None None O
at None None O
early None None O
pregnancy None None O
were None None O
significantly None None O
correlated None None O
to None None O
glucose None None O
level None None O
after None None O
OGTT None None O
at None None O
1-h None None O
and None None O
2-h None None O
( None None O
rho=0.21 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.05 None None O
; None None O
rho=0.43 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
respectively None None O
) None None O
. None None O

In None None O
multivariate None None O
regression None None O
analysis None None O
, None None O
serum None None O
ferritin None None I-PROTEIN
was None None O
a None None O
significant None None O
determinant None None O
of None None O
glycemia None None O
at None None O
2-h None None O
OGTT None None O
. None None O

We None None O
report None None O
for None None O
the None None O
first None None O
time None None O
that None None O
high None None O
ferritin None None I-PROTEIN
values None None O
in None None O
early None None O
pregnancy None None O
are None None O
predictors None None O
of None None O
impaired None None O
glucose None None O
tolerance None None O
in None None O
non-anemic None None O
women None None O
. None None O

Workplace None None O
discrimination None None O
is None None O
common None None O
, None None O
associated None None O
with None None O
smoking None None O
and None None O
alcohol None None O
use None None O
, None None O
and None None O
merits None None O
further None None O
policy None None O
attention None None I-FUNC
, None None O
given None None O
the None None O
impact None None O
of None None O
these None None O
behaviors None None O
on None None O
morbidity None None O
and None None O
mortality None None O
. None None O

The None None O
University None None O
of None None O
New None None O
Mexico None None O
Health None None O
Sciences None None O
Center None None O
( None None O
UNMHSC None None O
) None None O
adopted None None O
a None None O
new None None O
Vision None None I-FUNC
to None None O
work None None O
with None None O
community None None O
partners None None O
to None None O
help None None O
New None None O
Mexico None None O
make None None O
more None None O
progress None None O
in None None O
health None None O
and None None O
health None None O
equity None None O
than None None O
any None None O
other None None O
state None None O
by None None O
2020 None None O
. None None O

National None None O
measures None None O
that None None O
compare None None O
states None None O
on None None O
the None None O
basis None None O
of None None O
health None None O
determinants None None O
and None None O
outcomes None None O
were None None O
adopted None None O
in None None O
2013 None None O
as None None O
part None None O
of None None O
Vision None None I-FUNC
2020 None None O
target None None O
measures None None O
for None None O
gauging None None O
progress None None O
toward None None O
improved None None O
health None None O
and None None O
health None None O
care None None O
in None None O
New None None O
Mexico None None O
. None None O

Early None None O
progress None None O
in None None O
New None None O
Mexico None None O
's None None O
health None None O
outcomes None None O
measures None None O
and None None O
state None None O
health None None O
ranking None None O
is None None O
a None None O
promising None None O
sign None None O
of None None O
movement None None I-FUNC
toward None None O
Vision None None I-FUNC
2020 None None O
. None None O

Excessive None None O
daytime None None O
sleepiness None None O
( None None O
EDS None None O
) None None O
has None None O
been None None O
associated None None O
with None None O
singular None None O
independent None None O
symptoms None None O
of None None O
metabolic None None O
syndrome None None O
, None None O
such None None O
as None None O
insulin None None I-PROTEIN
resistance None None O
and None None O
diabetes None None O
. None None O

Since None None O
variations None None O
in None None O
( None None O
123 None None O
) None None O
I-PIA None None O
levels None None O
reflect None None O
variations None None O
in None None O
CYP2C19 None None O
activity None None O
, None None O
CYP2C19 None None O
activity None None O
can None None O
be None None O
estimated None None O
by None None O
quantitative None None O
analysis None None O
of None None O
( None None O
123 None None O
) None None O
I-PIA None None O
levels None None O
. None None O

The None None O
amount None None O
of None None O
( None None O
125 None None O
) None None O
I-PIA None None O
generated None None O
was None None O
calculated None None O
as None None O
the None None O
normalized None None O
peak None None O
area None None O
of None None O
the None None O
chromatogram None None O
. None None O

A None None O
biodistribution None None O
study None None O
of None None O
( None None O
125 None None O
) None None O
I-IMP None None O
was None None O
performed None None O
to None None O
determine None None O
the None None O
organ None None O
distribution None None O
of None None O
( None None O
125 None None O
) None None O
I-IMP/ None None O
( None None O
125 None None O
) None None O
I-IMP None None O
metabolites None None O
and None None O
the None None O
effect None None O
of None None O
SKF-525A None None O
. None None O

SKF-525A None None O
did None None O
not None None O
greatly None None O
affect None None O
the None None O
biodistribution None None O
of None None O
( None None O
125 None None O
) None None O
I-IMP/ None None O
( None None O
125 None None O
) None None O
I-IMP None None O
metabolites None None O
in None None O
vivo None None O
. None None O

However None None O
, None None O
( None None O
123 None None O
) None None O
I-PIA None None O
was None None O
not None None O
detected None None O
in None None O
the None None O
livers None None O
or None None O
kidneys None None O
of None None O
mice None None O
treated None None O
with None None O
SKF-525A None None O
. None None O

Variations None None O
in None None O
CYP None None O
activity None None O
could None None O
be None None O
detected None None O
in None None O
the None None O
blood None None O
, None None O
liver None None O
and None None O
kidney None None O
as None None O
changes None None O
in None None O
the None None O
peak None None O
area None None O
of None None O
( None None O
123 None None O
) None None O
I-PIA None None O
. None None O

We None None O
investigated None None O
zinc None None I-TRANS
protoporphyrin None None O
IX None None I-REGION
( None None O
ZnPP None None O
) None None O
-forming None None O
properties None None O
of None None O
various None None O
internal None None O
organs None None O
from None None O
pigs None None O
and None None O
chickens None None O
. None None O

Situation None None O
awareness None None O
( None None O
SA None None O
) None None O
is None None O
a None None O
vital None None O
construct None None O
for None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
intense None None O
, None None O
dynamic None None O
environments None None O
such None None O
as None None O
trauma None None O
resuscitation None None O
. None None O

The None None O
condition None None O
is None None O
usually None None O
associated None None O
with None None O
a None None O
phosphaturic None None O
mesenchymal None None O
tumor None None O
, None None O
which None None O
produces None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
23 None None O
, None None O
the None None O
primary None None O
circulating None None O
factor None None O
responsible None None O
for None None O
reduced None None O
tubular None None O
phosphate None None O
reabsorption None None O
. None None O

He None None O
had None None O
a None None O
tingling None None O
sensation None None I-FUNC
and None None O
paresthesia None None O
in None None O
the None None O
sole None None O
and None None O
medial None None O
border None None O
of None None O
the None None O
foot None None O
along None None O
the None None O
distribution None None O
of None None O
the None None O
medial None None O
and None None O
lateral None None O
plantar None None O
nerves None None O
. None None O

The None None O
postoperative None None O
patient None None O
perceptions None None I-FUNC
of None None O
foot None None O
pain None None O
were None None O
significantly None None O
better None None O
than None None O
those None None O
from None None O
a None None O
comparable None None O
sample None None O
of None None O
patients None None O
presenting None None O
for None None O
a None None O
surgical None None O
opinion None None O
( None None O
t None None O
[ None None O
69 None None O
] None None O
= None None O
6.80 None None O
) None None O
, None None O
just None None O
as None None O
were None None O
the None None O
perceptions None None I-FUNC
of None None O
foot None None O
function None None O
, None None O
foot None None O
health None None O
, None None O
and None None O
footwear None None O
comfort None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
.001 None None O
for None None O
all None None O
) None None O
. None None O

Numbers None None O
of None None O
TH2 None None O
memory None None I-FUNC
cells None None O
gradually None None O
increase None None O
in None None O
allergic None None O
patients None None O
with None None O
the None None O
progression None None O
of None None O
disease None None O
and None None O
persist None None O
in None None O
the None None O
lungs None None O
during None None O
remission None None O
, None None O
although None None O
the None None O
mechanism None None O
is None None O
not None None O
clear None None O
. None None O

Memory None None I-FUNC
cells None None O
in None None O
peripheral None None O
blood None None O
were None None O
monitored None None O
weekly None None O
with None None O
flow None None O
cytometry None None O
. None None O

TSLP None None O
signaling None None O
in None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
is None None O
required None None O
for None None O
the None None O
generation/maintenance None None O
of None None O
memory None None I-FUNC
cells None None O
after None None O
in None None O
vivo None None O
priming None None O
. None None O

Although None None O
in None None O
vitro-differentiated None None O
TSLPR-deficient None None O
TH2 None None O
cells None None O
develop None None O
into None None O
memory None None I-FUNC
cells None None O
with None None O
equal None None O
efficiency None None O
to None None O
wild-type None None O
cells None None O
, None None O
the None None O
recall None None O
response None None O
to None None O
airway None None O
antigen None None O
challenge None None O
is None None O
impaired None None O
. None None O

TSLP None None O
signaling None None O
in None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
is None None O
required None None O
for None None O
not None None O
only None None O
TH2 None None O
memory None None I-FUNC
cell None None O
formation None None O
in None None O
vivo None None O
but None None O
also None None O
the None None O
recall None None O
response None None O
of None None O
the None None O
memory None None I-FUNC
cells None None O
to None None O
local None None O
antigen None None O
challenge None None O
. None None O

Major None None I-DISEASE
Depressive None None I-DISEASE
Disorder None None I-DISEASE
was None None O
associated None None O
with None None O
significantly None None O
greater None None O
suicidal None None O
intent None None O
compared None None O
with None None O
other None None O
diagnoses None None O
and None None O
no None None O
diagnosis None None O
. None None O

The None None O
discussion None None O
links None None O
the None None O
findings None None O
to None None O
relevant None None O
theory None None O
and None None O
empirical None None O
work None None O
that None None O
has None None O
called None None O
attention None None I-FUNC
to None None O
the None None O
need None None O
to None None O
include None None O
the None None O
political None None O
in None None O
frameworks None None O
of None None O
quality None None O
of None None O
life None None O
. None None O

These None None O
findings None None O
demonstrate None None O
a None None O
critical None None O
feature None None O
of None None O
early None None O
social None None I-FUNC
cognition None None I-FUNC
and None None O
promote None None O
needed None None O
, None None O
further None None O
research None None O
on None None O
the None None O
role None None O
of None None O
social None None O
allegiances None None O
in None None O
social None None I-FUNC
cognition None None I-FUNC
across None None O
development None None O
. None None O

The None None O
nicotinic None None I-PROTEIN
acetylcholine None None I-TRANS
receptors None None I-PROTEIN
( None None O
nAChRs None None O
) None None O
are None None O
ligand-gated None None I-PROTEIN
ion None None I-PROTEIN
channels None None I-PROTEIN
broadly None None O
involved None None O
in None None O
regulating None None O
neurotransmission None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
by None None O
conducting None None O
cation None None O
currents None None O
through None None O
the None None O
membrane None None O
of None None O
neurons None None O
. None None O

The None None O
focus None None O
of None None O
the None None O
present None None O
MiniReview None None O
is None None O
on None None O
the None None O
heteromeric None None O
α4β2 None None O
nAChR None None O
, None None O
as None None O
activity None None O
at None None O
this None None O
subtype None None O
contributes None None O
to None None O
cognitive None None O
functioning None None O
through None None O
interactions None None O
with None None O
multiple None None O
neurotransmitter None None I-TRANS
systems None None O
and None None O
is None None O
implicated None None O
in None None O
various None None O
CNS None None O
disorders None None O
, None None O
for None None O
example None None O
schizophrenia None None I-DISEASE
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

A None None O
modified None None O
Quick None None O
, None None O
Easy None None O
, None None O
Cheap None None O
, None None O
Effective None None O
, None None O
Rugged None None O
and None None O
Safe None None O
( None None O
QuEChERS None None O
) None None O
method None None O
based None None O
on None None O
the None None O
dispersive None None O
solid-phase None None O
extraction None None O
( None None O
dSPE None None O
) None None O
combined None None O
with None None O
high None None O
performance None None O
liquid None None O
chromatography None None O
( None None O
HPLC None None O
) None None O
was None None O
developed None None O
for None None O
the None None O
determination None None O
of None None O
non-steroidal None None O
estrogens None None I-PROTEIN
in None None O
water None None O
samples None None O
. None None O

While None None O
TPs None None O
are None None O
the None None O
result None None O
of None None O
hydrolysis None None O
and None None O
decarboxylation None None O
processes None None O
, None None O
as None None O
already None None O
indicated None None O
, None None O
an None None O
enzymatic None None O
conjugation None None O
with None None O
amino None None I-TRANS
acids None None I-TRANS
is None None O
suggested None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
formation None None O
of None None O
metabolites None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
separation None None O
of None None O
twelve None None O
nucleobases None None O
and None None O
nucleosides None None O
was None None O
optimized None None O
via None None O
chromatogram None None O
simulation None None O
( None None O
i.e. None None O
, None None O
prediction None None O
of None None O
individual None None O
retention None None I-FUNC
times None None O
and None None O
estimation None None O
of None None O
the None None O
peak None None O
widths None None O
) None None O
with None None O
the None None O
use None None O
of None None O
an None None O
empirical None None O
( None None O
reversed-phase None None O
) None None O
non-linear None None O
model None None O
proposed None None O
by None None O
Neue None None O
and None None O
Kuss None None O
. None None O

As None None O
such None None O
, None None O
this None None O
study None None O
provides None None O
an None None O
example None None O
of None None O
a None None O
case None None O
where None None O
individual None None O
retention None None I-FUNC
modeling None None O
can None None O
be None None O
used None None O
as None None O
a None None O
way None None O
to None None O
optimize None None O
the None None O
gradient None None O
conditions None None O
in None None O
the None None O
HILIC None None O
mode None None O
using None None O
a None None O
non-linear None None O
model None None O
such None None O
as None None O
the None None O
Neue None None O
and None None O
Kuss None None O
model None None O
. None None O

As None None O
a None None O
matter None None O
of None None O
fact None None O
, None None O
by None None O
employing None None O
elution None None O
strategies None None O
using None None O
sodium None None O
chloride None None O
or None None O
arginine None None I-TRANS
, None None O
an None None O
improvement None None O
in None None O
the None None O
final None None O
pre-miR-29 None None O
yields None None O
( None None O
97.33 None None O
and None None O
94.88 None None O
% None None O
, None None O
respectively None None O
) None None O
as None None O
well None None O
as None None O
purity None None O
( None None O
75.21 None None O
and None None O
90.11 None None O
% None None O
, None None O
respectively None None O
) None None O
were None None O
obtained None None O
. None None O

In None None O
this None None O
paper None None O
we None None O
present None None O
a None None O
model None None O
relating None None O
experimental None None O
factors None None O
( None None O
column None None O
lengths None None O
, None None O
diameters None None O
and None None O
thickness None None O
, None None O
modulation None None O
times None None O
, None None O
pressures None None O
and None None O
temperature None None O
programs None None O
) None None O
with None None O
retention None None I-FUNC
times None None O
. None None O

In None None O
this None None O
paper None None O
we None None O
present None None O
a None None O
computational None None O
physical None None O
model None None O
of None None O
GC None None O
× None None O
GC None None O
, None None O
capable None None O
of None None O
predicting None None O
with None None O
a None None O
high None None O
accuracy None None O
retention None None I-FUNC
times None None O
in None None O
both None None O
dimensions None None O
. None None O

In None None O
this None None O
way None None O
, None None O
the None None O
prediction None None O
can None None O
result None None O
rather None None O
in None None O
a None None O
probability None None O
distribution None None O
of None None O
( None None O
predicted None None O
) None None O
retention None None I-FUNC
times None None O
than None None O
in None None O
a None None O
fixed None None O
( None None O
most None None O
likely None None O
) None None O
value None None O
. None None O

This None None O
method None None O
is None None O
based None None O
on None None O
estimation None None O
of None None O
the None None O
accuracy None None O
of None None O
the None None O
model None None O
by None None O
the None None O
partial None None O
derivatives None None O
of None None O
the None None O
retention None None I-FUNC
time None None O
prediction None None O
with None None O
respect None None O
to None None O
the None None O
fitted None None O
parameters None None O
( None None O
in None None O
this None None O
case None None O
entropy None None O
and None None O
enthalpy None None O
for None None O
each None None O
component None None O
) None None O
in None None O
a None None O
set None None O
of None None O
given None None O
conditions None None O
. None None O

Moreover None None O
, None None O
the None None O
two-electrode None None O
device None None O
demonstrates None None O
an None None O
excellent None None O
rate None None O
capability None None O
and None None O
cycling None None O
stability None None O
with None None O
capacitance None None O
retention None None I-FUNC
of None None O
85.1 None None O
% None None O
after None None O
2000 None None O
charge-discharge None None O
cycles None None O
at None None O
a None None O
current None None O
density None None O
of None None O
1 None None O
A None None O
g None None O
( None None O
-1 None None O
) None None O
. None None O

Due None None O
to None None O
the None None O
`` None None O
memory None None I-FUNC
effect None None O
'' None None O
, None None O
the None None O
microspheres None None O
showed None None O
higher None None O
adsorption None None O
capacity None None O
compared None None O
with None None O
Fe3O4 None None O
@ None None O
layered None None O
double None None O
hydroxide None None O
. None None O

This None None O
study None None O
aims None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
( None None O
MMPs None None O
) None None O
in None None O
determining None None O
semen None None O
quality None None O
and None None O
to None None O
evaluate None None O
the None None O
expression None None O
and None None O
cellular None None O
localization None None O
of None None O
MMP-2 None None O
, None None O
MMP-9 None None O
, None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinase-1 None None O
( None None O
TIMP-1 None None O
) None None O
and None None O
TIMP-2 None None O
in None None O
the None None O
testes None None O
, None None O
epididymis None None O
and None None O
ejaculated None None O
spermatozoa None None O
. None None O

Psychol None None O
, None None O
2015 None None O
; None None O
33 None None O
, None None O
1-17 None None O
) None None O
who None None O
demonstrate None None O
an None None O
important None None O
link None None O
between None None O
theory None None I-FUNC
of None None I-FUNC
mind None None I-FUNC
and None None O
children None None O
's None None O
social None None O
lives None None O
. None None O

Going None None O
further None None O
, None None O
I None None O
suggest None None O
needed None None O
steps None None O
for None None O
the None None O
field None None O
to None None O
experimentally None None O
demonstrate None None O
causal None None O
links None None O
between None None O
children None None O
's None None O
theory None None I-FUNC
of None None I-FUNC
mind None None I-FUNC
and None None O
their None None O
social None None O
actions None None O
and None None O
interactions None None O
. None None O

Child None None O
Development None None O
© None None O
2014 None None O
Society None None O
for None None O
Research None None O
in None None O
Child None None O
Development None None O
, None None O
Inc. None None O
To None None O
discover None None O
long-term None None O
learning None None I-FUNC
outcomes None None O
in None None O
a None None O
short-term None None O
study None None O
abroad None None O
program None None O
. None None O

Sensing None None O
activity None None O
was None None O
retained None None O
by None None O
the None None O
bacteria None None O
after None None O
12-weeks None None O
storage None None I-FUNC
of None None O
freeze-dried None None O
biochips None None O
, None None O
demonstrating None None O
the None None O
biochip None None O
potential None None O
as None None O
a None None O
simple None None O
minimal None None O
maintenance None None O
`` None None O
plug-in None None O
'' None None O
cartridge None None O
. None None O

MTX None None O
concentrations None None O
in None None O
a None None O
patient None None O
's None None O
serum None None O
undergoing None None O
chemotherapy None None O
treatments None None O
can None None O
be None None O
determined None None O
by None None O
surface None None O
plasmon None None O
resonance None None O
( None None O
SPR None None O
) None None O
sensing None None O
using None None O
folic None None O
acid-functionalized None None O
gold None None O
nanoparticles None None O
( None None O
FA-AuNP None None O
) None None O
in None None O
competition None None O
with None None O
MTX None None O
for None None O
the None None O
bioreceptor None None I-PROTEIN
, None None O
human None None O
dihydrofolate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
hDHFR None None O
) None None O
immobilized None None O
on None None O
the None None O
SPR None None O
sensor None None O
chip None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
systematic None None O
review None None O
was None None O
to None None O
evaluate None None O
the None None O
efficacy None None O
and None None O
safety None None O
of None None O
targeted None None O
agents None None O
added None None O
to None None O
chemotherapy None None O
or None None O
endocrine None None O
therapy None None O
in None None O
patients None None O
with None None O
previously None None O
untreated None None O
metastatic None None O
breast None None O
cancer None None O
( None None O
MBC None None O
) None None O
depending None None O
on None None O
their None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
( None None O
HER2 None None O
) None None O
and None None O
hormone None None O
receptor None None I-PROTEIN
( None None O
HR None None O
) None None O
status None None O
( None None O
positive None None O
or None None O
negative None None O
) None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
Nrf2 None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
protection None None O
against None None O
heat None None O
shock-induced None None O
collagen None None I-PROTEIN
breakdown None None O
in None None O
skin None None O
. None None O

Transient None None O
receptor None None I-PROTEIN
Potential None None O
, None None O
Melastatin-related None None O
, None None O
member None None O
4 None None O
( None None O
TRPM4 None None O
) None None O
channels None None O
are None None O
Ca2 None None I-REGION
( None None O
+ None None O
) None None O
-activated None None O
Ca2 None None I-REGION
( None None O
+ None None O
) None None O
-impermeable None None O
cation None None O
channels None None O
. None None O

p73 None None O
is None None O
a None None O
structural None None O
and None None O
functional None None O
homologue None None O
of None None O
the None None O
p53 None None I-PROTEIN
tumor None None O
suppressor None None O
protein None None O
. None None O

Most None None O
adverse None None O
events None None O
were None None O
related None None O
to None None O
needle None None O
dislodgement None None O
( None None O
n=18 None None O
) None None O
or None None O
air None None O
embolism None None I-DISEASE
( None None O
n=6 None None O
) None None O
. None None O

The None None O
work None None O
demonstrates None None O
the None None O
potential None None O
of None None O
lignocellulolytic None None O
enzymes None None I-PROTEIN
from None None O
a None None O
novel None None O
uncultured None None O
microbial None None O
resource None None O
for None None O
enhancing None None O
efficiency None None O
of None None O
biomass-degrading None None O
enzyme None None O
systems None None O
for None None O
bio-industries None None O
. None None O

Penicillium None None O
purpurogenum None None O
attracts None None O
attention None None I-FUNC
in None None O
the None None O
food None None O
industry None None O
and None None O
biomass None None O
degradation None None O
. None None O

Published None None O
by None None O
Elsevier None None O
B.V. None None O
Tyrosinase None None I-PROTEIN
( None None O
EC None None O
1.14.18.1 None None O
) None None O
is None None O
the None None O
key None None O
enzyme None None O
of None None O
melanin None None O
synthesis None None O
and None None O
fruit-vegetable None None O
browning None None O
. None None O

In None None O
addition None None O
, None None O
special None None O
attention None None I-FUNC
is None None O
given None None O
to None None O
the None None O
experimental None None O
release None None O
methodology None None O
and None None O
the None None O
implementation None None O
of None None O
proper None None O
diffusion None None O
models None None O
to None None O
describe None None O
the None None O
release None None O
. None None O

In None None O
the None None O
United None None O
States None None O
, None None O
cancer None None O
vaccines None None O
and None None O
immunotherapies None None O
, None None O
including None None O
cell None None O
and None None O
gene None None O
therapies None None O
and None None O
peptides None None I-TRANS
and None None O
proteins None None O
used None None O
as None None O
therapeutic None None O
vaccines None None O
, None None O
are None None O
regulated None None O
by None None O
the None None O
Food None None O
and None None O
Drug None None O
Administration None None O
's None None O
Center None None O
for None None O
Biologics None None O
Evaluation None None O
and None None O
Research None None O
in None None O
the None None O
Office None None O
of None None O
Cellular None None O
, None None O
Tissue None None O
, None None O
and None None O
Gene None None O
Therapies None None O
( None None O
OCTGT None None O
) None None O
. None None O

Resident None None O
responses None None O
, None None O
compared None None O
with None None O
those None None O
from None None O
a None None O
similar None None O
2011 None None O
survey None None O
, None None O
indicate None None O
a None None O
perception None None I-FUNC
that None None O
CT None None O
training None None O
and None None O
CT None None O
expertise None None O
gained None None O
in None None O
ACGME-accredited None None O
NM None None O
programs None None O
have None None O
improved None None O
. None None O

The None None O
authors None None O
review None None O
the None None O
general None None O
movement None None I-FUNC
toward None None O
American None None O
health None None O
care None None O
value None None O
transparency None None O
within None None O
the None None O
public None None O
, None None O
private None None O
, None None O
and None None O
nonprofit None None O
sectors None None O
, None None O
with None None O
an None None O
emphasis None None O
on None None O
those None None O
initiatives None None O
most None None O
relevant None None O
to None None O
radiology None None O
. None None O

SAPHO None None O
( None None O
synovitis None None O
, None None O
acne None None O
, None None O
pustulosis None None O
, None None O
hyperostosis None None O
and None None O
osteitis None None O
) None None O
syndrome None None O
is None None O
a None None O
cluster None None O
of None None O
osteo-cutaneous None None O
manifestations None None O
that None None O
can None None O
lead None None O
to None None O
serious None None O
complications None None O
such None None O
as None None O
thrombosis None None I-DISEASE
of None None O
the None None O
subclavian None None O
vein None None O
or None None O
superior None None O
vena None None O
cava None None O
, None None O
mainly None None O
in None None O
patients None None O
with None None O
significant None None O
inflammatory None None O
involvement None None O
of None None O
the None None O
anterior-chest-wall None None O
. None None O

We None None O
analyzed None None O
11 None None O
published None None O
reports None None O
of None None O
isolated None None O
clinical None None O
cases None None O
or None None O
case None None O
series None None O
, None None O
a None None O
total None None O
of None None O
144 None None O
patients None None O
, None None O
which None None O
described None None O
a None None O
total None None O
of None None O
15 None None O
cases None None O
of None None O
venous None None O
thrombosis None None I-DISEASE
. None None O

The None None O
use None None O
of None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
to None None O
map None None O
language None None I-FUNC
and None None O
sensorimotor None None O
regions None None O
in None None O
the None None O
brain None None O
is None None O
rapidly None None O
becoming None None O
a None None O
clinical None None O
standard None None O
in None None O
neurosurgical None None O
centers None None O
. None None O

The None None O
current None None O
review None None O
documents None None O
some None None O
of None None O
the None None O
successes None None O
that None None O
have None None O
been None None O
achieved None None O
, None None O
using None None O
both None None O
activation None None O
and None None O
resting-state None None O
functional None None O
connectivity None None O
in None None O
the None None O
clinical None None O
context None None O
of None None O
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
, None None O
and None None O
discusses None None O
some None None O
of None None O
the None None O
challenges None None O
that None None O
remain None None O
to None None O
be None None O
addressed None None O
. None None O

Functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
is None None O
used None None O
clinically None None O
to None None O
map None None O
the None None O
visual None None O
cortex None None O
before None None O
brain None None O
surgery None None O
or None None O
other None None O
invasive None None O
treatments None None O
to None None O
achieve None None O
an None None O
optimal None None O
balance None None O
between None None O
therapeutic None None O
effect None None O
and None None O
the None None O
avoidance None None O
of None None O
postoperative None None O
vision None None I-FUNC
deficits None None O
. None None O

Emerging None None O
techniques None None O
such None None O
as None None O
resting-state None None O
fMRI None None O
may None None O
facilitate None None O
the None None O
use None None O
of None None O
fMRI-based None None O
vision None None I-FUNC
mapping None None O
in None None O
a None None O
broader None None O
range None None O
of None None O
patients None None O
. None None O

Although None None O
mapping None None O
has None None O
multiple None None O
steps None None O
and None None O
complimentary None None O
localization None None O
sources None None O
, None None O
diffusion None None O
tensor None None O
imaging None None O
( None None O
DTI None None O
) None None O
excels None None O
in None None O
its None None O
essential None None O
role None None O
in None None O
depicting None None O
white None None I-REGION
matter None None I-REGION
tracts None None O
. None None O

In None None O
this None None O
article None None O
, None None O
some None None O
specificities None None O
of None None O
functional None None O
magnetic None None O
resonance None None O
imaging None None O
( None None O
fMRI None None O
) None None O
in None None O
children None None O
( None None O
eg None None O
, None None O
blood-oxygen-level-dependent None None O
response None None O
and None None O
brain None None O
maturation None None O
, None None O
paradigm None None O
design None None O
, None None O
technical None None O
issues None None O
, None None O
feasibility None None O
, None None O
data None None O
analysis None None O
) None None O
are None None O
reviewed None None O
, None None O
the None None O
main None None O
knowledge None None O
on None None O
presurgical None None O
cortical None None O
mapping None None O
in None None O
children None None O
( None None O
motor None None O
, None None O
language None None I-FUNC
, None None O
reading None None O
, None None O
memory None None I-FUNC
) None None O
is None None O
summarized None None O
, None None O
and None None O
the None None O
emergence None None O
of None None O
resting None None O
state None None O
fMRI None None O
in None None O
presurgical None None O
cortical None None O
mapping None None O
is None None O
discussed None None O
. None None O

The None None O
nature None None O
of None None O
medical None None O
transport None None O
and None None O
the None None O
heterogeneity None None O
of None None O
patients None None O
who None None O
are None None O
transferred None None O
present None None O
unique None None O
challenges None None O
in None None O
designing None None O
and None None O
conducting None None O
clinical None None O
research None None O
trials None None O
that None None O
could None None O
contribute None None O
to None None O
the None None O
evidence-based None None O
decision None None I-FUNC
making None None I-FUNC
for None None O
patient None None O
care None None O
and None None O
transport None None O
. None None O

Using None None O
the None None O
angiocatherter None None O
already None None O
in None None O
place None None O
, None None O
a None None O
guide None None O
wire None None O
was None None O
placed None None O
through None None O
and None None O
a None None O
quadruple None None O
lumen None None O
CVC None None O
was None None O
placed None None O
without None None O
complication None None O
allowing None None O
for None None O
infusion None None O
of None None O
medications None None O
( None None O
adrenaline None None I-TRANS
drip None None O
, None None O
meropenem None None O
) None None O
and None None O
IVF None None O
. None None O

We None None O
evaluated None None O
the None None O
performance None None O
of None None O
two None None O
glucose None None O
meters None None O
, None None O
the None None O
StatStrip None None O
( None None O
Nova None None O
Biomedical None None O
) None None O
, None None O
a None None O
POCT None None O
device None None O
, None None O
and None None O
the None None O
Medisafe None None O
Mini None None O
( None None O
Terumo None None O
) None None O
, None None O
an None None O
SMBG None None O
device None None O
, None None O
to None None O
detect None None O
hypoglycemia None None I-DISEASE
in None None O
neonates None None O
. None None O

Whole None None O
blood None None O
samples None None O
were None None O
drawn None None O
from None None O
neonates None None O
who None None O
were None None O
at None None O
risk None None O
of None None O
hypoglycemia None None I-DISEASE
and None None O
analyzed None None O
with None None O
the None None O
StatStrip None None O
and None None O
Medisafe None None O
Mini None None O
. None None O

Any None None O
post-stress None None O
movement None None I-FUNC
was None None O
considered None None O
a None None O
failure None None O
and None None O
recorded None None O
in None None O
millimeters None None O
. None None O

Isolated None None O
movements None None I-FUNC
of None None O
a None None O
single None None O
tuberosity None None O
occurred None None O
in None None O
2 None None O
specimens None None O
. None None O

Shoulder None None O
joint None None O
stability None None O
mediated None None O
by None None O
proprioception None None O
is None None O
often None None O
quantified None None O
by None None O
arm None None O
repositioning None None O
tests None None O
( None None O
i.e. None None O
, None None O
static None None O
end-position None None O
accuracy None None O
) None None O
, None None O
overlooking None None O
ongoing None None O
movement None None I-FUNC
quality None None O
. None None O

Identifying None None O
these None None O
changes None None O
may None None O
guide None None O
surgical None None O
decision None None I-FUNC
making None None I-FUNC
during None None O
rTSA None None O
placement None None O
. None None O

OB None None O
, None None O
T2DM None None O
, None None O
and None None O
T2DOB None None O
individuals None None O
had None None O
higher None None O
ferritin None None I-PROTEIN
, None None O
retinol-binding None None O
protein None None O
4 None None O
, None None O
and None None O
thiobarbituric None None O
acid None None O
reactive None None O
substance None None O
( None None O
TBAR None None O
) None None O
levels None None O
than None None O
controls None None O
. None None O

Heme None None O
oxygenase None None O
activity None None O
was None None O
high None None O
in None None O
OB None None O
and None None O
T2DM None None O
and None None O
there None None O
were None None O
no None None O
differences None None O
observed None None O
in None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
glutathione None None O
parameters None None O
. None None O

Multiple None None O
linear None None O
regression None None O
analysis None None O
showed None None O
an None None O
association None None O
between None None O
diabetes None None O
and None None O
obesity None None O
with None None O
ferritin None None I-PROTEIN
, None None O
TBARS None None O
, None None O
and None None O
hsCRP None None O
levels None None O
. None None O

Treatment None None O
of None None O
hyperglycemia None None O
with None None O
insulin None None I-PROTEIN
is None None O
potentially None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
for None None O
hypoglycemia None None I-DISEASE
. None None O

The None None O
study None None O
included None None O
605 None None O
patients None None O
of None None O
whom None None O
6.8 None None O
% None None O
( None None O
n None None O
= None None O
41 None None O
) None None O
had None None O
at None None O
least None None O
one None None O
capillary None None O
blood None None O
glucose None None O
& None None O
lt None None O
; None None O
70 None None O
mg/dL None None O
and None None O
2.6 None None O
% None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
had None None O
symptomatic None None O
hypoglycemia None None I-DISEASE
. None None O

In None None O
univariate None None O
analysis None None O
, None None O
hypoglycemia None None I-DISEASE
was None None O
significantly None None O
associated None None O
with None None O
the None None O
presence None None O
of None None O
diabetes None None O
, None None O
a None None O
lower None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
, None None O
and None None O
treatment None None O
with None None O
intravenous None None O
( None None O
IV None None O
) None None O
insulin None None I-PROTEIN
. None None O

Multiple None None O
logistic None None O
regression None None O
analysis None None O
showed None None O
that None None O
a None None O
lower None None O
BMI None None O
, None None O
high None None O
blood None None O
glucose None None O
variability None None O
, None None O
and None None O
TPN None None O
duration None None O
were None None O
risk None None O
factors None None O
for None None O
hypoglycemia None None I-DISEASE
. None None O

The None None O
occurrence None None O
of None None O
hypoglycemia None None I-DISEASE
in None None O
noncritically None None O
ill None None O
patients None None O
receiving None None O
PN None None O
is None None O
low None None O
. None None O

IV None None O
insulin None None I-PROTEIN
and None None O
glucose None None O
variability None None O
were None None O
predictors None None O
of None None O
symptomatic None None O
hypoglycemia None None I-DISEASE
. None None O

Transgenic None None O
( None None O
Tg None None O
) None None O
mice None None O
, None None O
which None None O
possess None None O
an None None O
amyloid None None O
precursor None None O
protein None None O
( None None O
APP None None I-TRANS
) None None O
gene None None O
mutation None None O
, None None O
develop None None O
extracellular None None O
amyloid None None O
β None None O
( None None O
Aβ None None O
) None None O
deposition None None O
in None None O
the None None O
brain None None O
, None None O
and None None O
severe None None O
memory None None I-FUNC
and None None O
behavioral None None O
deficits None None O
with None None O
age None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
dietary None None O
supplementation None None O
of None None O
Omani None None O
pomegranate None None O
extract None None O
on None None O
memory None None I-FUNC
, None None O
anxiety None None O
, None None O
and None None O
learning None None I-FUNC
skills None None O
in None None O
an None None O
AD None None O
mouse None None O
model None None O
possessing None None O
the None None O
double None None O
Swedish None None O
APP None None I-TRANS
mutation None None O
( None None O
APPsw/Tg2576 None None O
) None None O
. None None O

We None None O
assessed None None O
spatial None None I-FUNC
memory None None I-FUNC
and None None O
learning None None I-FUNC
ability None None O
, None None O
psychomotor None None O
coordination None None O
, None None O
and None None O
anxiety-related None None O
behavior None None O
in None None O
Tg None None O
and None None O
wild-type None None O
mice None None O
at None None O
the None None O
age None None O
of None None O
4 None None O
to None None O
5 None None O
mo None None O
and None None O
18 None None O
to None None O
19 None None O
mo None None O
using None None O
the None None O
Morris None None O
water None None O
maze None None O
test None None O
, None None O
rotarod None None O
performance None None O
test None None O
, None None O
elevated None None O
plus-maze None None O
test None None O
, None None O
and None None O
open None None O
field None None O
test None None O
. None None O

In None None O
contrast None None O
, None None O
APPsw/Tg2576 None None O
mice None None O
that None None O
were None None O
fed None None O
a None None O
diet None None O
containing None None O
4 None None O
% None None O
pomegranates None None O
showed None None O
significant None None O
improvements None None O
in None None O
memory None None I-FUNC
, None None O
learning None None I-FUNC
, None None O
locomotor None None O
function None None O
, None None O
as None None O
well None None O
as None None O
reduction None None O
in None None O
anxiety None None O
, None None O
compared None None O
with None None O
APPsw/Tg2576 None None O
mice None None O
fed None None O
the None None O
standard None None O
chow None None O
diet None None O
. None None O

These None None O
are None None O
supported None None O
by None None O
two None None O
different None None O
pathways None None O
, None None O
encoding None None I-FUNC
two None None O
dimensions None None O
of None None O
pain None None O
perception None None I-FUNC
: None None O
In None None O
Neo-spino-thalamic None None O
pathway None None O
, None None O
the None None O
wide None None O
dynamic None None O
range None None O
neuron None None O
system None None O
is None None O
able None None O
to None None O
provide None None O
the None None O
information None None O
needed None None O
for None None O
mapping None None O
the None None O
`` None None O
sensory-discriminative None None O
'' None None O
dimension None None O
of None None O
pain None None O
. None None O

Special None None O
attention None None I-FUNC
was None None O
paid None None O
to None None O
literature None None O
that None None O
reported None None O
hearing None None O
findings None None O
and None None O
the None None O
audiology None None O
literature None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
surgical None None O
techniques None None O
that None None O
are None None O
essential None None O
for None None O
normal None None O
speech None None I-FUNC
on None None O
the None None O
basis None None O
of None None O
each None None O
surgical None None O
characteristic None None O
. None None O

Speech None None I-FUNC
outcomes None None O
, None None O
i.e. None None O
, None None O
nasal None None O
emission None None O
, None None O
velopharyngeal None None O
insufficiency None None O
, None None O
and None None O
malarticulation None None O
after None None O
one-stage None None O
pushback None None O
( None None O
PB None None O
) None None O
, None None O
one-stage None None O
modified None None O
Furlow None None O
( None None O
MF None None O
) None None O
, None None O
or None None O
conventional None None O
two-stage None None O
MF None None O
palatoplasty None None O
, None None O
were None None O
evaluated None None O
at None None O
4 None None O
( None None O
before None None O
intensive None None O
speech None None I-FUNC
therapy None None O
) None None O
and None None O
8 None None O
( None None O
after None None O
closure None None O
of None None O
oronasal None None O
fistula/unclosed None None O
hard None None O
palate None None O
) None None O
years None None O
of None None O
age None None O
. None None O

Muscle None None O
damage None None O
induced None None O
by None None O
inertial None None O
exercise None None O
performed None None O
on None None O
a None None O
flywheel None None O
device None None O
was None None O
assessed None None O
through None None O
the None None O
serum None None O
evolution None None O
of None None O
muscle None None O
enzymes None None I-PROTEIN
, None None O
interleukin None None O
6 None None O
, None None O
and None None O
fiber None None O
type-specific None None O
sarcomere None None O
proteins None None O
such None None O
as None None O
fast None None O
myosin None None O
( None None O
FM None None O
) None None O
and None None O
slow None None O
myosin None None O
( None None O
SM None None O
) None None O
. None None O

Considering None None O
sexual None None O
maturation None None O
of None None O
the None None O
rat None None O
, None None O
the None None O
results None None O
reveal None None O
that None None O
GCs None None O
of None None O
the None None O
rat None None O
begins None None O
to None None O
develop None None O
postnatal None None O
and None None O
reaches None None O
to None None O
the None None O
peak None None O
of None None O
their None None O
development None None O
after None None O
puberty None None O
and None None O
continues None None O
to None None O
exist None None O
until None None O
old None None O
age None None O
, None None O
in None None O
contrast None None O
to None None O
prenatal None None O
and None None O
early None None O
postnatal None None O
development None None O
of None None O
other None None O
sensory None None O
receptors None None I-PROTEIN
of None None O
glabrous None None O
skin None None O
. None None O

Retention None None I-FUNC
of None None O
a None None O
single None None O
form None None O
of None None O
most None None O
genes None None O
could None None O
be None None O
advantageous None None O
to None None O
minimize None None O
intracellular None None O
incompatibilities None None O
and/or None None O
reflect None None O
neutral None None O
forces None None O
that None None O
preferentially None None O
eliminate None None O
duplicated None None O
regions None None O
. None None O

Using None None O
a None None O
preterm None None O
rabbit None None O
pup None None O
model None None O
of None None O
IVH None None O
, None None O
the None None O
structural None None O
and None None O
functional None None O
integrity None None O
, None None O
cellular None None O
, None None O
inflammatory None None O
and None None O
oxidative None None O
response None None O
of None None O
the None None O
choroid None None I-REGION
plexus None None I-REGION
, None None O
at None None O
24 None None O
and None None O
72 None None O
hours None None O
following None None O
IVH None None O
+ None None O
PHVD None None O
, None None O
were None None O
investigated None None O
. None None O

This None None O
was None None O
associated None None O
with None None O
structural None None O
disintegration None None O
, None None O
caspase None None O
activation None None O
and None None O
cell None None O
death None None O
in None None O
the None None O
choroid None None I-REGION
plexus None None I-REGION
epithelium None None O
. None None O

Regardless None None O
, None None O
such None None O
impairments None None O
represent None None O
dysfunction None None O
of None None O
the None None O
brainstem None None I-REGION
and None None O
or None None O
cerebrum None None I-REGION
. None None O

The None None O
hereditary None None O
ataxias None None O
are None None O
a None None O
group None None O
of None None O
neurodegenerative None None O
diseases None None O
that None None O
cause None None O
a None None O
progressive None None O
( None None O
or None None O
episodic None None O
) None None O
cerebellar None None I-DISEASE
ataxia None None I-DISEASE
. None None O

Signs None None O
emanate None None O
from None None O
the None None O
central None None O
nervous None None O
system None None O
; None None O
consciousness None None I-FUNC
is None None O
not None None O
impaired None None O
, None None O
ictal None None O
electroencephalography None None O
is None None O
normal None None O
, None None O
and None None O
there None None O
are None None O
no None None O
autonomic None None O
signs None None O
, None None O
distinguishing None None O
them None None O
from None None O
seizure None None O
disorders None None O
. None None O

Aging None None O
dogs None None O
and None None O
cats None None O
show None None O
neurodegenerative None None O
features None None O
that None None O
are None None O
similar None None O
to None None O
human None None O
aging None None O
and None None O
Alzheimer None None I-DISEASE
disease None None O
. None None O

Mast None None O
cell None None O
( None None O
MC None None O
) None None O
mediators None None O
( None None O
histamine None None I-TRANS
, None None O
serotonin None None I-TRANS
, None None O
leukotriene None None O
C₄ None None O
, None None O
prostaglandin None None O
D2 None None O
, None None O
and None None O
mouse None None O
mast None None O
cell None None O
protease None None O
1 None None O
) None None O
were None None O
quantified None None O
in None None O
serum None None O
. None None O

Epinephrine None None I-TRANS
( None None O
adrenaline None None I-TRANS
) None None O
treatment None None O
is None None O
underused None None O
in None None O
health None None O
care None None O
and None None O
community None None O
settings None None O
. None None O

Future None None O
research None None O
should None None O
include None None O
validation None None O
of None None O
the None None O
clinical None None O
criteria None None O
for None None O
anaphylaxis None None O
diagnosis None None O
in None None O
infants None None O
, None None O
prospective None None O
longitudinal None None O
monitoring None None O
of None None O
baseline None None O
serum None None O
tryptase None None O
levels None None O
in None None O
healthy None None O
and None None O
atopic None None O
infants None None O
during None None O
the None None O
first None None O
year None None O
of None None O
life None None O
, None None O
studies None None O
of None None O
infant None None O
comorbidities None None O
and None None O
cofactors None None O
that None None O
increase None None O
the None None O
risk None None O
of None None O
severe None None O
anaphylaxis None None O
, None None O
development None None O
of None None O
autoinjectors None None O
containing None None O
a None None O
0.1-mg None None O
epinephrine None None I-TRANS
dose None None O
suitable None None O
for None None O
infants None None O
, None None O
and None None O
inclusion None None O
of None None O
infants None None O
in None None O
prospective None None O
studies None None O
of None None O
immune None None O
modulation None None O
to None None O
prevent None None O
anaphylaxis None None O
recurrences None None O
. None None O

A None None O
recombinant None None O
hypoallergenic None None O
grass None None O
pollen None None O
allergy None None O
vaccine None None O
( None None O
BM32 None None O
) None None O
consisting None None O
of None None O
4 None None O
recombinant None None O
PreS-fused None None O
grass None None O
pollen None None O
allergen None None O
peptides None None I-TRANS
was None None O
developed None None O
for None None O
safe None None O
immunotherapy None None O
of None None O
grass None None O
pollen None None O
allergy None None O
. None None O

Despite None None O
lower None None O
fraction None None O
of None None O
exhaled None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
30.0 None None O
vs None None O
62.6 None None O
ppb None None O
; None None O
P None None O
= None None O
.037 None None O
) None None O
and None None O
reduced None None O
methacholine None None O
responsiveness None None O
( None None O
PC20FEV1 None None O
1.87 None None O
vs None None O
0.45 None None O
mg/mL None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.012 None None O
) None None O
, None None O
overweight/obese None None O
children None None O
reported None None O
more None None O
than None None O
thrice None None O
frequent None None O
rescue None None O
treatments None None O
( None None O
3.7 None None O
vs None None O
1.1 None None O
treatments/wk None None O
; None None O
P None None O
= None None O
.0002 None None O
) None None O
than None None O
did None None O
lean None None O
children None None O
. None None O

Parents None None O
of None None O
children None None O
with None None O
a None None O
current None None O
acute None None O
cough None None O
( None None O
& None None O
lt None None O
; None None O
2 None None O
weeks None None O
) None None O
at None None O
enrollment None None O
completed None None O
2 None None O
validated None None O
cough None None O
score None None O
measures None None O
, None None O
the None None O
preliminary None None O
48-item None None O
PAC-QoL None None O
, None None O
and None None O
3 None None O
other None None O
questionnaires None None O
( None None O
the None None O
State None None O
Trait None None O
Anxiety None None O
Inventory None None O
[ None None O
STAI None None O
] None None O
, None None O
the None None O
Short-Form None None O
8-item None None O
24-hour None None O
recall None None O
Health None None O
Survey None None O
[ None None O
SF-8 None None O
] None None O
, None None O
and None None O
the None None O
Depression None None I-DISEASE
, None None O
Anxiety None None O
, None None O
and None None O
Stress None None O
21-item None None O
Scale None None O
[ None None O
DASS21 None None O
] None None O
) None None O
. None None O

A None None O
subset None None O
of None None O
these None None O
methylation None None O
markers None None O
related None None O
to None None O
epithelium None None O
development None None O
and None None O
asthma None None O
and None None O
specific None None O
to None None O
NEC-iPSCs None None O
persisted None None O
after None None O
several None None O
passages None None O
in None None O
vitro None None O
, None None O
suggesting None None O
the None None O
retention None None I-FUNC
of None None O
an None None O
epigenetic None None O
memory None None I-FUNC
of None None O
their None None O
tissue None None O
of None None O
origin None None O
. None None O

NECs None None O
are None None O
an None None O
excellent None None O
tissue None None O
source None None O
to None None O
generate None None O
iPSCs None None O
in None None O
pediatric None None O
asthmatic None None O
patients None None O
, None None O
and None None O
detailed None None O
characterization None None O
of None None O
the None None O
resulting None None O
iPSC None None O
lines None None O
would None None O
help None None O
us None None O
better None None O
understand None None O
the None None O
reprogramming None None O
process None None O
and None None O
retention None None I-FUNC
of None None O
epigenetic None None O
memory None None I-FUNC
. None None O

The None None O
receptors None None I-PROTEIN
for None None O
these None None O
mediators None None O
are None None O
drug None None O
targets None None O
in None None O
the None None O
treatment None None O
of None None O
allergic None None O
diseases None None O
, None None O
and None None O
hence None None O
understanding None None O
their None None O
interaction None None O
is None None O
likely None None O
to None None O
have None None O
clinical None None O
implications None None O
. None None O

PGD2 None None O
and None None O
LTE4 None None O
altered None None O
the None None O
transcription None None O
of None None O
a None None O
wide None None O
range None None O
of None None O
genes None None O
and None None O
induced None None O
diverse None None O
functional None None O
responses None None O
in None None O
TH2 None None O
cells None None O
, None None O
including None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
, None None O
migration None None O
, None None O
and None None O
survival None None O
and None None O
cytokine None None O
production None None O
. None None O

Between None None O
December None None O
2011 None None O
and None None O
June None None O
2012 None None O
, None None O
all None None O
DBPs None None O
who None None O
evaluated None None O
children None None O
with None None O
ADHD None None O
or None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorders None None I-DISEASE
were None None O
asked None None O
to None None O
complete None None O
a None None O
diagnostic None None O
encounter None None O
survey None None O
form None None O
for None None O
up None None O
to None None O
10 None None O
consecutive None None O
new None None O
cases None None O
that None None O
resulted None None O
in None None O
the None None O
diagnosis None None O
of None None O
ADHD None None O
or None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
. None None O

They None None O
typically None None O
identified None None O
coexisting None None O
developmental None None O
and None None O
learning None None I-FUNC
conditions None None O
. None None O

Brain None None O
ischemia None None O
was None None O
induced None None O
by None None O
60 None None O
min None None O
middle None None O
cerebral None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
( None None O
MCAO None None O
) None None O
under None None O
continuous None None O
recording None None O
of None None O
regional None None O
cerebral None None O
blood None None O
flow None None O
( None None O
rCBF None None O
) None None O
followed None None O
by None None O
12 None None O
h None None O
reperfusion None None O
. None None O

The None None O
findings None None O
of None None O
this None None O
study None None O
indicated None None O
that None None O
brain None None O
I/R None None O
injury None None O
provokes None None O
brain None None I-DISEASE
edema None None I-DISEASE
by None None O
alterations None None O
of None None O
AQPs None None O
expression None None O
, None None O
and None None O
the None None O
NO None None O
is None None O
the None None O
main None None O
signaling None None O
factor None None O
that None None O
modulates None None O
gene None None O
expression None None O
of None None O
these None None O
channels None None O
. None None O

We None None O
found None None O
in None None O
the None None O
HI None None O
group None None O
a None None O
higher None None O
frequency None None O
of None None O
hyaline None None O
degeneration None None O
in None None O
both None None O
palatine None None O
and None None O
lingual None None O
tonsils None None O
; None None O
smaller None None O
follicle None None O
areas None None O
, None None O
and None None O
a None None O
higher None None O
percentage None None O
of None None O
collagen None None I-PROTEIN
in None None O
comparison None None O
with None None O
the None None O
CO None None O
group None None O
. None None O

In None None O
the None None O
HI None None O
group None None O
, None None O
there None None O
were None None O
significant None None O
positive None None O
correlations None None O
between None None O
palatine None None O
and None None O
lingual None None O
tonsils None None O
and None None O
the None None O
area None None O
of None None O
lymphoid None None O
follicles None None O
, None None O
and None None O
between None None O
the None None O
percentage None None O
of None None O
blood None None O
vessels None None O
and None None O
collagen None None I-PROTEIN
in None None O
palatine None None O
tonsils None None O
. None None O

Airway None None O
multilayer None None O
ciliated None None O
epithelium None None O
develops None None O
, None None O
with None None O
cilia None None O
fallen None None O
off None None O
; None None O
goblet None None O
cells None None O
increased None None O
and None None O
irregular None None O
, None None O
mitochondrial None None O
basement None None O
membrane None None O
density None None O
is None None O
decreased None None O
, None None O
mitochondrial None None O
crista None None O
is None None O
reduced None None O
, None None O
and None None O
the None None O
nucleus None None O
has None None O
more None None O
incisures None None O
and None None O
irregular None None O
shape None None O
in None None O
asthmatic None None O
rats None None O
; None None O
airway None None O
epithelial None None O
cell None None O
matrix None None O
collagen None None I-PROTEIN
deposition None None O
increased None None O
; None None O
and None None O
lamellar None None O
body None None O
and None None O
mitochondrial None None O
cavity None None O
formation None None O
. None None O

We None None O
found None None O
that None None O
interleukin None None O
( None None O
IL None None O
) None None O
6 None None O
( None None O
IL-6 None None O
) None None O
, None None O
IL-1β None None O
, None None O
monocyte None None O
chemoattractant None None O
protein-1 None None O
( None None O
CCL2 None None O
) None None O
macrophage None None O
inflammatory None None O
protein-1α None None O
( None None O
CCL3 None None O
) None None O
, None None O
E-selectin None None O
( None None O
SELE None None O
) None None O
, None None O
intercellular None None O
adhesion None None O
molecule None None O
1 None None O
( None None O
ICAM1 None None O
) None None O
, None None O
and None None O
matrix None None I-PROTEIN
metalloproteinase-3 None None O
( None None O
MMP-3 None None O
) None None O
, None None O
and None None O
9 None None O
( None None O
MMP-9 None None O
) None None O
gene None None O
variants None None O
were None None O
independently None None O
and None None O
significantly None None O
associated None None O
with None None O
ICAS None None O
. None None O

PAD None None O
patients None None O
presented None None O
with None None O
increased None None O
levels None None O
of None None O
MMP-10 None None O
( None None O
702 None None O
± None None O
326 None None O
pg/mL None None O
control None None O
vs None None O
946 None None O
± None None O
473 None None O
pg/mL None None O
PAD None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
decreased None None O
levels None None O
of None None O
tissue None None O
inhibitor None None O
of None None O
matrix None None I-PROTEIN
metalloproteinase None None I-PROTEIN
1 None None O
( None None O
312 None None O
± None None O
117 None None O
ng/mL None None O
control None None O
vs None None O
235 None None O
± None None O
110 None None O
ng/mL None None O
PAD None None O
; None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
compared None None O
with None None O
controls None None O
. None None O

There None None O
was None None O
no None None O
thrombosis None None I-DISEASE
in None None O
any None None O
patients None None O
after None None O
arterial None None O
reconstruction None None O
. None None O

At None None O
30 None None O
days None None O
, None None O
there None None O
were None None O
six None None O
deaths None None O
in None None O
group None None O
1 None None O
and None None O
four None None O
in None None O
group None None O
2 None None O
( None None O
8.5 None None O
% None None O
vs None None O
13.8 None None O
% None None O
; None None O
odds None None O
ratio None None O
, None None O
1.7 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
, None None O
0.45-6.66 None None O
; None None O
P None None O
= None None O
.47 None None O
) None None O
, None None O
and None None O
four None None O
strokes None None I-DISEASE
in None None O
group None None O
1 None None O
and None None O
one None None O
in None None O
group None None O
2 None None O
( None None O
odds None None O
ratio None None O
, None None O
0.59 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
, None None O
0.06-5.59 None None O
; None None O
P None None O
= None None O
1 None None O
) None None O
. None None O

Adjunctive None None O
false None None O
lumen None None O
embolization None None O
with None None O
a None None O
covered None None O
stent None None O
device None None O
promotes None None O
thrombosis None None I-DISEASE
and None None O
remodeling None None O
after None None O
stent None None O
grafting None None O
the None None O
true None None O
lumen None None O
for None None O
chronic None None O
dissection None None O
. None None O

Nonelective None None O
admissions None None O
for None None O
critical None None O
limb None None O
ischemia None None O
( None None O
CLI None None O
) None None O
and None None O
acute None None O
limb None None O
ischemia None None O
( None None O
ALI None None O
) None None O
from None None O
lower None None O
extremity None None O
thrombosis None None I-DISEASE
or None None O
embolism None None I-DISEASE
were None None O
identified None None O
in None None O
the None None O
2005 None None O
to None None O
2010 None None O
Nationwide None None O
Inpatient None None O
Sample None None O
, None None O
and None None O
outcomes None None O
were None None O
compared None None O
based None None O
on None None O
weekend None None O
vs None None O
weekday None None O
admission None None O
by None None O
using None None O
multiple None None O
logistic None None O
and None None O
linear None None O
regression None None O
. None None O

The None None O
ZFX None None O
( None None O
zinc None None I-TRANS
finger None None O
protein None None O
, None None O
X-linked None None O
) None None O
gene None None O
located None None O
on None None O
the None None O
human None None O
X None None O
chromosome None None O
controls None None O
the None None O
self-renewal None None O
of None None O
embryonic None None O
and None None O
hematopoietic None None O
stem None None O
cells None None O
as None None O
a None None O
transcriptional None None O
regulator None None O
. None None O

The None None O
t None None O
( None None O
4 None None O
; None None O
14 None None O
) None None O
( None None O
p16 None None O
; None None O
q32 None None O
) None None O
with None None O
fusion None None O
of None None O
the None None O
IGH None None O
( None None O
immunoglobulin None None O
heavy None None O
chain None None O
) None None O
and None None O
FGFR3 None None O
( None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
3 None None O
) None None O
genes None None O
are None None O
rarely None None O
present None None O
in None None O
patients None None O
with None None O
chronic None None O
lymphocytic None None O
leukemia None None O
( None None O
CLL None None O
) None None O
, None None O
with None None O
only None None O
two None None O
previously None None O
reported None None O
cases None None O
. None None O

The None None O
data None None O
indicate None None O
that None None O
fentanyl None None O
's None None O
popularity None None O
has None None O
occurred None None O
because None None O
it None None O
has None None O
minimal None None O
cardiovascular None None O
effects None None O
, None None O
does None None O
not None None O
result None None O
in None None O
increases None None O
in None None O
plasma None None O
histamine None None I-TRANS
, None None O
is None None O
relatively None None O
short None None O
in None None O
onset None None O
of None None O
action None None O
and None None O
duration None None O
of None None O
effect None None O
, None None O
is None None O
easy None None O
and None None O
inexpensive None None O
to None None O
synthesize None None O
and None None O
prepare None None O
for None None O
the None None O
marketplace None None O
, None None O
and None None O
is None None O
now None None O
familiar None None O
to None None O
clinicians None None O
working None None O
in None None O
pain None None O
and None None O
perioperative None None O
medicine None None O
throughout None None O
the None None O
world None None O
. None None O

Dietary None None O
macronutrient None None O
composition None None O
has None None O
been None None O
examined None None O
in None None O
a None None O
number None None O
of None None O
articles None None O
, None None O
and None None O
diets None None O
enriched None None O
in None None O
saturated None None O
fatty None None O
acids None None O
, None None O
and None None O
possibly None None O
in None None O
fructose None None O
, None None O
appear None None O
to None None O
be None None O
most None None O
consistently None None O
associated None None O
with None None O
the None None O
development None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Histological None None O
examination None None O
revealed None None O
a None None O
diffuse None None O
polymorphic None None O
inflammatory None None O
infiltrate None None O
including None None O
numerous None None O
foamy None None O
histiocytes None None O
which None None O
displayed None None O
large None None O
eosinophilic None None O
CD68-positive None None O
, None None O
CD1a-negative None None O
cytoplasms None None O
, None None O
and None None O
collagen None None I-PROTEIN
deposition None None O
, None None O
characteristic None None O
of None None O
Erdheim-Chester None None O
disease None None O
. None None O

Products None None O
should None None O
be None None O
internationally None None O
assessed None None O
against None None O
WHO None None O
performance None None O
targets None None O
and None None O
also None None O
locally None None O
approved None None O
, None None O
considering None None O
language None None I-FUNC
, None None O
culture None None O
and None None O
usability None None O
, None None O
to None None O
ensure None None O
effective None None O
HWT None None O
. None None O

We None None O
recommend None None O
increased None None O
attention None None I-FUNC
and None None O
monitoring None None O
of None None O
fertile None None O
women None None O
with None None O
hypothyroidism None None O
who None None O
are None None O
planning None None O
pregnancy None None O
. None None O

Our None None O
findings None None O
may None None O
, None None O
in None None O
part None None O
, None None O
reflect None None O
a None None O
learning None None I-FUNC
curve None None O
, None None O
patient None None O
selection None None O
, None None O
or None None O
that None None O
a None None O
low None None O
success None None O
rate None None O
is None None O
associated None None O
with None None O
the None None O
use None None O
of None None O
THD None None O
per None None O
se None None O
. None None O

Tumour None None O
necrosis None None O
factor None None O
α None None O
( None None O
TNF-α None None O
) None None O
plays None None O
a None None O
role None None O
in None None O
the None None O
immune None None O
defence None None O
, None None O
angiogenesis None None O
and None None O
collagen None None I-PROTEIN
synthesis None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
evaluate None None O
the None None O
correlation None None O
between None None O
a None None O
parental None None O
questionnaire None None O
assessing None None O
motor None None O
function None None O
at None None O
the None None O
age None None O
of None None O
five None None O
years None None O
and None None O
the None None O
clinical None None O
test None None O
Movement None None I-FUNC
Assessment None None O
Battery None None O
for None None O
Children None None O
( None None O
M-ABC None None O
) None None O
, None None O
and None None O
to None None O
assess None None O
whether None None O
one None None O
or None None O
more None None O
questions None None O
could None None O
be None None O
used None None O
to None None O
screen None None O
for None None O
motor None None O
problems None None O
at None None O
the None None O
age None None O
of None None O
five None None O
years None None O
. None None O

Melatonin None None I-TRANS
and None None O
cortisol None None O
levels None None O
display None None O
circadian None None O
rhythmicity None None O
and None None O
are None None O
known None None O
to None None O
affect None None O
and None None O
regulate None None O
sleep/wake None None O
patterns None None O
. None None O

The None None O
levels None None O
of None None O
salivary None None O
melatonin None None I-TRANS
and None None O
cortisol None None O
were None None O
analysed None None O
by None None O
specific None None O
enzyme-linked None None O
immunoassays None None O
. None None O

The None None O
WS None None O
group None None O
had None None O
shallower None None O
drops None None O
in None None O
cortisol None None O
and None None O
less None None O
pronounced None None O
increase None None O
in None None O
melatonin None None I-TRANS
at None None O
bedtime None None O
compared None None O
to None None O
the None None O
controls None None O
. None None O

Increased None None O
bedtime None None O
cortisol None None O
and None None O
less None None O
pronounced None None O
rise None None O
in None None O
melatonin None None I-TRANS
levels None None O
before None None O
sleep None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
occurrence None None O
of None None O
sleep None None O
disturbances None None O
, None None O
such None None O
as None None O
delayed None None O
sleep None None O
onset None None O
, None None O
observed None None O
in None None O
children None None O
with None None O
WS None None O
. None None O

Higher None None O
sleep None None O
efficiency None None O
( None None O
but None None O
not None None O
sleep None None O
duration None None O
) None None O
was None None O
associated None None O
with None None O
better None None O
grades None None O
in None None O
math None None O
, None None O
English None None O
language None None I-FUNC
, None None O
and None None O
French None None O
as None None O
a None None O
second None None O
language None None I-FUNC
, None None O
above None None O
and None None O
beyond None None O
the None None O
contributions None None O
of None None O
age None None O
, None None O
gender None None O
, None None O
and None None O
SES None None O
. None None O

The None None O
integration None None O
of None None O
strategies None None O
to None None O
improve None None O
sleep None None O
efficiency None None O
might None None O
represent None None O
a None None O
successful None None O
approach None None O
for None None O
improving None None O
children None None O
's None None O
readiness None None O
and/or None None O
performance None None O
in None None O
math None None O
and None None O
languages None None I-FUNC
. None None O

Pearson None None O
's None None O
and None None O
Spearman None None O
's None None O
correlations None None O
identified None None O
significant None None O
relationships None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
between None None O
parents None None O
' None None O
self-efficacy None None O
and None None O
disease None None O
severity None None O
, None None O
child None None O
behaviour None None O
difficulties None None O
, None None O
parent None None O
depression None None I-DISEASE
and None None O
stress None None O
, None None O
parenting None None O
conflict None None O
, None None O
and None None O
relationship None None O
satisfaction None None O
. None None O

Less None None O
competent None None O
task None None O
performance None None O
was None None O
also None None O
associated None None O
with None None O
greater None None O
parent-reported None None O
child None None O
behaviour None None O
difficulties None None O
, None None O
parent None None O
depression None None I-DISEASE
and None None O
stress None None O
, None None O
parenting None None O
conflict None None O
, None None O
and None None O
relationship None None O
dissatisfaction None None O
. None None O

According None None O
to None None O
our None None O
results None None O
, None None O
DPC-derived None None O
iPSC None None O
colonies None None O
that None None O
could None None O
be None None O
subcultured None None O
and None None O
propagated None None O
were None None O
established None None O
as None None O
early None None O
as None None O
10 None None O
days None None O
after None None O
transduction None None O
, None None O
in None None O
comparison None None O
with None None O
the None None O
skin None None O
fibroblast None None O
( None None O
DPC-derived None None O
iPSCs None None O
) None None O
without None None O
c-Myc None None I-PROTEIN
presented None None O
embryonic None None O
stem None None O
cell-like None None O
properties None None O
and None None O
the None None O
pluripotent None None O
potential None None O
to None None O
differentiate None None O
into None None O
neuron-like None None O
cells None None O
, None None O
which None None O
resemble None None O
neurons None None O
both None None O
morphologically None None O
and None None O
functionally None None O
. None None O

Integrins None None I-PROTEIN
are None None O
a None None O
group None None O
of None None O
transmembrane None None O
heterodimeric None None O
proteins None None O
that None None O
mediate None None O
cell-cell None None O
and None None O
cell-extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
interactions None None O
. None None O

Clinical None None O
trials None None O
investigating None None O
integrin None None I-PROTEIN
antagonists None None O
, None None O
however None None O
, None None O
have None None O
shown None None O
that None None O
these None None O
compounds None None O
are None None O
relatively None None O
ineffective None None O
. None None O

Recent None None O
studies None None O
have None None O
identified None None O
integrins None None I-PROTEIN
as None None O
important None None O
players None None O
in None None O
this None None O
process None None O
, None None O
with None None O
a None None O
particular None None O
role None None O
for None None O
β1 None None O
and None None O
αv None None O
integrins None None I-PROTEIN
. None None O

Older None None O
stroke None None I-DISEASE
survivors None None O
are None None O
at None None O
an None None O
increased None None O
risk None None O
for None None O
readmission None None O
with None None O
approximately None None O
40 None None O
% None None O
being None None O
readmitted None None O
in None None O
the None None O
first None None O
year None None O
after None None O
stroke None None I-DISEASE
. None None O

From None None O
the None None O
29 None None O
semi-structured None None O
interviews None None O
conducted None None O
with None None O
20 None None O
stroke None None I-DISEASE
survivors None None O
and/or None None O
their None None O
caregivers None None O
, None None O
the None None O
following None None O
themes None None O
were None None O
identified None None O
: None None O
preparing None None O
to None None O
go None None O
home None None O
after None None O
the None None O
stroke None None I-DISEASE
, None None O
what None None O
to None None O
expect None None O
at None None O
home None None O
, None None O
complexity None None O
of None None O
medication None None O
management None None O
, None None O
support None None O
for None None O
self-care None None O
in None None O
the None None O
community None None O
and None None O
the None None O
influence None None O
of None None O
social None None O
factors None None O
. None None O

In None None O
the None None O
present None None O
report None None O
we None None O
describe None None O
our None None O
clinical None None O
experience None None O
using None None O
specific None None O
image-based None None O
decision None None I-FUNC
making None None I-FUNC
and None None O
anatomic None None O
considerations None None O
for None None O
transcatheter None None O
valve-in-valve None None O
( None None O
ViV None None O
) None None O
implantation None None O
in None None O
degenerated None None O
xenografts None None O
with None None O
their None None O
pericardial None None O
leaflets None None O
externally None None O
mounted None None O
around None None O
the None None O
stent None None O
( None None O
Mitroflow None None O
[ None None O
SORIN None None O
Group None None O
, None None O
Milan None None O
, None None O
Italy None None O
] None None O
or None None O
Trifecta None None O
[ None None O
St. None None O
Jude None None O
Medical None None O
, None None O
St None None O
Paul None None O
, None None O
MN None None O
] None None O
) None None O
. None None O

Precise None None O
preoperative None None O
image-based None None O
decision None None I-FUNC
making None None I-FUNC
is None None O
mandatory None None O
. None None O

The None None O
right None None O
atrial None None O
volume None None O
was None None O
estimated None None O
at None None O
more None None O
than None None O
1,900 None None O
mL None None O
, None None O
with None None O
normal None None O
sized None None O
left None None O
atrium None None O
and None None O
ventricles None None I-REGION
. None None O

Based None None O
on None None O
his None None O
clinical None None O
course None None O
, None None O
the None None O
patient None None O
was None None O
diagnosed None None O
with None None O
acute None None O
adrenal None None I-TRANS
insufficiency None None O
and None None O
diabetes None None O
insipidus None None O
due None None O
to None None O
pituitary None None O
apoplexy None None O
. None None O

We None None O
present None None O
the None None O
case None None O
of None None O
a None None O
previously None None O
healthy None None O
man None None O
with None None O
acute None None O
onset None None O
of None None O
ischemic None None O
cerebral None None O
stroke None None I-DISEASE
. None None O

The None None O
patient None None O
subsequently None None O
underwent None None O
uncomplicated None None O
therapy None None O
for None None O
stroke None None I-DISEASE
, None None O
including None None O
thrombolysis None None O
followed None None O
by None None O
excision None None O
of None None O
the None None O
giant None None O
pulmonary None None O
venous None None O
aneurysm None None O
. None None O

When None None O
preserving None None O
a None None O
twisted None None O
lobe None None O
, None None O
it None None O
is None None O
important None None O
to None None O
consider None None O
the None None O
damage None None O
to None None O
the None None O
twisted None None O
lung None None O
, None None O
risk None None O
of None None O
thrombosis None None I-DISEASE
, None None O
and None None O
residual None None O
pulmonary None None O
function None None O
. None None O

Despite None None O
changes None None O
in None None O
wastewater None None O
characteristics None None O
, None None O
a None None O
stable None None O
anaerobic None None O
process None None O
was None None O
maintained None None O
with None None O
hydraulic None None O
retention None None I-FUNC
times None None O
( None None O
HRTs None None O
) None None O
between None None O
7 None None O
and None None O
14 None None O
h. None None O
Lowering None None O
the None None O
HRT None None O
( None None O
from None None O
13.5 None None O
to None None O
8.5 None None O
h None None O
) None None O
did None None O
not None None O
significantly None None O
affect None None O
the None None O
process None None O
, None None O
and None None O
the None None O
stable None None O
performance None None O
at None None O
8.5 None None O
h None None O
leaves None None O
room None None O
for None None O
further None None O
decreases None None O
in None None O
HRT None None O
. None None O

The None None O
recent None None O
massive None None O
destruction None None O
of None None O
Syrian None None O
civilians None None O
by None None O
nerve None None O
gas None None O
sarin None None O
, None None O
has None None O
again None None O
renewed None None O
the None None O
research None None O
attention None None I-FUNC
of None None O
global None None O
science None None O
fraternity None None O
towards None None O
nerve None None O
agents None None O
, None None O
their None None O
mode None None O
of None None O
action None None O
and None None O
most None None O
prominently None None O
their None None O
therapeutic None None O
treatment None None O
. None None O

Another None None O
gene None None O
mutation None None O
methylenetetrahydrofolate None None I-PROTEIN
reductase None None I-PROTEIN
( None None O
MTHFr None None O
) None None O
is None None O
now None None O
being None None O
recognized None None O
much None None O
commonly None None O
than None None O
previous None None O
with None None O
chronic None None O
fatigue None None O
, None None O
chronic None None O
Lyme None None O
diseases None None O
and None None O
as None None O
`` None None O
the None None O
missing None None O
link None None O
'' None None O
in None None O
other None None O
chronic None None O
diseases None None O
. None None O

This None None O
is None None O
because None None O
of None None O
its None None O
ability None None O
to None None O
reveal None None O
conscious None None O
and None None O
subconscious None None O
behaviors None None O
when None None O
subjects None None O
are None None O
tasked None None O
with None None O
observation None None O
, None None O
decision None None I-FUNC
making None None I-FUNC
, None None O
and None None O
surgical None None O
performance None None O
. None None O

The None None O
experience None None O
of None None O
surgeons None None O
does None None O
appear None None O
to None None O
modify None None O
gaze None None O
behavior None None O
with None None O
respect None None O
to None None O
time None None O
and None None O
attention None None I-FUNC
, None None O
such None None O
that None None O
less None None O
overall None None O
time None None O
spent None None O
per None None O
image None None O
is None None O
needed None None O
by None None O
the None None O
advanced None None O
group None None O
, None None O
with None None O
improved None None O
efficiency None None O
. None None O

The None None O
English None None O
language None None I-FUNC
literature None None O
was None None O
searched None None O
for None None O
documented None None O
cases None None O
of None None O
HCC None None O
metastasis None None O
to None None O
the None None O
jaw None None O
, None None O
applicable None None O
data None None O
was None None O
evaluated None None O
. None None O

The None None O
chelating None None O
agent None None O
ethylenediamine None None O
tetraacetic None None O
acid None None O
was None None O
used None None O
to None None O
remove None None O
other None None O
ions None None O
in None None O
the None None O
seawater None None O
matrix None None O
( None None O
Na None None I-TRANS
, None None O
Mg None None O
, None None O
and None None O
Ca None None O
) None None O
that None None O
interfere None None O
with None None O
the None None O
ICP-MS None None O
analysis None None O
. None None O

Acid-extracted None None O
rat None None O
liver None None O
histones None None I-PROTEIN
were None None O
first None None O
mixed None None O
with None None O
CuSO4 None None O
solution None None O
and None None O
then None None O
separated None None O
in None None O
one None None O
dimension None None O
with None None O
triton-acid-urea None None O
( None None O
TAU None None O
) None None O
gel None None O
electrophoresis None None O
and None None O
in None None O
a None None O
second None None O
dimension None None O
using None None O
sodium None None O
dodecyl None None O
sulfate None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
( None None O
SDS-PAGE None None O
) None None O
. None None O

Tryptophan None None I-TRANS
doped None None O
carbon None None O
dots None None O
( None None O
Trp-CD None None O
) None None O
were None None O
microwave None None O
synthesized None None O
. None None O

First-order None None O
kinetic None None O
rate None None O
constants None None O
were None None O
calculated None None O
for None None O
51 None None O
selected None None O
compounds None None O
and None None O
utilized None None O
to None None O
develop None None O
predictive None None O
models None None O
for None None O
evaporation None None O
rate None None O
constants None None O
, None None O
using None None O
GC None None O
retention None None I-FUNC
indices None None O
on None None O
a None None O
nonpolar None None O
stationary None None O
phase None None O
. None None O

The None None O
two None None O
sets None None O
of None None O
encodings None None I-FUNC
allow None None O
for None None O
the None None O
bases None None O
to None None O
be None None O
sequentially None None O
decoded None None O
, None None O
moving None None O
from None None O
first None None O
to None None O
last None None O
, None None O
in None None O
a None None O
deterministic None None O
manner None None O
. None None O

Moreover None None O
, None None O
streptococcal None None O
strains None None O
could None None O
be None None O
differentiated None None O
by None None O
comparing None None O
signal None None O
intensity None None O
in None None O
each None None O
cycle None None O
and None None O
encoding None None I-FUNC
size None None O
of None None O
each None None O
template None None O
. None None O

According None None O
to None None O
the None None O
three-dimensional None None O
fluorescence None None O
( None None O
EEM None None O
) None None O
results None None O
, None None O
the None None O
aromatic None None O
protein-like None None O
and None None O
tryptophan None None I-TRANS
protein-like None None O
substances None None O
were None None O
more None None O
abundant None None O
in None None O
the None None O
granular None None O
sludge None None O
than None None O
that None None O
in None None O
flocs None None O
, None None O
suggesting None None O
they None None O
are None None O
the None None O
key None None O
components None None O
in None None O
the None None O
structural None None O
stability None None O
of None None O
granular None None O
sludge None None O
. None None O

Furthermore None None O
, None None O
DEHP None None O
down-regulated None None O
the None None O
expressions None None O
of None None O
androgen None None O
receptor None None I-PROTEIN
( None None O
AR None None O
) None None O
in None None O
pubertal None None O
male None None O
hippocampus None None I-REGION
and None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
ER None None O
) None None O
β None None O
in None None O
pubertal None None O
female None None O
and None None O
adult None None O
hippocampus None None I-REGION
of None None O
both None None O
sexes None None O
and None None O
inhibited None None O
the None None O
phosphorylation None None O
of None None O
ERK1/2 None None O
of None None O
hippocampus None None I-REGION
in None None O
pubertal None None O
mice None None O
and None None O
adult None None O
males None None O
. None None O

The None None O
disruption None None O
of None None O
gonadal None None O
hormones None None I-PROTEIN
' None None O
modulation None None O
of None None O
behaviors None None O
due None None O
to None None O
down-regulation None None O
of None None O
AR None None O
or None None O
ERβ None None O
in None None O
the None None O
hippocampus None None I-REGION
may None None O
be None None O
associated None None O
with None None O
the None None O
aggravated None None O
anxiety- None None O
and None None O
depression-like None None O
status None None O
induced None None O
by None None O
DEHP None None O
. None None O

Facial None None I-REGION
nerve None None I-REGION
preservation None None O
and None None O
complete None None O
resection None None O
of None None O
the None None O
tumor None None O
are None None O
the None None O
main None None O
principles None None O
of None None O
the None None O
operation None None O
. None None O

Case-based None None O
learning None None I-FUNC
is None None O
a None None O
method None None O
of None None O
problem-based None None O
learning None None I-FUNC
that None None O
is None None O
designed None None O
to None None O
heighten None None O
higher-order None None O
thinking None None O
. None None O

This None None O
study None None O
examined None None O
student None None O
perspectives None None O
of None None O
their None None O
learning None None I-FUNC
after None None O
immersion None None O
into None None O
case-based None None O
learning None None I-FUNC
in None None O
nutrition None None O
courses None None O
. None None O

The None None O
analysis None None O
of None None O
the None None O
coding None None O
was None None O
the None None O
constructive None None O
stage None None O
that None None O
led None None O
to None None O
configuration None None O
of None None O
themes None None O
and None None O
theoretical None None O
practice None None O
pathways None None O
about None None O
student None None O
learning None None I-FUNC
. None None O

Story None None O
or None None O
Scenario None None O
represents None None O
the None None O
ways None None O
that None None O
students None None O
described None None O
case-based None None O
learning None None I-FUNC
, None None O
changes None None O
in None None O
student None None O
thought None None O
processes None None O
to None None O
accommodate None None O
case-based None None O
learning None None I-FUNC
are None None O
illustrated None None O
in None None O
Method None None O
of None None O
Learning None None I-FUNC
, None None O
higher None None O
cognitive None None O
learning None None I-FUNC
that None None O
was None None O
achieved None None O
from None None O
case-based None None O
learning None None I-FUNC
is None None O
represented None None O
in None None O
Problem None None I-FUNC
Solving None None I-FUNC
, None None O
and None None O
Future None None O
Practice None None O
details None None O
how None None O
students None None O
explained None None O
perceived None None O
professional None None O
competency None None O
gains None None O
from None None O
case-based None None O
learning None None I-FUNC
. None None O

In None None O
addition None None O
, None None O
the None None O
common None None O
concept None None O
of None None O
Big None None O
Picture None None O
was None None O
iterated None None O
throughout None None O
the None None O
themes None None O
and None None O
demonstrated None None O
that None None O
case-based None None O
learning None None I-FUNC
prepares None None O
students None None O
for None None O
multifaceted None None O
problems None None O
that None None O
they None None O
are None None O
likely None None O
to None None O
encounter None None O
in None None O
professional None None O
practice None None O
. None None O

The None None O
largest None None O
increases None None O
in None None O
K None None O
values None None O
for None None O
thickened None None O
beverages None None O
were None None O
observed None None O
at None None O
1-hour None None O
storage None None I-FUNC
, None None O
and None None O
at None None O
longer None None O
times None None O
their None None O
K None None O
values None None O
, None None O
except None None O
for None None O
milk None None O
, None None O
remained None None O
approximately None None O
constant None None O
. None None O

Children None None O
( None None O
9-11 None None O
years None None O
) None None O
performed None None O
a None None O
tennis None None O
hitting None None O
task None None O
in None None O
two None None O
attention None None I-FUNC
conditions None None O
( None None O
single-task None None O
and None None O
dual-task None None O
) None None O
using None None O
two None None O
types None None O
of None None O
equipment None None O
( None None O
scaled None None O
and None None O
full None None O
size None None O
) None None O
. None None O

The None None O
more None None O
skilled None None O
group None None O
displayed None None O
greater None None O
working None None I-FUNC
memory None None I-FUNC
capacity None None O
than None None O
the None None O
less None None O
skilled None None O
group None None O
. None None O

The None None O
cue None None O
condition None None O
was None None O
designed None None O
to None None O
provide None None O
an None None O
index None None O
of None None O
the None None O
contents None None O
of None None O
iconic None None O
memory None None I-FUNC
of None None O
the None None O
display None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
scene None None O
gist None None O
is None None O
contained None None O
in None None O
iconic None None O
memory None None I-FUNC
even None None O
in None None O
the None None O
visual None None O
periphery None None O
; None None O
however None None O
, None None O
iconic None None O
representations None None O
are None None O
not None None O
sufficiently None None O
detailed None None O
to None None O
distinguish None None O
between None None O
scenes None None O
coming None None O
from None None O
the None None O
same None None O
category None None O
. None None O

Moreover None None O
, None None O
whereas None None O
some None None O
neurodegenerative None None O
disorders None None O
such None None O
as None None O
multiple None None O
sclerosis None None O
, None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
involve None None O
the None None O
participation None None O
of None None O
inflammatory None None O
CD4 None None O
( None None O
+ None None O
) None None O
T-cells None None O
'naturally None None O
' None None O
, None None O
the None None O
physiopathology None None O
of None None O
other None None O
neurodegenerative None None O
diseases None None O
, None None O
such None None O
as None None O
amyotrophic None None O
lateral None None O
sclerosis None None O
, None None O
is None None O
associated None None O
with None None O
the None None O
participation None None O
of None None O
anti-inflammatory None None O
CD4 None None O
( None None O
+ None None O
) None None O
T-cells None None O
that None None O
delay None None O
the None None O
neurodegenerative None None O
process None None O
. None None O

In None None O
vitro None None O
filaricidal None None O
activity None None O
of None None O
AEA None None O
is None None O
possibly None None O
through None None O
disturbing None None O
redox None None O
homeostasis None None O
by None None O
down-regulating None None O
and None None O
altering None None O
the None None O
level None None O
of None None O
some None None O
key None None O
antioxidants None None O
and None None O
regulatory None None O
enzymes None None I-PROTEIN
like None None O
reduced None None O
glutathione None None O
, None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
, None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
, None None O
catalase None None I-PROTEIN
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
of None None O
S. None None O
cervi None None O
. None None O

Phagocytic None None O
activity None None O
was None None O
determined None None O
by None None O
the None None O
ingestion None None O
of None None O
Latex None None O
Beads-Rabbit None None O
IgG-FITC None None O
using None None O
the None None O
fluorescent None None O
microscopy None None O
and None None O
flow None None O
cytometry None None O
analysis None None O
and None None O
nitric None None I-TRANS
oxide None None I-TRANS
production None None O
was None None O
measured None None O
using None None O
Griess None None O
reaction None None O
assay None None O
. None None O

Enzymes None None I-PROTEIN
were None None O
partially None None O
purified None None O
by None None O
ammonium None None O
sulfate None None O
precipitation None None O
followed None None O
by None None O
membrane None None O
dialysis None None O
. None None O

To None None O
construct None None O
a None None O
PSA None None O
luciferase None None I-PROTEIN
report None None O
plasmid None None O
and None None O
monitor None None O
the None None O
growth None None O
and None None O
metastasis None None O
of None None O
prostate None None O
cancer None None O
after None None O
emasculation None None O
in None None O
SCID None None O
mice None None O
. None None O

We None None O
successfully None None O
constructed None None O
a None None O
PSA None None O
luciferase None None I-PROTEIN
plasmid None None O
, None None O
pPSA-FL-Luc None None O
. None None O

We None None O
construct None None O
a None None O
pPSA-FL-Luc None None O
plasmid None None O
, None None O
which None None O
stably None None O
expresses None None O
luciferase None None I-PROTEIN
and None None O
can None None O
be None None O
applied None None O
to None None O
monitor None None O
tumor None None O
development None None O
in None None O
a None None O
prostate None None O
SCID None None O
mouse None None O
model None None O
. None None O

The None None O
compound None None O
preparations None None O
of None None O
HA None None O
in None None O
combination None None O
with None None O
GB None None O
for None None O
dementia None None I-DISEASE
caused None None O
by None None O
cerebral None None O
ischemic None None O
have None None O
synergistic None None O
effects None None O
on None None O
the None None O
pharmacodynamics None None O
, None None O
and None None O
improve None None O
the None None O
bioavailability None None O
through None None O
BBB None None O
. None None O

Two None None O
patients None None O
had None None O
a None None O
lesion None None O
in None None O
the None None O
interventricular None None O
septum None None I-REGION
, None None O
whereas None None O
one None None O
patient None None O
had None None O
the None None O
lesion None None O
in None None O
apicoinferior None None O
wall None None O
of None None O
LV None None O
. None None O

LHb None None O
was None None O
found None None O
to None None O
be None None O
metabolically None None O
modified None None O
in None None O
dyskinetic None None O
monkeys None None O
and None None O
its None None O
neuronal None None O
firing None None O
frequency None None O
significantly None None O
increased None None O
in None None O
ON None None O
L-DOPA None None I-TRANS
dyskinetic None None O
6-hydroxydopamine-lesioned None None O
rats None None O
, None None O
suggesting None None O
that None None O
increased None None O
LHb None None O
neuronal None None O
activity None None O
in None None O
response None None O
to None None O
L-DOPA None None I-TRANS
is None None O
related None None O
to None None O
AIM None None O
manifestation None None O
. None None O

Three None None O
days None None O
after None None O
Daun02 None None O
administration None None O
, None None O
animals None None O
were None None O
tested None None O
daily None None O
with None None O
L-DOPA None None I-TRANS
to None None O
assess None None O
LID None None O
and None None O
L-DOPA-induced None None O
rotations None None O
. None None O

To None None O
manipulate None None O
Hsp90 None None O
acetylation None None O
, None None O
we None None O
pharmacologically None None O
inhibited None None O
histone None None O
deacetylase None None O
6 None None O
, None None O
a None None O
known None None O
deacetylase None None O
of None None O
Hsp90 None None O
, None None O
or None None O
overexpressed None None O
a None None O
point None None O
mutant None None O
that None None O
mimics None None O
the None None O
hyperacetylated None None O
state None None O
of None None O
Hsp90 None None O
at None None O
lysine None None I-TRANS
K294 None None O
. None None O

The None None O
use None None O
of None None O
noninvasive None None O
eye None None O
tracking None None O
extends None None O
the None None O
findings None None O
from None None O
rodent None None O
MIA None None O
models None None O
to None None O
more None None O
human-like None None O
behaviors None None O
resembling None None O
those None None O
in None None O
both None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
and None None O
schizophrenia None None I-DISEASE
. None None O

Cognitive None None O
decline None None O
, None None O
particularly None None O
in None None O
the None None O
context None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
is None None O
an None None O
area None None O
that None None O
has None None O
attracted None None O
numerous None None O
recent None None O
studies None None O
, None None O
and None None O
the None None O
proposed None None O
biomarkers None None O
used None None O
in None None O
these None None O
investigations None None O
need None None O
to None None O
be None None O
validated None None O
. None None O

Structural None None O
changes None None O
determined None None O
on None None O
cross-sectional None None O
and None None O
longitudinal None None O
magnetic None None O
resonance None None O
imaging None None O
provide None None O
early None None O
prediction None None O
of None None O
dementia None None I-DISEASE
, None None O
particularly None None O
when None None O
combined None None O
with None None O
other None None O
measures None None O
. None None O

Importantly None None O
, None None O
when None None O
combined None None O
, None None O
4αPDD None None O
positively None None O
interacted None None O
with None None O
hyperosmolarity None None O
to None None O
modulate None None O
its None None O
effects None None O
on None None O
tensile None None O
stiffness None None O
and None None O
collagen None None I-PROTEIN
content None None O
. None None O

Through None None O
immunohistochemical None None O
examination None None O
, None None O
in None None O
of None None O
a None None O
total None None O
of None None O
21 None None O
pediatric None None O
patients None None O
in None None O
whom None None O
ganglion None None I-NEURON
cells None None I-NEURON
were None None O
detected None None O
in None None O
first None None O
rectal None None O
biopsies None None O
and None None O
in None None O
re-biopsies None None O
, None None O
ganglion None None I-NEURON
cells None None I-NEURON
were None None O
seen None None O
through None None O
nuclear None None O
and None None O
cytoplasmic None None O
staining None None O
. None None O

Out None None O
of None None O
a None None O
total None None O
of None None O
5 None None O
biopsies None None O
( None None O
including None None O
one None None O
re-biopsy None None O
) None None O
of None None O
non-HD None None O
patients None None O
, None None O
where None None O
ganglion None None I-NEURON
cells None None I-NEURON
could None None O
not None None O
be None None O
seen None None O
, None None O
the None None O
nerve None None O
fibers None None O
were None None O
all None None O
stained None None O
. None None O

In None None O
vitro None None O
assays None None O
identified None None O
CTSX None None O
as None None O
relevant None None O
factor None None O
for None None O
cell-cell None None O
adhesion None None I-PROTEIN
and None None O
tumor None None O
cell None None O
anchorage None None O
to None None O
fibroblasts None None O
and None None O
basal None None O
membrane None None O
components None None O
, None None O
whereas None None O
inhibition None None O
of None None O
CTSX None None O
caused None None O
increased None None O
invasiveness None None O
of None None O
colon None None O
carcinoma None None O
cells None None O
in None None O
mono- None None O
and None None O
co-culture None None O
. None None O

Follicle None None O
development None None O
is None None O
coordinated None None O
by None None O
gonadotropins None None O
, None None O
steroids None None O
, None None O
and None None O
growth None None I-PROTEIN
factors None None I-PROTEIN
, None None O
which None None O
activate None None O
multiple None None O
signaling None None O
pathways None None O
. None None O

Various None None O
quantitative None None O
magnetic None None O
resonance None None O
imaging None None O
techniques None None O
have None None O
been None None O
developed None None O
for None None O
noninvasive None None O
assessment None None O
of None None O
the None None O
proteoglycan None None O
and None None O
collagen None None I-PROTEIN
components None None O
of None None O
cartilage None None O
. None None O

Clearer None None O
definitions None None O
of None None O
late None None O
rectal None None O
bleeding None None O
toxicity None None O
should None None O
be None None O
constructed None None O
to None None O
reduce None None O
this None None O
variability None None O
and None None O
avoid None None O
ambiguity None None I-FUNC
in None None O
both None None O
reporting None None O
and None None O
interpretation None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
periplasmic None None O
sensor None None O
domain None None O
of None None O
SsrA None None O
is None None O
enriched None None O
in None None O
histidine None None I-TRANS
residues None None O
that None None O
increase None None O
SsrA None None O
signaling None None O
below None None O
external None None O
pH None None O
of None None O
6 None None O
. None None O

A None None O
sensor None None O
mutant None None O
lacking None None O
critical None None O
pH-responsive None None O
histidines None None I-TRANS
was None None O
defective None None O
for None None O
acid-promoted None None O
activity None None O
, None None O
yet None None O
retained None None O
basal None None O
activity None None O
similar None None O
to None None O
wild None None O
type None None O
at None None O
neutral None None O
pH None None O
, None None O
indicating None None O
that None None O
the None None O
role None None O
of None None O
these None None O
histidines None None I-TRANS
is None None O
to None None O
enhance None None O
signaling None None O
in None None O
response None None O
to None None O
acidification None None O
. None None O

Therefore None None O
, None None O
the None None O
core None None O
of None None O
this None None O
initiative None None O
is None None O
the None None O
knowledge None None I-FUNC
representation None None I-FUNC
and None None O
the None None O
reasoning None None I-FUNC
. None None O

In None None O
this None None O
sense None None O
, None None O
hard-coded None None O
knowledge None None O
, None None O
semantic None None O
and None None O
usability None None O
gaps None None O
are None None O
to None None O
be None None O
reduced None None O
by None None O
a None None O
leading None None O
, None None O
active None None O
role None None O
of None None O
reasoning None None I-FUNC
and None None O
of None None O
semantic None None O
approaches None None O
. None None O

The None None O
strongest None None O
disparity None None O
in None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
negative None None O
was None None O
observed None None O
in None None O
Louisiana None None O
which None None O
with None None O
Detroit None None O
, None None O
have None None O
had None None O
the None None O
highest None None O
rates None None O
of None None O
estrogen None None I-PROTEIN
receptor None None I-PROTEIN
negative None None O
. None None O

The None None O
learning None None I-FUNC
curve None None O
for None None O
the None None O
staging None None O
of None None O
gastric None None O
cancer None None O
, None None O
however None None O
, None None O
has None None O
not None None O
been None None O
evaluated None None O
. None None O

The None None O
interaction None None O
of None None O
amyloid-beta None None O
( None None O
Aβ None None O
) None None O
and None None O
tau None None O
in None None O
the None None O
pathogenesis None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
is None None O
a None None O
subject None None O
of None None O
intense None None O
inquiry None None O
, None None O
with None None O
the None None O
bulk None None O
of None None O
evidence None None O
indicating None None O
that None None O
changes None None O
in None None O
tau None None O
are None None O
downstream None None O
of None None O
Aβ None None O
. None None O

Previously None None O
, None None O
the None None O
blockade None None O
of None None O
the None None O
MR None None O
has None None O
been None None O
shown None None O
to None None O
impair None None O
visuospatial None None O
and None None O
working None None I-FUNC
memory None None I-FUNC
in None None O
healthy None None O
young None None O
men None None O
. None None O

As None None O
expected None None O
, None None O
young None None O
participants None None O
performed None None O
significantly None None O
better None None O
than None None O
elderly None None O
individuals None None O
in None None O
visuospatial None None O
memory None None I-FUNC
( None None O
effect None None O
of None None O
group None None O
: None None O
F None None O
= None None O
42.7 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
verbal None None O
memory None None I-FUNC
( None None O
F None None O
= None None O
33.1 None None O
, None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
and None None O
working None None I-FUNC
memory None None I-FUNC
( None None O
digit-span None None O
backward None None O
: None None O
F None None O
= None None O
4.5 None None O
, None None O
p None None O
= None None O
0.04 None None O
) None None O
. None None O

In None None O
concert None None O
with None None O
the None None O
previous None None O
studies None None O
, None None O
our None None O
data None None O
suggest None None O
a None None O
role None None O
of None None O
the None None O
MR None None O
in None None O
memory None None I-FUNC
function None None O
. None None O

TDP-43 None None O
inclusions None None O
are None None O
also None None O
found None None O
in None None O
up None None O
to None None O
approximately None None O
60 None None O
% None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
brains None None O
. None None O

Early None None O
cognitive None None O
deficits None None O
in None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
seem None None O
to None None O
be None None O
correlated None None O
to None None O
dysregulation None None O
of None None O
glutamate None None I-TRANS
receptors None None I-PROTEIN
evoked None None O
by None None O
amyloid-beta None None O
( None None O
Aβ None None O
) None None O
peptide None None O
. None None O

Bay None None O
60-7550 None None O
reversed None None O
stress-induced None None O
cognitive None None O
impairment None None O
in None None O
the None None O
Morris None None O
water None None O
maze None None O
, None None O
novel None None O
object None None I-FUNC
recognition None None I-FUNC
, None None O
and None None O
location None None O
tasks None None O
( None None O
object None None I-FUNC
recognition None None I-FUNC
test None None O
and/or None None O
object None None O
location None None O
test None None O
) None None O
, None None O
effects None None O
prevented None None O
by None None O
treatment None None O
with None None O
7-NI None None O
, None None O
a None None O
selective None None O
inhibitor None None O
of None None O
neuronal None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
; None None O
MK801 None None O
, None None O
a None None O
glutamate None None I-TRANS
receptor None None I-PROTEIN
( None None O
NMDAR None None O
) None None O
inhibitor None None O
; None None O
myr-AIP None None O
, None None O
a None None O
CaMKII None None O
inhibitor None None O
; None None O
and None None O
KT5823 None None O
, None None O
a None None O
protein None None O
kinase None None O
G None None O
inhibitor None None O
. None None O

Pretreatment None None O
with None None O
inhibitors None None O
of None None O
NMDA None None O
, None None O
CaMKII None None O
, None None O
neuronal None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
, None None O
and None None O
protein None None O
kinase None None O
G None None O
( None None O
or None None O
protein None None O
kinase None None O
A None None O
) None None O
blocked None None O
the None None O
effects None None O
of None None O
Bay None None O
60-7550 None None O
on None None O
cGMP None None O
or None None O
cAMP None None O
signaling None None O
. None None O

Therefore None None O
, None None O
we None None O
examined None None O
whether None None O
alterations None None O
in None None O
sleep None None O
spindles None None O
and None None O
slow None None O
waves None None O
at None None O
baseline None None O
visit None None O
were None None O
associated None None O
with None None O
increased None None O
likelihood None None O
of None None O
developing None None O
dementia None None I-DISEASE
at None None O
follow-up None None O
in None None O
PD None None O
. None None O

At None None O
follow-up None None O
( None None O
mean None None O
: None None O
4.5 None None O
years None None O
later None None O
) None None O
, None None O
18 None None O
PD None None O
patients None None O
developed None None O
dementia None None I-DISEASE
( None None O
70.2 None None O
± None None O
7.6 None None O
years None None O
old None None O
; None None O
13 None None O
men None None O
) None None O
and None None O
50 None None O
remained None None O
dementia-free None None O
( None None O
63.0 None None O
± None None O
8.5 None None O
years None None O
old None None O
; None None O
33 None None O
men None None O
) None None O
. None None O

Dementia-free None None O
PD None None O
patients None None O
were None None O
intermediate None None O
between None None O
dementia None None I-DISEASE
patients None None O
and None None O
controls None None O
, None None O
with None None O
lower None None O
baseline None None O
sleep None None O
spindle None None O
density None None O
in None None O
all None None O
cortical None None O
areas None None O
compared None None O
with None None O
controls None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
. None None O

Although None None O
slow None None O
wave None None O
amplitude None None O
was None None O
lower None None O
in None None O
PD None None O
patients None None O
compared None None O
with None None O
controls None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.0001 None None O
) None None O
, None None O
no None None O
difference None None O
was None None O
observed None None O
between None None O
those None None O
who None None O
developed None None O
or None None O
did None None O
not None None O
develop None None O
dementia None None I-DISEASE
. None None O

Sleep None None O
spindle None None O
activity None None O
was None None O
particularly None None O
impaired None None O
in None None O
PD None None O
patients None None O
who None None O
developed None None O
dementia None None I-DISEASE
, None None O
with None None O
a None None O
more None None O
posterior None None O
topographic None None O
pattern None None O
. None None O

Occipital None None O
sources None None O
of None None O
resting-state None None O
electroencephalographic None None O
( None None O
EEG None None O
) None None O
alpha None None O
rhythms None None O
are None None O
abnormal None None O
, None None O
at None None O
the None None O
group None None O
level None None O
, None None O
in None None O
patients None None O
with None None O
amnesic None None O
mild None None O
cognitive None None O
impairment None None O
( None None O
MCI None None O
) None None O
and None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

Levels None None O
of None None O
serotonin None None I-TRANS
( None None O
5HT None None O
) None None O
, None None O
norepinephrine None None I-TRANS
( None None O
NE None None I-TRANS
) None None O
and None None O
dopamine None None I-TRANS
( None None O
DA None None O
) None None O
were None None O
quantified None None O
in None None O
the None None O
CSF None None O
after None None O
1 None None O
h None None O
of None None O
sham None None O
, None None O
standard None None O
and None None O
microburst None None O
VNS None None O
with None None O
a None None O
wash-out None None O
period None None O
of None None O
1 None None O
month None None O
. None None O

VNS None None O
induces None None O
an None None O
increase None None O
of None None O
NE None None I-TRANS
in None None O
the None None O
canine None None O
brain None None O
, None None O
which None None O
supports None None O
previous None None O
findings None None O
indicating None None O
that None None O
VNS None None O
influences None None O
the None None O
locus None None O
coeruleus-NE None None O
( None None O
LC/NE None None O
) None None O
system None None O
. None None O

In None None O
a None None O
second None None O
study None None O
, None None O
ten None None O
healthy None None O
subjects None None O
were None None O
exposed None None O
to None None O
60 None None O
s None None O
of None None O
tACS None None O
( None None O
1000 None None O
μA None None O
, None None O
2 None None O
Hz None None O
versus None None O
16 None None O
Hz None None O
, None None O
F3/F4 None None O
versus None None O
P3/P4 None None O
) None None O
and None None O
were None None O
asked None None O
to None None O
rate None None O
the None None O
intensity None None O
of None None O
sensations None None I-FUNC
every None None O
12 None None O
s. None None O
The None None O
first None None O
study None None O
showed None None O
that None None O
all None None O
stimulation None None O
parameters None None O
had None None O
an None None O
influence None None O
on None None O
the None None O
probability None None O
and None None O
intensity None None O
of None None O
sensations None None I-FUNC
. None None O

The None None O
second None None O
study None None O
also None None O
revealed None None O
that None None O
the None None O
probability None None O
and None None O
the None None O
intensity None None O
of None None O
sensations None None I-FUNC
were None None O
neither None None O
modified None None O
during None None O
more None None O
extended None None O
periods None None O
of None None O
stimulation None None O
nor None None O
affected None None O
by None None O
carry-over None None O
effects None None O
. None None O

The None None O
present None None O
study None None O
examined None None O
a None None O
wide None None O
range None None O
of None None O
emotion None None I-FUNC
regulation None None O
( None None O
ER None None O
) None None O
strategies None None O
in None None O
32 None None O
individuals None None O
with None None O
ASD None None O
compared None None O
to None None O
31 None None O
group-matched None None O
typically None None O
developing None None O
( None None O
TD None None O
) None None O
participants None None O
in None None O
three None None O
emotional None None O
domains None None O
( None None O
anger None None O
, None None O
anxiety None None O
, None None O
and None None O
amusement None None O
) None None O
. None None O

problem None None I-FUNC
solving None None I-FUNC
, None None O
cognitive None None O
reappraisal None None O
) None None O
, None None O
and None None O
made None None O
more None None O
frequent None None O
use None None O
of None None O
maladaptive None None O
strategies None None O
( None None O
e.g None None O
. None None O

Lidocaine None None O
2 None None O
% None None O
without None None O
epinephrine None None I-TRANS
( None None O
0.79 None None O
± None None O
0.19 None None O
mL None None O
) None None O
was None None O
injected None None O
into None None O
the None None O
periconal None None O
space None None O
. None None O

Ultrasonography None None O
is None None O
a None None O
painless None None O
, None None O
noninvasive None None O
tool None None O
that None None O
may None None O
improve None None O
safety None None O
of None None O
ophthalmic None None O
regional None None O
blocks None None O
, None None O
potentially None None O
by None None O
reducing None None O
the None None O
prevalence None None O
of None None O
globe None None O
perforation None None O
or None None O
penetration None None O
of None None O
the None None O
optic None None I-REGION
nerve None None I-REGION
associated None None O
with None None O
the None None O
needle-based None None O
techniques None None O
. None None O

Better None None O
understanding None None O
of None None O
these None None O
regulatory None None O
factors None None O
will None None O
hopefully None None O
bring None None O
greater None None O
attention None None I-FUNC
to None None O
strategically None None O
targeting None None O
aberrant None None O
cell None None O
migration None None O
, None None O
which None None O
has None None O
many None None O
therapeutic None None O
implications None None O
for None None O
common None None O
human None None O
diseases None None O
. None None O

To None None O
investigate None None O
the None None O
effects None None O
of None None O
impaired None None O
insulin None None I-PROTEIN
secretion None None O
( None None O
IIS None None O
) None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
IR None None O
) None None O
according None None O
to None None O
BMI None None O
on None None O
the None None O
incidence None None O
of None None O
diabetes None None O
in None None O
the None None O
Saku None None O
Study None None O
. None None O

For None None O
participants None None O
with None None O
BMI None None O
23.0-24.9 None None O
, None None O
risk None None O
was None None O
higher None None O
in None None O
the None None O
i-IIS None None I-REGION
( None None O
9.9 None None O
; None None O
4.4 None None O
, None None O
22.1 None None O
) None None O
; None None O
i-IR None None O
( None None O
3.4 None None O
; None None O
1.2 None None O
, None None O
9.5 None None O
) None None O
; None None O
and None None O
IIS None None O
plus None None O
IR None None O
( None None O
23.4 None None O
; None None O
9.3 None None O
, None None O
58.9 None None O
) None None O
groups None None O
. None None O

To None None O
assess None None O
prevalence None None O
and None None O
trends None None O
in None None O
overweight/obesity None None O
among None None O
U.S. None None O
service None None O
members None None O
and None None O
to None None O
examine None None O
the None None O
associations None None O
of None None O
sociodemographic None None O
characteristics None None O
, None None O
exercise None None O
, None None O
depression None None I-DISEASE
, None None O
and None None O
substance None None O
use None None O
with None None O
these None None O
patterns None None O
. None None O

The None None O
high None None O
prevalence None None O
of None None O
overweight None None O
and None None O
obesity None None O
needs None None O
attention None None I-FUNC
and None None O
has None None O
implications None None O
for None None O
Department None None O
of None None O
Defense None None O
efforts None None O
to None None O
improve None None O
the None None O
health None None O
, None None O
fitness None None O
, None None O
readiness None None O
, None None O
and None None O
quality None None O
of None None O
life None None O
of None None O
the None None O
Active None None O
Forces None None O
. None None O

To None None O
describe None None O
the None None O
use None None O
of None None O
epinephrine None None I-TRANS
auto-injectors None None I-TRANS
in None None O
Chicago None None O
Public None None O
Schools None None O
during None None O
the None None O
2012-2013 None None O
school None None O
year None None O
, None None O
specifically None None O
for None None O
food-induced None None O
allergic None None O
reactions None None O
. None None O

Epinephrine None None I-TRANS
auto-injectors None None I-TRANS
were None None O
administered None None O
to None None O
students None None O
( None None O
92.1 None None O
% None None O
) None None O
and None None O
school None None O
staff None None O
( None None O
7.9 None None O
% None None O
) None None O
. None None O

More None None O
than None None O
half None None O
( None None O
55.0 None None O
% None None O
) None None O
of None None O
all None None O
district-issued None None O
epinephrine None None I-TRANS
auto-injectors None None I-TRANS
were None None O
administered None None O
for None None O
first-time None None O
anaphylactic None None O
events None None O
. None None O

Chicago None None O
Public None None O
Schools None None O
is None None O
the None None O
first None None O
large None None O
, None None O
urban None None O
school None None O
district None None O
in None None O
the None None O
U.S. None None O
to None None O
develop None None O
and None None O
implement None None O
the None None O
District-Issued None None O
Emergency None None O
Epinephrine None None I-TRANS
Initiative None None O
, None None O
which None None O
helped None None O
38 None None O
students None None O
and None None O
staff None None O
avoid None None O
potential None None O
morbidity None None O
and None None O
mortality None None O
. None None O

IO None None O
patients None None O
compared None None O
with None None O
controls None None O
exhibited None None O
insulin None None I-PROTEIN
resistance None None O
( None None O
HOMA-IR None None O
( None None O
homoeostasis None None O
model None None O
assessment-estimated None None O
insulin None None I-PROTEIN
resistance None None O
) None None O
: None None O
+93 None None O
% None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

C282Y None None O
homozygotes None None O
( None None O
n=7 None None O
) None None O
presented None None O
a None None O
reduced None None O
β-cell None None O
function None None O
and None None O
insulin None None I-PROTEIN
secretion None None O
compared None None O
with None None O
non-C282Y None None O
patients None None O
( None None O
n=11 None None O
) None None O
( None None O
-58 None None O
% None None O
and None None O
-73 None None O
% None None O
, None None O
respectively None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Neurovascular None None O
compression None None O
( None None O
NVC None None O
) None None O
of None None O
the None None O
trigeminal None None I-REGION
nerve None None I-REGION
is None None O
the None None O
primary None None O
cause None None O
of None None O
trigeminal None None O
neuralgia None None O
( None None O
TN None None O
) None None O
but None None O
is None None O
known None None O
to None None O
occur None None O
in None None O
both None None O
symptomatic None None O
and None None O
asymptomatic None None O
nerves None None O
. None None O

The None None O
mean None None O
distance None None O
from None None O
the None None O
trigeminal None None I-REGION
nerve None None I-REGION
root None None I-REGION
to None None O
the None None O
site None None O
of None None O
NVC None None O
in None None O
asymptomatic None None O
nerves None None O
( None None O
3.85 None None O
± None None O
2.69 None None O
mm None None O
) None None O
was None None O
significantly None None O
greater None None O
than None None O
that None None O
in None None O
symptomatic None None O
nerves None None O
( None None O
0.94 None None O
± None None O
1.27 None None O
mm None None O
) None None O
. None None O

They None None O
responded None None O
to None None O
17β-estradiol None None O
by None None O
increased None None O
proliferation None None O
rate None None O
and None None O
mRNA None None O
levels None None O
of None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
ALP None None O
) None None O
, None None O
type None None O
I None None O
collagen None None I-PROTEIN
, None None O
and None None O
osteocalcin None None O
. None None O

Further None None O
drug None None O
resistance None None O
mechanisms None None O
analyzed None None O
study None None O
was None None O
the None None O
tumor None None O
suppressor None None O
TP53 None None O
and None None O
the None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
. None None O

The None None O
observations None None O
from None None O
in None None O
vitro None None O
Caco-2 None None O
cell None None O
showed None None O
that None None O
the None None O
absorption None None O
of None None O
phenylethanoid None None O
glycosides None None O
in None None O
Fructus None None O
Forsythiae None None O
extract None None O
so None None O
with None None O
that None None O
in None None O
monomers None None O
was None None O
mainly None None O
restricted None None O
by None None O
the None None O
tight None None O
junctions None None O
, None None O
and None None O
influenced None None O
by None None O
efflux None None O
transporters None None I-PROTEIN
( None None O
P-gp None None O
and None None O
MRP2 None None O
) None None O
. None None O

Aortic None None O
rings None None O
pre-contracted None None O
with None None O
noradrenaline None None I-TRANS
( None None O
NA None None I-TRANS
) None None O
could None None O
completely None None O
be None None O
relaxed None None O
by None None O
HLE None None O
( None None O
EC50 None None O
: None None O
51.98 None None O
mg/l None None O
) None None O
. None None O

Therefore None None O
, None None O
it None None O
can None None O
be None None O
suggested None None O
that None None O
the None None O
vasodilating None None O
effect None None O
of None None O
HLE None None O
is None None O
primarily None None O
the None None O
result None None O
of None None O
an None None O
inhibition None None O
of None None O
G None None O
protein-induced None None O
increase None None O
in None None O
intracellular None None O
calcium None None O
and None None O
not None None O
of None None O
a None None O
blockade None None O
of None None O
voltage-operated None None O
L-type None None O
calcium None None I-PROTEIN
channels None None I-PROTEIN
. None None O

Experiments None None O
in None None O
aortic None None O
rat None None O
cells None None O
revealed None None O
that None None O
calcium None None O
transients None None O
evoked None None O
by None None O
vasopressin None None I-TRANS
were None None O
suppressed None None O
by None None O
60 None None O
mg/l None None O
COU None None O
supporting None None O
the None None O
idea None None O
of None None O
an None None O
inhibition None None O
of None None O
G None None O
protein-induced None None O
intracellular None None O
calcium None None O
release None None O
by None None O
a None None O
constituent None None O
of None None O
HLE None None O
. None None O

LPS-induced None None O
elevation None None O
of None None O
mRNA None None O
encoding None None I-FUNC
for None None O
E-selectin None None O
and None None O
interleukin-8 None None O
was None None O
also None None O
suppressed None None O
. None None O

Sesquiterpene None None O
lactones None None O
from None None O
N. None None O
lobata None None O
interfered None None O
with None None O
the None None O
induction None None O
of None None O
inflammatory None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecules None None O
and None None O
chemokines None None O
in None None O
cells None None O
stimulated None None O
with None None O
bacterial None None O
products None None O
and None None O
cytokines None None O
. None None O

Treatment None None O
of None None O
coelogin None None O
to None None O
osteoblasts None None O
led None None O
to None None O
enhanced None None O
ALP None None O
activity None None O
( None None O
a None None O
marker None None O
of None None O
osteoblast None None O
differentiation None None O
) None None O
, None None O
mineral None None O
nodule None None O
formation None None O
and None None O
mRNA None None O
levels None None O
of None None O
osteogenic None None O
markers None None O
like None None O
BMP-2 None None O
, None None O
Type None None O
1 None None O
Collagen None None I-PROTEIN
and None None O
RUNX-2 None None O
. None None O

To None None O
test None None O
whether None None O
the None None O
anti-proliferative None None O
activity None None O
of None None O
( None None O
+ None None O
) None None O
-PA None None O
is None None O
associated None None O
with None None O
effects None None O
on None None O
FASN None None O
and None None O
HER2 None None O
( None None O
human None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
2 None None O
) None None O
and None None O
major None None O
signalling None None O
pathways None None O
. None None O

Blood None None O
levels None None O
of None None O
glucose None None O
, None None O
insulin None None I-PROTEIN
, None None O
advanced None None O
glycation None None O
end None None O
products None None O
( None None O
AGEs None None O
) None None O
and None None O
tumour None None O
necrosis None None O
factor-α None None O
( None None O
TNF-α None None O
) None None O
were None None O
determined None None O
. None None O

Both None None O
models None None O
resulted None None O
in None None O
elevated None None O
BP None None O
, None None O
increased None None O
vasoconstriction None None O
and None None O
impaired None None O
relaxation None None O
KCl None None O
, None None O
elevated None None O
TNF-α None None O
and None None O
AGEs None None O
, None None O
NF-κB None None O
activation None None O
, None None O
marked None None O
infiltration None None O
of None None O
leukocytes None None O
in None None O
the None None O
adventitia None None O
, None None O
pyknosis None None O
of None None O
endothelial None None O
cells None None O
and None None O
marked None None O
collagen None None I-PROTEIN
deposition None None O
. None None O

Size None None O
variations None None O
were None None O
found None None O
in None None O
both None None O
introns None None O
and None None O
in None None O
the None None O
first None None O
exon None None O
, None None O
the None None O
latter None None O
being None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
an None None O
intragenic None None O
tandem None None O
repeat None None O
sequence None None O
corresponding None None O
to None None O
a None None O
stretch None None O
of None None O
glycine None None I-TRANS
residues None None O
in None None O
the None None O
deduced None None O
proteins None None O
. None None O

Manganese-dependent None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
MnSOD None None O
) None None O
is None None O
one None None O
of None None O
the None None O
key None None O
enzymes None None I-PROTEIN
involved None None O
in None None O
the None None O
cellular None None O
defense None None O
against None None O
oxidative None None O
stress None None O
. None None O

Conserved None None O
domains None None O
within None None O
this None None O
polypeptide None None O
included None None O
those None None O
for None None O
a None None O
viral None None O
methyltransferase None None O
, None None O
a None None O
viral None None O
RNA None None O
helicase None None I-PROTEIN
1 None None O
and None None O
an None None O
RNA-dependent None None O
RNA None None O
polymerase None None O
. None None O

The None None O
progressive None None O
wood None None O
polymer None None O
degradation None None O
appeared None None O
related None None O
to None None O
the None None O
secretion None None O
of None None O
hydrolytic None None I-PROTEIN
enzymes None None I-PROTEIN
, None None O
as None None O
well None None O
as None None O
to None None O
Fe None None O
( None None O
3+ None None O
) None None O
-reducing None None O
activity None None O
, None None O
which None None O
was None None O
restored None None O
in None None O
the None None O
cultures None None O
after None None O
the None None O
first None None O
week None None O
of None None O
biodegradation None None O
. None None O

SPADI None None O
score None None O
, None None O
passive None None O
shoulder None None O
range None None O
of None None O
motion None None O
( None None O
ROM None None O
) None None O
and None None O
strength None None O
, None None O
grip None None O
strength None None O
, None None O
hand None None O
sensation None None I-FUNC
, None None O
dexterity None None O
and None None O
limited None None O
joint None None O
mobility None None O
of None None O
the None None O
hand None None O
. None None O

Western None None O
blot None None O
was None None O
performed None None O
to None None O
examine None None O
cleaved None None O
caspase-3 None None O
, None None O
platelet None None O
endothelial None None O
cell None None I-PROTEIN
adhesion None None I-PROTEIN
molecule None None O
( None None O
PECAM None None O
) None None O
-1 None None O
, None None O
and None None O
smooth None None O
muscle None None O
actin None None I-PROTEIN
( None None O
SMA None None O
) None None O
. None None O

Superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
( None None O
SOD None None O
) None None O
and None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
levels None None O
were None None O
detected None None O
by None None O
colorimetry None None O
. None None O

Histological None None O
analysis None None O
of None None O
specimens None None O
stained None None O
for None None O
NADPH None None O
showed None None O
a None None O
significant None None O
change None None O
in None None O
the None None O
staining None None O
quality None None O
of None None O
the None None O
neurons None None O
in None None O
the None None O
dorsal None None I-NEURON
nerves None None O
; None None O
TUNEL None None O
showed None None O
a None None O
greater None None O
apoptotic None None O
index None None O
in None None O
corpus None None O
cavernosum None None O
cells None None O
. None None O

Oral None None O
gavage None None O
with None None O
Rg3 None None O
appears None None O
to None None O
both None None O
prevent None None O
degeneration None None O
of None None O
neurons None None O
in None None O
the None None O
dorsal None None I-NEURON
nerves None None O
and None None O
exert None None O
an None None O
antioxidant None None O
effect None None O
in None None O
the None None O
corpus None None O
cavernosum None None O
of None None O
rats None None O
. None None O

In None None O
preliminary None None O
study None None O
to None None O
evaluate None None O
their None None O
antioxidant None None O
and None None O
neuroprotective None None O
activities None None O
new None None O
derivatives None None O
were None None O
subjected None None O
to None None O
DPPH None None O
free None None O
radical None None O
scavenging None None O
assay None None O
and None None O
the None None O
Xanthine None None I-PROTEIN
oxidase None None I-PROTEIN
( None None O
XO None None O
) None None O
inhibition None None O
models None None O
assay None None O
. None None O

A None None O
series None None O
of None None O
sulfonamides None None O
incorporating None None O
cyclic None None O
imide None None O
moieties None None O
were None None O
investigated None None O
as None None O
inhibitors None None O
of None None O
several None None O
human None None O
α-carbonic None None O
anhydrase None None I-PROTEIN
( None None O
hCA None None O
, None None O
EC None None O
4.2.1.1 None None O
) None None O
isoforms None None O
. None None O

The None None O
cytosolic None None O
isoform None None O
hCA None None O
I None None O
was None None O
moderately None None O
inhibited None None O
by None None O
most None None O
of None None O
the None None O
30 None None O
investigated None None O
derivatives None None O
; None None O
many None None O
low None None O
nanomolar None None O
hCA None None O
II None None O
inhibitors None None O
were None None O
detected None None O
, None None O
whereas None None O
some None None O
of None None O
these None None O
compounds None None O
were None None O
low None None O
nanomolar/subnanomolar None None O
inhibitors None None O
of None None O
the None None O
transmembrane None None O
, None None O
tumor-associated None None O
isoforms None None O
hCA None None O
IX None None I-REGION
and None None O
XII None None O
. None None O

A None None O
small None None O
molecule None None O
containing None None O
a None None O
rhodium None None O
( None None O
II None None O
) None None O
tetracarboxylate None None O
fragment None None O
is None None O
shown None None O
to None None O
be None None O
a None None O
potent None None O
inhibitor None None O
of None None O
the None None O
prolyl None None O
isomerase None None I-PROTEIN
FKBP12 None None O
. None None O

Compounds None None O
2 None None O
, None None O
5 None None O
and None None O
11 None None O
were None None O
found None None O
to None None O
inhibit None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
production None None O
in None None O
RAW None None O
264.7 None None O
macrophages None None O
with None None O
IC50 None None O
values None None O
of None None O
52.78 None None O
± None None O
8.61 None None O
, None None O
0.69 None None O
± None None O
0.23 None None O
and None None O
5.18 None None O
± None None O
1.33 None None O
, None None O
respectively None None O
, None None O
while None None O
indomethacin None None O
, None None O
the None None O
positive None None O
control None None O
, None None O
showed None None O
an None None O
IC50 None None O
value None None O
of None None O
1.25 None None O
± None None O
0.52 None None O
μM None None O
. None None O

One None None O
GH84 None None O
and None None O
two None None O
GH20 None None O
microbial None None O
glycosidases None None O
were None None O
employed None None O
as None None O
model None None O
enzymes None None I-PROTEIN
for None None O
the None None O
inhibition None None O
assays None None O
. None None O

Unlike None None O
with None None O
the None None O
substrates None None O
, None None O
the None None O
4-hydroxyl None None O
group None None O
of None None O
the None None O
inhibitor None None O
's None None O
sugar None None O
ring None None O
seems None None O
to None None O
be None None O
crucial None None O
for None None O
binding None None O
the None None O
inhibitor None None O
to None None O
the None None O
active None None O
sites None None O
of None None O
these None None O
enzymes None None I-PROTEIN
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
clarify None None O
the None None O
effects None None O
of None None O
hypothalamic None None O
dopamine None None I-TRANS
( None None O
DA None None O
) None None O
on None None O
the None None O
secretion None None O
of None None O
growth None None O
hormone None None O
( None None O
GH None None O
) None None O
in None None O
goats None None O
. None None O

injection None None O
of None None O
GH-releasing None None O
hormone None None O
( None None O
GHRH None None O
, None None O
0.25 None None O
μg/kg None None O
body None None O
weight None None O
( None None O
BW None None O
) None None O
) None None O
was None None O
examined None None O
after None None O
treatments None None O
to None None O
augment None None O
central None None O
DA None None O
using None None O
carbidopa None None O
( None None O
carbi None None O
, None None O
1 None None O
mg/kg None None O
BW None None O
) None None O
and None None O
L-dopa None None I-TRANS
( None None O
1 None None O
mg/kg None None O
BW None None O
) None None O
in None None O
male None None O
and None None O
female None None O
goats None None O
under None None O
a None None O
16-h None None O
photoperiod None None O
( None None O
16 None None O
h None None O
light None None O
, None None O
8 None None O
h None None O
dark None None O
) None None O
condition None None O
. None None O

The None None O
treatments None None O
with None None O
carbi None None O
and None None O
L-dopa None None I-TRANS
significantly None None O
reduced None None O
TRH-induced None None O
PRL None None O
release None None O
in None None O
goats None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
Ca None None O
( None None O
2+ None None O
) None None O
influx None None O
was None None O
inhibited None None O
by None None O
extracellular None None O
Gd None None O
( None None O
3+ None None O
) None None O
, None None O
a None None O
nonspecific None None O
inhibitor None None O
of None None O
mechanosensitive None None O
ion None None I-PROTEIN
channels None None I-PROTEIN
, None None O
but None None O
it None None O
was None None O
not None None O
affected None None O
by None None O
the None None O
more None None O
specific None None O
inhibitor None None O
, None None O
GsMTx4 None None O
. None None O

Pulmonary None None O
function None None O
declined None None O
from None None O
baseline None None O
to None None O
after None None O
surgery None None O
( None None O
by None None O
21 None None O
% None None O
for None None O
forced None None O
vital None None O
capacity None None O
, None None O
16 None None O
% None None O
for None None O
forced None None O
expiratory None None O
volume None None O
in None None O
1 None None O
second None None O
, None None O
and None None O
19 None None O
% None None O
for None None O
lung None None O
diffusion None None O
of None None O
carbon None None I-TRANS
monoxide None None I-TRANS
[ None None O
P None None O
for None None O
all None None O
= None None O
.01 None None O
] None None O
) None None O
and None None O
declined None None O
still None None O
further None None O
after None None O
IMRT None None O
( None None O
by None None O
31 None None O
% None None O
for None None O
forced None None O
vital None None O
capacity None None O
[ None None O
P=.02 None None O
] None None O
, None None O
25 None None O
% None None O
for None None O
forced None None O
expiratory None None O
volume None None O
in None None O
1 None None O
second None None O
[ None None O
P=.01 None None O
] None None O
, None None O
and None None O
30 None None O
% None None O
for None None O
lung None None O
diffusion None None O
of None None O
carbon None None I-TRANS
monoxide None None I-TRANS
[ None None O
P=.01 None None O
] None None O
) None None O
. None None O

To None None O
determine None None O
the None None O
frequency None None O
and None None O
clinical None None O
significance None None O
of None None O
epidermal None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
receptor None None I-PROTEIN
( None None O
EGFR None None O
) None None O
mutations None None O
in None None O
patients None None O
with None None O
potentially None None O
curable None None O
stage None None O
III None None O
non-small-cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
who None None O
are None None O
eligible None None O
for None None O
definitive None None O
chemoradiotherapy None None O
( None None O
CRT None None O
) None None O
. None None O

Interfraction None None O
movement None None I-FUNC
is None None O
greater None None O
than None None O
suggested None None O
by None None O
2-dimensional None None O
imaging None None O
, None None O
thus None None O
a None None O
margin None None O
of None None O
at None None O
least None None O
4 None None O
to None None O
8 None None O
mm None None O
must None None O
be None None O
retained None None O
despite None None O
the None None O
use None None O
of None None O
daily None None O
IGRT None None O
. None None O

The None None O
proposed None None O
method None None O
combines None None O
the None None O
atlas None None O
registration None None O
method None None O
, None None O
which None None O
captures None None O
the None None O
global None None O
variation None None O
of None None O
anatomy None None O
, None None O
with None None O
a None None O
machine None None O
learning None None I-FUNC
technology None None O
, None None O
which None None O
captures None None O
the None None O
local None None O
statistical None None O
features None None O
, None None O
to None None O
automatically None None O
segment None None O
the None None O
parotid None None O
glands None None O
from None None O
the None None O
MRIs None None O
. None None O

This None None O
analogy None None I-FUNC
can None None O
be None None O
used None None O
as None None O
a None None O
starting None None O
point None None O
to None None O
improve None None O
knowledge None None O
of None None O
these None None O
parameters None None O
, None None O
including None None O
how None None O
RAK None None O
is None None O
measured None None O
, None None O
how None None O
RAK None None O
correlates None None O
with None None O
skin None None O
dose None None O
, None None O
and None None O
how None None O
parameters None None O
are None None O
displayed None None O
differently None None O
during None None O
fluoroscopy None None O
and None None O
fluorography None None O
. None None O

The None None O
discovery None None O
of None None O
mirror None None I-NEURON
neurons None None I-NEURON
compellingly None None O
shows None None O
that None None O
the None None O
monkey None None O
premotor None None O
area None None O
F5 None None O
is None None O
active None None O
not None None O
only None None O
during None None O
the None None O
execution None None O
but None None O
also None None O
during None None O
the None None O
observation None None O
of None None O
goal-directed None None O
motor None None O
acts None None O
. None None O

Furthermore None None O
, None None O
they None None O
may None None O
provide None None O
information None None O
about None None O
the None None O
functional None None O
architecture None None O
of None None O
action None None O
perception None None I-FUNC
in None None O
primates None None O
. None None O

All None None O
nine None None O
articles None None O
addressed None None O
at None None O
least None None O
one None None O
of None None O
three None None O
factors None None O
that None None O
contribute None None O
to None None O
HIV None None O
sexual None None O
risk None None O
: None None O
Behavioral None None O
( None None O
inconsistent None None O
condom None None O
use None None O
and None None O
multiple None None O
sexual None None O
partners None None O
) None None O
, None None O
psychological None None O
( None None O
risk None None O
perception None None I-FUNC
, None None O
depression/stress None None O
, None None O
trauma None None O
, None None O
and None None O
self-esteem None None O
issues None None O
) None None O
, None None O
and None None O
social None None O
factors None None O
( None None O
economics None None O
, None None O
education None None O
, None None O
and None None O
drugs/alcohol None None O
use None None O
) None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
explore None None O
the None None O
effects None None O
of None None O
patient None None O
and None None O
caregiver None None O
variables None None O
on None None O
the None None O
perceptions None None I-FUNC
of None None O
burden None None O
in None None O
families None None O
caring None None O
for None None O
a None None O
loved None None O
one None None O
living None None O
with None None O
advanced None None O
cancer None None O
in None None O
Greece None None O
. None None O

Caregiving None None O
burden None None O
was None None O
linked None None O
to None None O
both None None O
patient None None O
( None None O
gender None None O
, None None O
age None None O
, None None O
past None None O
surgery None None O
or None None O
chemotherapy None None O
treatment None None O
, None None O
depression None None I-DISEASE
and None None O
impact None None O
of None None O
cancer-related None None O
symptoms None None O
) None None O
and None None O
caregiver None None O
variables None None O
( None None O
gender None None O
, None None O
family None None O
status None None O
, None None O
education None None O
, None None O
place None None O
of None None O
residence None None O
, None None O
previous None None O
experience None None O
of None None O
care None None O
, None None O
employment None None O
status None None O
, None None O
difficulty None None O
of None None O
caregiving None None O
, None None O
anxiety None None O
and None None O
depression None None I-DISEASE
) None None O
. None None O

Greek None None O
family None None O
caregivers None None O
reporting None None O
greater None None O
depressive None None O
mood None None I-FUNC
and None None O
difficulty None None O
with None None O
caregiving None None O
tasks None None O
, None None O
those None None O
married None None O
, None None O
those None None O
not None None O
employed None None O
, None None O
and None None O
those None None O
who None None O
cared None None O
for None None O
patients None None O
who None None O
had None None O
not None None O
undergone None None O
surgery None None O
were None None O
found None None O
at None None O
greater None None O
distress None None O
and None None O
disadvantage None None O
. None None O

The None None O
first None None O
contact None None O
between None None O
the None None O
mould None None O
and None None O
the None None O
patient None None O
, None None O
the None None O
host None None O
defense None None O
to None None O
different None None O
fungi None None O
, None None O
including None None O
the None None O
role None None O
of None None O
mucosa None None O
in None None O
the None None O
innate None None O
immune None None O
system None None O
, None None O
the None None O
whole None None O
innate None None O
immune None None O
recognition None None O
receptors None None I-PROTEIN
, None None O
and None None O
the None None O
pathways None None O
connecting None None O
innate None None O
and None None O
adaptive None None O
immunity None None O
, None None O
as None None O
well None None O
as None None O
the None None O
virulence None None O
factors None None O
of None None O
fungi None None O
, None None O
are None None O
discussed None None O
in None None O
this None None O
paper None None O
. None None O

GnRH None None O
receptors None None I-PROTEIN
play None None O
vital None None O
roles None None O
in None None O
mammalian None None O
reproduction None None O
via None None O
regulation None None O
of None None O
gonadotropin None None O
secretion None None O
, None None O
which None None O
is None None O
essential None None O
for None None O
gametogenesis None None O
and None None O
production None None O
of None None O
gonadal None None O
steroids None None O
. None None O

This None None O
study None None O
reports None None O
the None None O
molecular None None O
cloning None None O
and None None O
sequencing None None O
of None None O
GnRH None None O
receptor None None I-PROTEIN
( None None O
GnRHR None None O
) None None O
cDNA None None O
from None None O
the None None O
pituitary None None I-REGION
gland None None I-REGION
of None None O
the None None O
domestic None None O
cat None None O
, None None O
an None None O
important None None O
species None None O
in None None O
biomedical None None O
research None None O
. None None O

Unlike None None O
the None None O
majority None None O
of None None O
mammalian None None O
species None None O
sequenced None None O
so None None O
far None None O
, None None O
but None None O
similar None None O
to None None O
canine None None O
GnRHR None None O
, None None O
feline None None O
GnRHR None None O
protein None None O
lacks None None O
asparagine None None I-TRANS
in None None O
position None None O
three None None O
of None None O
the None None O
extracellular None None O
domain None None O
of None None O
the None None O
protein None None O
. None None O

Temporal None None O
relationships None None O
among None None O
circulating None None O
concentrations None None O
of None None O
nitric None None I-TRANS
oxide None None I-TRANS
metabolites None None O
( None None O
NOM None None O
) None None O
, None None O
progesterone None None O
( None None O
P4 None None O
) None None O
, None None O
and None None O
luteinizing None None O
hormone None None O
( None None O
LH None None O
) None None O
within None None O
the None None O
hours None None O
of None None O
a None None O
PGFM None None O
pulse None None O
were None None O
studied None None O
during None None O
luteolysis None None O
in None None O
heifers None None O
. None None O

The None None O
resulting None None O
spheres None None O
were None None O
placed None None O
in None None O
cryotubes None None O
for None None O
storage None None I-FUNC
in None None O
liquid None None O
nitrogen None None O
. None None O

After None None O
thawing None None O
, None None O
the None None O
following None None O
sperm None None O
quality None None O
parameters None None O
were None None O
determined None None O
by None None O
flow None None O
cytometry None None O
: None None O
DNA None None O
fragmentation None None O
( None None O
terminal None None O
deoxynucleotidyl None None O
transferase None None I-PROTEIN
dUTP None None O
nick None None O
end None None O
labeling None None O
) None None O
, None None O
plasma None None O
membrane None None O
integrity None None O
( None None O
SYBR-14/PI None None O
, None None O
staining None None O
technique None None O
) None None O
, None None O
and None None O
mitochondrial None None O
membrane None None O
potential None None O
( None None O
JC-1 None None O
staining None None O
) None None O
. None None O

Higher None None O
expression None None O
of None None O
1-acylglycerol-3-phosphate None None O
O-acyltransferase None None O
9 None None O
( None None O
AGPAT9 None None O
) None None O
( None None O
lipid None None O
metabolism None None O
) None None O
, None None O
Chloride None None O
intracellular None None O
channel None None O
3 None None O
( None None O
CLIC3 None None O
) None None O
, None None O
Keratin None None I-PROTEIN
8 None None O
( None None O
KRT8 None None O
) None None O
, None None O
and None None O
Lumican None None O
( None None O
LUM None None O
) None None O
( None None O
molecular None None O
transport None None O
) None None O
was None None O
observed None None O
in None None O
CC-2-8-cells None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
WHO None None O
's None None O
regions None None O
in None None O
Eastern None None O
Mediterranean None None O
( None None O
EMRO None None O
) None None O
, None None O
Southeast None None O
Asian None None O
( None None O
SEARO None None O
) None None O
and None None O
Africa None None O
( None None O
AFRO None None O
) None None O
together None None O
account None None O
for None None O
about None None O
47 None None O
% None None O
of None None O
the None None O
global None None O
population None None O
, None None O
but None None O
only None None O
3.7 None None O
% None None O
of None None O
all None None O
IFPMA None None O
IVS None None I-REGION
doses None None O
distributed None None O
. None None O

A None None O
large None None O
number None None O
of None None O
the None None O
differentially None None O
expressed None None O
genes None None O
identified None None O
were None None O
linked None None O
to None None O
ripening None None O
dependent None None O
processes None None O
including None None O
ethylene None None O
biosynthesis None None O
, None None O
perception None None I-FUNC
and None None O
signalling None None O
, None None O
cell None None O
wall None None O
degradation None None O
and None None O
production None None O
of None None O
aromatic None None O
volatiles None None O
. None None O

The None None O
emergence None None O
of None None O
active None None O
control None None O
mechanisms None None O
allows None None O
infants None None O
to None None O
integrate None None O
sensory None None O
information None None O
into None None O
their None None O
movements None None I-FUNC
so None None O
that None None O
they None None O
can None None O
exhibit None None O
more None None O
adaptive None None O
sitting None None O
. None None O

Re-enforcing None None O
myocyte None None O
division None None O
is None None O
a None None O
vision None None I-FUNC
that None None O
has None None O
been None None O
desired None None O
for None None O
decades None None O
, None None O
leading None None O
to None None O
years None None O
of None None O
experience None None O
in None None O
myocyte None None O
resistance None None O
to None None O
proproliferative None None O
stimuli None None O
. None None O

Percutaneous None None O
left None None O
atrial None None O
appendage None None O
( None None O
LAA None None O
) None None O
occlusion None None O
using None None O
the None None O
Watchman None None O
device None None O
( None None O
Atritech None None O
, None None O
Plymouth None None O
, None None O
MN None None O
) None None O
is None None O
suggested None None O
as None None O
an None None O
alternative None None O
modality None None O
to None None O
warfarin None None O
for None None O
stroke None None I-DISEASE
prevention None None O
in None None O
patients None None O
with None None O
nonvalvular None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
progressive None None O
increase None None O
in None None O
peridevice None None O
leakage None None O
after None None O
Watchman None None O
device None None O
implantation None None O
on None None O
long-term None None O
transesophageal None None O
echocardiographic None None O
follow-up None None O
accompanied None None O
by None None O
stroke None None I-DISEASE
. None None O

However None None O
, None None O
in None None O
our None None O
case None None O
, None None O
the None None O
follow-up None None O
echocardiography None None O
and None None O
coronary None None O
angiography None None O
demonstrated None None O
rapid None None O
progression None None O
of None None O
the None None O
coronary None None O
pseudoaneurysm None None O
as None None O
a None None O
balloon-like None None O
cavity None None O
within None None O
the None None O
septum None None I-REGION
. None None O

A None None O
65 None None O
year-old None None O
woman None None O
was None None O
admitted None None O
for None None O
acute None None O
heart None None O
failure None None O
and None None O
severe None None O
sepsis None None O
revealing None None O
definite None None O
mitral None None O
infective None None O
endocarditis None None O
with None None O
severe None None O
regurgitation None None O
, None None O
complicated None None O
by None None O
multiple None None O
embolisms None None I-DISEASE
. None None O

The None None O
patients None None O
were None None O
followed None None O
for None None O
a None None O
median None None O
period None None O
of None None O
583 None None O
days None None O
, None None O
and None None O
the None None O
primary None None O
end None None O
point None None O
was None None O
major None None O
adverse None None O
cardiovascular None None O
events None None O
( None None O
MACE None None O
) None None O
defined None None O
as None None O
a None None O
composite None None O
of None None O
cardiovascular None None O
death None None O
, None None O
heart None None O
failure None None O
, None None O
nonfatal None None O
recurrent None None O
MI None None O
, None None O
revascularization None None O
, None None O
and None None O
stroke None None I-DISEASE
. None None O

A None None O
59-year-old None None O
woman None None O
with None None O
stroke None None I-DISEASE
and None None O
thromboembolic None None O
aortoiliac None None O
disease None None O
in None None O
the None None O
setting None None O
of None None O
profound None None O
stress None None O
was None None O
found None None O
to None None O
have None None O
severe None None O
left None None O
ventricular None None O
( None None O
LV None None O
) None None O
systolic None None O
dysfunction None None O
and None None O
large None None O
mobile None None O
clot None None O
on None None O
focused None None O
cardiac None None O
ultrasonography None None O
( None None O
FCU None None O
) None None O
. None None O

Acanthosis None None O
nigricans None None O
in None None O
children None None O
is None None O
often None None O
a None None O
cutaneous None None O
marker None None O
of None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

All None None O
the None None O
patients None None O
underwent None None O
endoscopic None None O
selective None None O
neck None None O
dissection None None O
( None None O
levels None None O
I-IV None None O
) None None O
of None None O
the None None O
ipsilateral None None O
neck None None O
and None None O
partial None None O
glossectomy None None O
or None None O
hemiglossectomy None None O
as None None O
the None None O
primary None None O
treatment None None O
. None None O

Two None None O
months None None O
after None None O
equal None None O
amounts None None O
of None None O
ELSCs None None O
or None None O
MSCs None None O
were None None O
injected None None O
through None None O
tail-vein None None O
injection None None O
, None None O
we None None O
evaluated None None O
skeletal None None O
muscle None None O
motor None None O
function None None O
and None None O
serum None None O
creatine None None O
kinase None None O
activity None None O
and None None O
measured None None O
dystrophin None None I-PROTEIN
expression None None O
by None None O
means None None O
of None None O
immunostaining None None O
, None None O
Western None None O
blotting None None O
and None None O
semi-quantitative None None O
reverse None None O
transcriptase-polymerase None None O
chain None None O
reaction None None O
. None None O

In None None O
eukaryotes None None O
, None None O
transcriptional None None O
regulation None None O
is None None O
usually None None O
mediated None None O
by None None O
interactions None None O
of None None O
multiple None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
TFs None None O
) None None O
with None None O
their None None O
respective None None O
specific None None O
cis-regulatory None None O
elements None None O
( None None O
CREs None None O
) None None O
in None None O
the None None O
so-called None None O
cis-regulatory None None O
modules None None O
( None None O
CRMs None None O
) None None O
in None None O
DNA None None O
. None None O

There None None O
was None None O
no None None O
documented None None O
recurrent None None O
thrombosis None None I-DISEASE
in None None O
any None None O
patients None None O
with None None O
SSPE None None O
, None None O
with None None O
or None None O
without None None O
anticoagulation None None O
. None None O

All None None O
redox/stress None None O
proteins None None O
were None None O
less None None O
or None None O
not None None O
expressed None None O
in None None O
JY73 None None O
, None None O
whereas None None O
the None None O
expression None None O
of None None O
the None None O
major None None O
storage None None I-FUNC
proteins None None O
, None None O
nitrogen None None O
and None None O
carbon None None O
metabolism-related None None O
proteins None None O
was None None O
higher None None O
in None None O
ZH13 None None O
. None None O

Meanwhile None None O
, None None O
their None None O
ROS None None O
reduction None None O
activities None None O
were None None O
consistent None None O
with None None O
glutathione None None I-PROTEIN
reductase None None I-PROTEIN
protein None None O
expression None None O
levels None None O
in None None O
HT-29 None None O
. None None O

All None None O
of None None O
the None None O
four None None O
proteases None None O
exhibited None None O
selective None None O
hydrolytic None None O
activity None None O
towards None None O
meat None None O
myofibrillar None None O
proteins None None O
including None None O
myosin None None O
and None None O
actin None None I-PROTEIN
. None None O

K None None O
( None None O
M None None O
) None None O
( None None O
app None None I-TRANS
) None None O
, None None O
Imax None None O
, None None O
LOD None None O
and None None O
sensitivity None None O
were None None O
calculated None None O
as None None O
0.229 None None O
mM None None O
, None None O
42.37 None None O
nA None None I-TRANS
, None None O
3.3 None None O
× None None O
10 None None O
( None None O
-4 None None O
) None None O
nM None None O
and None None O
6.4 None None O
nA/mM None None O
cm None None O
( None None O
2 None None O
) None None O
, None None O
respectively None None O
. None None O

In None None O
general None None O
, None None O
the None None O
baby None None O
foods None None O
analysed None None O
were None None O
sufficient None None O
for None None O
an None None O
adequate None None O
mineral None None O
intake None None O
, None None O
but None None O
contributions None None O
to None None O
AI None None O
and None None O
EAR None None O
for None None O
iron None None O
, None None O
zinc None None I-TRANS
and None None O
calcium None None O
were None None O
very None None O
low None None O
( None None O
5-20 None None O
% None None O
, None None O
10-60 None None O
% None None O
and None None O
10-70 None None O
% None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
utility None None O
of None None O
the None None O
model None None O
is None None O
illustrated None None O
by None None O
a None None O
simple None None O
example None None O
where None None O
meat None None O
is None None O
assumed None None O
to None None O
be None None O
heated None None O
homogeneously None None O
, None None O
and None None O
myofibrillar None None O
proteins None None O
to None None O
be None None O
directly None None O
in None None O
contact None None O
with None None O
pepsin None None I-PROTEIN
. None None O

Hereto None None O
, None None O
the None None O
structure None None O
of None None O
pectic None None O
polysaccharide None None O
and None None O
the None None O
presence None None O
of None None O
sufficiently None None O
active None None O
endogenous None None O
enzymes None None I-PROTEIN
of None None O
ripe None None O
mango None None O
were None None O
determined None None O
. None None O

The None None O
capacity None None O
of None None O
the None None O
βlg-based None None O
coagulum None None O
to None None O
increase None None O
the None None O
long None None O
term None None O
stability None None O
of None None O
D3 None None O
in None None O
cold None None O
storage None None I-FUNC
, None None O
upon None None O
exposure None None O
to None None O
intensive None None O
UV-light None None O
, None None O
and None None O
in None None O
the None None O
presence None None O
and None None O
absence None None O
of None None O
intestinal None None O
proteases None None O
, None None O
was None None O
evaluated None None O
. None None O

The None None O
water None None O
solubility None None O
, None None O
long-term None None O
storage None None I-FUNC
and None None O
UV-light None None O
stability None None O
of None None O
D3 None None O
were None None O
significantly None None O
increased None None O
( None None O
p None None O
& None None O
lt None None O
; None None O
0.0001 None None O
) None None O
due None None O
to None None O
the None None O
high None None O
encapsulation None None O
efficiency None None O
( None None O
94.5 None None O
± None None O
1.8 None None O
% None None O
) None None O
. None None O

Sixteen None None O
amino None None I-TRANS
acids None None I-TRANS
were None None O
identified None None O
with None None O
similar None None O
spectral None None O
chromatograms None None O
. None None O

The None None O
PCA None None O
model None None O
demonstrated None None O
the None None O
relationships None None O
among None None O
amino None None I-TRANS
acids None None I-TRANS
in None None O
the None None O
correlation None None O
loadings None None O
plot None None O
to None None O
the None None O
group None None O
of None None O
gelatins None None O
in None None O
the None None O
scores None None O
plot None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
K None None O
( None None O
+ None None O
) None None O
substitution None None O
of None None O
Na None None I-TRANS
( None None O
+ None None O
) None None O
by None None O
more None None O
than None None O
40 None None O
% None None O
may None None O
significantly None None O
change None None O
profiles None None O
of None None O
volatiles None None O
in None None O
finished None None O
dry-cured None None O
bacons None None O
and None None O
therefore None None O
would None None O
result None None O
in None None O
changes None None O
in None None O
the None None O
product None None O
aroma None None O
and/or None None O
flavour None None O
. None None O

Dipeptidyl None None O
peptidase None None O
( None None O
DPP None None O
) None None O
-IV None None O
inhibitory None None O
peptides None None I-TRANS
were None None O
purified None None O
and None None O
identified None None O
from None None O
an None None O
aqueous None None O
Palmaria None None O
palmata None None O
protein None None O
extract None None O
hydrolysed None None O
with None None O
Corolase None None O
PP None None O
. None None O

Three None None O
novel None None O
DPP-IV None None O
inhibitory None None O
peptides None None I-TRANS
, None None O
Ile-Leu-Ala-Pro None None O
, None None O
Leu-Leu-Ala-Pro None None O
and None None O
Met-Ala-Gly-Val-Asp-His-Ile None None O
, None None O
with None None O
IC50 None None O
values None None O
in None None O
the None None O
range None None O
43-159 None None O
μM None None O
were None None O
identified None None O
. None None O

MKP None None O
showed None None O
angiotensin None None O
I-converting None None O
enzyme None None O
( None None O
ACE None None O
) None None O
-inhibitory None None O
activity None None O
in None None O
vitro None None O
( None None O
IC50 None None O
= None None O
0.43 None None O
μM None None O
) None None O
. None None O

However None None O
, None None O
the None None O
MS-based None None O
analysis None None O
showed None None O
minor None None O
modifications None None O
, None None O
including None None O
the None None O
extensive None None O
oxidation None None O
of None None O
methionines None None I-TRANS
. None None O

These None None O
results None None O
underline None None O
the None None O
importance None None O
of None None O
controlling None None O
lactose None None O
hydrolysis None None O
, None None O
and None None O
processing None None O
and None None O
storage None None I-FUNC
conditions None None O
to None None O
preserve None None O
the None None O
quality None None O
and None None O
increase None None O
the None None O
bioactivity None None O
of None None O
dairy None None O
preparations None None O
designed None None O
for None None O
elderly None None O
people None None O
. None None O

Out None None O
of None None O
21 None None O
major None None O
polypeptides None None O
observed None None O
( None None O
9-100 None None O
kDa None None O
) None None O
, None None O
11 None None O
showed None None O
differential None None O
trypsin None None I-PROTEIN
inhibitory None None O
activity None None O
( None None O
TIA None None O
) None None O
under None None O
non-reducing None None O
conditions None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
endogenous None None O
proteolytic None None O
activities None None O
in None None O
a None None O
cod None None O
product None None O
and None None O
their None None O
impact None None O
on None None O
muscle None None O
proteins None None O
and None None O
textural None None O
properties None None O
during None None O
fermentation None None O
and None None O
storage None None I-FUNC
. None None O

In None None O
conclusion None None O
, None None O
cathepsins None None O
had None None O
more None None O
impact None None O
on None None O
muscle None None O
proteins None None O
and None None O
textural None None O
properties None None O
than None None O
other None None O
proteases None None O
during None None O
fermentation None None O
but None None O
had None None O
little None None O
impact None None O
on None None O
gel None None O
strength None None O
during None None O
storage None None I-FUNC
at None None O
4 None None O
°C None None O
. None None O

Analysis None None O
of None None O
partial None None O
least None None O
squares None None O
( None None O
PLS None None O
) None None O
revealed None None O
that None None O
wine None None O
appearance None None O
quality None None O
was None None O
positively None None O
correlated None None O
with None None O
the None None O
levels None None O
of None None O
malvidin-3-O- None None O
( None None O
6-O-acetyl None None O
) None None O
-glucoside-4-vinylguaiacol None None O
, None None O
gallocatechin None None O
and None None O
dihydrokaempferol-3-O-rhamnos None None O
, None None O
while None None O
the None None O
development None None O
of None None O
mouthfeel None None O
properties None None O
was None None O
positively None None O
associated None None O
with None None O
the None None O
evolutions None None O
of None None O
malvidin-3-O-glucoside-ethyl- None None O
( None None O
epi None None I-TRANS
) None None O
catechin None None O
, None None O
peonidin-3-O- None None O
( None None O
6-O-acetyl None None O
) None None O
-glucoside None None O
, None None O
malvidin-3-O- None None O
( None None O
6-O-coumaryl None None O
) None None O
-glucoside-pyruvic None None O
acid None None O
and None None O
peonidin-3-O-glucoside-4-vinylphenol None None O
. None None O

The None None O
microarray None None O
data None None O
mining None None O
revealed None None O
that None None O
R. None None O
paludigenum None None O
activated None None O
transcription None None O
of None None O
genes None None O
important None None O
for None None O
plant None None O
hormones None None I-PROTEIN
, None None O
signalling None None O
transduction None None O
, None None O
stress None None O
and None None O
defensive None None O
responses None None O
in None None O
orange None None O
peel None None O
tissue None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
IC50 None None O
and None None O
reaction None None O
rates None None O
( None None O
k None None O
) None None O
, None None O
β-carbolines None None O
( None None O
norharman None None O
and None None O
harman None None O
) None None O
, None None O
and None None O
tetrahydro-β-carbolines None None O
( None None O
tetrahydro-β-carboline None None O
, None None O
1-methyltetrahydro-β-carboline None None O
and None None O
pinoline None None O
) None None O
were None None O
good None None O
OH None None O
radical None None O
scavengers None None O
and None None O
their None None O
activity None None O
was None None O
comparable None None O
to None None O
that None None O
of None None O
the None None O
indole None None O
, None None O
melatonin None None I-TRANS
, None None O
which None None O
is None None O
an None None O
effective None None O
hydroxyl None None O
radical None None O
scavenger None None O
and None None O
antioxidant None None O
. None None O

Quality None None O
parameters None None O
and None None O
microbial None None O
growth None None O
were None None O
evaluated None None O
after None None O
processing None None O
and None None O
during None None O
storage None None I-FUNC
at None None O
4 None None O
°C None None O
. None None O

Samples None None O
sonicated None None O
at None None O
58 None None O
°C None None O
had None None O
the None None O
best None None O
quality None None O
; None None O
microbial None None O
growth None None O
remained None None O
low None None O
at None None O
around None None O
3-log None None O
for None None O
mesophiles None None O
, None None O
4.5-log None None O
for None None O
yeasts None None O
and None None O
molds None None O
and None None O
2-log None None O
for None None O
enterobacteria None None O
after None None O
20 None None O
d None None O
of None None O
storage None None I-FUNC
. None None O

Rice None None O
bran None None O
byproduct None None O
obtained None None O
from None None O
the None None O
milling None None O
of None None O
brown None None O
rice None None O
was None None O
treated None None O
under None None O
anaerobic None None O
storage None None I-FUNC
with None None O
nitrogen None None O
at None None O
different None None O
temperatures None None O
( None None O
20-60 None None O
°C None None O
) None None O
and None None O
moisture None None O
contents None None O
( None None O
10-50 None None O
% None None O
) None None O
up None None O
to None None O
12h None None O
. None None O

Utilisation None None O
of None None O
an None None O
electrolyzed None None O
oxidizing None None O
water None None O
( None None O
EOW None None O
, None None O
pH None None O
3.3 None None O
) None None O
for None None O
moisture None None O
adjustment None None O
and None None O
addition None None O
of None None O
glutamic None None I-TRANS
acid None None I-TRANS
increased None None O
the None None O
GABA None None I-TRANS
content None None O
in None None O
rice None None O
bran None None O
. None None O

According None None O
to None None O
saccharide None None O
profile None None O
comparison None None O
between None None O
starch None None O
syrups None None O
and None None O
pure None None O
honeys None None O
analysed None None O
through None None O
high None None O
performance None None O
liquid None None O
chromatography None None O
( None None O
HPLC None None O
) None None O
, None None O
a None None O
characteristic None None O
peak None None O
was None None O
found None None O
at None None O
15.25 None None O
min None None O
retention None None I-FUNC
time None None O
in None None O
HPLC None None O
chromatogram None None O
of None None O
syrup None None O
, None None O
but None None O
no None None O
peak None None O
was None None O
observed None None O
at None None O
the None None O
same None None O
retention None None I-FUNC
time None None O
in None None O
chromatogram None None O
of None None O
pure None None O
honeys None None O
. None None O

A None None O
decrease None None O
of None None O
approximately None None O
35 None None O
% None None O
lycopene None None O
content None None O
occurred None None O
at None None O
storage None None I-FUNC
times None None O
longer None None O
than None None O
15 None None O
days None None O
, None None O
due None None O
to None None O
isomerisation None None O
and None None O
oxidation None None O
reactions None None O
. None None O

Losses None None O
of None None O
lycopene None None O
in None None O
vitro None None O
bioaccessibility None None O
ranging None None O
between None None O
50 None None O
% None None O
and None None O
80 None None O
% None None O
occurred None None O
in None None O
the None None O
untreated None None O
and None None O
ultrasonically None None O
treated None None O
tomato None None O
pulps None None O
with None None O
and None None O
without None None O
oil None None O
during None None O
storage None None I-FUNC
, None None O
mainly None None O
due None None O
to None None O
carotenoid None None O
degradation None None O
. None None O

The None None O
essential None None O
oil None None O
fumigation None None O
treatment None None O
also None None O
increased None None O
the None None O
antioxidant None None O
enzyme None None O
activities None None O
of None None O
CAT None None O
, None None O
SOD None None O
, None None O
APX None None O
and None None O
GR None None O
throughout None None O
the None None O
storage None None I-FUNC
periods None None O
. None None O

serine None None I-TRANS
and None None O
glutathione None None O
metabolism None None O
) None None O
and None None O
nitrogen None None O
metabolism None None O
( None None O
urea None None O
cycle None None O
intermediates None None O
) None None O
accumulated None None O
until None None O
the None None O
end None None O
of None None O
the None None O
assayed None None O
period None None O
. None None O

Finally None None O
, None None O
statistical None None O
analyses None None O
revealed None None O
that None None O
glutamate None None I-TRANS
, None None O
serine None None I-TRANS
and None None O
arginine None None I-TRANS
could None None O
serve None None O
as None None O
good None None O
predictors None None O
of None None O
ultimate None None O
meat None None O
quality None None O
parameters None None O
, None None O
even None None O
though None None O
further None None O
studies None None O
are None None O
mandatory None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
effects None None O
of None None O
alkaline None None O
pretreatments None None O
and None None O
acid None None O
extraction None None O
conditions None None O
on None None O
the None None O
production None None O
of None None O
acid-soluble None None O
collagen None None I-PROTEIN
( None None O
ASC None None O
) None None O
from None None O
grass None None O
carp None None O
skin None None O
. None None O

The None None O
immobilised None None O
enzyme None None O
appeared None None O
suitable None None O
for None None O
industrial None None O
applications None None O
due None None O
to None None O
the None None O
non-toxic None None O
nature None None O
of None None O
chosen None None O
matrices None None O
, None None O
ease None None O
of None None O
immobilisation None None O
procedure None None O
, None None O
enhanced None None O
stability None None O
and None None O
reusability None None O
with None None O
retention None None I-FUNC
of None None O
72 None None O
% None None O
and None None O
60 None None O
% None None O
residual None None O
activity None None O
after None None O
10 None None O
uses None None O
for None None O
the None None O
enzyme None None O
immobilised None None O
on None None O
chitosan None None O
coated None None O
PVC None None O
beads None None O
and None None O
on None None O
the None None O
beads None None O
of None None O
chitosan/PVP None None O
blend None None O
, None None O
respectively None None O
. None None O

Due None None O
to None None O
the None None O
increasing None None O
dispersibility None None O
and None None O
effective None None O
surface None None O
area None None O
of None None O
the None None O
CNT None None O
caused None None O
by None None O
decoration None None O
of None None O
ppy None None I-TRANS
to None None O
the None None O
CNT None None O
, None None O
the None None O
proposed None None O
electrode None None O
exhibited None None O
excellent None None O
electrochemical None None O
sensitivity None None O
and None None O
high None None O
selectivity None None O
toward None None O
the None None O
oxidation None None O
of None None O
Amaranth None None O
and None None O
Ponceau None None O
4R None None O
. None None O

These None None O
phenolic None None O
compounds None None O
not None None O
only None None O
contributed None None O
significantly None None O
to None None O
the None None O
antioxidant None None O
activities None None O
, None None O
but None None O
they None None O
were None None O
also None None O
good None None O
inhibitors None None O
of None None O
α-glucosidase None None O
and None None O
lipase None None O
, None None O
two None None O
enzymes None None I-PROTEIN
, None None O
respectively None None O
, None None O
associated None None O
with None None O
glucose None None O
and None None O
lipid None None O
digestion None None O
in None None O
the None None O
human None None O
intestine None None O
, None None O
thus None None O
contributing None None O
significantly None None O
to None None O
the None None O
control None None O
of None None O
blood None None O
glucose None None O
levels None None O
and None None O
obesity None None O
. None None O

However None None O
, None None O
these None None O
compounds None None O
are None None O
susceptible None None O
to None None O
degradation None None O
during None None O
processing None None O
and None None O
storage None None I-FUNC
. None None O

Results None None O
showed None None O
that None None O
there None None O
are None None O
no None None O
significant None None O
differences None None O
in None None O
most None None O
of None None O
the None None O
biogenic None None I-TRANS
amines None None I-TRANS
including None None O
histamine None None I-TRANS
, None None O
while None None O
there None None O
are None None O
significant None None O
differences None None O
in None None O
total None None O
UCA None None O
content None None O
, None None O
and None None O
trans- None None O
and None None O
cis-UCA None None O
contents None None O
between None None O
the None None O
two None None O
samples None None O
. None None O

The None None O
retention None None I-FUNC
of None None O
the None None O
total None None O
tocochromanols None None O
and None None O
α-tocopherol None None O
equivalent None None O
decreased None None O
after None None O
extrusion None None O
( None None O
69.1-84.8 None None O
% None None O
and None None O
52.4-85.0 None None O
% None None O
, None None O
respectively None None O
) None None O
but None None O
increased None None O
after None None O
DHCO None None O
( None None O
106.8-114.7 None None O
% None None O
and None None O
109.9-115.8 None None O
% None None O
, None None O
respectively None None O
) None None O
. None None O

This None None O
study None None O
characterized None None O
the None None O
impact None None O
of None None O
technological None None O
treatments None None O
on None None O
the None None O
protein None None O
secondary None None O
structure None None O
of None None O
a None None O
newly None None O
developed None None O
egg None None O
yolk None None O
livetin None None O
formulation None None O
and None None O
its None None O
components None None O
α-livetin None None O
, None None O
which None None O
is None None O
identical None None O
with None None O
chicken None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
, None None O
and None None O
γ-livetin None None O
, None None O
the None None O
bioactive None None O
antibody None None O
immunoglobulin None None O
Y. None None O
Fourier None None O
transform None None O
infrared None None O
( None None O
FTIR None None O
) None None O
spectroscopy None None O
at None None O
25 None None O
°C None None O
revealed None None O
that None None O
the None None O
largest None None O
proportion None None O
of None None O
conformal None None O
elements None None O
comprised None None O
intramolecular None None O
( None None O
native None None O
) None None O
β-sheets None None O
( None None O
60-80 None None O
% None None O
) None None O
in None None O
γ-livetin None None O
, None None O
and None None O
α-helices/random None None O
coils None None O
( None None O
60.59 None None O
% None None O
) None None O
in None None O
α-livetin None None O
. None None O

Most None None O
cardiovascular None None O
events None None O
were None None O
related None None O
to None None O
unstable None None O
angina None None O
or None None O
myocardial None None O
infarcts None None O
, None None O
21 None None O
were None None O
associated None None O
with None None O
arrhythmia None None O
and None None O
41 None None O
were None None O
vascular None None O
events None None O
such None None O
as None None O
aortic None None O
aneurysm None None O
and None None O
cerebrovascular None None I-DISEASE
accident None None I-DISEASE
. None None O

This None None O
study None None O
aimed None None O
to None None O
quantify None None O
the None None O
learning None None I-FUNC
curve None None O
for None None O
arthroscopic None None O
suprascapular None None O
nerve None None O
decompression None None O
( None None O
SSND None None O
) None None O
using None None O
the None None O
log-linear None None O
model None None O
. None None O

The None None O
objective None None O
of None None O
the None None O
current None None O
study None None O
was None None O
to None None O
compare None None O
surgeon-rated None None O
visualization None None O
in None None O
shoulder None None O
arthroscopy None None O
using None None O
irrigation None None O
fluid None None O
with None None O
and None None O
without None None O
epinephrine None None I-TRANS
. None None O

There None None O
was None None O
a None None O
significant None None O
difference None None O
, None None O
with None None O
improved None None O
visualization None None O
in None None O
the None None O
epinephrine None None I-TRANS
group None None O
versus None None O
the None None O
group None None O
without None None O
epinephrine None None I-TRANS
when None None O
comparing None None O
all None None O
procedures None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.0001 None None O
) None None O
and None None O
when None None O
comparing None None O
only None None O
rotator None None O
cuff None None O
repairs None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.0001 None None O
) None None O
. None None O

The None None O
addition None None O
of None None O
epinephrine None None I-TRANS
to None None O
irrigation None None O
fluid None None O
significantly None None O
improves None None O
surgeon-rated None None O
visualization None None O
in None None O
shoulder None None O
arthroscopy None None O
. None None O

Arm None None O
swing None None O
asymmetry None None O
during None None O
gait None None O
may None None O
be None None O
a None None O
sensitive None None O
sign None None O
for None None O
early None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

Additionally None None O
, None None O
a None None O
group None None O
of None None O
7 None None O
patients None None O
with None None O
early None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
was None None O
investigated None None O
. None None O

Evaluation None None O
of None None O
arm None None O
swing None None O
asymmetry None None O
may None None O
be None None O
used None None O
as None None O
part None None O
of None None O
a None None O
test None None O
battery None None O
for None None O
early None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

The None None O
spontaneous None None O
alternation None None O
performance None None O
and None None O
Morris None None O
water None None O
maze None None O
confirmed None None O
the None None O
impaired None None O
learning None None I-FUNC
capacity None None O
and None None O
memory None None I-FUNC
performance None None O
induced None None O
by None None O
prenatal None None O
stress None None O
in None None O
both None None O
male None None O
and None None O
female None None O
offspring None None O
, None None O
and None None O
these None None O
effects None None O
were None None O
markedly None None O
restored None None O
in None None O
the None None O
HT None None O
supplement None None O
groups None None O
. None None O

Meanwhile None None O
, None None O
HT None None O
significantly None None O
increased None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
FOXO1 None None O
and None None O
FOXO3 None None O
, None None O
as None None O
well None None O
as None None O
phase None None O
II None None O
enzyme-related None None O
proteins None None O
, None None O
including None None O
Nrf2 None None O
and None None O
HO-1 None None O
, None None O
which None None O
may None None O
contribute None None O
to None None O
the None None O
decreased None None O
oxidative None None O
stress None None O
and None None O
increased None None O
mitochondrial None None O
function None None O
shown None None O
with None None O
HT None None O
supplementation None None O
. None None O

Visualisation None None O
of None None O
lumbar None None O
movement None None I-FUNC
may None None O
significantly None None O
improve None None O
movement-related None None O
pain None None O
severity None None O
and None None O
duration None None O
. None None O

To None None O
investigate None None O
if None None O
McKenzie None None O
exercises None None O
when None None O
applied None None O
to None None O
a None None O
cohort None None O
of None None O
patients None None O
with None None O
chronic None None O
LBP None None O
who None None O
have None None O
a None None O
directional None None O
preference None None O
demonstrate None None O
improved None None O
recruitment None None O
of None None O
the None None O
transversus None None O
abdominis None None O
compared None None O
to None None O
motor None None I-FUNC
control None None I-FUNC
exercises None None O
when None None O
measurements None None O
were None None O
assessed None None O
from None None O
ultrasound None None O
images None None O
. None None O

McKenzie None None O
techniques None None O
or None None O
motor None None I-FUNC
control None None I-FUNC
exercises None None O
for None None O
12-sessions None None O
over None None O
eight None None O
weeks None None O
. None None O

This None None O
study None None O
will None None O
be None None O
the None None O
first None None O
to None None O
investigate None None O
the None None O
possible None None O
mechanism None None O
of None None O
action None None O
that None None O
McKenzie None None O
therapy None None O
and None None O
motor None None I-FUNC
control None None I-FUNC
exercises None None O
have None None O
on None None O
the None None O
recruitment None None O
of None None O
the None None O
transversus None None O
abdominus None None O
in None None O
a None None O
cohort None None O
of None None O
low None None O
back None None O
pain None None O
patients None None O
sub-classified None None O
with None None O
a None None O
directional None None O
preference None None O
. None None O

A None None O
better None None O
understanding None None O
of None None O
the None None O
mechanism None None O
of None None O
action None None O
that None None O
specific None None O
treatments None None O
such None None O
as None None O
motor None None I-FUNC
control None None I-FUNC
exercises None None O
or None None O
McKenzie None None O
exercises None None O
have None None O
on None None O
patients None None O
classified None None O
with None None O
a None None O
directional None None O
preference None None O
will None None O
allow None None O
therapist None None O
to None None O
make None None O
a None None O
more None None O
informed None None O
choice None None O
about None None O
treatment None None O
options None None O
. None None O

Transcript None None O
levels None None O
of None None O
hemeoxygenase None None O
1 None None O
( None None O
HO-1 None None O
) None None O
, None None O
endothelin None None O
1 None None O
( None None O
ET1 None None O
) None None O
, None None O
endothelin None None O
receptors None None I-PROTEIN
A None None O
, None None O
B None None O
( None None O
ETA None None O
, None None O
ETB None None O
) None None O
, None None O
tissue None None O
factor None None O
( None None O
TF None None O
) None None O
, None None O
and None None O
plasminogen None None O
activator None None O
inhibitor-1 None None O
( None None O
PAI-1 None None O
) None None O
were None None O
measured None None O
in None None O
the None None O
lung None None O
and None None O
heart None None O
to None None O
assess None None O
oxidative None None O
stress None None O
, None None O
endothelial None None O
dysfunction None None O
and None None O
coagulation None None O
cascade None None O
. None None O

UfCP None None O
exposure None None O
increased None None O
BP None None O
and None None O
HR None None O
in None None O
aged None None O
SHRs None None O
rats None None O
which None None O
was None None O
associated None None O
with None None O
lung None None O
inflammation None None O
, None None O
and None None O
increased None None O
expression None None O
of None None O
inflammatory None None O
, None None O
vasoconstriction None None O
and None None O
coagulation None None O
markers None None O
as None None O
well None None O
as None None O
systemic None None O
changes None None O
in None None O
biomarkers None None O
of None None O
thrombosis None None I-DISEASE
in None None O
aged None None O
SHRs None None O
. None None O

We None None O
sought None None O
to None None O
examine None None O
the None None O
effect None None O
of None None O
community None None O
and None None O
national None None O
SSS None None O
on None None O
symptoms None None O
of None None O
depression None None I-DISEASE
in None None O
a None None O
racially/ethnically None None O
diverse None None O
sample None None O
of None None O
adult None None O
women None None O
with None None O
noncancerous None None O
uterine None None O
conditions None None O
. None None O

We None None O
hypothesized None None O
that None None O
women None None O
who None None O
had None None O
low None None O
community None None O
and None None O
national None None O
SSS None None O
at None None O
baseline None None O
, None None O
as None None O
measured None None O
by None None O
the None None O
MacArthur None None O
SSS None None O
ladder None None O
, None None O
would None None O
be None None O
at None None O
higher None None O
risk None None O
of None None O
experiencing None None O
symptoms None None O
of None None O
depression None None I-DISEASE
at None None O
follow-up None None O
. None None O

Low None None O
perceived None None O
community None None O
social None None O
status None None O
is None None O
predictive None None O
of None None O
symptoms None None O
suggestive None None O
of None None O
major None None O
or None None O
other None None O
depressive None None I-DISEASE
disorder None None I-DISEASE
among None None O
women None None O
with None None O
noncancerous None None O
uterine None None O
conditions None None O
. None None O

This None None O
study None None O
was None None O
conducted None None O
to None None O
evaluate None None O
effects None None O
of None None O
beet None None O
pulp None None O
supplementation None None O
on None None O
growth None None O
performance None None O
, None None O
fecal None None O
moisture None None O
, None None O
serum None None O
hormones None None I-PROTEIN
and None None O
litter None None O
performance None None O
in None None O
lactating None None O
sows None None O
. None None O

No None None O
effect None None O
was None None O
observed None None O
on None None O
bodyweight None None O
, None None O
average None None O
daily None None O
intake None None O
, None None O
weaning None None O
to None None O
estrus None None O
interval None None O
, None None O
epinephrine None None I-TRANS
level None None O
in None None O
sows None None O
and None None O
litter None None O
weight None None O
, None None O
litter None None O
size None None O
, None None O
survivability None None O
in None None O
piglets None None O
among None None O
dietary None None O
treatments None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
effect None None O
of None None O
different None None O
post None None O
surface None None O
treatments None None O
on None None O
the None None O
retention None None I-FUNC
of None None O
glass None None O
fiber-reinforced None None O
post None None O
to None None O
root None None O
dentin None None O
was None None O
evaluated None None O
. None None O

Only None None O
silane None None O
did None None O
not None None O
enhance None None O
post None None O
retention None None I-FUNC
compared None None O
with None None O
control None None O
( None None O
P None None O
& None None O
gt None None O
; None None O
.05 None None O
) None None O
. None None O

Whereas None None O
silanization None None O
as None None O
the None None O
only None None O
post None None O
surface None None O
treatment None None O
did None None O
not None None O
improve None None O
retention None None I-FUNC
, None None O
the None None O
combination None None O
of None None O
silane None None O
plus None None O
resin None None O
adhesive None None O
enhanced None None O
post None None O
retention None None I-FUNC
to None None O
dentin None None O
in None None O
the None None O
middle None None O
and None None O
coronal None None O
root None None O
regions None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
prospective None None O
, None None O
randomized None None O
, None None O
double-blind None None O
study None None O
was None None O
to None None O
compare None None O
the None None O
anesthetic None None O
efficacy None None O
of None None O
buffered None None O
with None None O
nonbuffered None None O
2 None None O
% None None O
lidocaine None None O
with None None O
1:80,000 None None O
epinephrine None None I-TRANS
solution None None O
for None None O
inferior None None O
alveolar None None O
nerve None None O
( None None O
IAN None None O
) None None O
block None None O
in None None O
patients None None O
with None None O
mandibular None None O
posterior None None O
teeth None None O
experiencing None None O
symptomatic None None O
irreversible None None O
pulpitis None None O
. None None O

The None None O
patients None None O
received None None O
2 None None O
cartridges None None O
of None None O
either None None O
2 None None O
% None None O
lidocaine None None O
with None None O
1:80,000 None None O
epinephrine None None I-TRANS
buffered None None O
with None None O
0.18 None None O
mL None None O
8.4 None None O
% None None O
sodium None None O
bicarbonate None None O
or None None O
2 None None O
% None None O
lidocaine None None O
with None None O
1:80,000 None None O
epinephrine None None I-TRANS
with None None O
0.18 None None O
mL None None O
sterile None None O
distilled None None O
water None None O
using None None O
conventional None None O
IAN None None O
block None None O
injections None None O
. None None O

Buffering None None O
the None None O
2 None None O
% None None O
lidocaine None None O
with None None O
1:80,000 None None O
epinephrine None None I-TRANS
with None None O
8.4 None None O
% None None O
sodium None None O
bicarbonate None None O
did None None O
not None None O
improve None None O
the None None O
success None None O
of None None O
the None None O
IAN None None O
block None None O
in None None O
mandibular None None O
molars None None O
in None None O
patients None None O
with None None O
symptomatic None None O
irreversible None None O
pulpitis None None O
. None None O

One None None O
hundred None None O
twenty-five None None O
emergency None None O
patients None None O
diagnosed None None O
with None None O
symptomatic None None O
irreversible None None O
pulpitis None None O
randomly None None O
received None None O
either None None O
a None None O
Gow-Gates None None O
or None None O
Vazirani-Akinosi None None O
injection None None O
using None None O
3.6 None None O
mL None None O
2 None None O
% None None O
lidocaine None None O
with None None O
1:100,000 None None O
epinephrine None None I-TRANS
to None None O
block None None O
the None None O
inferior None None O
alveolar None None O
nerve None None O
before None None O
endodontic None None O
access None None O
. None None O

Extracted None None O
molars None None O
were None None O
prepared None None O
and None None O
mounted None None O
to None None O
a None None O
slow-speed None None O
alternating-current None None O
motor None None O
of None None O
a None None O
custom None None O
testing None None O
apparatus None None O
, None None O
which None None O
provided None None O
a None None O
5-mm None None O
linear None None O
movement None None I-FUNC
at None None O
an None None O
approximate None None O
rate None None O
of None None O
4 None None O
mm/s None None O
. None None O

Emerging None None O
evidence None None O
has None None O
shown None None O
a None None O
consistent None None O
association None None O
between None None O
AF None None O
and None None O
risk None None O
of None None O
dementia None None I-DISEASE
, None None O
including None None O
Alzheimer׳s None None O
disease None None O
. None None O

Both None None O
AF None None O
and None None O
dementia None None I-DISEASE
share None None O
multiple None None O
common None None O
risk None None O
factors None None O
, None None O
and None None O
as None None O
such None None O
these None None O
may None None O
be None None O
targets None None O
of None None O
early None None O
prevention None None O
strategies None None O
to None None O
reduce None None O
risk None None O
. None None O

Depressed None None O
doctors None None O
avoid None None O
diagnosis None None O
and None None O
treatment None None O
, None None O
fearing None None O
consequences None None O
, None None O
yet None None O
are None None O
more None None O
prone None None O
to None None O
marital None None O
problems None None O
, None None O
substance None None I-DISEASE
dependence None None I-DISEASE
and None None O
needing None None O
psychotherapy None None O
. None None O

Hard None None O
radio None None O
frequency None None O
pulses None None O
, None None O
short None None O
echo None None O
spacing None None O
and None None O
centrically None None O
ordered None None O
sectoral None None O
phase None None O
encoding None None I-FUNC
ensure None None O
accurate None None O
and None None O
time-efficient None None O
full None None O
volume None None O
imaging None None O
. None None O

Our None None O
study None None O
aimed None None O
to None None O
assess None None O
the None None O
longitudinal None None O
association None None O
of None None O
frequency None None O
of None None O
contact None None O
with None None O
non-cohabitating None None O
adult None None O
children None None O
and None None O
risk None None O
of None None O
depression None None I-DISEASE
in None None O
the None None O
elderly None None O
. None None O

These None None O
results None None O
propose None None O
that None None O
the None None O
risk None None O
of None None O
subsequent None None O
depression None None I-DISEASE
in None None O
elderly None None O
is None None O
associated None None O
with None None O
frequency None None O
of None None O
contact None None O
with None None O
non-cohabitating None None O
adult None None O
children None None O
. None None O

There None None O
is None None O
little None None O
known None None O
about None None O
predictors None None O
of None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
in None None O
older None None O
adults None None O
or None None O
impact None None O
of None None O
common None None O
interventions None None O
during None None O
hospitalization None None O
. None None O

Participants None None O
( None None O
n=1206 None None O
) None None O
were None None O
older None None O
adults None None O
admitted None None O
within None None O
two None None O
Australian None None O
hospitals None None O
, None None O
the None None O
majority None None O
of None None O
participants None None O
completed None None O
the None None O
Geriatric None None O
Depression None None I-DISEASE
Scale None None O
- None None O
Short None None O
Form None None O
( None None O
GDS None None O
) None None O
at None None O
admission None None O
( None None O
n=1168 None None O
) None None O
. None None O

At None None O
admission None None O
53 None None O
% None None O
( None None O
619 None None O
out None None O
of None None O
1168 None None O
) None None O
of None None O
participants None None O
had None None O
symptoms None None O
of None None O
clinical None None O
depression None None I-DISEASE
and None None O
symptoms None None O
remained None None O
at None None O
the None None O
same None None O
level None None O
at None None O
discharge None None O
for None None O
55 None None O
% None None O
( None None O
543 None None O
out None None O
of None None O
987 None None O
) None None O
. None None O

The None None O
only None None O
factor None None O
other None None O
than None None O
admission None None O
level None None O
of None None O
depression None None I-DISEASE
that None None O
affected None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
change None None O
was None None O
if None None O
the None None O
participant None None O
was None None O
worried None None O
about None None O
falling None None O
. None None O

Arginine None None I-TRANS
decarboxylase None None O
( None None O
ADC None None O
) None None O
is None None O
a None None O
rate-limiting None None O
enzyme None None O
of None None O
agmatine None None O
synthesis None None O
and None None O
is None None O
known None None O
to None None O
exist None None O
in None None O
the None None O
CNS None None O
of None None O
mammals None None O
. None None O

On None None O
the None None O
7th None None O
and None None O
8th None None O
days None None O
after None None O
KA None None O
treatment None None O
, None None O
all None None O
groups None None O
of None None O
mice None None O
were None None O
subjected None None O
to None None O
cognitive None None O
and None None O
depression None None I-DISEASE
assessment None None O
by None None O
use None None O
of None None O
a None None O
novel None None O
object None None I-FUNC
recognition None None I-FUNC
test None None O
and None None O
a None None O
forced None None O
swim None None O
test None None O
, None None O
respectively None None O
. None None O

We None None O
found None None O
that None None O
infusion None None O
of None None O
HEK None None O
cells/HEK-CM None None O
improves None None O
cognitive None None O
function None None O
and None None O
alleviates None None O
symptoms None None O
of None None O
depression None None I-DISEASE
. None None O

Stressors None None O
negatively None None O
impact None None O
emotional None None O
state None None O
and None None O
drive None None O
drug None None O
seeking None None O
, None None O
in None None O
part None None O
, None None O
by None None O
modulating None None O
the None None O
activity None None O
of None None O
the None None O
mesolimbic None None O
dopamine None None I-TRANS
system None None O
. None None O

In None None O
a None None O
series None None O
of None None O
experiments None None O
, None None O
we None None O
scrutinized None None O
the None None O
subsecond None None O
regulation None None O
of None None O
dopamine None None I-TRANS
signaling None None O
by None None O
the None None O
aversive None None O
stimulus None None O
, None None O
quinine None None O
, None None O
and None None O
tested None None O
its None None O
ability None None O
to None None O
cause None None O
cocaine None None O
seeking None None O
. None None O

Combining None None O
fast-scan None None O
cyclic None None O
voltammetry None None O
with None None O
behavioral None None O
pharmacology None None O
, None None O
we None None O
examined None None O
the None None O
effect None None O
of None None O
intraoral None None O
quinine None None O
administration None None O
on None None O
nucleus None None I-REGION
accumbens None None I-REGION
dopamine None None I-TRANS
signaling None None O
and None None O
hedonic None None O
expression None None O
in None None O
21 None None O
male None None O
Sprague-Dawley None None O
rats None None O
. None None O

We None None O
found None None O
that None None O
quinine None None O
rapidly None None O
reduced None None O
dopamine None None I-TRANS
signaling None None O
on None None O
two None None O
distinct None None O
time None None O
scales None None O
. None None O

Further None None O
, None None O
we None None O
found None None O
that None None O
the None None O
reduction None None O
of None None O
dopamine None None I-TRANS
tone None None O
and None None O
quinine-induced None None O
cocaine None None O
seeking None None O
were None None O
eliminated None None O
by None None O
blocking None None O
the None None O
actions None None O
of None None O
CRF None None O
in None None O
the None None O
VTA None None O
during None None O
the None None O
experience None None O
of None None O
the None None O
aversive None None O
stimulus None None O
. None None O

Cognitive None None O
dysfunction None None O
in None None O
schizophrenia None None I-DISEASE
is None None O
one None None O
of None None O
the None None O
most None None O
pervasive None None O
and None None O
debilitating None None O
aspects None None O
of None None O
the None None O
disorder None None O
. None None O

However None None O
, None None O
how None None O
prefrontal None None O
GABA None None I-TRANS
dysfunction None None O
contributes None None O
to None None O
cognitive None None O
impairment None None O
in None None O
schizophrenia None None I-DISEASE
remains None None O
unclear None None O
. None None O

These None None O
studies None None O
have None None O
provided None None O
an None None O
important None None O
link None None O
between None None O
GABA None None I-TRANS
transmission None None O
and None None O
cognitive None None O
dysfunction None None O
in None None O
schizophrenia None None I-DISEASE
because None None O
they None None O
show None None O
that None None O
reducing None None O
prefrontal None None O
inhibitory None None O
transmission None None O
induces None None O
various None None O
cognitive None None O
, None None O
emotional None None O
, None None O
and None None O
dopaminergic None None O
abnormalities None None O
that None None O
resemble None None O
aspects None None O
of None None O
the None None O
disorder None None O
. None None O

Future None None O
studies None None O
using None None O
this None None O
approach None None O
will None None O
yield None None O
information None None O
to None None O
refine None None O
further None None O
a None None O
putative None None O
`` None None O
GABA None None I-TRANS
hypothesis None None O
'' None None O
of None None O
schizophrenia None None I-DISEASE
. None None O

An None None O
e-mail None None O
invitation None None O
was None None O
sent None None O
to None None O
the None None O
Association None None O
of None None O
University None None O
Radiologists None None O
membership None None O
( None None O
comprising None None O
910 None None O
members None None O
) None None O
to None None O
participate None None O
in None None O
an None None O
online None None O
survey None None O
that None None O
addressed None None O
development None None O
, None None O
use None None O
, None None O
and None None O
experience None None O
of None None O
structured None None O
reporting None None O
, None None O
language None None I-FUNC
, None None O
and None None O
imaging None None O
classification None None O
or None None O
reporting None None O
systems None None O
and None None O
personal None None O
dictation None None O
styles None None O
. None None O

Published None None O
by None None O
Elsevier None None O
Inc. None None O
Fibronectin None None I-PROTEIN
is None None O
a None None O
globular None None O
protein None None O
that None None O
circulates None None O
in None None O
the None None O
blood None None O
and None None O
undergoes None None O
fibrillogenesis None None O
if None None O
stretched None None O
or None None O
under None None O
other None None O
partially None None O
denaturing None None O
conditions None None O
, None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
cells None None O
. None None O

Our None None O
electron None None O
microscopy None None O
analysis None None O
of None None O
their None None O
ultrastructure None None O
now None None O
reveals None None O
that None None O
the None None O
manually None None O
pulled None None O
fibronectin None None I-PROTEIN
fibers None None O
are None None O
composed None None O
of None None O
densely None None O
packed None None O
lamellar None None O
spirals None None O
, None None O
whose None None O
interlamellar None None O
distances None None O
are None None O
dictated None None O
by None None O
ion-tunable None None O
electrostatic None None O
interactions None None O
. None None O

This None None O
far None None O
from None None O
equilibrium None None O
process None None O
is None None O
driven None None O
by None None O
the None None O
externally None None O
applied None None O
force None None O
, None None O
interfacial None None O
surface None None O
tension None None O
, None None O
shear-induced None None O
fibronectin None None I-PROTEIN
self-association None None O
, None None O
and None None O
capillary None None O
force-induced None None O
buffer None None O
drainage None None O
. None None O

The None None O
circadian None None O
rhythm None None O
disruption None None O
through None None O
night None None O
work None None O
and None None O
time None None O
zones None None O
leading None None O
to None None O
disorder None None O
of None None O
melatonin None None I-TRANS
secretion None None O
just None None O
as None None O
exposure None None O
to None None O
cosmic None None O
radiation None None O
could None None O
account None None O
for None None O
this None None O
increase None None O
of None None O
risk None None O
. None None O

Host None None O
cactus None None O
effects None None O
on None None O
female None None O
gene None None O
expression None None O
revealed None None O
population- None None O
and None None O
stage-specific None None O
differences None None O
, None None O
including None None O
significant None None O
host None None O
plant None None O
effects None None O
on None None O
larval None None O
metabolism None None O
and None None O
development None None O
, None None O
as None None O
well None None O
as None None O
adult None None O
neurotransmitter None None I-TRANS
binding None None O
and None None O
courtship None None O
behaviour None None O
gene None None O
expression None None O
levels None None O
. None None O

We None None O
previously None None O
developed None None O
a None None O
rodent None None O
model None None O
of None None O
temporal None None I-REGION
lobe None None I-REGION
seizures None None O
that None None O
recapitulates None None O
the None None O
human None None O
electroencephalography None None O
( None None O
EEG None None O
) None None O
signature None None O
of None None O
ictal None None O
and None None O
postictal None None O
neocortical None None O
slow None None O
waves None None O
associated None None O
with None None O
behavioral None None O
impairments None None O
in None None O
level None None O
of None None O
consciousness None None I-FUNC
. None None O

We None None O
demonstrated None None O
a None None O
proof-of-principle None None O
restoration None None O
of None None O
electrophysiologic None None O
and None None O
behavioral None None O
measures None None O
of None None O
consciousness None None I-FUNC
by None None O
stimulating None None O
the None None O
intralaminar None None O
thalamic None None O
nuclei None None O
after None None O
seizures None None O
. None None O

Impaired None None O
consciousness None None I-FUNC
with None None O
epilepsy None None O
has None None O
dangerous None None O
consequences None None O
including None None O
decreased None None O
school/work None None O
performance None None O
, None None O
social None None O
stigmatization None None O
, None None O
and None None O
impaired None None O
airway None None O
protection None None O
. None None O

If None None O
paired None None O
with None None O
responsive None None O
neurostimulation None None O
, None None O
this None None O
may None None O
allow None None O
rapid None None O
implementation None None O
to None None O
improve None None O
level None None O
of None None O
consciousness None None I-FUNC
in None None O
patients None None O
with None None O
epilepsy None None O
. None None O

Overall None None O
, None None O
our None None O
results None None O
provide None None O
a None None O
new None None O
insight None None O
into None None O
the None None O
way None None O
children None None O
see None None O
and None None O
understand None None O
the None None O
environment None None O
, None None O
and None None O
they None None O
illustrate None None O
the None None O
fundamental None None O
nature None None O
of None None O
ensemble None None I-FUNC
coding None None I-FUNC
in None None O
visual None None I-FUNC
perception None None I-FUNC
. None None O

Recent None None O
work None None O
on None None O
vision None None I-FUNC
, None None O
and None None O
other None None O
sensory None None O
modalities None None O
, None None O
has None None O
shown None None O
that None None O
this None None O
description None None O
has None None O
substantial None None O
shortcomings None None O
. None None O

The None None O
measures None None O
known None None O
as None None O
the None None O
coupling None None O
ratio None None O
( None None O
CR None None O
) None None O
and None None O
coupling None None O
constant None None O
( None None O
CC None None O
) None None O
were None None O
redefined None None O
to None None O
ensure None None O
validity None None O
in None None O
most None None O
cases None None O
of None None O
incisional None None O
procedures None None O
and None None O
laser None None O
vision None None I-FUNC
correction None None O
procedures None None O
. None None O

Cultured None None O
human None None O
corneal None None O
endothelial None None O
cells None None O
were None None O
exposed None None O
to None None O
histones None None I-PROTEIN
for None None O
18 None None O
hours None None O
, None None O
and None None O
cell None None O
viability None None O
was None None O
determined None None O
by None None O
2- None None O
( None None O
2-methoxy-4-nitrophenyl None None O
) None None O
-3- None None O
( None None O
4-nitro-phenyl None None O
) None None O
-5- None None O
( None None O
2,4-disulfophenyl None None O
) None None O
-2H-tetrazolium None None O
, None None O
monosodium None None O
salt None None O
assay None None O
. None None O

Cellular None None O
debris None None O
containing None None O
histones None None I-PROTEIN
was None None O
observed None None O
in None None O
the None None O
anterior None None O
chamber None None O
of None None O
pig None None O
eyes None None O
after None None O
phacoemulsification None None O
. None None O

The None None O
IL-6 None None O
concentration None None O
was None None O
significantly None None O
increased None None O
dose None None O
dependently None None O
after None None O
exposure None None O
of None None O
human None None O
corneal None None O
endothelial None None O
cells None None O
to None None O
histones None None I-PROTEIN
( None None O
P None None O
& None None O
lt None None O
; None None O
.01 None None O
) None None O
. None None O

Co-incubation None None O
of None None O
hyaluronan None None O
and None None O
histones None None I-PROTEIN
caused None None O
formation None None O
of None None O
histone None None O
aggregates None None O
, None None O
decreased None None O
the None None O
cytotoxic None None O
effects None None O
of None None O
the None None O
histones None None I-PROTEIN
, None None O
and None None O
blocked None None O
the None None O
increase None None O
in None None O
IL-6 None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.01 None None O
) None None O
. None None O

The None None O
intraoperative None None O
use None None O
of None None O
hyaluronan None None O
may None None O
decrease None None O
the None None O
cytotoxic None None O
effects None None O
of None None O
histones None None I-PROTEIN
released None None O
during None None O
cataract None None O
surgery None None O
. None None O

Serum None None O
levels None None O
of None None O
insulin None None I-PROTEIN
, None None O
IGF-1 None None O
and None None O
IGF-2 None None O
were None None O
tested None None O
by None None O
ELISA None None O
. None None O

It None None O
rapidly None None O
evolved None None O
to None None O
an None None O
unfavourable None None O
outcome None None O
with None None O
intracranial None None I-DISEASE
hypertension None None I-DISEASE
state None None O
. None None O

Resistance None None O
of None None O
Candida None None O
species None None O
to None None O
antifungal None None O
drugs None None O
has None None O
led None None O
scientists None None O
to None None O
pay None None O
more None None O
attention None None I-FUNC
to None None O
traditional None None O
medicine None None O
herbs None None O
. None None O

Several None None O
large None None O
pharmaceutical None None O
companies None None O
have None None O
selectively None None O
downsized None None O
their None None O
neuroscience None None O
research None None O
divisions None None O
, None None O
reflecting None None O
a None None O
growing None None O
view None None O
that None None O
developing None None O
drugs None None O
to None None O
treat None None O
brain None None I-DISEASE
diseases None None I-DISEASE
is None None O
more None None O
difficult None None O
and None None O
often None None O
more None None O
time-consuming None None O
and None None O
expensive None None O
than None None O
developing None None O
drugs None None O
for None None O
other None None O
therapeutic None None O
areas None None O
, None None O
and None None O
thus None None O
represents None None O
a None None O
weak None None O
area None None O
for None None O
investment None None O
. None None O

Neurodegenerative None None O
diseases None None O
such None None O
as None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
, None None O
amyotrophic None None O
lateral None None O
sclerosis None None O
, None None O
and None None O
frontotemporal None None I-DISEASE
dementia None None I-DISEASE
have None None O
several None None O
important None None O
features None None O
in None None O
common None None O
. None None O

In None None O
this None None O
review None None O
, None None O
I None None O
will None None O
describe None None O
the None None O
potential None None O
utility None None O
of None None O
such None None O
an None None O
approach None None O
to None None O
biomarker None None O
discovery None None O
, None None O
using None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
as None None O
a None None O
case None None O
example None None O
. None None O

In None None O
particular None None O
, None None O
in None None O
preclinical None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
, None None O
the None None O
temporal None None O
relationship None None O
of None None O
amyloid None None O
markers None None O
to None None O
markers None None O
of None None O
neurodegeneration None None O
and None None O
their None None O
relative None None O
utility None None O
in None None O
the None None O
prediction None None O
of None None O
cognitive None None O
decline None None O
among None None O
clinically None None O
normal None None O
older None None O
individuals None None O
remains None None O
to None None O
be None None O
fully None None O
elucidated None None O
. None None O

Amino None None I-TRANS
acids None None I-TRANS
are None None O
important None None O
fermentation None None O
products None None O
that None None O
are None None O
used None None O
in None None O
the None None O
food None None O
, None None O
animal None None O
feed None None O
, None None O
pharmaceutical None None O
, None None O
and None None O
cosmetics None None O
industries None None O
. None None O

Here None None O
we None None O
report None None O
the None None O
development None None O
of None None O
an None None O
assay None None O
that None None O
allows None None O
the None None O
rapid None None O
measurement None None O
of None None O
threonine None None I-TRANS
concentration None None O
. None None O

The None None O
resulting None None O
acetaldehyde None None O
is None None O
further None None O
converted None None O
into None None O
ethanol None None O
by None None O
alcohol None None I-PROTEIN
dehydrogenase None None I-PROTEIN
accompanying None None O
NADH None None O
reduction None None O
. None None O

This None None O
LTA None None O
assay None None O
can None None O
distinguish None None O
a None None O
0.5mM None None O
difference None None O
in None None O
threonine None None I-TRANS
concentration None None O
in None None O
some None None O
certain None None O
mediums None None O
. None None O

It None None O
was None None O
further None None O
observed None None O
that None None O
the None None O
expression None None O
levels None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
xyr1 None None O
and None None O
ace2 None None O
also None None O
increased None None O
in None None O
the None None O
ΔTrpac1 None None O
mutant None None O
at None None O
neutral None None O
pH None None O
. None None O

In None None O
order None None O
to None None O
obtain None None O
an None None O
antimicrobial None None O
biodegradable None None O
material None None O
, None None O
corn None None O
flour None None O
was None None O
extruded None None O
with None None O
1 None None O
% None None O
of None None O
lysozyme None None I-PROTEIN
. None None O

To None None O
assess None None O
the None None O
contribution None None O
of None None O
process None None O
parameters None None O
such None None O
as None None O
temperature None None O
, None None O
shear None None O
stress None None O
and None None O
of None None O
related None None O
formulation None None O
parameters None None O
such None None O
as None None O
glycerol None None O
and None None O
moisture None None O
contents None None O
, None None O
the None None O
stability None None O
of None None O
lysozyme None None I-PROTEIN
following None None O
its None None O
extrusion None None O
or None None O
its None None O
thermoforming None None O
with None None O
plasticized None None O
corn None None O
starch None None O
or None None O
thermal None None O
treatments None None O
in None None O
aqueous None None O
glycerol None None O
solutions None None O
was None None O
also None None O
studied None None O
. None None O

These None None O
observations None None O
open None None O
the None None O
possibility None None O
to None None O
prepare None None O
active None None O
materials None None O
retaining None None O
more None None O
than None None O
60±7 None None O
% None None O
of None None O
initial None None O
lysozyme None None I-PROTEIN
activity None None O
. None None O

Mucor None None O
circinelloides None None O
produces None None O
plant None None O
cell None None O
wall None None O
degrading None None O
enzymes None None I-PROTEIN
that None None O
allow None None O
it None None O
to None None O
grow None None O
on None None O
complex None None O
polysaccharides None None O
. None None O

We None None O
applied None None O
peptide None None O
pattern None None O
recognition None None O
, None None O
which None None O
is None None O
a None None O
non-alignment None None O
based None None O
method None None O
for None None O
sequence None None O
analysis None None O
to None None O
map None None O
conserved None None O
sequences None None O
in None None O
glycoside None None O
hydrolase None None I-PROTEIN
families None None O
. None None O

We None None O
found None None O
12 None None O
different None None O
novel None None O
genes None None O
encoding None None I-FUNC
members None None O
of None None O
the None None O
GH3 None None O
, None None O
GH5 None None O
, None None O
GH9 None None O
, None None O
GH16 None None O
, None None O
GH38 None None O
, None None O
GH47 None None O
and None None O
GH125 None None O
families None None O
in None None O
M. None None O
circinelloides None None O
. None None O

In None None O
the None None O
present None None O
work None None O
nanoparticles None None O
( None None O
NPs None None O
) None None O
of None None O
pepsin None None I-PROTEIN
were None None O
generated None None O
in None None O
an None None O
aqueous None None O
solution None None O
using None None O
high-intensity None None O
ultrasound None None O
, None None O
and None None O
were None None O
subsequently None None O
immobilized None None O
on None None O
low-density None None O
polyethylene None None O
( None None O
PE None None O
) None None O
films None None O
, None None O
or None None O
on None None O
polycarbonate None None O
( None None O
PC None None O
) None None O
plates None None O
, None None O
or None None O
on None None O
microscope None None O
glass None None O
slides None None O
. None None O

Compared None None O
to None None O
native None None O
pepsin None None I-PROTEIN
, None None O
pepsin None None I-PROTEIN
coated None None O
onto None None O
PE None None O
showed None None O
the None None O
best None None O
catalytic None None O
activity None None O
in None None O
all None None O
the None None O
examined None None O
parameters None None O
. None None O

Enzyme None None O
activity None None O
of None None O
pepsin None None I-PROTEIN
immobilized None None O
on None None O
PC None None O
was None None O
no None None O
better None None O
than None None O
native None None O
enzyme None None O
activity None None O
at None None O
all None None O
temperatures None None O
at None None O
pH None None O
2 None None O
, None None O
and None None O
only None None O
over None None O
a None None O
narrow None None O
pH None None O
range None None O
at None None O
37°C None None O
was None None O
the None None O
activity None None O
improved None None O
over None None O
the None None O
native None None O
enzyme None None O
. None None O

The None None O
new None None O
generations None None O
like None None O
recombinant None None O
tissue None None I-PROTEIN
plasminogen None None I-PROTEIN
activator None None I-PROTEIN
( None None O
t-PA None None O
, None None O
alteplase None None O
) None None O
are None None O
not None None O
showing None None O
promising None None O
results None None O
in None None O
clinical None None O
practice None None O
in None None O
spite None None O
of None None O
displaying None None O
specific None None O
binding None None O
to None None O
fibrin None None O
in None None O
vitro None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
KHRR None None O
sequence None None O
at None None O
the None None O
initial None None O
part None None O
of None None O
protease None None O
domain None None O
was None None O
replaced None None O
by None None O
four None None O
alanine None None I-TRANS
residues None None O
. None None O

Genomic None None O
prediction None None O
accuracies None None O
using None None O
1748 None None O
trees None None O
and None None O
6932 None None O
SNPs None None O
representative None None O
of None None O
as None None O
many None None O
distinct None None O
gene None None O
loci None None O
were None None O
determined None None O
for None None O
growth None None O
and None None O
wood None None O
traits None None O
in None None O
white None None O
spruce None None O
, None None O
within None None O
and None None O
between None None O
environments None None O
and None None O
breeding None None O
groups None None O
( None None O
BG None None O
) None None O
, None None O
each None None O
with None None O
an None None O
effective None None O
size None None O
of None None O
Ne None None I-TRANS
≈ None None O
20 None None O
. None None O

Our None None O
results None None O
also None None O
show None None O
that None None O
a None None O
non-drinking None None O
adolescent None None O
with None None O
a None None O
majority None None O
of None None O
drinking None None O
friends None None O
is None None O
significantly None None O
less None None O
likely None None O
to None None O
initiate None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
if None None O
he None None O
or None None O
she None None O
has None None O
a None None O
minority None None O
of None None O
non-drinking None None O
friend None None O
( None None O
s None None O
) None None O
. None None O

The None None O
gold None None O
standard None None O
was None None O
defined None None O
as None None O
characteristic None None O
storage None None I-FUNC
in None None O
an None None O
endomyocardial None None O
biopsy None None O
on None None O
electron None None O
microscopy None None O
. None None O

Elevated None None O
serum None None O
aspartate None None I-TRANS
and None None O
alanine None None I-TRANS
aminotransferase None None O
( None None O
AST None None O
and None None O
ALT None None O
) None None O
are None None O
often None None O
observed None None O
in None None O
patients None None O
with None None O
acute None None O
ST-segment None None O
elevation None None O
myocardial None None O
infarction None None O
( None None O
STEMI None None O
) None None O
and None None O
the None None O
condition None None O
is None None O
ascribed None None O
to None None O
liver None None O
hypoperfusion None None O
. None None O

Adamts13 None None O
( None None O
-/- None None O
) None None O
mice None None O
were None None O
hydrodynamically None None O
injected None None O
with None None O
wild-type None None O
and None None O
mutant None None O
expression None None O
plasmids None None O
and None None O
triggered None None O
with None None O
recombinant None None O
human None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
. None None O

In None None O
Adamts13 None None O
( None None O
-/- None None O
) None None O
mice None None O
, None None O
the None None O
homozygous None None O
p.D187H None None O
mutation None None O
reduced None None O
ADAMTS13 None None O
secretion None None O
and None None O
activity None None O
and None None O
contributed None None O
to None None O
TTP None None O
when None None O
these None None O
mice None None O
were None None O
triggered None None O
with None None O
recombinant None None O
human None None O
von None None I-PROTEIN
Willebrand None None I-PROTEIN
factor None None I-PROTEIN
. None None O

© None None O
2014 None None O
International None None O
Society None None O
on None None O
Thrombosis None None I-DISEASE
and None None O
Haemostasis None None O
. None None O

The None None O
introduction None None O
of None None O
transcatheter None None O
aortic None None O
valve None None O
replacement None None O
mandates None None O
attention None None I-FUNC
to None None O
outcomes None None O
after None None O
surgical None None O
aortic None None O
valve None None O
replacement None None O
( None None O
SAVR None None O
) None None O
in None None O
low-risk None None O
, None None O
intermediate-risk None None O
, None None O
and None None O
very None None O
high-risk None None O
patients None None O
. None None O

The None None O
p None None O
values None None O
from None None O
logistic None None O
regression None None O
models None None O
indicated None None O
that None None O
in None None O
both None None O
groups None None O
combined None None O
, None None O
the None None O
ACP None None O
, None None O
cardiopulmonary None None O
bypass None None O
, None None O
and None None O
cardiac None None O
ischemia None None O
times None None O
predicted None None O
hospital None None O
mortality None None O
( None None O
p None None O
= None None O
0.035 None None O
, None None O
p None None O
= None None O
0.0033 None None O
, None None O
and None None O
p None None O
= None None O
0.035 None None O
, None None O
respectively None None O
) None None O
but None None O
not None None O
stroke None None I-DISEASE
. None None O

Of None None O
the None None O
survivors None None O
, None None O
13 None None O
of None None O
88 None None O
u-ACP None None O
patients None None O
( None None O
14.8 None None O
% None None O
) None None O
and None None O
8 None None O
of None None O
62 None None O
b-ACP None None O
patients None None O
( None None O
12.9 None None O
% None None O
) None None O
had None None O
a None None O
postoperative None None O
stroke None None I-DISEASE
( None None O
p None None O
= None None O
0.75 None None O
) None None O
. None None O

Risk None None O
models None None O
were None None O
developed None None O
for None None O
each None None O
operation None None O
for None None O
operative None None O
death None None O
, None None O
permanent None None O
stroke None None I-DISEASE
, None None O
renal None None O
failure None None O
, None None O
prolonged None None O
ventilation None None O
( None None O
& None None O
gt None None O
; None None O
24 None None O
hours None None O
) None None O
, None None O
deep None None O
sternal None None O
wound None None O
infection None None O
, None None O
and None None O
reoperation None None O
for None None O
bleeding None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
Stat3 None None O
activation None None O
( None None O
tyrosine None None I-TRANS
phosphorylation None None O
) None None O
may None None O
be None None O
protective None None O
and None None O
that None None O
TLR4 None None O
inhibition None None O
could None None O
be None None O
targeted None None O
pharmacologically None None O
to None None O
treat None None O
calcific None None O
aortic None None O
valve None None O
disease None None O
. None None O

Predicted None None O
forced None None O
expiratory None None O
volume None None O
in None None O
1 None None O
second None None O
( None None O
FEV1 None None O
) None None O
was None None O
obtained None None O
in None None O
all None None O
patients None None O
and None None O
diffusion None None O
capacity None None O
of None None O
the None None O
lung None None O
for None None O
carbon None None I-TRANS
monoxide None None I-TRANS
( None None O
DLCO None None O
) None None O
, None None O
arterial None None O
oxygen None None O
tension None None O
( None None O
PaO2 None None O
) None None O
, None None O
and None None O
arterial None None O
carbon None None O
dioxide None None O
tension None None O
( None None O
PaCO2 None None O
) None None O
in None None O
31 None None O
% None None O
. None None O

The None None O
TransMedics None None O
Organ None None O
Care None None O
System None None O
( None None O
OCS None None O
) None None O
( None None O
TransMedics None None O
, None None O
Inc None None O
, None None O
Boston None None O
) None None O
allows None None O
preservation None None O
of None None O
the None None O
donor None None O
heart None None O
by None None O
perfusing None None O
the None None O
organ None None O
at None None O
34°C None None O
in None None O
a None None O
beating None None O
state None None O
, None None O
potentially None None O
reducing None None O
the None None O
detrimental None None O
effect None None O
of None None O
cold None None O
storage None None I-FUNC
and None None O
providing None None O
additional None None O
assessment None None O
options None None O
. None None O

Eight None None O
hearts None None O
were None None O
cold None None O
preserved None None O
for None None O
4 None None O
hours None None O
by None None O
retrograde None None O
machine None None O
perfusion None None O
or None None O
static None None O
storage None None I-FUNC
( None None O
n None None O
= None None O
4/group None None O
) None None O
, None None O
then None None O
reimplanted None None O
and None None O
reperfused None None O
for None None O
6 None None O
hours None None O
. None None O

The None None O
stroke None None I-DISEASE
rate None None O
on None None O
VAD None None O
support None None O
was None None O
43 None None O
% None None O
( None None O
2 None None O
thromboembolic None None O
and None None O
1 None None O
hemorrhagic None None O
; None None O
3 None None O
with None None O
satisfactory None None O
recovery None None O
) None None O
. None None O

The None None O
reprogramming None None O
of None None O
passage None None O
3 None None O
myocardial None None O
fibroblasts None None O
was None None O
performed None None O
by None None O
using None None O
the None None O
lentiviral None None O
vector None None O
containing None None O
4 None None O
human None None O
factors None None O
: None None O
OCT4 None None O
, None None O
SOX2 None None O
, None None O
KLF4 None None O
, None None O
and None None O
c-MYC None None I-PROTEIN
. None None O

Increased None None O
smooth None None O
muscle None None O
actin None None I-PROTEIN
or None None O
vWF None None O
positive None None O
cells None None O
were None None O
found None None O
inside None None O
and None None O
around None None O
the None None O
iPSC None None O
clusters None None O
, None None O
compared None None O
with None None O
non-injected None None O
areas None None O
. None None O

Stagnation None None O
of None None O
blood None None O
flow None None O
between None None O
the None None O
two None None O
cavopulmonary None None O
anastomoses None None O
may None None O
increase None None O
the None None O
risk None None O
of None None O
thrombosis None None I-DISEASE
and None None O
impair None None O
central None None O
pulmonary None None O
artery None None O
growth None None O
. None None O

None None None O
of None None O
the None None O
patients None None O
experienced None None O
thrombosis None None I-DISEASE
. None None O

Bilateral None None O
BDG None None O
did None None O
not None None O
increase None None O
the None None O
risks None None O
of None None O
thrombosis None None I-DISEASE
and None None O
central None None O
pulmonary None None O
artery None None O
hypoplasia None None O
and None None O
can None None O
be None None O
performed None None O
safely None None O
without None None O
altering None None O
the None None O
outcome None None O
of None None O
the None None O
Fontan None None O
procedure None None O
. None None O

The None None O
referees None None O
are None None O
asked None None O
to None None O
submit None None O
their None None O
review None None O
noting None None O
errors None None O
, None None O
areas None None O
of None None O
ambiguity None None I-FUNC
or None None O
clarification None None O
required None None O
before None None O
the None None O
editor None None O
and None None O
editorial None None O
team None None O
consider None None O
the None None O
manuscript None None O
ready None None O
for None None O
publication None None O
. None None O

The None None O
insulin None None I-PROTEIN
response None None O
to None None O
glucose None None O
alone None None O
fell None None O
progressively None None O
over None None O
12 None None O
months None None O
but None None O
the None None O
glucose None None O
clearance/metabolism None None O
( None None O
M None None O
of None None O
H-clamp None None O
) None None O
did None None O
not None None O
change None None O
significantly None None O
until None None O
12 None None O
months None None O
. None None O

Enhanced None None O
peripheral None None O
tissue None None O
sensitivity None None O
to None None O
insulin None None I-PROTEIN
starts None None O
at None None O
3 None None O
months None None O
and None None O
is None None O
associated None None O
with None None O
fat None None O
mass None None O
loss None None O
. None None O

To None None O
our None None O
knowledge None None O
this None None O
is None None O
the None None O
first None None O
report None None O
of None None O
a None None O
paraneoplastic None None O
brainstem None None I-REGION
cerebellar None None O
syndrome None None O
with None None O
coexisting None None O
limbic None None O
encephalitis None None I-DISEASE
involving None None O
anti-Ri None None O
positivity None None O
and None None O
associated None None O
mixed None None O
neuroendocrine/NSCLC None None O
of None None O
the None None O
lung None None O
with None None O
marked None None O
improvement None None O
after None None O
tumor None None O
resection None None O
. None None O

To None None O
our None None O
knowledge None None O
this None None O
is None None O
the None None O
first None None O
reported None None O
patient None None O
with None None O
brainstem None None I-REGION
DLBCL None None O
after None None O
azathioprine None None O
treatment None None O
in None None O
MG. None None O
Lymphoma None None O
has None None O
been None None O
reported None None O
in None None O
MG None None O
patients None None O
treated None None O
with None None O
azathioprine None None O
, None None O
although None None O
the None None O
incidence None None O
is None None O
unknown None None O
. None None O

We None None O
investigated None None O
the None None O
clinical None None O
and None None O
imaging None None O
characteristics None None O
of None None O
initial None None O
and None None O
recurrent None None O
strokes None None I-DISEASE
in None None O
patients None None O
with None None O
occult None None O
lung None None O
cancer None None O
associated None None O
ischemic None None O
stroke None None I-DISEASE
( None None O
OLCA-stroke None None O
) None None O
. None None O

Multiple None None O
small None None O
and None None O
large None None O
disseminated None None O
lesions None None O
in None None O
multiple None None O
vascular None None O
territories None None O
were None None O
more None None O
frequent None None O
in None None O
recurrent None None O
strokes None None I-DISEASE
in None None O
comparison None None O
with None None O
initial None None O
strokes None None I-DISEASE
. None None O

Overall None None O
, None None O
58 None None O
% None None O
of None None O
patients None None O
had None None O
their None None O
first None None O
recurrent None None O
stroke None None I-DISEASE
within None None O
the None None O
first None None O
month None None O
, None None O
and None None O
69 None None O
% None None O
had None None O
a None None O
poor None None O
outcome None None O
, None None O
especially None None O
for None None O
those None None O
with None None O
multiple None None O
recurrent None None O
strokes None None I-DISEASE
and None None O
metastases None None O
. None None O

The None None O
severity None None O
of None None O
malignancy None None O
and None None O
cancer None None O
treatments None None O
and None None O
stroke None None I-DISEASE
influenced None None O
the None None O
recurrences None None O
and None None O
outcome None None O
. None None O

Revascularization None None O
surgery None None O
may None None O
prevent None None O
the None None O
progression None None O
of None None O
clinical None None O
symptoms None None O
and None None O
reduce None None O
the None None O
risk None None O
of None None O
subsequent None None O
strokes None None I-DISEASE
. None None O

Severe None None O
acute None None O
basilar None None I-DISEASE
artery None None I-DISEASE
occlusion None None I-DISEASE
( None None O
BAO None None O
) None None O
has None None O
a None None O
high None None O
mortality None None O
rate None None O
but None None O
as None None O
yet None None O
no None None O
effective None None O
treatment None None O
has None None O
been None None O
developed None None O
. None None O

PEEP None None O
inflation None None O
of None None O
the None None O
respiratory None None O
system None None O
is None None O
extremely None None O
slow None None O
, None None O
and None None O
allows None None O
the None None O
chest None None O
wall None None O
complex None None O
, None None O
especially None None O
the None None O
abdomen None None O
, None None O
to None None O
yield None None O
and None None O
adapt None None O
to None None O
intrusion None None O
of None None O
the None None O
diaphragm None None I-REGION
. None None O

Logistic None None O
regression None None O
models None None O
were None None O
used None None O
to None None O
explore None None O
the None None O
relationship None None O
between None None O
seeking None None O
health None None O
services None None O
and None None O
maternal None None O
and None None O
household None None O
characteristics None None O
, None None O
with None None O
special None None O
attention None None I-FUNC
to None None O
geographic None None O
and None None O
financial None None O
access None None O
to None None O
care None None O
. None None O

This None None O
finding None None O
should None None O
focus None None O
additional None None O
attention None None I-FUNC
on None None O
reducing None None O
homelessness None None O
. None None O

Neighbourhoods None None O
with None None O
dual None None O
diagnosis None None O
were None None O
generally None None O
similar None None O
to None None O
those None None O
with None None O
anxiety/mood None None O
disorder None None I-DISEASE
only None None O
, None None O
in None None O
terms None None O
of None None O
ethnic None None O
and None None O
gender/age None None O
composition None None O
. None None O

Measures None None O
to None None O
control None None O
access None None O
to None None O
alcohol None None O
outlets None None O
may None None O
be None None O
an None None O
important None None O
area None None O
for None None O
alcohol/substance None None O
abuse None None I-DISEASE
intervention None None O
, None None O
particularly None None O
for None None O
vulnerable None None O
sub-populations None None O
. None None O

We None None O
administered None None O
the None None O
Team None None O
Strategies None None O
& None None O
amp None None O
; None None O
Tools None None O
to None None O
Enhance None None O
Performance None None O
and None None O
Patient None None O
Safety None None O
( None None O
TeamSTEPPS® None None O
) None None O
Teamwork None None O
Perception None None I-FUNC
Questionnaire None None O
to None None O
measure None None O
the None None O
perception None None I-FUNC
of None None O
teamwork None None O
. None None O

The None None O
emulsions None None O
showed None None O
rapid None None O
creaming None None O
irrespective None None O
of None None O
the None None O
preparation None None O
method None None O
, None None O
but None None O
a None None O
few None None O
days None None O
storage None None I-FUNC
did None None O
not None None O
significantly None None O
change None None O
the None None O
drop None None O
size None None O
in None None O
the None None O
creamed None None O
layer None None O
, None None O
nor None None O
was None None O
separation None None O
of None None O
the None None O
oils None None O
detected None None O
. None None O

Alcohol None None I-DISEASE
abuse None None I-DISEASE
and None None O
alcohol None None O
poisoning None None O
accounted None None O
for None None O
less None None O
than None None O
2 None None O
% None None O
of None None O
the None None O
total None None O
HICs None None O
. None None O

The None None O
red None None O
wine None None O
polyphenols None None O
resveratrol None None O
and None None O
quercetin None None O
are None None O
known None None O
for None None O
their None None O
vasorelaxant None None O
and None None O
antioxidant None None O
capacity None None O
, None None O
which None None O
is None None O
assumed None None O
to None None O
rely None None O
on None None O
the None None O
activation None None O
of None None O
the None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
/soluble None None O
guanylyl None None O
cyclase None None O
( None None O
sGC None None O
) None None O
pathway None None O
. None None O

Functional None None O
studies None None O
based None None O
on None None O
luciferase None None I-PROTEIN
reporter None None O
and None None O
Western None None O
blot None None O
assays None None O
suggest None None O
that None None O
miR-19a None None O
enhances None None O
cell None None O
proliferation None None O
of None None O
BEC None None O
in None None O
severe None None O
asthma None None O
through None None O
targeting None None O
TGF-β None None O
receptor None None I-PROTEIN
2 None None O
mRNA None None O
. None None O

We None None O
sought None None O
to None None O
analyze None None O
the None None O
prevalence None None O
and None None O
incremental None None O
burden None None O
of None None O
depression None None I-DISEASE
among None None O
elderly None None O
with None None O
prostate None None O
cancer None None O
. None None O

Poisson None None O
, None None O
general None None O
linear None None O
( None None O
log-link None None O
) None None O
and None None O
Cox None None O
regression None None O
models None None O
were None None O
used None None O
to None None O
determine None None O
the None None O
association None None O
between None None O
depression None None I-DISEASE
status None None O
during None None O
treatment None None O
and None None O
follow-up None None O
phases None None O
and None None O
outcomes-health None None O
resource None None O
utilization None None O
, None None O
cost None None O
and None None O
mortality None None O
. None None O

A None None O
diagnosis None None O
of None None O
depression None None I-DISEASE
during None None O
treatment None None O
phase None None O
was None None O
associated None None O
with None None O
higher None None O
odds None None O
of None None O
emergency None None O
room None None O
visits None None O
( None None O
odds None None O
ratio None None O
( None None O
OR None None O
) None None O
= None None O
4.45 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
4.13 None None O
, None None O
4.80 None None O
) None None O
, None None O
hospitalizations None None O
( None None O
OR None None O
= None None O
3.22 None None O
, None None O
CI None None O
= None None O
3.08 None None O
, None None O
3.37 None None O
) None None O
, None None O
outpatient None None O
visits None None O
( None None O
OR None None O
= None None O
1.71 None None O
, None None O
CI None None O
= None None O
1.67 None None O
, None None O
1.75 None None O
) None None O
and None None O
excess None None O
risk None None O
of None None O
death None None O
over None None O
the None None O
course None None O
of None None O
the None None O
follow-up None None O
interval None None O
( None None O
hazard None None O
ratio None None O
= None None O
2.82 None None O
, None None O
CI None None O
= None None O
2.60 None None O
, None None O
3.06 None None O
) None None O
. None None O

Depression None None I-DISEASE
during None None O
the None None O
treatment None None O
phase None None O
was None None O
associated None None O
with None None O
significant None None O
health None None O
resource None None O
utilization None None O
, None None O
costs None None O
and None None O
mortality None None O
among None None O
men None None O
with None None O
prostate None None O
cancer None None O
. None None O

Gross None None O
changes None None O
in None None O
the None None O
stifle None None O
joints None None O
were None None O
recorded None None O
and None None O
biopsy None None O
samples None None O
of None None O
femoral None None O
and None None O
tibial None None O
articular None None O
cartilage None None O
were None None O
evaluated None None O
for None None O
thickness None None O
; None None O
chondrocyte None None O
number None None O
, None None O
density None None O
, None None O
surface None None O
area None None O
and None None O
morphology None None O
; None None O
isogenous None None O
group None None O
morphology None None O
; None None O
tidemark None None O
integrity None None O
; None None O
subchondral None None O
bone None None O
structure None None O
; None None O
presence None None O
of None None O
proteoglycans/ None None O
glycosaminoglycans None None O
; None None O
and None None O
expression None None O
of None None O
type None None O
I None None O
, None None O
II None None O
and None None O
X None None O
collagens None None I-PROTEIN
. None None O

There None None O
was None None O
also None None O
expression None None O
of None None O
type None None O
X None None O
collagen None None I-PROTEIN
in None None O
the None None O
femoral None None O
and None None O
tibial None None O
calcified None None O
and None None O
non-calcified None None O
cartilage None None O
; None None O
however None None O
, None None O
type None None O
X None None O
collagen None None I-PROTEIN
was None None O
not None None O
detected None None O
in None None O
the None None O
superficial None None O
zone None None O
of None None O
old None None O
working None None O
dogs None None O
. None None O

ColAh None None O
possess None None O
the None None O
consensus None None O
HEXXH None None O
sequence None None O
and None None O
a None None O
glutamic None None I-TRANS
acid None None I-TRANS
as None None O
the None None O
third None None O
zinc None None I-TRANS
binding None None O
positioned None None O
downstream None None O
the None None O
HEXXH None None O
motif None None O
, None None O
but None None O
has None None O
low None None O
sequence None None O
similarity None None O
and None None O
distinct None None O
domain None None O
architecture None None O
to None None O
the None None O
well-known None None O
clostridial None None O
collagenases None None O
. None None O

Collagenases None None O
play None None O
a None None O
central None None O
role None None O
in None None O
processes None None O
where None None O
collagen None None I-PROTEIN
digestion None None O
is None None O
needed None None O
, None None O
for None None O
example None None O
host None None O
invasion None None O
by None None O
pathogenic None None O
micro-organisms None None O
. None None O

This None None O
enzyme None None O
is None None O
able None None O
to None None O
bind None None O
and None None O
cleave None None O
collagen None None I-PROTEIN
, None None O
contributes None None O
for None None O
AH-3 None None O
cytotoxicity None None O
and None None O
shares None None O
low None None O
similarity None None O
with None None O
known None None O
bacterial None None O
collagenases None None O
. None None O

This None None O
study None None O
increases None None O
the None None O
current None None O
knowledge None None O
on None None O
collagenolytic None None O
enzymes None None I-PROTEIN
bringing None None O
new None None O
perspectives None None O
for None None O
biotechnology/medical None None O
purposes None None O
. None None O

In None None O
acute None None O
stage None None O
of None None O
ischemic None None O
stroke None None I-DISEASE
, None None O
the None None O
surrounding None None O
zone None None O
of None None O
fresh None None O
infarcts None None O
is None None O
termed None None O
penumbra None None O
, None None O
where None None O
microglia None None O
are None None O
activated None None O
in None None O
response None None O
to None None O
damaged None None O
cell-derived None None O
proinflammatory None None O
mediators None None O
. None None O

To None None O
elucidate None None O
mechanisms None None O
by None None O
which None None O
inflammation None None O
occurs None None O
in None None O
penumbra None None O
, None None O
we None None O
performed None None O
immunohistochemical None None O
investigations None None O
using None None O
autopsied None None O
human None None O
brains None None O
affected None None O
by None None O
acute None None O
, None None O
subacute None None O
and None None O
chronic None None O
stages None None O
of None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
as None None O
well None None O
as None None O
cell None None O
culture None None O
experiments None None O
using None None O
a None None O
murine None None O
microglia-derived None None O
cell None None O
line None None O
( None None O
BV-2 None None O
) None None O
. None None O

Furthermore None None O
, None None O
immunoreactivities None None O
for None None O
the None None O
LPC None None O
receptors None None I-PROTEIN
G None None O
protein-coupled None None O
receptor None None I-PROTEIN
132 None None O
( None None O
G2A None None O
) None None O
and None None O
P2X None None O
purinoreceptor None None I-PROTEIN
7 None None O
( None None O
P2X7R None None O
) None None O
, None None O
as None None O
well None None O
as None None O
the None None O
CC None None O
chemokine None None O
monocyte None None O
chemoattractant None None O
protein-1 None None O
( None None O
MCP-1 None None O
) None None O
and None None O
its None None O
receptor None None I-PROTEIN
CCR2 None None O
, None None O
were None None O
detectable None None O
in None None O
activated None None O
microglia None None O
. None None O

Those None None O
with None None O
a None None O
comorbidity None None O
of None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
or None None O
dementia None None I-DISEASE
and None None O
those None None O
assessed None None O
with None None O
impaired None None O
brain None None O
function None None O
were None None O
more None None O
likely None None O
to None None O
have None None O
a None None O
documented None None O
Advance None None O
Care None None O
Plan None None O
on None None O
arrival None None O
at None None O
ED None None O
. None None O

The None None O
sensation None None I-FUNC
and None None O
mobility None None O
of None None O
injured None None O
and None None O
uninjured None None O
contralateral None None O
fingers None None O
did None None O
not None None O
differ None None O
statistically None None O
. None None O

Laboratory None None O
analyses None None O
of None None O
chronic None None O
ankle None None O
instability None None O
populations None None O
during None None O
gait None None O
have None None O
elucidated None None O
a None None O
number None None O
of None None O
anomalous None None O
movement None None I-FUNC
patterns None None O
. None None O

It None None O
is None None O
possible None None O
that None None O
participants None None O
with None None O
an None None O
acute None None O
LAS None None O
display None None O
movement None None I-FUNC
patterns None None O
continuous None None O
with None None O
their None None O
chronically None None O
impaired None None O
counterparts None None O
. None None O

Less None None O
GMV None None O
in None None O
schizophrenia None None I-DISEASE
is None None O
related None None O
to None None O
worse None None O
social None None I-FUNC
cognition None None I-FUNC
and None None O
social None None O
functioning None None O
, None None O
but None None O
the None None O
relationship None None O
between None None O
GMV None None O
and None None O
social None None O
functioning None None O
in None None O
CHR None None O
individuals None None O
has None None O
yet None None O
to None None O
be None None O
investigated None None O
. None None O

Results None None O
showed None None O
that None None O
the None None O
CHR None None O
group None None O
had None None O
less None None O
GMV None None O
in None None O
the None None O
left None None I-REGION
postcentral None None I-REGION
gyrus None None I-REGION
, None None O
bilateral None None O
parahippocampual None None O
gyri None None O
, None None O
and None None O
left None None I-REGION
anterior None None I-REGION
cingulate None None I-REGION
cortex None None I-REGION
. None None O

There None None O
are None None O
only None None O
a None None O
few None None O
published None None O
reports None None O
of None None O
neural None None O
abnormalities None None O
within None None O
the None None O
families None None O
of None None O
children None None O
with None None O
attention None None I-FUNC
deficit/hyperactivity None None O
disorder None None O
( None None O
ADHD None None O
) None None O
. None None O

Reduced None None O
activations None None O
in None None O
ADHD None None O
dyads None None O
were None None O
found None None O
in None None O
the None None O
inferior None None I-REGION
frontal None None I-REGION
gyrus None None I-REGION
, None None O
right None None O
superior None None O
parietal None None O
lobule None None O
and None None O
left None None I-REGION
inferior None None I-REGION
parietal None None I-REGION
lobule None None I-REGION
. None None O

Near None None O
reflex None None O
spasm None None O
is None None O
characterized None None O
as None None O
miosis None None O
, None None O
pseudomyopia None None O
, None None O
and None None O
convergent None None O
strabismus None None O
that None None O
lead None None O
to None None O
diplopia None None O
, None None O
blurred None None O
vision None None I-FUNC
, None None O
headache None None O
, None None O
and None None O
variable None None O
, None None O
progressive None None O
, None None O
and None None O
intermittent None None O
esotropia None None O
. None None O

A None None O
46 None None O
year-old None None O
man None None O
was None None O
seen None None O
in None None O
the None None O
emergency None None O
department None None O
complaining None None O
of None None O
vision None None I-FUNC
loss None None O
and None None O
exophthalmos None None O
in None None O
his None None O
right None None O
eye None None O
. None None O

The None None O
case None None O
involves None None O
a None None O
22-year-old None None O
woman None None O
who None None O
presented None None O
with None None O
headache None None O
and None None O
decreased None None O
vision None None I-FUNC
. None None O

She None None O
was None None O
diagnosed None None O
with None None O
secondary None None O
intracranial None None I-DISEASE
hypertension None None I-DISEASE
coinciding None None O
with None None O
the None None O
symptoms None None O
of None None O
a None None O
Chiari None None O
malformation None None O
( None None O
MC None None O
) None None O
. None None O

In None None O
this None None O
case None None O
, None None O
the None None O
MC None None O
was None None O
not None None O
the None None O
responsible None None O
for None None O
triggering None None O
the None None O
secondary None None O
intracranial None None I-DISEASE
hypertension None None I-DISEASE
, None None O
but None None O
a None None O
mere None None O
coincidence None None O
of None None O
both None None O
processes None None O
. None None O

The None None O
predisposing None None O
factors None None O
involved None None O
are None None O
: None None O
advancing None None O
age None None O
, None None O
vascular None None O
illness None None O
( None None O
especially None None O
atherosclerosis None None I-DISEASE
) None None O
, None None O
glaucoma None None O
, None None O
and None None O
severe None None O
corneal None None O
damage None None O
. None None O

Serum None None O
iron None None O
and None None O
ferritin None None I-PROTEIN
and None None O
transferrin None None O
saturation None None O
were None None O
unusually None None O
high None None O
. None None O

Once None None O
all None None O
modifying None None O
factors None None O
of None None O
the None None O
intraocular None None O
pressure None None O
( None None O
IOP None None I-TRANS
) None None O
have None None O
been None None O
removed None None O
, None None O
baseline None None O
IOP None None I-TRANS
should None None O
be None None O
evaluated None None O
again None None O
, None None O
choosing None None O
preservative-free None None O
antiglaucomatous None None O
drugs None None O
when None None O
needed None None O
. None None O

One None None O
way None None O
of None None O
tackling None None O
lack None None O
of None None O
adherence None None O
is None None O
by None None O
identifying None None O
patients None None O
' None None O
barriers None None O
to None None O
medication None None O
and None None O
involving None None O
them None None O
in None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Identifying None None O
the None None O
scale None None O
of None None O
the None None O
problem None None O
and None None O
developing None None O
strategies None None O
to None None O
involve None None O
the None None O
patient None None O
in None None O
decision None None I-FUNC
making None None I-FUNC
is None None O
crucial None None O
to None None O
improve None None O
treatment None None O
adherence None None O
. None None O

Calcium None None O
and None None O
zinc None None I-TRANS
concentrations None None O
were None None O
reduced None None O
after None None O
12 None None O
mo None None O
. None None O

This None None O
study None None O
demonstrates None None O
the None None O
applicability None None O
of None None O
using None None O
an None None O
external None None O
focus None None O
during None None O
rehabilitation None None O
of None None O
patients None None O
after None None O
ACLR None None O
to None None O
enhance None None O
safer None None O
movement None None I-FUNC
patterns None None O
compared None None O
to None None O
an None None O
internal None None O
focus None None O
of None None O
attention None None I-FUNC
and None None O
subsequently None None O
may None None O
help None None O
to None None O
reduce None None O
second None None O
ACL None None O
injury None None O
risk None None O
. None None O

Functional None None O
movement None None I-FUNC
control None None O
was None None O
measured None None O
using None None O
posturography None None O
on None None O
a None None O
force None None O
platform None None O
and None None O
the None None O
Star None None O
Excursion None None O
Balance None None O
Test None None O
( None None O
SEBT None None O
) None None O
. None None O

A None None O
trend None None O
towards None None O
impairment None None O
of None None O
functional None None O
movement None None I-FUNC
control None None O
was None None O
observed None None O
in None None O
the None None O
netballers None None O
with None None O
GJH None None O
. None None O

As None None O
atrial None None O
fibrillation None None O
( None None O
AF None None O
) None None O
substantially None None O
increases None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
and None None O
other None None O
thromboembolic None None O
events None None O
, None None O
most None None O
AF None None O
patients None None O
require None None O
appropriate None None O
antithrombotic None None O
prophylaxis None None O
. None None O

Therefore None None O
, None None O
risk None None O
assessment None None O
of None None O
stroke None None I-DISEASE
and None None O
bleeding None None O
is None None O
an None None O
obligatory None None O
part None None O
of None None O
AF None None O
management None None O
, None None O
and None None O
risk None None O
has None None O
to None None O
be None None O
weighed None None O
individually None None O
. None None O

MI None None O
, None None O
major None None O
stroke None None I-DISEASE
as None None O
well None None O
as None None O
in-hospital None None O
death None None O
rate None None O
( None None O
7.0 None None O
% None None O
LA None None O
vs None None O
5.3 None None O
% None None O
GA None None O
, None None O
p=0.053 None None O
) None None O
had None None O
a None None O
similar None None O
incidence None None O
between None None O
groups None None O
, None None O
confirmed None None O
in None None O
multivariate None None O
regression None None O
analysis None None O
after None None O
adjusting None None O
for None None O
confounders None None O
. None None O

The None None O
outcomes None None O
included None None O
the None None O
number None None O
of None None O
chronic None None O
medical None None O
conditions None None O
, None None O
adherence None None O
with None None O
long-term None None O
medications None None O
( None None O
MMAS-8 None None O
) None None O
, None None O
and None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
( None None O
CESD-20 None None O
) None None O
. None None O

We None None O
developed None None O
a None None O
statistical None None O
tool None None O
to None None O
help None None O
identify None None O
the None None O
patients None None O
with None None O
TGP5 None None O
who None None O
are None None O
at None None O
the None None O
highest None None O
risk None None O
of None None O
BCR None None O
after None None O
RP None None O
, None None O
thereby None None O
helping None None O
with None None O
the None None O
clinical None None O
decision None None I-FUNC
making None None I-FUNC
regarding None None O
adjuvant None None O
trials None None O
and None None O
follow-up None None O
scheduling None None O
. None None O

Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
is None None O
an None None O
extremely None None O
prevalent None None O
cause None None O
of None None O
dementia None None I-DISEASE
. None None O

Long-term None None I-FUNC
potentiation None None I-FUNC
has None None O
proven None None O
to None None O
be None None O
a None None O
sensitive None None O
tool None None O
for None None O
the None None O
`` None None O
diagnosis None None O
'' None None O
of None None O
such None None O
synaptic None None O
dysfunctions None None O
. None None O

Therefore None None O
, None None O
we None None O
analyzed None None O
the None None O
effects None None O
of None None O
age None None O
on None None O
neuronal None None O
sensitivity None None O
to None None O
glucose None None O
deprivation None None O
by None None O
monitoring None None O
changes None None O
in None None O
field None None O
excitatory None None O
postsynaptic None None O
potentials None None O
( None None O
fEPSPs None None O
) None None O
, None None O
tissue None None O
Po2 None None O
, None None O
and None None O
NADH None None O
fluorescence None None O
imaging None None O
in None None O
the None None O
CA1 None None I-REGION
region None None O
of None None O
hippocampal None None O
slices None None O
obtained None None O
from None None O
F344 None None O
rats None None O
( None None O
1-2 None None O
, None None O
3-6 None None O
, None None O
12-20 None None O
, None None O
and None None O
& None None O
gt None None O
; None None O
22 None None O
months None None O
) None None O
. None None O

The None None O
NAD None None I-TRANS
( None None O
+ None None O
) None None O
/NADH None None O
ratio None None O
remained None None O
relatively None None O
oxidized None None O
after None None O
low None None O
glucose None None O
, None None O
even None None O
during None None O
recovery None None O
. None None O

Indeed None None O
, None None O
growing None None O
evidence None None O
suggests None None O
that None None O
downregulation None None O
of None None O
Wnt None None O
signaling None None O
could None None O
be None None O
involved None None O
in None None O
the None None O
cognitive None None O
decline None None O
associated None None O
with None None O
aging None None O
and None None O
also None None O
with None None O
the None None O
physiopathology None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
AD None None O
) None None O
. None None O

Our None None O
results None None O
suggest None None O
a None None O
relationship None None O
between None None O
age-related None None O
downregulation None None O
of None None O
canonical None None O
Wnt None None O
signaling None None O
and None None O
neuronal None None O
loss None None O
observed None None O
in None None O
the None None O
hippocampus None None I-REGION
of None None O
SAMP8 None None O
mice None None O
. None None O

In None None O
a None None O
rodent None None O
model None None O
of None None O
familial None None O
amyotrophic None None O
lateral None None O
sclerosis None None O
( None None O
ALS None None O
) None None O
overexpressing None None O
mutant None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
1 None None O
( None None O
SOD1 None None O
) None None O
, None None O
the None None O
rate None None O
of None None O
astrocytes None None O
acquiring None None O
a None None O
senescent None None O
phenotype None None O
is None None O
accelerated None None O
and None None O
they None None O
subsequently None None O
provide None None O
less None None O
support None None O
to None None O
motor None None I-NEURON
neurons None None I-NEURON
. None None O

Replacing None None O
aging None None O
astrocytes None None O
with None None O
young None None O
ones None None O
producing None None O
GDNF None None O
may None None O
therefore None None O
have None None O
a None None O
significant None None O
survival None None O
promoting None None O
affect None None O
on None None O
aging None None O
motor None None I-NEURON
neurons None None I-NEURON
and None None O
those None None O
lost None None O
through None None O
diseases None None O
such None None O
as None None O
ALS None None O
. None None O

Brain None None O
iron None None O
accumulates None None O
during None None O
aging None None O
and None None O
has None None O
been None None O
associated None None O
with None None O
neurodegenerative None None O
disorders None None O
including None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
. None None O

We None None O
investigated None None O
if None None O
during None None O
normal None None O
brain None None O
aging None None O
iron None None O
load None None O
relates None None O
to None None O
cognitive None None O
impairment None None O
in None None O
region-specific None None O
patterns None None O
in None None O
a None None O
community-dwelling None None O
cohort None None O
of None None O
336 None None O
healthy None None O
, None None O
middle None None O
aged None None O
, None None O
and None None O
older None None O
adults None None O
from None None O
the None None O
Austrian None None O
Stroke None None I-DISEASE
Prevention None None O
Family None None O
Study None None O
. None None O

Comprehensive None None O
neuropsychological None None O
testing None None O
assessed None None O
memory None None I-FUNC
, None None O
executive None None O
function None None O
, None None O
and None None O
psychomotor None None O
speed None None O
. None None O

We None None O
conclude None None O
that None None O
higher None None O
R2*-determined None None O
iron None None O
in None None O
the None None O
basal None None I-REGION
ganglia None None I-REGION
correlates None None O
with None None O
cognitive None None O
impairment None None O
during None None O
brain None None O
aging None None O
independent None None O
of None None O
concomitant None None O
brain None None O
abnormalities None None O
. None None O

The None None O
reduction None None O
in None None O
neuroinflammation None None O
did None None O
not None None O
affect None None O
spatial None None O
learning None None I-FUNC
and None None O
memory None None I-FUNC
in None None O
APP/PS1*CB2 None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

This None None O
tool None None O
was None None O
originally None None O
developed None None O
in None None O
English None None O
language None None I-FUNC
and None None O
its None None O
Spanish None None O
version None None O
is None None O
still None None O
inexistent None None O
. None None O

To None None O
adapt None None O
the None None O
CAPE-V None None O
protocol None None O
to None None O
the None None O
Spanish None None O
language None None I-FUNC
, None None O
we None None O
proposed None None O
6 None None O
phrases None None O
phonetically None None O
designed None None O
according None None O
to None None O
the None None O
CAPE-V None None O
requirements None None O
. None None O

Together None None O
, None None O
plakin None None O
, None None O
integrin None None I-PROTEIN
, None None O
and None None O
hemicentin None None O
are None None O
founding None None O
components None None O
of None None O
a None None O
cell-directed None None O
adhesion None None O
system None None O
, None None O
which None None O
we None None O
name None None O
a None None O
BM-LINKage None None O
( None None O
B-LINK None None O
) None None O
, None None O
that None None O
connects None None O
adjacent None None O
tissues None None O
through None None O
adjoining None None O
BMs None None O
. None None O

Depression None None I-DISEASE
and None None O
physical None None O
frailty None None O
in None None O
older None None O
persons None None O
are None None O
both None None O
associated None None O
with None None O
somatic None None O
diseases None None O
, None None O
but None None O
are None None O
hardly None None O
examined None None O
in None None O
concert None None O
. None None O

Physical None None O
frailty None None O
, None None O
however None None O
, None None O
partly None None O
mediated None None O
the None None O
association None None O
between None None O
depression None None I-DISEASE
and None None O
somatic None None O
diseases None None O
, None None O
as None None O
the None None O
strength None None O
of None None O
this None None O
association None None O
decreased None None O
by None None O
over None None O
10 None None O
% None None O
when None None O
frailty None None O
was None None O
added None None O
to None None O
the None None O
model None None O
( None None O
B=0.47 None None O
, None None O
p=.003 None None O
, None None O
versus None None O
B=0.41 None None O
, None None O
p=.01 None None O
) None None O
. None None O

Of None None O
the None None O
remaining None None O
frailty None None O
components None None O
, None None O
only None None O
slowness None None O
was None None O
associated None None O
with None None O
the None None O
number None None O
of None None O
somatic None None O
diseases None None O
; None None O
but None None O
this None None O
association None None O
was None None O
fully None None O
independent None None O
of None None O
depression None None I-DISEASE
. None None O

The None None O
Master None None O
Activation None None O
model None None O
of None None O
attention None None I-FUNC
( None None O
Michael None None O
, None None O
Vairet None None O
, None None O
and None None O
Fernandez None None O
, None None O
Capture None None O
attentionnelle None None O
en None None O
vision None None I-FUNC
: None None O
La None None O
saillance None None O
, None None O
la None None O
pertinence None None O
, None None O
et None None O
la None None O
balance None None O
cortico-sous-corticale None None O
. None None O

165-201 None None O
, None None O
2007 None None O
; None None O
Michael None None O
, None None O
Lété None None O
, None None O
and None None O
Ducrot None None O
, None None O
Trajectories None None O
of None None O
Attentional None None O
Development None None O
: None None O
An None None O
Exploration None None O
with None None O
the None None O
Master None None O
Activation None None O
Map None None O
Model None None O
, None None O
Developmental None None O
Psychology None None O
, None None O
49:615-631 None None O
, None None O
2013 None None O
) None None O
was None None O
used None None O
to None None O
study None None O
visual None None I-FUNC
attention None None I-FUNC
and None None O
driving None None O
behaviours None None O
of None None O
younger None None O
and None None O
older None None O
drivers None None O
while None None O
parking None None O
a None None O
car None None O
. None None O

In None None O
fact None None O
, None None O
high-level None None O
spatial None None O
processing None None O
, None None O
including None None O
allocentric None None O
location None None O
encoding None None I-FUNC
, None None O
is None None O
already None None O
available None None O
to None None O
very None None O
young None None O
children None None O
, None None O
but None None O
navigational None None O
strategies None None O
are None None O
not None None O
mature None None O
until None None O
late None None O
childhood None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
MC None None O
and None None O
the None None O
CBT None None O
were None None O
used None None O
to None None O
assess None None O
spatial None None I-FUNC
memory None None I-FUNC
for None None O
navigation None None O
and None None O
for None None O
reaching None None O
, None None O
respectively None None O
. None None O

Bruton None None O
tyrosine None None I-TRANS
kinase None None O
( None None O
BTK None None O
) None None O
mutations None None O
were None None O
identified None None O
in None None O
all None None O
cases None None O
. None None O

Despite None None O
the None None O
small None None O
number None None O
of None None O
patients None None O
, None None O
our None None O
findings None None O
were None None O
similar None None O
to None None O
those None None O
in None None O
the None None O
literature None None O
, None None O
showing None None O
coronary None None O
artery None None O
disease None None O
in None None O
young None None O
people None None O
with None None O
SLE None None O
due None None O
to None None O
premature None None O
atherosclerosis None None I-DISEASE
and None None O
a None None O
high None None O
mortality None None O
rate None None O
. None None O

The None None O
authors None None O
present None None O
a None None O
case None None O
of None None O
citrullinemia None None O
with None None O
a None None O
genotype None None O
of None None O
argininosuccinate None None I-PROTEIN
synthetase None None I-PROTEIN
( None None O
ASS1 None None O
) None None O
, None None O
c.380 None None O
G None None O
& None None O
gt None None O
; None None O
A None None O
( None None O
p.R127Q None None O
) None None O
/c.380 None None O
G None None O
& None None O
gt None None O
; None None O
A None None O
( None None O
p.R127Q None None O
) None None O
, None None O
in None None O
two None None O
alleles None None O
. None None O

Both None None O
severe None None O
thyrotoxicosis None None O
and None None O
hypothyroidism None None O
may None None O
affect None None O
brain None None O
function None None O
and None None O
cause None None O
a None None O
change None None O
in None None O
consciousness None None I-FUNC
, None None O
as None None O
seen None None O
with None None O
a None None O
thyroid None None O
storm None None O
or None None O
myxedema None None O
coma None None O
. None None O

Body None None O
weight None None O
, None None O
absolute None None O
and None None O
relative None None O
organ None None O
weights None None O
, None None O
food None None O
and None None O
fluid None None O
intake None None O
, None None O
levels None None O
of None None O
serum None None O
glucose None None O
and None None O
liver None None O
enzymes None None I-PROTEIN
and None None O
kidney None None O
parameters None None O
were None None O
calculated None None O
and None None O
compared None None O
. None None O

The None None O
contents None None O
of None None O
5-hydroxytryptamine None None I-TRANS
( None None O
5-HT None None I-TRANS
) None None O
and None None O
its None None O
metabolite None None O
, None None O
5-hydroxyindoleacetic None None O
acid None None O
( None None O
5-HIAA None None O
) None None O
, None None O
in None None O
mouse None None O
hippocampus None None I-REGION
were None None O
determined None None O
by None None O
HPLC-ECD None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
CUMS None None O
significantly None None O
decreased None None O
the None None O
levels None None O
of None None O
5-HT None None I-TRANS
and None None O
5-HIAA None None O
in None None O
the None None O
hippocampus None None I-REGION
, None None O
with None None O
an None None O
increase None None O
in None None O
plasma None None O
IL-6 None None O
, None None O
IL-1β None None O
, None None O
and None None O
TNF-α None None O
levels None None O
. None None O

EOPF None None O
administration None None O
could None None O
effectively None None O
reverse None None O
the None None O
alterations None None O
in None None O
the None None O
concentrations None None O
of None None O
5-HT None None I-TRANS
and None None O
5-HIAA None None O
; None None O
reduce None None O
the None None O
IL-6 None None O
, None None O
IL-1β None None O
, None None O
and None None O
TNF-α None None O
levels None None O
. None None O

RT-PCR None None O
analysis None None O
showed None None O
that None None O
p53 None None I-PROTEIN
mRNA None None O
expression None None O
and None None O
the None None O
ratio None None O
of None None O
Bax/Bcl-2 None None O
in None None O
the None None O
S None None O
group None None O
were None None O
significantly None None O
altered None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
( None None O
*P None None O
& None None O
lt None None O
; None None O
0.05 None None O
) None None O
. None None O

Compunds None None O
1 None None O
and None None O
2 None None O
are None None O
new None None O
and None None O
neither None None O
showed None None O
inhibitory None None O
effects None None O
on None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
production None None O
in None None O
lipopolysaccharide-induced None None O
RAW264.7 None None O
macrophages None None O
. None None O

gambiae None None O
complex None None O
, None None O
as None None O
well None None O
as None None O
phenotypes None None O
for None None O
insensitive None None O
acetylcholinesterase None None I-PROTEIN
( None None O
AChE1 None None O
) None None O
. None None O

CHIMERA None None O
is None None O
distinct None None O
from None None O
existing None None O
neurotrauma None None O
model None None O
systems None None O
in None None O
that None None O
it None None O
uses None None O
a None None O
completely None None O
non-surgical None None O
procedure None None O
to None None O
precisely None None O
deliver None None O
impacts None None O
of None None O
prescribed None None O
dynamic None None O
characteristics None None O
to None None O
a None None O
closed None None O
skull None None O
while None None O
enabling None None O
kinematic None None O
analysis None None O
of None None O
unconstrained None None O
head None None O
movement None None I-FUNC
. None None O

Repeated None None O
TBI None None O
led None None O
to None None O
diffuse None None O
axonal None None O
injury None None O
with None None O
extensive None None O
microgliosis None None O
in None None O
white None None I-REGION
matter None None I-REGION
from None None O
2-14d None None O
post-rTBI None None O
. None None O

An None None O
extracellular None None O
signal None None O
like None None O
a None None O
cytokine None None O
or None None O
chemokine None None O
, None None O
secreted None None O
in None None O
the None None O
inflammatory None None O
microenvironment None None O
can None None O
activate None None O
the None None O
mitogen None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
pathway None None O
by None None O
binding None None O
to None None O
a None None O
cytokine None None O
receptor None None I-PROTEIN
tyrosine None None I-TRANS
kinase None None O
, None None O
which None None O
further None None O
activates None None O
tyrosine None None I-TRANS
kinases None None I-PROTEIN
such None None O
as None None O
Janus None None O
Kinase-3 None None O
( None None O
Jak-3 None None O
) None None O
. None None O

The None None O
latter None None O
phosphorylates None None O
c-myc None None I-PROTEIN
, None None O
an None None O
oncogene None None O
, None None O
which None None O
alters None None O
the None None O
levels None None O
and None None O
activities None None O
of None None O
many None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
leading None None O
to None None O
cell None None O
survival None None O
, None None O
proliferation None None O
and None None O
invasion None None O
. None None O

The None None O
present None None O
study None None O
explores None None O
the None None O
role None None O
of None None O
ulcerative None None O
colitis None None O
in None None O
colon None None O
cancer None None O
by None None O
investigating None None O
the None None O
activities None None O
of None None O
tyrosine None None I-TRANS
kinase None None O
activated None None O
MAPK None None O
pathway None None O
and None None O
various None None O
components None None O
of None None O
the None None O
PI3K None None O
pathway None None O
including None None O
PI3K None None O
, None None O
PTEN None None O
, None None O
PDK1 None None O
, None None O
GSK3β None None O
, None None O
Akt None None O
, None None O
mTOR None None O
, None None O
Wnt None None O
and None None O
β-catenin None None O
. None None O

with None None O
inherited None None O
deficiency None None O
of None None O
4-hydroxyphenylpyruvate None None I-PROTEIN
dioxygenase None None I-PROTEIN
( None None O
HPPD None None O
) None None O
, None None O
exhibited None None O
a None None O
far None None O
higher None None O
NO None None O
release None None O
than None None O
controls None None O
, None None O
when None None O
NO None None O
was None None O
estimated None None O
in None None O
terms None None O
of None None O
nitrite None None O
content None None O
in None None O
the None None O
suspending None None O
media None None O
. None None O

Moreover None None O
, None None O
we None None O
found None None O
that None None O
500μM None None O
l-tyrosine None None O
increases None None O
nitrite None None O
release None None O
and None None O
accumulation None None O
in None None O
suspending None None O
media None None O
of None None O
U-937 None None O
cells None None O
, None None O
a None None O
human None None O
monoblast-like None None O
lymphoma None None O
cell None None O
line None None O
which None None O
displays None None O
many None None O
characteristics None None O
of None None O
macrophages None None O
, None None O
including None None O
the None None O
expression None None O
of None None O
inducible None None O
and None None O
endothelial None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthases None None I-PROTEIN
. None None O

The None None O
western None None O
blotting None None O
study None None O
of None None O
p53 None None I-PROTEIN
, None None O
Bcl-2 None None O
and None None O
Bax None None O
also None None O
showed None None O
altered None None O
expression None None O
. None None O

Primary None None O
outcomes None None O
measured None None O
at None None O
baseline None None O
and None None O
week None None O
12 None None O
included None None O
the None None O
Perceived None None O
Stress None None O
Scale None None O
, None None O
Linear None None O
Analog None None O
Self-Assessment None None O
Scale None None O
, None None O
Mindful None None O
Attention None None I-FUNC
Awareness None None O
Scale None None O
, None None O
and None None O
Connor-Davidson None None O
Resilience None None O
Scale None None O
. None None O

Furthermore None None O
, None None O
the None None O
intervention None None O
afforded None None O
statistically None None O
significant None None O
and None None O
clinically None None O
meaningful None None O
improvement None None O
in None None O
anxiety None None O
, None None O
stress None None O
, None None O
quality None None O
of None None O
life None None O
, None None O
and None None O
mindful None None O
attention None None I-FUNC
. None None O

These None None O
alterations None None O
in None None O
metabolism None None O
can None None O
include None None O
resistance None None O
to None None O
the None None O
hormone None None O
insulin None None I-PROTEIN
, None None O
lipid None None O
accumulation None None O
, None None O
mitochondrial None None O
dysfunction None None O
and None None O
transcriptional None None O
remodelling None None O
of None None O
major None None O
metabolic None None O
pathways None None O
. None None O

Fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
FGF None None O
) None None O
signaling None None O
is None None O
essential None None O
for None None O
early None None O
trophoblast None None O
expansion None None O
and None None O
maintenance None None O
in None None O
the None None O
mouse None None O
, None None O
but None None O
is None None O
not None None O
required None None O
for None None O
trophectoderm None None O
specification None None O
during None None O
blastocyst None None O
formation None None O
. None None O

We None None O
also None None O
investigated None None O
the None None O
expression None None O
of None None O
FGF None None O
receptors None None I-PROTEIN
( None None O
FGFRs None None O
) None None O
in None None O
blastocysts None None O
, None None O
and None None O
the None None O
expression None None O
of None None O
FGFR2 None None O
and None None O
activated None None O
ERK1/2 None None O
in None None O
first None None O
trimester None None O
human None None O
placentae None None O
. None None O

In None None O
North None None O
America None None O
, None None O
we None None O
have None None O
a None None O
growing None None O
population None None O
of None None O
individuals None None O
whose None None O
first None None O
language None None I-FUNC
is None None O
not None None O
English None None O
. None None O

Specifically None None O
, None None O
this None None O
research None None O
aimed None None O
to None None O
explore None None O
the None None O
experiences None None O
and None None O
needs None None O
of None None O
Chinese None None O
stroke None None I-DISEASE
survivors None None O
and None None O
family None None O
caregivers None None O
as None None O
they None None O
return None None O
to None None O
community None None O
living None None O
using None None O
the None None O
Timing None None O
it None None O
Right None None O
Framework None None O
as None None O
a None None O
conceptual None None O
guide None None O
. None None O

To None None O
optimise None None O
Chinese None None O
stroke None None I-DISEASE
survivors None None O
' None None O
and None None O
caregivers None None O
' None None O
community None None O
re-integration None None O
, None None O
healthcare None None O
professionals None None O
should None None O
provide None None O
timely None None O
and None None O
accessible None None O
education None None O
and None None O
be None None O
aware None None O
of None None O
the None None O
role None None O
of None None O
Chinese None None O
diet None None O
and None None O
traditional None None O
medicine None None O
in None None O
stroke None None I-DISEASE
survivors None None O
' None None O
rehabilitation None None O
. None None O

This None None O
article None None O
aims None None O
to None None O
discover None None O
which None None O
variables None None O
influence None None O
the None None O
development None None O
of None None O
post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
in None None O
patients None None O
with None None O
burn None None O
injuries None None O
. None None O

Post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
is None None O
an None None O
important None None O
psychopathology None None O
for None None O
burned None None O
patients None None O
as None None O
it None None O
can None None O
affect None None O
both None None O
physical None None O
outcomes None None O
and None None O
quality None None O
of None None O
life None None O
for None None O
those None None O
affected None None O
. None None O

Sixty-two None None O
consecutive None None O
patients None None O
with None None O
medial None None O
temporal None None I-REGION
lobe None None I-REGION
epilepsy None None I-DISEASE
( None None O
MMTLE None None O
) None None O
were None None O
assessed None None O
using None None O
the None None O
Clinical None None O
Memory None None I-FUNC
Scale None None O
( None None O
CMS None None O
) None None O
and None None O
MRI None None O
to None None O
measure None None O
the None None O
volumes None None O
of None None O
the None None O
hippocampus None None I-REGION
, None None O
amygdala None None I-REGION
, None None O
and None None O
EC None None O
. None None O

One-way None None O
analysis None None O
of None None O
variance None None O
( None None O
ANOVA None None O
) None None O
was None None O
used None None O
to None None O
assess None None O
group None None O
differences None None O
for None None O
all None None O
volumetric None None O
data None None O
( None None O
Z None None O
scores None None O
or None None O
asymmetry None None O
indexes None None O
( None None O
AI None None O
) None None O
) None None O
, None None O
memory None None I-FUNC
scale None None O
scores None None O
, None None O
and None None O
clinical None None O
parameters None None O
. None None O

The None None O
nonsense None None O
graphical None None O
recognition None None O
tests None None O
and None None O
the None None O
facial None None O
memory None None I-FUNC
tests None None O
were None None O
significantly None None O
different None None O
between None None O
the None None O
three None None O
groups None None O
. None None O

Nonverbal None None O
memory None None I-FUNC
was None None O
correlated None None O
with None None O
the None None O
status None None O
of None None O
the None None O
right None None I-REGION
hippocampus None None I-REGION
. None None O

Bevacizumab None None O
could None None O
be None None O
a None None O
safe None None O
and None None O
effective None None O
anti-scarring None None O
agent None None O
; None None O
however None None O
IOP None None I-TRANS
reduction None None O
appears None None O
to None None O
be None None O
greater None None O
with None None O
MMC None None O
, None None O
and None None O
also None None O
less None None O
antiglaucoma None None O
medications None None O
are None None O
needed None None O
with None None O
this None None O
anti-scarring None None O
agent None None O
. None None O

Children None None O
with None None O
AD None None O
had None None O
higher None None O
median None None O
levels None None O
of None None O
serum None None O
IgE None None O
( None None O
110.0 None None O
vs. None None O
53.0 None None O
kU/l None None O
) None None O
, None None O
peripheral None None O
lymphocyte None None O
( None None O
2.9 None None O
vs. None None O
2.5 None None O
× None None O
10 None None O
( None None O
3 None None O
) None None O
cells/μl None None O
) None None O
, None None O
and None None O
eosinophil None None O
counts None None O
( None None O
0.3 None None O
vs. None None O
0.2 None None O
× None None O
10 None None O
( None None O
3 None None O
) None None O
cells/μl None None O
) None None O
( None None O
Mann-Whitney None None O
U-test None None O
, None None O
p None None O
≤ None None O
0.003 None None O
for None None O
all None None O
) None None O
, None None O
but None None O
not None None O
CRP None None O
levels None None O
( None None O
0.03 None None O
vs. None None O
0.04 None None O
mg/dl None None O
) None None O
and None None O
higher None None O
odds None None O
of None None O
25-OH None None O
vitamin None None O
D None None O
deficiency None None O
( None None O
survey None None O
logistic None None O
regression None None O
; None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
[ None None O
95 None None O
% None None O
CI None None O
] None None O
: None None O
4.81 None None O
[ None None O
1.21 None None O
, None None O
20.81 None None O
] None None O
) None None O
, None None O
low None None O
calcium None None O
( None None O
2.56 None None O
[ None None O
1.24 None None O
, None None O
5.28 None None O
] None None O
) None None O
, None None O
low None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
( None None O
2.56 None None O
[ None None O
1.20 None None O
, None None O
5.44 None None O
] None None O
) None None O
, None None O
and None None O
higher None None O
tertiles None None O
of None None O
LDH None None O
( None None O
tertile None None O
2 None None O
: None None O
6.36 None None O
[ None None O
1.75 None None O
, None None O
23.18 None None O
] None None O
; None None O
tertile-3 None None O
: None None O
4.57 None None O
[ None None O
1.32 None None O
, None None O
15.85 None None O
] None None O
) None None O
, None None O
but None None O
not None None O
parathyroid None None O
hormone None None O
( None None O
PTH None None O
) None None O
or None None O
albumin None None O
. None None O

To None None O
investigate None None O
the None None O
expression None None O
of None None O
p53 None None I-PROTEIN
, None None O
p16 None None O
( None None O
INK4A None None O
) None None O
and None None O
VEGF-C None None O
proteins None None O
in None None O
cervical None None O
cancer None None O
and None None O
their None None O
clinical None None O
importance None None O
. None None O

( None None O
1 None None O
) None None O
The None None O
positive None None O
expression None None O
rates None None O
of None None O
p53 None None I-PROTEIN
, None None O
p16 None None O
( None None O
INK4A None None O
) None None O
and None None O
VEGF-C None None O
proteins None None O
were None None O
56.8 None None O
% None None O
, None None O
95.2 None None O
% None None O
and None None O
88 None None O
% None None O
, None None O
respectively None None O
. None None O

The None None O
presence None None O
of None None O
difference None None O
for None None O
positive None None O
significant None None O
p53 None None I-PROTEIN
in None None O
squamous None None O
cell None None O
carcinoma None None O
and None None O
adenocarcinoma None None O
is None None O
intensively None None O
large None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.01 None None O
) None None O
, None None O
but None None O
its None None O
expression None None O
is None None O
not None None O
much None None O
influenced None None O
by None None O
age None None O
, None None O
degree None None O
of None None O
differentiation None None O
, None None O
parametric None None O
infiltration None None O
, None None O
vascular None None O
metastasis None None O
or None None O
clinical None None O
staging None None O
( None None O
P None None O
& None None O
gt None None O
; None None O
0.05 None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
some None None O
immune None None O
enzymes None None I-PROTEIN
in None None O
cervical None None O
cancer None None O
has None None O
a None None O
reference None None O
value None None O
for None None O
early None None O
diagnosis None None O
and None None O
prognosis None None O
of None None O
cervical None None O
cancer None None O
, None None O
and None None O
has None None O
a None None O
certain None None O
guiding None None O
significance None None O
for None None O
development None None O
of None None O
the None None O
treatment None None O
program None None O
. None None O

Many None None O
studies None None O
have None None O
investigated None None O
the None None O
association None None O
between None None O
glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
M1 None None O
( None None O
GSTM1 None None O
) None None O
null None None O
genotype None None O
and None None O
the None None O
risk None None O
of None None O
endometriosis None None O
. None None O

The None None O
c.1865G None None O
& None None O
gt None None O
; None None O
A None None O
, None None O
p.Gly622Asp None None O
( None None O
G622D None None O
) None None O
, None None O
located None None O
at None None O
the None None O
NBD1 None None O
C None None O
terminus None None O
of None None O
the None None O
CFTR None None I-PROTEIN
protein None None O
, None None O
was None None O
initially None None O
reported None None O
in None None O
patients None None O
with None None O
male None None O
infertility None None O
. None None O

These None None O
IL-27-producing None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
were None None O
effector None None O
memory None None I-FUNC
cells None None O
and None None O
exhibited None None O
a None None O
transcription None None O
profile None None O
clearly None None O
separated None None O
from None None O
those None None O
of None None O
Th2 None None O
, None None O
Th17 None None O
, None None O
Th9 None None O
, None None O
and None None O
Th22 None None O
cells None None O
. None None O

Transcription None None I-PROTEIN
factors None None O
c-Fos None None O
and None None O
T-bet None None O
were None None O
required None None O
for None None O
IL-27 None None O
( None None O
+ None None O
) None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cell None None O
differentiation None None O
. None None O

These None None O
data None None O
suggested None None O
that None None O
human None None O
IL-27 None None O
( None None O
+ None None O
) None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
might None None O
represent None None O
a None None O
distinct None None O
human None None O
T None None O
cell None None O
subset None None O
with None None O
unique None None O
expression None None O
profiles None None O
of None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
and None None O
proinflammatory None None O
cytokines None None O
, None None O
and None None O
these None None O
IL-27 None None O
( None None O
+ None None O
) None None O
CD4 None None O
( None None O
+ None None O
) None None O
T None None O
cells None None O
may None None O
play None None O
important None None O
roles None None O
in None None O
tuberculosis None None O
immunity None None O
by None None O
affecting None None O
pleural None None O
mesothelial None None O
cells None None O
. None None O

In None None O
the None None O
multivariate None None O
model None None O
, None None O
the None None O
variable None None O
associated None None O
with None None O
a None None O
decrease None None O
in None None O
drug None None O
nonadherence None None O
was None None O
years None None O
of None None O
known None None O
hypertension None None O
( None None O
OR None None O
= None None O
0.962 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
0.937-0.988 None None O
) None None O
, None None O
and None None O
the None None O
variables None None O
associated None None O
with None None O
an None None O
increase None None O
in None None O
drug None None O
nonadherence None None O
were None None O
loose-pill None None O
combination None None O
therapy None None O
versus None None O
fixed-dose None None O
combination None None O
therapy None None O
or None None O
monotherapy None None O
( None None O
OR None None O
= None None O
4.099 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
2.494-6.757 None None O
) None None O
and None None O
good None None O
perception None None I-FUNC
of None None O
quality None None O
of None None O
life None None O
( None None O
OR None None O
= None None O
1.276 None None O
, None None O
95 None None O
% None None O
CI None None O
= None None O
1.109-1.471 None None O
) None None O
. None None O

The None None O
m-URS None None O
technique None None O
is None None O
feasible None None O
, None None O
simple None None O
and None None O
effective None None O
for None None O
the None None O
treatment None None O
of None None O
pelvic None None O
ureteral None None O
lithiasis None None O
in None None O
women None None O
and None None O
optimizes None None O
minimal None None O
invasion None None O
, None None O
with None None O
results None None O
that None None O
can None None O
be None None O
comparable None None O
to None None O
conventional None None O
endoscopic None None O
techniques None None O
in None None O
terms None None O
of None None O
ease None None O
of None None O
access None None O
and None None O
quality None None O
of None None O
endoscopic None None O
vision None None I-FUNC
without None None O
affecting None None O
the None None O
resolution None None O
capacity None None O
. None None O

The None None O
study None None O
group None None O
was None None O
a None None O
consecutive None None O
series None None O
of None None O
5526 None None O
patients None None O
who None None O
had None None O
CEA None None O
for None None O
symptomatic None None O
carotid None None I-DISEASE
artery None None I-DISEASE
stenosis None None I-DISEASE
during None None O
a None None O
4.5 None None O
year None None O
period None None O
. None None O

The None None O
30 None None O
day None None O
combined None None O
stroke None None I-DISEASE
and None None O
death None None O
rate None None O
was None None O
3.5 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
1.69-6.99 None None O
) None None O
for None None O
those None None O
having None None O
IVT None None O
+ None None O
CEA None None O
, None None O
4.1 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
3.46-4.39 None None O
) None None O
for None None O
those None None O
having None None O
CEA None None O
without None None O
previous None None O
IVT None None O
( None None O
odds None None O
ratio None None O
0.84 None None O
[ None None O
95 None None O
% None None O
CI None None O
0.39-1.81 None None O
] None None O
) None None O
, None None O
3.4 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
1.33-8.39 None None O
) None None O
for None None O
those None None O
having None None O
IVT None None O
+ None None O
CEA None None O
within None None O
14 None None O
days None None O
, None None O
and None None O
5.1 None None O
% None None O
( None None O
95 None None O
% None None O
CI None None O
1.74-13.91 None None O
) None None O
for None None O
those None None O
having None None O
IVT None None O
+ None None O
CEA None None O
within None None O
7 None None O
days None None O
. None None O

Despite None None O
its None None O
weaknesses None None O
, None None O
this None None O
study None None O
reasserts None None O
that None None O
CEA None None O
can None None O
be None None O
performed None None O
within None None O
the None None O
recommended None None O
2 None None O
weeks None None O
of None None O
the None None O
onset None None O
of None None O
symptoms None None O
and None None O
IVT None None O
without None None O
increasing None None O
the None None O
risk None None O
of None None O
peri-operative None None O
stroke None None I-DISEASE
or None None O
death None None O
. None None O

Results None None O
obtained None None O
for None None O
these None None O
heavy None None O
metals None None O
in None None O
all None None O
samples None None O
were None None O
lower None None O
than None None O
the None None O
corresponding None None O
limits None None O
, None None O
whereas None None O
arsenic None None O
and None None O
mercury None None O
contents None None O
might None None O
raise None None O
some None None O
attention None None I-FUNC
. None None O

To None None O
describe None None O
the None None O
clinical None None O
, None None O
pathological None None O
, None None O
and None None O
genetic None None O
features None None O
of None None O
three None None O
sib-pairs None None O
of None None O
pathologically-confirmed None None O
progressive None None I-DISEASE
supranuclear None None I-DISEASE
palsy None None I-DISEASE
( None None O
PSP None None O
) None None O
. None None O

Inclusion None None O
criteria None None O
were None None O
diagnosis None None O
of None None O
PD None None O
and None None O
any None None O
current None None O
pharmacological None None O
treatment None None O
of None None O
PD None None O
while None None O
exclusion None None O
criteria None None O
were None None O
evident None None O
cognitive None None O
or None None O
depressive None None O
impairment None None O
, None None O
infusion None None O
with None None O
dopamine None None I-TRANS
agonists None None O
or None None O
Duodopa None None O
, None None O
or None None O
Deep None None O
Brain None None O
Stimulation None None O
therapy None None O
. None None O

Hyperalgesic None None O
FM None None O
had None None O
a None None O
significantly None None O
lower None None O
FIQ None None O
score None None O
than None None O
the None None O
somatoform None None I-DISEASE
disorder None None I-DISEASE
and None None O
depressive None None O
subtypes None None O
. None None O

Previous None None O
research None None O
has None None O
consistently None None O
indicated None None O
that None None O
theory None None I-FUNC
of None None I-FUNC
mind None None I-FUNC
( None None O
ToM None None O
) None None O
is None None O
associated None None O
with None None O
executive None None O
control None None O
in None None O
the None None O
preschool None None O
years None None O
. None None O

We None None O
review None None O
the None None O
epidemiology None None O
and None None O
pathophysiology None None O
that None None O
link None None O
CKD None None O
and None None O
stroke None None I-DISEASE
and None None O
the None None O
impact None None O
of None None O
CKD None None O
on None None O
stroke None None I-DISEASE
outcomes None None O
. None None O

In None None O
general None None O
, None None O
the None None O
ability None None O
to None None O
mount None None O
T None None O
dependent None None O
antibody None None O
responses None None O
after None None O
injury None None O
are None None O
intact None None O
, None None O
as None None O
are None None O
pre-existing None None O
memory None None I-FUNC
B None None O
cell None None O
pools None None O
and None None O
antibody None None O
levels None None O
. None None O

T2 None None O
hypodensity None None O
in None None O
the None None O
globus None None I-REGION
pallidus None None I-REGION
is None None O
a None None O
characteristic None None O
radiographic None None O
sign None None O
of None None O
neurodegeneration None None O
with None None O
iron None None O
accumulation None None O
in None None O
the None None O
brain None None O
that None None O
is None None O
observed None None O
in None None O
GM1 None None O
gangliosidosis None None I-DISEASE
, None None O
but None None O
the None None O
exact None None O
timing None None O
when None None O
this None None O
radiographic None None O
sign None None O
becomes None None O
apparent None None O
remains None None O
to None None O
be None None O
elucidated None None O
. None None O

A None None O
retrospective None None O
review None None O
of None None O
neuroimaging None None O
studies None None O
revealed None None O
that None None O
the None None O
two None None O
patients None None O
had None None O
strikingly None None O
similar None None O
clinical None None O
courses None None O
and None None O
radiographic None None O
progressions None None O
with None None O
cortical None None O
atrophy None None O
that None None O
preceded None None O
the None None O
T2 None None O
hypointensity None None O
in None None O
the None None O
globus None None I-REGION
pallidus None None I-REGION
. None None O

PCOPD None None O
patients None None O
showed None None O
increased None None O
presence None None O
of None None O
fever None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.05 None None O
) None None O
, None None O
lower None None O
blood None None O
pressure None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
more None None O
laboratory None None O
abnormalities None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.05 None None O
; None None O
leukocytosis None None O
, None None O
elevated None None O
CRP None None O
, None None O
low None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
) None None O
and None None O
increased None None O
presence None None O
of None None O
crepitus None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.01 None None O
) None None O
. None None O

Within None None O
Yoga None None O
group None None O
, None None O
there None None O
was None None O
significant None None O
decrease None None O
in None None O
perceived None None O
stress None None O
( None None O
p None None O
= None None O
0.001 None None O
) None None O
, None None O
anxiety None None O
( None None O
p None None O
= None None O
0.001 None None O
) None None O
, None None O
depression None None I-DISEASE
( None None O
p None None O
= None None O
0.001 None None O
) None None O
, None None O
and None None O
negative None None O
affect None None O
( None None O
p None None O
= None None O
0.03 None None O
) None None O
while None None O
in None None O
the None None O
control None None O
group None None O
there None None O
was None None O
reduction None None O
( None None O
p None None O
= None None O
0.003 None None O
) None None O
only None None O
in None None O
scores None None O
on None None O
anxiety None None O
. None None O

The None None O
patient None None O
was None None O
managed None None O
uniquely None None O
by None None O
pulmonary None None O
endarterectomy None None O
( None None O
PEA None None I-TRANS
) None None O
and None None O
combination None None O
antifungal None None O
chemotherapy None None O
with None None O
Liposomal None None O
amphotericin-B None None O
+ None None O
caspofungin None None O
. None None O

Even None None O
though None None O
the None None O
clinical None None O
picture None None O
suggested None None O
pulmonary None None O
embolism None None I-DISEASE
, None None O
a None None O
subtle None None O
sign None None O
was None None O
missed None None O
from None None O
the None None O
first None None O
chest None None O
X-ray None None O
taken None None O
in None None O
the None None O
emergency None None O
department None None O
. None None O

Systemic None None O
embolism None None I-DISEASE
is None None O
one None None O
of None None O
the None None O
dreaded None None O
complications None None O
of None None O
PTMC None None O
, None None O
which None None O
is None None O
reported None None O
in None None O
0.5-5 None None O
% None None O
of None None O
cases None None O
and None None O
involves None None O
cerebral None None O
circulation None None O
in None None O
1 None None O
% None None O
of None None O
cases None None O
. None None O

We None None O
report None None O
an None None O
unusual None None O
case None None O
of None None O
acute None None O
stroke None None I-DISEASE
due None None O
embolization None None O
of None None O
mitral None None O
valve None None O
tissue None None O
during None None O
PTMC None None O
. None None O

The None None O
prognosis None None O
in None None O
patients None None O
with None None O
single None None O
coronary None None O
varies None None O
according None None O
to None None O
the None None O
anatomic None None O
distribution None None O
and None None O
associated None None O
coronary None None O
atherosclerosis None None I-DISEASE
. None None O

No None None O
effects None None O
are None None O
found None None O
on None None O
depression None None I-DISEASE
and None None O
cognitive None None O
capacity None None O
. None None O

Our None None O
data None None O
show None None O
that None None O
LTB4 None None O
engagement None None O
of None None O
BLT1 None None O
and None None O
BLT2 None None O
receptors None None I-PROTEIN
on None None O
osteoclast None None O
precursors None None O
leads None None O
to None None O
activation None None O
of None None O
phospholipase None None I-PROTEIN
C None None I-PROTEIN
and None None O
calcium None None O
release-activated None None O
channel-mediated None None O
intracellular None None O
calcium None None O
flux None None O
, None None O
which None None O
can None None O
activate None None O
further None None O
LTB4 None None O
autocrine None None O
production None None O
. None None O

Multivariate None None O
analysis None None O
showed None None O
that None None O
lymphedema None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.0005 None None O
) None None O
, None None O
chronic None None O
venous None None O
insufficiency None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.0005 None None O
) None None O
, None None O
peripheral None None O
vascular None None O
disease None None O
( None None O
P None None O
= None None O
.002 None None O
) None None O
, None None O
and None None O
deep None None O
vein None None O
thrombosis None None I-DISEASE
( None None O
P None None O
= None None O
.008 None None O
) None None O
predicted None None O
for None None O
recurrence None None O
. None None O

Among None None O
diabetic None None O
patients None None O
without None None O
history None None O
of None None O
insulin None None I-PROTEIN
use None None O
, None None O
frequent None None O
use None None O
of None None O
thiazolidinedione None None O
was None None O
associated None None O
with None None O
lower None None O
risk None None O
of None None O
psoriasis None None O
( None None O
adjusted None None O
odds None None O
ratio None None O
0.87 None None O
, None None O
95 None None O
% None None O
CI None None O
0.77-0.99 None None O
) None None O
. None None O

Among None None O
diabetic None None O
patients None None O
, None None O
regular None None O
insulin None None I-PROTEIN
use None None O
is None None O
associated None None O
with None None O
psoriasis None None O
development None None O
. None None O

Linear None None O
Ubiquitin None None O
chain None None O
Assembly None None O
Complex None None O
( None None O
LUBAC None None O
) None None O
is None None O
an None None O
E3 None None O
ligase None None I-PROTEIN
complex None None O
that None None O
generates None None O
linear None None O
ubiquitin None None O
chains None None O
and None None O
is None None O
important None None O
for None None O
tumour None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
signaling None None O
activation None None O
. None None O

Gestational None None O
diabetes None None O
mellitus None None O
( None None O
GDM None None O
) None None O
is None None O
characterised None None O
by None None O
maternal None None O
glucose None None O
intolerance None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
during None None O
pregnancy None None O
. None None O

Furthermore None None O
, None None O
myostatin None None O
protein None None O
expression None None O
( None None O
Western None None O
blot None None O
) None None O
was None None O
studied None None O
in None None O
placentae None None O
of None None O
pregnant None None O
women None None O
with None None O
GDM None None O
( None None O
treated None None O
with None None O
diet None None O
or None None O
insulin None None I-PROTEIN
) None None O
compared None None O
to None None O
placentae None None O
of None None O
NGT None None O
women None None O
. None None O

Demographic None None O
, None None O
medical None None O
and None None O
surgical None None O
factors None None O
were None None O
also None None O
measured None None O
, None None O
along None None O
with None None O
depression None None I-DISEASE
, None None O
social None None O
support None None O
and None None O
health-related None None O
quality None None O
of None None O
life None None O
. None None O

Depression None None I-DISEASE
is None None O
a None None O
major None None O
cause None None O
of None None O
morbidity None None O
and None None O
cost None None O
in None None O
primary None None O
care None None O
patient None None O
populations None None O
. None None O

All None None O
five None None O
implementation None None O
capability None None O
measures None None O
independently None None O
predicted None None O
practice None None O
leaders None None O
' None None O
relative None None O
commitment None None O
to None None O
improving None None O
depression None None I-DISEASE
care None None O
in None None O
the None None O
following None None O
year None None O
. None None O

Higher None None O
relative None None O
commitment None None O
( None None O
p None None O
= None None O
0.002 None None O
) None None O
and None None O
prior None None O
depression None None I-DISEASE
quality None None O
improvement None None O
activities None None O
appeared None None O
to None None O
be None None O
associated None None O
with None None O
earlier None None O
participation None None O
in None None O
the None None O
DIAMOND None None O
initiative None None O
. None None O

Practice None None O
leaders None None O
' None None O
relative None None O
commitment None None O
to None None O
depression None None I-DISEASE
care None None O
improvement None None O
may None None O
be None None O
a None None O
useful None None O
measure None None O
of None None O
the None None O
likelihood None None O
that None None O
a None None O
practice None None O
is None None O
ready None None O
to None None O
initiate None None O
evidence-based None None O
depression None None I-DISEASE
care None None O
changes None None O
. None None O

Recent None None O
studies None None O
demonstrated None None O
the None None O
expression None None O
of None None O
several None None O
potassium None None I-PROTEIN
channels None None I-PROTEIN
in None None O
the None None O
inner None None O
mitochondrial None None O
membrane None None O
. None None O

Using None None O
these None None O
mitochondrial None None O
Ca None None O
( None None O
2+ None None O
) None None O
indicators None None O
, None None O
our None None O
results None None O
show None None O
that None None O
mitochondrial None None O
Ca None None O
( None None O
2+ None None O
) None None O
uptake None None O
in None None O
individual None None O
mitochondria None None O
in None None O
cultured None None O
astrocytes None None O
and None None O
neurons None None O
can None None O
be None None O
seen None None O
after None None O
stimulations None None O
by None None O
ATP None None O
and None None O
glutamate None None I-TRANS
, None None O
respectively None None O
. None None O

Combined None None O
with None None O
molecular None None O
intervention None None O
in None None O
Ca None None O
( None None O
2+ None None O
) None None O
signaling None None O
pathway None None O
, None None O
our None None O
results None None O
demonstrated None None O
that None None O
the None None O
mitochondrial None None O
Ca None None O
( None None O
2+ None None O
) None None O
uptake None None O
is None None O
tightly None None O
coupled None None O
with None None O
inositol None None O
1,4,5-trisphosphate None None O
receptor-mediated None None O
Ca None None O
( None None O
2+ None None O
) None None O
release None None O
from None None O
the None None O
endoplasmic None None O
reticulum None None O
and None None O
the None None O
activation None None O
of None None O
G None None O
protein-coupled None None O
receptors None None I-PROTEIN
. None None O

EC None None O
monitoring None None O
by None None O
culturable None None O
methods None None O
is None None O
not None None O
by None None O
itself None None O
a None None O
suitable None None O
method None None O
for None None O
assessing None None O
the None None O
hygienization None None O
achieved None None O
in None None O
sludge None None O
as None None O
EC None None O
can None None O
enter None None O
into None None O
VBNC None None O
from None None O
which None None O
it None None O
can None None O
recover None None O
during None None O
the None None O
first None None O
hours None None O
of None None O
storage None None I-FUNC
. None None O

This None None O
study None None O
aimed None None O
to None None O
evaluate None None O
whether None None O
multiple None None O
sclerosis None None O
( None None O
MS None None O
) None None O
increases None None O
stroke None None I-DISEASE
risk None None O
. None None O

Both None None O
cohorts None None O
were None None O
followed None None O
up None None O
until None None O
the None None O
occurrence None None O
of None None O
stroke None None I-DISEASE
or None None O
censor None None O
. None None O

The None None O
hazard None None O
ratio None None O
( None None O
HR None None O
) None None O
of None None O
stroke None None I-DISEASE
was None None O
assessed None None O
using None None O
a None None O
Cox None None O
proportional None None O
hazards None None O
regression None None O
model None None O
. None None O

Amongst None None O
participants None None O
without None None O
comorbidities None None O
, None None O
the None None O
MS None None O
cohort None None O
was None None O
still None None O
at None None O
a None None O
greater None None O
stroke None None I-DISEASE
risk None None O
than None None O
the None None O
control None None O
cohort None None O
[ None None O
HR None None O
4.93 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
2.85-8.55 None None O
] None None O
. None None O

Multiple None None O
sclerosis None None O
is None None O
declared None None O
to None None O
be None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
in None None O
developing None None O
stroke None None I-DISEASE
, None None O
which None None O
requires None None O
closer None None O
attention None None I-FUNC
to None None O
this None None O
group None None O
of None None O
patients None None O
for None None O
stroke None None I-DISEASE
prevention None None O
, None None O
especially None None O
in None None O
the None None O
younger None None O
population None None O
. None None O

The None None O
mechanism None None O
of None None O
action None None O
is None None O
thought None None O
to None None O
be None None O
stimulation None None O
of None None O
mitochondrial None None O
respiration None None O
in None None O
muscles None None O
, None None O
and None None O
to None None O
increase None None O
adenosine None None I-TRANS
triphosphate None None I-TRANS
( None None O
ATP None None O
) None None O
needed None None O
to None None O
perform None None O
exercise None None O
. None None O

In None None O
contrast None None O
, None None O
E6 None None O
proteins None None O
from None None O
HPV None None O
types None None O
detected None None O
in None None O
skin None None O
warts None None O
or None None O
cancer None None O
, None None O
notably None None O
10 None None O
, None None O
49 None None O
and None None O
38 None None O
, None None O
attenuated None None O
UVB None None O
induced None None O
protective None None O
responses None None O
in None None O
PHKs None None O
including None None O
cell None None O
death None None O
, None None O
proliferation None None O
arrest None None O
and None None O
accumulation None None O
of None None O
the None None O
proapoptotic None None O
proteins None None O
, None None O
p53 None None I-PROTEIN
, None None O
bax None None O
or None None O
bak None None O
. None None O

Such None None O
a None None O
high None None O
rate None None O
would None None O
require None None O
coordination None None O
of None None O
motor None None O
movements None None I-FUNC
at None None O
millisecond None None O
timescale None None O
. None None O

Here None None O
, None None O
by None None O
using None None O
sequence None None O
alignments None None O
, None None O
structural None None O
modeling None None O
, None None O
combinatorial None None O
mutagenesis None None O
, None None O
and None None O
recombinational None None O
rescue None None O
, None None O
we None None O
replaced None None O
all None None O
nine None None O
cysteines None None I-TRANS
of None None O
gp17 None None O
and None None O
introduced None None O
single None None O
cysteines None None I-TRANS
at None None O
defined None None O
positions None None O
. None None O

The None None O
ATPase None None I-PROTEIN
Walker None None O
B None None O
motif None None O
, None None O
thus None None O
, None None O
may None None O
be None None O
redefined None None O
as None None O
`` None None O
β-strand None None O
( None None O
4-6 None None O
hydrophobic-rich None None O
amino None None I-TRANS
acids None None I-TRANS
) None None O
-DE-hydrophobic/nonpolar None None O
amino None None O
acid None None O
'' None None O
. None None O

We None None O
propose None None O
that None None O
in None None O
some None None O
peanut-allergic None None O
patients None None O
( None None O
depending None None O
on None None O
history None None O
of None None O
reactivity None None O
to None None O
trace None None O
levels None None O
of None None O
peanut None None O
, None None O
reaction None None O
severity None None O
, None None O
other None None O
medical None None O
conditions None None O
, None None O
willingness None None O
to None None O
always None None O
carry None None O
adrenaline None None I-TRANS
, None None O
etc None None O
. None None O

First-generation None None O
mechanical None None O
thrombectomy None None O
devices None None O
such None None O
as None None O
the None None O
MERCI None None O
Retriever None None O
( None None O
Stryker None None O
, None None O
Kalamazoo None None O
, None None O
MI None None O
, None None O
USA None None O
) None None O
and None None O
Penumbra None None O
aspiration None None O
device None None O
( None None O
Penumbra None None O
Inc. None None O
, None None O
Alameda None None O
, None None O
CA None None O
, None None O
USA None None O
) None None O
demonstrated None None O
safety None None O
and None None O
higher None None O
rates None None O
of None None O
recanalisation None None O
in None None O
the None None O
MERCI None None O
and None None O
Penumbra None None O
Pivotal None None O
Stroke None None I-DISEASE
Trial None None O
; None None O
however None None O
, None None O
there None None O
was None None O
no None None O
significant None None O
improvement None None O
in None None O
clinical None None O
outcome None None O
. None None O

In None None O
preliminary None None O
trials None None O
, None None O
SOLITAIRE None None O
with None None O
the None None O
Intention None None O
for None None O
Thrombectomy None None O
( None None O
SWIFT None None O
) None None O
and None None O
Thrombectomy None None O
Revascularization None None O
of None None O
Large None None O
Vessel None None O
Occlusions None None O
( None None O
TREVO None None O
) None None O
, None None O
both None None O
showed None None O
rates None None O
of None None O
recanalisation None None O
close None None O
to None None O
90 None None O
% None None O
and None None O
significantly None None O
improved None None O
clinical None None O
outcomes None None O
compared None None O
with None None O
the None None O
MERCI None None O
study None None O
, None None O
but None None O
the None None O
recent None None O
landmark None None O
studies None None O
for None None O
endovascular None None O
treatment None None O
( None None O
Interventional None None O
Management None None O
of None None O
Stroke None None I-DISEASE
( None None O
IMS None None O
III None None O
) None None O
, None None O
Mechanical None None O
Retrieval None None O
and None None O
Recanalisation None None O
of None None O
Stroke None None I-DISEASE
Clots None None O
Using None None O
Embolectomy None None O
( None None O
MR-RESCUE None None O
) None None O
and None None O
SYNTHESIS None None O
) None None O
did None None O
not None None O
show None None O
any None None O
clinical None None O
benefit None None O
from None None O
endovascular None None O
treatment None None O
compared None None O
with None None O
standard None None O
intravenous None None O
therapy None None O
. None None O

Overall None None O
, None None O
although None None O
evidence None None O
regarding None None O
the None None O
efficacy None None O
of None None O
endovascular None None O
treatment None None O
in None None O
acute None None O
stroke None None I-DISEASE
has None None O
been None None O
equivocal None None O
, None None O
recent None None O
publications None None O
of None None O
large None None O
multicentre None None O
randomised None None O
controlled None None O
trials None None O
indicate None None O
benefit None None O
of None None O
intra-arterial None None O
stent None None O
retriever None None O
reperfusion None None O
in None None O
patients None None O
selected None None O
by None None O
appropriate None None O
imaging None None O
and None None O
treated None None O
early None None O
by None None O
experienced None None O
operators None None O
, None None O
and None None O
it None None O
will None None O
likely None None O
remain None None O
an None None O
important None None O
adjunct None None O
to None None O
established None None O
medical None None O
treatment None None O
with None None O
intravenous None None O
tPA None None O
. None None O

The None None O
authors None None O
examined None None O
negative None None O
and None None O
positive None None O
emotion None None I-FUNC
regulation None None O
patterns None None O
, None None O
as None None O
well None None O
as None None O
the None None O
BAS-relevant None None O
cognitive None None O
style None None O
of None None O
self-criticism None None O
, None None O
as None None O
potential None None O
mechanisms None None O
through None None O
which None None O
a None None O
hypersensitive None None O
BAS None None O
might None None O
be None None O
related None None O
to None None O
NSSI None None O
frequency None None O
. None None O

Results None None O
indicated None None O
that None None O
self-criticism None None O
and None None O
positive None None O
emotion None None I-FUNC
dampening None None O
independently None None O
mediated None None O
the None None O
relationship None None O
between None None O
BAS None None O
and None None O
last-year None None O
frequency None None O
of None None O
NSSI None None O
. None None O

To None None O
investigate None None O
the None None O
associations None None O
between None None O
the None None O
2 None None O
main None None O
components None None O
of None None O
metabolic None None O
acidosis None None O
( None None O
unmeasured None None O
anions None None O
[ None None O
UA None None O
] None None O
and None None O
hyperchloremia None None O
) None None O
with None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
and None None O
intact None None O
parathormone None None O
( None None O
iPTH None None O
) None None O
in None None O
patients None None O
with None None O
advanced None None O
chronic None None O
kidney None None O
disease None None O
. None None O

Considering None None O
the None None O
main None None O
acid-base None None O
status None None O
determinants None None O
, None None O
only None None O
UA None None O
had None None O
a None None O
significant None None O
correlation None None O
with None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
( None None O
r None None O
= None None O
-0.278 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Our None None O
data None None O
brings None None O
further None None O
knowledge None None O
on None None O
the None None O
associations None None O
between None None O
metabolic None None O
acidosis None None O
with None None O
bone None None O
disorders None None O
and None None O
nutritional None None O
status None None O
, None None O
suggesting None None O
that None None O
the None None O
two None None O
main None None O
metabolic None None O
acidosis None None O
components None None O
( None None O
UA None None O
and None None O
hyperchloremia None None O
) None None O
have None None O
different None None O
effects None None O
on None None O
serum None None O
parathormone None None O
and None None O
serum None None I-PROTEIN
albumin None None I-PROTEIN
. None None O

Although None None O
N-terminal None None O
pro-B-type None None O
natriuretic None None I-TRANS
peptide None None I-TRANS
( None None O
NT-proBNP None None O
) None None O
has None None O
a None None O
strong None None O
relationship None None O
with None None O
incident None None O
cardiovascular None None O
disease None None O
( None None O
CVD None None O
) None None O
, None None O
few None None O
studies None None O
have None None O
examined None None O
whether None None O
NT-proBNP None None O
adds None None O
to None None O
risk None None O
prediction None None O
algorithms None None O
, None None O
particularly None None O
in None None O
women None None O
. None None O

Using None None O
a None None O
prospective None None O
case-cohort None None O
within None None O
the None None O
WHI None None O
( None None O
Women None None O
's None None O
Health None None O
Initiative None None O
) None None O
observational None None O
study None None O
, None None O
we None None O
selected None None O
1,821 None None O
incident None None O
cases None None O
of None None O
CVD None None O
( None None O
746 None None O
myocardial None None O
infarctions None None O
, None None O
754 None None O
ischemic None None O
strokes None None I-DISEASE
, None None O
160 None None O
hemorrhagic None None O
strokes None None I-DISEASE
, None None O
and None None O
161 None None O
other None None O
cardiovascular None None O
[ None None O
CV None None O
] None None O
deaths None None O
) None None O
and None None O
a None None O
randomly None None O
selected None None O
reference None None O
cohort None None O
of None None O
1,992 None None O
women None None O
without None None O
CVD None None O
at None None O
baseline None None O
. None None O

This None None O
study None None O
tested None None O
the None None O
hypothesis None None O
that None None O
serum None None O
DHEA None None O
and None None O
DHEA-S None None O
are None None O
predictors None None O
of None None O
major None None O
coronary None None O
heart None None O
disease None None O
( None None O
CHD None None O
) None None O
and/or None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
( None None O
CBD None None O
) None None O
events None None O
in None None O
a None None O
large None None O
cohort None None O
of None None O
elderly None None O
men None None O
. None None O

Immediately None None O
after None None O
implantation None None O
, None None O
systemic None None O
arterial None None O
pressure None None O
and None None O
stroke None None I-DISEASE
volume None None O
increased None None O
and None None O
pulmonary None None O
pressure None None O
decreased None None O
dramatically None None O
. None None O

The None None O
present None None O
study None None O
was None None O
carried None None O
out None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
a None None O
single None None O
systemic None None O
administration None None O
of None None O
CP55,940 None None O
, None None O
a None None O
potent None None O
synthetic None None O
agonist None None O
of None None O
cannabinoid None None O
receptors None None I-PROTEIN
, None None O
on None None O
spatial None None I-FUNC
memory None None I-FUNC
retrieval None None O
assessed None None O
in None None O
a None None O
Morris None None O
water None None O
maze None None O
. None None O

CP55,940 None None O
was None None O
given None None O
intraperitoneally None None O
once None None O
, None None O
at None None O
doses None None O
of None None O
0.025 None None O
, None None O
0.125 None None O
or None None O
0.25mg/kg None None O
on None None O
the None None O
fourth None None O
day None None O
, None None O
30min None None O
before None None O
testing None None O
memory None None I-FUNC
retrieval None None O
, None None O
and None None O
in None None O
separate None None O
groups None None O
before None None O
testing None None O
psychomotor None None O
activity None None O
and None None O
anxiety None None O
level None None O
in None None O
a None None O
hole-board None None O
test None None O
. None None O

Since None None O
the None None O
attenuated None None O
psychomotor None None O
activity None None O
after None None O
a None None O
dose None None O
of None None O
0.125mg/kg None None O
did None None O
not None None O
interfere None None O
with None None O
memory None None I-FUNC
retrieval None None O
, None None O
we None None O
assume None None O
that None None O
the None None O
impairment None None O
of None None O
spatial None None I-FUNC
memory None None I-FUNC
observed None None O
after None None O
the None None O
highest None None O
dose None None O
of None None O
CP55,940 None None O
( None None O
0.25mg/kg None None O
) None None O
was None None O
exerted None None O
by None None O
its None None O
influence None None O
on None None O
cognitive None None O
processes None None O
, None None O
however None None O
, None None O
the None None O
impact None None O
on None None O
locomotion None None O
could None None O
not None None O
be None None O
excluded None None O
. None None O

In None None O
this None None O
work None None O
we None None O
investigated None None O
whether None None O
phenytoin None None O
( None None O
PHT None None O
) None None O
, None None O
could None None O
induce None None O
efflux None None O
transporters None None I-PROTEIN
overexpression None None O
, None None O
at None None O
different None None O
biological None None O
barriers None None O
and None None O
to None None O
evaluate None None O
the None None O
implication None None O
it None None O
could None None O
have None None O
on None None O
its None None O
pharmacokinetics None None O
and None None O
therapeutic/toxic None None O
response None None O
. None None O

Overexpression None None O
of None None O
efflux None None O
transporters None None I-PROTEIN
can None None O
be None None O
mediated None None O
by None None O
inducer None None O
agents None None O
like None None O
PHT None None O
in None None O
a None None O
local-concentration None None O
dependent None None O
manner None None O
, None None O
and None None O
it None None O
is None None O
reversible None None O
once None None O
the None None O
substance None None O
is None None O
removed None None O
from None None O
the None None O
body None None O
. None None O

Activation None None O
of None None O
histamine None None I-TRANS
H1 None None O
receptor None None I-PROTEIN
( None None O
H1R None None O
) None None O
is None None O
a None None O
well-known None None O
hallmark None None O
of None None O
allergic None None O
and None None O
inflammatory None None O
pathology None None O
. None None O

Here None None O
we None None O
use None None O
an None None O
experimental None None O
model None None O
of None None O
rat None None O
paw None None O
oedema None None O
formation None None O
to None None O
examine None None O
the None None O
effect None None O
of None None O
exogenously None None O
added None None O
histamine None None I-TRANS
on None None O
the None None O
gene None None O
expression None None O
of None None O
H1R None None O
and None None O
bradykinin None None O
receptors None None I-PROTEIN
B1R None None O
and None None O
B2R None None O
, None None O
alone None None O
or None None O
in None None O
combination None None O
to None None O
rupatadine None None O
, None None O
a None None O
second None None O
generation None None O
antihistamine None None O
agent None None O
. None None O

TRPV1 None None O
and None None O
ASIC3 None None O
proteins None None O
were None None O
expressed None None O
in None None O
dorsal None None I-NEURON
root None None O
ganglion None None O
in None None O
normal None None O
conditions None None O
, None None O
and None None O
1 None None O
% None None O
formalin None None O
injection None None O
increased None None O
expression None None O
of None None O
both None None O
proteins None None O
in None None O
this None None O
location None None O
at None None O
1 None None O
and None None O
6 None None O
days None None O
compared None None O
to None None O
naive None None O
rats None None O
. None None O

Nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
precursors None None O
, None None O
especially None None O
l-arginine None None O
, None None O
may None None O
have None None O
protective None None O
effects None None O
on None None O
tissue None None O
ischemia/reperfusion None None O
injury None None O
( None None O
IRI None None O
) None None O
; None None O
however None None O
, None None O
their None None O
molecular None None O
mechanisms None None O
are None None O
unclear None None O
. None None O

Pre-treatment None None O
with None None O
l-arginine None None O
( None None O
10 None None O
( None None O
-2 None None O
) None None O
M None None O
) None None O
alone None None O
or None None O
in None None O
combination None None O
with None None O
celecoxib None None O
significantly None None O
potentiated None None O
the None None O
acetylcholine None None I-TRANS
( None None O
Ach None None I-TRANS
) None None O
-induced None None O
relaxations None None O
in None None O
control None None O
and None None O
hypoxic None None O
rings None None O
. None None O

The None None O
aim None None O
of None None O
our None None O
study None None O
was None None O
to None None O
understand None None O
the None None O
mechanism None None O
of None None O
clinical None None O
efficacy None None O
of None None O
the None None O
combination None None O
of None None O
an None None O
antidepressant None None O
and None None O
risperidone None None O
in None None O
drug-resistant None None O
depression None None I-DISEASE
. None None O

Risperidone None None O
increased None None O
the None None O
cortical None None O
extracellular None None O
levels None None O
of None None O
DA None None O
, None None O
5-HT None None I-TRANS
and None None O
NA None None I-TRANS
. None None O

A None None O
combination None None O
of None None O
mirtazapine None None O
either None None O
at None None O
the None None O
higher None None O
dose None None O
( None None O
20mg/kg None None O
) None None O
or None None O
at None None O
both None None O
doses None None O
( None None O
10 None None O
and None None O
20mg/kg None None O
) None None O
with None None O
risperidone None None O
produced None None O
a None None O
significant None None O
effect None None O
on None None O
DA None None O
and None None O
NA None None I-TRANS
release None None O
, None None O
respectively None None O
compared None None O
to None None O
the None None O
effect None None O
of None None O
any None None O
drug None None O
given None None O
alone None None O
. None None O

Our None None O
data None None O
indicate None None O
that None None O
the None None O
increase None None O
of None None O
cortical None None O
extracellular None None O
levels None None O
of None None O
DA None None O
and None None O
NA None None I-TRANS
by None None O
combined None None O
administration None None O
of None None O
mirtazapine None None O
and None None O
risperidone None None O
may None None O
be None None O
of None None O
crucial None None O
importance None None O
to None None O
the None None O
pharmacotherapy None None O
of None None O
drug None None O
resistant None None O
depression None None I-DISEASE
, None None O
and None None O
that None None O
, None None O
among None None O
other None None O
mechanisms None None O
, None None O
5-HT1A None None O
, None None O
5-HT2A None None O
, None None O
α2-adrenergic None None O
and None None O
histamine None None I-TRANS
H1 None None O
receptors None None I-PROTEIN
may None None O
play None None O
some None None O
role None None O
in None None O
this None None O
effect None None O
. None None O

In None None O
vitro None None O
studies None None O
demonstrated None None O
that None None O
omentin None None O
induces None None O
vasorelaxation None None O
in None None O
isolated None None O
rat None None O
mesenteric None None O
arteries None None O
, None None O
and None None O
in None None O
vivo None None O
studies None None O
showed None None O
inhibition None None O
of None None O
agonist-induced None None O
increases None None O
in None None O
blood None None O
pressure None None O
, None None O
possibly None None O
mediated None None O
by None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
-dependent None None O
mechanisms None None O
. None None O

Amelioration None None O
of None None O
pathophysiological None None O
conditions None None O
by None None O
fisetin None None O
at None None O
different None None O
time None None O
points None None O
was None None O
measured None None O
by None None O
analysing None None O
the None None O
levels None None O
of None None O
expression None None O
of None None O
liver None None O
urea None None O
cycle None None O
enzymes None None I-PROTEIN
( None None O
carbamoyl None None O
phosphate None None O
synthetase-I None None O
( None None O
CPS-I None None O
) None None O
, None None O
ornithine None None I-PROTEIN
transcarbamoylase None None I-PROTEIN
( None None O
OTC None None O
) None None O
and None None O
argininosuccinate None None I-PROTEIN
synthetase None None I-PROTEIN
( None None O
ASS None None O
) None None O
) None None O
, None None O
nuclear None None O
transcription None None O
factor None None O
kappaB None None O
( None None O
NF-κB None None O
p65 None None O
) None None O
, None None O
brain None None O
glutamine None None I-TRANS
synthetase None None I-PROTEIN
( None None O
GS None None O
) None None O
and None None O
inducible None None O
nitric None None I-TRANS
oxide None None I-TRANS
synthase None None I-PROTEIN
( None None O
iNOS None None O
) None None O
by None None O
Western None None O
blot None None O
analysis None None O
. None None O

The None None O
temporal None None O
variation None None O
in None None O
the None None O
effect None None O
of None None O
fisetin None None O
could None None O
be None None O
due None None O
to None None O
the None None O
( None None O
i None None O
) None None O
chronopharmacological None None O
, None None O
chronopharmacokinetic None None O
properties None None O
of None None O
fisetin None None O
and None None O
( None None O
ii None None O
) None None O
modulations None None O
in None None O
the None None O
endogenous None None O
circadian None None O
rhythms None None O
of None None O
urea None None O
cycle None None O
enzymes None None I-PROTEIN
, None None O
brain None None O
markers None None O
, None None O
redox None None O
enzymes None None I-PROTEIN
and None None O
renal None None O
clearance None None O
during None None O
hyperammonaemia None None O
by None None O
fisetin None None O
. None None O

Effects None None O
of None None O
locally None None O
( None None O
intraplantar None None O
) None None O
remifentanil None None O
, None None O
NMDA None None O
and None None O
MK801 None None O
or None None O
their None None O
combinations None None O
were None None O
investigated None None O
by None None O
measuring None None O
the None None O
latencies None None O
, None None O
thresholds None None O
and None None O
two None None O
biochemical None None O
parameters None None O
( None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
and None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
NO None None O
) None None O
) None None O
, None None O
in None None O
streptozotocin None None O
induced None None O
diabetic None None O
rats None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
verify None None O
whether None None O
or None None O
not None None O
an None None O
increased None None O
prevalence None None O
of None None O
excessive None None O
daytime None None O
sleepiness None None O
( None None O
EDS None None O
) None None O
or None None O
EEG None None O
abnormalities None None O
is None None O
observed None None O
in None None O
patients None None O
with None None O
schizophrenia None None I-DISEASE
spectrum None None O
disorders None None O
( None None O
SSD None None O
) None None O
, None None O
and None None O
to None None O
compare None None O
the None None O
effects None None O
of None None O
second None None O
generation None None O
antipsychotics None None O
( None None O
SGA None None O
) None None O
on None None O
patients None None O
' None None O
daytime None None O
sleepiness None None O
level None None O
and None None O
EEG None None O
recordings None None O
. None None O

Patients None None O
with None None O
schizophrenia None None I-DISEASE
may None None O
compensate None None O
sedative None None O
effects None None O
of None None O
antipsychotic None None O
treatment None None O
with None None O
sleep None None O
duration None None O
prolongation None None O
and None None O
report None None O
even None None O
less None None O
sleepiness None None O
than None None O
non-psychotic None None O
patients None None O
. None None O

The None None O
chemopreventive None None O
action None None O
of None None O
celecoxib None None O
in None None O
colitis None None O
mediated None None O
colon None None O
carcinogenesis None None O
may None None O
include None None O
the None None O
regulation None None O
of None None O
DNA None None O
mismatch None None O
repair None None O
enzymes None None I-PROTEIN
, None None O
cell None None O
cycle None None O
check None None O
points None None O
, None None O
cell None None O
proliferation None None O
and None None O
apoptosis None None O
. None None O

Either None None O
rutin None None O
or None None O
naringin None None O
or None None O
hesperidin None None O
( None None O
50mg/kg None None O
each None None O
) None None O
was None None O
administered None None O
to None None O
L-T4-induced None None O
hyperthyroid None None O
rats None None O
for None None O
two None None O
weeks None None O
and None None O
their None None O
effects None None O
were None None O
evaluated None None O
on None None O
the None None O
alterations None None O
in None None O
levels None None O
of None None O
thyroid None None O
hormones None None I-PROTEIN
, None None O
5'-deiodinase None None O
I None None O
( None None O
5'DI None None O
) None None O
activity None None O
, None None O
hepatic None None O
lipid None None O
peroxidation None None O
as None None O
well None None O
as None None O
in None None O
antioxidants None None O
. None None O

Perindopril None None O
arginine None None I-TRANS
( None None O
10mg/kg None None O
) None None O
raised None None O
the None None O
convulsive None None O
threshold None None O
for None None O
LEV None None O
administered None None O
at None None O
doses None None O
of None None O
100 None None O
, None None O
300 None None O
and None None O
500mg/kg None None O
. None None O

Kynurenic None None O
acid None None O
( None None O
KYNA None None O
) None None O
, None None O
a None None O
unique None None O
tryptophan None None I-TRANS
derivative None None O
, None None O
displays None None O
pleiotropic None None O
effects None None O
including None None O
blockade None None O
of None None O
ionotropic None None O
glutamate None None I-TRANS
and None None O
α7 None None O
nicotinic None None O
receptors None None I-PROTEIN
. None None O

Five None None O
weeks None None O
later None None O
, None None O
KYNA None None O
content None None O
and None None O
the None None O
activity None None O
of None None O
semi-purified None None O
kynurenine None None O
aminotransferases None None O
( None None O
KATs None None O
) None None O
were None None O
measured None None O
in None None O
frontal None None I-REGION
cortex None None I-REGION
, None None O
hippocampus None None I-REGION
and None None O
striatum None None I-REGION
of None None O
diabetic None None O
and None None O
insulin-treated None None O
rats None None O
, None None O
using None None O
HPLC-based None None O
methods None None O
. None None O

Insulin None None I-PROTEIN
treatment None None O
normalized None None O
cortical None None O
but None None O
not None None O
hippocampal None None O
KAT None None O
II None None O
activity None None O
. None None O

Chronic None None O
quinolinic None None O
acid None None O
( None None O
QA None None O
) None None O
lesions None None O
in None None O
rats None None O
closely None None O
resemble None None O
Huntington None None I-DISEASE
's None None O
disease None None O
like None None O
conditions None None O
. None None O

Reports None None O
suggest None None O
that None None O
inhibition None None O
of None None O
adenosine None None I-TRANS
A2A None None O
receptor None None I-PROTEIN
function None None O
elicits None None O
neuroprotective None None O
effect None None O
in None None O
QA None None O
induced None None O
neurotoxicity None None O
in None None O
rats None None O
. None None O

The None None O
glossopharyngeal None None O
insufflation None None O
maneuver None None O
( None None O
lung None None O
packing None None O
) None None O
is None None O
largely None None O
performed None None O
by None None O
competitive None None O
breath-hold None None O
divers None None O
to None None O
improve None None O
their None None O
performance None None O
, None None O
despite None None O
observational None None O
evidence None None O
of None None O
fainting None None O
and None None O
loss None None O
of None None O
consciousness None None I-FUNC
in None None O
the None None O
first None None O
seconds None None O
of None None O
apnea None None O
. None None O

Individuals None None O
with None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
( None None O
BD None None O
) None None O
are None None O
differentially None None O
affected None None O
by None None O
overweight/obesity None None O
, None None O
chaotic None None O
eating None None O
patterns None None O
( None None O
e.g. None None O
, None None O
binge None None O
eating None None O
) None None O
, None None O
as None None O
well None None O
as None None O
cardiovascular None None O
morbidity None None O
and None None O
mortality None None O
. None None O

It None None O
is None None O
a None None O
current None None O
trend None None O
in None None O
psychiatry None None O
to None None O
discard None None O
the None None O
Kraepelinian None None O
dichotomy None None O
schizophrenia None None I-DISEASE
vs. None None O
manic-depressive None None O
illness None None O
and None None O
use None None O
the None None O
overinclusive None None O
label None None O
'psychosis None None O
' None None O
to None None O
broadly None None O
indicate None None O
the None None O
whole None None O
spectrum None None O
of None None O
severe None None O
mental None None O
disorders None None O
. None None O

We None None O
compare None None O
delusions None None O
in None None O
schizophrenia None None I-DISEASE
and None None O
major None None O
depression None None I-DISEASE
and None None O
demonstrate None None O
how None None O
these None None O
phenomena None None O
radically None None O
differ None None O
under None None O
these None None O
two None None O
psychopathological None None O
conditions None None O
. None None O

The None None O
prevalence None None O
of None None O
both None None O
parkinsonian None None O
signs None None O
and None None O
Parkinson None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
( None None O
PD None None O
) None None O
per None None O
se None None O
increases None None O
with None None O
age None None O
. None None O

Significant None None O
functional None None O
changes None None O
were None None O
predominantly None None O
seen None None O
in None None O
the None None O
external None None O
segment None None O
of None None O
the None None O
globus None None I-REGION
pallidus None None I-REGION
( None None O
GPe None None O
) None None O
in None None O
aged None None O
animals None None O
and None None O
in None None O
the None None O
striatum None None I-REGION
( None None O
caudate None None I-REGION
nucleus None None I-REGION
and None None O
putamen None None I-REGION
) None None O
in None None O
MPTP-lesioned None None O
animals None None O
. None None O

Laboratory None None O
results None None O
suggestive None None O
for None None O
rickets None None O
are None None O
elevated None None O
alkaline None None I-PROTEIN
phosphatase None None I-PROTEIN
and None None O
disturbances None None O
in None None O
calcium None None O
and None None O
phosphate None None O
homeostasis None None O
. None None O

MR None None O
spectra None None O
were None None O
recorded None None O
from None None O
a None None O
normal-appearing None None O
cerebellum None None I-REGION
region None None O
. None None O

In None None O
the None None O
cerebellum None None I-REGION
of None None O
the None None O
patients None None O
after None None O
HS None None O
, None None O
NAA/Cr None None O
ratios None None O
were None None O
found None None O
to None None O
be None None O
significantly None None O
decreased None None O
compared None None O
to None None O
normal None None O
controls None None O
( None None O
p None None O
= None None O
0.004 None None O
) None None O
and None None O
Cho/Cr None None O
ratios None None O
were None None O
found None None O
to None None O
be None None O
decreased None None O
compared None None O
to None None O
normal None None O
controls None None O
( None None O
p None None O
= None None O
0.032 None None O
) None None O
. None None O

Metabolite None None O
abnormalities None None O
were None None O
seen None None O
in None None O
normal-appearing None None O
cerebellum None None I-REGION
structures None None O
in None None O
patients None None O
after None None O
HS None None O
. None None O

The None None O
innate None None O
immune None None O
system None None O
recognizes None None O
pathogens None None O
via None None O
its None None O
pattern None None O
recognition None None O
receptors None None I-PROTEIN
. None None O

Thus None None O
, None None O
low None None O
frequency None None O
mechanical None None O
stimulation None None O
has None None O
qualitatively None None O
different None None O
effects None None O
on None None O
osteoclast None None O
formation None None O
compared None None O
to None None O
stimulation None None O
associated None None O
with None None O
the None None O
fundamental None None O
frequencies None None O
of None None O
normal None None O
movement None None I-FUNC
. None None O

In None None O
this None None O
context None None O
, None None O
the None None O
Sociedad None None O
Española None None O
de None None O
Geriatría None None O
y None None O
Gerontología None None O
( None None O
SEGG None None O
-- None None O
Spanish None None O
Geriatrics None None O
and None None O
Gerontology None None O
Society None None O
) None None O
, None None O
aware None None O
of None None O
the None None O
significance None None O
and None None O
transcendence None None O
of None None O
the None None O
issue None None O
, None None O
and None None O
in None None O
an None None O
attempt None None O
to None None O
preserve None None O
and None None O
guarantee None None O
maximum None None O
freedom None None O
, None None O
dignity None None O
and None None O
self-esteem None None O
, None None O
on None None O
the None None O
one None None O
hand None None O
, None None O
and None None O
to None None O
ensure None None O
the None None O
maximum None None O
integrity None None O
and None None O
legal None None O
certainty None None O
of None None O
the None None O
persons None None O
cared None None O
for None None O
in None None O
geriatric None None O
and None None O
gerontology None None O
services None None O
and None None O
centers None None O
, None None O
on None None O
the None None O
other None None O
, None None O
decided None None O
to None None O
create None None O
an None None O
`` None None O
Interdisciplinary None None O
Committee None None O
on None None O
Restraints None None O
'' None None O
made None None O
up None None O
by None None O
members None None O
from None None O
different None None O
disciplines None None O
and None None O
members None None O
of None None O
SEGG None None O
Working None None O
Groups None None O
or None None O
Committees None None O
, None None O
external None None O
health None None O
care None None O
workers None None O
, None None O
groups None None O
, None None O
organizations None None O
, None None O
and None None O
associations None None O
, None None O
who None None O
are None None O
experts None None O
in None None O
restraints None None O
, None None O
as None None O
well None None O
as None None O
the None None O
main None None O
`` None None O
anti-restraint None None O
'' None None O
movements None None I-FUNC
. None None O

There None None O
is None None O
a None None O
wide None None O
variation None None O
in None None O
the None None O
choice None None O
of None None O
general None None O
batteries None None O
of None None O
tests None None O
for None None O
the None None O
assessment None None O
of None None O
dementia None None I-DISEASE
( None None O
CAMCOG-R None None O
, None None O
ADAS-Cog None None O
, None None O
abbreviated None None O
Barcelona None None O
Test None None O
) None None O
, None None O
and None None O
of None None O
the None None O
use None None O
of None None O
specific None None O
tests None None O
and None None O
a None None O
severe None None O
impairment None None O
battery None None O
. None None O

Much None None O
attention None None I-FUNC
has None None O
been None None O
focused None None O
on None None O
thermoplastic None None O
polyurethanes None None O
in None None O
view None None O
of None None O
their None None O
generally None None O
good None None O
physico-chemical None None O
properties None None O
and None None O
versatility None None O
in None None O
processing None None O
, None None O
coupled None None O
with None None O
the None None O
improving None None O
biocompatibility None None O
and None None O
stability None None O
of None None O
recent None None O
formulations None None O
. None None O

in None None O
absence None None O
of None None O
plasma None None I-PROTEIN
proteins None None I-PROTEIN
) None None O
with None None O
hydrophilic None None O
and None None O
silanized-glass None None O
activators None None O
spanning None None O
the None None O
observable None None O
range None None O
of None None O
water None None O
wettability None None O
( None None O
hydrophilic None None O
to None None O
hydrophobic None None O
) None None O
, None None O
shows None None O
no None None O
evidence None None O
of None None O
proteolytic None None O
cleavage None None O
of None None O
FXII None None O
into None None O
αFXIIa None None O
or None None O
βFXIIa None None O
. None None O

suppress None None O
creation None None O
of None None O
enzymes None None I-PROTEIN
with None None O
procoagulant None None O
potential None None O
) None None O
. None None O

Hereditary None None O
tyrosinemia None None O
is None None O
an None None O
autosomal None None O
recessive None None O
inherited None None O
disease None None O
that None None O
manifests None None O
as None None O
three None None O
types None None O
( None None O
types None None O
I-III None None O
) None None O
. None None O

A None None O
definitive None None O
diagnosis None None O
of None None O
tyrosinemia None None O
type None None O
I None None O
is None None O
difficult None None O
to None None O
obtain None None O
based None None O
only None None O
on None None O
blood None None O
tyrosine None None I-TRANS
level None None O
. None None O

We None None O
used None None O
data None None O
from None None O
the None None O
Metabolic None None O
Syndrome None None O
and None None O
Atherosclerosis None None I-DISEASE
in None None O
South-Asians None None O
Living None None O
in None None O
America None None O
pilot None None O
study None None O
. None None O

To None None O
evaluate None None O
the None None O
inflammatory None None O
axis None None O
mediated None None O
by None None O
tumour None None O
necrosis None None O
factor-like None None O
weak None None O
inducer None None O
of None None O
apoptosis None None O
( None None O
TWEAK None None O
) None None O
and None None O
its None None O
scavenger None None O
receptor None None I-PROTEIN
CD163 None None O
during None None O
pregnancy None None O
and None None O
their None None O
influence None None O
on None None O
insulin None None I-PROTEIN
sensitivity None None O
in None None O
normal None None O
pregnancy None None O
and None None O
in None None O
gestational None None O
diabetes None None O
mellitus None None O
( None None O
GDM None None O
) None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
insulin None None I-PROTEIN
resistance None None O
during None None O
pregnancy None None O
is None None O
closely None None O
linked None None O
to None None O
inflammatory None None O
imbalance None None O
and None None O
sTWEAK None None O
may None None O
represent None None O
a None None O
new None None O
candidate None None O
associated None None O
with None None O
GDM None None O
. None None O

Hydrodeoxygenation None None O
( None None O
HDO None None O
) None None O
processes None None O
have None None O
recently None None O
received None None O
considerable None None O
attention None None I-FUNC
to None None O
upgrade None None O
biomass-derived None None O
feedstocks None None O
into None None O
liquid None None O
transportation None None O
fuels None None O
. None None O

Coronary None None O
heart None None O
disease None None O
and None None O
stroke None None I-DISEASE
causes None None O
42.5 None None O
% None None O
and None None O
28.8 None None O
% None None O
, None None O
respectively None None O
of None None O
the None None O
CVD None None O
mortality None None O
in None None O
the None None O
region None None O
. None None O

Improving None None O
in None None O
socioeconomic None None O
status None None O
, None None O
increased None None O
life None None O
expectancy None None O
and None None O
high None None O
prevalence None None O
of None None O
risk None None O
factors None None O
for None None O
atherosclerosis None None I-DISEASE
have None None O
been None None O
the None None O
major None None O
determinants None None O
of None None O
this None None O
marked None None O
epidemiologic None None O
change None None O
. None None O

Arabidopsis None None O
thaliana None None O
INDUCER None None O
OF None None O
CBF None None O
EXPRESSION1 None None O
and None None O
2 None None O
( None None O
ICE1 None None O
and None None O
ICE2 None None O
) None None O
encode None None O
MYC-type None None O
bHLH None None O
( None None O
basic None None O
helix-loop-helix None None O
) None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Soybean None None O
MYB None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
have None None O
been None None O
related None None O
to None None O
the None None O
plant None None O
response None None O
to None None O
biotic None None O
stresses None None O
. None None O

An None None O
amino None None O
acid None None O
substitution None None O
in None None O
the None None O
psbA None None O
gene None None O
( None None O
serine264 None None O
to None None O
glycine None None I-TRANS
) None None O
conferred None None O
resistance None None O
and None None O
also None None O
significantly None None O
affected None None O
the None None O
flowering None None O
and None None O
shoot None None O
dry None None O
weight None None O
of None None O
the None None O
resistant None None O
accession None None O
, None None O
as None None O
compared None None O
to None None O
the None None O
sensitive None None O
accession None None O
. None None O

Ozone None None O
treatments None None O
are None None O
used None None O
to None None O
preserve None None O
quality None None O
during None None O
cold None None O
storage None None I-FUNC
of None None O
commercially None None O
important None None O
fruits None None O
due None None O
to None None O
its None None O
ethylene None None O
oxidizing None None O
capacity None None O
and None None O
its None None O
antimicrobial None None O
attributes None None O
. None None O

We None None O
identified None None O
40 None None O
IQD None None O
genes None None O
( None None O
PtIQD1-40 None None O
) None None O
classified None None O
in None None O
four None None O
subfamilies None None O
( None None O
I-IV None None O
) None None O
. None None O

Cinnamyl None None O
alcohol None None I-PROTEIN
dehydrogenase None None I-PROTEIN
( None None O
CAD None None O
) None None O
catalyses None None O
the None None O
final None None O
step None None O
in None None O
the None None O
biosynthesis None None O
of None None O
monolignol None None O
, None None O
the None None O
main None None O
component None None O
of None None O
lignin None None O
. None None O

Functional None None O
characterisation None None O
of None None O
both None None O
enzymes None None I-PROTEIN
, None None O
produced None None O
in None None O
Escherichia None None O
coli None None O
( None None O
pET32a/BL21 None None O
( None None O
DE3 None None O
) None None O
) None None O
as None None O
recombinant None None O
proteins None None O
, None None O
showed None None O
that None None O
simultaneous None None O
incubation None None O
of None None O
CYP97C27 None None O
and None None O
CPR None None O
I None None O
with None None O
the None None O
substrate None None O
geranylgeraniol None None O
( None None O
GGOH None None O
) None None O
and None None O
coenzyme None None O
NADPH None None O
led None None O
to None None O
formation None None O
of None None O
the None None O
product None None O
plaunotol None None O
. None None O

The None None O
recently None None O
cloned None None O
rice None None O
transglutaminase None None I-PROTEIN
gene None None O
( None None O
tgo None None O
) None None O
is None None O
the None None O
second None None O
plant None None O
transglutaminase None None I-PROTEIN
identified None None O
to None None O
date None None O
( None None O
Campos None None O
et None None O
al None None O
. None None O

A None None O
variety None None O
of None None O
factors None None O
, None None O
including None None O
nitrate None None O
, None None O
light None None O
, None None O
metabolites None None O
, None None O
phytohormones None None O
, None None O
low None None O
temperature None None O
, None None O
and None None O
drought None None O
, None None O
modulate None None O
the None None O
expression None None O
levels None None O
of None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
genes None None O
as None None O
well None None O
as None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
activity None None O
, None None O
which None None O
is None None O
consistent None None O
with None None O
its None None O
physiological None None O
role None None O
. None None O

NODULE-INCEPTION-like None None O
proteins None None O
( None None O
NLPs None None O
) None None O
are None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
responsible None None O
for None None O
nitrate-inducible None None O
expression None None O
of None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
genes None None O
. None None O

LATERAL None None O
ORGAN None None O
BOUNDARIES None None O
DOMAIN None None O
( None None O
LBD None None O
) None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
( None None O
LBD37-LBD39 None None O
) None None O
are None None O
strong None None O
candidates None None O
for None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
mediating None None O
negative None None O
feedback None None O
regulation None None O
in None None O
response None None O
to None None O
increases None None O
in None None O
the None None O
contents None None O
of None None O
nitrogen-containing None None O
metabolites None None O
, None None O
whereas None None O
LONG None None O
HYPOCOTYL None None O
5 None None O
( None None O
HY5 None None O
) None None O
that None None O
promotes None None O
photomorphogenesis None None O
in None None O
light None None O
may None None O
be None None O
a None None O
transcription None None O
factor None None O
involved None None O
in None None O
light-induced None None O
expression None None O
of None None O
a None None O
nitrate None None I-PROTEIN
reductase None None I-PROTEIN
gene None None O
. None None O

This None None O
review None None O
presents None None O
a None None O
summary None None O
of None None O
our None None O
current None None O
knowledge None None O
of None None O
such None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
. None None O

Protein None None O
ubiquitination None None O
is None None O
a None None O
common None None O
posttranslational None None O
modification None None O
that None None O
often None None O
occurs None None O
on None None O
lysine None None I-TRANS
residues None None O
. None None O

Four None None O
Ubiquitin-Associated None None O
( None None O
UBA None None O
) None None O
domains None None O
were None None O
sequentially None None O
fused None None O
with None None O
Glutathione None None I-PROTEIN
S-transferase None None I-PROTEIN
( None None O
GST None None O
) None None O
tag None None O
( None None O
GST-qUBA None None O
) None None O
as None None O
bait None None O
protein None None O
in None None O
this None None O
study None None O
. None None O

Wall-Associated None None O
Kinases None None I-PROTEIN
( None None O
WAK None None O
) None None O
are None None O
a None None O
subfamily None None O
of None None O
receptor-like None None O
kinases None None I-PROTEIN
associated None None O
with None None O
the None None O
cell None None O
wall None None O
. None None O

They None None O
belong None None O
to None None O
the None None O
ePK None None O
superfamily None None O
with None None O
or None None O
without None None O
a None None O
conserved None None O
arginine None None I-TRANS
before None None O
the None None O
catalytic None None O
subdomain None None O
VIB None None O
, None None O
which None None O
characterizes None None O
RD None None O
and None None O
non-RD None None O
WAKs None None O
. None None O

We None None O
comprehensively None None O
review None None O
how None None O
these None None O
secondary None None O
wall-associated None None O
transcription None None I-PROTEIN
factors None None I-PROTEIN
function None None O
together None None O
to None None O
turn None None O
on None None O
the None None O
secondary None None O
wall None None O
biosynthetic None None O
program None None O
, None None O
which None None O
leads None None O
to None None O
secondary None None O
wall None None O
deposition None None O
in None None O
vascular None None O
plants None None O
. None None O

Significantly None None O
modulated None None O
expression None None O
included None None O
genes None None O
encoding None None I-FUNC
synthesis None None O
and None None O
catabolism None None O
to None None O
manage None None O
plant None None O
hormone None None O
homeostasis None None O
, None None O
hormone None None O
transporters None None I-PROTEIN
, None None O
receptors None None I-PROTEIN
and None None O
key None None O
components None None O
in None None O
signaling None None O
pathways None None O
; None None O
exogenous None None O
GA3 None None O
induced None None O
multipoint None None O
cross None None O
talk None None O
with None None O
auxin None None O
, None None O
cytokinin None None O
, None None O
brassinosteroid None None O
, None None O
ABA None None O
and None None O
ethylene None None O
. None None O

Amino None None I-TRANS
acids None None I-TRANS
serve None None O
as None None O
constituents None None O
of None None O
proteins None None O
, None None O
precursors None None O
for None None O
anabolism None None O
, None None O
and None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
as None None O
signaling None None O
molecules None None O
in None None O
mammalians None None O
and None None O
plants None None O
. None None O

Serine None None I-TRANS
acts None None O
as None None O
signal None None O
in None None O
brain None None O
tissue None None O
and None None O
mammalian None None O
cancer None None O
cells None None O
. None None O

GABA None None I-TRANS
functions None None O
as None None O
inhibitory None None I-TRANS
neurotransmitter None None I-TRANS
in None None O
the None None O
brain None None O
. None None O

The None None O
aromatic None None O
amino None None I-TRANS
acids None None I-TRANS
phenylalanine None None I-TRANS
, None None O
tyrosine None None I-TRANS
, None None O
and None None O
tryptophan None None I-TRANS
are None None O
precursors None None O
for None None O
the None None O
production None None O
of None None O
secondary None None O
plant None None O
products None None O
. None None O

Although None None O
amyloid None None O
imaging None None O
with None None O
PiB-PET None None O
( None None O
[ None None O
C-11 None None O
] None None O
Pittsburgh None None O
Compound-B None None O
positron None None O
emission None None O
tomography None None O
) None None O
, None None O
and None None O
now None None O
with None None O
F-18-labeled None None O
tracers None None O
, None None O
has None None O
produced None None O
remarkably None None O
consistent None None O
qualitative None None O
findings None None O
across None None O
a None None O
large None None O
number None None O
of None None O
centers None None O
, None None O
there None None O
has None None O
been None None O
considerable None None O
variability None None O
in None None O
the None None O
exact None None O
numbers None None O
reported None None O
as None None O
quantitative None None O
outcome None None O
measures None None O
of None None O
tracer None None O
retention None None I-FUNC
. None None O

Our None None O
working None None O
group None None O
was None None O
formed None None O
to None None O
standardize None None O
quantitative None None O
amyloid None None O
imaging None None O
measures None None O
by None None O
scaling None None O
the None None O
outcome None None O
of None None O
each None None O
particular None None O
analysis None None O
method None None O
or None None O
tracer None None O
to None None O
a None None O
0 None None O
to None None O
100 None None O
scale None None O
, None None O
anchored None None O
by None None O
young None None O
controls None None O
( None None O
≤ None None O
45 None None O
years None None O
) None None O
and None None O
typical None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
patients None None O
. None None O

Thus None None O
, None None O
there None None O
is None None O
an None None O
increasing None None O
need None None O
for None None O
additional None None O
noninvasive None None O
and/or None None O
cost-effective None None O
tools None None O
, None None O
allowing None None O
identification None None O
of None None O
subjects None None O
in None None O
the None None O
preclinical None None O
or None None O
early None None O
clinical None None O
stages None None O
of None None O
AD None None O
who None None O
could None None O
be None None O
suitable None None O
for None None O
further None None O
cognitive None None O
evaluation None None O
and None None O
dementia None None I-DISEASE
diagnostics None None O
. None None O

Copyright None None O
© None None O
2015 None None O
The None None O
Alzheimer None None I-DISEASE
's None None O
Association None None O
. None None O

Treatment None None O
with None None O
10058-F4 None None O
, None None O
a None None O
small None None O
molecule None None O
inhibitor None None O
of None None O
MYC-MAX None None O
heterodimerization None None O
, None None O
or None None O
c-Myc None None I-PROTEIN
siRNA None None O
significantly None None O
induced None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
we None None O
conclude None None O
that None None O
MSCs None None O
protected None None O
leukemia None None O
cells None None O
from None None O
apoptosis None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
through None None O
c-Myc None None I-PROTEIN
dependent None None O
mechanisms None None O
, None None O
and None None O
that None None O
c-Myc None None I-PROTEIN
contributed None None O
to None None O
microenvironment-mediated None None O
drug None None O
resistance None None O
in None None O
AML None None O
. None None O

Those None None O
in None None O
the None None O
AG None None O
were None None O
younger None None O
and None None O
healthier None None O
, None None O
with None None O
fewer None None O
chronic None None O
diseases None None O
and None None O
fewer None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
than None None O
those None None O
in None None O
the None None O
IG None None O
. None None O

In None None O
pilot None None O
study None None O
1 None None O
, None None O
three None None O
BCP None None O
materials None None O
( None None O
OSTEON™II None None O
, None None O
OSTEON™III None None O
, None None O
and None None O
OSTEON™II None None O
Collagen None None I-PROTEIN
) None None O
were None None O
grafted None None O
in None None O
rabbit None None O
calvarial None None O
defects None None O
after None None O
impregnating None None O
in None None O
rhBMP-2 None None O
. None None O

In None None O
pilot None None O
study None None O
2 None None O
, None None O
increased None None O
new None None O
bone None None O
formation None None O
was None None O
observed None None O
in None None O
time-dependent None None O
manner None None O
after None None O
graft None None O
of None None O
BCP None None O
and None None O
BCP-collagen None None O
( None None O
OSTEON™II None None O
, None None O
OSTEON™III None None O
, None None O
OSTEON™II None None O
Collagen None None I-PROTEIN
, None None O
and None None O
OSTEON™III None None O
Collagen None None I-PROTEIN
) None None O
impregnated None None O
with None None O
rhBMP-2 None None O
. None None O

After None None O
adjustment None None O
for None None O
age None None O
, None None O
sex None None O
and None None O
known None None O
cardiovascular None None O
risk None None O
factors None None O
, None None O
multivariable None None O
hazard None None O
ratios None None O
( None None O
95 None None O
% None None O
CI None None O
) None None O
of None None O
ischemic None None O
cardiovascular None None O
disease None None O
( None None O
ischemic None None O
heart None None O
disease None None O
and None None O
ischemic None None O
stroke None None I-DISEASE
) None None O
for None None O
the None None O
highest None None O
versus None None O
lowest None None O
quartiles None None O
of None None O
triglycerides None None O
were None None O
1.71 None None O
( None None O
1.14-2.59 None None O
) None None O
, None None O
P None None O
for None None O
trend None None O
= None None O
0.013 None None O
, None None O
for None None O
fasting None None O
participants None None O
and None None O
1.60 None None O
( None None O
1.25-2.05 None None O
) None None O
, None None O
P None None O
for None None O
trend None None O
& None None O
lt None None O
; None None O
0.001 None None O
, None None O
for None None O
non-fasting None None O
participants None None O
. None None O

They None None O
were None None O
stronger None None O
for None None O
ischemic None None O
heart None None O
disease None None O
than None None O
for None None O
ischemic None None O
stroke None None I-DISEASE
. None None O

Acute None None O
and None None O
chronic None None O
infections None None O
could None None O
contribute None None O
to None None O
different None None O
aetiological None None O
mechanisms None None O
of None None O
atherosclerosis None None I-DISEASE
that None None O
lead None None O
to None None O
cerebrovascular None None I-DISEASE
disease None None I-DISEASE
. None None O

This None None O
was None None O
a None None O
prospective None None O
case-control None None O
study None None O
involving None None O
11 None None O
Italian None None O
stroke None None I-DISEASE
units None None O
. None None O

A None None O
total None None O
of None None O
1002 None None O
participants None None O
were None None O
included None None O
( None None O
mean None None O
age None None O
69 None None O
years None None O
) None None O
with None None O
749 None None O
ischaemic None None O
stroke None None I-DISEASE
patients None None O
. None None O

At None None O
multivariate None None O
analysis None None O
of None None O
the None None O
seropositivity None None O
of None None O
IgA None None O
antibodies None None O
against None None O
C. None None O
pneumoniae None None O
increased None None O
the None None O
risk None None O
of None None O
stroke None None I-DISEASE
significantly None None O
( None None O
relative None None O
risk None None O
2.121 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
1.255-3.584 None None O
) None None O
and None None O
an None None O
early None None O
previous None None O
infection None None O
( None None O
up None None O
to None None O
7 None None O
days None None O
before None None O
the None None O
event None None O
) None None O
contributed None None O
to None None O
a None None O
rise None None O
in None None O
probability None None O
of None None O
acute None None O
cerebral None None O
ischaemia None None O
( None None O
relative None None O
risk None None O
3.692 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
1.134-6.875 None None O
) None None O
. None None O

In None None O
vitro None None O
mechanical None None O
loading None None O
, None None O
produced None None O
during None None O
chewing None None O
and None None O
bruxism None None I-DISEASE
( None None O
square None None O
or None None O
hold None None O
24 None None O
and None None O
72 None None O
h None None O
waveforms None None O
) None None O
, None None O
induced None None O
remineralization None None O
at None None O
the None None O
resin-dentin None None O
bonded None None O
interface None None O
. None None O

Extended-spectrum None None O
beta-lactamase None None I-PROTEIN
( None None O
ESBL None None O
) None None O
-producing None None O
E None None O
coli None None O
were None None O
detected None None O
continuously None None O
since None None O
2008 None None O
and None None O
found None None O
in None None O
10 None None O
patients None None O
( None None O
21.3 None None O
% None None O
) None None O
in None None O
blood None None O
and None None O
8 None None O
patients None None O
( None None O
20.5 None None O
% None None O
) None None O
in None None O
urine None None O
. None None O

A None None O
surgeon None None O
with None None O
extensive None None O
open None None O
and None None O
laparoscopic None None O
experience None None O
presents None None O
a None None O
safe None None O
learning None None I-FUNC
curve None None O
in None None O
regard None None O
to None None O
robot-assisted None None O
radical None None O
prostatectomy None None O
and None None O
extended None None O
pelvic None None O
lymph None None O
node None None O
dissection None None O
. None None O

PioH None None O
animals None None O
demonstrated None None O
increased None None O
expression None None O
of None None O
endothelial None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
eNOS None None O
) None None O
and None None O
neuronal None None O
nitric None None I-TRANS
oxide None None I-TRANS
( None None O
nNOS None None O
) None None O
, None None O
whereas None None O
both None None O
PioL None None O
and None None O
PioH None None O
animals None None O
had None None O
increased None None O
staining None None O
for None None O
anti None None O
-- None None O
smooth None None O
muscle None None O
actin None None I-PROTEIN
antibody None None O
and None None O
nonsignificant None None O
increases None None O
in None None O
cyclic None None O
guanosine None None O
monophosphate None None O
( None None O
cGMP None None O
) None None O
. None None O

On None None O
multivariate None None O
analysis None None O
, None None O
the None None O
presence None None O
of None None O
MetS None None O
was None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
an None None O
IPSS None None O
storage None None I-FUNC
subscore None None O
≥4 None None O
( None None O
odds None None O
ratio None None O
, None None O
1.782 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
, None None O
1.045-3.042 None None O
; None None O
P None None O
= None None O
.030 None None O
) None None O
. None None O

The None None O
rats None None O
treated None None O
with None None O
nifedipine None None O
had None None O
a None None O
significant None None O
decrease None None O
in None None O
malondialdehyde None None O
level None None O
and None None O
apoptosis None None O
and None None O
had None None O
significant None None O
increases None None O
in None None O
superoxide None None I-PROTEIN
dismutase None None I-PROTEIN
and None None O
glutathione None None I-PROTEIN
peroxidase None None I-PROTEIN
activities None None O
in None None O
ipsilateral None None O
testes None None O
compared None None O
with None None O
those None None O
of None None O
the None None O
T/D None None O
group None None O
. None None O

To None None O
compare None None O
the None None O
safety None None O
and None None O
efficacy None None O
of None None O
patients None None O
undergoing None None O
dorsal None None I-NEURON
penile None None O
plication None None O
with None None O
patients None None O
undergoing None None O
ventral None None I-NEURON
and None None O
lateral None None O
plication None None O
. None None O

Dorsal None None I-NEURON
plication None None O
was None None O
performed None None O
with None None O
minimal None None O
displacement None None O
of None None O
the None None O
neurovascular None None O
bundle None None O
. None None O

Dorsal None None I-NEURON
plication None None O
without None None O
degloving None None O
produces None None O
favorable None None O
objective None None O
and None None O
subjective None None O
results None None O
comparable None None O
to None None O
ventral None None I-NEURON
and None None O
lateral None None O
plication None None O
. None None O

To None None O
compare None None O
the None None O
effects None None O
of None None O
subcutaneous None None O
penile None None O
injection None None O
of None None O
basic None None O
fibroblast None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
bFGF None None O
) None None O
-hydrogel None None O
and None None O
intracavernous None None O
injection None None O
of None None O
human None None O
adipose-derived None None O
stem None None O
cells None None O
( None None O
h-ADSCs None None O
) None None O
on None None O
improving None None O
erectile None None O
function None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
cavernous None None O
nerve None None O
injury None None O
. None None O

The None None O
evaluation None None O
of None None O
filamentous None None O
actin None None I-PROTEIN
content None None O
, None None O
CD31 None None O
expression None None O
, None None O
and None None O
cGMP None None O
concentration None None O
in None None O
the None None O
corpus None None O
cavernosum None None O
were None None O
meaningfully None None O
increased None None O
in None None O
the None None O
bFGF-hydrogel None None O
and None None O
ADSC None None O
groups None None O
compared None None O
with None None O
BCNI None None O
group None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
fiducial None None O
coil None None O
use None None O
in None None O
a None None O
man None None O
undergoing None None O
a None None O
robot-assisted None None O
laparoscopic None None O
resection None None O
of None None O
a None None O
metastatic None None O
nodule None None O
under None None O
the None None O
ipsilateral None None O
diaphragm None None I-REGION
after None None O
robot-assisted None None O
partial None None O
nephrectomy None None O
performed None None O
2 None None O
years None None O
ago None None O
for None None O
a None None O
left None None O
upper None None O
pole None None O
renal None None O
tumor None None O
. None None O

High None None O
levels None None O
of None None O
amylase None None I-PROTEIN
and None None O
lipase None None O
were None None O
observed None None O
in None None O
a None None O
test None None O
puncture None None O
of None None O
renal None None O
fluid None None O
collection None None O
. None None O

In None None O
this None None O
chapter None None O
, None None O
we None None O
review None None O
our None None O
contribution None None O
to None None O
( None None O
i None None O
) None None O
the None None O
determination None None O
of None None O
the None None O
reaction None None O
mechanism None None O
of None None O
amide None None O
hydrolysis None None O
catalyzed None None O
by None None O
cysteine None None I-TRANS
Ntn-hydrolases None None O
and None None O
( None None O
ii None None O
) None None O
the None None O
discovery None None O
and None None O
optimization None None O
of None None O
active-site-directed None None O
inhibitors None None O
of None None O
NAAA None None O
characterized None None O
by None None O
a None None O
β-lactone None None O
warhead None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
functionalities None None O
that None None O
have None None O
recently None None O
been None None O
integrated None None O
into None None O
CHARMM-GUI None None O
PDB None None O
Manipulator None None O
, None None O
such None None O
as None None O
ligand None None O
force None None O
field None None O
generation None None O
, None None O
incorporation None None O
of None None O
methanethiosulfonate None None O
spin None None O
labels None None O
and None None O
chemical None None O
modifiers None None O
, None None O
and None None O
substitution None None O
of None None O
amino None None I-TRANS
acids None None I-TRANS
with None None O
unnatural None None O
amino None None I-TRANS
acids None None I-TRANS
. None None O

The None None O
aim None None O
of None None O
this None None O
longitudinal None None O
study None None O
was None None O
to None None O
explore None None O
the None None O
links None None O
between None None O
alexithymia None None I-DISEASE
and None None O
two None None O
types None None O
of None None O
difficulties None None O
in None None O
AN None None O
: None None O
eating None None O
symptoms None None O
and None None O
social None None O
avoidance None None O
. None None O

They None None O
completed None None O
self-administered None None O
questionnaires None None O
of None None O
alexithymia None None I-DISEASE
( None None O
TAS-20 None None O
) None None O
, None None O
of None None O
central None None O
symptoms None None O
of None None O
the None None O
eating None None I-DISEASE
disorders None None I-DISEASE
( None None O
EDI None None O
) None None O
, None None O
and None None O
of None None O
anxious None None O
and None None O
depressive None None O
affects None None O
( None None O
SCL-90 None None O
) None None O
. None None O

These None None O
effects None None O
appeared None None O
more None None O
particularly None None O
linked None None O
to None None O
the None None O
implication None None O
of None None O
the None None O
dimensions None None O
difficulties None None O
identifying None None O
and None None O
describing None None O
feelings None None I-FUNC
, None None O
interpersonal None None O
mistrust None None O
, None None O
feelings None None I-FUNC
of None None O
inadequacy None None O
and None None O
interoceptive None None O
awareness None None O
deficit None None O
. None None O

Difficulties None None O
in None None O
describing None None O
feelings None None I-FUNC
appeared None None O
particularly None None O
involved None None O
here None None O
. None None O

The None None O
effects None None O
of None None O
hyperlipidemia None None O
on None None O
insulin None None I-PROTEIN
secretion None None O
and None None O
pro-inflammatory None None O
cytokines None None O
production None None O
( None None O
TNF-α None None O
, None None O
IL-1β None None O
) None None O
play None None O
an None None O
important None None O
role None None O
on None None O
the None None O
pathogenesis None None O
of None None O
diabetes None None O
and None None O
periodontitis None None O
. None None O

Over None None O
the None None O
past None None O
decade None None O
, None None O
research None None O
has None None O
begun None None O
to None None O
focus None None O
on None None O
how None None O
metaphors None None O
are None None O
processed None None O
during None None O
language None None I-FUNC
comprehension None None I-FUNC
. None None O

However None None O
, None None O
no None None O
research None None O
to None None O
date None None O
has None None O
asked None None O
whether None None O
the None None O
same None None O
is None None O
true None None O
while None None O
speakers None None O
produce None None O
language None None I-FUNC
. None None O

Its None None O
results None None O
demonstrate None None O
that None None O
visually None None O
activating None None O
a None None O
concrete None None O
source None None O
domain None None O
can None None O
trigger None None O
the None None O
use None None O
of None None O
metaphorical None None O
language None None I-FUNC
drawn None None O
from None None O
that None None O
same None None O
concrete None None O
domain None None O
, None None O
even None None O
in None None O
sentences None None O
that None None O
are None None O
thematically None None O
unrelated None None O
to None None O
the None None O
primes None None O
, None None O
a None None O
metaphorical None None O
priming None None O
effect None None O
. None None O

Contrary None None O
to None None O
previous None None O
studies None None O
reporting None None O
that None None O
metaphorical None None O
language None None I-FUNC
understanding None None O
differs None None O
from None None O
literal None None O
language None None I-FUNC
understanding None None O
with None None O
regard None None O
to None None O
simulation None None O
effects None None O
, None None O
the None None O
results None None O
show None None O
compatibility None None O
effects None None O
between None None O
sentence None None O
implied None None O
pitch None None O
height None None O
and None None O
response None None O
location None None O
. None None O

To None None O
investigate None None O
the None None O
impact None None O
of None None O
a None None O
12-week None None O
exercise None None O
programme None None O
in None None O
addition None None O
to None None O
usual None None O
care None None O
for None None O
post-traumatic None None I-DISEASE
stress None None I-DISEASE
disorder None None I-DISEASE
( None None O
PTSD None None O
) None None O
. None None O

There None None O
were None None O
significant None None O
between-group None None O
differences None None O
at None None O
follow-up None None O
for None None O
depressive None None I-DISEASE
symptoms None None I-DISEASE
, None None O
waist None None O
circumference None None O
, None None O
sleep None None O
quality None None O
, None None O
and None None O
sedentary None None O
time None None O
. None None O

Quantification None None O
of None None O
benefit None None O
for None None O
travellers None None O
from None None O
the None None O
United None None O
Kingdom None None O
( None None O
UK None None O
) None None O
was None None O
modelled None None O
to None None O
assist None None O
clinical None None O
and None None O
public None None O
health None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

The None None O
number None None O
of None None O
travellers None None O
experiencing None None O
moderate None None O
adverse None None O
events None None O
( None None O
AE None None O
) None None O
or None None O
those None None O
requiring None None O
medical None None O
attention None None I-FUNC
or None None O
drug None None O
withdrawal None None O
per None None O
case None None O
prevented None None O
is None None O
as None None O
follows None None O
: None None O
C None None O
± None None O
P None None O
170 None None O
, None None O
Mq None None O
146 None None O
, None None O
Dx None None O
114 None None O
, None None O
AP None None O
103 None None O
. None None O

To None None O
evaluate None None O
pedestrian None None O
behavior None None O
, None None O
including None None O
reaction None None O
time None None O
, None None O
impulsivity None None O
, None None O
risk-taking None None O
, None None O
attention None None I-FUNC
, None None O
and None None O
decision-making None None O
, None None O
in None None O
children None None O
with None None O
obstructive None None O
sleep None None O
apnea None None O
syndrome None None O
( None None O
OSAS None None O
) None None O
compared None None O
with None None O
healthy None None O
controls None None O
. None None O

Results None None O
highlight None None O
the None None O
need None None O
for None None O
heightened None None O
awareness None None O
of None None O
the None None O
consequences None None O
of None None O
untreated None None O
sleep None None I-DISEASE
disorders None None I-DISEASE
and None None O
identify None None O
a None None O
possible None None O
target None None O
for None None O
pediatric None None O
injury None None O
prevention None None O
. None None O

Within None None O
adolescents None None O
with None None O
TOF None None O
without None None O
genetic None None O
disorders None None O
, None None O
lower None None O
PsS None None O
scores None None O
were None None O
highly None None O
associated None None O
with None None O
worse None None O
neurocognitive None None O
measures None None O
, None None O
particularly None None O
the None None O
parent-reported None None O
Behavior None None O
Rating None None O
Inventory None None O
of None None O
Executive None None O
Function None None O
composite None None O
( None None O
r None None O
= None None O
-0.66 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
and None None O
Parent None None O
Conners None None O
' None None O
attention None None I-FUNC
deficit-hyperactivity None None O
disorder None None O
Index None None O
T None None O
score None None O
( None None O
r None None O
= None None O
-0.54 None None O
, None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
, None None O
whereas None None O
associations None None O
of None None O
PhS None None O
scores None None O
with None None O
neurocognitive None None O
measures None None O
were None None O
weaker None None O
. None None O

Within None None O
these None None O
subjects None None O
with None None O
TOF None None O
, None None O
worse None None O
psychosocial None None O
health None None O
status None None O
was None None O
most None None O
highly None None O
associated None None O
with None None O
concurrent None None O
executive None None O
dysfunction None None O
and None None O
attention None None I-FUNC
deficit-hyperactivity None None O
disorder None None O
. None None O

The None None O
negative None None O
relationship None None O
between None None O
IS None None O
and None None O
body None None O
image None None O
dissatisfaction None None O
described None None O
in None None O
patients None None O
with None None O
anorexia None None I-DISEASE
nervosa None None I-DISEASE
also None None O
exists None None O
in None None O
healthy None None O
individuals None None O
. None None O

Little None None O
is None None O
known None None O
about None None O
the None None O
regional None None O
variations None None O
in None None O
ischemic None None O
stroke None None I-DISEASE
care None None O
in None None O
Japan None None O
. None None O

Using None None O
administrative None None O
claims None None O
data None None O
from None None O
National None None O
Claims None None O
Database None None O
, None None O
we None None O
identified None None O
National None None O
Health None None O
Insurance None None O
beneficiaries None None O
aged None None O
65 None None O
years None None O
and None None O
older None None O
and None None O
Long None None O
Life None None O
Medical None None O
Care None None O
System None None O
beneficiaries None None O
from None None O
9 None None O
prefectures None None O
who None None O
had None None O
been None None O
hospitalized None None O
for None None O
acute None None O
ischemic None None O
stroke None None I-DISEASE
between None None O
April None None O
2010 None None O
and None None O
March None None O
2012 None None O
. None None O

The None None O
associations None None O
between None None O
regional None None O
supply None None O
of None None O
physicians None None O
for None None O
stroke None None I-DISEASE
care None None O
and None None O
the None None O
various None None O
quality None None O
measures None None O
were None None O
investigated None None O
. None None O

Improving None None O
the None None O
allocative None None O
efficiency None None O
of None None O
physicians None None O
and None None O
establishing None None O
continuity None None O
of None None O
care None None O
networks None None O
may None None O
be None None O
useful None None O
in None None O
mitigating None None O
regional None None O
disparities None None O
and None None O
reconstructing None None O
the None None O
stroke None None I-DISEASE
care None None O
system None None O
. None None O

Motor None None O
function None None O
rehabilitation None None O
after None None O
stroke None None I-DISEASE
demands None None O
for None None O
methods None None O
oriented None None O
to None None O
the None None O
recovery None None O
of None None O
the None None O
walking None None O
capacity None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
article None None O
is None None O
to None None O
review None None O
the None None O
state None None O
of None None O
the None None O
art None None O
applications None None O
of None None O
cycling None None O
leg None None O
exercise None None O
as None None O
a None None O
( None None O
1 None None O
) None None O
motor None None O
function None None O
rehabilitation None None O
method None None O
and None None O
an None None O
( None None O
2 None None O
) None None O
aerobic None None O
training None None O
method None None O
for None None O
stroke None None I-DISEASE
patients None None O
as None None O
well None None O
as None None O
the None None O
commonly None None O
used None None O
( None None O
3 None None O
) None None O
assessment None None O
tools None None O
. None None O

We None None O
describe None None O
the None None O
case None None O
of None None O
a None None O
50-year-old None None O
female None None O
diabetic None None O
with None None O
a None None O
history None None O
of None None O
otitis None None O
media None None O
, None None O
an None None O
uncharacterized None None O
inflammatory None None O
nasopharyngeal None None O
process None None O
, None None O
and None None O
prior None None O
ischemic None None O
strokes None None I-DISEASE
who None None O
presented None None O
with None None O
a None None O
new None None O
cerebral None None I-DISEASE
infarction None None I-DISEASE
in None None O
the None None O
setting None None O
of None None O
an None None O
angioinvasive None None O
fungal None None O
infection None None O
of None None O
the None None O
large None None O
cerebral None None O
arteries None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

He None None O
presented None None O
with None None O
a None None O
1-day None None O
history None None O
of None None O
acute None None O
severe None None O
right-sided None None O
hemiparesis None None O
and None None O
aphasia None None I-DISEASE
and None None O
a None None O
3-week None None O
history None None O
of None None O
high None None O
metabolic None None O
syndrome None None O
. None None O

We None None O
suggest None None O
that None None O
lipid None None O
storage None None I-FUNC
myopathy None None O
is None None O
secondary None None O
to None None O
GD None None O
, None None O
and None None O
it None None O
is None None O
likely None None O
mitochondrial None None O
dysfunction None None O
or None None O
immune None None O
dysfunction None None O
induced None None O
by None None O
GD None None O
responsible None None O
for None None O
the None None O
myopathy None None O
and None None O
that None None O
magnetic None None O
resonance None None O
spectroscopy None None O
( None None O
MRS None None O
) None None O
is None None O
capable None None O
of None None O
establishing None None O
the None None O
diagnosis None None O
of None None O
myopathy None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

The None None O
FFT None None O
almost None None O
disappeared None None O
during None None O
treatment None None O
with None None O
intravenous None None O
anticoagulation None None O
therapy None None O
for None None O
acute None None O
stroke None None I-DISEASE
, None None O
but None None O
it None None O
reappeared None None O
when None None O
the None None O
therapy None None O
was None None O
discontinued None None O
. None None O

Copyright None None O
© None None O
2015 None None O
National None None O
Stroke None None I-DISEASE
Association None None O
. None None O

Although None None O
chronic None None O
risk None None O
factors None None O
for None None O
stroke None None I-DISEASE
are None None O
reasonably None None O
well None None O
understood None None O
, None None O
the None None O
acute None None O
precipitants None None O
, None None O
or None None O
triggers None None O
, None None O
of None None O
stroke None None I-DISEASE
relatively None None O
remain None None O
understudied None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
prevalence None None O
of None None O
trigger None None O
factors None None O
in None None O
acute None None O
stroke None None I-DISEASE
patients None None O
and None None O
to None None O
investigate None None O
the None None O
association None None O
of None None O
the None None O
presence None None O
of None None O
trigger None None O
factors None None O
with None None O
initial None None O
stroke None None I-DISEASE
severity None None O
at None None O
presentation None None O
( None None O
National None None O
Institutes None None O
of None None O
Health None None O
Stroke None None I-DISEASE
Scale None None O
( None None O
NIHSS None None O
) None None O
score None None O
in None None O
ischemic None None O
stroke None None I-DISEASE
patients None None O
and None None O
volume None None O
of None None O
hematoma None None O
in None None O
hemorrhagic None None O
stroke None None I-DISEASE
patients None None O
) None None O
. None None O

All None None O
consecutive None None O
patients None None O
of None None O
recent None None O
stroke None None I-DISEASE
( None None O
reporting None None O
within None None O
1 None None O
week None None O
of None None O
stroke None None I-DISEASE
onset None None O
) None None O
were None None O
included None None O
in None None O
the None None O
study None None O
. None None O

Psychological None None O
stress None None O
was None None O
present None None O
in None None O
51 None None O
( None None O
17.6 None None O
% None None O
) None None O
patients None None O
, None None O
among None None O
psychological None None O
stress None None O
: None None O
stressful None None O
life None None O
event None None O
in None None O
34 None None O
( None None O
11.7 None None O
% None None O
) None None O
, None None O
negative None None O
affect None None O
in None None O
17 None None O
( None None O
5.9 None None O
% None None O
) None None O
, None None O
acute None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
in None None O
31 None None O
( None None O
10.7 None None O
% None None O
) None None O
, None None O
clinical None None O
infections None None O
in None None O
24 None None O
( None None O
8.3 None None O
% None None O
) None None O
, None None O
and None None O
anger None None O
and None None O
coffee None None O
intake None None O
in None None O
12 None None O
( None None O
4.1 None None O
% None None O
) None None O
each None None O
. None None O

Clinical None None O
variables None None O
independently None None O
associated None None O
with None None O
the None None O
presence None None O
of None None O
trigger None None O
factors None None O
in None None O
acute None None O
stroke None None I-DISEASE
after None None O
multivariate None None O
analysis None None O
were None None O
younger None None O
age None None O
( None None O
& None None O
lt None None O
; None None O
60 None None O
years None None O
) None None O
and None None O
stroke None None I-DISEASE
severity None None O
at None None O
initial None None O
presentation None None O
( None None O
ie None None O
, None None O
higher None None O
NIHSS None None O
score None None O
and None None O
higher None None O
hematoma None None O
volume None None O
) None None O
. None None O

Psychological None None O
stress None None O
( None None O
17.6 None None O
% None None O
) None None O
, None None O
acute None None O
alcohol None None I-DISEASE
abuse None None I-DISEASE
( None None O
10.7 None None O
% None None O
) None None O
, None None O
and None None O
clinical None None O
infections None None O
( None None O
8.3 None None O
% None None O
) None None O
were None None O
the None None O
most None None O
common None None O
triggers None None O
. None None O

The None None O
newer None None O
markers None None O
N-terminal None None O
pro-brain None None O
natriuretic None None O
peptide None None O
, None None O
troponin None None O
I None None O
, None None O
C-reactive None None O
protein None None O
, None None O
and None None O
cystatin None None O
C None None O
may None None O
affect None None O
the None None O
risk None None O
of None None O
cardiovascular None None O
events None None O
and None None O
potentially None None O
, None None O
thereby None None O
, None None O
also None None O
stroke None None I-DISEASE
. None None O

Hypertension None None O
( None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
2.6 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
1.4 None None O
, None None O
4.7 None None O
) None None O
and None None O
obesity None None O
( None None O
OR None None O
1.3 None None O
; None None O
CI None None O
1.0 None None O
, None None O
1.8 None None O
) None None O
were None None O
significantly None None O
associated None None O
with None None O
increased None None O
risk None None O
of None None O
brain None None I-DISEASE
infarction None None I-DISEASE
. None None O

Types None None O
and None None O
ratios None None O
of None None O
each None None O
presentation None None O
of None None O
our None None O
95 None None O
patients None None O
with None None O
46 None None O
, None None O
XX None None O
DSD None None O
were None None O
as None None O
follows None None O
: None None O
82 None None O
had None None O
androgen None None O
excess None None O
( None None O
86.3 None None O
% None None O
) None None O
: None None O
( None None O
74 None None O
had None None O
classical None None O
congenital None None O
adrenal None None I-TRANS
hyperplasia None None O
, None None O
2 None None O
had None None O
CAH None None O
variant None None O
possibility None None O
of None None O
P450-oxidoreductase None None O
gene None None O
defect None None O
) None None O
, None None O
6 None None O
had None None O
disorders None None O
of None None O
ovarian None None O
development None None O
( None None O
6.3 None None O
% None None O
) None None O
: None None O
( None None O
1 None None O
patient None None O
had None None O
gonadal None None O
dysgenesis None None O
with None None O
virilization None None O
at None None O
birth None None O
with None None O
bilateral None None O
streak None None O
gonad None None O
, None None O
4 None None O
patients None None O
had None None O
complete None None O
gonadal None None O
dysgenesis None None O
, None None O
and None None O
1 None None O
patient None None O
had None None O
ovotesticular None None O
DSD None None O
) None None O
and None None O
7 None None O
had None None O
other None None O
46 None None O
, None None O
XX None None O
DSD None None O
. None None O

To None None O
evaluate None None O
national None None O
trends None None O
in None None O
nonvascular None None O
invasive None None O
radiology None None O
procedures None None O
performed None None O
by None None O
advanced None None O
practice None None O
providers None None O
( None None O
APPs None None I-TRANS
) None None O
, None None O
focusing None None O
specifically None None O
on None None O
nurse None None O
practitioners None None O
and None None O
physician None None O
assistants None None O
. None None O

Of None None O
1,352 None None O
nonvascular None None O
invasive None None O
procedures None None O
performed None None O
by None None O
APPs None None I-TRANS
at None None O
our None None O
facilities None None O
over None None O
a None None O
1-year None None O
period None None O
through None None O
August None None O
2013 None None O
, None None O
a None None O
total None None O
of None None O
1,161 None None O
( None None O
85.9 None None O
% None None O
) None None O
fell None None O
into None None O
the None None O
7 None None O
defined None None O
categories None None O
. None None O

Overall None None O
, None None O
volumes None None O
increased None None O
for None None O
both None None O
radiologists None None O
and None None O
all None None O
providers None None O
, None None O
with None None O
the None None O
total None None O
fraction None None O
of None None O
national None None O
services None None O
performed None None O
by None None O
APPs None None I-TRANS
increasing None None O
from None None O
0 None None O
% None None O
to None None O
10.7 None None O
% None None O
for None None O
paracentesis None None O
, None None O
0.1 None None O
% None None O
to None None O
5.7 None None O
% None None O
for None None O
thoracentesis None None O
, None None O
0 None None O
% None None O
to None None O
2.1 None None O
% None None O
for None None O
FNA None None O
, None None O
0 None None O
% None None O
to None None O
1.4 None None O
% None None O
for None None O
superficial None None O
lymph None None O
node None None O
biopsy None None O
, None None O
0 None None O
% None None O
to None None O
1.7 None None O
% None None O
for None None O
abdominal None None O
biopsy None None O
, None None O
0 None None O
% None None O
to None None O
1.0 None None O
% None None O
for None None O
thoracic None None O
biopsy None None O
, None None O
and None None O
0.1 None None O
% None None O
to None None O
1.2 None None O
% None None O
for None None O
abdominal None None O
drainage None None O
. None None O

Given None None O
the None None O
multiple None None O
hurdles None None O
involved None None O
in None None O
obtaining None None O
Medicare None None O
reimbursement None None O
, None None O
that None None O
growth None None O
indicates None None O
increasing None None O
acceptance None None O
of None None O
APPs None None I-TRANS
as None None O
procedure None None O
service None None O
providers None None O
at None None O
the None None O
institutional None None O
credentialing None None O
, None None O
state None None O
licensure None None O
, None None O
and None None O
payer None None O
policy None None O
levels None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
aimed None None O
to None None O
analyze None None O
cannabinoid None None O
receptor None None I-PROTEIN
1 None None O
( None None O
CB1 None None O
) None None O
, None None O
CB2 None None O
and None None O
fatty None None O
acid None None O
amid None None O
hydrolase None None I-PROTEIN
( None None O
FAAH None None O
) None None O
expressions None None O
and None None O
localization None None O
in None None O
normal None None O
and None None O
preeclamptic None None O
placenta None None O
, None None O
in None None O
order None None O
to None None O
determine None None O
whether None None O
placental None None O
endocannabinoid None None O
expression None None O
pattern None None O
differs None None O
between None None O
normal None None O
pregnancy None None O
and None None O
preeclampsia None None O
. None None O

Participants None None O
completed None None O
a None None O
battery None None O
of None None O
psychological None None O
instruments None None O
assessing None None O
aggression-impulsivity None None O
, None None O
mental None None O
pain None None O
( None None O
including None None O
depression None None I-DISEASE
and None None O
hopelessness None None O
) None None O
and None None O
communication None None O
difficulties None None O
, None None O
in None None O
addition None None O
to None None O
negative None None O
life None None O
events None None O
. None None O

Microscopically None None O
, None None O
there None None O
were None None O
haphazardly None None O
oriented None None O
trabecular None None O
bands None None O
of None None O
dense None None O
eosinophilic None None O
collagen None None I-PROTEIN
, None None O
separated None None O
by None None O
wide None None O
, None None O
clear None None O
areas None None O
containing None None O
variable None None O
numbers None None O
of None None O
fibroblasts None None O
, None None O
eosinophils None None O
, None None O
mast None None O
cells None None O
, None None O
neutrophils None None O
, None None O
macrophages None None O
, None None O
lymphocytes None None O
and None None O
plasma None None O
cells None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
is None None O
to None None O
examine None None O
the None None O
association None None O
of None None O
iron None None O
indices None None O
( None None O
serum None None O
ferritin None None I-PROTEIN
and None None O
transferrin None None O
saturation None None O
) None None O
with None None O
risk None None O
of None None O
impaired None None O
fasting None None O
glucose None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
. None None O

Impaired None None O
fasting None None O
glucose None None O
was None None O
more None None O
prevalent None None O
in None None O
the None None O
highest None None O
compared None None O
with None None O
the None None O
lowest None None O
serum None None O
ferritin None None I-PROTEIN
quartile None None O
among None None O
men None None O
( None None O
odds None None O
ratio None None O
[ None None O
OR None None O
] None None O
, None None O
1.97 None None O
; None None O
95 None None O
% None None O
confidence None None O
interval None None O
[ None None O
CI None None O
] None None O
, None None O
1.20-3.24 None None O
) None None O
after None None O
adjustment None None O
for None None O
multiple None None O
covariates None None O
. None None O

Moreover None None O
, None None O
a None None O
higher None None O
ferritin None None I-PROTEIN
level None None O
was None None O
significantly None None O
associated None None O
with None None O
higher None None O
HOMA-IR None None O
after None None O
adjusting None None O
for None None O
confounders None None O
in None None O
men None None O
. None None O

Lower None None O
transferrin None None O
saturations None None O
were None None O
associated None None O
with None None O
an None None O
increased None None O
risk None None O
of None None O
impaired None None O
fasting None None O
glucose None None O
and None None O
insulin None None I-PROTEIN
resistance None None O
among None None O
general None None O
South None None O
Korean None None O
population None None O
. None None O

Although None None O
randomization None None O
is None None O
considered None None O
essential None None O
for None None O
causal None None O
inference None None I-FUNC
, None None O
it None None O
is None None O
often None None O
not None None O
possible None None O
to None None O
randomize None None O
in None None O
nutrition None None O
and None None O
obesity None None O
research None None O
. None None O

As None None O
such None None O
, None None O
researchers None None O
are None None O
left None None O
to None None O
develop None None O
and None None O
apply None None O
PREs None None O
on None None O
an None None O
ad None None O
hoc None None O
basis None None O
, None None O
limiting None None O
its None None O
potential None None O
to None None O
improve None None O
causal None None O
inferences None None I-FUNC
among None None O
nutrition None None O
and None None O
obesity None None O
researchers None None O
. None None O

In None None O
a None None O
visual None None O
word None None O
rhyming None None O
judgment None None O
task None None O
, None None O
we None None O
found None None O
a None None O
significant None None O
interaction None None O
between None None O
age None None O
and None None O
language None None I-FUNC
in None None O
left None None I-REGION
inferior None None I-REGION
parietal None None I-REGION
lobule None None I-REGION
and None None O
left None None I-REGION
superior None None I-REGION
temporal None None I-REGION
gyrus None None I-REGION
, None None O
which None None O
was None None O
due None None O
to None None O
greater None None O
developmental None None O
increases None None O
in None None O
English None None O
than None None O
in None None O
Chinese None None O
. None None O

In None None O
contrast None None O
, None None O
greater None None O
developmental None None O
increases None None O
in None None O
Chinese None None O
than None None O
in None None O
English None None O
were None None O
found None None O
in None None O
right None None O
middle None None O
occipital None None I-REGION
gyrus None None I-REGION
, None None O
suggesting None None O
the None None O
importance None None O
of None None O
holistic None None O
visual-orthographic None None O
analysis None None O
in None None O
Chinese None None O
reading None None O
acquisition None None O
. None None O

Perinatal None None O
arterial None None O
ischemic None None O
stroke None None I-DISEASE
is None None O
the None None O
most None None O
common None None O
identifiable None None O
cause None None O
of None None O
cerebral None None I-DISEASE
palsy None None I-DISEASE
and None None O
can None None O
lead None None O
to None None O
cognitive None None O
and None None O
behavioral None None O
difficulties None None O
that None None O
are None None O
amortized None None O
over None None O
a None None O
lifetime None None O
. None None O

Risk None None O
factors None None O
for None None O
perinatal None None O
arterial None None O
ischemic None None O
stroke None None I-DISEASE
include None None O
those None None O
that None None O
are None None O
maternal None None O
, None None O
neonatal None None O
, None None O
and None None O
placental None None O
. None None O

Published None None O
by None None O
Elsevier None None O
Inc. None None O
Lower None None O
extremity None None O
venous None None O
ultrasonography None None O
is None None O
an None None O
accurate None None O
method None None O
to None None O
diagnose None None O
acute None None O
deep None None O
venous None None O
thrombosis None None I-DISEASE
( None None O
DVT None None O
) None None O
. None None O

Another None None O
robust None None O
inference None None I-FUNC
is None None O
that None None O
the None None O
number None None O
of None None O
adaptive None None O
evolutionary None None O
paths None None O
is None None O
often None None O
limited None None O
to None None O
a None None O
relatively None None O
small None None O
fraction None None O
of None None O
the None None O
theoretical None None O
possibilities None None O
, None None O
owing None None O
largely None None O
to None None O
sign None None O
epistasis None None O
requiring None None O
evolutionary None None O
steps None None O
that None None O
would None None O
entail None None O
a None None O
decrease None None O
in None None O
fitness None None O
. None None O

Bacteria None None O
detect None None O
changes None None O
in None None O
population None None O
density None None O
by None None O
quorum None None O
sensing None None O
and None None O
particular None None O
environmental None None O
conditions None None O
, None None O
using None None O
signals None None O
such None None O
as None None O
cyclic None None O
di-GMP None None O
or None None O
nitric None None I-TRANS
oxide None None I-TRANS
. None None O

Due None None O
to None None O
the None None O
importance None None O
of None None O
these None None O
features None None O
, None None O
we None None O
here None None O
review None None O
the None None O
signaling None None O
network None None O
and None None O
regulatory None None O
connections None None O
among None None O
quorum None None O
sensing None None O
, None None O
c-di-GMP None None O
and None None O
nitric None None I-TRANS
oxide None None I-TRANS
involving None None O
biofilm None None O
formation None None O
. None None O

Loss None None O
of None None O
lateral None None O
shortening None None O
of None None O
IPMD None None O
tethers None None O
the None None O
leaflet None None O
edges None None O
and None None O
impairs None None O
their None None O
systolic None None O
closure None None O
, None None O
resulting None None O
in None None O
mitral None None O
regurgitation None None O
, None None O
even None None O
in None None O
small None None O
ventricles None None I-REGION
. None None O

There None None O
was None None O
modest None None O
but None None O
significant None None O
correlation None None O
between None None O
TMAO None None O
concentrations None None O
and None None O
B-type None None I-TRANS
natriuretic None None I-TRANS
peptide None None I-TRANS
( None None O
BNP None None I-TRANS
) None None O
levels None None O
( None None O
r None None O
= None None O
0.23 None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Following None None O
adjustments None None O
for None None O
traditional None None O
risk None None O
factors None None O
and None None O
BNP None None I-TRANS
levels None None O
, None None O
elevated None None O
TMAO None None O
levels None None O
remained None None O
predictive None None O
of None None O
5-year None None O
mortality None None O
risk None None O
( None None O
hazard None None O
ratio None None O
[ None None O
HR None None O
] None None O
: None None O
2.2 None None O
; None None O
95 None None O
% None None O
CI None None O
: None None O
1.42 None None O
to None None O
3.43 None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
, None None O
as None None O
well None None O
as None None O
following None None O
the None None O
addition None None O
of None None O
estimated None None O
glomerular None None O
filtration None None O
rate None None O
to None None O
the None None O
model None None O
( None None O
HR None None O
: None None O
1.75 None None O
; None None O
95 None None O
% None None O
CI None None O
: None None O
1.07 None None O
to None None O
2.86 None None O
; None None O
p None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
. None None O

Finally None None O
, None None O
the None None O
transglottal None None O
pressure None None O
was None None O
estimated None None O
, None None O
necessary None None O
for None None O
the None None O
voicing None None O
of None None O
[ None None O
b None None O
] None None O
, None None O
to None None O
establish None None O
the None None O
difference None None O
in None None O
the None None O
IOP None None I-TRANS
mean None None O
peak None None O
of None None O
[ None None O
p None None O
] None None O
and None None O
[ None None O
b None None O
] None None O
at None None O
the None None O
same None None O
intensity None None O
. None None O

This None None O
study None None O
highlights None None O
an None None O
increase None None O
of None None O
the None None O
IOP None None I-TRANS
and None None O
the None None O
OAF None None O
in None None O
voiceless None None O
contexts None None O
for None None O
both None None O
groups None None O
. None None O

Genetic None None O
haploinsufficiency None None O
of None None O
SYNGAP1/Syngap1 None None O
commonly None None O
occurs None None O
in None None O
developmental None None O
brain None None O
disorders None None O
, None None O
such None None O
as None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
, None None O
epilepsy None None O
, None None O
schizophrenia None None I-DISEASE
, None None O
and None None O
autism None None I-DISEASE
spectrum None None I-DISEASE
disorder None None I-DISEASE
. None None O

We None None O
used None None O
mice None None O
with None None O
a None None O
mutation None None O
in None None O
Npas2 None None O
and None None O
adeno-associated None None O
virus-short None None O
hairpin None None O
RNA None None O
mediated None None O
knockdown None None O
of None None O
Npas2 None None O
and None None O
Clock None None O
in None None O
the None None O
nucleus None None I-REGION
accumbens None None I-REGION
( None None O
NAc None None O
) None None O
. None None O

It None None O
is None None O
unclear None None O
at None None O
the None None O
present None None O
time None None O
whether None None O
anxiety None None O
and None None O
depression None None I-DISEASE
are None None O
neurobiologically None None O
distinct None None O
or None None O
similar None None O
processes None None O
. None None O

A None None O
cross-sectional None None O
neuroimaging None None O
study None None O
was None None O
conducted None None O
of None None O
patients None None O
with None None O
generalized None None I-DISEASE
anxiety None None I-DISEASE
disorder None None I-DISEASE
( None None O
GAD None None O
) None None O
, None None O
major None None I-DISEASE
depressive None None I-DISEASE
disorder None None I-DISEASE
( None None O
MDD None None O
) None None O
, None None O
comorbid None None O
GAD None None O
and None None O
MDD None None O
( None None O
GAD/MDD None None O
) None None O
, None None O
or None None O
neither None None O
GAD None None O
nor None None O
MDD None None O
( None None O
control None None O
subjects None None O
) None None O
. None None O

Instead None None O
, None None O
the None None O
data None None O
support None None O
an None None O
additive None None O
model None None O
that None None O
best None None O
captures None None O
abnormal None None O
neural None None O
patterns None None O
in None None O
patients None None O
with None None O
anxiety None None O
and None None O
depression None None I-DISEASE
. None None O

Growth None None O
velocity None None O
of None None O
head None None O
circumference None None O
at None None O
3 None None O
months None None O
of None None O
age None None O
, None None O
adjusting None None O
for None None O
gestational None None O
age None None O
at None None O
birth None None O
and None None O
maternal None None O
age None None O
, None None O
is None None O
significantly None None O
associated None None O
with None None O
autism None None O
( None None O
p None None O
= None None O
.014 None None O
) None None O
; None None O
the None None O
finding None None O
was None None O
observed None None O
in None None O
subjects None None O
with None None O
comorbid None None O
intellectual None None I-DISEASE
disability None None I-DISEASE
( None None O
ID None None O
) None None O
( None None O
p None None O
= None None O
.025 None None O
) None None O
but None None O
not None None O
in None None O
those None None O
without None None O
ID None None O
( None None O
p None None O
= None None O
.15 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
although None None O
control None None O
subjects None None O
displayed None None O
a None None O
relationship None None O
between None None O
IIV None None O
and None None O
conflict-related None None O
brain None None O
activity None None O
in None None O
bilateral None None O
prefrontal None None I-REGION
cortex None None I-REGION
such None None O
that None None O
increased None None O
IIV None None O
was None None O
associated None None O
with None None O
increased None None O
activity None None O
, None None O
the None None O
MAP+ None None O
group None None O
displayed None None O
this None None O
relationship None None O
in None None O
right None None I-REGION
prefrontal None None I-REGION
cortex None None I-REGION
only None None O
, None None O
perhaps None None O
reflecting None None O
elevated None None O
vigilance None None O
in None None O
the None None O
MAP+ None None O
group None None O
. None None O

Prenatal None None O
stress None None O
( None None O
PRS None None O
) None None O
is None None O
considered None None O
a None None O
risk None None O
factor None None O
for None None O
several None None O
neurodevelopmental None None O
disorders None None O
including None None O
schizophrenia None None I-DISEASE
( None None O
SZ None None O
) None None O
. None None O

Studying None None O
adult None None O
offspring None None O
of None None O
pregnant None None O
mice None None O
subjected None None O
to None None O
PRS None None O
, None None O
we None None O
explored None None O
the None None O
long-term None None O
effects None None O
of None None O
PRS None None O
on None None O
behavior None None O
and None None O
on None None O
the None None O
expression None None O
of None None O
key None None O
chromatin None None O
remodeling None None O
factors None None O
including None None O
DNA None None I-PROTEIN
methyltransferase None None I-PROTEIN
1 None None O
, None None O
ten-eleven-translocation None None O
hydroxylases None None O
, None None O
methyl None None O
CpG None None O
binding None None O
protein None None O
2 None None O
, None None O
histone None None O
deacetylases None None O
, None None O
and None None O
histone None None I-PROTEIN
methyltransferases None None I-PROTEIN
and None None O
demethylase None None O
in None None O
the None None O
frontal None None I-REGION
cortex None None I-REGION
and None None O
hippocampus None None I-REGION
. None None O

Main None None O
findings None None O
were None None O
significant None None O
while None None O
adjusting None None O
for None None O
sex None None O
hormones None None I-PROTEIN
( None None O
estradiol-to-progesterone None None O
ratio None None O
in None None O
women None None O
and None None O
testosterone None None O
in None None O
men None None O
) None None O
, None None O
age None None O
, None None O
self-esteem None None O
, None None O
and None None O
disclosure None None O
status None None O
( None None O
whether None None O
LGB None None O
participants None None O
had None None O
completed None None O
their None None O
`` None None O
coming None None O
out None None O
'' None None O
) None None O
. None None O

The None None O
delta None None O
opioid None None O
receptor None None I-PROTEIN
( None None O
DOR None None O
) None None O
is None None O
broadly None None O
expressed None None O
throughout None None O
the None None O
nervous None None O
system None None O
; None None O
it None None O
regulates None None O
chronic None None O
pain None None O
, None None O
emotional None None O
responses None None O
, None None O
motivation None None O
, None None O
and None None O
memory None None I-FUNC
. None None O

We None None O
used None None O
conditional None None O
mouse None None O
mutagenesis None None O
to None None O
elucidate None None O
receptor None None I-PROTEIN
function None None O
in None None O
GABAergic None None I-NEURON
neurons None None I-NEURON
of None None O
the None None O
forebrain None None I-REGION
. None None O

The None None O
DOR None None O
proteins None None O
were None None O
strongly None None O
deleted None None O
in None None O
olfactory None None I-REGION
bulb None None I-REGION
and None None O
striatum None None I-REGION
and None None O
remained None None O
intact None None O
in None None O
cortex None None O
and None None O
basolateral None None O
amygdala None None I-REGION
. None None O

We None None O
demonstrate None None O
that None None O
DORs None None O
expressed None None O
in None None O
the None None O
forebrain None None I-REGION
mediate None None O
the None None O
described None None O
locomotor None None O
effect None None O
of None None O
SNC80 None None O
and None None O
inhibit None None O
D1-stimulated None None O
hyperactivity None None O
. None None O

In None None O
emotional None None O
responses None None O
, None None O
DORs None None O
exert None None O
dual None None O
anxiolytic None None O
and None None O
anxiogenic None None O
roles None None O
, None None O
both None None O
of None None O
which None None O
may None None O
have None None O
implications None None O
in None None O
the None None O
area None None O
of None None O
anxiety None None I-DISEASE
disorders None None I-DISEASE
. None None O

Noninvasive None None O
neuroimaging None None O
studies None None O
have None None O
provided None None O
rich None None O
evidence None None O
that None None O
these None None O
behavioral None None O
deficits None None O
in None None O
depression None None I-DISEASE
are None None O
associated None None O
with None None O
structural None None O
and None None O
functional None None O
abnormalities None None O
in None None O
specific None None O
regions None None O
and None None O
connections None None O
. None None O

These None None O
system-level None None O
disruptions None None O
show None None O
important None None O
correlates None None O
with None None O
genetic None None O
and None None O
environmental None None O
factors None None O
, None None O
which None None O
provide None None O
an None None O
integrative None None O
perspective None None O
on None None O
mood None None I-FUNC
and None None O
cognitive None None O
deficits None None O
in None None O
depressive None None O
syndrome None None O
. None None O

These None None O
connectome-based None None O
imaging None None O
studies None None O
present None None O
new None None O
opportunities None None O
to None None O
reconceptualize None None O
the None None O
pathogenesis None None O
of None None O
depression None None I-DISEASE
, None None O
improve None None O
our None None O
knowledge None None O
of None None O
the None None O
biological None None O
mechanisms None None O
of None None O
therapeutic None None O
effects None None O
, None None O
and None None O
identify None None O
appropriate None None O
stimulation None None O
targets None None O
to None None O
optimize None None O
the None None O
clinical None None O
response None None O
in None None O
depression None None I-DISEASE
treatment None None O
. None None O

Among None None O
mRNA None None O
examined None None O
, None None O
FABP4 None None O
was None None O
downregulated None None O
in None None O
schizophrenia None None I-DISEASE
subjects None None O
by None None O
two None None O
independent None None O
sample None None O
sets None None O
. None None O

hsa-miR-4449 None None O
expression None None O
was None None O
increased None None O
in None None O
Brodmann None None O
area None None O
46 None None O
from None None O
schizophrenia None None I-DISEASE
( None None O
p None None O
= None None O
.0007 None None O
) None None O
. None None O

Scalp None None O
hair None None O
follicles None None O
could None None O
be None None O
a None None O
beneficial None None O
genetic None None O
biomarker None None O
resource None None O
for None None O
brain None None I-DISEASE
diseases None None I-DISEASE
, None None O
and None None O
further None None O
studies None None O
of None None O
FABP4 None None O
are None None O
merited None None O
in None None O
schizophrenia None None I-DISEASE
pathogenesis None None O
. None None O

The None None O
syndrome None None O
may None None O
be None None O
underdiagnosed None None O
due None None O
( None None O
1 None None O
) None None O
to None None O
mild None None O
language None None I-FUNC
difficulties None None O
during None None O
the None None O
early None None O
stages None None O
of None None O
the None None O
disease None None O
or None None O
( None None O
2 None None O
) None None O
to None None O
being None None O
mistaken None None O
for None None O
mild None None O
cognitive None None O
impairment None None O
or None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
when None None O
the None None O
evaluation None None O
of None None O
episodic None None I-FUNC
memory None None I-FUNC
is None None O
based None None O
on None None O
verbal None None O
material None None O
and None None O
( None None O
3 None None O
) None None O
finally None None O
, None None O
it None None O
is None None O
not None None O
uncommon None None O
that None None O
the None None O
disorders None None O
are None None O
attributed None None O
to None None O
psychiatric None None O
co-morbidities None None O
such None None O
as None None O
, None None O
for None None O
example None None O
, None None O
anxiety None None O
. None None O

The None None O
left None None I-REGION
temporoparietal None None I-REGION
junction None None I-REGION
is None None O
initially None None O
affected None None O
. None None O

Consequently None None O
this None None O
variant None None O
of None None O
primary None None O
progressive None None O
aphasia None None I-DISEASE
does None None O
not None None O
fall None None O
under None None O
the None None O
traditional None None O
concept None None O
of None None O
frontotemporal None None O
lobar None None O
degeneration None None O
. None None O

The None None O
logopenic None None O
variant None None O
of None None O
primary None None O
progressive None None O
aphasia None None I-DISEASE
is None None O
a None None O
specific None None O
form None None O
of None None O
Alzheimer None None I-DISEASE
's None None I-DISEASE
disease None None I-DISEASE
frequently None None O
presenting None None O
a None None O
rapid None None O
decline None None O
; None None O
specific None None O
linguistic None None O
therapies None None O
are None None O
needed None None O
. None None O

Toll-like None None O
receptors None None I-PROTEIN
( None None O
TLRs None None O
) None None O
are None None O
a None None O
family None None O
of None None O
highly None None O
conserved None None O
transmembrane None None O
proteins None None O
expressed None None O
in None None O
epithelial None None O
and None None O
immune None None O
cells None None O
that None None O
recognize None None O
pathogen None None O
associated None None O
molecular None None O
patterns None None O
. None None O

An None None O
association None None O
between None None O
arterial None None O
aneurysms None None O
and None None O
matrix None None I-PROTEIN
metalloproteinases None None I-PROTEIN
( None None O
MMPs None None O
) None None O
has None None O
been None None O
described None None O
previously None None O
. None None O

In None None O
an None None O
observational None None O
study None None O
of None None O
four None None O
stroke None None I-DISEASE
centers None None O
, None None O
all None None O
women None None O
aged None None O
16-45 None None O
years None None O
with None None O
primary None None O
CAD None None O
in None None O
the None None O
previous None None O
decade None None O
were None None O
asked None None O
to None None O
participate None None O
in None None O
a None None O
standardized None None O
assessment None None O
on None None O
long-term None None O
follow-up None None O
with None None O
a None None O
special None None O
focus None None O
on None None O
pregnancies None None O
and None None O
recurrent None None O
CAD None None O
. None None O

After None None O
a None None O
strict None None O
selection None None O
process None None O
, None None O
91 None None O
participants None None O
with None None O
schizophrenia None None I-DISEASE
spectrum None None O
disorders None None O
were None None O
retained None None O
for None None O
the None None O
final None None O
analyses None None O
. None None O

During None None O
favorite-food None None O
cue None None O
exposure None None O
, None None O
smokers None None O
versus None None O
non-smokers None None O
exhibited None None O
diminished None None O
activations None None O
in None None O
the None None O
caudate None None O
, None None O
putamen None None I-REGION
, None None O
insula None None I-REGION
, None None O
and None None O
thalamus None None I-REGION
. None None O

Transfection None None O
with None None O
pre-miR-211 None None O
precursor None None O
molecules None None O
in None None O
melb-a None None O
and None None O
melan-a None None O
cells None None O
leads None None O
to None None O
a None None O
decrease None None O
in None None O
the None None O
expression None None O
of None None O
TGF-β None None O
receptor None None I-PROTEIN
2 None None O
and None None O
reduces None None O
the None None O
TGF-β None None O
signaling-mediated None None O
downregulation None None O
of None None O
two None None O
melanogenic None None O
enzymes None None I-PROTEIN
, None None O
tyrosinase None None I-PROTEIN
and None None O
tyrosinase-related None None O
protein None None O
1 None None O
. None None O

An None None O
alternative None None O
strategy None None O
named None None O
vectored None None O
immunoprophylaxis None None O
( None None O
VIP None None I-TRANS
) None None O
now None None O
would None None O
allow None None O
genetically None None O
transduced None None O
host None None O
cells None None O
to None None O
assemble None None O
and None None O
secrete None None O
antibodies None None O
that None None O
neutralize None None O
the None None O
infectivity None None O
of None None O
the None None O
malaria None None O
parasite None None O
and None None O
prevent None None O
disease None None O
. None None O

Furthermore None None O
, None None O
using None None O
this None None O
language None None I-FUNC
used None None O
worldwide None None O
remains None None O
uneasy None None O
in None None O
daily None None O
clinical None None O
practice None None O
. None None O

Recent None None O
studies None None O
show None None O
that None None O
VA None None O
can None None O
also None None O
be None None O
used None None O
to None None O
treat None None O
migraine None None I-DISEASE
headaches None None O
, None None O
bipolar None None I-DISEASE
disorder None None I-DISEASE
, None None O
and None None O
other None None O
diseases None None O
such None None O
as None None O
Alzheimer None None I-DISEASE
disease None None O
. None None O

Viable None None O
protoplasts None None O
were None None O
released None None O
from None None O
fungal None None O
mycelium None None O
using None None O
enzyme None None O
cocktail None None O
containing None None O
5 None None O
mg None None O
ml None None O
( None None O
-1 None None O
) None None O
lysing None None O
enzymes None None I-PROTEIN
from None None O
T. None None O
harzianum None None O
, None None O
0.06 None None O
mg None None O
ml None None O
( None None O
-1 None None O
) None None O
β-glucuronidase None None O
from None None O
Helix None None O
pomatia None None O
and None None O
1 None None O
mg None None O
ml None None O
( None None O
-1 None None O
) None None O
purified None None O
Penicillium None None O
ochrochloron None None O
chitinase None None I-PROTEIN
in None None O
0.8 None None O
mol None None O
l None None O
( None None O
-1 None None O
) None None O
sorbitol None None O
as None None O
an None None O
osmotic None None O
stabilizer None None O
. None None O

This None None O
study None None O
revealed None None O
protoplast None None O
fusion None None O
between None None O
A. None None O
oryzae None None O
and None None O
T. None None O
harzianum None None O
significantly None None O
enhanced None None O
chitinase None None I-PROTEIN
activity None None O
which None None O
ultimately None None O
provides None None O
potential None None O
strain None None O
for None None O
degradation None None O
of None None O
shellfish None None O
waste None None O
. None None O

Now None None O
it None None O
is None None O
need None None O
to None None O
provide None None O
attention None None I-FUNC
over None None O
effective None None O
chitin None None O
degradation None None O
to None None O
manage None None O
shrimp None None O
processing None None O
issues None None O
. None None O

Acute None None O
care None None O
hospitals None None O
( None None O
ACHs None None I-TRANS
) None None O
, None None O
chronic None None O
care None None O
hospitals None None O
( None None O
CCHs None None O
) None None O
, None None O
and None None O
long-term None None O
care None None O
facilities None None O
( None None O
LTCFs None None O
) None None O
were None None O
contacted None None O
and None None O
the None None O
individual None None O
responsible None None O
for None None O
oversight None None O
of None None O
wheelchair None None O
cleaning None None O
and None None O
disinfection None None O
was None None O
identified None None O
. None None O

Interviews None None O
were None None O
completed None None O
at None None O
48 None None O
of None None O
the None None O
54 None None O
facilities None None O
contacted None None O
( None None O
89 None None O
% None None O
) None None O
, None None O
including None None O
18 None None O
ACHs None None I-TRANS
, None None O
16 None None O
CCHs None None O
, None None O
and None None O
14 None None O
LTCFs None None O
. None None O

Recently None None O
, None None O
monolithic None None O
zirconia None None O
restorations None None O
have None None O
received None None O
attention None None I-FUNC
as None None O
an None None O
alternative None None O
to None None O
zirconia None None O
veneered None None O
with None None O
feldspathic None None O
porcelain None None O
to None None O
eliminate None None O
chipping None None O
failures None None O
of None None O
veneer None None O
ceramics None None O
. None None O

According None None O
to None None O
the None None O
severity None None O
, None None O
the None None O
strategic None None O
treatment None None O
options None None O
are None None O
as None None O
follows None None O
: None None O
simple None None O
retention None None I-FUNC
; None None O
adjustment None None O
or None None O
replacement None None O
of None None O
the None None O
implant None None O
restoration None None O
, None None O
possibly None None O
including None None O
adjacent None None O
teeth None None O
; None None O
surgical None None O
implant None None O
repositioning None None O
by None None O
segmental None None O
osteotomy None None O
combined None None O
with None None O
osseodistraction None None O
; None None O
or None None O
submergence None None O
or None None O
removal None None O
of None None O
the None None O
implant None None O
. None None O

The None None O
lessons None None O
learned None None O
from None None O
this None None O
study None None O
are None None O
likely None None O
to None None O
be None None O
applicable None None O
to None None O
other None None O
settings None None O
committed None None O
to None None O
evidence-based None None O
decision None None I-FUNC
making None None I-FUNC
. None None O

Brazil None None O
is None None O
a None None O
country None None O
with None None O
no None None O
tradition None None O
in None None O
the None None O
production None None O
and None None O
use None None O
of None None O
health None None O
economic None None O
evaluation None None O
( None None O
HEE None None O
) None None O
to None None O
guide None None O
decision None None I-FUNC
making None None I-FUNC
in None None O
the None None O
public None None O
health None None O
system None None O
. None None O

HIV None None O
support None None O
agencies None None O
need None None O
to None None O
pay None None O
attention None None I-FUNC
to None None O
the None None O
way None None O
HIV None None O
and None None O
antiretroviral None None O
treatment None None O
( None None O
ART None None O
) None None O
influence None None O
men None None O
's None None O
perception None None I-FUNC
of None None O
their None None O
masculinity None None O
and None None O
support None None O
them None None O
to None None O
overcome None None O
the None None O
anxieties None None O
about None None O
dented None None O
or None None O
eroded None None O
masculinity None None O
, None None O
while None None O
building None None O
on None None O
the None None O
positive None None O
ways None None O
in None None O
which None None O
treatment None None O
restores None None O
masculinity None None O
to None None O
support None None O
men None None O
's None None O
adherence None None O
to None None O
HIV None None O
treatment None None O
. None None O

An None None O
EM None None O
of None None O
& None None O
gt None None O
; None None O
3.0 None None O
kPa None None O
was None None O
correlated None None O
with None None O
histologic None None O
findings None None O
including None None O
increased None None O
ratios None None O
of None None O
azan-Mallory None None O
positivity None None O
( None None O
P None None O
= None None O
.003 None None O
) None None O
and None None O
α-smooth None None O
muscle None None O
actin None None I-PROTEIN
positivity None None O
( None None O
P None None O
= None None O
.006 None None O
) None None O
, None None O
a None None O
decreased None None O
lobular None None O
ratio None None O
( None None O
P None None O
= None None O
.021 None None O
) None None O
, None None O
and None None O
an None None O
increased None None O
vessel None None O
density None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
.001 None None O
) None None O
. None None O

Between None None O
preoperative None None O
and None None O
postoperative None None O
assessment None None O
, None None O
the None None O
mean None None O
increase None None O
of None None O
distance-corrected None None O
PAV None None O
for None None O
near None None O
vision None None I-FUNC
was None None O
+0.25±0.64 None None O
D None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
for None None O
dominant None None O
eyes None None O
and None None O
+0.63±0.55 None None O
D None None O
( None None O
P None None O
& None None O
lt None None O
; None None O
0.001 None None O
) None None O
for None None O
nondominant None None O
eyes None None O
. None None O

Aspheric None None O
hyperopic None None O
LASIK None None O
can None None O
increase None None O
the None None O
depth None None O
of None None O
focus None None O
without None None O
impairing None None O
far None None O
vision None None I-FUNC
, None None O
but None None O
this None None O
benefit None None O
would None None O
be None None O
maximal None None O
and None None O
reproducible None None O
if None None O
we None None O
could None None O
define None None O
and None None O
achieve None None O
an None None O
optimal None None O
SA None None O
value None None O
determined None None O
by None None O
preoperative None None O
assessment None None O
using None None O
an None None O
adaptive None None O
optics None None O
instrument None None O
. None None O

Vascular None None I-PROTEIN
endothelial None None I-PROTEIN
growth None None I-PROTEIN
factor None None I-PROTEIN
( None None O
VEGF None None O
) None None O
signaling None None O
is None None O
important None None O
in None None O
both None None O
physiologic None None O
and None None O
pathologic None None O
developmental None None O
angiogenesis None None O
. None None O

We None None O
found None None O
no None None O
correlation None None O
between None None O
ffERG None None O
abnormalities None None O
and None None O
the None None O
rate None None O
of None None O
vision None None I-FUNC
loss None None O
. None None O

However None None O
, None None O
data None None O
on None None O
the None None O
influence None None O
of None None O
pancreatic None None O
steatosis None None O
on None None O
subclinical None None O
atherosclerosis None None I-DISEASE
are None None O
lacking None None O
. None None O

However None None O
, None None O
significant None None O
associations None None O
between None None O
pancreatic None None O
steatosis None None O
and None None O
atherosclerosis None None I-DISEASE
were None None O
not None None O
found None None O
in None None O
the None None O
obese None None O
group None None O
. None None O

Based None None O
on None None O
the None None O
efficacy None None O
of None None O
EBRT None None O
in None None O
optic None None I-REGION
nerve None None I-REGION
sheath None None O
meningioma None None O
, None None O
we None None O
used None None O
this None None O
treatment None None O
to None None O
decrease None None O
the None None O
risk None None O
of None None O
recurrence None None O
in None None O
our None None O
two None None O
patients None None O
and None None O
found None None O
no None None O
tumor None None O
recurrence None None O
at None None O
follow-ups None None O
of None None O
24 None None O
and None None O
74 None None O
months None None O
, None None O
but None None O
one None None O
patient None None O
had None None O
severe None None O
vision None None I-FUNC
loss None None O
from None None O
radiation None None O
retinopathy None None O
. None None O

The None None O
outcome None None O
of None None O
patients None None O
with None None O
chronic None None O
thromboembolic None None O
pulmonary None None O
hypertension None None O
( None None O
CTEPH None None O
) None None O
undergoing None None O
pulmonary None None O
endarterectomy None None O
( None None O
PEA None None I-TRANS
) None None O
after None None O
urgent None None O
hospitalization None None O
for None None O
decompensated None None O
right None None O
heart None None O
failure None None O
( None None O
DRHF None None O
) None None O
remains None None O
unclear None None O
. None None O

The None None O
overall None None O
in-hospital None None O
mortality None None O
after None None O
PEA None None I-TRANS
was None None O
4 None None O
% None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
. None None O

A None None O
history None None O
of None None O
DRHF None None O
by None None O
itself None None O
was None None O
not None None O
a None None O
risk None None O
factor None None O
for None None O
residual None None O
PH None None O
after None None O
PEA None None I-TRANS
. None None O